<SEC-DOCUMENT>0001636282-26-000096.txt : 20260804
<SEC-HEADER>0001636282-26-000096.hdr.sgml : 20260804
<ACCEPTANCE-DATETIME>20260804160217
ACCESSION NUMBER:		0001636282-26-000096
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		73
CONFORMED PERIOD OF REPORT:	20260630
FILED AS OF DATE:		20260804
DATE AS OF CHANGE:		20260804

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Spyre Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001636282
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				464312787
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37722
		FILM NUMBER:		261238397

	BUSINESS ADDRESS:	
		STREET 1:		221 CRESCENT STREET
		STREET 2:		BUILDING 23, SUITE 105
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02453
		BUSINESS PHONE:		6176515940

	MAIL ADDRESS:	
		STREET 1:		221 CRESCENT STREET
		STREET 2:		BUILDING 23, SUITE 105
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02453

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Aeglea BioTherapeutics, Inc.
		DATE OF NAME CHANGE:	20150311
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>syre-20260630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019e22c4-8e13-79c8-aa17-b3b58ba33655,g:1a770671-d821-405f-804e-c086c0f29bbb,d:7ac5520bfa654a33b8eea56f2b4c5e97-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2026" xmlns:us-gaap="http://fasb.org/us-gaap/2026" xmlns:srt="http://fasb.org/srt/2026" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ecd="http://xbrl.sec.gov/ecd/2026" xmlns:syre="http://spyre.com/20260630" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>syre-20260630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-27">0001636282</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="f-28">12-31</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-29">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-30">2026</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-31">Q2</ix:nonNumeric><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="0" id="f-208">0</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="0" id="f-209">0</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-184" decimals="2" name="syre:RoyaltyStepDownPercent" scale="-2" id="f-675">33</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-5" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="0" id="f-709">0</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-5" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="0" id="f-710">0</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="INF" name="us-gaap:AccountsPayableOtherCurrent" scale="0" id="f-711">0</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="INF" name="us-gaap:AccountsPayableOtherCurrent" scale="0" id="f-712">0</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-5" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="0" id="f-713">0</ix:nonFraction><ix:nonNumeric contextRef="c-240" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-822">0.00</ix:nonNumeric><ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" scale="0" id="f-865">1</ix:nonFraction><ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" scale="0" id="f-866">1</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="f-867">0</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="f-868">0</ix:nonFraction><ix:nonNumeric contextRef="c-262" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-951">720</ix:nonNumeric><ix:nonNumeric contextRef="c-264" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-952">461</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="syre-20260630.xsd"/></ix:references><ix:resources><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>syre:segment</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="bank"><xbrli:measure>syre:bank</xbrli:measure></xbrli:unit><xbrli:unit id="seat"><xbrli:measure>syre:seat</xbrli:measure></xbrli:unit><xbrli:unit id="installment"><xbrli:measure>syre:installment</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2026-07-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesBNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesBNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:PreferredStockExcludingSeriesAAndBNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:PreferredStockExcludingSeriesAAndBNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesBNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesBNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesBNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesBNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesBNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesBNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesBNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesBNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesBNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesBNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesBNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesBNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">syre:SpyreTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-22</xbrli:startDate><xbrli:endDate>2023-06-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">syre:AtTheMarketOffering2024SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">syre:AtTheMarketOffering2024SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">syre:AtTheMarketOffering2024SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">syre:AtTheMarketOffering2026SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">syre:AtTheMarketOffering2026SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">syre:October2025UnderwrittenOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-15</xbrli:startDate><xbrli:endDate>2025-10-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-15</xbrli:startDate><xbrli:endDate>2025-10-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">syre:October2025UnderwrittenOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">syre:April2026UnderwritingOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-16</xbrli:startDate><xbrli:endDate>2026-04-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-16</xbrli:startDate><xbrli:endDate>2026-04-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">syre:April2026UnderwritingOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-04-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2015-03-10</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">syre:ContingentValueRightLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">syre:ContingentValueRightLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">syre:ContingentValueRightLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">syre:ContingentValueRightLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">syre:ContingentValueRightLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">syre:USBankingInstitutionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:SPY003LicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:SPY002AndSPY072LicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:Spy001LicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:SPY003LicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-11</xbrli:startDate><xbrli:endDate>2024-10-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:SPY002AndSPY072LicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-14</xbrli:startDate><xbrli:endDate>2024-05-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:Spy001LicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-14</xbrli:startDate><xbrli:endDate>2024-05-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ParagonAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:SPY002AndSPY072LicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ParagonAgreementLicenseMilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ParagonAgreementLicenseMilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ParagonAgreementLicenseMilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ParagonAgreementLicenseMilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ParagonAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ParagonAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ParagonAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ParagonAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ParagonAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ParagonAgreementLicenseMilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ParagonAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">syre:ParagonTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ParagonAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">syre:FairmountFundsManagementLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:AppointOfBoardMembersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:OtherParagonReimbursableExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:OtherParagonReimbursableExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:OtherParagonReimbursableExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:OtherParagonReimbursableExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ParagonAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ParagonAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ParagonAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ParagonAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ConsultingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-22</xbrli:startDate><xbrli:endDate>2023-11-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ConsultingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ConsultingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-22</xbrli:startDate><xbrli:endDate>2023-11-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ConsultingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ConsultingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ConsultingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ConsultingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ParagonAgreementSubsequentToAssetAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ParagonAgreementSubsequentToAssetAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">syre:ParapyreWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesBNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">syre:AtTheMarketOffering2024SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">syre:AtTheMarketOffering2024SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndEighteenEquityInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndEighteenEquityInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">syre:ServiceBasedAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">syre:A2016ESPPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">syre:A2016ESPPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">syre:A2016ESPPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">syre:A2016ESPPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis"><us-gaap:QName.domain>us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</us-gaap:QName.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis"><us-gaap:QName.domain>us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</us-gaap:QName.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis"><us-gaap:QName.domain>us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</us-gaap:QName.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis"><us-gaap:QName.domain>us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</us-gaap:QName.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis"><us-gaap:QName.domain>us-gaap:GeneralAndAdministrativeExpense</us-gaap:QName.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis"><us-gaap:QName.domain>us-gaap:GeneralAndAdministrativeExpense</us-gaap:QName.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis"><us-gaap:QName.domain>us-gaap:GeneralAndAdministrativeExpense</us-gaap:QName.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis"><us-gaap:QName.domain>us-gaap:GeneralAndAdministrativeExpense</us-gaap:QName.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">syre:GlobalRightsToPegzilarginaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-27</xbrli:startDate><xbrli:endDate>2023-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">syre:GlobalRightsToPegzilarginaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">syre:GlobalRightsToPegzilarginaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">syre:GlobalRightsToPegzilarginaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">syre:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">syre:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">syre:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">syre:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">syre:ParapyreWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">syre:ParapyreWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">syre:ParapyreWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">syre:ParapyreWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">syre:HeidyKingJonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">syre:HeidyKingJonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">syre:JeffreyAlbersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-265"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">syre:JeffreyAlbersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-266"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">syre:JeffreyAlbersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:TradingArrAxis">syre:JeffreyAlbersRuleTradingArrangementDirectorStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-110 f-111 f-112 f-113" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-1" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-114 f-115 f-116 f-117" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-2" order="2"/></ix:resources></ix:header></div><div id="i7ac5520bfa654a33b8eea56f2b4c5e97_1"></div><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:17pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:17pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:17pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________________</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.264%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="f-2">x</ix:nonNumeric></span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">June 30, 2026</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.264%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-4">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-37722</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:22pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-6">SPYRE THERAPEUTICS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified in its Charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________________</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-7">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-8">46-4312787</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-9">221 Crescent Street</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-10">Building 23</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine3" id="f-11">Suite 105</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-12">Waltham</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-13">MA</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-14">02453</ix:nonNumeric></span></div></td></tr><tr><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices including zip code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-15">617</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-16">651-5940</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Former name, former address and former fiscal year, if changed since last report: N/A</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Exchange Act:</span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Title of each class</span></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock, $0.0001 Par Value Per Share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">SYRE</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">The Nasdaq Stock Market LLC</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Nasdaq Global Select Market)</span></div></td></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-20">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-21">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.203%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.203%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-22">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accelerated filer</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-accelerated filer</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smaller reporting company</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="f-23">o</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:top"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-24">o</ix:nonNumeric></span></td></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-25">x</ix:nonNumeric></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of July&#160;28, 2026, the registrant had <ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-26">88,173,762</ix:nonFraction> shares of common stock, $0.0001 par value per share, outstanding.</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:18pt;padding-left:3pt;padding-right:3pt;text-align:center"><span><br/></span></div></div></div><div id="i7ac5520bfa654a33b8eea56f2b4c5e97_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPYRE THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUARTERLY REPORT ON FORM 10-Q</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE QUARTER ENDED JUNE 30, 2026</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:79.657%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.992%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Page No.</span></td></tr><tr><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7ac5520bfa654a33b8eea56f2b4c5e97_13">PART I. FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i7ac5520bfa654a33b8eea56f2b4c5e97_13">1</a></span></div></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i7ac5520bfa654a33b8eea56f2b4c5e97_16">Item 1.</a></span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7ac5520bfa654a33b8eea56f2b4c5e97_16">Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i7ac5520bfa654a33b8eea56f2b4c5e97_16">1</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7ac5520bfa654a33b8eea56f2b4c5e97_19">Condensed Consolidated Balance Sheets as of </a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7ac5520bfa654a33b8eea56f2b4c5e97_19">June 30, 2026</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7ac5520bfa654a33b8eea56f2b4c5e97_19"> and December 31, 2025</a></span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i7ac5520bfa654a33b8eea56f2b4c5e97_19">1</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7ac5520bfa654a33b8eea56f2b4c5e97_22">Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2026 and 2025</a></span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i7ac5520bfa654a33b8eea56f2b4c5e97_22">2</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7ac5520bfa654a33b8eea56f2b4c5e97_28">Condensed Consolidated Statements of Comprehensive Loss for the Three and Six Months Ended June 30, 2026 and 2025</a></span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i7ac5520bfa654a33b8eea56f2b4c5e97_28">3</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7ac5520bfa654a33b8eea56f2b4c5e97_31">Condensed Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders&#8217; Equity for the Three and Six Months Ended June 30, 2026 and 2025</a></span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i7ac5520bfa654a33b8eea56f2b4c5e97_31">4</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7ac5520bfa654a33b8eea56f2b4c5e97_37">Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2026 and 2025</a></span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i7ac5520bfa654a33b8eea56f2b4c5e97_37">6</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7ac5520bfa654a33b8eea56f2b4c5e97_43">Notes to Unaudited Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i7ac5520bfa654a33b8eea56f2b4c5e97_43">7</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i7ac5520bfa654a33b8eea56f2b4c5e97_109">Item 2.</a></span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7ac5520bfa654a33b8eea56f2b4c5e97_109">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i7ac5520bfa654a33b8eea56f2b4c5e97_109">22</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i7ac5520bfa654a33b8eea56f2b4c5e97_145">Item 3.</a></span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7ac5520bfa654a33b8eea56f2b4c5e97_145">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i7ac5520bfa654a33b8eea56f2b4c5e97_145">34</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i7ac5520bfa654a33b8eea56f2b4c5e97_148">Item 4.</a></span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7ac5520bfa654a33b8eea56f2b4c5e97_148">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i7ac5520bfa654a33b8eea56f2b4c5e97_148">35</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7ac5520bfa654a33b8eea56f2b4c5e97_151">PART II. OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i7ac5520bfa654a33b8eea56f2b4c5e97_151">36</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i7ac5520bfa654a33b8eea56f2b4c5e97_154">Item 1.</a></span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7ac5520bfa654a33b8eea56f2b4c5e97_154">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i7ac5520bfa654a33b8eea56f2b4c5e97_154">36</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i7ac5520bfa654a33b8eea56f2b4c5e97_157">Item 1A.</a></span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7ac5520bfa654a33b8eea56f2b4c5e97_157">Risk Factors</a></span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i7ac5520bfa654a33b8eea56f2b4c5e97_160">36</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i7ac5520bfa654a33b8eea56f2b4c5e97_163">Item 2.</a></span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7ac5520bfa654a33b8eea56f2b4c5e97_163">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i7ac5520bfa654a33b8eea56f2b4c5e97_163">84</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i7ac5520bfa654a33b8eea56f2b4c5e97_166">Item 3.</a></span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7ac5520bfa654a33b8eea56f2b4c5e97_166">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i7ac5520bfa654a33b8eea56f2b4c5e97_166">84</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i7ac5520bfa654a33b8eea56f2b4c5e97_169">Item 4.</a></span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7ac5520bfa654a33b8eea56f2b4c5e97_169">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i7ac5520bfa654a33b8eea56f2b4c5e97_169">84</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i7ac5520bfa654a33b8eea56f2b4c5e97_172">Item 5.</a></span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7ac5520bfa654a33b8eea56f2b4c5e97_172">Other Information</a></span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i7ac5520bfa654a33b8eea56f2b4c5e97_172">85</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i7ac5520bfa654a33b8eea56f2b4c5e97_178">Item 6.</a></span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7ac5520bfa654a33b8eea56f2b4c5e97_178">Exhibits</a></span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i7ac5520bfa654a33b8eea56f2b4c5e97_178">86</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7ac5520bfa654a33b8eea56f2b4c5e97_181">Signatures</a></span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i7ac5520bfa654a33b8eea56f2b4c5e97_181">88</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:18pt;padding-left:3pt;padding-right:3pt;text-align:center"><span><br/></span></div></div></div><div id="i7ac5520bfa654a33b8eea56f2b4c5e97_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE ABOUT FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q for the quarter ended June&#160;30, 2026 (this &#8220;Quarterly Report&#8221;) contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and Section 27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). All statements contained in this Quarterly Report, other than statements of historical fact, including, without limitation, statements regarding any future payouts under our contingent value rights (&#8220;CVRs&#8221;) issued in connection with the acquisition of Spyre Therapeutics, Inc. (the &#8220;Asset Acquisition&#8221;); our future results of operations and financial position; our business strategy, including our ability to elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients and to develop best-in-class therapeutics for inflammatory bowel disease (&#8220;IBD&#8221;), rheumatoid arthritis (&#8220;RA&#8221;), psoriatic arthritis (&#8220;PsA&#8221;), axial spondyloarthritis (&#8220;axSpA&#8221;) and other immune-mediated diseases that meaningfully improve both efficacy and convenience compared to today's standard of care and our ability to develop first-in-class therapeutics for rheumatic diseases (&#8220;RD&#8221;); our plans to expand the development of our product candidates, including SPY002, to indications beyond IBD and RD; our ability to achieve the expected benefits or opportunities with respect to our product candidates, including their potential commercialization; the potential consistency of the SPY001, SPY002, SPY072 and SPY003 Phase 1 trial and Phase 2 trial final data readouts with previously disclosed data for our programs; expectations regarding the drug delivery of our product candidates, including in the form of a subcutaneous injection; the planned dosing regimen for SPY001, SPY002, SPY072 and SPY003, and combinations thereof, including the potential for a Q3M-Q6M dosing profile and the potential for such dosing profile to be the leading product profile in IBD and RD; our non-clinical and&#160;clinical development activities, including our plans for and timing of cohort initiation and data readouts for the ongoing SKYWAY Phase 2 basket trial and SKYLINE Phase 2 platform trial, and the inclusion of each rational combination in Part B of the SKYLINE Phase 2 platform trial and the number of data readouts expected to be delivered in 2026 and 2027; estimated market sizes and potential growth opportunities; the potential efficacy, tolerability, convenience, commercial viability and safety profile of our product candidates, including in combinations; the potential therapeutic benefits and economic value of our product candidates as monotherapies or in combinations and their extended half-life; our ability to achieve the expected benefits or opportunities and related timing with respect to the Asset Acquisition; the expected impact of macroeconomic conditions, including inflation, increasing interest rates and volatile market conditions, and current or potential bank failures, as well as global events, including the ongoing military conflict between the United States and Iran and Ukraine and Russia, the conflicts in the Middle East, and geopolitical tensions between the United States and other countries, including China, on our operations, and the implementation of changes in law, tariffs, sanctions, export or import controls, and other government measures that could impact our business operations, including restricting international trade by the United States, China or other countries; are forward-looking statements. The words &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;potentially,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;predict,&#8221; &#8220;target,&#8221; &#8220;intend,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;project,&#8221; &#8220;plan,&#8221; &#8220;expect,&#8221; and similar expressions that convey uncertainty of future events or outcomes are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to, uncertainties and risks arising from regulatory feedback, including potential disagreement by regulatory authorities with our interpretation of data and our ongoing or planned clinical trials for our product candidates, including our plans for and timing of cohort initiation for combination arms for the ongoing SKYLINE Phase 2 platform trial across different jurisdictions; the unpredictable relationship between preclinical study results and clinical study results; the potential for interim data not being delivered within expected time frames or final clinical data not being consistent with or different than the previously disclosed data for our programs; the impacts of adverse events or disappointing results in clinical trials of third parties, including our competitors developing product candidates that target similar mechanisms of action and/or indications as our product candidates; the expected or potential impact of macroeconomic conditions, including inflationary pressures, rising interest rates, general economic slowdown or a recession, changes in tariff/trade and monetary policy, volatile market conditions and financial institution instability, as well as geopolitical instability, including the ongoing military conflicts between the United States and Iran and Ukraine and Russia, conflicts in the Middle East, and geopolitical tensions between the United States and other countries, including China, on our operations; the implementation of changes in law, tariffs, sanctions, export or import controls, and other government measures that could impact our business operations, including restricting international trade by the United States, China or other countries and the BIOSECURE Act; and those uncertainties and factors described in Item 1A, &#8220;Risk Factors&#8221; included in this Quarterly Report. Moreover, we operate in a very </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:18pt;padding-left:3pt;padding-right:3pt;text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties, and assumptions, the forward-looking events and circumstances discussed in this Quarterly Report may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this report to conform these statements to actual results or to changes in our expectations, except as required by law. You should read this Quarterly Report with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially different from what we expect.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless the context indicates otherwise, as used in this Quarterly Report, the terms &#8220;Spyre,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Spyre Therapeutics, Inc., a Delaware corporation, and its consolidated subsidiaries taken as a whole. &#8220;Spyre&#8221; and all product candidate names are our common law trademarks. This Quarterly Report contains additional trade names, trademarks and service marks of other companies, which are the property of their respective owners. We do not intend our use or display of other companies&#8217; trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, these other companies.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All references to &#8220;our product candidates,&#8221; &#8220;our programs&#8221; and &#8220;our pipeline&#8221; in this Quarterly Report refer to the research programs with respect to which we have signed a license agreement for or have the option to acquire intellectual property license rights to pursuant to that certain antibody discovery and option agreement, dated May 25, 2023, and subsequently amended and restated on September 29, 2023 and May 14, 2024, by and among us, Paragon Therapeutics, Inc. (&#8220;Paragon&#8221;) and Parapyre Holding LLC (&#8220;Parapyre&#8221;) (as amended, the &#8220;Paragon Agreement&#8221;).</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:18pt;padding-left:3pt;padding-right:3pt;text-align:center"><span><br/></span></div></div></div><div id="i7ac5520bfa654a33b8eea56f2b4c5e97_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I. &#8211; Financial Information</span></div><div id="i7ac5520bfa654a33b8eea56f2b4c5e97_16"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Financial Statements (Unaudited).</span></div><div id="i7ac5520bfa654a33b8eea56f2b4c5e97_19"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Spyre Therapeutics, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited, in thousands, except share and per share amounts)</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">CURRENT ASSETS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-32">162,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-33">85,721</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-34">983,339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-35">670,812</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-36">27,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-37">21,248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-38">1,173,003</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-39">777,781</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">TOTAL ASSETS</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-40">1,173,003</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-41">777,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">CURRENT LIABILITIES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-42">5,722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-43">8,904</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">CVR liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-44">31,350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-45">22,820</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accrued and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-46">26,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-47">26,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Related party accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="3" id="f-48">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="3" id="f-49">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-50">63,302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-51">58,685</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current CVR liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-52">7,270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-53">3,860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-54">1,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="3" id="f-55">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">TOTAL LIABILITIES</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-56">71,862</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-57">62,545</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Commitments and Contingencies (Notes 6 and 7)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-3" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-58"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-4" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-59"></ix:nonFraction></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Series A non-voting convertible preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-9" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-60"><ix:nonFraction unitRef="usdPerShare" contextRef="c-10" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-61">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-62"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-63">1,086,341</ix:nonFraction></ix:nonFraction> shares authorized as of June&#160;30, 2026 and December&#160;31, 2025; <ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-64"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-65"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-66"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-67">346,045</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding as of June&#160;30, 2026 and December&#160;31, 2025.</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:num-dot-decimal" scale="3" id="f-68">146,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:num-dot-decimal" scale="3" id="f-69">146,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Series B non-voting convertible preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-11" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-70"><ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-71">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-12" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-72"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-73">271,625</ix:nonFraction></ix:nonFraction> shares authorized as of June 30, 2026 and December 31, 2025; <ix:nonFraction unitRef="shares" contextRef="c-11" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-74"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-75">nil</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-12" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-76"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-77">16,667</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of June&#160;30, 2026 and December&#160;31, 2025, respectively.</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-78">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:num-dot-decimal" scale="3" id="f-79">9,395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-80"><ix:nonFraction unitRef="usdPerShare" contextRef="c-14" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-81">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-13" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-82"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-83">8,642,034</ix:nonFraction></ix:nonFraction> shares authorized as of June&#160;30, 2026 and December&#160;31, 2025; <ix:nonFraction unitRef="shares" contextRef="c-13" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-84"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-85"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-86"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-87">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding as of June&#160;30, 2026 and December&#160;31, 2025.</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-88">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-89">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-90"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-91">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-92"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-93">400,000,000</ix:nonFraction></ix:nonFraction> shares authorized as of June&#160;30, 2026 and December&#160;31, 2025; <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-94"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-95">88,064,133</ix:nonFraction></ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-96"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-97">78,189,811</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of June&#160;30, 2026 and December&#160;31, 2025, respectively.</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-98">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-99">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-100">2,189,936</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-101">1,686,167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accumulated other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-102">2,396</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-103">869</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-104">1,232,840</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-105">1,127,635</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">TOTAL STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-106">1,101,141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-107">715,236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; EQUITY</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-108">1,173,003</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-109">777,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i7ac5520bfa654a33b8eea56f2b4c5e97_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Spyre Therapeutics, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited, in thousands, except share and per share amounts)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:52.769%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.982%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"/><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="f-110">65,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="f-111">40,145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="f-112">125,914</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="f-113">81,768</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">General and administrative </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-114">16,136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-115">11,790</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-116">31,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-117">23,734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gain on sale of in-process research and development asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" format="ixt:num-dot-decimal" scale="3" id="f-118">40,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" format="ixt:num-dot-decimal" scale="3" id="f-119">10,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" format="ixt:num-dot-decimal" scale="3" id="f-120">70,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" format="ixt:num-dot-decimal" scale="3" id="f-121">10,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-122">41,639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-123">41,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-124">87,280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-125">95,502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-126">41,639</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-127">41,935</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-128">87,280</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-129">95,502</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:InvestmentIncomeNet" format="ixt:num-dot-decimal" scale="3" id="f-130">10,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:InvestmentIncomeNet" format="ixt:num-dot-decimal" scale="3" id="f-131">5,874</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InvestmentIncomeNet" format="ixt:num-dot-decimal" scale="3" id="f-132">17,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:InvestmentIncomeNet" format="ixt:num-dot-decimal" scale="3" id="f-133">12,367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other (expense) income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-134">4,614</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-135">656</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-136">34,973</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-137">1,630</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total other income (expense)</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-138">5,439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-139">5,218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-140">17,925</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-141">13,997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Loss before income tax expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-142">36,200</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-143">36,717</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-144">105,205</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-145">81,505</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-146">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-147">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-148">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-149">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-150">36,200</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-151">36,717</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-152">105,205</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-153">81,490</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss per share, basic and diluted, Series A Preferred Stock</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-18" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-154"><ix:nonFraction unitRef="usdPerShare" contextRef="c-18" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-155">14.60</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-19" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-156"><ix:nonFraction unitRef="usdPerShare" contextRef="c-19" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-157">19.62</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-20" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-158"><ix:nonFraction unitRef="usdPerShare" contextRef="c-20" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-159">43.77</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-21" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-160"><ix:nonFraction unitRef="usdPerShare" contextRef="c-21" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-161">43.57</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted-average Series A non-voting convertible preferred stock outstanding, basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-18" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-162"><ix:nonFraction unitRef="shares" contextRef="c-18" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-163">346,045</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-19" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-164"><ix:nonFraction unitRef="shares" contextRef="c-19" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-165">346,045</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-20" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-166"><ix:nonFraction unitRef="shares" contextRef="c-20" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-167">346,045</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-168"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-169">346,045</ix:nonFraction></ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss per share, basic and diluted, Series B Preferred Stock</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-22" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-170"><ix:nonFraction unitRef="usdPerShare" contextRef="c-22" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-171">14.60</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-23" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-172"><ix:nonFraction unitRef="usdPerShare" contextRef="c-23" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-173">19.62</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-24" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-174"><ix:nonFraction unitRef="usdPerShare" contextRef="c-24" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-175">43.77</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-25" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-176"><ix:nonFraction unitRef="usdPerShare" contextRef="c-25" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-177">43.57</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted-average Series B non-voting convertible preferred stock outstanding, basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-22" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-178"><ix:nonFraction unitRef="shares" contextRef="c-22" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-179">15,385</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-23" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-180"><ix:nonFraction unitRef="shares" contextRef="c-23" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-181">16,667</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-24" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-182"><ix:nonFraction unitRef="shares" contextRef="c-24" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-183">16,022</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-184"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-185">16,667</ix:nonFraction></ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss per share, basic and diluted, common</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-26" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-186"><ix:nonFraction unitRef="usdPerShare" contextRef="c-26" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-187">0.36</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-27" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-188"><ix:nonFraction unitRef="usdPerShare" contextRef="c-27" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-189">0.49</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-28" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-190"><ix:nonFraction unitRef="usdPerShare" contextRef="c-28" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-191">1.09</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-29" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-192"><ix:nonFraction unitRef="usdPerShare" contextRef="c-29" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-193">1.09</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted-average common stock outstanding, basic and diluted</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-26" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-194"><ix:nonFraction unitRef="shares" contextRef="c-26" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-195">84,729,435</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-196"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-197">60,333,838</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-28" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-198"><ix:nonFraction unitRef="shares" contextRef="c-28" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-199">81,656,119</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-29" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-200"><ix:nonFraction unitRef="shares" contextRef="c-29" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-201">60,300,073</ix:nonFraction></ix:nonFraction></span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><ix:footnote id="fn-1" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt">Includes de minimis related party expenses for the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">three</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> months ended June&#160;30, 2026 and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Includes related party expenses of $<ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="f-202">3.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="f-203">2.6</ix:nonFraction> million for the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">six</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> months ended June&#160;30, 2026 and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2025, respectively</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></ix:footnote></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><ix:footnote id="fn-2" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt">Includes related party expenses of $<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="f-204"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="f-205">0.2</ix:nonFraction></ix:nonFraction> million for the three months ended June&#160;30, 2026 and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2025, and</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> $<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="f-206"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="f-207">0.5</ix:nonFraction></ix:nonFraction> million for the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">six months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">June&#160;30, 2026 and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></ix:footnote></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i7ac5520bfa654a33b8eea56f2b4c5e97_28"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Spyre Therapeutics, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited, in thousands)</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.303%"><tr><td style="width:1.0%"/><td style="width:46.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.471%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.471%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.471%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.487%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-210">36,200</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-211">36,717</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-212">105,205</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-213">81,490</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="f-214">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" id="f-215">36</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="f-216">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" id="f-217">22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Unrealized (loss) gain on marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-218">1,629</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-219">192</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-220">3,265</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-221">296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total comprehensive loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-222">37,829</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-223">36,945</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-224">108,470</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-225">81,216</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i7ac5520bfa654a33b8eea56f2b4c5e97_31"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Spyre Therapeutics, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Changes in </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Convertible Preferred Stock and Stockholders&#8217; Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited, in thousands)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.219%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.207%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.207%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.207%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.914%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.207%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.914%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.207%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.792%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.207%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.207%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.768%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.207%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.768%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.207%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.965%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="57" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three and Six Months Ended June 30, 2026</span></div></td></tr><tr style="height:32pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Series A <br/>Non-Voting Convertible<br/>Preferred Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Series B <br/>Non-Voting Convertible<br/>Preferred Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Additional</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Paid-In</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Capital </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Comprehensive</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Income</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Deficit </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Stockholders'</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Equity</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Balances - December 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-34" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="f-226">346</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-227">146,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-35" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="f-228">17</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-229">9,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-36" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-230">78,190</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-231">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-232">1,686,167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-233">869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-234">1,127,635</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-235">715,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Issuance of common stock in connection with at-the-market offering program, net of financing costs</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-40" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="f-236">296</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-237">9,747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-238">9,747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Issuance of common stock in connection with exercise of stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-40" decimals="-3" name="syre:StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan" scale="3" id="f-239">354</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="syre:StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan" format="ixt:num-dot-decimal" scale="3" id="f-240">3,663</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="syre:StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan" format="ixt:num-dot-decimal" scale="3" id="f-241">3,663</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-242">12,806</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-243">12,806</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unrealized loss on marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-244">1,636</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-245">1,636</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-246">69,005</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-247">69,005</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Balances - March 31, 2026</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-45" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="f-248">346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-249">146,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-46" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="f-250">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-251">9,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-47" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-252">78,840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-253">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-254">1,712,383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-255">767</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-256">1,196,640</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-257">670,811</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Conversion of Series B Non-Voting Convertible Preferred Stock to common stock</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-52" decimals="INF" sign="-" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="3" id="f-258">17</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-259">9,395</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-53" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="3" id="f-260">667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-261">9,395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:fixed-zero" scale="3" id="f-262">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Issuance of common stock in connection with follow-on offering, net of offering costs</span></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-55" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-263">7,475</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-264">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-265">434,897</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-266">434,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Issuance of common stock in connection with exercise of stock options and employee stock purchase plan</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-55" decimals="-3" name="syre:StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan" format="ixt:num-dot-decimal" scale="3" id="f-267">1,083</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="syre:StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan" format="ixt:num-dot-decimal" scale="3" id="f-268">19,749</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="syre:StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan" format="ixt:num-dot-decimal" scale="3" id="f-269">19,749</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-270">13,512</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-271">13,512</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unrealized loss on marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-272">1,629</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-273">1,629</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-274">36,200</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-275">36,200</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Balances - June 30, 2026</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-58" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="f-276">346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-277">146,425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-59" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="3" id="f-278">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-279">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-60" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-280">88,064</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-281">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-282">2,189,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-283">2,396</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-284">1,232,840</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-285">1,101,141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i7ac5520bfa654a33b8eea56f2b4c5e97_34"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="padding-right:-13.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:729.00pt"><tr><td style="width:1.0pt"/><td style="width:199.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:37.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:51.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:37.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:34.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:49.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:57.25pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="57" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three and Six Months Ended June 30, 2025</span></div></td></tr><tr style="height:42pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Series A <br/>Non-Voting Convertible<br/>Preferred Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Series B <br/>Non-Voting Convertible<br/>Preferred Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Additional</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Paid-In</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Capital </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Comprehensive</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Income</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Deficit </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Stockholders'</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Equity</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-64" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="f-286">346</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-287">146,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-65" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="f-288">17</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-289">9,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-66" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-290">60,257</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-291">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-292">1,334,223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-293">180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-294">972,432</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-295">517,804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:29pt"><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Issuance of common stock in connection with exercise of stock options and employee stock purchase plan</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-71" decimals="-3" name="syre:StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan" scale="3" id="f-296">19</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="syre:StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan" scale="3" id="f-297">218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="syre:StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan" scale="3" id="f-298">218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-299">8,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-300">8,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Foreign currency translation adjustment</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" id="f-301">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" id="f-302">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unrealized gain on marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-303">488</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-304">488</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-305">44,773</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-306">44,773</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Balances - March 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-76" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="f-307">346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-308">146,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-77" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="f-309">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-310">9,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-78" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-311">60,276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-312">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-313">1,343,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-314">682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-315">1,017,205</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-316">482,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:29pt"><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Issuance of common stock in connection with exercise of stock options and employee stock purchase plan</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-83" decimals="-3" name="syre:StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan" scale="3" id="f-317">97</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="syre:StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan" scale="3" id="f-318">730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="syre:StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan" scale="3" id="f-319">730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-320">9,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-321">9,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Foreign currency translation adjustment</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" id="f-322">36</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" id="f-323">36</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unrealized loss on marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-324">192</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-325">192</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-326">36,717</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-327">36,717</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Balances - June 30, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-87" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="f-328">346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-329">146,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-88" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="f-330">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-331">9,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-89" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-332">60,373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-333">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-334">1,353,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-335">454</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-336">1,053,922</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-337">455,773</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;padding-right:-13.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i7ac5520bfa654a33b8eea56f2b4c5e97_37"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Spyre Therapeutics, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited, in thousands)</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"/><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">CASH FLOWS FROM OPERATING ACTIVITIES</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-338">105,205</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-339">81,490</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-340">26,318</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-341">18,237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Change in fair value of CVR liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" format="ixt:num-dot-decimal" scale="3" id="f-342">34,873</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" format="ixt:num-dot-decimal" scale="3" id="f-343">1,800</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Gain on sale of in-process research and development asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" format="ixt:num-dot-decimal" scale="3" id="f-344">70,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" format="ixt:num-dot-decimal" scale="3" id="f-345">10,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Net accretion of discount on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="3" id="f-346">5,152</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="3" id="f-347">4,655</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Interest proceeds from maturities of zero coupon U.S. Treasury Bills</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="syre:InterestProceedsDebtSecurities" scale="3" id="f-348">683</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="syre:InterestProceedsDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-349">1,760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" format="ixt:num-dot-decimal" scale="3" id="f-350">3,182</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" format="ixt:num-dot-decimal" scale="3" id="f-351">3,046</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Accrued and other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="f-352">225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-353">8,299</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Related party accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" scale="3" id="f-354">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" scale="3" id="f-355">572</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-356">5,841</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-357">3,784</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-358">127,249</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-359">87,557</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">CASH FLOWS FROM INVESTING ACTIVITIES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Proceeds from maturities and sales of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-360">217,187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-361">178,249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="f-362">528,510</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="f-363">106,312</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Proceeds from sale of in-process research and development asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-364">70,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:ProceedsFromSaleOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-365">7,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Net cash (used in) provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-366">241,323</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-367">78,937</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">CASH FLOWS FROM FINANCING ACTIVITIES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Proceeds from issuance of common stock in connection with follow-on offering, net of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" format="ixt:num-dot-decimal" scale="3" id="f-368">435,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" format="ixt:fixed-zero" scale="3" id="f-369">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Proceeds from issuance of common stock in connection with at-the-market offering program, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="syre:ProceedsFromIssuanceOfCommonStockAtTheMarketOfferingsNet" format="ixt:num-dot-decimal" scale="3" id="f-370">9,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="syre:ProceedsFromIssuanceOfCommonStockAtTheMarketOfferingsNet" format="ixt:fixed-zero" scale="3" id="f-371">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Payment of deferred offering costs in connection with shelf registration</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="syre:PaymentForDeferredOfferingCosts" scale="3" id="f-372">454</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="syre:PaymentForDeferredOfferingCosts" scale="3" id="f-373">93</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Payments related to contingent value rights liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="syre:PaymentsRelatedToContingentValueRightsLiability" format="ixt:num-dot-decimal" scale="3" id="f-374">22,933</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="syre:PaymentsRelatedToContingentValueRightsLiability" format="ixt:fixed-zero" scale="3" id="f-375">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Proceeds from employee stock option exercises and employee stock plan purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="3" id="f-376">23,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="f-377">949</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-378">444,858</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="f-379">856</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-380">76,286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-381">7,764</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">CASH AND CASH EQUIVALENTS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-382">85,721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-383">89,423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">End of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-384">162,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-385">81,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Supplemental Disclosure of Non-Cash Financing Information:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Proceeds from stock option exercises received in subsequent period</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="syre:IssuanceOfConvertiblePreferredStockRelatedToPrivatePlacementUnpaidAmount" scale="3" id="f-386">157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="syre:IssuanceOfConvertiblePreferredStockRelatedToPrivatePlacementUnpaidAmount" format="ixt:fixed-zero" scale="3" id="f-387">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Allocation of deferred offering costs against proceeds of issuance of common stock</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="syre:DeferredOfferingCostsAllocatedAmountOfProceedsOfIssuanceOfCommonStock" scale="3" id="f-388">345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="syre:DeferredOfferingCostsAllocatedAmountOfProceedsOfIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="f-389">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Unpaid deferred offering costs in connection with shelf registration</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="syre:DeferredOfferingCostsUnpaidAmount" scale="3" id="f-390">301</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="syre:DeferredOfferingCostsUnpaidAmount" format="ixt:fixed-zero" scale="3" id="f-391">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Conversion of Series B non-voting convertible preferred stock into common stock</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ConversionOfStockAmountConverted1" format="ixt:num-dot-decimal" scale="3" id="f-392">9,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:ConversionOfStockAmountConverted1" format="ixt:fixed-zero" scale="3" id="f-393">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i7ac5520bfa654a33b8eea56f2b4c5e97_43"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Spyre Therapeutics, Inc.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Unaudited Condensed Consolidated Financial Statements</span></div><div id="i7ac5520bfa654a33b8eea56f2b4c5e97_46"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="f-394" continuedAt="f-394-1" escape="true">The Company and Basis of Presentation</ix:nonNumeric></span></div><ix:continuation id="f-394-1" continuedAt="f-394-2"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Spyre Therapeutics, Inc., formerly Aeglea BioTherapeutics, Inc. (&#8220;Spyre&#8221; or the &#8220;Company&#8221;), is a clinical stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients. The Company was formed as a Limited Liability Company in Delaware on December 16, 2013 under the name Aeglea BioTherapeutics Holdings, LLC and was converted from a Delaware LLC to a Delaware corporation on March 10, 2015. On June 22, 2023, the Company acquired the assets of Spyre Therapeutics, Inc., a privately held biotechnology company (the &#8220;Asset Acquisition&#8221;), and on November 27, 2023, the Company completed its corporate rebranding, changing the name of the Company to Spyre Therapeutics, Inc. The Company operates in <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-395">one</ix:nonFraction> segment and has its principal offices in Waltham, Massachusetts.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Asset Acquisition, a non-transferable contingent value right (&#8220;CVR&#8221;) was distributed to stockholders of record of the Company as of the close of business on July 3, 2023 (the &#8220;Legacy Stockholders&#8221;). Holders of the CVRs will be entitled to receive certain cash payments from proceeds received by the Company prior to the third anniversary of the contingent value rights agreement (the "CVR Agreement") we entered into with Equiniti Trust Company LLC (f/k/a American Stock Transfer &amp; Trust Company LLC) as rights agent in connection with the Asset Acquisition, if any, related to the disposition or monetization of its legacy assets during the <ix:nonNumeric contextRef="c-94" name="syre:AssetAcquisitionCashPaymentThresholdPeriod" format="ixt-sec:durwordsen" id="f-396">one-year</ix:nonNumeric> period following the closing of the Asset Acquisition.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 6, 2024, the Company entered into a sales agreement (the &#8220;2024 Sales Agreement&#8221;) with TD Securities (USA) LLC as its agent, pursuant to which the Company may issue and sell up to $<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-5" name="syre:SaleOfStockAuthorizedAmount" scale="6" id="f-397">200.0</ix:nonFraction>&#160;million of shares of common stock under an at-the-market (&#8220;ATM&#8221;) offering program. During the three and six months ended June&#160;30, 2026, the Company sold an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-96" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:fixed-zero" scale="0" id="f-398">nil</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-97" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-399">296,396</ix:nonFraction>, respectively, shares of common stock under the ATM offering program pursuant to the 2024 Sales Agreement resulting in net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="f-400">9.7</ix:nonFraction>&#160;million. The 2024 Sales Agreement was terminated on June 26, 2026 and the Company concurrently entered into a new sales agreement (the &#8220;2026 Sales Agreement&#8221;) with TD Securities (USA) LLC as its agent, pursuant to which the Company may issue and sell up to $<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-5" name="syre:SaleOfStockAuthorizedAmount" scale="6" id="f-401">500.0</ix:nonFraction>&#160;million of shares of common stock under an ATM offering program. During the three months ended June 30, 2026, the Company did <ix:nonFraction unitRef="shares" contextRef="c-99" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:fixed-zero" scale="0" id="f-402">not</ix:nonFraction> sell any shares under the ATM offering program pursuant to the 2026 Sales Agreement. As of June&#160;30, 2026, $<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-5" name="syre:SaleOfStockRemainingAuthorizedAmount" scale="6" id="f-403">500.0</ix:nonFraction>&#160;million remained available for sale under the 2026 Sales Agreement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 13, 2025, the Company entered into an underwriting agreement (the &#8220;October 2025 Underwriting Agreement&#8221;), pursuant to which the Company sold an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-100" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-404">17,094,594</ix:nonFraction> shares of its common stock, inclusive of <ix:nonFraction unitRef="shares" contextRef="c-101" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-405">2,229,729</ix:nonFraction> shares pursuant to the full exercise of the underwriters' over-allotment option, at a public offering price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-102" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-406">18.50</ix:nonFraction>, resulting in net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="f-407">296.4</ix:nonFraction>&#160;million after deducting approximately $<ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-5" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="f-408">19.9</ix:nonFraction>&#160;million of underwriting discounts and other offering costs (the &#8220;October 2025 Offering&#8221;). The over-allotment option was exercised in full on October 14, 2025 and the transaction closed on October 15, 2025.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 13, 2026, the Company entered into an underwriting agreement (the &#8220;April 2026 Underwriting Agreement&#8221;), pursuant to which the Company sold an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-103" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-409">7,475,000</ix:nonFraction> shares of its common stock, inclusive of <ix:nonFraction unitRef="shares" contextRef="c-104" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-410">975,000</ix:nonFraction> shares pursuant to the full exercise of the underwriters' over-allotment option, at a public offering price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-105" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-411">62.00</ix:nonFraction>, resulting in net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="f-412">435.2</ix:nonFraction>&#160;million after deducting approximately $<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-5" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="f-413">28.2</ix:nonFraction>&#160;million of underwriting discounts and other offering costs (the &#8220;April 2026 Offering&#8221;). The over-allotment option was exercised in full on April 15, 2026 and the transaction closed on April 16, 2026.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a clinical stage biotechnology company with a limited operating history, and due to its significant research and development expenditures, the Company has generated operating losses since its inception and has not generated any revenue from the commercial sale of any products. There can be no assurance that profitable operations will ever be achieved, and, if achieved, whether profitability can be sustained on a continuing basis.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><ix:continuation id="f-394-2"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its inception and through June&#160;30, 2026, the Company has funded its operations by raising an aggregate of approximately $<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-8" name="syre:ProceedsFromRaisingCapital" scale="9" id="f-414">2.1</ix:nonFraction>&#160;billion of gross proceeds from the sale and issuance of convertible preferred stock and common stock, pre-funded warrants, the collection of grant proceeds, and the licensing of its product rights for commercialization of pegzilarginase in Europe and certain countries in the Middle East. As of June&#160;30, 2026, Spyre had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-8" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="9" id="f-415">1.2</ix:nonFraction>&#160;billion, and cash, cash equivalents, and marketable securities of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-8" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="9" id="f-416">1.1</ix:nonFraction>&#160;billion.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on its current operating plans, the Company has sufficient resources to fund operations for at least one year from the issuance date of these financial statements with existing cash, cash equivalents, and marketable securities. The Company will need to secure additional financing in the future to fund additional research and development, and before a commercial drug can be produced, marketed and sold. If the Company is unable to obtain additional financing or generate license or product revenue, the lack of liquidity could have a material adverse effect on the Company.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-417" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (&#8220;U.S. GAAP&#8221;) as defined by the Financial Accounting Standards Board (&#8220;FASB&#8221;) and include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Financial Information</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interim condensed consolidated financial statements included in this Quarterly Report on Form 10-Q are unaudited. The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and reflect, in the opinion of management, all adjustments of a normal and recurring nature that are necessary for a fair statement of the Company&#8217;s financial position as of June&#160;30, 2026, and its results of operations for the three and six months ended June&#160;30, 2026 and 2025, changes in convertible preferred stock and stockholders&#8217; equity for the three and six months ended June&#160;30, 2026 and 2025, and cash flows for the six months ended June&#160;30, 2026 and 2025. The results of operations for the three and six months ended June&#160;30, 2026 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2026 or for any other future annual or interim period. The December&#160;31, 2025 balance sheet was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP for complete financial statements. These financial statements should be read in conjunction with the audited financial statements included in the Company&#8217;s Form 10-K for the year ended December&#160;31, 2025 (the &#8220;Annual Report&#8221;) as filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) on February 19, 2026.</span></div></ix:continuation><div id="i7ac5520bfa654a33b8eea56f2b4c5e97_49"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-418" continuedAt="f-418-1" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="f-418-1" continuedAt="f-418-2"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These interim condensed consolidated financial statements have been prepared in accordance with U.S. GAAP and SEC instructions for interim financial information, and should be read in conjunction with the Annual Report. Significant accounting policies and other disclosures normally provided have been omitted since such items are disclosed in the Annual Report. The Company uses the same accounting policies in preparing quarterly and annual financial statements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes from the significant accounting policies and estimates disclosed in the Notes titled &#8220;1. The Company and Basis of Presentation&#8221; and "2. Summary of Significant Accounting Policies&#8221; of the Annual Report, except as disclosed below:</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="f-419" continuedAt="f-419-1" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Value Rights</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2026, Contingent Value Rights are no longer a significant accounting policy. The Company determined that its future payment obligations under the CVR Agreement no longer qualify as derivatives under ASC 815, Derivatives and Hedging, as all contingencies have been resolved. Accordingly, the Company has measured the fair value of its CVR liability by discounting the estimated future payments to be made under the CVR Agreement using the Company&#8217;s weighted average cost of capital. This fair value measurement is based on inputs observable in the market and thus represents a Level 2 measurement as defined in ASC 820, Fair Value Measurement. The estimated value of the CVR consideration is based upon </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><ix:continuation id="f-418-2"><ix:continuation id="f-419-1"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">available information and certain assumptions which the Company's management believes are reasonable under the circumstances. The ultimate payout under the CVRs may differ materially from the assumptions used in determining the fair value of the CVR consideration.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-420" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no recent accounting pronouncements or changes in accounting pronouncements adopted during the three months ended June&#160;30, 2026 that are of significance or potential significance to the Company.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Not Yet Adopted Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued Accounting Standards Update 2024-03 (&#8220;ASU 2024-03&#8221;) Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses to require more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation, amortization, and depletion) included in certain expense captions presented on the face of the income statement. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either (1) prospectively to financial statements issued for reporting periods after the effective date of this ASU 2024-03 or (2) retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact ASU 2024-03 will have on its disclosures.</span></div></ix:nonNumeric></ix:continuation><div id="i7ac5520bfa654a33b8eea56f2b4c5e97_52"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-421" continuedAt="f-421-1" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="f-421-1" continuedAt="f-421-2"><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures and reports certain financial instruments as assets and liabilities at fair value on a recurring basis. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="f-422" continuedAt="f-422-1" escape="true">The following tables set forth the fair value of the Company&#8217;s financial assets and liabilities at fair value on a recurring basis based on the three-tier fair value hierarchy (in thousands):</ix:nonNumeric></span></div><ix:continuation id="f-422-1" continuedAt="f-422-2"><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2026</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-423">139,330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="3" id="f-424">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="3" id="f-425">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-426">139,330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 15.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-427">256,457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-428">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-429">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-430">256,457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 15.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-431">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-432">176,095</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-433">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-434">176,095</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 15.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-435">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-436">425,578</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-437">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-438">425,578</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 15.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-439">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-440">146,141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-441">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-442">146,141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total financial assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-443">395,787</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-444">747,814</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-445">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-446">1,143,601</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 12.37pt;text-align:left;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CVR liability</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="3" id="f-447">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-448">38,620</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="3" id="f-449">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-450">38,620</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-451">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-452">38,620</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-453">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-454">38,620</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><ix:continuation id="f-421-2" continuedAt="f-421-3"><ix:continuation id="f-422-2"><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-3" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-455">74,004</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-3" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="3" id="f-456">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-3" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="3" id="f-457">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-458">74,004</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-459">266,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-460">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-461">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-462">266,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-463">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-464">119,590</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-465">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-466">119,590</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 15.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-467">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-468">194,355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-469">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-470">194,355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 15.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-471">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-472">100,790</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-473">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-474">100,790</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total financial assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-475">340,068</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-476">414,735</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-477">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-478">754,803</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CVR liability</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="3" id="f-479">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="3" id="f-480">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-481">26,680</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-482">26,680</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-483">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-484">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-485">26,680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-486">26,680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the fair value of money market funds and U.S. government treasury securities on quoted prices in active markets for identical assets or liabilities. The Level 2 assets include U.S. government agency securities, commercial paper and corporate bonds, and are valued based on quoted prices for similar assets in active markets and inputs other than quoted prices that are derived from observable market data. The Company evaluates transfers between levels at the end of each reporting period. There were no financial asset transfers between Level 1, Level 2, or Level 3 during the periods presented.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CVR Liability </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Asset Acquisition, a non-transferable CVR was distributed to the Legacy Stockholders. Holders of the CVR are entitled to receive certain cash payments from proceeds received by the Company for a <ix:nonNumeric contextRef="c-94" name="syre:AssetAcquisitionStockholderPaymentPeriod" format="ixt-sec:durwordsen" id="f-487">three-year</ix:nonNumeric> period ending July 3, 2026, related to the disposition or monetization of the Company&#8217;s legacy assets for a period of <ix:nonNumeric contextRef="c-94" name="syre:AssetAcquisitionCashPaymentThresholdPeriod" format="ixt-sec:durwordsen" id="f-488">one year</ix:nonNumeric> following the closing of the Asset Acquisition.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2025, the fair value of the CVR liability was determined using the probability weighted discounted cash flow method to estimate future cash flows associated with the sale of the legacy assets. Analogous to a dividend being declared/approved in one period and paid out in another, the liability was recorded at the date of approval, June 22, 2023, as a common stock dividend, returning capital to the Legacy Stockholders. Changes in fair value of the liability were recognized as a component of Other income (expense), net in the consolidated statement of operations and comprehensive loss in each reporting period. The liability value was based on significant inputs not observable in the market such as estimated cash flows, estimated probabilities of regulatory success, and discount rates, which represent a Level 3 measurement within the fair value hierarchy.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2026, all contingencies related to the disposition or monetization of the Company&#8217;s legacy assets are resolved and the fair value of the CVR liability was determined by discounting future estimated payments to holders of the CVR. Changes in fair value of the liability will be recognized as a component of Other income (expense), net in the consolidated statement of operations and comprehensive loss in each reporting period. The liability is based on inputs observable in the market such as estimated discount rates which represent a Level 2 measurement within the fair value hierarchy.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="f-489" continuedAt="f-489-1" escape="true">The significant inputs used to estimate the fair value of the CVR liability were as follows:</ix:nonNumeric></span></div><ix:continuation id="f-489-1"><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.052%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2026</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-adjusted discount rate</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-153" decimals="4" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="f-490">12.10</ix:nonFraction>%</span></div></td></tr></table></div></ix:continuation><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in fair value between December&#160;31, 2025 and June&#160;30, 2026 was a $<ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="f-491">34.9</ix:nonFraction>&#160;million increase, primarily driven by the achievement status of certain milestones and the receipt of certain cash consideration within the CVR term and time value of money adjustments, partially offset by a $<ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="f-492">22.9</ix:nonFraction>&#160;million payment to CVR holders. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="f-493" escape="true"><ix:continuation id="f-421-3"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents changes in the CVR liability for the periods presented (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">CVR Liability</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning balance as of December 31, 2025</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-494">26,680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of the CVR liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="f-495">34,873</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" format="ixt:num-dot-decimal" scale="3" id="f-496">22,933</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ending Balance as of June 30, 2026</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-497">38,620</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div id="i7ac5520bfa654a33b8eea56f2b4c5e97_55"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="c-1" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" id="f-498" continuedAt="f-498-1" escape="true">Cash Equivalents and Marketable Securities</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="f-499" escape="true"><ix:continuation id="f-498-1" continuedAt="f-498-2"><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the estimated fair value of the Company&#8217;s cash equivalents and marketable securities and the gross unrealized gains and losses (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2026</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gains</span></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Losses</span></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-500">139,330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="syre:CashEquivalentsUnrealizedGains" format="ixt:fixed-zero" scale="3" id="f-501">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="syre:CashEquivalentsUnrealizedLosses" format="ixt:fixed-zero" scale="3" id="f-502">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-503">139,330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 15.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-3" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-504">20,932</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-3" name="syre:CashEquivalentsUnrealizedGains" format="ixt:fixed-zero" scale="3" id="f-505">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-3" name="syre:CashEquivalentsUnrealizedLosses" format="ixt:fixed-zero" scale="3" id="f-506">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-507">20,932</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash equivalents</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-508">160,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="syre:CashEquivalentsUnrealizedGains" format="ixt:fixed-zero" scale="3" id="f-509">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="syre:CashEquivalentsUnrealizedLosses" format="ixt:fixed-zero" scale="3" id="f-510">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-511">160,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-512">405,173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-513">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-514">527</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-515">404,646</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-516">146,423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-517">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-518">283</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-519">146,141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-520">257,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-521">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-522">741</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-523">256,457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.68pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-524">177,028</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-525">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-526">935</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-527">176,095</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-528">985,735</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-529">90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-530">2,486</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-531">983,339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gains</span></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Losses </span></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-532">74,004</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" name="syre:CashEquivalentsUnrealizedGains" format="ixt:fixed-zero" scale="3" id="f-533">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" name="syre:CashEquivalentsUnrealizedLosses" format="ixt:fixed-zero" scale="3" id="f-534">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-535">74,004</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-3" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-536">9,987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-3" name="syre:CashEquivalentsUnrealizedGains" format="ixt:fixed-zero" scale="3" id="f-537">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-3" name="syre:CashEquivalentsUnrealizedLosses" format="ixt:fixed-zero" scale="3" id="f-538">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-539">9,987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash equivalents</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-540">83,991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="syre:CashEquivalentsUnrealizedGains" format="ixt:fixed-zero" scale="3" id="f-541">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="syre:CashEquivalentsUnrealizedLosses" format="ixt:fixed-zero" scale="3" id="f-542">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-543">83,991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-544">184,423</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-545">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-546">80</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-547">184,368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-548">100,753</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-549">60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-550">23</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-551">100,790</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-552">265,316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-553">748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-554">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-555">266,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.68pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-556">119,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-557">153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-558">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-559">119,590</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-560">669,942</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-561">986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-562">116</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-563">670,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><ix:continuation id="f-498-2" continuedAt="f-498-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" id="f-564" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the available-for-sale securities in an unrealized loss position for which an allowance for credit losses has not been recorded as of June&#160;30, 2026 and December&#160;31, 2025, aggregated by major security type and length of time in a continuous unrealized loss position:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.964%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2026</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Less Than 12 Months</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">12 Months or Longer</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Losses </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Losses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Losses </span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="f-565">421,580</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="f-566">527</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="3" id="f-567">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="f-568">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="f-569">421,580</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="f-570">527</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="f-571">144,148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="f-572">283</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="3" id="f-573">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="f-574">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="f-575">144,148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="f-576">283</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="f-577">164,843</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="f-578">741</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="3" id="f-579">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="f-580">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="f-581">164,843</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="f-582">741</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="f-583">173,125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="f-584">935</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="3" id="f-585">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="f-586">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="f-587">173,125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="f-588">935</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total marketable securities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="f-589">903,696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" format="ixt:num-dot-decimal" scale="3" id="f-590">2,486</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="3" id="f-591">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="f-592">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="f-593">903,696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:num-dot-decimal" scale="3" id="f-594">2,486</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Less Than 12 Months</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">12 Months or Longer</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Losses </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Losses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Losses </span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="f-595">99,837</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="f-596">80</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="3" id="f-597">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="f-598">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="f-599">99,837</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="f-600">80</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="f-601">58,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="f-602">23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="3" id="f-603">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="f-604">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="f-605">58,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="f-606">23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="f-607">22,828</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="f-608">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="3" id="f-609">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="f-610">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="f-611">22,828</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="f-612">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="f-613">180,961</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="f-614">116</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="3" id="f-615">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="f-616">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="f-617">180,961</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="f-618">116</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated its securities for credit losses and considered the decline in market value to be primarily attributable to current economic and market conditions and not to a credit loss or other factors. Additionally, the Company does not intend to sell the securities in an unrealized loss position and does not expect it will be required to sell the securities before recovery of the unamortized cost basis. As of June&#160;30, 2026 and December&#160;31, 2025, an allowance for credit losses had <ix:nonFraction unitRef="usd" contextRef="c-162" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" format="ixt:fixed-zero" scale="0" id="f-619"><ix:nonFraction unitRef="usd" contextRef="c-163" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" format="ixt:fixed-zero" scale="0" id="f-620">not</ix:nonFraction></ix:nonFraction> been recognized. Given the Company's intent and ability to hold such securities until recovery, and the lack of significant change in credit risk of these investments, the Company does <ix:nonFraction unitRef="usd" contextRef="c-164" decimals="INF" name="syre:ImpairmentOfMarketableSecurities" format="ixt:fixed-zero" scale="0" id="f-621"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="INF" name="syre:ImpairmentOfMarketableSecurities" format="ixt:fixed-zero" scale="0" id="f-622">not</ix:nonFraction></ix:nonFraction> consider these marketable securities to be impaired as of June&#160;30, 2026 and December&#160;31, 2025. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial instruments that potentially subject the Company to a concentration of credit risk consist principally of cash deposits. Accounts at each of the Company's <ix:nonFraction unitRef="bank" contextRef="c-3" decimals="INF" name="syre:NumberOfDomesticBankingInstitutions" format="ixt-sec:numwordsen" scale="0" id="f-623">two</ix:nonFraction> U.S. banking institutions are insured by the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) up to $<ix:nonFraction unitRef="usd" contextRef="c-166" decimals="INF" name="us-gaap:CashFDICInsuredAmount" format="ixt:num-dot-decimal" scale="0" id="f-624">250,000</ix:nonFraction> per depositor. As of June&#160;30, 2026 and December&#160;31, 2025, cash deposits at the Company's U.S. banking institutions exceeded the FDIC limits.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="usd" contextRef="c-165" decimals="INF" name="us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" format="ixt:fixed-zero" scale="0" id="f-625"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="INF" name="us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" format="ixt:fixed-zero" scale="0" id="f-626">no</ix:nonFraction></ix:nonFraction> realized gains or losses on marketable securities for both the three and six months ended June&#160;30, 2026 and 2025. Interest on marketable securities is included in interest income. Accrued interest receivable on available-for-sale debt securities as of June&#160;30, 2026 and December&#160;31, 2025, was $<ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-5" name="us-gaap:InterestReceivable" scale="6" id="f-627">5.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-5" name="us-gaap:InterestReceivable" scale="6" id="f-628">4.5</ix:nonFraction> million, respectively, and is reflected in Prepaid expenses and other current assets.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="f-629" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the contractual maturities of the Company&#8217;s marketable securities at estimated fair value (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due in one year or less</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="f-630">703,969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="f-631">440,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due in 1 - 2 years</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="syre:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne" format="ixt:num-dot-decimal" scale="3" id="f-632">279,370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="syre:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne" format="ixt:num-dot-decimal" scale="3" id="f-633">229,917</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-634">983,339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-635">670,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><ix:continuation id="f-498-3"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may sell investments at any time for use in current operations even if they have not yet reached maturity. As a result, the Company classifies marketable securities, including securities with maturities beyond twelve months as current assets.</span></div></ix:continuation><div id="i7ac5520bfa654a33b8eea56f2b4c5e97_58"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="c-1" name="syre:AccruedAndOtherCurrentLiabilitiesTextBlock" id="f-636" continuedAt="f-636-1" escape="true">Accrued and Other Current Liabilities </ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="f-637" escape="true"><ix:continuation id="f-636-1"><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued and other current liabilities consist of the following (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2025</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedSalariesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-638">5,722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedSalariesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-639">7,940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued contracted research and development costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="syre:AccruedContractedResearchAndDevelopmentCosts" format="ixt:num-dot-decimal" scale="3" id="f-640">17,952</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="syre:AccruedContractedResearchAndDevelopmentCosts" format="ixt:num-dot-decimal" scale="3" id="f-641">17,424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued professional and consulting fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-642">2,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-643">1,404</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued other</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="f-644">135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="f-645">179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total accrued and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-646">26,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-647">26,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div id="i7ac5520bfa654a33b8eea56f2b4c5e97_61"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="f-648" continuedAt="f-648-1" escape="true">Licensing Agreements</ix:nonNumeric></span></div><ix:continuation id="f-648-1" continuedAt="f-648-2"><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 12, 2023, December 14, 2023, and June 5, 2024, the Company exercised the Option (as defined below) available under the antibody discovery and option agreement, dated May 25, 2023, and subsequently amended and restated on September 29, 2023 and May 14, 2024, by and among the Company, Paragon Therapeutics, Inc. (&#8220;Paragon&#8221;) and Parapyre Holding LLC (&#8220;Parapyre&#8221;) (as amended, the &#8220;Paragon Agreement&#8221;) with respect to the SPY001, SPY002 and SPY072, and SPY003 research programs, respectively. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 14, 2024, the Company and Paragon entered into (i) a license agreement (the &#8220;SPY001 License Agreement&#8221;), pursuant to which Paragon granted the Company a royalty-bearing, world-wide, exclusive license to develop, manufacture, commercialize or otherwise exploit certain antibodies and products targeting &#945;4&#223;7 integrin and (ii) a license agreement (the &#8220;SPY002 and SPY072 License Agreement&#8221;), pursuant to which Paragon granted the Company a royalty-bearing, world-wide, exclusive license to develop, manufacture, commercialize or otherwise exploit certain antibodies and products targeting TL1A, respectively, which includes the Company's SPY002 and SPY072 product candidates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 11, 2024, the Company and Paragon entered into a license agreement (as amended, the &#8220;SPY003 License Agreement&#8221;, and together with the SPY001 License Agreement and the SPY002 and SPY072 License Agreement, the &#8220;License Agreements&#8221;), pursuant to which Paragon granted the Company a royalty-bearing, world-wide, exclusive license to develop, manufacture, commercialize or otherwise exploit certain antibodies and products targeting IL-23 in the field of IBD.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 24, 2025, the SPY003 License Agreement was amended and restated to, among other things, clarify each party's rights and obligations with respect to license exclusivity and patent prosecution. On May 29, 2026, the SPY003 License Agreement was further amended to expand the definition of &#8220;Field&#8221; to encompass all therapeutic, prophylactic, palliative and diagnostic uses of SPY003, subject to certain restrictions (as summarized below).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of each License Agreement, the Company is obligated to pay Paragon up to $<ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-5" name="syre:AmountToBePaidUnderAgreement" scale="6" id="f-649"><ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-5" name="syre:AmountToBePaidUnderAgreement" scale="6" id="f-650"><ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-5" name="syre:AmountToBePaidUnderAgreement" scale="6" id="f-651">22.0</ix:nonFraction></ix:nonFraction></ix:nonFraction> million based on specific development, regulatory and clinical milestones for the first product under each agreement, respectively, that achieves such specified milestones, including a milestone payment of $<ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-5" name="syre:PaymentOfMilestone" scale="6" id="f-652"><ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-5" name="syre:PaymentOfMilestone" scale="6" id="f-653"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-5" name="syre:PaymentOfMilestone" scale="6" id="f-654">3.0</ix:nonFraction></ix:nonFraction></ix:nonFraction> million upon the first dosing of a human patient in a Phase 2 trial. In addition, the following summarizes other key terms of each License Agreement:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Paragon will provide the Company with an exclusive license to its patents covering the related antibody, the method of use and its method of manufacture.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><ix:continuation id="f-648-2"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Paragon will not conduct any new campaigns that generate anti-&#945;4&#223;7 or anti-TL1A monospecific antibodies in any field or anti-IL-23 monospecific antibodies in the field of IBD, in each case for at least <ix:nonNumeric contextRef="c-174" name="syre:CampaignTimelineMinimumTerm" format="ixt-sec:duryear" id="f-655">5</ix:nonNumeric> years.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The Company will pay Paragon a low single-digit percentage royalty for single antibody products and a mid single-digit percentage royalty for products containing more than one antibody from Paragon.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">There is a royalty step-down of 1/3rd if there is no Paragon patent in effect during the royalty term.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The royalty term ends on the later of (i) the last-to-expire licensed patent or Company patent directed to the manufacture, use or sale of a licensed antibody in the country at issue or (ii) <ix:nonNumeric contextRef="c-174" name="syre:RoyaltyTermExpirationPeriod" format="ixt-sec:duryear" id="f-656">12</ix:nonNumeric> years from the date of first sale of a Company product. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Each License Agreement may be terminated on <ix:nonNumeric contextRef="c-174" name="syre:TerminationNoticePeriod" format="ixt-sec:durday" id="f-657">60</ix:nonNumeric> days&#8217; notice by the Company; on material breach without cure; and to the extent permitted by law, on a party&#8217;s insolvency or bankruptcy.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">With respect to the SPY002 and SPY072 License Agreement only, on a product by product basis, the Company will pay sublicensing fees of up to approximately $<ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-6" name="syre:SublicensingFee" scale="6" id="f-658">20</ix:nonFraction> million upon the achievement of mostly commercial milestones.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">With respect to the SPY003 License Agreement only, the Company will not dose a human patient in a clinical trial of SPY003 for an indication outside of inflammatory bowel disease as part of a combination until June 1, 2028 or as a monotherapy until June 1, 2030 (the &#8220;Monotherapy Dosing Restriction&#8221;). In the event the Company or a licensee of Paragon's retained rights under the SPY003 License Agreement consummates a material transaction, including a change of control of the Company or such licensee, then any remaining restrictions outside of the initial definition of &#8220;Field&#8221; set forth in the Monotherapy Dosing Restriction shall remain in effect only until June 1, 2028 and thereafter terminate and be of no further force or effect.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the expense associated with each milestone when the achievement of the milestone is deemed probable.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized <ix:nonFraction unitRef="usd" contextRef="c-176" decimals="INF" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:fixed-zero" scale="0" id="f-659"><ix:nonFraction unitRef="usd" contextRef="c-177" decimals="INF" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:fixed-zero" scale="0" id="f-660">no</ix:nonFraction></ix:nonFraction> expenses related to milestone payments to Paragon for the three months ended June&#160;30, 2026 and 2025. The Company recognized expense related to Paragon license milestone payments, recorded within Research and development expenses, in the accompanying condensed statement of operations of $<ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="f-661">3.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="f-662">2.5</ix:nonFraction> million for the six months ended June&#160;30, 2026 and 2025, respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company paid milestone payments to Paragon totaling <ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-5" name="syre:LicenseAgreementMilestonePayments" format="ixt:fixed-zero" scale="6" id="f-663">nil</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-5" name="syre:LicenseAgreementMilestonePayments" scale="6" id="f-664">2.5</ix:nonFraction>&#160;million for the three months ended June&#160;30, 2026 and 2025, respectively. The Company paid milestone payments to Paragon totaling $<ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-5" name="syre:LicenseAgreementMilestonePayments" scale="6" id="f-665">3.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-5" name="syre:LicenseAgreementMilestonePayments" scale="6" id="f-666">2.5</ix:nonFraction>&#160;million for the six months ended June&#160;30, 2026 and 2025, respectively. As of June&#160;30, 2026 and December&#160;31, 2025, there were <ix:nonFraction unitRef="usd" contextRef="c-183" decimals="INF" name="syre:LicenseAgreementMilestonePaymentsOutstandingAndPayable" format="ixt:fixed-zero" scale="0" id="f-667"><ix:nonFraction unitRef="usd" contextRef="c-184" decimals="INF" name="syre:LicenseAgreementMilestonePaymentsOutstandingAndPayable" format="ixt:fixed-zero" scale="0" id="f-668">no</ix:nonFraction></ix:nonFraction> milestone payments outstanding and payable to Paragon.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company did not recognize any sublicensing fees expense for the three or six months ended June&#160;30, 2026 or 2025.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-5" name="syre:PaymentForSublicensingFee" format="ixt:fixed-zero" scale="6" id="f-669"><ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-5" name="syre:PaymentForSublicensingFee" format="ixt:fixed-zero" scale="6" id="f-670">no</ix:nonFraction></ix:nonFraction> payments related to sublicensing fees for the three months ended June&#160;30, 2026 and 2025. The Company paid sublicensing fees to Paragon totaling <ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-5" name="syre:PaymentForSublicensingFee" format="ixt:fixed-zero" scale="0" id="f-671">no</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-5" name="syre:PaymentForSublicensingFee" scale="6" id="f-672">0.5</ix:nonFraction>&#160;million for the six months ended June&#160;30, 2026 and 2025, respectively. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2026 and December&#160;31, 2025, there were <ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-5" name="syre:SublicensingFeeOutstandingAndPayable" format="ixt:fixed-zero" scale="6" id="f-673"><ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-5" name="syre:SublicensingFeeOutstandingAndPayable" format="ixt:fixed-zero" scale="6" id="f-674">nil</ix:nonFraction></ix:nonFraction> sublicensing fees outstanding and payable to Paragon.</span></div></ix:continuation><div id="i7ac5520bfa654a33b8eea56f2b4c5e97_67"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="c-1" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="f-676" continuedAt="f-676-1" escape="true">Related Party Transactions</ix:nonNumeric></span></div><ix:continuation id="f-676-1" continuedAt="f-676-2"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Paragon and Parapyre each beneficially own less than <ix:nonFraction unitRef="number" contextRef="c-186" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="f-677">5</ix:nonFraction>% of a class of the Company's voting securities through their respective holdings of the Company's common stock. Fairmount Funds Management LLC (&#8220;Fairmount&#8221;) beneficially owns more than <ix:nonFraction unitRef="number" contextRef="c-187" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="f-678">5</ix:nonFraction>% of a class of the Company's voting securities, has <ix:nonFraction unitRef="seat" contextRef="c-188" decimals="INF" name="syre:RelatedPartyTransactionNumberOfBoardSeats" format="ixt-sec:numwordsen" scale="0" id="f-679">one</ix:nonFraction> seat on the Board (held by Tomas Kiselak) and beneficially owns more than <ix:nonFraction unitRef="number" contextRef="c-187" decimals="2" name="syre:MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty" scale="-2" id="f-680">5</ix:nonFraction>% of Paragon. Fairmount appointed Paragon's </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><ix:continuation id="f-676-2" continuedAt="f-676-3"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">board of directors and has the contractual right to approve the appointment of any executive officers of Paragon.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" id="f-681" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is the summary of expenses related to the License Agreements and other Paragon reimbursable expenses, which are ultimately settled in cash (in millions) and recorded within Research and development in the consolidated statement of operations for the periods presented:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.627%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.023%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License Agreements milestone and sublicensing fees</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-176" decimals="INF" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:fixed-zero" scale="6" id="f-682"><ix:nonFraction unitRef="usd" contextRef="c-177" decimals="INF" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:fixed-zero" scale="6" id="f-683">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:fixed-zero" scale="6" id="f-684">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="f-685">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="f-686">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Paragon reimbursable expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:fixed-zero" scale="6" id="f-687">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:fixed-zero" scale="6" id="f-688">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="f-689">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="f-690">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total related party expense (excludes stock-based compensation)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:fixed-zero" scale="6" id="f-691">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:fixed-zero" scale="6" id="f-692">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="f-693">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="f-694">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized de minimis related party expenses in connection with other Paragon reimbursable expenses for the three months ended June&#160;30, 2026 and 2025, which were recorded as Research and development expenses in the consolidated statements of operations. For the six months ended June&#160;30, 2026 and 2025, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="f-695"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="f-696">0.1</ix:nonFraction></ix:nonFraction> million of Paragon reimbursable expenses. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were de minimis Related party accounts payable as of June 30, 2026 and December 31, 2025.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended June&#160;30, 2026 and 2025, the Company made payments totaling $<ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-5" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="6" id="f-697">0.1</ix:nonFraction> million and de minimis payments, respectively, in connection with Paragon reimbursable expenses. For the six months ended June&#160;30, 2026 and 2025, the Company made payments totaling $<ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-5" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="6" id="f-698">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-5" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="6" id="f-699">0.2</ix:nonFraction> million, respectively, in connection with Paragon reimbursable expenses.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Paragon License Agreements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 6 for disclosures related to the License Agreements entered into with Paragon.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mark McKenna Option Grant</span></div></ix:continuation><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-676-3">On February 1, 2024, the Board appointed Mark McKenna as a Class I director. Mr. McKenna and the Company are parties to a consulting agreement, pursuant to which Mr. McKenna agreed to continue to provide consulting services as an independent contractor to the Company, with an effective date of August 1, 2023 (the &#8220;Vesting Commencement Date&#8221;). As compensation for Mr. McKenna&#8217;s consulting services, on November 22, 2023, he was granted non-qualified stock options to purchase <ix:nonFraction unitRef="shares" contextRef="c-197" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-700">477,000</ix:nonFraction> shares of the Company&#8217;s common stock under the 2016 Plan (as defined in Note 9) with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-198" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="f-701">10.39</ix:nonFraction> per share, which vest as to <ix:nonFraction unitRef="number" contextRef="c-199" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-702">25</ix:nonFraction>% on the <ix:nonNumeric contextRef="c-199" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-703">one year</ix:nonNumeric> anniversary of the Vesting Commencement Date and thereafter vest and become exercisable in <ix:nonFraction unitRef="installment" contextRef="c-198" decimals="0" name="syre:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMonthlyInstallments" scale="0" id="f-704">36</ix:nonFraction> equal monthly installments, subject to Mr. McKenna&#8217;s continued service to the Company through each applicable vesting date. The Company recognized stock-based compensation expense related to Mr. McKenna's consulting agreement of $<ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-705"><ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-706">0.2</ix:nonFraction></ix:nonFraction> million for the three months ended June&#160;30, 2026 and 2025, respectively, and $<ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-707"><ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-708">0.5</ix:nonFraction></ix:nonFraction> million for the six months ended June&#160;30, 2026 and 2025, respectively.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="i7ac5520bfa654a33b8eea56f2b4c5e97_73"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="c-1" name="us-gaap:PreferredStockTextBlock" id="f-714" continuedAt="f-714-1" escape="true">Convertible Preferred Stock and Stockholders&#8217; Equity</ix:nonNumeric></span></div><ix:continuation id="f-714-1" continuedAt="f-714-2"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2026, a total of</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonFraction unitRef="shares" contextRef="c-206" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-715">1,532,591</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> warrants previously issued to Parapyre pursuant to the Paragon Agreement with a weighted-average exercise price of</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $<ix:nonFraction unitRef="usdPerShare" contextRef="c-206" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-716">22.49</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> remain outstanding.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Series A Non-Voting Convertible Preferred Stock</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Company's Certificate of Designation of Preferences, Rights and Limitations of the Series A Non-Voting Convertible Preferred Stock (the &#8220;Series A Certificate of Designation&#8221;), holders of Series A Preferred Stock are entitled to receive dividends on shares of Series A Preferred Stock equal to, on an as-if-converted-to-common stock basis, and in the same form as, dividends actually paid on shares of common stock. Except as provided in the Series A Certificate of Designation or as otherwise required by law, the Series A Preferred Stock does not have voting rights. However, as long as any shares of Series A Preferred Stock are outstanding, the Company will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series A Preferred Stock: (a) alter or change adversely the powers, preferences or rights given to the Series A Preferred Stock, or alter or amend the Series A Certificate of Designation, amend or repeal any provision of, or add any provision to, the Company&#8217;s Certificate of Incorporation or its Bylaws, or file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of preferred stock, if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series A Preferred Stock, regardless of whether any of the foregoing actions will be by means of amendment to the Certificate of Incorporation or by merger, consolidation, recapitalization, reclassification, conversion or otherwise, (b) issue further shares of Series A Preferred Stock or increase or decrease (other than by conversion) the number of authorized shares of Series A Preferred Stock, (c) prior to the stockholder approval of the conversion of the Series A Preferred Stock into shares of common stock in accordance with Nasdaq Stock Market Rules or at any time while at least <ix:nonFraction unitRef="number" contextRef="c-207" decimals="2" name="syre:PreferredStockRemainsIssuedAndOutstandingPercentage" scale="-2" id="f-717">30</ix:nonFraction>% of the originally issued Series A Preferred Stock remains issued and outstanding, consummate (x) any Fundamental Transaction (as defined in the Series A Certificate of Designation) or (y) any merger or consolidation of the Company with or into another entity or any stock sale to, or other business combination in which the Company's stockholders immediately before such transaction do not hold at least a majority of the Company's capital stock immediately after such transaction or (d) enter into any agreement with respect to any of the foregoing. The Series A Preferred Stock does not have a preference upon any liquidation, dissolution or winding-up of the Company. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2026, <ix:nonFraction unitRef="shares" contextRef="c-9" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-718">346,045</ix:nonFraction> shares of Series A Preferred Stock remained outstanding and are convertible into <ix:nonFraction unitRef="shares" contextRef="c-9" decimals="INF" name="us-gaap:PreferredStockConvertibleSharesIssuable" format="ixt:num-dot-decimal" scale="0" id="f-719">13,841,800</ix:nonFraction> common shares.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Series B Non-Voting Convertible Preferred Stock</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Company's Certificate of Designation of Preferences, Rights and Limitations of Series B Non-Voting Convertible Preferred Stock (as amended, the &#8220;Series B Certificate of Designation&#8221;), holders of Series B Preferred Stock are entitled to receive dividends on shares of Series B Preferred Stock equal to, on an as-if-converted-to-common stock basis, and in the same form as, dividends actually paid on shares of common stock. Except as provided in the Series B Certificate of Designation or as otherwise required by law, the Series B Preferred Stock does not have voting rights. However, as long as any shares of Series B Preferred Stock are outstanding, the Company will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series B Preferred Stock, alter or change adversely the powers, preferences or rights given to the Series B Preferred Stock, or alter or amend the Series B Certificate of Designation, amend or repeal any provision of, or add any provision to, the Company&#8217;s Certificate of Incorporation or its Bylaws, or file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of preferred stock, if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series B Preferred Stock, regardless of whether any of the foregoing actions will be by means of amendment to the Certificate of Incorporation or by merger, consolidation, recapitalization, reclassification, conversion or otherwise. The Series B Preferred Stock does not have a preference upon any liquidation, dissolution or winding-up of the Company.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><ix:continuation id="f-714-2"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 23, 2026, <ix:nonFraction unitRef="shares" contextRef="c-208" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-720">16,667</ix:nonFraction> shares of Series B Preferred Stock were converted at the option of the holder into <ix:nonFraction unitRef="shares" contextRef="c-11" decimals="INF" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" format="ixt:num-dot-decimal" scale="0" id="f-721">666,680</ix:nonFraction> shares of common stock. As of June 30, 2026, <ix:nonFraction unitRef="shares" contextRef="c-11" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-722">no</ix:nonFraction> shares of Series B Preferred Stock remained outstanding.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ATM Facility</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 6, 2024, the Company entered into the 2024 Sales Agreement, pursuant to which the Company may issue and sell up to $<ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-5" name="syre:SaleOfStockAggregateOfferingPrice" scale="6" id="f-723">200.0</ix:nonFraction>&#160;million of shares of common stock under an ATM offering program. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2025, the Company sold an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-210" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-724">445,668</ix:nonFraction> shares of common stock under its ATM offering program pursuant to the 2024 Sales Agreement resulting in net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="f-725">14.8</ix:nonFraction>&#160;million.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2026, the Company sold an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-97" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-726">296,396</ix:nonFraction> shares of common stock under the ATM offering program pursuant to the 2024 Sales Agreement resulting in net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="f-727">9.7</ix:nonFraction>&#160;million. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Sales Agreement was terminated on June 26, 2026 and the Company concurrently entered into a new sales agreement (the &#8220;2026 Sales Agreement&#8221;) with TD Securities (USA) LLC as its agent, pursuant to which the Company may issue and sell up to $<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-5" name="syre:SaleOfStockAuthorizedAmount" scale="6" id="f-728">500.0</ix:nonFraction>&#160;million of shares of common stock under an ATM offering program. During the three months ended June 30, 2026, the Company did <ix:nonFraction unitRef="shares" contextRef="c-99" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:fixed-zero" scale="0" id="f-729">not</ix:nonFraction> sell any shares under the ATM offering program pursuant to the 2026 Sales Agreement. As of June&#160;30, 2026, $<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-5" name="syre:SaleOfStockRemainingAuthorizedAmount" scale="6" id="f-730">500.0</ix:nonFraction>&#160;million remained available for sale under the 2026 Sales Agreement. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">October 2025 Underwritten Offering</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 13, 2025, the Company entered into the October 2025 Underwriting Agreement, pursuant to which the Company sold an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-100" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-731">17,094,594</ix:nonFraction> shares of common stock, inclusive of <ix:nonFraction unitRef="shares" contextRef="c-101" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-732">2,229,729</ix:nonFraction> shares pursuant to the full exercise of the underwriters&#8217; over-allotment option, at a public offering price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-102" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-733">18.50</ix:nonFraction>, resulting in net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="f-734">296.4</ix:nonFraction>&#160;million after deducting approximately $<ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-5" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="f-735">19.9</ix:nonFraction>&#160;million of underwriting discounts and other offering costs. The over-allotment option was exercised in full on October 14, 2025 and the transaction closed on October 15, 2025.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">April 2026 Underwritten Offering</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 13, 2026, the Company entered into the April 2026 Underwriting Agreement, pursuant to which the Company sold an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-103" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-736">7,475,000</ix:nonFraction> shares of its common stock, inclusive of <ix:nonFraction unitRef="shares" contextRef="c-104" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-737">975,000</ix:nonFraction> shares pursuant to the full exercise of the underwriters' over-allotment option, at a public offering price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-105" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-738">62.00</ix:nonFraction>, resulting in net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="f-739">435.2</ix:nonFraction>&#160;million after deducting approximately $<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-5" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="f-740">28.2</ix:nonFraction>&#160;million of underwriting discounts and other offering costs. The over-allotment option was exercised in full on April 15, 2026 and the transaction closed on April 16, 2026.</span></div></ix:continuation><div id="i7ac5520bfa654a33b8eea56f2b4c5e97_76"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-741" continuedAt="f-741-1" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="f-741-1" continuedAt="f-741-2"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2016 Equity Incentive Plan</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's 2016 Equity Incentive Plan (the &#8220;2016 Plan&#8221;) became effective in April 2016 and serves as the successor to the Company&#8217;s 2015 Equity Incentive Plan. Under the 2016 Plan, the Company may grant stock options, stock appreciation rights, restricted stock awards, restricted stock units, performance awards, and stock bonuses. The 2016 Plan, as amended, provides for an automatic increase in the number of shares reserved for issuance thereunder on January 1 of each year for the remaining term of the plan equal to (a) <ix:nonFraction unitRef="number" contextRef="c-211" decimals="3" name="syre:AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares" scale="-2" id="f-742">5.0</ix:nonFraction>% of the number of issued and outstanding shares of common stock </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(including such shares issuable pursuant to the exercise or conversion, as applicable, of any outstanding pre-funded warrants and nonvoting convertible preferred stock) on December 31 of the immediately preceding year, or (b) a lesser amount as approved by the board each year (the &#8220;Evergreen Provision&#8221;). As a result of the Evergreen Provision, on January 1, 2026 and </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><ix:continuation id="f-741-2" continuedAt="f-741-3"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025, an additional <ix:nonFraction unitRef="shares" contextRef="c-212" decimals="INF" name="syre:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-743">4,711,544</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-213" decimals="INF" name="syre:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-744">3,814,905</ix:nonFraction> shares, respectively, became available for issuance under the 2016 Plan.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2026, the 2016 Plan had <ix:nonFraction unitRef="shares" contextRef="c-214" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-745">15,084,463</ix:nonFraction> shares available for future issuance, of which <ix:nonFraction unitRef="shares" contextRef="c-214" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-746">6,876,693</ix:nonFraction> shares were subject to outstanding option awards and restricted unit awards.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 Equity Inducement Plan</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2018 Equity Inducement Plan (&#8220;2018 Plan&#8221;) became effective in February 2018.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2025, the Company amended the 2018 Plan to increase the number of shares of common stock reserved for issuance by <ix:nonFraction unitRef="shares" contextRef="c-215" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-747">750,000</ix:nonFraction>. After this amendment and as of June&#160;30, 2026, the 2018 Plan had <ix:nonFraction unitRef="shares" contextRef="c-216" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-748">6,481,956</ix:nonFraction> shares available for future issuance, of which <ix:nonFraction unitRef="shares" contextRef="c-216" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-749">5,981,072</ix:nonFraction> shares were subject to outstanding option awards and restricted unit awards.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service-based awards granted under the 2018 Plan and 2016 Plan generally vest over <ix:nonNumeric contextRef="c-217" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-750">four years</ix:nonNumeric> and expire after <ix:nonNumeric contextRef="c-217" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="f-751">ten years</ix:nonNumeric>, although awards have been granted with vesting terms less than <ix:nonNumeric contextRef="c-217" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-752">four years</ix:nonNumeric>. Under the 2016 Plan and 2018 Plan, the Company may grant stock-based awards with service conditions, performance conditions, and market conditions. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock" id="f-753" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s stock awards granted under all equity incentive and inducement plans for each of the periods indicated:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.676%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.105%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.026%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.105%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.026%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.218%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.218%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.218%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.616%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Grants</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Grant Date Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Grants</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Grant Date Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Grants</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Grant Date Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Grants</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-754">190,456</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-15" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-755">62.94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-756">427,800</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-16" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-757">15.29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-758">2,769,061</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-759">33.19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-760">2,325,717</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-17" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-761">20.32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-218" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="f-762">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-218" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-763">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-219" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="f-764">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-219" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-765">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-220" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-766">125,400</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-220" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-767">30.61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-221" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="f-768">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-221" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-769">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2016 Employee Stock Purchase Plan</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Company&#8217;s Amended and Restated 2016 Employee Stock Purchase Plan (&#8220;2016 ESPP&#8221;), the Company issued and sold <ix:nonFraction unitRef="shares" contextRef="c-222" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-770"><ix:nonFraction unitRef="shares" contextRef="c-223" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-771">19,967</ix:nonFraction></ix:nonFraction> shares of the Company&#8217;s common stock during the three and six months ended June&#160;30, 2026, resulting in aggregate cash proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="f-772"><ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="f-773">0.5</ix:nonFraction></ix:nonFraction>&#160;million.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="shares" contextRef="c-224" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:fixed-zero" scale="0" id="f-774">no</ix:nonFraction> shares issued and sold during the three months ended June&#160;30, 2025. The Company issued and sold <ix:nonFraction unitRef="shares" contextRef="c-225" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-775">16,877</ix:nonFraction> shares during the six months ended June&#160;30, 2025, resulting in aggregate cash proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="f-776">0.3</ix:nonFraction>&#160;million. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based Compensation Expense</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="f-777" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation expense recognized from the Company&#8217;s equity incentive plans, 2018 Plan and 2016 ESPP during the periods presented was as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.869%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.839%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.023%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></div></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-226" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-778">6,218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-227" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-779">4,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-780">12,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-781">7,612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-782">7,294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-783">5,278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-784">14,309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-233" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-785">10,625</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation expense</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-786">13,512</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-787">9,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-788"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-789">26,318</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-790">18,237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-791" escape="true"><ix:continuation id="f-741-3"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the weighted-average Black-Scholes option pricing model assumptions used to estimate the fair value of stock options granted under the Company's equity incentive plans, and the shares purchased under the 2016 ESPP during the periods presented: </span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.545%"><tr><td style="width:1.0%"/><td style="width:44.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.145%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock Options Granted</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-234" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-792">5.93</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-235" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-793">5.74</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-236" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-794">6.02</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-237" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-795">5.97</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-234" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-796">67</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-235" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-797">74</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-236" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-798">73</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-237" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-799">76</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-234" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-800">4.16</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-235" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-801">4.02</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-236" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-802">3.88</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-237" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-803">4.38</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-234" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-804">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-235" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-805">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-236" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-806">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-237" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-807">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 5.37pt;text-align:left;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2016 ESPP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-238" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-808">0.50</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-239" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-809">0.50</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-240" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" format="ixt:fixed-zero" scale="-2" id="f-810">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-241" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" format="ixt:fixed-zero" scale="-2" id="f-811">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-238" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-812">64</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-239" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-813">69</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-240" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" format="ixt:fixed-zero" scale="-2" id="f-814">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-241" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" format="ixt:fixed-zero" scale="-2" id="f-815">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-238" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-816">3.59</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-239" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-817">4.23</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-240" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-818">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-241" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-819">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-238" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-820">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-239" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-821">&#8212;</ix:nonFraction></span></td></tr></table></div></ix:continuation></ix:nonNumeric><div id="i7ac5520bfa654a33b8eea56f2b4c5e97_82"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="c-1" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="f-823" continuedAt="f-823-1" escape="true">Sale of Pegzilarginase to Immedica</ix:nonNumeric></span></div><ix:continuation id="f-823-1"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 27, 2023, the Company announced that it had entered into an agreement to sell the global rights to pegzilarginase to Immedica Pharma AB (&#8220;Immedica&#8221;) for $<ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-5" name="us-gaap:ProceedsFromSaleOfIntangibleAssets" scale="6" id="f-824">15.0</ix:nonFraction>&#160;million in upfront cash proceeds and up to $<ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-5" name="syre:DisposalGroupIncludingDiscontinuedOperationContingentConsideration" scale="6" id="f-825">100.0</ix:nonFraction>&#160;million in contingent milestone payments.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The milestone payments are contingent on formal reimbursement decisions by national authorities in key European markets and pegzilarginase approval by the U.S. Food and Drug Administration (&#8220;FDA&#8221;), among other events. In the three months ended June 30, 2026, the Company recognized a gain of $<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" scale="6" id="f-826">40.0</ix:nonFraction> million within Gain on Sale of in-process research and development, for achieving certain milestones during the period. As of June&#160;30, 2026 and December 31, 2025, $<ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" scale="6" id="f-827"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" scale="6" id="f-828">3.0</ix:nonFraction></ix:nonFraction> million remains outstanding and due to the Company from a previously achieved milestone, which is reflected in Prepaid expenses and other current assets. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestone payments received by the Company by July 3, 2026, net of allowable expenses and adjustments, will be distributed to CVR holders pursuant to the CVR agreement resulting from the Asset Acquisition and will reduce the CVR liability.</span></div></ix:continuation><div id="i7ac5520bfa654a33b8eea56f2b4c5e97_85"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. &#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingDisclosureTextBlock" id="f-829" continuedAt="f-829-1" escape="true">Segment Reporting</ix:nonNumeric></span></div><ix:continuation id="f-829-1" continuedAt="f-829-2"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates under a single operating and reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and rheumatic diseases. The Company's Chief Operating Decision Maker (&#8220;CODM&#8221;) is the Company's Chief Executive Officer. The CODM uses consolidated Net loss as the measure of segment profit or loss and uses consolidated Total Assets as reported on the balance sheet as the measure of segment assets. The CODM compares Net loss against budgeted and/or forecasted amounts to track the Company's financial performance against expectations and to inform, along with development timelines and scientific and commercial considerations, their decisions regarding resource allocations to fund the Company's development of its pipeline. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" id="f-830" continuedAt="f-830-1" escape="true"><ix:continuation id="f-829-2" continuedAt="f-829-3"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the significant expenses provided to the CODM on a regular basis (in thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.860%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Compensation</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" name="us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold" format="ixt:num-dot-decimal" scale="3" id="f-831">12,862</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-3" name="us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold" format="ixt:num-dot-decimal" scale="3" id="f-832">8,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-3" name="us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold" format="ixt:num-dot-decimal" scale="3" id="f-833">24,305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-249" decimals="-3" name="us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold" format="ixt:num-dot-decimal" scale="3" id="f-834">15,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Stock-based compensation </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-835">13,512</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-836">9,378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-837">26,318</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-249" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-838">18,237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development, excluding compensation and stock-based compensation </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2) (3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-839">50,447</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-840">30,749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-841">97,340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-249" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-842">64,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other segment items</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> (4) (5)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" sign="-" name="us-gaap:SegmentReportingOtherItemAmount" format="ixt:num-dot-decimal" scale="3" id="f-843">40,621</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-3" sign="-" name="us-gaap:SegmentReportingOtherItemAmount" format="ixt:num-dot-decimal" scale="3" id="f-844">11,530</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-3" sign="-" name="us-gaap:SegmentReportingOtherItemAmount" format="ixt:num-dot-decimal" scale="3" id="f-845">42,758</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-249" decimals="-3" sign="-" name="us-gaap:SegmentReportingOtherItemAmount" format="ixt:num-dot-decimal" scale="3" id="f-846">16,158</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Segment net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-847">36,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-848">36,717</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-849">105,205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-249" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-850">81,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Includes related party expenses of $<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="f-851"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="f-852">0.2</ix:nonFraction></ix:nonFraction> million for the three months ended June&#160;30, 2026 and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025, and</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $<ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-853"><ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-854">0.5</ix:nonFraction></ix:nonFraction> million for the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">six months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2026 and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Includes non-clinical study, clinical trial, and manufacturing expenses. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Includes de minimis related party expenses for the three months ended June 30, 2026 and 2025. Includes related party expenses of $<ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-855">3.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-856">2.6</ix:nonFraction> million for the six months ended June 30, 2026 and 2025, respectively. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Includes general and administrative expenses such as audit, legal, and other professional fees, interest income, and other expense, net. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Includes gains of $<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" scale="6" id="f-857">40.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" scale="6" id="f-858">10.0</ix:nonFraction> million for the three months ended June 30, 2026 and 2025, respectively, related to the achievement of milestones under the 2023 sale of the global rights to the legacy assets, pegzilarginase, to Immedica. The 2026 gain was triggered by the sale of the related priority review voucher (&#8220;PRV&#8221;), while the 2025 gain was triggered by a favorable reimbursement decision for pegzilarginase in Europe.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Includes gains of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" scale="6" id="f-859">70.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" scale="6" id="f-860">10.0</ix:nonFraction> million for the six months ended June 30, 2026 and 2025, respectively, related to milestone payments earned in connection with the 2023 sale of the global rights to the legacy assets, pegzilarginase, to Immedica. The 2026 gain was triggered by the FDA approval of pegzilarginase and the subsequent sale of the related PRV, while the 2025 gain was triggered by a favorable reimbursement decision for pegzilarginase in Europe.</span></div></ix:continuation></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><ix:continuation id="f-830-1" continuedAt="f-830-2"><ix:continuation id="f-829-3" continuedAt="f-829-4"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Includes a $<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="syre:IncreaseDecreaseInFairValueOfContingentValueRightLiability" scale="6" id="f-861">4.6</ix:nonFraction>&#160;million increase and a $<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" sign="-" name="syre:IncreaseDecreaseInFairValueOfContingentValueRightLiability" scale="6" id="f-862">0.6</ix:nonFraction>&#160;million decrease in the fair value of the CVR liability for the three months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2026</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2025, respectively. Includes a $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="syre:IncreaseDecreaseInFairValueOfContingentValueRightLiability" scale="6" id="f-863">34.9</ix:nonFraction>&#160;million increase and a $<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="syre:IncreaseDecreaseInFairValueOfContingentValueRightLiability" scale="6" id="f-864">1.8</ix:nonFraction>&#160;million decrease in the fair value of the CVR liability for the six months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2026</span></ix:continuation></ix:continuation><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-830-2"><ix:continuation id="f-829-4"> and 2025, respectively.</ix:continuation></ix:continuation> </span></div><div id="i7ac5520bfa654a33b8eea56f2b4c5e97_91"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-869" continuedAt="f-869-1" escape="true">Net Loss Per Share</ix:nonNumeric></span></div><ix:continuation id="f-869-1" continuedAt="f-869-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-870" continuedAt="f-870-1" escape="true"><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company computes net loss per share of common stock, Series A Preferred Stock, and Series B Preferred Stock using the two-class method required for multiple classes of common stock and other participating securities.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The two-class method is an earnings (loss) allocation method under which earnings (loss) per share is calculated for each class of common stock. The Company has determined that the Series A Preferred Stock and Series B Preferred Stock do not have preferential rights when compared to the Company's common stock and therefore it must allocate losses to these other classes of common stock, as illustrated in the table below.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-870-1">Basic and diluted net loss per share is computed by dividing the net loss by the weighted-average number of shares outstanding during the period, without consideration of potential dilutive securities. For periods in which the Company generated a net loss, the Company does not include potential shares of common stock in diluted net loss per share when the impact of these items is anti-dilutive. The Company has generated a net loss for all periods presented, therefore diluted net loss per share is the same as basic net loss per share since the inclusion of potential shares of common stock would be anti-dilutive.</ix:continuation>  </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><ix:continuation id="f-869-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" id="f-871" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted net loss per share of common stock, Series A Preferred Stock, and Series B Preferred Stock (in thousands, except share and per share amounts):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.445%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.445%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.445%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.445%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.445%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.449%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></div></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="15" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="15" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Series A Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Series B Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Common<br/>Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Series A Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Series B Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Common<br/>Stock</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net loss per share, basic and diluted:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numerator</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Allocation of losses</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-872">5,052</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="f-873">225</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-874">30,923</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-875">6,791</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="f-876">327</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-877">29,599</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Denominator</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Weighted-average shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-18" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" format="ixt:num-dot-decimal" scale="0" id="f-878">346,045</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-22" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" format="ixt:num-dot-decimal" scale="0" id="f-879">15,385</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-26" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" format="ixt:num-dot-decimal" scale="0" id="f-880">84,729,435</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-19" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" format="ixt:num-dot-decimal" scale="0" id="f-881">346,045</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-23" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" format="ixt:num-dot-decimal" scale="0" id="f-882">16,667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" format="ixt:num-dot-decimal" scale="0" id="f-883">60,333,838</ix:nonFraction></span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net loss per share, basic and diluted</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-18" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-884"><ix:nonFraction unitRef="usdPerShare" contextRef="c-18" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-885">14.60</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-22" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-886"><ix:nonFraction unitRef="usdPerShare" contextRef="c-22" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-887">14.60</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-26" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-888"><ix:nonFraction unitRef="usdPerShare" contextRef="c-26" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-889">0.36</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-19" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-890"><ix:nonFraction unitRef="usdPerShare" contextRef="c-19" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-891">19.62</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-23" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-892"><ix:nonFraction unitRef="usdPerShare" contextRef="c-23" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-893">19.62</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-27" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-894"><ix:nonFraction unitRef="usdPerShare" contextRef="c-27" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-895">0.49</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="33" style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></div></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="15" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="15" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Series A Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Series B Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Common<br/>Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Series A Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Series B Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Common<br/>Stock</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net loss per share, basic and diluted:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numerator</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Allocation of losses</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-896">15,147</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="f-897">701</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-898">89,357</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-899">15,078</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="f-900">726</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-901">65,686</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Denominator</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Weighted-average shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-20" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" format="ixt:num-dot-decimal" scale="0" id="f-902">346,045</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-24" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" format="ixt:num-dot-decimal" scale="0" id="f-903">16,022</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-28" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" format="ixt:num-dot-decimal" scale="0" id="f-904">81,656,119</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" format="ixt:num-dot-decimal" scale="0" id="f-905">346,045</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" format="ixt:num-dot-decimal" scale="0" id="f-906">16,667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-29" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" format="ixt:num-dot-decimal" scale="0" id="f-907">60,300,073</ix:nonFraction></span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net loss per share, basic and diluted</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-20" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-908"><ix:nonFraction unitRef="usdPerShare" contextRef="c-20" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-909">43.77</ix:nonFraction></ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-24" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-910"><ix:nonFraction unitRef="usdPerShare" contextRef="c-24" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-911">43.77</ix:nonFraction></ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-912"><ix:nonFraction unitRef="usdPerShare" contextRef="c-28" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-913">1.09</ix:nonFraction></ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-21" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-914"><ix:nonFraction unitRef="usdPerShare" contextRef="c-21" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-915">43.57</ix:nonFraction></ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-25" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-916"><ix:nonFraction unitRef="usdPerShare" contextRef="c-25" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-917">43.57</ix:nonFraction></ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-29" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-918"><ix:nonFraction unitRef="usdPerShare" contextRef="c-29" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-919">1.09</ix:nonFraction></ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-920" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following weighted-average equity instruments were excluded from the calculation of diluted net loss per share because their effect would have been anti-dilutive for the periods presented:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.303%"><tr><td style="width:1.0%"/><td style="width:41.666%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.731%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.435%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.731%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.435%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.731%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.435%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.736%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options to purchase common stock</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-250" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-921">8,042,158</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-251" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-922">805,306</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-252" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-923">6,630,827</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-253" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-924">1,324,645</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-254" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-925">137,358</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-255" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="f-926">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-256" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-927">113,115</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-257" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-928">11,943</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding Parapyre warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-258" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-929">1,532,591</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-259" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="f-930">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-260" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-931">1,532,591</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-261" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="f-932">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="padding-left:9pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="i7ac5520bfa654a33b8eea56f2b4c5e97_109"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our unaudited condensed consolidated financial statements and related notes included in Part I, Item 1 of this Quarterly Report for the quarterly period ended June&#160;30, 2026 (this &#8220;Quarterly Report&#8221;) as well as the audited consolidated financial statements and notes and Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations, included in our Annual Report on Form 10-K for the year ended December 31, 2025 (the &#8220;Annual Report&#8221;), filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) on February 19, 2026. This discussion and other parts of this Quarterly Report contain forward-looking statements that involve risks and uncertainties, such as statements regarding our expected results, outcomes, and the timing of these results and outcomes, plans, objectives, expectations and intentions. As a result of many factors, including those factors set forth in the &#8220;Risk Factors&#8221; section of this Quarterly Report, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. As used in this report, unless the context suggests otherwise, &#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221;, the &#8220;Company,&#8221; or &#8220;Spyre&#8221; refers to Spyre Therapeutics, Inc. and its consolidated subsidiaries taken as a whole.</span></div><div id="i7ac5520bfa654a33b8eea56f2b4c5e97_115"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients. Our pipeline includes extended half-life antibodies targeting &#945;4&#946;7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Strategy</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goal is to develop next-generation therapeutics to redefine the standard of care for the treatment of inflammatory bowel disease (&#8220;IBD&#8221;) and other immune-mediated diseases, relying on three strategic pillars:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Advancing a portfolio of next-generation monotherapies - novel antibody candidates engineered for optimized potency, selectivity, and pharmacokinetics (&#8220;PK&#8221;) against validated targets</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Evaluating paradigm-changing IBD combinations - fixed-dose combinations of our engineered investigational antibodies designed to enable superior efficacy, safety, and convenience</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expansion of our anti-TL1A program into additional indications - pipeline-in-a-product potential in diseases with first-in-class and best-in-class opportunity, starting with rheumatoid arthritis (&#8220;RA&#8221;), psoriatic arthritis (&#8220;PsA&#8221;), and axial spondyloarthritis (&#8220;axSpA&#8221;)</span></div><div id="i7ac5520bfa654a33b8eea56f2b4c5e97_118"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Portfolio and Development Plan Updates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are advancing a pipeline of monoclonal antibodies (&#8220;mAbs&#8221;) for the treatment of IBD and other immune-mediated diseases. The following table (Figure 1) summarizes our pipeline and development strategy, including our SKYLINE Phase 2 platform trial evaluating SPY001, SPY002, SPY003, and pairwise combinations thereof in subjects with moderately to severely active ulcerative colitis (&#8220;UC&#8221;) and our SKYWAY basket trial evaluating SPY072 in three rheumatic diseases: RA, PsA, and axSpA:</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Figure 1. Spyre portfolio</span></div><div style="margin-top:9pt;text-align:justify"><span><br/></span></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><img src="syre-20260630_g1.jpg" alt="Pipeline.jpg" style="height:226px;margin-bottom:5pt;vertical-align:text-bottom;width:612px" id="i-1"/></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SKYLINE Phase 2 Platform Trial in UC </span></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2025, we initiated our SKYLINE Phase 2 platform trial evaluating SPY001, SPY002 and SPY003, as well as pairwise combinations thereof (six investigational agents in total), in subjects with moderately to severely active UC (Figure 2). The trial consists of two parts:</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Part A:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Open-label assessment of the safety and preliminary efficacy of a single dose level of each investigational monotherapy. Enrollment for Part A has completed, with initial SPY001 and SPY002 Part A topline induction data announced in April 2026 and June 2026, respectively, and with SPY003 topline induction data expected in September 2026.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Part B:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Randomized and placebo-controlled assessment of the safety and efficacy of monotherapies and combinations, designed to provide dose-ranging data on monotherapies, proof-of-concept and contribution of components for combinations, with induction data expected in 2027.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SKYLINE is currently enrolling subjects into Part B of the trial. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Figure 2. SKYLINE trial design</span></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><img src="syre-20260630_g2.jpg" alt="SKYLINE.jpg" style="height:258px;margin-bottom:5pt;vertical-align:text-bottom;width:612px" id="i-2"/></div><div style="margin-top:9pt;text-align:justify"><span><br/></span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">mMS=modified mayo score; RHI=Robarts Histopathology Index; HEMI=Histo-Endoscopic Mucosal Improvement; P=primary endpoint; S=secondary endpoint. Initiation of each cohort subject to regulatory clearance.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Topline induction data from Part A of the SKYLINE trial in UC subjects were presented in April 2026 (SPY001) and June 2026 (SPY002). Baseline characteristics were consistent with expectations (Figure 3). SPY001 and SPY002 were well-tolerated with a safety profile consistent with in-class comparators (Figure 4). SPY001 and SPY002 achieved their respective primary endpoints, demonstrating a statistically significant reduction in the RHI score of 9.2 points and 10.7 points, respectively. Rates of key secondary endpoints of clinical remission and endoscopic improvement were clinically meaningful at 40% and 51%, respectively, for SPY001 and 33% and 42%, respectively, for SPY002 (Figure 5). The change in the modified Mayo Score from baseline at Week 12 for both SPY001 and SPY002 was -3.7, reflecting consistency across secondary endpoints. Topline induction data for SPY003 are expected in September 2026.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Figure 3. SPY001 and SPY002 baseline demographics from SKYLINE Part A Induction Topline</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><img src="syre-20260630_g3.jpg" alt="Baseline demographics.jpg" style="height:278px;margin-bottom:5pt;vertical-align:text-bottom;width:612px" id="i-3"/></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Figure 4. SPY001 and SPY002 safety summary from SKYLINE Part A Induction Topline</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><img src="syre-20260630_g4.jpg" alt="Safety table.jpg" style="height:248px;margin-bottom:5pt;vertical-align:text-bottom;width:612px" id="i-4"/></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:112%;position:relative;top:-2.8pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:112%">Hospitalization for exacerbation of UC in one subject, not drug-related.</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Hospitalization for worsening heart failure in one subject with history of heart failure &amp; atrial fibrillation who was later diagnosed with worsening aortic stenosis, not drug related.</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">One case each of nausea, hypertension, arthromyalgia.</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exacerbation of UC, not drug-related.</span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Figure 5. SPY001 and SPY002 efficacy summary from SKYLINE Part A Induction Topline</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><img src="syre-20260630_g5.jpg" alt="Efficacy endpoints.jpg" style="height:241px;margin-bottom:5pt;vertical-align:text-bottom;width:612px" id="i-5"/></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Primary endpoint of &#916;RHI was analyzed using per protocol analysis set and t-test was applied to test against the null hypothesis of &#916;RHI=0; Secondary endpoints including Clinical Remission and Endoscopic Improvement rates were analyzed using full analysis set.</span></div><div style="margin-top:9pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SKYWAY Phase 2 Basket Trial in Rheumatic Diseases (RA, PsA, axSpA)</span></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2025, we initiated our SKYWAY Phase 2 randomized and placebo-controlled basket trial of SPY072 in subjects with moderately to severely active RA, PsA, or axSpA (Figure 6). The trial consists of three sub-studies, all of which have completed enrollment on or ahead of schedule:</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">RA sub-study:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Double-blind, placebo-controlled safety and efficacy study of two dose levels of SPY072 at Week 12 with open-label follow-up through Week 36. Topline proof-of-concept data are expected in September 2026.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">PsA sub-study:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Double-blind, placebo-controlled safety and efficacy study of a single dose level of SPY072 at Week 16 with open-label follow-up through Week 40. Topline proof-of-concept data are expected in the fourth quarter of 2026.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">axSpA sub-study:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Double-blind, placebo-controlled safety and efficacy study of a single dose level of SPY072 at Week 16 with open-label follow-up through Week 40. Topline proof-of-concept data are expected in the fourth quarter of 2026.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-top:3pt;text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Figure 6. SKYWAY trial design</span></div><div style="margin-top:3pt;text-align:justify;text-indent:36pt"><img src="syre-20260630_g6.jpg" alt="SKYWAY.jpg" style="height:263px;margin-bottom:5pt;vertical-align:text-bottom;width:612px" id="i-6"/></div><div style="margin-top:9pt;text-align:justify"><span><br/></span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">RF=rheumatoid factor; ACPA= Anti-citrullinated protein antibodies; cs/b/tsDMARD=conventional synthetic, biologic, or targeted synthetic disease modifying antirheumatic drugs; BASDAI=Bath Ankylosing Spondylitis Disease Activity Index; P=primary endpoint; S=secondary endpoint; E=exploratory endpoint. IR=inadequate response.</span></div><div style="margin-top:9pt"><span><br/></span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPY001 &#8211; anti-&#945;4&#946;7 mAb</span></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SPY001 is a highly potent, highly selective, and humanized monoclonal immunoglobulin G1 investigational antibody designed to bind selectively to the &#945;4&#946;7 integrin being developed for the treatment of IBD (UC and Crohn&#8217;s Disease (&#8220;CD&#8221;)). The &#945;4&#946;7 integrin is a protein found on the surface of immune cells. This integrin regulates the migration of immune cells to the gut where they contribute to the inflammatory process in IBD. By selectively binding to the &#945;4&#946;7 integrin, SPY001 is designed to prevent the interaction of these immune cells with MAdCAM-1, a molecule expressed on endothelial cells lining the blood vessels in the gut. By blocking the interaction between &#945;4&#946;7 integrin and MAdCAM-1, SPY001 aims to reduce the recruitment of immune cells to the gut, leading to a decrease in inflammation. Since it specifically targets the gut immune system, SPY001 is designed to minimize systemic immunosuppressive effects unrelated to IBD pathology.</span></div><div style="margin-top:9pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPY002 and SPY072 &#8211; anti-TL1A mAbs</span></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our anti-TL1A program, we nominated two highly potent, highly selective, and fully human mAb candidates designed to bind to tumor necrosis factor-like ligand 1A (&#8220;TL1A&#8221;). SPY002 (formerly SPY002-091) is being developed for the treatment of IBD (UC and CD) and SPY072 (formerly SPY002-072) is being developed for the treatment of RD. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TL1A is a protein that plays a role in regulating the immune system and is elevated in gut tissue of individuals with IBD and serum or synovial tissue of individuals with RA, PsA, and axSpA. TL1A interacts with its receptor, death receptor 3 (&#8220;DR3&#8221;), which is expressed in various immune cells, including T cells and fibroblast-like synoviocytes. This interaction triggers signaling pathways that contribute to inflammation and joint injury in RD, leading to symptomology, such as pain and swelling. SPY002 and SPY072 have been designed to block the interaction between TL1A and DR3, and thereby inhibit the downstream signaling events to dampen the inflammatory response. By neutralizing TL1A, we believe that SPY002 and SPY072 have the potential to modulate the immune response in IBD and rheumatic disease patients, potentially reducing disease activity.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPY003 &#8211; anti-IL-23 mAb</span></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SPY003 is a clinical-stage program designed to bind to interleukin 23 (&#8220;IL-23&#8221;) and incorporates half-life extending modifications. IL-23 is a cytokine that is produced by immune cells and is involved in immune response regulation. IL-23 promotes the survival, expansion, and activity of Th17 cells. Th17 cells produce inflammatory cytokines, such as IL-17, which contribute to the inflammation seen in IBD. IL-23 also helps in the recruitment and activation of other immune cells, such as neutrophils, which further contribute to tissue damage in the gut. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SPY003 binds to the p19 subunit of IL-23 with subnanomolar potency in cellular assays. SPY003 also exhibited extended PK half-life of greater than three-fold relative to a synthesized risankizumab comparator that does not incorporate half-life extending modifications, based on head-to-head preclinical studies in non-human primates (&#8220;NHPs&#8221;). </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPY120 - combination, anti-&#945;4&#946;7 and anti-TL1A mAbs</span></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SPY120 combines SPY001 (anti-&#945;4&#946;7) and SPY002 (anti-TL1A) antibodies, pairing two complementary mechanisms studied in third-party clinical trials targeting non-overlapping sites of action.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February and May 2025, we presented preclinical data demonstrating that combinations resulted in additive or greater than additive in vivo biological activity relative to either monotherapy in mouse hapten reagent 2,4,6-trinitrobenzene sulfonic acid (&#8220;TNBS&#8221;) and anti-CD40 colitis models. In October 2025, we presented preclinical data further demonstrating that combined inhibition resulted in superior efficacy relative to constituent monotherapies in a mouse TNBS-induced colitis model. In addition, combination toxicology studies have been completed with no drug-related adverse findings observed.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPY130 - combination anti-&#945;4&#946;7 and anti-IL-23 mAbs</span></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SPY130 combines SPY001 (anti-&#945;4&#946;7) and SPY003 (anti-IL-23) antibodies, pairing two commercially validated mechanisms targeting non-overlapping sites of action. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2024, we presented preclinical data, demonstrating in a T-cell transfer model of IBD, that combinations with anti-IL-23 and anti-&#945;4&#223;7 improved body weight and reduced colonic CD4+ infiltration and IL-17 levels relative to monotherapy. In March and October 2025, we presented additional preclinical data, demonstrating that combinations resulted in superior in vivo biological activity relative to either monotherapy in mouse TNBS model. In addition, combination toxicology studies have been completed with no drug-related adverse findings observed.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPY230 &#8211; combination anti-TL1A and anti-IL-23 mAbs</span></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SPY230 combines SPY002 (anti-TL1A) and SPY003 (anti-IL-23) antibodies, pairing two complementary mechanisms of action with potential to address overlapping and non-overlapping triggers of inflammation.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2024, we presented preclinical data, demonstrating that anti-IL-23 and anti-TL1A have a synergistic effect on promoting IL-17 secretion from human and mouse cells, and that the combination of anti-IL-23 and anti-TL1A suppressed IL-17 secretion more effectively than either agent alone. In March and October </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025, we presented additional preclinical data, demonstrating that combinations resulted in superior in vivo biological activity relative to either monotherapy in mouse TNBS model. In addition, combination toxicology studies have been completed with no drug-related adverse findings observed.</span></div><div id="i7ac5520bfa654a33b8eea56f2b4c5e97_121"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Paragon Agreement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Paragon Agreement, we received the option to license the intellectual property rights related to four research programs (collectively, the &#8220;Option&#8221;) from Paragon in accordance with a license agreement to be entered into following each exercise of the Option. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 12, 2023, December 14, 2023 and June 5, 2024, we exercised our Option available under the Paragon Agreement with respect to the SPY001, SPY002 and SPY003 research programs, respectively. In May 2024, we signed license agreements with Paragon for rights to royalty-bearing, world-wide, exclusive licenses to develop, manufacture, commercialize or otherwise exploit certain antibodies and products targeting &#593;4&#946;7 integrin (SPY001 program) (the &#8220;SPY001 License Agreement&#8221;) and TL1A (SPY002 and SPY072 programs) (the &#8220;SPY002 and SPY072 License Agreement&#8221;) and, in October 2024, we signed a license agreement for rights to a royalty-bearing, world-wide, exclusive license to develop, manufacture, commercialize or otherwise exploit certain antibodies and products targeting IL-23 (SPY003 program) (the &#8220;SPY003 License Agreement&#8221; and, together with the SPY001 License Agreement and the SPY002 and SPY072 License Agreement, the &#8220;License Agreements&#8221;) in the field of IBD. The SPY003 License Agreement was subsequently amended and restated in February 2025 and further amended in May 2026 to expand the definition of &#8220;Field&#8221; to encompass all therapeutic, prophylactic, palliative and diagnostic uses for SPY003, subject to certain restrictions. The Option with respect to one additional program remains unexercised under the Paragon Agreement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of each License Agreement, we are obligated to pay Paragon up to $22.0 million upon the achievement of specific development, regulatory and clinical milestones for the first product under each agreement, respectively, that achieves such specified milestones, including a milestone payment of $5 million upon the first dosing of a human patient in a Phase 3 trial. With respect to the SPY002 and SPY072 License Agreement only, on a product-by-product basis, we are obligated to pay sublicensing fees of up to approximately $20 million upon the achievement of mostly commercial milestones. Subject to the execution of the Option with respect to the remaining research program, we expect to be obligated to make similar payments upon and following the execution of a license agreement with respect to such research program.</span></div><div id="i7ac5520bfa654a33b8eea56f2b4c5e97_124"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States (&#8220;U.S. GAAP&#8221;). The preparation of these condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, costs and expenses, and related disclosures. These estimates form the basis for judgments we make about the carrying values of our assets, liabilities and equity and the amount of revenues and expenses, which are not readily apparent from other sources. We base our estimates on historical experience and on various other assumptions that we believe are reasonable under the circumstances. On an ongoing basis, we evaluate our estimates and assumptions. Our actual results may differ materially from these estimates under different assumptions or conditions. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our critical accounting policies are those policies which require the most significant judgments and estimates in the preparation of our consolidated financial statements. The most significant estimates and assumptions that management considers in the preparation of our financial statements relate to accrued research and development costs and inputs used in the Black-Scholes model for stock-based compensation expense. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We define our critical accounting policies as those accounting principles generally accepted in the United States that require us to make subjective estimates and judgments about matters that are uncertain and are likely to have a material impact on our financial condition and results of operations, as well as the specific manner in which we apply those principles. There have been no significant changes to our critical accounting policies and estimates as compared to the critical accounting policies and estimates disclosed in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Operations&#8221; included in our Annual Report, except as disclosed below:</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Value Rights</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2026, Contingent Value Rights are no longer a critical accounting policy or estimate. We determined that our future payment obligations under the contingent value rights agreement (the "CVR Agreement") we entered into with Equiniti Trust Company LLC (f/k/a American Stock Transfer &amp; Trust Company LLC) as rights agent in connection with the Asset Acquisition no longer qualify as derivatives under ASC 815, Derivatives and Hedging, as all contingencies have been resolved. Accordingly, we have measured the fair value of our CVR liability by discounting the estimated future payments to be made under the CVR Agreement using our weighted average cost of capital. The estimated value of the CVR consideration is based upon available information and certain assumptions which our management believes are reasonable under the circumstances. The ultimate payout under the CVRs may differ materially from the assumptions used in determining the fair value of the CVR consideration.</span></div><div id="i7ac5520bfa654a33b8eea56f2b4c5e97_127"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comparison of the Three Months Ended June&#160;30, 2026 and 2025</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the three months ended June&#160;30, 2026 and 2025, together with the changes in those items in dollars and as a percentage:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.263%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.263%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.263%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.054%"/><td style="width:0.1%"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Increase/(Decrease)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating expenses:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">65,503&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">40,145&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25,358&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">63&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16,136&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,790&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,346&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">37&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gain on sale of in-process research and development asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(40,000)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(10,000)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(30,000)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">41,639&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">41,935&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(296)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(41,639)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(41,935)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(296)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,053&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,874&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,179&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other expense, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,614)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(656)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,958)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total other income, net</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,439&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,218&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">221&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Loss before income tax expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(36,200)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(36,717)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(517)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(36,200)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(36,717)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(517)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.11pt">Percentage not meaningful</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Research and development expenses increased by $25.4 million, or 63%, to $65.5 million for the three months ended June&#160;30, 2026, from $40.1 million for the three months ended June&#160;30, 2025. The increase was primarily driven by higher manufacturing expenses, clinical trial expenses, and compensation costs partially offset by lower early-stage research and development costs. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.263%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.263%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.263%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.054%"/><td style="width:0.1%"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Increase/(Decrease)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2026</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">External research and development expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Preclinical</span></div></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,822&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,078&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,256)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(55)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">IBD</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">33,563&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">23,178&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,385&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">45&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Rheumatic diseases</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,714&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,120&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,594&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">243&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,785&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(23)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,808&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16,557&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total external research and development expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">49,884&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">30,353&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19,531&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">64&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Internal research and development expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,838&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,296&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,542&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">67&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,218&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,100&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,118&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">52&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">563&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">396&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">167&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">42&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total internal research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,619&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,792&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,827&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">60&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total research and development expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">65,503&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">40,145&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25,358&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">63&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.11pt">Percentage not meaningful</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">External research and development expenses include costs associated with third parties contracted to conduct research and development activities on our behalf, including through Paragon, contract research organizations (&#8220;CROs&#8221;), contract manufacturing organizations (&#8220;CMOs&#8221;), and third-party laboratories. For the three months ended June&#160;30, 2026 and 2025, external research and development costs accounted for $49.9 million and $30.4 million, respectively. Preclinical expenses decreased primarily due to a reduction in early-stage research and development activities given our pipeline's advancement. IBD and Rheumatic diseases expenses increased primarily due to an increase in manufacturing costs and clinical development activities related to ongoing or planned clinical trials. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Internal research and development expenses include compensation and related costs associated with our research and development employees. For the three months ended June&#160;30, 2026 and 2025, internal research and development costs accounted for $15.6 million and $9.8 million, respectively. The increase was primarily driven by an increase in compensation costs due to an increase in research and development headcount.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> General and administrative expenses increased by $4.3 million, or 37%, to $16.1 million for the three months ended June&#160;30, 2026, from $11.8 million for the three months ended June&#160;30, 2025. The increase was primarily attributable to an increase in compensation costs due to an increase in general and administrative headcount.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gain on Sale of In-Process Research and Development Asset</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. During the three months ended June&#160;30, 2026 and 2025, the Company recognized gains of $40.0 million and $10.0 million, respectively, upon the achievement of milestones related to the 2023 sale of the global rights to the legacy assets, pegzilarginase, to Immedica, which were triggered by the sale of the related priority review voucher (&#8220;PRV&#8221;) and a favorable reimbursement decision for pegzilarginase in Europe, respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Income. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income was $10.1 million and $5.9 million for the three months ended  June&#160;30, 2026 and 2025, respectively. The increase was primarily due to higher investment balances. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other expense, net. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net for the three months ended June&#160;30, 2026 increased by $4.0 million versus the three months ended June&#160;30, 2025 primarily driven by changes in the fair value of the CVR liability, which was primarily driven by changes in the likelihood of achievement of certain milestones, changes in the risk-adjusted discount rates and time value of money adjustments.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><div id="i7ac5520bfa654a33b8eea56f2b4c5e97_130"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comparison of the Six Months Ended June&#160;30, 2026 and 2025</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the six months ended June&#160;30, 2026 and 2025, together with the changes in those items in dollars and as a percentage:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.263%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.263%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.263%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.054%"/><td style="width:0.1%"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Increase/(Decrease)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(dollars in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating expenses (income):</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">125,914&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">81,768&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">44,146&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">54&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="background-color:#cff0fc;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31,366&#160;</span></td><td style="background-color:#cff0fc;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">23,734&#160;</span></td><td style="background-color:#cff0fc;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,632&#160;</span></td><td style="background-color:#cff0fc;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">32&#160;</span></td><td style="background-color:#cff0fc;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gain on sale of in-process research and development asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(70,000)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(10,000)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(60,000)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2.62pt 1pt 1.5pt 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total operating expenses</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">87,280&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">95,502&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(8,222)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(9)</span></td><td style="background-color:#cff0fc;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(87,280)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(95,502)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(8,222)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(9)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other (expense) income:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest income</span></td><td colspan="2" style="background-color:#cff0fc;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17,048&#160;</span></td><td style="background-color:#cff0fc;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12,367&#160;</span></td><td style="background-color:#cff0fc;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,681&#160;</span></td><td style="background-color:#cff0fc;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other (expense) income, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(34,973)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,630&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(36,603)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total other (expense) income</span></div></td><td colspan="2" style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(17,925)</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,997&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(31,922)</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Loss before income tax expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(105,205)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(81,505)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">23,700&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income tax benefit (expense)</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15&#160;</span></td><td style="background-color:#cff0fc;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(15)</span></td><td style="background-color:#cff0fc;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(105,205)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(81,490)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">23,715&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.11pt">Percentage not meaningful</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Research and development expenses increased by $44.1 million, or 54%, to $125.9 million for the six months ended June&#160;30, 2026, from $81.8 million for the six months ended June&#160;30, 2025. The increase was primarily driven by higher manufacturing expenses, clinical trial expenses, and compensation costs, partially offset by lower early-stage research and development.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.263%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.263%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.263%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.054%"/><td style="width:0.1%"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Increase/(Decrease)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">External research and development expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Preclinical</span></div></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,703&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12,557&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(8,854)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(71)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">IBD</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">68,032&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">46,008&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22,024&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">48&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Rheumatic diseases</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20,638&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,149&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,489&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">301&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,770&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">178&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,592&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,018&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total external research and development expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">96,143&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">63,892&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">32,251&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">50&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Internal research and development expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16,566&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,856&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,710&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">68&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12,009&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,612&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,397&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">58&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,196&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">408&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">788&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">193&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total internal research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">29,771&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17,876&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,895&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">67&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total research and development expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">125,914&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">81,768&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">44,146&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">54&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">External research and development expenses include costs associated with third parties contracted to conduct research and development activities on our behalf, including through Paragon, CROs, CMOs, and third-</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">party laboratories.  For the six months ended June&#160;30, 2026 and 2025, external research and development costs accounted for $96.1 million and $63.9 million, respectively. Preclinical expenses decreased primarily due to a reduction in early-stage research and development activities given our pipeline's advancement. IBD and Rheumatic diseases expenses increased primarily due to an increase in manufacturing costs and clinical development activities related to ongoing or planned clinical trials.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Internal research and development expenses include compensation and related costs associated with our research and development employees. For the six months ended June&#160;30, 2026 and 2025, internal research and development costs accounted for $29.8 million and $17.9 million, respectively. The increase was primarily driven by an increase in research and development headcount. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> General and administrative expenses increased by $7.6 million, or 32%, to $31.4 million for the six months ended June&#160;30, 2026, from $23.7 million for the six months ended June&#160;30, 2025. The increase was primarily attributable to an increase in compensation costs due to an increase in general and administrative headcount.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gain on Sale of In-Process Research and Development Asset. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2026 and 2025, the Company recognized gains of $70.0 million and $10.0 million, respectively, related to milestone payments earned in connection with the 2023 sale of the global rights to the legacy Aeglea asset pegzilarginase to Immedica. The 2026 gain was triggered by the regulatory approval of pegzilarginase in the United States and the sale of the related PRV, while the 2025 gain was triggered by a favorable reimbursement decision for pegzilarginase in Europe.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Income. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income was $17.0 million and $12.4 million for the six months ended June&#160;30, 2026 and 2025, respectively. The increase was primarily due to higher investment balances. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (expense) income, net.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Other (expense) income, net for the six months ended June&#160;30, 2026 increased by $36.6&#160;million versus the six months ended June&#160;30, 2025 primarily driven by changes in the fair value of the CVR liability, which was primarily driven by changes in the likelihood of achievement of certain milestones and receipt of certain cash consideration within the CVR term, changes in estimated reimbursement rates compared to reimbursement target rates, changes in estimated cash flow dates, and an increase in risk-adjusted discount rates, partially offset by time value of money adjustments.</span></div><div id="i7ac5520bfa654a33b8eea56f2b4c5e97_133"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical stage biotechnology company with a limited operating history, and due to our significant research and development expenditures, we have generated operating losses since our inception and have not generated any revenue from the commercial sale of any products. There can be no assurance that profitable operations will ever be achieved, and, if achieved, whether profitability can be sustained on a continuing basis. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception and through June&#160;30, 2026, we have funded our operations by raising an aggregate of approximately $2.1 billion of gross proceeds from the sale and issuance of convertible preferred stock and common stock, pre-funded warrants, the collection of grant proceeds, and the licensing of our product rights for commercialization of pegzilarginase in Europe and certain countries in the Middle East. As of June&#160;30, 2026, we had an accumulated deficit of $1.2 billion. In April 2026, we raised an additional approximately $435.2&#160;million in net proceeds from a public underwritten offering of our common stock.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary use of cash is to fund the development of our product candidates, and advance our pipeline. This includes both the research and development costs and the general and administrative expenses required to support those operations. Since we are a clinical stage biotechnology company, we have incurred significant operating losses since our inception and we anticipate such losses, in absolute dollar terms, to increase as we continue to pursue clinical development of our product candidates, prepare for the potential commercialization of our product candidates, and expand our development efforts in our pipeline of nonclinical candidates. Based on current operating plans, we have sufficient resources to fund operations for at least one year from the issuance date of the financial statements included in this Quarterly Report with existing cash, cash equivalents, and marketable securities. We will need to secure additional financing in the future to fund additional research and development, and before a commercial drug can be produced, marketed and sold. If we </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are unable to obtain additional financing or generate license or product revenue, the lack of liquidity could have a material adverse effect on us.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources of Liquidity</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 6, 2024, the Company entered into a sales agreement (the &#8220;2024 Sales Agreement&#8221;) with TD Securities (USA) LLC as its agent, pursuant to which the Company may issue and sell up to $200.0 million of shares of common stock under an at-the-market (&#8220;ATM&#8221;) offering program. During the year ended December 31, 2025, we sold an aggregate of 445,668 shares of common stock under the ATM offering program pursuant to the 2024 Sales Agreement resulting in net proceeds of $14.8&#160;million. During the six months ended June&#160;30, 2026, the Company sold an aggregate of 296,396 shares of common stock under the ATM offering program pursuant to the 2024 Sales Agreement resulting in net proceeds of $9.7&#160;million. The 2024 Sales Agreement was terminated on June 26, 2026 and the Company concurrently entered into a new sales agreement (the &#8220;2026 Sales Agreement&#8221;) with TD Securities (USA) LLC as its agent, pursuant to which the Company may issue and sell up to $500.0 million of shares of common stock under an ATM offering program. During the three months ended June 30, 2026, the Company did not sell any shares under the ATM offering program pursuant to the 2026 Sales Agreement. As of June&#160;30, 2026, $500.0 million remained available for sale under the 2026 Sales Agreement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2025, we sold 17,094,594 shares of our common stock in an underwritten public offering, inclusive of 2,229,729 shares pursuant to the full exercise of the underwriters' over-allotment option, under our shelf registration statement on Form S-3 at a price per share of $18.50, resulting in net proceeds of $296.4&#160;million after deducting approximately $19.9&#160;million of underwriting discounts and other offering costs.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In April 2026, we sold an aggregate of 7,475,000 shares of our common stock in an underwritten public offering, inclusive of 975,000 shares pursuant to the full exercise of the underwriters' over-allotment option, at a public offering price per share of $62.00, resulting in net proceeds of approximately $435.2&#160;million after deducting approximately $28.2&#160;million of underwriting discounts and other offering costs.</span></div><div id="i7ac5520bfa654a33b8eea56f2b4c5e97_136"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows for the periods indicated (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash and cash equivalents (used in) provided by:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating activities</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(127,249)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(87,557)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(241,323)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78,937&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">444,858&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">856&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net increase (decrease) in cash and cash equivalents</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76,286&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,764)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Used in Operating Activities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in operating activities for the six months ended June&#160;30, 2026 was $127.2 million and primarily reflected a net loss of $105.2 million adjusted for a $70.0 million non-operating gain on sale of in-process research and development, a $8.8 million decrease in net operating assets and liabilities driven by timing of payments to vendors, a $4.5 million in net accretion of discount on marketable securities, net of interest proceeds from maturities of zero coupon U.S. Treasury Bills, partially offset by non-cash expenses of $34.9 million due to an increase in the fair value of the CVR liability, and $26.3 million for share-based compensation expense.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in operating activities for the six months ended June&#160;30, 2025 was $87.6 million and primarily reflected a net loss of $81.5 million coupled with net loss adjustments of a $10.0 million gain on sale of in-process research and development and a $9.6 million decrease in net operating assets and liabilities driven by timing of payments to vendors, partially offset by stock-based compensation of $18.2 million.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash (Used in) Provided By Investing Activities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in investing activities for the six months ended June&#160;30, 2026 was $241.3 million and primarily consisted of $528.5 million in purchases of marketable securities, partially offset by $217.2 million in maturities and sales of marketable securities and $70.0 million in proceeds from the sale of an in-process research &amp; development asset.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by investing activities for the six months ended June 30, 2025 was $78.9 million and primarily consisted of $178.2 million in maturities and sales of marketable securities, $7.0 million in proceeds from the sale of an in-process research &amp; development asset, partially offset by $106.3 million in purchases of marketable securities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Provided by Financing Activities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by financing activities for the six months ended June&#160;30, 2026 was $444.9 million, which primarily consisted of $435.2 million and $9.8 million net proceeds from the issuance of common stock in connection with the April 2026 follow-on offering and ATM offering program, respectively, and $23.3 million proceeds from stock option exercises and sales of common stock under our ESPP, partially offset by a $22.9 million payment to CVR holders.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by financing activities for the six months ended June&#160;30, 2025 was $0.9 million.</span></div><div id="i7ac5520bfa654a33b8eea56f2b4c5e97_139"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Contractual Obligations</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through the Asset Acquisition, we received the Option to license certain intellectual property rights related to certain research programs. The exercise of the Option allows for us to enter into an exclusive license agreement with Paragon for the respective research program. Thus far we have exercised the Option and entered into license agreements with respect to SPY001, SPY002, SPY072 and SPY003. Under the terms of each License Agreement, we are obligated to pay Paragon up to $22.0 million based on specific development, regulatory and clinical milestones for the first product under each agreement. As of June&#160;30, 2026, we have incurred a total of $21.0 million of milestone fees out of a total maximum of $66.0 million in potential milestone fees across all License Agreements. As of June&#160;30, 2026, no achieved milestone fees are outstanding and payable. With respect to the SPY002 and SPY072 License Agreement only, on a product-by-product basis, we are obligated to pay sublicensing fees of up to approximately $20.0 million upon the achievement of mostly commercial milestones. As of June&#160;30, 2026, we have incurred $2.6 million of sublicensing fees of which none is outstanding and payable.</span></div><div id="i7ac5520bfa654a33b8eea56f2b4c5e97_142"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no recent adopted accounting pronouncements that have had a material effect on our financial position or results of operations.</span></div><div id="i7ac5520bfa654a33b8eea56f2b4c5e97_145"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risk.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risks in the ordinary course of our business. These risks primarily include interest rate sensitivities related to our interest-earning investments, foreign currency exchange rates and inflation risk affecting labor costs and clinical trial costs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Risk</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of United States interest rates, particularly because our investments are in marketable securities. As of June&#160;30, 2026, we held $1.1 billion in cash, cash equivalents, and marketable securities, all of which were denominated in U.S. dollars, and consisted primarily of investments in money market funds, commercial paper, U.S. government obligations, and corporate bonds. Our marketable securities are subject to interest rate risk and could fall in value if market interest rates increase. However, we believe that our exposure to interest rate risk is not significant as the majority of our investments are short-term in duration and have a low risk profile. A </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hypothetical 10% change in interest rates during any of the periods presented would not have had a material effect on the total market value of our cash equivalents and marketable securities as of June&#160;30, 2026. To date, we have not experienced a loss of principal on any of our investments and as of June&#160;30, 2026, we did not record any allowance for credit loss from our investments.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Risk</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also exposed to market risk related to changes in foreign currency exchange rates as a result of our entering into transactions denominated in currencies other than U.S. dollars. Due to the uncertain timing of expected payments in foreign currencies, we do not utilize any forward exchange contracts. All foreign transactions settle on the applicable spot exchange basis at the time such payments are made. Volatile market conditions arising from the macroeconomic environment (including financial conditions affecting the banking system and financial institutions), inflation, tariff/trade policy, or global political instability may result in significant changes in exchange rates, and in particular, a weakening of the U.S. dollar relative to foreign currencies may negatively affect our expenses and net income as expressed in U.S. dollars. An adverse movement in foreign exchange rates could have a material effect on payments made to foreign suppliers. For the six months ended June&#160;30, 2026, a majority of our expenditures were denominated in U.S. dollars. A hypothetical 10% change in foreign exchange rates during any of the periods presented would not have had a material impact on our consolidated financial statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inflation Fluctuation Risk</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inflation generally affects us by increasing our costs, such as the cost of labor and research and development contract costs. We do not believe inflation has had a material adverse effect on the results of our operations during the three months ended June&#160;30, 2026.</span></div><div id="i7ac5520bfa654a33b8eea56f2b4c5e97_148"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our principal executive officer and principal financial officer, evaluated, as of the end of the period covered by this Quarterly Report, the effectiveness of our disclosure controls and procedures. Based on the foregoing evaluation of our disclosure controls and procedures, as of June&#160;30, 2026, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act are recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting during the quarter ended June&#160;30, 2026, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><div id="i7ac5520bfa654a33b8eea56f2b4c5e97_151"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. &#8211; Other Information</span></div><div id="i7ac5520bfa654a33b8eea56f2b4c5e97_154"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may become involved in legal proceedings relating to claims arising from the ordinary course of business. Our management believes that there are currently no claims or actions pending against us, the ultimate disposition of which could have a material adverse effect on our results of operations, financial condition or cash flows.</span></div><div id="i7ac5520bfa654a33b8eea56f2b4c5e97_160"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following summarizes the principal factors that make an investment in the Company speculative or risky, all of which are more fully described in the Risk Factors section below. This summary should be read in conjunction with the Risk Factors section and should not be relied upon as an exhaustive summary of the material risks facing our business. Some of the factors, events and contingencies discussed below may have occurred in the past, but the disclosures below are not representations as to whether or not the factors, events or contingencies have occurred in the past, and instead reflect our beliefs and opinions as to the factors, events or contingencies that could materially and adversely affect us in the future. The occurrence of any of these risks, could harm our business, financial condition, results of operations and/or growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made in this Quarterly Report and those we may make from time to time. You should consider all of the risk factors described in our public filings when evaluating our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk Factor Summary </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Our Financial Condition and Capital Requirements</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will not be able to continue as a going concern if we are unable to raise additional capital when needed and raising additional capital may cause dilution to our stockholders and restrict our operations.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have never generated any revenue from product sales and may never be profitable. </span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We anticipate that we will continue to incur significant losses for the foreseeable future.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Discovery, Development and Commercialization</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our programs are in clinical and preclinical stages of development and may fail or suffer delays or may be more costly than anticipated for various reasons, including but not limited to delays or failures in achieving alignment with regulatory authorities on interpretation of data and its sufficiency to support approval of our product candidates, participant recruitment or other clinical trial or supply challenges.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are substantially dependent on the success of the SPY001, SPY002, SPY072 and SPY003 programs, alone or in combination, and may fail to achieve our development goals in the time frames we expect.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Any drug delivery device used may have its own regulatory development, supply, and other risks.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be successful in building a pipeline of product candidates with commercial value.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our studies and trials may be insufficient to support regulatory approval of any product candidates.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be successful in discovering, developing and commercializing our intra-portfolio investigational drug combinations to achieve superior outcomes relative to the use of other therapies.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Preliminary or &#8220;topline&#8221; data from our clinical trials may change as more data becomes available.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our current or future clinical trials may reveal significant adverse events or undesirable side effects.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may fail to capitalize on more profitable or potentially successful product candidates.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our products may not achieve regulatory approval, market acceptance or commercial success.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our programs may compete with each other and may face third-party program competition.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Regulatory authorities may not accept data from clinical trials we conduct at sites outside the United States or other jurisdiction.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Government Regulation</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be able to achieve our timelines or obtain timely regulatory approvals of product candidates.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be able to meet requirements for chemistry, manufacturing and control of our programs.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our product candidates may face competition sooner than anticipated based on rules and regulations that may apply or government decisions with respect to our intellectual property.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Even if we receive regulatory approval, we will be subject to extensive ongoing regulatory obligations.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may be negatively impacted by healthcare legislative reform measures and other changes in law.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our potential revenue may be adversely affected due to unfavorable regulations, laws and/or policies.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may face criminal liability or other consequences if we violate U.S. and foreign trade regulations.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Any accelerated review designations we may pursue may not hasten development or regulatory review.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may be negatively impacted by disruptions at the FDA and other government agencies, including as a result of a government shutdown.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may fail in obtaining, maintaining and protecting our patents and other proprietary rights. </span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may be subject to patent infringement claims or may need to file such claims.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may be subject to claims of wrongful hiring of employees or wrongful use of confidential information.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our patents and our ability to protect our products may be impaired by changes to patent laws.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our patent protection could be reduced or eliminated for non-compliance with legal requirements.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may fail to identify or interpret relevant third-party patents.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may become subject to claims challenging the inventorship or ownership of our intellectual property.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Patent terms may be inadequate to protect our competitive position of our programs.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our technology licensed from various third parties may be subject to retained rights or may be affected by failure to comply with obligations in license agreements or other disruptions to business relationships with licensors resulting in loss of license rights that are important to our business.</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have limited foreign intellectual property rights and may not be able to protect our intellectual property and proprietary rights throughout the world. </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The intellectual property landscape around engineered antibodies is highly dynamic, and third parties may initiate legal proceedings alleging that we are infringing, misappropriating, or otherwise violating their intellectual property rights, the outcome of which would be uncertain and may prevent, delay or otherwise interfere with our product discovery and development efforts.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Our Reliance on Third Parties</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may fail to maintain collaborations and licensing arrangements with third parties that we rely on.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Third parties we rely on for nonclinical studies and clinical trials may fail to satisfy contractual duties.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may be unable to use third-party manufacturing sites, our third-party manufacturers may encounter difficulties in production or we may need to switch or create third-party manufacturer redundancies.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Employee Matters, Managing Growth and Other Risks Related to Our Business</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may experience difficulties in managing the growth of our organization.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may fail to attract or retain highly qualified personnel.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to operate in foreign markets is subject to regulatory burdens, risks and uncertainties.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our estimates of market opportunity may be inaccurate and our business may not grow at similar rates. </span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our employees or third parties may engage in misconduct or other improper activities.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may be impacted by information security incidents, cybersecurity or data breaches or other improper access to our data that could have a negative impact on our business or reputation.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our expanding use of AI exposes us to operational, regulatory, legal, and ethical risks that could adversely affect our business, reputation, financial condition, and results of operations.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may fail to comply with privacy, data security, safety and other regulations despite compliance efforts.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may be subject to adverse legislative or regulatory tax changes.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may fail to realize the benefits of our business or product acquisitions or our strategic alliances.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Our Common Stock</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The market price of our common stock has historically been volatile and may drop in the future.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our certificate of incorporation, Delaware law and certain contracts include anti-takeover provisions. </span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We do not anticipate paying any dividends in the foreseeable future.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Future sales and issuances of equity/debt may dilute stockholders and/or result in a drop in our stock price.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our principal stockholders own a significant percentage of our stock. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our product liability insurance may be insufficient to cover costly and damaging liability claims.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Litigation costs and the outcome of litigation could have a material adverse effect on our business.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We continue to incur significant costs for compliance with public company laws and regulations.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our failure to maintain proper and effective internal controls may adversely affect our ability to report our financial condition and results of operations in a timely and accurate manner, decrease investor confidence in us, and reduce the value of our common stock. For example, in the fourth quarter of 2024, we identified a material weakness in our internal control over financial reporting which resulted in restatements of our previously-issued financial statements to amend certain net loss per share disclosures.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business could be adversely affected by macroeconomic conditions, including geopolitical unrest.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Condition and Capital Requirements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need to raise additional capital, and if we are unable to do so when needed, we will not be able to continue as a going concern.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2026</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we had $1,145.3&#160;million of cash, cash equivalents, and marketable securities. We will need to raise additional capital to continue to fund our operations in the future. If we are unable to raise additional capital when needed, we will not be able to continue as a going concern.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developing our product candidates requires a substantial amount of capital. We expect our research and development expenses to increase in connection with our ongoing activities, particularly as we advance our product candidates through clinical trials. We will need to raise additional capital to fund our operations and such funding may not be available to us on acceptable terms, or at all, and such funding may become even more difficult to obtain due to macroeconomic conditions, including rising interest rates, tariffs and trade restrictions, global conflicts, and other conditions that could result in volatility in the U.S. capital markets and the biotechnology sector in general. Competition for additional capital among biotechnology companies may be particularly intense during economic uncertainty. We may be unable to raise capital through public offerings of our common stock and may need to turn to alternative financing arrangements. Such arrangements, if we pursue them, could involve sources of funding, such as issuances of secured debt and structured revenue-based financing, and/or issuances of one or more types of securities, including common stock, preferred stock, convertible debt, warrants to acquire common stock or other securities. These securities could be issued at or below the then prevailing market price for our common stock. In addition, if we issue secured debt or debt securities, the holders of the debt would have a claim to our assets that would be superior to the rights of stockholders until the principal, accrued and unpaid interest and any premium or make-whole has been paid. Interest on any newly-issued debt securities and/or newly-incurred borrowings would increase our operating costs and reduce our net income (or increase our net loss), and these impacts may be material. If the issuance of new securities results in diminished rights to holders of our common stock, the market price of our common stock could be materially and adversely affected.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently have any products approved for sale and do not generate any revenue from product sales. Accordingly, we expect to rely primarily on equity and/or debt financings to fund our continued operations. Our ability to raise additional funds will depend, in part, on the success of our nonclinical studies and clinical trials and other product development activities, regulatory events, our ability to identify and enter into licensing or other strategic arrangements, and other events or conditions that may affect our value or prospects, as well as factors related to political, financial, economic and market conditions, many of which are beyond our control. There can be no assurances that sufficient funds will be available to us when required or on acceptable terms, if at all. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to raise additional capital when required or on acceptable terms, we may be required to:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significantly delay, scale back, or discontinue the development or commercialization of our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek strategic partnerships, or amend existing partnerships, for research and development programs at an earlier stage than otherwise would be desirable or that we otherwise would have sought to develop independently, or on terms that are less favorable than might otherwise be available in the future;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">dispose of technology assets, or relinquish or license on unfavorable terms, our rights to technologies or any of our product candidates that we otherwise would seek to develop or commercialize ourselves;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pursue the sale of our company to a third party at a price that may result in a loss on investment for our stockholders; or</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">file for bankruptcy or cease operations altogether (and face any related legal proceedings).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could have a material adverse effect on our business, operating results and prospects. Even if successful in raising new capital, we could be limited in the amount of capital we raise due to investor demand restrictions placed on the amount of capital we raise or other reasons.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, any capital raising efforts are subject to significant risks and contingencies, as described in more detail under the risk factor titled &#8220;Raising additional capital may cause dilution to our stockholders, restrict our operations, or require us to relinquish rights.&#8221;</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have never generated any revenue from product sales and may never be profitable.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no products approved for commercialization and have never generated any revenue from product sales. Our ability to generate revenue and achieve profitability depends on our ability, alone or with strategic collaborators, to successfully complete the development of, and obtain the regulatory and marketing approvals necessary to commercialize one or more of our product candidates. We do not anticipate generating revenue from product sales for the foreseeable future. Our ability to generate future revenue from product sales depends heavily on our success in many areas, including but not limited to:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">completing research and development of our product candidates; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining regulatory and marketing approvals for our product candidates for which we complete clinical trials; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing product candidates and establishing and maintaining supply and manufacturing relationships with third parties that are commercially feasible, meet regulatory requirements and our supply needs in sufficient quantities to meet market demand for our product candidates, if approved; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">qualify for adequate coverage and reimbursement by government and third-party payors for any product candidates for which we obtain regulatory and marketing approval;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">marketing, launching, and commercializing product candidates for which we obtain regulatory and marketing approval, either directly or with a collaborator or distributor; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">gaining market acceptance of our product candidates as treatment options;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">addressing any competing products and technological and market developments;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">implementing internal systems and infrastructure, as needed;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">protecting and enforcing our intellectual property rights, including patents, trade secrets, and know-how;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">negotiating favorable terms in any collaboration, licensing, or other arrangements into which we may enter;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining coverage and adequate reimbursement from third-party payors and maintaining pricing for our product candidates that supports profitability; and </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">attracting, hiring, and retaining qualified personnel. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if one or more of the product candidates that we develop is approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product candidate. Our expenses could increase beyond expectations if we are required by regulatory authorities to perform clinical and other studies in addition to those that we are currently conducting or anticipate. Even if we are able to generate revenues from the sale of any approved products, we may not become profitable and may need to obtain additional funding to continue operations. Portions of our research programs may be in-licensed from third parties, which make the commercial sale of such in-licensed products potentially subject to additional royalty and milestone payments to such third parties. We will also have to develop or acquire manufacturing capabilities or continue to contract with contract manufacturers in order to continue development and potential commercialization of our product candidates. For instance, if the costs of manufacturing our biologic product are not commercially feasible, we will need to develop or procure our biologic product in a commercially feasible manner in order to successfully commercialize a future approved product, if any. Additionally, if we are not able to generate revenue from the sale of any approved products, we may never become profitable.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have historically incurred losses, have a limited operating history on which to assess our business, and anticipate that we will continue to incur significant losses for the foreseeable future.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company with a limited operating history. Since inception, we have incurred significant operating losses. For the years ended December 31, 2025, 2024 and 2023, we reported a net loss of $155.2 million, $208.0 million and $338.8 million, respectively. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2026</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we had an accumulated deficit of $1.2 billion. We will need to raise substantial additional capital to continue to fund our operations in the future.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to raise capital as and when needed, on favorable terms or at all, would have a negative impact on our financial condition and our ability to develop our product candidates. Changing circumstances may cause us to consume capital significantly faster or slower than we currently anticipate. If we are unable to acquire additional capital or resources, we will be required to modify our operational plans to complete future milestones and we may be required to delay, limit, reduce or eliminate development or future commercialization efforts of product candidates and/or programs. We have based these estimates on assumptions that may prove to be wrong, and we could exhaust our available financial resources sooner than we currently anticipate. We may be forced to reduce our operating expenses and raise additional funds to meet our working capital needs, principally through the additional sales of our securities or debt financings or entering into strategic collaborations. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have devoted substantially all of our financial resources to identify, acquire, and develop our product candidates, including conducting nonclinical and clinical development of the legacy rare disease clinical trials conducted by us prior to the Asset Acquisition and the nonclinical and clinical development of our current pipeline, and providing general and administrative support for our operations. To date, we have funded our operations primarily from the sale and issuance of convertible preferred and common equity securities, pre-funded warrants, the collection of grant proceeds, and the licensing of our product rights for commercialization of pegzilarginase in Europe and certain countries in the Middle East. The amount of our future net losses will depend, in part, on the rate of our future expenditures and our ability to obtain funding through equity or debt financings, strategic collaborations, or grants. Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. We expect our losses to increase as our product candidates enter more advanced clinical trials. It may be several years, if ever, before we complete pivotal clinical trials or have a product candidate approved for commercialization. We expect to invest significant funds into the research and development of our current product candidates to determine the potential to advance these product candidates to regulatory approval. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we obtain regulatory approval to market a product candidate, our future revenue will depend upon the size of any markets in which our product candidates may receive approval, and our ability to achieve sufficient market acceptance, pricing, coverage and adequate reimbursement from third-party payors, and adequate market share for our product candidates in those markets. Even if we obtain adequate market share for our product candidates, because the potential markets in which our product candidates may ultimately receive regulatory approval could be very small, we may never become profitable despite obtaining such market share and acceptance of our products.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future and our expenses will increase substantially if and as we:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue the nonclinical and clinical development of our product candidates; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue efforts to discover and develop new product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue the manufacturing of our product candidates or increase volumes manufactured by third parties;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">advance our product candidates into larger, more expensive clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">initiate additional nonclinical studies or clinical trials for our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek regulatory and marketing approvals and reimbursement for our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish a sales, marketing, and distribution infrastructure to commercialize any products for which we may obtain marketing approval and market for ourselves;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek to identify, assess, acquire, and/or develop other product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">make milestone, royalty, or other payments under third-party license agreements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek to maintain, protect, and expand our intellectual property portfolio;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek to attract and retain skilled personnel; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">experience any delays or encounter issues with the development and potential for regulatory approval of our clinical and product candidates such as safety issues, manufacturing delays, clinical trial accrual delays, longer follow-up for ongoing or planned studies or trials, additional major studies or trials, or supportive trials necessary to support marketing approval.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the net losses we incur may fluctuate significantly from quarter to quarter and year to year, such that a period-to-period comparison of our results of operations may not be a good indication of our future performance.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Raising additional capital may cause dilution to our stockholders, restrict our operations, or require us to relinquish rights. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate substantial revenue from the sale of our product candidates, we expect to finance our cash needs through a combination of equity offerings, debt financings and license and development agreements. To the extent that we raise additional capital through the sale of equity securities or convertible debt securities, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a holder of common stock. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may be required to relinquish valuable rights to our research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements with third parties when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to third parties to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that we raise additional capital through the sale of equity, including pursuant to any sales under convertible debt or other securities convertible into equity, the ownership interest of our stockholders will be diluted, and the terms of these new securities may include liquidation or other preferences that adversely affect the rights of our stockholders. For instance, in December 2023, we sold an aggregate of 6,000,000 shares of our common stock and 150,000 shares of our Series B Preferred Stock pursuant to a private placement to certain investors for gross proceeds of approximately $180 million, in March 2024, we sold an aggregate of 121,625 shares of our Series B Preferred Stock pursuant to a private placement to certain investors for gross proceeds of approximately $180 million, in October 2025, we sold 17,094,594 shares of our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">common stock in an underwritten public offering for gross proceeds of approximately $316 million and in April 2026, we sold 7,475,000 shares of our common stock in an underwritten public offering for gross proceeds of approximately $463 million. Since stockholder approval of the Series B Conversion Proposal, an aggregate of 271,625 shares of Series B Preferred Stock have been converted to 10,865,000 shares of common stock</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt financing, if available, would likely involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, making additional product acquisitions, or declaring dividends. If we raise additional funds through strategic collaborations or licensing arrangements with third parties, we may have to relinquish valuable rights to our product candidates or future revenue streams or grant licenses on terms that are not favorable to us. We cannot be assured that we will be able to obtain additional funding if and when necessary to fund our entire portfolio of product candidates to meet our projected plans. If we are unable to obtain funding on a timely basis, we may be required to delay or discontinue one or more of our development programs or the commercialization of any product candidates or be unable to expand our operations or otherwise capitalize on potential business opportunities, which could materially harm our business, financial condition, and results of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Discovery, Development and Commercialization</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face competition from entities that have developed or may develop programs for the diseases and/or mechanisms of action targeted by our product candidates. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development and commercialization of drugs is highly competitive. Our product candidates, if approved, will face significant competition and our failure to effectively compete may prevent us from achieving significant market penetration. We compete with a variety of multinational biopharmaceutical companies, specialized biotechnology companies and emerging biotechnology companies, as well as academic institutions, governmental agencies, and public and private research institutions, among others. Many of the companies with which we are currently competing or will compete against in the future have significantly greater financial resources and expertise in research and development, manufacturing, nonclinical testing, clinical trial conduct, regulatory approvals, marketing and market access than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industry may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites, recruiting participants for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our product candidates. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our competitors have developed, are developing or will develop programs and processes competitive with our programs and processes. Competitive therapeutic treatments include those that have already been approved and accepted by the medical community and any new treatments. Our success will depend partially on our ability to develop and commercialize products that have competitive safety, efficacy, dosing and/or presentation profiles. Our commercial opportunity and success will be reduced or eliminated if competing products are safer, more effective, have a more attractive dosing profile or presentation or are less expensive than the products we develop, or if our competitors develop competing products or if biosimilars enter the market more quickly than we do and are able to gain market acceptance. See the section titled &#8220;Business &#8211; Competition&#8221; in our most recent Annual Report for more discussion about our competitors.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, adverse events or disappointing results in clinical trials of third parties, including our competitors developing product candidates that target similar mechanisms of action and/or in the same indications as our product candidates, could reduce expectations regarding the potential success or perceived benefits of any of our programs, increase regulatory scrutiny of our product candidates, decrease confidence of current or potential trial participants and clinical trial collaborators in our investigational programs and/or have a negative impact on collaborations or demand for any product we may develop. These events also could result in the suspension, discontinuation, or clinical hold of or modification to our clinical trials. If public perception is influenced by claims that the use of therapies with shared or similar characteristics as ours is unsafe, ineffective or otherwise fails to meet expectations, our product candidates may not be accepted or favored by the general public, the medical community or the investment community and potential clinical trial subjects may be discouraged from enrolling in our clinical trials or may discontinue their participation in our clinical trials. Negative developments could result in reduced probability of success of clinical trials involving our product </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidates, challenges enrolling clinical trial participants, greater governmental regulation, stricter labeling requirements, decreased market potential and potential regulatory delays in the testing or approvals of our product candidates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, because of the competitive landscape for inflammatory and immunology (&#8220;I&amp;I&#8221;) indications, we may also face competition for clinical trial enrollment. Clinical trial enrollment will depend on many factors, including if potential clinical trial participants choose to undergo treatment with approved products or enroll in competitors&#8217; ongoing clinical trials for programs that are under development for the same indications as our programs. An increase in the number of approved products for the indications we are targeting with our programs may further exacerbate this competition. Our inability to enroll a sufficient number of participants could, among other things, delay our development timeline, which may further harm our competitive position.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates are in clinical or preclinical stages of development and may fail in development or suffer delays that materially and adversely affect their commercial viability. If we or our current or future collaborators are unable to complete development of, or commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no products on the market and all of our product candidates are in clinical or preclinical stages of development. As a result, we expect it will be many years before we commercialize any product candidate, if ever. Our ability to achieve and sustain profitability depends on obtaining regulatory approvals for, and successfully commercializing, our product candidates, either alone or with third parties, and we cannot guarantee that we will ever obtain regulatory approval for any of our product candidates. We have not yet demonstrated our ability to obtain regulatory approvals, manufacture a commercial-scale product or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. Before obtaining regulatory approval for the commercial distribution of our product candidates, we or an existing or future collaborator must conduct extensive nonclinical tests and clinical trials to demonstrate the safety, potency and purity of our current and future product candidates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our collaborators may experience delays in initiating or completing nonclinical studies or clinical trials. We or our collaborators also may experience numerous unforeseen events during, or as a result of, any current or future nonclinical studies and clinical trials that we conduct that could delay or prevent our ability to achieve our development timelines, receive marketing approval or commercialize our current product candidates or any future product candidates, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulators, such as the U.S. Food and Drug Administration (&#8220;FDA&#8221;), or ethics committees (&#8220;ECs&#8221;)/institutional review boards (&#8220;IRBs&#8221;) may not authorize us or our investigators to commence a clinical trial, conduct a clinical trial at a prospective trial site or as otherwise planned; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may experience delays in reaching, or fail to reach, agreement on acceptable terms with prospective trial sites and prospective contract research organizations (&#8220;CROs&#8221;), the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites, and any CRO personnel changes could lead to operational delays or complications;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical trial sites may deviate from trial protocol or drop out of a clinical trial;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">clinical trials of any product candidates may fail to demonstrate safety or efficacy, produce negative or inconclusive results, or may otherwise fail to improve on the existing standard of care, and we may decide, or regulators may require us, to conduct additional nonclinical studies or clinical trials, or we may decide to abandon product development programs;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of participants required for clinical trials of any product candidates may be larger than we anticipate and enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials or fail to return for post-treatment follow-up at a higher rate than we anticipate;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our CROs or other third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all, or may deviate from the clinical trial protocol or drop out of the trial, which may require that we add new clinical trial sites or investigators;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may fail to adhere to clinical trial protocols or fail to perform in accordance with the FDA&#8217;s or any other regulatory authority&#8217;s good clinical practice (&#8220;GCP&#8221;) requirements or applicable regulatory guidelines in other countries or our clinical trial protocols may require changes;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may elect to, or regulators and/or ECs/IRBs may require that we or our investigators materially modify, suspend or terminate clinical research or trials for various reasons, including noncompliance with regulatory requirements or a finding that the participants in our trials are being exposed to unacceptable health risks;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may select clinical endpoints that require prolonged periods of observation or analyses of resulting data; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may experience delays if we or our contract manufacturing organizations (&#8220;CMOs&#8221;) are required to make changes to manufacturing processes; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may experience delays in identifying, recruiting and training suitable clinical investigators and their study teams; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of clinical trials of any of our programs may be greater than we anticipate;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be inadequate to initiate or complete a given clinical trial;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to manufacture sufficient quantities of our product candidates for use in clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reports from clinical testing of other therapies may raise safety or efficacy concerns about our programs;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or other regulatory authorities may not agree with our interpretation of the results of clinical trials or non-clinical studies or our clinical trial designs and plans;  </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may fail to establish an appropriate safety profile for a product candidate based on clinical or nonclinical data for such product candidates as well as data emerging from other therapies in the same class as our product candidates; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or other regulatory authorities may require us to submit additional data such as long-term toxicology studies, additional clinical data or additional manufacturing data or impose other requirements before permitting us to initiate clinical trials or approving marketing/commercial sales.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commencing clinical trials in the United States and in other countries is subject to acceptance by the FDA and other regulatory authorities of an investigational new drug (&#8220;IND&#8221;) application or similar application and finalizing the trial design based on discussions with the FDA or other regulatory authority. In the event that the FDA or other regulatory authority requires us to complete additional nonclinical studies or clinical trials or we are required to satisfy other regulatory authority requests prior to commencing future planned clinical trials, the start of such planned clinical trials may be delayed or such planned clinical trials may be commenced in a modified manner. Even after we receive and incorporate guidance from these regulatory authorities, the FDA or other regulatory authorities could disagree that we have satisfied their requirements to commence any future clinical trial or change their position on the acceptability of our trial design or the clinical endpoints selected, which may require us to complete additional nonclinical studies or clinical trials, delay the enrollment of our clinical trials or impose stricter approval conditions than we currently expect. Additionally, if the results of our nonclinical studies or clinical trials are not positive or are only modestly positive or if there are safety concerns, we may be required to repeat or conduct additional clinical trials or nonclinical studies for our product candidates beyond those that we currently expect. Even if we conduct such additional nonclinical studies or clinical trials or otherwise modify our planned clinical trials, the FDA or other regulatory authorities could determine that the data from our nonclinical studies or clinical trials are insufficient to support the approval of our product candidates. There are equivalent processes and risks applicable to clinical trial applications in other countries outside of the United States, which may require us to complete additional nonclinical studies or clinical trials, delay the enrollment of our clinical trials or otherwise modify our planned clinical trials or impose stricter approval conditions than we currently expect. Most product candidates that commence clinical trials are never approved as products, and our current or future clinical trials ultimately may fail to support the approval of our current or any future product candidates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not have the financial resources to continue development of, or to modify existing or enter into new collaborations for, a product candidate if we experience any issues that delay or prevent regulatory approval of, or our ability to commercialize, our product candidates. We or our current or future collaborators&#8217; inability to complete development of, or commercialize our product candidates, or significant delays in doing so, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">could have a material and adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are substantially dependent on the success of our SPY001, SPY002, SPY072 and SPY003 programs, alone or in combination, and our current and planned clinical trials of such programs may not be successful.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future success is substantially dependent on our ability to timely obtain marketing approval for, and then successfully commercialize, our SPY001, SPY002, SPY072 and SPY003 programs, alone or in combination. We are investing a majority of our efforts and financial resources into the research and development of these programs. We initiated a Phase 2 platform trial of SPY001, SPY002 and SPY003, including their pairwise combinations, for IBD in the United States and certain other countries beginning with SPY001 in May 2025. Enrollment for Part A of the Phase 2 UC platform trial is now complete. Part B, which includes combination arms, with each arm subject to regulatory feedback and approval, was opened for enrollment in March 2026. We also initiated a Phase 2 basket trial of SPY072 for RD, including RA, PsA and axSpA, in the United States and Europe in Q3 2025 through Q2 2026. Enrollment for the Phase 2 basket trial is complete. Alignment with regulatory authorities on issues that arise before clinical trials commence, during clinical trials or after our clinical trials are completed could result in additional capital expenditures or delays in development that could have a material adverse impact on our business. The success of our programs is dependent on observing longer half-lives of our product candidates and/or their combinations in humans and comparable or better safety and efficacy profiles than other mAbs currently marketed or in development. We believe longer half-lives have the potential to result in more favorable dosing schedules for our product candidates, assuming they successfully complete clinical development and obtain marketing approval. To the extent we do not observe these extended half-lives with favorable safety and efficacy profiles when we dose patients with our product candidates in our clinical trials, it would significantly and adversely affect the clinical and commercial potential of our product candidates and our business. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our programs will require additional clinical, nonclinical and manufacturing development and activities, marketing approval in multiple jurisdictions, substantial investment and significant marketing efforts before we generate any revenues from product sales. We are not permitted to market or promote these programs, or any other programs, before we receive marketing approval from the FDA and/or comparable foreign regulatory authorities, and we may never receive such marketing approvals. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our product candidates will depend on a variety of factors. We do not have complete control over many of these factors, including certain aspects of clinical development and the regulatory submission process, potential threats to our intellectual property rights and the manufacturing, marketing, distribution and sales efforts of any current or future collaborator. Accordingly, we cannot assure you that we will ever be able to generate revenue through the sale of these product candidates, even if approved. If we are not successful in commercializing SPY001, SPY002, SPY072 or SPY003, alone or in combination, or are significantly delayed in doing so, our business will be materially harmed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not achieve our projected development goals in the time frames we announce and expect, the commercialization of our product candidates may be delayed and our expenses may increase and, as a result, our stock price may decline.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we estimate the timing of the anticipated accomplishment of various scientific, clinical, regulatory and other product development goals, which we sometimes refer to as milestones. These milestones may include the commencement or completion of nonclinical studies and clinical trials, such as the expected timing of enrollment and readouts for topline data from our ongoing clinical trials, as well as the submission of regulatory filings. From time to time, we may publicly announce the expected timing of some of these milestones. All of these milestones are and will be based on numerous assumptions. The actual timing of these milestones can vary dramatically compared to our estimates, in some cases for reasons beyond our control, including positions that may be taken by or requirements of regulatory authorities. If we do not meet these milestones as publicly announced, or at all, the commercialization of our product candidates may be delayed or never achieved and, as a result, our stock price may decline. Additionally, delays relative to our projected timelines are likely to cause overall expenses to increase, which may require us to raise additional capital sooner than expected and prior to achieving targeted development milestones.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any drug delivery device that we potentially use to deliver our product candidates may have its own regulatory, development, supply and other risks.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to deliver our product candidates via a drug delivery device, such as an injector or other delivery system. There may be unforeseen technical complications related to the development activities required to bring such a product to market, including primary container compatibility and/or dose volume requirements. If our product candidates are intended to be used with drug delivery devices, we expect to utilize drug delivery devices authorized for marketing under clearances or approvals held by third parties. Our product candidates may not be approved or may be substantially delayed in receiving approval if the devices that we choose to develop do not gain and/or maintain their own regulatory approvals or clearances. Where approval of the drug product and device is sought under a single application, the increased complexity of the review process may delay approval. In addition, some drug delivery devices are provided by single-source unaffiliated third-party companies. We may be dependent on the sustained cooperation and effort of those third-party companies both to supply the devices and, in some cases, to conduct the studies required for approval or other regulatory clearance of the devices. Even if approval is obtained for our products, we may also be dependent on those third-party companies continuing to maintain such approvals or clearances, if required, for their drug delivery devices once they have been received. Failure of third-party companies to supply the devices, to successfully complete studies on the devices in a timely manner, or to obtain or maintain required approvals or clearances of the devices could result in increased development costs, delays in or failure to obtain regulatory approval and delays in product candidates reaching the market or in gaining approval or clearance for expanded labels for new indications.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our approach to the discovery and development of our programs is unproven, and we may not be successful in our efforts to build a pipeline of programs with commercial value.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our approach to the discovery and development of our research programs leverages clinically validated mechanisms of action and incorporates advanced antibody engineering to optimize half-life and other properties designed to overcome limitations of existing therapies. Our programs are purposefully designed to improve upon existing product candidates and products while maintaining the same well-established mechanisms of action. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The long-term safety and efficacy of these technologies and the extended half-lives and exposure profiles of our programs compared to currently approved products are unknown.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may ultimately discover that our investigational products developed with half-life extension technologies do not possess certain properties required for therapeutic effectiveness and could lead to adverse effects. We currently have only reported interim Phase 2 induction topline data for SPY001 and SPY002 from our SKYLINE clinical trial, Phase 1 clinical data in healthy volunteers for SPY001, SPY002, SPY072 and SPY003, and nonclinical data for these programs. We have limited available data on the increased half-life and drug clearance properties of our programs and the anticipated half-life extension and/or drug clearance properties of each of our product candidates may not be seen in participants in our future clinical trial results. In addition, programs using half-life extension technologies may demonstrate different chemical and pharmacological properties in participants than they do in laboratory studies. This technology and any programs resulting therefrom may not demonstrate the same chemical and pharmacological properties in humans and may interact with human biological systems in unforeseen, ineffective or harmful ways. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may in the future seek to discover and develop programs that are based on novel targets and technologies that are unproven. If our discovery activities fail to identify novel targets or technologies for drug discovery, or such targets prove to be unsuitable for treating human disease, we may not be able to develop viable additional programs. We and our existing or future collaborators may never receive approval to market and commercialize any product candidate. Even if we or an existing or future collaborator obtains regulatory approval, the approval may be for targets, disease indications or patient populations that are not as broad as we intended or desired or may require labeling that includes significant use or distribution restrictions or safety warnings. If the products resulting from our research programs prove to be ineffective, unsafe or commercially unviable, our programs and pipeline would have little, if any, value, which would have a material and adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preclinical and clinical development involve lengthy and expensive processes that are subject to delays and may result in uncertain outcomes, and results of earlier studies and trials may not be predictive of future clinical trial results. If our preclinical studies and clinical trials are not sufficient to support regulatory approval of any of our product candidates, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of such product candidate. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before obtaining marketing approval from regulatory authorities for the sale of any product candidate, we must complete preclinical studies and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidate in humans. Our clinical trials may not be conducted as planned or completed on schedule, if at all, and failure can occur at any time during the preclinical study or clinical trial process. For example, we depend on the availability of NHPs to conduct certain preclinical studies that we are required to complete prior to submitting an IND or foreign equivalent and initiating clinical development. There is no guarantee that we will always be able to source NHPs for our drug development activities on our preferred timelines. The cost of obtaining NHPs for our future preclinical development activities could increase significantly if short or long term shortages occur in their availability. If we are unable to source NHPs on our preferred timelines, it could result in delays to our development timelines. Similarly, we may experience difficulty in conducting our clinical trials as planned if we are unable to enroll a sufficient number of participants in any such trial as a result of variables outside of our control. See the risk factor titled &#8220;If we encounter difficulties enrolling participants in our current and future clinical trials, our clinical development activities could be delayed or otherwise adversely affected.&#8221;  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, a failure of one or more clinical trials can occur at any stage of testing. The outcome of preclinical studies and early-stage clinical trials may not be predictive of the success of later stage clinical trials. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their product candidates. In addition, we expect to rely on participants to provide feedback on measures such as measures of disease activity and measures of quality of life, which are subjective and inherently difficult to evaluate. These measures can be influenced by factors outside of our control and can vary widely from day to day for a particular participant, from participant to participant, and from site to site within a clinical trial. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot be sure that the FDA, or comparable foreign regulatory authority, as applicable, will agree with our clinical development plans. If the FDA and/or comparable foreign regulatory authority requires us to materially modify our proposed trial designs, conduct additional trials or enroll additional participants, our development timelines may be delayed. We cannot be sure that submission of an IND, clinical trial application or similar application will result in the FDA or comparable foreign regulatory authorities, as applicable, allowing clinical trials to begin in a timely manner, if at all. Moreover, even if these trials begin, issues may arise that could cause regulatory authorities to suspend or terminate them.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We could also encounter delays if an ongoing or planned clinical trial is required to be materially modified or suspended or terminated by us, by the ECs/IRBs of the institutions in which such clinical trials are being conducted, by the external Data Monitoring Committee or equivalent body, if any, for such clinical trial or by the FDA or comparable foreign regulatory authorities. Such authorities may suspend, put on clinical hold or terminate a clinical trial due to a number of factors, including not aligning with or supporting our clinical trial designs or our failure to conduct the clinical trial in accordance with regulatory requirements or our clinical trial protocols, inspection of the clinical trial operations or trial site by the FDA or comparable foreign regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from the programs, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates, if the results of these trials are not positive or the safety and efficacy results do not support regulatory approval of or commercial viability of our product candidates, our business and results of operations may be materially and adversely affected and we may incur significant additional costs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A key element of our strategy is the development of intra-portfolio investigational drug combinations. If we are not successful in discovering, developing and commercializing investigational products that </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">take advantage of different mechanisms of action to achieve superior outcomes relative to the use of monotherapies or other combinations, our ability to achieve our strategic objectives would likely be impaired. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A key element of our strategy is to build a broad portfolio of investigational products that will allow for the development of intra-portfolio combinations. We believe that by developing or licensing these investigational products, we can control the combinations we pursue and, if and when approved, maximize the commercial potential of these combinations. However, these combinations have not been tested before and may fail to achieve superior outcomes relative to the use of single agents or other combinations, may exacerbate adverse events associated with one of the investigational products when used as monotherapy, may yield new adverse events not observed with either of the monotherapies, or may fail to demonstrate sufficient safety or efficacy in clinical trials to enable us to complete those clinical trials or obtain marketing approval for the combinations. In addition, demonstrating that our combinations are superior to our single agents is likely necessary for marketing authorization of the combinations. However, comparing active treatments may be difficult to do in a controlled manner in our clinical trials, and we may be unable to interpret the results of comparisons between our combinations and single agents in a manner that satisfies regulatory requirements. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we are successful in developing combinations, competition from other investigational products in the same class which are either already approved or further along in development than ours may prevent us from realizing the commercial potential of our combinations and prevent us from achieving our strategic objectives, which would have a material and adverse effect on our business, financial condition, results of operations and prospects. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Development of combination therapies may present more or different challenges than development of monotherapies.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to pursue development of our investigational products in combination with one or more additional products or investigational products. The development of combination therapies may be more complex than the development of monotherapies and generally requires that sponsors demonstrate the contribution of each investigational product to the claimed effect and the safety and efficacy of the combination as a whole. Regulatory authority requirements for the development of combination therapies may make the design and conduct of clinical trials more complex and/or burdensome, requiring more clinical trial participants and additional time and cost to complete than we plan or anticipate. We also may not be able to meet the FDA&#8217;s or comparable foreign regulatory authority's current or future approval standards required for combination therapies or combination products, including if we decided to administer or package combinations as a single drug product. For example, under the &#8220;combination rule&#8221;, the FDA may not file or approve a fixed-dose combination product unless each component of a proposed drug product is shown to make a contribution to the claimed effects and the dosage of each component (amount, frequency, duration) is safe and effective for the intended population. To satisfy these requirements, the FDA typically requires a clinical factorial trial, designed to assess the effects attributable to each drug in the combination product. This is particularly true when the ingredients are directed at the same sign or symptom of the disease or condition. Aside from factorial trials, the FDA has accepted a variety of approaches to satisfy the combination rule and has made statements that it may be possible to use other types of clinical and nonclinical data and mechanistic information available to demonstrate the contributions of the individual active ingredients to the effect of the combination. In addition, combination products may require dose selection for each agent in the combination, which may require more and/or larger groups of participants than single agents. Our clinical trial and research efforts may not satisfy regulators' expectations of adequate exploration of dose ranging required for drug approval. Moreover, the applicable requirements for approval of combinations may differ from country to country.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event that one of our investigational products were to fail to demonstrate sufficient safety and efficacy data or establish its contribution to the claimed effects of combinations or if we are unable to meet the FDA&#8217;s or comparable foreign regulatory authority's current or future approval standards required for combination therapies or combination products in a timely manner, we would need to identify and research alternative monotherapy or combination treatments, run additional trials to produce supportive data or modify existing clinical trial plans. In the event we are unable to do so or are unable to do so on commercially reasonable terms or we are unable to continue development of one or more of investigational products, our business and prospects would be materially harmed.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we encounter difficulties enrolling participants in our current and future clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may experience difficulties in participant enrollment in our current and future clinical trials for a variety of reasons. The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of participants who remain in the trial until its conclusion. The enrollment of participants will depend on many factors, including: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of the disease under investigation;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the participant eligibility and the inclusion and exclusion criteria defined in the protocol;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the incidence and prevalence of target trial populations under clinical investigation;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the proximity of participants to trial sites;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the design of the trial;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinicians&#8217; and participants&#8217; perceptions as to the potential advantages of the drug candidate(s) being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain participant consents;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to monitor participants adequately during and after treatment;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the risk that participants enrolled in clinical trials will drop out of the trials before completion or fail to attend scheduled trial visits; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">factors we may not be able to control, including the impacts of geopolitical unrest or public health crises, which may limit the availability of participants, investigators or their staff, or clinical sites.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our clinical trials will compete with other clinical trials with product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of participants available to us, because some participants who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Since the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of participants who are available for our clinical trials at such clinical trial sites. Additionally, the number of participants required for clinical trials of our programs may be larger than we anticipate. Even if we are able to enroll a sufficient number of participants for our current or future clinical trials, we may have difficulty maintaining participants in our clinical trials. Our inability to enroll or maintain a sufficient number of participants would result in significant delays in completing clinical trials or receipt of marketing approvals, increased development costs or our cessation of one or more clinical trials altogether.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our ability to successfully initiate, enroll, and complete a clinical trial in any foreign country is subject to numerous risks unique to conducting business in foreign countries, including, without limitation: difficulty in establishing or managing relationships with CROs and physicians; different standards for the conduct of clinical trials; different standard-of-care for patients with a particular disease; difficulty in locating qualified local consultants, physicians and partners; and potential burden of complying with a variety of foreign laws, medical standards and regulatory requirements, including the regulation of pharmaceutical and biotechnology products and treatment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preliminary, &#8220;topline&#8221; or interim data from our clinical trials that we announce or publish from time to time may change as more participant data become available and are subject to audit and verification procedures.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may publicly disclose preliminary or topline data from our nonclinical studies and clinical trials, which are based on a preliminary analysis of then-available data. The results and related findings and conclusions are subject to change following a more comprehensive review or taking into account additional data that becomes available. In reviewing preliminary or topline data, we also make assumptions, estimations, calculations and conclusions as part of our analyses that may change once a complete data set is available. As </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a result, the preliminary or topline results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated or subsequently made subject to audit and verification procedures. Any preliminary or topline data should be viewed with caution until the final data are available.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular product candidate, the approvability or commercialization of the particular product candidate and our company in general. In addition, the information we choose to publicly disclose regarding a particular nonclinical study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure. If the preliminary, topline or interim data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our current and future clinical trials or those of our future collaborators may reveal significant adverse events or undesirable side effects not seen in our clinical and nonclinical studies and may result in a safety profile that could halt clinical development, inhibit regulatory approval or limit commercial potential or market acceptance of any of our product candidates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Results of our nonclinical studies or clinical trials could reveal a high and unacceptable severity and/or prevalence of side effects, adverse events or unexpected characteristics at any point in time during the development process for our product candidates. We cannot assure you that the future results of our nonclinical studies or clinical trials will not reveal such characteristics. If significant adverse events or undesirable side effects are observed in any of our current or future nonclinical studies or clinical trials, we may have difficulty recruiting participants to such trials, participants may drop out of our trials, or we may be required to cease or materially modify our development efforts of one or more programs. We, the FDA or other applicable regulatory authorities, or an EC/IRB, may suspend or require the material modification of any clinical trials of any program at any time for various reasons, including a belief that participants in such trials are being exposed to unacceptable health risks or adverse side effects. Some potential products developed in the biotechnology industry that initially showed therapeutic promise in early-stage studies and trials have later been found to cause side effects that prevented their further development. Other potential products have shown side effects in nonclinical studies, which side effects do not present themselves in clinical trials in humans. Even if the side effects do not preclude the product candidate from obtaining or maintaining marketing approval, undesirable side effects may inhibit market acceptance of the approved product due to its tolerability versus other therapies. In addition, an extended half-life could prolong the duration of undesirable side effects, which could also inhibit market acceptance. Treatment-emergent adverse events could also affect participant recruitment or the ability of enrolled participants to complete our clinical trials or could result in potential product liability claims. Potential side effects associated with our product candidates may not be appropriately recognized or managed by the treating medical staff, as toxicities resulting from our product candidates may not be normally encountered in the general patient population and by medical personnel. In addition, safety findings associated with competing products or product candidates that target similar pathways could result in the FDA or comparable foreign regulatory authorities imposing restrictions on our clinical trials or product labeling or denying approval of our products. Any of these occurrences could harm our business, financial condition, results of operations and prospects significantly.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates have mechanisms of action in common with other approved drugs that have been associated with certain adverse reactions and/or events in patients. For example, nasopharyngitis, headache, arthralgia, nausea, pyrexia, upper respiratory tract infection, fatigue, cough, bronchitis, influenza, back pain, rash, pruritus, sinusitis, oropharyngeal pain, and pain in extremities are the most common adverse reactions noted with ENTYVIO&#174;, which is in the same drug class as SPY001 and is approved for the treatment of moderately to severely active UC in adults and of moderately to severely active CD in adults. In addition, mAbs targeting TL1A such as our product candidates SPY002 and SPY072 in clinical trials are associated with patient adverse events that most commonly include headache, nausea, nasopharyngitis, urinary tract infection, SARS-CoV-2 infection, fever, fatigue, arthralgia, and back pain. Finally, for SKYRIZI&#174;, which is in the same drug class as SPY003 and is approved for the treatment of moderately to severely active UC in adults and of moderately to severely active CD in adults, the most common adverse reactions are upper respiratory </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">infections, headache, arthralgia, injection site reactions, abdominal pain, anemia, pyrexia, back pain, arthropathy, and urinary tract infection in patients with CD and arthralgia, pyrexia, injection site reactions, and rash in patients with UC. Participants in our clinical trials for SPY001, SPY002, SPY072 and SPY003, or combinations thereof, may experience similar or additional adverse reactions and/or events such as infections (including rare infections such as tuberculosis or JC virus reactivation, which could lead to multifocal leukoencephalopathy, which is a theoretical risk for the drug class), infusion-related reactions, other hypersensitivity reactions (including injection site reactions and delayed hypersensitivity reactions), and hepatotoxicity, as has been observed with other biologics, including those with similar mechanisms of action. Although our product candidates have observed to be well tolerated to date, we have observed adverse events, including serious adverse events, in our clinical trials consistent with known safety profiles of drugs with the same mechanisms of action. It is possible we may observe additional safety events that may or may not be consistent with such third-party product safety profiles.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, even if we successfully advance our product candidates or any future product candidates through clinical trials, such trials will only include a limited number of participants and limited duration of exposure to our product candidates. As a result, we cannot be assured that adverse effects of our product candidates will not be uncovered when a significantly larger number of participants are exposed to the product after approval. Further, any clinical trials may not be sufficient to determine the effect and safety consequences of using any of our products over a multi-year period.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of the foregoing events occurs or has a negative impact on the safety profile of one or more of our product candidates, or if one or more of our research programs prove to be unsafe, our entire pipeline could be affected, which would have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may expend our limited resources to pursue a particular program and fail to capitalize on programs that may be more profitable or for which there is a greater likelihood of success.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we have limited financial and managerial resources, we focus our research and development efforts on certain selected programs. For example, we are initially focused on our SPY001, SPY002 and SPY003 programs, including combinations thereof, and our SPY072 program. As a result, we may forgo or delay pursuit of opportunities with other programs that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs for specific indications may not yield any commercially viable product candidates. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any approved products resulting from our current programs or any future program may not achieve adequate market acceptance among clinicians, patients, healthcare third-party payors and others in the medical community necessary for commercial success and we may not generate any future revenue from the sale or licensing of such products.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if regulatory approval is obtained for a product candidate resulting from one of our current or future programs, they may not gain market acceptance among physicians, patients, healthcare payors or the medical community. We may not generate or sustain revenue from sales of the product due to factors such as whether the product can be sold at a competitive cost and whether it will otherwise be accepted in the market. There are several approved products and product candidates in later stages of development for the treatment of IBD and the treatment of RD. However, our programs incorporate advanced antibody engineering to optimize the half-life and formulation of antibodies; to date, no such antibody has been approved by the FDA for the treatment of IBD, RA, PsA or axSpA. Market participants with significant influence over acceptance of new treatments, such as clinicians and third-party payors, may not adopt a biologic that incorporates half-life extension for our targeted indications, and we may not be able to convince the medical community and third-party payors to accept and use, or to provide favorable reimbursement for, any programs developed by us or our existing or future collaborators. An extended half-life may make it more difficult for patients to change treatments and there is a perception that half-life extension could exacerbate side effects or experience waning </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">efficacy, each of which may adversely affect our ability to gain market acceptance. Market acceptance of our product candidates will depend on many factors, including factors that are not within our control.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of medical products also depend on the willingness of clinicians to prescribe the treatment. We cannot predict whether clinicians, clinicians&#8217; organizations, hospitals, other healthcare providers, government agencies or private insurers will determine that our product is safe, therapeutically effective, cost effective or less burdensome as compared with competing treatments. If any current or future product candidate is approved but does not achieve an adequate level of acceptance by such parties, we may not generate or derive sufficient revenue from that product candidate and may not become or remain profitable.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Some of our programs may compete with our other programs, which could negatively impact our business and reduce our future revenue.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have multiple product candidates, alone and in combination, in development for the same indication, IBD, and are developing one product candidate (SPY072) for RD. We may in the future develop our programs for other I&amp;I indications. Each such program targets a single or multiple mechanisms of action that could provide differentiation from standard of care or each other. However, developing multiple programs for a single indication may negatively impact our business if the programs compete with each other. For example, if multiple programs are conducting clinical trials at the same time, they could compete for the enrollment of participants. In addition, if multiple product candidates are approved for the same indication, they may compete for market share, which could limit our future revenue. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are conducting and may conduct future clinical trials for our programs at sites in the United States and various other jurisdictions, and the FDA and comparable foreign regulatory authorities may not accept data from such trials.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are conducting and may conduct future clinical trials in the United States and various other countries. The acceptance of trial data from clinical trials conducted outside the United States or other jurisdiction by the FDA or comparable foreign regulatory authority may be subject to conditions imposed by such regulatory authority or may not be accepted at all. For example, in cases where data from foreign clinical trials are intended to serve as the basis for marketing approval in the United States, the FDA will generally not approve the applicable clinical trial data on the basis of foreign data alone unless, among other conditions, (i) the clinical trial is well-designed and conducted and performed by qualified investigators in accordance with ethical principles, (ii) the trial population adequately represents the U.S. population, and (iii) the data is applicable to the U.S. population and U.S. medical practice in ways that the FDA deems clinically meaningful. Many foreign regulatory authorities have similar approval requirements. In addition, clinical trials are subject to the applicable local laws of the jurisdictions where the trials are conducted and acceptance of the data by the FDA or any comparable foreign regulatory authority may depend on its determination that the trials also complied with all applicable local laws and regulations. There can be no assurance that the FDA or any comparable foreign regulatory authority will accept data from trials conducted outside of the United States or the applicable jurisdiction. If the FDA or any comparable foreign regulatory authority does not accept such data, it would likely result in the need for additional trials, which would be costly and time-consuming and would delay or permanently halt our development of the applicable product candidates. Even if the FDA or any comparable foreign regulatory authority accepted such data, it could require us to modify our ongoing or planned clinical trials to receive clearance to initiate such trials in the applicable jurisdiction or to continue such trials once initiated. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, conducting international clinical trials presents additional risks that may delay completion of our clinical trials. These risks include the failure of enrolled participants in foreign countries to adhere to the clinical protocol as a result of differences in healthcare services or cultural customs that could restrict or limit our ability to conduct our clinical trials, the administrative burdens of conducting clinical trials under multiple sets of foreign regulations, foreign exchange fluctuations, as well as political and economic risks relevant to foreign countries. For additional disclosures regarding political and economic risks involved with international clinical trials, see the risk factor titled &#8220;Our business could be adversely affected by economic downturns, inflation, increases in interest rates, natural disasters, public health crises, political crises, U.S. elections, international or geopolitical events, such as the conflict between Russia and Ukraine, recent events in Venezuela, conflicts between the U.S. and other countries, including Iran, and conflicts in the Middle East, the implementation of measures that </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">restrict international trade or other macroeconomic conditions, which could have a material and adverse effect on our results of operations and financial condition.&#8221;</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Government Regulation </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The regulatory approval processes of the FDA and other comparable foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable. If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for our product candidates, we will not be able to commercialize, or will be delayed in commercializing, our product candidates, and our ability to generate revenue will be materially impaired.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of obtaining regulatory approvals, both in the United States and abroad, is unpredictable, expensive and typically takes many years following commencement of clinical trials, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. We cannot commercialize product candidates in the United States without first obtaining regulatory approval from the FDA. Similarly, we cannot commercialize product candidates outside of the United States without obtaining regulatory approval from comparable foreign regulatory authorities. Before obtaining regulatory approvals for the commercial sale of our product candidates, including SPY001, SPY002, SPY072 and SPY003, alone or in combination, we must demonstrate through lengthy, complex and expensive nonclinical studies and clinical trials that our product candidates are both safe and effective for each targeted indication. Securing regulatory approval also requires the submission of information about the drug manufacturing process to, and potential inspection of manufacturing facilities by, the relevant regulatory authority. Further, our product candidates may not be effective or more effective than the standard of care or competing products or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or successfully commercializing them. The FDA and comparable foreign regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional nonclinical, clinical or other data. Our product candidates could be delayed in receiving, or fail to receive, regulatory approval for many reasons, including: the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials; we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indication; the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval; serious and unexpected drug-related side effects may be experienced by participants in our clinical trials or by individuals using drugs similar to our product candidates; we may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks; the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from nonclinical studies or clinical trials; the data collected from clinical trials of our product candidates may not be acceptable or sufficient to support the submission of a BLA or other submission or to obtain regulatory approval in the United States or elsewhere, and we may be required to conduct additional clinical trials; the FDA or the applicable foreign regulatory authority may disagree regarding the formulation, labeling and/or the specifications of our product candidates; the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval. In addition, the FDA and comparable foreign regulatory authorities may undergo leadership changes, change their policies, issue additional regulations or revise existing regulations, or take other actions, which may impact our clinical development plans or prevent or delay approval of our programs under development on a timely basis. Such policy or regulatory changes could impose additional requirements upon us that could delay our ability to obtain approvals and increase the costs of compliance.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the large number of drugs in development, only a small percentage successfully complete the FDA or foreign regulatory approval processes and are commercialized. The lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market our product candidates, which would significantly harm our business, results of operations and prospects. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, including failing to approve the most commercially promising indications, may grant approval contingent on the performance of costly post-marketing clinical trials, or may </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for our product candidates, we will not be able to commercialize, or will be delayed in commercializing, our product candidates and our ability to generate revenue will be materially impaired.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to meet requirements for the chemistry, manufacturing and control of our programs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to receive approval of our products by the FDA and comparable foreign regulatory authorities, we must show that we and our contract manufacturing partners are able to manufacture, characterize, and control our drug products and drug delivery devices safely and in accordance with regulatory requirements. This includes manufacturing the active ingredient, developing an acceptable formulation and drug delivery device, manufacturing the drug product and drug delivery device, performing tests to adequately characterize the formulated product, documenting a repeatable manufacturing process, meeting facility, process, testing, validation and commercialization requirements, and demonstrating that our drug products meet standards for parenteral administration as well as stability and quality requirements. Meeting these chemistry, manufacturing and control requirements is a complex task that requires specialized expertise. If we are not able to meet the chemistry, manufacturing and control requirements, we may not be successful in getting our products approved. In addition, we must show, or show through data from a third-party, that the drug delivery device is of adequate quality to deliver the drug product in a commercial setting.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing biologics is highly susceptible to losses due to contamination, equipment failure, improper installation or operation of equipment, vendor or operator error, inconsistency in yields, variability in product characteristics and difficulties in scaling the production process. The impact to drug supply may be compounded by the long lead times needed to manufacture additional drug product due to plant capacity limitations or other potential restrictions at our CMOs. In some cases, even minor deviations from normal manufacturing processes may result in reduced production yields, lot failures, product defects, product liability claims, or other supply disruptions. If issues arise at our third-party manufacturers&#8217; facilities, such facilities may need to be closed for an extended period of time to investigate and remedy the issues, which could delay clinical trials and adversely affect our business. Problems in third-party manufacturing processes or facilities could restrict our ability to ensure sufficient clinical material for our clinical trials or delay or prevent us from obtaining marketing approval. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Scaling up a biologic manufacturing process can be a difficult task and is associated with additional risks, including cost overruns, process scale-up, process reproducibility, stability issues, compliance with current good manufacturing practices (&#8220;cGMPs&#8221;), lot consistency and timely availability of sufficient quantity of raw materials. Even if we obtain regulatory approval for any of our product candidates, manufacturers may not be able to manufacture the approved product to specifications acceptable to the FDA or other comparable foreign regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential launch of the product or to meet potential future demand. If our third-party manufacturers are unable, or decide not, to adequately validate or scale-up the manufacturing process at our current manufacturers&#8217; facilities, we will need to transfer to another manufacturer and complete the manufacturing validation process, which can be lengthy. If our manufacturers are unable to produce sufficient quantities of drug substance and/or drug product for clinical trials or for commercialization we will need to identify and negotiate with other CMOs an agreement for clinical and/or commercial supply and it is not certain we will be able to come to agreement timely or on terms acceptable to us, which would likely jeopardize our ability to provide any product candidates to trial subjects in clinical trials and products to patients, if approved.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates for which we intend to seek approval as biologics may face competition sooner than anticipated.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Patient Protection and Affordable Care Act, as amended by the Healthcare and Education Reconciliation Act, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009 (&#8220;BPCIA&#8221;), which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. Under the BPCIA, an application for a highly similar or &#8220;biosimilar&#8221; product may not be submitted to the FDA until four years following the date that the reference product was first approved by the FDA. In addition, the approval of a biosimilar product may not be </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">made effective by the FDA until 12 years from the date on which the reference product was first approved. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor&#8217;s own nonclinical data and data from the sponsor's own adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that any of our product candidates approved as biologics under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not accord our product candidates reference product exclusivity relative to biosimilar products, potentially creating the opportunity for competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any reference products in a way that is similar to traditional generic substitution for non-biological products will depend on a number of marketplace and regulatory factors that are still developing.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we receive regulatory approval of our product candidates, we will be subject to extensive ongoing post marketing regulatory obligations and continued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with post marketing regulatory requirements or experience unanticipated problems with our products.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any regulatory approvals that we may receive for our product candidates will require the submission of reports to regulatory authorities and surveillance to monitor the safety and efficacy of the product, may impose significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, and may include burdensome post-approval trial or risk management requirements. For example, the FDA may require a risk evaluation and mitigation strategy in order to approve our product candidates, which could entail requirements for a medication guide, physician training and communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or comparable foreign regulatory authorities approve our product candidates, our product candidates and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, distribution, import and export will be subject to comprehensive regulation by the FDA and other regulatory agencies in the United States and by comparable foreign regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as on-going compliance with current cGMPs, good pharmacovigilance practices (&#8220;GVPs&#8221;) and GCPs for any post-approval trials that we conduct following approval. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic, unannounced inspections by the FDA and other regulatory authorities for compliance with cGMPs. Following approval, sponsors are also subject to continual review and periodic, unannounced inspections for compliance with GVPs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or a regulatory authority discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facilities where the product is manufactured, a regulatory authority may impose restrictions on that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing, restrictions on our ability to conduct post-approval trials, including full or partial holds on ongoing or planned trials, restrictions on the manufacturing process, warning or untitled letters, civil and criminal penalties, injunctions, product seizures, detentions or import bans, voluntary or mandatory publicity requirements and imposition of restrictions on operations, including costly new manufacturing requirements. The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue and could require us to expend significant time and resources in response and could generate negative publicity.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be negatively impacted by changes in law or other policy, including healthcare reform initiatives</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Existing regulatory policies may change, and additional government regulations may be enacted that could prevent, limit or delay development of or regulatory approval of our product candidates and/or increase our manufacturing costs, including raw materials, general operating costs or other costs. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we fail to adequately prepare for the impacts of or are slow or </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, our product candidates may be delayed in obtaining regulatory approval or may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability. In addition, the impact of legislative, executive, and administrative actions and any future healthcare measures and agency rules implemented by the current presidential administration on us and the pharmaceutical industry as a whole is unclear. These government actions could cause delays in our business plans, increase the cost of execution of our business plans or otherwise have a material adverse effect on our business. For example, recent actions and statements by the U.S., including those relating to the imposition or threatened imposition of tariffs (including tariffs on patented pharmaceutical products), affecting (among others) certain products manufactured in China and other non-U.S. countries. These measures could impact the cost of manufacturing our product candidates for our ongoing and planned clinical trials and may increase other costs such as import and export costs across different jurisdictions, costs of drug product and clinical trial supplies, and other costs of running our trials and executing on our business plans, which could negatively impact our financial position. We may seek alternative or additional sources for our drug substance or drug product for our clinical trials, clinical trial sites, or service providers, which could negatively impact our expected costs, timelines and business plan. Additionally, the BIOSECURE Act enacted as part of the FY 2026 National Defense Authorization Act has the potential to severely restrict our ability to purchase services or products from, or otherwise collaborate with, certain Chinese &#8220;biotechnology companies of concern&#8221; (&#8220;BCOC&#8221;) without losing the ability to contract with, or otherwise receive funding from, the U.S. government. We currently rely on foreign CMOs, including WuXi Biologics, which is based in China. Although none of our CMOs have yet been named as a BCOC, if any of our CMOs are identified as a BCOC, we could be required to switch or move development of our product candidates from one CMO to another, and as a result we may incur additional development costs or delays in manufacturing product for clinical trials or commercialization. We are in the process of creating manufacturing capabilities with third parties outside of China, including within the United States, and have taken several measures to strengthen our supply chain in the event that our manufacturers are impacted. In the U.S., in recent years, the pharmaceutical industry has been a particular focus of healthcare reform efforts and has been significantly affected by major legislative, administrative and executive initiatives addressing drug pricing and payment, access to healthcare or funding of healthcare as well as more general actions affecting federal budgets and tariffs. See the section titled &#8220;Business &#8211; Government Regulation &#8211; Healthcare Reform&#8221; in our most recent Annual Report for a more detailed description of healthcare reform measures that may prevent us from being able to generate revenue, attain profitability, or commercialize our product candidates. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations, patients and others will be subject to applicable healthcare regulatory laws, which could expose us to penalties.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute our product candidates, if approved. In the U.S., these laws include, but are not limited to the following, some of which are likely to apply only if or when we obtain marketing approval for a product candidate: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal false claims, false statements, and civil monetary penalties laws prohibiting, among other things, any person from knowingly presenting, or causing to be presented, a false claim for payment of government funds or knowingly making, or causing to be made, a false statement to get a false claim paid;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal anti-kickback law, which prohibits, among other things, persons from offering, soliciting, receiving, or providing remuneration, directly or indirectly, to induce either the referral of an individual for, or the purchasing or ordering of, a good or service for which payment may be made under federal healthcare programs such as Medicare and Medicaid;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), which, in addition to privacy protections applicable to healthcare providers and other entities, prohibits executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDCA, which among other things, strictly regulates drug marketing, prohibits manufacturers from marketing products prior to approval or for off-label use and regulates the distribution of samples;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal laws that require pharmaceutical manufacturers to calculate, report and certify certain complex product prices and other data to the government or provide certain discounts or rebates to government authorities or private entities, often as a condition of reimbursement under government healthcare programs, which data may be used in the calculation of reimbursement and/or discounts on approved products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Open Payments (or federal &#8220;sunshine&#8221; law), which requires pharmaceutical and medical device companies to monitor and report certain financial interactions with certain healthcare providers to the Center for Medicare &amp; Medicaid Services within the U.S. Department of Health and Human Services for re-disclosure to the public, as well as ownership and investment interests held by physicians and their immediate family members;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">analogous state laws and regulations, including state anti-kickback and false claims laws, consumer protection and unfair competition laws and laws governing privacy, security and breaches of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state laws that require pharmaceutical companies to comply with specific compliance standards, restrict financial interactions between pharmaceutical companies and healthcare providers, report drug product pricing information, financial interactions with health care providers, or marketing expenditures and/or require the registration of pharmaceutical sales representatives.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The distribution of biopharmaceutical products is subject to additional requirements and regulations, including extensive record-keeping, licensing, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See the section titled &#8220;Business &#8211; Government Regulation &#8211; Other Healthcare Laws and Compliance Requirements&#8221; in our most recent Annual Report for a more detailed description of certain laws that may affect our ability to operate.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ensuring compliance is time-consuming and costly. If and when one of our product candidates is approved, our compliance efforts will need to expand and evolve to address newly applicable laws. Given the breadth of the laws and regulations, limited guidance for certain laws and regulations and evolving government interpretations of the laws and regulations, governmental authorities may possibly conclude that our business practices are non-compliant. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. If our operations are found to be in violation of any of the laws described above or any other government regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion from participation in government healthcare programs, such as Medicare and Medicaid, imprisonment, and the curtailment or restructuring of our operations, any of which could adversely affect our business, financial condition, results of operations, and prospects. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we are able to commercialize any product candidates, due to unfavorable pricing regulations and/or third-party coverage and reimbursement policies, we may not be able to offer such product candidates at competitive prices, which would seriously harm our business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to seek approval to market our product candidates in both the United States and in selected foreign jurisdictions. If we obtain approval in one or more foreign jurisdictions for our product candidates, we will be subject to rules and regulations in those jurisdictions. Our ability to successfully commercialize any product candidates that we may develop will depend in significant part on the extent to which reimbursement or coverage for these product candidates and related treatments will be available from government health administration authorities, government health benefit programs, private health insurers, such as managed care plans, and other organizations. Government authorities and other third-party payors decide which medications they will pay for and establish reimbursement levels. Government authorities and other third-party payors have attempted to control costs by restricting coverage, controlling utilization and limiting the amount of reimbursement for particular medications. Third party payors may take action to encourage use of other products perceived to be clinically superior or more cost effective which may limit demand for our products. Our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ability to commercialize our product candidates successfully may also be adversely affected by discounts or rebates that we are required to provide in order to ensure coverage of our products and compete in the marketplace. Additionally, if any of our product candidates is approved and we are found to have improperly promoted off-label uses of those product candidates, we may become subject to significant liability, which would materially adversely affect our business and financial condition. See the sections titled &#8220;Business &#8211; Government Regulation &#8211; Coverage and Reimbursement&#8221; and &#8220;Business &#8211; Government Regulation &#8211; Regulation in the European Union&#8221; in our most recent Annual Report for a more detailed description of the government regulations and third-party payor practices that may affect our ability to commercialize our product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations. We can face criminal liability and other serious consequences for violations, which can harm our business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, various economic and trade sanctions regulations administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Controls, the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act and other state and national anti-bribery and anti-money laundering laws in the countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors, and other collaborators from authorizing, promising, offering, or providing, directly or indirectly, improper payments or anything else of value to or from recipients in the public or private sector. We may engage third parties to sell our products outside the United States, to conduct clinical trials, and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors, and other collaborators, even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Governments outside the United States tend to impose strict price controls, which may adversely affect our revenue, if any.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some countries, particularly member states of the EU, the pricing of prescription drugs is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after receipt of marketing approval for a therapeutic. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU member states and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices. To obtain coverage and reimbursement or pricing approvals in some countries, we or current or future collaborators may be required to conduct a clinical trial or other studies that compare the cost-effectiveness of our product candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If reimbursement of any product candidate approved for marketing is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business, financial condition, results of operations or prospects could be materially and adversely affected. If the UK or certain EU member states were to significantly alter their regulations affecting the pricing of prescription pharmaceuticals, we could face significant new costs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A breakthrough therapy, fast track, or other expedited designation for our product candidates may not lead to a faster development or regulatory review or approval process, and it does not increase the likelihood that those product candidates will receive marketing approval.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek a breakthrough therapy, fast track, or other designation for appropriate product candidates. Designations such as these are within the discretion of the FDA, or other comparable foreign </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulatory authorities. The receipt of a designation for a product candidate may not result in a faster development process, review or approval compared to products considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify under one of FDA&#8217;s designation programs, the FDA may later decide that the products no longer meet the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. Additionally, changes in the leadership of the FDA and other actions taken by the presidential administration, including mass layoffs within the federal government, may impose constraints on the FDA&#8217;s ability to engage in activities in the normal course and may result in reductions to the FDA&#8217;s budget, employees and operations, which may lead to slower response times and longer review periods, potentially affecting our ability to take advantage of the benefits for the Fast Track Designation and progress development of our programs or obtain regulatory approval for our programs. See the section titled &#8220;Business &#8211; Government Regulation &#8211; United States Biologics Regulation &#8211; Expedited Development and Review Programs&#8221; in our most recent Annual Report for a more detailed description of the process for seeking expedited designations such as fast track or breakthrough therapy designations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disruptions at the FDA and other government agencies, including as a result of a government shutdown, could negatively affect the review of our regulatory submissions, which could negatively impact our business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and approve regulatory submissions can be affected by a variety of factors, including a government shutdown as well as statutory, regulatory and policy changes, inadequate government budget funding levels or a reduction in the FDA&#8217;s workforce and its ability to hire and retain key personnel, disruptions caused by government shutdowns and public health crises. There have been mass layoffs of federal employees since the start of the current presidential administration in January 2025, the full impact of which is unclear at this time. Such disruptions could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business. In addition, the presidential administration has made and is expected to continue to make significant changes in the leadership of the FDA and other U.S. federal regulatory agencies and changes to U.S. federal government policy that have led to, in some cases, legal challenges and uncertainty around the funding, functioning and policy priorities of the U.S. federal regulatory agencies, including the FDA. In addition, certain senior employees of FDA have not maintained long tenure in their positions, marking a period of high leadership turnover.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are unable to predict the extent to which the presidential administration may impose or seek to impose leadership or policy changes at the FDA or changes to rules and policies impacting our business and operations. It is unclear how these executive actions or other potential actions by the federal government will impact the FDA or other regulatory authorities that oversee our business. Government proposals to reduce or eliminate budgetary deficits may include reduced allocations to the FDA and other related government agencies. These budgetary pressures may reduce the FDA&#8217;s ability to perform its responsibilities, which could result in delays in our clinical trial timelines. If a significant reduction in the FDA&#8217;s workforce occurs, the FDA&#8217;s budget is significantly reduced or a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions or take other actions critical to the development or manufacturing of our product candidates, which could have a material adverse effect on our business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the U.S. Supreme Court&#8217;s June 2024 decision in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loper Bright Enterprises v. Raimondo </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">overturned the longstanding Chevron doctrine, under which courts were required to give deference to regulatory agencies&#8217; reasonable interpretations of ambiguous federal statutes. The </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loper</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> decision could result in additional legal challenges to regulations and guidance issued by federal agencies, including FDA and the Center for Medicare &amp; Medicaid Services, on which we rely. Any such legal challenges, if successful, could have a material impact on our business. Additionally, the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loper</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> decision may result in increased regulatory uncertainty, inconsistent judicial interpretations, and other impacts to the agency rulemaking process, any of which could adversely impact our business and operations. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action or as a result of legal challenges, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, our business could be materially harmed.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to obtain and protect our patents and other proprietary rights is uncertain, exposing us to the possible loss of competitive advantage.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely upon a combination of patents, trademarks, trade secret protection, confidentiality agreements, license agreements, including the License Agreements, and the Paragon Agreement to protect the intellectual property related to our programs and technologies and to prevent third parties from competing unfairly with us. Our success depends in large part on our ability to obtain and maintain patent protection for our platform technologies, programs and their uses, as well as our ability to operate without infringing on or violating the proprietary rights of others. We own and have licensed rights to pending patent applications and expect to continue to file patent applications in the United States and abroad related to our novel discoveries and technologies that are important to our business. However, we may not be able to protect our intellectual property rights throughout the world and the legal systems in certain countries may not favor enforcement or protection of patents, trade secrets and other intellectual property. Filing, prosecuting and defending patents on programs worldwide would be expensive and our intellectual property rights in some foreign jurisdictions can be less extensive than those in the United States; the reverse may also occur. As such, we may not have patents in all countries or all major markets and may not be able to obtain patents in all jurisdictions even if we apply for them. Our competitors may operate in countries where we do not have patent protection and can freely use our technologies and discoveries in such countries to the extent such technologies and discoveries are publicly known or disclosed in countries where we do have patent protection or pending patent applications.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our pending and future patent applications may not result in patents being issued. Any issued patents may not afford sufficient protection of our programs or their intended uses against competitors, nor can there be any assurance that the patents issued will not be infringed, designed around, invalidated by third parties, or effectively prevent others from commercializing competitive technologies, products or programs. Even if these patents are granted, they may be difficult to enforce. Further, any issued patents that we may license or own covering our programs could be narrowed or found invalid or unenforceable if challenged in court or before administrative bodies in the United States or abroad, including the United States Patent and Trademark Office (&#8220;USPTO&#8221;). Further, if we encounter delays in our clinical trials or delays in obtaining regulatory approval, the period of time during which we could market our product candidates under patent protection would be reduced. Thus, the patents that we may own or license may not afford us any meaningful competitive advantage. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to seeking patents for some of our technology and programs, we may also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. Any disclosure, either intentional or unintentional, by our employees, the employees of third parties with whom we share our facilities or third-party consultants and vendors that we engage to perform research, clinical trials or manufacturing activities, or misappropriation by third parties (such as through a cybersecurity breach) of our trade secrets or proprietary information could enable competitors to duplicate or surpass our technological achievements, thus eroding our competitive position in our market. In order to protect our proprietary technology and processes, we rely in part on confidentiality agreements with our collaborators, employees, consultants, outside scientific collaborators and sponsored researchers and other advisors. These agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. We may need to share our proprietary information, including trade secrets, with future business partners, collaborators, contractors and others located in countries at heightened risk of theft of trade secrets, including through direct intrusion by private parties or state actors and those affiliated with or controlled by state actors. In addition, while we undertake efforts to protect our trade secrets and other confidential information from disclosure, others may independently discover trade secrets and proprietary information, and in such cases, we may not be able to assert any trade secret rights against such party. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights and failure to obtain or maintain trade secret protection could adversely affect our competitive business position. Enforcing a claim that a party illegally obtained and is using our trade secrets is challenging and the outcome is unpredictable. In addition, courts outside of the U.S. may be less willing to protect trade secrets.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lastly, if our trademarks and trade names are not registered or adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in obtaining or maintaining necessary rights to our programs through acquisitions and in-licenses.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because our development programs currently do and may in the future require the use of proprietary rights held by third parties, the growth of our business may depend in part on our ability to acquire, in-license, or use these third-party proprietary rights. We may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify as necessary for our programs. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the relevant program, which could have a material adverse effect on our business, financial condition, results of operations, and prospects. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we normally seek to obtain the right to control prosecution, maintenance and enforcement of the patents relating to our programs, there may be times when the filing and prosecution activities for patents and patent applications relating to our programs are controlled by our current and future licensors or collaboration partners. If any of our current and future licensors or collaboration partners fail to prosecute, maintain and enforce such patents and patent applications in a manner consistent with the best interests of our business, including by payment of all applicable fees for patents covering our product candidates, we could lose our rights to the intellectual property or our exclusivity with respect to those rights, our ability to develop and commercialize those product candidates may be adversely affected and we may not be able to prevent competitors from making, using and selling competing products. In addition, even where we have the right to control patent prosecution of patents and patent applications we have licensed to and from third parties, we may still be adversely affected or prejudiced by actions or inactions of our licensees, our current and future licensors and their counsel that took place prior to the date upon which we assumed control over patent prosecution. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current and future licensors may rely on third-party consultants or collaborators or on funds from third parties such that our current and future licensors are not the sole and exclusive owners of the patents we in-license. If other third parties have ownership rights to our current and future in-licensed patents, they may be able to license such patents to our competitors, and our competitors could market competing products and technology. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that we may be unable to obtain licenses at a reasonable cost or on reasonable terms, if at all. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to redesign our technology, programs, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates, which could harm our business, financial condition, results of operations, and prospects significantly. We cannot provide any assurances that third-party patents do not exist which might be enforced against our current technology, manufacturing methods, programs, or future methods or products resulting in either an injunction prohibiting our manufacture or future sales, or, with respect to our future sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties, which could be significant. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disputes may arise between us and our current and future licensors regarding intellectual property subject to a license agreement, including: the scope of rights granted under the license agreement and other interpretation-related issues; whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; our right to sublicense patents and other rights to third parties; our right to transfer or assign the license; the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our current and future licensors and us and our partners; and the priority of invention of patented technology.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to patent infringement claims or may need to file claims to protect our intellectual property, which could result in substantial costs and liability and prevent us from commercializing our potential products.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because the intellectual property landscape in the biotechnology industry is rapidly evolving and interdisciplinary, it is difficult to conclusively assess our freedom to operate and guarantee that we can operate without infringing on or violating third-party rights. If certain of our product candidates are ultimately granted regulatory approval, patent rights held by third parties, if found to be valid and enforceable, could be alleged to render one or more of our product candidates infringing. If a third party successfully brings a claim against us, we may be required to pay substantial damages, be forced to abandon any affected product candidate and/or seek a license from the patent holder. In addition, any intellectual property claims (e.g. patent infringement or trade secret theft) brought against us, whether or not successful, may cause us to incur significant legal expenses and divert the attention of our management and key personnel from other business concerns. We cannot be certain that patents owned or licensed by us will not be challenged by others in the course of litigation. Some of our competitors may be able to sustain the costs of complex intellectual property litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise funds and on the market price of our common stock. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors may infringe or otherwise violate our patents, trademarks, copyrights or other intellectual property. To counter infringement or other violations, we may be required to file claims, which can be expensive and time-consuming. Any such claims could provoke these parties to assert counterclaims against us, including claims alleging that we infringe their patents or other intellectual property rights. In addition, in a patent infringement proceeding, a court or administrative body may decide that one or more of the patents we assert is invalid or unenforceable, in whole or in part, construe the patent&#8217;s claims narrowly or refuse to prevent the other party from using the technology at issue on the grounds that our patents do not cover the technology. Similarly, if we assert trademark infringement claims, a court or administrative body may determine that the marks we have asserted are invalid or unenforceable or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In such a case, we could ultimately be forced to cease use of such marks. In any intellectual property litigation, even if we are successful, any award of monetary damages or other remedy we receive may not be commercially valuable.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, we may be required to protect our patents through procedures created to attack the validity of a patent at the USPTO. An adverse determination in any such submission or proceeding could reduce the scope or enforceability of, or invalidate, our patent rights, which could adversely affect our competitive position. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if our programs are found to infringe the intellectual property rights of third parties, these third parties may assert infringement claims against our future licensees and other parties with whom we have business relationships and we may be required to indemnify those parties for any damages they suffer as a result of these claims, which may require us to initiate or defend protracted and costly litigation on behalf of licensees and other parties regardless of the merits of such claims. If any of these claims succeed, we may be forced to pay damages on behalf of those parties or may be required to obtain licenses for the products they use. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or other legal proceedings relating to our intellectual property rights, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or other proceedings.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that we have wrongfully hired an employee from a competitor or that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is common in the biotechnology industry, in addition to our employees, we engage the services of consultants to assist us in the development of our programs. Many of these consultants, and many of our employees, were previously employed at, or may have previously provided or may be currently providing consulting services to, other biotechnology or pharmaceutical companies including our competitors or potential competitors. Despite our training and compliance efforts, we could in the future be subject to claims that we or our employees have inadvertently or otherwise used or disclosed alleged trade secrets or other confidential information of former employers or competitors. Although we try to ensure that our employees and consultants do not use the intellectual property, proprietary information, know-how or trade secrets of others in their work for us, we may become subject to claims that we caused an employee to breach the terms of his or her non-competition or non-solicitation agreement, or that we or these individuals have, inadvertently or otherwise, used or disclosed the alleged trade secrets or other proprietary information of a former employer or competitor. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we may litigate to defend ourselves against these claims, even if we are successful, litigation could result in substantial costs and could be a distraction to management. If our defenses to these claims fail, in addition to requiring us to pay monetary damages, a court could prohibit us from using technologies or features that are essential to our programs, if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of the former employers. Moreover, any such litigation or the threat thereof may adversely affect our reputation, our ability to form strategic alliances or sublicense our rights to collaborators, engage with scientific advisors or hire employees or consultants, each of which would have an adverse effect on our business, results of operations and financial condition. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes to patent laws in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in either the patent laws or interpretation of patent laws in the United States, including patent reform legislation such as the Leahy-Smith America Invents Act (the &#8220;Leahy-Smith Act&#8221;) could increase the uncertainties and costs surrounding the prosecution of our owned and in-licensed patent applications and the maintenance, enforcement or defense of our owned and in-licensed issued patents. The Leahy-Smith Act includes a number of significant changes to United States patent law. These changes include provisions that affect the way patent applications are prosecuted, redefine prior art, provide more efficient and cost-effective avenues for competitors to challenge the validity of patents, and enable third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent at USPTO-administered post-grant proceedings, including post-grant review, inter partes review and derivation proceedings. Assuming that other requirements for patentability are met, prior to March 2013, in the United States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. After March 2013, under the Leahy-Smith Act, the United States transitioned to a first-to-file system in which, assuming that the other statutory requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. As such, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly uncertain. U.S. Supreme Court and U.S. Court of Appeals for the Federal Circuit rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations, including in the antibody arts. For example, the United States Supreme Court in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amgen, Inc. v. Sanofi (Amgen)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> recently held that </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amgen</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;s patent claims to a class of antibodies functionally defined by their ability to bind a particular antigen were invalid for lack of enablement where the patent specification provided twenty-six exemplary antibodies, but the claimed class of antibodies covered a &#8220;vast number&#8221; of additional antibodies not disclosed in the specification. The Court stated that if patent claims are directed to an entire class of compositions of matter, then the patent specification must enable a person skilled in the art to make and use the entire class of compositions. This decision makes it unlikely that we will be granted U.S. patents with composition of matter claims directed to antibodies functionally defined by their ability to bind a particular antigen. Even if we are granted claims directed to functionally defined antibodies, it is possible that a third party may challenge our patents, when issued, relying on the reasoning in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amgen</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other recent precedential court decisions. Additionally, there have been proposals for additional changes to the patent laws of the United States and other countries that, if adopted, could impact our ability to enforce our proprietary technology. This combination of events has created uncertainty with respect to the validity and enforceability of patents once obtained. Depending on future actions by the U.S. Congress, the federal courts, the USPTO and the relevant law-making bodies in other countries, the laws and regulations governing patents could change in ways that could have a material adverse effect on our patent rights and weaken our ability to protect, defend and enforce our patent rights in the future. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Geopolitical instability in the United States and in foreign countries could increase the uncertainties and costs surrounding the prosecution or maintenance of patent applications and the maintenance, enforcement or defense of issued patents. For example, the United States and foreign government actions related to Russia&#8217;s invasion of Ukraine may limit or prevent filing, prosecution and maintenance of patent applications in Russia. Government actions may also prevent maintenance of issued patents in Russia. These actions could result in abandonment or lapse of patents or patent applications, resulting in partial or complete loss of patent rights in Russia. If such an event were to occur, it could have a material adverse effect on our business. In addition, a decree was adopted by the Russian government in March 2022, allowing Russian companies and individuals to exploit inventions owned by patentees that have citizenship or nationality in, are registered in, or have predominately primary place of business or profit-making activities in the United States and other countries that Russia has deemed unfriendly without consent or compensation. Consequently, we would not be able to prevent third parties from practicing our inventions in Russia or from selling or importing products made using our inventions in and into Russia. Accordingly, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected. In addition, a European Unified Patent Court (&#8220;UPC&#8221;) entered into force on June 1, 2023. The UPC is a common patent court that hears patent infringement and revocation proceedings effective for member states of the EU. This could enable third parties to seek revocation of a European patent in a single proceeding at the UPC rather than through multiple proceedings in each of the jurisdictions in which the European patent is validated. Given that we own or license certain European patents or applications for our current pipeline, any such revocation and loss of patent protection could have a material adverse impact on our business and our ability to commercialize or license our technology and products. Moreover, the controlling laws and regulations of the UPC will develop over time, and may adversely affect our ability to enforce or defend the validity of any European patents we may obtain. We may decide to opt out from the UPC any future European patent applications that we may file and any patents we may obtain. If certain formalities and requirements are not met, however, such European patents and patent applications could be challenged for non-compliance and brought under the jurisdiction of the UPC. We cannot be certain that future European patents and patent applications will avoid falling under the jurisdiction of the UPC, if we decide to opt out of the UPC, or that we will have the ability to opt out of the UPC in the future.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining patent protection depends on compliance with various procedural, document submissions, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodic maintenance fees, renewal fees, annuities fees and various other governmental fees on patents and/or patent applications are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent and/or patent application. The USPTO and various foreign governmental patent agencies also require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we fail to maintain the patents and patent applications covering our programs, our competitive position would be adversely affected.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop and market our products.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot guarantee that any of our patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the United States and abroad that is relevant to or necessary for the commercialization of our product candidates in any jurisdiction. The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect. For example, we may incorrectly determine that our products are not covered by a third-party patent or may incorrectly predict whether a third party&#8217;s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our products. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, because some patent applications in the United States may be maintained in secrecy until the patents are issued, patent applications in the United States and many foreign jurisdictions are typically not published until 18 months after priority filing, and publications in the scientific literature often lag behind actual discoveries, we cannot be certain that others have not filed patent applications for technology covered by our issued patents or our pending applications, or that we were the first to invent the technology. Our competitors may have filed, and may in the future file, patent applications covering our products or technology similar to ours. Any such patent application may have priority over our patent applications or patents, which could require us to obtain rights to issued patents covering such technologies.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be subject to claims that former employees, collaborators or other third parties have an interest in our patents or other intellectual property as an inventor or co-inventor. The failure to name the proper inventors on a patent application can result in the patents issuing thereon being unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject matter of the patent, conflicting obligations of third parties involved in developing our programs or as a result of questions regarding co-ownership of potential joint inventions. Litigation may be necessary to resolve these and other claims challenging inventorship and/or ownership. Alternatively, or additionally, we may enter into agreements to clarify the scope of our rights in such intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current and future licensors may have relied on third-party consultants or collaborators or on funds from third parties, such as the U.S. government, such that our licensors are not the sole and exclusive owners of the patents we in-licensed. The U.S. government has certain rights in such inventions under the applicable funding agreements and under applicable law. If other third parties have ownership rights or other rights to our in-licensed patents, they may be able to license such patents to our competitors, and our competitors could market competing products and technology. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent terms may be inadequate to protect the competitive position of our product candidates for an adequate amount of time.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest United States non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products, including generics or biosimilars. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such product candidates might expire before or shortly after such product candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our technology licensed from various third parties may be subject to retained rights or may be affected by our failure to comply with obligations under license agreements or other disruptions to business relationships with licensors resulting in loss of license rights that are important to our business. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our current or future licensors may retain certain rights under the relevant agreements with us, including the right to use the underlying technology for noncommercial academic and research use, to publish general scientific findings from research related to the technology, and to make customary scientific and scholarly disclosures of information relating to the technology. It is difficult to monitor whether our licensors limit their use of the technology to these uses, and we could incur substantial expenses to enforce our rights to our licensed technology in the event of misuse. In addition, under our license agreements, we may be generally responsible for bringing any actions against third parties for infringing on the patents we have licensed. Certain of our license agreements may also require us to meet development thresholds to maintain the license, including establishing a set timeline for developing and commercializing products. In spite of our efforts, our licensors might conclude that we have materially breached our obligations under such license agreements and might therefore terminate the license agreements, thereby removing or limiting our ability to develop and commercialize products and technology covered by these license agreements. If these in-licenses are terminated, or if the underlying patents fail to provide the intended exclusivity, competitors or other third parties may seek regulatory approval of, and to market, products identical to ours or we may be required to cease our development and commercialization of one or more product candidates. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and growth prospects. Disputes may arise regarding intellectual property subject to a licensing agreement, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope of rights granted under the license agreement and other interpretation-related issues; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the sublicensing of patent and other rights to third parties under our collaborative development relationships; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our diligence obligations under the license agreement with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates and what activities satisfy those diligence obligations; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the priority of invention of patented technology. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:32.39pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology or broaden what we believe to be the scope of the licensor&#8217;s rights to our intellectual property and technology, or increase what we believe to be our financial or other obligations under the relevant agreement, any of which could have a material adverse effect on our business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. It is also possible that a third party could be granted limited licenses to some of the same technology, in certain circumstances. Any such events could result in the loss of our ability to develop and commercialize one or more product candidates or we could lose other significant rights, any of which could have a material adverse effect on our business, financial conditions, results of operations, and prospects.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have limited foreign intellectual property rights and may not be able to protect our intellectual property and proprietary rights throughout the world.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited intellectual property rights outside of the United States. Filing, prosecuting, and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of foreign countries do not protect intellectual property rights to the same extent as the federal and state laws of the United States. In addition, intellectual property license agreements we enter into may not always include worldwide rights. Consequently, we may not be able to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">prevent third parties from using our intellectual property in all countries outside the United States, or from selling or importing products made using our intellectual property in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection but where enforcement is difficult or impractical. These products may compete with our product candidates and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology and pharmaceutical products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products against third parties in violation of our intellectual property and proprietary rights generally. Proceedings to enforce our patents and intellectual property rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Moreover, the initiation of proceedings by third parties to challenge the scope or validity of our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business. Accordingly, our efforts to enforce our intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many countries have invoked compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations, and prospects may be adversely affected.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The intellectual property landscape around engineered antibodies is highly dynamic, and third parties may initiate legal proceedings alleging that we are infringing, misappropriating, or otherwise violating their intellectual property rights, the outcome of which would be uncertain and may prevent, delay or otherwise interfere with our product discovery and development efforts.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the intense research and development that is taking place in the field of engineered antibodies, including by us and our competitors, the intellectual property landscape is evolving and in flux, and it may remain uncertain for the coming years. There may be significant intellectual property related litigation and proceedings relating to our owned and in-licensed, and other third party, intellectual property and proprietary rights in the future.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends upon our ability and the ability of our collaborators and licensors to develop, manufacture, market, and sell any product candidates that we may develop and use our proprietary technologies without infringing, misappropriating, or otherwise violating the intellectual property and proprietary rights of third parties. The biotechnology and pharmaceutical industries are characterized by extensive litigation regarding patents and other intellectual property rights as well as administrative proceedings for challenging patents, including interference, derivation, inter partes review, post grant review, and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. We may be subject to and may in the future become party to, or threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our product candidates we may develop, including interference proceedings, post-grant review, inter partes review, and derivation proceedings before the USPTO and similar proceedings in foreign jurisdictions such as oppositions before the EPO. Numerous U.S. and foreign issued patents and pending patent applications that are owned by third parties exist in the fields in which we are developing our product candidates and they may assert infringement claims against us based on existing patents or patents that may be granted in the future, regardless of their merit.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may give rise to claims of infringement of the patent rights of others. Moreover, it is not always clear to industry participants, including us, which patents cover various types of therapies, products or their methods of use or manufacture. We are aware of certain third-party patent applications that, if issued, may be construed to cover some of our product candidates. There may also be third-party patents of which we are currently unaware with claims to technologies, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the large number of patents issued and patent applications filed in our field, third parties may allege they have patent rights encompassing our product candidates, technologies or methods. Third parties may assert that we are employing their proprietary technology without authorization and may file patent infringement claims or lawsuit against us, and if we are found to infringe such third-party patents, we may be required to pay damages, cease commercialization of the infringing technology, or obtain a license from such third parties, which may not be available on commercially reasonable terms or at all.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to commercialize our product candidates in the United States and abroad may be adversely affected if we cannot obtain a license on commercially reasonable terms to relevant third-party patents that cover our product candidates. Even if we believe third-party intellectual property claims are without merit, there can be no assurance that a court would find in our favor on questions of infringement, validity, enforceability, or priority. A court of competent jurisdiction could hold that these third-party patents are valid, enforceable, and infringed, which could materially and adversely affect our ability to commercialize any product candidates we may develop and any other product candidates or technologies covered by the asserted third-party patents. In order to successfully challenge the validity of any such U.S. patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring us to present clear and convincing evidence as to the invalidity of any such U.S. patent claim, there can be no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. If we are found to infringe a third party&#8217;s intellectual property rights, and we are unsuccessful in demonstrating that such patents are invalid or unenforceable, we could be required to obtain a license from such third party to continue developing, manufacturing, and marketing impacted product candidates we may develop and our technology. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us, and it could require us to make substantial licensing and royalty payments. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, we may be unable to commercialize certain product candidates or such commercialization efforts may be significantly delayed, which could in turn significantly harm our business. We also could be forced, including by court order, to cease developing, manufacturing, and commercializing the infringing technology or product candidates. In addition, we could be found liable for significant monetary damages, including treble damages and attorneys&#8217; fees, if we are found to have willfully infringed a patent or other intellectual property right. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar material adverse effect on our business, financial condition, results of operations, and prospects. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Defense of third-party claims of infringement of misappropriation, or violation of intellectual property rights involves substantial litigation expense and would be a substantial diversion of management and employee time and resources from our business. Some third parties may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations or could otherwise have a material adverse effect on our business, financial condition, results of operations and prospects. There could also be public announcements of the results of hearings, motions, or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Any of the foregoing events could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Reliance on Third Parties</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on collaborations and licensing arrangements with third parties, including our arrangement with Paragon. If we are unable to maintain these collaborations or licensing arrangements, or if these collaborations or licensing arrangements are not successful, our business could be negatively impacted.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently rely on our collaborations and licensing arrangements with third parties, including Paragon, for a substantial portion of our discovery capabilities and in-licenses. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaborations or licensing arrangements that we enter into may not be successful, and any success will depend heavily on the efforts and activities of such collaborators or licensors. If any of our collaborators or licensors experiences delays in performance of, or fails to perform its obligations under their agreement with us, disagrees with our interpretation of the terms of such agreement or terminates their agreement with us, our research programs and development timeline could be adversely affected. If we fail to comply with any of the obligations under our collaborations or license agreements, including payment terms and diligence terms, our collaborators or licensors may have the right to terminate such agreements, in which event we may lose intellectual property rights and may not be able to develop, manufacture, market or sell the products covered by our agreements or may face other penalties under our agreements. Our collaborators and licensors may also fail to properly maintain or defend the intellectual property we have licensed from them, if required by our agreement with them, or even infringe upon, our intellectual property rights, leading to the potential invalidation of our intellectual property or subjecting us to litigation or arbitration, any of which would be time-consuming and expensive and could harm our ability to commercialize our product candidates. In addition, collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our programs and products if the collaborators believe that the competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our strategy, we plan to evaluate additional opportunities to enhance our capabilities and expand our development pipeline or provide development or commercialization capabilities that complement our own. We may not realize the benefits of such collaborations, alliances or licensing arrangements. Any of these relationships may require us to incur non-recurring and other charges, increase our near and long-term expenditures, issue securities that dilute our existing stockholders or disrupt our management and business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may face significant competition in attracting appropriate collaborators, and more established companies may also be pursuing strategies to license or acquire third-party intellectual property rights that we consider attractive. These companies may have a competitive advantage over us due to their size, financial resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. Whether we reach a definitive agreement for a collaboration will depend upon, among other things, our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Collaborations are complex and time-consuming to negotiate, document and execute. In addition, consolidation among large pharmaceutical and biotechnology companies has reduced the number of potential future collaborators. We may not be able to negotiate additional collaborations on a timely basis, on acceptable terms or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop our product candidates or bring them to market.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently rely, and plan to rely in the future, on third parties to conduct and support our nonclinical studies and clinical trials. If these third parties do not properly and successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of or commercialize our product candidates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have utilized and plan to continue to utilize and depend upon independent investigators and collaborators, such as medical institutions, CROs, contract testing labs and strategic partners, to conduct and support our nonclinical studies and clinical trials under agreements with us. We will rely heavily on these third parties over the course of our nonclinical studies and clinical trials, and we control only certain aspects of their activities. As a result, we will have less direct control over the conduct, timing and completion of these nonclinical studies and clinical trials and the management of data developed through nonclinical studies and clinical trials than would be the case if we were relying entirely upon our own staff. Nevertheless, we are responsible for ensuring that each of our studies and trials is conducted in accordance with the applicable </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">protocol, legal, regulatory and scientific standards, and our reliance on these third parties does not relieve us of our regulatory responsibilities. We and our third-party contractors and CROs are required to comply with good laboratory practice (&#8220;GLP&#8221;), GCP and GVP regulations, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for all of our programs in clinical development. If we or any of these third parties fail to comply with applicable GLP, GCP and GVP regulations, the nonclinical and clinical data generated in our nonclinical studies and clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional nonclinical and clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our nonclinical studies and clinical trials comply with GLP, GCP and GVP regulations. In addition, our clinical trials must be conducted with products produced under cGMP regulations. Our failure to comply with these regulations may require us to repeat nonclinical studies and clinical trials, which would delay the regulatory approval process. Moreover, our business may be implicated if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any third parties conducting our nonclinical studies and clinical trials will not be our employees and, except for remedies available to us under our agreements with such third parties, we cannot control whether they devote sufficient time and resources to our programs. These third parties may be involved in mergers, acquisitions or similar transactions and may have relationships with other commercial entities, including our competitors, for whom they may also be conducting nonclinical studies, clinical trials or other product development activities, which could negatively affect their performance on our behalf and the timing thereof and could lead to products that compete directly or indirectly with our current or future product candidates. If any of our relationships with these third parties, including CMOs and CROs, are terminated, we may not be able to enter into arrangements with alternative CMOs, CROs or other third parties or to do so on commercially reasonable terms. Switching or adding additional CMOs or CROs involves additional cost and requires company resources. In addition, there is a natural transition period when a new CMO or CRO begins work. As a result, delays may occur, which can materially impact our ability to meet our desired clinical development timelines. Though we carefully manage our relationships with our CMOs and CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If these CMOs, CROs or other third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure (including by clinical sites or investigators) to adhere to our nonclinical and clinical protocols or regulatory requirements or for other reasons, our nonclinical studies and clinical trials may be extended, delayed or terminated and we may not be able to complete development of, obtain regulatory approval of or successfully commercialize our product candidates. As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase substantially and our ability to generate revenues could be delayed significantly.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we currently rely on foreign CROs and CMOs, including WuXi Biologics, and will likely continue to rely on foreign CROs and CMOs in the future. We or the foreign CROs or CMOs we work with may be subject to U.S. legislation, including the BIOSECURE Act included as part of the FY 2026 National Defense Authorization Act, sanctions, trade restrictions and other foreign regulatory requirements which could increase the cost or reduce the supply of material available to us, delay the procurement or supply of such material or have an adverse effect on our ability to secure significant commitments from governments to purchase our potential therapies or disrupt our supply chain. For example, in April 2025, the United States government imposed significant tariffs on imports from China and other countries and may impose more restrictions on goods, including biologically derived substances, manufactured in or imported from China or impose other restrictions on companies&#8217; ability to work with Chinese biotechnology companies. In April 2026, the U.S. announced the imposition of tariffs on patented pharmaceutical products, which may further increase costs or restrictions. We are in the process of creating manufacturing capabilities with third parties outside of China, including within the United States, and have taken several measures to strengthen our supply chain in the event that our manufacturers are impacted; however, to the extent the aforementioned restrictions or future tariffs are applicable to the material we import from China and other countries or if we are not able to secure supply of our product candidates as a result of applicable legislation, our business and financial condition could be adversely affected despite our mitigation efforts.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the biopharmaceutical industry in China is strictly regulated by the Chinese government. Changes to Chinese regulations or government policies affecting biopharmaceutical companies are unpredictable and may have a material adverse effect on our collaborators in China which could have an adverse effect on our business, financial condition, results of operations and prospects. Evolving changes in China&#8217;s public health, economic, political, and social conditions and the uncertainty around China&#8217;s relationship with other governments, such as the United States and the UK, could also negatively impact our ability to manufacture our product candidates for our ongoing or planned clinical trials or have an adverse effect on our ability to secure government funding, which could adversely affect our financial condition and cause us to delay our clinical development programs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently rely and expect to rely in the future on the use of manufacturing suites in third-party facilities or on third parties to manufacture our product candidates, and we may rely on third parties to produce and process our products, if approved. Our business could be adversely affected if we are unable to use third-party manufacturing suites or if the third-party manufacturers encounter difficulties in production.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently own any facility that may be used as our clinical or commercial manufacturing and processing facility and must currently rely on CMOs to manufacture our product candidates. We have not yet caused our product candidates to be manufactured on a commercial scale and may not be able to do so for any of our programs, if approved. Historically, we have generally had a sole source relationship for our supply of the SPY001, SPY002, SPY072 and SPY003 Phase 2 programs and are working to build dual sourcing for our potential Phase 3 clinical trials. If there should be any disruption in our product supply arrangements, including any adverse events affecting our suppliers, it could have a negative effect on the clinical development of our programs and other operations while we work to identify and qualify alternate supply sources. We may not control the manufacturing process of, and may be completely dependent on, our contract manufacturing partners for compliance with cGMP requirements and any other regulatory requirements of the FDA or comparable foreign regulatory authorities for the manufacture of our product candidates. Beyond periodic audits, we have limited control over the ability of our CMOs to maintain adequate quality control, quality assurance and other qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any approval in the future, we may need to find alternative manufacturing facilities, which would require the incurrence of significant additional costs and delays, and materially adversely affect our ability to develop, obtain regulatory approval for or market our product candidates, if approved. Similarly, our failure, or the failure of our CMOs, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or drugs, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates or drugs and harm our business and results of operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, our CMOs may experience manufacturing difficulties due to resource constraints, supply chain issues, proposed or actual legislative changes or requirements, or as a result of labor disputes or unstable political environments, including tariffs and restrictions imposed by the United States or other foreign governments on goods required for the operation of their business. If any CMOs on which we will rely fail to manufacture quantities of our product candidates at quality levels necessary to meet regulatory requirements and at a scale sufficient to meet anticipated demand at a cost that allows us to achieve profitability, our business, financial condition and prospects could be materially and adversely affected. In addition, our CMOs and other third parties are responsible for transporting temperature-controlled materials that can be inadvertently degraded during transport due to several factors, rendering certain batches unsuitable for trial use for failure to meet, among others, our integrity and purity specifications. We and any of our CMOs may also face product seizure or detention or refusal to permit the import or export of products or increased costs as a result of tariffs on imports imposed by the United States or other foreign governments. Our business could be materially adversely affected by business disruptions to our third-party providers that could materially adversely affect our anticipated timelines, potential future revenue and financial condition and increase our costs and expenses. Each of these risks could delay or prevent the completion of our nonclinical studies and clinical trials or the approval of any of our product candidates by the FDA, resulting in higher costs or adversely impact commercialization of our product candidates. See the section titled &#8220;Business &#8211; Manufacturing and Supply&#8221; in our most recent Annual Report for a more detailed description of our manufacturing plans and assumptions and the factors that may affect the success of our programs.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Employee Matters, Managing Growth and Other Risks Related to Our Business</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In order to successfully implement our plans and strategies, we will need to grow the size of our organization and we may experience difficulties in managing this growth.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of clinical drug development, technical operations, clinical operations, regulatory affairs and, potentially, commercial operations. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial personnel and systems and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the experience of our management team, who have only worked together for a limited time in managing a public company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are highly dependent on our key personnel and anticipate hiring new key personnel. If we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical stage biotechnology company with a limited operating history, and, as of June&#160;30, 2026, we had 125 employees. We have been and will continue to be highly dependent on the research and development, clinical and business development expertise of our executive officers, as well as the other principal members of our management, scientific and clinical team. Any such officers and other principal members may terminate their employment with us at any time. We do not maintain &#8220;key person&#8221; insurance for any of our executives or other employees.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attracting and retaining qualified personnel will also be critical to our success, including with respect to any strategic transaction that we may pursue. The loss of the services of our executive officers or other key employees could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers and key personnel may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, facilitate regulatory approval of and commercialize product candidates. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our discovery and nonclinical and clinical development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future growth may depend, in part, on our ability to operate in foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future growth may depend, in part, on our ability to develop and commercialize our product candidates in foreign markets for which we may rely on collaboration with third parties. Recent and ongoing changes in the United States trade policy with foreign countries, including the continued uncertainty surrounding U.S. tariffs and retaliatory measures by foreign governments may disrupt the global supply chain for biopharmaceutical products. Any direct tariffs imposed on pharmaceutical products may result in increased costs for raw materials and contract manufacturing services, reduced ability to source critical CMOs, and a delay in our development timelines.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not permitted to market or promote any of our product candidates before we receive regulatory approval from the applicable foreign regulatory authority, and may never receive such regulatory approval for any of our product candidates. To obtain separate regulatory approval in many other countries, we must comply with numerous and varying regulatory requirements of such countries regarding safety and efficacy and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">governing, among other things, clinical trials and commercial sales, pricing and distribution of our product candidates, and we cannot predict success in these jurisdictions. If we fail to comply with the regulatory requirements in international markets and receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed and our business will be adversely affected. Moreover, even if we obtain approval of our product candidates and ultimately commercialize our product candidates in foreign markets, we would be subject to the risks and uncertainties, including the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements and reduced protection of intellectual property rights in some foreign countries.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our estimates of market opportunity and forecasts of market growth may prove to be inaccurate, and even if the markets in which we compete achieve the forecasted growth, our business may not grow at similar rates, or at all. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our market opportunity estimates and growth forecasts are subject to significant uncertainty and are based on assumptions and estimates which may not prove to be accurate. Our estimates and forecasts relating to size and expected growth of our target market may prove to be inaccurate. Even if the markets in which we compete meet our size estimates and growth forecasts, our business may not grow at similar rates, or at all. Our growth is subject to many factors, including our success in implementing our business strategy, which is subject to many risks and uncertainties.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval, the accepted price for the product, the ability to obtain coverage and reimbursement and whether we own the commercial rights for that territory. If the number of our addressable patients is not as significant as we estimate, the indication approved by regulatory authorities is narrower than we expect or the treatment population is narrowed by competition, physician choice or treatment guidelines, we may not generate significant revenue from sales of such products, even if approved.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, CMOs, suppliers and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite our employee training and compliance programs, we are exposed to the risk that our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, CMOs, suppliers and vendors acting for or on our behalf may engage in misconduct or other improper activities. We have adopted a code of conduct and ethics, policies, standard operating procedures and other compliance efforts but it is not always possible to identify and deter misconduct by these parties and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our internal information technology systems, as well as those of any of our CROs, manufacturers, other contractors or consultants, third-party service providers, and potential future collaborators, are subject to the risk of failure, security breaches, data privacy incidents, or other unauthorized or improper access to, use of, or destruction of proprietary, confidential, employee, or personal data, which could result in additional costs, loss of revenue, significant liabilities, harm to our brand, and material disruption to our business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To achieve our business objectives, we depend on our own internal IT systems and networks, as well as those of third parties and their vendors. These systems are used to process and store sensitive data&#8212;including confidential research, business plans, financial information, intellectual property, trade secrets and various personal data that may be legally protected. They also play a critical role in maintaining the continuity of our supply chain and operations, and are integral to many of the products provided to customers.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have implemented security measures designed to protect our information systems and the data they store, the size and complexity of these systems&#8212;and the increasing volume of information maintained on our internal IT systems and those of our third-party CROs, other contractors (including clinical trial sites), service providers, supply chain partners, and consultants&#8212;make them potentially vulnerable to a range of risks. These risks include breakdowns or other damage or interruption from service interruptions, system malfunction, natural disasters, terrorism, war and telecommunication and electrical failures, as well as security breaches </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from inadvertent or intentional actions by our employees, contractors, consultants, business partners and/or other third parties, or from cyber-attacks by malicious third parties. Such incidents could compromise our system infrastructure or lead to the loss, destruction, alteration or dissemination of, or damage to, our data. The evolving use of new and emerging technologies, such as AI, machine learning and quantum computing, by malicious actors is expected to further intensify cybersecurity threats. For example, AI can be leveraged to develop adaptive malware, generate highly convincing phishing or impersonation attacks (such as deepfakes), or automate the discovery and exploitation of software vulnerabilities, thereby increasing the likelihood and sophistication of future attacks. Furthermore, quantum computing could render encryption methods obsolete, exposing us to increased risks of data breaches, authentication bypasses and new types of cybersecurity threats. The increasing velocity of such disruptive innovations may outpace our ability to manage the risk appropriately.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some actors now engage and are expected to continue to engage in cyber-attacks, including without limitation nation-state actors for geopolitical reasons and in conjunction with military conflicts and defense activities. During times of war and other major conflicts, we, and the third parties upon which we rely, may be vulnerable to a heightened risk of these attacks, including retaliatory cyber-attacks, that could materially disrupt our systems and operations, supply chain, and ability to produce, sell and distribute our goods and services. In particular, severe ransomware attacks are becoming increasingly prevalent and can lead to significant interruptions in our operations, ability to provide our products or services, loss of sensitive data and income, reputational harm, and diversion of funds. Extortion payments may alleviate the negative impact of a ransomware attack, but we may be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting such payments.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that any disruption or security breach were to result in loss, destruction, unavailability, alteration or dissemination of, or damage to, our data or applications, or for it to be believed or reported that any of these occurred, we could incur liability and reputational damage and the development and commercialization of our product candidates could be delayed. Even prompt detection and response may not fully mitigate impacts, and remediation efforts could divert management attention and increase costs. The use of AI by attackers may also contribute to faster, more coordinated attacks that evade traditional detection methods, placing additional pressure on our security infrastructure and incident response capabilities. Further, our insurance policies may not be adequate to compensate us for the potential losses arising from any such disruption in, or failure or security breach of, our systems or third-party systems where information important to our business operations or commercial development is stored. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our fully-remote workforce may create additional risks for our information technology systems and data because our employees work remotely and utilize network connections, computers, and devices working at home, while in transit and in public locations. Remote work may increase exposure to insecure networks, device loss, and compromised credentials. Additionally, business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired or integrated entities&#8217; systems and technologies.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have implemented security measures designed to protect against security incidents, there can be no assurance that these measures will be effective. We may be unable in the future to detect vulnerabilities in our information technology systems because such threats and techniques change frequently, are often sophisticated in nature, and may not be detected until after a security incident has occurred. Further, we may experience delays in developing and deploying remedial measures designed to address any such identified vulnerabilities. Applicable data privacy and security obligations may require us to notify relevant stakeholders of security incidents. Such disclosures are costly, and the disclosure or the failure to comply with such requirements could lead to adverse consequences. For further discussion of our evolving privacy and data security compliance obligations, see the sections titled &#8220;Business - Government Regulation - Data Privacy and Cybersecurity Requirements (U.S.)&#8221; and &#8220;Regulation in the European Union - European Data and Security Laws&#8221; in our most recent Annual Report.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on third-party service providers and technologies to operate critical business systems to process sensitive information in a variety of contexts. Certain third-party platforms or vendors may incorporate AI-driven automation or analytics into their offerings, which may expose us to new categories of risk, such as data being repurposed for AI training, unexplainable outputs generated by machine learning models, or unintended reliance on automated decision-making systems that lack transparency or auditability. Our ability to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">monitor these third parties&#8217; information security practices is limited, and these third parties may not have adequate information security measures in place. If our third-party service providers experience a security incident or other interruption, we could experience adverse consequences. While we may be entitled to damages if our third-party service providers fail to satisfy their privacy or security-related obligations to us, any award may be insufficient to cover our damages, or we may be unable to recover such award. In addition, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that third parties&#8217; infrastructure in our supply chain or our third-party partners&#8217; supply chains have not been compromised. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Internally, we are also evaluating and, in some cases, implementing AI-enabled technologies to support business operations, data analysis, and other workflow efficiencies. Although these tools offer potential benefits, they also present new and evolving risks, including exposure to biased outputs, regulatory uncertainty around AI governance, and the possibility that sensitive data could inadvertently be incorporated into AI model training datasets or disclosed through model inference. As global laws and guidance surrounding AI systems continue to evolve, noncompliance could result in restrictions on our use of AI, reputational consequences, or enforcement activity.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we (or a third party upon whom we rely) experience a security incident or are perceived to have experienced a security incident, we may experience adverse consequences, such as government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on processing sensitive information (including personal data); litigation (including class claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; interruptions in our operations (including availability of data); financial loss; and other similar harms. Security incidents and attendant consequences may cause stakeholders (including investors and potential customers) to stop supporting our platform, deter new customers from products, and negatively impact our ability to grow and operate our business. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts may not always include limitations of liability, and even when such provisions are present, there can be no assurance that they will be adequate to protect us from liabilities, damages, or claims arising from our data privacy and security obligations. We can also not guarantee that our cybersecurity insurance coverage will be sufficient to protect us from or mitigate liabilities arising out of our privacy and security practices or that such coverage will continue to be available on commercially reasonable terms or at all. Moreover, even robust cybersecurity and privacy controls under frameworks such as the National Institute of Standards and Technology (&#8220;NIST&#8221;) cannot eliminate all risk, and we have identified cybersecurity risks that, if realized, are reasonably likely to materially affect us.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our expanding use of AI exposes us to operational, regulatory, legal, and ethical risks that could adversely affect our business, reputation, financial condition, and results of operations. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We increasingly develop, procure, and deploy AI and machine learning (&#8220;ML&#8221;) tools across our operations. While these tools may create efficiencies, they also introduce material risks related to data quality and bias, transparency and explainability, validation and lifecycle management, cybersecurity, intellectual property, privacy, discrimination, liability, and third-party dependencies. Errors or bias in AI outputs, inadequate monitoring, or insufficient documentation could impair clinical development, pharmacovigilance, manufacturing quality, or commercial activities, resulting in delays, higher costs, product or batch actions, or reputational harm. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The emergence of AI and other technologies may exacerbate other risks, including those related to regulation, litigation, compliance issues, ethical concerns, confidentiality, and data privacy or security. For example, regulatory uncertainty related to AI or other emerging technologies may require significant resources to adjust business practices to comply with developing laws. Several governmental authorities have already proposed or enacted laws and other guidance governing AI. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, in the United States, the FDA has outlined a risk based credibility framework for AI used to support drug and biologics development, signaling expectations for context of use validation, lifecycle maintenance, traceability, and explainability, and continues to oversee AI/ML enabled medical devices; these expectations could increase development costs and elongate review. These and other developing obligations may prevent or make it harder for us to conduct or enhance our business using AI, or lead to regulatory fines, penalties, or other liability. Further, use of AI technologies could lead to unintended consequences, such as data leakage, healthcare fraud and abuse, cybersecurity incidents, intellectual property infringement, or unintended </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">biases. Our AI use must also comply with privacy regimes, including the UK GDPR and EU GDPR (e.g., restrictions on automated decision making and profiling, and stringent transparency and data subject rights). Divergent and evolving requirements across jurisdictions may require region specific controls, duplicated validation, or delayed deployments; failure to comply could lead to investigations, fines, injunctions, adverse regulatory outcomes, litigation, loss of market access, or reputational damage.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an ownership change, the corporation&#8217;s ability to use its pre-change net operating loss carryforwards (&#8220;NOLs&#8221;), and other pre-change tax attributes (such as research tax credits) to offset its post-change income or taxes may be limited. For these purposes, an ownership change generally occurs where the aggregate stock ownership of one or more stockholders or groups of stockholders who owns at least 5% of a corporation&#8217;s stock increases its ownership by more than 50 percentage points over its lowest ownership percentage over a 3-year period. Upon certain events since our conversion from a Delaware limited liability company to a Delaware corporation in 2015, it is possible that we may have triggered an &#8220;ownership change&#8221; limitation. We may also experience ownership changes in the future as a result of subsequent shifts in our stock ownership (some of which are outside of our control). As a result, if we earn net taxable income, our ability to use our pre-change NOLs and other pre-change tax attributes to offset U.S. federal taxable income or taxes may be subject to limitations, which could potentially result in increased future tax liability to us. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to stringent and changing laws, regulations and standards, and contractual obligations relating to privacy, data protection, and data security. The actual or perceived failure to comply with such obligations could lead to government enforcement actions (which could include civil or criminal penalties), fines and sanctions, private litigation and/or adverse publicity and could negatively affect our operating results and business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, and the third parties upon whom we rely, are or may become subject to numerous domestic and foreign laws, regulations, and standards governing privacy, data protection, and information security, as well as contractual and ethical obligations, many of which overlap or conflict and are subject to changing interpretations. As noted, these include the HIPAA/HITECH framework for protected health information in certain contexts; the amended CCPA and other comprehensive state privacy laws and their implementing regulations; state health data laws; federal and state consumer protection laws; data breach notification statutes; and the DOJ Bulk Data Rule. Outside the United States, we are subject to the GDPR, the DPA 2018, DUAA, the ePrivacy Directive, among others. These regimes impose obligations such as purpose limitation, data minimization, security safeguards, vendor contracting, impact/risk assessments, transparency and individual rights, breach notification, and restrictions on automated decision-making and profiling. New and proposed laws increasingly emphasize data localization and restrictions on cross-border transfers, and regulators have signaled heightened enforcement. Failure or perceived failure by us or our third parties to comply with any of these requirements could result in investigations, enforcement actions, litigation (including class claims), fines and penalties, remedial orders, restrictions on processing, reputational harm, increased compliance and operational costs, and other adverse consequences that could materially and negatively affect our business, financial condition and results of operations. See the section titled &#8220;Business &#8211; Government Regulation &#8211; Data Privacy and Cybersecurity Requirements (U.S.)&#8221; and related international data protection disclosures in our most recent Annual Report for a more detailed description of the laws that may affect our ability to operate.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations may involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulations may impair our research, development or commercialization efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to adverse legislative or regulatory tax changes that could negatively impact our financial condition.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rules dealing with U.S. federal, state and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect our stockholders or us. We assess the impact of various tax reform proposals and modifications to existing tax treaties in all jurisdictions where we have operations to determine the potential effect on our business and any assumptions we have made about our future taxable income. We cannot predict whether any specific proposals will be enacted, the terms of any such proposals or what effect, if any, such proposals would have on our business if they were to be enacted. For example, the United States enacted the Inflation Reduction Act of 2022, which implements, among other changes, a 1% excise tax on certain stock buybacks. In addition, beginning in 2022, the Tax Cuts and Jobs Act eliminated the previously available option to deduct research and development expenditures and requires taxpayers to amortize them generally over five years for research activities conducted in the United States and over 15 years for research activities conducted outside the United States. On July 4, 2025, the U.S. Congress enacted the One Big Beautiful Bill Act, which includes a provision restoring the immediate deductibility of domestic research and development expenditures. The impact of this newly enacted law on our tax position will depend on how the provision is implemented and interpreted by the Internal Revenue Service and other regulatory authorities. In addition, we have no assurance as to whether, when and how this provision may be subject to further amendment or repeal. Such changes, among others, may adversely affect our effective tax rate, results of operation and general business condition.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may acquire businesses or products, or form strategic alliances, in the future, and may not realize the benefits of such acquisitions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may acquire additional businesses or products, form strategic alliances, or create joint ventures with third parties that we believe will complement or augment our existing business. If we acquire businesses with promising markets or technologies, we may not be able to realize the benefit of acquiring such businesses if we are unable to successfully integrate them with our existing operations and company culture. We may encounter numerous difficulties in developing, manufacturing and marketing any new product candidates or products resulting from a strategic alliance or acquisition that delay or prevent us from realizing their expected benefits or enhancing our business. There is no assurance that, following any such acquisition, we will achieve the synergies expected in order to justify the transaction, which could result in a material adverse effect on our business and prospects.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We maintain our cash at financial institutions, often in balances that exceed federally-insured limits. The failure of financial institutions could adversely affect our ability to pay our operational expenses or make other payments.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash held in non-interest-bearing and interest-bearing accounts exceeds the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) insurance limits. If such banking institutions were to fail, we could lose all or a portion of those amounts held in excess of such insurance limitations. However, the FDIC may not make all account holders whole in the event of future bank failures. In addition, even if account holders are ultimately made whole with respect to a future bank failure, account holders&#8217; access to their accounts and assets held in their accounts may be substantially delayed. Any material loss that we may experience in the future or inability for a material time period to access our cash and cash equivalents could have an adverse effect on our ability to pay our operational expenses or make other payments, which could adversely affect our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Common Stock</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The market price of our common stock has historically been volatile, and the market price of our common stock may decline in the future.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our common stock has been, and may continue to be, subject to significant fluctuations. Market prices for securities of clinical-stage pharmaceutical, biotechnology, and other life sciences </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">companies have historically been particularly volatile. Some of the factors that may cause the market price of our common stock to fluctuate include:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain regulatory approvals for our product candidates, and delays or failures to obtain such approvals; </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure of any of our product candidates, if approved, to achieve commercial success; </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to maintain our existing third-party license and supply agreements; </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in laws or regulations applicable to our product candidates;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any inability to obtain adequate supply of our product candidates or the inability to do so at acceptable prices;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse regulatory authority decisions;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">introduction of new products, services, or technologies by our competitors;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to meet or exceed financial and development projections we may provide to the public and the investment community;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the perception of the pharmaceutical industry by the public, legislatures, regulators, and the investment community;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of significant acquisitions, strategic collaborations, joint ventures, or capital commitments by us or our competitors;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes or other developments relating to proprietary rights, including patents, litigation matters, and our ability to obtain patent protection for our technologies;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additions or departures of key personnel;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant lawsuits, including patent or stockholder litigation;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our business and stock;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the market valuations of similar companies;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general market or macroeconomic conditions, including global inflationary pressures, rising interest rates, general economic slowdown or a recession, changes in tariff/trade and monetary policies, instability in financial institutions and the prospect of a shutdown of the U.S. federal government;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">geopolitical instability and government actions, including the ongoing military conflict in Ukraine, conflicts in the Middle East, recent events in Venezuela, geopolitical tensions between the United States and other countries, including China and Iran, and the implementation of measures that restrict international trade by the United States, China or other governments; </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of our common stock by us or our stockholders in the future; </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">trading volume of our common stock;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements by commercial partners or competitors of new commercial products, clinical progress or the lack thereof, significant contracts, commercial relationships, or capital commitments;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the introduction of technological innovations or new therapies that compete with our potential products; </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the structure of health care payment systems; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">period-to-period fluctuations in our financial results.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, the capital markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies. These broad market fluctuations may also adversely affect the trading price of our common stock. For example, escalating trade tensions, elevated interest rates and regulatory uncertainty have caused significant market volatility in recent months, and particularly in the biotechnology and biopharmaceutical industries. If the market price of our common stock does not exceed the price at which a stockholder purchases its shares, such stockholder may not realize any return on its investment in us and may lose some or all of its investment. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past, following periods of volatility in the market price of a company&#8217;s securities, stockholders have often instituted class action securities litigation against those companies. Such litigation, if instituted, could result in substantial costs and diversion of management attention and resources, which could significantly harm our profitability and reputation.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions in our charter documents and under Delaware law and the terms of some of our contracts could make an acquisition of us more difficult and may prevent attempts by our stockholders to replace or remove our management.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our Certificate of Incorporation and Bylaws may delay or prevent an acquisition or a change in management. These provisions include a prohibition on actions by written consent of our stockholders and the ability of our board of directors to issue preferred stock without stockholder approval. In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law (&#8220;DGCL&#8221;), which prohibits stockholders owning in excess of 15% of our outstanding voting stock from merging or combining with us. Although we believe these provisions collectively will provide for an opportunity to receive higher bids by requiring potential acquirers to negotiate with our board of directors, they would apply even if the offer may be considered beneficial by some stockholders. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove then current management by making it more difficult for stockholders to replace members of the board of directors, which is responsible for appointing the members of management.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Certificate of Designation of Preferences, Rights and Limitations of the Series A Preferred Stock (the &#8220;Series A Certificate of Designation&#8221;) relating to our Series A Preferred Stock may delay or prevent a change in control of our company. At any time while at least 30% of the originally issued Series A Preferred Stock remains issued and outstanding, we may not consummate a Fundamental Transaction (as defined in the Series A Certificate of Designation) or any merger or consolidation of the Company with or into another entity or any stock sale to, or other business combination in which our stockholders immediately before such transaction do not hold at least a majority of our capital stock immediately after such transaction, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series A Preferred Stock. This provision of the Series A Certificate of Designation may make it more difficult for us to enter into any of the aforementioned transactions as it would require the separate consent of a majority of the holders of the Series A Preferred Stock.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Certificate of Incorporation and Bylaws provide that the Court of Chancery of the State of Delaware is the exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, and our Bylaws designate the federal courts of the United States as the exclusive forum for actions arising under the Securities Act, each of which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, employees or agents</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Certificate of Incorporation and Bylaws provide that, unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, employees or agents to us or our stockholders, any action asserting a claim arising pursuant to any provision of the DGCL, our Certificate of Incorporation or our Bylaws or any action asserting a claim that is governed by the internal affairs doctrine, in each case subject to the Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein and the claim not being one which is vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery or for which the Court of Chancery does not have subject matter jurisdiction. Any person purchasing or otherwise acquiring any interest in any shares of our capital stock shall be deemed to have notice of and to have consented to this provision of our Certificate of Incorporation and Bylaws. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Bylaws provide that the federal district courts of the United States of America will, to the fullest extent permitted by law, be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act (a &#8220;Federal Forum Provision&#8221;). Our decision to adopt a Federal Forum Provision followed a decision by the Supreme Court of the State of Delaware holding that such provisions are facially valid under Delaware law. While there can be no assurance that federal or state courts will follow the holding of the Delaware Supreme Court or determine that the Federal Forum Provision should be enforced in a particular case, application of the Federal Forum Provision means that suits brought by our stockholders to enforce any duty or liability created by the Securities Act must be brought in federal court and cannot be brought in state court. In addition, investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These choice of forum provisions will not apply to claims brought to enforce a duty or liability created by the Exchange Act</span><span style="color:#008080;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These choice of forum provisions may limit our stockholders&#8217; ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, employees or agents, which may discourage such lawsuits against us and our directors, officers, employees and agents even though an action, if successful, might benefit our stockholders. Stockholders who do bring a claim in the specified courts could face additional litigation costs in pursuing any such claim. The specified courts may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments or results may be more favorable to us than to our stockholders. Alternatively, if a court were to find these provisions of our governance documents inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could have a material adverse effect on our business, financial condition or results of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not anticipate that we will pay any cash dividends in the foreseeable future.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current expectation is that we will retain our future earnings, if any, to fund the development and growth of our business. As a result, capital appreciation, if any, of our common stock will be your sole source of gain, if any, for the foreseeable future.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future sales of shares by existing stockholders could cause our stock price to decline. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market after legal restrictions on resale lapse, the trading price of our common stock could decline. In addition, shares of our common stock that are subject to our outstanding options and restricted stock units will become eligible for sale in the public market to the extent permitted by the provisions of various vesting agreements and Rules 144 and 701 under the Securities Act</span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future sales and issuances of equity and debt could result in additional dilution to our stockholders.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that we will need significant additional capital to fund our current and future operations, including to complete ongoing and potential preclinical and clinical trials for our product candidates. To raise capital, we may sell common stock, convertible securities, or other equity securities in one or more transactions at prices and in a manner we determine from time to time. As a result, our stockholders may experience additional dilution, which could cause our stock price to fall. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to our equity incentive plans, we may grant equity awards and issue additional shares of our common stock to our employees, directors and consultants, and the number of shares of our common stock reserved for future issuance under certain of these plans will be subject to automatic annual increases in accordance with the terms of the plans. To the extent that new options or other stock-based equity awards are granted and, if applicable, exercised, or we issue additional shares of common stock in the future, our stockholders may experience additional dilution, which could cause our stock price to fall.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our principal stockholders own a significant percentage of our stock and are able to exert significant control over matters subject to stockholder approval.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our directors, officers, 5% stockholders, and their affiliates currently beneficially own a substantial portion of our outstanding voting stock. Therefore, these stockholders have the ability and may continue to have the ability to influence us through this ownership position. These stockholders may be able to determine some or all matters requiring stockholder approval. For example, these stockholders, acting together, may be able to control elections of directors, amendments of organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may believe are in your best interest as one of our stockholders.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become exposed to costly and damaging liability claims, either when testing our programs in the clinic or at the commercial stage, and our product liability insurance may not cover all damages from such claims.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to potential product liability and professional indemnity risks that are inherent in the research, development, manufacturing, marketing and use of pharmaceutical products. While we currently have no products that have been approved for commercial sale, the use of our product candidates in clinical trials, and the sale of any approved products in the future, may expose us to liability claims. These claims may be made by participants or patients that use the product candidate or product, healthcare providers, pharmaceutical companies, or others selling such products. Any claims against us, regardless of their merit, could be difficult and costly to defend and could materially and adversely affect the market for our products or any prospects for commercialization of our products. Although we currently maintain adequate product liability insurance for our product candidates, it is possible that our liabilities could exceed our insurance coverage or that in the future we may not be able to maintain insurance coverage at a reasonable cost or obtain insurance coverage that will be adequate to satisfy any liability that may arise. If a successful product liability claim or series of claims is brought against us for uninsured liabilities or in excess of insured liabilities, our assets may not be sufficient to cover such claims and our business operations could be impaired.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation costs and the outcome of litigation could have a material adverse effect on our business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may be subject to litigation claims through the ordinary course of our business operations regarding, but not limited to, securities litigation, employment matters, security of patient and employee personal information, contractual relations with collaborators and licensors and intellectual property rights. Litigation to defend ourselves against claims by third parties, or to enforce any rights that we may have against third parties, could result in substantial costs and diversion of our resources, causing a material adverse effect on our business, financial condition, results of operations or cash flows.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We continue to incur significant costs and demands upon management as a result of complying with the laws and regulations regulating public companies.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, and particularly after December 31, 2024, when we ceased to be a &#8220;smaller reporting company&#8221; and &#8220;non-accelerated filer,&#8221; and became a &#8220;large accelerated filer,&#8221; we have and will continue to incur significant legal, accounting and other expenses associated with public company reporting requirements, including costs associated with corporate governance requirements, such as requirements under the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, as well as rules implemented by the SEC and Nasdaq. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact (in ways we cannot currently anticipate) the manner in which we operate our business. In addition, changing laws, regulations, and standards relating to corporate governance and public disclosure, including those related to climate change and other environmental, social and governance focused disclosures, are creating uncertainty for public companies, increasing legal and financial compliance costs, and making some activities more time-consuming. These rules and regulations increase our legal and financial compliance costs and make some activities more time-consuming and costly. These rules and regulations may also make it difficult and expensive for us to obtain directors&#8217; and officers&#8217; liability insurance. Our management and other personnel will continue to devote a substantial amount of time to these compliance initiatives, and we will continue to incur increased legal and financial compliance costs. As a result, it may be more difficult for us to attract and retain qualified individuals to serve on our board of directors or as our executive officers, which may adversely affect investor confidence and could cause our business or stock price to suffer. In addition, the increased costs may require us to reduce costs in other areas of our business or increase the prices of our product candidates, once commercialized. Moreover, these rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are no longer a &#8220;smaller reporting company&#8221; within the meaning of the Securities Act and as a result we are or will be subject to certain enhanced disclosure requirements which will require us to incur significant expenses and expend time and resources. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are no longer a &#8220;smaller reporting company,&#8221; as of January 1, 2025 and, as a result, we are required to comply with various disclosure and compliance requirements that did not previously apply, such as the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act, the requirement that we hold </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a nonbinding advisory vote on executive compensation and obtain stockholder approval of any golden parachute payments not previously approved, the requirement to provide full and more detailed executive compensation disclosure and the reduction in the amount of time for filing our periodic and annual reports. Compliance with these additional requirements increases our legal and financial compliance costs and causes management and other personnel to divert attention from operational and other business matters to these additional public company reporting requirements. In addition, if we are not able to comply with changing requirements in a timely manner, the market price of our stock could decline and we could be subject to delisting proceedings by the stock exchange on which our common shares are listed, or sanctions or investigations by the SEC or other regulatory authorities, which would require additional financial and management resources.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business, or our market, our stock price and trading volume could decline.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock is influenced by the research and reports that equity research analysts publish about us and our business. Equity research analysts may elect not to provide research coverage of our common stock and such lack of research coverage may adversely affect the market price of our common stock. In the event we do have equity research analyst coverage, we will not have any control over the analysts or the content and opinions included in their reports. The price of our common stock could decline if one or more equity research analysts downgrade our stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of us or fails to publish reports on us regularly, demand for our common stock could decrease, which in turn could cause our stock price or trading volume to decline.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired, investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our common stock may be negatively affected. For example, in the fourth quarter of 2024, we identified a material weakness in our internal control over financial reporting which resulted in restatements of our previously-issued financial statements to amend certain net loss per share disclosures.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act, and the rules and regulations of Nasdaq. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. In addition to our management&#8217;s report on the effectiveness of our internal controls over financial reporting, our independent registered public accounting firm is required to attest to the effectiveness of our internal control over financial reporting pursuant to Section 404 of the Sarbanes-Oxley Act. The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing, and possible remediation. We must perform system and process evaluation and testing of our internal control over financial reporting to allow management to report on the effectiveness of our internal controls over financial reporting in our annual report filing for that year, as required by Section 404 of the Sarbanes-Oxley Act.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are not able to comply with the requirements of Section 404 of the Sarbanes-Oxley Act, or if we are unable to maintain proper and effective internal controls, it could result in a material misstatement of our financial statements that would not be prevented or detected on a timely basis, which could require a restatement, cause us to be subject to sanctions or investigations by Nasdaq, the SEC, or other regulatory authorities, cause investors to lose confidence in our financial information, or cause our stock price to decline.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim consolidated financial statements will not be prevented or detected on a timely basis. As described in our Annual Report for the year ended December 31, 2024, we identified a material weakness in our internal control over financial reporting in connection with our net earnings (loss) per share disclosures, which resulted in the restatement of our consolidated financial statements as of and for the year ended December 31, 2023, as well as the quarterly condensed consolidated financial information for the interim periods ended March 31, 2024, June 30, 2024, and September 30, 2024. We have implemented measures designed to improve our disclosure controls and procedures and internal control over financial reporting to address the underlying causes of this </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">material weakness, including enhancing the design of controls relevant to the preparation and presentation of financial reporting matters related to net earnings (loss) per share calculations and disclosures to ensure that economic substance beyond the legal form of our capital structure is considered when preparing disclosures related to net earnings (loss) per share. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our internal control over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected. In addition, we may encounter problems or delays in completing the implementation of any requested improvements and receiving a favorable attestation in connection with the attestation provided by our independent registered public accounting firm.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, we incur significant legal, accounting, insurance, and other expenses, and our management and other personnel have and will need to continue to devote a substantial amount of time to compliance initiatives resulting from operating as a public company. We may experience difficulty in meeting these reporting requirements in a timely manner for each period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could be adversely affected by economic downturns, inflation, increases in interest rates, natural disasters, public health crises, political crises, U.S. elections, international or geopolitical events, such as the conflict between Russia and Ukraine, recent events in Venezuela, conflicts between the U.S. and other countries, including Iran, and conflicts in the Middle East, the implementation of measures that restrict international trade or other macroeconomic conditions, which could have a material and adverse effect on our results of operations and financial condition.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global economy, including credit and financial markets, has experienced extreme volatility and disruptions, including, among other things, diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, supply chain shortages, increases in inflation rates, higher interest rates, and uncertainty about economic stability. Adverse macroeconomic conditions, including inflation, slower growth or recession, new or increased tariffs and other barriers to trade, especially in light of recent comments and executive orders made by the Trump administration, changes to fiscal and monetary policy or government budget dynamics (particularly in the pharmaceutical and biotechnology areas), tighter credit, higher interest rates, volatility in financial markets, high unemployment, labor availability constraints, currency fluctuations and other challenges in the global economy have in the past adversely affected, and may in the future adversely affect, us and our business partners and suppliers. The United States has previously announced tariffs on imports from most countries, including significant tariffs on imports from Canada, Mexico and China. Historically, tariffs have led to increased trade and political tensions. In response to tariffs, other countries have implemented retaliatory tariffs on U.S. goods. In April 2026, the U.S. announced the imposition of tariffs on patented pharmaceutical products, and there can be no guarantee that further retaliatory tariffs will not be forthcoming. Political tensions as a result of trade policies could reduce trade volume, investment, technological exchange and other economic activities between major international economies, resulting in a material adverse effect on global economic conditions and the stability of global financial markets. There is substantial uncertainty about the duration of existing tariffs and whether additional tariffs may be imposed, modified or suspended. The Federal Reserve has raised interest rates multiple times in response to concerns about inflation and it may raise them again. Higher interest rates, coupled with reduced government spending and volatility in financial markets, may increase economic uncertainty and affect consumer spending. Similarly, geopolitical uncertainties, international conflicts and government actions, including the ongoing military conflicts between Russia and Ukraine, recent events in Venezuela, conflicts between U.S. and other countries, including Iran, and conflicts in the Middle East involving Israel and various other parties, including Iran, Hamas and Hezbollah, as well as other conflicts in the region, rising tensions with China and the implementation of tariffs, sanctions, export or import controls, and other measures that restrict international trade by the United States, China or other governments, have created extreme volatility in the global capital markets and may have further global economic consequences, including disruptions of the global supply chain. Any such volatility and disruptions may adversely affect our business or the third parties on whom we rely. If the equity and credit markets deteriorate, including as a result of political unrest or war, it may make any necessary debt or equity financing more costly, more dilutive, or more difficult to obtain in a timely manner or on favorable terms, if at all. Increased inflation rates can adversely affect us by increasing our costs, including labor and employee benefit costs.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may in the future experience disruptions as a result of such macroeconomic conditions, including delays or difficulties in initiating or expanding clinical trials and manufacturing or shipping sufficient quantities of materials. Any one or a combination of these events could have a material and adverse effect on our results of operations and financial condition. For example, our business may be generally exposed to the impact of political or civil unrest or military action. While we do not have any employees or offices in Ukraine, Venezuela, Russia or countries in the Middle East, including Israel and Jordan, we do have third-party partners and clinical trial sites with locations in Europe, South America and the Middle East, which may be affected by the ongoing conflicts affecting such countries. These third parties or clinical trial sites may be materially impacted by the increasing military conflicts in Europe and the Middle East, could result in difficulties enrolling and retaining participants and/or delivering drug samples in such areas on schedule and cause delay in our clinical trials and/or increase trial costs. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic or political climate and financial market conditions could adversely impact our business.</span></div><div id="i7ac5520bfa654a33b8eea56f2b4c5e97_163"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">None. </span></div><div id="i7ac5520bfa654a33b8eea56f2b4c5e97_166"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None. </span></div><div id="i7ac5520bfa654a33b8eea56f2b4c5e97_169"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><div id="i7ac5520bfa654a33b8eea56f2b4c5e97_172"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Other Information.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trading Plans </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fiscal quarter ended June 30, 2026, no director or Section 16 officer <ix:nonNumeric contextRef="c-15" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-933">adopted</ix:nonNumeric> or <ix:nonNumeric contextRef="c-15" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-934"><ix:nonNumeric contextRef="c-15" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-935">terminated</ix:nonNumeric></ix:nonNumeric> any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (in each case, as defined in Item 408(a) of Regulation S-K) except as described below.</span></div><ix:nonNumeric contextRef="c-262" name="ecd:MtrlTermsOfTrdArrTextBlock" id="f-936" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On <ix:nonNumeric contextRef="c-262" name="ecd:TrdArrAdoptionDate" id="f-937">April 16, 2026</ix:nonNumeric>, <ix:nonNumeric contextRef="c-262" name="ecd:TrdArrIndName" id="f-938">Heidy King-Jones</ix:nonNumeric>, our <ix:nonNumeric contextRef="c-262" name="ecd:TrdArrIndTitle" id="f-939">Chief Legal Officer and Corporate Secretary</ix:nonNumeric>, <ix:nonNumeric contextRef="c-262" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-940">adopted</ix:nonNumeric> a trading plan intended to satisfy Rule 10b5-1(c) to sell up to <ix:nonFraction unitRef="shares" contextRef="c-263" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-941">76,000</ix:nonFraction> shares of our common stock over a period ending <ix:nonNumeric contextRef="c-262" name="ecd:TrdArrExpirationDate" id="f-942">April 5, 2028</ix:nonNumeric>, subject to certain conditions, all of which are to be acquired upon the exercise of employee stock options.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-264" name="ecd:MtrlTermsOfTrdArrTextBlock" id="f-943" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On <ix:nonNumeric contextRef="c-264" name="ecd:TrdArrAdoptionDate" id="f-944">April 16, 2026</ix:nonNumeric>, <ix:nonNumeric contextRef="c-264" name="ecd:TrdArrIndName" id="f-945">Jeffrey Albers</ix:nonNumeric>, one of our <ix:nonNumeric contextRef="c-264" name="ecd:TrdArrIndTitle" id="f-946">directors</ix:nonNumeric>, and Sessions LLC, an investment company of which Mr. Albers is a managing director and owns 10% or more of the equity interest in or otherwise exercises significant influence over, <ix:nonNumeric contextRef="c-264" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-947">adopted</ix:nonNumeric> a trading plan intended to satisfy Rule 10b5-1(c) to sell up to <ix:nonFraction unitRef="shares" contextRef="c-265" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-948">23,000</ix:nonFraction> shares of our common stock over a period ending <ix:nonNumeric contextRef="c-264" name="ecd:TrdArrExpirationDate" id="f-949">July 31, 2027</ix:nonNumeric>, subject to certain conditions, <ix:nonFraction unitRef="shares" contextRef="c-266" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-950">5,000</ix:nonFraction> of which  are to be acquired upon the exercise of director stock options.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><div id="i7ac5520bfa654a33b8eea56f2b4c5e97_178"></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exhibits filed or furnished as part of this Quarterly Report on Form 10-Q are set forth below.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.748%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.415%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.869%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.172%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.415%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.933%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Form</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">File No</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Date of Filing</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit<br/>No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Filed<br/>Herewith</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1636282/000119312523302158/d518298dex21.htm">Agreement and Plan of Merger, dated June 22, 2023, by and among Aeglea BioTherapeutics, Inc. Aspen Merger Sub I, Inc., Sequoia Merger Sub II, LLC and Spyre Therapeutics, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-1</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">333-276251</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12/22/2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1636282/000119312524138893/d839821dex32.htm">Second Amended and Restated Certificate of Incorporation of the Company, effective as of May 14, 2024</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">001-37722</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">05/15/2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1636282/000119312524023071/d518298dex32.htm">Amended and Restated Bylaws</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">333-276251</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">02/05/2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1636282/000119312523302158/d518298dex33.htm">Certificate of Designation of Series A Non-Voting Convertible Preferred Stock</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-1</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">333-276251</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12/22/2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1636282/000119312523302158/d518298dex34.htm">Certificate of Designation of Series B Non-Voting Convertible Preferred Stock</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-1</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">333-276251</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12/22/2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.5</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1636282/000119312524069693/d784263dex32.htm">Certificate of Amendment to Certificate of Designation of Series B Non-Voting Convertible Preferred Stock</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">001-37722</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">03/18/2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1636282/000163628226000056/exhibit101arespp.htm">Spyre Therapeutics, Inc. Amended and Restated 2016 Employee Stock Purchase </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1636282/000163628226000056/exhibit101arespp.htm">Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">001-37722</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">05/29/2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1636282/000163628226000075/paragon-spyrexfirstamendme.htm">First Amendment to Amended and Restated IL-23 (SPY003) Agreement</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">001-37722</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">06/01/2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.1</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1636282/000162828026045742/exhibit12-sx3asr.htm">Sales Agreement, dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1636282/000162828026045742/exhibit12-sx3asr.htm">June 26</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1636282/000162828026045742/exhibit12-sx3asr.htm">, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1636282/000162828026045742/exhibit12-sx3asr.htm">6</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1636282/000162828026045742/exhibit12-sx3asr.htm">, between Spyre Therapeutics, Inc. and TD Securities (USA) LLC</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-3ASR</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">333-297063</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">06/26/2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.2</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="spyre-20260630xex311.htm">Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="spyre-20260630xex312.htm">Certification of the Principal Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.1(1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="spyre-20260630xex321.htm">Certification of the Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.INS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:6pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.748%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.415%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.869%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.172%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.415%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.933%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Form</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">File No</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Date of Filing</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit<br/>No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Filed<br/>Herewith</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cover page from this Quarterly Report formatted in Inline XBRL and contained in Exhibit 101</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt">The certifications on Exhibit 32 hereto are deemed furnished and not &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that Section. Such certifications will not be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><div id="i7ac5520bfa654a33b8eea56f2b4c5e97_181"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Signatures</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: August&#160;4, 2026</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:46.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.997%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.852%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Spyre Therapeutics, Inc.</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Scott Burrows</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Scott Burrows</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chief Financial Officer</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Principal Financial Officer and Principal Accounting Officer)</span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>spyre-20260630xex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i090a01d470b54a45b4a98c276ab94471_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary;margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Cameron Turtle, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">I have reviewed this Quarterly Report on Form 10-Q of Spyre Therapeutics, Inc.&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.23pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; August&#160;4, 2026</font></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; Cameron Turtle, D.Phil</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cameron Turtle, D.Phil</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">Chief Executive Officer</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">(Principal Executive Officer)</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>spyre-20260630xex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i2cdfb094932042919b1066cac98e4713_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary;margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Scott Burrows, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">I have reviewed this Quarterly Report on Form 10-Q of Spyre Therapeutics, Inc.&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.23pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; August&#160;4, 2026</font></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.597%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; Scott Burrows</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Scott Burrows</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer and Principal Accounting Officer)</font></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>spyre-20260630xex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i7af7fa0aa46348e7aa43fdf929835a7b_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary;margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certifications of the</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principal Executive Officer and Principal Financial Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant To 18 U.S.C. Section 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Adopted Pursuant To</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 906 of The Sarbanes-Oxley Act Of 2002</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Spyre Therapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the quarter ended June&#160;30, 2026, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), each of the undersigned officers of the Company hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge&#58;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.11pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.11pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.787%"><tr><td style="width:1.0%"></td><td style="width:43.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.575%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Date&#58; August&#160;4, 2026</font></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; Cameron Turtle, D.Phil</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cameron Turtle, D.Phil</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">Chief Executive Officer</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Principal Executive Officer)</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; Scott Burrows</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Scott Burrows</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">Chief Financial Officer</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">(Principal Financial Officer and Principal Accounting Officer)</font></td></tr></table></div><div style="margin-top:9pt"><font><br></font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. &#167;1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Note&#58; A signed original of this written statement required by &#167;906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>syre-20260630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019e22c4-8e13-79c8-aa17-b3b58ba33655,g:1a770671-d821-405f-804e-c086c0f29bbb-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:syre="http://spyre.com/20260630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://spyre.com/20260630">
  <xs:import namespace="http://fasb.org/srt/2026" schemaLocation="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2026" schemaLocation="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2026" schemaLocation="https://xbrl.sec.gov/dei/2026/dei-2026.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2026" schemaLocation="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="syre-20260630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="syre-20260630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="syre-20260630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="syre-20260630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://spyre.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://spyre.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>9952151 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://spyre.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>9952152 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperations" roleURI="http://spyre.com/role/CondensedConsolidatedStatementsofOperations">
        <link:definition>9952153 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsParenthetical" roleURI="http://spyre.com/role/CondensedConsolidatedStatementsofOperationsParenthetical">
        <link:definition>9952154 - Statement - Condensed Consolidated Statements of Operations (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveLoss" roleURI="http://spyre.com/role/CondensedConsolidatedStatementsofComprehensiveLoss">
        <link:definition>9952155 - Statement - Condensed Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquity" roleURI="http://spyre.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquity">
        <link:definition>9952156 - Statement - Condensed Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://spyre.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>9952157 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TheCompanyandBasisofPresentation" roleURI="http://spyre.com/role/TheCompanyandBasisofPresentation">
        <link:definition>9952158 - Disclosure - The Company and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://spyre.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>9952159 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://spyre.com/role/FairValueMeasurements">
        <link:definition>9952160 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashEquivalentsandMarketableSecurities" roleURI="http://spyre.com/role/CashEquivalentsandMarketableSecurities">
        <link:definition>9952161 - Disclosure - Cash Equivalents and Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedandOtherCurrentLiabilities" roleURI="http://spyre.com/role/AccruedandOtherCurrentLiabilities">
        <link:definition>9952162 - Disclosure - Accrued and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicensingAgreements" roleURI="http://spyre.com/role/LicensingAgreements">
        <link:definition>9952163 - Disclosure - Licensing Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://spyre.com/role/RelatedPartyTransactions">
        <link:definition>9952164 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertiblePreferredStockandStockholdersEquity" roleURI="http://spyre.com/role/ConvertiblePreferredStockandStockholdersEquity">
        <link:definition>9952165 - Disclosure - Convertible Preferred Stock and Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://spyre.com/role/StockBasedCompensation">
        <link:definition>9952166 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SaleofPegzilarginasetoImmedica" roleURI="http://spyre.com/role/SaleofPegzilarginasetoImmedica">
        <link:definition>9952167 - Disclosure - Sale of Pegzilarginase to Immedica</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReporting" roleURI="http://spyre.com/role/SegmentReporting">
        <link:definition>9952168 - Disclosure - Segment Reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://spyre.com/role/NetLossPerShare">
        <link:definition>9952169 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://spyre.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://spyre.com/role/FairValueMeasurementsTables">
        <link:definition>9955512 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashEquivalentsandMarketableSecuritiesTables" roleURI="http://spyre.com/role/CashEquivalentsandMarketableSecuritiesTables">
        <link:definition>9955513 - Disclosure - Cash Equivalents and Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedandOtherCurrentLiabilitiesTables" roleURI="http://spyre.com/role/AccruedandOtherCurrentLiabilitiesTables">
        <link:definition>9955514 - Disclosure - Accrued and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsTables" roleURI="http://spyre.com/role/RelatedPartyTransactionsTables">
        <link:definition>9955515 - Disclosure - Related Party Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://spyre.com/role/StockBasedCompensationTables">
        <link:definition>9955516 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingTables" roleURI="http://spyre.com/role/SegmentReportingTables">
        <link:definition>9955517 - Disclosure - Segment Reporting (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://spyre.com/role/NetLossPerShareTables">
        <link:definition>9955518 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TheCompanyandBasisofPresentationDetails" roleURI="http://spyre.com/role/TheCompanyandBasisofPresentationDetails">
        <link:definition>9955519 - Disclosure - The Company and Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofFairValueofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" roleURI="http://spyre.com/role/FairValueMeasurementsScheduleofFairValueofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails">
        <link:definition>9955520 - Disclosure - Fair Value Measurements - Schedule of Fair Value of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://spyre.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>9955521 - Disclosure - Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofSignificantInputsUsedtoEstimatetheFairValueofCVRLiabilityDetails" roleURI="http://spyre.com/role/FairValueMeasurementsScheduleofSignificantInputsUsedtoEstimatetheFairValueofCVRLiabilityDetails">
        <link:definition>9955522 - Disclosure - Fair Value Measurements - Schedule of Significant Inputs Used to Estimate the Fair Value of CVR Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofChangesinCVRLiabilityDetails" roleURI="http://spyre.com/role/FairValueMeasurementsScheduleofChangesinCVRLiabilityDetails">
        <link:definition>9955523 - Disclosure - Fair Value Measurements - Schedule of Changes in CVR Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashEquivalentsandMarketableSecuritiesScheduleofEstimatedFairValueofCashEquivalentsandMarketableSecuritiesandGrossUnrealizedGainsandLossesDetails" roleURI="http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofEstimatedFairValueofCashEquivalentsandMarketableSecuritiesandGrossUnrealizedGainsandLossesDetails">
        <link:definition>9955524 - Disclosure - Cash Equivalents and Marketable Securities - Schedule of Estimated Fair Value of Cash Equivalents and Marketable Securities and Gross Unrealized Gains and Losses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashEquivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetails" roleURI="http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetails">
        <link:definition>9955525 - Disclosure - Cash Equivalents and Marketable Securities - Schedule of Available-for-Sale Securities in an Unrealized Loss Position (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashEquivalentsandMarketableSecuritiesNarrativeDetails" roleURI="http://spyre.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails">
        <link:definition>9955526 - Disclosure - Cash Equivalents and Marketable Securities - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashEquivalentsandMarketableSecuritiesScheduleofContractualMaturitiesofMarketableSecuritiesatEstimatedFairValueDetails" roleURI="http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofContractualMaturitiesofMarketableSecuritiesatEstimatedFairValueDetails">
        <link:definition>9955527 - Disclosure - Cash Equivalents and Marketable Securities - Schedule of Contractual Maturities of Marketable Securities at Estimated Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedandOtherCurrentLiabilitiesDetails" roleURI="http://spyre.com/role/AccruedandOtherCurrentLiabilitiesDetails">
        <link:definition>9955528 - Disclosure - Accrued and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicensingAgreementsDetails" roleURI="http://spyre.com/role/LicensingAgreementsDetails">
        <link:definition>9955529 - Disclosure - Licensing Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsNarrativeDetails" roleURI="http://spyre.com/role/RelatedPartyTransactionsNarrativeDetails">
        <link:definition>9955530 - Disclosure - Related Party Transactions - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsScheduleofExpensesRelatedtoRelatedPartyWhichareSettledinCashDetails" roleURI="http://spyre.com/role/RelatedPartyTransactionsScheduleofExpensesRelatedtoRelatedPartyWhichareSettledinCashDetails">
        <link:definition>9955531 - Disclosure - Related Party Transactions - Schedule of Expenses Related to Related Party Which are Settled in Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertiblePreferredStockandStockholdersEquityDetails" roleURI="http://spyre.com/role/ConvertiblePreferredStockandStockholdersEquityDetails">
        <link:definition>9955532 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://spyre.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>9955533 - Disclosure - Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofStockAwardsGrantedUnderallEquityIncentiveandInducementPlansDetails" roleURI="http://spyre.com/role/StockBasedCompensationScheduleofStockAwardsGrantedUnderallEquityIncentiveandInducementPlansDetails">
        <link:definition>9955534 - Disclosure - Stock-Based Compensation - Schedule of Stock Awards Granted Under all Equity Incentive and Inducement Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails" roleURI="http://spyre.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails">
        <link:definition>9955535 - Disclosure - Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails_1" roleURI="http://spyre.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails_1">
        <link:definition>9955535 - Disclosure - Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedinCalculatingFairValueofAwardsDetails" roleURI="http://spyre.com/role/StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedinCalculatingFairValueofAwardsDetails">
        <link:definition>9955536 - Disclosure - Stock-Based Compensation - Schedule of Weighted-Average Assumptions Used in Calculating Fair Value of Awards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SaleofPegzilarginasetoImmedicaDetails" roleURI="http://spyre.com/role/SaleofPegzilarginasetoImmedicaDetails">
        <link:definition>9955537 - Disclosure - Sale of Pegzilarginase to Immedica (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingNarrativeDetails" roleURI="http://spyre.com/role/SegmentReportingNarrativeDetails">
        <link:definition>9955538 - Disclosure - Segment Reporting - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingScheduleofSignificantExpensesProvidedtotheCODMonaRegularBasisDetails" roleURI="http://spyre.com/role/SegmentReportingScheduleofSignificantExpensesProvidedtotheCODMonaRegularBasisDetails">
        <link:definition>9955539 - Disclosure - Segment Reporting - Schedule of Significant Expenses Provided to the CODM on a Regular Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareScheduleofComputationofBasicandDilutedNetLossPerShareDetails" roleURI="http://spyre.com/role/NetLossPerShareScheduleofComputationofBasicandDilutedNetLossPerShareDetails">
        <link:definition>9955540 - Disclosure - Net Loss Per Share - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareScheduleofWeightedAverageEquityInstrumentsExcludedfromCalculationofDilutedNetLossPerShareDetails" roleURI="http://spyre.com/role/NetLossPerShareScheduleofWeightedAverageEquityInstrumentsExcludedfromCalculationofDilutedNetLossPerShareDetails">
        <link:definition>9955541 - Disclosure - Net Loss Per Share - Schedule of Weighted-Average Equity Instruments Excluded from Calculation of Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="syre_SeriesANonVotingConvertiblePreferredStockMember" abstract="true" name="SeriesANonVotingConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="syre_SeriesBNonVotingConvertiblePreferredStockMember" abstract="true" name="SeriesBNonVotingConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="syre_PreferredStockExcludingSeriesAAndBNonVotingConvertiblePreferredStockMember" abstract="true" name="PreferredStockExcludingSeriesAAndBNonVotingConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="syre_StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan" abstract="false" name="StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="syre_StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan" abstract="false" name="StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="syre_InterestProceedsDebtSecurities" abstract="false" name="InterestProceedsDebtSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="syre_ProceedsFromIssuanceOfCommonStockAtTheMarketOfferingsNet" abstract="false" name="ProceedsFromIssuanceOfCommonStockAtTheMarketOfferingsNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="syre_PaymentForDeferredOfferingCosts" abstract="false" name="PaymentForDeferredOfferingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="syre_PaymentsRelatedToContingentValueRightsLiability" abstract="false" name="PaymentsRelatedToContingentValueRightsLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="syre_IssuanceOfConvertiblePreferredStockRelatedToPrivatePlacementUnpaidAmount" abstract="false" name="IssuanceOfConvertiblePreferredStockRelatedToPrivatePlacementUnpaidAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="syre_DeferredOfferingCostsAllocatedAmountOfProceedsOfIssuanceOfCommonStock" abstract="false" name="DeferredOfferingCostsAllocatedAmountOfProceedsOfIssuanceOfCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="syre_DeferredOfferingCostsUnpaidAmount" abstract="false" name="DeferredOfferingCostsUnpaidAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="syre_AccruedAndOtherCurrentLiabilitiesTextBlock" abstract="false" name="AccruedAndOtherCurrentLiabilitiesTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="syre_LicensingAgreementsAbstract" abstract="true" name="LicensingAgreementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="syre_CompanyAndBasisOfPresentationTable" abstract="true" name="CompanyAndBasisOfPresentationTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="syre_SpyreTherapeuticsIncMember" abstract="true" name="SpyreTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="syre_AtTheMarketOffering2024SalesAgreementMember" abstract="true" name="AtTheMarketOffering2024SalesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="syre_AtTheMarketOffering2026SalesAgreementMember" abstract="true" name="AtTheMarketOffering2026SalesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="syre_October2025UnderwrittenOfferingMember" abstract="true" name="October2025UnderwrittenOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="syre_April2026UnderwritingOfferingMember" abstract="true" name="April2026UnderwritingOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="syre_CompanyAndBasisOfPresentationLineItems" abstract="true" name="CompanyAndBasisOfPresentationLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="syre_AssetAcquisitionCashPaymentThresholdPeriod" abstract="false" name="AssetAcquisitionCashPaymentThresholdPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="syre_SaleOfStockAuthorizedAmount" abstract="false" name="SaleOfStockAuthorizedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="syre_SaleOfStockRemainingAuthorizedAmount" abstract="false" name="SaleOfStockRemainingAuthorizedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="syre_ProceedsFromRaisingCapital" abstract="false" name="ProceedsFromRaisingCapital" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="syre_ContingentValueRightLiabilityMember" abstract="true" name="ContingentValueRightLiabilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="syre_AssetAcquisitionStockholderPaymentPeriod" abstract="false" name="AssetAcquisitionStockholderPaymentPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="syre_CashEquivalentsUnrealizedGains" abstract="false" name="CashEquivalentsUnrealizedGains" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="syre_CashEquivalentsUnrealizedLosses" abstract="false" name="CashEquivalentsUnrealizedLosses" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="syre_CashEquivalentsAndMarketableSecuritiesTable" abstract="true" name="CashEquivalentsAndMarketableSecuritiesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="syre_USBankingInstitutionMember" abstract="true" name="USBankingInstitutionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="syre_CashEquivalentsAndMarketableSecuritiesLineItems" abstract="true" name="CashEquivalentsAndMarketableSecuritiesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="syre_ImpairmentOfMarketableSecurities" abstract="false" name="ImpairmentOfMarketableSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="syre_NumberOfDomesticBankingInstitutions" abstract="false" name="NumberOfDomesticBankingInstitutions" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="syre_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne" abstract="false" name="DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="syre_AccruedContractedResearchAndDevelopmentCosts" abstract="false" name="AccruedContractedResearchAndDevelopmentCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="syre_ParagonAgreementMember" abstract="true" name="ParagonAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="syre_Spy001LicenseAgreementMember" abstract="true" name="Spy001LicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="syre_SPY002AndSPY072LicenseAgreementMember" abstract="true" name="SPY002AndSPY072LicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="syre_SPY003LicenseAgreementMember" abstract="true" name="SPY003LicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="syre_ParagonAgreementLicenseMilestonePaymentsMember" abstract="true" name="ParagonAgreementLicenseMilestonePaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="syre_AmountToBePaidUnderAgreement" abstract="false" name="AmountToBePaidUnderAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="syre_PaymentOfMilestone" abstract="false" name="PaymentOfMilestone" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="syre_CampaignTimelineMinimumTerm" abstract="false" name="CampaignTimelineMinimumTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="syre_RoyaltyStepDownPercent" abstract="false" name="RoyaltyStepDownPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="syre_RoyaltyTermExpirationPeriod" abstract="false" name="RoyaltyTermExpirationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="syre_TerminationNoticePeriod" abstract="false" name="TerminationNoticePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="syre_SublicensingFee" abstract="false" name="SublicensingFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="syre_LicenseAgreementMilestonePayments" abstract="false" name="LicenseAgreementMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="syre_LicenseAgreementMilestonePaymentsOutstandingAndPayable" abstract="false" name="LicenseAgreementMilestonePaymentsOutstandingAndPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="syre_PaymentForSublicensingFee" abstract="false" name="PaymentForSublicensingFee" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="syre_SublicensingFeeOutstandingAndPayable" abstract="false" name="SublicensingFeeOutstandingAndPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="syre_ParagonTherapeuticsIncMember" abstract="true" name="ParagonTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="syre_FairmountFundsManagementLlcMember" abstract="true" name="FairmountFundsManagementLlcMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="syre_AppointOfBoardMembersMember" abstract="true" name="AppointOfBoardMembersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="syre_OtherParagonReimbursableExpensesMember" abstract="true" name="OtherParagonReimbursableExpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="syre_ParagonAgreementSubsequentToAssetAcquisitionMember" abstract="true" name="ParagonAgreementSubsequentToAssetAcquisitionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="syre_ConsultingAgreementMember" abstract="true" name="ConsultingAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="syre_RelatedPartyTransactionNumberOfBoardSeats" abstract="false" name="RelatedPartyTransactionNumberOfBoardSeats" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="syre_MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty" abstract="false" name="MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMonthlyInstallments" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMonthlyInstallments" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="syre_ParagonAndLicenseAgreementMember" abstract="true" name="ParagonAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="syre_ParapyreWarrantsMember" abstract="true" name="ParapyreWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="syre_PreferredStockRemainsIssuedAndOutstandingPercentage" abstract="false" name="PreferredStockRemainsIssuedAndOutstandingPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="syre_SaleOfStockAggregateOfferingPrice" abstract="false" name="SaleOfStockAggregateOfferingPrice" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="syre_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember" abstract="true" name="TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="syre_TwoThousandAndSixteenEquityIncentivePlanMember" abstract="true" name="TwoThousandAndSixteenEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="syre_TwoThousandAndEighteenEquityInducementPlanMember" abstract="true" name="TwoThousandAndEighteenEquityInducementPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="syre_TwoThousandAndSixteenEmployeeStockPurchasePlanMember" abstract="true" name="TwoThousandAndSixteenEmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="syre_ServiceBasedAwardsMember" abstract="true" name="ServiceBasedAwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="syre_A2016ESPPMember" abstract="true" name="A2016ESPPMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="syre_AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares" abstract="false" name="AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="syre_GlobalRightsToPegzilarginaseMember" abstract="true" name="GlobalRightsToPegzilarginaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="syre_DisposalGroupIncludingDiscontinuedOperationContingentConsideration" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationContingentConsideration" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="syre_ReportableSegmentMember" abstract="true" name="ReportableSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="syre_IncreaseDecreaseInFairValueOfContingentValueRightLiability" abstract="false" name="IncreaseDecreaseInFairValueOfContingentValueRightLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="syre_HeidyKingJonesMember" abstract="true" name="HeidyKingJonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="syre_JeffreyAlbersMember" abstract="true" name="JeffreyAlbersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="syre_JeffreyAlbersRuleTradingArrangementDirectorStockOptionsMember" abstract="true" name="JeffreyAlbersRuleTradingArrangementDirectorStockOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>syre-20260630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019e22c4-8e13-79c8-aa17-b3b58ba33655,g:1a770671-d821-405f-804e-c086c0f29bbb-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:type="simple" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item"/>
  <link:roleRef roleURI="http://spyre.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="syre-20260630.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://spyre.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_019e22c4-8fac-7cc1-b4ac-8ab9bf50b1dc" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_019e22c4-8fac-7adf-8418-0567a17e5c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_019e22c4-8fac-7cc1-b4ac-8ab9bf50b1dc" xlink:to="loc_us-gaap_Liabilities_019e22c4-8fac-7adf-8418-0567a17e5c3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_019e22c4-8fac-7f57-af97-417cd83377f9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_019e22c4-8fac-7cc1-b4ac-8ab9bf50b1dc" xlink:to="loc_us-gaap_CommitmentsAndContingencies_019e22c4-8fac-7f57-af97-417cd83377f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019e22c4-8fac-7d46-960e-9778c5f4145b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_019e22c4-8fac-7cc1-b4ac-8ab9bf50b1dc" xlink:to="loc_us-gaap_StockholdersEquity_019e22c4-8fac-7d46-960e-9778c5f4145b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_019e22c4-8fac-798a-aa2b-aa0a16aa9135" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_019e22c4-8fac-71b0-9b7b-32bbacd40cee" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_019e22c4-8fac-798a-aa2b-aa0a16aa9135" xlink:to="loc_us-gaap_LiabilitiesCurrent_019e22c4-8fac-71b0-9b7b-32bbacd40cee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_019e22c4-8fac-7dca-9ce9-bc3038aca9c5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_019e22c4-8fac-798a-aa2b-aa0a16aa9135" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_019e22c4-8fac-7dca-9ce9-bc3038aca9c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_019e22c4-8fac-74d9-bc3c-5e28ac0085ad" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_019e22c4-8fac-798a-aa2b-aa0a16aa9135" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_019e22c4-8fac-74d9-bc3c-5e28ac0085ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_019e22c4-8fac-7cff-bd9e-837aba5e0b25" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019e22c4-8fac-76ee-9720-b9754d7fdaac" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_019e22c4-8fac-7cff-bd9e-837aba5e0b25" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019e22c4-8fac-76ee-9720-b9754d7fdaac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_019e22c4-8fac-73e1-8228-812dde528663" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_019e22c4-8fac-7cff-bd9e-837aba5e0b25" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_019e22c4-8fac-73e1-8228-812dde528663" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_019e22c4-8fac-713f-a4c5-0b772d9b2450" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_019e22c4-8fac-7cff-bd9e-837aba5e0b25" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_019e22c4-8fac-713f-a4c5-0b772d9b2450" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019e22c4-8fac-7dd4-af11-84b674298768" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_019e22c4-8fac-7aa2-9687-c07804ce3979" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_019e22c4-8fac-7dd4-af11-84b674298768" xlink:to="loc_us-gaap_PreferredStockValue_019e22c4-8fac-7aa2-9687-c07804ce3979" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_019e22c4-8fac-7708-8147-2fc778f4b014" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_019e22c4-8fac-7dd4-af11-84b674298768" xlink:to="loc_us-gaap_CommonStockValue_019e22c4-8fac-7708-8147-2fc778f4b014" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_019e22c4-8fac-7583-b1b4-475ac8e76263" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_019e22c4-8fac-7dd4-af11-84b674298768" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_019e22c4-8fac-7583-b1b4-475ac8e76263" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_019e22c4-8fac-7a0c-9ada-5b3f26f5f95f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_019e22c4-8fac-7dd4-af11-84b674298768" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_019e22c4-8fac-7a0c-9ada-5b3f26f5f95f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019e22c4-8fac-7954-bae7-c222f87bcb41" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_019e22c4-8fac-7dd4-af11-84b674298768" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019e22c4-8fac-7954-bae7-c222f87bcb41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_019e22c4-8fac-7eb4-9629-64f3d6ed3396" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_019e22c4-8fac-7453-bfa5-80169fd480e0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_019e22c4-8fac-7eb4-9629-64f3d6ed3396" xlink:to="loc_us-gaap_AssetsCurrent_019e22c4-8fac-7453-bfa5-80169fd480e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_019e22c4-8fac-73c3-9cfa-0de85ea0eeb1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_019e22c4-8fac-726d-9841-5c1ed8301993" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_019e22c4-8fac-73c3-9cfa-0de85ea0eeb1" xlink:to="loc_us-gaap_AccountsPayableCurrent_019e22c4-8fac-726d-9841-5c1ed8301993" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_019e22c4-8fac-700d-9c24-724dbd20f5c9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_019e22c4-8fac-73c3-9cfa-0de85ea0eeb1" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_019e22c4-8fac-700d-9c24-724dbd20f5c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_019e22c4-8fac-7ac9-a0f0-a7074865b9de" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_019e22c4-8fac-73c3-9cfa-0de85ea0eeb1" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_019e22c4-8fac-7ac9-a0f0-a7074865b9de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_019e22c4-8fac-735b-8c3e-05d6b450a156" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_019e22c4-8fac-73c3-9cfa-0de85ea0eeb1" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_019e22c4-8fac-735b-8c3e-05d6b450a156" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://spyre.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="syre-20260630.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://spyre.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019e22c4-8fac-774e-b224-80475925746c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_019e22c4-8fac-775d-ab47-1e2368d99636" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019e22c4-8fac-774e-b224-80475925746c" xlink:to="loc_us-gaap_OperatingIncomeLoss_019e22c4-8fac-775d-ab47-1e2368d99636" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_019e22c4-8fac-7fd8-9e32-ff47f1e4315e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019e22c4-8fac-774e-b224-80475925746c" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_019e22c4-8fac-7fd8-9e32-ff47f1e4315e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_019e22c4-8fac-7808-a880-c1e035958e57" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_019e22c4-8fac-7039-bb0f-7b5668afb969" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_019e22c4-8fac-7808-a880-c1e035958e57" xlink:to="loc_us-gaap_InvestmentIncomeNet_019e22c4-8fac-7039-bb0f-7b5668afb969" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_019e22c4-8fac-7e1f-a1b5-957075405a8c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_019e22c4-8fac-7808-a880-c1e035958e57" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_019e22c4-8fac-7e1f-a1b5-957075405a8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_019e22c4-8fac-7f38-b1f0-d220cdf267cb" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_019e22c4-8fac-7dc2-8d8f-40af735ca714" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_019e22c4-8fac-7f38-b1f0-d220cdf267cb" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_019e22c4-8fac-7dc2-8d8f-40af735ca714" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_019e22c4-8fac-7db4-944f-5a7362468940" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_019e22c4-8fac-7f38-b1f0-d220cdf267cb" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_019e22c4-8fac-7db4-944f-5a7362468940" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_019e22c4-8fac-787c-872b-9dd6061c8f72" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_019e22c4-8fac-7f38-b1f0-d220cdf267cb" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_019e22c4-8fac-787c-872b-9dd6061c8f72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_019e22c4-8fac-7a94-a211-53d87bb7b960" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_019e22c4-8fac-7477-8f82-fb829eee1b49" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_019e22c4-8fac-7a94-a211-53d87bb7b960" xlink:to="loc_us-gaap_OperatingExpenses_019e22c4-8fac-7477-8f82-fb829eee1b49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019e22c4-8fac-763b-9dcb-1fcbdfd826fd" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019e22c4-8fac-74cd-bec4-8e07cd0c4650" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_019e22c4-8fac-763b-9dcb-1fcbdfd826fd" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019e22c4-8fac-74cd-bec4-8e07cd0c4650" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_019e22c4-8fac-7ecb-912b-efd8f3af195e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_019e22c4-8fac-763b-9dcb-1fcbdfd826fd" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_019e22c4-8fac-7ecb-912b-efd8f3af195e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://spyre.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="syre-20260630.xsd#CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://spyre.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_019e22c4-8fac-7196-bdad-2b0daddf505f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019e22c4-8fac-7f00-8e78-ec98a0ae19e7" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_019e22c4-8fac-7196-bdad-2b0daddf505f" xlink:to="loc_us-gaap_NetIncomeLoss_019e22c4-8fac-7f00-8e78-ec98a0ae19e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_019e22c4-8fac-719e-8b9b-4a382f05e04a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_019e22c4-8fac-7196-bdad-2b0daddf505f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_019e22c4-8fac-719e-8b9b-4a382f05e04a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_019e22c4-8fac-7b3c-b039-1faae9c664e5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_019e22c4-8fac-7196-bdad-2b0daddf505f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_019e22c4-8fac-7b3c-b039-1faae9c664e5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://spyre.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="syre-20260630.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://spyre.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019e22c4-8fac-7506-9ab0-f6d23ad8a656" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_019e22c4-8fac-7049-85d8-a51de75b4e0e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019e22c4-8fac-7506-9ab0-f6d23ad8a656" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_019e22c4-8fac-7049-85d8-a51de75b4e0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_ProceedsFromIssuanceOfCommonStockAtTheMarketOfferingsNet_019e22c4-8fac-7880-9841-f9c36e495263" xlink:href="syre-20260630.xsd#syre_ProceedsFromIssuanceOfCommonStockAtTheMarketOfferingsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019e22c4-8fac-7506-9ab0-f6d23ad8a656" xlink:to="loc_syre_ProceedsFromIssuanceOfCommonStockAtTheMarketOfferingsNet_019e22c4-8fac-7880-9841-f9c36e495263" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_PaymentForDeferredOfferingCosts_019e22c4-8fac-70e9-8a0b-c308bede0e16" xlink:href="syre-20260630.xsd#syre_PaymentForDeferredOfferingCosts"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019e22c4-8fac-7506-9ab0-f6d23ad8a656" xlink:to="loc_syre_PaymentForDeferredOfferingCosts_019e22c4-8fac-70e9-8a0b-c308bede0e16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_PaymentsRelatedToContingentValueRightsLiability_019f5e68-c138-71f0-92c7-d03fb86c67e4" xlink:href="syre-20260630.xsd#syre_PaymentsRelatedToContingentValueRightsLiability"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019e22c4-8fac-7506-9ab0-f6d23ad8a656" xlink:to="loc_syre_PaymentsRelatedToContingentValueRightsLiability_019f5e68-c138-71f0-92c7-d03fb86c67e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_019f5e68-c138-75f8-a00c-5329d56f8aef" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019e22c4-8fac-7506-9ab0-f6d23ad8a656" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_019f5e68-c138-75f8-a00c-5329d56f8aef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019e22c4-8fac-788d-b506-1349c45b1996" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019e22c4-8fac-78ca-9dc3-32eac25dbb45" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019e22c4-8fac-788d-b506-1349c45b1996" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019e22c4-8fac-78ca-9dc3-32eac25dbb45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019e22c4-8fac-7f47-bd8c-d8243a7170a7" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019e22c4-8fac-788d-b506-1349c45b1996" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019e22c4-8fac-7f47-bd8c-d8243a7170a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019e22c4-8fac-7381-9cdc-904ddc36273d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019e22c4-8fac-788d-b506-1349c45b1996" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019e22c4-8fac-7381-9cdc-904ddc36273d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019e22c4-8fac-7d9a-a3a6-179b3539eca2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_019e22c4-8fac-764f-a5f0-6deb0cf641ba" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019e22c4-8fac-7d9a-a3a6-179b3539eca2" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_019e22c4-8fac-764f-a5f0-6deb0cf641ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_019e22c4-8fac-7097-8020-fff009be9559" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019e22c4-8fac-7d9a-a3a6-179b3539eca2" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_019e22c4-8fac-7097-8020-fff009be9559" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_019e22c4-8fac-7697-8482-7531de28d55f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019e22c4-8fac-7d9a-a3a6-179b3539eca2" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_019e22c4-8fac-7697-8482-7531de28d55f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019e22c4-8fac-7427-8ab2-13d5579cfca3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019e22c4-8fac-7b3a-b553-9f2ff3e55ff0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019e22c4-8fac-7427-8ab2-13d5579cfca3" xlink:to="loc_us-gaap_NetIncomeLoss_019e22c4-8fac-7b3a-b553-9f2ff3e55ff0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_019e22c4-8fac-7305-a107-8ab3f9a1a9e1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019e22c4-8fac-7427-8ab2-13d5579cfca3" xlink:to="loc_us-gaap_ShareBasedCompensation_019e22c4-8fac-7305-a107-8ab3f9a1a9e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_019e22c4-8fac-76d3-866a-47638581c370" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019e22c4-8fac-7427-8ab2-13d5579cfca3" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_019e22c4-8fac-76d3-866a-47638581c370" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_019e22c4-8fac-75da-a029-f6474640afc1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019e22c4-8fac-7427-8ab2-13d5579cfca3" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_019e22c4-8fac-75da-a029-f6474640afc1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_019e22c4-8fac-7bba-b22b-155eae498143" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019e22c4-8fac-7427-8ab2-13d5579cfca3" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_019e22c4-8fac-7bba-b22b-155eae498143" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_InterestProceedsDebtSecurities_019e22c4-8fac-7c40-aab8-52d852d085e3" xlink:href="syre-20260630.xsd#syre_InterestProceedsDebtSecurities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019e22c4-8fac-7427-8ab2-13d5579cfca3" xlink:to="loc_syre_InterestProceedsDebtSecurities_019e22c4-8fac-7c40-aab8-52d852d085e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_019e22c4-8fac-7d62-bb19-b870835b1394" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019e22c4-8fac-7427-8ab2-13d5579cfca3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_019e22c4-8fac-7d62-bb19-b870835b1394" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_019e22c4-8fac-759e-8fb6-9884e228a949" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019e22c4-8fac-7427-8ab2-13d5579cfca3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_019e22c4-8fac-759e-8fb6-9884e228a949" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable_019e22c4-8fac-7385-8a11-e4b98c19d344" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019e22c4-8fac-7427-8ab2-13d5579cfca3" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable_019e22c4-8fac-7385-8a11-e4b98c19d344" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_019e22c4-8fac-7921-b153-488298374cf9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019e22c4-8fac-7427-8ab2-13d5579cfca3" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_019e22c4-8fac-7921-b153-488298374cf9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://spyre.com/role/FairValueMeasurementsScheduleofFairValueofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="syre-20260630.xsd#FairValueMeasurementsScheduleofFairValueofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://spyre.com/role/FairValueMeasurementsScheduleofFairValueofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_019e22c4-8fac-7644-9369-a33021483698" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_019e22c4-8fac-7fcf-a233-6732aca638e1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_019e22c4-8fac-7644-9369-a33021483698" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_019e22c4-8fac-7fcf-a233-6732aca638e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_019e22c4-8fac-77fc-8895-41dcd51cf994" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_019e22c4-8fac-7644-9369-a33021483698" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_019e22c4-8fac-77fc-8895-41dcd51cf994" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_019e22c4-8fac-706e-be95-84856819b0c6" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_019e22c4-8fac-7eaf-950f-fc09decb0a4d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativeLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_019e22c4-8fac-706e-be95-84856819b0c6" xlink:to="loc_us-gaap_DerivativeLiabilities_019e22c4-8fac-7eaf-950f-fc09decb0a4d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofEstimatedFairValueofCashEquivalentsandMarketableSecuritiesandGrossUnrealizedGainsandLossesDetails" xlink:type="simple" xlink:href="syre-20260630.xsd#CashEquivalentsandMarketableSecuritiesScheduleofEstimatedFairValueofCashEquivalentsandMarketableSecuritiesandGrossUnrealizedGainsandLossesDetails"/>
  <link:calculationLink xlink:role="http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofEstimatedFairValueofCashEquivalentsandMarketableSecuritiesandGrossUnrealizedGainsandLossesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_019e22c4-9076-76fa-a701-45e8def223d6" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_CashEquivalentsUnrealizedLosses_019e22c4-9076-747f-8b01-d687ee4ce604" xlink:href="syre-20260630.xsd#syre_CashEquivalentsUnrealizedLosses"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue_019e22c4-9076-76fa-a701-45e8def223d6" xlink:to="loc_syre_CashEquivalentsUnrealizedLosses_019e22c4-9076-747f-8b01-d687ee4ce604" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_CashEquivalentsUnrealizedGains_019e22c4-9076-7a2b-979e-8bccc37f4951" xlink:href="syre-20260630.xsd#syre_CashEquivalentsUnrealizedGains"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue_019e22c4-9076-76fa-a701-45e8def223d6" xlink:to="loc_syre_CashEquivalentsUnrealizedGains_019e22c4-9076-7a2b-979e-8bccc37f4951" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_019e22c4-9076-773b-90ed-c3a11e32021b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue_019e22c4-9076-76fa-a701-45e8def223d6" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_019e22c4-9076-773b-90ed-c3a11e32021b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_019e22c4-9076-7ab2-87d8-f765de8db037" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_019e22c4-9076-7fea-a958-dbc948c070b0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_019e22c4-9076-7ab2-87d8-f765de8db037" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_019e22c4-9076-7fea-a958-dbc948c070b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_019e22c4-9076-71c5-b5fb-4b01b4a8e5a2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_019e22c4-9076-7ab2-87d8-f765de8db037" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_019e22c4-9076-71c5-b5fb-4b01b4a8e5a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_019e22c4-9076-7880-a339-f01689197e11" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_019e22c4-9076-7ab2-87d8-f765de8db037" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_019e22c4-9076-7880-a339-f01689197e11" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="syre-20260630.xsd#CashEquivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetails"/>
  <link:calculationLink xlink:role="http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_019e22c4-9076-7f84-93ea-0a3d10f8115c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_019e22c4-9076-729f-9a2a-711a76be8ddb" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_019e22c4-9076-7f84-93ea-0a3d10f8115c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_019e22c4-9076-729f-9a2a-711a76be8ddb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_019e22c4-9076-7b79-8c37-c963b010f271" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_019e22c4-9076-7f84-93ea-0a3d10f8115c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_019e22c4-9076-7b79-8c37-c963b010f271" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_019e22c4-9076-7c2d-aa70-0e266e75ef0e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_019e22c4-9076-705b-9694-8830ce0d5e53" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_019e22c4-9076-7c2d-aa70-0e266e75ef0e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_019e22c4-9076-705b-9694-8830ce0d5e53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_019e22c4-9076-7e77-a6ed-e6eedbbe225a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_019e22c4-9076-7c2d-aa70-0e266e75ef0e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_019e22c4-9076-7e77-a6ed-e6eedbbe225a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofContractualMaturitiesofMarketableSecuritiesatEstimatedFairValueDetails" xlink:type="simple" xlink:href="syre-20260630.xsd#CashEquivalentsandMarketableSecuritiesScheduleofContractualMaturitiesofMarketableSecuritiesatEstimatedFairValueDetails"/>
  <link:calculationLink xlink:role="http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofContractualMaturitiesofMarketableSecuritiesatEstimatedFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_019e22c4-9076-7512-8603-67fd1ed4fa63" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_019e22c4-9076-77fc-a58a-1cfa758eea2e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_019e22c4-9076-7512-8603-67fd1ed4fa63" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_019e22c4-9076-77fc-a58a-1cfa758eea2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne_019e22c4-9076-7ae1-a8ed-b0894f6b3556" xlink:href="syre-20260630.xsd#syre_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_019e22c4-9076-7512-8603-67fd1ed4fa63" xlink:to="loc_syre_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne_019e22c4-9076-7ae1-a8ed-b0894f6b3556" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://spyre.com/role/AccruedandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="syre-20260630.xsd#AccruedandOtherCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://spyre.com/role/AccruedandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_019e22c4-9076-727e-abb6-1424165050a8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_019e22c4-9076-7417-a3cd-a1926fec08c9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_019e22c4-9076-727e-abb6-1424165050a8" xlink:to="loc_us-gaap_AccruedSalariesCurrent_019e22c4-9076-7417-a3cd-a1926fec08c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_AccruedContractedResearchAndDevelopmentCosts_019e22c4-9076-768d-9be0-73f574491eca" xlink:href="syre-20260630.xsd#syre_AccruedContractedResearchAndDevelopmentCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_019e22c4-9076-727e-abb6-1424165050a8" xlink:to="loc_syre_AccruedContractedResearchAndDevelopmentCosts_019e22c4-9076-768d-9be0-73f574491eca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_019e22c4-9076-7a47-aad7-870885e3c804" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_019e22c4-9076-727e-abb6-1424165050a8" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_019e22c4-9076-7a47-aad7-870885e3c804" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_019e22c4-9076-7ae0-b30e-a1623256a606" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_019e22c4-9076-727e-abb6-1424165050a8" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_019e22c4-9076-7ae0-b30e-a1623256a606" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://spyre.com/role/SegmentReportingScheduleofSignificantExpensesProvidedtotheCODMonaRegularBasisDetails" xlink:type="simple" xlink:href="syre-20260630.xsd#SegmentReportingScheduleofSignificantExpensesProvidedtotheCODMonaRegularBasisDetails"/>
  <link:calculationLink xlink:role="http://spyre.com/role/SegmentReportingScheduleofSignificantExpensesProvidedtotheCODMonaRegularBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019e22c4-9076-7845-b2be-bddf81c1e370" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_019e22c4-9076-752f-9462-0d98917985b2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_019e22c4-9076-7845-b2be-bddf81c1e370" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_019e22c4-9076-752f-9462-0d98917985b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_019e22c4-9076-7e6c-a18e-d5daff676daa" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_019e22c4-9076-7845-b2be-bddf81c1e370" xlink:to="loc_us-gaap_ShareBasedCompensation_019e22c4-9076-7e6c-a18e-d5daff676daa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount_019e22c4-9076-771b-af1b-8332e3f4e66d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_019e22c4-9076-7845-b2be-bddf81c1e370" xlink:to="loc_us-gaap_SegmentReportingOtherItemAmount_019e22c4-9076-771b-af1b-8332e3f4e66d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold_019e22c4-9076-7f19-b196-bb483be61033" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_019e22c4-9076-7845-b2be-bddf81c1e370" xlink:to="loc_us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold_019e22c4-9076-7f19-b196-bb483be61033" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>syre-20260630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019e22c4-8e13-79c8-aa17-b3b58ba33655,g:1a770671-d821-405f-804e-c086c0f29bbb-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://spyre.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="syre-20260630.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://spyre.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_019e22c4-8fac-7fb9-84fc-2fd14dcc16ca" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_019e22c4-8fac-77cc-a899-e375d04f86ac" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_019e22c4-8fac-7fb9-84fc-2fd14dcc16ca" xlink:to="loc_us-gaap_StatementTable_019e22c4-8fac-77cc-a899-e375d04f86ac" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e22c4-8fac-74c2-b086-8364ebb201d2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_019e22c4-8fac-77cc-a899-e375d04f86ac" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e22c4-8fac-74c2-b086-8364ebb201d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019e22c4-8fac-74c2-b086-8364ebb201d2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e22c4-8fac-74c2-b086-8364ebb201d2" xlink:to="loc_us-gaap_RelatedPartyDomain_019e22c4-8fac-74c2-b086-8364ebb201d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019e22c4-8fac-7ef7-9366-d46f911586ad" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e22c4-8fac-74c2-b086-8364ebb201d2" xlink:to="loc_us-gaap_RelatedPartyDomain_019e22c4-8fac-7ef7-9366-d46f911586ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_019e22c4-8fac-7058-8896-45ae9ff2ec99" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_019e22c4-8fac-7ef7-9366-d46f911586ad" xlink:to="loc_us-gaap_NonrelatedPartyMember_019e22c4-8fac-7058-8896-45ae9ff2ec99" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_019e22c4-8fac-7889-bf09-0a6f7c0e2044" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_019e22c4-8fac-7ef7-9366-d46f911586ad" xlink:to="loc_us-gaap_RelatedPartyMember_019e22c4-8fac-7889-bf09-0a6f7c0e2044" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_019e22c4-8fac-7805-95a9-ce7cc0c85dd9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_019e22c4-8fac-77cc-a899-e375d04f86ac" xlink:to="loc_us-gaap_StatementClassOfStockAxis_019e22c4-8fac-7805-95a9-ce7cc0c85dd9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019e22c4-8fac-7805-95a9-ce7cc0c85dd9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019e22c4-8fac-7805-95a9-ce7cc0c85dd9" xlink:to="loc_us-gaap_ClassOfStockDomain_019e22c4-8fac-7805-95a9-ce7cc0c85dd9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019e22c4-8fac-70e0-b006-18c8391b2ce4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019e22c4-8fac-7805-95a9-ce7cc0c85dd9" xlink:to="loc_us-gaap_ClassOfStockDomain_019e22c4-8fac-70e0-b006-18c8391b2ce4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_SeriesANonVotingConvertiblePreferredStockMember_019e22c4-8fac-7f21-8f33-a957169226f6" xlink:href="syre-20260630.xsd#syre_SeriesANonVotingConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_019e22c4-8fac-70e0-b006-18c8391b2ce4" xlink:to="loc_syre_SeriesANonVotingConvertiblePreferredStockMember_019e22c4-8fac-7f21-8f33-a957169226f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_SeriesBNonVotingConvertiblePreferredStockMember_019e22c4-8fac-79f1-a802-83e50bee25ee" xlink:href="syre-20260630.xsd#syre_SeriesBNonVotingConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_019e22c4-8fac-70e0-b006-18c8391b2ce4" xlink:to="loc_syre_SeriesBNonVotingConvertiblePreferredStockMember_019e22c4-8fac-79f1-a802-83e50bee25ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_PreferredStockExcludingSeriesAAndBNonVotingConvertiblePreferredStockMember_019e22c4-8fac-7b46-9f2f-246dd16b50e4" xlink:href="syre-20260630.xsd#syre_PreferredStockExcludingSeriesAAndBNonVotingConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_019e22c4-8fac-70e0-b006-18c8391b2ce4" xlink:to="loc_syre_PreferredStockExcludingSeriesAAndBNonVotingConvertiblePreferredStockMember_019e22c4-8fac-7b46-9f2f-246dd16b50e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_019e22c4-8fac-7835-a428-aefd1ccf948b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019e22c4-8fac-7fb9-84fc-2fd14dcc16ca" xlink:to="loc_us-gaap_AssetsAbstract_019e22c4-8fac-7835-a428-aefd1ccf948b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_019e22c4-8fac-75e3-80f0-703666cbda32" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_019e22c4-8fac-7835-a428-aefd1ccf948b" xlink:to="loc_us-gaap_AssetsCurrentAbstract_019e22c4-8fac-75e3-80f0-703666cbda32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019e22c4-8fac-77ef-bbeb-d8be1c0de0ee" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_019e22c4-8fac-75e3-80f0-703666cbda32" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019e22c4-8fac-77ef-bbeb-d8be1c0de0ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_019e22c4-8fac-7671-b94d-a31204fce8b7" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_019e22c4-8fac-75e3-80f0-703666cbda32" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_019e22c4-8fac-7671-b94d-a31204fce8b7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_019e22c4-8fac-7ef9-a096-f70ad5861dfb" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_019e22c4-8fac-75e3-80f0-703666cbda32" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_019e22c4-8fac-7ef9-a096-f70ad5861dfb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_019e22c4-8fac-7713-bd54-42c1996c6680" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_019e22c4-8fac-75e3-80f0-703666cbda32" xlink:to="loc_us-gaap_AssetsCurrent_019e22c4-8fac-7713-bd54-42c1996c6680" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_019e22c4-8fac-7690-84bf-8065eace60e5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_019e22c4-8fac-7835-a428-aefd1ccf948b" xlink:to="loc_us-gaap_Assets_019e22c4-8fac-7690-84bf-8065eace60e5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019e22c4-8fac-7348-9e89-34b19a253bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019e22c4-8fac-7fb9-84fc-2fd14dcc16ca" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019e22c4-8fac-7348-9e89-34b19a253bf6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_019e22c4-8fac-78b8-9f6d-c6be0e6924ad" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019e22c4-8fac-7348-9e89-34b19a253bf6" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_019e22c4-8fac-78b8-9f6d-c6be0e6924ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_019e22c4-8fac-7a62-bd23-580f220b8a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_019e22c4-8fac-78b8-9f6d-c6be0e6924ad" xlink:to="loc_us-gaap_AccountsPayableCurrent_019e22c4-8fac-7a62-bd23-580f220b8a7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_019e22c4-8fac-7aa2-8a8a-2d882c54d892" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_019e22c4-8fac-78b8-9f6d-c6be0e6924ad" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_019e22c4-8fac-7aa2-8a8a-2d882c54d892" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_019e22c4-8fac-77c1-a352-6fb1f7c6cef9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_019e22c4-8fac-78b8-9f6d-c6be0e6924ad" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_019e22c4-8fac-77c1-a352-6fb1f7c6cef9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_019e22c4-8fac-7f68-b019-ec609917a71f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_019e22c4-8fac-78b8-9f6d-c6be0e6924ad" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_019e22c4-8fac-7f68-b019-ec609917a71f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_019e22c4-8fac-7d94-9a8f-c3c809ce41be" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_019e22c4-8fac-78b8-9f6d-c6be0e6924ad" xlink:to="loc_us-gaap_LiabilitiesCurrent_019e22c4-8fac-7d94-9a8f-c3c809ce41be" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_019e22c4-8fac-7af6-9062-f4cb7a003cf8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019e22c4-8fac-7348-9e89-34b19a253bf6" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_019e22c4-8fac-7af6-9062-f4cb7a003cf8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_019e22c4-8fac-7d95-8f23-6bd3e7931560" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019e22c4-8fac-7348-9e89-34b19a253bf6" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_019e22c4-8fac-7d95-8f23-6bd3e7931560" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_019e22c4-8fac-7e62-9830-9248f34e719f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019e22c4-8fac-7348-9e89-34b19a253bf6" xlink:to="loc_us-gaap_Liabilities_019e22c4-8fac-7e62-9830-9248f34e719f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_019e22c4-8fac-71f4-8fab-ada521debd81" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019e22c4-8fac-7348-9e89-34b19a253bf6" xlink:to="loc_us-gaap_CommitmentsAndContingencies_019e22c4-8fac-71f4-8fab-ada521debd81" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_019e22c4-8fac-7565-9505-b2aa40f362c4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019e22c4-8fac-7348-9e89-34b19a253bf6" xlink:to="loc_us-gaap_StockholdersEquityAbstract_019e22c4-8fac-7565-9505-b2aa40f362c4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_019e22c4-8fac-7600-b269-6d89d33c541f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_019e22c4-8fac-7565-9505-b2aa40f362c4" xlink:to="loc_us-gaap_PreferredStockValue_019e22c4-8fac-7600-b269-6d89d33c541f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_019e22c4-8fac-7993-9e08-8f06493cee6a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_019e22c4-8fac-7565-9505-b2aa40f362c4" xlink:to="loc_us-gaap_CommonStockValue_019e22c4-8fac-7993-9e08-8f06493cee6a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_019e22c4-8fac-7809-966a-2b114841f89e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_019e22c4-8fac-7565-9505-b2aa40f362c4" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_019e22c4-8fac-7809-966a-2b114841f89e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_019e22c4-8fac-7679-b958-707203ab1b92" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_019e22c4-8fac-7565-9505-b2aa40f362c4" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_019e22c4-8fac-7679-b958-707203ab1b92" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019e22c4-8fac-712c-8479-93322783237d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_019e22c4-8fac-7565-9505-b2aa40f362c4" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019e22c4-8fac-712c-8479-93322783237d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019e22c4-8fac-7e8d-bd7d-d6da4d739343" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_019e22c4-8fac-7565-9505-b2aa40f362c4" xlink:to="loc_us-gaap_StockholdersEquity_019e22c4-8fac-7e8d-bd7d-d6da4d739343" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_019e22c4-8fac-796d-b7ce-0744a8bacae6" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019e22c4-8fac-7348-9e89-34b19a253bf6" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_019e22c4-8fac-796d-b7ce-0744a8bacae6" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://spyre.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="syre-20260630.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://spyre.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_019e22c4-8fac-7896-b311-361d4f620016" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_019e22c4-8fac-7fb0-b94d-f9e45761583d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_019e22c4-8fac-7896-b311-361d4f620016" xlink:to="loc_us-gaap_StatementTable_019e22c4-8fac-7fb0-b94d-f9e45761583d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_019e22c4-8fac-7dde-a407-3bc46b96d9f6" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_019e22c4-8fac-7fb0-b94d-f9e45761583d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_019e22c4-8fac-7dde-a407-3bc46b96d9f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019e22c4-8fac-7dde-a407-3bc46b96d9f6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019e22c4-8fac-7dde-a407-3bc46b96d9f6" xlink:to="loc_us-gaap_ClassOfStockDomain_019e22c4-8fac-7dde-a407-3bc46b96d9f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019e22c4-8fac-79df-9b46-97b7a1c3233d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019e22c4-8fac-7dde-a407-3bc46b96d9f6" xlink:to="loc_us-gaap_ClassOfStockDomain_019e22c4-8fac-79df-9b46-97b7a1c3233d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_SeriesANonVotingConvertiblePreferredStockMember_019e22c4-8fac-78a3-8a36-1a0b1b5bafe0" xlink:href="syre-20260630.xsd#syre_SeriesANonVotingConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_019e22c4-8fac-79df-9b46-97b7a1c3233d" xlink:to="loc_syre_SeriesANonVotingConvertiblePreferredStockMember_019e22c4-8fac-78a3-8a36-1a0b1b5bafe0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_SeriesBNonVotingConvertiblePreferredStockMember_019e22c4-8fac-7fee-b78c-3952d864066e" xlink:href="syre-20260630.xsd#syre_SeriesBNonVotingConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_019e22c4-8fac-79df-9b46-97b7a1c3233d" xlink:to="loc_syre_SeriesBNonVotingConvertiblePreferredStockMember_019e22c4-8fac-7fee-b78c-3952d864066e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_PreferredStockExcludingSeriesAAndBNonVotingConvertiblePreferredStockMember_019e22c4-8fac-792a-81da-3fe53ac90149" xlink:href="syre-20260630.xsd#syre_PreferredStockExcludingSeriesAAndBNonVotingConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_019e22c4-8fac-79df-9b46-97b7a1c3233d" xlink:to="loc_syre_PreferredStockExcludingSeriesAAndBNonVotingConvertiblePreferredStockMember_019e22c4-8fac-792a-81da-3fe53ac90149" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_019e22c4-8fac-7638-b70d-40557b67d779" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019e22c4-8fac-7896-b311-361d4f620016" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_019e22c4-8fac-7638-b70d-40557b67d779" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_019e22c4-8fac-7e78-a7eb-11a10bead770" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019e22c4-8fac-7896-b311-361d4f620016" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_019e22c4-8fac-7e78-a7eb-11a10bead770" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_019e22c4-8fac-7b17-832f-5814ce788505" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019e22c4-8fac-7896-b311-361d4f620016" xlink:to="loc_us-gaap_PreferredStockSharesIssued_019e22c4-8fac-7b17-832f-5814ce788505" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_019e22c4-8fac-748a-9bd5-452386c7c1d5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019e22c4-8fac-7896-b311-361d4f620016" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_019e22c4-8fac-748a-9bd5-452386c7c1d5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_019e22c4-8fac-75f1-82f1-0cda8c9530e9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019e22c4-8fac-7896-b311-361d4f620016" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_019e22c4-8fac-75f1-82f1-0cda8c9530e9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_019e22c4-8fac-724a-b5fd-90d43386686c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019e22c4-8fac-7896-b311-361d4f620016" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_019e22c4-8fac-724a-b5fd-90d43386686c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_019e22c4-8fac-7029-9cfe-56c43e8767a8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019e22c4-8fac-7896-b311-361d4f620016" xlink:to="loc_us-gaap_CommonStockSharesIssued_019e22c4-8fac-7029-9cfe-56c43e8767a8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_019e22c4-8fac-70f2-8fce-4d619edfd3ff" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019e22c4-8fac-7896-b311-361d4f620016" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_019e22c4-8fac-70f2-8fce-4d619edfd3ff" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://spyre.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="syre-20260630.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:definitionLink xlink:role="http://spyre.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_019e22c4-8fac-77a6-a1ac-b1ca56bc1c3a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_019e22c4-8fac-7362-a536-6fb845b562d6" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_019e22c4-8fac-77a6-a1ac-b1ca56bc1c3a" xlink:to="loc_us-gaap_StatementTable_019e22c4-8fac-7362-a536-6fb845b562d6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_019e22c4-8fac-766d-a4d6-407de26af1f9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_019e22c4-8fac-7362-a536-6fb845b562d6" xlink:to="loc_us-gaap_StatementClassOfStockAxis_019e22c4-8fac-766d-a4d6-407de26af1f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019e22c4-8fac-766d-a4d6-407de26af1f9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019e22c4-8fac-766d-a4d6-407de26af1f9" xlink:to="loc_us-gaap_ClassOfStockDomain_019e22c4-8fac-766d-a4d6-407de26af1f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019e22c4-8fac-7570-91a0-0f07999e7d4f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019e22c4-8fac-766d-a4d6-407de26af1f9" xlink:to="loc_us-gaap_ClassOfStockDomain_019e22c4-8fac-7570-91a0-0f07999e7d4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_SeriesANonVotingConvertiblePreferredStockMember_019e22c4-8fac-7bed-ab89-d110c66be40f" xlink:href="syre-20260630.xsd#syre_SeriesANonVotingConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_019e22c4-8fac-7570-91a0-0f07999e7d4f" xlink:to="loc_syre_SeriesANonVotingConvertiblePreferredStockMember_019e22c4-8fac-7bed-ab89-d110c66be40f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_SeriesBNonVotingConvertiblePreferredStockMember_019e22c4-8fac-7d13-ab32-769645332f8c" xlink:href="syre-20260630.xsd#syre_SeriesBNonVotingConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_019e22c4-8fac-7570-91a0-0f07999e7d4f" xlink:to="loc_syre_SeriesBNonVotingConvertiblePreferredStockMember_019e22c4-8fac-7d13-ab32-769645332f8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_019e22c4-8fac-7f73-bc9e-cd53448b3d5c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_019e22c4-8fac-7570-91a0-0f07999e7d4f" xlink:to="loc_us-gaap_CommonStockMember_019e22c4-8fac-7f73-bc9e-cd53448b3d5c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e22c4-8fac-75da-b965-b68756ec1eda" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_019e22c4-8fac-7362-a536-6fb845b562d6" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e22c4-8fac-75da-b965-b68756ec1eda" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019e22c4-8fac-75da-b965-b68756ec1eda_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e22c4-8fac-75da-b965-b68756ec1eda" xlink:to="loc_us-gaap_RelatedPartyDomain_019e22c4-8fac-75da-b965-b68756ec1eda_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019e22c4-8fac-7718-b2ff-98408a482d65" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e22c4-8fac-75da-b965-b68756ec1eda" xlink:to="loc_us-gaap_RelatedPartyDomain_019e22c4-8fac-7718-b2ff-98408a482d65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_019e22c4-8fac-786b-8788-ad701d5b8bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_019e22c4-8fac-7718-b2ff-98408a482d65" xlink:to="loc_us-gaap_RelatedPartyMember_019e22c4-8fac-786b-8788-ad701d5b8bd8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_019e22c4-8fac-7b62-9b1c-639298dd7bf0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019e22c4-8fac-77a6-a1ac-b1ca56bc1c3a" xlink:to="loc_us-gaap_OperatingExpensesAbstract_019e22c4-8fac-7b62-9b1c-639298dd7bf0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_019e22c4-8fac-71d4-a77c-28516d6e8fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019e22c4-8fac-7b62-9b1c-639298dd7bf0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_019e22c4-8fac-71d4-a77c-28516d6e8fe2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_019e22c4-8fac-7b06-89d8-d39e1fda7200" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019e22c4-8fac-7b62-9b1c-639298dd7bf0" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_019e22c4-8fac-7b06-89d8-d39e1fda7200" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_019e22c4-8fac-7a01-b877-29ebb8444e6b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019e22c4-8fac-7b62-9b1c-639298dd7bf0" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_019e22c4-8fac-7a01-b877-29ebb8444e6b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_019e22c4-8fac-75b1-818d-ccf518b63cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019e22c4-8fac-7b62-9b1c-639298dd7bf0" xlink:to="loc_us-gaap_OperatingExpenses_019e22c4-8fac-75b1-818d-ccf518b63cc1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_019e22c4-8fac-71f4-9d3c-c85941247261" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019e22c4-8fac-77a6-a1ac-b1ca56bc1c3a" xlink:to="loc_us-gaap_OperatingIncomeLoss_019e22c4-8fac-71f4-9d3c-c85941247261" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_019e22c4-8fac-75fc-a279-96e75947ad5a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019e22c4-8fac-77a6-a1ac-b1ca56bc1c3a" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_019e22c4-8fac-75fc-a279-96e75947ad5a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_019e22c4-8fac-77c2-82af-22f282d9dcce" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_019e22c4-8fac-75fc-a279-96e75947ad5a" xlink:to="loc_us-gaap_InvestmentIncomeNet_019e22c4-8fac-77c2-82af-22f282d9dcce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_019e22c4-8fac-771d-9004-2ee657b4c024" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_019e22c4-8fac-75fc-a279-96e75947ad5a" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_019e22c4-8fac-771d-9004-2ee657b4c024" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_019e22c4-8fac-70b8-b3a2-1416fb454c7a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_019e22c4-8fac-75fc-a279-96e75947ad5a" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_019e22c4-8fac-70b8-b3a2-1416fb454c7a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019e22c4-8fac-7765-acb6-e3c4b49a2f3d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019e22c4-8fac-77a6-a1ac-b1ca56bc1c3a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019e22c4-8fac-7765-acb6-e3c4b49a2f3d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_019e22c4-8fac-7de8-ae7d-966c9f29888d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019e22c4-8fac-77a6-a1ac-b1ca56bc1c3a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_019e22c4-8fac-7de8-ae7d-966c9f29888d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019e22c4-8fac-73b3-8edd-2b714962ccb0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019e22c4-8fac-77a6-a1ac-b1ca56bc1c3a" xlink:to="loc_us-gaap_NetIncomeLoss_019e22c4-8fac-73b3-8edd-2b714962ccb0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_019e22c4-8fac-7c85-87ee-53ad6ebf11fb" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019e22c4-8fac-77a6-a1ac-b1ca56bc1c3a" xlink:to="loc_us-gaap_EarningsPerShareBasic_019e22c4-8fac-7c85-87ee-53ad6ebf11fb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_019e22c4-8fac-7edb-a96b-d8e07fb37fa7" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019e22c4-8fac-77a6-a1ac-b1ca56bc1c3a" xlink:to="loc_us-gaap_EarningsPerShareDiluted_019e22c4-8fac-7edb-a96b-d8e07fb37fa7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_019e22c4-8fac-7650-8f16-1d9d9c947536" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019e22c4-8fac-77a6-a1ac-b1ca56bc1c3a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_019e22c4-8fac-7650-8f16-1d9d9c947536" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019e22c4-8fac-7f48-97d8-87b71e330900" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019e22c4-8fac-77a6-a1ac-b1ca56bc1c3a" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019e22c4-8fac-7f48-97d8-87b71e330900" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://spyre.com/role/CondensedConsolidatedStatementsofOperationsParenthetical" xlink:type="simple" xlink:href="syre-20260630.xsd#CondensedConsolidatedStatementsofOperationsParenthetical"/>
  <link:definitionLink xlink:role="http://spyre.com/role/CondensedConsolidatedStatementsofOperationsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_019e22c4-8fac-7c29-931b-27037b8d7cee" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_019e22c4-8fac-7d93-af78-e16f7b7f0b88" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_019e22c4-8fac-7c29-931b-27037b8d7cee" xlink:to="loc_us-gaap_StatementTable_019e22c4-8fac-7d93-af78-e16f7b7f0b88" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e22c4-8fac-7cdb-8050-8335cfb92b9b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_019e22c4-8fac-7d93-af78-e16f7b7f0b88" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e22c4-8fac-7cdb-8050-8335cfb92b9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019e22c4-8fac-7cdb-8050-8335cfb92b9b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e22c4-8fac-7cdb-8050-8335cfb92b9b" xlink:to="loc_us-gaap_RelatedPartyDomain_019e22c4-8fac-7cdb-8050-8335cfb92b9b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019e22c4-8fac-783f-8a3f-dfec92c66275" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e22c4-8fac-7cdb-8050-8335cfb92b9b" xlink:to="loc_us-gaap_RelatedPartyDomain_019e22c4-8fac-783f-8a3f-dfec92c66275" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_019e22c4-8fac-7c13-af79-82301c693e82" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_019e22c4-8fac-783f-8a3f-dfec92c66275" xlink:to="loc_us-gaap_RelatedPartyMember_019e22c4-8fac-7c13-af79-82301c693e82" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_019e22c4-8fac-763d-8d67-859ff5bdf4cc" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019e22c4-8fac-7c29-931b-27037b8d7cee" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_019e22c4-8fac-763d-8d67-859ff5bdf4cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_019e22c4-8fac-7fbc-a1d1-68886cf5706e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019e22c4-8fac-7c29-931b-27037b8d7cee" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_019e22c4-8fac-7fbc-a1d1-68886cf5706e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://spyre.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquity" xlink:type="simple" xlink:href="syre-20260630.xsd#CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquity"/>
  <link:definitionLink xlink:role="http://spyre.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_019e22c4-8fac-7691-88b1-f71d82472e27" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_019e22c4-8fac-7f59-b895-da231b300f1c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_019e22c4-8fac-7691-88b1-f71d82472e27" xlink:to="loc_us-gaap_StatementTable_019e22c4-8fac-7f59-b895-da231b300f1c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_019e22c4-8fac-7eaf-beaa-af40f5df6b1d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_019e22c4-8fac-7f59-b895-da231b300f1c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_019e22c4-8fac-7eaf-beaa-af40f5df6b1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019e22c4-8fac-7eaf-beaa-af40f5df6b1d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019e22c4-8fac-7eaf-beaa-af40f5df6b1d" xlink:to="loc_us-gaap_ClassOfStockDomain_019e22c4-8fac-7eaf-beaa-af40f5df6b1d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019e22c4-8fac-7da6-ae56-b707672724f0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019e22c4-8fac-7eaf-beaa-af40f5df6b1d" xlink:to="loc_us-gaap_ClassOfStockDomain_019e22c4-8fac-7da6-ae56-b707672724f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_SeriesANonVotingConvertiblePreferredStockMember_019e22c4-8fac-76f6-9c65-8b0ee64f689a" xlink:href="syre-20260630.xsd#syre_SeriesANonVotingConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_019e22c4-8fac-7da6-ae56-b707672724f0" xlink:to="loc_syre_SeriesANonVotingConvertiblePreferredStockMember_019e22c4-8fac-76f6-9c65-8b0ee64f689a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_SeriesBNonVotingConvertiblePreferredStockMember_019e22c4-8fac-7134-bc10-0a212565ca4f" xlink:href="syre-20260630.xsd#syre_SeriesBNonVotingConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_019e22c4-8fac-7da6-ae56-b707672724f0" xlink:to="loc_syre_SeriesBNonVotingConvertiblePreferredStockMember_019e22c4-8fac-7134-bc10-0a212565ca4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_019e22c4-8fac-73f6-be68-cbf09c3d8791" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_019e22c4-8fac-7f59-b895-da231b300f1c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_019e22c4-8fac-73f6-be68-cbf09c3d8791" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_019e22c4-8fac-73f6-be68-cbf09c3d8791_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_019e22c4-8fac-73f6-be68-cbf09c3d8791" xlink:to="loc_us-gaap_EquityComponentDomain_019e22c4-8fac-73f6-be68-cbf09c3d8791_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_019e22c4-8fac-7b6d-9178-065201e8d47a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_019e22c4-8fac-73f6-be68-cbf09c3d8791" xlink:to="loc_us-gaap_EquityComponentDomain_019e22c4-8fac-7b6d-9178-065201e8d47a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_019e22c4-8fac-7646-9dd1-84a431a4563f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_019e22c4-8fac-7b6d-9178-065201e8d47a" xlink:to="loc_us-gaap_PreferredStockMember_019e22c4-8fac-7646-9dd1-84a431a4563f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_019e22c4-8fac-76b4-943a-67a458698c08" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_019e22c4-8fac-7b6d-9178-065201e8d47a" xlink:to="loc_us-gaap_CommonStockMember_019e22c4-8fac-76b4-943a-67a458698c08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_019e22c4-8fac-79e8-b7fc-3cb5678a3ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_019e22c4-8fac-7b6d-9178-065201e8d47a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_019e22c4-8fac-79e8-b7fc-3cb5678a3ce0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019e22c4-8fac-71e2-b0ef-bed0e8d316f8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_019e22c4-8fac-7b6d-9178-065201e8d47a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019e22c4-8fac-71e2-b0ef-bed0e8d316f8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_019e22c4-8fac-760e-8a47-b79e13afdd0a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_019e22c4-8fac-7b6d-9178-065201e8d47a" xlink:to="loc_us-gaap_RetainedEarningsMember_019e22c4-8fac-760e-8a47-b79e13afdd0a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e22c4-8fac-74b9-8acf-0b44bb8eda5a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019e22c4-8fac-7691-88b1-f71d82472e27" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e22c4-8fac-74b9-8acf-0b44bb8eda5a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_019e22c4-8fac-7d95-96d1-8d037f54a8d7" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e22c4-8fac-74b9-8acf-0b44bb8eda5a" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_019e22c4-8fac-7d95-96d1-8d037f54a8d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019e22c4-8fac-7b79-8a86-54bd3db3639b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e22c4-8fac-74b9-8acf-0b44bb8eda5a" xlink:to="loc_us-gaap_StockholdersEquity_019e22c4-8fac-7b79-8a86-54bd3db3639b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_019e22c4-8fac-78f5-8370-728d2d474389" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e22c4-8fac-74b9-8acf-0b44bb8eda5a" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_019e22c4-8fac-78f5-8370-728d2d474389" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_019f5e6a-4e70-73cc-9ce4-7b10caab4cfc" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e22c4-8fac-74b9-8acf-0b44bb8eda5a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_019f5e6a-4e70-73cc-9ce4-7b10caab4cfc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_019f5e6b-3557-74de-914d-bee25c1e009d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e22c4-8fac-74b9-8acf-0b44bb8eda5a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_019f5e6b-3557-74de-914d-bee25c1e009d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_019e22c4-8fac-758b-9600-6f2454a56e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e22c4-8fac-74b9-8acf-0b44bb8eda5a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_019e22c4-8fac-758b-9600-6f2454a56e0a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_019e22c4-8fac-72df-b838-15b634e0445a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e22c4-8fac-74b9-8acf-0b44bb8eda5a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_019e22c4-8fac-72df-b838-15b634e0445a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan_019e22c4-8fac-7fe4-bbb2-6109457cf803" xlink:href="syre-20260630.xsd#syre_StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e22c4-8fac-74b9-8acf-0b44bb8eda5a" xlink:to="loc_syre_StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan_019e22c4-8fac-7fe4-bbb2-6109457cf803" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan_019e22c4-8fac-72df-bce9-59bd5fad14a2" xlink:href="syre-20260630.xsd#syre_StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e22c4-8fac-74b9-8acf-0b44bb8eda5a" xlink:to="loc_syre_StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan_019e22c4-8fac-72df-bce9-59bd5fad14a2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_019e22c4-8fac-79d0-ada8-c397385c52d8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e22c4-8fac-74b9-8acf-0b44bb8eda5a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_019e22c4-8fac-79d0-ada8-c397385c52d8" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_019e22c4-8fac-7a96-82c6-9a2dc2ef1661" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e22c4-8fac-74b9-8acf-0b44bb8eda5a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_019e22c4-8fac-7a96-82c6-9a2dc2ef1661" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_019e22c4-8fac-7afb-8b15-1832a16c2dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e22c4-8fac-74b9-8acf-0b44bb8eda5a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_019e22c4-8fac-7afb-8b15-1832a16c2dfd" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019e22c4-8fac-7231-8bdb-778525c8c5b6" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e22c4-8fac-74b9-8acf-0b44bb8eda5a" xlink:to="loc_us-gaap_NetIncomeLoss_019e22c4-8fac-7231-8bdb-778525c8c5b6" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_019e22c4-8fac-7034-aba4-42893f77dff0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019e22c4-8fac-7397-8ad8-f37a5a2a0a6a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_019e22c4-8fac-721a-b62a-8f79bb521a8c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesOutstanding"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://spyre.com/role/TheCompanyandBasisofPresentationDetails" xlink:type="simple" xlink:href="syre-20260630.xsd#TheCompanyandBasisofPresentationDetails"/>
  <link:definitionLink xlink:role="http://spyre.com/role/TheCompanyandBasisofPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_syre_CompanyAndBasisOfPresentationLineItems_019e22c4-8fac-7d17-9972-201dfeac166a" xlink:href="syre-20260630.xsd#syre_CompanyAndBasisOfPresentationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_CompanyAndBasisOfPresentationTable_019e22c4-8fac-7794-9e61-7ce31a4d6f06" xlink:href="syre-20260630.xsd#syre_CompanyAndBasisOfPresentationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_syre_CompanyAndBasisOfPresentationLineItems_019e22c4-8fac-7d17-9972-201dfeac166a" xlink:to="loc_syre_CompanyAndBasisOfPresentationTable_019e22c4-8fac-7794-9e61-7ce31a4d6f06" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_019e22c4-8fac-7bdc-9115-3482d4c38790" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_syre_CompanyAndBasisOfPresentationTable_019e22c4-8fac-7794-9e61-7ce31a4d6f06" xlink:to="loc_us-gaap_AssetAcquisitionAxis_019e22c4-8fac-7bdc-9115-3482d4c38790" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_019e22c4-8fac-7bdc-9115-3482d4c38790_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_019e22c4-8fac-7bdc-9115-3482d4c38790" xlink:to="loc_us-gaap_AssetAcquisitionDomain_019e22c4-8fac-7bdc-9115-3482d4c38790_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_019e22c4-8fac-7c4c-b682-1802bc31908a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_019e22c4-8fac-7bdc-9115-3482d4c38790" xlink:to="loc_us-gaap_AssetAcquisitionDomain_019e22c4-8fac-7c4c-b682-1802bc31908a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_SpyreTherapeuticsIncMember_019e22c4-8fac-72ad-ae58-0baaa3ac7918" xlink:href="syre-20260630.xsd#syre_SpyreTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_019e22c4-8fac-7c4c-b682-1802bc31908a" xlink:to="loc_syre_SpyreTherapeuticsIncMember_019e22c4-8fac-72ad-ae58-0baaa3ac7918" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_019e22c4-8fac-7afc-8b8c-3eeffe44f81d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_syre_CompanyAndBasisOfPresentationTable_019e22c4-8fac-7794-9e61-7ce31a4d6f06" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_019e22c4-8fac-7afc-8b8c-3eeffe44f81d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019e22c4-8fac-7afc-8b8c-3eeffe44f81d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_019e22c4-8fac-7afc-8b8c-3eeffe44f81d" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019e22c4-8fac-7afc-8b8c-3eeffe44f81d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019e22c4-8fac-79bc-8d41-cafc01c86b75" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_019e22c4-8fac-7afc-8b8c-3eeffe44f81d" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019e22c4-8fac-79bc-8d41-cafc01c86b75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_AtTheMarketOffering2024SalesAgreementMember_019e22c4-8fac-777d-b3ab-e94a10d2247a" xlink:href="syre-20260630.xsd#syre_AtTheMarketOffering2024SalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019e22c4-8fac-79bc-8d41-cafc01c86b75" xlink:to="loc_syre_AtTheMarketOffering2024SalesAgreementMember_019e22c4-8fac-777d-b3ab-e94a10d2247a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_AtTheMarketOffering2026SalesAgreementMember_019f84dd-5fe3-71c4-b812-4ca901480187" xlink:href="syre-20260630.xsd#syre_AtTheMarketOffering2026SalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019e22c4-8fac-79bc-8d41-cafc01c86b75" xlink:to="loc_syre_AtTheMarketOffering2026SalesAgreementMember_019f84dd-5fe3-71c4-b812-4ca901480187" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_October2025UnderwrittenOfferingMember_019e22c4-8fac-7876-b5ff-4448ef172113" xlink:href="syre-20260630.xsd#syre_October2025UnderwrittenOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019e22c4-8fac-79bc-8d41-cafc01c86b75" xlink:to="loc_syre_October2025UnderwrittenOfferingMember_019e22c4-8fac-7876-b5ff-4448ef172113" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_019e22c4-8fac-7859-ac4f-27d63974e9f7" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019e22c4-8fac-79bc-8d41-cafc01c86b75" xlink:to="loc_us-gaap_OverAllotmentOptionMember_019e22c4-8fac-7859-ac4f-27d63974e9f7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_April2026UnderwritingOfferingMember_019e22c4-8fac-7ffb-8001-6cd5a2b0e0b8" xlink:href="syre-20260630.xsd#syre_April2026UnderwritingOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019e22c4-8fac-79bc-8d41-cafc01c86b75" xlink:to="loc_syre_April2026UnderwritingOfferingMember_019e22c4-8fac-7ffb-8001-6cd5a2b0e0b8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_019e22c4-8fac-72c1-9b8c-c65488824ef2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_syre_CompanyAndBasisOfPresentationTable_019e22c4-8fac-7794-9e61-7ce31a4d6f06" xlink:to="loc_us-gaap_StatementClassOfStockAxis_019e22c4-8fac-72c1-9b8c-c65488824ef2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019e22c4-8fac-72c1-9b8c-c65488824ef2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019e22c4-8fac-72c1-9b8c-c65488824ef2" xlink:to="loc_us-gaap_ClassOfStockDomain_019e22c4-8fac-72c1-9b8c-c65488824ef2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019e22c4-8fac-7bc6-b524-a106bba33608" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019e22c4-8fac-72c1-9b8c-c65488824ef2" xlink:to="loc_us-gaap_ClassOfStockDomain_019e22c4-8fac-7bc6-b524-a106bba33608" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_019e22c4-8fac-7c5b-9406-19a556bd83fe" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_019e22c4-8fac-7bc6-b524-a106bba33608" xlink:to="loc_us-gaap_CommonStockMember_019e22c4-8fac-7c5b-9406-19a556bd83fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_019e22c4-8fac-77e6-9a9a-d47ff17356a5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_CompanyAndBasisOfPresentationLineItems_019e22c4-8fac-7d17-9972-201dfeac166a" xlink:to="loc_us-gaap_NumberOfOperatingSegments_019e22c4-8fac-77e6-9a9a-d47ff17356a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_AssetAcquisitionCashPaymentThresholdPeriod_019e22c4-8fac-761a-8bce-c0c12016bb55" xlink:href="syre-20260630.xsd#syre_AssetAcquisitionCashPaymentThresholdPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_CompanyAndBasisOfPresentationLineItems_019e22c4-8fac-7d17-9972-201dfeac166a" xlink:to="loc_syre_AssetAcquisitionCashPaymentThresholdPeriod_019e22c4-8fac-761a-8bce-c0c12016bb55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_SaleOfStockAuthorizedAmount_019e22c4-8fac-7afb-9d4a-01f3ab0a5e72" xlink:href="syre-20260630.xsd#syre_SaleOfStockAuthorizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_CompanyAndBasisOfPresentationLineItems_019e22c4-8fac-7d17-9972-201dfeac166a" xlink:to="loc_syre_SaleOfStockAuthorizedAmount_019e22c4-8fac-7afb-9d4a-01f3ab0a5e72" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_019e22c4-8fac-775a-bc1d-cdbebeefa26a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_CompanyAndBasisOfPresentationLineItems_019e22c4-8fac-7d17-9972-201dfeac166a" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_019e22c4-8fac-775a-bc1d-cdbebeefa26a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_019e22c4-8fac-7910-b4d9-07bb3c9f09fa" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_CompanyAndBasisOfPresentationLineItems_019e22c4-8fac-7d17-9972-201dfeac166a" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_019e22c4-8fac-7910-b4d9-07bb3c9f09fa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_019fa2dd-b937-7d30-be54-62c1bc83c180" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_CompanyAndBasisOfPresentationLineItems_019e22c4-8fac-7d17-9972-201dfeac166a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_019fa2dd-b937-7d30-be54-62c1bc83c180" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_SaleOfStockRemainingAuthorizedAmount_019f35c1-b9f3-7cee-b2f5-558dac751537" xlink:href="syre-20260630.xsd#syre_SaleOfStockRemainingAuthorizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_CompanyAndBasisOfPresentationLineItems_019e22c4-8fac-7d17-9972-201dfeac166a" xlink:to="loc_syre_SaleOfStockRemainingAuthorizedAmount_019f35c1-b9f3-7cee-b2f5-558dac751537" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_019e22c4-8fac-719d-b38c-c68bd58cd32a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_CompanyAndBasisOfPresentationLineItems_019e22c4-8fac-7d17-9972-201dfeac166a" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_019e22c4-8fac-719d-b38c-c68bd58cd32a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_019e22c4-8fac-7272-855d-321d3df3364c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_CompanyAndBasisOfPresentationLineItems_019e22c4-8fac-7d17-9972-201dfeac166a" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_019e22c4-8fac-7272-855d-321d3df3364c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_ProceedsFromRaisingCapital_019e22c4-8fac-7b48-967a-85ebccfac5ad" xlink:href="syre-20260630.xsd#syre_ProceedsFromRaisingCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_CompanyAndBasisOfPresentationLineItems_019e22c4-8fac-7d17-9972-201dfeac166a" xlink:to="loc_syre_ProceedsFromRaisingCapital_019e22c4-8fac-7b48-967a-85ebccfac5ad" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019e22c4-8fac-7b1a-8e0e-b69b87a3fe6b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_CompanyAndBasisOfPresentationLineItems_019e22c4-8fac-7d17-9972-201dfeac166a" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019e22c4-8fac-7b1a-8e0e-b69b87a3fe6b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_019e22c4-8fac-7f6a-8343-249ca702e24f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_CompanyAndBasisOfPresentationLineItems_019e22c4-8fac-7d17-9972-201dfeac166a" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_019e22c4-8fac-7f6a-8343-249ca702e24f" xlink:type="arc" order="11"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://spyre.com/role/FairValueMeasurementsScheduleofFairValueofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="syre-20260630.xsd#FairValueMeasurementsScheduleofFairValueofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://spyre.com/role/FairValueMeasurementsScheduleofFairValueofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019e22c4-8fac-78cf-a987-7916c428af01" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019e22c4-8fac-72ed-bda4-695d46db9441" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019e22c4-8fac-78cf-a987-7916c428af01" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019e22c4-8fac-72ed-bda4-695d46db9441" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019e22c4-8fac-7e90-99e3-c7e73889c977" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019e22c4-8fac-72ed-bda4-695d46db9441" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019e22c4-8fac-7e90-99e3-c7e73889c977" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019e22c4-8fac-7e90-99e3-c7e73889c977_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019e22c4-8fac-7e90-99e3-c7e73889c977" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019e22c4-8fac-7e90-99e3-c7e73889c977_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019e22c4-8fac-7c41-85e6-01f8bbd99b41" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019e22c4-8fac-7e90-99e3-c7e73889c977" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019e22c4-8fac-7c41-85e6-01f8bbd99b41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_019e22c4-8fac-7324-9cc5-b1a0c5f08df3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019e22c4-8fac-7c41-85e6-01f8bbd99b41" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_019e22c4-8fac-7324-9cc5-b1a0c5f08df3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_019e22c4-8fac-7471-9c7a-565c47648cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019e22c4-8fac-7c41-85e6-01f8bbd99b41" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_019e22c4-8fac-7471-9c7a-565c47648cf0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_019e22c4-8fac-7aab-a0ac-f1481c0a30d6" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019e22c4-8fac-7c41-85e6-01f8bbd99b41" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_019e22c4-8fac-7aab-a0ac-f1481c0a30d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_019e22c4-8fac-7421-8c72-a0415ea916ab" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019e22c4-8fac-72ed-bda4-695d46db9441" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_019e22c4-8fac-7421-8c72-a0415ea916ab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019e22c4-8fac-7421-8c72-a0415ea916ab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_019e22c4-8fac-7421-8c72-a0415ea916ab" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019e22c4-8fac-7421-8c72-a0415ea916ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019e22c4-8fac-7fb1-8e44-11e23deb8960" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_019e22c4-8fac-7421-8c72-a0415ea916ab" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019e22c4-8fac-7fb1-8e44-11e23deb8960" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_019e22c4-8fac-74c0-984d-fc8fa84b2760" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019e22c4-8fac-7fb1-8e44-11e23deb8960" xlink:to="loc_us-gaap_MoneyMarketFundsMember_019e22c4-8fac-74c0-984d-fc8fa84b2760" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_019e22c4-8fac-7460-b2f1-ba35fa391bf4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019e22c4-8fac-72ed-bda4-695d46db9441" xlink:to="loc_us-gaap_FinancialInstrumentAxis_019e22c4-8fac-7460-b2f1-ba35fa391bf4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e22c4-8fac-7460-b2f1-ba35fa391bf4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019e22c4-8fac-7460-b2f1-ba35fa391bf4" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e22c4-8fac-7460-b2f1-ba35fa391bf4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e22c4-8fac-79d6-b774-6f6f11cb8c96" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019e22c4-8fac-7460-b2f1-ba35fa391bf4" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e22c4-8fac-79d6-b774-6f6f11cb8c96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_019e22c4-8fac-7592-a2f8-126c18bd9efe" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e22c4-8fac-79d6-b774-6f6f11cb8c96" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_019e22c4-8fac-7592-a2f8-126c18bd9efe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_019e22c4-8fac-7216-b09d-8fa0e94563b9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e22c4-8fac-79d6-b774-6f6f11cb8c96" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_019e22c4-8fac-7216-b09d-8fa0e94563b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_019e22c4-8fac-7031-8d85-68302e118bf5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e22c4-8fac-79d6-b774-6f6f11cb8c96" xlink:to="loc_us-gaap_CommercialPaperMember_019e22c4-8fac-7031-8d85-68302e118bf5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_019e22c4-8fac-7ae7-9f53-21c4b09730a7" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e22c4-8fac-79d6-b774-6f6f11cb8c96" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_019e22c4-8fac-7ae7-9f53-21c4b09730a7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_019e22c4-8fac-726d-9233-7632868cf91d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019e22c4-8fac-78cf-a987-7916c428af01" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_019e22c4-8fac-726d-9233-7632868cf91d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_019e22c4-8fac-75b9-aa64-83d60e7a0575" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_019e22c4-8fac-726d-9233-7632868cf91d" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_019e22c4-8fac-75b9-aa64-83d60e7a0575" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_019e22c4-8fac-7dcf-bee0-f308d78aa482" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_019e22c4-8fac-726d-9233-7632868cf91d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_019e22c4-8fac-7dcf-bee0-f308d78aa482" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_019e22c4-8fac-74ae-88af-35551c7f5d45" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_019e22c4-8fac-726d-9233-7632868cf91d" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_019e22c4-8fac-74ae-88af-35551c7f5d45" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_019e22c4-8fac-7cf3-9c25-5c6b3546838d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019e22c4-8fac-78cf-a987-7916c428af01" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_019e22c4-8fac-7cf3-9c25-5c6b3546838d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_019e22c4-8fac-7473-be1c-1887458303d3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_019e22c4-8fac-7cf3-9c25-5c6b3546838d" xlink:to="loc_us-gaap_DerivativeLiabilities_019e22c4-8fac-7473-be1c-1887458303d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_019e22c4-8fac-71be-a3ae-18f3b4b966c1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_019e22c4-8fac-7cf3-9c25-5c6b3546838d" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_019e22c4-8fac-71be-a3ae-18f3b4b966c1" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://spyre.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="syre-20260630.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://spyre.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019e22c4-8fac-7ecf-92d5-d9aed672acf9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019e22c4-8fac-7b02-a17e-9f3a705546d8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019e22c4-8fac-7ecf-92d5-d9aed672acf9" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019e22c4-8fac-7b02-a17e-9f3a705546d8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_019e22c4-8fac-7014-a95f-c3ed5f3be7f2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019e22c4-8fac-7b02-a17e-9f3a705546d8" xlink:to="loc_us-gaap_AssetAcquisitionAxis_019e22c4-8fac-7014-a95f-c3ed5f3be7f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_019e22c4-8fac-7014-a95f-c3ed5f3be7f2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_019e22c4-8fac-7014-a95f-c3ed5f3be7f2" xlink:to="loc_us-gaap_AssetAcquisitionDomain_019e22c4-8fac-7014-a95f-c3ed5f3be7f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_019e22c4-8fac-7982-bcde-83647fd16678" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_019e22c4-8fac-7014-a95f-c3ed5f3be7f2" xlink:to="loc_us-gaap_AssetAcquisitionDomain_019e22c4-8fac-7982-bcde-83647fd16678" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_SpyreTherapeuticsIncMember_019e22c4-8fac-78ff-b11e-99ace64e1ea7" xlink:href="syre-20260630.xsd#syre_SpyreTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_019e22c4-8fac-7982-bcde-83647fd16678" xlink:to="loc_syre_SpyreTherapeuticsIncMember_019e22c4-8fac-78ff-b11e-99ace64e1ea7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_019e22c4-8fac-7bdf-a96e-677956d42647" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019e22c4-8fac-7b02-a17e-9f3a705546d8" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_019e22c4-8fac-7bdf-a96e-677956d42647" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_019e22c4-8fac-7bdf-a96e-677956d42647_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_019e22c4-8fac-7bdf-a96e-677956d42647" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_019e22c4-8fac-7bdf-a96e-677956d42647_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_019e22c4-8fac-77cd-9bc3-3d3223e8aa69" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_019e22c4-8fac-7bdf-a96e-677956d42647" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_019e22c4-8fac-77cd-9bc3-3d3223e8aa69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_ContingentValueRightLiabilityMember_019e22c4-8fac-7ce4-9018-d3bcbdd20cef" xlink:href="syre-20260630.xsd#syre_ContingentValueRightLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_019e22c4-8fac-77cd-9bc3-3d3223e8aa69" xlink:to="loc_syre_ContingentValueRightLiabilityMember_019e22c4-8fac-7ce4-9018-d3bcbdd20cef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_AssetAcquisitionStockholderPaymentPeriod_019e22c4-8fac-7452-b0a9-716fbc17ee99" xlink:href="syre-20260630.xsd#syre_AssetAcquisitionStockholderPaymentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019e22c4-8fac-7ecf-92d5-d9aed672acf9" xlink:to="loc_syre_AssetAcquisitionStockholderPaymentPeriod_019e22c4-8fac-7452-b0a9-716fbc17ee99" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_AssetAcquisitionCashPaymentThresholdPeriod_019e22c4-8fac-749b-ab27-a332828904ca" xlink:href="syre-20260630.xsd#syre_AssetAcquisitionCashPaymentThresholdPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019e22c4-8fac-7ecf-92d5-d9aed672acf9" xlink:to="loc_syre_AssetAcquisitionCashPaymentThresholdPeriod_019e22c4-8fac-749b-ab27-a332828904ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_019e22c4-8fac-70ad-a69f-75a6e71173f7" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019e22c4-8fac-7ecf-92d5-d9aed672acf9" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_019e22c4-8fac-70ad-a69f-75a6e71173f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_019fa2d9-0fbe-7a9f-9267-07dceafa69a6" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019e22c4-8fac-7ecf-92d5-d9aed672acf9" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_019fa2d9-0fbe-7a9f-9267-07dceafa69a6" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://spyre.com/role/FairValueMeasurementsScheduleofSignificantInputsUsedtoEstimatetheFairValueofCVRLiabilityDetails" xlink:type="simple" xlink:href="syre-20260630.xsd#FairValueMeasurementsScheduleofSignificantInputsUsedtoEstimatetheFairValueofCVRLiabilityDetails"/>
  <link:definitionLink xlink:role="http://spyre.com/role/FairValueMeasurementsScheduleofSignificantInputsUsedtoEstimatetheFairValueofCVRLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_019e22c4-8fac-7311-8a76-671818df12ec" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_019e22c4-8fac-7878-83b9-3507bcda7153" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_019e22c4-8fac-7311-8a76-671818df12ec" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_019e22c4-8fac-7878-83b9-3507bcda7153" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_019e22c4-8fac-7d14-88c4-43cbe917cb00" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_019e22c4-8fac-7878-83b9-3507bcda7153" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_019e22c4-8fac-7d14-88c4-43cbe917cb00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_019e22c4-8fac-7d14-88c4-43cbe917cb00_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_019e22c4-8fac-7d14-88c4-43cbe917cb00" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_019e22c4-8fac-7d14-88c4-43cbe917cb00_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_019e22c4-8fac-7454-a208-215d073a32bc" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_019e22c4-8fac-7d14-88c4-43cbe917cb00" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_019e22c4-8fac-7454-a208-215d073a32bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_ContingentValueRightLiabilityMember_019e22c4-8fac-7d99-8b14-811e068486d8" xlink:href="syre-20260630.xsd#syre_ContingentValueRightLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_019e22c4-8fac-7454-a208-215d073a32bc" xlink:to="loc_syre_ContingentValueRightLiabilityMember_019e22c4-8fac-7d99-8b14-811e068486d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019e22c4-8fac-741e-a201-b87df10ed5c9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_019e22c4-8fac-7878-83b9-3507bcda7153" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019e22c4-8fac-741e-a201-b87df10ed5c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019e22c4-8fac-741e-a201-b87df10ed5c9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019e22c4-8fac-741e-a201-b87df10ed5c9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019e22c4-8fac-741e-a201-b87df10ed5c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019e22c4-8fac-7ad3-ab2d-7589baca2e38" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019e22c4-8fac-741e-a201-b87df10ed5c9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019e22c4-8fac-7ad3-ab2d-7589baca2e38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_019e22c4-8fac-7e85-9299-08c5d27f77b7" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019e22c4-8fac-7ad3-ab2d-7589baca2e38" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_019e22c4-8fac-7e85-9299-08c5d27f77b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_019e22c4-8fac-79ca-8b09-91785e1cb3ed" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_019e22c4-8fac-7878-83b9-3507bcda7153" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_019e22c4-8fac-79ca-8b09-91785e1cb3ed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_019e22c4-8fac-79ca-8b09-91785e1cb3ed_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_019e22c4-8fac-79ca-8b09-91785e1cb3ed" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_019e22c4-8fac-79ca-8b09-91785e1cb3ed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_019e22c4-8fac-754a-9c2b-67ed5349fe60" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_019e22c4-8fac-79ca-8b09-91785e1cb3ed" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_019e22c4-8fac-754a-9c2b-67ed5349fe60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_019e22c4-8fac-7bf8-8a1d-13b3760b77cd" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_019e22c4-8fac-754a-9c2b-67ed5349fe60" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_019e22c4-8fac-7bf8-8a1d-13b3760b77cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityMeasurementInput_019e22c4-8fac-7832-97f3-564b67d55db4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativeLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_019e22c4-8fac-7311-8a76-671818df12ec" xlink:to="loc_us-gaap_DerivativeLiabilityMeasurementInput_019e22c4-8fac-7832-97f3-564b67d55db4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://spyre.com/role/FairValueMeasurementsScheduleofChangesinCVRLiabilityDetails" xlink:type="simple" xlink:href="syre-20260630.xsd#FairValueMeasurementsScheduleofChangesinCVRLiabilityDetails"/>
  <link:definitionLink xlink:role="http://spyre.com/role/FairValueMeasurementsScheduleofChangesinCVRLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_019e22c4-9076-7746-b945-33c68d00d577" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_019e22c4-9076-7761-b991-9b1f4a233097" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_019e22c4-9076-7746-b945-33c68d00d577" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_019e22c4-9076-7761-b991-9b1f4a233097" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_019e22c4-9076-72fb-8823-bf7687cfcdf1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_019e22c4-9076-7761-b991-9b1f4a233097" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_019e22c4-9076-72fb-8823-bf7687cfcdf1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_019e22c4-9076-72fb-8823-bf7687cfcdf1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_019e22c4-9076-72fb-8823-bf7687cfcdf1" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_019e22c4-9076-72fb-8823-bf7687cfcdf1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_019e22c4-9076-7de0-8fa1-5c18230f3dc4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_019e22c4-9076-72fb-8823-bf7687cfcdf1" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_019e22c4-9076-7de0-8fa1-5c18230f3dc4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_ContingentValueRightLiabilityMember_019e22c4-9076-7ebc-8f12-b860e16854fe" xlink:href="syre-20260630.xsd#syre_ContingentValueRightLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_019e22c4-9076-7de0-8fa1-5c18230f3dc4" xlink:to="loc_syre_ContingentValueRightLiabilityMember_019e22c4-9076-7ebc-8f12-b860e16854fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019e22c4-9076-75be-a6c4-ebd92cbf3ea4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_019e22c4-9076-7746-b945-33c68d00d577" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019e22c4-9076-75be-a6c4-ebd92cbf3ea4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_019e22c4-9076-7658-b380-9732d6b25a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019e22c4-9076-75be-a6c4-ebd92cbf3ea4" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_019e22c4-9076-7658-b380-9732d6b25a6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_019e22c4-9076-7e29-b400-851656bee77c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019e22c4-9076-75be-a6c4-ebd92cbf3ea4" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_019e22c4-9076-7e29-b400-851656bee77c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_019f82ed-dad5-7569-883c-20fa46de27cc" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019e22c4-9076-75be-a6c4-ebd92cbf3ea4" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_019f82ed-dad5-7569-883c-20fa46de27cc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_019e22c4-9076-79f8-a861-a3f6355c74f5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofEstimatedFairValueofCashEquivalentsandMarketableSecuritiesandGrossUnrealizedGainsandLossesDetails" xlink:type="simple" xlink:href="syre-20260630.xsd#CashEquivalentsandMarketableSecuritiesScheduleofEstimatedFairValueofCashEquivalentsandMarketableSecuritiesandGrossUnrealizedGainsandLossesDetails"/>
  <link:definitionLink xlink:role="http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofEstimatedFairValueofCashEquivalentsandMarketableSecuritiesandGrossUnrealizedGainsandLossesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019e22c4-9076-74bf-8d39-158aabff1f52" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019e22c4-9076-71d2-9778-f234e737b47e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019e22c4-9076-74bf-8d39-158aabff1f52" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019e22c4-9076-71d2-9778-f234e737b47e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_019e22c4-9076-7793-89c3-878370190188" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019e22c4-9076-71d2-9778-f234e737b47e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_019e22c4-9076-7793-89c3-878370190188" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019e22c4-9076-7793-89c3-878370190188_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_019e22c4-9076-7793-89c3-878370190188" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019e22c4-9076-7793-89c3-878370190188_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019e22c4-9076-706c-be27-42e48d813a76" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_019e22c4-9076-7793-89c3-878370190188" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019e22c4-9076-706c-be27-42e48d813a76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_019e22c4-9076-7d12-87d1-e9b0197d87ed" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019e22c4-9076-706c-be27-42e48d813a76" xlink:to="loc_us-gaap_MoneyMarketFundsMember_019e22c4-9076-7d12-87d1-e9b0197d87ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_019e22c4-9076-79a6-ac8e-5b2a92f53daf" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019e22c4-9076-706c-be27-42e48d813a76" xlink:to="loc_us-gaap_CommercialPaperMember_019e22c4-9076-79a6-ac8e-5b2a92f53daf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_019e22c4-9076-7a7c-9195-70482e4bb43b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019e22c4-9076-71d2-9778-f234e737b47e" xlink:to="loc_us-gaap_FinancialInstrumentAxis_019e22c4-9076-7a7c-9195-70482e4bb43b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e22c4-9076-7a7c-9195-70482e4bb43b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019e22c4-9076-7a7c-9195-70482e4bb43b" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e22c4-9076-7a7c-9195-70482e4bb43b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e22c4-9076-71ca-9097-b5925464c054" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019e22c4-9076-7a7c-9195-70482e4bb43b" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e22c4-9076-71ca-9097-b5925464c054" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_019e22c4-9076-7a22-9436-02abe6eb73a2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e22c4-9076-71ca-9097-b5925464c054" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_019e22c4-9076-7a22-9436-02abe6eb73a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_019e22c4-9076-796f-b763-6bc99b0b9cf8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e22c4-9076-71ca-9097-b5925464c054" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_019e22c4-9076-796f-b763-6bc99b0b9cf8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_019e22c4-9076-7357-8129-90bc23515419" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e22c4-9076-71ca-9097-b5925464c054" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_019e22c4-9076-7357-8129-90bc23515419" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_019e22c4-9076-7eec-bdc4-105c17710405" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e22c4-9076-71ca-9097-b5925464c054" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_019e22c4-9076-7eec-bdc4-105c17710405" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_019e22c4-9076-7e9a-a249-80c5ce29df2f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019e22c4-9076-74bf-8d39-158aabff1f52" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_019e22c4-9076-7e9a-a249-80c5ce29df2f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_CashEquivalentsUnrealizedGains_019e22c4-9076-78c0-a776-e56757dfe700" xlink:href="syre-20260630.xsd#syre_CashEquivalentsUnrealizedGains"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019e22c4-9076-74bf-8d39-158aabff1f52" xlink:to="loc_syre_CashEquivalentsUnrealizedGains_019e22c4-9076-78c0-a776-e56757dfe700" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_CashEquivalentsUnrealizedLosses_019e22c4-9076-7d99-92fb-59ccde8eaed1" xlink:href="syre-20260630.xsd#syre_CashEquivalentsUnrealizedLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019e22c4-9076-74bf-8d39-158aabff1f52" xlink:to="loc_syre_CashEquivalentsUnrealizedLosses_019e22c4-9076-7d99-92fb-59ccde8eaed1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_019e22c4-9076-7133-be27-9f2782960f2f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019e22c4-9076-74bf-8d39-158aabff1f52" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_019e22c4-9076-7133-be27-9f2782960f2f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_019e22c4-9076-7b27-803d-0af2dc9f8acb" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019e22c4-9076-74bf-8d39-158aabff1f52" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_019e22c4-9076-7b27-803d-0af2dc9f8acb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_019e22c4-9076-7a45-b651-30f6b1a95e93" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019e22c4-9076-74bf-8d39-158aabff1f52" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_019e22c4-9076-7a45-b651-30f6b1a95e93" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_019e22c4-9076-7df8-ab29-1319fb535117" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019e22c4-9076-74bf-8d39-158aabff1f52" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_019e22c4-9076-7df8-ab29-1319fb535117" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_019e22c4-9076-70e6-9de5-25e64ca39d07" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019e22c4-9076-74bf-8d39-158aabff1f52" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_019e22c4-9076-70e6-9de5-25e64ca39d07" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="syre-20260630.xsd#CashEquivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetails"/>
  <link:definitionLink xlink:role="http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019e22c4-9076-79f9-9efb-71ab61d27fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019e22c4-9076-7000-8d93-ee54e8d9b682" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019e22c4-9076-79f9-9efb-71ab61d27fe0" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019e22c4-9076-7000-8d93-ee54e8d9b682" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_019e22c4-9076-77ed-bf0a-0a844c6faa74" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019e22c4-9076-7000-8d93-ee54e8d9b682" xlink:to="loc_us-gaap_FinancialInstrumentAxis_019e22c4-9076-77ed-bf0a-0a844c6faa74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e22c4-9076-77ed-bf0a-0a844c6faa74_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019e22c4-9076-77ed-bf0a-0a844c6faa74" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e22c4-9076-77ed-bf0a-0a844c6faa74_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e22c4-9076-704c-9b7a-ee7f95c86a31" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019e22c4-9076-77ed-bf0a-0a844c6faa74" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e22c4-9076-704c-9b7a-ee7f95c86a31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_019e22c4-9076-7958-beab-269be7700669" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e22c4-9076-704c-9b7a-ee7f95c86a31" xlink:to="loc_us-gaap_CommercialPaperMember_019e22c4-9076-7958-beab-269be7700669" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_019e22c4-9076-7f2b-9293-f91a59a53df2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e22c4-9076-704c-9b7a-ee7f95c86a31" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_019e22c4-9076-7f2b-9293-f91a59a53df2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_019e22c4-9076-7a0e-97dc-92e57a9bb9ec" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e22c4-9076-704c-9b7a-ee7f95c86a31" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_019e22c4-9076-7a0e-97dc-92e57a9bb9ec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_019e22c4-9076-74ff-b597-739173fd75a0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e22c4-9076-704c-9b7a-ee7f95c86a31" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_019e22c4-9076-74ff-b597-739173fd75a0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_019e22c4-9076-7d94-9703-ea5497bdcc5c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019e22c4-9076-79f9-9efb-71ab61d27fe0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_019e22c4-9076-7d94-9703-ea5497bdcc5c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_019e22c4-9076-7b36-b102-47d636a0d896" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_019e22c4-9076-7d94-9703-ea5497bdcc5c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_019e22c4-9076-7b36-b102-47d636a0d896" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_019e22c4-9076-761c-91dd-0dc85c366680" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_019e22c4-9076-7d94-9703-ea5497bdcc5c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_019e22c4-9076-761c-91dd-0dc85c366680" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_019e22c4-9076-773d-b571-bede66050e6b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_019e22c4-9076-7d94-9703-ea5497bdcc5c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_019e22c4-9076-773d-b571-bede66050e6b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_019e22c4-9076-7659-907d-9c6a1816648d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019e22c4-9076-79f9-9efb-71ab61d27fe0" xlink:to="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_019e22c4-9076-7659-907d-9c6a1816648d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_019e22c4-9076-7226-b8a0-e739fafc2dab" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_019e22c4-9076-7659-907d-9c6a1816648d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_019e22c4-9076-7226-b8a0-e739fafc2dab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_019e22c4-9076-7ee2-ab1d-3e96ab03d75c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_019e22c4-9076-7659-907d-9c6a1816648d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_019e22c4-9076-7ee2-ab1d-3e96ab03d75c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_019e22c4-9076-7f5e-bc63-a22b0df64e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_019e22c4-9076-7659-907d-9c6a1816648d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_019e22c4-9076-7f5e-bc63-a22b0df64e6a" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://spyre.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails" xlink:type="simple" xlink:href="syre-20260630.xsd#CashEquivalentsandMarketableSecuritiesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://spyre.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_syre_CashEquivalentsAndMarketableSecuritiesLineItems_019e22c4-9076-795d-9b17-6a08d675f618" xlink:href="syre-20260630.xsd#syre_CashEquivalentsAndMarketableSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_CashEquivalentsAndMarketableSecuritiesTable_019e22c4-9076-7a30-ac51-bc3e721c935e" xlink:href="syre-20260630.xsd#syre_CashEquivalentsAndMarketableSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_syre_CashEquivalentsAndMarketableSecuritiesLineItems_019e22c4-9076-795d-9b17-6a08d675f618" xlink:to="loc_syre_CashEquivalentsAndMarketableSecuritiesTable_019e22c4-9076-7a30-ac51-bc3e721c935e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_019e22c4-9076-7a6c-9049-67c97514eae4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_syre_CashEquivalentsAndMarketableSecuritiesTable_019e22c4-9076-7a30-ac51-bc3e721c935e" xlink:to="loc_us-gaap_FinancialInstrumentAxis_019e22c4-9076-7a6c-9049-67c97514eae4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e22c4-9076-7a6c-9049-67c97514eae4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019e22c4-9076-7a6c-9049-67c97514eae4" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e22c4-9076-7a6c-9049-67c97514eae4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e22c4-9076-7e40-873f-94ec78f5415f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019e22c4-9076-7a6c-9049-67c97514eae4" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e22c4-9076-7e40-873f-94ec78f5415f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_019e22c4-9076-79f9-a9bb-4cfb89ef6b3a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e22c4-9076-7e40-873f-94ec78f5415f" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_019e22c4-9076-79f9-a9bb-4cfb89ef6b3a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_USBankingInstitutionMember_019e22c4-9076-70b8-bb38-589faf3d6c27" xlink:href="syre-20260630.xsd#syre_USBankingInstitutionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e22c4-9076-7e40-873f-94ec78f5415f" xlink:to="loc_syre_USBankingInstitutionMember_019e22c4-9076-70b8-bb38-589faf3d6c27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_019e22c4-9076-7284-b5db-d1ca3bbe259a" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_syre_CashEquivalentsAndMarketableSecuritiesTable_019e22c4-9076-7a30-ac51-bc3e721c935e" xlink:to="loc_srt_RangeAxis_019e22c4-9076-7284-b5db-d1ca3bbe259a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019e22c4-9076-7284-b5db-d1ca3bbe259a_default" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_019e22c4-9076-7284-b5db-d1ca3bbe259a" xlink:to="loc_srt_RangeMember_019e22c4-9076-7284-b5db-d1ca3bbe259a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019e22c4-9076-72df-867e-494470e8e70a" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_019e22c4-9076-7284-b5db-d1ca3bbe259a" xlink:to="loc_srt_RangeMember_019e22c4-9076-72df-867e-494470e8e70a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_019e22c4-9076-7ad6-b85a-7448b199ab2d" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_019e22c4-9076-72df-867e-494470e8e70a" xlink:to="loc_srt_MaximumMember_019e22c4-9076-7ad6-b85a-7448b199ab2d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest_019e22c4-9076-7f08-8119-84949d747f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_CashEquivalentsAndMarketableSecuritiesLineItems_019e22c4-9076-795d-9b17-6a08d675f618" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest_019e22c4-9076-7f08-8119-84949d747f8a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_ImpairmentOfMarketableSecurities_019e22c4-9076-7825-bd42-9f98754fd6c2" xlink:href="syre-20260630.xsd#syre_ImpairmentOfMarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_CashEquivalentsAndMarketableSecuritiesLineItems_019e22c4-9076-795d-9b17-6a08d675f618" xlink:to="loc_syre_ImpairmentOfMarketableSecurities_019e22c4-9076-7825-bd42-9f98754fd6c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_NumberOfDomesticBankingInstitutions_019e22c4-9076-76c8-b357-80ad4b55de06" xlink:href="syre-20260630.xsd#syre_NumberOfDomesticBankingInstitutions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_CashEquivalentsAndMarketableSecuritiesLineItems_019e22c4-9076-795d-9b17-6a08d675f618" xlink:to="loc_syre_NumberOfDomesticBankingInstitutions_019e22c4-9076-76c8-b357-80ad4b55de06" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFDICInsuredAmount_019e22c4-9076-789d-97c9-e2cdf7e48363" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashFDICInsuredAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_CashEquivalentsAndMarketableSecuritiesLineItems_019e22c4-9076-795d-9b17-6a08d675f618" xlink:to="loc_us-gaap_CashFDICInsuredAmount_019e22c4-9076-789d-97c9-e2cdf7e48363" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_019e22c4-9076-78b3-bb92-68ae9c773e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_CashEquivalentsAndMarketableSecuritiesLineItems_019e22c4-9076-795d-9b17-6a08d675f618" xlink:to="loc_us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_019e22c4-9076-78b3-bb92-68ae9c773e7d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable_019e22c4-9076-7f28-9638-ce7a32a84141" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_CashEquivalentsAndMarketableSecuritiesLineItems_019e22c4-9076-795d-9b17-6a08d675f618" xlink:to="loc_us-gaap_InterestReceivable_019e22c4-9076-7f28-9638-ce7a32a84141" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://spyre.com/role/LicensingAgreementsDetails" xlink:type="simple" xlink:href="syre-20260630.xsd#LicensingAgreementsDetails"/>
  <link:definitionLink xlink:role="http://spyre.com/role/LicensingAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_019e22c4-9076-7996-bb55-fd978e0fb2d3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019e22c4-9076-727d-97f3-a25aa95dab55" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019e22c4-9076-7996-bb55-fd978e0fb2d3" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019e22c4-9076-727d-97f3-a25aa95dab55" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_019e22c4-9076-7f4f-a768-668dc3631589" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019e22c4-9076-727d-97f3-a25aa95dab55" xlink:to="loc_srt_RangeAxis_019e22c4-9076-7f4f-a768-668dc3631589" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019e22c4-9076-7f4f-a768-668dc3631589_default" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_019e22c4-9076-7f4f-a768-668dc3631589" xlink:to="loc_srt_RangeMember_019e22c4-9076-7f4f-a768-668dc3631589_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019e22c4-9076-7888-b93d-32161eec804d" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_019e22c4-9076-7f4f-a768-668dc3631589" xlink:to="loc_srt_RangeMember_019e22c4-9076-7888-b93d-32161eec804d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_019e22c4-9076-7c6f-9841-1fcb46539be9" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_019e22c4-9076-7888-b93d-32161eec804d" xlink:to="loc_srt_MaximumMember_019e22c4-9076-7c6f-9841-1fcb46539be9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_019e22c4-9076-7ba6-8b7b-a0fb13981021" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019e22c4-9076-727d-97f3-a25aa95dab55" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_019e22c4-9076-7ba6-8b7b-a0fb13981021" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_019e22c4-9076-7ba6-8b7b-a0fb13981021_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_019e22c4-9076-7ba6-8b7b-a0fb13981021" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_019e22c4-9076-7ba6-8b7b-a0fb13981021_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_019e22c4-9076-723f-9eab-d283d43b84aa" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_019e22c4-9076-7ba6-8b7b-a0fb13981021" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_019e22c4-9076-723f-9eab-d283d43b84aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_ParagonAgreementMember_019e22c4-9076-757c-8519-784a4b6e110a" xlink:href="syre-20260630.xsd#syre_ParagonAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_019e22c4-9076-723f-9eab-d283d43b84aa" xlink:to="loc_syre_ParagonAgreementMember_019e22c4-9076-757c-8519-784a4b6e110a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_Spy001LicenseAgreementMember_019e22c4-9076-73e2-a4d2-ddeccc226107" xlink:href="syre-20260630.xsd#syre_Spy001LicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_ParagonAgreementMember_019e22c4-9076-757c-8519-784a4b6e110a" xlink:to="loc_syre_Spy001LicenseAgreementMember_019e22c4-9076-73e2-a4d2-ddeccc226107" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_SPY002AndSPY072LicenseAgreementMember_019e22c4-9076-76cd-b2ae-cda7d6dc836d" xlink:href="syre-20260630.xsd#syre_SPY002AndSPY072LicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_ParagonAgreementMember_019e22c4-9076-757c-8519-784a4b6e110a" xlink:to="loc_syre_SPY002AndSPY072LicenseAgreementMember_019e22c4-9076-76cd-b2ae-cda7d6dc836d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_SPY003LicenseAgreementMember_019e22c4-9076-7f6a-88c0-cb3cd4830930" xlink:href="syre-20260630.xsd#syre_SPY003LicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_ParagonAgreementMember_019e22c4-9076-757c-8519-784a4b6e110a" xlink:to="loc_syre_SPY003LicenseAgreementMember_019e22c4-9076-7f6a-88c0-cb3cd4830930" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_ParagonAgreementLicenseMilestonePaymentsMember_019e22c4-9076-7f78-8ba0-6a012a3a72b0" xlink:href="syre-20260630.xsd#syre_ParagonAgreementLicenseMilestonePaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_ParagonAgreementMember_019e22c4-9076-757c-8519-784a4b6e110a" xlink:to="loc_syre_ParagonAgreementLicenseMilestonePaymentsMember_019e22c4-9076-7f78-8ba0-6a012a3a72b0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e22c4-9076-7370-871b-7cef5c5f83d8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019e22c4-9076-727d-97f3-a25aa95dab55" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e22c4-9076-7370-871b-7cef5c5f83d8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019e22c4-9076-7370-871b-7cef5c5f83d8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e22c4-9076-7370-871b-7cef5c5f83d8" xlink:to="loc_us-gaap_RelatedPartyDomain_019e22c4-9076-7370-871b-7cef5c5f83d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019e22c4-9076-7196-aaa6-3a61728921b2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e22c4-9076-7370-871b-7cef5c5f83d8" xlink:to="loc_us-gaap_RelatedPartyDomain_019e22c4-9076-7196-aaa6-3a61728921b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_019e22c4-9076-7e84-a27b-92751968ec87" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_019e22c4-9076-7196-aaa6-3a61728921b2" xlink:to="loc_us-gaap_RelatedPartyMember_019e22c4-9076-7e84-a27b-92751968ec87" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_AmountToBePaidUnderAgreement_019e22c4-9076-759b-b5bd-e51639ffcf11" xlink:href="syre-20260630.xsd#syre_AmountToBePaidUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019e22c4-9076-7996-bb55-fd978e0fb2d3" xlink:to="loc_syre_AmountToBePaidUnderAgreement_019e22c4-9076-759b-b5bd-e51639ffcf11" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_PaymentOfMilestone_019e22c4-9076-7fe2-afc4-c4bb28a2c11a" xlink:href="syre-20260630.xsd#syre_PaymentOfMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019e22c4-9076-7996-bb55-fd978e0fb2d3" xlink:to="loc_syre_PaymentOfMilestone_019e22c4-9076-7fe2-afc4-c4bb28a2c11a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_CampaignTimelineMinimumTerm_019e22c4-9076-7f58-a62c-4b4e2f8d3e97" xlink:href="syre-20260630.xsd#syre_CampaignTimelineMinimumTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019e22c4-9076-7996-bb55-fd978e0fb2d3" xlink:to="loc_syre_CampaignTimelineMinimumTerm_019e22c4-9076-7f58-a62c-4b4e2f8d3e97" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_RoyaltyStepDownPercent_019e22c4-9076-739c-8246-b7ab51f59883" xlink:href="syre-20260630.xsd#syre_RoyaltyStepDownPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019e22c4-9076-7996-bb55-fd978e0fb2d3" xlink:to="loc_syre_RoyaltyStepDownPercent_019e22c4-9076-739c-8246-b7ab51f59883" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_RoyaltyTermExpirationPeriod_019e22c4-9076-7e4a-87a2-6d90ecb6f1e2" xlink:href="syre-20260630.xsd#syre_RoyaltyTermExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019e22c4-9076-7996-bb55-fd978e0fb2d3" xlink:to="loc_syre_RoyaltyTermExpirationPeriod_019e22c4-9076-7e4a-87a2-6d90ecb6f1e2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_TerminationNoticePeriod_019e22c4-9076-726d-8c9c-9230e4747d9d" xlink:href="syre-20260630.xsd#syre_TerminationNoticePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019e22c4-9076-7996-bb55-fd978e0fb2d3" xlink:to="loc_syre_TerminationNoticePeriod_019e22c4-9076-726d-8c9c-9230e4747d9d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_SublicensingFee_019e22c4-9076-7251-a28e-961798073d04" xlink:href="syre-20260630.xsd#syre_SublicensingFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019e22c4-9076-7996-bb55-fd978e0fb2d3" xlink:to="loc_syre_SublicensingFee_019e22c4-9076-7251-a28e-961798073d04" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_019e22c4-9076-7f95-abf7-cbaaaeb35783" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019e22c4-9076-7996-bb55-fd978e0fb2d3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_019e22c4-9076-7f95-abf7-cbaaaeb35783" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_LicenseAgreementMilestonePayments_019e22c4-9076-7301-9997-ab6d68a43f19" xlink:href="syre-20260630.xsd#syre_LicenseAgreementMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019e22c4-9076-7996-bb55-fd978e0fb2d3" xlink:to="loc_syre_LicenseAgreementMilestonePayments_019e22c4-9076-7301-9997-ab6d68a43f19" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_LicenseAgreementMilestonePaymentsOutstandingAndPayable_019e22c4-9076-7a9a-b9c9-c2903b74a651" xlink:href="syre-20260630.xsd#syre_LicenseAgreementMilestonePaymentsOutstandingAndPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019e22c4-9076-7996-bb55-fd978e0fb2d3" xlink:to="loc_syre_LicenseAgreementMilestonePaymentsOutstandingAndPayable_019e22c4-9076-7a9a-b9c9-c2903b74a651" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_PaymentForSublicensingFee_019e22c4-9076-7365-83b9-bc5eef03aca5" xlink:href="syre-20260630.xsd#syre_PaymentForSublicensingFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019e22c4-9076-7996-bb55-fd978e0fb2d3" xlink:to="loc_syre_PaymentForSublicensingFee_019e22c4-9076-7365-83b9-bc5eef03aca5" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_SublicensingFeeOutstandingAndPayable_019e22c4-9076-7a82-a2a5-a340eed494ec" xlink:href="syre-20260630.xsd#syre_SublicensingFeeOutstandingAndPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019e22c4-9076-7996-bb55-fd978e0fb2d3" xlink:to="loc_syre_SublicensingFeeOutstandingAndPayable_019e22c4-9076-7a82-a2a5-a340eed494ec" xlink:type="arc" order="11"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://spyre.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:type="simple" xlink:href="syre-20260630.xsd#RelatedPartyTransactionsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://spyre.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_019e22c4-9076-717e-b9eb-6640bd7aa670" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019e22c4-9076-73a3-a665-53c603dfc6b2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019e22c4-9076-717e-b9eb-6640bd7aa670" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019e22c4-9076-73a3-a665-53c603dfc6b2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_019e22c4-9076-7775-aa5b-88ae5063af3d" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019e22c4-9076-73a3-a665-53c603dfc6b2" xlink:to="loc_srt_OwnershipAxis_019e22c4-9076-7775-aa5b-88ae5063af3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_019e22c4-9076-7775-aa5b-88ae5063af3d_default" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_019e22c4-9076-7775-aa5b-88ae5063af3d" xlink:to="loc_srt_OwnershipDomain_019e22c4-9076-7775-aa5b-88ae5063af3d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_019e22c4-9076-70f2-aa49-e189b199327e" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_019e22c4-9076-7775-aa5b-88ae5063af3d" xlink:to="loc_srt_OwnershipDomain_019e22c4-9076-70f2-aa49-e189b199327e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_ParagonTherapeuticsIncMember_019e22c4-9076-738a-be0a-4cdb0e3cafe9" xlink:href="syre-20260630.xsd#syre_ParagonTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_019e22c4-9076-70f2-aa49-e189b199327e" xlink:to="loc_syre_ParagonTherapeuticsIncMember_019e22c4-9076-738a-be0a-4cdb0e3cafe9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_FairmountFundsManagementLlcMember_019e22c4-9076-767f-bdd3-0094f9cd7c66" xlink:href="syre-20260630.xsd#syre_FairmountFundsManagementLlcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_019e22c4-9076-70f2-aa49-e189b199327e" xlink:to="loc_syre_FairmountFundsManagementLlcMember_019e22c4-9076-767f-bdd3-0094f9cd7c66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_019e22c4-9076-7cd7-bc93-ef0142f13a72" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019e22c4-9076-73a3-a665-53c603dfc6b2" xlink:to="loc_srt_RangeAxis_019e22c4-9076-7cd7-bc93-ef0142f13a72" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019e22c4-9076-7cd7-bc93-ef0142f13a72_default" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_019e22c4-9076-7cd7-bc93-ef0142f13a72" xlink:to="loc_srt_RangeMember_019e22c4-9076-7cd7-bc93-ef0142f13a72_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019e22c4-9076-700e-b40e-66cfeec4d95f" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_019e22c4-9076-7cd7-bc93-ef0142f13a72" xlink:to="loc_srt_RangeMember_019e22c4-9076-700e-b40e-66cfeec4d95f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_019e22c4-9076-7667-b590-921113076e7b" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_019e22c4-9076-700e-b40e-66cfeec4d95f" xlink:to="loc_srt_MaximumMember_019e22c4-9076-7667-b590-921113076e7b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_019e22c4-9076-7efe-a1fc-21933f866756" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_019e22c4-9076-700e-b40e-66cfeec4d95f" xlink:to="loc_srt_MinimumMember_019e22c4-9076-7efe-a1fc-21933f866756" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_019e22c4-9076-7d53-b100-36b0fa040068" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019e22c4-9076-73a3-a665-53c603dfc6b2" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_019e22c4-9076-7d53-b100-36b0fa040068" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_019e22c4-9076-7d53-b100-36b0fa040068_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_019e22c4-9076-7d53-b100-36b0fa040068" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_019e22c4-9076-7d53-b100-36b0fa040068_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_019e22c4-9076-71c2-97da-66947967e2a7" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_019e22c4-9076-7d53-b100-36b0fa040068" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_019e22c4-9076-71c2-97da-66947967e2a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_ParagonAgreementMember_019e22c4-9076-7290-ab4b-9ea9d84b967d" xlink:href="syre-20260630.xsd#syre_ParagonAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_019e22c4-9076-71c2-97da-66947967e2a7" xlink:to="loc_syre_ParagonAgreementMember_019e22c4-9076-7290-ab4b-9ea9d84b967d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_AppointOfBoardMembersMember_019e22c4-9076-7c70-8e87-f1025bb28af5" xlink:href="syre-20260630.xsd#syre_AppointOfBoardMembersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_019e22c4-9076-71c2-97da-66947967e2a7" xlink:to="loc_syre_AppointOfBoardMembersMember_019e22c4-9076-7c70-8e87-f1025bb28af5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_OtherParagonReimbursableExpensesMember_019e43ef-3a0d-7762-b14a-ccb9250c98b5" xlink:href="syre-20260630.xsd#syre_OtherParagonReimbursableExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_019e22c4-9076-71c2-97da-66947967e2a7" xlink:to="loc_syre_OtherParagonReimbursableExpensesMember_019e43ef-3a0d-7762-b14a-ccb9250c98b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_ParagonAgreementSubsequentToAssetAcquisitionMember_019e22c4-9076-730e-aa67-0ce2172bad44" xlink:href="syre-20260630.xsd#syre_ParagonAgreementSubsequentToAssetAcquisitionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_019e22c4-9076-71c2-97da-66947967e2a7" xlink:to="loc_syre_ParagonAgreementSubsequentToAssetAcquisitionMember_019e22c4-9076-730e-aa67-0ce2172bad44" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_ConsultingAgreementMember_019e22c4-9076-7a4b-86f3-0eaab0570673" xlink:href="syre-20260630.xsd#syre_ConsultingAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_019e22c4-9076-71c2-97da-66947967e2a7" xlink:to="loc_syre_ConsultingAgreementMember_019e22c4-9076-7a4b-86f3-0eaab0570673" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e22c4-9076-7f49-982d-4359975d1a32" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019e22c4-9076-73a3-a665-53c603dfc6b2" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e22c4-9076-7f49-982d-4359975d1a32" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019e22c4-9076-7f49-982d-4359975d1a32_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e22c4-9076-7f49-982d-4359975d1a32" xlink:to="loc_us-gaap_RelatedPartyDomain_019e22c4-9076-7f49-982d-4359975d1a32_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019e22c4-9076-742e-87b1-64db5a2d4fda" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e22c4-9076-7f49-982d-4359975d1a32" xlink:to="loc_us-gaap_RelatedPartyDomain_019e22c4-9076-742e-87b1-64db5a2d4fda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_019e22c4-9076-7e1d-9275-5d7fe4bd1d56" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_019e22c4-9076-742e-87b1-64db5a2d4fda" xlink:to="loc_us-gaap_RelatedPartyMember_019e22c4-9076-7e1d-9275-5d7fe4bd1d56" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_019e22c4-9076-70cd-8352-e140f62c634d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019e22c4-9076-73a3-a665-53c603dfc6b2" xlink:to="loc_us-gaap_VestingAxis_019e22c4-9076-70cd-8352-e140f62c634d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_019e22c4-9076-70cd-8352-e140f62c634d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_019e22c4-9076-70cd-8352-e140f62c634d" xlink:to="loc_us-gaap_VestingDomain_019e22c4-9076-70cd-8352-e140f62c634d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_019e22c4-9076-7fc6-bdd1-abd4eb8db4c6" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_019e22c4-9076-70cd-8352-e140f62c634d" xlink:to="loc_us-gaap_VestingDomain_019e22c4-9076-7fc6-bdd1-abd4eb8db4c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_019e22c4-9076-79fa-9b1b-d3917eba541b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_019e22c4-9076-7fc6-bdd1-abd4eb8db4c6" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_019e22c4-9076-79fa-9b1b-d3917eba541b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_019e22c4-9076-7899-b41d-aae6eaa52fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019e22c4-9076-717e-b9eb-6640bd7aa670" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_019e22c4-9076-7899-b41d-aae6eaa52fdb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_RelatedPartyTransactionNumberOfBoardSeats_019e22c4-9076-79f3-8be3-2dac2e0a429f" xlink:href="syre-20260630.xsd#syre_RelatedPartyTransactionNumberOfBoardSeats"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019e22c4-9076-717e-b9eb-6640bd7aa670" xlink:to="loc_syre_RelatedPartyTransactionNumberOfBoardSeats_019e22c4-9076-79f3-8be3-2dac2e0a429f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty_019e22c4-9076-7627-9965-f1e749d998eb" xlink:href="syre-20260630.xsd#syre_MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019e22c4-9076-717e-b9eb-6640bd7aa670" xlink:to="loc_syre_MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty_019e22c4-9076-7627-9965-f1e749d998eb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_019fa2ee-9a8c-7749-a0a4-0e6632c636d5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019e22c4-9076-717e-b9eb-6640bd7aa670" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_019fa2ee-9a8c-7749-a0a4-0e6632c636d5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent_019e22c4-9076-71ce-93a2-a9f14e0e810f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019e22c4-9076-717e-b9eb-6640bd7aa670" xlink:to="loc_us-gaap_AccountsPayableOtherCurrent_019e22c4-9076-71ce-93a2-a9f14e0e810f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_019e22c4-9076-7fb8-b3d5-4af4f3a1c14f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019e22c4-9076-717e-b9eb-6640bd7aa670" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_019e22c4-9076-7fb8-b3d5-4af4f3a1c14f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_019e22c4-9076-7c51-a9b6-4f13e69f2e68" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019e22c4-9076-717e-b9eb-6640bd7aa670" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_019e22c4-9076-7c51-a9b6-4f13e69f2e68" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_019e22c4-9076-7e49-b8a5-df99f189e187" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019e22c4-9076-717e-b9eb-6640bd7aa670" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_019e22c4-9076-7e49-b8a5-df99f189e187" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_019e22c4-9076-7333-a963-4757ac579c51" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019e22c4-9076-717e-b9eb-6640bd7aa670" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_019e22c4-9076-7333-a963-4757ac579c51" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_019e22c4-9076-7940-b42e-7e6aff9f90f0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019e22c4-9076-717e-b9eb-6640bd7aa670" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_019e22c4-9076-7940-b42e-7e6aff9f90f0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMonthlyInstallments_019e22c4-9076-733a-98f5-dac457a7a053" xlink:href="syre-20260630.xsd#syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMonthlyInstallments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019e22c4-9076-717e-b9eb-6640bd7aa670" xlink:to="loc_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMonthlyInstallments_019e22c4-9076-733a-98f5-dac457a7a053" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_019e22c4-9076-7ab0-9dfb-c14c1027a6c4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019e22c4-9076-717e-b9eb-6640bd7aa670" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_019e22c4-9076-7ab0-9dfb-c14c1027a6c4" xlink:type="arc" order="11"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://spyre.com/role/RelatedPartyTransactionsScheduleofExpensesRelatedtoRelatedPartyWhichareSettledinCashDetails" xlink:type="simple" xlink:href="syre-20260630.xsd#RelatedPartyTransactionsScheduleofExpensesRelatedtoRelatedPartyWhichareSettledinCashDetails"/>
  <link:definitionLink xlink:role="http://spyre.com/role/RelatedPartyTransactionsScheduleofExpensesRelatedtoRelatedPartyWhichareSettledinCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_019e22c4-9076-7913-8c10-9d8894a1660e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019e22c4-9076-7f08-9398-00b914851473" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019e22c4-9076-7913-8c10-9d8894a1660e" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019e22c4-9076-7f08-9398-00b914851473" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_019e22c4-9076-7467-866c-0681271d9a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019e22c4-9076-7f08-9398-00b914851473" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_019e22c4-9076-7467-866c-0681271d9a5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_019e22c4-9076-7467-866c-0681271d9a5b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_019e22c4-9076-7467-866c-0681271d9a5b" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_019e22c4-9076-7467-866c-0681271d9a5b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_019e22c4-9076-7211-bc0e-15f25addf70b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_019e22c4-9076-7467-866c-0681271d9a5b" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_019e22c4-9076-7211-bc0e-15f25addf70b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_ParagonAndLicenseAgreementMember_019e22c4-9076-71a1-bbde-fbcc6d51412e" xlink:href="syre-20260630.xsd#syre_ParagonAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_019e22c4-9076-7211-bc0e-15f25addf70b" xlink:to="loc_syre_ParagonAndLicenseAgreementMember_019e22c4-9076-71a1-bbde-fbcc6d51412e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_ParagonAgreementLicenseMilestonePaymentsMember_019e22c4-9076-79ae-9dfb-45d3a58cece5" xlink:href="syre-20260630.xsd#syre_ParagonAgreementLicenseMilestonePaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_ParagonAndLicenseAgreementMember_019e22c4-9076-71a1-bbde-fbcc6d51412e" xlink:to="loc_syre_ParagonAgreementLicenseMilestonePaymentsMember_019e22c4-9076-79ae-9dfb-45d3a58cece5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_OtherParagonReimbursableExpensesMember_019e22c4-9076-7cd0-9e0a-eddfb46c11ee" xlink:href="syre-20260630.xsd#syre_OtherParagonReimbursableExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_ParagonAndLicenseAgreementMember_019e22c4-9076-71a1-bbde-fbcc6d51412e" xlink:to="loc_syre_OtherParagonReimbursableExpensesMember_019e22c4-9076-7cd0-9e0a-eddfb46c11ee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e22c4-9076-7132-adc3-10dc0254752c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019e22c4-9076-7f08-9398-00b914851473" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e22c4-9076-7132-adc3-10dc0254752c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019e22c4-9076-7132-adc3-10dc0254752c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e22c4-9076-7132-adc3-10dc0254752c" xlink:to="loc_us-gaap_RelatedPartyDomain_019e22c4-9076-7132-adc3-10dc0254752c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019e22c4-9076-738a-a3ad-9d12070cc70d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e22c4-9076-7132-adc3-10dc0254752c" xlink:to="loc_us-gaap_RelatedPartyDomain_019e22c4-9076-738a-a3ad-9d12070cc70d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_019e22c4-9076-728d-bfa2-224bc1ab34e0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_019e22c4-9076-738a-a3ad-9d12070cc70d" xlink:to="loc_us-gaap_RelatedPartyMember_019e22c4-9076-728d-bfa2-224bc1ab34e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_019e22c4-9076-7e5d-9ce5-48bc09fb5102" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019e22c4-9076-7913-8c10-9d8894a1660e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_019e22c4-9076-7e5d-9ce5-48bc09fb5102" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://spyre.com/role/ConvertiblePreferredStockandStockholdersEquityDetails" xlink:type="simple" xlink:href="syre-20260630.xsd#ConvertiblePreferredStockandStockholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://spyre.com/role/ConvertiblePreferredStockandStockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_019e22c4-9076-7706-a981-479e98e5647a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_019e22c4-9076-73d5-8975-07d44e6bea29" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_019e22c4-9076-7706-a981-479e98e5647a" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_019e22c4-9076-73d5-8975-07d44e6bea29" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_019e22c4-9076-708c-af18-2d5a0f8f1c75" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_019e22c4-9076-73d5-8975-07d44e6bea29" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_019e22c4-9076-708c-af18-2d5a0f8f1c75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_019e22c4-9076-708c-af18-2d5a0f8f1c75_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_019e22c4-9076-708c-af18-2d5a0f8f1c75" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_019e22c4-9076-708c-af18-2d5a0f8f1c75_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_019e22c4-9076-7ede-9ecf-987c8d2e810b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_019e22c4-9076-708c-af18-2d5a0f8f1c75" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_019e22c4-9076-7ede-9ecf-987c8d2e810b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_ParapyreWarrantsMember_019e22c4-9076-7165-9ab5-28eb3f12c3f9" xlink:href="syre-20260630.xsd#syre_ParapyreWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_019e22c4-9076-7ede-9ecf-987c8d2e810b" xlink:to="loc_syre_ParapyreWarrantsMember_019e22c4-9076-7165-9ab5-28eb3f12c3f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_019e22c4-9076-7842-b05c-05b917147d25" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_019e22c4-9076-73d5-8975-07d44e6bea29" xlink:to="loc_us-gaap_StatementClassOfStockAxis_019e22c4-9076-7842-b05c-05b917147d25" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019e22c4-9076-7842-b05c-05b917147d25_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019e22c4-9076-7842-b05c-05b917147d25" xlink:to="loc_us-gaap_ClassOfStockDomain_019e22c4-9076-7842-b05c-05b917147d25_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019e22c4-9076-7c8f-b19a-869c6f9f36f1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019e22c4-9076-7842-b05c-05b917147d25" xlink:to="loc_us-gaap_ClassOfStockDomain_019e22c4-9076-7c8f-b19a-869c6f9f36f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_SeriesANonVotingConvertiblePreferredStockMember_019e22c4-9076-7429-8537-a8271aceeb28" xlink:href="syre-20260630.xsd#syre_SeriesANonVotingConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_019e22c4-9076-7c8f-b19a-869c6f9f36f1" xlink:to="loc_syre_SeriesANonVotingConvertiblePreferredStockMember_019e22c4-9076-7429-8537-a8271aceeb28" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_SeriesBNonVotingConvertiblePreferredStockMember_019e22c4-9076-73e5-a7ca-d32f270d2d01" xlink:href="syre-20260630.xsd#syre_SeriesBNonVotingConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_019e22c4-9076-7c8f-b19a-869c6f9f36f1" xlink:to="loc_syre_SeriesBNonVotingConvertiblePreferredStockMember_019e22c4-9076-73e5-a7ca-d32f270d2d01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_019e22c4-9076-747e-9edc-535979622899" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_019e22c4-9076-7c8f-b19a-869c6f9f36f1" xlink:to="loc_us-gaap_CommonStockMember_019e22c4-9076-747e-9edc-535979622899" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_019e22c4-9076-7857-93b2-8b16de1ee2a9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_019e22c4-9076-73d5-8975-07d44e6bea29" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_019e22c4-9076-7857-93b2-8b16de1ee2a9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019e22c4-9076-7857-93b2-8b16de1ee2a9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_019e22c4-9076-7857-93b2-8b16de1ee2a9" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019e22c4-9076-7857-93b2-8b16de1ee2a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019e22c4-9076-79ed-a08a-f2fb0039d323" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_019e22c4-9076-7857-93b2-8b16de1ee2a9" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019e22c4-9076-79ed-a08a-f2fb0039d323" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_AtTheMarketOffering2024SalesAgreementMember_019e22c4-9076-72e7-abc0-507f743f72d8" xlink:href="syre-20260630.xsd#syre_AtTheMarketOffering2024SalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019e22c4-9076-79ed-a08a-f2fb0039d323" xlink:to="loc_syre_AtTheMarketOffering2024SalesAgreementMember_019e22c4-9076-72e7-abc0-507f743f72d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_AtTheMarketOffering2026SalesAgreementMember_019f8509-408c-7ca7-887a-4d932b61ce3d" xlink:href="syre-20260630.xsd#syre_AtTheMarketOffering2026SalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019e22c4-9076-79ed-a08a-f2fb0039d323" xlink:to="loc_syre_AtTheMarketOffering2026SalesAgreementMember_019f8509-408c-7ca7-887a-4d932b61ce3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_October2025UnderwrittenOfferingMember_019e22c4-9076-7832-92d1-110bc3e01230" xlink:href="syre-20260630.xsd#syre_October2025UnderwrittenOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019e22c4-9076-79ed-a08a-f2fb0039d323" xlink:to="loc_syre_October2025UnderwrittenOfferingMember_019e22c4-9076-7832-92d1-110bc3e01230" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_019e22c4-9076-745c-bf03-06be284be5bc" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019e22c4-9076-79ed-a08a-f2fb0039d323" xlink:to="loc_us-gaap_OverAllotmentOptionMember_019e22c4-9076-745c-bf03-06be284be5bc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_April2026UnderwritingOfferingMember_019e22c4-9076-7587-8880-68fc1d305720" xlink:href="syre-20260630.xsd#syre_April2026UnderwritingOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019e22c4-9076-79ed-a08a-f2fb0039d323" xlink:to="loc_syre_April2026UnderwritingOfferingMember_019e22c4-9076-7587-8880-68fc1d305720" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_019e22c4-9076-7790-a237-457f0aae3cb4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019e22c4-9076-7706-a981-479e98e5647a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_019e22c4-9076-7790-a237-457f0aae3cb4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_019e22c4-9076-7144-992a-d6fcb4dd1606" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019e22c4-9076-7706-a981-479e98e5647a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_019e22c4-9076-7144-992a-d6fcb4dd1606" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_PreferredStockRemainsIssuedAndOutstandingPercentage_019e22c4-9076-74d2-ae69-0ddbe0dc5274" xlink:href="syre-20260630.xsd#syre_PreferredStockRemainsIssuedAndOutstandingPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019e22c4-9076-7706-a981-479e98e5647a" xlink:to="loc_syre_PreferredStockRemainsIssuedAndOutstandingPercentage_019e22c4-9076-74d2-ae69-0ddbe0dc5274" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_019e22c4-9076-709b-850e-20b9c825347d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019e22c4-9076-7706-a981-479e98e5647a" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_019e22c4-9076-709b-850e-20b9c825347d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockConvertibleSharesIssuable_019e22c4-9076-7347-b427-8ea528c21c8d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockConvertibleSharesIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019e22c4-9076-7706-a981-479e98e5647a" xlink:to="loc_us-gaap_PreferredStockConvertibleSharesIssuable_019e22c4-9076-7347-b427-8ea528c21c8d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_019fa2d7-373d-74cd-93f2-67892802c1ec" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019e22c4-9076-7706-a981-479e98e5647a" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_019fa2d7-373d-74cd-93f2-67892802c1ec" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_SaleOfStockAggregateOfferingPrice_019e22c4-9076-78c3-b0d8-62f05fab6091" xlink:href="syre-20260630.xsd#syre_SaleOfStockAggregateOfferingPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019e22c4-9076-7706-a981-479e98e5647a" xlink:to="loc_syre_SaleOfStockAggregateOfferingPrice_019e22c4-9076-78c3-b0d8-62f05fab6091" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_019e22c4-9076-7efc-bb2b-f6ed95ecc4d5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019e22c4-9076-7706-a981-479e98e5647a" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_019e22c4-9076-7efc-bb2b-f6ed95ecc4d5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_019e22c4-9076-772b-acbc-ab6371844664" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019e22c4-9076-7706-a981-479e98e5647a" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_019e22c4-9076-772b-acbc-ab6371844664" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_SaleOfStockAuthorizedAmount_019f35c0-a234-76d5-a7c6-4046d7245c0e" xlink:href="syre-20260630.xsd#syre_SaleOfStockAuthorizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019e22c4-9076-7706-a981-479e98e5647a" xlink:to="loc_syre_SaleOfStockAuthorizedAmount_019f35c0-a234-76d5-a7c6-4046d7245c0e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_019fa2e0-f06f-7fc5-bd45-3a3856505125" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019e22c4-9076-7706-a981-479e98e5647a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_019fa2e0-f06f-7fc5-bd45-3a3856505125" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_SaleOfStockRemainingAuthorizedAmount_019f35c0-a234-71d1-a003-b7b755692d0c" xlink:href="syre-20260630.xsd#syre_SaleOfStockRemainingAuthorizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019e22c4-9076-7706-a981-479e98e5647a" xlink:to="loc_syre_SaleOfStockRemainingAuthorizedAmount_019f35c0-a234-71d1-a003-b7b755692d0c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_019e22c4-9076-78c8-87a0-8b04895adc40" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019e22c4-9076-7706-a981-479e98e5647a" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_019e22c4-9076-78c8-87a0-8b04895adc40" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_019e22c4-9076-7157-a527-13ebaa5e86b6" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019e22c4-9076-7706-a981-479e98e5647a" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_019e22c4-9076-7157-a527-13ebaa5e86b6" xlink:type="arc" order="13"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://spyre.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="syre-20260630.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://spyre.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e22c4-9076-7351-8778-ee1b2cd5e163" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019e22c4-9076-75cf-8ace-212afa550609" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e22c4-9076-7351-8778-ee1b2cd5e163" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019e22c4-9076-75cf-8ace-212afa550609" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_019e22c4-9076-7259-bc9d-cc5a61c56b23" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019e22c4-9076-75cf-8ace-212afa550609" xlink:to="loc_us-gaap_PlanNameAxis_019e22c4-9076-7259-bc9d-cc5a61c56b23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_019e22c4-9076-7259-bc9d-cc5a61c56b23_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_019e22c4-9076-7259-bc9d-cc5a61c56b23" xlink:to="loc_us-gaap_PlanNameDomain_019e22c4-9076-7259-bc9d-cc5a61c56b23_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_019e22c4-9076-764a-8566-400e4019e214" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_019e22c4-9076-7259-bc9d-cc5a61c56b23" xlink:to="loc_us-gaap_PlanNameDomain_019e22c4-9076-764a-8566-400e4019e214" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember_019e22c4-9076-73a7-bee2-17ab200f07d6" xlink:href="syre-20260630.xsd#syre_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_019e22c4-9076-764a-8566-400e4019e214" xlink:to="loc_syre_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember_019e22c4-9076-73a7-bee2-17ab200f07d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_TwoThousandAndSixteenEquityIncentivePlanMember_019e22c4-9076-779e-b5d7-5b5840ca855d" xlink:href="syre-20260630.xsd#syre_TwoThousandAndSixteenEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember_019e22c4-9076-73a7-bee2-17ab200f07d6" xlink:to="loc_syre_TwoThousandAndSixteenEquityIncentivePlanMember_019e22c4-9076-779e-b5d7-5b5840ca855d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_TwoThousandAndEighteenEquityInducementPlanMember_019e22c4-9076-76de-af91-1f06e08767c0" xlink:href="syre-20260630.xsd#syre_TwoThousandAndEighteenEquityInducementPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember_019e22c4-9076-73a7-bee2-17ab200f07d6" xlink:to="loc_syre_TwoThousandAndEighteenEquityInducementPlanMember_019e22c4-9076-76de-af91-1f06e08767c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_TwoThousandAndSixteenEmployeeStockPurchasePlanMember_019e22c4-9076-7ffd-a3bd-e26e30404c31" xlink:href="syre-20260630.xsd#syre_TwoThousandAndSixteenEmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_019e22c4-9076-764a-8566-400e4019e214" xlink:to="loc_syre_TwoThousandAndSixteenEmployeeStockPurchasePlanMember_019e22c4-9076-7ffd-a3bd-e26e30404c31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019e22c4-9076-7bc8-8303-f21dc66e2937" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019e22c4-9076-75cf-8ace-212afa550609" xlink:to="loc_us-gaap_AwardTypeAxis_019e22c4-9076-7bc8-8303-f21dc66e2937" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e22c4-9076-7bc8-8303-f21dc66e2937_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_019e22c4-9076-7bc8-8303-f21dc66e2937" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e22c4-9076-7bc8-8303-f21dc66e2937_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e22c4-9076-785e-940b-babd0a5ed2e4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_019e22c4-9076-7bc8-8303-f21dc66e2937" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e22c4-9076-785e-940b-babd0a5ed2e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_ServiceBasedAwardsMember_019e22c4-9076-76be-889e-b1a8312bd2ca" xlink:href="syre-20260630.xsd#syre_ServiceBasedAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e22c4-9076-785e-940b-babd0a5ed2e4" xlink:to="loc_syre_ServiceBasedAwardsMember_019e22c4-9076-76be-889e-b1a8312bd2ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_019e22c4-9076-7622-8bae-fe6932cb722d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019e22c4-9076-75cf-8ace-212afa550609" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_019e22c4-9076-7622-8bae-fe6932cb722d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_019e22c4-9076-7622-8bae-fe6932cb722d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_019e22c4-9076-7622-8bae-fe6932cb722d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_019e22c4-9076-7622-8bae-fe6932cb722d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_019e22c4-9076-7e78-aa97-b8c47747fb3c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_019e22c4-9076-7622-8bae-fe6932cb722d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_019e22c4-9076-7e78-aa97-b8c47747fb3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_ParapyreWarrantsMember_019e22c4-9076-72d1-bb34-36f1dd998e6e" xlink:href="syre-20260630.xsd#syre_ParapyreWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_019e22c4-9076-7e78-aa97-b8c47747fb3c" xlink:to="loc_syre_ParapyreWarrantsMember_019e22c4-9076-72d1-bb34-36f1dd998e6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_019e22c4-9076-7b72-b3db-f97bbffc6ead" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019e22c4-9076-75cf-8ace-212afa550609" xlink:to="loc_us-gaap_StatementClassOfStockAxis_019e22c4-9076-7b72-b3db-f97bbffc6ead" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019e22c4-9076-7b72-b3db-f97bbffc6ead_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019e22c4-9076-7b72-b3db-f97bbffc6ead" xlink:to="loc_us-gaap_ClassOfStockDomain_019e22c4-9076-7b72-b3db-f97bbffc6ead_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019e22c4-9076-7ad9-aec2-11cb3366c25a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019e22c4-9076-7b72-b3db-f97bbffc6ead" xlink:to="loc_us-gaap_ClassOfStockDomain_019e22c4-9076-7ad9-aec2-11cb3366c25a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_019e22c4-9076-7f2e-9281-39d182923402" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_019e22c4-9076-7ad9-aec2-11cb3366c25a" xlink:to="loc_us-gaap_EmployeeStockMember_019e22c4-9076-7f2e-9281-39d182923402" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_019e22c4-9076-7ffd-9b2e-c7abcdaf07be" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019e22c4-9076-75cf-8ace-212afa550609" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_019e22c4-9076-7ffd-9b2e-c7abcdaf07be" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019e22c4-9076-7ffd-9b2e-c7abcdaf07be_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_019e22c4-9076-7ffd-9b2e-c7abcdaf07be" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019e22c4-9076-7ffd-9b2e-c7abcdaf07be_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019e22c4-9076-7781-bb14-241e5c1b64bf" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_019e22c4-9076-7ffd-9b2e-c7abcdaf07be" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019e22c4-9076-7781-bb14-241e5c1b64bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_A2016ESPPMember_019e22c4-9076-7f2f-b184-7a90c7101a4e" xlink:href="syre-20260630.xsd#syre_A2016ESPPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019e22c4-9076-7781-bb14-241e5c1b64bf" xlink:to="loc_syre_A2016ESPPMember_019e22c4-9076-7f2f-b184-7a90c7101a4e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares_019e22c4-9076-749e-b1ec-9be4ebcd9718" xlink:href="syre-20260630.xsd#syre_AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e22c4-9076-7351-8778-ee1b2cd5e163" xlink:to="loc_syre_AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares_019e22c4-9076-749e-b1ec-9be4ebcd9718" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant_019e22c4-9076-7413-8ddf-227c3a7b587e" xlink:href="syre-20260630.xsd#syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e22c4-9076-7351-8778-ee1b2cd5e163" xlink:to="loc_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant_019e22c4-9076-7413-8ddf-227c3a7b587e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_019e22c4-9076-7626-9661-33c42f30f323" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e22c4-9076-7351-8778-ee1b2cd5e163" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_019e22c4-9076-7626-9661-33c42f30f323" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019e22c4-9076-7200-a122-574b31303e83" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e22c4-9076-7351-8778-ee1b2cd5e163" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019e22c4-9076-7200-a122-574b31303e83" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_019e22c4-9076-713a-9853-90497b7640e8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e22c4-9076-7351-8778-ee1b2cd5e163" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_019e22c4-9076-713a-9853-90497b7640e8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_019e22c4-9076-7913-b397-7004a5e0bcb3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e22c4-9076-7351-8778-ee1b2cd5e163" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_019e22c4-9076-7913-b397-7004a5e0bcb3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_019e22c4-9076-730d-bcb9-bbc0145b8c23" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e22c4-9076-7351-8778-ee1b2cd5e163" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_019e22c4-9076-730d-bcb9-bbc0145b8c23" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_019e22c4-9076-7394-bf4f-e2438edaccee" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e22c4-9076-7351-8778-ee1b2cd5e163" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_019e22c4-9076-7394-bf4f-e2438edaccee" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_019e22c4-9076-742a-9f6c-4212fe0ce7e4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e22c4-9076-7351-8778-ee1b2cd5e163" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_019e22c4-9076-742a-9f6c-4212fe0ce7e4" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://spyre.com/role/StockBasedCompensationScheduleofStockAwardsGrantedUnderallEquityIncentiveandInducementPlansDetails" xlink:type="simple" xlink:href="syre-20260630.xsd#StockBasedCompensationScheduleofStockAwardsGrantedUnderallEquityIncentiveandInducementPlansDetails"/>
  <link:definitionLink xlink:role="http://spyre.com/role/StockBasedCompensationScheduleofStockAwardsGrantedUnderallEquityIncentiveandInducementPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e22c4-9076-7ecc-9a0c-216ee5d43683" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019e22c4-9076-72b4-9df4-b54d8ac6e7db" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e22c4-9076-7ecc-9a0c-216ee5d43683" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019e22c4-9076-72b4-9df4-b54d8ac6e7db" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019e22c4-9076-754e-9e6f-193ccf6a05fc" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019e22c4-9076-72b4-9df4-b54d8ac6e7db" xlink:to="loc_us-gaap_AwardTypeAxis_019e22c4-9076-754e-9e6f-193ccf6a05fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e22c4-9076-754e-9e6f-193ccf6a05fc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_019e22c4-9076-754e-9e6f-193ccf6a05fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e22c4-9076-754e-9e6f-193ccf6a05fc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e22c4-9076-79c4-a7b7-b8251e27355d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_019e22c4-9076-754e-9e6f-193ccf6a05fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e22c4-9076-79c4-a7b7-b8251e27355d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_019e22c4-9076-778c-b385-7eeff7f95625" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e22c4-9076-79c4-a7b7-b8251e27355d" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_019e22c4-9076-778c-b385-7eeff7f95625" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_019e22c4-9076-7a14-ac03-fef43bc5625a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e22c4-9076-7ecc-9a0c-216ee5d43683" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_019e22c4-9076-7a14-ac03-fef43bc5625a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_019e22c4-9076-7e68-adb9-a2f4336515ef" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e22c4-9076-7ecc-9a0c-216ee5d43683" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_019e22c4-9076-7e68-adb9-a2f4336515ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_019e22c4-9076-7bb9-aef7-98420603cf24" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e22c4-9076-7ecc-9a0c-216ee5d43683" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_019e22c4-9076-7bb9-aef7-98420603cf24" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019e22c4-9076-72a3-be6d-72a3f84b2704" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e22c4-9076-7ecc-9a0c-216ee5d43683" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019e22c4-9076-72a3-be6d-72a3f84b2704" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://spyre.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="syre-20260630.xsd#StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://spyre.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019e22c4-9076-77e6-863d-332cff678a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_019e22c4-9076-75c2-85aa-f2c9384f1963" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019e22c4-9076-77e6-863d-332cff678a4b" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_019e22c4-9076-75c2-85aa-f2c9384f1963" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeLocationBalanceAxis_019e22c4-9076-7b22-aa18-fad22da1de70" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfIncomeLocationBalanceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_019e22c4-9076-75c2-85aa-f2c9384f1963" xlink:to="loc_us-gaap_StatementOfIncomeLocationBalanceAxis_019e22c4-9076-7b22-aa18-fad22da1de70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_019e22c4-9076-7500-b9a6-ba4fd951e841" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019e22c4-9076-77e6-863d-332cff678a4b" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_019e22c4-9076-7500-b9a6-ba4fd951e841" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://spyre.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails_1" xlink:type="simple" xlink:href="syre-20260630.xsd#StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails_1"/>
  <link:definitionLink xlink:role="http://spyre.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019e22c4-9076-77e6-863d-332cff678a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_019e22c4-9076-75c2-85aa-f2c9384f1963" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019e22c4-9076-77e6-863d-332cff678a4b" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_019e22c4-9076-75c2-85aa-f2c9384f1963" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_019e22c4-9076-7500-b9a6-ba4fd951e841" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019e22c4-9076-77e6-863d-332cff678a4b" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_019e22c4-9076-7500-b9a6-ba4fd951e841" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://spyre.com/role/StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedinCalculatingFairValueofAwardsDetails" xlink:type="simple" xlink:href="syre-20260630.xsd#StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedinCalculatingFairValueofAwardsDetails"/>
  <link:definitionLink xlink:role="http://spyre.com/role/StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedinCalculatingFairValueofAwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019e22c4-9076-7df9-a5cc-bb733b612718" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_019e22c4-9076-7367-a007-707f2f58c60a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019e22c4-9076-7df9-a5cc-bb733b612718" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_019e22c4-9076-7367-a007-707f2f58c60a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_019e22c4-9076-7c1b-a04b-d2beff182958" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_019e22c4-9076-7367-a007-707f2f58c60a" xlink:to="loc_us-gaap_PlanNameAxis_019e22c4-9076-7c1b-a04b-d2beff182958" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_019e22c4-9076-7c1b-a04b-d2beff182958_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_019e22c4-9076-7c1b-a04b-d2beff182958" xlink:to="loc_us-gaap_PlanNameDomain_019e22c4-9076-7c1b-a04b-d2beff182958_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_019e22c4-9076-7501-bb1e-eb81c9f3156a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_019e22c4-9076-7c1b-a04b-d2beff182958" xlink:to="loc_us-gaap_PlanNameDomain_019e22c4-9076-7501-bb1e-eb81c9f3156a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_TwoThousandAndSixteenEquityIncentivePlanMember_019e22c4-9076-70d1-859e-b9d3e0c98f60" xlink:href="syre-20260630.xsd#syre_TwoThousandAndSixteenEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_019e22c4-9076-7501-bb1e-eb81c9f3156a" xlink:to="loc_syre_TwoThousandAndSixteenEquityIncentivePlanMember_019e22c4-9076-70d1-859e-b9d3e0c98f60" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_TwoThousandAndSixteenEmployeeStockPurchasePlanMember_019e22c4-9076-7df9-aba9-6cbedb7d6e71" xlink:href="syre-20260630.xsd#syre_TwoThousandAndSixteenEmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_019e22c4-9076-7501-bb1e-eb81c9f3156a" xlink:to="loc_syre_TwoThousandAndSixteenEmployeeStockPurchasePlanMember_019e22c4-9076-7df9-aba9-6cbedb7d6e71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_019e22c4-9076-740c-b5c2-1365a16a764d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019e22c4-9076-7df9-a5cc-bb733b612718" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_019e22c4-9076-740c-b5c2-1365a16a764d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_019e22c4-9076-7c8c-9b08-185aaef61a26" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019e22c4-9076-7df9-a5cc-bb733b612718" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_019e22c4-9076-7c8c-9b08-185aaef61a26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_019e22c4-9076-7879-8f64-a73b72fe41ce" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019e22c4-9076-7df9-a5cc-bb733b612718" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_019e22c4-9076-7879-8f64-a73b72fe41ce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_019e22c4-9076-712b-afb4-0024d50caec8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019e22c4-9076-7df9-a5cc-bb733b612718" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_019e22c4-9076-712b-afb4-0024d50caec8" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://spyre.com/role/SaleofPegzilarginasetoImmedicaDetails" xlink:type="simple" xlink:href="syre-20260630.xsd#SaleofPegzilarginasetoImmedicaDetails"/>
  <link:definitionLink xlink:role="http://spyre.com/role/SaleofPegzilarginasetoImmedicaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_019e22c4-9076-73a7-956a-ea6da95c1338" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_019e22c4-9076-70fd-9542-05115fcbd6f2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_019e22c4-9076-73a7-956a-ea6da95c1338" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_019e22c4-9076-70fd-9542-05115fcbd6f2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_019e22c4-9076-7c9e-bf6f-7ad30c82b110" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_019e22c4-9076-70fd-9542-05115fcbd6f2" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_019e22c4-9076-7c9e-bf6f-7ad30c82b110" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_019e22c4-9076-7c9e-bf6f-7ad30c82b110_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_019e22c4-9076-7c9e-bf6f-7ad30c82b110" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_019e22c4-9076-7c9e-bf6f-7ad30c82b110_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_019e22c4-9076-7391-a924-8f785ad05467" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_019e22c4-9076-7c9e-bf6f-7ad30c82b110" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_019e22c4-9076-7391-a924-8f785ad05467" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_019e22c4-9076-7803-8b28-6a834432c962" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_019e22c4-9076-7391-a924-8f785ad05467" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_019e22c4-9076-7803-8b28-6a834432c962" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019e22c4-9076-7acd-92ee-47cd33f7dc90" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_019e22c4-9076-70fd-9542-05115fcbd6f2" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019e22c4-9076-7acd-92ee-47cd33f7dc90" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019e22c4-9076-7acd-92ee-47cd33f7dc90_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019e22c4-9076-7acd-92ee-47cd33f7dc90" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019e22c4-9076-7acd-92ee-47cd33f7dc90_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019e22c4-9076-7e95-9c52-978bf7807b9e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019e22c4-9076-7acd-92ee-47cd33f7dc90" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019e22c4-9076-7e95-9c52-978bf7807b9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_GlobalRightsToPegzilarginaseMember_019e22c4-9076-7251-aba9-de546e934184" xlink:href="syre-20260630.xsd#syre_GlobalRightsToPegzilarginaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019e22c4-9076-7e95-9c52-978bf7807b9e" xlink:to="loc_syre_GlobalRightsToPegzilarginaseMember_019e22c4-9076-7251-aba9-de546e934184" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_019e22c4-9076-7547-bc6f-4f077236aaa9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_019e22c4-9076-73a7-956a-ea6da95c1338" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_019e22c4-9076-7547-bc6f-4f077236aaa9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_019e22c4-9076-77dd-9ff4-4fbbf79e424d" xlink:href="syre-20260630.xsd#syre_DisposalGroupIncludingDiscontinuedOperationContingentConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_019e22c4-9076-73a7-956a-ea6da95c1338" xlink:to="loc_syre_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_019e22c4-9076-77dd-9ff4-4fbbf79e424d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_019e22c4-9076-7cb0-9f17-30c9fc799a54" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_019e22c4-9076-73a7-956a-ea6da95c1338" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_019e22c4-9076-7cb0-9f17-30c9fc799a54" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_019e22c4-9076-77b2-b211-67b69cfbc484" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_019e22c4-9076-73a7-956a-ea6da95c1338" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_019e22c4-9076-77b2-b211-67b69cfbc484" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://spyre.com/role/SegmentReportingScheduleofSignificantExpensesProvidedtotheCODMonaRegularBasisDetails" xlink:type="simple" xlink:href="syre-20260630.xsd#SegmentReportingScheduleofSignificantExpensesProvidedtotheCODMonaRegularBasisDetails"/>
  <link:definitionLink xlink:role="http://spyre.com/role/SegmentReportingScheduleofSignificantExpensesProvidedtotheCODMonaRegularBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_019e22c4-9076-7a63-bd32-1eb49f30278b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019e22c4-9076-7767-9efe-7b5c99caf98b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e22c4-9076-7a63-bd32-1eb49f30278b" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019e22c4-9076-7767-9efe-7b5c99caf98b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_019e22c4-9076-79df-960d-1182563a9bd1" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019e22c4-9076-7767-9efe-7b5c99caf98b" xlink:to="loc_srt_ConsolidationItemsAxis_019e22c4-9076-79df-960d-1182563a9bd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_019e22c4-9076-79df-960d-1182563a9bd1_default" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_019e22c4-9076-79df-960d-1182563a9bd1" xlink:to="loc_srt_ConsolidationItemsDomain_019e22c4-9076-79df-960d-1182563a9bd1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_019e22c4-9076-719b-8a2a-6f4a9c8f4b80" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_019e22c4-9076-79df-960d-1182563a9bd1" xlink:to="loc_srt_ConsolidationItemsDomain_019e22c4-9076-719b-8a2a-6f4a9c8f4b80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_019e22c4-9076-782b-b7d9-3c6006d9c544" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_019e22c4-9076-719b-8a2a-6f4a9c8f4b80" xlink:to="loc_us-gaap_OperatingSegmentsMember_019e22c4-9076-782b-b7d9-3c6006d9c544" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_019e22c4-9076-7e2d-97b9-b36e08e3c77c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019e22c4-9076-7767-9efe-7b5c99caf98b" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_019e22c4-9076-7e2d-97b9-b36e08e3c77c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_019e22c4-9076-7e2d-97b9-b36e08e3c77c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_019e22c4-9076-7e2d-97b9-b36e08e3c77c" xlink:to="loc_us-gaap_SegmentDomain_019e22c4-9076-7e2d-97b9-b36e08e3c77c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_019e22c4-9076-7ccf-bfe2-0d9dd46104c1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_019e22c4-9076-7e2d-97b9-b36e08e3c77c" xlink:to="loc_us-gaap_SegmentDomain_019e22c4-9076-7ccf-bfe2-0d9dd46104c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_ReportableSegmentMember_019e22c4-9076-7451-8cd9-6d186e59d1c6" xlink:href="syre-20260630.xsd#syre_ReportableSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_019e22c4-9076-7ccf-bfe2-0d9dd46104c1" xlink:to="loc_syre_ReportableSegmentMember_019e22c4-9076-7451-8cd9-6d186e59d1c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e22c4-9076-7973-af7f-5834510484e9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019e22c4-9076-7767-9efe-7b5c99caf98b" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e22c4-9076-7973-af7f-5834510484e9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019e22c4-9076-7973-af7f-5834510484e9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e22c4-9076-7973-af7f-5834510484e9" xlink:to="loc_us-gaap_RelatedPartyDomain_019e22c4-9076-7973-af7f-5834510484e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019e22c4-9076-7c93-9d94-95f418642d54" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e22c4-9076-7973-af7f-5834510484e9" xlink:to="loc_us-gaap_RelatedPartyDomain_019e22c4-9076-7c93-9d94-95f418642d54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_019e22c4-9076-7ec5-be6e-d44c9fe5922e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_019e22c4-9076-7c93-9d94-95f418642d54" xlink:to="loc_us-gaap_RelatedPartyMember_019e22c4-9076-7ec5-be6e-d44c9fe5922e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold_019e22c4-9076-789f-87ae-2de59378fcfc" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e22c4-9076-7a63-bd32-1eb49f30278b" xlink:to="loc_us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold_019e22c4-9076-789f-87ae-2de59378fcfc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_019e22c4-9076-78be-9de0-e1a2d284659f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e22c4-9076-7a63-bd32-1eb49f30278b" xlink:to="loc_us-gaap_ShareBasedCompensation_019e22c4-9076-78be-9de0-e1a2d284659f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_019e22c4-9076-70cd-987f-4ac1be046c9f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e22c4-9076-7a63-bd32-1eb49f30278b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_019e22c4-9076-70cd-987f-4ac1be046c9f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount_019e22c4-9076-76ad-a449-605f23d3446b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e22c4-9076-7a63-bd32-1eb49f30278b" xlink:to="loc_us-gaap_SegmentReportingOtherItemAmount_019e22c4-9076-76ad-a449-605f23d3446b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019e22c4-9076-751d-9843-116fc6e10a6c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e22c4-9076-7a63-bd32-1eb49f30278b" xlink:to="loc_us-gaap_NetIncomeLoss_019e22c4-9076-751d-9843-116fc6e10a6c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_019e22c4-9076-7bcc-8320-a79cbe2b41e8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e22c4-9076-7a63-bd32-1eb49f30278b" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_019e22c4-9076-7bcc-8320-a79cbe2b41e8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_IncreaseDecreaseInFairValueOfContingentValueRightLiability_019e22c4-9076-7df5-8e4a-34e6d0ccc144" xlink:href="syre-20260630.xsd#syre_IncreaseDecreaseInFairValueOfContingentValueRightLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e22c4-9076-7a63-bd32-1eb49f30278b" xlink:to="loc_syre_IncreaseDecreaseInFairValueOfContingentValueRightLiability_019e22c4-9076-7df5-8e4a-34e6d0ccc144" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://spyre.com/role/NetLossPerShareScheduleofComputationofBasicandDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="syre-20260630.xsd#NetLossPerShareScheduleofComputationofBasicandDilutedNetLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://spyre.com/role/NetLossPerShareScheduleofComputationofBasicandDilutedNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_019e22c4-9076-7788-b778-f3144f2cfc58" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_019e22c4-9076-7a77-9fd7-74697d6a0ece" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_019e22c4-9076-7788-b778-f3144f2cfc58" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_019e22c4-9076-7a77-9fd7-74697d6a0ece" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_019e22c4-9076-72a3-8d28-a3033527749a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_019e22c4-9076-7a77-9fd7-74697d6a0ece" xlink:to="loc_us-gaap_StatementClassOfStockAxis_019e22c4-9076-72a3-8d28-a3033527749a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019e22c4-9076-72a3-8d28-a3033527749a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019e22c4-9076-72a3-8d28-a3033527749a" xlink:to="loc_us-gaap_ClassOfStockDomain_019e22c4-9076-72a3-8d28-a3033527749a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019e22c4-9076-719b-b79c-46e022de1700" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019e22c4-9076-72a3-8d28-a3033527749a" xlink:to="loc_us-gaap_ClassOfStockDomain_019e22c4-9076-719b-b79c-46e022de1700" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_SeriesANonVotingConvertiblePreferredStockMember_019e22c4-9076-7e58-a65b-38e18ec7c6fc" xlink:href="syre-20260630.xsd#syre_SeriesANonVotingConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_019e22c4-9076-719b-b79c-46e022de1700" xlink:to="loc_syre_SeriesANonVotingConvertiblePreferredStockMember_019e22c4-9076-7e58-a65b-38e18ec7c6fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_SeriesBNonVotingConvertiblePreferredStockMember_019e22c4-9076-7387-801b-c83639af95ba" xlink:href="syre-20260630.xsd#syre_SeriesBNonVotingConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_019e22c4-9076-719b-b79c-46e022de1700" xlink:to="loc_syre_SeriesBNonVotingConvertiblePreferredStockMember_019e22c4-9076-7387-801b-c83639af95ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_019e22c4-9076-7f35-8366-1fc69f955c27" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_019e22c4-9076-719b-b79c-46e022de1700" xlink:to="loc_us-gaap_CommonStockMember_019e22c4-9076-7f35-8366-1fc69f955c27" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_019e22c4-9076-70c4-9cad-3e5c850d3493" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_019e22c4-9076-7788-b778-f3144f2cfc58" xlink:to="loc_us-gaap_EarningsPerShareReconciliationAbstract_019e22c4-9076-70c4-9cad-3e5c850d3493" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_019e22c4-9076-7d7c-875f-b71f45bbdbdb" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_019e22c4-9076-70c4-9cad-3e5c850d3493" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_019e22c4-9076-7d7c-875f-b71f45bbdbdb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019e22c4-9076-75e9-9308-b6146c961c57" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_019e22c4-9076-7d7c-875f-b71f45bbdbdb" xlink:to="loc_us-gaap_NetIncomeLoss_019e22c4-9076-75e9-9308-b6146c961c57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_019e22c4-9076-71b3-a900-10a68c6930f5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_019e22c4-9076-70c4-9cad-3e5c850d3493" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_019e22c4-9076-71b3-a900-10a68c6930f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_019e22c4-9076-7ce3-8470-f398f09823be" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_019e22c4-9076-71b3-a900-10a68c6930f5" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_019e22c4-9076-7ce3-8470-f398f09823be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_019e22c4-9076-7b15-a04b-e9fa38e14b44" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_019e22c4-9076-70c4-9cad-3e5c850d3493" xlink:to="loc_us-gaap_EarningsPerShareBasic_019e22c4-9076-7b15-a04b-e9fa38e14b44" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_019e22c4-9076-78ba-831d-420d31d3002a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_019e22c4-9076-70c4-9cad-3e5c850d3493" xlink:to="loc_us-gaap_EarningsPerShareDiluted_019e22c4-9076-78ba-831d-420d31d3002a" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://spyre.com/role/NetLossPerShareScheduleofWeightedAverageEquityInstrumentsExcludedfromCalculationofDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="syre-20260630.xsd#NetLossPerShareScheduleofWeightedAverageEquityInstrumentsExcludedfromCalculationofDilutedNetLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://spyre.com/role/NetLossPerShareScheduleofWeightedAverageEquityInstrumentsExcludedfromCalculationofDilutedNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019e22c4-9076-7501-b24c-653a7a17d94f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019e22c4-9076-7fd8-ac16-3d984dee6b88" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019e22c4-9076-7501-b24c-653a7a17d94f" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019e22c4-9076-7fd8-ac16-3d984dee6b88" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019e22c4-9076-7fbc-869d-4ac23b3273b2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019e22c4-9076-7fd8-ac16-3d984dee6b88" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019e22c4-9076-7fbc-869d-4ac23b3273b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019e22c4-9076-7fbc-869d-4ac23b3273b2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019e22c4-9076-7fbc-869d-4ac23b3273b2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019e22c4-9076-7fbc-869d-4ac23b3273b2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019e22c4-9076-7360-af26-e94621fe9dc4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019e22c4-9076-7fbc-869d-4ac23b3273b2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019e22c4-9076-7360-af26-e94621fe9dc4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_019e22c4-9076-7b8d-b57f-d4244485afc6" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019e22c4-9076-7360-af26-e94621fe9dc4" xlink:to="loc_us-gaap_EmployeeStockOptionMember_019e22c4-9076-7b8d-b57f-d4244485afc6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_019e22c4-9076-7b41-bf9c-38db2017dd62" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019e22c4-9076-7360-af26-e94621fe9dc4" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_019e22c4-9076-7b41-bf9c-38db2017dd62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_ParapyreWarrantsMember_019e22c4-9076-7d31-8ee0-c2c745f15885" xlink:href="syre-20260630.xsd#syre_ParapyreWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019e22c4-9076-7360-af26-e94621fe9dc4" xlink:to="loc_syre_ParapyreWarrantsMember_019e22c4-9076-7d31-8ee0-c2c745f15885" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_019e22c4-9076-7d3e-a631-89e76afe85aa" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019e22c4-9076-7501-b24c-653a7a17d94f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_019e22c4-9076-7d3e-a631-89e76afe85aa" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#IndividualsOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AllIndividualsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_HeidyKingJonesMember_019f359e-f744-7886-9239-afbf9780d3d5" xlink:href="syre-20260630.xsd#syre_HeidyKingJonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_syre_HeidyKingJonesMember_019f359e-f744-7886-9239-afbf9780d3d5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_JeffreyAlbersMember_019f359c-7c20-7df0-81f1-2f6691021d17" xlink:href="syre-20260630.xsd#syre_JeffreyAlbersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_syre_JeffreyAlbersMember_019f359c-7c20-7df0-81f1-2f6691021d17" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#TradingArrangmentsOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AllTradingArrangementsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_JeffreyAlbersRuleTradingArrangementDirectorStockOptionsMember_019fa2cc-1950-7775-8652-5f6b34fc07ea" xlink:href="syre-20260630.xsd#syre_JeffreyAlbersRuleTradingArrangementDirectorStockOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="loc_syre_JeffreyAlbersRuleTradingArrangementDirectorStockOptionsMember_019fa2cc-1950-7775-8652-5f6b34fc07ea" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>syre-20260630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019e22c4-8e13-79c8-aa17-b3b58ba33655,g:1a770671-d821-405f-804e-c086c0f29bbb-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_019e22c4-9140-7e51-b19b-751d7a7d8d6f_verboseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_019e22c4-9140-7bce-8930-cffb037a9e73_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_ParagonAgreementMember_019e22c4-913f-7140-89de-a4e2a7eed1f3_terseLabel_en-US" xlink:label="lab_syre_ParagonAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Paragon Agreement</link:label>
    <link:label id="lab_syre_ParagonAgreementMember_label_en-US" xlink:label="lab_syre_ParagonAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Paragon Agreement [Member]</link:label>
    <link:label id="lab_syre_ParagonAgreementMember_documentation_en-US" xlink:label="lab_syre_ParagonAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Paragon agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_ParagonAgreementMember" xlink:href="syre-20260630.xsd#syre_ParagonAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_ParagonAgreementMember" xlink:to="lab_syre_ParagonAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_019e22c4-9077-7ef9-85ba-c56a6e042a72_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_019e22c4-9076-70c2-8b89-3ad8e233b271_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_019e22c4-9076-7222-a55d-4f063c589991_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_019e22c4-9076-7fec-9773-987889570656_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_IncreaseDecreaseInFairValueOfContingentValueRightLiability_019e22c4-913f-7089-ae21-79b378dbc4f9_terseLabel_en-US" xlink:label="lab_syre_IncreaseDecreaseInFairValueOfContingentValueRightLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (decrease) in fair value of contingent value right liability</link:label>
    <link:label id="lab_syre_IncreaseDecreaseInFairValueOfContingentValueRightLiability_label_en-US" xlink:label="lab_syre_IncreaseDecreaseInFairValueOfContingentValueRightLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Fair Value Of Contingent Value Right Liability</link:label>
    <link:label id="lab_syre_IncreaseDecreaseInFairValueOfContingentValueRightLiability_documentation_en-US" xlink:label="lab_syre_IncreaseDecreaseInFairValueOfContingentValueRightLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Fair Value Of Contingent Value Right Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_IncreaseDecreaseInFairValueOfContingentValueRightLiability" xlink:href="syre-20260630.xsd#syre_IncreaseDecreaseInFairValueOfContingentValueRightLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_IncreaseDecreaseInFairValueOfContingentValueRightLiability" xlink:to="lab_syre_IncreaseDecreaseInFairValueOfContingentValueRightLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_019e22c4-913f-7352-93fe-70d0f77f77f2_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_019e22c4-9140-7947-aca7-6236c089d911_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.0001 par value; 400,000,000 shares authorized as of June&#160;30, 2026 and December&#160;31, 2025; 88,064,133 shares and 78,189,811 shares issued and outstanding as of June&#160;30, 2026 and December&#160;31, 2025, respectively.</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_019e22c4-913f-7708-bb43-805af92c6616_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_019e22c4-9140-7e0f-b03d-f14413e5d79c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_019e22c4-9140-7531-9583-19785bcb71eb_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants to purchase shares (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_CompanyAndBasisOfPresentationTable_019e22c4-9077-7b53-96ab-2203661174c1_terseLabel_en-US" xlink:label="lab_syre_CompanyAndBasisOfPresentationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company and Basis of Presentation [Table]</link:label>
    <link:label id="lab_syre_CompanyAndBasisOfPresentationTable_label_en-US" xlink:label="lab_syre_CompanyAndBasisOfPresentationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company and Basis of Presentation [Table]</link:label>
    <link:label id="lab_syre_CompanyAndBasisOfPresentationTable_documentation_en-US" xlink:label="lab_syre_CompanyAndBasisOfPresentationTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Company and basis of presentation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_CompanyAndBasisOfPresentationTable" xlink:href="syre-20260630.xsd#syre_CompanyAndBasisOfPresentationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_CompanyAndBasisOfPresentationTable" xlink:to="lab_syre_CompanyAndBasisOfPresentationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_019e22c4-9140-7250-a3a3-d4fae634bbd8_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_019e22c4-9076-71e9-9e6e-64eb0f9a9e1b_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CURRENT LIABILITIES</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_019e22c4-9140-7af2-b792-62b66a24a329_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_019e22c4-9077-7898-8dd1-187d848866d2_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_019e22c4-913f-76e8-af50-4f6081c85f21_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Marketable securities, gross unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_LicenseAgreementMilestonePayments_019e22c4-913f-7cb4-8505-7d804cee73eb_terseLabel_en-US" xlink:label="lab_syre_LicenseAgreementMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash milestone payments</link:label>
    <link:label id="lab_syre_LicenseAgreementMilestonePayments_label_en-US" xlink:label="lab_syre_LicenseAgreementMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement, Milestone Payments</link:label>
    <link:label id="lab_syre_LicenseAgreementMilestonePayments_documentation_en-US" xlink:label="lab_syre_LicenseAgreementMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Agreement, Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_LicenseAgreementMilestonePayments" xlink:href="syre-20260630.xsd#syre_LicenseAgreementMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_LicenseAgreementMilestonePayments" xlink:to="lab_syre_LicenseAgreementMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_019e22c4-913f-733a-adfc-2accac55db88_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableOtherCurrent_019e22c4-9140-70fe-ac4a-0e8af94800a8_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total related party accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableOtherCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Other, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableOtherCurrent" xlink:to="lab_us-gaap_AccountsPayableOtherCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_019e22c4-913f-71d7-b168-2056973192ee_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_019e22c4-9140-77d6-95f9-dac8c57def50_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total, unrealized losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_019e22c4-9140-77fb-9605-06b7eac63305_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options granted to purchase (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_019e22c4-9140-749f-a535-0c8d896ca9f8_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock options, Grants (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_019e22c4-9140-7fd4-97ab-bb0a7c03f87e_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_019e22c4-9140-725f-a736-d9bc6051ff38_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_019e22c4-913f-752d-9c3f-350e57330b31_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_019e22c4-913f-7dae-bb49-5f275ac4f7c1_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis" xlink:to="lab_us-gaap_AssetAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_019e22c4-913f-7cb9-84c6-c1d345570fa2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_019e22c4-9077-721a-8d5c-f9e663a8f435_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average common stock outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_019e22c4-9140-7b50-be2d-578d10cd2e6d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_019e22c4-9140-7bfb-a1ad-9c832057485d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Expenses Related to Related Party Which are Settled in Cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_019e22c4-9076-7d30-a169-30923cf5c94f_negatedLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Net accretion of discount on marketable securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_GlobalRightsToPegzilarginaseMember_019e22c4-9140-7dae-ae2d-23086cce99ee_terseLabel_en-US" xlink:label="lab_syre_GlobalRightsToPegzilarginaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Global Rights to Pegzilarginase</link:label>
    <link:label id="lab_syre_GlobalRightsToPegzilarginaseMember_label_en-US" xlink:label="lab_syre_GlobalRightsToPegzilarginaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Global Rights To Pegzilarginase [Member]</link:label>
    <link:label id="lab_syre_GlobalRightsToPegzilarginaseMember_documentation_en-US" xlink:label="lab_syre_GlobalRightsToPegzilarginaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Global Rights To Pegzilarginase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_GlobalRightsToPegzilarginaseMember" xlink:href="syre-20260630.xsd#syre_GlobalRightsToPegzilarginaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_GlobalRightsToPegzilarginaseMember" xlink:to="lab_syre_GlobalRightsToPegzilarginaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_019e22c4-913f-7c64-ad00-8c07e7d50105_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_019e22c4-9140-7397-bfd2-343e680a8519_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_LicensingAgreementsAbstract_label_en-US" xlink:label="lab_syre_LicensingAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Licensing Agreements [Abstract]</link:label>
    <link:label id="lab_syre_LicensingAgreementsAbstract_documentation_en-US" xlink:label="lab_syre_LicensingAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Licensing Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_LicensingAgreementsAbstract" xlink:href="syre-20260630.xsd#syre_LicensingAgreementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_LicensingAgreementsAbstract" xlink:to="lab_syre_LicensingAgreementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesCurrent_019e22c4-9140-7079-b39d-6e88f0bdbfee_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CVR liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesCurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_019e22c4-9140-75b3-ba5b-14478b952d91_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_ReportableSegmentMember_019e22c4-9076-72af-b550-6ed8d7ac37e6_terseLabel_en-US" xlink:label="lab_syre_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reportable Segment</link:label>
    <link:label id="lab_syre_ReportableSegmentMember_label_en-US" xlink:label="lab_syre_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reportable Segment [Member]</link:label>
    <link:label id="lab_syre_ReportableSegmentMember_documentation_en-US" xlink:label="lab_syre_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reportable Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_ReportableSegmentMember" xlink:href="syre-20260630.xsd#syre_ReportableSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_ReportableSegmentMember" xlink:to="lab_syre_ReportableSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_019e22c4-9140-7f86-831e-83e5f96c8536_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units, Grants (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e22c4-913f-7146-a7e8-da7b519edcf1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_PreferredStockRemainsIssuedAndOutstandingPercentage_019e22c4-913f-7120-b2e7-03002df6c719_terseLabel_en-US" xlink:label="lab_syre_PreferredStockRemainsIssuedAndOutstandingPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock issued and outstanding (as percent)</link:label>
    <link:label id="lab_syre_PreferredStockRemainsIssuedAndOutstandingPercentage_label_en-US" xlink:label="lab_syre_PreferredStockRemainsIssuedAndOutstandingPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock Remains Issued and Outstanding Percentage.</link:label>
    <link:label id="lab_syre_PreferredStockRemainsIssuedAndOutstandingPercentage_documentation_en-US" xlink:label="lab_syre_PreferredStockRemainsIssuedAndOutstandingPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Preferred stock remains issued and outstanding percentage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_PreferredStockRemainsIssuedAndOutstandingPercentage" xlink:href="syre-20260630.xsd#syre_PreferredStockRemainsIssuedAndOutstandingPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_PreferredStockRemainsIssuedAndOutstandingPercentage" xlink:to="lab_syre_PreferredStockRemainsIssuedAndOutstandingPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_PaymentsRelatedToContingentValueRightsLiability_019fb971-958c-7126-97bf-bcb58abc4cb3_negatedTerseLabel_en-US" xlink:label="lab_syre_PaymentsRelatedToContingentValueRightsLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments related to contingent value rights liability</link:label>
    <link:label id="lab_syre_PaymentsRelatedToContingentValueRightsLiability_label_en-US" xlink:label="lab_syre_PaymentsRelatedToContingentValueRightsLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Related To Contingent Value Rights Liability</link:label>
    <link:label id="lab_syre_PaymentsRelatedToContingentValueRightsLiability_documentation_en-US" xlink:label="lab_syre_PaymentsRelatedToContingentValueRightsLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments Related To Contingent Value Rights Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_PaymentsRelatedToContingentValueRightsLiability" xlink:href="syre-20260630.xsd#syre_PaymentsRelatedToContingentValueRightsLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_PaymentsRelatedToContingentValueRightsLiability" xlink:to="lab_syre_PaymentsRelatedToContingentValueRightsLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_019e22c4-913f-7df0-9c2b-d7111b3d29ad_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_019e22c4-9140-75f8-92b8-3e3f680f29b7_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_019e22c4-9077-7b9d-96c5-757280ddccd3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_019e22c4-9076-78e2-82a5-6d84e1f468dc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_019e22c4-913f-7f63-b18a-5989c10263e4_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_DeferredOfferingCostsUnpaidAmount_019f5e66-77be-7c94-8c0e-01c0bcea2433_terseLabel_en-US" xlink:label="lab_syre_DeferredOfferingCostsUnpaidAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unpaid deferred offering costs in connection with shelf registration</link:label>
    <link:label id="lab_syre_DeferredOfferingCostsUnpaidAmount_label_en-US" xlink:label="lab_syre_DeferredOfferingCostsUnpaidAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Offering Costs, Unpaid Amount</link:label>
    <link:label id="lab_syre_DeferredOfferingCostsUnpaidAmount_documentation_en-US" xlink:label="lab_syre_DeferredOfferingCostsUnpaidAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Offering Costs, Unpaid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_DeferredOfferingCostsUnpaidAmount" xlink:href="syre-20260630.xsd#syre_DeferredOfferingCostsUnpaidAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_DeferredOfferingCostsUnpaidAmount" xlink:to="lab_syre_DeferredOfferingCostsUnpaidAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_019e22c4-9140-7f52-b53d-eea97f26c941_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_019e22c4-913f-7fda-858d-bee787bce1c7_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recently Adopted Accounting Pronouncements and Not Yet Adopted Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_019e22c4-913f-77c2-b9d9-da97cce610c3_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Issued, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e22c4-913f-7238-931c-947aeb7b7331_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_019e22c4-9076-7352-8b1a-55fdc31786ec_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accrued and Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_019e22c4-9140-7c30-b800-b0c7a65fdaa9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Changes in CVR Liability</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_019e22c4-9076-703a-8f99-fb90759802dd_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price per warrant (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_CashEquivalentsUnrealizedLosses_019e22c4-9076-705a-afa4-e18cd516b4ed_negatedLabel_en-US" xlink:label="lab_syre_CashEquivalentsUnrealizedLosses" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents, gross unrealized losses</link:label>
    <link:label id="lab_syre_CashEquivalentsUnrealizedLosses_label_en-US" xlink:label="lab_syre_CashEquivalentsUnrealizedLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents Unrealized Losses</link:label>
    <link:label id="lab_syre_CashEquivalentsUnrealizedLosses_documentation_en-US" xlink:label="lab_syre_CashEquivalentsUnrealizedLosses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash equivalents unrealized losses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_CashEquivalentsUnrealizedLosses" xlink:href="syre-20260630.xsd#syre_CashEquivalentsUnrealizedLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_CashEquivalentsUnrealizedLosses" xlink:to="lab_syre_CashEquivalentsUnrealizedLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_019e22c4-913f-70ce-b9cf-5e93636728c3_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019e22c4-9076-7fc0-8e74-7557c7244926_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_019e22c4-9140-79c0-8f98-448e40c39f00_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_PreferredStockExcludingSeriesAAndBNonVotingConvertiblePreferredStockMember_019e22c4-913f-75b6-b1b8-210d1afd34bb_terseLabel_en-US" xlink:label="lab_syre_PreferredStockExcludingSeriesAAndBNonVotingConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock, Excluding Series A Non Voting Convertible Preferred Stock</link:label>
    <link:label id="lab_syre_PreferredStockExcludingSeriesAAndBNonVotingConvertiblePreferredStockMember_label_en-US" xlink:label="lab_syre_PreferredStockExcludingSeriesAAndBNonVotingConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Excluding Series A and B Non Voting Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_syre_PreferredStockExcludingSeriesAAndBNonVotingConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_syre_PreferredStockExcludingSeriesAAndBNonVotingConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Preferred Stock, Excluding Series A and B Non Voting Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_PreferredStockExcludingSeriesAAndBNonVotingConvertiblePreferredStockMember" xlink:href="syre-20260630.xsd#syre_PreferredStockExcludingSeriesAAndBNonVotingConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_PreferredStockExcludingSeriesAAndBNonVotingConvertiblePreferredStockMember" xlink:to="lab_syre_PreferredStockExcludingSeriesAAndBNonVotingConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold_019e22c4-9140-7113-a7d8-0c31e0b44f2b_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation</link:label>
    <link:label id="lab_us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold_label_en-US" xlink:label="lab_us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Expense, Excluding Cost of Good and Service Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold" xlink:to="lab_us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_AccruedAndOtherCurrentLiabilitiesTextBlock_019e22c4-913f-771a-92e6-cb2709170388_terseLabel_en-US" xlink:label="lab_syre_AccruedAndOtherCurrentLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued and Other Current Liabilities</link:label>
    <link:label id="lab_syre_AccruedAndOtherCurrentLiabilitiesTextBlock_label_en-US" xlink:label="lab_syre_AccruedAndOtherCurrentLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued And Other Current Liabilities [Text Block]</link:label>
    <link:label id="lab_syre_AccruedAndOtherCurrentLiabilitiesTextBlock_documentation_en-US" xlink:label="lab_syre_AccruedAndOtherCurrentLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure for accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_AccruedAndOtherCurrentLiabilitiesTextBlock" xlink:href="syre-20260630.xsd#syre_AccruedAndOtherCurrentLiabilitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_AccruedAndOtherCurrentLiabilitiesTextBlock" xlink:to="lab_syre_AccruedAndOtherCurrentLiabilitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_019e22c4-9140-73eb-ac17-db90d0f021e2_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_019e22c4-9140-76d5-b188-155acfa2da1a_periodStartLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance, preferred stock (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_019e22c4-9140-738c-ba1a-261a6431eac2_periodEndLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance, preferred stock (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_019e22c4-9140-7ff1-8497-d52861452188_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_019e22c4-913f-7a4a-8cfe-50c172104afb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options, Weighted Average Grant Date Fair Value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant_019e22c4-9140-7f75-bb89-67bff2dc5dd3_terseLabel_en-US" xlink:label="lab_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional number of shares available for issuance (in shares)</link:label>
    <link:label id="lab_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Additional Number Of Shares Available For Grant</link:label>
    <link:label id="lab_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant_documentation_en-US" xlink:label="lab_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, additional number of shares available for grant.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant" xlink:href="syre-20260630.xsd#syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant" xlink:to="lab_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_October2025UnderwrittenOfferingMember_019e22c4-9140-7696-b12f-f96034461549_terseLabel_en-US" xlink:label="lab_syre_October2025UnderwrittenOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">October 2025 Underwritten Offering</link:label>
    <link:label id="lab_syre_October2025UnderwrittenOfferingMember_label_en-US" xlink:label="lab_syre_October2025UnderwrittenOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">October 2025 Underwritten Offering [Member]</link:label>
    <link:label id="lab_syre_October2025UnderwrittenOfferingMember_documentation_en-US" xlink:label="lab_syre_October2025UnderwrittenOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">October 2025 Underwritten Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_October2025UnderwrittenOfferingMember" xlink:href="syre-20260630.xsd#syre_October2025UnderwrittenOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_October2025UnderwrittenOfferingMember" xlink:to="lab_syre_October2025UnderwrittenOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockTextBlock_019e22c4-9140-7735-b50e-15b3d9190e09_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock and Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_PreferredStockTextBlock_label_en-US" xlink:label="lab_us-gaap_PreferredStockTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockTextBlock" xlink:to="lab_us-gaap_PreferredStockTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_SaleOfStockAuthorizedAmount_019e22c4-9140-70a4-a7ef-443286ea2d83_terseLabel_en-US" xlink:label="lab_syre_SaleOfStockAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, authorized amount</link:label>
    <link:label id="lab_syre_SaleOfStockAuthorizedAmount_label_en-US" xlink:label="lab_syre_SaleOfStockAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Authorized Amount</link:label>
    <link:label id="lab_syre_SaleOfStockAuthorizedAmount_documentation_en-US" xlink:label="lab_syre_SaleOfStockAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale of Stock, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_SaleOfStockAuthorizedAmount" xlink:href="syre-20260630.xsd#syre_SaleOfStockAuthorizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_SaleOfStockAuthorizedAmount" xlink:to="lab_syre_SaleOfStockAuthorizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_AccruedContractedResearchAndDevelopmentCosts_019e22c4-913f-770b-b614-8e54535a1006_terseLabel_en-US" xlink:label="lab_syre_AccruedContractedResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued contracted research and development costs</link:label>
    <link:label id="lab_syre_AccruedContractedResearchAndDevelopmentCosts_label_en-US" xlink:label="lab_syre_AccruedContractedResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Contracted Research And Development Costs</link:label>
    <link:label id="lab_syre_AccruedContractedResearchAndDevelopmentCosts_documentation_en-US" xlink:label="lab_syre_AccruedContractedResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued contracted research and development costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_AccruedContractedResearchAndDevelopmentCosts" xlink:href="syre-20260630.xsd#syre_AccruedContractedResearchAndDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_AccruedContractedResearchAndDevelopmentCosts" xlink:to="lab_syre_AccruedContractedResearchAndDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_019e22c4-913f-7b2f-b00d-ff89edf2212b_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_019e22c4-9140-7a1c-a8ba-32cb58d08fe3_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_019e22c4-913f-73de-97e4-ba5e86e80bf9_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_019e22c4-9076-736b-9222-574cd5b2c7ce_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_019e22c4-913f-799d-8f2a-8c7f552f43f0_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Increase in fair value of derivative</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_019e22c4-913f-759e-934f-ef88089eae62_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Changes in the fair value of the CVR liability</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_019e22c4-913f-74a9-bf78-4de9cf96e197_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">12 Months or Longer</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_019e22c4-913f-744d-a348-662ee32a4e51_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_SpyreTherapeuticsIncMember_019e22c4-9077-792a-8708-71851771a2c5_terseLabel_en-US" xlink:label="lab_syre_SpyreTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Spyre Therapeutics, Inc.</link:label>
    <link:label id="lab_syre_SpyreTherapeuticsIncMember_label_en-US" xlink:label="lab_syre_SpyreTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Spyre Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_syre_SpyreTherapeuticsIncMember_documentation_en-US" xlink:label="lab_syre_SpyreTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Spyre Therapeutics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_SpyreTherapeuticsIncMember" xlink:href="syre-20260630.xsd#syre_SpyreTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_SpyreTherapeuticsIncMember" xlink:to="lab_syre_SpyreTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_019e22c4-9140-74c2-b30a-b29266e13df4_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_019e22c4-913f-78ea-b864-e8a0009a05c6_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_019e22c4-9140-74ce-b7da-1bf9eee74459_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Computation of Basic and Diluted Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Weighted Average Number of Shares [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_019e22c4-9076-7bfe-81a6-0221a539b49a_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_019e22c4-913f-7401-bcc1-1d322987e592_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">TOTAL LIABILITIES</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_019e22c4-9140-7421-afdb-986c497750d4_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_019e22c4-9140-74b6-8cdb-10bafdff0f50_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-adjusted discount rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_019fa2d7-373d-7db2-8c69-c26244158b3f_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Converted at the option of the holder (in shares)</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_AtTheMarketOffering2024SalesAgreementMember_019e22c4-913f-7ce4-a9f7-7e5a7118055f_terseLabel_en-US" xlink:label="lab_syre_AtTheMarketOffering2024SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">At-The-Market Offering, 2024 Sales Agreement</link:label>
    <link:label id="lab_syre_AtTheMarketOffering2024SalesAgreementMember_label_en-US" xlink:label="lab_syre_AtTheMarketOffering2024SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At-The-Market Offering, 2024 Sales Agreement [Member]</link:label>
    <link:label id="lab_syre_AtTheMarketOffering2024SalesAgreementMember_documentation_en-US" xlink:label="lab_syre_AtTheMarketOffering2024SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">At-The-Market Offering, 2024 Sales Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_AtTheMarketOffering2024SalesAgreementMember" xlink:href="syre-20260630.xsd#syre_AtTheMarketOffering2024SalesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_AtTheMarketOffering2024SalesAgreementMember" xlink:to="lab_syre_AtTheMarketOffering2024SalesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_019e22c4-9077-7b3b-8f39-b93e09a6b94d_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denominator</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_TwoThousandAndSixteenEquityIncentivePlanMember_019e22c4-9140-7ce1-8429-33dca5ceef43_terseLabel_en-US" xlink:label="lab_syre_TwoThousandAndSixteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2016 Equity Incentive Plan</link:label>
    <link:label id="lab_syre_TwoThousandAndSixteenEquityIncentivePlanMember_019e22c4-9140-7792-a290-dc810102953d_verboseLabel_en-US" xlink:label="lab_syre_TwoThousandAndSixteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock Options Granted</link:label>
    <link:label id="lab_syre_TwoThousandAndSixteenEquityIncentivePlanMember_label_en-US" xlink:label="lab_syre_TwoThousandAndSixteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand And Sixteen Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_syre_TwoThousandAndSixteenEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_syre_TwoThousandAndSixteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two thousand and sixteen equity incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_TwoThousandAndSixteenEquityIncentivePlanMember" xlink:href="syre-20260630.xsd#syre_TwoThousandAndSixteenEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_TwoThousandAndSixteenEquityIncentivePlanMember" xlink:to="lab_syre_TwoThousandAndSixteenEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_019e22c4-913f-7723-8b93-39fa92f84c0d_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_019e22c4-9076-7412-96fe-eacab0c7ac5f_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_019e22c4-9076-75cb-89bc-1e7b81fbfc48_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental Disclosure of Non-Cash Financing Information:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_019e22c4-9076-7baf-9dc1-6aaa4f98c115_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. government agency securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_019e22c4-9076-76c2-98d2-8e144ea5f545_verboseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">U.S. government agency securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_019e22c4-9076-71c8-85e5-828828433267_netLabel_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">U.S. government agency securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Government Corporations and Agencies Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicLineItems_019e22c4-9076-7bb3-9563-f9a6940cb9e0_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicLineItems_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems" xlink:to="lab_us-gaap_EarningsPerShareBasicLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne_019e22c4-9140-74b9-b750-46c8ee275b2a_terseLabel_en-US" xlink:label="lab_syre_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due in 1 - 2 years</link:label>
    <link:label id="lab_syre_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne_label_en-US" xlink:label="lab_syre_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, After Year One</link:label>
    <link:label id="lab_syre_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne_documentation_en-US" xlink:label="lab_syre_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, After Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne" xlink:href="syre-20260630.xsd#syre_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne" xlink:to="lab_syre_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_019e22c4-9076-7926-9729-a37b7f83b983_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Estimated Fair Value of Cash Equivalents and Marketable Securities and Gross Unrealized Gains and Losses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, and Investment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_019e22c4-9140-79b5-ade2-edf8c96ce43e_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_019e22c4-9076-7081-952f-1230e7222f26_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019e22c4-9140-7900-beab-f792ab2f309c_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average common stock outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_019e22c4-9140-7638-9b25-9a17e00dd6ed_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_019e22c4-9076-7e42-b96f-d61eccc8320c_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019e22c4-913f-7256-adc4-5a3485a3a0ea_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_019e22c4-9140-7fd5-9f62-0aa0316b5bdb_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_019e22c4-9140-7059-ab81-cfec4510d19b_verboseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_019e22c4-9140-74a3-80b0-f13e157cdff6_netLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_019e22c4-9077-7350-bedc-39640447b3d0_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. government treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_019e22c4-9077-736b-803e-c97b1633e6b6_verboseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">U.S. government treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_019e22c4-9077-7747-8045-cd1744384137_netLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">U.S. government treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_019e22c4-9140-785a-93f0-562a3b5b8f9b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019e22c4-9140-7041-a015-19ff87e3d0e9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019e22c4-9140-7120-a03d-ad92ca9b5aa8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_JeffreyAlbersRuleTradingArrangementDirectorStockOptionsMember_label_en-US" xlink:label="lab_syre_JeffreyAlbersRuleTradingArrangementDirectorStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Jeffrey Albers Rule Trading Arrangement, Director Stock Options [Member]</link:label>
    <link:label id="lab_syre_JeffreyAlbersRuleTradingArrangementDirectorStockOptionsMember_documentation_en-US" xlink:label="lab_syre_JeffreyAlbersRuleTradingArrangementDirectorStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Jeffrey Albers Rule Trading Arrangement, Director Stock Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_JeffreyAlbersRuleTradingArrangementDirectorStockOptionsMember" xlink:href="syre-20260630.xsd#syre_JeffreyAlbersRuleTradingArrangementDirectorStockOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_JeffreyAlbersRuleTradingArrangementDirectorStockOptionsMember" xlink:to="lab_syre_JeffreyAlbersRuleTradingArrangementDirectorStockOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_019e22c4-9077-72c3-9465-cffe46fa4440_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_April2026UnderwritingOfferingMember_019e22c4-9076-7402-b056-5b62437690b1_terseLabel_en-US" xlink:label="lab_syre_April2026UnderwritingOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">April 2026 Underwriting Agreement</link:label>
    <link:label id="lab_syre_April2026UnderwritingOfferingMember_label_en-US" xlink:label="lab_syre_April2026UnderwritingOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">April 2026 Underwriting Offering [Member]</link:label>
    <link:label id="lab_syre_April2026UnderwritingOfferingMember_documentation_en-US" xlink:label="lab_syre_April2026UnderwritingOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">April 2026 Underwriting Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_April2026UnderwritingOfferingMember" xlink:href="syre-20260630.xsd#syre_April2026UnderwritingOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_April2026UnderwritingOfferingMember" xlink:to="lab_syre_April2026UnderwritingOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019e22c4-913f-7167-8988-07c4d974b514_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_CampaignTimelineMinimumTerm_019e22c4-913f-7750-b89e-07cfe0ad6ea4_terseLabel_en-US" xlink:label="lab_syre_CampaignTimelineMinimumTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Campaign timeline, minimum term (in years)</link:label>
    <link:label id="lab_syre_CampaignTimelineMinimumTerm_label_en-US" xlink:label="lab_syre_CampaignTimelineMinimumTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Campaign Timeline, Minimum Term</link:label>
    <link:label id="lab_syre_CampaignTimelineMinimumTerm_documentation_en-US" xlink:label="lab_syre_CampaignTimelineMinimumTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Campaign Timeline, Minimum Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_CampaignTimelineMinimumTerm" xlink:href="syre-20260630.xsd#syre_CampaignTimelineMinimumTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_CampaignTimelineMinimumTerm" xlink:to="lab_syre_CampaignTimelineMinimumTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_019e22c4-9076-72c4-9243-5bc060eb2c54_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_019e22c4-913f-7591-9463-886c8f09211b_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Realized gains or losses on marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Security, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:to="lab_us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_019e22c4-913f-732f-9cdb-d20e8b3ea3d2_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_019e22c4-9076-76ec-9ae1-898adcee2dda_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_019e22c4-913f-798f-a914-2ddacc70f710_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_PaymentOfMilestone_019e22c4-9076-7b60-95c4-896936d7c431_terseLabel_en-US" xlink:label="lab_syre_PaymentOfMilestone" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">First milestone payment</link:label>
    <link:label id="lab_syre_PaymentOfMilestone_label_en-US" xlink:label="lab_syre_PaymentOfMilestone" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment Of Milestone</link:label>
    <link:label id="lab_syre_PaymentOfMilestone_documentation_en-US" xlink:label="lab_syre_PaymentOfMilestone" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payment of milestone.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_PaymentOfMilestone" xlink:href="syre-20260630.xsd#syre_PaymentOfMilestone"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_PaymentOfMilestone" xlink:to="lab_syre_PaymentOfMilestone" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019e22c4-9140-7b70-a79c-dde27a0e2cd9_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_019e22c4-9076-76fc-9d50-d60b7b0005cd_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain" xlink:to="lab_us-gaap_AssetAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_SeriesBNonVotingConvertiblePreferredStockMember_019e22c4-9140-7929-a922-75e02a0af8f7_terseLabel_en-US" xlink:label="lab_syre_SeriesBNonVotingConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series B Non Voting Convertible Preferred Stock</link:label>
    <link:label id="lab_syre_SeriesBNonVotingConvertiblePreferredStockMember_019e22c4-9140-712c-afbb-56c8c207fe95_netLabel_en-US" xlink:label="lab_syre_SeriesBNonVotingConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Series B Non-Voting Convertible Preferred Stock</link:label>
    <link:label id="lab_syre_SeriesBNonVotingConvertiblePreferredStockMember_019e22c4-9140-78f7-b3be-3441c7c21633_verboseLabel_en-US" xlink:label="lab_syre_SeriesBNonVotingConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Series B Preferred Stock</link:label>
    <link:label id="lab_syre_SeriesBNonVotingConvertiblePreferredStockMember_label_en-US" xlink:label="lab_syre_SeriesBNonVotingConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series B Non Voting Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_syre_SeriesBNonVotingConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_syre_SeriesBNonVotingConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series B Non Voting Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_SeriesBNonVotingConvertiblePreferredStockMember" xlink:href="syre-20260630.xsd#syre_SeriesBNonVotingConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_SeriesBNonVotingConvertiblePreferredStockMember" xlink:to="lab_syre_SeriesBNonVotingConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_019e22c4-9140-7bfc-a2b5-586fb198e476_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_019e22c4-9140-74bb-a731-1c65f213d688_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_019e22c4-913f-79ba-b9f9-5b809581cb28_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_RelatedPartyTransactionNumberOfBoardSeats_019e22c4-9140-7f6e-8719-88da013a900b_terseLabel_en-US" xlink:label="lab_syre_RelatedPartyTransactionNumberOfBoardSeats" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of board seats held by related party</link:label>
    <link:label id="lab_syre_RelatedPartyTransactionNumberOfBoardSeats_label_en-US" xlink:label="lab_syre_RelatedPartyTransactionNumberOfBoardSeats" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Number Of Board Seats</link:label>
    <link:label id="lab_syre_RelatedPartyTransactionNumberOfBoardSeats_documentation_en-US" xlink:label="lab_syre_RelatedPartyTransactionNumberOfBoardSeats" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Number Of Board Seats</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_RelatedPartyTransactionNumberOfBoardSeats" xlink:href="syre-20260630.xsd#syre_RelatedPartyTransactionNumberOfBoardSeats"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_RelatedPartyTransactionNumberOfBoardSeats" xlink:to="lab_syre_RelatedPartyTransactionNumberOfBoardSeats" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_SaleOfStockAggregateOfferingPrice_019e22c4-913f-7eff-8ce6-06bd13012e31_terseLabel_en-US" xlink:label="lab_syre_SaleOfStockAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, aggregate offering price</link:label>
    <link:label id="lab_syre_SaleOfStockAggregateOfferingPrice_label_en-US" xlink:label="lab_syre_SaleOfStockAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Aggregate Offering Price</link:label>
    <link:label id="lab_syre_SaleOfStockAggregateOfferingPrice_documentation_en-US" xlink:label="lab_syre_SaleOfStockAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale of Stock, Aggregate Offering Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_SaleOfStockAggregateOfferingPrice" xlink:href="syre-20260630.xsd#syre_SaleOfStockAggregateOfferingPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_SaleOfStockAggregateOfferingPrice" xlink:to="lab_syre_SaleOfStockAggregateOfferingPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_ProceedsFromIssuanceOfCommonStockAtTheMarketOfferingsNet_019e22c4-913f-7d73-9e41-80a2f130fc3f_terseLabel_en-US" xlink:label="lab_syre_ProceedsFromIssuanceOfCommonStockAtTheMarketOfferingsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock in connection with at-the-market offering program, net of issuance costs</link:label>
    <link:label id="lab_syre_ProceedsFromIssuanceOfCommonStockAtTheMarketOfferingsNet_label_en-US" xlink:label="lab_syre_ProceedsFromIssuanceOfCommonStockAtTheMarketOfferingsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Issuance of Common Stock, At-The-Market Offerings, Net</link:label>
    <link:label id="lab_syre_ProceedsFromIssuanceOfCommonStockAtTheMarketOfferingsNet_documentation_en-US" xlink:label="lab_syre_ProceedsFromIssuanceOfCommonStockAtTheMarketOfferingsNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Issuance of Common Stock, At-The-Market Offerings, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_ProceedsFromIssuanceOfCommonStockAtTheMarketOfferingsNet" xlink:href="syre-20260630.xsd#syre_ProceedsFromIssuanceOfCommonStockAtTheMarketOfferingsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_ProceedsFromIssuanceOfCommonStockAtTheMarketOfferingsNet" xlink:to="lab_syre_ProceedsFromIssuanceOfCommonStockAtTheMarketOfferingsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_AppointOfBoardMembersMember_019e22c4-9076-78bb-b9e2-ae1ade8d05f3_terseLabel_en-US" xlink:label="lab_syre_AppointOfBoardMembersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Appoint Of Board Members</link:label>
    <link:label id="lab_syre_AppointOfBoardMembersMember_label_en-US" xlink:label="lab_syre_AppointOfBoardMembersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Appoint Of Board Members [Member]</link:label>
    <link:label id="lab_syre_AppointOfBoardMembersMember_documentation_en-US" xlink:label="lab_syre_AppointOfBoardMembersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Appoint Of Board Members</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_AppointOfBoardMembersMember" xlink:href="syre-20260630.xsd#syre_AppointOfBoardMembersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_AppointOfBoardMembersMember" xlink:to="lab_syre_AppointOfBoardMembersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_019e22c4-913f-7aa5-9e0d-9c4675ca4de0_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeLocationBalanceAxis_019e22c4-913f-7cb8-a620-2b16b1fc293c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeLocationBalanceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Location, Statement of Income, Balance [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeLocationBalanceAxis_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeLocationBalanceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Location, Statement of Income, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeLocationBalanceAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfIncomeLocationBalanceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeLocationBalanceAxis" xlink:to="lab_us-gaap_StatementOfIncomeLocationBalanceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_019e22c4-913f-7ed1-8394-878bafdc27c8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract" xlink:to="lab_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_019e22c4-9140-7d0d-ab56-59ccb5815058_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents, estimated fair value</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_InterestProceedsDebtSecurities_019e22c4-9076-7c6a-8ac8-af04165fbdba_terseLabel_en-US" xlink:label="lab_syre_InterestProceedsDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest proceeds from maturities of zero coupon U.S. Treasury Bills</link:label>
    <link:label id="lab_syre_InterestProceedsDebtSecurities_label_en-US" xlink:label="lab_syre_InterestProceedsDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Proceeds, Debt Securities</link:label>
    <link:label id="lab_syre_InterestProceedsDebtSecurities_documentation_en-US" xlink:label="lab_syre_InterestProceedsDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest Proceeds, Debt Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_InterestProceedsDebtSecurities" xlink:href="syre-20260630.xsd#syre_InterestProceedsDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_InterestProceedsDebtSecurities" xlink:to="lab_syre_InterestProceedsDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_019e22c4-9140-72fe-902c-1c94864b195a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonrelatedPartyMember_019e22c4-9140-7201-9e3b-00e013786f19_terseLabel_en-US" xlink:label="lab_us-gaap_NonrelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nonrelated Party</link:label>
    <link:label id="lab_us-gaap_NonrelatedPartyMember_label_en-US" xlink:label="lab_us-gaap_NonrelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonrelated Party [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonrelatedPartyMember" xlink:to="lab_us-gaap_NonrelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_019e22c4-913f-7a98-be92-1bbbaae07d68_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_RoyaltyTermExpirationPeriod_019e22c4-913f-786d-8113-381b11ecbd1f_terseLabel_en-US" xlink:label="lab_syre_RoyaltyTermExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty term expiration period (in years)</link:label>
    <link:label id="lab_syre_RoyaltyTermExpirationPeriod_label_en-US" xlink:label="lab_syre_RoyaltyTermExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Term, Expiration Period</link:label>
    <link:label id="lab_syre_RoyaltyTermExpirationPeriod_documentation_en-US" xlink:label="lab_syre_RoyaltyTermExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty Term, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_RoyaltyTermExpirationPeriod" xlink:href="syre-20260630.xsd#syre_RoyaltyTermExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_RoyaltyTermExpirationPeriod" xlink:to="lab_syre_RoyaltyTermExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_019e22c4-913f-7798-b75b-dc9d2d797628_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_019e22c4-9076-71e7-9537-3b5e27a40c95_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share, basic and diluted:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:to="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019e22c4-913f-718a-a991-c5714ba2df7e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_ConsultingAgreementMember_019e22c4-913f-7459-8bf6-3efb7bfe7477_terseLabel_en-US" xlink:label="lab_syre_ConsultingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consulting Agreement</link:label>
    <link:label id="lab_syre_ConsultingAgreementMember_label_en-US" xlink:label="lab_syre_ConsultingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consulting Agreement [Member]</link:label>
    <link:label id="lab_syre_ConsultingAgreementMember_documentation_en-US" xlink:label="lab_syre_ConsultingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Consulting Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_ConsultingAgreementMember" xlink:href="syre-20260630.xsd#syre_ConsultingAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_ConsultingAgreementMember" xlink:to="lab_syre_ConsultingAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_019e22c4-913f-7c52-b354-74693a6633cb_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares of common stock sold (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_019e22c4-913f-7c86-8cc3-7af09b6f8c04_verboseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of shares sold (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_019e22c4-9077-7b8d-a9ed-36cde40c1973_terseLabel_en-US" xlink:label="lab_syre_DisposalGroupIncludingDiscontinuedOperationContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_syre_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_label_en-US" xlink:label="lab_syre_DisposalGroupIncludingDiscontinuedOperationContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Contingent Consideration</link:label>
    <link:label id="lab_syre_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_documentation_en-US" xlink:label="lab_syre_DisposalGroupIncludingDiscontinuedOperationContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Contingent Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_DisposalGroupIncludingDiscontinuedOperationContingentConsideration" xlink:href="syre-20260630.xsd#syre_DisposalGroupIncludingDiscontinuedOperationContingentConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_DisposalGroupIncludingDiscontinuedOperationContingentConsideration" xlink:to="lab_syre_DisposalGroupIncludingDiscontinuedOperationContingentConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019e22c4-9076-70a4-9566-ab2dae41aaa7_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_019e22c4-9076-7ad1-a285-21fbd492aa33_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_019e22c4-913f-7af1-853d-bb9b55244118_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_019e22c4-913f-7b93-944c-381a98914b0c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from maturities and sales of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_019e22c4-9076-74b9-9471-8b80e35f6dbf_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_019e22c4-913f-7a8e-b013-49f562a46b16_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_019e22c4-9077-7dae-8f5e-8e3f561b76ed_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019e22c4-9077-7a25-9a5f-931d72d08d25_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan_019e22c4-9076-7849-891b-bbd52c373fdc_terseLabel_en-US" xlink:label="lab_syre_StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in connection with exercise of stock options and employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_syre_StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan_label_en-US" xlink:label="lab_syre_StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Options Exercised And Employee Stock Ownership Plan</link:label>
    <link:label id="lab_syre_StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan_documentation_en-US" xlink:label="lab_syre_StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Options Exercised And Employee Stock Ownership Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan" xlink:href="syre-20260630.xsd#syre_StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan" xlink:to="lab_syre_StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_CashEquivalentsAndMarketableSecuritiesLineItems_019e22c4-9077-746d-99c9-0e68fb1a7937_terseLabel_en-US" xlink:label="lab_syre_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Equivalents And Marketable Securities [Line Items]</link:label>
    <link:label id="lab_syre_CashEquivalentsAndMarketableSecuritiesLineItems_label_en-US" xlink:label="lab_syre_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents And Marketable Securities [Line Items]</link:label>
    <link:label id="lab_syre_CashEquivalentsAndMarketableSecuritiesLineItems_documentation_en-US" xlink:label="lab_syre_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash equivalents and marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:href="syre-20260630.xsd#syre_CashEquivalentsAndMarketableSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="lab_syre_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_019e22c4-913f-7fc5-abfb-c715410f3cac_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_RoyaltyStepDownPercent_019e22c4-9076-73f2-9488-f0d04df82354_terseLabel_en-US" xlink:label="lab_syre_RoyaltyStepDownPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty step-down (as percent)</link:label>
    <link:label id="lab_syre_RoyaltyStepDownPercent_label_en-US" xlink:label="lab_syre_RoyaltyStepDownPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Step-Down, Percent</link:label>
    <link:label id="lab_syre_RoyaltyStepDownPercent_documentation_en-US" xlink:label="lab_syre_RoyaltyStepDownPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty Step-Down, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_RoyaltyStepDownPercent" xlink:href="syre-20260630.xsd#syre_RoyaltyStepDownPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_RoyaltyStepDownPercent" xlink:to="lab_syre_RoyaltyStepDownPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_019e22c4-9077-736f-8c86-080adde73972_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_019e22c4-9076-738a-ab22-10d7b51fa1d0_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_019e22c4-913f-70e3-bd42-8613288c9915_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, proceeds received</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_019e22c4-913f-723f-978a-377c6384276b_verboseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Receivable outstanding</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_019e22c4-913f-73bd-8ea3-5179ec7f557d_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">TOTAL STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_019e22c4-913f-7299-b79a-e26b3562e358_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_019e22c4-913f-795f-b4e8-82bcb4d5292e_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_019e22c4-913f-7ba6-8284-b9aba029e9f4_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other income (expense)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_019e22c4-9076-7e3b-976a-3b1f082965b4_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group, Disposed of by Sale, Not Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:to="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_019e22c4-9077-7505-96ce-5d834d6f71b1_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_PaymentForSublicensingFee_019e22c4-913f-7279-82b1-3b61974b9201_terseLabel_en-US" xlink:label="lab_syre_PaymentForSublicensingFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment for sublicensing fee</link:label>
    <link:label id="lab_syre_PaymentForSublicensingFee_label_en-US" xlink:label="lab_syre_PaymentForSublicensingFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment For Sublicensing Fee</link:label>
    <link:label id="lab_syre_PaymentForSublicensingFee_documentation_en-US" xlink:label="lab_syre_PaymentForSublicensingFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payment For Sublicensing Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_PaymentForSublicensingFee" xlink:href="syre-20260630.xsd#syre_PaymentForSublicensingFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_PaymentForSublicensingFee" xlink:to="lab_syre_PaymentForSublicensingFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_019e22c4-913f-70da-b3b9-0f5a15d566a1_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Marketable securities, amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_019e22c4-9140-7907-ba94-c6f4207eae40_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_019e22c4-9140-70eb-bf78-bd848d43d03c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_019e22c4-9140-74a3-b2ad-f1bd2b6132f3_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Placement agent and other offering costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019e22c4-913f-7ecc-966a-aad51795e13e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding option awards (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_019e22c4-9140-74b0-9055-3d0ee1e57701_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019e22c4-9140-7505-acb3-3a2ca82d8e61_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_019e22c4-913f-7a20-b86f-243efc6327d9_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_019e22c4-9076-750c-8399-e5eb2e07e71e_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_019e22c4-913f-7a08-9a26-93aac5ba540c_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_019e22c4-913f-7092-80dd-b5c5ae9d082f_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unvested restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_019e22c4-913f-7f0c-81b9-a43f40b12825_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Weighted-Average Equity Instruments Excluded from Calculation of Diluted Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_019e22c4-9076-7641-8c53-d2a515fe7b54_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_019e22c4-9140-710a-825a-9f9ade03153b_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_019e22c4-9076-7c57-b326-83766c4199eb_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_019e22c4-9140-737a-abdf-e0f33e71443d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock in connection with follow-on offering, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Private Placement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_019e22c4-913f-7a51-b421-1d166e7387fd_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_019e22c4-913f-78e6-a99a-6eaff1f37aec_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_019e22c4-9140-7d2c-8223-8a8498ea07a4_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_019e22c4-9076-70db-9f22-7e4f788c1a23_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_019e22c4-9140-7f6a-b32f-c8ae07b53ccd_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember_019e22c4-9077-70c8-938b-4a063063dbfd_terseLabel_en-US" xlink:label="lab_syre_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2015 and 2016 and 2018 Equity Inducement Plan</link:label>
    <link:label id="lab_syre_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember_label_en-US" xlink:label="lab_syre_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand And Fifteen And Two Thousand And Sixteen Equity Incentive Plan And Two Thousand And Eighteen Equity Inducement Plan [Member]</link:label>
    <link:label id="lab_syre_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember_documentation_en-US" xlink:label="lab_syre_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two thousand and fifteen and two thousand and sixteen equity incentive plan and two thousand and eighteen equity inducement plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember" xlink:href="syre-20260630.xsd#syre_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember" xlink:to="lab_syre_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_019e22c4-913f-7be7-a7a7-db04ccf7344e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_019e22c4-9140-707d-978f-690bb64cadf2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares_019e22c4-9140-7fd2-b4b7-4ffc20be20ff_terseLabel_en-US" xlink:label="lab_syre_AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual percentage of additional shares</link:label>
    <link:label id="lab_syre_AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares_label_en-US" xlink:label="lab_syre_AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Annual Percentage Of Additional Shares Which Equals To Issued And Outstanding Shares</link:label>
    <link:label id="lab_syre_AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares_documentation_en-US" xlink:label="lab_syre_AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Annual percentage of additional shares which equals to the issued and outstanding shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares" xlink:href="syre-20260630.xsd#syre_AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares" xlink:to="lab_syre_AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_019e22c4-9140-7865-8d46-49823c124331_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Weighted-Average Assumptions Used in Calculating Fair Value of Awards</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_019e22c4-9140-7bd0-a757-923602e2c84f_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019e22c4-9140-72c2-8154-a10cf89701db_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_TerminationNoticePeriod_019e22c4-913f-7e82-a46a-cbf9f07613c6_terseLabel_en-US" xlink:label="lab_syre_TerminationNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination notice period (in days)</link:label>
    <link:label id="lab_syre_TerminationNoticePeriod_label_en-US" xlink:label="lab_syre_TerminationNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Termination Notice Period</link:label>
    <link:label id="lab_syre_TerminationNoticePeriod_documentation_en-US" xlink:label="lab_syre_TerminationNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Termination Notice Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_TerminationNoticePeriod" xlink:href="syre-20260630.xsd#syre_TerminationNoticePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_TerminationNoticePeriod" xlink:to="lab_syre_TerminationNoticePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_SeriesANonVotingConvertiblePreferredStockMember_019e22c4-9076-7cea-9d24-d31f9a30e9d1_terseLabel_en-US" xlink:label="lab_syre_SeriesANonVotingConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A Non Voting Convertible Preferred Stock</link:label>
    <link:label id="lab_syre_SeriesANonVotingConvertiblePreferredStockMember_019e22c4-9076-7620-8c04-ace3a1dc992b_netLabel_en-US" xlink:label="lab_syre_SeriesANonVotingConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Series A Non-Voting Convertible Preferred Stock</link:label>
    <link:label id="lab_syre_SeriesANonVotingConvertiblePreferredStockMember_019e22c4-9076-7fd6-b4ce-78a4d8a26533_verboseLabel_en-US" xlink:label="lab_syre_SeriesANonVotingConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Series A Preferred Stock</link:label>
    <link:label id="lab_syre_SeriesANonVotingConvertiblePreferredStockMember_label_en-US" xlink:label="lab_syre_SeriesANonVotingConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A Non Voting Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_syre_SeriesANonVotingConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_syre_SeriesANonVotingConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series A non voting convertible preferred stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_SeriesANonVotingConvertiblePreferredStockMember" xlink:href="syre-20260630.xsd#syre_SeriesANonVotingConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_SeriesANonVotingConvertiblePreferredStockMember" xlink:to="lab_syre_SeriesANonVotingConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_019fabf3-4eed-79a5-aa84-7a67785364a3_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Value Rights</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_019e22c4-913f-7fbe-9825-1b178d39b168_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_019e22c4-9077-7ae4-8d5d-9087edb34a14_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">TOTAL ASSETS</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_019e22c4-9140-778f-82e4-82132850c66e_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNet" xlink:to="lab_us-gaap_InvestmentIncomeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_019e22c4-9140-7248-9de8-e22e2f577737_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_019e22c4-913f-7452-8c2e-25d8d0d1b015_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock available for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_LicenseAgreementMilestonePaymentsOutstandingAndPayable_019e22c4-9076-7c01-a869-050c666eff7e_terseLabel_en-US" xlink:label="lab_syre_LicenseAgreementMilestonePaymentsOutstandingAndPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payments, outstanding and payable</link:label>
    <link:label id="lab_syre_LicenseAgreementMilestonePaymentsOutstandingAndPayable_label_en-US" xlink:label="lab_syre_LicenseAgreementMilestonePaymentsOutstandingAndPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement, Milestone Payments Outstanding and Payable</link:label>
    <link:label id="lab_syre_LicenseAgreementMilestonePaymentsOutstandingAndPayable_documentation_en-US" xlink:label="lab_syre_LicenseAgreementMilestonePaymentsOutstandingAndPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Agreement, Milestone Payments Outstanding and Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_LicenseAgreementMilestonePaymentsOutstandingAndPayable" xlink:href="syre-20260630.xsd#syre_LicenseAgreementMilestonePaymentsOutstandingAndPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_LicenseAgreementMilestonePaymentsOutstandingAndPayable" xlink:to="lab_syre_LicenseAgreementMilestonePaymentsOutstandingAndPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_019e22c4-9140-71e3-8cd1-340d3ba63c99_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockAmountConverted1_019f5e67-f4a7-7896-bba3-7ec92c91ef6c_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountConverted1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of Series B non-voting convertible preferred stock into common stock</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockAmountConverted1_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountConverted1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Amount Converted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockAmountConverted1" xlink:to="lab_us-gaap_ConversionOfStockAmountConverted1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_019e22c4-9076-7793-aeb8-7b24a0bf6726_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities, gross unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_019e22c4-9076-78ef-aeb0-86e74ff1fe05_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_019e22c4-9076-7d48-90ce-950a23803390_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_019e22c4-913f-7047-82a8-6051519d4a47_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in connection with at-the-market and follow-on offering program, net of financing costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_019e22c4-913f-723b-86e0-fc0fb47a694f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related party accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019e22c4-9077-781b-a17e-a78bc045e627_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_019e22c4-913f-78a9-920f-c712a52ede6e_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_019e22c4-913f-7377-9207-5a3e80f5ae2e_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_019e22c4-913f-73bf-9c9e-d8104495c742_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_019e22c4-913f-704a-9d5a-dec26c74fd1d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock available for future issuance, additional amount authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019e22c4-9077-767c-a889-3e003d2459b3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units, Weighted Average Grant Date Fair Value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_019e22c4-9077-7bde-af76-0a571ee73645_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_019e22c4-9077-7d06-af9c-fe220f12f92c_totalLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents, amortized cost</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_019e22c4-913f-7b7a-b263-21f9e40e337d_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_019e22c4-913f-7e03-849c-64b08f52e980_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_019e22c4-913f-7860-9e58-bf4f8b0b50bf_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_019e22c4-9140-7468-9b9a-157b849b185d_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_019e22c4-9140-730e-bd0e-e9e3fcf37926_verboseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_019e22c4-9140-7b7f-a967-9fa7231cf82c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Significant Inputs Used to Estimate the Fair Value of CVR Liability</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e22c4-9077-798a-af00-db693074036d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_019e22c4-913f-72ce-bcda-d0882de7fc38_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized (loss) gain on marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_019e22c4-913f-7093-a6bd-38c65e409374_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_019e22c4-913f-7dcb-a803-1f51a12cd28a_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance, common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_019e22c4-913f-7561-98bd-75d11888156d_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance, common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_019e22c4-913f-7e73-8a27-f03958f73640_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_019e22c4-913f-7099-a178-5fdd86aa76cb_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_019e22c4-9076-778a-9ec5-0e1f78bad01f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_CashEquivalentsAndMarketableSecuritiesTable_019e22c4-9140-7870-8681-9b0e3f12d022_terseLabel_en-US" xlink:label="lab_syre_CashEquivalentsAndMarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Equivalents And Marketable Securities [Table]</link:label>
    <link:label id="lab_syre_CashEquivalentsAndMarketableSecuritiesTable_label_en-US" xlink:label="lab_syre_CashEquivalentsAndMarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents And Marketable Securities [Table]</link:label>
    <link:label id="lab_syre_CashEquivalentsAndMarketableSecuritiesTable_documentation_en-US" xlink:label="lab_syre_CashEquivalentsAndMarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash equivalents and marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_CashEquivalentsAndMarketableSecuritiesTable" xlink:href="syre-20260630.xsd#syre_CashEquivalentsAndMarketableSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_CashEquivalentsAndMarketableSecuritiesTable" xlink:to="lab_syre_CashEquivalentsAndMarketableSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_019e22c4-9077-7794-bc66-cf2edd9dc692_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_019e22c4-913f-7eb3-b682-4c980eed9092_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_019e22c4-9140-7ada-8616-a49bd323138e_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_019e22c4-9140-78cb-8ae0-add2cb09103e_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development, excluding compensation and share-based compensation</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019e22c4-913f-78f3-a97f-10cc06af8ff7_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_DeferredOfferingCostsAllocatedAmountOfProceedsOfIssuanceOfCommonStock_019e22c4-9140-7cbc-954e-1adef2758a96_terseLabel_en-US" xlink:label="lab_syre_DeferredOfferingCostsAllocatedAmountOfProceedsOfIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allocation of deferred offering costs against proceeds of issuance of common stock</link:label>
    <link:label id="lab_syre_DeferredOfferingCostsAllocatedAmountOfProceedsOfIssuanceOfCommonStock_label_en-US" xlink:label="lab_syre_DeferredOfferingCostsAllocatedAmountOfProceedsOfIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Offering Costs, Allocated Amount of Proceeds of Issuance of Common Stock</link:label>
    <link:label id="lab_syre_DeferredOfferingCostsAllocatedAmountOfProceedsOfIssuanceOfCommonStock_documentation_en-US" xlink:label="lab_syre_DeferredOfferingCostsAllocatedAmountOfProceedsOfIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Offering Costs, Allocated Amount of Proceeds of Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_DeferredOfferingCostsAllocatedAmountOfProceedsOfIssuanceOfCommonStock" xlink:href="syre-20260630.xsd#syre_DeferredOfferingCostsAllocatedAmountOfProceedsOfIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_DeferredOfferingCostsAllocatedAmountOfProceedsOfIssuanceOfCommonStock" xlink:to="lab_syre_DeferredOfferingCostsAllocatedAmountOfProceedsOfIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019e22c4-9140-7927-91fc-e4d7f2aa70e8_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019e22c4-913f-74a1-a11d-1064c7b0350e_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_A2016ESPPMember_019e22c4-913f-7674-9a2f-d78f2f725ad9_terseLabel_en-US" xlink:label="lab_syre_A2016ESPPMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2016 ESPP</link:label>
    <link:label id="lab_syre_A2016ESPPMember_label_en-US" xlink:label="lab_syre_A2016ESPPMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2016 ESPP [Member]</link:label>
    <link:label id="lab_syre_A2016ESPPMember_documentation_en-US" xlink:label="lab_syre_A2016ESPPMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2016 ESPP</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_A2016ESPPMember" xlink:href="syre-20260630.xsd#syre_A2016ESPPMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_A2016ESPPMember" xlink:to="lab_syre_A2016ESPPMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e22c4-9140-73e3-83de-b155a2d71e09_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_019e22c4-913f-7ca6-a1f2-6458141cba35_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Numerator</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_ParagonTherapeuticsIncMember_019e22c4-9140-7164-a51e-508b6b4c338b_terseLabel_en-US" xlink:label="lab_syre_ParagonTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Paragon Therapeutics Inc</link:label>
    <link:label id="lab_syre_ParagonTherapeuticsIncMember_label_en-US" xlink:label="lab_syre_ParagonTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Paragon Therapeutics Inc [Member]</link:label>
    <link:label id="lab_syre_ParagonTherapeuticsIncMember_documentation_en-US" xlink:label="lab_syre_ParagonTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Paragon therapeutics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_ParagonTherapeuticsIncMember" xlink:href="syre-20260630.xsd#syre_ParagonTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_ParagonTherapeuticsIncMember" xlink:to="lab_syre_ParagonTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_019e22c4-9077-77a8-a1ae-91f14fab2797_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in connection with at-the-market and follow-on offering program, net of financing costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_019e22c4-9076-7670-954d-01f4e661a80c_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Over-Allotment Option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_NumberOfDomesticBankingInstitutions_019e22c4-913f-7bbe-925a-b06065c8872f_terseLabel_en-US" xlink:label="lab_syre_NumberOfDomesticBankingInstitutions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of domestic banking institutions (in banks)</link:label>
    <link:label id="lab_syre_NumberOfDomesticBankingInstitutions_label_en-US" xlink:label="lab_syre_NumberOfDomesticBankingInstitutions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Domestic Banking Institutions</link:label>
    <link:label id="lab_syre_NumberOfDomesticBankingInstitutions_documentation_en-US" xlink:label="lab_syre_NumberOfDomesticBankingInstitutions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Domestic Banking Institutions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_NumberOfDomesticBankingInstitutions" xlink:href="syre-20260630.xsd#syre_NumberOfDomesticBankingInstitutions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_NumberOfDomesticBankingInstitutions" xlink:to="lab_syre_NumberOfDomesticBankingInstitutions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_019e22c4-9077-7227-b22b-de2e5623b2a1_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from employee stock option exercises and employee stock plan purchases</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_019e22c4-9140-7f2b-a211-5cc15c98d1e9_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_SublicensingFeeOutstandingAndPayable_019e22c4-9140-78a0-be74-f2b515a334a5_terseLabel_en-US" xlink:label="lab_syre_SublicensingFeeOutstandingAndPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sublicensing fee, outstanding and payable</link:label>
    <link:label id="lab_syre_SublicensingFeeOutstandingAndPayable_label_en-US" xlink:label="lab_syre_SublicensingFeeOutstandingAndPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sublicensing Fee, Outstanding And Payable</link:label>
    <link:label id="lab_syre_SublicensingFeeOutstandingAndPayable_documentation_en-US" xlink:label="lab_syre_SublicensingFeeOutstandingAndPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sublicensing Fee, Outstanding And Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_SublicensingFeeOutstandingAndPayable" xlink:href="syre-20260630.xsd#syre_SublicensingFeeOutstandingAndPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_SublicensingFeeOutstandingAndPayable" xlink:to="lab_syre_SublicensingFeeOutstandingAndPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_SublicensingFee_019e22c4-913f-7549-a493-682db9da60c6_terseLabel_en-US" xlink:label="lab_syre_SublicensingFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sublicensing fee</link:label>
    <link:label id="lab_syre_SublicensingFee_label_en-US" xlink:label="lab_syre_SublicensingFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sublicensing Fee</link:label>
    <link:label id="lab_syre_SublicensingFee_documentation_en-US" xlink:label="lab_syre_SublicensingFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sublicensing Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_SublicensingFee" xlink:href="syre-20260630.xsd#syre_SublicensingFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_SublicensingFee" xlink:to="lab_syre_SublicensingFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019e22c4-9140-7bca-a1a2-8aca856f34b6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019e22c4-9140-7ce9-baa0-0613420b9887_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_019e22c4-913f-7b67-855d-d971ecd90b0c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMonthlyInstallments_019e22c4-9076-7366-9d46-75531c03506a_terseLabel_en-US" xlink:label="lab_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMonthlyInstallments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of monthly installments</link:label>
    <link:label id="lab_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMonthlyInstallments_label_en-US" xlink:label="lab_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMonthlyInstallments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Monthly Installments</link:label>
    <link:label id="lab_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMonthlyInstallments_documentation_en-US" xlink:label="lab_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMonthlyInstallments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Monthly Installments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMonthlyInstallments" xlink:href="syre-20260630.xsd#syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMonthlyInstallments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMonthlyInstallments" xlink:to="lab_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMonthlyInstallments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_019e22c4-913f-7961-9193-347cd80e4edd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less Than 12 Months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_019e22c4-9140-7464-b559-0906d26ba23d_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_019e22c4-9140-7c2f-8fe7-8290beddc799_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_019e22c4-913f-7232-9375-9f3eec433851_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_019e22c4-913f-7259-9ea9-29aef54d343c_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_IssuanceOfConvertiblePreferredStockRelatedToPrivatePlacementUnpaidAmount_019e22c4-9140-711f-927d-8a973a2f1b7e_terseLabel_en-US" xlink:label="lab_syre_IssuanceOfConvertiblePreferredStockRelatedToPrivatePlacementUnpaidAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from stock option exercises received in subsequent period</link:label>
    <link:label id="lab_syre_IssuanceOfConvertiblePreferredStockRelatedToPrivatePlacementUnpaidAmount_label_en-US" xlink:label="lab_syre_IssuanceOfConvertiblePreferredStockRelatedToPrivatePlacementUnpaidAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of Convertible Preferred Stock Related to Private Placement, Unpaid Amount</link:label>
    <link:label id="lab_syre_IssuanceOfConvertiblePreferredStockRelatedToPrivatePlacementUnpaidAmount_documentation_en-US" xlink:label="lab_syre_IssuanceOfConvertiblePreferredStockRelatedToPrivatePlacementUnpaidAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Issuance of Convertible Preferred Stock Related to Private Placement, Unpaid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_IssuanceOfConvertiblePreferredStockRelatedToPrivatePlacementUnpaidAmount" xlink:href="syre-20260630.xsd#syre_IssuanceOfConvertiblePreferredStockRelatedToPrivatePlacementUnpaidAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_IssuanceOfConvertiblePreferredStockRelatedToPrivatePlacementUnpaidAmount" xlink:to="lab_syre_IssuanceOfConvertiblePreferredStockRelatedToPrivatePlacementUnpaidAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_019e22c4-913f-7f8e-9b3b-96cb2498111a_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_019e22c4-9140-73f6-a313-d337ac095842_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_AtTheMarketOffering2026SalesAgreementMember_019f84dd-5fe3-7381-a62d-3d39cfddf3c3_terseLabel_en-US" xlink:label="lab_syre_AtTheMarketOffering2026SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">At-The-Market Offering, 2026 Sales Agreement</link:label>
    <link:label id="lab_syre_AtTheMarketOffering2026SalesAgreementMember_label_en-US" xlink:label="lab_syre_AtTheMarketOffering2026SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At-The-Market Offering, 2026 Sales Agreement [Member]</link:label>
    <link:label id="lab_syre_AtTheMarketOffering2026SalesAgreementMember_documentation_en-US" xlink:label="lab_syre_AtTheMarketOffering2026SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">At-The-Market Offering, 2026 Sales Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_AtTheMarketOffering2026SalesAgreementMember" xlink:href="syre-20260630.xsd#syre_AtTheMarketOffering2026SalesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_AtTheMarketOffering2026SalesAgreementMember" xlink:to="lab_syre_AtTheMarketOffering2026SalesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_SaleOfStockRemainingAuthorizedAmount_019e22c4-9140-7019-a46d-c81b52e39946_terseLabel_en-US" xlink:label="lab_syre_SaleOfStockRemainingAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, remaining authorized amount</link:label>
    <link:label id="lab_syre_SaleOfStockRemainingAuthorizedAmount_label_en-US" xlink:label="lab_syre_SaleOfStockRemainingAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Remaining Authorized Amount</link:label>
    <link:label id="lab_syre_SaleOfStockRemainingAuthorizedAmount_documentation_en-US" xlink:label="lab_syre_SaleOfStockRemainingAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale of Stock, Remaining Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_SaleOfStockRemainingAuthorizedAmount" xlink:href="syre-20260630.xsd#syre_SaleOfStockRemainingAuthorizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_SaleOfStockRemainingAuthorizedAmount" xlink:to="lab_syre_SaleOfStockRemainingAuthorizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_019e22c4-913f-73cb-9f35-1d541cbb31b2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_019e22c4-913f-7f9d-9041-7187ad793d99_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Contractual Maturities of Marketable Securities at Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_019e22c4-913f-7541-954b-65bf8a7d018d_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_019e22c4-913f-7e31-81fd-5390f15eb0ad_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_019e22c4-913f-78f8-8e8d-b04f6428f097_netLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019e22c4-913f-7cd2-9289-af861cae719a_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_019e22c4-9140-7711-b800-97fdc5c749c9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty_019e22c4-913f-7b87-8f97-8f39523d6bf1_terseLabel_en-US" xlink:label="lab_syre_MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of ownership held in third party</link:label>
    <link:label id="lab_syre_MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty_label_en-US" xlink:label="lab_syre_MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minority Interest Ownership Percentage By Noncontrolling Owners Held In Third Party</link:label>
    <link:label id="lab_syre_MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty_documentation_en-US" xlink:label="lab_syre_MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Minority interest ownership percentage by noncontrolling owners held in third party.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty" xlink:href="syre-20260630.xsd#syre_MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty" xlink:to="lab_syre_MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_USBankingInstitutionMember_019e22c4-913f-7cc4-a19f-123931b17d43_terseLabel_en-US" xlink:label="lab_syre_USBankingInstitutionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. Banking Institution</link:label>
    <link:label id="lab_syre_USBankingInstitutionMember_label_en-US" xlink:label="lab_syre_USBankingInstitutionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">U.S. Banking Institution [Member]</link:label>
    <link:label id="lab_syre_USBankingInstitutionMember_documentation_en-US" xlink:label="lab_syre_USBankingInstitutionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">U.S. Banking Institution [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_USBankingInstitutionMember" xlink:href="syre-20260630.xsd#syre_USBankingInstitutionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_USBankingInstitutionMember" xlink:to="lab_syre_USBankingInstitutionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_019e22c4-9077-77a8-a4a4-e75d1cbfed98_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">12 Months or Longer</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_019e22c4-9076-720b-b0bb-a05cfc3c0810_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_019e22c4-9076-7830-9fc4-1c3b92f81c12_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities, estimated fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_019e22c4-9076-7353-8175-6825c3bbffd5_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_019e22c4-9076-7287-bf2c-47eecf25e527_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyMember_019e22c4-9140-7d5e-bd74-09a10065fac3_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyMember_label_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyMember" xlink:to="lab_us-gaap_RelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_019e22c4-9076-75d1-a0b7-3c1db4a4a6aa_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_ParagonAgreementLicenseMilestonePaymentsMember_019e22c4-913f-785a-9057-3d1bfa47f88d_terseLabel_en-US" xlink:label="lab_syre_ParagonAgreementLicenseMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License Agreement</link:label>
    <link:label id="lab_syre_ParagonAgreementLicenseMilestonePaymentsMember_label_en-US" xlink:label="lab_syre_ParagonAgreementLicenseMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Paragon Agreement, License Milestone Payments [Member]</link:label>
    <link:label id="lab_syre_ParagonAgreementLicenseMilestonePaymentsMember_documentation_en-US" xlink:label="lab_syre_ParagonAgreementLicenseMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Paragon Agreement, License Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_ParagonAgreementLicenseMilestonePaymentsMember" xlink:href="syre-20260630.xsd#syre_ParagonAgreementLicenseMilestonePaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_ParagonAgreementLicenseMilestonePaymentsMember" xlink:to="lab_syre_ParagonAgreementLicenseMilestonePaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_019e22c4-913f-7f8a-b892-e7d568d6a197_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_ParagonAgreementSubsequentToAssetAcquisitionMember_019e22c4-913f-771a-9bc3-557f6213c7e0_terseLabel_en-US" xlink:label="lab_syre_ParagonAgreementSubsequentToAssetAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent to Asset Acquisition</link:label>
    <link:label id="lab_syre_ParagonAgreementSubsequentToAssetAcquisitionMember_label_en-US" xlink:label="lab_syre_ParagonAgreementSubsequentToAssetAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Paragon Agreement, Subsequent to Asset Acquisition [Member]</link:label>
    <link:label id="lab_syre_ParagonAgreementSubsequentToAssetAcquisitionMember_documentation_en-US" xlink:label="lab_syre_ParagonAgreementSubsequentToAssetAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Paragon Agreement, Subsequent to Asset Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_ParagonAgreementSubsequentToAssetAcquisitionMember" xlink:href="syre-20260630.xsd#syre_ParagonAgreementSubsequentToAssetAcquisitionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_ParagonAgreementSubsequentToAssetAcquisitionMember" xlink:to="lab_syre_ParagonAgreementSubsequentToAssetAcquisitionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_CashEquivalentsUnrealizedGains_019e22c4-913f-71e3-82b1-4b1171d6d1ec_terseLabel_en-US" xlink:label="lab_syre_CashEquivalentsUnrealizedGains" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents, gross unrealized gains</link:label>
    <link:label id="lab_syre_CashEquivalentsUnrealizedGains_label_en-US" xlink:label="lab_syre_CashEquivalentsUnrealizedGains" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents Unrealized Gains</link:label>
    <link:label id="lab_syre_CashEquivalentsUnrealizedGains_documentation_en-US" xlink:label="lab_syre_CashEquivalentsUnrealizedGains" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash equivalents unrealized gains.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_CashEquivalentsUnrealizedGains" xlink:href="syre-20260630.xsd#syre_CashEquivalentsUnrealizedGains"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_CashEquivalentsUnrealizedGains" xlink:to="lab_syre_CashEquivalentsUnrealizedGains" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_019e22c4-9140-7ce3-b577-76f2b5bdea27_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_019e22c4-913f-76f3-9f13-dc0097cbdfb9_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_019e22c4-9140-738b-84d6-0168c9da34c4_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Trade</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_019fa2d9-8816-7401-b2bb-58f7e3bd1693_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Payment to CVR holders</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_019e22c4-913f-7b24-890d-f5aac441ceb1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019e22c4-913f-79eb-af3a-2f70204528d9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_019e22c4-9140-7c47-aa46-ee2fa3659ca8_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Pegzilarginase to Immedica</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_019e22c4-913f-733d-b37f-6c138b14a605_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_Spy001LicenseAgreementMember_019e22c4-913f-70df-8454-0875e06016a2_terseLabel_en-US" xlink:label="lab_syre_Spy001LicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SPY001 License Agreement</link:label>
    <link:label id="lab_syre_Spy001LicenseAgreementMember_label_en-US" xlink:label="lab_syre_Spy001LicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SPY001 License Agreement [Member]</link:label>
    <link:label id="lab_syre_Spy001LicenseAgreementMember_documentation_en-US" xlink:label="lab_syre_Spy001LicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">SPY001 License Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_Spy001LicenseAgreementMember" xlink:href="syre-20260630.xsd#syre_Spy001LicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_Spy001LicenseAgreementMember" xlink:to="lab_syre_Spy001LicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_019e22c4-913f-776f-9650-34fc05084f3a_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019e22c4-9140-7e2a-b27b-beca63c63ea8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest_019e22c4-9140-76da-8bc1-761aa956a90a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowance for credit loss</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Allowance for Credit Loss, Excluding Accrued Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_019e22c4-9140-7d6b-8e26-a73d448f6dd4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-Sale Securities in an Unrealized Loss Position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_019e22c4-9140-7d25-a97a-4386edb4056f_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_019e22c4-9076-715f-b71e-167f50b12c83_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract_019e22c4-9140-7fee-ab00-0f561c343a4e_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH AND CASH EQUIVALENTS</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_AssetAcquisitionCashPaymentThresholdPeriod_019e22c4-9076-78c9-9841-295016bb8636_terseLabel_en-US" xlink:label="lab_syre_AssetAcquisitionCashPaymentThresholdPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset acquisition, cash payment, threshold period (in years)</link:label>
    <link:label id="lab_syre_AssetAcquisitionCashPaymentThresholdPeriod_label_en-US" xlink:label="lab_syre_AssetAcquisitionCashPaymentThresholdPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition, Cash Payment, Threshold Period</link:label>
    <link:label id="lab_syre_AssetAcquisitionCashPaymentThresholdPeriod_documentation_en-US" xlink:label="lab_syre_AssetAcquisitionCashPaymentThresholdPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Asset Acquisition, Cash Payment, Threshold Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_AssetAcquisitionCashPaymentThresholdPeriod" xlink:href="syre-20260630.xsd#syre_AssetAcquisitionCashPaymentThresholdPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_AssetAcquisitionCashPaymentThresholdPeriod" xlink:to="lab_syre_AssetAcquisitionCashPaymentThresholdPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_019e22c4-913f-7a84-adea-d22f5b9f607e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_019e22c4-913f-7696-b191-8dfc27088c7b_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_019e22c4-9077-7fc1-af95-895935a5a5fc_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_019e22c4-913f-70f5-acb3-5ad02a7fffe3_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_019e22c4-9076-7e0d-af8f-90a93a7d2888_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_019e22c4-9140-719f-bbb1-a8d805369a1d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_019e22c4-913f-753d-a77d-98cc37c8ffcd_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_019e22c4-9077-75b2-bcf8-53d02205cbc8_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less Than 12 Months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019e22c4-9077-7194-9b5d-9442c4d5632f_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_019e22c4-9076-7e2e-afdc-a8c52115f75a_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies (Notes 6 and 7)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_019e22c4-9140-7470-b293-499c40111a4e_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_ImpairmentOfMarketableSecurities_019e22c4-913f-7cb9-ba65-5c4b2db80718_terseLabel_en-US" xlink:label="lab_syre_ImpairmentOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of marketable securities</link:label>
    <link:label id="lab_syre_ImpairmentOfMarketableSecurities_label_en-US" xlink:label="lab_syre_ImpairmentOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment Of Marketable Securities</link:label>
    <link:label id="lab_syre_ImpairmentOfMarketableSecurities_documentation_en-US" xlink:label="lab_syre_ImpairmentOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Impairment of marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_ImpairmentOfMarketableSecurities" xlink:href="syre-20260630.xsd#syre_ImpairmentOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_ImpairmentOfMarketableSecurities" xlink:to="lab_syre_ImpairmentOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_PaymentForDeferredOfferingCosts_019e22c4-9077-72e7-a27c-b4eca339b340_negatedTerseLabel_en-US" xlink:label="lab_syre_PaymentForDeferredOfferingCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment of deferred offering costs in connection with shelf registration</link:label>
    <link:label id="lab_syre_PaymentForDeferredOfferingCosts_label_en-US" xlink:label="lab_syre_PaymentForDeferredOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment For Deferred Offering Costs</link:label>
    <link:label id="lab_syre_PaymentForDeferredOfferingCosts_documentation_en-US" xlink:label="lab_syre_PaymentForDeferredOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payment For Deferred Offering Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_PaymentForDeferredOfferingCosts" xlink:href="syre-20260630.xsd#syre_PaymentForDeferredOfferingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_PaymentForDeferredOfferingCosts" xlink:to="lab_syre_PaymentForDeferredOfferingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_019e22c4-9140-70ee-89f5-933b54f45341_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vest period grant date (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_019e22c4-9140-740c-bdea-9d54a2c82b81_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based award, vesting period (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019e22c4-9077-7d1a-bd4c-db9358ca35e0_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_019e22c4-9140-76bd-8ac7-697cd6850663_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e22c4-913f-7622-80c6-997bf9dee1c6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_ParagonAndLicenseAgreementMember_019e22c4-9140-76af-b9a1-efade1756f96_terseLabel_en-US" xlink:label="lab_syre_ParagonAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Paragon and License Agreement</link:label>
    <link:label id="lab_syre_ParagonAndLicenseAgreementMember_label_en-US" xlink:label="lab_syre_ParagonAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Paragon and License Agreement [Member]</link:label>
    <link:label id="lab_syre_ParagonAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_syre_ParagonAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Paragon and License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_ParagonAndLicenseAgreementMember" xlink:href="syre-20260630.xsd#syre_ParagonAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_ParagonAndLicenseAgreementMember" xlink:to="lab_syre_ParagonAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_019e22c4-9140-7712-92a0-0ec0fe840fba_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_019e22c4-9140-773c-b736-ae943f17f447_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan_019e22c4-9077-7823-8c1d-4d695a97e5b6_terseLabel_en-US" xlink:label="lab_syre_StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in connection with exercise of stock options and employee stock purchase plan</link:label>
    <link:label id="lab_syre_StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan_label_en-US" xlink:label="lab_syre_StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Options Exercised And Employee Stock Ownership Plan</link:label>
    <link:label id="lab_syre_StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan_documentation_en-US" xlink:label="lab_syre_StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Options Exercised And Employee Stock Ownership Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan" xlink:href="syre-20260630.xsd#syre_StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan" xlink:to="lab_syre_StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_019e22c4-913f-7a6a-a94a-a00d1e8d5897_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">US Government Agencies Debt Securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_019e22c4-9140-77e0-bcf8-0a3624b273ca_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_019e22c4-9140-745a-b9f5-19cbc7f0d1ca_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of ownership by noncontrolling owner</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary, Ownership Percentage, Noncontrolling Owner</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_AssetAcquisitionStockholderPaymentPeriod_019e22c4-9140-7e1b-bfe3-4cc7754ae949_verboseLabel_en-US" xlink:label="lab_syre_AssetAcquisitionStockholderPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Asset acquisition, stockholder payment period (in years)</link:label>
    <link:label id="lab_syre_AssetAcquisitionStockholderPaymentPeriod_label_en-US" xlink:label="lab_syre_AssetAcquisitionStockholderPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition, Stockholder Payment Period</link:label>
    <link:label id="lab_syre_AssetAcquisitionStockholderPaymentPeriod_documentation_en-US" xlink:label="lab_syre_AssetAcquisitionStockholderPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Asset Acquisition, Stockholder Payment Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_AssetAcquisitionStockholderPaymentPeriod" xlink:href="syre-20260630.xsd#syre_AssetAcquisitionStockholderPaymentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_AssetAcquisitionStockholderPaymentPeriod" xlink:to="lab_syre_AssetAcquisitionStockholderPaymentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_019e22c4-9076-7452-a2a6-de5fc259c0a4_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_019e22c4-9076-737f-b63c-fe6b8935cf24_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities and Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_ProceedsFromRaisingCapital_019e22c4-9140-7456-a81d-56fd5889cc71_terseLabel_en-US" xlink:label="lab_syre_ProceedsFromRaisingCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from raising capital</link:label>
    <link:label id="lab_syre_ProceedsFromRaisingCapital_label_en-US" xlink:label="lab_syre_ProceedsFromRaisingCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Raising Capital</link:label>
    <link:label id="lab_syre_ProceedsFromRaisingCapital_documentation_en-US" xlink:label="lab_syre_ProceedsFromRaisingCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Raising Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_ProceedsFromRaisingCapital" xlink:href="syre-20260630.xsd#syre_ProceedsFromRaisingCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_ProceedsFromRaisingCapital" xlink:to="lab_syre_ProceedsFromRaisingCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_019e22c4-913f-732f-89e5-0da88361ed54_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, and marketable securities</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingOtherItemAmount_019e22c4-913f-762b-bdb7-7a9d59cb6bd5_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other segment items</link:label>
    <link:label id="lab_us-gaap_SegmentReportingOtherItemAmount_label_en-US" xlink:label="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Other Segment Item, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingOtherItemAmount" xlink:to="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_019e22c4-9140-798e-b21e-a4ae90de4294_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_019fb96c-9098-7ae9-a66f-f2b8e41f3dc1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_SPY003LicenseAgreementMember_019e22c4-913f-7c59-acb3-e02db2d06b7b_terseLabel_en-US" xlink:label="lab_syre_SPY003LicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SPY003 License Agreement</link:label>
    <link:label id="lab_syre_SPY003LicenseAgreementMember_label_en-US" xlink:label="lab_syre_SPY003LicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SPY003 License Agreement [Member]</link:label>
    <link:label id="lab_syre_SPY003LicenseAgreementMember_documentation_en-US" xlink:label="lab_syre_SPY003LicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">SPY003 License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_SPY003LicenseAgreementMember" xlink:href="syre-20260630.xsd#syre_SPY003LicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_SPY003LicenseAgreementMember" xlink:to="lab_syre_SPY003LicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019e22c4-9077-76c5-a324-faca16c07fc2_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019e22c4-9077-7499-9748-0e1b84a45036_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">End of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_019e22c4-9140-7263-9ade-88b75ee94852_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued professional and consulting fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_019e22c4-913f-7b89-a152-035a1c21b2ab_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_019e22c4-913f-79aa-bad9-48c6bb48de4a_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_019e22c4-9140-7233-8cc2-20f574986471_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">The Company and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_019e22c4-9140-76ca-b76a-1bbe1755b606_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_ParapyreWarrantsMember_019e22c4-913f-7625-81d7-2cd5fd7626f9_terseLabel_en-US" xlink:label="lab_syre_ParapyreWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Parapyre warrants</link:label>
    <link:label id="lab_syre_ParapyreWarrantsMember_label_en-US" xlink:label="lab_syre_ParapyreWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Parapyre Warrants [Member]</link:label>
    <link:label id="lab_syre_ParapyreWarrantsMember_documentation_en-US" xlink:label="lab_syre_ParapyreWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Parapyre Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_ParapyreWarrantsMember" xlink:href="syre-20260630.xsd#syre_ParapyreWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_ParapyreWarrantsMember" xlink:to="lab_syre_ParapyreWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_ServiceBasedAwardsMember_019e22c4-9076-7ecd-88e9-924a19379f1d_terseLabel_en-US" xlink:label="lab_syre_ServiceBasedAwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Service Based Awards</link:label>
    <link:label id="lab_syre_ServiceBasedAwardsMember_label_en-US" xlink:label="lab_syre_ServiceBasedAwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Service Based Awards [Member]</link:label>
    <link:label id="lab_syre_ServiceBasedAwardsMember_documentation_en-US" xlink:label="lab_syre_ServiceBasedAwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Service-based awards.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_ServiceBasedAwardsMember" xlink:href="syre-20260630.xsd#syre_ServiceBasedAwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_ServiceBasedAwardsMember" xlink:to="lab_syre_ServiceBasedAwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019e22c4-9077-7362-a56e-b064e53fff74_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_019e22c4-913f-7dae-a652-34b3872f7fa5_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of Series B Non-Voting Convertible Preferred Stock to common Stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_019e22c4-913f-709a-8a99-9c6a7801dab9_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_019e22c4-913f-7d6a-a186-ec374c848225_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount of related party transaction</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_019e22c4-913f-7091-86f2-9afab73682c9_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_019e22c4-913f-7a43-adfb-b35db31026ec_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_FairmountFundsManagementLlcMember_019e22c4-913f-71c3-a2a5-48c5622651f9_terseLabel_en-US" xlink:label="lab_syre_FairmountFundsManagementLlcMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fairmount Funds Management LLC</link:label>
    <link:label id="lab_syre_FairmountFundsManagementLlcMember_label_en-US" xlink:label="lab_syre_FairmountFundsManagementLlcMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fairmount Funds Management LLC [Member]</link:label>
    <link:label id="lab_syre_FairmountFundsManagementLlcMember_documentation_en-US" xlink:label="lab_syre_FairmountFundsManagementLlcMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fairmount Funds Management LLC.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_FairmountFundsManagementLlcMember" xlink:href="syre-20260630.xsd#syre_FairmountFundsManagementLlcMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_FairmountFundsManagementLlcMember" xlink:to="lab_syre_FairmountFundsManagementLlcMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_019e22c4-9140-7932-b6ae-57bc5af0cc6f_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_019e22c4-913f-7ac8-ba00-9da7ee78666f_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_AmountToBePaidUnderAgreement_019e22c4-913f-7664-a397-19588885028e_terseLabel_en-US" xlink:label="lab_syre_AmountToBePaidUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent obligation based on milestones</link:label>
    <link:label id="lab_syre_AmountToBePaidUnderAgreement_label_en-US" xlink:label="lab_syre_AmountToBePaidUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amount To Be Paid Under Agreement</link:label>
    <link:label id="lab_syre_AmountToBePaidUnderAgreement_documentation_en-US" xlink:label="lab_syre_AmountToBePaidUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount to be paid under agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_AmountToBePaidUnderAgreement" xlink:href="syre-20260630.xsd#syre_AmountToBePaidUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_AmountToBePaidUnderAgreement" xlink:to="lab_syre_AmountToBePaidUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_019e22c4-913f-7713-9846-7eb5444a712a_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_019e22c4-9140-7b9d-8c87-7eb82c967d41_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_019e22c4-9140-7577-876f-2a4cc0530f4b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock_019e22c4-913f-7a4f-a8a3-76c9a7e64253_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock Awards Granted Under all Equity Incentive and Inducement Plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_019e22c4-913f-7756-bf1e-40e473e04891_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_019e22c4-913f-7511-90de-f4f6723a8ce8_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_019e22c4-913f-7c59-9a61-47fbe70558d7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gain on sale of in-process research and development asset</link:label>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_019e22c4-913f-7a14-9b76-c292038780b2_negatedLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gain on sale of in-process research and development asset</link:label>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_019e22c4-913f-7567-a0b4-9795a0c5475d_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on sale of in-process research and development asset</link:label>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_label_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:to="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_019e22c4-913f-7222-9c79-50c098495e51_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial assets</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_019e22c4-9140-74af-9ad3-db468ff0ff5d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayable_019e22c4-9140-768c-bb90-4908e1039f2b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related party accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_019e22c4-9077-7905-8e72-2c91c6cd9795_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_TwoThousandAndEighteenEquityInducementPlanMember_019e22c4-913f-7bd6-9ee4-c109b8cafd47_terseLabel_en-US" xlink:label="lab_syre_TwoThousandAndEighteenEquityInducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2018 Equity Inducement Plan</link:label>
    <link:label id="lab_syre_TwoThousandAndEighteenEquityInducementPlanMember_label_en-US" xlink:label="lab_syre_TwoThousandAndEighteenEquityInducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand And Eighteen Equity Inducement Plan [Member]</link:label>
    <link:label id="lab_syre_TwoThousandAndEighteenEquityInducementPlanMember_documentation_en-US" xlink:label="lab_syre_TwoThousandAndEighteenEquityInducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2018 equity inducement plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_TwoThousandAndEighteenEquityInducementPlanMember" xlink:href="syre-20260630.xsd#syre_TwoThousandAndEighteenEquityInducementPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_TwoThousandAndEighteenEquityInducementPlanMember" xlink:to="lab_syre_TwoThousandAndEighteenEquityInducementPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_019e22c4-9140-7519-b6fa-215ee8e59f47_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_019e22c4-913f-7992-809a-c274444f9209_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_HeidyKingJonesMember_label_en-US" xlink:label="lab_syre_HeidyKingJonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Heidy King-Jones [Member]</link:label>
    <link:label id="lab_syre_HeidyKingJonesMember_documentation_en-US" xlink:label="lab_syre_HeidyKingJonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Heidy King-Jones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_HeidyKingJonesMember" xlink:href="syre-20260630.xsd#syre_HeidyKingJonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_HeidyKingJonesMember" xlink:to="lab_syre_HeidyKingJonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_019e22c4-9076-7e9a-8afb-1a17dbfef608_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Licensing Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_019e22c4-913f-7e12-be8f-f678c21bc553_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_019e22c4-9140-78a4-8709-72023349614f_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current CVR liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_019e22c4-9077-7e95-800d-d5a62a84e1ca_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Salaries, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalariesCurrent" xlink:to="lab_us-gaap_AccruedSalariesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_019e22c4-9140-767c-b072-6a0512cb6c40_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_019e22c4-9140-7891-8d98-774e890ee6bf_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockConvertibleSharesIssuable_019e22c4-913f-70e8-9f38-6e06eed0e7ee_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockConvertibleSharesIssuable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of common shares issuable upon conversion (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockConvertibleSharesIssuable_label_en-US" xlink:label="lab_us-gaap_PreferredStockConvertibleSharesIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Convertible, Shares Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockConvertibleSharesIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockConvertibleSharesIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockConvertibleSharesIssuable" xlink:to="lab_us-gaap_PreferredStockConvertibleSharesIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_019e22c4-9140-746e-a836-9f1bce63c234_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_019e22c4-913f-744e-a22e-f84a8208762f_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_CompanyAndBasisOfPresentationLineItems_019e22c4-9077-717e-9937-649dfd95a531_terseLabel_en-US" xlink:label="lab_syre_CompanyAndBasisOfPresentationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company and Basis of Presentation [Line Items]</link:label>
    <link:label id="lab_syre_CompanyAndBasisOfPresentationLineItems_label_en-US" xlink:label="lab_syre_CompanyAndBasisOfPresentationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company and Basis of Presentation [Line Items]</link:label>
    <link:label id="lab_syre_CompanyAndBasisOfPresentationLineItems_documentation_en-US" xlink:label="lab_syre_CompanyAndBasisOfPresentationLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Company and basis of presentation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_CompanyAndBasisOfPresentationLineItems" xlink:href="syre-20260630.xsd#syre_CompanyAndBasisOfPresentationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_CompanyAndBasisOfPresentationLineItems" xlink:to="lab_syre_CompanyAndBasisOfPresentationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_019e22c4-9140-7a53-8239-f886afc90617_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityMeasurementInput_019e22c4-9140-77b6-936e-0d1b7e1d6bc7_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative liability, measurement input</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativeLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityMeasurementInput" xlink:to="lab_us-gaap_DerivativeLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_019e22c4-9140-7ad4-ae02-fc438f5245d6_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_019e22c4-9076-7eb7-b809-248c16f0a7c8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_019e22c4-9077-7519-a11d-8444c0f3f05d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other (expense) income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_019e22c4-9076-7966-8d85-69e9504ba70a_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_019fb96d-2274-780d-924b-3e2e6ac8e28c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_019e22c4-913f-7dbf-97f5-f2d23a3a7239_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_019e22c4-9076-78e6-8de4-80e0077e7845_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of Series B Non-Voting Convertible Preferred Stock to common stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_019e22c4-9076-78cc-b7d6-19ae451403e3_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_019e22c4-9077-7bd3-a0f5-5f992eaf1bd9_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_019e22c4-913f-7946-a34a-0538b992e4ef_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_OtherParagonReimbursableExpensesMember_019e22c4-9076-78c4-ae9a-eef55371f29c_terseLabel_en-US" xlink:label="lab_syre_OtherParagonReimbursableExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Paragon Reimbursable Expenses</link:label>
    <link:label id="lab_syre_OtherParagonReimbursableExpensesMember_label_en-US" xlink:label="lab_syre_OtherParagonReimbursableExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Paragon Reimbursable Expenses [Member]</link:label>
    <link:label id="lab_syre_OtherParagonReimbursableExpensesMember_documentation_en-US" xlink:label="lab_syre_OtherParagonReimbursableExpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Paragon Reimbursable Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_OtherParagonReimbursableExpensesMember" xlink:href="syre-20260630.xsd#syre_OtherParagonReimbursableExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_OtherParagonReimbursableExpensesMember" xlink:to="lab_syre_OtherParagonReimbursableExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_019e22c4-9140-7811-b238-53a5ccc4c738_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_JeffreyAlbersMember_label_en-US" xlink:label="lab_syre_JeffreyAlbersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Jeffrey Albers [Member]</link:label>
    <link:label id="lab_syre_JeffreyAlbersMember_documentation_en-US" xlink:label="lab_syre_JeffreyAlbersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Jeffrey Albers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_JeffreyAlbersMember" xlink:href="syre-20260630.xsd#syre_JeffreyAlbersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_JeffreyAlbersMember" xlink:to="lab_syre_JeffreyAlbersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_019e22c4-9076-7891-a8da-e403daeade98_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total financial assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_019e22c4-9076-7aa5-b0ed-e498a7e8c1b6_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019e22c4-9076-7177-b59e-4e1362e40e7d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_019e22c4-9076-7a42-bb26-c0b581d7ec9b_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_019e22c4-9077-7296-8f31-e65bbb9d247d_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_019e22c4-9140-7f9f-a14b-1fb64b377da0_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total, fair value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets_019e22c4-913f-7411-9978-a85f11ed9782_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of in-process research and development asset</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets_019e22c4-913f-7020-842a-646f2c240aa3_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of in-process research and development asset</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:to="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestReceivable_019e22c4-9140-7ccb-92f4-32564ddd8ee9_terseLabel_en-US" xlink:label="lab_us-gaap_InterestReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued interest receivable on available-for-sale debt securities</link:label>
    <link:label id="lab_us-gaap_InterestReceivable_label_en-US" xlink:label="lab_us-gaap_InterestReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestReceivable" xlink:to="lab_us-gaap_InterestReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_019e22c4-913f-73c5-8f4f-78e8debf4de6_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_019e22c4-9076-7167-adc7-1ace473c4a5c_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of CVR liability</link:label>
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_label_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Derivative Instruments, Net, Pretax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:to="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_019e22c4-9140-7532-a330-2a87a38e93c8_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Significant Expenses Provided to the CODM on a Regular Basis</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Reconciliation of Profit (Loss) by Segment to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine3_019e22c4-913f-7585-8aed-6690da2a86ee_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Three</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine3_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine3" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine3"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine3" xlink:to="lab_dei_EntityAddressAddressLine3" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_019e22c4-9076-766e-8d7f-fdede0bc2ce5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_019e22c4-913f-7c77-80c0-e297d10fe306_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_019e22c4-913f-771a-b3dc-2b32af6ed52f_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper, Not Included with Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_019e22c4-913f-783c-8814-56f5a00241e0_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CURRENT ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_019e22c4-9140-7323-a35e-69ec37c0e97c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CVR liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_019e22c4-9077-7fa4-9680-fc5630851d90_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_SPY002AndSPY072LicenseAgreementMember_019e22c4-913f-7a10-8984-acb5f1f03e6a_terseLabel_en-US" xlink:label="lab_syre_SPY002AndSPY072LicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SPY002 and SPY072 License Agreement</link:label>
    <link:label id="lab_syre_SPY002AndSPY072LicenseAgreementMember_label_en-US" xlink:label="lab_syre_SPY002AndSPY072LicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SPY002 And SPY 072 License Agreement [Member]</link:label>
    <link:label id="lab_syre_SPY002AndSPY072LicenseAgreementMember_documentation_en-US" xlink:label="lab_syre_SPY002AndSPY072LicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">SPY002 And SPY 072 License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_SPY002AndSPY072LicenseAgreementMember" xlink:href="syre-20260630.xsd#syre_SPY002AndSPY072LicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_SPY002AndSPY072LicenseAgreementMember" xlink:to="lab_syre_SPY002AndSPY072LicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_019e22c4-913f-7016-9305-676d431eb901_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019e22c4-9076-708e-b902-1729325d1dc3_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_019e22c4-913f-7733-b213-4e85790ed6fe_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Equivalents and Marketable Securities</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, and Marketable Security [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_TwoThousandAndSixteenEmployeeStockPurchasePlanMember_019e22c4-9077-7cf9-9df3-ff11a44e5b9a_terseLabel_en-US" xlink:label="lab_syre_TwoThousandAndSixteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2016 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_syre_TwoThousandAndSixteenEmployeeStockPurchasePlanMember_019e22c4-9077-7a29-92e0-ecc603b4c5ad_verboseLabel_en-US" xlink:label="lab_syre_TwoThousandAndSixteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2016 ESPP</link:label>
    <link:label id="lab_syre_TwoThousandAndSixteenEmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_syre_TwoThousandAndSixteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand And Sixteen Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_syre_TwoThousandAndSixteenEmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_syre_TwoThousandAndSixteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two thousand and sixteen employee stock purchase plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_TwoThousandAndSixteenEmployeeStockPurchasePlanMember" xlink:href="syre-20260630.xsd#syre_TwoThousandAndSixteenEmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_TwoThousandAndSixteenEmployeeStockPurchasePlanMember" xlink:to="lab_syre_TwoThousandAndSixteenEmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_019e22c4-9140-75eb-a568-be11dd1132ad_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_019e22c4-9140-7e73-91ad-65f8d1147dea_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total related party expense (excludes stock-based compensation)</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_syre_ContingentValueRightLiabilityMember_019e22c4-913f-74db-a3c0-75fb66e27280_terseLabel_en-US" xlink:label="lab_syre_ContingentValueRightLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CVR liability</link:label>
    <link:label id="lab_syre_ContingentValueRightLiabilityMember_019e22c4-913f-7c1a-a298-cf86e502cb93_verboseLabel_en-US" xlink:label="lab_syre_ContingentValueRightLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">CVR Liability</link:label>
    <link:label id="lab_syre_ContingentValueRightLiabilityMember_label_en-US" xlink:label="lab_syre_ContingentValueRightLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Value Right Liability [Member]</link:label>
    <link:label id="lab_syre_ContingentValueRightLiabilityMember_documentation_en-US" xlink:label="lab_syre_ContingentValueRightLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent Value Right Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_syre_ContingentValueRightLiabilityMember" xlink:href="syre-20260630.xsd#syre_ContingentValueRightLiabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_ContingentValueRightLiabilityMember" xlink:to="lab_syre_ContingentValueRightLiabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_019e22c4-913f-7b91-a90d-4cc23f8dbbf1_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_019e22c4-913f-72fa-be17-8753f87f1ed5_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_019e22c4-913f-766d-94b8-e4b83fb462d8_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_019e22c4-913f-74a7-a852-53d5e724971a_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Allocation of losses</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFDICInsuredAmount_019e22c4-9140-7c59-8101-d21a8795fe4f_terseLabel_en-US" xlink:label="lab_us-gaap_CashFDICInsuredAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, FDIC insured amount (up to)</link:label>
    <link:label id="lab_us-gaap_CashFDICInsuredAmount_label_en-US" xlink:label="lab_us-gaap_CashFDICInsuredAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, FDIC Insured Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFDICInsuredAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashFDICInsuredAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFDICInsuredAmount" xlink:to="lab_us-gaap_CashFDICInsuredAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_019e22c4-913f-7442-a7ea-60244d3ab76f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_019e22c4-9140-7d62-876e-140a3eeeae5e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_019e22c4-9140-71a3-8ce8-bd77e0d3cdb9_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_019e22c4-9076-7f6b-be00-c061c85a456d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>syre-20260630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019e22c4-8e13-79c8-aa17-b3b58ba33655,g:1a770671-d821-405f-804e-c086c0f29bbb-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://spyre.com/role/Cover" xlink:type="simple" xlink:href="syre-20260630.xsd#Cover"/>
  <link:presentationLink xlink:role="http://spyre.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_019e22c4-8fac-771d-b282-04648db2fe48" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_019e22c4-8fac-7355-a262-19037a4efc53" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e22c4-8fac-771d-b282-04648db2fe48" xlink:to="loc_dei_DocumentType_019e22c4-8fac-7355-a262-19037a4efc53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_019e22c4-8fac-76c5-89c5-1500649a7af9" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e22c4-8fac-771d-b282-04648db2fe48" xlink:to="loc_dei_DocumentQuarterlyReport_019e22c4-8fac-76c5-89c5-1500649a7af9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_019e22c4-8fac-741a-a61a-147f4eeb674f" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e22c4-8fac-771d-b282-04648db2fe48" xlink:to="loc_dei_DocumentPeriodEndDate_019e22c4-8fac-741a-a61a-147f4eeb674f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_019e22c4-8fac-77d6-acc4-93fdec7f7f5d" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e22c4-8fac-771d-b282-04648db2fe48" xlink:to="loc_dei_DocumentTransitionReport_019e22c4-8fac-77d6-acc4-93fdec7f7f5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_019e22c4-8fac-7feb-bfc7-6e0038d952ae" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e22c4-8fac-771d-b282-04648db2fe48" xlink:to="loc_dei_EntityFileNumber_019e22c4-8fac-7feb-bfc7-6e0038d952ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_019e22c4-8fac-7716-b38a-d8ab95fb0696" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e22c4-8fac-771d-b282-04648db2fe48" xlink:to="loc_dei_EntityRegistrantName_019e22c4-8fac-7716-b38a-d8ab95fb0696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_019e22c4-8fac-784c-b2d1-ec3ed18bc25b" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e22c4-8fac-771d-b282-04648db2fe48" xlink:to="loc_dei_EntityIncorporationStateCountryCode_019e22c4-8fac-784c-b2d1-ec3ed18bc25b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_019e22c4-8fac-72aa-a72a-1aab5ef648cc" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e22c4-8fac-771d-b282-04648db2fe48" xlink:to="loc_dei_EntityTaxIdentificationNumber_019e22c4-8fac-72aa-a72a-1aab5ef648cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_019e22c4-8fac-730d-a08d-5901fc342da3" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e22c4-8fac-771d-b282-04648db2fe48" xlink:to="loc_dei_EntityAddressAddressLine1_019e22c4-8fac-730d-a08d-5901fc342da3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_019e22c4-8fac-7748-a3d4-46ae8cfbecb8" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e22c4-8fac-771d-b282-04648db2fe48" xlink:to="loc_dei_EntityAddressAddressLine2_019e22c4-8fac-7748-a3d4-46ae8cfbecb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine3_019e22c4-8fac-7192-b32d-30058d966d06" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine3"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e22c4-8fac-771d-b282-04648db2fe48" xlink:to="loc_dei_EntityAddressAddressLine3_019e22c4-8fac-7192-b32d-30058d966d06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_019e22c4-8fac-7e48-bf9c-1a41ce4d9fd3" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e22c4-8fac-771d-b282-04648db2fe48" xlink:to="loc_dei_EntityAddressCityOrTown_019e22c4-8fac-7e48-bf9c-1a41ce4d9fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_019e22c4-8fac-742b-87c8-daec8d11250c" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e22c4-8fac-771d-b282-04648db2fe48" xlink:to="loc_dei_EntityAddressStateOrProvince_019e22c4-8fac-742b-87c8-daec8d11250c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_019e22c4-8fac-71fe-9b45-870ad533da33" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e22c4-8fac-771d-b282-04648db2fe48" xlink:to="loc_dei_EntityAddressPostalZipCode_019e22c4-8fac-71fe-9b45-870ad533da33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_019e22c4-8fac-7caa-92fc-4ba8945f7f77" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e22c4-8fac-771d-b282-04648db2fe48" xlink:to="loc_dei_CityAreaCode_019e22c4-8fac-7caa-92fc-4ba8945f7f77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_019e22c4-8fac-7958-8a95-7d4934a8c56e" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e22c4-8fac-771d-b282-04648db2fe48" xlink:to="loc_dei_LocalPhoneNumber_019e22c4-8fac-7958-8a95-7d4934a8c56e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_019e22c4-8fac-78bc-95ed-cadda32737d4" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e22c4-8fac-771d-b282-04648db2fe48" xlink:to="loc_dei_Security12bTitle_019e22c4-8fac-78bc-95ed-cadda32737d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_019e22c4-8fac-7e87-a898-f567ddb39eec" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e22c4-8fac-771d-b282-04648db2fe48" xlink:to="loc_dei_TradingSymbol_019e22c4-8fac-7e87-a898-f567ddb39eec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_019e22c4-8fac-77e3-bd94-786cc2ac09f7" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e22c4-8fac-771d-b282-04648db2fe48" xlink:to="loc_dei_SecurityExchangeName_019e22c4-8fac-77e3-bd94-786cc2ac09f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_019e22c4-8fac-757b-af16-cf46c1a5313c" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e22c4-8fac-771d-b282-04648db2fe48" xlink:to="loc_dei_EntityInteractiveDataCurrent_019e22c4-8fac-757b-af16-cf46c1a5313c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_019e22c4-8fac-717d-8fa1-0f2f162e7ce1" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e22c4-8fac-771d-b282-04648db2fe48" xlink:to="loc_dei_EntityCurrentReportingStatus_019e22c4-8fac-717d-8fa1-0f2f162e7ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_019e22c4-8fac-77c6-833e-c1fd9fd4f8a5" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e22c4-8fac-771d-b282-04648db2fe48" xlink:to="loc_dei_EntityFilerCategory_019e22c4-8fac-77c6-833e-c1fd9fd4f8a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_019e22c4-8fac-7bb0-abb4-2e31faa6a9bf" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e22c4-8fac-771d-b282-04648db2fe48" xlink:to="loc_dei_EntitySmallBusiness_019e22c4-8fac-7bb0-abb4-2e31faa6a9bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_019e22c4-8fac-7f66-ad82-fd3faaa154a9" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e22c4-8fac-771d-b282-04648db2fe48" xlink:to="loc_dei_EntityEmergingGrowthCompany_019e22c4-8fac-7f66-ad82-fd3faaa154a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_019e22c4-8fac-704e-9729-16a7d4a47200" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e22c4-8fac-771d-b282-04648db2fe48" xlink:to="loc_dei_EntityShellCompany_019e22c4-8fac-704e-9729-16a7d4a47200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_019e22c4-8fac-7848-a4dd-265cf51cb49b" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e22c4-8fac-771d-b282-04648db2fe48" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_019e22c4-8fac-7848-a4dd-265cf51cb49b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_019e22c4-8fac-78d6-b6a9-a412ca4f02c9" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e22c4-8fac-771d-b282-04648db2fe48" xlink:to="loc_dei_EntityCentralIndexKey_019e22c4-8fac-78d6-b6a9-a412ca4f02c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_019e22c4-8fac-72a5-a547-b720ede6430d" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e22c4-8fac-771d-b282-04648db2fe48" xlink:to="loc_dei_CurrentFiscalYearEndDate_019e22c4-8fac-72a5-a547-b720ede6430d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_019e22c4-8fac-7b8a-ae95-cdee40e15515" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e22c4-8fac-771d-b282-04648db2fe48" xlink:to="loc_dei_AmendmentFlag_019e22c4-8fac-7b8a-ae95-cdee40e15515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_019e22c4-8fac-7780-804e-8d546f18686c" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e22c4-8fac-771d-b282-04648db2fe48" xlink:to="loc_dei_DocumentFiscalYearFocus_019e22c4-8fac-7780-804e-8d546f18686c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_019e22c4-8fac-7f0f-ba66-09bb0342a2d9" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e22c4-8fac-771d-b282-04648db2fe48" xlink:to="loc_dei_DocumentFiscalPeriodFocus_019e22c4-8fac-7f0f-ba66-09bb0342a2d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://spyre.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="syre-20260630.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://spyre.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_019e22c4-8fac-7104-a68b-6ed630911ad5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_019e22c4-8fac-77cc-a899-e375d04f86ac" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019e22c4-8fac-7104-a68b-6ed630911ad5" xlink:to="loc_us-gaap_StatementTable_019e22c4-8fac-77cc-a899-e375d04f86ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e22c4-8fac-74c2-b086-8364ebb201d2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_019e22c4-8fac-77cc-a899-e375d04f86ac" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e22c4-8fac-74c2-b086-8364ebb201d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019e22c4-8fac-7ef7-9366-d46f911586ad" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e22c4-8fac-74c2-b086-8364ebb201d2" xlink:to="loc_us-gaap_RelatedPartyDomain_019e22c4-8fac-7ef7-9366-d46f911586ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_019e22c4-8fac-7058-8896-45ae9ff2ec99" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_019e22c4-8fac-7ef7-9366-d46f911586ad" xlink:to="loc_us-gaap_NonrelatedPartyMember_019e22c4-8fac-7058-8896-45ae9ff2ec99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_019e22c4-8fac-7889-bf09-0a6f7c0e2044" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_019e22c4-8fac-7ef7-9366-d46f911586ad" xlink:to="loc_us-gaap_RelatedPartyMember_019e22c4-8fac-7889-bf09-0a6f7c0e2044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_019e22c4-8fac-7805-95a9-ce7cc0c85dd9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_019e22c4-8fac-77cc-a899-e375d04f86ac" xlink:to="loc_us-gaap_StatementClassOfStockAxis_019e22c4-8fac-7805-95a9-ce7cc0c85dd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019e22c4-8fac-70e0-b006-18c8391b2ce4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019e22c4-8fac-7805-95a9-ce7cc0c85dd9" xlink:to="loc_us-gaap_ClassOfStockDomain_019e22c4-8fac-70e0-b006-18c8391b2ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_SeriesANonVotingConvertiblePreferredStockMember_019e22c4-8fac-7f21-8f33-a957169226f6" xlink:href="syre-20260630.xsd#syre_SeriesANonVotingConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_019e22c4-8fac-70e0-b006-18c8391b2ce4" xlink:to="loc_syre_SeriesANonVotingConvertiblePreferredStockMember_019e22c4-8fac-7f21-8f33-a957169226f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_SeriesBNonVotingConvertiblePreferredStockMember_019e22c4-8fac-79f1-a802-83e50bee25ee" xlink:href="syre-20260630.xsd#syre_SeriesBNonVotingConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_019e22c4-8fac-70e0-b006-18c8391b2ce4" xlink:to="loc_syre_SeriesBNonVotingConvertiblePreferredStockMember_019e22c4-8fac-79f1-a802-83e50bee25ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_PreferredStockExcludingSeriesAAndBNonVotingConvertiblePreferredStockMember_019e22c4-8fac-7b46-9f2f-246dd16b50e4" xlink:href="syre-20260630.xsd#syre_PreferredStockExcludingSeriesAAndBNonVotingConvertiblePreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_019e22c4-8fac-70e0-b006-18c8391b2ce4" xlink:to="loc_syre_PreferredStockExcludingSeriesAAndBNonVotingConvertiblePreferredStockMember_019e22c4-8fac-7b46-9f2f-246dd16b50e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_019e22c4-8fac-7fb9-84fc-2fd14dcc16ca" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_019e22c4-8fac-77cc-a899-e375d04f86ac" xlink:to="loc_us-gaap_StatementLineItems_019e22c4-8fac-7fb9-84fc-2fd14dcc16ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_019e22c4-8fac-7835-a428-aefd1ccf948b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019e22c4-8fac-7fb9-84fc-2fd14dcc16ca" xlink:to="loc_us-gaap_AssetsAbstract_019e22c4-8fac-7835-a428-aefd1ccf948b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_019e22c4-8fac-75e3-80f0-703666cbda32" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_019e22c4-8fac-7835-a428-aefd1ccf948b" xlink:to="loc_us-gaap_AssetsCurrentAbstract_019e22c4-8fac-75e3-80f0-703666cbda32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019e22c4-8fac-77ef-bbeb-d8be1c0de0ee" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_019e22c4-8fac-75e3-80f0-703666cbda32" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019e22c4-8fac-77ef-bbeb-d8be1c0de0ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_019e22c4-8fac-7671-b94d-a31204fce8b7" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_019e22c4-8fac-75e3-80f0-703666cbda32" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_019e22c4-8fac-7671-b94d-a31204fce8b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_019e22c4-8fac-7ef9-a096-f70ad5861dfb" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_019e22c4-8fac-75e3-80f0-703666cbda32" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_019e22c4-8fac-7ef9-a096-f70ad5861dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_019e22c4-8fac-7713-bd54-42c1996c6680" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_019e22c4-8fac-75e3-80f0-703666cbda32" xlink:to="loc_us-gaap_AssetsCurrent_019e22c4-8fac-7713-bd54-42c1996c6680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_019e22c4-8fac-7690-84bf-8065eace60e5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Assets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_019e22c4-8fac-7835-a428-aefd1ccf948b" xlink:to="loc_us-gaap_Assets_019e22c4-8fac-7690-84bf-8065eace60e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019e22c4-8fac-7348-9e89-34b19a253bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019e22c4-8fac-7fb9-84fc-2fd14dcc16ca" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019e22c4-8fac-7348-9e89-34b19a253bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_019e22c4-8fac-78b8-9f6d-c6be0e6924ad" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019e22c4-8fac-7348-9e89-34b19a253bf6" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_019e22c4-8fac-78b8-9f6d-c6be0e6924ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_019e22c4-8fac-7a62-bd23-580f220b8a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_019e22c4-8fac-78b8-9f6d-c6be0e6924ad" xlink:to="loc_us-gaap_AccountsPayableCurrent_019e22c4-8fac-7a62-bd23-580f220b8a7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_019e22c4-8fac-7aa2-8a8a-2d882c54d892" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_019e22c4-8fac-78b8-9f6d-c6be0e6924ad" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_019e22c4-8fac-7aa2-8a8a-2d882c54d892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_019e22c4-8fac-77c1-a352-6fb1f7c6cef9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_019e22c4-8fac-78b8-9f6d-c6be0e6924ad" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_019e22c4-8fac-77c1-a352-6fb1f7c6cef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_019e22c4-8fac-7f68-b019-ec609917a71f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_019e22c4-8fac-78b8-9f6d-c6be0e6924ad" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_019e22c4-8fac-7f68-b019-ec609917a71f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_019e22c4-8fac-7d94-9a8f-c3c809ce41be" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_019e22c4-8fac-78b8-9f6d-c6be0e6924ad" xlink:to="loc_us-gaap_LiabilitiesCurrent_019e22c4-8fac-7d94-9a8f-c3c809ce41be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_019e22c4-8fac-7af6-9062-f4cb7a003cf8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019e22c4-8fac-7348-9e89-34b19a253bf6" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_019e22c4-8fac-7af6-9062-f4cb7a003cf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_019e22c4-8fac-7d95-8f23-6bd3e7931560" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019e22c4-8fac-7348-9e89-34b19a253bf6" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_019e22c4-8fac-7d95-8f23-6bd3e7931560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_019e22c4-8fac-7e62-9830-9248f34e719f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019e22c4-8fac-7348-9e89-34b19a253bf6" xlink:to="loc_us-gaap_Liabilities_019e22c4-8fac-7e62-9830-9248f34e719f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_019e22c4-8fac-71f4-8fab-ada521debd81" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019e22c4-8fac-7348-9e89-34b19a253bf6" xlink:to="loc_us-gaap_CommitmentsAndContingencies_019e22c4-8fac-71f4-8fab-ada521debd81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_019e22c4-8fac-7565-9505-b2aa40f362c4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019e22c4-8fac-7348-9e89-34b19a253bf6" xlink:to="loc_us-gaap_StockholdersEquityAbstract_019e22c4-8fac-7565-9505-b2aa40f362c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_019e22c4-8fac-7600-b269-6d89d33c541f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_019e22c4-8fac-7565-9505-b2aa40f362c4" xlink:to="loc_us-gaap_PreferredStockValue_019e22c4-8fac-7600-b269-6d89d33c541f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_019e22c4-8fac-7993-9e08-8f06493cee6a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_019e22c4-8fac-7565-9505-b2aa40f362c4" xlink:to="loc_us-gaap_CommonStockValue_019e22c4-8fac-7993-9e08-8f06493cee6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_019e22c4-8fac-7809-966a-2b114841f89e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_019e22c4-8fac-7565-9505-b2aa40f362c4" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_019e22c4-8fac-7809-966a-2b114841f89e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_019e22c4-8fac-7679-b958-707203ab1b92" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_019e22c4-8fac-7565-9505-b2aa40f362c4" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_019e22c4-8fac-7679-b958-707203ab1b92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019e22c4-8fac-712c-8479-93322783237d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_019e22c4-8fac-7565-9505-b2aa40f362c4" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019e22c4-8fac-712c-8479-93322783237d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019e22c4-8fac-7e8d-bd7d-d6da4d739343" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_019e22c4-8fac-7565-9505-b2aa40f362c4" xlink:to="loc_us-gaap_StockholdersEquity_019e22c4-8fac-7e8d-bd7d-d6da4d739343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_019e22c4-8fac-796d-b7ce-0744a8bacae6" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019e22c4-8fac-7348-9e89-34b19a253bf6" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_019e22c4-8fac-796d-b7ce-0744a8bacae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://spyre.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="syre-20260630.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://spyre.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_019e22c4-8fac-7bdd-a781-f9fa5f3c2491" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_019e22c4-8fac-7fb0-b94d-f9e45761583d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019e22c4-8fac-7bdd-a781-f9fa5f3c2491" xlink:to="loc_us-gaap_StatementTable_019e22c4-8fac-7fb0-b94d-f9e45761583d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_019e22c4-8fac-7dde-a407-3bc46b96d9f6" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_019e22c4-8fac-7fb0-b94d-f9e45761583d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_019e22c4-8fac-7dde-a407-3bc46b96d9f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019e22c4-8fac-79df-9b46-97b7a1c3233d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019e22c4-8fac-7dde-a407-3bc46b96d9f6" xlink:to="loc_us-gaap_ClassOfStockDomain_019e22c4-8fac-79df-9b46-97b7a1c3233d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_SeriesANonVotingConvertiblePreferredStockMember_019e22c4-8fac-78a3-8a36-1a0b1b5bafe0" xlink:href="syre-20260630.xsd#syre_SeriesANonVotingConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_019e22c4-8fac-79df-9b46-97b7a1c3233d" xlink:to="loc_syre_SeriesANonVotingConvertiblePreferredStockMember_019e22c4-8fac-78a3-8a36-1a0b1b5bafe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_SeriesBNonVotingConvertiblePreferredStockMember_019e22c4-8fac-7fee-b78c-3952d864066e" xlink:href="syre-20260630.xsd#syre_SeriesBNonVotingConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_019e22c4-8fac-79df-9b46-97b7a1c3233d" xlink:to="loc_syre_SeriesBNonVotingConvertiblePreferredStockMember_019e22c4-8fac-7fee-b78c-3952d864066e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_PreferredStockExcludingSeriesAAndBNonVotingConvertiblePreferredStockMember_019e22c4-8fac-792a-81da-3fe53ac90149" xlink:href="syre-20260630.xsd#syre_PreferredStockExcludingSeriesAAndBNonVotingConvertiblePreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_019e22c4-8fac-79df-9b46-97b7a1c3233d" xlink:to="loc_syre_PreferredStockExcludingSeriesAAndBNonVotingConvertiblePreferredStockMember_019e22c4-8fac-792a-81da-3fe53ac90149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_019e22c4-8fac-7896-b311-361d4f620016" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_019e22c4-8fac-7fb0-b94d-f9e45761583d" xlink:to="loc_us-gaap_StatementLineItems_019e22c4-8fac-7896-b311-361d4f620016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_019e22c4-8fac-7638-b70d-40557b67d779" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019e22c4-8fac-7896-b311-361d4f620016" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_019e22c4-8fac-7638-b70d-40557b67d779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_019e22c4-8fac-7e78-a7eb-11a10bead770" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019e22c4-8fac-7896-b311-361d4f620016" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_019e22c4-8fac-7e78-a7eb-11a10bead770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_019e22c4-8fac-7b17-832f-5814ce788505" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019e22c4-8fac-7896-b311-361d4f620016" xlink:to="loc_us-gaap_PreferredStockSharesIssued_019e22c4-8fac-7b17-832f-5814ce788505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_019e22c4-8fac-748a-9bd5-452386c7c1d5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019e22c4-8fac-7896-b311-361d4f620016" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_019e22c4-8fac-748a-9bd5-452386c7c1d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_019e22c4-8fac-75f1-82f1-0cda8c9530e9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019e22c4-8fac-7896-b311-361d4f620016" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_019e22c4-8fac-75f1-82f1-0cda8c9530e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_019e22c4-8fac-724a-b5fd-90d43386686c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019e22c4-8fac-7896-b311-361d4f620016" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_019e22c4-8fac-724a-b5fd-90d43386686c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_019e22c4-8fac-7029-9cfe-56c43e8767a8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019e22c4-8fac-7896-b311-361d4f620016" xlink:to="loc_us-gaap_CommonStockSharesIssued_019e22c4-8fac-7029-9cfe-56c43e8767a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_019e22c4-8fac-70f2-8fce-4d619edfd3ff" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019e22c4-8fac-7896-b311-361d4f620016" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_019e22c4-8fac-70f2-8fce-4d619edfd3ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://spyre.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="syre-20260630.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://spyre.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_019e22c4-8fac-704a-a574-05544849c69c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_019e22c4-8fac-7362-a536-6fb845b562d6" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_019e22c4-8fac-704a-a574-05544849c69c" xlink:to="loc_us-gaap_StatementTable_019e22c4-8fac-7362-a536-6fb845b562d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_019e22c4-8fac-766d-a4d6-407de26af1f9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_019e22c4-8fac-7362-a536-6fb845b562d6" xlink:to="loc_us-gaap_StatementClassOfStockAxis_019e22c4-8fac-766d-a4d6-407de26af1f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019e22c4-8fac-7570-91a0-0f07999e7d4f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019e22c4-8fac-766d-a4d6-407de26af1f9" xlink:to="loc_us-gaap_ClassOfStockDomain_019e22c4-8fac-7570-91a0-0f07999e7d4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_SeriesANonVotingConvertiblePreferredStockMember_019e22c4-8fac-7bed-ab89-d110c66be40f" xlink:href="syre-20260630.xsd#syre_SeriesANonVotingConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_019e22c4-8fac-7570-91a0-0f07999e7d4f" xlink:to="loc_syre_SeriesANonVotingConvertiblePreferredStockMember_019e22c4-8fac-7bed-ab89-d110c66be40f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_SeriesBNonVotingConvertiblePreferredStockMember_019e22c4-8fac-7d13-ab32-769645332f8c" xlink:href="syre-20260630.xsd#syre_SeriesBNonVotingConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_019e22c4-8fac-7570-91a0-0f07999e7d4f" xlink:to="loc_syre_SeriesBNonVotingConvertiblePreferredStockMember_019e22c4-8fac-7d13-ab32-769645332f8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_019e22c4-8fac-7f73-bc9e-cd53448b3d5c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_019e22c4-8fac-7570-91a0-0f07999e7d4f" xlink:to="loc_us-gaap_CommonStockMember_019e22c4-8fac-7f73-bc9e-cd53448b3d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e22c4-8fac-75da-b965-b68756ec1eda" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_019e22c4-8fac-7362-a536-6fb845b562d6" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e22c4-8fac-75da-b965-b68756ec1eda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019e22c4-8fac-7718-b2ff-98408a482d65" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e22c4-8fac-75da-b965-b68756ec1eda" xlink:to="loc_us-gaap_RelatedPartyDomain_019e22c4-8fac-7718-b2ff-98408a482d65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_019e22c4-8fac-786b-8788-ad701d5b8bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_019e22c4-8fac-7718-b2ff-98408a482d65" xlink:to="loc_us-gaap_RelatedPartyMember_019e22c4-8fac-786b-8788-ad701d5b8bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_019e22c4-8fac-77a6-a1ac-b1ca56bc1c3a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_019e22c4-8fac-7362-a536-6fb845b562d6" xlink:to="loc_us-gaap_StatementLineItems_019e22c4-8fac-77a6-a1ac-b1ca56bc1c3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_019e22c4-8fac-7b62-9b1c-639298dd7bf0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019e22c4-8fac-77a6-a1ac-b1ca56bc1c3a" xlink:to="loc_us-gaap_OperatingExpensesAbstract_019e22c4-8fac-7b62-9b1c-639298dd7bf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_019e22c4-8fac-71d4-a77c-28516d6e8fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019e22c4-8fac-7b62-9b1c-639298dd7bf0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_019e22c4-8fac-71d4-a77c-28516d6e8fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_019e22c4-8fac-7b06-89d8-d39e1fda7200" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019e22c4-8fac-7b62-9b1c-639298dd7bf0" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_019e22c4-8fac-7b06-89d8-d39e1fda7200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_019e22c4-8fac-7a01-b877-29ebb8444e6b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019e22c4-8fac-7b62-9b1c-639298dd7bf0" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_019e22c4-8fac-7a01-b877-29ebb8444e6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_019e22c4-8fac-75b1-818d-ccf518b63cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019e22c4-8fac-7b62-9b1c-639298dd7bf0" xlink:to="loc_us-gaap_OperatingExpenses_019e22c4-8fac-75b1-818d-ccf518b63cc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_019e22c4-8fac-71f4-9d3c-c85941247261" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019e22c4-8fac-77a6-a1ac-b1ca56bc1c3a" xlink:to="loc_us-gaap_OperatingIncomeLoss_019e22c4-8fac-71f4-9d3c-c85941247261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_019e22c4-8fac-75fc-a279-96e75947ad5a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019e22c4-8fac-77a6-a1ac-b1ca56bc1c3a" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_019e22c4-8fac-75fc-a279-96e75947ad5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_019e22c4-8fac-77c2-82af-22f282d9dcce" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_019e22c4-8fac-75fc-a279-96e75947ad5a" xlink:to="loc_us-gaap_InvestmentIncomeNet_019e22c4-8fac-77c2-82af-22f282d9dcce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_019e22c4-8fac-771d-9004-2ee657b4c024" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_019e22c4-8fac-75fc-a279-96e75947ad5a" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_019e22c4-8fac-771d-9004-2ee657b4c024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_019e22c4-8fac-70b8-b3a2-1416fb454c7a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_019e22c4-8fac-75fc-a279-96e75947ad5a" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_019e22c4-8fac-70b8-b3a2-1416fb454c7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019e22c4-8fac-7765-acb6-e3c4b49a2f3d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019e22c4-8fac-77a6-a1ac-b1ca56bc1c3a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019e22c4-8fac-7765-acb6-e3c4b49a2f3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_019e22c4-8fac-7de8-ae7d-966c9f29888d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019e22c4-8fac-77a6-a1ac-b1ca56bc1c3a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_019e22c4-8fac-7de8-ae7d-966c9f29888d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019e22c4-8fac-73b3-8edd-2b714962ccb0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019e22c4-8fac-77a6-a1ac-b1ca56bc1c3a" xlink:to="loc_us-gaap_NetIncomeLoss_019e22c4-8fac-73b3-8edd-2b714962ccb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_019e22c4-8fac-7c85-87ee-53ad6ebf11fb" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019e22c4-8fac-77a6-a1ac-b1ca56bc1c3a" xlink:to="loc_us-gaap_EarningsPerShareBasic_019e22c4-8fac-7c85-87ee-53ad6ebf11fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_019e22c4-8fac-7edb-a96b-d8e07fb37fa7" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019e22c4-8fac-77a6-a1ac-b1ca56bc1c3a" xlink:to="loc_us-gaap_EarningsPerShareDiluted_019e22c4-8fac-7edb-a96b-d8e07fb37fa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_019e22c4-8fac-7650-8f16-1d9d9c947536" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019e22c4-8fac-77a6-a1ac-b1ca56bc1c3a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_019e22c4-8fac-7650-8f16-1d9d9c947536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019e22c4-8fac-7f48-97d8-87b71e330900" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019e22c4-8fac-77a6-a1ac-b1ca56bc1c3a" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019e22c4-8fac-7f48-97d8-87b71e330900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://spyre.com/role/CondensedConsolidatedStatementsofOperationsParenthetical" xlink:type="simple" xlink:href="syre-20260630.xsd#CondensedConsolidatedStatementsofOperationsParenthetical"/>
  <link:presentationLink xlink:role="http://spyre.com/role/CondensedConsolidatedStatementsofOperationsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_019e22c4-8fac-7e27-8a43-6ec00b346ea5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_019e22c4-8fac-7d93-af78-e16f7b7f0b88" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_019e22c4-8fac-7e27-8a43-6ec00b346ea5" xlink:to="loc_us-gaap_StatementTable_019e22c4-8fac-7d93-af78-e16f7b7f0b88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e22c4-8fac-7cdb-8050-8335cfb92b9b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_019e22c4-8fac-7d93-af78-e16f7b7f0b88" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e22c4-8fac-7cdb-8050-8335cfb92b9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019e22c4-8fac-783f-8a3f-dfec92c66275" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e22c4-8fac-7cdb-8050-8335cfb92b9b" xlink:to="loc_us-gaap_RelatedPartyDomain_019e22c4-8fac-783f-8a3f-dfec92c66275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_019e22c4-8fac-7c13-af79-82301c693e82" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_019e22c4-8fac-783f-8a3f-dfec92c66275" xlink:to="loc_us-gaap_RelatedPartyMember_019e22c4-8fac-7c13-af79-82301c693e82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_019e22c4-8fac-7c29-931b-27037b8d7cee" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_019e22c4-8fac-7d93-af78-e16f7b7f0b88" xlink:to="loc_us-gaap_StatementLineItems_019e22c4-8fac-7c29-931b-27037b8d7cee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_019e22c4-8fac-763d-8d67-859ff5bdf4cc" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019e22c4-8fac-7c29-931b-27037b8d7cee" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_019e22c4-8fac-763d-8d67-859ff5bdf4cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_019e22c4-8fac-7fbc-a1d1-68886cf5706e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019e22c4-8fac-7c29-931b-27037b8d7cee" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_019e22c4-8fac-7fbc-a1d1-68886cf5706e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://spyre.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="syre-20260630.xsd#CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://spyre.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_019e22c4-8fac-77d2-a4e6-18e58c363d83" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019e22c4-8fac-755a-9bba-d8c020ba2891" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_019e22c4-8fac-77d2-a4e6-18e58c363d83" xlink:to="loc_us-gaap_NetIncomeLoss_019e22c4-8fac-755a-9bba-d8c020ba2891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_019e22c4-8fac-7e79-a657-7a78d1399bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_019e22c4-8fac-77d2-a4e6-18e58c363d83" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_019e22c4-8fac-7e79-a657-7a78d1399bb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_019e22c4-8fac-70c7-a26a-8865194a4368" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_019e22c4-8fac-7e79-a657-7a78d1399bb0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_019e22c4-8fac-70c7-a26a-8865194a4368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_019e22c4-8fac-799f-923a-0af5474cd5ff" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_019e22c4-8fac-7e79-a657-7a78d1399bb0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_019e22c4-8fac-799f-923a-0af5474cd5ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_019e22c4-8fac-7e48-a521-2f98c806f729" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_019e22c4-8fac-77d2-a4e6-18e58c363d83" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_019e22c4-8fac-7e48-a521-2f98c806f729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://spyre.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquity" xlink:type="simple" xlink:href="syre-20260630.xsd#CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquity"/>
  <link:presentationLink xlink:role="http://spyre.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_019e22c4-8fac-7bc4-a135-eb0f9516cf9d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_019e22c4-8fac-7f59-b895-da231b300f1c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_019e22c4-8fac-7bc4-a135-eb0f9516cf9d" xlink:to="loc_us-gaap_StatementTable_019e22c4-8fac-7f59-b895-da231b300f1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_019e22c4-8fac-7eaf-beaa-af40f5df6b1d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_019e22c4-8fac-7f59-b895-da231b300f1c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_019e22c4-8fac-7eaf-beaa-af40f5df6b1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019e22c4-8fac-7da6-ae56-b707672724f0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019e22c4-8fac-7eaf-beaa-af40f5df6b1d" xlink:to="loc_us-gaap_ClassOfStockDomain_019e22c4-8fac-7da6-ae56-b707672724f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_SeriesANonVotingConvertiblePreferredStockMember_019e22c4-8fac-76f6-9c65-8b0ee64f689a" xlink:href="syre-20260630.xsd#syre_SeriesANonVotingConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_019e22c4-8fac-7da6-ae56-b707672724f0" xlink:to="loc_syre_SeriesANonVotingConvertiblePreferredStockMember_019e22c4-8fac-76f6-9c65-8b0ee64f689a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_SeriesBNonVotingConvertiblePreferredStockMember_019e22c4-8fac-7134-bc10-0a212565ca4f" xlink:href="syre-20260630.xsd#syre_SeriesBNonVotingConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_019e22c4-8fac-7da6-ae56-b707672724f0" xlink:to="loc_syre_SeriesBNonVotingConvertiblePreferredStockMember_019e22c4-8fac-7134-bc10-0a212565ca4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_019e22c4-8fac-73f6-be68-cbf09c3d8791" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_019e22c4-8fac-7f59-b895-da231b300f1c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_019e22c4-8fac-73f6-be68-cbf09c3d8791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_019e22c4-8fac-7b6d-9178-065201e8d47a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_019e22c4-8fac-73f6-be68-cbf09c3d8791" xlink:to="loc_us-gaap_EquityComponentDomain_019e22c4-8fac-7b6d-9178-065201e8d47a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_019e22c4-8fac-7646-9dd1-84a431a4563f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_019e22c4-8fac-7b6d-9178-065201e8d47a" xlink:to="loc_us-gaap_PreferredStockMember_019e22c4-8fac-7646-9dd1-84a431a4563f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_019e22c4-8fac-76b4-943a-67a458698c08" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_019e22c4-8fac-7b6d-9178-065201e8d47a" xlink:to="loc_us-gaap_CommonStockMember_019e22c4-8fac-76b4-943a-67a458698c08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_019e22c4-8fac-79e8-b7fc-3cb5678a3ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_019e22c4-8fac-7b6d-9178-065201e8d47a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_019e22c4-8fac-79e8-b7fc-3cb5678a3ce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019e22c4-8fac-71e2-b0ef-bed0e8d316f8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_019e22c4-8fac-7b6d-9178-065201e8d47a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019e22c4-8fac-71e2-b0ef-bed0e8d316f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_019e22c4-8fac-760e-8a47-b79e13afdd0a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_019e22c4-8fac-7b6d-9178-065201e8d47a" xlink:to="loc_us-gaap_RetainedEarningsMember_019e22c4-8fac-760e-8a47-b79e13afdd0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_019e22c4-8fac-7691-88b1-f71d82472e27" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_019e22c4-8fac-7f59-b895-da231b300f1c" xlink:to="loc_us-gaap_StatementLineItems_019e22c4-8fac-7691-88b1-f71d82472e27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e22c4-8fac-74b9-8acf-0b44bb8eda5a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019e22c4-8fac-7691-88b1-f71d82472e27" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e22c4-8fac-74b9-8acf-0b44bb8eda5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_019e22c4-8fac-7d95-96d1-8d037f54a8d7" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e22c4-8fac-74b9-8acf-0b44bb8eda5a" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_019e22c4-8fac-7d95-96d1-8d037f54a8d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019e22c4-8fac-7b79-8a86-54bd3db3639b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e22c4-8fac-74b9-8acf-0b44bb8eda5a" xlink:to="loc_us-gaap_StockholdersEquity_019e22c4-8fac-7b79-8a86-54bd3db3639b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_019e22c4-8fac-78f5-8370-728d2d474389" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e22c4-8fac-74b9-8acf-0b44bb8eda5a" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_019e22c4-8fac-78f5-8370-728d2d474389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_019f5e6a-4e70-73cc-9ce4-7b10caab4cfc" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e22c4-8fac-74b9-8acf-0b44bb8eda5a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_019f5e6a-4e70-73cc-9ce4-7b10caab4cfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_019f5e6b-3557-74de-914d-bee25c1e009d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e22c4-8fac-74b9-8acf-0b44bb8eda5a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_019f5e6b-3557-74de-914d-bee25c1e009d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_019e22c4-8fac-758b-9600-6f2454a56e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e22c4-8fac-74b9-8acf-0b44bb8eda5a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_019e22c4-8fac-758b-9600-6f2454a56e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_019e22c4-8fac-72df-b838-15b634e0445a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e22c4-8fac-74b9-8acf-0b44bb8eda5a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_019e22c4-8fac-72df-b838-15b634e0445a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan_019e22c4-8fac-7fe4-bbb2-6109457cf803" xlink:href="syre-20260630.xsd#syre_StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e22c4-8fac-74b9-8acf-0b44bb8eda5a" xlink:to="loc_syre_StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan_019e22c4-8fac-7fe4-bbb2-6109457cf803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan_019e22c4-8fac-72df-bce9-59bd5fad14a2" xlink:href="syre-20260630.xsd#syre_StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e22c4-8fac-74b9-8acf-0b44bb8eda5a" xlink:to="loc_syre_StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan_019e22c4-8fac-72df-bce9-59bd5fad14a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_019e22c4-8fac-79d0-ada8-c397385c52d8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e22c4-8fac-74b9-8acf-0b44bb8eda5a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_019e22c4-8fac-79d0-ada8-c397385c52d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_019e22c4-8fac-7a96-82c6-9a2dc2ef1661" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e22c4-8fac-74b9-8acf-0b44bb8eda5a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_019e22c4-8fac-7a96-82c6-9a2dc2ef1661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_019e22c4-8fac-7afb-8b15-1832a16c2dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e22c4-8fac-74b9-8acf-0b44bb8eda5a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_019e22c4-8fac-7afb-8b15-1832a16c2dfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019e22c4-8fac-7231-8bdb-778525c8c5b6" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e22c4-8fac-74b9-8acf-0b44bb8eda5a" xlink:to="loc_us-gaap_NetIncomeLoss_019e22c4-8fac-7231-8bdb-778525c8c5b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_019e22c4-8fac-7034-aba4-42893f77dff0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e22c4-8fac-74b9-8acf-0b44bb8eda5a" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_019e22c4-8fac-7034-aba4-42893f77dff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019e22c4-8fac-7397-8ad8-f37a5a2a0a6a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e22c4-8fac-74b9-8acf-0b44bb8eda5a" xlink:to="loc_us-gaap_StockholdersEquity_019e22c4-8fac-7397-8ad8-f37a5a2a0a6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_019e22c4-8fac-721a-b62a-8f79bb521a8c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019e22c4-8fac-74b9-8acf-0b44bb8eda5a" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_019e22c4-8fac-721a-b62a-8f79bb521a8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://spyre.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="syre-20260630.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://spyre.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_019e22c4-8fac-709d-9618-fa96145a9d66" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_019e22c4-8fac-78d2-aa87-f98125cd5779" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_019e22c4-8fac-709d-9618-fa96145a9d66" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_019e22c4-8fac-78d2-aa87-f98125cd5779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019e22c4-8fac-7b8e-a899-8c3597158023" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_019e22c4-8fac-78d2-aa87-f98125cd5779" xlink:to="loc_us-gaap_NetIncomeLoss_019e22c4-8fac-7b8e-a899-8c3597158023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019e22c4-8fac-76f6-b46c-afb7ee1aa442" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_019e22c4-8fac-78d2-aa87-f98125cd5779" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019e22c4-8fac-76f6-b46c-afb7ee1aa442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_019e22c4-8fac-7d06-936b-87aca6ce811e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019e22c4-8fac-76f6-b46c-afb7ee1aa442" xlink:to="loc_us-gaap_ShareBasedCompensation_019e22c4-8fac-7d06-936b-87aca6ce811e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_019e22c4-8fac-7382-bb60-5f6ace59fcea" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019e22c4-8fac-76f6-b46c-afb7ee1aa442" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_019e22c4-8fac-7382-bb60-5f6ace59fcea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_019e22c4-8fac-7cd6-b181-046b8f0456ec" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019e22c4-8fac-76f6-b46c-afb7ee1aa442" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_019e22c4-8fac-7cd6-b181-046b8f0456ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_019e22c4-8fac-7336-8bd0-1f87f88fc2b7" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019e22c4-8fac-76f6-b46c-afb7ee1aa442" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_019e22c4-8fac-7336-8bd0-1f87f88fc2b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_InterestProceedsDebtSecurities_019e22c4-8fac-74cd-b476-3de80f369e6e" xlink:href="syre-20260630.xsd#syre_InterestProceedsDebtSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019e22c4-8fac-76f6-b46c-afb7ee1aa442" xlink:to="loc_syre_InterestProceedsDebtSecurities_019e22c4-8fac-74cd-b476-3de80f369e6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019e22c4-8fac-745f-afc2-23afc7c2644e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_019e22c4-8fac-78d2-aa87-f98125cd5779" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019e22c4-8fac-745f-afc2-23afc7c2644e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_019e22c4-8fac-7fb6-9b8f-1773d27cc348" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019e22c4-8fac-745f-afc2-23afc7c2644e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_019e22c4-8fac-7fb6-9b8f-1773d27cc348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_019e22c4-8fac-75c4-84d7-625db279c112" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019e22c4-8fac-745f-afc2-23afc7c2644e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_019e22c4-8fac-75c4-84d7-625db279c112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable_019e22c4-8fac-7237-8ad4-2ca7771e3728" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019e22c4-8fac-745f-afc2-23afc7c2644e" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable_019e22c4-8fac-7237-8ad4-2ca7771e3728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_019e22c4-8fac-755d-9919-d7e844a592f4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019e22c4-8fac-745f-afc2-23afc7c2644e" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_019e22c4-8fac-755d-9919-d7e844a592f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019e22c4-8fac-7778-b39e-2962ddf055f0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_019e22c4-8fac-78d2-aa87-f98125cd5779" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019e22c4-8fac-7778-b39e-2962ddf055f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019e22c4-8fac-72e5-999a-e3fcb16b22a4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_019e22c4-8fac-709d-9618-fa96145a9d66" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019e22c4-8fac-72e5-999a-e3fcb16b22a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_019e22c4-8fac-7457-98cc-03a4a7f124d9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019e22c4-8fac-72e5-999a-e3fcb16b22a4" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_019e22c4-8fac-7457-98cc-03a4a7f124d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_019e22c4-8fac-7b4d-ab5c-5ef6aeb7ecdc" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019e22c4-8fac-72e5-999a-e3fcb16b22a4" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_019e22c4-8fac-7b4d-ab5c-5ef6aeb7ecdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_019e22c4-8fac-72ba-81e8-f5d458d027f8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019e22c4-8fac-72e5-999a-e3fcb16b22a4" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_019e22c4-8fac-72ba-81e8-f5d458d027f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019e22c4-8fac-7d8c-9765-4682700b8a2b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019e22c4-8fac-72e5-999a-e3fcb16b22a4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019e22c4-8fac-7d8c-9765-4682700b8a2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019e22c4-8fac-7ae4-8ae9-849ac07d7190" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_019e22c4-8fac-709d-9618-fa96145a9d66" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019e22c4-8fac-7ae4-8ae9-849ac07d7190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_019f5e63-e662-7740-b757-45c2dfa510ef" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019e22c4-8fac-7ae4-8ae9-849ac07d7190" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_019f5e63-e662-7740-b757-45c2dfa510ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_ProceedsFromIssuanceOfCommonStockAtTheMarketOfferingsNet_019e22c4-8fac-7165-94ab-85923e811de2" xlink:href="syre-20260630.xsd#syre_ProceedsFromIssuanceOfCommonStockAtTheMarketOfferingsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019e22c4-8fac-7ae4-8ae9-849ac07d7190" xlink:to="loc_syre_ProceedsFromIssuanceOfCommonStockAtTheMarketOfferingsNet_019e22c4-8fac-7165-94ab-85923e811de2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_PaymentForDeferredOfferingCosts_019e22c4-8fac-772d-aacd-a8c5207d006b" xlink:href="syre-20260630.xsd#syre_PaymentForDeferredOfferingCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019e22c4-8fac-7ae4-8ae9-849ac07d7190" xlink:to="loc_syre_PaymentForDeferredOfferingCosts_019e22c4-8fac-772d-aacd-a8c5207d006b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_PaymentsRelatedToContingentValueRightsLiability_019f5e64-638b-78fc-8dd2-2b620f9f1f09" xlink:href="syre-20260630.xsd#syre_PaymentsRelatedToContingentValueRightsLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019e22c4-8fac-7ae4-8ae9-849ac07d7190" xlink:to="loc_syre_PaymentsRelatedToContingentValueRightsLiability_019f5e64-638b-78fc-8dd2-2b620f9f1f09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_019e22c4-8fac-7564-a679-9532b05d57b9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019e22c4-8fac-7ae4-8ae9-849ac07d7190" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_019e22c4-8fac-7564-a679-9532b05d57b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019e22c4-8fac-7b1a-b3e2-61b92ce6294d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019e22c4-8fac-7ae4-8ae9-849ac07d7190" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019e22c4-8fac-7b1a-b3e2-61b92ce6294d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019e22c4-8fac-7406-887a-6f5876bf4180" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_019e22c4-8fac-709d-9618-fa96145a9d66" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019e22c4-8fac-7406-887a-6f5876bf4180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract_019e22c4-8fac-7441-bb7b-acbacf9970d4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_019e22c4-8fac-709d-9618-fa96145a9d66" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract_019e22c4-8fac-7441-bb7b-acbacf9970d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019e22c4-8fac-70ea-83c0-6cde2e82814e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract_019e22c4-8fac-7441-bb7b-acbacf9970d4" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019e22c4-8fac-70ea-83c0-6cde2e82814e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019e22c4-8fac-75b3-b0ea-02d79398af01" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract_019e22c4-8fac-7441-bb7b-acbacf9970d4" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019e22c4-8fac-75b3-b0ea-02d79398af01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_019e22c4-8fac-7452-8287-1b6870c3a68f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_019e22c4-8fac-709d-9618-fa96145a9d66" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_019e22c4-8fac-7452-8287-1b6870c3a68f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_IssuanceOfConvertiblePreferredStockRelatedToPrivatePlacementUnpaidAmount_019f5e65-0337-7124-a0ce-4f6626a0e1b4" xlink:href="syre-20260630.xsd#syre_IssuanceOfConvertiblePreferredStockRelatedToPrivatePlacementUnpaidAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_019e22c4-8fac-7452-8287-1b6870c3a68f" xlink:to="loc_syre_IssuanceOfConvertiblePreferredStockRelatedToPrivatePlacementUnpaidAmount_019f5e65-0337-7124-a0ce-4f6626a0e1b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_DeferredOfferingCostsAllocatedAmountOfProceedsOfIssuanceOfCommonStock_019e22c4-8fac-7380-b761-743a0107d83a" xlink:href="syre-20260630.xsd#syre_DeferredOfferingCostsAllocatedAmountOfProceedsOfIssuanceOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_019e22c4-8fac-7452-8287-1b6870c3a68f" xlink:to="loc_syre_DeferredOfferingCostsAllocatedAmountOfProceedsOfIssuanceOfCommonStock_019e22c4-8fac-7380-b761-743a0107d83a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_DeferredOfferingCostsUnpaidAmount_019f5e66-77bd-7335-9b42-99d39aef50b3" xlink:href="syre-20260630.xsd#syre_DeferredOfferingCostsUnpaidAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_019e22c4-8fac-7452-8287-1b6870c3a68f" xlink:to="loc_syre_DeferredOfferingCostsUnpaidAmount_019f5e66-77bd-7335-9b42-99d39aef50b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_019f5e67-f4a7-76ff-b55a-2c23ec0d31bd" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_019e22c4-8fac-7452-8287-1b6870c3a68f" xlink:to="loc_us-gaap_ConversionOfStockAmountConverted1_019f5e67-f4a7-76ff-b55a-2c23ec0d31bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://spyre.com/role/TheCompanyandBasisofPresentation" xlink:type="simple" xlink:href="syre-20260630.xsd#TheCompanyandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://spyre.com/role/TheCompanyandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019e22c4-8fac-7732-8b58-712c03b571b3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_019e22c4-8fac-7bab-bd07-51d22ff669ab" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019e22c4-8fac-7732-8b58-712c03b571b3" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_019e22c4-8fac-7bab-bd07-51d22ff669ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://spyre.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="syre-20260630.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://spyre.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_019e22c4-8fac-71c6-b47e-29581d8e6109" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_019e22c4-8fac-70f8-b9dc-0f01c278dbc9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019e22c4-8fac-71c6-b47e-29581d8e6109" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_019e22c4-8fac-70f8-b9dc-0f01c278dbc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://spyre.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="syre-20260630.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://spyre.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_019e22c4-8fac-772b-943d-3ff247278116" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_019e22c4-8fac-78e8-9312-b840860c6c6e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_019e22c4-8fac-772b-943d-3ff247278116" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_019e22c4-8fac-78e8-9312-b840860c6c6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://spyre.com/role/CashEquivalentsandMarketableSecurities" xlink:type="simple" xlink:href="syre-20260630.xsd#CashEquivalentsandMarketableSecurities"/>
  <link:presentationLink xlink:role="http://spyre.com/role/CashEquivalentsandMarketableSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_019e22c4-9076-7738-b3cb-5859b6a6b0b2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_019e22c4-9076-7d30-8bca-ca28349a00c5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_019e22c4-9076-7738-b3cb-5859b6a6b0b2" xlink:to="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_019e22c4-9076-7d30-8bca-ca28349a00c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://spyre.com/role/AccruedandOtherCurrentLiabilities" xlink:type="simple" xlink:href="syre-20260630.xsd#AccruedandOtherCurrentLiabilities"/>
  <link:presentationLink xlink:role="http://spyre.com/role/AccruedandOtherCurrentLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_019e22c4-9076-73d2-8d8c-cda9388f2c44" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_AccruedAndOtherCurrentLiabilitiesTextBlock_019e22c4-9076-736f-939b-ef31b6e1072c" xlink:href="syre-20260630.xsd#syre_AccruedAndOtherCurrentLiabilitiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_019e22c4-9076-73d2-8d8c-cda9388f2c44" xlink:to="loc_syre_AccruedAndOtherCurrentLiabilitiesTextBlock_019e22c4-9076-736f-939b-ef31b6e1072c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://spyre.com/role/LicensingAgreements" xlink:type="simple" xlink:href="syre-20260630.xsd#LicensingAgreements"/>
  <link:presentationLink xlink:role="http://spyre.com/role/LicensingAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_syre_LicensingAgreementsAbstract_019e22c4-9076-7126-939a-33d5868f00e1" xlink:href="syre-20260630.xsd#syre_LicensingAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_019e22c4-9076-7616-9692-71d747a4cb50" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_LicensingAgreementsAbstract_019e22c4-9076-7126-939a-33d5868f00e1" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_019e22c4-9076-7616-9692-71d747a4cb50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://spyre.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="syre-20260630.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://spyre.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_019e22c4-9076-799a-ad43-2ee57a8aa07d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_019e22c4-9076-7e65-92be-6cd904fa93c9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_019e22c4-9076-799a-ad43-2ee57a8aa07d" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_019e22c4-9076-7e65-92be-6cd904fa93c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://spyre.com/role/ConvertiblePreferredStockandStockholdersEquity" xlink:type="simple" xlink:href="syre-20260630.xsd#ConvertiblePreferredStockandStockholdersEquity"/>
  <link:presentationLink xlink:role="http://spyre.com/role/ConvertiblePreferredStockandStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_019e22c4-9076-7f6e-b08d-d9226ddab29f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockTextBlock_019e22c4-9076-7026-9caf-73ba3283e0db" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_019e22c4-9076-7f6e-b08d-d9226ddab29f" xlink:to="loc_us-gaap_PreferredStockTextBlock_019e22c4-9076-7026-9caf-73ba3283e0db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://spyre.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="syre-20260630.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://spyre.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019e22c4-9076-70f0-b129-24bbdb1c81eb" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_019e22c4-9076-70ad-94ca-1647a7656137" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019e22c4-9076-70f0-b129-24bbdb1c81eb" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_019e22c4-9076-70ad-94ca-1647a7656137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://spyre.com/role/SaleofPegzilarginasetoImmedica" xlink:type="simple" xlink:href="syre-20260630.xsd#SaleofPegzilarginasetoImmedica"/>
  <link:presentationLink xlink:role="http://spyre.com/role/SaleofPegzilarginasetoImmedica" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_019e22c4-9076-7812-b317-56b4de01a854" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_019e22c4-9076-7b3b-bd92-7ebe771e6f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_019e22c4-9076-7812-b317-56b4de01a854" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_019e22c4-9076-7b3b-bd92-7ebe771e6f9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://spyre.com/role/SegmentReporting" xlink:type="simple" xlink:href="syre-20260630.xsd#SegmentReporting"/>
  <link:presentationLink xlink:role="http://spyre.com/role/SegmentReporting" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_019e22c4-9076-7d6c-8a61-0a899c292a4c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_019e22c4-9076-7452-8103-829699219462" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_019e22c4-9076-7d6c-8a61-0a899c292a4c" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_019e22c4-9076-7452-8103-829699219462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://spyre.com/role/NetLossPerShare" xlink:type="simple" xlink:href="syre-20260630.xsd#NetLossPerShare"/>
  <link:presentationLink xlink:role="http://spyre.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_019e22c4-9076-7daa-8947-f9c58a0cde44" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_019e22c4-9076-7e6d-8fb0-b1d556322ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_019e22c4-9076-7daa-8947-f9c58a0cde44" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_019e22c4-9076-7e6d-8fb0-b1d556322ab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://spyre.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="syre-20260630.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://spyre.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_019e22c4-8fac-7220-a74f-f8f0ebd0ff12" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_019e22c4-8fac-7b28-afda-da40417dba4f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019e22c4-8fac-7220-a74f-f8f0ebd0ff12" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_019e22c4-8fac-7b28-afda-da40417dba4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_019fabf3-4eed-777a-bee5-e17609b14579" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019e22c4-8fac-7220-a74f-f8f0ebd0ff12" xlink:to="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_019fabf3-4eed-777a-bee5-e17609b14579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_019e22c4-8fac-7590-805d-3676df8440c4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019e22c4-8fac-7220-a74f-f8f0ebd0ff12" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_019e22c4-8fac-7590-805d-3676df8440c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_019e22c4-8fac-7b53-b8b3-9879628c907a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019e22c4-8fac-7220-a74f-f8f0ebd0ff12" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_019e22c4-8fac-7b53-b8b3-9879628c907a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://spyre.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="syre-20260630.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://spyre.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_019e22c4-8fac-793f-bbe0-c0b7db29c2e9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_019e22c4-8fac-7823-86af-2a08bc7c0f1e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_019e22c4-8fac-793f-bbe0-c0b7db29c2e9" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_019e22c4-8fac-7823-86af-2a08bc7c0f1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_019e22c4-8fac-7552-991a-0999859e2473" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_019e22c4-8fac-793f-bbe0-c0b7db29c2e9" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_019e22c4-8fac-7552-991a-0999859e2473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_019e22c4-8fac-792b-8530-386ff2a9270f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_019e22c4-8fac-793f-bbe0-c0b7db29c2e9" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_019e22c4-8fac-792b-8530-386ff2a9270f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://spyre.com/role/CashEquivalentsandMarketableSecuritiesTables" xlink:type="simple" xlink:href="syre-20260630.xsd#CashEquivalentsandMarketableSecuritiesTables"/>
  <link:presentationLink xlink:role="http://spyre.com/role/CashEquivalentsandMarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_019e22c4-9076-7cc3-a5a8-b54315a25c9d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_019e22c4-9076-7d79-a1fd-944d3085e6e3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_019e22c4-9076-7cc3-a5a8-b54315a25c9d" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_019e22c4-9076-7d79-a1fd-944d3085e6e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_019e22c4-9076-747c-992f-5025e1ae8c02" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_019e22c4-9076-7cc3-a5a8-b54315a25c9d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_019e22c4-9076-747c-992f-5025e1ae8c02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_019e22c4-9076-7258-a5b7-d1ca573e981f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_019e22c4-9076-7cc3-a5a8-b54315a25c9d" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_019e22c4-9076-7258-a5b7-d1ca573e981f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://spyre.com/role/AccruedandOtherCurrentLiabilitiesTables" xlink:type="simple" xlink:href="syre-20260630.xsd#AccruedandOtherCurrentLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://spyre.com/role/AccruedandOtherCurrentLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_019e22c4-9076-77b2-8e8e-2e21aa45f6a2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_019e22c4-9076-7d2f-8d88-16170dde50cb" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_019e22c4-9076-77b2-8e8e-2e21aa45f6a2" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_019e22c4-9076-7d2f-8d88-16170dde50cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://spyre.com/role/RelatedPartyTransactionsTables" xlink:type="simple" xlink:href="syre-20260630.xsd#RelatedPartyTransactionsTables"/>
  <link:presentationLink xlink:role="http://spyre.com/role/RelatedPartyTransactionsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_019e22c4-9076-7e5d-8685-d8003a40adfe" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_019e22c4-9076-7917-aad5-c15b93921ff1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_019e22c4-9076-7e5d-8685-d8003a40adfe" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_019e22c4-9076-7917-aad5-c15b93921ff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://spyre.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="syre-20260630.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://spyre.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019e22c4-9076-7bb2-9d4b-4997e7ffb0c1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock_019e22c4-9076-72ae-96e2-b0d46c88c884" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019e22c4-9076-7bb2-9d4b-4997e7ffb0c1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock_019e22c4-9076-72ae-96e2-b0d46c88c884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_019e22c4-9076-78aa-b2ea-e248b19de9e4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019e22c4-9076-7bb2-9d4b-4997e7ffb0c1" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_019e22c4-9076-78aa-b2ea-e248b19de9e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_019e22c4-9076-7b95-9fd8-5a50f23fc254" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019e22c4-9076-7bb2-9d4b-4997e7ffb0c1" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_019e22c4-9076-7b95-9fd8-5a50f23fc254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://spyre.com/role/SegmentReportingTables" xlink:type="simple" xlink:href="syre-20260630.xsd#SegmentReportingTables"/>
  <link:presentationLink xlink:role="http://spyre.com/role/SegmentReportingTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_019e22c4-9076-7735-b56f-30f9867f3688" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_019e22c4-9076-7050-8e43-a66b80533fd2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_019e22c4-9076-7735-b56f-30f9867f3688" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_019e22c4-9076-7050-8e43-a66b80533fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://spyre.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="syre-20260630.xsd#NetLossPerShareTables"/>
  <link:presentationLink xlink:role="http://spyre.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_019e22c4-9076-780d-b7d3-f782a7be45a2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_019e22c4-9076-7ede-8908-b5ac04dc49da" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_019e22c4-9076-780d-b7d3-f782a7be45a2" xlink:to="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_019e22c4-9076-7ede-8908-b5ac04dc49da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_019e22c4-9076-7b7b-9a41-c85cc32fe2a9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_019e22c4-9076-780d-b7d3-f782a7be45a2" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_019e22c4-9076-7b7b-9a41-c85cc32fe2a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://spyre.com/role/TheCompanyandBasisofPresentationDetails" xlink:type="simple" xlink:href="syre-20260630.xsd#TheCompanyandBasisofPresentationDetails"/>
  <link:presentationLink xlink:role="http://spyre.com/role/TheCompanyandBasisofPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019e22c4-8fac-7fde-9362-fd87a9f6f2d0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_CompanyAndBasisOfPresentationTable_019e22c4-8fac-7794-9e61-7ce31a4d6f06" xlink:href="syre-20260630.xsd#syre_CompanyAndBasisOfPresentationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019e22c4-8fac-7fde-9362-fd87a9f6f2d0" xlink:to="loc_syre_CompanyAndBasisOfPresentationTable_019e22c4-8fac-7794-9e61-7ce31a4d6f06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_019e22c4-8fac-7bdc-9115-3482d4c38790" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_CompanyAndBasisOfPresentationTable_019e22c4-8fac-7794-9e61-7ce31a4d6f06" xlink:to="loc_us-gaap_AssetAcquisitionAxis_019e22c4-8fac-7bdc-9115-3482d4c38790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_019e22c4-8fac-7c4c-b682-1802bc31908a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_019e22c4-8fac-7bdc-9115-3482d4c38790" xlink:to="loc_us-gaap_AssetAcquisitionDomain_019e22c4-8fac-7c4c-b682-1802bc31908a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_SpyreTherapeuticsIncMember_019e22c4-8fac-72ad-ae58-0baaa3ac7918" xlink:href="syre-20260630.xsd#syre_SpyreTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_019e22c4-8fac-7c4c-b682-1802bc31908a" xlink:to="loc_syre_SpyreTherapeuticsIncMember_019e22c4-8fac-72ad-ae58-0baaa3ac7918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_019e22c4-8fac-7afc-8b8c-3eeffe44f81d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_CompanyAndBasisOfPresentationTable_019e22c4-8fac-7794-9e61-7ce31a4d6f06" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_019e22c4-8fac-7afc-8b8c-3eeffe44f81d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019e22c4-8fac-79bc-8d41-cafc01c86b75" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_019e22c4-8fac-7afc-8b8c-3eeffe44f81d" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019e22c4-8fac-79bc-8d41-cafc01c86b75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_AtTheMarketOffering2024SalesAgreementMember_019e22c4-8fac-777d-b3ab-e94a10d2247a" xlink:href="syre-20260630.xsd#syre_AtTheMarketOffering2024SalesAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019e22c4-8fac-79bc-8d41-cafc01c86b75" xlink:to="loc_syre_AtTheMarketOffering2024SalesAgreementMember_019e22c4-8fac-777d-b3ab-e94a10d2247a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_AtTheMarketOffering2026SalesAgreementMember_019f84dd-5fe3-71c4-b812-4ca901480187" xlink:href="syre-20260630.xsd#syre_AtTheMarketOffering2026SalesAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019e22c4-8fac-79bc-8d41-cafc01c86b75" xlink:to="loc_syre_AtTheMarketOffering2026SalesAgreementMember_019f84dd-5fe3-71c4-b812-4ca901480187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_October2025UnderwrittenOfferingMember_019e22c4-8fac-7876-b5ff-4448ef172113" xlink:href="syre-20260630.xsd#syre_October2025UnderwrittenOfferingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019e22c4-8fac-79bc-8d41-cafc01c86b75" xlink:to="loc_syre_October2025UnderwrittenOfferingMember_019e22c4-8fac-7876-b5ff-4448ef172113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_019e22c4-8fac-7859-ac4f-27d63974e9f7" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019e22c4-8fac-79bc-8d41-cafc01c86b75" xlink:to="loc_us-gaap_OverAllotmentOptionMember_019e22c4-8fac-7859-ac4f-27d63974e9f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_April2026UnderwritingOfferingMember_019e22c4-8fac-7ffb-8001-6cd5a2b0e0b8" xlink:href="syre-20260630.xsd#syre_April2026UnderwritingOfferingMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019e22c4-8fac-79bc-8d41-cafc01c86b75" xlink:to="loc_syre_April2026UnderwritingOfferingMember_019e22c4-8fac-7ffb-8001-6cd5a2b0e0b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_019e22c4-8fac-72c1-9b8c-c65488824ef2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_CompanyAndBasisOfPresentationTable_019e22c4-8fac-7794-9e61-7ce31a4d6f06" xlink:to="loc_us-gaap_StatementClassOfStockAxis_019e22c4-8fac-72c1-9b8c-c65488824ef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019e22c4-8fac-7bc6-b524-a106bba33608" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019e22c4-8fac-72c1-9b8c-c65488824ef2" xlink:to="loc_us-gaap_ClassOfStockDomain_019e22c4-8fac-7bc6-b524-a106bba33608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_019e22c4-8fac-7c5b-9406-19a556bd83fe" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_019e22c4-8fac-7bc6-b524-a106bba33608" xlink:to="loc_us-gaap_CommonStockMember_019e22c4-8fac-7c5b-9406-19a556bd83fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_CompanyAndBasisOfPresentationLineItems_019e22c4-8fac-7d17-9972-201dfeac166a" xlink:href="syre-20260630.xsd#syre_CompanyAndBasisOfPresentationLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_CompanyAndBasisOfPresentationTable_019e22c4-8fac-7794-9e61-7ce31a4d6f06" xlink:to="loc_syre_CompanyAndBasisOfPresentationLineItems_019e22c4-8fac-7d17-9972-201dfeac166a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_019e22c4-8fac-77e6-9a9a-d47ff17356a5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_CompanyAndBasisOfPresentationLineItems_019e22c4-8fac-7d17-9972-201dfeac166a" xlink:to="loc_us-gaap_NumberOfOperatingSegments_019e22c4-8fac-77e6-9a9a-d47ff17356a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_AssetAcquisitionCashPaymentThresholdPeriod_019e22c4-8fac-761a-8bce-c0c12016bb55" xlink:href="syre-20260630.xsd#syre_AssetAcquisitionCashPaymentThresholdPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_CompanyAndBasisOfPresentationLineItems_019e22c4-8fac-7d17-9972-201dfeac166a" xlink:to="loc_syre_AssetAcquisitionCashPaymentThresholdPeriod_019e22c4-8fac-761a-8bce-c0c12016bb55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_SaleOfStockAuthorizedAmount_019e22c4-8fac-7afb-9d4a-01f3ab0a5e72" xlink:href="syre-20260630.xsd#syre_SaleOfStockAuthorizedAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_CompanyAndBasisOfPresentationLineItems_019e22c4-8fac-7d17-9972-201dfeac166a" xlink:to="loc_syre_SaleOfStockAuthorizedAmount_019e22c4-8fac-7afb-9d4a-01f3ab0a5e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_019e22c4-8fac-775a-bc1d-cdbebeefa26a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_CompanyAndBasisOfPresentationLineItems_019e22c4-8fac-7d17-9972-201dfeac166a" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_019e22c4-8fac-775a-bc1d-cdbebeefa26a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_019e22c4-8fac-7910-b4d9-07bb3c9f09fa" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_CompanyAndBasisOfPresentationLineItems_019e22c4-8fac-7d17-9972-201dfeac166a" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_019e22c4-8fac-7910-b4d9-07bb3c9f09fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_019fa2dd-b937-7d30-be54-62c1bc83c180" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_CompanyAndBasisOfPresentationLineItems_019e22c4-8fac-7d17-9972-201dfeac166a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_019fa2dd-b937-7d30-be54-62c1bc83c180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_SaleOfStockRemainingAuthorizedAmount_019f35c1-b9f3-7cee-b2f5-558dac751537" xlink:href="syre-20260630.xsd#syre_SaleOfStockRemainingAuthorizedAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_CompanyAndBasisOfPresentationLineItems_019e22c4-8fac-7d17-9972-201dfeac166a" xlink:to="loc_syre_SaleOfStockRemainingAuthorizedAmount_019f35c1-b9f3-7cee-b2f5-558dac751537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_019e22c4-8fac-719d-b38c-c68bd58cd32a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_CompanyAndBasisOfPresentationLineItems_019e22c4-8fac-7d17-9972-201dfeac166a" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_019e22c4-8fac-719d-b38c-c68bd58cd32a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_019e22c4-8fac-7272-855d-321d3df3364c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_CompanyAndBasisOfPresentationLineItems_019e22c4-8fac-7d17-9972-201dfeac166a" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_019e22c4-8fac-7272-855d-321d3df3364c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_ProceedsFromRaisingCapital_019e22c4-8fac-7b48-967a-85ebccfac5ad" xlink:href="syre-20260630.xsd#syre_ProceedsFromRaisingCapital"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_CompanyAndBasisOfPresentationLineItems_019e22c4-8fac-7d17-9972-201dfeac166a" xlink:to="loc_syre_ProceedsFromRaisingCapital_019e22c4-8fac-7b48-967a-85ebccfac5ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019e22c4-8fac-7b1a-8e0e-b69b87a3fe6b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_CompanyAndBasisOfPresentationLineItems_019e22c4-8fac-7d17-9972-201dfeac166a" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019e22c4-8fac-7b1a-8e0e-b69b87a3fe6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_019e22c4-8fac-7f6a-8343-249ca702e24f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_CompanyAndBasisOfPresentationLineItems_019e22c4-8fac-7d17-9972-201dfeac166a" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_019e22c4-8fac-7f6a-8343-249ca702e24f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://spyre.com/role/FairValueMeasurementsScheduleofFairValueofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="syre-20260630.xsd#FairValueMeasurementsScheduleofFairValueofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://spyre.com/role/FairValueMeasurementsScheduleofFairValueofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_019e22c4-8fac-712a-8976-ebc1a2947198" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019e22c4-8fac-72ed-bda4-695d46db9441" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_019e22c4-8fac-712a-8976-ebc1a2947198" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019e22c4-8fac-72ed-bda4-695d46db9441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019e22c4-8fac-7e90-99e3-c7e73889c977" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019e22c4-8fac-72ed-bda4-695d46db9441" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019e22c4-8fac-7e90-99e3-c7e73889c977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019e22c4-8fac-7c41-85e6-01f8bbd99b41" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019e22c4-8fac-7e90-99e3-c7e73889c977" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019e22c4-8fac-7c41-85e6-01f8bbd99b41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_019e22c4-8fac-7324-9cc5-b1a0c5f08df3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019e22c4-8fac-7c41-85e6-01f8bbd99b41" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_019e22c4-8fac-7324-9cc5-b1a0c5f08df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_019e22c4-8fac-7471-9c7a-565c47648cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019e22c4-8fac-7c41-85e6-01f8bbd99b41" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_019e22c4-8fac-7471-9c7a-565c47648cf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_019e22c4-8fac-7aab-a0ac-f1481c0a30d6" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019e22c4-8fac-7c41-85e6-01f8bbd99b41" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_019e22c4-8fac-7aab-a0ac-f1481c0a30d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_019e22c4-8fac-7421-8c72-a0415ea916ab" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019e22c4-8fac-72ed-bda4-695d46db9441" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_019e22c4-8fac-7421-8c72-a0415ea916ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019e22c4-8fac-7fb1-8e44-11e23deb8960" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_019e22c4-8fac-7421-8c72-a0415ea916ab" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019e22c4-8fac-7fb1-8e44-11e23deb8960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_019e22c4-8fac-74c0-984d-fc8fa84b2760" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019e22c4-8fac-7fb1-8e44-11e23deb8960" xlink:to="loc_us-gaap_MoneyMarketFundsMember_019e22c4-8fac-74c0-984d-fc8fa84b2760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_019e22c4-8fac-7460-b2f1-ba35fa391bf4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019e22c4-8fac-72ed-bda4-695d46db9441" xlink:to="loc_us-gaap_FinancialInstrumentAxis_019e22c4-8fac-7460-b2f1-ba35fa391bf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e22c4-8fac-79d6-b774-6f6f11cb8c96" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019e22c4-8fac-7460-b2f1-ba35fa391bf4" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e22c4-8fac-79d6-b774-6f6f11cb8c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_019e22c4-8fac-7592-a2f8-126c18bd9efe" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e22c4-8fac-79d6-b774-6f6f11cb8c96" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_019e22c4-8fac-7592-a2f8-126c18bd9efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_019e22c4-8fac-7216-b09d-8fa0e94563b9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e22c4-8fac-79d6-b774-6f6f11cb8c96" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_019e22c4-8fac-7216-b09d-8fa0e94563b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_019e22c4-8fac-7031-8d85-68302e118bf5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e22c4-8fac-79d6-b774-6f6f11cb8c96" xlink:to="loc_us-gaap_CommercialPaperMember_019e22c4-8fac-7031-8d85-68302e118bf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_019e22c4-8fac-7ae7-9f53-21c4b09730a7" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e22c4-8fac-79d6-b774-6f6f11cb8c96" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_019e22c4-8fac-7ae7-9f53-21c4b09730a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019e22c4-8fac-78cf-a987-7916c428af01" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019e22c4-8fac-72ed-bda4-695d46db9441" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019e22c4-8fac-78cf-a987-7916c428af01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_019e22c4-8fac-726d-9233-7632868cf91d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019e22c4-8fac-78cf-a987-7916c428af01" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_019e22c4-8fac-726d-9233-7632868cf91d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_019e22c4-8fac-75b9-aa64-83d60e7a0575" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_019e22c4-8fac-726d-9233-7632868cf91d" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_019e22c4-8fac-75b9-aa64-83d60e7a0575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_019e22c4-8fac-7dcf-bee0-f308d78aa482" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_019e22c4-8fac-726d-9233-7632868cf91d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_019e22c4-8fac-7dcf-bee0-f308d78aa482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_019e22c4-8fac-74ae-88af-35551c7f5d45" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_019e22c4-8fac-726d-9233-7632868cf91d" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_019e22c4-8fac-74ae-88af-35551c7f5d45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_019e22c4-8fac-7cf3-9c25-5c6b3546838d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019e22c4-8fac-78cf-a987-7916c428af01" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_019e22c4-8fac-7cf3-9c25-5c6b3546838d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_019e22c4-8fac-7473-be1c-1887458303d3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_019e22c4-8fac-7cf3-9c25-5c6b3546838d" xlink:to="loc_us-gaap_DerivativeLiabilities_019e22c4-8fac-7473-be1c-1887458303d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_019e22c4-8fac-71be-a3ae-18f3b4b966c1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_019e22c4-8fac-7cf3-9c25-5c6b3546838d" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_019e22c4-8fac-71be-a3ae-18f3b4b966c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://spyre.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="syre-20260630.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://spyre.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_019e22c4-8fac-7aa4-ac11-ab576658f10e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019e22c4-8fac-7b02-a17e-9f3a705546d8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_019e22c4-8fac-7aa4-ac11-ab576658f10e" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019e22c4-8fac-7b02-a17e-9f3a705546d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_019e22c4-8fac-7014-a95f-c3ed5f3be7f2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019e22c4-8fac-7b02-a17e-9f3a705546d8" xlink:to="loc_us-gaap_AssetAcquisitionAxis_019e22c4-8fac-7014-a95f-c3ed5f3be7f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_019e22c4-8fac-7982-bcde-83647fd16678" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_019e22c4-8fac-7014-a95f-c3ed5f3be7f2" xlink:to="loc_us-gaap_AssetAcquisitionDomain_019e22c4-8fac-7982-bcde-83647fd16678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_SpyreTherapeuticsIncMember_019e22c4-8fac-78ff-b11e-99ace64e1ea7" xlink:href="syre-20260630.xsd#syre_SpyreTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_019e22c4-8fac-7982-bcde-83647fd16678" xlink:to="loc_syre_SpyreTherapeuticsIncMember_019e22c4-8fac-78ff-b11e-99ace64e1ea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_019e22c4-8fac-7bdf-a96e-677956d42647" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019e22c4-8fac-7b02-a17e-9f3a705546d8" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_019e22c4-8fac-7bdf-a96e-677956d42647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_019e22c4-8fac-77cd-9bc3-3d3223e8aa69" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_019e22c4-8fac-7bdf-a96e-677956d42647" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_019e22c4-8fac-77cd-9bc3-3d3223e8aa69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_ContingentValueRightLiabilityMember_019e22c4-8fac-7ce4-9018-d3bcbdd20cef" xlink:href="syre-20260630.xsd#syre_ContingentValueRightLiabilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_019e22c4-8fac-77cd-9bc3-3d3223e8aa69" xlink:to="loc_syre_ContingentValueRightLiabilityMember_019e22c4-8fac-7ce4-9018-d3bcbdd20cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019e22c4-8fac-7ecf-92d5-d9aed672acf9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019e22c4-8fac-7b02-a17e-9f3a705546d8" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019e22c4-8fac-7ecf-92d5-d9aed672acf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_AssetAcquisitionStockholderPaymentPeriod_019e22c4-8fac-7452-b0a9-716fbc17ee99" xlink:href="syre-20260630.xsd#syre_AssetAcquisitionStockholderPaymentPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019e22c4-8fac-7ecf-92d5-d9aed672acf9" xlink:to="loc_syre_AssetAcquisitionStockholderPaymentPeriod_019e22c4-8fac-7452-b0a9-716fbc17ee99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_AssetAcquisitionCashPaymentThresholdPeriod_019e22c4-8fac-749b-ab27-a332828904ca" xlink:href="syre-20260630.xsd#syre_AssetAcquisitionCashPaymentThresholdPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019e22c4-8fac-7ecf-92d5-d9aed672acf9" xlink:to="loc_syre_AssetAcquisitionCashPaymentThresholdPeriod_019e22c4-8fac-749b-ab27-a332828904ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_019e22c4-8fac-70ad-a69f-75a6e71173f7" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019e22c4-8fac-7ecf-92d5-d9aed672acf9" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_019e22c4-8fac-70ad-a69f-75a6e71173f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_019fa2d9-0fbe-7a9f-9267-07dceafa69a6" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019e22c4-8fac-7ecf-92d5-d9aed672acf9" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_019fa2d9-0fbe-7a9f-9267-07dceafa69a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://spyre.com/role/FairValueMeasurementsScheduleofSignificantInputsUsedtoEstimatetheFairValueofCVRLiabilityDetails" xlink:type="simple" xlink:href="syre-20260630.xsd#FairValueMeasurementsScheduleofSignificantInputsUsedtoEstimatetheFairValueofCVRLiabilityDetails"/>
  <link:presentationLink xlink:role="http://spyre.com/role/FairValueMeasurementsScheduleofSignificantInputsUsedtoEstimatetheFairValueofCVRLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_019e22c4-8fac-75e1-8878-59f9177ec312" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_019e22c4-8fac-7878-83b9-3507bcda7153" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_019e22c4-8fac-75e1-8878-59f9177ec312" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_019e22c4-8fac-7878-83b9-3507bcda7153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_019e22c4-8fac-7d14-88c4-43cbe917cb00" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_019e22c4-8fac-7878-83b9-3507bcda7153" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_019e22c4-8fac-7d14-88c4-43cbe917cb00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_019e22c4-8fac-7454-a208-215d073a32bc" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_019e22c4-8fac-7d14-88c4-43cbe917cb00" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_019e22c4-8fac-7454-a208-215d073a32bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_ContingentValueRightLiabilityMember_019e22c4-8fac-7d99-8b14-811e068486d8" xlink:href="syre-20260630.xsd#syre_ContingentValueRightLiabilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_019e22c4-8fac-7454-a208-215d073a32bc" xlink:to="loc_syre_ContingentValueRightLiabilityMember_019e22c4-8fac-7d99-8b14-811e068486d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019e22c4-8fac-741e-a201-b87df10ed5c9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_019e22c4-8fac-7878-83b9-3507bcda7153" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019e22c4-8fac-741e-a201-b87df10ed5c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019e22c4-8fac-7ad3-ab2d-7589baca2e38" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019e22c4-8fac-741e-a201-b87df10ed5c9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019e22c4-8fac-7ad3-ab2d-7589baca2e38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_019e22c4-8fac-7e85-9299-08c5d27f77b7" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019e22c4-8fac-7ad3-ab2d-7589baca2e38" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_019e22c4-8fac-7e85-9299-08c5d27f77b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_019e22c4-8fac-79ca-8b09-91785e1cb3ed" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_019e22c4-8fac-7878-83b9-3507bcda7153" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_019e22c4-8fac-79ca-8b09-91785e1cb3ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_019e22c4-8fac-754a-9c2b-67ed5349fe60" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_019e22c4-8fac-79ca-8b09-91785e1cb3ed" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_019e22c4-8fac-754a-9c2b-67ed5349fe60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_019e22c4-8fac-7bf8-8a1d-13b3760b77cd" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_019e22c4-8fac-754a-9c2b-67ed5349fe60" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_019e22c4-8fac-7bf8-8a1d-13b3760b77cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_019e22c4-8fac-7311-8a76-671818df12ec" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_019e22c4-8fac-7878-83b9-3507bcda7153" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_019e22c4-8fac-7311-8a76-671818df12ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityMeasurementInput_019e22c4-8fac-7832-97f3-564b67d55db4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativeLiabilityMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_019e22c4-8fac-7311-8a76-671818df12ec" xlink:to="loc_us-gaap_DerivativeLiabilityMeasurementInput_019e22c4-8fac-7832-97f3-564b67d55db4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://spyre.com/role/FairValueMeasurementsScheduleofChangesinCVRLiabilityDetails" xlink:type="simple" xlink:href="syre-20260630.xsd#FairValueMeasurementsScheduleofChangesinCVRLiabilityDetails"/>
  <link:presentationLink xlink:role="http://spyre.com/role/FairValueMeasurementsScheduleofChangesinCVRLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_019e22c4-8fac-7e18-a985-ae3f59691ab8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_019e22c4-9076-7761-b991-9b1f4a233097" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_019e22c4-8fac-7e18-a985-ae3f59691ab8" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_019e22c4-9076-7761-b991-9b1f4a233097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_019e22c4-9076-72fb-8823-bf7687cfcdf1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_019e22c4-9076-7761-b991-9b1f4a233097" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_019e22c4-9076-72fb-8823-bf7687cfcdf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_019e22c4-9076-7de0-8fa1-5c18230f3dc4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_019e22c4-9076-72fb-8823-bf7687cfcdf1" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_019e22c4-9076-7de0-8fa1-5c18230f3dc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_ContingentValueRightLiabilityMember_019e22c4-9076-7ebc-8f12-b860e16854fe" xlink:href="syre-20260630.xsd#syre_ContingentValueRightLiabilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_019e22c4-9076-7de0-8fa1-5c18230f3dc4" xlink:to="loc_syre_ContingentValueRightLiabilityMember_019e22c4-9076-7ebc-8f12-b860e16854fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_019e22c4-9076-7746-b945-33c68d00d577" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_019e22c4-9076-7761-b991-9b1f4a233097" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_019e22c4-9076-7746-b945-33c68d00d577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019e22c4-9076-75be-a6c4-ebd92cbf3ea4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_019e22c4-9076-7746-b945-33c68d00d577" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019e22c4-9076-75be-a6c4-ebd92cbf3ea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_019e22c4-9076-7658-b380-9732d6b25a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019e22c4-9076-75be-a6c4-ebd92cbf3ea4" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_019e22c4-9076-7658-b380-9732d6b25a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_019e22c4-9076-7e29-b400-851656bee77c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019e22c4-9076-75be-a6c4-ebd92cbf3ea4" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_019e22c4-9076-7e29-b400-851656bee77c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_019f82ed-dad5-7569-883c-20fa46de27cc" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019e22c4-9076-75be-a6c4-ebd92cbf3ea4" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_019f82ed-dad5-7569-883c-20fa46de27cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_019e22c4-9076-79f8-a861-a3f6355c74f5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019e22c4-9076-75be-a6c4-ebd92cbf3ea4" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_019e22c4-9076-79f8-a861-a3f6355c74f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofEstimatedFairValueofCashEquivalentsandMarketableSecuritiesandGrossUnrealizedGainsandLossesDetails" xlink:type="simple" xlink:href="syre-20260630.xsd#CashEquivalentsandMarketableSecuritiesScheduleofEstimatedFairValueofCashEquivalentsandMarketableSecuritiesandGrossUnrealizedGainsandLossesDetails"/>
  <link:presentationLink xlink:role="http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofEstimatedFairValueofCashEquivalentsandMarketableSecuritiesandGrossUnrealizedGainsandLossesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_019e22c4-9076-7a47-8016-a3702026e0dd" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019e22c4-9076-71d2-9778-f234e737b47e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_019e22c4-9076-7a47-8016-a3702026e0dd" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019e22c4-9076-71d2-9778-f234e737b47e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_019e22c4-9076-7793-89c3-878370190188" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019e22c4-9076-71d2-9778-f234e737b47e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_019e22c4-9076-7793-89c3-878370190188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019e22c4-9076-706c-be27-42e48d813a76" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_019e22c4-9076-7793-89c3-878370190188" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019e22c4-9076-706c-be27-42e48d813a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_019e22c4-9076-7d12-87d1-e9b0197d87ed" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019e22c4-9076-706c-be27-42e48d813a76" xlink:to="loc_us-gaap_MoneyMarketFundsMember_019e22c4-9076-7d12-87d1-e9b0197d87ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_019e22c4-9076-79a6-ac8e-5b2a92f53daf" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019e22c4-9076-706c-be27-42e48d813a76" xlink:to="loc_us-gaap_CommercialPaperMember_019e22c4-9076-79a6-ac8e-5b2a92f53daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_019e22c4-9076-7a7c-9195-70482e4bb43b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019e22c4-9076-71d2-9778-f234e737b47e" xlink:to="loc_us-gaap_FinancialInstrumentAxis_019e22c4-9076-7a7c-9195-70482e4bb43b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e22c4-9076-71ca-9097-b5925464c054" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019e22c4-9076-7a7c-9195-70482e4bb43b" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e22c4-9076-71ca-9097-b5925464c054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_019e22c4-9076-7a22-9436-02abe6eb73a2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e22c4-9076-71ca-9097-b5925464c054" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_019e22c4-9076-7a22-9436-02abe6eb73a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_019e22c4-9076-796f-b763-6bc99b0b9cf8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e22c4-9076-71ca-9097-b5925464c054" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_019e22c4-9076-796f-b763-6bc99b0b9cf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_019e22c4-9076-7357-8129-90bc23515419" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e22c4-9076-71ca-9097-b5925464c054" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_019e22c4-9076-7357-8129-90bc23515419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_019e22c4-9076-7eec-bdc4-105c17710405" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e22c4-9076-71ca-9097-b5925464c054" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_019e22c4-9076-7eec-bdc4-105c17710405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019e22c4-9076-74bf-8d39-158aabff1f52" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019e22c4-9076-71d2-9778-f234e737b47e" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019e22c4-9076-74bf-8d39-158aabff1f52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_019e22c4-9076-7e9a-a249-80c5ce29df2f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019e22c4-9076-74bf-8d39-158aabff1f52" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_019e22c4-9076-7e9a-a249-80c5ce29df2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_CashEquivalentsUnrealizedGains_019e22c4-9076-78c0-a776-e56757dfe700" xlink:href="syre-20260630.xsd#syre_CashEquivalentsUnrealizedGains"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019e22c4-9076-74bf-8d39-158aabff1f52" xlink:to="loc_syre_CashEquivalentsUnrealizedGains_019e22c4-9076-78c0-a776-e56757dfe700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_CashEquivalentsUnrealizedLosses_019e22c4-9076-7d99-92fb-59ccde8eaed1" xlink:href="syre-20260630.xsd#syre_CashEquivalentsUnrealizedLosses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019e22c4-9076-74bf-8d39-158aabff1f52" xlink:to="loc_syre_CashEquivalentsUnrealizedLosses_019e22c4-9076-7d99-92fb-59ccde8eaed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_019e22c4-9076-7133-be27-9f2782960f2f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019e22c4-9076-74bf-8d39-158aabff1f52" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_019e22c4-9076-7133-be27-9f2782960f2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_019e22c4-9076-7b27-803d-0af2dc9f8acb" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019e22c4-9076-74bf-8d39-158aabff1f52" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_019e22c4-9076-7b27-803d-0af2dc9f8acb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_019e22c4-9076-7a45-b651-30f6b1a95e93" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019e22c4-9076-74bf-8d39-158aabff1f52" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_019e22c4-9076-7a45-b651-30f6b1a95e93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_019e22c4-9076-7df8-ab29-1319fb535117" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019e22c4-9076-74bf-8d39-158aabff1f52" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_019e22c4-9076-7df8-ab29-1319fb535117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_019e22c4-9076-70e6-9de5-25e64ca39d07" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019e22c4-9076-74bf-8d39-158aabff1f52" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_019e22c4-9076-70e6-9de5-25e64ca39d07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="syre-20260630.xsd#CashEquivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetails"/>
  <link:presentationLink xlink:role="http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_019e22c4-9076-7200-910e-77d2ec6b5426" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019e22c4-9076-7000-8d93-ee54e8d9b682" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_019e22c4-9076-7200-910e-77d2ec6b5426" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019e22c4-9076-7000-8d93-ee54e8d9b682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_019e22c4-9076-77ed-bf0a-0a844c6faa74" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019e22c4-9076-7000-8d93-ee54e8d9b682" xlink:to="loc_us-gaap_FinancialInstrumentAxis_019e22c4-9076-77ed-bf0a-0a844c6faa74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e22c4-9076-704c-9b7a-ee7f95c86a31" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019e22c4-9076-77ed-bf0a-0a844c6faa74" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e22c4-9076-704c-9b7a-ee7f95c86a31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_019e22c4-9076-7958-beab-269be7700669" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e22c4-9076-704c-9b7a-ee7f95c86a31" xlink:to="loc_us-gaap_CommercialPaperMember_019e22c4-9076-7958-beab-269be7700669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_019e22c4-9076-7f2b-9293-f91a59a53df2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e22c4-9076-704c-9b7a-ee7f95c86a31" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_019e22c4-9076-7f2b-9293-f91a59a53df2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_019e22c4-9076-7a0e-97dc-92e57a9bb9ec" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e22c4-9076-704c-9b7a-ee7f95c86a31" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_019e22c4-9076-7a0e-97dc-92e57a9bb9ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_019e22c4-9076-74ff-b597-739173fd75a0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e22c4-9076-704c-9b7a-ee7f95c86a31" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_019e22c4-9076-74ff-b597-739173fd75a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019e22c4-9076-79f9-9efb-71ab61d27fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019e22c4-9076-7000-8d93-ee54e8d9b682" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019e22c4-9076-79f9-9efb-71ab61d27fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_019e22c4-9076-7d94-9703-ea5497bdcc5c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019e22c4-9076-79f9-9efb-71ab61d27fe0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_019e22c4-9076-7d94-9703-ea5497bdcc5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_019e22c4-9076-7b36-b102-47d636a0d896" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_019e22c4-9076-7d94-9703-ea5497bdcc5c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_019e22c4-9076-7b36-b102-47d636a0d896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_019e22c4-9076-761c-91dd-0dc85c366680" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_019e22c4-9076-7d94-9703-ea5497bdcc5c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_019e22c4-9076-761c-91dd-0dc85c366680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_019e22c4-9076-773d-b571-bede66050e6b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_019e22c4-9076-7d94-9703-ea5497bdcc5c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_019e22c4-9076-773d-b571-bede66050e6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_019e22c4-9076-7659-907d-9c6a1816648d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019e22c4-9076-79f9-9efb-71ab61d27fe0" xlink:to="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_019e22c4-9076-7659-907d-9c6a1816648d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_019e22c4-9076-7226-b8a0-e739fafc2dab" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_019e22c4-9076-7659-907d-9c6a1816648d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_019e22c4-9076-7226-b8a0-e739fafc2dab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_019e22c4-9076-7ee2-ab1d-3e96ab03d75c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_019e22c4-9076-7659-907d-9c6a1816648d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_019e22c4-9076-7ee2-ab1d-3e96ab03d75c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_019e22c4-9076-7f5e-bc63-a22b0df64e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_019e22c4-9076-7659-907d-9c6a1816648d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_019e22c4-9076-7f5e-bc63-a22b0df64e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://spyre.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails" xlink:type="simple" xlink:href="syre-20260630.xsd#CashEquivalentsandMarketableSecuritiesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://spyre.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_019e22c4-9076-731e-acee-bd013b8f7b81" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_CashEquivalentsAndMarketableSecuritiesTable_019e22c4-9076-7a30-ac51-bc3e721c935e" xlink:href="syre-20260630.xsd#syre_CashEquivalentsAndMarketableSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_019e22c4-9076-731e-acee-bd013b8f7b81" xlink:to="loc_syre_CashEquivalentsAndMarketableSecuritiesTable_019e22c4-9076-7a30-ac51-bc3e721c935e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_019e22c4-9076-7a6c-9049-67c97514eae4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_CashEquivalentsAndMarketableSecuritiesTable_019e22c4-9076-7a30-ac51-bc3e721c935e" xlink:to="loc_us-gaap_FinancialInstrumentAxis_019e22c4-9076-7a6c-9049-67c97514eae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e22c4-9076-7e40-873f-94ec78f5415f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019e22c4-9076-7a6c-9049-67c97514eae4" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e22c4-9076-7e40-873f-94ec78f5415f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_019e22c4-9076-79f9-a9bb-4cfb89ef6b3a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e22c4-9076-7e40-873f-94ec78f5415f" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_019e22c4-9076-79f9-a9bb-4cfb89ef6b3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_USBankingInstitutionMember_019e22c4-9076-70b8-bb38-589faf3d6c27" xlink:href="syre-20260630.xsd#syre_USBankingInstitutionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019e22c4-9076-7e40-873f-94ec78f5415f" xlink:to="loc_syre_USBankingInstitutionMember_019e22c4-9076-70b8-bb38-589faf3d6c27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_019e22c4-9076-7284-b5db-d1ca3bbe259a" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_CashEquivalentsAndMarketableSecuritiesTable_019e22c4-9076-7a30-ac51-bc3e721c935e" xlink:to="loc_srt_RangeAxis_019e22c4-9076-7284-b5db-d1ca3bbe259a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019e22c4-9076-72df-867e-494470e8e70a" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_019e22c4-9076-7284-b5db-d1ca3bbe259a" xlink:to="loc_srt_RangeMember_019e22c4-9076-72df-867e-494470e8e70a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_019e22c4-9076-7ad6-b85a-7448b199ab2d" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_019e22c4-9076-72df-867e-494470e8e70a" xlink:to="loc_srt_MaximumMember_019e22c4-9076-7ad6-b85a-7448b199ab2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_CashEquivalentsAndMarketableSecuritiesLineItems_019e22c4-9076-795d-9b17-6a08d675f618" xlink:href="syre-20260630.xsd#syre_CashEquivalentsAndMarketableSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_CashEquivalentsAndMarketableSecuritiesTable_019e22c4-9076-7a30-ac51-bc3e721c935e" xlink:to="loc_syre_CashEquivalentsAndMarketableSecuritiesLineItems_019e22c4-9076-795d-9b17-6a08d675f618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest_019e22c4-9076-7f08-8119-84949d747f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_CashEquivalentsAndMarketableSecuritiesLineItems_019e22c4-9076-795d-9b17-6a08d675f618" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest_019e22c4-9076-7f08-8119-84949d747f8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_ImpairmentOfMarketableSecurities_019e22c4-9076-7825-bd42-9f98754fd6c2" xlink:href="syre-20260630.xsd#syre_ImpairmentOfMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_CashEquivalentsAndMarketableSecuritiesLineItems_019e22c4-9076-795d-9b17-6a08d675f618" xlink:to="loc_syre_ImpairmentOfMarketableSecurities_019e22c4-9076-7825-bd42-9f98754fd6c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_NumberOfDomesticBankingInstitutions_019e22c4-9076-76c8-b357-80ad4b55de06" xlink:href="syre-20260630.xsd#syre_NumberOfDomesticBankingInstitutions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_CashEquivalentsAndMarketableSecuritiesLineItems_019e22c4-9076-795d-9b17-6a08d675f618" xlink:to="loc_syre_NumberOfDomesticBankingInstitutions_019e22c4-9076-76c8-b357-80ad4b55de06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFDICInsuredAmount_019e22c4-9076-789d-97c9-e2cdf7e48363" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashFDICInsuredAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_CashEquivalentsAndMarketableSecuritiesLineItems_019e22c4-9076-795d-9b17-6a08d675f618" xlink:to="loc_us-gaap_CashFDICInsuredAmount_019e22c4-9076-789d-97c9-e2cdf7e48363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_019e22c4-9076-78b3-bb92-68ae9c773e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_CashEquivalentsAndMarketableSecuritiesLineItems_019e22c4-9076-795d-9b17-6a08d675f618" xlink:to="loc_us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_019e22c4-9076-78b3-bb92-68ae9c773e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable_019e22c4-9076-7f28-9638-ce7a32a84141" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestReceivable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_CashEquivalentsAndMarketableSecuritiesLineItems_019e22c4-9076-795d-9b17-6a08d675f618" xlink:to="loc_us-gaap_InterestReceivable_019e22c4-9076-7f28-9638-ce7a32a84141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofContractualMaturitiesofMarketableSecuritiesatEstimatedFairValueDetails" xlink:type="simple" xlink:href="syre-20260630.xsd#CashEquivalentsandMarketableSecuritiesScheduleofContractualMaturitiesofMarketableSecuritiesatEstimatedFairValueDetails"/>
  <link:presentationLink xlink:role="http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofContractualMaturitiesofMarketableSecuritiesatEstimatedFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_019e22c4-9076-73f4-806d-3fc50633da74" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_019e22c4-9076-7d0e-a205-1bad18651024" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_019e22c4-9076-73f4-806d-3fc50633da74" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_019e22c4-9076-7d0e-a205-1bad18651024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne_019e22c4-9076-795d-8fad-83afd15ed836" xlink:href="syre-20260630.xsd#syre_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_019e22c4-9076-73f4-806d-3fc50633da74" xlink:to="loc_syre_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne_019e22c4-9076-795d-8fad-83afd15ed836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_019e22c4-9076-7e27-a592-b53fc342ccae" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_019e22c4-9076-73f4-806d-3fc50633da74" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_019e22c4-9076-7e27-a592-b53fc342ccae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://spyre.com/role/AccruedandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="syre-20260630.xsd#AccruedandOtherCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://spyre.com/role/AccruedandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_019e22c4-9076-7f4e-9a48-017a2101e3cd" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_019e22c4-9076-7b12-87f1-1def8f46046c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_019e22c4-9076-7f4e-9a48-017a2101e3cd" xlink:to="loc_us-gaap_AccruedSalariesCurrent_019e22c4-9076-7b12-87f1-1def8f46046c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_AccruedContractedResearchAndDevelopmentCosts_019e22c4-9076-7533-a480-828bc355d70b" xlink:href="syre-20260630.xsd#syre_AccruedContractedResearchAndDevelopmentCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_019e22c4-9076-7f4e-9a48-017a2101e3cd" xlink:to="loc_syre_AccruedContractedResearchAndDevelopmentCosts_019e22c4-9076-7533-a480-828bc355d70b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_019e22c4-9076-7bc5-9082-9fd5c9d24a88" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_019e22c4-9076-7f4e-9a48-017a2101e3cd" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_019e22c4-9076-7bc5-9082-9fd5c9d24a88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_019e22c4-9076-7f06-85c6-882eb682e3fd" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_019e22c4-9076-7f4e-9a48-017a2101e3cd" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_019e22c4-9076-7f06-85c6-882eb682e3fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_019e22c4-9076-7216-b72c-0d7cb3301177" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_019e22c4-9076-7f4e-9a48-017a2101e3cd" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_019e22c4-9076-7216-b72c-0d7cb3301177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://spyre.com/role/LicensingAgreementsDetails" xlink:type="simple" xlink:href="syre-20260630.xsd#LicensingAgreementsDetails"/>
  <link:presentationLink xlink:role="http://spyre.com/role/LicensingAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_syre_LicensingAgreementsAbstract_019e22c4-9076-7d2b-83e0-65a96edfd6ec" xlink:href="syre-20260630.xsd#syre_LicensingAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019e22c4-9076-727d-97f3-a25aa95dab55" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_LicensingAgreementsAbstract_019e22c4-9076-7d2b-83e0-65a96edfd6ec" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019e22c4-9076-727d-97f3-a25aa95dab55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_019e22c4-9076-7f4f-a768-668dc3631589" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019e22c4-9076-727d-97f3-a25aa95dab55" xlink:to="loc_srt_RangeAxis_019e22c4-9076-7f4f-a768-668dc3631589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019e22c4-9076-7888-b93d-32161eec804d" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_019e22c4-9076-7f4f-a768-668dc3631589" xlink:to="loc_srt_RangeMember_019e22c4-9076-7888-b93d-32161eec804d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_019e22c4-9076-7c6f-9841-1fcb46539be9" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_019e22c4-9076-7888-b93d-32161eec804d" xlink:to="loc_srt_MaximumMember_019e22c4-9076-7c6f-9841-1fcb46539be9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_019e22c4-9076-7ba6-8b7b-a0fb13981021" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019e22c4-9076-727d-97f3-a25aa95dab55" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_019e22c4-9076-7ba6-8b7b-a0fb13981021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_019e22c4-9076-723f-9eab-d283d43b84aa" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_019e22c4-9076-7ba6-8b7b-a0fb13981021" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_019e22c4-9076-723f-9eab-d283d43b84aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_ParagonAgreementMember_019e22c4-9076-757c-8519-784a4b6e110a" xlink:href="syre-20260630.xsd#syre_ParagonAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_019e22c4-9076-723f-9eab-d283d43b84aa" xlink:to="loc_syre_ParagonAgreementMember_019e22c4-9076-757c-8519-784a4b6e110a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_Spy001LicenseAgreementMember_019e22c4-9076-73e2-a4d2-ddeccc226107" xlink:href="syre-20260630.xsd#syre_Spy001LicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_ParagonAgreementMember_019e22c4-9076-757c-8519-784a4b6e110a" xlink:to="loc_syre_Spy001LicenseAgreementMember_019e22c4-9076-73e2-a4d2-ddeccc226107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_SPY002AndSPY072LicenseAgreementMember_019e22c4-9076-76cd-b2ae-cda7d6dc836d" xlink:href="syre-20260630.xsd#syre_SPY002AndSPY072LicenseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_ParagonAgreementMember_019e22c4-9076-757c-8519-784a4b6e110a" xlink:to="loc_syre_SPY002AndSPY072LicenseAgreementMember_019e22c4-9076-76cd-b2ae-cda7d6dc836d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_SPY003LicenseAgreementMember_019e22c4-9076-7f6a-88c0-cb3cd4830930" xlink:href="syre-20260630.xsd#syre_SPY003LicenseAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_ParagonAgreementMember_019e22c4-9076-757c-8519-784a4b6e110a" xlink:to="loc_syre_SPY003LicenseAgreementMember_019e22c4-9076-7f6a-88c0-cb3cd4830930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_ParagonAgreementLicenseMilestonePaymentsMember_019e22c4-9076-7f78-8ba0-6a012a3a72b0" xlink:href="syre-20260630.xsd#syre_ParagonAgreementLicenseMilestonePaymentsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_ParagonAgreementMember_019e22c4-9076-757c-8519-784a4b6e110a" xlink:to="loc_syre_ParagonAgreementLicenseMilestonePaymentsMember_019e22c4-9076-7f78-8ba0-6a012a3a72b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e22c4-9076-7370-871b-7cef5c5f83d8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019e22c4-9076-727d-97f3-a25aa95dab55" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e22c4-9076-7370-871b-7cef5c5f83d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019e22c4-9076-7196-aaa6-3a61728921b2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e22c4-9076-7370-871b-7cef5c5f83d8" xlink:to="loc_us-gaap_RelatedPartyDomain_019e22c4-9076-7196-aaa6-3a61728921b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_019e22c4-9076-7e84-a27b-92751968ec87" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_019e22c4-9076-7196-aaa6-3a61728921b2" xlink:to="loc_us-gaap_RelatedPartyMember_019e22c4-9076-7e84-a27b-92751968ec87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_019e22c4-9076-7996-bb55-fd978e0fb2d3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019e22c4-9076-727d-97f3-a25aa95dab55" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_019e22c4-9076-7996-bb55-fd978e0fb2d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_AmountToBePaidUnderAgreement_019e22c4-9076-759b-b5bd-e51639ffcf11" xlink:href="syre-20260630.xsd#syre_AmountToBePaidUnderAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019e22c4-9076-7996-bb55-fd978e0fb2d3" xlink:to="loc_syre_AmountToBePaidUnderAgreement_019e22c4-9076-759b-b5bd-e51639ffcf11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_PaymentOfMilestone_019e22c4-9076-7fe2-afc4-c4bb28a2c11a" xlink:href="syre-20260630.xsd#syre_PaymentOfMilestone"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019e22c4-9076-7996-bb55-fd978e0fb2d3" xlink:to="loc_syre_PaymentOfMilestone_019e22c4-9076-7fe2-afc4-c4bb28a2c11a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_CampaignTimelineMinimumTerm_019e22c4-9076-7f58-a62c-4b4e2f8d3e97" xlink:href="syre-20260630.xsd#syre_CampaignTimelineMinimumTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019e22c4-9076-7996-bb55-fd978e0fb2d3" xlink:to="loc_syre_CampaignTimelineMinimumTerm_019e22c4-9076-7f58-a62c-4b4e2f8d3e97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_RoyaltyStepDownPercent_019e22c4-9076-739c-8246-b7ab51f59883" xlink:href="syre-20260630.xsd#syre_RoyaltyStepDownPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019e22c4-9076-7996-bb55-fd978e0fb2d3" xlink:to="loc_syre_RoyaltyStepDownPercent_019e22c4-9076-739c-8246-b7ab51f59883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_RoyaltyTermExpirationPeriod_019e22c4-9076-7e4a-87a2-6d90ecb6f1e2" xlink:href="syre-20260630.xsd#syre_RoyaltyTermExpirationPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019e22c4-9076-7996-bb55-fd978e0fb2d3" xlink:to="loc_syre_RoyaltyTermExpirationPeriod_019e22c4-9076-7e4a-87a2-6d90ecb6f1e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_TerminationNoticePeriod_019e22c4-9076-726d-8c9c-9230e4747d9d" xlink:href="syre-20260630.xsd#syre_TerminationNoticePeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019e22c4-9076-7996-bb55-fd978e0fb2d3" xlink:to="loc_syre_TerminationNoticePeriod_019e22c4-9076-726d-8c9c-9230e4747d9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_SublicensingFee_019e22c4-9076-7251-a28e-961798073d04" xlink:href="syre-20260630.xsd#syre_SublicensingFee"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019e22c4-9076-7996-bb55-fd978e0fb2d3" xlink:to="loc_syre_SublicensingFee_019e22c4-9076-7251-a28e-961798073d04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_019e22c4-9076-7f95-abf7-cbaaaeb35783" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019e22c4-9076-7996-bb55-fd978e0fb2d3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_019e22c4-9076-7f95-abf7-cbaaaeb35783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_LicenseAgreementMilestonePayments_019e22c4-9076-7301-9997-ab6d68a43f19" xlink:href="syre-20260630.xsd#syre_LicenseAgreementMilestonePayments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019e22c4-9076-7996-bb55-fd978e0fb2d3" xlink:to="loc_syre_LicenseAgreementMilestonePayments_019e22c4-9076-7301-9997-ab6d68a43f19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_LicenseAgreementMilestonePaymentsOutstandingAndPayable_019e22c4-9076-7a9a-b9c9-c2903b74a651" xlink:href="syre-20260630.xsd#syre_LicenseAgreementMilestonePaymentsOutstandingAndPayable"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019e22c4-9076-7996-bb55-fd978e0fb2d3" xlink:to="loc_syre_LicenseAgreementMilestonePaymentsOutstandingAndPayable_019e22c4-9076-7a9a-b9c9-c2903b74a651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_PaymentForSublicensingFee_019e22c4-9076-7365-83b9-bc5eef03aca5" xlink:href="syre-20260630.xsd#syre_PaymentForSublicensingFee"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019e22c4-9076-7996-bb55-fd978e0fb2d3" xlink:to="loc_syre_PaymentForSublicensingFee_019e22c4-9076-7365-83b9-bc5eef03aca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_SublicensingFeeOutstandingAndPayable_019e22c4-9076-7a82-a2a5-a340eed494ec" xlink:href="syre-20260630.xsd#syre_SublicensingFeeOutstandingAndPayable"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019e22c4-9076-7996-bb55-fd978e0fb2d3" xlink:to="loc_syre_SublicensingFeeOutstandingAndPayable_019e22c4-9076-7a82-a2a5-a340eed494ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://spyre.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:type="simple" xlink:href="syre-20260630.xsd#RelatedPartyTransactionsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://spyre.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_019e22c4-9076-7140-8a1f-58209e8110a1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019e22c4-9076-73a3-a665-53c603dfc6b2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_019e22c4-9076-7140-8a1f-58209e8110a1" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019e22c4-9076-73a3-a665-53c603dfc6b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_019e22c4-9076-7775-aa5b-88ae5063af3d" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019e22c4-9076-73a3-a665-53c603dfc6b2" xlink:to="loc_srt_OwnershipAxis_019e22c4-9076-7775-aa5b-88ae5063af3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_019e22c4-9076-70f2-aa49-e189b199327e" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_019e22c4-9076-7775-aa5b-88ae5063af3d" xlink:to="loc_srt_OwnershipDomain_019e22c4-9076-70f2-aa49-e189b199327e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_ParagonTherapeuticsIncMember_019e22c4-9076-738a-be0a-4cdb0e3cafe9" xlink:href="syre-20260630.xsd#syre_ParagonTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_019e22c4-9076-70f2-aa49-e189b199327e" xlink:to="loc_syre_ParagonTherapeuticsIncMember_019e22c4-9076-738a-be0a-4cdb0e3cafe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_FairmountFundsManagementLlcMember_019e22c4-9076-767f-bdd3-0094f9cd7c66" xlink:href="syre-20260630.xsd#syre_FairmountFundsManagementLlcMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_019e22c4-9076-70f2-aa49-e189b199327e" xlink:to="loc_syre_FairmountFundsManagementLlcMember_019e22c4-9076-767f-bdd3-0094f9cd7c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_019e22c4-9076-7cd7-bc93-ef0142f13a72" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019e22c4-9076-73a3-a665-53c603dfc6b2" xlink:to="loc_srt_RangeAxis_019e22c4-9076-7cd7-bc93-ef0142f13a72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019e22c4-9076-700e-b40e-66cfeec4d95f" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_019e22c4-9076-7cd7-bc93-ef0142f13a72" xlink:to="loc_srt_RangeMember_019e22c4-9076-700e-b40e-66cfeec4d95f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_019e22c4-9076-7667-b590-921113076e7b" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_019e22c4-9076-700e-b40e-66cfeec4d95f" xlink:to="loc_srt_MaximumMember_019e22c4-9076-7667-b590-921113076e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_019e22c4-9076-7efe-a1fc-21933f866756" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_019e22c4-9076-700e-b40e-66cfeec4d95f" xlink:to="loc_srt_MinimumMember_019e22c4-9076-7efe-a1fc-21933f866756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_019e22c4-9076-7d53-b100-36b0fa040068" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019e22c4-9076-73a3-a665-53c603dfc6b2" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_019e22c4-9076-7d53-b100-36b0fa040068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_019e22c4-9076-71c2-97da-66947967e2a7" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_019e22c4-9076-7d53-b100-36b0fa040068" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_019e22c4-9076-71c2-97da-66947967e2a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_ParagonAgreementMember_019e22c4-9076-7290-ab4b-9ea9d84b967d" xlink:href="syre-20260630.xsd#syre_ParagonAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_019e22c4-9076-71c2-97da-66947967e2a7" xlink:to="loc_syre_ParagonAgreementMember_019e22c4-9076-7290-ab4b-9ea9d84b967d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_AppointOfBoardMembersMember_019e22c4-9076-7c70-8e87-f1025bb28af5" xlink:href="syre-20260630.xsd#syre_AppointOfBoardMembersMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_019e22c4-9076-71c2-97da-66947967e2a7" xlink:to="loc_syre_AppointOfBoardMembersMember_019e22c4-9076-7c70-8e87-f1025bb28af5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_OtherParagonReimbursableExpensesMember_019e43ef-3a0d-7762-b14a-ccb9250c98b5" xlink:href="syre-20260630.xsd#syre_OtherParagonReimbursableExpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_019e22c4-9076-71c2-97da-66947967e2a7" xlink:to="loc_syre_OtherParagonReimbursableExpensesMember_019e43ef-3a0d-7762-b14a-ccb9250c98b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_ParagonAgreementSubsequentToAssetAcquisitionMember_019e22c4-9076-730e-aa67-0ce2172bad44" xlink:href="syre-20260630.xsd#syre_ParagonAgreementSubsequentToAssetAcquisitionMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_019e22c4-9076-71c2-97da-66947967e2a7" xlink:to="loc_syre_ParagonAgreementSubsequentToAssetAcquisitionMember_019e22c4-9076-730e-aa67-0ce2172bad44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_ConsultingAgreementMember_019e22c4-9076-7a4b-86f3-0eaab0570673" xlink:href="syre-20260630.xsd#syre_ConsultingAgreementMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_019e22c4-9076-71c2-97da-66947967e2a7" xlink:to="loc_syre_ConsultingAgreementMember_019e22c4-9076-7a4b-86f3-0eaab0570673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e22c4-9076-7f49-982d-4359975d1a32" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019e22c4-9076-73a3-a665-53c603dfc6b2" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e22c4-9076-7f49-982d-4359975d1a32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019e22c4-9076-742e-87b1-64db5a2d4fda" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e22c4-9076-7f49-982d-4359975d1a32" xlink:to="loc_us-gaap_RelatedPartyDomain_019e22c4-9076-742e-87b1-64db5a2d4fda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_019e22c4-9076-7e1d-9275-5d7fe4bd1d56" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_019e22c4-9076-742e-87b1-64db5a2d4fda" xlink:to="loc_us-gaap_RelatedPartyMember_019e22c4-9076-7e1d-9275-5d7fe4bd1d56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_019e22c4-9076-70cd-8352-e140f62c634d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019e22c4-9076-73a3-a665-53c603dfc6b2" xlink:to="loc_us-gaap_VestingAxis_019e22c4-9076-70cd-8352-e140f62c634d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_019e22c4-9076-7fc6-bdd1-abd4eb8db4c6" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_019e22c4-9076-70cd-8352-e140f62c634d" xlink:to="loc_us-gaap_VestingDomain_019e22c4-9076-7fc6-bdd1-abd4eb8db4c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_019e22c4-9076-79fa-9b1b-d3917eba541b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_019e22c4-9076-7fc6-bdd1-abd4eb8db4c6" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_019e22c4-9076-79fa-9b1b-d3917eba541b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_019e22c4-9076-717e-b9eb-6640bd7aa670" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019e22c4-9076-73a3-a665-53c603dfc6b2" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_019e22c4-9076-717e-b9eb-6640bd7aa670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_019e22c4-9076-7899-b41d-aae6eaa52fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019e22c4-9076-717e-b9eb-6640bd7aa670" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_019e22c4-9076-7899-b41d-aae6eaa52fdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_RelatedPartyTransactionNumberOfBoardSeats_019e22c4-9076-79f3-8be3-2dac2e0a429f" xlink:href="syre-20260630.xsd#syre_RelatedPartyTransactionNumberOfBoardSeats"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019e22c4-9076-717e-b9eb-6640bd7aa670" xlink:to="loc_syre_RelatedPartyTransactionNumberOfBoardSeats_019e22c4-9076-79f3-8be3-2dac2e0a429f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty_019e22c4-9076-7627-9965-f1e749d998eb" xlink:href="syre-20260630.xsd#syre_MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019e22c4-9076-717e-b9eb-6640bd7aa670" xlink:to="loc_syre_MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty_019e22c4-9076-7627-9965-f1e749d998eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_019fa2ee-9a8c-7749-a0a4-0e6632c636d5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019e22c4-9076-717e-b9eb-6640bd7aa670" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_019fa2ee-9a8c-7749-a0a4-0e6632c636d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent_019e22c4-9076-71ce-93a2-a9f14e0e810f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019e22c4-9076-717e-b9eb-6640bd7aa670" xlink:to="loc_us-gaap_AccountsPayableOtherCurrent_019e22c4-9076-71ce-93a2-a9f14e0e810f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_019e22c4-9076-7fb8-b3d5-4af4f3a1c14f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019e22c4-9076-717e-b9eb-6640bd7aa670" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_019e22c4-9076-7fb8-b3d5-4af4f3a1c14f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_019e22c4-9076-7c51-a9b6-4f13e69f2e68" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019e22c4-9076-717e-b9eb-6640bd7aa670" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_019e22c4-9076-7c51-a9b6-4f13e69f2e68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_019e22c4-9076-7e49-b8a5-df99f189e187" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019e22c4-9076-717e-b9eb-6640bd7aa670" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_019e22c4-9076-7e49-b8a5-df99f189e187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_019e22c4-9076-7333-a963-4757ac579c51" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019e22c4-9076-717e-b9eb-6640bd7aa670" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_019e22c4-9076-7333-a963-4757ac579c51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_019e22c4-9076-7940-b42e-7e6aff9f90f0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019e22c4-9076-717e-b9eb-6640bd7aa670" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_019e22c4-9076-7940-b42e-7e6aff9f90f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMonthlyInstallments_019e22c4-9076-733a-98f5-dac457a7a053" xlink:href="syre-20260630.xsd#syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMonthlyInstallments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019e22c4-9076-717e-b9eb-6640bd7aa670" xlink:to="loc_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMonthlyInstallments_019e22c4-9076-733a-98f5-dac457a7a053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_019e22c4-9076-7ab0-9dfb-c14c1027a6c4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019e22c4-9076-717e-b9eb-6640bd7aa670" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_019e22c4-9076-7ab0-9dfb-c14c1027a6c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://spyre.com/role/RelatedPartyTransactionsScheduleofExpensesRelatedtoRelatedPartyWhichareSettledinCashDetails" xlink:type="simple" xlink:href="syre-20260630.xsd#RelatedPartyTransactionsScheduleofExpensesRelatedtoRelatedPartyWhichareSettledinCashDetails"/>
  <link:presentationLink xlink:role="http://spyre.com/role/RelatedPartyTransactionsScheduleofExpensesRelatedtoRelatedPartyWhichareSettledinCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_019e22c4-9076-71d0-9263-5d6c445671e2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019e22c4-9076-7f08-9398-00b914851473" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_019e22c4-9076-71d0-9263-5d6c445671e2" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019e22c4-9076-7f08-9398-00b914851473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_019e22c4-9076-7467-866c-0681271d9a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019e22c4-9076-7f08-9398-00b914851473" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_019e22c4-9076-7467-866c-0681271d9a5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_019e22c4-9076-7211-bc0e-15f25addf70b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_019e22c4-9076-7467-866c-0681271d9a5b" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_019e22c4-9076-7211-bc0e-15f25addf70b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_ParagonAndLicenseAgreementMember_019e22c4-9076-71a1-bbde-fbcc6d51412e" xlink:href="syre-20260630.xsd#syre_ParagonAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_019e22c4-9076-7211-bc0e-15f25addf70b" xlink:to="loc_syre_ParagonAndLicenseAgreementMember_019e22c4-9076-71a1-bbde-fbcc6d51412e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_ParagonAgreementLicenseMilestonePaymentsMember_019e22c4-9076-79ae-9dfb-45d3a58cece5" xlink:href="syre-20260630.xsd#syre_ParagonAgreementLicenseMilestonePaymentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_ParagonAndLicenseAgreementMember_019e22c4-9076-71a1-bbde-fbcc6d51412e" xlink:to="loc_syre_ParagonAgreementLicenseMilestonePaymentsMember_019e22c4-9076-79ae-9dfb-45d3a58cece5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_OtherParagonReimbursableExpensesMember_019e22c4-9076-7cd0-9e0a-eddfb46c11ee" xlink:href="syre-20260630.xsd#syre_OtherParagonReimbursableExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_ParagonAndLicenseAgreementMember_019e22c4-9076-71a1-bbde-fbcc6d51412e" xlink:to="loc_syre_OtherParagonReimbursableExpensesMember_019e22c4-9076-7cd0-9e0a-eddfb46c11ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e22c4-9076-7132-adc3-10dc0254752c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019e22c4-9076-7f08-9398-00b914851473" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e22c4-9076-7132-adc3-10dc0254752c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019e22c4-9076-738a-a3ad-9d12070cc70d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e22c4-9076-7132-adc3-10dc0254752c" xlink:to="loc_us-gaap_RelatedPartyDomain_019e22c4-9076-738a-a3ad-9d12070cc70d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_019e22c4-9076-728d-bfa2-224bc1ab34e0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_019e22c4-9076-738a-a3ad-9d12070cc70d" xlink:to="loc_us-gaap_RelatedPartyMember_019e22c4-9076-728d-bfa2-224bc1ab34e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_019e22c4-9076-7913-8c10-9d8894a1660e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019e22c4-9076-7f08-9398-00b914851473" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_019e22c4-9076-7913-8c10-9d8894a1660e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_019e22c4-9076-7e5d-9ce5-48bc09fb5102" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019e22c4-9076-7913-8c10-9d8894a1660e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_019e22c4-9076-7e5d-9ce5-48bc09fb5102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://spyre.com/role/ConvertiblePreferredStockandStockholdersEquityDetails" xlink:type="simple" xlink:href="syre-20260630.xsd#ConvertiblePreferredStockandStockholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://spyre.com/role/ConvertiblePreferredStockandStockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_019e22c4-9076-7e3e-917a-685228934d89" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_019e22c4-9076-73d5-8975-07d44e6bea29" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_019e22c4-9076-7e3e-917a-685228934d89" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_019e22c4-9076-73d5-8975-07d44e6bea29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_019e22c4-9076-708c-af18-2d5a0f8f1c75" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_019e22c4-9076-73d5-8975-07d44e6bea29" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_019e22c4-9076-708c-af18-2d5a0f8f1c75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_019e22c4-9076-7ede-9ecf-987c8d2e810b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_019e22c4-9076-708c-af18-2d5a0f8f1c75" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_019e22c4-9076-7ede-9ecf-987c8d2e810b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_ParapyreWarrantsMember_019e22c4-9076-7165-9ab5-28eb3f12c3f9" xlink:href="syre-20260630.xsd#syre_ParapyreWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_019e22c4-9076-7ede-9ecf-987c8d2e810b" xlink:to="loc_syre_ParapyreWarrantsMember_019e22c4-9076-7165-9ab5-28eb3f12c3f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_019e22c4-9076-7842-b05c-05b917147d25" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_019e22c4-9076-73d5-8975-07d44e6bea29" xlink:to="loc_us-gaap_StatementClassOfStockAxis_019e22c4-9076-7842-b05c-05b917147d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019e22c4-9076-7c8f-b19a-869c6f9f36f1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019e22c4-9076-7842-b05c-05b917147d25" xlink:to="loc_us-gaap_ClassOfStockDomain_019e22c4-9076-7c8f-b19a-869c6f9f36f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_SeriesANonVotingConvertiblePreferredStockMember_019e22c4-9076-7429-8537-a8271aceeb28" xlink:href="syre-20260630.xsd#syre_SeriesANonVotingConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_019e22c4-9076-7c8f-b19a-869c6f9f36f1" xlink:to="loc_syre_SeriesANonVotingConvertiblePreferredStockMember_019e22c4-9076-7429-8537-a8271aceeb28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_SeriesBNonVotingConvertiblePreferredStockMember_019e22c4-9076-73e5-a7ca-d32f270d2d01" xlink:href="syre-20260630.xsd#syre_SeriesBNonVotingConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_019e22c4-9076-7c8f-b19a-869c6f9f36f1" xlink:to="loc_syre_SeriesBNonVotingConvertiblePreferredStockMember_019e22c4-9076-73e5-a7ca-d32f270d2d01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_019e22c4-9076-747e-9edc-535979622899" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_019e22c4-9076-7c8f-b19a-869c6f9f36f1" xlink:to="loc_us-gaap_CommonStockMember_019e22c4-9076-747e-9edc-535979622899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_019e22c4-9076-7857-93b2-8b16de1ee2a9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_019e22c4-9076-73d5-8975-07d44e6bea29" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_019e22c4-9076-7857-93b2-8b16de1ee2a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019e22c4-9076-79ed-a08a-f2fb0039d323" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_019e22c4-9076-7857-93b2-8b16de1ee2a9" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019e22c4-9076-79ed-a08a-f2fb0039d323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_AtTheMarketOffering2024SalesAgreementMember_019e22c4-9076-72e7-abc0-507f743f72d8" xlink:href="syre-20260630.xsd#syre_AtTheMarketOffering2024SalesAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019e22c4-9076-79ed-a08a-f2fb0039d323" xlink:to="loc_syre_AtTheMarketOffering2024SalesAgreementMember_019e22c4-9076-72e7-abc0-507f743f72d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_AtTheMarketOffering2026SalesAgreementMember_019f8509-408c-7ca7-887a-4d932b61ce3d" xlink:href="syre-20260630.xsd#syre_AtTheMarketOffering2026SalesAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019e22c4-9076-79ed-a08a-f2fb0039d323" xlink:to="loc_syre_AtTheMarketOffering2026SalesAgreementMember_019f8509-408c-7ca7-887a-4d932b61ce3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_October2025UnderwrittenOfferingMember_019e22c4-9076-7832-92d1-110bc3e01230" xlink:href="syre-20260630.xsd#syre_October2025UnderwrittenOfferingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019e22c4-9076-79ed-a08a-f2fb0039d323" xlink:to="loc_syre_October2025UnderwrittenOfferingMember_019e22c4-9076-7832-92d1-110bc3e01230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_019e22c4-9076-745c-bf03-06be284be5bc" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019e22c4-9076-79ed-a08a-f2fb0039d323" xlink:to="loc_us-gaap_OverAllotmentOptionMember_019e22c4-9076-745c-bf03-06be284be5bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_April2026UnderwritingOfferingMember_019e22c4-9076-7587-8880-68fc1d305720" xlink:href="syre-20260630.xsd#syre_April2026UnderwritingOfferingMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019e22c4-9076-79ed-a08a-f2fb0039d323" xlink:to="loc_syre_April2026UnderwritingOfferingMember_019e22c4-9076-7587-8880-68fc1d305720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_019e22c4-9076-7706-a981-479e98e5647a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_019e22c4-9076-73d5-8975-07d44e6bea29" xlink:to="loc_us-gaap_ClassOfStockLineItems_019e22c4-9076-7706-a981-479e98e5647a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_019e22c4-9076-7790-a237-457f0aae3cb4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019e22c4-9076-7706-a981-479e98e5647a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_019e22c4-9076-7790-a237-457f0aae3cb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_019e22c4-9076-7144-992a-d6fcb4dd1606" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019e22c4-9076-7706-a981-479e98e5647a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_019e22c4-9076-7144-992a-d6fcb4dd1606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_PreferredStockRemainsIssuedAndOutstandingPercentage_019e22c4-9076-74d2-ae69-0ddbe0dc5274" xlink:href="syre-20260630.xsd#syre_PreferredStockRemainsIssuedAndOutstandingPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019e22c4-9076-7706-a981-479e98e5647a" xlink:to="loc_syre_PreferredStockRemainsIssuedAndOutstandingPercentage_019e22c4-9076-74d2-ae69-0ddbe0dc5274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_019e22c4-9076-709b-850e-20b9c825347d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019e22c4-9076-7706-a981-479e98e5647a" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_019e22c4-9076-709b-850e-20b9c825347d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockConvertibleSharesIssuable_019e22c4-9076-7347-b427-8ea528c21c8d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockConvertibleSharesIssuable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019e22c4-9076-7706-a981-479e98e5647a" xlink:to="loc_us-gaap_PreferredStockConvertibleSharesIssuable_019e22c4-9076-7347-b427-8ea528c21c8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_019fa2d7-373d-74cd-93f2-67892802c1ec" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019e22c4-9076-7706-a981-479e98e5647a" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_019fa2d7-373d-74cd-93f2-67892802c1ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_SaleOfStockAggregateOfferingPrice_019e22c4-9076-78c3-b0d8-62f05fab6091" xlink:href="syre-20260630.xsd#syre_SaleOfStockAggregateOfferingPrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019e22c4-9076-7706-a981-479e98e5647a" xlink:to="loc_syre_SaleOfStockAggregateOfferingPrice_019e22c4-9076-78c3-b0d8-62f05fab6091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_019e22c4-9076-7efc-bb2b-f6ed95ecc4d5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019e22c4-9076-7706-a981-479e98e5647a" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_019e22c4-9076-7efc-bb2b-f6ed95ecc4d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_019e22c4-9076-772b-acbc-ab6371844664" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019e22c4-9076-7706-a981-479e98e5647a" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_019e22c4-9076-772b-acbc-ab6371844664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_SaleOfStockAuthorizedAmount_019f35c0-a234-76d5-a7c6-4046d7245c0e" xlink:href="syre-20260630.xsd#syre_SaleOfStockAuthorizedAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019e22c4-9076-7706-a981-479e98e5647a" xlink:to="loc_syre_SaleOfStockAuthorizedAmount_019f35c0-a234-76d5-a7c6-4046d7245c0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_019fa2e0-f06f-7fc5-bd45-3a3856505125" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019e22c4-9076-7706-a981-479e98e5647a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_019fa2e0-f06f-7fc5-bd45-3a3856505125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_SaleOfStockRemainingAuthorizedAmount_019f35c0-a234-71d1-a003-b7b755692d0c" xlink:href="syre-20260630.xsd#syre_SaleOfStockRemainingAuthorizedAmount"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019e22c4-9076-7706-a981-479e98e5647a" xlink:to="loc_syre_SaleOfStockRemainingAuthorizedAmount_019f35c0-a234-71d1-a003-b7b755692d0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_019e22c4-9076-78c8-87a0-8b04895adc40" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019e22c4-9076-7706-a981-479e98e5647a" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_019e22c4-9076-78c8-87a0-8b04895adc40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_019e22c4-9076-7157-a527-13ebaa5e86b6" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019e22c4-9076-7706-a981-479e98e5647a" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_019e22c4-9076-7157-a527-13ebaa5e86b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://spyre.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="syre-20260630.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://spyre.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019e22c4-9076-7de9-832b-b4a18c7c7af2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019e22c4-9076-75cf-8ace-212afa550609" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019e22c4-9076-7de9-832b-b4a18c7c7af2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019e22c4-9076-75cf-8ace-212afa550609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_019e22c4-9076-7259-bc9d-cc5a61c56b23" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019e22c4-9076-75cf-8ace-212afa550609" xlink:to="loc_us-gaap_PlanNameAxis_019e22c4-9076-7259-bc9d-cc5a61c56b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_019e22c4-9076-764a-8566-400e4019e214" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_019e22c4-9076-7259-bc9d-cc5a61c56b23" xlink:to="loc_us-gaap_PlanNameDomain_019e22c4-9076-764a-8566-400e4019e214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember_019e22c4-9076-73a7-bee2-17ab200f07d6" xlink:href="syre-20260630.xsd#syre_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_019e22c4-9076-764a-8566-400e4019e214" xlink:to="loc_syre_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember_019e22c4-9076-73a7-bee2-17ab200f07d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_TwoThousandAndSixteenEquityIncentivePlanMember_019e22c4-9076-779e-b5d7-5b5840ca855d" xlink:href="syre-20260630.xsd#syre_TwoThousandAndSixteenEquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember_019e22c4-9076-73a7-bee2-17ab200f07d6" xlink:to="loc_syre_TwoThousandAndSixteenEquityIncentivePlanMember_019e22c4-9076-779e-b5d7-5b5840ca855d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_TwoThousandAndEighteenEquityInducementPlanMember_019e22c4-9076-76de-af91-1f06e08767c0" xlink:href="syre-20260630.xsd#syre_TwoThousandAndEighteenEquityInducementPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember_019e22c4-9076-73a7-bee2-17ab200f07d6" xlink:to="loc_syre_TwoThousandAndEighteenEquityInducementPlanMember_019e22c4-9076-76de-af91-1f06e08767c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_TwoThousandAndSixteenEmployeeStockPurchasePlanMember_019e22c4-9076-7ffd-a3bd-e26e30404c31" xlink:href="syre-20260630.xsd#syre_TwoThousandAndSixteenEmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_019e22c4-9076-764a-8566-400e4019e214" xlink:to="loc_syre_TwoThousandAndSixteenEmployeeStockPurchasePlanMember_019e22c4-9076-7ffd-a3bd-e26e30404c31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019e22c4-9076-7bc8-8303-f21dc66e2937" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019e22c4-9076-75cf-8ace-212afa550609" xlink:to="loc_us-gaap_AwardTypeAxis_019e22c4-9076-7bc8-8303-f21dc66e2937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e22c4-9076-785e-940b-babd0a5ed2e4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_019e22c4-9076-7bc8-8303-f21dc66e2937" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e22c4-9076-785e-940b-babd0a5ed2e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_ServiceBasedAwardsMember_019e22c4-9076-76be-889e-b1a8312bd2ca" xlink:href="syre-20260630.xsd#syre_ServiceBasedAwardsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e22c4-9076-785e-940b-babd0a5ed2e4" xlink:to="loc_syre_ServiceBasedAwardsMember_019e22c4-9076-76be-889e-b1a8312bd2ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_019e22c4-9076-7622-8bae-fe6932cb722d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019e22c4-9076-75cf-8ace-212afa550609" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_019e22c4-9076-7622-8bae-fe6932cb722d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_019e22c4-9076-7e78-aa97-b8c47747fb3c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_019e22c4-9076-7622-8bae-fe6932cb722d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_019e22c4-9076-7e78-aa97-b8c47747fb3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_ParapyreWarrantsMember_019e22c4-9076-72d1-bb34-36f1dd998e6e" xlink:href="syre-20260630.xsd#syre_ParapyreWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_019e22c4-9076-7e78-aa97-b8c47747fb3c" xlink:to="loc_syre_ParapyreWarrantsMember_019e22c4-9076-72d1-bb34-36f1dd998e6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_019e22c4-9076-7b72-b3db-f97bbffc6ead" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019e22c4-9076-75cf-8ace-212afa550609" xlink:to="loc_us-gaap_StatementClassOfStockAxis_019e22c4-9076-7b72-b3db-f97bbffc6ead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019e22c4-9076-7ad9-aec2-11cb3366c25a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019e22c4-9076-7b72-b3db-f97bbffc6ead" xlink:to="loc_us-gaap_ClassOfStockDomain_019e22c4-9076-7ad9-aec2-11cb3366c25a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_019e22c4-9076-7f2e-9281-39d182923402" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_019e22c4-9076-7ad9-aec2-11cb3366c25a" xlink:to="loc_us-gaap_EmployeeStockMember_019e22c4-9076-7f2e-9281-39d182923402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_019e22c4-9076-7ffd-9b2e-c7abcdaf07be" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019e22c4-9076-75cf-8ace-212afa550609" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_019e22c4-9076-7ffd-9b2e-c7abcdaf07be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019e22c4-9076-7781-bb14-241e5c1b64bf" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_019e22c4-9076-7ffd-9b2e-c7abcdaf07be" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019e22c4-9076-7781-bb14-241e5c1b64bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_A2016ESPPMember_019e22c4-9076-7f2f-b184-7a90c7101a4e" xlink:href="syre-20260630.xsd#syre_A2016ESPPMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019e22c4-9076-7781-bb14-241e5c1b64bf" xlink:to="loc_syre_A2016ESPPMember_019e22c4-9076-7f2f-b184-7a90c7101a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e22c4-9076-7351-8778-ee1b2cd5e163" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019e22c4-9076-75cf-8ace-212afa550609" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e22c4-9076-7351-8778-ee1b2cd5e163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares_019e22c4-9076-749e-b1ec-9be4ebcd9718" xlink:href="syre-20260630.xsd#syre_AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e22c4-9076-7351-8778-ee1b2cd5e163" xlink:to="loc_syre_AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares_019e22c4-9076-749e-b1ec-9be4ebcd9718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant_019e22c4-9076-7413-8ddf-227c3a7b587e" xlink:href="syre-20260630.xsd#syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e22c4-9076-7351-8778-ee1b2cd5e163" xlink:to="loc_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant_019e22c4-9076-7413-8ddf-227c3a7b587e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_019e22c4-9076-7626-9661-33c42f30f323" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e22c4-9076-7351-8778-ee1b2cd5e163" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_019e22c4-9076-7626-9661-33c42f30f323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019e22c4-9076-7200-a122-574b31303e83" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e22c4-9076-7351-8778-ee1b2cd5e163" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019e22c4-9076-7200-a122-574b31303e83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_019e22c4-9076-713a-9853-90497b7640e8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e22c4-9076-7351-8778-ee1b2cd5e163" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_019e22c4-9076-713a-9853-90497b7640e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_019e22c4-9076-7913-b397-7004a5e0bcb3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e22c4-9076-7351-8778-ee1b2cd5e163" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_019e22c4-9076-7913-b397-7004a5e0bcb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_019e22c4-9076-730d-bcb9-bbc0145b8c23" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e22c4-9076-7351-8778-ee1b2cd5e163" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_019e22c4-9076-730d-bcb9-bbc0145b8c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_019e22c4-9076-7394-bf4f-e2438edaccee" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e22c4-9076-7351-8778-ee1b2cd5e163" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_019e22c4-9076-7394-bf4f-e2438edaccee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_019e22c4-9076-742a-9f6c-4212fe0ce7e4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e22c4-9076-7351-8778-ee1b2cd5e163" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_019e22c4-9076-742a-9f6c-4212fe0ce7e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://spyre.com/role/StockBasedCompensationScheduleofStockAwardsGrantedUnderallEquityIncentiveandInducementPlansDetails" xlink:type="simple" xlink:href="syre-20260630.xsd#StockBasedCompensationScheduleofStockAwardsGrantedUnderallEquityIncentiveandInducementPlansDetails"/>
  <link:presentationLink xlink:role="http://spyre.com/role/StockBasedCompensationScheduleofStockAwardsGrantedUnderallEquityIncentiveandInducementPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019e22c4-9076-7670-a7d6-6901b0d38913" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019e22c4-9076-72b4-9df4-b54d8ac6e7db" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019e22c4-9076-7670-a7d6-6901b0d38913" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019e22c4-9076-72b4-9df4-b54d8ac6e7db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019e22c4-9076-754e-9e6f-193ccf6a05fc" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019e22c4-9076-72b4-9df4-b54d8ac6e7db" xlink:to="loc_us-gaap_AwardTypeAxis_019e22c4-9076-754e-9e6f-193ccf6a05fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e22c4-9076-79c4-a7b7-b8251e27355d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_019e22c4-9076-754e-9e6f-193ccf6a05fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e22c4-9076-79c4-a7b7-b8251e27355d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_019e22c4-9076-778c-b385-7eeff7f95625" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019e22c4-9076-79c4-a7b7-b8251e27355d" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_019e22c4-9076-778c-b385-7eeff7f95625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e22c4-9076-7ecc-9a0c-216ee5d43683" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019e22c4-9076-72b4-9df4-b54d8ac6e7db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e22c4-9076-7ecc-9a0c-216ee5d43683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_019e22c4-9076-7a14-ac03-fef43bc5625a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e22c4-9076-7ecc-9a0c-216ee5d43683" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_019e22c4-9076-7a14-ac03-fef43bc5625a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_019e22c4-9076-7e68-adb9-a2f4336515ef" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e22c4-9076-7ecc-9a0c-216ee5d43683" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_019e22c4-9076-7e68-adb9-a2f4336515ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_019e22c4-9076-7bb9-aef7-98420603cf24" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e22c4-9076-7ecc-9a0c-216ee5d43683" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_019e22c4-9076-7bb9-aef7-98420603cf24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019e22c4-9076-72a3-be6d-72a3f84b2704" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019e22c4-9076-7ecc-9a0c-216ee5d43683" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019e22c4-9076-72a3-be6d-72a3f84b2704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://spyre.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="syre-20260630.xsd#StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://spyre.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019e22c4-9076-7f7c-8cac-c299474a537e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_019e22c4-9076-75c2-85aa-f2c9384f1963" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019e22c4-9076-7f7c-8cac-c299474a537e" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_019e22c4-9076-75c2-85aa-f2c9384f1963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeLocationBalanceAxis_019e22c4-9076-7b22-aa18-fad22da1de70" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfIncomeLocationBalanceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_019e22c4-9076-75c2-85aa-f2c9384f1963" xlink:to="loc_us-gaap_StatementOfIncomeLocationBalanceAxis_019e22c4-9076-7b22-aa18-fad22da1de70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019e22c4-9076-77e6-863d-332cff678a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_019e22c4-9076-75c2-85aa-f2c9384f1963" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019e22c4-9076-77e6-863d-332cff678a4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_019e22c4-9076-7500-b9a6-ba4fd951e841" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019e22c4-9076-77e6-863d-332cff678a4b" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_019e22c4-9076-7500-b9a6-ba4fd951e841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://spyre.com/role/StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedinCalculatingFairValueofAwardsDetails" xlink:type="simple" xlink:href="syre-20260630.xsd#StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedinCalculatingFairValueofAwardsDetails"/>
  <link:presentationLink xlink:role="http://spyre.com/role/StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedinCalculatingFairValueofAwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019e22c4-9076-7d35-893b-aa83e51f9013" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_019e22c4-9076-7367-a007-707f2f58c60a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019e22c4-9076-7d35-893b-aa83e51f9013" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_019e22c4-9076-7367-a007-707f2f58c60a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_019e22c4-9076-7c1b-a04b-d2beff182958" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_019e22c4-9076-7367-a007-707f2f58c60a" xlink:to="loc_us-gaap_PlanNameAxis_019e22c4-9076-7c1b-a04b-d2beff182958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_019e22c4-9076-7501-bb1e-eb81c9f3156a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_019e22c4-9076-7c1b-a04b-d2beff182958" xlink:to="loc_us-gaap_PlanNameDomain_019e22c4-9076-7501-bb1e-eb81c9f3156a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_TwoThousandAndSixteenEquityIncentivePlanMember_019e22c4-9076-70d1-859e-b9d3e0c98f60" xlink:href="syre-20260630.xsd#syre_TwoThousandAndSixteenEquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_019e22c4-9076-7501-bb1e-eb81c9f3156a" xlink:to="loc_syre_TwoThousandAndSixteenEquityIncentivePlanMember_019e22c4-9076-70d1-859e-b9d3e0c98f60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_TwoThousandAndSixteenEmployeeStockPurchasePlanMember_019e22c4-9076-7df9-aba9-6cbedb7d6e71" xlink:href="syre-20260630.xsd#syre_TwoThousandAndSixteenEmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_019e22c4-9076-7501-bb1e-eb81c9f3156a" xlink:to="loc_syre_TwoThousandAndSixteenEmployeeStockPurchasePlanMember_019e22c4-9076-7df9-aba9-6cbedb7d6e71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019e22c4-9076-7df9-a5cc-bb733b612718" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_019e22c4-9076-7367-a007-707f2f58c60a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019e22c4-9076-7df9-a5cc-bb733b612718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_019e22c4-9076-740c-b5c2-1365a16a764d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019e22c4-9076-7df9-a5cc-bb733b612718" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_019e22c4-9076-740c-b5c2-1365a16a764d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_019e22c4-9076-7c8c-9b08-185aaef61a26" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019e22c4-9076-7df9-a5cc-bb733b612718" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_019e22c4-9076-7c8c-9b08-185aaef61a26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_019e22c4-9076-7879-8f64-a73b72fe41ce" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019e22c4-9076-7df9-a5cc-bb733b612718" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_019e22c4-9076-7879-8f64-a73b72fe41ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_019e22c4-9076-712b-afb4-0024d50caec8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019e22c4-9076-7df9-a5cc-bb733b612718" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_019e22c4-9076-712b-afb4-0024d50caec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://spyre.com/role/SaleofPegzilarginasetoImmedicaDetails" xlink:type="simple" xlink:href="syre-20260630.xsd#SaleofPegzilarginasetoImmedicaDetails"/>
  <link:presentationLink xlink:role="http://spyre.com/role/SaleofPegzilarginasetoImmedicaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_019e22c4-9076-7fd5-866a-60a9d64f75f3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_019e22c4-9076-70fd-9542-05115fcbd6f2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_019e22c4-9076-7fd5-866a-60a9d64f75f3" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_019e22c4-9076-70fd-9542-05115fcbd6f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_019e22c4-9076-7c9e-bf6f-7ad30c82b110" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_019e22c4-9076-70fd-9542-05115fcbd6f2" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_019e22c4-9076-7c9e-bf6f-7ad30c82b110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_019e22c4-9076-7391-a924-8f785ad05467" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_019e22c4-9076-7c9e-bf6f-7ad30c82b110" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_019e22c4-9076-7391-a924-8f785ad05467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_019e22c4-9076-7803-8b28-6a834432c962" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_019e22c4-9076-7391-a924-8f785ad05467" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_019e22c4-9076-7803-8b28-6a834432c962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019e22c4-9076-7acd-92ee-47cd33f7dc90" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_019e22c4-9076-70fd-9542-05115fcbd6f2" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019e22c4-9076-7acd-92ee-47cd33f7dc90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019e22c4-9076-7e95-9c52-978bf7807b9e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019e22c4-9076-7acd-92ee-47cd33f7dc90" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019e22c4-9076-7e95-9c52-978bf7807b9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_GlobalRightsToPegzilarginaseMember_019e22c4-9076-7251-aba9-de546e934184" xlink:href="syre-20260630.xsd#syre_GlobalRightsToPegzilarginaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019e22c4-9076-7e95-9c52-978bf7807b9e" xlink:to="loc_syre_GlobalRightsToPegzilarginaseMember_019e22c4-9076-7251-aba9-de546e934184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_019e22c4-9076-73a7-956a-ea6da95c1338" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_019e22c4-9076-70fd-9542-05115fcbd6f2" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_019e22c4-9076-73a7-956a-ea6da95c1338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_019e22c4-9076-7547-bc6f-4f077236aaa9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_019e22c4-9076-73a7-956a-ea6da95c1338" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_019e22c4-9076-7547-bc6f-4f077236aaa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_019e22c4-9076-77dd-9ff4-4fbbf79e424d" xlink:href="syre-20260630.xsd#syre_DisposalGroupIncludingDiscontinuedOperationContingentConsideration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_019e22c4-9076-73a7-956a-ea6da95c1338" xlink:to="loc_syre_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_019e22c4-9076-77dd-9ff4-4fbbf79e424d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_019e22c4-9076-7cb0-9f17-30c9fc799a54" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_019e22c4-9076-73a7-956a-ea6da95c1338" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_019e22c4-9076-7cb0-9f17-30c9fc799a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_019e22c4-9076-77b2-b211-67b69cfbc484" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_019e22c4-9076-73a7-956a-ea6da95c1338" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_019e22c4-9076-77b2-b211-67b69cfbc484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://spyre.com/role/SegmentReportingNarrativeDetails" xlink:type="simple" xlink:href="syre-20260630.xsd#SegmentReportingNarrativeDetails"/>
  <link:presentationLink xlink:role="http://spyre.com/role/SegmentReportingNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_019e22c4-9076-7a27-b1aa-c0e7c0ed471b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_019e22c4-9076-713c-b9f7-2d289da2e88b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_019e22c4-9076-7a27-b1aa-c0e7c0ed471b" xlink:to="loc_us-gaap_NumberOfOperatingSegments_019e22c4-9076-713c-b9f7-2d289da2e88b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_019e22c4-9076-7da6-9796-2e9fa1c42f10" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_019e22c4-9076-7a27-b1aa-c0e7c0ed471b" xlink:to="loc_us-gaap_NumberOfReportableSegments_019e22c4-9076-7da6-9796-2e9fa1c42f10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://spyre.com/role/SegmentReportingScheduleofSignificantExpensesProvidedtotheCODMonaRegularBasisDetails" xlink:type="simple" xlink:href="syre-20260630.xsd#SegmentReportingScheduleofSignificantExpensesProvidedtotheCODMonaRegularBasisDetails"/>
  <link:presentationLink xlink:role="http://spyre.com/role/SegmentReportingScheduleofSignificantExpensesProvidedtotheCODMonaRegularBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_019e22c4-9076-7465-897c-ecb25ed67a06" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019e22c4-9076-7767-9efe-7b5c99caf98b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_019e22c4-9076-7465-897c-ecb25ed67a06" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019e22c4-9076-7767-9efe-7b5c99caf98b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_019e22c4-9076-79df-960d-1182563a9bd1" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019e22c4-9076-7767-9efe-7b5c99caf98b" xlink:to="loc_srt_ConsolidationItemsAxis_019e22c4-9076-79df-960d-1182563a9bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_019e22c4-9076-719b-8a2a-6f4a9c8f4b80" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_019e22c4-9076-79df-960d-1182563a9bd1" xlink:to="loc_srt_ConsolidationItemsDomain_019e22c4-9076-719b-8a2a-6f4a9c8f4b80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_019e22c4-9076-782b-b7d9-3c6006d9c544" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_019e22c4-9076-719b-8a2a-6f4a9c8f4b80" xlink:to="loc_us-gaap_OperatingSegmentsMember_019e22c4-9076-782b-b7d9-3c6006d9c544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_019e22c4-9076-7e2d-97b9-b36e08e3c77c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019e22c4-9076-7767-9efe-7b5c99caf98b" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_019e22c4-9076-7e2d-97b9-b36e08e3c77c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_019e22c4-9076-7ccf-bfe2-0d9dd46104c1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_019e22c4-9076-7e2d-97b9-b36e08e3c77c" xlink:to="loc_us-gaap_SegmentDomain_019e22c4-9076-7ccf-bfe2-0d9dd46104c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_ReportableSegmentMember_019e22c4-9076-7451-8cd9-6d186e59d1c6" xlink:href="syre-20260630.xsd#syre_ReportableSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_019e22c4-9076-7ccf-bfe2-0d9dd46104c1" xlink:to="loc_syre_ReportableSegmentMember_019e22c4-9076-7451-8cd9-6d186e59d1c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e22c4-9076-7973-af7f-5834510484e9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019e22c4-9076-7767-9efe-7b5c99caf98b" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e22c4-9076-7973-af7f-5834510484e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019e22c4-9076-7c93-9d94-95f418642d54" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019e22c4-9076-7973-af7f-5834510484e9" xlink:to="loc_us-gaap_RelatedPartyDomain_019e22c4-9076-7c93-9d94-95f418642d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_019e22c4-9076-7ec5-be6e-d44c9fe5922e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_019e22c4-9076-7c93-9d94-95f418642d54" xlink:to="loc_us-gaap_RelatedPartyMember_019e22c4-9076-7ec5-be6e-d44c9fe5922e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_019e22c4-9076-7a63-bd32-1eb49f30278b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019e22c4-9076-7767-9efe-7b5c99caf98b" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_019e22c4-9076-7a63-bd32-1eb49f30278b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold_019e22c4-9076-789f-87ae-2de59378fcfc" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e22c4-9076-7a63-bd32-1eb49f30278b" xlink:to="loc_us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold_019e22c4-9076-789f-87ae-2de59378fcfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_019e22c4-9076-78be-9de0-e1a2d284659f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e22c4-9076-7a63-bd32-1eb49f30278b" xlink:to="loc_us-gaap_ShareBasedCompensation_019e22c4-9076-78be-9de0-e1a2d284659f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_019e22c4-9076-70cd-987f-4ac1be046c9f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e22c4-9076-7a63-bd32-1eb49f30278b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_019e22c4-9076-70cd-987f-4ac1be046c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount_019e22c4-9076-76ad-a449-605f23d3446b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e22c4-9076-7a63-bd32-1eb49f30278b" xlink:to="loc_us-gaap_SegmentReportingOtherItemAmount_019e22c4-9076-76ad-a449-605f23d3446b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019e22c4-9076-751d-9843-116fc6e10a6c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e22c4-9076-7a63-bd32-1eb49f30278b" xlink:to="loc_us-gaap_NetIncomeLoss_019e22c4-9076-751d-9843-116fc6e10a6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_019e22c4-9076-7bcc-8320-a79cbe2b41e8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e22c4-9076-7a63-bd32-1eb49f30278b" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_019e22c4-9076-7bcc-8320-a79cbe2b41e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_IncreaseDecreaseInFairValueOfContingentValueRightLiability_019e22c4-9076-7df5-8e4a-34e6d0ccc144" xlink:href="syre-20260630.xsd#syre_IncreaseDecreaseInFairValueOfContingentValueRightLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019e22c4-9076-7a63-bd32-1eb49f30278b" xlink:to="loc_syre_IncreaseDecreaseInFairValueOfContingentValueRightLiability_019e22c4-9076-7df5-8e4a-34e6d0ccc144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://spyre.com/role/NetLossPerShareScheduleofComputationofBasicandDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="syre-20260630.xsd#NetLossPerShareScheduleofComputationofBasicandDilutedNetLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://spyre.com/role/NetLossPerShareScheduleofComputationofBasicandDilutedNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_019e22c4-9076-794a-8a6e-ff9e615bb26b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_019e22c4-9076-7a77-9fd7-74697d6a0ece" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_019e22c4-9076-794a-8a6e-ff9e615bb26b" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_019e22c4-9076-7a77-9fd7-74697d6a0ece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_019e22c4-9076-72a3-8d28-a3033527749a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_019e22c4-9076-7a77-9fd7-74697d6a0ece" xlink:to="loc_us-gaap_StatementClassOfStockAxis_019e22c4-9076-72a3-8d28-a3033527749a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019e22c4-9076-719b-b79c-46e022de1700" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019e22c4-9076-72a3-8d28-a3033527749a" xlink:to="loc_us-gaap_ClassOfStockDomain_019e22c4-9076-719b-b79c-46e022de1700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_SeriesANonVotingConvertiblePreferredStockMember_019e22c4-9076-7e58-a65b-38e18ec7c6fc" xlink:href="syre-20260630.xsd#syre_SeriesANonVotingConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_019e22c4-9076-719b-b79c-46e022de1700" xlink:to="loc_syre_SeriesANonVotingConvertiblePreferredStockMember_019e22c4-9076-7e58-a65b-38e18ec7c6fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_SeriesBNonVotingConvertiblePreferredStockMember_019e22c4-9076-7387-801b-c83639af95ba" xlink:href="syre-20260630.xsd#syre_SeriesBNonVotingConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_019e22c4-9076-719b-b79c-46e022de1700" xlink:to="loc_syre_SeriesBNonVotingConvertiblePreferredStockMember_019e22c4-9076-7387-801b-c83639af95ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_019e22c4-9076-7f35-8366-1fc69f955c27" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_019e22c4-9076-719b-b79c-46e022de1700" xlink:to="loc_us-gaap_CommonStockMember_019e22c4-9076-7f35-8366-1fc69f955c27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_019e22c4-9076-7788-b778-f3144f2cfc58" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_019e22c4-9076-7a77-9fd7-74697d6a0ece" xlink:to="loc_us-gaap_EarningsPerShareBasicLineItems_019e22c4-9076-7788-b778-f3144f2cfc58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_019e22c4-9076-70c4-9cad-3e5c850d3493" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_019e22c4-9076-7788-b778-f3144f2cfc58" xlink:to="loc_us-gaap_EarningsPerShareReconciliationAbstract_019e22c4-9076-70c4-9cad-3e5c850d3493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_019e22c4-9076-7d7c-875f-b71f45bbdbdb" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_019e22c4-9076-70c4-9cad-3e5c850d3493" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_019e22c4-9076-7d7c-875f-b71f45bbdbdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019e22c4-9076-75e9-9308-b6146c961c57" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_019e22c4-9076-7d7c-875f-b71f45bbdbdb" xlink:to="loc_us-gaap_NetIncomeLoss_019e22c4-9076-75e9-9308-b6146c961c57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_019e22c4-9076-71b3-a900-10a68c6930f5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_019e22c4-9076-70c4-9cad-3e5c850d3493" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_019e22c4-9076-71b3-a900-10a68c6930f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_019e22c4-9076-7ce3-8470-f398f09823be" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_019e22c4-9076-71b3-a900-10a68c6930f5" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_019e22c4-9076-7ce3-8470-f398f09823be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_019e22c4-9076-7b15-a04b-e9fa38e14b44" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_019e22c4-9076-70c4-9cad-3e5c850d3493" xlink:to="loc_us-gaap_EarningsPerShareBasic_019e22c4-9076-7b15-a04b-e9fa38e14b44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_019e22c4-9076-78ba-831d-420d31d3002a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_019e22c4-9076-70c4-9cad-3e5c850d3493" xlink:to="loc_us-gaap_EarningsPerShareDiluted_019e22c4-9076-78ba-831d-420d31d3002a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://spyre.com/role/NetLossPerShareScheduleofWeightedAverageEquityInstrumentsExcludedfromCalculationofDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="syre-20260630.xsd#NetLossPerShareScheduleofWeightedAverageEquityInstrumentsExcludedfromCalculationofDilutedNetLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://spyre.com/role/NetLossPerShareScheduleofWeightedAverageEquityInstrumentsExcludedfromCalculationofDilutedNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_019e22c4-9076-79a8-8893-0547fe9edf4f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019e22c4-9076-7fd8-ac16-3d984dee6b88" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_019e22c4-9076-79a8-8893-0547fe9edf4f" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019e22c4-9076-7fd8-ac16-3d984dee6b88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019e22c4-9076-7fbc-869d-4ac23b3273b2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019e22c4-9076-7fd8-ac16-3d984dee6b88" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019e22c4-9076-7fbc-869d-4ac23b3273b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019e22c4-9076-7360-af26-e94621fe9dc4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019e22c4-9076-7fbc-869d-4ac23b3273b2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019e22c4-9076-7360-af26-e94621fe9dc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_019e22c4-9076-7b8d-b57f-d4244485afc6" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019e22c4-9076-7360-af26-e94621fe9dc4" xlink:to="loc_us-gaap_EmployeeStockOptionMember_019e22c4-9076-7b8d-b57f-d4244485afc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_019e22c4-9076-7b41-bf9c-38db2017dd62" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019e22c4-9076-7360-af26-e94621fe9dc4" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_019e22c4-9076-7b41-bf9c-38db2017dd62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_ParapyreWarrantsMember_019e22c4-9076-7d31-8ee0-c2c745f15885" xlink:href="syre-20260630.xsd#syre_ParapyreWarrantsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019e22c4-9076-7360-af26-e94621fe9dc4" xlink:to="loc_syre_ParapyreWarrantsMember_019e22c4-9076-7d31-8ee0-c2c745f15885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019e22c4-9076-7501-b24c-653a7a17d94f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019e22c4-9076-7fd8-ac16-3d984dee6b88" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019e22c4-9076-7501-b24c-653a7a17d94f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_019e22c4-9076-7d3e-a631-89e76afe85aa" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019e22c4-9076-7501-b24c-653a7a17d94f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_019e22c4-9076-7d3e-a631-89e76afe85aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_JeffreyAlbersRuleTradingArrangementDirectorStockOptionsMember" xlink:href="syre-20260630.xsd#syre_JeffreyAlbersRuleTradingArrangementDirectorStockOptionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="loc_syre_JeffreyAlbersRuleTradingArrangementDirectorStockOptionsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_HeidyKingJonesMember" xlink:href="syre-20260630.xsd#syre_HeidyKingJonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_syre_HeidyKingJonesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_syre_JeffreyAlbersMember" xlink:href="syre-20260630.xsd#syre_JeffreyAlbersMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_syre_JeffreyAlbersMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>syre-20260630_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 syre-20260630_g1.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '(!-(# 2(  A$! Q$!_\0
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MM'X9U_Q8W_"$3P_V?X;M%N;KYKMOGV,Z#:,<G/<5T8:DJLW&79O30ENQ[/\
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M/0M0^W7.@7[Z7J2>1)'Y%RH!9,NH#8R.5R/>OE;X0^/]>\&? O\ 99L-'O\
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MT9\1O']S<V+Z/XCL-.M;2"*1S<(UO&5<R*4"@$],,??%>H?VK;^DW_@/)_\
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M5D?-]A\'/CM!X$TKX;_\)OX?TWPO8"&S'BS2S=1:ZUE$PVHJ8\M)"BA#('/
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M,^G/HOBY)?LA61MWG1/&KE)1TSM.1CFO</[5M_2;_P !Y/\ XFC^U;?TF_\
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M:]V9KJS=WCD\V[FF4@NJL3MD7.1USUZGTC^U;?TF_P# >3_XFC^U;?TF_P#
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M&ZMDD::V#C !E1!EE'5@"O['P:=N=_>O\@]I+L?K5%_P4*_9_FD5%^("AF.
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M##<O(WK??Y'QG$>2X?*/9>PE)\_->]NENR7<****\L^,"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ JII'_(*L_^N*?R%6ZJ:1_R"K/_ *XI_(570"W1
M114@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%9?B?Q)8>#] OM9U286]A9Q&65^^!V'J2> /4TF[:LB<XTXN<W
M9+5LU**^"O'7[;/C;6]4<^&S!X<TY21&A@CGF<9X+EP1G&. ./4UV?P1_;/U
M&_URTT3QRD$L-TXBCU>!!$8V/ \Q!\I7/< 8ST-<2QE*4N4^%H\;917Q*PRD
MU=V4FK1?XW7JTC["HI 0P!!R#T(HKN/O1:*** "BBB@ HHHH **** "BBB@
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MS&=RI(P"K$#W"JH&?4M7O=?G>/JQK8F<X;?Y:'7%65@HHHK@*"BBB@ HHHH
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M !1110 4444 %%%% !1110 54TC_ )!5G_UQ3^0JW532/^059_\ 7%/Y"JZ
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M*_%5_8P0O#%I6I:BLED@8YR(E10"#G!'J:K^//V=]*\?>.4\63>*/%&CZM%
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M5^)=6UN[U7Q#'=ZE=RWDR0W$ 17D<NP4&$D#+'&2?K6;_P ,"_#[_H,>)?\
MP*M__C%?2M%=*Q==*RFSW8YYF4(J,:[LCYJ_X8%^'W_08\2_^!5O_P#&*/\
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MBBB@ HHHH **** "BBB@ HHHH **** "JFD?\@JS_P"N*?R%6ZJ:1_R"K/\
MZXI_(570"W1114@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 4]1^[
M;_\ 7=/YU<JGJ/W;?_KNG\ZN53V0!1114@%%%% !1110 4444 %%%% !1110
M 4444 %4V_Y"T?\ UP;_ -"6KE4V_P"0M'_UP;_T):J(%RBBN1LOB_X#U+Q0
MWAJT\;>';KQ&LTELVCPZM ]X)4SYD9A#[]R[6RN,C:<]*%%RV0'745Q_BCXQ
M^ ?!&J'3/$?CCPWH&I!!(;/5-7M[:8*>C;'<'!P<'%3P?%;P3=:3INJ0^,-
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M#;R'8, I^4MA3]9_9N!I6C.+;^?Z:&'/)GUG_P /?O\ JDO_ )<G_P!R4?\
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MN'[/[P_U2RSM+[S[Y_X;Z^'W_0'\2_\ @+;_ /Q^C_AOKX??] ?Q+_X"V_\
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M;:)==79'Z&45%:W,5[;0W$#B6"5!)&Z]&4C((_"BO3/U1--71+1110,****
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M VKN).ZO7M*^&6EZ1\3=>\<PSW;:MK-C;:?<0NZF!8X"Y0HH4,&/F'.6(Z8
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M110 4444 %%%% %/4?NV_P#UW3^=7*IZC]VW_P"NZ?SJY5/9 %%%%2 4444
M%%%% !1110 4444 %%%% !1110 53;_D+1_]<&_]"6KE4V_Y"T?_ %P;_P!"
M6JB!<HHHJ0"BBB@ HHHH **** "BBB@ HHHH **** "BBB@"G8?ZZ^_Z[_\
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M[2?\S#ZWB/\ GY+[V<;_ ,*8^'W_ $(OAK_P46__ ,11_P *8^'W_0B^&O\
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M(!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(.FN1_W]2OORO*S"*CB'9=CY3B!06/ER*UT@HHHKS3YL**** "BBB@ HHHH
M**** *>H_=M_^NZ?SJY5/4?NV_\ UW3^=7*I[( HHHJ0"BBB@ HHHH ****
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M7Y_DQN_VG=YAVYV8\O!QG[QKZU9;@:=H35V_-_IH8<\F?7G_  ]^_P"J2_\
MER?_ ')1_P /?O\ JDO_ )<G_P!R5^<U>WWG[/GAZ\L_&-GX:^(,/B3Q-X3T
MO^U]0@M]/4:9<PH$^T&SO5G?SO++@9>*,/@E:N>78&G;FA^,O\PYY,^K8O\
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MOD'&=N<9.,]36-_P\._ZD#_RL_\ W/7S5\9_^2P^.O\ L/7_ /Z4/7&U]7#
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ME]6_[Z-'E+ZM_P!]&@!]%,\I?5O^^C1Y2^K?]]&@!]%,\I?5O^^C1Y2^K?\
M?1H ?13/*7U;_OHT>4OJW_?1H ?13/*7U;_OHT>4OJW_ 'T: 'T4SRE]6_[Z
M-'E+ZM_WT: 'T4SRE]6_[Z-'E+ZM_P!]&@!]%,\I?5O^^C1Y2^K?]]&@!]%,
M\I?5O^^C1Y2^K?\ ?1H ?13!$ >K?]]&GT %%%% !1110 4444 %%%% !111
M0 4444 %?/\ ^VY\&O$OQT^#EOX<\*QVTNIIJL%VPNIO*7RU24'G!YRZ\5]
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M7_@+<?\ Q^C_ (;Z^(/_ $!_#7_@+<?_ !^OFJBCZGA_Y$']@Y9_SXB?2O\
MPWU\0?\ H#^&O_ 6X_\ C]'_  WU\0?^@/X:_P# 6X_^/U\U44?4\/\ R(/[
M!RS_ )\1/I7_ (;Z^(/_ $!_#7_@+<?_ !^OOFOQQK]CJ\7,J-.ER<BM>_Z'
MY[Q;@,+@?8?5J:C?FO;K;EM^84445XI^>A1110 4444 %%%% !1110 4444
M%%%% !1110 54TC_ )!5G_UQ3^0JW532/^059_\ 7%/Y"JZ 6Z***D HHHH
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M>)+&.>2_=0[QH0JC8#P7=RW)Z8]Z\P@^#/[:-W!'.?&UY#YBA_+?6L,N><$
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MH\7S%0K;E4GY2<8YQ6?_ ,,V_%S_ *)9XU_\)Z[_ /C='_#-OQ<_Z)9XU_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P#%S_H;?_*;:?\ QJC_ (:_^+G_ $-O_E-M/_C5>-T4?5Z/\B^Y!_967_\
M0/#_ ,!C_D>R?\-?_%S_ *&W_P IMI_\:H_X:_\ BY_T-O\ Y3;3_P"-5XW1
M1]7H_P B^Y!_967_ /0/#_P&/^1[)_PU_P#%S_H;?_*;:?\ QJOTJK\<:_8Z
MO#S.G"GR<D4M]OD?G'&&$P^%^K^PIQA?FO9)7^'L%%%%>&?G 4444 %%%% !
M1110 4444 %%%% !1110 4444 %5-(_Y!5G_ -<4_D*MU4TC_D%6?_7%/Y"J
MZ >#_M1>#_#U_+::]XNU6YO--ALY+'2_"MHKB6[U&0D)*A5P6894;=N..20=
MIX*S^'-YXO\ &/@3X>?$.YN;FWL/!DFHR0FZ<"*Y:>1%+$$;FB38O4CY>X//
MM_Q*_9_TGXG>+=.\17GB'Q%I&HZ?#Y-J='O(X!#R264F-F#'=@D'H .U5?$'
M[-NB>)=+T:"\\1^*/[3TR&:U77$U,?;[B&1F9HII"A#K\Q&-HXXZ9SZ5.O&,
M(QYM?3;T_4^SPN9T:.&ITG5=TGK;X&T[<NW?5[MOR/%=.T_3?&?[/W@/Q7\2
M->O+KP[I=O=6R>'UWB75;OS)8K<HZ2!FD"J H*G&')(4N2_QA\,M-\/?LVZ!
MJ7CS1)=:\=1VRZ1I,-Q=S*\+2RN;>$A)%#>6K$X(_AV]!7L'B3]EWPSK\'AB
M"#6/$&A0>&X/)TZ/2;U(O*8MN:7+1L?,8X)8$=!6U_PHW3;BQ\+VVH>(/$.L
MMX>U0:M;7.IWB3S2R@Y42LR<J.P&"/6K^LP5FI/>]MM-=/\ /_@&SS>@G&5.
MHTN=RY4K65Y-137>_O/=Z+:)3^'/PSU[X2>$?"/ASP]-I5S9PRM)KT^H&;S9
M"V"QM@O .<@!N,!>^:^;?^"I5GHVH:?\$+;Q%X<U3Q?H4OC2-+W0=$C>2]OX
MC ^Z&%4=&+L. %93GN*^R?$'A7^W]5T6^_MC5M-_LR<S_9M/NO*AN\X^2=<'
M>O'3CJ:YKXI_!'0OBYKO@35=8N]0MKCP;K4>NV"V,D:)+.BE0LH9&)3!Z*5/
MO7FSFYOF>Y\CB:SQ$E5F[R=V].K;W[_TC\V+GX<2^&?A=^TEK7@7X;>-?A'\
M&KCP2EJOA[QN)H)[G5Q,C-<1PS22-M$65+[R,G'LOTA\"OCK\8--\=?#?X8>
M,M(\(Z)I'C#P2;[PS?:+)<7=YI[P6L9 O/,VQRL!R5C"KG #MCGZJ^+GPQTO
MXS_#7Q#X(UNXO+72=<M6M+F:P=$G1"024+JR@\=U/TKC-7_9@\.:KXI\#^(D
MUK7]/U7P?H%UX>TR:RN(4(AG@$+2MF(GS5 #*PPH89*D<5D<A\D?L[? ;2?
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M#_8A^'?AO0_ .FZ=-K4!\(>(O^$K2]>[26YU74BNUY[V1XR96? W;=G0 8
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M)XDUZ59-5\3>*;\WVIWNS(C5Y=JC:H)  49XSG KU^@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** *>H_=M_P#KNG\ZN53U'[MO_P!=T_G5RJ>R ****D HHHH
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M;[DX>4:A%BUC)(BMUC51R[!G(*S_ /#O']H+_H0/_*SI_P#\D4?\.\?V@O\
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M_P".T?\ #('Q<_Z%+_RI6G_QVCZQ1_G7WH/[5R__ *"(?^!1_P SQNBO9/\
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MJ=A_KK[_ *[_ /LBU<JI;@%%%%2 4444 %%%% !1110 4444 %%%% !1110
MAZ55TC_D$V7_ %P3_P!!%6CTJKI'_()LO^N"?^@BJZ 6Z***D HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *J:1_R"K/_KBG\A5NJFD?\@JS_P"N
M*?R%5T MT445(!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5G=B5+8YQC  K[*<:5#W8TU:S?W6\O,YU=]3YG_X:2^+G_14_&O_ (4-W_\
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M_$'_ *'KQ+_X-[C_ .+H_P"%S_$'_H>O$O\ X-[C_P"+KC:*/9P_E0?5,/\
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M_P BU4<9@8-N,TKARR/CSQ%K]_XL\0:GK>JS_:M4U*ZEO;N?8J>9-(Y=VVJ
MHRS$X  &>!7MOAW]J&STRWT2SU'PG/>V%EX)O/!=PEKJJP2SQW$CNUPCM XC
M8"0@*5<9&<]J]6_X=/?%S_H8O!7_ ('7?_R+1_PZ>^+G_0Q>"O\ P.N__D6E
M/%X&HDI35D'+)'S:WQ'T_P '74=_\,/^$Q\":JZ-!=7I\4+,\T)*MY8-O:V[
M ;E4G+,#M' QFNRM?V@/#E[\+G\):[X9\2W=[J5ZVH>(M;T[Q1%!<Z_/O+1&
MZ::QG=DBZK&'V[B7(+X8>P?\.GOBY_T,7@K_ ,#KO_Y%H_X=/?%S_H8O!7_@
M==__ "+4O%8&5KS7WL.61X/X<^*O@.PT_2+/5_AJ^HC0]3DO=-N[/5H[.ZN(
M6D\P6^H2"U;[4%P '40L!N V@C' ^.O&6H?$3QGKGB?5O*_M+6+R6^N! FR,
M/(Q8A1DX S@9)..I-?6Z_P#!)WXMEAN\1^"PN>2+V[)_]):]Q^!7_!+30/!^
MKVVL_$36X_%<T!WIHUG"8[(M_P!-&;YI1WQA!QSD<5,L?@J-YJ5W\W_PP^63
MT.H_X)A_"._^'_P2U#Q%JD#VMWXIO%N(89!AA:Q*4B8CMN9I6'^R5/>OL:F1
M1);Q)%$BQQHH5408"@= !V%/KXG$5GB*LJLNIT)65A#TJKI'_()LO^N"?^@B
MK1Z55TC_ )!-E_UP3_T$5CT&?E=\9_\ DL/CK_L/7_\ Z4/7&U]:?$']B7QS
MXK\>^)=;M-5\/1VFI:G<WD*37$X=4DE9U# 0D X89P3]:P/^&!?B#_T&/#7_
M (%7'_QBOKX8N@H).:/WS#9YEL*$(RKJZ2_(^:J*^E?^&!?B#_T&/#7_ (%7
M'_QBC_A@7X@_]!CPU_X%7'_QBK^N8?\ G1T?V]EG_/\ B?-5%?2O_# OQ!_Z
M#'AK_P "KC_XQ1_PP+\0?^@QX:_\"KC_ .,4?7,/_.@_M[+/^?\ $^:J*^E?
M^&!?B#_T&/#7_@5<?_&*/^&!?B#_ -!CPU_X%7'_ ,8H^N8?^=!_;V6?\_XG
MS517TK_PP+\0?^@QX:_\"KC_ .,4?\,"_$'_ *#'AK_P*N/_ (Q1]<P_\Z#^
MWLL_Y_Q/FJBOI7_A@7X@_P#08\-?^!5Q_P#&*/\ A@7X@_\ 08\-?^!5Q_\
M&*/KF'_G0?V]EG_/^)\U45]*_P## OQ!_P"@QX:_\"KC_P",4?\ # OQ!_Z#
M'AK_ ,"KC_XQ1]<P_P#.@_M[+/\ G_$^:J*^E?\ A@7X@_\ 08\-?^!5Q_\
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M5<HHOY 4_P#3_2V_\>H_T_TMO_'JN447\@*?^G^EM_X]1_I_I;?^/5<HHOY
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MQ1\,/@Q>>*O[7U;XQ^-V\>:3XS\530V"VTNJVMH63R+>SB)4!$<':"<[6(P
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MHHH IZC]VW_Z[I_.KE4]1^[;_P#7=/YU<JGL@.1\#?"?PI\-CX@/AS21I_\
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M?HE7E8K#O#5'![=/0\C$4?8U''IT"BBBN0Y@HHHH **** "BBB@"GJ/W;?\
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MD HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M *"*M'I572/^039?]<$_]!%5T _*[XS_ /)8?'7_ &'K_P#]*'KC:[+XS_\
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MP'&"5.2.,GPQ^,,GC;7M6\-:YX?N/"?BS3$6>;2YYUN%>%C@21RJ '&2 <#
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M_LJ/^'34'_10)/\ P '_ ,57Z%44?VIB_P"?\%_D%C\]?^'3</\ T4"3_P
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M@2?^  _^*H_X=-0'_FH$G_@ /_BJ_0JBH_M3%_S_ (+_ "'8_/7_ (=-P?\
M10)/_  ?_%5[G^RG^QJG[,OB+7-43Q*VN?VE:I;^6UMY>S:V[.<G-?2]%95,
M?B:T'"<KI^2"P4445YXPHHHH **** *>H_=M_P#KNG\ZN53U'[MO_P!=T_G5
MRJ>R ****D HHHH **** "BBB@ HHHH **** "BBB@ JFW_(6C_ZX-_Z$M7*
MIM_R%H_^N#?^A+51 N4445(!1110 4444 %%%% !1110 4444 %%%% !1110
M!3L/]=??]=__ &1:^ ?^"G_[-NI^(9+#XJ>'K.2\^QVHLM:@A4LZQJ_[J<*.
M2!O96] %/3-??UA_KK[_ *[_ /LBU:=%D4JP#*PP01D$5V8?$2PM958DM<RL
M?SG5U5_\4?$^IZ]X9UJYU/S-3\-VUI::5/\ 9XA]GBM2#;KM"X?;@<N"3W)K
M]<OB5_P3P^"_Q(U*74/[$NO#%[,Q:63P]<"W1SZ^4RO&O_ 5%<'_ ,.GOA'_
M -#%XU_\#K3_ .1:^L6<82:3DG?T,/9R/S=\7?'#Q/XYM]1CUB'PW/+J+F6Z
MO(/"NEV]W(Y;>S_:(K990Q;DL&!.3DG)JKH'QC\7>&+7PO;:=JD<4'AC4)-5
MTB.2R@E%K=/LW2_.AW',:$;LA2H( -?I9_PZ>^$?_0Q>-?\ P.M/_D6C_AT]
M\(_^AB\:_P#@=:?_ "+1_:F!2Y;:>@<DC\P?#OQ"\1>%/'-MXRTK59K7Q-;W
M9OH]1(5W\XDEF8,"&SDY# @Y(((-9C_;_%.N.T<#7FI7\[.(;2  R2.V2$C0
M #)/"J !T K]4X_^"4'PB1U8Z_XSD /*M?6F#^5J#7MGP9_9$^%WP)N5OO#/
MAQ'UE05&KZC(;FZ&1@[6;B/()!V!<CKFIJ9QAH+FIIM^EAJF^IS_ .P[^S[=
M?L^?!6#3]8C6/Q+J]PVHZD@.?)8@+'%GOM11G_:9J^A:**^.JU95INI/=FZ5
ME8****R&%%%% !1110 AZ55TC_D$V7_7!/\ T$5:/2JND?\ ()LO^N"?^@BJ
MZ ?E=\9_^2P^.O\ L/7_ /Z4/7&U^A?B?]B7P-XK\2ZMK=WJOB&.[U*[EO)D
MAN( BO(Y=@H,)(&6.,D_6LW_ (8%^'W_ $&/$O\ X%6__P 8KZ>&8T(Q2;?W
M'[30XJRVG1A"3=TDMO(^!J*^^?\ A@7X??\ 08\2_P#@5;__ !BC_A@7X??]
M!CQ+_P"!5O\ _&*O^TL/W?W&_P#K;EG>7W'P-17WS_PP+\/O^@QXE_\  JW_
M /C%'_# OP^_Z#'B7_P*M_\ XQ1_:6'[O[@_UMRSO+[CX&HK[Y_X8%^'W_08
M\2_^!5O_ /&*/^&!?A]_T&/$O_@5;_\ QBC^TL/W?W!_K;EG>7W'P-17WS_P
MP+\/O^@QXE_\"K?_ .,4?\,"_#[_ *#'B7_P*M__ (Q1_:6'[O[@_P!;<L[R
M^X^!J*^^?^&!?A]_T&/$O_@5;_\ QBC_ (8%^'W_ $&/$O\ X%6__P 8H_M+
M#]W]P?ZVY9WE]Q\#45]\_P## OP^_P"@QXE_\"K?_P",4?\ # OP^_Z#'B7_
M ,"K?_XQ1_:6'[O[@_UMRSO+[CX&HK[Y_P"&!?A]_P!!CQ+_ .!5O_\ &*/^
M&!?A]_T&/$O_ (%6_P#\8H_M+#]W]P?ZVY9WE]Q\#45]\_\ # OP^_Z#'B7_
M ,"K?_XQ1_PP+\/O^@QXE_\  JW_ /C%']I8?N_N#_6W+.\ON/@:BOOG_A@7
MX??]!CQ+_P"!5O\ _&*/^&!?A]_T&/$O_@5;_P#QBC^TL/W?W!_K;EG>7W'P
M-6QX2\):KXY\06FBZ+:/>:A<MM2-1P!W9CV [FON'_A@7X??]!CQ+_X%6_\
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MHJ0"BBB@ HHHH **** "BBB@ HHHH **** "J;?\A:/_ *X-_P"A+5RJ;?\
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MN_\ XU1_PU_\(_\ H;?_ "FW?_QJCZO6_D?W,/[*S#_H'G_X#+_(]DHKQO\
MX:_^$?\ T-O_ )3;O_XU1_PU_P#"/_H;?_*;=_\ QJCZO6_D?W,/[*S#_H'G
M_P" R_R/9**\;_X:_P#A'_T-O_E-N_\ XU7LE9SISI_'%KU.6OA,1A;>WIRA
M?:Z:O]X4445F<H4444 %%%% !1110 4444 %%%% !1110 4444 %5-(_Y!5G
M_P!<4_D*MU4TC_D%6?\ UQ3^0JN@%NBBBI **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MOV..XSWKYH^ 7[>GP[^!'PMT[PC8^!-4NBB%[ZY:XB_TJ9OOL05Z=@#T'%>
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M5\7?AU8Z.NK6OBW2X+.RO(IMBLUG+91R!XF*B1AYJ@Y0Y89VKTWC0_'3QA\
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MO:HF25%(<NVXY?8 1"#D$XKZ?KR<3&"JOV;]UZKY]/EL6KVU"BBBN4H****
M"BBB@ JFW_(6C_ZX-_Z$M7*IM_R%H_\ K@W_ *$M5$"Y1114@%%%% !1110
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M]T<R%&'[UNQKZ%IJ1K$H5%"*.RC IU<E6I[6I*I;=W&M$%%%%9#*>H_=M_\
MKNG\ZN55OHVD$&T%MLRL<=AFK54]D 4445(!45U:PWUM-;7,,=Q;S(8Y(I5#
M(ZD8*L#P01P0:EHH SO#_AW2?">CV^DZ'IEGHVE6P(AL=/MT@@B!8L=J( HR
MQ).!U)-:-%%-MMW8!1112 **** "BBB@ HHHH *IM_R%H_\ K@W_ *$M7*JM
M&W]I))@[/)9<^^X52 M4445(!1110 4444 %%%% !1110 4444 %%%% !111
M0!3L/]=??]=__9%JY56SC:.6\+*0&FW+[C8H_I5JJEN 4445(!1110 4444
M%%%% !1110 4444 %%%% "'I572/^039?]<$_P#015HU6TR-HM-M$=2KK"@(
M/4' JN@'Y6_&?_DL/CK_ +#U_P#^E#UQM?IOK7[+'PO\0ZQ?ZKJ'AC[1?WT\
MEU<2_P!H72[Y'8LS864 9))P !5+_AD#X1_]"E_Y4KO_ ..U])#,Z,8I-/\
M#_,_7Z'&& I4H0<)W22VCT7^(_-6BOTJ_P"&0/A'_P!"E_Y4KO\ ^.T?\,@?
M"/\ Z%+_ ,J5W_\ ':K^U*/9_A_F;_ZYY?\ R3^Z/_R1^:M%?I5_PR!\(_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
(* "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>syre-20260630_g2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 syre-20260630_g2.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 1K"G(# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% 'YX?\%!M0G;XM:=:M/(;=-/C
M9(BQVJ2S9(';.!7OO[.'[*'@[PAX?T7Q-J,/_"0Z[=V\5VDMX@\FW+*& 2/D
M9&?O-D^F*^<?^"ALWE_&FP'_ %#8O_0FK[W^%9S\,_"A_P"H5;?^BEKW<14E
M3PE)1=KGUV,Q56EEM"G3E9-:V/SNTF;/[9,"_P#4R8_\BU^A'QD./A3XL/\
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MTKX2U3]J[QM=?!G0OAAI%P="\/V,+17)LG(GORSEL2/U"\XVK@'OFNI\#_L
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M.6M_Z_I$17-JS-\"> ]!^&GA:Q\.^&].ATO2;--L4$(ZGNS'JS'J2>37R/\
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MC_\ 125]?_\ !0&XDB_8^\#1*Y6.5K .HZ-BWR*^0/VZ_P#DZOQO_P!?,?\
MZ*2OKO\ X*"_\FA^ O\ >L?_ $FKV)[X3^NB(74\:_X)V?&SX8_!:'Q?>^-]
M7M]&U:[:&*TFDM)9G:(!BZ@QHV!G;P<5]H?\-[_ ;_H>X?\ P77?_P :K\UO
MV9OV0=>_:<L-<NM&US3M(72I(XI%OED)<N"1C:#Z=Z]L_P"'3?CG_H=/#_\
MW[G_ /B:RQ=#!3K2E6J-2[?TAIRMHCZ]_P"&]_@-_P!#W#_X+KO_ .-4?\-[
M_ ;_ *'N'_P77?\ \:KY"_X=-^.?^AT\/_\ ?N?_ .)H_P"'3?CG_H=/#_\
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M]:^*'_0N>%?_  'N/_CU?;?_  PK\"_^B?67_@5<?_'*/^&%?@7_ -$^LO\
MP*N/_CE>G];R[_GR_P"OF3:7<^)/^'K7Q0_Z%SPK_P" ]Q_\>K+\3_\ !4#X
MJ^(O#]_ID6F>'=*:[B:$WEI;2F6(,,$KOE9<X[D&ON__ (85^!?_ $3ZR_\
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M!\__ ,<H_P"%7_M5_P#/G\0/_ ^?_P".4?V9'_G]'^OF&G<_8FBOQV_X5?\
MM5_\^?Q _P# ^?\ ^.4?\*O_ &J_^?/X@?\ @?/_ /'*/[,C_P _H_U\PT[G
M[$T5^.W_  J_]JO_ )\_B!_X'S__ !RC_A5_[5?_ #Y_$#_P/G_^.4?V9'_G
M]'^OF&G<_8FBOQV_X5?^U7_SY_$#_P #Y_\ XY1_PJ_]JO\ Y\_B!_X'S_\
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M2%H?25%%%>6 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_<E_(?XT?\)%;?W)?R'^-')+L%S4HK+_ .$BMO[DOY#_ !H_X2*V_N2_D/\
M&CDEV"YJ45E_\)%;?W)?R'^-'_"16W]R7\A_C1R2[!<U**R_^$BMO[DOY#_&
MC_A(K;^Y+^0_QHY)=@N:E%9?_"16W]R7\A_C1_PD5M_<E_(?XT<DNP7-2BLO
M_A(K;^Y+^0_QH_X2*V_N2_D/\:.278+FI167_P )%;?W)?R'^-'_  D5M_<E
M_(?XT<DNP7-2BLO_ (2*V_N2_D/\:/\ A(K;^Y+^0_QHY)=@N:E%9?\ PD5M
M_<E_(?XT?\)%;?W)?R'^-')+L%S4HK+_ .$BMO[DOY#_ !H_X2*V_N2_D/\
M&CDEV"YJ45E_\)%;?W)?R'^-'_"16W]R7\A_C1R2[!<U**R_^$BMO[DOY#_&
MC_A(K;^Y+^0_QHY)=@N:E%9?_"16W]R7\A_C1_PD5M_<E_(?XT<DNP7-2BLO
M_A(K;^Y+^0_QH_X2*V_N2_D/\:.278+FI167_P )%;?W)?R'^-'_  D5M_<E
M_(?XT<DNP7-2BLO_ (2*V_N2_D/\:/\ A(K;^Y+^0_QHY)=@N:E%9?\ PD5M
M_<E_(?XT?\)%;?W)?R'^-')+L%S4HK+_ .$BMO[DOY#_ !H_X2*V_N2_D/\
M&CDEV"YJ45E_\)%;?W)?R'^-'_"16W]R7\A_C1R2[!<U**R_^$BMO[DOY#_&
MIK35X+R7RT#JQY 8=:3A):V&7J***@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M HHHH **** "N!_: _Y(/\2/^Q:U+_TEDKOJX']H#_D@_P 2/^Q:U+_TEDH
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M!!Y7_@E_^V-X9\1^$/\ A"?''CF\U7XL^(_$5Y>16U];W4\EPAAC8'SA&8E
M6)\*7  4  <"N8_;&_X)\_"+]G/]B7QKJ^A66JZQXBT>[MKRPUK6;XM<0&YO
M+*WE3;"L43H8UP Z,068@@GBY_P2+_9O^'7B/X5V/Q7U'P[]H\?:3K]Y;V6K
M_;;E?*C$,:@>2L@B;B6099"?F]A@ _3*OF[_ (*&_&@_!#]E#QGJEM.UOJ^K
M0C0M-9&VL)[@%693V9(A*X([I7TC7Y#?\%B_BJ?'7QH\"?".QU"VM;;28TN[
M^:YG6."*ZNF"Q^<QX01Q /N) "SDF@#XY\+Z)XN_9@U3X+?&0Q,EKJT[ZQIJ
M*Q1Y4M;HQ31-[.FWGNLW3'7^B[PYK]CXK\/:7K>F3BYTW4K6*\M9EZ212('1
MA]58&OS/_P""B ^"GB+]C#PSX<\#_$GP9K6K> 'LDTRRTS7K.:ZN+<(+:55C
M20LQ(996QS^[SSS7MW_!)GXT?\+0_98L] NYO,U;P9=/I$FYLLUL?WELV.P"
ML8A_UQ- 'U=_PLSP?_PFW_"&_P#"5Z)_PE_E^;_PC_\ :,/V_9LW[OL^[S,;
M?FSMZ<]*Z6O-O^&<OAW_ ,+L_P"%N?\ "/?\7#\C[-_;'VVX_P!7Y7E;?)\S
MRON<9V9[]>:])H \6_:\_:3T[]E7X):KXVN[=+_4=Z66E:<[[1=7D@.Q2>NU
M0KNV.=J-CG%?,7PQ_8+\2?M+^'K3Q[^TMX]\2:YJVMQ+>0>$=.O/LEAIL+@,
MD;( 0& *DJ@7:<Y+G)JG_P %>46\E^ >GWISHESXH<7B2<1$?N%&X]OE:3\"
M:_1*@#\ZOB]^QYXR_8P\-W?Q._9R\<Z_%9: C7VK>"-:NOM=C=VJ?-*47"@[
M54DA@7QN*.K  _7?[.O[1F@?M _ C2/B9 T6BV4UO(VI0W4ZA-/EAR)U>0X
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MP3\$HQ^TM_P4@^)/Q)D_TKPQ\,+0>&-%<\H;QMZ2NAS@X/VOIGB6,YZ9^]J
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M-^UWXT\;?"W_ (*:_$7Q_P"!;>2ZU'PE#INK7D2<JUD-.L8IUD'4QL)@K8Y
M8MQMR/UX^"WQ=T'X[_##P_XY\-3&72M7MQ,L;$&2"0<20OC@.CAE/N..,5\-
M>!=-M-:_X+(_&73[^VBO+&[\)QP7%O.H:.6-K#359&!X(()!'O69\$]3NO\
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M?0--\-:IXV^(?B*-SH>@:= ["8J<;G903@'^% 6..P^8?,'_  3;UKX@:_\
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M\IUL1F>25ZLES3=5-V7]V*V1Q.@?\GB2_P#8?N?YO6C^V/\ \EET#_L%6_\
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M#[AMQOST.<=JYO\ 94^"W_"03Z=X[_MG[/\ V;J#Q?V?]EW>9M0<^9O&/O\
M]T]*]&^)2,_[&MF%!)_L323QZ!K<FLS]CWQGH6G^ 6T2YU6UAU>?59/*L7D
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M >4_L5_\FD?"'_L6+#_T2M?(?[#'@D?$O_AM?P@T_P!E'B#7+_23/C/E^?\
M;HMWX;\_A7Z,:)HFG>&M(L]*TBPM=*TNSB6"VLK*%88((U&%1$4!54#@ # K
M,\+_  ^\+>"+K5;GPYX:T?0+G5I_M.H3:7816SWDN2?,F**#(V68[FR?F/K0
M!^??["'[6?AC]F?P'<? ;XV3/\.O%7A&]NDM9-4@<6UW!+,\V5D"X'SO(03\
MKJR%6;) H?%'XD6G_!0G]KWX2^'OAE;W.K> ?AWJ0UK7/$[6S1VSD21.44N
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M=ES]Y&0KGD#](*Y/QO\ "7P/\3#;GQAX,\/^*S;<0'7-+@O/*_W?-1MO4]*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M \]_X:(^%7_13?!W_@_M/_CE'_#1'PJ_Z*;X._\ !_:?_'*]"HHO2_E?W_\
M "\.S^__ (!Y[_PT1\*O^BF^#O\ P?VG_P <H_X:(^%7_13?!W_@_M/_ (Y7
MH5%%Z7\K^_\ X 7AV?W_ / //?\ AHCX5?\ 13?!W_@_M/\ XY1_PT1\*O\
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M (:(^%7_ $4WP=_X/[3_ ..4?\-$?"K_ **;X._\']I_\<KT*BB]+^5_?_P
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M]_X:(^%7_13?!W_@_M/_ (Y1_P -$?"K_HIO@[_P?VG_ ,<KT*BB]+^5_?\
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M (/[3_XY7H5%%Z7\K^__ ( 7AV?W_P# //?^&B/A5_T4WP=_X/[3_P".4?\
M#1'PJ_Z*;X._\']I_P#'*]"HHO2_E?W_ / "\.S^_P#X!Y[_ ,-$?"K_ **;
MX._\']I_\<H_X:(^%7_13?!W_@_M/_CE>A447I?RO[_^ %X=G]__  #SW_AH
MCX5?]%-\'?\ @_M/_CE'_#1'PJ_Z*;X._P#!_:?_ !RO0J*+TOY7]_\ P O#
ML_O_ . >>_\ #1'PJ_Z*;X._\']I_P#'*/\ AHCX5?\ 13?!W_@_M/\ XY7H
M5%%Z7\K^_P#X 7AV?W_\ \]_X:(^%7_13?!W_@_M/_CE'_#1'PJ_Z*;X._\
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M*O\ HIO@[_P?VG_QRC_AHCX5?]%-\'?^#^T_^.5Z%11>E_*_O_X 7AV?W_\
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M \]_X:(^%7_13?!W_@_M/_CE'_#1'PJ_Z*;X._\ !_:?_'*]"HHO2_E?W_\
M "\.S^__ (!Y[_PT1\*O^BF^#O\ P?VG_P <H_X:(^%7_13?!W_@_M/_ (Y7
MH5%%Z7\K^_\ X 7AV?W_ / //?\ AHCX5?\ 13?!W_@_M/\ XY1_PT1\*O\
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M (:(^%7_ $4WP=_X/[3_ ..4?\-$?"K_ **;X._\']I_\<KT*BB]+^5_?_P
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M]_X:(^%7_13?!W_@_M/_ (Y1_P -$?"K_HIO@[_P?VG_ ,<KT*BB]+^5_?\
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M (/[3_XY7H5%%Z7\K^__ ( 7AV?W_P# //?^&B/A5_T4WP=_X/[3_P".4?\
M#1'PJ_Z*;X._\']I_P#'*]"HHO2_E?W_ / "\.S^_P#X!Y[_ ,-$?"K_ **;
MX._\']I_\<H_X:(^%7_13?!W_@_M/_CE>A447I?RO[_^ %X=G]__  #SW_AH
MCX5?]%-\'?\ @_M/_CE'_#1'PJ_Z*;X._P#!_:?_ !RO0J*+TOY7]_\ P O#
ML_O_ . >>_\ #1'PJ_Z*;X._\']I_P#'*/\ AHCX5?\ 13?!W_@_M/\ XY7H
M5%%Z7\K^_P#X 7AV?W_\ \]_X:(^%7_13?!W_@_M/_CE'_#1'PJ_Z*;X._\
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M*O\ HIO@[_P?VG_QRC_AHCX5?]%-\'?^#^T_^.5Z%11>E_*_O_X 7AV?W_\
M //?^&B/A5_T4WP=_P"#^T_^.4?\-$?"K_HIO@[_ ,']I_\ '*]"HHO2_E?W
M_P# "\.S^_\ X!Y[_P -$?"K_HIO@[_P?VG_ ,<H_P"&B/A5_P!%-\'?^#^T
M_P#CE>A447I?RO[_ /@!>'9_?_P#SW_AHCX5?]%-\'?^#^T_^.4?\-$?"K_H
MIO@[_P ']I_\<KT*BB]+^5_?_P  +P[/[_\ @'GO_#1'PJ_Z*;X._P#!_:?_
M !RC_AHCX5?]%-\'?^#^T_\ CE>A447I?RO[_P#@!>'9_?\ \ \]_P"&B/A5
M_P!%-\'?^#^T_P#CE'_#1'PJ_P"BF^#O_!_:?_'*]"HHO2_E?W_\ +P[/[_^
M >>_\-$?"K_HIO@[_P ']I_\<H_X:(^%7_13?!W_ (/[3_XY7H5%%Z7\K^__
M ( 7AV?W_P# //?^&B/A5_T4WP=_X/[3_P".4?\ #1'PJ_Z*;X._\']I_P#'
M*]"HHO2_E?W_ / "\.S^_P#X!Y[_ ,-$?"K_ **;X._\']I_\<H_X:(^%7_1
M3?!W_@_M/_CE>A447I?RO[_^ %X=G]__  #SW_AHCX5?]%-\'?\ @_M/_CE'
M_#1'PJ_Z*;X._P#!_:?_ !RO0J*+TOY7]_\ P O#L_O_ . >>_\ #1'PJ_Z*
M;X._\']I_P#'*/\ AHCX5?\ 13?!W_@_M/\ XY7H5%%Z7\K^_P#X 7AV?W_\
M \]_X:(^%7_13?!W_@_M/_CE'_#1'PJ_Z*;X._\ !_:?_'*]"HHO2_E?W_\
M "\.S^__ (!Y[_PT1\*O^BF^#O\ P?VG_P <H_X:(^%7_13?!W_@_M/_ (Y7
MH5%%Z7\K^_\ X 7AV?W_ / //?\ AHCX5?\ 13?!W_@_M/\ XY1_PT1\*O\
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MEB< #7K7)_\ (E>@T45$G%_"OQ_X")=N@4445!(4444 %%%% !1110 4444
M%%%% !1110!C2.TCEF.33:#UHKH("BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "@'!XHHH UK5S) C$Y-2U!9?\>R?
MC_.IZP>Y84444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M2U#2HKJ<:+=7?F/,D47F!O,\M=H8Y7[IQCOTKS+_ (;V\)_]")\0/_!/#_\
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M,[H]-^"_P@U;X4_VQ_:GC_Q!XY^W^3Y?]NW#R_9=F_/E[G;&[>,XQ]Q:\/\
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M+?'_ ,//#7P+_:K^%<?PQG?3-2UB_6#6-"MIVE1+5G0,[!F)561I&VGC]V&
M&*^Y*\F^$7[,'@/X+:A+J>B6-Q>:W*I1M6U2;S[D*>H4X"KGN5 )Z&O6:)RY
MK!&-KA1116984444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;2O&WAV_T+7+*/4=)OXC#<6TA(#J?<$$$'!!!!! (((H]I[]^@<GNVZG@_[
M/_)M>C?]?MW_ .C37,_\%+/^2%:%_P!C)!_Z2W5?2'P_^'GA_P"%WAJ'P_X8
MT_\ LS2(7>1+?SI)<,QRQW2,S<D^M5?B7\*?"WQ@T*#1O%VE_P!KZ;!<K=QP
M?:)8=LJJR!MT;*3\KN,9QSTX%"FO:<XW%\G*=;7QUXPU.ST?_@HMX>NK^[@L
M;5- 8-/<R+&BY@G RQ('6OL6O+_B+^S-\-?BQXB_MWQ5X;_M75?)6#[1]NN8
M?D7.T;8Y%7C)YQFIA)1;N.2;V.N_X6/X3_Z&C1?_  80_P#Q58GQ+U[3-?\
M@]XZETS4;348DT6^5WM)UE"G[.YP2I.#7"?\,-?!'_H2?_*M??\ Q^NZ\%?
MCP-\._"NL^&_#VA_V?HNL!UOK;[7/+YP=/+;YG<LN5X^4C\Z/<6J#WGN>5_L
M&6D&H?LP:;:W,23VT]S>Q2Q2#*NIE8%2.X(.*^8?VA-!UO\ 9ETKQU\-XXY[
MSX?>,_)OM$D9LK:317,,CID]PB;".I'E-ZU^AOP_^'GA_P"%WAJ'P_X8T_\
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ML(U4DN3V"YS6OXP\$:!\0-&?2O$>D6FM:>YW>1>1!PK?WE/56YZC!%>8:?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%1V\ZW5O%,F=D
MBAUSZ$9% $E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !14<LZPO"C9S*VQ<>NTM_
M)34E !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45Y-^
MT+\>[3X'^';>5+=-0UN^8K:6;OM7 QN=\<[1D=.I.,BOC:__ &R?BO>7#21>
M(8;%#TAM].MRH_[[1C^M=]#!5:\>:.B\SZ?+N'<;F=+VU*T8]')M7]+)GZ14
M5^:O_#7_ ,7/^AM_\IMI_P#&J/\ AK_XN?\ 0V_^4VT_^-5T_P!EUNZ_'_(]
M;_4S,/YX??+_ .1/TJHK\U?^&O\ XN?]#;_Y3;3_ .-4?\-?_%S_ *&W_P I
MMI_\:H_LNMW7X_Y!_J9F'\\/OE_\B?I517YJ_P##7_Q<_P"AM_\ *;:?_&J/
M^&O_ (N?]#;_ .4VT_\ C5']EUNZ_'_(/]3,P_GA]\O_ )$_2JBOS5_X:_\
MBY_T-O\ Y3;3_P"-4?\ #7_Q<_Z&W_RFVG_QJC^RZW=?C_D'^IF8?SP^^7_R
M)^E5%?FK_P -?_%S_H;?_*;:?_&J/^&O_BY_T-O_ )3;3_XU1_9=;NOQ_P @
M_P!3,P_GA]\O_D3]*J*_-7_AK_XN?]#;_P"4VT_^-4?\-?\ Q<_Z&W_RFVG_
M ,:H_LNMW7X_Y!_J9F'\\/OE_P#(GZ545^:O_#7_ ,7/^AM_\IMI_P#&J/\
MAK_XN?\ 0V_^4VT_^-4?V76[K\?\@_U,S#^>'WR_^1/TJHK\U?\ AK_XN?\
M0V_^4VT_^-4?\-?_ !<_Z&W_ ,IMI_\ &J/[+K=U^/\ D'^IF8?SP^^7_P B
M?I517YJ_\-?_ !<_Z&W_ ,IMI_\ &J/^&O\ XN?]#;_Y3;3_ .-4?V76[K\?
M\@_U,S#^>'WR_P#D3]*J*_-7_AK_ .+G_0V_^4VT_P#C5'_#7_Q<_P"AM_\
M*;:?_&J/[+K=U^/^0?ZF9A_/#[Y?_(GZ545^:O\ PU_\7/\ H;?_ "FVG_QJ
MC_AK_P"+G_0V_P#E-M/_ (U1_9=;NOQ_R#_4S,/YX??+_P"1/TJHK\U?^&O_
M (N?]#;_ .4VT_\ C5'_  U_\7/^AM_\IMI_\:H_LNMW7X_Y!_J9F'\\/OE_
M\B?I517YJ_\ #7_Q<_Z&W_RFVG_QJC_AK_XN?]#;_P"4VT_^-4?V76[K\?\
M(/\ 4S,/YX??+_Y$_2JBOS5_X:_^+G_0V_\ E-M/_C5'_#7_ ,7/^AM_\IMI
M_P#&J/[+K=U^/^0?ZF9A_/#[Y?\ R)^E5%?FK_PU_P#%S_H;?_*;:?\ QJC_
M (:_^+G_ $-O_E-M/_C5']EUNZ_'_(/]3,P_GA]\O_D3]*J*_-7_ (:_^+G_
M $-O_E-M/_C5'_#7_P 7/^AM_P#*;:?_ !JC^RZW=?C_ )!_J9F'\\/OE_\
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MU1_9=;NOQ_R#_4S,/YX??+_Y$_2JBOS5_P"&O_BY_P!#;_Y3;3_XU1_PU_\
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M-M/_ (U1_9=;NOQ_R#_4S,/YX??+_P"1/TJHK\U?^&O_ (N?]#;_ .4VT_\
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M/^AM_P#*;:?_ !JC_AK_ .+G_0V_^4VT_P#C5']EUNZ_'_(/]3,P_GA]\O\
MY$_2JBOS5_X:_P#BY_T-O_E-M/\ XU1_PU_\7/\ H;?_ "FVG_QJC^RZW=?C
M_D'^IF8?SP^^7_R)^E5%?FK_ ,-?_%S_ *&W_P IMI_\:H_X:_\ BY_T-O\
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MU_\ %S_H;?\ RFVG_P :H_LNMW7X_P"0?ZF9A_/#[Y?_ ")^E5%?FK_PU_\
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M"M]=L8/Y&OJK]F?]I@?&9;G1]8MH+'Q':1B7]P2([J,8#.JGE2">1D]16%;
M5J,>=V:\CS<?PUCLOHNO.THK?E;T^](]\HHHKSCY0*C@G6X0NF<!F3GU5BI_
M4&I*AM84@B94;<ID=\Y[EB2/P)(H FHHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *I:+_ ,@:P_Z]X_\ T$5=
MJEHO_(&L/^O>/_T$4 7:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *5__ ,?6F_\
M7P?_ $5)5VJ5_P#\?6F_]?!_]%25=H **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBOF_\ ; ^&?QR\51^'?$WP/\>CP_K6@><\WANZ"K:ZP&VD!F;*[@%9
M0L@VG?G=&1D@'TA17PY\#_\ @I=8?\),OP]_:!\/2_!_X@P (]SJ$;0Z9<DG
MAMS\P!AR&8M&0"1)R!7V_;W$5Y;Q3P2I/!*H>.6-@RNI&001P01WH DHHHH
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MT\R&!O-W;O-EQN'.W>VW\,8H LT444 ?'O\ P4,N94M? EN&(AD>^D9?5E$
M!_ ,WYU\9U]C_P#!0[_F0/\ N(?^VU?'%?89?_NT?G^;/WKAA?\ "31_[>_]
M*84445Z!]2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !7M/['5S+!^T-X92-BJSI=QR#^\OV:5L?FH/X5XM7LG[(
M'_)Q7A+_ +>__22:N?$_P9^C_(\K-E?+\1_@E_Z2S]*J***^'/YQ"J]C;M;0
M,CD$F61^/1G9A^AJQ5;3S(8&\W=N\V7&X<[=[;?PQB@"S1110 4444 %%%%
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MD/\ 9&DV.N_;(M>VW-[NDMY/L=R_E_O+4;MHBP,*JC/%0_"KX9>,_BU^V_\
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MXH^,"7NC:I9:O9_V;!']HL;A)X]P9\KN4D9&1Q[USNC'ZZI6TM?YGESP%/\
MUAC4Y-'#F\N:[5^U[?CJ>C_\$]=G]I^.,X\SR;/'KC=-G^E>??";S3^V3'NW
M>;_;]_OQU_Y;;OZUA_LO_&2U^#GQ":[U3S?[#U&#[+>-$-QB^8,DNT#+;2""
M!SAFQD@ _4EG'\!_"GCR]^)T'BS3#JD@DG\B+48Y0DCAA)(D"_O-[!FR.>O
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M$#)P>/:ME1<<%:2]Y)_B=\<O=+A]0K4_WD82MIJN9M_)VM<Q?VLO^3A/%_\
MUT@_])HJ\CKU']IS6+#7_CGXIO\ 3+ZVU&QFDA,5U:2K+$^((P=K*2#@@CCN
M*\NKTJ"M1@GV7Y'UN6)QP-!/?DC^2/MWXKQQ>'?V&/#UG;IY<=[9::S!!P6D
M*3L3]6!/UJK^QIX?TGP9\)?%'Q&O;>.:^B^T$38+/%;01!V4<<%FW9QU 7Z5
M-XDNQ\1/V$+.>TB\V?2K2WC>/@LGV:58G/M^[4M]#^%<#^R'\<M!\&6.L>"_
M%LR6>C:I(9H;N7/EJ[H(Y$D/\*LJK@]!@Y/->*HSEAZD5OS.Y^?*C6JY5BJ5
M--R55\R6[5U?^O(Z7X"_M-^(OBM\4!X5\8P6&IZ)K:RB*U%JH6V=$,B@=V4[
M"/FW')!!&*@^/GA74/CM^U59^#+25XK32[*%;J0GY;>(@32R =V(E11ZG:#Q
MTO\ @SPO\&_V>O%,OC,?$.V\2R1!X].L+.2.>6#>NTEO*9BQVEAN(4 $\$XK
M'^./Q>A^&'QZ'COP+J'A[Q$VK:0+2X*7 ND1U90=PBD!4[4BP2>>>.*N*3K\
MU"-O=TTLK_\ #&U.$)9BZF64G%.FU&\7&//I=ZKMOW?<]HOM1UK2/C#X!\"^
M&O#6JV'@;1 QO-06SF%K(PMI!&GFE=K*I()))W.P[KS\_?MS^'-6/Q276AI=
MZ='&GV\!U#[._P!G$FZ3Y/,QMW>V<UUGPF_;8\1^+/B%I&D^)XO#6C:%<M(+
MF^VR0>4!&S+\\DQ5<L%'([XK$_;(^/'_  DMY_PANBW>C:OX;:."\-_8R^?(
M)@7RGF*Y3 XXVYYZU-"G5I8B*<>FOW[^IGEV$QV#S2C"=))\FKO>Z<FW)O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M"'_L6+#_ -$K7M-% 'PS^TU_RDH_9@_Z\]3_ /14M-^-W_*63]G;_L6M3_\
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M_P"5*T_^.UK]8H_SK[T=?]JY?_T$0_\  H_YGC=%>R?\,@?%S_H4O_*E:?\
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M$\2J\.>22^..RZ+4\;HKV3_AD#XN?]"E_P"5*T_^.T?\,@?%S_H4O_*E:?\
MQVM?K%'^=?>CK_M7+_\ H(A_X%'_ #/&Z*]D_P"&0/BY_P!"E_Y4K3_X[1_P
MR!\7/^A2_P#*E:?_ !VCZQ1_G7WH/[5R_P#Z"(?^!1_S/&Z*]D_X9 ^+G_0I
M?^5*T_\ CM'_  R!\7/^A2_\J5I_\=H^L4?YU]Z#^U<O_P"@B'_@4?\ ,\;H
MKV3_ (9 ^+G_ $*7_E2M/_CM'_#('Q<_Z%+_ ,J5I_\ ':/K%'^=?>@_M7+_
M /H(A_X%'_,\;HKV3_AD#XN?]"E_Y4K3_P".T?\ #('Q<_Z%+_RI6G_QVCZQ
M1_G7WH/[5R__ *"(?^!1_P SQNBO9/\ AD#XN?\ 0I?^5*T_^.T?\,@?%S_H
M4O\ RI6G_P =H^L4?YU]Z#^U<O\ ^@B'_@4?\SQNO:/V.K:2?]H;PRZ*66%+
MN20_W5^RRKG\V _&BV_8[^+,\RH_AA+=2>9)-1M2J_7;(3^0KZI_9G_9F'P:
M%QK.LW,-]XCNHA$/(!,=K&<%E5CRQ)ZG@<5R8K%4E2DE)-M6T/#SK.L## U:
M=.K&4I1:233W5NA[[1117R1^&A4-K%'#$RQ-N4R.Q.<\EB6'X$D5-5>RMVM8
M61B"3+(_'HSEA_.@"Q1110!\>_\ !0RVD>V\"7 4F&-[Z-F]&80$#\E;\J^,
MZ_5#XU?"/3_C+X*GT2\D^RW*-YUG>!=Q@E (!QW!!((]#7Q'KG[%WQ1TN^DA
ML](MM8@#$+<6M]"BL,\'$C*1GTQ7TV Q-)453E*S7<_8.&<XP=/ QPU:HH2C
M?=VNFV]WIU/"Z*]D_P"&0/BY_P!"E_Y4K3_X[1_PR!\7/^A2_P#*E:?_ !VO
M2^L4?YU]Z/KO[5R__H(A_P"!1_S/&Z*]D_X9 ^+G_0I?^5*T_P#CM'_#('Q<
M_P"A2_\ *E:?_':/K%'^=?>@_M7+_P#H(A_X%'_,\;HKV3_AD#XN?]"E_P"5
M*T_^.T?\,@?%S_H4O_*E:?\ QVCZQ1_G7WH/[5R__H(A_P"!1_S/&Z*]D_X9
M ^+G_0I?^5*T_P#CM'_#('Q<_P"A2_\ *E:?_':/K%'^=?>@_M7+_P#H(A_X
M%'_,\;HKV3_AD#XN?]"E_P"5*T_^.T?\,@?%S_H4O_*E:?\ QVCZQ1_G7WH/
M[5R__H(A_P"!1_S/&Z*]D_X9 ^+G_0I?^5*T_P#CM'_#('Q<_P"A2_\ *E:?
M_':/K%'^=?>@_M7+_P#H(A_X%'_,\;HKV3_AD#XN?]"E_P"5*T_^.T?\,@?%
MS_H4O_*E:?\ QVCZQ1_G7WH/[5R__H(A_P"!1_S/&Z*]D_X9 ^+G_0I?^5*T
M_P#CM'_#('Q<_P"A2_\ *E:?_':/K%'^=?>@_M7+_P#H(A_X%'_,\;HKV3_A
MD#XN?]"E_P"5*T_^.T?\,@?%S_H4O_*E:?\ QVCZQ1_G7WH/[5R__H(A_P"!
M1_S/&Z*]D_X9 ^+G_0I?^5*T_P#CM'_#('Q<_P"A2_\ *E:?_':/K%'^=?>@
M_M7+_P#H(A_X%'_,\;HKV3_AD#XN?]"E_P"5*T_^.T?\,@?%S_H4O_*E:?\
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M_M7+_P#H(A_X%'_,\;HKV3_AD#XN?]"E_P"5*T_^.T?\,@?%S_H4O_*E:?\
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M_M7+_P#H(A_X%'_,\;HKV3_AD#XN?]"E_P"5*T_^.T?\,@?%S_H4O_*E:?\
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M_M7+_P#H(A_X%'_,\;HKV3_AD#XN?]"E_P"5*T_^.T?\,@?%S_H4O_*E:?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!2O_P#CZTW_ *^#_P"BI*NU
M2O\ _CZTW_KX/_HJ2KM !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX@G\1V5]>^($TYM%N;@#S1<(R,\J#:H C#$J@.[)( !E?LS?"RX\)?MT^/\
MPW%K-_K7@WX:^'H;3P_!J4QN)=,&I^3<& RMEF"B"4)N.0C <@5W_P"P ?\
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M/^'AW[/O_0__ /E&U#_Y'K\6:*/[#PW\TOO7^0>T9^TW_#P[]GW_ *'_ /\
M*-J'_P CT?\ #P[]GW_H?_\ RC:A_P#(]?BS11_8>&_FE]Z_R#VC/VF_X>'?
ML^_]#_\ ^4;4/_D>C_AX=^S[_P!#_P#^4;4/_D>OQ9HH_L/#?S2^]?Y![1G[
M3?\ #P[]GW_H?_\ RC:A_P#(]'_#P[]GW_H?_P#RC:A_\CU^+-%']AX;^:7W
MK_(/:,_:;_AX=^S[_P!#_P#^4;4/_D>C_AX=^S[_ -#_ /\ E&U#_P"1Z_%F
MBC^P\-_-+[U_D'M&?M-_P\._9]_Z'_\ \HVH?_(]'_#P[]GW_H?_ /RC:A_\
MCU^+-%']AX;^:7WK_(/:,_:;_AX=^S[_ -#_ /\ E&U#_P"1Z/\ AX=^S[_T
M/_\ Y1M0_P#D>OQ9HH_L/#?S2^]?Y![1G[3?\/#OV??^A_\ _*-J'_R/1_P\
M._9]_P"A_P#_ "C:A_\ (]?BS11_8>&_FE]Z_P @]HS]IO\ AX=^S[_T/_\
MY1M0_P#D>C_AX=^S[_T/_P#Y1M0_^1Z_%FBC^P\-_-+[U_D'M&?M-_P\._9]
M_P"A_P#_ "C:A_\ (]'_  \._9]_Z'__ ,HVH?\ R/7XLT4?V'AOYI?>O\@]
MHS]IO^'AW[/O_0__ /E&U#_Y'H_X>'?L^_\ 0_\ _E&U#_Y'K\6:*/[#PW\T
MOO7^0>T9^TW_  \._9]_Z'__ ,HVH?\ R/1_P\._9]_Z'_\ \HVH?_(]?BS1
M1_8>&_FE]Z_R#VC/VF_X>'?L^_\ 0_\ _E&U#_Y'H_X>'?L^_P#0_P#_ )1M
M0_\ D>OQ9HH_L/#?S2^]?Y![1G[3?\/#OV??^A__ /*-J'_R/1_P\._9]_Z'
M_P#\HVH?_(]?BS11_8>&_FE]Z_R#VC/VF_X>'?L^_P#0_P#_ )1M0_\ D>C_
M (>'?L^_]#__ .4;4/\ Y'K\6:*/[#PW\TOO7^0>T9^TW_#P[]GW_H?_ /RC
M:A_\CT?\/#OV??\ H?\ _P HVH?_ "/7XLT4?V'AOYI?>O\ (/:,_:;_ (>'
M?L^_]#__ .4;4/\ Y'H_X>'?L^_]#_\ ^4;4/_D>OQ9HH_L/#?S2^]?Y![1G
M[3?\/#OV??\ H?\ _P HVH?_ "/1_P /#OV??^A__P#*-J'_ ,CU^+-%']AX
M;^:7WK_(/:,_:;_AX=^S[_T/_P#Y1M0_^1Z/^'AW[/O_ $/_ /Y1M0_^1Z_%
MFBC^P\-_-+[U_D'M&?M9:?\ !03X 7MS'!'\08U=S@&;2KZ-?Q9H !^)KW'P
MOXLT;QMHEMK&@:I::QI=PNZ*[LI1)&WXCOSTZBOYXJ^R?^"7_P 5-2\,_'A?
M!8N7.C>)+:<M:L25%Q#$TJN!T!V(X)[C'H*XL7D].E2E4I2=UKK_ $BHU&W9
MGZU4445\J;!5;3Q(('\W=N\V7&[KM\QMOX8QCVJS5>QN&N86=P 1+(G'HKLH
M_04 6**** &331V\3RRNL<2*6=W.%4#DDGL*\+\3?MS? OPCJ<NGZA\0K)KJ
M)V1Q8VMS>(&!P1OAB=>OO7C/_!5#XJZIX,^%OASPKIET]HOBBXG%X8\AI+>!
M8RT>1V+2ID=P,5^5-?1X#*HXFE[6K)I/:QE*=G9'[3?\/#OV??\ H?\ _P H
MVH?_ "/1_P /#OV??^A__P#*-J'_ ,CU^+-%>I_8>&_FE]Z_R(]HS]IO^'AW
M[/O_ $/_ /Y1M0_^1Z/^'AW[/O\ T/\ _P"4;4/_ )'K\6:*/[#PW\TOO7^0
M>T9^TW_#P[]GW_H?_P#RC:A_\CT?\/#OV??^A_\ _*-J'_R/7XLT4?V'AOYI
M?>O\@]HS]IO^'AW[/O\ T/\ _P"4;4/_ )'H_P"'AW[/O_0__P#E&U#_ .1Z
M_%FBC^P\-_-+[U_D'M&?M-_P\._9]_Z'_P#\HVH?_(]'_#P[]GW_ *'_ /\
M*-J'_P CU^+-%']AX;^:7WK_ "#VC/VF_P"'AW[/O_0__P#E&U#_ .1Z/^'A
MW[/O_0__ /E&U#_Y'K\6:*/[#PW\TOO7^0>T9^TW_#P[]GW_ *'_ /\ *-J'
M_P CT?\ #P[]GW_H?_\ RC:A_P#(]?BS11_8>&_FE]Z_R#VC/VF_X>'?L^_]
M#_\ ^4;4/_D>C_AX=^S[_P!#_P#^4;4/_D>OQ9HH_L/#?S2^]?Y![1G[3?\
M#P[]GW_H?_\ RC:A_P#(]'_#P[]GW_H?_P#RC:A_\CU^+-%']AX;^:7WK_(/
M:,_:;_AX=^S[_P!#_P#^4;4/_D>C_AX=^S[_ -#_ /\ E&U#_P"1Z_%FBC^P
M\-_-+[U_D'M&?M-_P\._9]_Z'_\ \HVH?_(]'_#P[]GW_H?_ /RC:A_\CU^+
M-%']AX;^:7WK_(/:,_:;_AX=^S[_ -#_ /\ E&U#_P"1Z/\ AX=^S[_T/_\
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M&_FE]Z_R#VC/VF_X>'?L^_\ 0_\ _E&U#_Y'H_X>'?L^_P#0_P#_ )1M0_\
MD>OQ9HH_L/#?S2^]?Y![1G[3?\/#OV??^A__ /*-J'_R/1_P\._9]_Z'_P#\
MHVH?_(]?BS11_8>&_FE]Z_R#VC/VF_X>'?L^_P#0_P#_ )1M0_\ D>C_ (>'
M?L^_]#__ .4;4/\ Y'K\6:*/[#PW\TOO7^0>T9^TW_#P[]GW_H?_ /RC:A_\
MCT?\/#OV??\ H?\ _P HVH?_ "/7XLT4?V'AOYI?>O\ (/:,_:;_ (>'?L^_
M]#__ .4;4/\ Y'H_X>'?L^_]#_\ ^4;4/_D>OQ9HH_L/#?S2^]?Y![1G[3?\
M/#OV??\ H?\ _P HVH?_ "/1_P /#OV??^A__P#*-J'_ ,CU^+-%']AX;^:7
MWK_(/:,_:;_AX=^S[_T/_P#Y1M0_^1Z/^'AW[/O_ $/_ /Y1M0_^1Z_%FBC^
MP\-_-+[U_D'M&?M-_P /#OV??^A__P#*-J'_ ,CT?\/#OV??^A__ /*-J'_R
M/7XLT4?V'AOYI?>O\@]HS]IO^'AW[/O_ $/_ /Y1M0_^1Z/^'AW[/O\ T/\
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MH?\ R/7XLT4?V'AOYI?>O\@]HS]IO^'AW[/O_0__ /E&U#_Y'H_X>'?L^_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]]IB8#\>U<GX$^,5C^S#XA_;)-U";E]$\3VWB"RTY<EKR\U6V5H(5 ')DE1
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M3\*ZI^S-9?!'PEJ<GA/PP-2M[[4+B6W^V7&HB.42R"1M\?[R1E3Y^BA0 N
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M++#/"Y1XW4Y5E8<@@@$$=*_4[_@J;J=W%^SCX4C2YECCO-=MUN$1RHF MIG
M<#[PW!6P>X![5^5=>^?'[]M#QM^T;X+TOPSXETO0+&PTZ[2\BDTJWGCE9UC>
M,!C),X(PYZ <XYI8G#SJUZ-2.T6[_@"=DT9?[&?BFT\'?M0_#K4KZ3RK8ZD+
M1G(R%,\;P*3Z#,HR>W6OJK_@HI^S1\0?B;\>/#NM>$?#5YKMAJ6FPZ>\]HA9
M+>=))2?./2--K(=[8'4=>OYVU]8^!O\ @IG\8_!7ABUT:4Z%XC^S1B*._P!:
MM)9+K:.!N>.5 Y P-S DXY).2<\30K>VCB*%FTK68TU:S/HO_@J%XM@\%_#S
MX6^'X)%DU6WU5=2A5QN&RUAV9;&."TJ^F<'TK6_X*-_"K6_CS\+?A]XK\"Z3
M=^*392R2K%IB&:1K6ZCC82*BY+#,4?0'&[/3)'YN_%?XM>*/C7XSNO%'B[4F
MU+5)E$:G:$C@B!)6*-!PJ#)X[DDDDDD^N?!+]O7XI_ KPO%X<TN;3-=T6WXM
M;77;>2;[*N22L;1R(VW)^Z20.V*Y%@*U&G2E2:<X7OV=]RN9-NY]=_%+1;G]
MGS_@F-;^%=;06FN7-I%9FTN7!99[F\-Q+'\O!*(TIP,XV=\9KR7]AW]C#3_$
M'AS_ (6W\1M-N[W0+56NM)T&&U>=[\1Y/FM"@+R*2I"1 9D(Z%2 WS5\?/VG
MO'G[1^I6EQXMOH%L[/)M=+T^(PVL#$89@I+%F./O,S'L,#BO:?#/_!4#XG>$
M?#FE:%IGACP5!IVF6L5G;1?8;OY8HT"*.+KT H>%Q=.@XT[<TVV]=K]$%XMZ
MFQ^U]\1?CI^T-</I-C\*?&WAOX>Z?(9(-/.@W:M<!?NS7!$>. ,A!\J>K$;J
M^)J^R]1_X*J?%C4]/NK.7P]X,6*XB:)REE=A@&!!Q_I77FOC2O0P5.I2AR3@
MHI;6=_O(DT]3]/\ _@EM(+O]GGX@V-NX%]_:\K  _,-]I$$/'/56_*OS K[(
M_P""8/QAMO 'QKO_  IJ,J06/BZW2WBD<X_TR$LT*YZ?,KS*/5F0#K7@O[3/
MPYD^%'QY\;>&FA$%O;:E++:*JD+]FE/FPX_[9NH^H-8X=>RQE:+^U9K\G^(W
MK%'V7_P2!_YJU_W"?_;VOA?XR_\ )7_'/_8=OO\ TH>NX_9P_:Q\7?LO_P#"
M1?\ "*Z=HNH?VY]G^T_VQ!-)L\GS=FSRY8\9\YLYST&,<Y\H\3:_<>*O$FJZ
MW=I%'=:E=RWDR0@A%>1R[!022!ECC)/UK6E0G#%U:SVE:WR0F]$C]3/BGX8U
MGQC_ ,$RO#6DZ!I-]KFJ3:!H9BL=-MGN)Y KV[-M1 6. "3@< $U^<__  S;
M\7/^B6>-?_">N_\ XW7M_@'_ (*7_$_X=>"-!\+:;H7A*?3]&L8;"WDNK.Z:
M5HXT"*7*W*@M@#. !["M[_A[#\7/^A=\%?\ @#=__)5<-"GC,-S1A!--M[]R
MFXL^-=2TV\T;4;K3]0M9[&_M)7@N+6YC,<L,BDJR.K %6!!!!&017Z;_  =_
MY14ZY_V"-8_]*9Z_-GQOXLO/'OC37_$VH1P0W^M:A<:E<1VRE8DDFD:1@@8D
MA06. 23CN:]>\-?MD^-/"W[/]U\(+33-!D\-7-M<VKW4UO,;P+.[.Y#B8)D%
MSCY.F,YKNQE"IB(04=U)-BBTKFE^P-\)A\5_VD_#R7,/G:5H.=;O <X(A(\H
M<=<S-%P>H#=:^[_VE_B1^RGXP\:+H'Q<U3[=KWAPO;BV6/556V,@1G&;90C$
MX3)R<8QQC%?GC^SG^UAXH_9BCUS_ (1;1= OY]8,7VBYU>">60+'NVHGES(
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ KZ-_X)X_\GA^ /\ N(?^F^YKYRKZ-_X)X_\ )X?@#_N(?^F^YKDQ?^[5
M/\+_ "''='[34445^9'8%06=N;6%D)#$R2/D?[3EOZU/5;3TD2!Q+G=YLI&X
M_P )D8K^F* +-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !5+1?\ D#6'_7O'_P"@BKM4M%_Y UA_U[Q_^@B@
M"[1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MB?X4ZO\ \)#_ &'_ ,()XGMO$GD_8OM'V[RG1O)SYB>7G9C?AL9^Z: /&O\
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MVEC3?[3^S>=Y7"C?Y6]=WW>FX=>M 'B=GIEII_\ P2J:"VMXX86^#\EP41<
MR/HYD=_J79F)]3FOF;]H EO^"-OP\R<_N]+'/_75J^^/^%%_\8L?\*:_MO\
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M!W[-DFJZMX>\8>-==US5M1\4>)YO!^BM?P:099"!)>3EECC)BBCD*[BP5E)
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M5_X3UI_\;H_MVG_(P]FS\$Z*_>S_ (9M^$?_ $2SP5_X3UI_\;H_X9M^$?\
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M-OPC_P"B6>"O_">M/_C=']NT_P"1A[-GX)T5^]G_  S;\(_^B6>"O_">M/\
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M (W1_P ,V_"/_HEG@K_PGK3_ .-T?V[3_D8>S9^"=%?O9_PS;\(_^B6>"O\
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M_HEG@K_PGK3_ .-T?V[3_D8>S9^"=%?O9_PS;\(_^B6>"O\ PGK3_P"-T?\
M#-OPC_Z)9X*_\)ZT_P#C=']NT_Y&'LV?@G17[V?\,V_"/_HEG@K_ ,)ZT_\
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MT_Y&'LV?@G17[V?\,V_"/_HEG@K_ ,)ZT_\ C='_  S;\(_^B6>"O_">M/\
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MXU+LQ[ #)-?(WQ!^/WB'Q)JTZZ3?S:3I2,5A2V/ER.O]YF'.3C.!C&:^GOB
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M]G1?\+'\6?\ 0T:U_P"#";_XJC_A8_BS_H:-:_\ !A-_\57.T4<J[!]:K_\
M/Q_>SHO^%C^+/^AHUK_P83?_ !5'_"Q_%G_0T:U_X,)O_BJYVBCE78/K5?\
MY^/[V=%_PL?Q9_T-&M?^#";_ .*H_P"%C^+/^AHUK_P83?\ Q5<[11RKL'UJ
MO_S\?WLZ+_A8_BS_ *&C6O\ P83?_%4?\+'\6?\ 0T:U_P"#";_XJN=HHY5V
M#ZU7_P"?C^]G1?\ "Q_%G_0T:U_X,)O_ (JC_A8_BS_H:-:_\&$W_P 57.T4
M<J[!]:K_ //Q_>SHO^%C^+/^AHUK_P &$W_Q5'_"Q_%G_0T:U_X,)O\ XJN=
MHHY5V#ZU7_Y^/[V=%_PL?Q9_T-&M?^#";_XJC_A8_BS_ *&C6O\ P83?_%5S
MM%'*NP?6J_\ S\?WLZ+_ (6/XL_Z&C6O_!A-_P#%4?\ "Q_%G_0T:U_X,)O_
M (JN=HHY5V#ZU7_Y^/[V=%_PL?Q9_P!#1K7_ (,)O_BJ/^%C^+/^AHUK_P &
M$W_Q5<[11RKL'UJO_P _'][.B_X6/XL_Z&C6O_!A-_\ %4?\+'\6?]#1K7_@
MPF_^*KG:*.5=@^M5_P#GX_O9T7_"Q_%G_0T:U_X,)O\ XJC_ (6/XL_Z&C6O
M_!A-_P#%5SM%'*NP?6J__/Q_>SHO^%C^+/\ H:-:_P#!A-_\51_PL?Q9_P!#
M1K7_ (,)O_BJYVBCE78/K5?_ )^/[V=%_P +'\6?]#1K7_@PF_\ BJ/^%C^+
M/^AHUK_P83?_ !5<[11RKL'UJO\ \_'][.B_X6/XL_Z&C6O_  83?_%4?\+'
M\6?]#1K7_@PF_P#BJYVBCE78/K5?_GX_O9T7_"Q_%G_0T:U_X,)O_BJ/^%C^
M+/\ H:-:_P#!A-_\57.T4<J[!]:K_P#/Q_>SHO\ A8_BS_H:-:_\&$W_ ,51
M_P +'\6?]#1K7_@PF_\ BJYVBCE78/K5?_GX_O9T7_"Q_%G_ $-&M?\ @PF_
M^*H_X6/XL_Z&C6O_  83?_%5SM%'*NP?6J__ #\?WLZ6'XF>+H)%=?$^KEAT
M#WLC#\B2#7O_ ,!/C->^,KF70M;=9=0CC\R"Y5=IE48W!L<;AUSQGFOENO1?
MV>W9?B[H0!(#"X! [CR)#_05E5A%Q>A[N2YCB:..I1YVU*233=UJ['V71117
MEG[D%0VJQ+$PA.4\QR>?XMQW?KFIJ@L[;[+$R;MV9'?.,?><MC]: )Z*** ,
M_7M>L?#.DW&I:E<+;6<"[G=N?P [D^E>):G^UG8P73I8>'IKN $@2SW0A+#L
M=H1OYT?M9ZG-!I7AZP1F$-Q+-*X!P"4" 9'?[YKYLKMHTHRCS2/S3/\ /\7A
M,6\+A7R\MKNR;;:OUNNI]$?\-<_]2I_Y4?\ [51_PUS_ -2I_P"5'_[57SO1
M6_L:?8^8_P!9<U_Y_?\ DL?\CZ(_X:Y_ZE3_ ,J/_P!JH_X:Y_ZE3_RH_P#V
MJOG>BCV-/L'^LN:_\_O_ "6/^1]$?\-<_P#4J?\ E1_^U4?\-<_]2I_Y4?\
M[57SO11[&GV#_67-?^?W_DL?\CZ(_P"&N?\ J5/_ "H__:J/^&N?^I4_\J/_
M -JKYWHH]C3[!_K+FO\ S^_\EC_D?1'_  US_P!2I_Y4?_M5'_#7/_4J?^5'
M_P"U5\[T4>QI]@_UES7_ )_?^2Q_R/HC_AKG_J5/_*C_ /:J/^&N?^I4_P#*
MC_\ :J^=Z*/8T^P?ZRYK_P _O_)8_P"1]$?\-<_]2I_Y4?\ [51_PUS_ -2I
M_P"5'_[57SO11[&GV#_67-?^?W_DL?\ (^B/^&N?^I4_\J/_ -JH_P"&N?\
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M_P"I4_\ *C_]JH_X:Y_ZE3_RH_\ VJOG>BCV-/L'^LN:_P#/[_R6/^1]$?\
M#7/_ %*G_E1_^U4?\-<_]2I_Y4?_ +57SO11[&GV#_67-?\ G]_Y+'_(^B/^
M&N?^I4_\J/\ ]JH_X:Y_ZE3_ ,J/_P!JKYWHH]C3[!_K+FO_ #^_\EC_ )'T
M1_PUS_U*G_E1_P#M5'_#7/\ U*G_ )4?_M5?.]%'L:?8/]9<U_Y_?^2Q_P C
MZ(_X:Y_ZE3_RH_\ VJC_ (:Y_P"I4_\ *C_]JKYWHH]C3[!_K+FO_/[_ ,EC
M_D?1'_#7/_4J?^5'_P"U4?\ #7/_ %*G_E1_^U5\[T4>QI]@_P!9<U_Y_?\
MDL?\CZ(_X:Y_ZE3_ ,J/_P!JH_X:Y_ZE3_RH_P#VJOG>BCV-/L'^LN:_\_O_
M "6/^1]$?\-<_P#4J?\ E1_^U4?\-<_]2I_Y4?\ [57SO11[&GV#_67-?^?W
M_DL?\CZ(_P"&N?\ J5/_ "H__:J/^&N?^I4_\J/_ -JKYWHH]C3[!_K+FO\
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M/KTS7$_L\:2^@_&/6],D<2O96US;,X& Q29%)_2NW\9R_!Z#Q??R>(0IUQ9
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MHH *]$_9\_Y*]H'_ &\?^D\E>=UZ)^SY_P E>T#_ +>/_2>2LY_ _0]/*_\
M?Z'^./\ Z4C[,HHHKR#^A0JMI\4D,#+(,,996&3G@NQ'Z$59JMI\SW$#LYRP
MEE3IV$C ?H!0!9HHHH ^=_VN?^94_P"WO_VC7SO7T1^US_S*G_;W_P"T:^=Z
M]2C_  T?AO$O_(UK?]N_^DH****W/F0HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#_KWC_\ 015VJ6B_\@:P_P"O>/\ ]!% %VBBB@ HHHH **** "BBB@ HHHH
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MKBSEDGM()9H3;S.BL\);=L8CE<]\=* )J*** "BO%OVIOVCO^&:?#'@_5_\
MA'O^$C_X2#Q/9^&_)^V_9?L_GI,WG9\M]VWRL;,#.[[PQS[30 4444 %%%%
M!1110 4444 %%<A\7/&FJ?#KX:^(?$NB>&;SQEJVF6K7%MH-@7$]\X(Q&FQ'
M;)SV1NG2K_P]\27WC+P!X:U_4]%N/#>I:KIEM?76BW>[SK"66)7>W?<JG=&S
M%#E5.5.0.E '04444 %%>8?\+8\1?\-$_P#"N_\ A7^J?\(O_87]K?\ "<9D
M^Q?:/,V?8\>3LWX^;_6YQ_#WKT^@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBN8^)WQ T[X4?#OQ)XRU>*XFTS0;";4;F*T4-*\<:%BJ D
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MVT$]LXSP*^9Z*Y_8Q[NQ]2N(\6K2<(.=K<_+[WWW_0]3^#'Q!T_0_B3JFO\
MB*\%HM[!,SRK$[@RO(CD *"1T:N7^*FN67B3X@:SJ6G3_:+*XE5HI=C+N&Q1
MT8 CD'J*Y2BM%!*7,>//'U:F%6$E;E4N:_6[^?Z!1116AYI[O^T'\3?#7CCP
MYIEKHFI?;9X;OS73R)8\+L89RZ@=2*\9\.Z[<^&==L-5M"!<6DRRH#T;!Y!]
MB,@^QK.HK.,%&/*CT\;F%;'8GZU.REIMY;;MGU!)\6/A;XPDT[6==A\C5[,
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MB!^QW^TS\/? .N^/=:^)GPO^(KSV6G7?BJ87&J:5?1A2%:X !E5R\8P<#DD
M;3NZ7]DKQGXC\(_M"_''X*^+]?U7Q!<:9J"^)?#MWK-[)=S-I5R%'E+)(Q8I
M$3"N!QN9^E>?W/C%_P!NW]JSX2ZYX"TS4V^$WPVN)]8N_%=_926D&HW;A/*B
MMQ*H9]K1)G@8#.6 PFZ?_@HMJ>K_ +.?CSP+^T7X8MC-?6-E?>$]414R)4N(
M)7LF?GA(Y]S$]R4'H" =#\(/B_JOC7]H#]HKXLZCK^JCX5?#ZVD\/Z?I4=](
M+"6:TC\Z^N?)W",R#R_E<C[LPYXS7C7PL^(-I^T]X8E^(7Q1_:VD^$VI:G<3
M2:5X*\*^,;+2%TF!79(EN4<[YB=N[#@$J1D\X'U!^SI^S2OA7]B.V^&&K%X-
M4\2Z!=C7)Y"6E^UW\3F8N0<LR>:$SGD1CGO7R3\!?%_P$_9V\!1_#G]I?X2Z
M!X<\?^'YI[4:SJ?@E-0BUR+S"T4L5PENYD.U@NYN"%!W9)  /6_V?_VF/$GC
M'X7?M#^ ]7\;6?C;7_A[I=W+I7CO0IXP-3M)+:9H)@\+%1-&4&64\$@9+*S'
MFOV7_@W\7/VHOV8_#OC7Q-\>O'WAS4Y;6:'0;70-1-LF(9'B6:^D(:6Z:1T9
MCN<?*0!@<#T/X;ZYX7\;_ /XY>)/"/P'L?A%X=;0M0M-,U==-@T^ZUZW%K*?
M-:".%&1 <8W,P.[@Y# =_P#\$XO^3)_A9_UXS_\ I5-0!\__ +)^A?%G]N7X
M%V?B[QQ\:O%G@Z.RDDTO3(O UPFFRW3Q8W7=[(%+2LQ;;Y:[%Q&&ZL:[3]F+
M]J[Q%HG[&'Q,\:>/[YO%.L?#?5M3T7[?*1')JA@2)H/,/9F:=8\\G !.XYS=
M_P""17_)F>D_]AB__P#1@KS']D[X43?'']C3]IGP-:R)#?:SX\UR&T>4D(+A
M8;-X=Q'1?,1,GTSP>E %'X<ZG8_&7P%I_CKXB_MM2>"?'>L0"_@T'PYXPL-.
MT[2!(-T<$UF7S(R@J&5BK Y4DD$GHO#W[5?B[XG?L'?'.:^\21R^/O +76CO
MXK\-7(B2_",ODWL$D) &\!OFCPIQN& V!R'P>^,7[,GPS^&FB^$OCI\&M$\(
M_%/0[9--OK#4O ,=S-JLT0$8GBE2W99#* K%F(!9C@L,,?0_&=]I?B+_ ()]
M_&OQ%I'P1LO@C8ZC8SK:V$-I!:W&I6Z,!%<S1111[,AB K;B/FP2I#, 3_"[
M]GKXN?'SX ^%OB!K?Q^\>>'_ !CJ6BP7VC:=H%\+73((S$IMQ<QXWW3NH1WD
M=P27;J.3S-]XWUW]K7_@E5J?BWQ/XGUC3?$>BV.H7%]<:!<BS757M4GC6&Z4
M)AX9$=&DC7 9E!!7&T?87[)W_)K'P;_[$S1O_2&&OBK]CWP_J'BK_@DMX^TG
M2K62]U*[LM>CM[6%2TDS[&(15')8XP .I(% 'T9_P3O^&/\ P@G[-7@_5O\
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M ,:KZJHH]O,/]5<M[/[SY5_X94\6?]!'1?\ O_-_\:H_X94\6?\ 01T7_O\
MS?\ QJOJJBCV\P_U5RWL_O/E7_AE3Q9_T$=%_P"_\W_QJC_AE3Q9_P!!'1?^
M_P#-_P#&J^JJ*/;S#_57+>S^\^5?^&5/%G_01T7_ +_S?_&J/^&5/%G_ $$=
M%_[_ ,W_ ,:KZJHH]O,/]5<M[/[SY5_X94\6?]!'1?\ O_-_\:H_X94\6?\
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M?_&J/^&5/%G_ $$=%_[_ ,W_ ,:KZJHH]O,/]5<M[/[SY5_X94\6?]!'1?\
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M%.LX*UCY#-N':69U?;J?)+KI=/\ %?F?G?17Z(45K]9\CPO]2_\ J(_\E_\
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M1110 4444 %%%% !1110 52T7_D#6'_7O'_Z"*NU2T7_ ) UA_U[Q_\ H(H
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MH_\ 9'_"0>.]0UG3/])AF^T6DFW9)^[=MN<'Y6PP[@5]/444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 56T^626!FD)+
M"651D8X$C ?H!5FFH6*G> #D_=.>,\?IB@!U%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %5M/EDE@9I"2PEE49&.!(P'Z 59IJ%BIW@ Y/W3GC/'Z8H =1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 52T7_D#6'_7O'_Z"*NU2T7_D#6'_ %[Q_P#H(H NT444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 4K_ /X^M-_Z^#_Z*DJ[5*__ ./K3?\ KX/_ **DJ[0 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2>/_  9I7@SQ%X6L/#$DJ^(3*OF[)69B<C:[#)VY.>!QCM0!]&4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 4;'7--U.XGM[/4+6[G@.)8H)E=HSG'S '(Y!'-,B\1:5/J3:=
M'J=G)J"DAK1+A#*".3E,YX^E>2:+/'X-^/>OPRMMM;^VDN-V/]D2L?PVR"O/
M?#U]>6'B?2?&]RY6"]UB6.4CJ =I<^F")&&/]DT ?4,^MZ=:ZA#837]K#?3
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MQHHHJ1!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MOAYJ-EXCN_%WA]K.*/3-+TT7<^KRW-N+A([*.-R[E4/SEU15..3D9\[^._\
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M@* .@  &*FH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *Y;XH?$32_A-X UOQ;K+$6&EVYF9%(#2
MMP$C7/\ $S%5'NPKJ:^4/^"E_P!J_P"&;5^S[O)_MJU^T[<X\O;+C/MOV=>^
M*Z<-35:M"G+9LN$>:23/B#X@_&CXR_M6:_J3:;:^(-3TN%MXT+PY;SS06L;$
MA/,6('<>,;GZD'&.E<CIVH?%W]G34++4U@\5>!9)V(A^W6T]I%<E<%EV2*%D
M R,C!ZBN^_9HTZWU;X)_'NTNM4M-%MY=+TT/?WRS-#%_I><L(8Y'.<8^5#R1
MVR:QI?%WAKX??L\^*_ EMXIM?&VJ^)-4M;N%=+MKJ.STI;?!:4M<PQ,99=VS
M"*1MCR6' /WB:BW1A!<J:5K=&EK?;2YZVWNI:'Z._L?_ +2L?[1OP^EN;V.*
MT\4:2Z6^IV\7".6&4G0=E?#<=BK#IBO>J_,K_@E?]K_X6YXNV;OL/]A_O<9V
M^9]HCV9]\>9^M?IK7QF8T(X?$RA#8\VM%0FT@HHHKS3 **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *I:+_P @:P_Z]X__ $$5=JEHO_(&L/\ KWC_ /01
M0!=HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[3GQ-^+W_"0_;?\ A-+.QM/[&^Q>7]C^S011;O.\P^9N\K.-BXSCG&:]IHH
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M^/V\%:7I]ZU]=P?V3]O6^D"@1!E,T8 3,AP=P)8<#;7$6W[)?[1MG;Q6]O\
MM<WD$$2"..*/P)9JJ*!@* )\  <8K[#HH P? >B:MX;\&:+I6O:ZWBC6K.TC
MAO-:>V6W:]E50&E,2DA-QYV@D#-;U%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M ,]O_'6_PH_MJS_Y[?\ CK?X5R]%'L8A<ZC^VK/_ )[?^.M_A1_;5G_SV_\
M'6_PKEZ*/8Q"YU']M6?_ #V_\=;_  H_MJS_ .>W_CK?X5R]%'L8A<ZC^VK/
M_GM_XZW^%']M6?\ SV_\=;_"N7HH]C$+G4?VU9_\]O\ QUO\*/[:L_\ GM_X
MZW^%<O11[&(7.H_MJS_Y[?\ CK?X4?VU9_\ /;_QUO\ "N7HH]C$+G4?VU9_
M\]O_ !UO\*/[:L_^>W_CK?X5R]%'L8A<ZC^VK/\ Y[?^.M_A1_;5G_SV_P#'
M6_PKEZ*/8Q"YU']M6?\ SV_\=;_"C^VK/_GM_P".M_A7+T4>QB%SJ/[:L_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5]0U"U
MTFPN;Z^N8;*RMHFFGN;B01QQ1J"6=F/"J "23P *L5P/[0'_ "0?XD?]BUJ7
M_I+)0!D?\-8_!#_HLGP__P#"HL?_ ([70>$/C=\.OB%??8O"WC[POXEO.?\
M1]'UFVNY..3\L;D\9%?C!_P3>_8I\#_M@_\ "Q/^$RU7Q!IG_"._V=]D_L*X
M@BW_ &C[5O\ ,\V&3./(3&,=6SGC&M^WS^PCI_[%5MX0\;^ /%FL3V-SJ/V5
M?[1E07MG=(IEBECEA1 1A&_A!4J,$YX /V^HKYY_9K_:5L?%/[&GA'XM^/\
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M* ^3,+6*9XK@H"0D@>%$SGCS&7)S0!^S=%>:_$/]HWX=_"GQ[X3\%^*?$/\
M9?B;Q7/';:-8_8KB;[5(\JQ(N^.-D3+NHR[*.<].:]*H S/$GB;1_!VB76LZ
M_JUCH>CVBAKC4-2N4M[>$$@ O(Y"J,D#D]2*\]_X:Q^"'_19/A__ .%18_\
MQVN!_P""CO\ R9/\4_\ KQ@_]*H:\>_8]_86^!/Q%_9C^'/B7Q'\.['5-<U/
M2H[B[O)+FX5I9"3EB%D '3L* /LGP7\6O _Q(:5?"7C/P_XI:(;I!HNJ07A0
M=,GRW;%6/&WQ(\)?#33X+_Q?XHT7PI8SR^1#<ZWJ$-G%))@ML5I64%L G YP
M#7YP?\%!/V1/ _[+GP]T7XR_!N&Z^'OBK0-7MT/]GW<TD4ZR$J#B1VVLI Z?
M*REPRG((=_P57\92_$7]BGX)>*YX#:SZ[>6&J20$8,;3Z;)(5Q[%\4 ?=?\
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MN<!0.I)["OG/5_\ @HM^SEHGB(Z)<_%/2WO0_EF2UM[FXM@?^OB.)HL>^_%
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M2^"GQUUQ=%\%?$#3]5UA\^783PSV<\V 2?+2=$9\ $G:#@"OFS_@H[_R=/\
ML7_]CFW_ *7:50!]_P!%<#XO^/'@;P'\1O"W@/7=<^P^*_%&[^R-/^R3R?:=
MIP?WB(43I_&RUT?C7QEH_P ._".L>)_$-Y_9^AZ1:R7M[=>4\OE0H-S-L0,S
M8 Z*"?:@#;HKF?AW\2?#?Q7\#:9XQ\+:D-3\-ZE&TUK?&&2 2(K,K'9(JLN"
MK#Y@.E>,>+_^"B?[.G@;6Y=)U3XH:<][$Q1QIUK=7\:L#@@R6\3I_P"/4 ?1
MM%<'X3^.W@#QW\/=0\<>'?%5AK?A;3X);B[O[!C+]G6-/,<.BC>K!>=A7=[<
MU^?W[//[>?@>\_;6^*NK^)OB+?77A'6Q:Z9X/%Q:7LD.#(H\N*$1$P@L>2ZI
MD\DT ?H]_P +!\+?\)E_PB/_  DND?\ "5^1]J_L+[?%]N\G_GIY&[?M_P!K
M&*WZ\"_XL9_PV/\ ]5Z_L3_I^_Y!^W_P%Z?\"KT+XL_'3P#\"M&BU3Q[XKT[
MPS:3$K#]LD_>SD?>$<2@O(1D9VJ<9% '=T5XK\(OVS_@I\=M:&C^"?B!IVJZ
MNV?+T^>*:RN)L#)\N.X2-I,#)^4'@$]J[#XJ_&[P5\$K;0[CQIK7]BPZWJ,>
ME6#?99Y_.NG!*1XB1MN0#\S87WH [JBOGOQ?_P % ?V?/ OBV;PUK'Q-TV+5
MX)3!-';6]Q=112 X97FBC:-2#D$%A@@@XQ7NGA_Q!IGBO1++6-%U"UU;2;V)
M9[6^LIEEAGC(R&1U)# ^HH T*H:]K^E^%M'N]7UK4K32-*LXS+<WU_.L$$"#
MJSNQ"J!ZDU?KXH_:KUI_VB/VHOAY^S=:S,WA>!!XK\;+$V/.MH3N@M'_ -EW
M";A_TUC(^[0!]6>)?BSX'\&>'M.U[Q!XR\/Z%H>I;/L6IZEJD%O;76Y-Z>5*
M[A7RGS#:3D<]*Z:UNH;ZUAN;::.XMYD$D4T3!D=2,AE(X((.017YW?\ !:Z)
M(/V>_ <42+'&GB955$& H%I/@ =A71_\$Y?CAK_A76/$'[,WQ0D^S^.?!#-'
MI,DK$_;;!>0B,<;@BLKH>IB=< ",T ?:?C7XA>%?AKI46I^+_$VC^%=-EF%M
M'>:W?Q6<+RE681AY&4%BJ.=N<X4GL:Z"O@#_ (+5_P#)K'A;_L<[7_TAOJ^W
M/&WQ(\)?#33X+_Q?XHT7PI8SR^1#<ZWJ$-G%))@ML5I64%L G YP#0!T=%>5
M?\-8_!#_ *+)\/\ _P *BQ_^.UT?@CXT?#WXF7]Q8^#_ !WX9\5WMO%YTUMH
MFL6]Y)''D#>RQ.Q"Y(&3QDB@#LJ*** ,_7_$&E^%-&N]7UO4K/1])LT,MS?W
M\Z000(.K/(Y"J/<FO.O^&L?@A_T63X?_ /A46/\ \=KPS_@K-XQ?PQ^QQK6F
MQ%Q<^(]4L=(B$?WF/F?:"H]<K;,,>]9'AK]D7]CKP_%H7@_Q#:>")/',5I!;
MW5A<^)=M[-<! KDQ?: Q9F#'A?I0!]A>#?'GAGXBZ0=5\*>(M)\3Z6)6A-]H
MU]%=P"0 %DWQLR[@",C.>17*:W^TK\(O#.KWFE:Q\5/!.E:I9RM#<V-]XBLX
M9X) <,CHT@96!Z@C-:7PQ^$W@KX"^#YM#\&:+!X;\/I-)>R6T,DCJ'*C>^79
MCT0=^U?FK^QG\+?@1\7_  7\0_B]\=X?#UM+XG\97TNFW/B;6?L(,1VROM)E
M0',DS@GKE?I0!^DW@_X\_#/XA:RND>%OB)X3\2ZLR-*+#1];MKN<HOWF\N-R
MV!W..*ZS6]>TSPSI=QJ6L:C::5IUNNZ:\OIUAAC'JSL0 /J:\8^!O[+_ ,!O
M .JVOCGX7>&M&AN9()(8-9TC4)+J-XVX<*WFNA!QV]*^8?BQI"?ML_\ !0JX
M^$7B.>Z?X7?#?2AJ=_I4$SQ1ZC>,D7WRI!X-RBYZA8I I&\F@#[I\$_%?P1\
M2Q/_ ,(AXQT#Q5Y',O\ 8FJ07GE_[WELV.HZUI^)/&&@^#8+.?7];T[0X;VZ
MCL;:34KN.W6>X?.R%"Y&Z1L'"C).#@5^>_[<W[+?AC]EGP;I7Q\^"EC_ ,('
MXG\':A:F[@T^1_LM[;2RK%MDC+$??=%.,!E=PP/RD?7GC[P9H/[87[,!L+F,
M1:;XRT&WU&QFD7+6DLL2S6\P[Y1BA]\$=Z /8ZR_$7_'DG_70?R-?/7_  3^
M^.^J_&GX'FP\5N3X]\&WLGAS7A(V9))H>$F;OEEP&/=TD/M7T+XB_P"/)/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M ()->#_!NE/#'K_V)K_2FN" AN8;V9@A)^[O7?'N[;\G@&K'PL_X*:Z'\)O
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M&. _X*+_ +.>N_M%_ #[)X27S?%_AW4(];TRWWA#<LBNCP@G@,5<E<]611D
MDUYIH?\ P5>\*:5X6M]+\8^!/&6F?%B&W$4_A*/2F#W-V!C$18@A&(S\R[E&
M>&QR <Q\=_A?K7_!/[]@7XAZ!X6\<:CK4&KZLD.GSW$7DR:5;W,BK-'$0[<E
M%;YAM^9V8 $U]"?LI_LB?#/X8? 7PQIK>#]#UC4M2TJWN-8U'4+".YDOII(@
MTFXR*3Y>6(5.@';.2?!= _9A^,G[1G[&?Q*M_B=K.I1>-_&6H_V]X?T'6+MW
M32$CD,T-N5<_N?,+R)L_Y9H8\@%=H7X0_P#!2;3/@A\/-(\!_'7P=XM\+?$#
MP]:)IIC33?-751$HC22(EAEV"KD_<).5;!P "A\(/#UG^RI_P5!U#X9>#GDL
M/ GCW0CJG]A(6:"UN$CEE!7KC:8)]O0!9MO9:P/V5O@EX5^*G_!0_P#:/UKQ
M5I5MKL7AO6))+*POHQ+;BXEGE F:,@JS(L;A=V<%R0,@$=]^RCX-\>?M$?M<
MZ]^TMXS\+WO@CPU!IG]D^%=(U-"EU+$04\TJ<$+M,K$D8+3C:2%S1^PI_P G
MP_M=?]AF'_THNJ /.OV_O@)X0N?VS?V>]/TW3(?#UOXSN&TK7!HZ"T^UVPGB
M1U;R]OS/%-)$6ZE2 <@ 5[3_ ,%%_P!GGX=:;^Q7XNFTCP9H6B77AR*VN=+N
M-/TZ*&2U/VF)7560 X=&92,X.03D@5S?[=?_ "?#^R+_ -AF;_THM:]I_P""
MCO\ R9/\4_\ KQ@_]*H: /GW]J[7[GQ1_P $AO#.J7LCS7EQH?ATSRR-N:20
M/;AG)]6()_&OH#]E[]D#X8_#_P#9Z\.:'=>#]$UV[U;2H+G6K[4;&.XDOYY8
ME:0LTBD[ 6(5>BCWR3\V_M%?\H;?"/\ V!/#_P#Z.@KI?AM_P4@TGX*?"SP]
MX0^+_@[Q5I/Q!TO3(+6WM[/3_/AUU$C589[:7< WF+L+9P S'&>@ *W[#EE_
MPH7]N7X^_ ?2'F'@^&VC\1Z=9NY=+/=]F.U<G/,=[&I/)(A7)R*TO^"4?_-?
MO^QWF_\ 9ZW/V"?A/XWUWXI_$[]HCXD:#+X5UWQRRVVE:'<J5GM;!2I'F!L,
M,B*!1N"D^46P PK#_P""4?\ S7[_ +'>;_V>@#S/_@CC\ _!?BWX9>*?B#XA
MT&PU_6X-<?1[%]3@6X6SBCMX96,2N"%9S<<L.<*!QSGK/B9X'T/X1_\ !6#X
M+S^#=-M_#<?B31K@ZI:Z;$L$%RWEW:LQC4 98)&3ZE%;KDG:_P""*G_)K'BG
M_L<[K_TAL:?^TC_RE4_9Q_[ US_Z#>T =G^TY\*?A'IW[1?AKXO?&_XD:3'H
M.E:>UKI7@C6[='@>3!S,$WLTN&8L0(B,B/)^49^6?V_OVD?V7?C'\$M6TCX?
MZ9!J_C>SDMY--UC2O#SV:6:B>,2B29XXV\MHRZ@8(+E/8UO_ +0\NF_ S_@H
MAK?Q+^._@>^\9_"S4M+BMM!U Z>M]9V$H2 +E'^3<CI<#8?FS,) "3R?M@?M
M-VG[0?[,'BOPQ\#_ (7:TO@6)(+_ %_Q3/I4>G:?#;02I,$A'!D?S$3.,$!6
MX()( /3_ -K*./Q+_P $D=*\0:K#%J&N-X1\,3_VC<1JTX>2;3S(P<C(+9.<
M=<UZ1IV@:9I'_!+N\N;'3K2RN+WX.>9<S6\"QO.W]B$[G( +'+,<G/4^M<3\
M2-!OOC#_ ,$@](TSPE;2ZS?_ /"%Z&$MK5?,DD:RDM6N$55R68?9Y1@<Y7&,
M\5F?"3]IGP;\9?\ @GCX_P#!6B-?0>)/ _PJFTW5[.]MC'MDCTN: LC9(8%H
M6/J RY .0 #S+1_B;K7PL_X(JZ#?^'[J2PU+4'N]*%W$Q62&.;6+I92I'0E
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M!IG]D^%=(U-"EU+$04\TJ<$+M,K$D8+3C:2%S1^PI_R?#^UU_P!AF'_THNJ
M.>_X*4_#GPU\.?B-^S_XZ\*Z+9>&_$W_  ET%I)>Z5;I;F>,/$Z^9L WE2N
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M (U?LZ:M.[2^$-9;5-'\YLO+838&X>@V_9Y,>MP:]4_8F\:?'+XJVWBSQO\
M%BT;PUX=U2[SX7\+3V4<-Q:VQ);?(VQ9&&"BJ7P6P[8 *U\Y?\%.'U_]FWXO
M>%_CQX/0QS:YH>H>#M497V 326\GV:4GG++N,@'K:(#US0!V7['$?_#1O[:7
MQK^/$Y6ZT+1)?^$2\-2 AHRB "25"/6-%;K_ ,O;?A:UGPE^SY^S=^T5\0/B
M1\:?B;H7BKQAXAD6XL]*U?3A<S:)#EB$C@0S/]P1(C%%.V/ SO->]_L/_!3_
M (4%^S%X)\+SP>1J[V@U'5 ?O?:Y_P!Y(K>I3<L>1VC%?GM\&?'7@?\ 9%^.
MOQ5C_:;^'][J/BS5M9>^TSQ9?:.FH0SQEW8O"7' <L&#Q@_W6VE,4 9O[6/Q
MY^!OQ4^,_P &_$'P5TV2Q\2:9XGM1>Z]8:.=.@G3S8C&K$JK/(I7(W+D*2,X
MXKZ2_P""CO\ R=/^Q?\ ]CFW_I=I5> ?MP_'_4?B]%\*/%6C?#C7/!GP6\,^
M)H"FMZS9)9M?W+D.## #D1+'!+AAP2V#M( KWS_@HQ*D_P"U%^Q9+$ZR1OXR
M+*Z'(8&]TK!![B@"S^U[_P I&?V6O^WC_P!"-?2'[:G_ ":1\7O^Q8O_ /T2
MU?.7_!1'0/%?@/XV_!'XZZ-X9OO%?A[P9<R1ZU:Z;$9)H(6=6W[1T!4R@,?E
M5E7<1N%<K^TE^WEIO[2_[._CCPQ\&O"?B76Y;G1+FYUO6+ZQ^S66D6,49EN?
M,DW$-(8U9%4'!+<$\ @'HW[-WP]D^*W_  2\\+^$U\6'P1;ZIHUQ#=:XL:O]
MGM_MDK3 [G0 ,@9&)/"LU<KX,^.'[$_[-/PQTWP*^N^%_%T]G:BWO[RT\/MJ
M#ZK,%'FRR2+$Z'>22 9" #M!(6N(U3P!XV^)/_!'/P;I'@6VN]1OUC6ZO=-L
M06GO+2.]G:2-%'+D-L?:.3Y9 !/!TO@!^VY^SUX"\ Z#X>\*_!W6Q\1;*RBM
MIO#VC>&(Y=0GNT0*S&8?,^7))=CNP<[<\4 9_P#P3 U?PSK7[3/[0MKX+TZZ
MTKX?:E'!=V>B7\ C\N,RR!5:(DA0!(X"Y^ZP%=3^R1X0T&X_X*&_M,6DNB:=
M+:V1MFM8'M(RD!WKRBXPI^F*P?\ @G]XB\2R?MX_'B/XA:,?"GC37]/BU<Z)
M)(CFWA:2.1(]RG#%8IX0>_#9 ((JOH_QGT7]CK_@H?\ &B_^)=EJNE:-XU6V
M;1]4ALVE@F!\LYR.H&Y@2,X*,#B@#O?^<QO_ ')'_LE<I^S_ . =(_:X_;Z^
M/OBWXD6,'B2S^'6HKH&BZ-J"B:TB59[F%'\HC:P M9'VMD;YBV"0".K_ .<Q
MO_<D?^R5S'B";Q7_ ,$]OVN?B)\0YO"&L>*_@O\ $>7^T-1O]$A\^;3;O>\I
M,BY &V26?&XJ&64;6W(5H [?_@IE^S9X+_X9^U;XF>'M&LO"WCKP=):W]CK&
MCPK:3,HN(T*.T8&<;]Z$\JRC! )SXS_P4'\;:C\9?V&?V=?$MW-Y6LZ]J>GS
M7$ZJ4 N7LI1(X  P-^XC';I6_P#M(?M8:A^WCX,/P;_9_P#".O:U!KUQ NM>
M)M0LS;65C;I*LFTOSM^95+%L<#:H<O@6?^"E/@"V^%/[+W[/W@RTF-Q;Z!XA
MTW35G88,OE6DB%R.Q8J3CWH ^PM*_8^^#^D?"O\ X5_%X"T1M!:T^RRM)8Q-
M<RG;M,S3%2YE_B\S.X$ @C KYQ_X(QZQ>:G^R=K%M=7#S0:=XLO+6U1CD11&
MVM92H]!OED;ZL:^\Z^ /^"*G_)K'BG_L<[K_ -(;&@#[_K\_?V*-23QS_P %
M _VK?$MUNDO]/NX]$BD8<B&*=X"OTQ9Q?]\BOT"KX$_9KM!\)/\ @IK\?O!]
MX@@3Q?8Q>)-/E8!1<9=9'"^IW7$X/_7%J ,?_@MG_P D \#?]C.O_I)/77?\
M%(O@!K;VNB?M!_#4/:?$?X?LMU<&V7YKRP1BS;@/O>4"Y(_BC:53G"BN1_X+
M9_\ ) / W_8SK_Z23U^B,D:31M'(H=&!5E89!!Z@B@#\KO\ @HE^T#H7[3/_
M  3X^'?CC1&2)KGQA:Q7]@'W/8W:V%[YL+=^"<@D#<K*W>OM/]LO4?@+IO@3
M1)/V@4@?PRVI!; 7%O>3#[7Y3]!:J6!V;^6X_'%?E5_P48_9YUS]EWQ?J.A:
M 98O@_XQU2/7].LT7,%G?11RQM /[I1;A]O3<C(.3&<?MYXG\%^'O&]I%:^(
MM"TS7[6)_-C@U2SCN41\$;@K@@'!(R/6@#\V_P#A*O\ @FE_SPTW_P %>O?_
M !NOH+]C36?V3=2\<:XG[/T=JGB1=.W:@;>SU*$_9?-3J;I0I^?9PO/X9KWW
M_AG_ .%__1-_"/\ X(K7_P"-UL^&/AIX0\$7<MUX=\*:)H%S,GE23:7IT-L[
MID':6102,@'!]* /ARY_9D_:]^)MB/B1<_'F;P)XSN@;NT\!VJRKI=DC<I;R
MLKE"R@@-NAEY'+-UJE;_ +6O[8_AW39O >I_L[7.M^/R#!;^+;5'&E$G(663
M8I@)[_Z^-?51TK]%:* /E#X[_L9:U^U7\#?A1X5\=^-Y]&UWP[#9W.N75E;+
M<F_O5MTCN&5BR!23YVU]IY<';@;2OB;_ ()A?L^Z[\/IO#5IX,71[OR"D&O6
MUS*U_%+@XE9V<B0Y.2K J>F!QBE_P4)\'?%UM'\#?$/X1:AK5U?^"]2^WZEX
M6TR[E2/5K<-&X+P(P$Y0Q%2F"2LSX!Q@\-J7_!6?PGK/A=]/\&_#_P 8:Q\4
MYHC%!X2?326@N<8_>,A)9 Q'W5W$8X7/ !7_ ."<?C3Q7\7_ -GCXI_"3Q+K
MTTNK>%KBY\.6NNMF:2*":*2.,_,P+^4Z2%<D?+L7C%=?\"_^"5?P:^%OAN:T
M\6:<OQ+UN9W#:GJT;PI%$6RL<4"R%4P.K9+$ECD A15_9(_9 \9?#S]E/QWI
M>M:U<>%_BK\0OM&HW.IV%PT4VESNA^SCS(B"&1B7;8>#(R@G&3YE\ ?V]KS]
ME?P2OPQ_:1\/>+M,\6Z')+%:ZW);M>KJD)<NG[TM\[#=M# LI51E@<B@"MX/
M\*C]A7_@HKX6^'O@B]NU^&/Q(L3-+H%Q</*EG/B559"Q))5X5PYRVR1E). :
M[+]D<K#_ ,%(?VH8I,).R6[JC<,4W)D@=<?,O/N/451^!7ASQC^V3^V+I_[0
M?B7PCJ'@OX=>$K!K'PO8ZQ&8KJ_D(D"S%,<@&:1RP.T,L:J7VL:E_:,TKQ3^
MR#^V4/VC-%\,:AXK^'_B?3%TKQ9;:1&9+BR95C43;,X Q!"P8X4E74E2X) /
M:O\ @I5+;P_L0_%%KG;Y9M;11O7(WF]MPGX[BN/0UVG[&$,D'[)?P@61"C'P
MMI[ ,,<&!"#^((/XU\8_M$?M'7'_  46TK1_@Q\$/#VMW6B:IJ%O<>(_%>I6
M306=C;QN'V]>2&VN<D$E%50Q;(_1_P *>&[+P;X7T?0--0QZ=I5G#8VR'^&*
M) B#\E% 'PS^R(S>$_\ @H[^U%X8M $T[4!!K,J)P/.+I(3CU)O)<GW]Z^Y_
M$7_'DG_70?R-?#7[!]N_Q*_; _:<^+$0+:0^JCP[87(/RSB)R&(QQPD-NWTD
M'O7W+XB_X\D_ZZ#^1JX?$A,YVBBBO0)"BBB@ HHHH **** "BBB@ HHHH X/
MX\?\D=\7?]@^2O"_V1?#=CXP^'OCK1=1C\VRO9(HI%[C*-AA[@X(/J!7TEX\
M\+?\)MX.U?0?M7V+^T+=H/M'E^9Y>>^W(S],BN0^!OP5_P"%,:?JMK_;/]L?
M;I4DW_9?(V;01C&]L]?:NN%2,:,HWUN?583'T:&45L/SVJ.46EKT:UOMT[GQ
M/XRTS6_ACJ'B'P3>N3;-/&[J<[)=A)BE7ZJQ_/!Y%?1>@:=<:I^Q \%K&991
M;7$NU1D[4OG=C^"J3^%>@_&_]GRQ^,DVG78U'^Q=2M 8VN1;>=YL1Y"%=Z]#
MD@Y[G\.M^&'@%?ASX T[PP]X-42T$H:X:'RQ('E=\%-S8^_CJ<XKHJ8F,Z<7
M]I--GN8_B##XK!8><?XT9QE)6>O*FKWM;73K<\0_8H\5Z7'X:UGP])/%#JQO
MC=I&[ -+&T:+\OKM*'/^\*XC]L+Q#8>*OB%HNEZ1+'J%Y:6Y@F-N0_[UW^6+
M(ZL,=/\ :]<UZ3XT_8P\/Z]J<EWH>KS^'TE)9K8P"XB4Y_@&Y2![$FN@^$_[
M+GA_X::O'J]S>2:]JL/,$LT0CBA;^\J9/S>A)..W/-/VM&,W63U[%K,LJHXV
M>;4ZDG-IVARM:M6UEM;^M3D_VK_ LS?"'PWJ+J9+S0?*MYW S\CHJ,2?]]8_
MSKRGX=N_QW^-/AN+549[2RTV*&8=25@@P3[;I3G_ (%7V=XZ\)P>.O"&K:!<
MR&&*_MVA\T+N\MNJOCC.& .,CI7G'P0_9TB^#>MZAJ9US^V9[JW%LH^Q^1Y:
M[@S?QMG)5?3I44Z\8TFG\6MOF<F SNC0RNI3J2M67,H:/:=KV>RL[O4^/+[7
MK[PIX9\2>!IE96;5HWE)XP8?-1U(]V,9_P" 5]Z?!OPG_P (3\,?#NDLNR>.
MU66<%<$2O\[@_1F(_"O-O%/[)MEXF^)L_BIM>,%G<7D=W-IGV+=NQM+KYGF#
M[Q#'.WC=WQ7OE3B:T:D4H^K]3+B#-\/CZ%*GAGJ_>GHU[UDNOSVT.4^+.GW&
MJ_##Q7:6K,MQ+IEP$"#)8^6?E_X%]W\:^-OV=O!U]XWNM5L-,^(5[X+OAY;B
MUM-X-XOS<_+*F2OIS][ZU]Z5\]>//V-M!\3ZU/J.C:M+X>\]B\EJ+83PACUV
M#<I4>V2!VP.*6'JQA&4).U^MKF.1YI1PV'K82M/V?-9J7*I6:[JSO_6Q@6/[
M-T%]XZM+^[^+<>MZY8W,4CQS1B6Y)1@RH2;@L#QQZ5RG[8XS\9-!!Z?V5;_^
ME$]>O?"W]E'0?AYKD&LWNHS:]J-LP>V+PB&*)Q_'LRQ)';)X],X(M?&/]G/_
M (6UXRL->_X2'^ROLMK';?9_L7G;MLCONW>8N,[\8QVK6->*JIRE=)=K'J4,
MXP]/,H5*V(<Z<8M)\G+J^B45>WJC9_:7&?@=XI_ZY0_^CXZ\R_9>_P"3=O&G
M_7U>_P#I)%7NOQ+\%?\ "Q/ ^J^'?MG]G_;D1?M/E>;LVNK?=W+G[N.HZUS'
MPO\ @K_PK;X=ZUX6_MG^T?[2EGD^U_9?*\OS(4CQLWMG&S/49SBN>%2*HN+>
MMSPL+CL/3RF6&E+WW44K6>VFM[6Z>IX9^P]"C>*/$\I'[Q;.)0?0%R3_ .@B
MMW]N;3YY=/\ !]ZL9-M#+=0N^.%9Q$5'XB-ORKT7X'?L_P#_  IC4=5NO[>_
MMC[=$D6S['Y&S:2<Y\QL]?:O1O%WA#2O'6@7.C:S:K=V-P/F4G#*1T93U##L
M:TG7BL1[1:K_ (!WXK.,/#/5F%)\T%;NM.6SWMM=G+?![QQH>L?"C0[V#4+:
M*WL-/@M[OS953[,Z($8/D_+RIQGJ,&OF;X83#QW^UA+J^C[OL'V^ZO3,HQ^Y
M"N-Q] Q*C_@==UJ'[#5A+?.]EXMN+:S+96&>Q660+Z;PZ@GWVU[+\*?@WH/P
MCTR6#2T>XO+C'VB_N,&67'0<?=4>@_'-/GI4U)P=V_P-'C,LR^GB:F$JNI.L
MFDG%KE3WNWO\CYCU'_D\M/\ L-1?^@+6C^V__P CIX=_[![?^C&KUNY_9L^T
M?&4>/?\ A(MN+U+S^S_L.?N@#;YGF>W7;^%6/C?^SQ_PN76M.U#_ (2#^Q_L
MEN8/+^Q>?ORQ;.?,7'7I6D:]-5(2OHD=U'.,#''82LZGNPI\LG9Z.VVVORT.
M0_:U_P"2$^%O^PA:_P#I+-26/_)DK?\ 7A)_Z5-7I7Q:^#G_  M+P)I?AO\
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M*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZU_\B4?\+S\.?] WQC_X1.M?_(E'L:O\K^X/9S[,]"HKSW_A>?AS_H&^,?\
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MOC'_ ,(G6O\ Y$H]C5_E?W![.?9GH5%>>_\ "\_#G_0-\8_^$3K7_P B4?\
M"\_#G_0-\8_^$3K7_P B4>QJ_P K^X/9S[,]"HKSW_A>?AS_ *!OC'_PB=:_
M^1*/^%Y^'/\ H&^,?_")UK_Y$H]C5_E?W![.?9GH5%>>_P#"\_#G_0-\8_\
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MY7]P>SGV9Z%17GO_  O/PY_T#?&/_A$ZU_\ (E'_  O/PY_T#?&/_A$ZU_\
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M][_(P]E/LRY15/\ X7GX<_Z!OC'_ ,(G6O\ Y$H_X7GX<_Z!OC'_ ,(G6O\
MY$H_>_R,/93[,N453_X7GX<_Z!OC'_PB=:_^1*/^%Y^'/^@;XQ_\(G6O_D2C
M][_(P]E/LRY15/\ X7GX<_Z!OC'_ ,(G6O\ Y$H_X7GX<_Z!OC'_ ,(G6O\
MY$H_>_R,/93[,N453_X7GX<_Z!OC'_PB=:_^1*/^%Y^'/^@;XQ_\(G6O_D2C
M][_(P]E/LRY15/\ X7GX<_Z!OC'_ ,(G6O\ Y$H_X7GX<_Z!OC'_ ,(G6O\
MY$H_>_R,/93[,N453_X7GX<_Z!OC'_PB=:_^1*/^%Y^'/^@;XQ_\(G6O_D2C
M][_(P]E/LRY15/\ X7GX<_Z!OC'_ ,(G6O\ Y$H_X7GX<_Z!OC'_ ,(G6O\
MY$H_>_R,/93[,N453_X7GX<_Z!OC'_PB=:_^1*/^%Y^'/^@;XQ_\(G6O_D2C
M][_(P]E/LRY15/\ X7GX<_Z!OC'_ ,(G6O\ Y$H_X7GX<_Z!OC'_ ,(G6O\
MY$H_>_R,/93[,N453_X7GX<_Z!OC'_PB=:_^1*/^%Y^'/^@;XQ_\(G6O_D2C
M][_(P]E/LRY15/\ X7GX<_Z!OC'_ ,(G6O\ Y$H_X7GX<_Z!OC'_ ,(G6O\
MY$H_>_R,/93[,N453_X7GX<_Z!OC'_PB=:_^1*/^%Y^'/^@;XQ_\(G6O_D2C
M][_(P]E/LRY15/\ X7GX<_Z!OC'_ ,(G6O\ Y$H_X7GX<_Z!OC'_ ,(G6O\
MY$H_>_R,/93[,N453_X7GX<_Z!OC'_PB=:_^1*/^%Y^'/^@;XQ_\(G6O_D2C
M][_(P]E/LRY15/\ X7GX<_Z!OC'_ ,(G6O\ Y$H_X7GX<_Z!OC'_ ,(G6O\
MY$H_>_R,/93[,N453_X7GX<_Z!OC'_PB=:_^1*/^%Y^'/^@;XQ_\(G6O_D2C
M][_(P]E/LRY15/\ X7GX<_Z!OC'_ ,(G6O\ Y$H_X7GX<_Z!OC'_ ,(G6O\
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MC_X1.M?_ ")1_P +S\.?] WQC_X1.M?_ ")1^]_D8>RGV9<HJG_PO/PY_P!
MWQC_ .$3K7_R)1_PO/PY_P! WQC_ .$3K7_R)1^]_D8>RGV9<HJG_P +S\.?
M] WQC_X1.M?_ ")1_P +S\.?] WQC_X1.M?_ ")1^]_D8>RGV9<K6\.HWVJ1
M\':$QGWR*YW_ (7GX<_Z!OC'_P (G6O_ )$H_P"%Y^'/^@;XQ_\ ")UK_P"1
M*F2JR5N1C]E/LST*BO/?^%Y^'/\ H&^,?_")UK_Y$H_X7GX<_P"@;XQ_\(G6
MO_D2L/8U?Y7]P_9S[,]"HKSW_A>?AS_H&^,?_")UK_Y$H_X7GX<_Z!OC'_PB
M=:_^1*/8U?Y7]P>SGV9Z%17GO_"\_#G_ $#?&/\ X1.M?_(E'_"\_#G_ $#?
M&/\ X1.M?_(E'L:O\K^X/9S[,]"HKSW_ (7GX<_Z!OC'_P (G6O_ )$H_P"%
MY^'/^@;XQ_\ ")UK_P"1*/8U?Y7]P>SGV9Z%17GO_"\_#G_0-\8_^$3K7_R)
M1_PO/PY_T#?&/_A$ZU_\B4>QJ_RO[@]G/LST*BO/?^%Y^'/^@;XQ_P#")UK_
M .1*/^%Y^'/^@;XQ_P#")UK_ .1*/8U?Y7]P>SGV9Z%17GO_  O/PY_T#?&/
M_A$ZU_\ (E'_  O/PY_T#?&/_A$ZU_\ (E'L:O\ *_N#V<^S/0J*\]_X7GX<
M_P"@;XQ_\(G6O_D2C_A>?AS_ *!OC'_PB=:_^1*/8U?Y7]P>SGV9Z%17GO\
MPO/PY_T#?&/_ (1.M?\ R)1_PO/PY_T#?&/_ (1.M?\ R)1[&K_*_N#V<^S/
M0J*\]_X7GX<_Z!OC'_PB=:_^1*/^%Y^'/^@;XQ_\(G6O_D2CV-7^5_<'LY]F
M>A45Y[_PO/PY_P! WQC_ .$3K7_R)1_PO/PY_P! WQC_ .$3K7_R)1[&K_*_
MN#V<^S/0J*\]_P"%Y^'/^@;XQ_\ ")UK_P"1*/\ A>?AS_H&^,?_  B=:_\
MD2CV-7^5_<'LY]F>A45Y[_PO/PY_T#?&/_A$ZU_\B4?\+S\.?] WQC_X1.M?
M_(E'L:O\K^X/9S[,]"HKSW_A>?AS_H&^,?\ PB=:_P#D2C_A>?AS_H&^,?\
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M$H]C5_E?W![.?9GH5%>>_P#"\_#G_0-\8_\ A$ZU_P#(E'_"\_#G_0-\8_\
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MXQ_\(G6O_D2C_A>?AS_H&^,?_")UK_Y$H]C5_E?W![.?9GH5%>>_\+S\.?\
M0-\8_P#A$ZU_\B4?\+S\.?\ 0-\8_P#A$ZU_\B4>QJ_RO[@]G/LST*BO/?\
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M^%.S8%JBJO\ :,?]U_R%']HQ_P!U_P A3LQ7+5%5?[1C_NO^0H_M&/\ NO\
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M5_M&/^Z_Y"C^T8_[K_D*+,+EJBJO]HQ_W7_(4?VC'_=?\A19A<M455_M&/\
MNO\ D*DBNXY3@'!]#2LQDU%%%( HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>!=)^)?[=^J^&=;@\_3=1\-&*0#AD/D95U/9E8!@?4"NK_94\>ZI\+?&6I_
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MT/[4/[3'A3XD_#FZ^'WP\O)/%_B?Q')%:1P:=!(5C3S%=B6( )(7;@$XR2<
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MO]+\&>'M-OE8.MS9Z5!%*&!R"&5 <Y[UUE3S))J/4?*V[R/D3]A#_D<OC?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !4<_P#J)/\ =/\ *I*CG_U$G^Z?Y4UN!D4445N0%?GG^QU_RD'^-_\
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M?^ MQ_\ 'Z/[-Q'9?>'^J69]H_>??-%? W_#?7Q!_P"@/X:_\!;C_P"/T?\
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M+[P_U2S/M'[S[YHKX&_X;Z^(/_0'\-?^ MQ_\?H_X;Z^(/\ T!_#7_@+<?\
MQ^C^S<1V7WA_JEF?:/WGWS17P-_PWU\0?^@/X:_\!;C_ ./T?\-]?$'_ * _
MAK_P%N/_ (_1_9N([+[P_P!4LS[1^\^^:*^!O^&^OB#_ - ?PU_X"W'_ ,?H
M_P"&^OB#_P! ?PU_X"W'_P ?H_LW$=E]X?ZI9GVC]Y]\T5\#?\-]?$'_ * _
MAK_P%N/_ (_1_P -]?$'_H#^&O\ P%N/_C]']FXCLOO#_5+,^T?O/OFBO@;_
M (;Z^(/_ $!_#7_@+<?_ !^C_AOKX@_] ?PU_P" MQ_\?H_LW$=E]X?ZI9GV
MC]Y]\T5\#?\ #?7Q!_Z _AK_ ,!;C_X_1_PWU\0?^@/X:_\  6X_^/T?V;B.
MR^\/]4LS[1^\^^:*^!O^&^OB#_T!_#7_ ("W'_Q^C_AOKX@_] ?PU_X"W'_Q
M^C^S<1V7WA_JEF?:/WGWS17P-_PWU\0?^@/X:_\  6X_^/T?\-]?$'_H#^&O
M_ 6X_P#C]']FXCLOO#_5+,^T?O/OFBO@;_AOKX@_] ?PU_X"W'_Q^C_AOKX@
M_P#0'\-?^ MQ_P#'Z/[-Q'9?>'^J69]H_>??-%? W_#?7Q!_Z _AK_P%N/\
MX_1_PWU\0?\ H#^&O_ 6X_\ C]']FXCLOO#_ %2S/M'[S[YHKX&_X;Z^(/\
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M-]?$'_H#^&O_  %N/_C]']FXCLOO#_5+,^T?O/OFBO@;_AOKX@_] ?PU_P"
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M !^C_AOKX@_] ?PU_P" MQ_\?H_LW$=E]X?ZI9GVC]Y]\T5\#?\ #?7Q!_Z
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[Q^:[A#[K@UZY1153J3J.\VV_,-@HHHJ "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** +NF_P#+3\/ZU>JCIO\ RT_#
M^M7JQEN4@HHHJ1A7P?\ M^WTLGQ1T"R)_<0Z,LRCT9YY0WZ1K7WA7P-^WU_R
M6'1_^P##_P"E%Q7J9;_O"]&?9<))/,X^C/FJBBBOK#]Q"BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** *6B_P#(&L/^O>/_ -!%7:I:+_R!K#_KWC_]
M!%7: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "HY_P#42?[I_E4E1S_ZB3_=/\J:W R****W("BBB@ HHKA-0^/GPQTF_N;&
M^^(WA*SO;:5H9[:XURUCDBD4D,C*9,JP(((/((JHQE+X5<#NZ*S/#GBC1O&.
ME1ZIH&KV&N:;(S*EYIMREQ"Q4X8!T)!(/!YK*TCXI^"_$&N2:+I?B_0=2UB,
MD/IUGJ<,MPI'7,:L6&/I1RRUTV ZBBBL'Q9X_P##'@*"WF\3>(](\.0W#%(9
M-6OHK596 R0ID89('84DG)V0&]17'^'/C)X \8:M%I>@^.?#>MZG*&:.RT[5
M[>XF<*,L0B.2< $GC@"K_BOXB^%/ A@'B7Q/HWAXW'^I&JZA%:^9_N^8PS^%
M5R2ORVU Z&BH+&_MM3LX;NSN(KNUF4/%/ X=)%/0JPX(]Q4]0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !169<^*-&LM>L]#N-7L8-;O(VEMM
M-EN46YG1<[F2,G<P&#D@8&*TZ=FMP"BBBD 4444 %%%% !1169HOBC1O$DNH
M1:3J]AJDFG7#6=ZEE<I,;:=?O12!2=CCNK8(]*=GN!IT444@"BBB@ HHHH *
M*** "BBB@"[IO_+3\/ZU>JCIO_+3\/ZU>K&6Y2"BBBI&%? W[?7_ "6'1_\
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M#<YR0N=QP/E)KP/X:_'Z?]EJ7Q1X)N/"[ZU+#K$SFXDO?LQP L8^7RFR"$#
MYY#"B%W*JL/OI;TZVN+#<[J8R.5)MM14+NUHN_,X\UM+['TI\&/C,GQ8^)'C
MBWTQA_PC>BQ6MM8;  )26E\R48[-M4 ?W57H2:^7O@1_R>='_P!A75?_ $3<
MU]0_L\_M&?\ "^9]=C_X1[^P_P"RUA;/VW[1YOF%_P#IFF,;/?.:\BT7XN?\
M+4_;'\)1_P!D_P!E_P!AMJ6G9^T^=Y^V&X^?[B[<XZ<_6LJ:E!U8<EO=[[:?
MC<Y<+&MAYXZA[#D7LK-<R?+:#L]-^;?3:Y5^-EQ\.(?VF=1?XCKJDEFEG9&U
M6S :W'RL7\\#YROW<!/5LU9_;>TWQ%KOA30-?T^^LK_P#&4>)+)#E'D7]W*S
M9(9"IPI& -W3G-=%^T7\ [+XW?$(2:!XFT^P\565M%!>Z7J#%=\/WDE3:"W1
MR.A!P!E2#FE^TQKNB_##]G;3?AF=2CU+7'@M;4+&!N5(71VE9<G8"4P 3D[N
M^"1I2FG*BX.\MFNR[G1@Z\)5<!*@W*HK1<6M(QLDY+3336ZW/G;]FCX7)\5O
MBMIVGW48DTFR!O[Y2.'B0C"=/XF*J1Z%O2NO_;/^)S^+_B6WARTEQH_AX?9U
MC0_*]P0/,; _N\)[;6]37J'[ VCP:=X1\9>(WR9'N$M><858HS(<=^?-&?\
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MRA_A"BBBNP]\**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[)_PR!\7/^A2_P#*E:?_ !VC_AD#XN?]"E_Y4K3_ ..T?6*/\Z^]!_:N7_\
M01#_ ,"C_F>-T5[)_P ,@?%S_H4O_*E:?_':/^&0/BY_T*7_ )4K3_X[1]8H
M_P Z^]!_:N7_ /01#_P*/^9XW17LG_#('Q<_Z%+_ ,J5I_\ ':/^&0/BY_T*
M7_E2M/\ X[1]8H_SK[T']JY?_P!!$/\ P*/^9XW17LG_  R!\7/^A2_\J5I_
M\=H_X9 ^+G_0I?\ E2M/_CM'UBC_ #K[T']JY?\ ]!$/_ H_YGC=%>R?\,@?
M%S_H4O\ RI6G_P =H_X9 ^+G_0I?^5*T_P#CM'UBC_.OO0?VKE__ $$0_P#
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M\,@?%S_H4O\ RI6G_P =H_X9 ^+G_0I?^5*T_P#CM:?6*/\ .OO1T_VKE_\
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MI_\ ':/K%'^=?>@_M7+_ /H(A_X%'_,\;HKV3_AD#XN?]"E_Y4K3_P".T?\
M#('Q<_Z%+_RI6G_QVCZQ1_G7WH/[5R__ *"(?^!1_P SQNBO9/\ AD#XN?\
M0I?^5*T_^.T?\,@?%S_H4O\ RI6G_P =H^L4?YU]Z#^U<O\ ^@B'_@4?\SQN
MBO9/^&0/BY_T*7_E2M/_ ([1_P ,@?%S_H4O_*E:?_':/K%'^=?>@_M7+_\
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MI_\ ':/K%'^=?>@_M7+_ /H(A_X%'_,\;HKV3_AD#XN?]"E_Y4K3_P".T?\
M#('Q<_Z%+_RI6G_QVCZQ1_G7WH/[5R__ *"(?^!1_P SQNBO9/\ AD#XN?\
M0I?^5*T_^.T?\,@?%S_H4O\ RI6G_P =H^L4?YU]Z#^U<O\ ^@B'_@4?\SQN
MBO9/^&0/BY_T*7_E2M/_ ([1_P ,@?%S_H4O_*E:?_':/K%'^=?>@_M7+_\
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MI_\ ':/K%'^=?>@_M7+_ /H(A_X%'_,\;HKV3_AD#XN?]"E_Y4K3_P".T?\
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MCG R1VOQZ_:WC\-?L5:G\=OAF;#6X_L]E<:>NK0R-"?-O8;:5)41T8.F^12
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M%YXQ\03I9:7IVEMJE],H)$<:1>8^T=3P#@=3P*^4O!WQ]_:J^-?A!/B'\/\
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M=@8(V03RRDCM7+_%#]FCX9?&;4H]1\8>$K75M01!$+Q99;>8H.BL\3HS 9.
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MSF44?V#_ -/?P_X(>U\C^C.BOYS**/[!_P"GOX?\$/:^1_1G17\YE%']@_\
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MXU/0?!GQ".I:=J_AIM0FNK1WABC*2A978AMTT9W;B1L.."0?4?"W@GQ%;_\
M!4#QAXJET#5(O"\_PZCL8M;>SD%E)<?:[5O)6?;L,F%8[0<X4G'%'[6?@GQ%
MXD_:R_94UC2= U35-)T;5=7DU._LK.2:"Q5X[0(T\BJ5C#;6P6(SM..E '!Z
MEX5E_;C_ &P/BAX,\9:MJ<7PG^&4=G9?\(OI]Y):QZK>7".QEN&C(9E!BE
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M^(1^$_P>\:^,U@%U)H.CW6HQP-TD>.)F13[%@ ?K7QU^S=^Q/X:^//P;\/\
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M1]2CB41PRR78;$.45=Q(8]20I)4 ''>!?BA\:+_]E/\ :,^'.E:O?>)_B?\
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MAS]B+]H_X":[\)IM4\,Z1XQ\31^&]>T/^TI[JUO5G*(LC+,[$L-['))P0I4
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M/X#.K3W_ (7\0>!K%=2E,$N#Y-U%N4Q%=O+'N6P"-I-K4?A?^T-\:?@/\?\
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MI!!.:ROVN/&VK_$?_@DOX*\1Z_=-?:S?II+W=V_WIY Y4R-_M-MR?<FOIO\
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M\:]3_9]_X),:]XST, :Y;ZE=6MA(RAA%-/<QPK(0>#LWE@#D$J >M>V^$/\
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M^O@/=W$4$7CO?+*P1%_LB_&23@#_ %%:1P]::YHP;7HQ71]!4445SC"BBB@
MHHK"\<^.=$^&OA34/$OB.]_L[1-/57N;KRGE\L%@H.U%9C\S < ]::3D[+<#
M=HJMIFHV^L:;:7]G)YUI=1)/#)M*[D8!E.#@C((X-<YXB^*OA;PIXT\.^$M5
MU3[+X@\0>9_9EG]GE?[1L&7^=5*+@?WB/:FHRD[) =917*Z=\4?#&J_$35?
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M32;:>.4R+/!& 3),XVXE;C&<@<^OEU<5B:=%5U!6M=ZE**;L?G=_PS;\7/\
MHEGC7_PGKO\ ^-UA6'PI\;:IX5D\367@[7[SPW'')*^L0:7.]FJ(2)&,P78
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MH]@.*MT5$81C\*L<F'P.%PC<L/2C!O?EBE?[D%%%%6=H4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% 'SW\&?V>_$7P[_ &HOC;\2-2O=+GT/QO\
MV=_9UO:RR-<Q?9XBC^<K1JJY)XVLW'7%?0E%% 'ROX__ &</BG\</CGHUS\0
MO%'AQ_@SX9UM==TGP_I$$RWU]-&#Y"WC,-@$;,?NL0PSE02"OU1110 4444
M%%%% !1110 4444 %%%% !7SW\9OV>_$7Q$_:B^"7Q(TV]TN#0_!']H_VC;W
M4LBW,OVB((GDJL;*V".=S+QTS7T)10 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 4M%_Y UA_P!>\?\ Z"*NU2T7_D#6'_7O'_Z"
M*NT >?\ Q;^ _@CXX:9'9^+]$BU%H@1!=HQCN(,\_)(N"!['(]J\+TO_ ()E
M?"'3]26ZGNO$NI0ALFSNK^,1'V)CB5\?\"KZTHKKIXNO1CR4YM(WA7JTURQD
MTC%\'^"]"^'^@6^B>'-+MM'TJWSY=K:IM4$]2>Y)]3DUM445RMN3N]S%MMW8
M4444A!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4<_P#J)/\ =/\
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M7/FC3E[O70&SL?V3_".G?$>7]H*?14N]%^&7BK5!9Z2^GM]GW )*EU+;C;A
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M SE64LC?-C# Y4C) !/GW[$'[1?P_P#!OPFU7PYXF\1:?X8U+3-4O+G&IRB
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M?D__ ,%8?^3BO#O_ &*MM_Z5WE>YDW^]+T9G4^$^+****^\.8**** "BBB@
MHHHH ^SOA1XK_:._8P^&]MXIE\.PWWPOOFAN5@O;R"Z@43@,DD?DRF2'>".2
M-N6&1N(S]-_ K]NKP/\ M5ZY:?#KQ1X#EM=3U9)0+2Y6/4-/E"1LY#%E5E)5
M6(RA Q][I7SE^S'_ ,%%H_AA\/[;P+\0O#L_B;0;&'[/9W5EY;3)!V@DBD(6
M10. =P(  (/6O3;7_@HY\#/AY97MQ\/OA+>:;JLZG*Q:98Z9',W;S)(7=L?\
M!-?*XG#U*DI<U"\^DHNWHV;)I=3B;7X+Z-\"_P#@I?X-T'PZ#%HEU(-1M;5B
M6-LLEO,&BW$DD!D8@GL0.<9/T7^U7^T+\"?A7\2;71_B5\-/^$O\02:;%<QW
M_P#8-A?;8&DD58_,GD5AAE<[<8&[W-? 'A+]J6XOOVM-*^,7CF.YNHH+MI9;
M/3%#M#"(6CCBA5W484$=6&?F)Y)RW]M7X_>'OVC_ (MV?BGPU9ZG8Z?#I$-@
MT>JQ1QRF1)97) CD<;<2+WSP>*Z)8.I5KT_;7LHV;3Z^HN9).Q[U^T)_P4JT
MSQ;\-;WP7\,?#-[X>M=0MWLI[^_6*!K>W;Y62&*)F4%E+#=N&W/ )P1\):7J
M=WHFIVFHV%Q):7UI,EQ;W$+;7BD1@RLI[$$ @^U5:*]BAAJ6&BX4UN9MM[G[
M&?&[XX^)[']@9/B'930V7B;5M"TYY;B!2JPO=&))7C&<J0)&*\G!QUQ7Y3_!
M._ATOXS> KVX<1P6VOV$TCL0 JK<1DDD^PKZ;^)7[:'@GQC^Q?IGPBLM+U^+
MQ):Z9IEF]U/;P"S+V[Q-(0PF+X(C;'R=QD"OC"O/R_#.E2J1E&UV_NZ%2=VC
M]#O^"N^F7 U7X::B(W-J8+ZW,@4[5<-"P!/3)!.!_LGTKLOCR/["_P""7'AJ
MRO?W%S<Z5HJ1QOP2QDBEVX/.=BDX]C7%_#?_ (*5^#-:^'NFZ%\9O ]SXGU+
M3_+ N[6RM;R&Z9,;)VBF=!')QDE<C(R-N<#Q#]LO]L^X_:;GTS1M(TN30O!F
MER_:(;:Y*M<7,^TJ)9-N0FU69512?O,23D!>&CA\0_94)PLJ;O?H];Z%-K5]
MSZ?_ &VX&\;_ /!/[X<Z[8AA:6IT;4I PR5C>S>$ XX!#3J#[\4W]AR)O!O[
M GQ(UK4ODL;F36-0C*@[FB2RCB/7&3OA<#!].?3QS]EW_@H!I7PT^&8^'?Q*
M\,W'BGPS;H\5K+:QQ3OY+'/D2PS,J.@).#NX&!@@"C]J+]O_ $GXE?#'_A77
MPS\,W'A;PS<(L5W+=1Q6[^2K9\B*&%F5$) R=W(RN "25]6Q'+]4Y/=YK\W2
MP[KXCP?]FC]F?Q+^TQXT;2-&*V&E68634]7F4M':QDG&!_$[8.U>,X.2 ":^
MMOCM^T=X$_9,^&M[\&/@F!-KY#PZKKB/O-O(Z[97,HQYER1@<?+'@ 8*A1E_
MLK_MU?!_]GKX+Z3X2G\.>*;C5\R7.JW=I8VACN;AV.2"UPI8*NQ 2 <(.*V/
M^&S_ -D?_HA7_EH:1_\ 'JUKRKU:_P"\I-PCLEU\W^@E9+1GYS5^A/\ P2'@
MA;Q!\39F"^>EK8(A[[2\Y;]57]*^#O&>I:?K/C#7=0TFU^PZ5=W\\]I:^6L?
MDPM(S(FU257"D# X&.*^G_\ @F5\3HO O[1(T2\N##8^*+%]/53@)]I4B2$D
M^N%D0>\H_#T<PC*IA)I;VO\ =J1'22/G_P".4TMQ\;/B#+,I69_$.H,ZD$88
MW,A/7WKZ<_X)/?\ )Q7B+_L5;G_TKLZ\;_;6\"R?#_\ :?\ 'UBT;I!>:@VJ
MP,PP'2Y F.WU 9V7_@)':M7]B+]H7P[^S7\5M5\3>)K+5+ZPN]%ETU(])BCD
ME$C3P2 D22(-N(FYSG)''HJZ=?!-4U>\58%I+4I?MT?\G8_$7_K]B_\ 2>*O
MM3X$_P#*++7_ /L Z]_Z-N:_/[]I'XEZ9\8?C?XK\9:-!=VVF:M<)+!%?HJ3
M*!$B'<%9E!RIZ,:^K?V8_P!N[X7_  E_9XTKX=>,?#6OZY)$+N.]B@L+6XLY
MXYIY'V$2SKN!5P"&7'4<BN7%4:KPM*,8W<7&Z]$5%KF9\$5?T;7]3\.73W.D
MZC=Z7<O&T+36<[0NT;##(2I!*D<$=#7Z%?\ #9_[(_\ T0K_ ,M#2/\ X]7Q
M9^T/XT\(_$+XP^(/$'@30O\ A&O"MY]G^QZ7]CAM/(V6\:2?NH247=(KM\IY
MW9/)->A1KSK2<9TG%>9+274^^O\ @F-_R:_\1/\ L+W7_I%!7YQ?#CP/??$O
MQ]X?\*:;D7NL7T5E&X3=Y>]@"Y''"C+'GH#7U+^QY^V3X+_9\^#?BKPEXBTS
M7KW4=5OI[J"72[>&2%5>WCB 8O,A!W(3P#QCZ5Y9^QO\8/!'P(^+8\9^-+#5
MM3%E9RQZ=#I-O%*R7$F$,C&26, ",R*!SG?GC'/'3A5HU,144=[6\]&4[.R/
MU$^/_P"RU_PN+X*Z#\,]"\3GP7H6EO;@[+#[7Y\,$92.(CS8\ ':V<G)05;T
MS]FYX?V5Y_@[KFOKXEQIDVGP:M)9"WV_,S6Q\O>_^J/E@'=SY8/6OR6_:H^.
M _:$^-6M>+[>.YMM)D6*VTZUO HEAMXU  8*2 2Q=R,G!<C) KLOV(OVH;#]
MF/Q]K-]KMOJ-]X<U:Q$%Q:Z9'&\WG(X:&0!W0< RC[W\?0UYKR[$QPZ:GJO>
MM9;^I7.K['D/@FSU#PK\7-!M;B%[35=-URWBDA<9:*:.X4%2/4,N/PK[G_X*
M^Q1BX^%$@ \UEU56/?:#:8_FU>*Z3<^&/VDOV^/#FK>!;/4M.TC6-9MM6N;;
M4[:..2-X0)KD@1R.,/Y+-N)SESD<<]!_P5)^)L'B_P".FG>%[259;?PO8"*8
MC/%S.1(XST.$$'3OD=1@>C)RJXR@[6:BV_*^GYD[19\9T445[9F%%%% !111
M0 4444 ?M#_P3K_Y- \#?[]__P"EUQ7TE7S;_P $Z_\ DT#P-_OW_P#Z77%?
M25?F6,_WFI_B?YG7'9!4*P*MY+,&RSQHA7T +$'_ ,>/Y5-5:.!EU&>8XV/%
M&@]<@N3_ .A"N0HLT444 ?D__P %8?\ DXKP[_V*MM_Z5WE?%E?:?_!6'_DX
MKP[_ -BK;?\ I7>5\65^D9?_ +K3]#DG\3"BBBO0)"BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KZ-_X)X_\GA^
M/^XA_P"F^YKYRKZ-_P"">/\ R>'X _[B'_ION:Y,7_NU3_"_R''='[34445^
M9'8%0V<"VMG!"C;UCC5 WJ ,9J:JVFP-:Z=:POC?'$B-CID  T 6:*** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@"EHO\ R!K#_KWC_P#015VJ6B_\@:P_Z]X_
M_015V@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ J.?\ U$G^Z?Y5)4<_^HD_W3_*FMP,BBBBMR KFO$?PR\'>,=0@O\ 7_">
MAZY?0 "*YU+38;B6,#H%9U)'X5TM%--Q=TP,JV\):'9Z\^MV^C:?!K3VPLWU
M&.U1;AH 01$9 -Q0$ A<XX'%3:[H&F>*-)N-+UG3K35M,N %FLKZ!9H90""
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M^W*+]#);LWYDU6_X=/?"/_H8O&O_ ('6G_R+7UW]LX7N_N,/9R/R?HK]8/\
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M/_?-? ]?T)^.O /A[XF>&[G0/%&DVVM:1<8,EK=+E<CHP/56'8@@BOE74O\
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M$?\ T,7C7_P.M/\ Y%H_MC"]W]P>SD?D_17ZP?\ #I[X1_\ 0Q>-?_ ZT_\
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M_P#D6C^V,+W?W![.1^3]%?K!_P .GOA'_P!#%XU_\#K3_P"1:/\ AT]\(_\
MH8O&O_@=:?\ R+1_;&%[O[@]G(_)^BOU@_X=/?"/_H8O&O\ X'6G_P BT?\
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M#K3_ .1:/^'3WPC_ .AB\:_^!UI_\BT?VQA>[^X/9R/R?HK]8/\ AT]\(_\
MH8O&O_@=:?\ R+1_PZ>^$?\ T,7C7_P.M/\ Y%H_MC"]W]P>SD?D_17ZP?\
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MB@ HHHH **\_\4_M"_"SP-KMUHGB3XE^#_#^M6NW[1IVJ:]:VUQ#N4.N^-Y
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M_$/_ ,=KY5HH]A /]:LR[K[CZJ_X:K\)_P#0.UK_ +\0_P#QVC_AJOPG_P!
M[6O^_$/_ ,=KY5HH]A /]:LR[K[CZJ_X:K\)_P#0.UK_ +\0_P#QVC_AJOPG
M_P! [6O^_$/_ ,=KY5HH]A /]:LR[K[CZJ_X:K\)_P#0.UK_ +\0_P#QVC_A
MJOPG_P! [6O^_$/_ ,=KY5HH]A /]:LR[K[CZJ_X:K\)_P#0.UK_ +\0_P#Q
MVC_AJOPG_P! [6O^_$/_ ,=KY5HH]A /]:LR[K[CZJ_X:K\)_P#0.UK_ +\0
M_P#QVC_AJOPG_P! [6O^_$/_ ,=KY5HH]A /]:LR[K[CZJ_X:K\)_P#0.UK_
M +\0_P#QVC_AJOPG_P! [6O^_$/_ ,=KY5HH]A /]:LR[K[CZJ_X:K\)_P#0
M.UK_ +\0_P#QVC_AJOPG_P! [6O^_$/_ ,=KY5HH]A /]:LR[K[CZJ_X:K\)
M_P#0.UK_ +\0_P#QVC_AJOPG_P! [6O^_$/_ ,=KY5HH]A /]:LR[K[CZJ_X
M:K\)_P#0.UK_ +\0_P#QVC_AJOPG_P! [6O^_$/_ ,=KY5HH]A /]:LR[K[C
MZJ_X:K\)_P#0.UK_ +\0_P#QVC_AJOPG_P! [6O^_$/_ ,=KY5HH]A /]:LR
M[K[CZJ_X:K\)_P#0.UK_ +\0_P#QVC_AJOPG_P! [6O^_$/_ ,=KY5HH]A /
M]:LR[K[CZJ_X:K\)_P#0.UK_ +\0_P#QVC_AJOPG_P! [6O^_$/_ ,=KY5HH
M]A /]:LR[K[CZJ_X:K\)_P#0.UK_ +\0_P#QVC_AJOPG_P! [6O^_$/_ ,=K
MY5HH]A /]:LR[K[CZJ_X:K\)_P#0.UK_ +\0_P#QVMSPO^T'X0\47L=HMQ<:
M;<2':BZA&$#'. -P8C)]S7QS0#@T/#P-*?%F81DG/E:[6/T0HKB_@UK<_B'X
M9Z%>W+M).8FB=VZL4=DR?^^:[2O.:L['Z]AZRQ%&%:.TDG]ZN%0J\1O)4"_O
MA&A9L=5);;S]0WYU-4*PHMY+*&S(T:*5ST +$'_QX_E2-R:BBB@"AK>NZ?X<
MTZ6_U.[CLK2/&Z64X&3T'N?85Y;=?M2>$+>8I';:K<J/^6D5N@4_]].#^E<1
M^U=KL[:_I&CB1A;):_:V0=&9G90?P"'\Z\'KMIT8RCS2/S3.>),3A<5+#X9)
M*.[:O=GU5_PU7X3_ .@=K7_?B'_X[1_PU7X3_P"@=K7_ 'XA_P#CM?*M%:^P
M@>#_ *U9EW7W'U5_PU7X3_Z!VM?]^(?_ ([1_P -5^$_^@=K7_?B'_X[7RK1
M1[" ?ZU9EW7W'U5_PU7X3_Z!VM?]^(?_ ([1_P -5^$_^@=K7_?B'_X[7RK1
M1[" ?ZU9EW7W'U5_PU7X3_Z!VM?]^(?_ ([1_P -5^$_^@=K7_?B'_X[7RK1
M1[" ?ZU9EW7W'U5_PU7X3_Z!VM?]^(?_ ([1_P -5^$_^@=K7_?B'_X[7RK1
M1[" ?ZU9EW7W'U5_PU7X3_Z!VM?]^(?_ ([1_P -5^$_^@=K7_?B'_X[7RK1
M1[" ?ZU9EW7W'U5_PU7X3_Z!VM?]^(?_ ([1_P -5^$_^@=K7_?B'_X[7RK1
M1[" ?ZU9EW7W'U5_PU7X3_Z!VM?]^(?_ ([1_P -5^$_^@=K7_?B'_X[7RK1
M1[" ?ZU9EW7W'U5_PU7X3_Z!VM?]^(?_ ([1_P -5^$_^@=K7_?B'_X[7RK1
M1[" ?ZU9EW7W'U5_PU7X3_Z!VM?]^(?_ ([1_P -5^$_^@=K7_?B'_X[7RK1
M1[" ?ZU9EW7W'U5_PU7X3_Z!VM?]^(?_ ([1_P -5^$_^@=K7_?B'_X[7RK1
M1[" ?ZU9EW7W'U5_PU7X3_Z!VM?]^(?_ ([1_P -5^$_^@=K7_?B'_X[7RK1
M1[" ?ZU9EW7W'U5_PU7X3_Z!VM?]^(?_ ([1_P -5^$_^@=K7_?B'_X[7RK1
M1[" ?ZU9EW7W'U5_PU7X3_Z!VM?]^(?_ ([1_P -5^$_^@=K7_?B'_X[7RK1
M1[" ?ZU9EW7W'U5_PU7X3_Z!VM?]^(?_ ([1_P -5^$_^@=K7_?B'_X[7RK1
M1[" ?ZU9EW7W'U5_PU7X3_Z!VM?]^(?_ ([1_P -5^$_^@=K7_?B'_X[7RK1
M1[" ?ZU9EW7W'U5_PU7X3_Z!VM?]^(?_ ([1_P -5^$_^@=K7_?B'_X[7RK1
M1[" ?ZU9EW7W'U5_PU7X3_Z!VM?]^(?_ ([1_P -5^$_^@=K7_?B'_X[7RK1
M1[" ?ZU9EW7W'U5_PU7X3_Z!VM?]^(?_ ([1_P -5^$_^@=K7_?B'_X[7RK1
M1[" ?ZU9EW7W'U5_PU7X3_Z!VM?]^(?_ ([1_P -5^$_^@=K7_?B'_X[7RK1
M1[" ?ZU9EW7W'U5_PU7X3_Z!VM?]^(?_ ([1_P -5^$_^@=K7_?B'_X[7RK1
M1[" ?ZU9EW7W'U5_PU7X3_Z!VM?]^(?_ ([1_P -5^$_^@=K7_?B'_X[7RK1
M1[" ?ZU9EW7W'U5_PU7X3_Z!VM?]^(?_ ([1_P -5^$_^@=K7_?B'_X[7RK1
M1[" ?ZU9EW7W'U5_PU7X3_Z!VM?]^(?_ ([1_P -5^$_^@=K7_?B'_X[7RK1
M1[" ?ZU9EW7W'U5_PU7X3_Z!VM?]^(?_ ([1_P -5^$_^@=K7_?B'_X[7RK1
M1[" ?ZU9EW7W'U5_PU7X3_Z!VM?]^(?_ ([1_P -5^$_^@=K7_?B'_X[7RK1
M1[" ?ZU9EW7W'U5_PU7X3_Z!VM?]^(?_ ([1_P -5^$_^@=K7_?B'_X[7RK1
M1[" ?ZU9EW7W'U5_PU7X3_Z!VM?]^(?_ ([1_P -5^$_^@=K7_?B'_X[7RK1
M1[" ?ZU9EW7W'U5_PU7X3_Z!VM?]^(?_ ([1_P -5^$_^@=K7_?B'_X[7RK1
M1[" ?ZU9EW7W'U5_PU7X3_Z!VM?]^(?_ ([1_P -5^$_^@=K7_?B'_X[7RK1
M1[" ?ZU9EW7W'U5_PU7X3_Z!VM?]^(?_ ([1_P -5^$_^@=K7_?B'_X[7RK1
M1[" ?ZU9EW7W'U5_PU7X3_Z!VM?]^(?_ ([1_P -5^$_^@=K7_?B'_X[7RK1
M1[" ?ZU9EW7W'U5_PU7X3_Z!VM?]^(?_ ([1_P -5^$_^@=K7_?B'_X[7RK1
M1[" ?ZU9EW7W'U5_PU7X3_Z!VM?]^(?_ ([1_P -5^$_^@=K7_?B'_X[7RK1
M1[" ?ZU9EW7W'U5_PU7X3_Z!VM?]^(?_ ([1_P -5^$_^@=K7_?B'_X[7RK1
M1[" ?ZU9EW7W'U5_PU7X3_Z!VM?]^(?_ ([1_P -5^$_^@=K7_?B'_X[7RK1
M1[" ?ZU9EW7W'U5_PU7X3_Z!VM?]^(?_ ([1_P -5^$_^@=K7_?B'_X[7RK1
M1[" ?ZU9EW7W'U5_PU7X3_Z!VM?]^(?_ ([1_P -5^$_^@=K7_?B'_X[7RK1
M1[" ?ZU9EW7W'U5_PU7X3_Z!VM?]^(?_ ([1_P -5^$_^@=K7_?B'_X[7RK1
M1[" ?ZU9EW7W'U5_PU7X3_Z!VM?]^(?_ ([1_P -5^$_^@=K7_?B'_X[7RK1
M1[" ?ZU9EW7W'U5_PU7X3_Z!VM?]^(?_ ([1_P -5^$_^@=K7_?B'_X[7RK1
M1[" ?ZU9EW7W'U5_PU7X3_Z!VM?]^(?_ ([1_P -5^$_^@=K7_?B'_X[7RK1
M1[" ?ZU9EW7W'U5_PU7X3_Z!VM?]^(?_ ([1_P -5^$_^@=K7_?B'_X[7RK1
M1[" ?ZU9EW7W'U5_PU7X3_Z!VM?]^(?_ ([1_P -5^$_^@=K7_?B'_X[7RK1
M1[" ?ZU9EW7W'U5_PU7X3_Z!VM?]^(?_ ([1_P -5^$_^@=K7_?B'_X[7RK1
M1[" ?ZU9EW7W'U5_PU7X3_Z!VM?]^(?_ ([1_P -5^$_^@=K7_?B'_X[7RK1
M1[" ?ZU9EW7W'U5_PU7X3_Z!VM?]^(?_ ([1_P -5^$_^@=K7_?B'_X[7RK1
M1[" ?ZU9EW7W'U9%^U1X1DD56LM7B!/+O!'@?E(3^E>E^%?&&D>--.%[H]XE
MW"" X'#1G&<,IY!KX(KU;]FK7)].^)5O8(["WU"&6.1!T)5&<'\-I_.LZE"*
MBW$]C*N)\56Q4*&)2<9-+16:;V_$^NJ***X3]1"H;-XI;.!X%VPM&I1<8PN.
M./I4U0V<*6]G!%&V^..-55LYR , T 35^8WQ@U;Q!\1_$VN^-KFSNWT-[]K*
MWNBA,$2K_JX@W0': 3CJ23WK].:_/P^*-1_9X^)/B;P?X@L#K?@V^G9;C3)Q
ME9;=SE)HL]'VGL1SD$Y (\W&JZBF[+^K'Y?QU!5:6'A6FXTFY7:5TI6]VZ[;
MWMKV/*/A_P##[6OB9XC@T70K1KFZD^9W/$<*#J[MV _F0.IKU,Z[X5^!7Q&\
M*+X/U*YUC5-,F\K7=267_1+L.0)(HU]%&[#9QG!Y(S4'C_XPZ!X9\.S^#/A7
M!-I^ASG??:S-D7E\3R4W$ J@X';.#Q@G=Y_\)? EY\1_B%HNAVD999IU>X<#
MB*%3F1S]%!QZD@=Z\M6@U&&LN_\ E_F?DM/V>"JT\+@;5*[E'WUJD[JRA\]Y
M==EI=O\ 4ZOB7]M?Q3KWQ:_:!^%O[,^B:O>>'])\502:SXIOK!_+GETV/S?]
M'1_X0_V>8'KDE 05W!OMJOA/]J6YB^#7_!0KX#_%K7Y%M?!VIZ7<>$KG4)?E
MAL[@_:#&TC]%#&Z').-L<A_A-?3']5'NT/["WP!@\(_\(X/A-X8:Q,/D&Y>P
M1KW&,;OM1_?;O]K?G-4OV3/@3XO_ &:]&\6^%];\6V_B#P!#?M/X4AGDD:ZT
MNRRQ,,TC@ J!LP%X4AST;"_0 E1HQ('4QD;@X/&/7-?)U]^TO_PTY\//VE_#
M'@+0KR:U\,:+J&DZ=XFM;D/!JEZ]G* MO@#YE<'D%A@QMD;Q0!6M?VZ?%GQ,
MO]5N?@I\"]:^*7A#2[A[6?Q+)K-OI,%PZ??^RK*K&<#VP>G R*].^#/[6'AK
MXX?"[Q-XIT6POM/U?PRL\>L^&=63R+VPN8D9C%(.<!MAPP!Z'(#*RCEO^";V
MKZ+JW[%_PV&B/"8[6TEMKN.' ,=TLSF4.!T8L=W/4,#WKQ7X2W-OKO[67[:V
MK^'R)/#0TBULYIH?]4]]'9,DHR."PD2XS]3ZT =5X _X*%>-/C/\/;?Q1\-/
MV>]<\8QVJ'^VBNN06EM9RC),,$LL8:[D";&*I&,;P.>ITO"?_!0;5/C9X3MM
M5^"GP8\0?$>[AA\S6(+G48-)@TR3+?N//E#":7"APL8/RNG0DJ-;_@EE:0VW
M[#'PZDBC"/</J<DK#^-AJ-RN3_P%5'X5SG_!)V&.']G3Q/Y<:IN\::F6V@#)
MVPC)_  ?@* .ZT/]HW1_VF_V0OB=XETW3+S0;^QTG6-*U71=1Q]HL+N*U<O&
MW3/#*0<#K@@$$#YT_8L_:F\>:/\ LL^#=%^''P*U[XEV'AJUE@UC5UU2#38E
ME,TDICM4D5GNF5'7(0 Y./0G4_93_P"2#_MG?]C3XG_])6KW+_@FGJ.C:C^Q
M5\.!HIB"6]O<07:1XRER+F4R[AV)8[N>H8'G(- !J_[3'@+X\_L9?$/QY'H%
MUK>@V6E7UOKGA/4+EK&Z62*+,UI+)'EHB01AUYPP.,\#GM7_ &MO#/[-7[('
MP2\<6/@DV/A'7Y=*TA-(&K22'1K2:VEEW^<T3O<>4D)&"%+YZCO\^>$)HM;^
M&G_!0CQ!HK(_@^_O+V.PDA(,4MRD-R;F1"."&\R)L^A')I?VA;*#4?\ @G?^
MR3:7,:S6T_B3PU%+&W1T:RN@0?J": />/%_[?/C/X>Z1;^-?$_[._BK1OA/,
M\?\ Q4LVJ6QOHHG("22Z<!OB!)'WW7J!G) KVWXW?M-^#_@=\*].\<Z@UUK=
MGK$EO;Z)8Z3%YESJL\Z[H8X5)'WERV3C '<X!YS]OJ-)?V-_BRKJK@:+(V&&
M>0RD'\" :\2\2_'>+X:_LV?LHZ%9^!]*^(/Q'\7Z1HT/AN/7]OV>SNH[2T)N
MVD96961Y82"I5N<[AMY .B\8?MV?$7X/V=OXA^*?[.6N>#? 4D\<,NOVGB*T
MU*2V#L%5I;>-08^HX9AR0!DD"O._^"G?CWQ8VL? J+0/!G]N^&3XJTK5].UI
M-9A@74=0+2^7I_DL-R;D"/Y[?(/,QC(-<Q^WS8_M'I^RCXMO_BMXR^'>EZ#+
M+8QMX<\*6%P\E_(;N%DB$]P=RE-OFG;DD1,.F37<?MISQW/PK_9'FB=9(I/&
MGAYT=3D,#!D$4 =W\4OB/87?QC_98/Q+^#WV#X@ZY?:J-/7_ (2=I/\ A&94
M%N'/[A?*O/,4Q'#8"[>.2:[_ .._[7-O\+?'^F?#CP?X-U3XG_$[4;8WL?AW
M2IDMX[>W&?WMS</E85.."0>V<97/F'[9O_)YG['?_88UK_T79U7^ <\&C_\
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M?#74OA3\0#8MJ5E8W.H1:C:WT"GYC%<1JH9@ QP 1A'^;(Q7TK7Q=\<V,/\
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MD\;"P^[7HN@7,-[H6FW%O9R:?;S6T<D=I+&(W@4J"$902%*C@@' Q0!\X?\
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M^%?A5\8;5&-U\.O&%G>SNBY*V<SJ)A_P)X[=<=\U]?\ A7_D6-'_ .O.'_T
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MY&)R\DC?Q.S$DGU/88%=A0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !7RK^U7_P E#T[_ +!<?_HZ:OJJOE7]JO\ Y*'IW_8+C_\
M1TU=%#XSY#BK_D6OU1XS1117IGXL%%%% !1110 4444 =#X%\"ZG\0=<73-,
M5 X4R2S2G"1(,#<>_4@8'K7L:_LD2F(%O%*"7'W18$KGZ^9_2N?_ &9_&FF>
M&?$6HV.I3I:?VDD:PSR'"!T+?*3VSNX)XXQW%>@^-OV?+C6-;EU_0/$=S:ZF
M[-,@NG9P&/("2+\R+R>S<&N2I.2G:]D?>97EF&K8%8A4?;3N[KFY7%>7?34\
M&^(GPUU7X:ZI%:ZCY<L,X9K>YA.5E //!Y!&1D>_>O1O"7[,G_"4>&=,U?\
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M6OPOD\8ZCJ!LE=PMI8^1N:<$@*=Q8;<_,>AX&>]:G_"C_P#BUO\ PF7]M?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@^,O[.'@;X]>!;'PMXPTZ6\M=.9);"^@F,-Y92H !+%*N"K8'/8]P<"O3Z*
M/DBX_P"":7PZU>XTV_\ $7C'XA^+]>TV\M[JSUSQ'KXO;NW2%]XMT+Q;%B9@
M-P";N!AASGV/X]?LT>!?VC=+TVW\6V-RFH:5-]HTO6M+N6M;_3Y>/FAF7D=
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M.;K5=4U6<W5[J4IS\\\K<O\ >;C  W,0,L<^1ZK_ ,$X?AP^IZI)X:\4^/\
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M]\.^'?C]XG^+UM>ZF_B7Q#ID.E75K++&;-(HO+VM&HC#AOW:Y)<CD\"O3J*
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M^699SC!*N^[)/[TX%?L+X+\6V/CSPII7B'38[N*PU*W6YA2_M)+6=58<!XI
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ME1$0D9QEV7]V"!P.6.,X[>%?$?P-X^!N_$OBJR8*657G:YA8+DX555'.!ST
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!2T7_ ) UA_U[
MQ_\ H(J[5+1?^0-8?]>\?_H(J[0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!Q?Q;^,G@WX%^#Y_$_CC7K70-(C;R
MUDN&^>>3!(CB0?-(Y )"J"< GH":^%M8_:?^/O[<NIW?A[]GWP_/\/?AXQ,-
MQX^UQ&AEE4<-Y3@,$/;;$'<<$M'GC[E^*WP1\"_'#3=-T_QWX:L_$UEIUVM]
M:P7F[;',%*YPI&X$,05.5/<'%==I>E66AZ=;:?IMG!I]A;1B*"UM8EBBB0#
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M\(>%M-T>-_-%I$$+XQN;.6/XDFMJBBN-N[N?HE.$:4%3@K)*R^05"L<8O)9
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M?ZE_]1'_ )+_ /;'YWT5^B%%'UGR#_4O_J(_\E_^V/SOHK]$**/K/D'^I?\
MU$?^2_\ VQ^=]%?HA11]9\@_U+_ZB/\ R7_[8_.^BOT0HH^L^0?ZE_\ 41_Y
M+_\ ;'YWT5^B%%'UGR#_ %+_ .HC_P E_P#MC\[Z*_1"BCZSY!_J7_U$?^2_
M_;'YWT5^B%%'UGR#_4O_ *B/_)?_ +8_.^BOT0HH^L^0?ZE_]1'_ )+_ /;'
MYWT5^B%%'UGR#_4O_J(_\E_^V/SOHK]$**/K/D'^I?\ U$?^2_\ VQ^=]%?H
MA11]9\@_U+_ZB/\ R7_[8_.^BOT0HH^L^0?ZE_\ 41_Y+_\ ;'YWT5^B%%'U
MGR#_ %+_ .HC_P E_P#MC\[Z*_1"BCZSY!_J7_U$?^2__;'YWT5^B%%'UGR#
M_4O_ *B/_)?_ +8_.^BOT0HH^L^0?ZE_]1'_ )+_ /;'YWT5^B%%'UGR#_4O
M_J(_\E_^V/SOHK]$**/K/D'^I?\ U$?^2_\ VQ^=]%?HA11]9\@_U+_ZB/\
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M2_\ VQ^=]%?HA11]9\@_U+_ZB/\ R7_[8_.^BOT0HH^L^0?ZE_\ 41_Y+_\
M;'YWT5^B%%'UGR#_ %+_ .HC_P E_P#MC\\8H9)Y%CB1I)&. J#)/X5]#?LY
M?"O5-+U=O$NK6LEBBQ&.TBF&UWW#ER.H&.!GKFOHBBHG7<E9(]/+N%J6"KQQ
M%2ISN.J5K:_>PHHHKE/N0J&SCCALX(X6WPK&JHV<Y4#@Y[\5-5>PMS:6%M Q
M#-%&J$CH2 !0!8HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *6B_\@:P_P"O
M>/\ ]!%7:I:+_P @:P_Z]X__ $$5=H **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MKBOC+\7_  U\!_AOK/CCQ;=O::)I<8>3R4WRRNS!4CC7(W.S,% R!SDD $@
M[6BODA_VOOC2FF#Q&?V5/$Q\&F,7'VL>(K0ZGY.W=N_LX+YF['\&<_C7OOP3
M^,WAGX__  WTGQOX2N)I]&U$,%2YC\N>"1&*O%(F3M=6!!P2#U!(() .ZHHH
MH **** "BBHKFYBL[:6XG<10Q(9'=NBJ!DD_A0!+17D/[*OQ\E_:9^#6G?$(
M^'3X9M=2N;F*TM&O/M1>*&9HO,+>6F"61_EP<8ZFO7J "BBB@ HHHH ****
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M^44?4\-_SZC]R#ZO1_D7W(^@_P#AOOX\_P#0]_\ E'L/_C%'_#??QY_Z'O\
M\H]A_P#&*^?**/J>&_Y]1^Y!]7H_R+[D?0?_  WW\>?^A[_\H]A_\8H_X;[^
M//\ T/?_ )1[#_XQ7SY11]3PW_/J/W(/J]'^1?<CZ#_X;[^//_0]_P#E'L/_
M (Q1_P -]_'G_H>__*/8?_&*^?**/J>&_P"?4?N0?5Z/\B^Y'T'_ ,-]_'G_
M *'O_P H]A_\8H_X;[^//_0]_P#E'L/_ (Q7SY11]3PW_/J/W(/J]'^1?<CZ
M#_X;[^//_0]_^4>P_P#C%'_#??QY_P"A[_\ */8?_&*^?**/J>&_Y]1^Y!]7
MH_R+[D?0?_#??QY_Z'O_ ,H]A_\ &*/^&^_CS_T/?_E'L/\ XQ7SY11]3PW_
M #ZC]R#ZO1_D7W(^@_\ AOOX\_\ 0]_^4>P_^,4?\-]_'G_H>_\ RCV'_P 8
MKY\HH^IX;_GU'[D'U>C_ "+[D?0?_#??QY_Z'O\ \H]A_P#&*/\ AOOX\_\
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MJ>&_Y]1^Y!]7H_R+[D?0?_#??QY_Z'O_ ,H]A_\ &*/^&^_CS_T/?_E'L/\
MXQ7SY11]3PW_ #ZC]R#ZO1_D7W(^@_\ AOOX\_\ 0]_^4>P_^,4?\-]_'G_H
M>_\ RCV'_P 8KY\HH^IX;_GU'[D'U>C_ "+[D?0?_#??QY_Z'O\ \H]A_P#&
M*/\ AOOX\_\ 0]_^4>P_^,5\^44?4\-_SZC]R#ZO1_D7W(^@_P#AOOX\_P#0
M]_\ E'L/_C%'_#??QY_Z'O\ \H]A_P#&*^?**/J>&_Y]1^Y!]7H_R+[D?0?_
M  WW\>?^A[_\H]A_\8H_X;[^//\ T/?_ )1[#_XQ7SY11]3PW_/J/W(/J]'^
M1?<CZ#_X;[^//_0]_P#E'L/_ (Q1_P -]_'G_H>__*/8?_&*^?**/J>&_P"?
M4?N0?5Z/\B^Y'T'_ ,-]_'G_ *'O_P H]A_\8H_X;[^//_0]_P#E'L/_ (Q7
MSY11]3PW_/J/W(/J]'^1?<CZ#_X;[^//_0]_^4>P_P#C%'_#??QY_P"A[_\
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M5_8GB^'WQ:^$<^L^%M9C\56.GZW'_:US=)J]M+YAD\]9I&WL2F,95<.W ."
M#](***^'?C19ZI^U=^VI/\#M1UW4M#^&/A+P_'K>MZ?I5RUM+K-Q*R;(I)%.
M?*"RH<>JOW*E0#[BKY>_:2_:-^(_A?XZ>!?@[\)]"\-W?B[Q)83ZJ^I^+I9Q
M86\$6_*[8")"Q\M^1G'R\')(\4^._P (]-_X)Z:]X!^)GP>NM2\/^$[SQ!;:
M'XE\'RZA/=V-Y;S[CYRK,[,LJ[&P<D@LN,#<&YKXU?LB_";7O^"DW@KPW?\
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M7XX^)_V7=%_:<^&NKZM>>,6^%-DFK>&;[5Y#+.]M<0;X()F[JA>#\'<
M'Z%T5\%_ C]@SP=\>?@[X<^(_P 8=3U_QO\ $/Q;I\6N#7'UFX@;35N$$L4=
MLD;A$"*R<,K '. %  Y+P[\0/%A_9=_:Z^#_ (QURX\4ZA\,[*ZL;+7+UMUQ
M=6,\$YMQ*W5G A8DG)PP&3@4 ?I#17Y\_LW?L&>"OCI^S#X#\1_$O4-?\0^*
M[[0K8Z5J0U>>%="MUC"VL=I"C"-=D:QD[U8EMQ/7%97PB_:P\8?#S_@F-XI\
M:ZCJDNN>,O"]]<>&[+4;[,KO*;B.*&1F;._RUG!&_J(@#GN ?HW17Y">%-7_
M &*];\#Z?J?Q!^,'B?5_B_<VJW%[XS_XG@O+.]8;G\C;#Y>U&8JN5;('7FNC
MU_X]ZQ\>/^"2'Q3D\0ZN?$&L^&M7L]"?6I PDU&%-1L)(;APP#;F24*2WS$I
MEN2: /U8KRC]JGXXO^S=\ _%GQ%CTE=<FT:.#R[!YO)61YKB*!2S8. #*&.!
MDA2.,YKY?U']@;PIXQ_9T7QSXIUCQ#JOQB;PZ-93Q=+K-PLEE=_9_.6*&)&$
M20(WR!0F=HX(/->5_'62U_:%_P""1?AOXH>,HYM;\:Z!;11V.KW$\BRK+_:T
M5C-(X5]LK/''@M(&.26X8T ?IGX-UF;Q'X0T/5KA$CGO[&"ZD2,$*K/&K$#)
M)QDUL5^>/[0/PEE^ /[#_A:Q^#^B:YI'A?5=9T[5_&\/AF[GFU*6SDMD%U)$
MTCLR!O*A!"D*,#("EZY3X1^&?V4?''B?PMJ'P!^*U]\(?'UMJ$$\\=]>7IEU
M9!DO:RQ74RQRF0XSY;,.HVG/ !^G-%%% !1110 4444 %%%% !1110!2T7_D
M#6'_ %[Q_P#H(J[5+1?^0-8?]>\?_H(KG/C'JEYHGPB\<:CIS,FH6>AWUQ;L
MAPPD2W=D(]\@545S-(:5W8^"?VN_^"C>NV/BS4?!_P *[B+3K33Y'M;SQ 8U
MEEGE4[6$ 8%50$$;\$MU&!@GY3TG]L'XTZ-JB7\/Q*\0S3*V[R[N\:XA/L8I
M,ICVQ7GOP^U;2-!\>^&]3\06!U70K+4[:YU"Q"*YN;=)5:6/:Q .Y PP2 <\
MFOL?5KCQO\1M9\:ZO\./BAX<^,7@VY2XBC^&VM33V\WV7RU?$.E3"-5^S90Q
MRV[ DP@KR6CK[#V5+#14%!-=W_G;\['O<D*24>7YGTE^Q#^V[_PT+YWA3Q7#
M!8^-[2%KA);8;(=0A4C<RK_"ZY&5!.1EA@ @?7=?A3^R)JEYI'[3GPSGL69)
MGURVMV*'!\J5O+D'T*.V:_=:O!S&A&A57)LSS,525.?N[,*^;?CE^UGJ?A?X
MJV?PB^%GA#_A8GQ1GMA>W=M)=?9K#1K8XQ-=RX.,AE(08)#+SED#?25?"O[
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M -*[NOU'K\N/^"I'_)P'A_\ [%BW_P#2N[KW<E_WM>C/2R_^.O1GQW1117Z
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M9M\'?#71_#WCOP;:)HMMJUU]CN=+A!$)9HVD26-3_J^$8,HXY7 '.>E_:/\
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M1QO-(L<:EW8A551DDGH *_2#]OTEOV./AH2<DZCIA)/_ &#KBOEW]AGX5_\
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M@89Z*"VW]2U<9SDU%%% 'Y<?\%2/^3@/#_\ V+%O_P"E=W7QW7V)_P %2/\
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M"?$7P^_9-TS1_%.@:IX:U9-5O9&L-7LY+6=5:0%6,<BA@#V..:^MZ* /D?\
MX)\>"/$7@O\ X7K_ ,)#H&J:%_:/Q$U*^LO[3LY+?[5;MMVS1;U&]#CAER#Z
MUF_LN>"?$7A;XI_M<:AK.@:GI%AK'B%KG3;J_LY((KV+9<_O(690)%^8?,I(
MY'K7V55+6K)]1T:_M(BJR3V\D2ESP"RD#/MS0!^97_!/3]H_QU\'/V8=&T[4
M/@_XR\?>%[BYNW\/:IX)LUORK&>02V]U'N5H0)0["3D$2=,BO9_@[^RKXK^*
M7A3X^^+/BM8Q^%/%GQ@A^R1:5%*)WT:SCA:.V#L.&<$H67TB7."64>R?L2?
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M^\1WKRG_ ()P>!O&%AX$\<^/_B'HE_X?\:>-M?:ZN++4[62VN(K6"-8H%9)
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M^,*_3,M=\)3]#Z_"?P(>@4445Z)V!1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MW^*O_0P>#O\ P-N__D:C_AUO\5?^A@\'?^!MW_\ (U?H+_PT1\*O^BF^#O\
MP?VG_P <H_X:(^%7_13?!W_@_M/_ (Y3_M3,.W_DH_KF*[?@?GU_PZW^*O\
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MO\5?^A@\'?\ @;=__(U?H+_PT1\*O^BF^#O_  ?VG_QRC_AHCX5?]%-\'?\
M@_M/_CE']J9AV_\ )0^N8KM^!^?7_#K?XJ_]#!X._P# V[_^1J/^'6_Q5_Z&
M#P=_X&W?_P C5^@O_#1'PJ_Z*;X._P#!_:?_ !RC_AHCX5?]%-\'?^#^T_\
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MW_@;=_\ R-7Z"_\ #1'PJ_Z*;X._\']I_P#'*/\ AHCX5?\ 13?!W_@_M/\
MXY1_:F8=O_)0^N8KM^!^?7_#K?XJ_P#0P>#O_ V[_P#D:C_AUO\ %7_H8/!W
M_@;=_P#R-7Z"_P##1'PJ_P"BF^#O_!_:?_'*/^&B/A5_T4WP=_X/[3_XY1_:
MF8=O_)0^N8KM^!^?7_#K?XJ_]#!X._\  V[_ /D:C_AUO\5?^A@\'?\ @;=_
M_(U?H+_PT1\*O^BF^#O_  ?VG_QRC_AHCX5?]%-\'?\ @_M/_CE']J9AV_\
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M<H_X:(^%7_13?!W_ (/[3_XY1_:F8=O_ "4/KF*[?@?GU_PZW^*O_0P>#O\
MP-N__D:C_AUO\5?^A@\'?^!MW_\ (U?H+_PT1\*O^BF^#O\ P?VG_P <H_X:
M(^%7_13?!W_@_M/_ (Y1_:F8=O\ R4/KF*[?@?GU_P .M_BK_P!#!X._\#;O
M_P"1J/\ AUO\5?\ H8/!W_@;=_\ R-7Z"_\ #1'PJ_Z*;X._\']I_P#'*/\
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M';_R4/KF*[?@?GU_PZW^*O\ T,'@[_P-N_\ Y&H_X=;_ !5_Z&#P=_X&W?\
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MW_@;=_\ R-7Z"_\ #1'PJ_Z*;X._\']I_P#'*/\ AHCX5?\ 13?!W_@_M/\
MXY1_:F8=O_)0^N8KM^!^?7_#K?XJ_P#0P>#O_ V[_P#D:C_AUO\ %7_H8/!W
M_@;=_P#R-7Z"_P##1'PJ_P"BF^#O_!_:?_'*/^&B/A5_T4WP=_X/[3_XY1_:
MF8=O_)0^N8KM^!^?7_#K?XJ_]#!X._\  V[_ /D:C_AUO\5?^A@\'?\ @;=_
M_(U?H+_PT1\*O^BF^#O_  ?VG_QRC_AHCX5?]%-\'?\ @_M/_CE']J9AV_\
M)0^N8KM^!^?]I_P2U^)SW""Y\2>$H8"?G>*YNI& ]E-NH/YBOL;]EO\ 9'T+
M]FS3[RY2]?7/$NH(J76HR1B-$0<^7$O.%SR222<#IC%>@6GQ]^&-_<)!;?$;
MPE<3N<)%%KEJS,?0 29-=Q!/'=0QS0R)+%(H9)$8,K ]"".HKCQ6/Q=:'LZN
MB?E8YZV*KU(\L]$24445Y!PA5;39WNM.M9I,%Y(D=L>I )JS4-G<"[LX)U78
MLL:N%],C.* )J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"EHO\ R!K#_KWC
M_P#015VJ6B_\@:P_Z]X__015V@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"%(H$; .TRR,J!L$'&<X.:T/B9^S1\3?@]IBZEXM\(W>EZ<6"&\22*YA1CC
M9XG=5R2 -Q&3P*AUJ2G[-R7-VNK_ '$^T@I<O,KGF5%>I?"W]F+XE_&GP_<:
MWX,\-?VSI=O=-923_;[:#;,J(Y7;+(K'Y9$.0,<]>#78_P## GQY_P"A$_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!2T7_ ) UA_U[Q_\
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MWB+2;_Q!I05M0TFUOHI+NS# %3+$K%XP01C<!G(K=K\]/@Y\3O!WPR_X*/\
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M_#GAL^/X_P!GCQ3<_!\*)_\ A*I=3MH;QK8GBX&G$&01D%6#.R@J020*XO\
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M*E:W<K^R^OA#3Y"NJ>-_$&F^'K5$SN=GF\[''.#Y&#_O8[U]?5XM\>/V<?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP]XJ^-O@#XI7^I:N_B3P79W5G8QI+$+:X6>%XI&G7RMQ;$C$;&09QP1Q7J=
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!\QQGU&*^ Z_2<LDI82%NB/KL')2H1L%%%%>H=H4444 %%%% !1110 4444
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MP]C_ .J6?^7#_P#<M/ZKFW>7_@7_  1^QQW=_P#@7_!/H/\ X8$^ W_0B?\
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M_P#'Z/\ A@3X#?\ 0B?^5B__ /C]?/G_  ]C_P"J6?\ EP__ '+1_P /8_\
MJEG_ )</_P!RT?5<V[R_\"_X(>QQW=_^!?\ !/H/_A@3X#?]")_Y6+__ ./T
M?\,"? ;_ *$3_P K%_\ _'Z^?/\ A['_ -4L_P#+A_\ N6C_ (>Q_P#5+/\
MRX?_ +EH^JYMWE_X%_P0]CCN[_\  O\ @GT'_P ,"? ;_H1/_*Q?_P#Q^C_A
M@3X#?]")_P"5B_\ _C]?/G_#V/\ ZI9_Y</_ -RT?\/8_P#JEG_EP_\ W+1]
M5S;O+_P+_@A[''=W_P"!?\$^@_\ A@3X#?\ 0B?^5B__ /C]'_# GP&_Z$3_
M ,K%_P#_ !^OGS_A['_U2S_RX?\ [EH_X>Q_]4L_\N'_ .Y:/JN;=Y?^!?\
M!#V..[O_ ,"_X)]!_P## GP&_P"A$_\ *Q?_ /Q^C_A@3X#?]")_Y6+_ /\
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M_P"J6?\ EP__ '+1_P /8_\ JEG_ )</_P!RT?5<V[R_\"_X(>QQW=_^!?\
M!/H/_A@3X#?]")_Y6+__ ./T?\,"? ;_ *$3_P K%_\ _'Z^?/\ A['_ -4L
M_P#+A_\ N6C_ (>Q_P#5+/\ RX?_ +EH^JYMWE_X%_P0]CCN[_\  O\ @GT'
M_P ,"? ;_H1/_*Q?_P#Q^C_A@3X#?]")_P"5B_\ _C]?/G_#V/\ ZI9_Y</_
M -RT?\/8_P#JEG_EP_\ W+1]5S;O+_P+_@A[''=W_P"!?\$^@_\ A@3X#?\
M0B?^5B__ /C]'_# GP&_Z$3_ ,K%_P#_ !^OGS_A['_U2S_RX?\ [EH_X>Q_
M]4L_\N'_ .Y:/JN;=Y?^!?\ !#V..[O_ ,"_X)]!_P## GP&_P"A$_\ *Q?_
M /Q^C_A@3X#?]")_Y6+_ /\ C]?/G_#V/_JEG_EP_P#W+1_P]C_ZI9_Y</\
M]RT?5<V[R_\  O\ @A[''=W_ .!?\$^@_P#A@3X#?]")_P"5B_\ _C]'_# G
MP&_Z$3_RL7__ ,?KY\_X>Q_]4L_\N'_[EH_X>Q_]4L_\N'_[EH^JYMWE_P"!
M?\$/8X[N_P#P+_@GT'_PP)\!O^A$_P#*Q?\ _P ?H_X8$^ W_0B?^5B__P#C
M]?/G_#V/_JEG_EP__<M'_#V/_JEG_EP__<M'U7-N\O\ P+_@A[''=W_X%_P3
MZ#_X8$^ W_0B?^5B_P#_ (_1_P ,"? ;_H1/_*Q?_P#Q^OGS_A['_P!4L_\
M+A_^Y:/^'L?_ %2S_P N'_[EH^JYMWE_X%_P0]CCN[_\"_X)]!_\,"? ;_H1
M/_*Q?_\ Q^C_ (8$^ W_ $(G_E8O_P#X_7SY_P /8_\ JEG_ )</_P!RT?\
M#V/_ *I9_P"7#_\ <M'U7-N\O_ O^"'L<=W?_@7_  3Z#_X8$^ W_0B?^5B_
M_P#C]'_# GP&_P"A$_\ *Q?_ /Q^OGS_ (>Q_P#5+/\ RX?_ +EH_P"'L?\
MU2S_ ,N'_P"Y:/JN;=Y?^!?\$/8X[N__  +_ ()]!_\ # GP&_Z$3_RL7_\
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M1_P]C_ZI9_Y</_W+1]5S;O+_ ,"_X(>QQW=_^!?\$^@_^&!/@-_T(G_E8O\
M_P"/T?\ # GP&_Z$3_RL7_\ \?KY\_X>Q_\ 5+/_ "X?_N6C_A['_P!4L_\
M+A_^Y:/JN;=Y?^!?\$/8X[N__ O^"?0?_# GP&_Z$3_RL7__ ,?H_P"&!/@-
M_P!")_Y6+_\ ^/U\^?\ #V/_ *I9_P"7#_\ <M'_  ]C_P"J6?\ EP__ '+1
M]5S;O+_P+_@A[''=W_X%_P $^@_^&!/@-_T(G_E8O_\ X_1_PP)\!O\ H1/_
M "L7_P#\?KY\_P"'L?\ U2S_ ,N'_P"Y:/\ A['_ -4L_P#+A_\ N6CZKFW>
M7_@7_!#V..[O_P "_P""?0?_  P)\!O^A$_\K%__ /'Z/^&!/@-_T(G_ )6+
M_P#^/U\^?\/8_P#JEG_EP_\ W+1_P]C_ .J6?^7#_P#<M'U7-N\O_ O^"'L<
M=W?_ (%_P3Z#_P"&!/@-_P!")_Y6+_\ ^/T?\,"? ;_H1/\ RL7_ /\ 'Z^?
M/^'L?_5+/_+A_P#N6C_A['_U2S_RX?\ [EH^JYMWE_X%_P $/8X[N_\ P+_@
MGT'_ ,,"? ;_ *$3_P K%_\ _'Z/^&!/@-_T(G_E8O\ _P"/U\^?\/8_^J6?
M^7#_ /<M'_#V/_JEG_EP_P#W+1]5S;O+_P "_P""'L<=W?\ X%_P3Z#_ .&!
M/@-_T(G_ )6+_P#^/T?\,"? ;_H1/_*Q?_\ Q^OGS_A['_U2S_RX?_N6C_A[
M'_U2S_RX?_N6CZKFW>7_ (%_P0]CCN[_ / O^"?0?_# GP&_Z$3_ ,K%_P#_
M !^C_A@3X#?]")_Y6+__ ./U\^?\/8_^J6?^7#_]RT?\/8_^J6?^7#_]RT?5
M<V[R_P# O^"'L<=W?_@7_!/H/_A@3X#?]")_Y6+_ /\ C]'_  P)\!O^A$_\
MK%__ /'Z^?/^'L?_ %2S_P N'_[EH_X>Q_\ 5+/_ "X?_N6CZKFW>7_@7_!#
MV..[O_P+_@GT'_PP)\!O^A$_\K%__P#'Z/\ A@3X#?\ 0B?^5B__ /C]?/G_
M  ]C_P"J6?\ EP__ '+1_P /8_\ JEG_ )</_P!RT?5<V[R_\"_X(>QQW=_^
M!?\ !/H/_A@3X#?]")_Y6+__ ./T?\,"? ;_ *$3_P K%_\ _'Z^?/\ A['_
M -4L_P#+A_\ N6C_ (>Q_P#5+/\ RX?_ +EH^JYMWE_X%_P0]CCN[_\  O\
M@GT'_P ,"? ;_H1/_*Q?_P#Q^C_A@3X#?]")_P"5B_\ _C]?/G_#V/\ ZI9_
MY</_ -RT?\/8_P#JEG_EP_\ W+1]5S;O+_P+_@A[''=W_P"!?\$^@_\ A@3X
M#?\ 0B?^5B__ /C]'_# GP&_Z$3_ ,K%_P#_ !^OGS_A['_U2S_RX?\ [EH_
MX>Q_]4L_\N'_ .Y:/JN;=Y?^!?\ !#V..[O_ ,"_X)]!_P## GP&_P"A$_\
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ML_\ +A_^Y:/^'L?_ %2S_P N'_[EH^JYMWE_X%_P0]CCN[_\"_X)]!_\,"?
M;_H1/_*Q?_\ Q^C_ (8$^ W_ $(G_E8O_P#X_7SY_P /8_\ JEG_ )</_P!R
MT?\ #V/_ *I9_P"7#_\ <M'U7-N\O_ O^"'L<=W?_@7_  3Z#_X8$^ W_0B?
M^5B__P#C]'_# GP&_P"A$_\ *Q?_ /Q^OGS_ (>Q_P#5+/\ RX?_ +EH_P"'
ML?\ U2S_ ,N'_P"Y:/JN;=Y?^!?\$/8X[N__  +_ ()]!_\ # GP&_Z$3_RL
M7_\ \?H_X8$^ W_0B?\ E8O_ /X_7SY_P]C_ .J6?^7#_P#<M'_#V/\ ZI9_
MY</_ -RT?5<V[R_\"_X(>QQW=_\ @7_!/H/_ (8$^ W_ $(G_E8O_P#X_1_P
MP)\!O^A$_P#*Q?\ _P ?KY\_X>Q_]4L_\N'_ .Y:/^'L?_5+/_+A_P#N6CZK
MFW>7_@7_  0]CCN[_P# O^"?1%I^P;\";.X2:/P'&SH<@2ZG>R+^*M,0?Q%>
MT^&?"VC^#-&M])T+3+72--@&V.ULXA'&OX#OQUZFOA2T_P""L,#W""Y^&$D,
M!/SO%KPD8#V4VZ@_F*^K?@)^T?X0_:'T&>^\-SRPWEIM%[IEVH6>W+#C.,AE
M/(#*2..W2N+%8?'0CS8B[7F[_JSGK4L3&-ZM[>MSU.BBBO).$*AL[<6EG! &
MW"*-4#>N!C-356TR![73K6&08>.)$8#U  - %FBBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH I:+_ ,@:P_Z]X_\ T$5=JEHO_(&L/^O>/_T$5=H **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'[+_ ,)/\1M9\.?:]_V?^UM<T^U\[;C=L\R ;L;ESCIN'K7EG@K]D/X2^/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5]
M,?\ !.WQ'=:-^U#H%A!(XM]6M;RUN$#$*RK;R3*2.^&B'YU\SU]!_L"?\G:^
M!/\ M_\ _2"XKCQJ3PU6_P#*_P CGQ"O1GZ,_8BBBBORX^,"JVF223:;:22D
MF5HD9R1@Y(&:LU!8W!O+*WG*[3+&K[<YQD9Q0!/1110 4444 %%%% !1110
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M ]!G+$ $UP/[#_[2.M?M3_"/5/&FM:59Z+(FO7FGVUG9JX\NWC$;1B0NS;I
M'PS#:"1PJ]* /H6BOE/X@_M-_$OQG\<O$'PH^ _A?P[J^J^%X(9/$/B3Q;<S
M)IMC)*,QP!(<2.Y /*D\AACY34_P>_:?\?6OQWA^#'QM\*:/X>\8ZC8OJ&AZ
MSX:N))=,U=(U+2I&LN71E5';#'.$.0/E+ 'U+1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7Y<?\%2
M/^3@/#__ &+%O_Z5W=?J/7Y<?\%2/^3@/#__ &+%O_Z5W=>[DO\ O:]&>EE_
M\=>C/CNBBBOT ^I/JW_@G]^T5X<^!OC/7],\52&QTGQ&EL@U/!9+:6$R;/,
MY"-YS MV(&>,D?4/CG]A+X5?&AY?%O@+Q%)H&H7<C7:7^BW2WED\S-N\S;NR
M.<D!'4#/3BOFG]A+X=_!OXO/KGA7Q_I"77BQI!<:7,^H7%N9X=F'C18Y%4LA
M7=@@DASU"G'?Z5_P3:^)?@OQP+OPE\2K+1M,W8&J6\MS;WZIG./+C&UN@_Y:
M 'VKY7%RI1Q,Y1JNG/2]UI+^OZ1XE=P5:34W"7X,\+_:R^%?Q>^%FH:;9_$/
MQ3JGC'0YG=M-U*XU*>[M]X^\NV4DQR;<$CN.A;!Q]OZG\(-9^.?["'@CPCH-
MS8VFI76BZ3*DNHR.D($:QNV2B.<X''%><_\ !3CQGI%G\+_!_@6755U'Q0FH
M1:A,IV^;Y,=O+$99 /N;WD! XSM;'2N@^+'B?6?!_P#P3G\(:GH.K7VB:E'I
M&C*EYIUR]O,H(B# .A! (X/-8SJU:]'#RLE+FTTT];&<ISJ4Z3V=_P"F/_9
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M +%BX_\ 2NTKT'_@K'_S2S_N*_\ MG7GW_!+?_DX#Q!_V+%Q_P"E=I7G4O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;2-!\>^&]3\06!U70K+4[:YU"Q"*YN;=)5:6/:Q .Y PP2 <\FOL?5KCQO\
M$;6?&NK_  X^*'ASXQ>#;E+B*/X;:U-/;S?9?+5\0Z5,(U7[-E#'+;L"3""O
M):.O.OCC\!O''[%'QLL_%OAVVEG\/65^+_1=6V-)"$W$BWN"""#M.Q@2-P.0
M>>.5TG]H+PCX.\;W?CGP=\.+C1O&DB2&T:ZUXW6EV,\J[)98K46Z2$E6EV*\
M[JI?.&"@5]G/]^E4I:Z>5OGU7R_R/?E^\M*&IB_LB:I>:1^TY\,Y[%F29]<M
MK=BAP?*E;RY!]"CMFOW6K\TO^"<G[(FMQ^+[7XI^+]-ETRPL$?\ L:SND*2W
M$S+M\\J>0BJS8SU8@C[O/Z6UX69U8U*R4>B/.QDXRJ670*_,70;KXSVO_!1/
M]HH_!FS\&WFI&+3QJ"^,3<B)8O(AV^5Y#*=V[.<\8K].J^-OV>/ ?B71/^"@
M?[1?B+4?#NK6'A_5;73UT_5KJQECM+PK%$&$4K*$D((.=I.,&O'. \^_:9U3
M]L67]GOXB)XQTCX00^%6T.[&IR:0^HF\6W\L^88=\A7?C.-PQGK6C_SAR_[D
MC_V>OIW]KK1-1\2_LO\ Q3TK2+"ZU75+SP[>P6UE90M-//(T3!41%!9F)X
MR:\!_P"%?>*?^'4G_"(_\(UJ_P#PE?\ PA_V7^POL$OV[SM_^K\C;OW?[.,T
M <?^S-^TA\?/#?[/?P[TO0?V7KWQ1HMGH=I#9ZTGC&UMUO8EC 641-"2FX<[
M221FOJ7X ?%OXF_$R[UJ+X@_!JX^%4-HD36<T^O0ZE]M9BV]0(XUV;<*><YW
M>U?,_P  ?VO_ !/\)/@EX'\%ZC^S7\:;R_T'2+;3I[BU\*R^5(\<84LN[!P2
M.,@5[W\%?VL=2^,'CB/P[=?!3XF^!8GMY)SJ_BK0FM+-2H'R&0G[S9X'?!H
M_.^_\$7^LV/[7WC;05QXI^'7Q67Q;ILJ\%?L][>>;D_W1&6<COY8K[0_;"^*
M2?%W]F?P%X:\'W1CO_C3>:;I5BT?SO!93[9KJ4CCY4B!1_3>>G;(_8K^%&LV
MGQ-_:WM?%_A;5--T'Q1XQO#:MJEC)!#J5I)->!GA9U EC9)!\RY&&'K7GO[#
M7P&^(^D_'>VTKXA:)J$'A3X,V6IZ/X4U+4;)XX]2EO+R0_:H'8;77R%V_+G:
M&09' H [C]CK0+'PI^W%^TWHFF0"VTW3;7P_9VL*](XH[38BCZ*H%1?L%_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !5_Z)EXQ_\ !!=__&Z/;4OYE]X>TAW1Y]17H/\ PSO\5?\ HF7C'_P07?\
M\;H_X9W^*O\ T3+QC_X(+O\ ^-T>VI?S+[P]I#NCSZBO0?\ AG?XJ_\ 1,O&
M/_@@N_\ XW1_PSO\5?\ HF7C'_P07?\ \;H]M2_F7WA[2'='GU%>@_\ #._Q
M5_Z)EXQ_\$%W_P#&Z/\ AG?XJ_\ 1,O&/_@@N_\ XW1[:E_,OO#VD.Z//J*]
M!_X9W^*O_1,O&/\ X(+O_P"-T?\ #._Q5_Z)EXQ_\$%W_P#&Z/;4OYE]X>TA
MW1Y]17H/_#._Q5_Z)EXQ_P#!!=__ !NC_AG?XJ_]$R\8_P#@@N__ (W1[:E_
M,OO#VD.Z//J*]!_X9W^*O_1,O&/_ ((+O_XW1_PSO\5?^B9>,?\ P07?_P ;
MH]M2_F7WA[2'='GU%>@_\,[_ !5_Z)EXQ_\ !!=__&Z/^&=_BK_T3+QC_P""
M"[_^-T>VI?S+[P]I#NCSZBO0?^&=_BK_ -$R\8_^""[_ /C='_#._P 5?^B9
M>,?_  07?_QNCVU+^9?>'M(=T>?45Z#_ ,,[_%7_ *)EXQ_\$%W_ /&Z/^&=
M_BK_ -$R\8_^""[_ /C='MJ7\R^\/:0[H\^HKT'_ (9W^*O_ $3+QC_X(+O_
M .-T?\,[_%7_ *)EXQ_\$%W_ /&Z/;4OYE]X>TAW1Y]17H/_  SO\5?^B9>,
M?_!!=_\ QNC_ (9W^*O_ $3+QC_X(+O_ .-T>VI?S+[P]I#NCSZBO0?^&=_B
MK_T3+QC_ .""[_\ C='_  SO\5?^B9>,?_!!=_\ QNCVU+^9?>'M(=T>?45Z
M#_PSO\5?^B9>,?\ P07?_P ;H_X9W^*O_1,O&/\ X(+O_P"-T>VI?S+[P]I#
MNCSZBO0?^&=_BK_T3+QC_P"""[_^-T?\,[_%7_HF7C'_ ,$%W_\ &Z/;4OYE
M]X>TAW1Y]17H/_#._P 5?^B9>,?_  07?_QNC_AG?XJ_]$R\8_\ @@N__C='
MMJ7\R^\/:0[H\^HKT'_AG?XJ_P#1,O&/_@@N_P#XW1_PSO\ %7_HF7C'_P $
M%W_\;H]M2_F7WA[2'='GU%>@_P##._Q5_P"B9>,?_!!=_P#QNC_AG?XJ_P#1
M,O&/_@@N_P#XW1[:E_,OO#VD.Z//J*]!_P"&=_BK_P!$R\8_^""[_P#C='_#
M._Q5_P"B9>,?_!!=_P#QNCVU+^9?>'M(=T>?45Z#_P ,[_%7_HF7C'_P07?_
M ,;H_P"&=_BK_P!$R\8_^""[_P#C='MJ7\R^\/:0[H\^HKT'_AG?XJ_]$R\8
M_P#@@N__ (W1_P ,[_%7_HF7C'_P07?_ ,;H]M2_F7WA[2'='GU%>@_\,[_%
M7_HF7C'_ ,$%W_\ &Z/^&=_BK_T3+QC_ .""[_\ C='MJ7\R^\/:0[H\^HKT
M'_AG?XJ_]$R\8_\ @@N__C='_#._Q5_Z)EXQ_P#!!=__ !NCVU+^9?>'M(=T
M>?45Z#_PSO\ %7_HF7C'_P $%W_\;H_X9W^*O_1,O&/_ ((+O_XW1[:E_,OO
M#VD.Z//J*]!_X9W^*O\ T3+QC_X(+O\ ^-T?\,[_ !5_Z)EXQ_\ !!=__&Z/
M;4OYE]X>TAW1Y]17H/\ PSO\5?\ HF7C'_P07?\ \;H_X9W^*O\ T3+QC_X(
M+O\ ^-T>VI?S+[P]I#NCSZBO0?\ AG?XJ_\ 1,O&/_@@N_\ XW1_PSO\5?\
MHF7C'_P07?\ \;H]M2_F7WA[2'='GU%>@_\ #._Q5_Z)EXQ_\$%W_P#&Z/\
MAG?XJ_\ 1,O&/_@@N_\ XW1[:E_,OO#VD.Z//J*]!_X9W^*O_1,O&/\ X(+O
M_P"-T?\ #._Q5_Z)EXQ_\$%W_P#&Z/;4OYE]X>TAW1Y]17H/_#._Q5_Z)EXQ
M_P#!!=__ !NC_AG?XJ_]$R\8_P#@@N__ (W1[:E_,OO#VD.Z//J*]!_X9W^*
MO_1,O&/_ ((+O_XW1_PSO\5?^B9>,?\ P07?_P ;H]M2_F7WA[2'='GU%>@_
M\,[_ !5_Z)EXQ_\ !!=__&Z/^&=_BK_T3+QC_P"""[_^-T>VI?S+[P]I#NCS
MZBO0?^&=_BK_ -$R\8_^""[_ /C='_#._P 5?^B9>,?_  07?_QNCVU+^9?>
M'M(=T>?45Z#_ ,,[_%7_ *)EXQ_\$%W_ /&Z/^&=_BK_ -$R\8_^""[_ /C=
M'MJ7\R^\/:0[H\^HKT'_ (9W^*O_ $3+QC_X(+O_ .-T?\,[_%7_ *)EXQ_\
M$%W_ /&Z/;4OYE]X>TAW1Y]17H/_  SO\5?^B9>,?_!!=_\ QNC_ (9W^*O_
M $3+QC_X(+O_ .-T>VI?S+[P]I#NCSZBO0?^&=_BK_T3+QC_ .""[_\ C='_
M  SO\5?^B9>,?_!!=_\ QNCVU+^9?>'M(=T>?45Z#_PSO\5?^B9>,?\ P07?
M_P ;H_X9W^*O_1,O&/\ X(+O_P"-T>VI?S+[P]I#NCSZBO0?^&=_BK_T3+QC
M_P"""[_^-T?\,[_%7_HF7C'_ ,$%W_\ &Z/;4OYE]X>TAW1Y]17H/_#._P 5
M?^B9>,?_  07?_QNC_AG?XJ_]$R\8_\ @@N__C='MJ7\R^\/:0[H\^HKT'_A
MG?XJ_P#1,O&/_@@N_P#XW1_PSO\ %7_HF7C'_P $%W_\;H]M2_F7WA[2'='G
MU%>@_P##._Q5_P"B9>,?_!!=_P#QNC_AG?XJ_P#1,O&/_@@N_P#XW1[:E_,O
MO#VD.Z//J*]!_P"&=_BK_P!$R\8_^""[_P#C='_#._Q5_P"B9>,?_!!=_P#Q
MNCVU+^9?>'M(=T>?45Z#_P ,[_%7_HF7C'_P07?_ ,;H_P"&=_BK_P!$R\8_
M^""[_P#C='MJ7\R^\/:0[H\^KZ%_8!B>3]K/P0RJ65!?,Q ^Z/L-P,G\2!^-
M<#:?LV_%B\N$AC^&GBU7<X!ET6XC7\69 !^)K[O_ &$OV.]=^$6KW/CCQM#'
M9:W+;&WL--20.]NC@%WD(X#$84*"<<YZXKS<PQ5&&&FN97::2]=#DQ5>G&E)
M7U:L?:M%%%?G)\F%5M.@:UT^U@?&^.)4;'3( %6:K:8TCZ;:--N\TQ(7W==V
M!G- %FBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH I:+_ ,@:P_Z]X_\ T$5=
MJEHO_(&L/^O>/_T$5=H BNK6&]MY+>XACN()%*O%*H96'H0>"*Y/2_@U\/\
M0]4&I:;X&\-:?J(;<+RUTBWBF!]=ZH#G\:[&BJ4FM$QIM;!1114B"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*^4O^$S\0?\ 0=U/_P #)/\ &C_A,_$'_0=U/_P,D_QH ^K:*^4O^$S\0?\
M0=U/_P #)/\ &C_A,_$'_0=U/_P,D_QH ^K:*^4O^$S\0?\ 0=U/_P #)/\
M&C_A,_$'_0=U/_P,D_QH ^K:*^4O^$S\0?\ 0=U/_P #)/\ &C_A,_$'_0=U
M/_P,D_QH ^K:*^4O^$S\0?\ 0=U/_P #)/\ &C_A,_$'_0=U/_P,D_QH ^K:
M*^4O^$S\0?\ 0=U/_P #)/\ &C_A,_$'_0=U/_P,D_QH ^K:*^4O^$S\0?\
M0=U/_P #)/\ &C_A,_$'_0=U/_P,D_QH ^K:*^4O^$S\0?\ 0=U/_P #)/\
M&C_A,_$'_0=U/_P,D_QH ^K:*^4O^$S\0?\ 0=U/_P #)/\ &C_A,_$'_0=U
M/_P,D_QH ^K:*^4O^$S\0?\ 0=U/_P #)/\ &C_A,_$'_0=U/_P,D_QH ^K:
M*^4O^$S\0?\ 0=U/_P #)/\ &C_A,_$'_0=U/_P,D_QH ^K:*^4O^$S\0?\
M0=U/_P #)/\ &C_A,_$'_0=U/_P,D_QH ^K:*^4O^$S\0?\ 0=U/_P #)/\
M&C_A,_$'_0=U/_P,D_QH ^K:*^4O^$S\0?\ 0=U/_P #)/\ &C_A,_$'_0=U
M/_P,D_QH ^K:*^4O^$S\0?\ 0=U/_P #)/\ &C_A,_$'_0=U/_P,D_QH ^K:
M*^4O^$S\0?\ 0=U/_P #)/\ &C_A,_$'_0=U/_P,D_QH ^K:*^4O^$S\0?\
M0=U/_P #)/\ &C_A,_$'_0=U/_P,D_QH ^K:*^4O^$S\0?\ 0=U/_P #)/\
M&C_A,_$'_0=U/_P,D_QH ^K:*^4O^$S\0?\ 0=U/_P #)/\ &C_A,_$'_0=U
M/_P,D_QH ^K:*^4O^$S\0?\ 0=U/_P #)/\ &C_A,_$'_0=U/_P,D_QH ^K:
M*^4O^$S\0?\ 0=U/_P #)/\ &C_A,_$'_0=U/_P,D_QH ^K:*^4O^$S\0?\
M0=U/_P #)/\ &C_A,_$'_0=U/_P,D_QH ^K:*^4O^$S\0?\ 0=U/_P #)/\
M&C_A,_$'_0=U/_P,D_QH ^K:*^4O^$S\0?\ 0=U/_P #)/\ &C_A,_$'_0=U
M/_P,D_QH ^K:*^4O^$S\0?\ 0=U/_P #)/\ &C_A,_$'_0=U/_P,D_QH ^K:
M*^4O^$S\0?\ 0=U/_P #)/\ &C_A,_$'_0=U/_P,D_QH ^K:*^4O^$S\0?\
M0=U/_P #)/\ &C_A,_$'_0=U/_P,D_QH ^K:*^4O^$S\0?\ 0=U/_P #)/\
M&C_A,_$'_0=U/_P,D_QH ^K:*^4O^$S\0?\ 0=U/_P #)/\ &C_A,_$'_0=U
M/_P,D_QH ^K:*^4O^$S\0?\ 0=U/_P #)/\ &C_A,_$'_0=U/_P,D_QH ^K:
M*^4O^$S\0?\ 0=U/_P #)/\ &C_A,_$'_0=U/_P,D_QH ^K:*^4O^$S\0?\
M0=U/_P #)/\ &C_A,_$'_0=U/_P,D_QH ^K:*^4O^$S\0?\ 0=U/_P #)/\
M&C_A,_$'_0=U/_P,D_QH ^K:*^4O^$S\0?\ 0=U/_P #)/\ &C_A,_$'_0=U
M/_P,D_QH ^K:*^4O^$S\0?\ 0=U/_P #)/\ &C_A,_$'_0=U/_P,D_QH ^K:
M*^4O^$S\0?\ 0=U/_P #)/\ &C_A,_$'_0=U/_P,D_QH ^K:*^4O^$S\0?\
M0=U/_P #)/\ &C_A,_$'_0=U/_P,D_QH ^K:*^4O^$S\0?\ 0=U/_P #)/\
M&C_A,_$'_0=U/_P,D_QH ^K:*^4O^$S\0?\ 0=U/_P #)/\ &C_A,_$'_0=U
M/_P,D_QH ^K:*^4O^$S\0?\ 0=U/_P #)/\ &C_A,_$'_0=U/_P,D_QH ^K:
M*^4O^$S\0?\ 0=U/_P #)/\ &C_A,_$'_0=U/_P,D_QH ^K:*^4O^$S\0?\
M0=U/_P #)/\ &C_A,_$'_0=U/_P,D_QH ^K:*^4O^$S\0?\ 0=U/_P #)/\
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !79_!]B/B)I0!(!$H/O\
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MDC8J2.XSQ6U0 4444 %%%% !115;4M3L]%T^YO\ 4+N"QL;:-I9[JYD$<42
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MUE;!&2.:>)W,I8'+?*#^N/I0 WX61)H/PSU;68%1KPI/,6(_YYJ=JGVR"?\
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M?'34_AI\<]+\+27,DGAKQ5+]AGM"WR)<L/W,RC^]N 0_[+GT%?L-7XA?L0>
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MYH,>IZ3_ &+.'N+^[>8H+7RB@6- B22M,TF%6,_+7E7[3'_(_?L-?]ANW_\
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MWOVXOC;H?P3^%.EW.I^"K#X@ZIK6LV^E:-H6IQQM;/>.'*22%U8*%"MR!G)
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M 'CE%>Q_\,\_]1__ ,DO_ME'_#//_4?_ /)+_P"V4 >.45['_P ,\_\ 4?\
M_)+_ .V4?\,\_P#4?_\ )+_[90!XY17L?_#//_4?_P#)+_[91_PSS_U'_P#R
M2_\ ME 'CE%>Q_\ #//_ %'_ /R2_P#ME'_#//\ U'__ "2_^V4 >.45['_P
MSS_U'_\ R2_^V4?\,\_]1_\ \DO_ +90!XY17L?_  SS_P!1_P#\DO\ [91_
MPSS_ -1__P DO_ME 'CE%>Q_\,\_]1__ ,DO_ME'_#//_4?_ /)+_P"V4 >.
M45['_P ,\_\ 4?\ _)+_ .V4?\,\_P#4?_\ )+_[90!XY17L?_#//_4?_P#)
M+_[91_PSS_U'_P#R2_\ ME 'CE%>Q_\ #//_ %'_ /R2_P#ME'_#//\ U'__
M "2_^V4 >.45['_PSS_U'_\ R2_^V4?\,\_]1_\ \DO_ +90!XY17L?_  SS
M_P!1_P#\DO\ [91_PSS_ -1__P DO_ME 'CE%>Q_\,\_]1__ ,DO_ME'_#//
M_4?_ /)+_P"V4 >.45['_P ,\_\ 4?\ _)+_ .V4?\,\_P#4?_\ )+_[90!X
MY17L?_#//_4?_P#)+_[91_PSS_U'_P#R2_\ ME 'CE%>Q_\ #//_ %'_ /R2
M_P#ME'_#//\ U'__ "2_^V4 >.45['_PSS_U'_\ R2_^V4?\,\_]1_\ \DO_
M +90!XY17L?_  SS_P!1_P#\DO\ [91_PSS_ -1__P DO_ME 'CE%>Q_\,\_
M]1__ ,DO_ME'_#//_4?_ /)+_P"V4 >.45['_P ,\_\ 4?\ _)+_ .V4?\,\
M_P#4?_\ )+_[90!XY17L?_#//_4?_P#)+_[91_PSS_U'_P#R2_\ ME 'CE%>
MQ_\ #//_ %'_ /R2_P#ME'_#//\ U'__ "2_^V4 >.45['_PSS_U'_\ R2_^
MV4?\,\_]1_\ \DO_ +90!XY17L?_  SS_P!1_P#\DO\ [91_PSS_ -1__P D
MO_ME 'CE%>Q_\,\_]1__ ,DO_ME'_#//_4?_ /)+_P"V4 >.45['_P ,\_\
M4?\ _)+_ .V4?\,\_P#4?_\ )+_[90!XY17L?_#//_4?_P#)+_[91_PSS_U'
M_P#R2_\ ME 'CE%>Q_\ #//_ %'_ /R2_P#ME'_#//\ U'__ "2_^V4 >.45
M['_PSS_U'_\ R2_^V4?\,\_]1_\ \DO_ +90!XY17L?_  SS_P!1_P#\DO\
M[91_PSS_ -1__P DO_ME 'CE%>Q_\,\_]1__ ,DO_ME'_#//_4?_ /)+_P"V
M4 >.45['_P ,\_\ 4?\ _)+_ .V4?\,\_P#4?_\ )+_[90!XY17L?_#//_4?
M_P#)+_[91_PSS_U'_P#R2_\ ME 'CE%>Q_\ #//_ %'_ /R2_P#ME'_#//\
MU'__ "2_^V4 >.45['_PSS_U'_\ R2_^V4?\,\_]1_\ \DO_ +90!XY17L?_
M  SS_P!1_P#\DO\ [91_PSS_ -1__P DO_ME 'CE%>Q_\,\_]1__ ,DO_ME'
M_#//_4?_ /)+_P"V4 >.45['_P ,\_\ 4?\ _)+_ .V4?\,\_P#4?_\ )+_[
M90!XY17L?_#//_4?_P#)+_[91_PSS_U'_P#R2_\ ME 'CE%>Q_\ #//_ %'_
M /R2_P#ME'_#//\ U'__ "2_^V4 >.45['_PSS_U'_\ R2_^V4?\,\_]1_\
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MC9SE0.#GZ4 34444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/)9B2:ZRBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "JZ6Y6^FGR-KQH@'<;
M2Y_]FJQ5:-9!J4['=Y)BC"\\;LOG_P!E_2@"S1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !5>PMS:6-M Q#-%&J$CH< "K%5M,61=-M%FW><(D#[CD[L#.: +-
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110!2T7_D#6'_7O'_Z"*NU2T7_ ) U
MA_U[Q_\ H(J[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45YG\:O%NM^"XM$O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MF:;!H^G6UC:IY=O;1K%&OHH&!5JLWPYH-OX8T2TTNU>62WMDV(TQ!<C)/)
M[^E:5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%07U[!IME<7=S((;:WC:661NBHHR2?
MH : %O+RWT^UEN;J>.VMXEW233.$1!ZDG@"N;T/XK>"?$VH_V?H_C'0-6O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
EBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>syre-20260630_g3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 syre-20260630_g3.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (L!,8# 2(  A$! Q$!_\0
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MBG_H9=8_\#Y?_BJ/^%A>*?\ H9=8_P# ^7_XJM_[*E_/^!Z/^I-7_G^ON?\
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M_G_ /]2:O_/]?<_\S];J*_)'_A87BG_H9=8_\#Y?_BJ/^%A>*?\ H9=8_P#
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M1]]T5\"?\);KG_09U#_P*D_QH_X2W7/^@SJ'_@5)_C1]6?</]<J7_/E_>O\
M(^^Z*X#X#W<]]\*-#GN9I+B=_/W22N68XGD R3ST%%<LERMH^]PU98FA"NE;
MF2?WJYW]%%%2=(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC17'?\+F^'__ $/7AK_P;V__ ,71_P +F^'_ /T/7AK_ ,&]O_\ %U7U:O\
MR/[F%UW.QHKCO^%S?#__ *'KPU_X-[?_ .+H_P"%S?#_ /Z'KPU_X-[?_P"+
MH^K5_P"1_<PNNYV-%<=_PN;X?_\ 0]>&O_!O;_\ Q='_  N;X?\ _0]>&O\
MP;V__P 71]6K_P C^YA==SL:*X[_ (7-\/\ _H>O#7_@WM__ (NC_A<WP_\
M^AZ\-?\ @WM__BZ/JU?^1_<PNNYV-%<=_P +F^'_ /T/7AK_ ,&]O_\ %T?\
M+F^'_P#T/7AK_P &]O\ _%T?5J_\C^YA==SL:*X[_A<WP_\ ^AZ\-?\ @WM_
M_BZ/^%S?#_\ Z'KPU_X-[?\ ^+H^K5_Y']S"Z[G8T5QW_"YOA_\ ]#UX:_\
M!O;_ /Q='_"YOA__ -#UX:_\&]O_ /%T?5J_\C^YA==SL:*X[_A<WP__ .AZ
M\-?^#>W_ /BZ/^%S?#__ *'KPU_X-[?_ .+H^K5_Y']S"Z[G8T5QW_"YOA__
M -#UX:_\&]O_ /%T?\+F^'__ $/7AK_P;V__ ,71]6K_ ,C^YA==SL:*X[_A
M<WP__P"AZ\-?^#>W_P#BZ/\ A<WP_P#^AZ\-?^#>W_\ BZ/JU?\ D?W,+KN=
MC17'?\+F^'__ $/7AK_P;V__ ,71_P +F^'_ /T/7AK_ ,&]O_\ %T?5J_\
M(_N877<[&BN._P"%S?#_ /Z'KPU_X-[?_P"+H_X7-\/_ /H>O#7_ (-[?_XN
MCZM7_D?W,+KN=C17'?\ "YOA_P#]#UX:_P#!O;__ !='_"YOA_\ ]#UX:_\
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MUX:_\&]O_P#%T?\ "YOA_P#]#UX:_P#!O;__ !='U:O_ "/[F%UW.QHKCO\
MA<WP_P#^AZ\-?^#>W_\ BZ/^%S?#_P#Z'KPU_P"#>W_^+H^K5_Y']S"Z[G8T
M5QW_  N;X?\ _0]>&O\ P;V__P 71_PN;X?_ /0]>&O_  ;V_P#\71]6K_R/
M[F%UW.QHKCO^%S?#_P#Z'KPU_P"#>W_^+H_X7-\/_P#H>O#7_@WM_P#XNCZM
M7_D?W,+KN=C17'?\+F^'_P#T/7AK_P &]O\ _%T?\+F^'_\ T/7AK_P;V_\
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M#C+=<Z_1GE&D:K=:%JUEJ5C*8+VSG2X@E SLD1@RG\"!7T!>_M?J9M3US3/
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M?_0I-_X,+3_X[5<^']G[.4TUZ_\ !-%6RIX9X2IB(RB[WO-=6WO>_7378J_
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M?\5?$W@V'Q9XBUN!+6U6/439QZ;", QQ@Q29RJ1KG@_*QR=YK"_X=[?M ?\
M1/V_\&]A_P#'Z/\ AWM^T!_T3]O_  ;V'_Q^LFLO?->4==_>^??3Y![Q/\8_
MVD_A?\7CXCU6X^",UIXRU='*^()_&E[<M;S$85Q"R!"J\ 1\*    !7COPA\
M>R?"[XI>%/%J"1AH^I07DL<6-TD2N#(@SQ\R;EZCKU%>M_\ #O;]H#_HG[?^
M#>P_^/T?\.]OV@/^B?M_X-[#_P"/UM"I@X0=-5%9]Y7_ #;%:6]C4_X*(^%D
MT[]HBY\46,RWFA>,-.M-9T^[A7]U(IB6)@K]&.8]_'02+ZY/,?\ #47_ !B=
M_P *4_X1G_E]^V?VY]O_ .GCSMOD>5_P'._WQVK3_P"'>W[0'_1/V_\ !O8?
M_'Z/^'>W[0'_ $3]O_!O8?\ Q^LX3PJIPISJQ?+:VJ6VW4=I7O8T_P!F?]LO
M3?@'\+]>\$:Q\.+7QWIFL:@U[.E]?K%"RF.-/+:)H) XS$#DGOTXI?C+^UC\
M.OB9\-M8\-Z%^S]X7\$:K>^3Y.O:<UL9[79,DC;=EI&WS*C(<..'/7H<O_AW
MM^T!_P!$_;_P;V'_ ,?H_P"'>W[0'_1/V_\ !O8?_'Z7^P>T]KSJ][_%U]+V
M#WK6,C]FS]IW_AGK0OB!IO\ PC7]O_\ "66"6/F_;_LWV7:LR[L>6^__ %W3
M*_=Z\\7?A-^UK=_!;X"^*_ GAC0YK#Q)X@N/.D\6PZD8YK=<(H6.-8@PPBN
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MGQ-XC_X4[\<=6UE-/74;>_A,\,:S>4'67!+[MK?Q*_;FN4_X9_\ 'W_0 /\
MX%P?_%T?\,_^/O\ H '_ ,"X/_BZ'R2=VR\/3S/#T53AAYW4E*+Y7H[6>C3O
M?3[C4\%_'&#PK;:_;77AN/5K?5[R2ZDAFN0$ ?JA!C8,/?CZ5'XG^+GAO7=
MO;"T^'FE:5<SIM2]@,>^(Y'(Q"#^HK/_ .&?_'W_ $ #_P"!<'_Q='_#/_C[
M_H '_P "X/\ XNE:E>]_Q+Y\[]E[%TI<MFOX?1[Z\MSBM$O8-,UBRN[JU%];
MP3)+):EMHE"D':3@X!Q@\5ZSXL^/.@^.$MTUOP.UY';Y,48UF6-5)[X1 "?<
MUS?_  S_ ./O^@ ?_ N#_P"+H_X9_P#'W_0 /_@7!_\ %U3=.3NW^)AAZ>;8
M6G*E2HRY9;IT[WMZQ8OACXKVV@6&MZ-<>'8=2\,ZC.TR:9+<LK0 D$*)<$G
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MA'P?8_#[P;\3/#6FO/+8Z5X_U6TBDNI3+-($6 ;W<\LQZDGJ2:^EZ "BBB@
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M 4444 %%%% !1110 4444 %%%% !1110 4444 9=A_R'-5^D/_H)K4K+L/\
MD.:K](?_ $$UJ4V 444UY%C&68*/<T@'45!]N@'\?Z&D^W0?W_T-!/-'N6**
MK_;H/[_Z&C[=!_?_ $- <T>Y8HJO]N@_O_H:/MT']_\ 0T!S1[EBBJ_VZ#^_
M^AH^W0?W_P!#0'-'N6**K_;H/[_Z&C[=!_?_ $- <T>Y8HJO]N@_O_H:/MT'
M]_\ 0T!S1[EBBJ_VZ#^_^AH^W0?W_P!#0'-'N6**K_;H/[_Z&C[=!_?_ $-
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MW,Z[X'\9^*+\WVLZ]I&KWI4(;F^\8:?-)M'0;FN2<#TK/_X5)KO_ #]^'/\
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MS_PJ-,_^2*/K-#^=?>@Y7V.,HKL_^%2:[_S]^'/_  J-,_\ DBC_ (5)KO\
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M/_!3=_\ QJ@#=HK"_P"$RT__ )XZI_X*;O\ ^-4?\)EI_P#SQU3_ ,%-W_\
M&J /"?C?^PC\*OB5X4\?3Z9X!\.P>/=?LM0>UUN[1UV:E/'(4N'9=Q&)7#DA
M2>N >E:.C?L+_!;_ (0[PYI.N?#?P_J%QI5DL&[RF9!(?FE*DD'#2%FY ZU[
M+_PF6G_\\=4_\%-W_P#&J/\ A,M/_P">.J?^"F[_ /C5 'CG[+_[)GAW]G75
MO'&J6.A:-8:AK.M7<EA<:7O+0Z4[1M!;/N P5*$E1D#C#&OH"L+_ (3+3_\
MGCJG_@IN_P#XU1_PF6G_ //'5/\ P4W?_P :H W:*PO^$RT__GCJG_@IN_\
MXU1_PF6G_P#/'5/_  4W?_QJ@#=HK"_X3+3_ /GCJG_@IN__ (U1_P )EI__
M #QU3_P4W?\ \:H W:*PO^$RT_\ YXZI_P""F[_^-4?\)EI__/'5/_!3=_\
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M1U2<;[;2?+=6;Z]'9VZ![)K<^7Z***^C,0HHHH **** "BBB@ HHHH ****
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M #QU3_P4W?\ \:H_X3+3_P#GCJG_ (*;O_XU0!NT5A?\)EI__/'5/_!3=_\
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M_P""F[_^-4 ;M%87_"9:?_SQU3_P4W?_ ,:H_P"$RT__ )XZI_X*;O\ ^-4
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M %%%% !1110 4444 %%%% &78?\ (>U7_=A_DU:E9=A_R'M5_P!V'^35J4V
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MRS2!%@&]W/+,>I)ZDFOI>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4:9_\D4?6:'\Z^]!ROL<9179_P#"I-=_Y^_#G_A4:9_\D4?\*DUW_G[\.?\
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M_P :H_X3+3_^>.J?^"F[_P#C5 &[16%_PF6G_P#/'5/_  4W?_QJC_A,M/\
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M #QU3_P4W?\ \:H_X3+3_P#GCJG_ (*;O_XU0!NT5A?\)EI__/'5/_!3=_\
MQJC_ (3+3_\ GCJG_@IN_P#XU0!NT5A?\)EI_P#SQU3_ ,%-W_\ &J/^$RT_
M_GCJG_@IN_\ XU0!NT5A?\)EI_\ SQU3_P %-W_\:H_X3+3_ /GCJG_@IN__
M (U0!NT5A?\ "9:?_P \=4_\%-W_ /&J/^$RT_\ YXZI_P""F[_^-4 6;#_D
M/:K_ +L/\FK4KC['QCIXUS5#Y.IX*P_\PFZ]&_Z9UI_\)EI__/'5/_!3=_\
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M^&/QIU:TU3QSX*TOQ-J%I!]F@N+^,LT<6XMM&".,L3^-=;_PF6G_ //'5/\
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M.X_DE?0U?A.;_P#(PK?XF>I3^!!1117D&@4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!EV'_(>
MU7_=A_DU:E9=A_R'M5_W8?Y-6I38!1112 **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH R[#_D.
M:K](?_036I678?\ (<U7Z0_^@FM2FP,F^_X^G_#^55ZL7W_'T_X?RJO3.&7Q
M,****9(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MM:SOJN6]K?>Q>TDSNOC+XM\*^,O&3WW@_P -+X9T=84A6#@-,RC'F,BDHA(
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MAJ^>?V%O^2%K_P!A.X_DE?0U?A.;_P#(PK?XF>I3^!!1117D&@4444 %%%%
M!1110 4444 %%%% !7S]XV_:9\3P?$3Q7X5^'7PON?B%_P (A#"_B"^.L1:>
MD,LL0F2VM@Z/]HF\LABN4 ) +9-?0-?#FF?#SQ7\?/C3^T'JW@GXA77P<6VU
M!?"VH6FG6J7,VJ306L>V_G\UL0@I($1H!&Y5"2^10![#KO[7NG7O@OX8ZGX
M\-7?CC7_ (CK))H&B-=1V/[N*/S+F2YF8,(DA&%8@.=Q  .:BL/VOH++P/\
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M %%%% !1110 4444 9=A_P A[5?]V'^35J5EV'_(>U7_ '8?Y-6I38!1112
M**** "BBB@ HHHH **** "BBB@ HHKY(_;!\#Z9\/O">M>-H?&/Q,D\4:U>Q
M:;H7A[1_&E]9VMSJ=P?+MX(X8Y%5$W#<P7'RJQZT ?6]%?.UGX#^,WPG^ 7A
M#P7X+UR/QOX[F?R=7\8^-=1DN%L=X9Y;@*Q,DX1B$BCSP-N[(!KA/!?CGQ\W
M_!.:#Q';:YJNL>-!:S?:=;4-/>^4-2>.YG08<EX[?S60 '&Q0, # !]B45\7
M>"/C7>>%])^)5MX \1ZA\0= O;[3-%^'VHZSJ$NI?:M8N8'^T1BZEW/-! 5C
MG<EFV 3#C;BOK/P'X9F\&>"]$T.YU:^UZZL+2.";5-2F::XNY HWRR,Q))9L
MGT&<#  H WJ*** "BBB@ HHHH **** "BBB@ HHHH **** ,NP_Y#FJ_2'_T
M$UJ5EV'_ "'-5^D/_H)K4IL#)OO^/I_P_E5>K%]_Q]/^'\JKTSAE\3"BBBF2
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% &GIO^H;_>_H*MU4TW_4-_O?T%6ZEG;#X45;3_CXO?\ KL/_ $6E
M%%I_Q\7O_78?^BTHI%GPI_P4$_Y*AX>_[ R_^CY:^7*^H_\ @H)_R5#P]_V!
ME_\ 1\M?+E?N.1_\BZCZ?J>95^-A1117N&04444 %>N_LW7"6NL^.)Y;:*\B
MC\'ZJ[6TY<1R@1 E&*,K8/0[6!YX(/->15HZ#XDU?PM??;=%U2]TB\V&/[18
M7#P2;3C*[E(.#@<>U<V)I.O1E374J+L[FEKGBK3-6L&M[7P=HFBS%@1=V,U\
MT@ [ 37,B8/^[GTQ7TCXCLYY/CU\=;E89&MX_!]WOE"G:N^T@*9/3Y@"1ZX-
M?.6K?%/QIKVGS6&I^+]>U&QF $MK=ZG-+%( 00&5F(/(!Y]*B;XD>+7TE-+;
MQ3K3:8D!M5LCJ$QA6$KM,83=@)MXVXQCBO/K8.I5LU9:-;M[N+O=_P"';SN4
MI)'T^=4N-4^-'@+0;JYDN;"'PC;7MAHTC%K6?4$L7:%WB/RLX/1CS\JC/05S
M?PIUC6/&FE:-JOC2ZGU'4+'Q]I$&DWNH,SW*RO*#=6X9N1&%$3>6, 'G'-?.
M-WX@U2_O+:[NM2N[F[M4CC@GFG9I(53[BHQ.5"]@.G:NBTSXJ:^/&WAKQ%KV
MJ:EXF?1+Z&\BAU&^DD)"2*Y16?=LW;0,@'Z'%<DLKE&GRQ:O9>MU=Z?XKV?Z
M]*4]3W9;^_\ &<GQ2T[XBW$Z^'=.U>RAMFNUVQZ=)]M6,1P9XB!@+@A?X?F/
MK5SQU?Q7>M_%?PY<R>(=6TS3--N#!X?DTNWMM-T<1 "TG@=KL[%"[<>7&&D6
M0G:<XKYU\=?$G7_'^H7,FI:MJ5SI[7,EQ;:==WLD\5J&)PJ!C@;0=O ' Z"J
M-]XY\2:GH<&BWGB#5;O1X JQ:?/>R/;QA1A0L9;:,#I@<40RRI=2NEMHME\.
MJ\_=Z6WWTU.=&)1117TAB%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^B7["W_)
M"U_["=Q_)*^AJ^>?V%O^2%K_ -A.X_DE?0U?A.;_ /(PK?XF>I3^!!1117D&
M@4444 %%%% !1110 4444 %%%% !7DGQ&_9/^%/Q8\2S>(/$OA..ZUFXB6&Z
MN[.]N;)KR-1@)<""1!.H QMD##''3BO6Z^9OVG?VOKSX.:O'X=\)^$K[Q'K<
M%UIHU?4[BU==*TFVNKJ*!&DE!7?*YE4)&ASSN;A2" >I>,?V=/AMX\\&Z+X5
MUCPC82:'HFTZ5;V>^T?3BH !MY861X3@#E&&<<UH_"SX+>"O@KI5WI_@S08=
M&AO9OM%W-YDD]Q=2_P!^:>5FDE;DX+L<9-<W\:O'/Q'TGQ#X4\*_#7PQ::AJ
MFMFXENO$6NPSMI&D00A"?.\K#/+(7 CC#KG:QS@5Y7-^U=XV\!Z/\5]$\;^'
MM$N?'G@F+39K6XT229-+U./4)?(MI"K[Y80DG^L4EL $AL<T ?16D?#GPWH:
M>)%M=*BQXDNI+S5_M#-.;V5XUC;S#(6ROEHJ!/NJJA0 !BL;X8_ OP1\'&OG
M\):*VGRWB10RS3WEQ=R^3'GRH5>>1V2)-S;8E(1=QPHS7F^C_M%ZUX(M?BM8
M?$B'2[[6? =O8WGVGPU;S00ZH+R-S;V\4,KR,L[2QF(+O;<7C/&[%>S^ YO$
M5SX+T2;Q;%8V_B:6TCDU&#3586\4Y4%TCW,Q(4G;DGG&>,X !O4444 %%%%
M!1110 4444 %%%% !1110 4444 9=A_R'M5_W8?Y-6I678?\A[5?]V'^35J4
MV 4444@"BBB@ HHHH **** "BBB@ HHHH *^??B;X5U;Q[^U[\)(9])O9?"/
MA/2M3\12WIMG-DVH/Y=K;QM)C9YJ+)-(J9W#EL8&:^@J* "O$_V,?#^J>%OV
M:O!^EZUIMYI&IP?;/-LK^!H)H]UY.R[D8 C*D$9'((/>O;** /FWQ_X1\9_%
MGQ+\3=?TRTO=(NO#'A_4/#_@3[8C6YEU:>V<3ZDFX<*&:&".3&,+.1E7!//?
MLB^##H'Q"O[OPOX*U[P!X('A:PL]3T_7;&6R:[UU97,LZQR8,KB,A9+A1ME)
M7#/MX^LZ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#+L/^0YJOTA_]
M!-:E9=A_R'-5^D/_ *":U*; R;[_ (^G_#^55ZL7W_'T_P"'\JKTSAE\3"BB
MBF2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% &GIO^H;_ 'OZ"K=5--_U#?[W]!5NI9VP^%%6T_X^+W_KL/\
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M]IXM\:>&=:O]"$EEI%G8V4VG-<@B[2W !RQ3Y0X'(VG&>]5;KXJ:I<?%UOB
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M9(#;)?WDUT(&?>8P[EMN[ SC.,X&?05F5[L.;E7-OU,F%%%%6 4444 %%%%
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M8?\ (<U7Z0_^@FM2FP,F^_X^G_#^55ZL7W_'T_X?RJO3.&7Q,****9(4444
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M=--UBZ\4V&M:K<0WD&M7'AK1)K9D2*XOXHII"958,?+/EQC"G.9 ,UYYX"\
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M2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-:E-@9-]_P ?3_A_*J]6+[_CZ?\ #^55Z9PR^)A1113)"BBB@ HHHH ****
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M'_(RT*/_  C&L?\ 0)OO_ 9_\*/^$8UC_H$WW_@,_P#A5[_A8?BK_H9M8_\
M ^7_ .*H_P"%A^*O^AFUC_P/E_\ BJ+U^R_'_(-"C_PC&L?] F^_\!G_ ,*/
M^$8UC_H$WW_@,_\ A5[_ (6'XJ_Z&;6/_ ^7_P"*H_X6'XJ_Z&;6/_ ^7_XJ
MB]?LOQ_R#0H_\(QK'_0)OO\ P&?_  H_X1C6/^@3??\ @,_^%7O^%A^*O^AF
MUC_P/E_^*H_X6'XJ_P"AFUC_ ,#Y?_BJ+U^R_'_(-"C_ ,(QK'_0)OO_  &?
M_"C_ (1C6/\ H$WW_@,_^%7O^%A^*O\ H9M8_P# ^7_XJC_A8?BK_H9M8_\
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M/_@.G^%'_"-:/_T"K'_P'3_"@"?^UK'_ )_+?_OZO^-']K6/_/Y;_P#?U?\
M&H/^$:T?_H%6/_@.G^%'_"-:/_T"K'_P'3_"@"?^UK'_ )_+?_OZO^-']K6/
M_/Y;_P#?U?\ &H/^$:T?_H%6/_@.G^%'_"-:/_T"K'_P'3_"@"?^UK'_ )_+
M?_OZO^-']K6/_/Y;_P#?U?\ &H/^$:T?_H%6/_@.G^%'_"-:/_T"K'_P'3_"
M@"?^UK'_ )_+?_OZO^-']K6/_/Y;_P#?U?\ &H/^$:T?_H%6/_@.G^%'_"-:
M/_T"K'_P'3_"@"?^UK'_ )_+?_OZO^-']K6/_/Y;_P#?U?\ &H/^$:T?_H%6
M/_@.G^%'_"-:/_T"K'_P'3_"@"?^UK'_ )_+?_OZO^-']K6/_/Y;_P#?U?\
M&H/^$:T?_H%6/_@.G^%'_"-:/_T"K'_P'3_"@"?^UK'_ )_+?_OZO^-']K6/
M_/Y;_P#?U?\ &H/^$:T?_H%6/_@.G^%'_"-:/_T"K'_P'3_"@"?^UK'_ )_+
M?_OZO^-']K6/_/Y;_P#?U?\ &H/^$:T?_H%6/_@.G^%'_"-:/_T"K'_P'3_"
M@"?^UK'_ )_+?_OZO^-']K6/_/Y;_P#?U?\ &H/^$:T?_H%6/_@.G^%'_"-:
M/_T"K'_P'3_"@"?^UK'_ )_+?_OZO^-']K6/_/Y;_P#?U?\ &H/^$:T?_H%6
M/_@.G^%'_"-:/_T"K'_P'3_"@"?^UK'_ )_+?_OZO^-']K6/_/Y;_P#?U?\
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MUK'_ )_+?_OZO^-0?\(UH_\ T"K'_P !T_PH_P"$:T?_ *!5C_X#I_A0!/\
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M_P !T_PH G_M:Q_Y_+?_ +^K_C1_:UC_ ,_EO_W]7_&H/^$:T?\ Z!5C_P"
MZ?X4?\(UH_\ T"K'_P !T_PH G_M:Q_Y_+?_ +^K_C1_:UC_ ,_EO_W]7_&H
M/^$:T?\ Z!5C_P" Z?X4?\(UH_\ T"K'_P !T_PH G_M:Q_Y_+?_ +^K_C1_
M:UC_ ,_EO_W]7_&H/^$:T?\ Z!5C_P" Z?X4?\(UH_\ T"K'_P !T_PH G_M
M:Q_Y_+?_ +^K_C1_:UC_ ,_EO_W]7_&H/^$:T?\ Z!5C_P" Z?X4?\(UH_\
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MP,# QQ@>E<7^S]XYT_X;_&'PUXAU5G33K6:1)Y(T+E$DB>(O@<D+OR0,G .
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M,DF]@A)/( <@%2?O5X9\(KVWTWXL>"KR\N(K6TM];LI9IYW"1QHLZ%F9CP
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M+U^R_'_(-"C_ ,(QK'_0)OO_  &?_"C_ (1C6/\ H$WW_@,_^%7O^%A^*O\
MH9M8_P# ^7_XJC_A8?BK_H9M8_\  ^7_ .*HO7[+\?\ (-"C_P (QK'_ $";
M[_P&?_"C_A&-8_Z!-]_X#/\ X5>_X6'XJ_Z&;6/_  /E_P#BJ/\ A8?BK_H9
MM8_\#Y?_ (JB]?LOQ_R#0H_\(QK'_0)OO_ 9_P#"C_A&-8_Z!-]_X#/_ (5>
M_P"%A^*O^AFUC_P/E_\ BJ/^%A^*O^AFUC_P/E_^*HO7[+\?\@T*/_",:Q_T
M";[_ ,!G_P */^$8UC_H$WW_ (#/_A5[_A8?BK_H9M8_\#Y?_BJ/^%A^*O\
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M7::C9/>VKV4\D=JV]H6*EE#;<KG: 2N"02,X8@P_\+#\5?\ 0S:Q_P"!\O\
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M'_A&-8_Z!-]_X#/_ (4?\(QK'_0)OO\ P&?_  J]_P +#\5?]#-K'_@?+_\
M%4?\+#\5?]#-K'_@?+_\51>OV7X_Y!H4?^$8UC_H$WW_ (#/_A1_PC&L?] F
M^_\  9_\*O?\+#\5?]#-K'_@?+_\51_PL/Q5_P!#-K'_ ('R_P#Q5%Z_9?C_
M )!H4?\ A&-8_P"@3??^ S_X4?\ ",:Q_P! F^_\!G_PJ]_PL/Q5_P!#-K'_
M ('R_P#Q5'_"P_%7_0S:Q_X'R_\ Q5%Z_9?C_D&A1_X1C6/^@3??^ S_ .%'
M_",:Q_T";[_P&?\ PJ]_PL/Q5_T,VL?^!\O_ ,51_P +#\5?]#-K'_@?+_\
M%47K]E^/^0:%'_A&-8_Z!-]_X#/_ (4?\(QK'_0)OO\ P&?_  J]_P +#\5?
M]#-K'_@?+_\ %4?\+#\5?]#-K'_@?+_\51>OV7X_Y!H4?^$8UC_H$WW_ (#/
M_A1_PC&L?] F^_\  9_\*O?\+#\5?]#-K'_@?+_\51_PL/Q5_P!#-K'_ ('R
M_P#Q5%Z_9?C_ )!H?>?[%"G1O@A'%?@V,K:E<$)<_NV(PG.#BO>O[6L?^?RW
M_P"_J_XUX-^QJ[>*_@I%<ZVQUBX34;A5FOSY[J,)P"^3BO<O^$:T?_H%6/\
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M JQ_\!T_PH_X1K1_^@58_P#@.G^% $_]K6/_ #^6_P#W]7_&C^UK'_G\M_\
MOZO^-0?\(UH__0*L?_ =/\*/^$:T?_H%6/\ X#I_A0!/_:UC_P _EO\ ]_5_
MQH_M:Q_Y_+?_ +^K_C4'_"-:/_T"K'_P'3_"C_A&M'_Z!5C_ . Z?X4 3_VM
M8_\ /Y;_ /?U?\:/[6L?^?RW_P"_J_XU!_PC6C_] JQ_\!T_PH_X1K1_^@58
M_P#@.G^% $_]K6/_ #^6_P#W]7_&C^UK'_G\M_\ OZO^-0?\(UH__0*L?_ =
M/\*/^$:T?_H%6/\ X#I_A0!/_:UC_P _EO\ ]_5_QH_M:Q_Y_+?_ +^K_C4'
M_"-:/_T"K'_P'3_"C_A&M'_Z!5C_ . Z?X4 3_VM8_\ /Y;_ /?U?\:/[6L?
M^?RW_P"_J_XU!_PC6C_] JQ_\!T_PH_X1K1_^@58_P#@.G^% $_]K6/_ #^6
M_P#W]7_&C^UK'_G\M_\ OZO^-0?\(UH__0*L?_ =/\*/^$:T?_H%6/\ X#I_
MA0!3L=5LO[=U3_3+?[L/_+5?1O>M/^UK'_G\M_\ OZO^-8ECX;T@Z[J@_LJR
MP%A_Y=T]&]JU/^$:T?\ Z!5C_P" Z?X4V!/_ &M8_P#/Y;_]_5_QH_M:Q_Y_
M+?\ [^K_ (U!_P (UH__ $"K'_P'3_"C_A&M'_Z!5C_X#I_A2 G_ +6L?^?R
MW_[^K_C1_:UC_P _EO\ ]_5_QJ#_ (1K1_\ H%6/_@.G^%'_  C6C_\ 0*L?
M_ =/\* )_P"UK'_G\M_^_J_XT?VM8_\ /Y;_ /?U?\:@_P"$:T?_ *!5C_X#
MI_A1_P (UH__ $"K'_P'3_"@"?\ M:Q_Y_+?_OZO^-']K6/_ #^6_P#W]7_&
MH/\ A&M'_P"@58_^ Z?X4?\ "-:/_P! JQ_\!T_PH G_ +6L?^?RW_[^K_C1
M_:UC_P _EO\ ]_5_QJ#_ (1K1_\ H%6/_@.G^%'_  C6C_\ 0*L?_ =/\* )
M_P"UK'_G\M_^_J_XT?VM8_\ /Y;_ /?U?\:@_P"$:T?_ *!5C_X#I_A1_P (
MUH__ $"K'_P'3_"@"?\ M:Q_Y_+?_OZO^-']K6/_ #^6_P#W]7_&H/\ A&M'
M_P"@58_^ Z?X4?\ "-:/_P! JQ_\!T_PH G_ +6L?^?RW_[^K_C1_:UC_P _
MEO\ ]_5_QJ#_ (1K1_\ H%6/_@.G^%'_  C6C_\ 0*L?_ =/\* )_P"UK'_G
M\M_^_J_XT?VM8_\ /Y;_ /?U?\:@_P"$:T?_ *!5C_X#I_A1_P (UH__ $"K
M'_P'3_"@"?\ M:Q_Y_+?_OZO^-']K6/_ #^6_P#W]7_&H/\ A&M'_P"@58_^
M Z?X4?\ "-:/_P! JQ_\!T_PH G_ +6L?^?RW_[^K_C1_:UC_P _EO\ ]_5_
MQJ#_ (1K1_\ H%6/_@.G^%'_  C6C_\ 0*L?_ =/\* )_P"UK'_G\M_^_J_X
MT?VM8_\ /Y;_ /?U?\:@_P"$:T?_ *!5C_X#I_A1_P (UH__ $"K'_P'3_"@
M"?\ M:Q_Y_+?_OZO^-']K6/_ #^6_P#W]7_&H/\ A&M'_P"@58_^ Z?X4?\
M"-:/_P! JQ_\!T_PH G_ +6L?^?RW_[^K_C1_:UC_P _EO\ ]_5_QJ#_ (1K
M1_\ H%6/_@.G^%'_  C6C_\ 0*L?_ =/\* )_P"UK'_G\M_^_J_XT?VM8_\
M/Y;_ /?U?\:@_P"$:T?_ *!5C_X#I_A1_P (UH__ $"K'_P'3_"@"?\ M:Q_
MY_+?_OZO^-']K6/_ #^6_P#W]7_&H/\ A&M'_P"@58_^ Z?X4?\ "-:/_P!
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M('RYZU-X1^+=WXL^$O@*S\)?%'0/A[J&CPIINLVFO?9PTB(J*LL7FJ=Q 4D
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MB@ HHHH **** /GW]L+6/B_9> =2@^&)TO0K"/1[^^U?Q7?2EKFP2&+>L5I
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MFM2FP,F^_P"/I_P_E5>K%]_Q]/\ A_*J],X9?$PHHHIDA1110 4444 %%%%
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M'_A&-8_Z!-]_X#/_ (4?\(QK'_0)OO\ P&?_  J]_P +#\5?]#-K'_@?+_\
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MM8_\#Y?_ (JC_A8?BK_H9M8_\#Y?_BJ+U^R_'_(-"C_PC&L?] F^_P# 9_\
M"C_A&-8_Z!-]_P" S_X5>_X6'XJ_Z&;6/_ ^7_XJC_A8?BK_ *&;6/\ P/E_
M^*HO7[+\?\@T*/\ PC&L?] F^_\  9_\*/\ A&-8_P"@3??^ S_X5>_X6'XJ
M_P"AFUC_ ,#Y?_BJ/^%A^*O^AFUC_P #Y?\ XJB]?LOQ_P @T*/_  C&L?\
M0)OO_ 9_\*/^$8UC_H$WW_@,_P#A5[_A8?BK_H9M8_\  ^7_ .*H_P"%A^*O
M^AFUC_P/E_\ BJ+U^R_'_(-"C_PC&L?] F^_\!G_ ,*/^$8UC_H$WW_@,_\
MA5[_ (6'XJ_Z&;6/_ ^7_P"*H_X6'XJ_Z&;6/_ ^7_XJB]?LOQ_R#0H_\(QK
M'_0)OO\ P&?_  H_X1C6/^@3??\ @,_^%7O^%A^*O^AFUC_P/E_^*H_X6'XJ
M_P"AFUC_ ,#Y?_BJ+U^R_'_(-"C_ ,(QK'_0)OO_  &?_"C_ (1C6/\ H$WW
M_@,_^%7O^%A^*O\ H9M8_P# ^7_XJC_A8?BK_H9M8_\  ^7_ .*HO7[+\?\
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M"?\ M:Q_Y_+?_OZO^-']K6/_ #^6_P#W]7_&H/\ A&M'_P"@58_^ Z?X4?\
M"-:/_P! JQ_\!T_PH G_ +6L?^?RW_[^K_C1_:UC_P _EO\ ]_5_QJ#_ (1K
M1_\ H%6/_@.G^%'_  C6C_\ 0*L?_ =/\* )_P"UK'_G\M_^_J_XT?VM8_\
M/Y;_ /?U?\:@_P"$:T?_ *!5C_X#I_A1_P (UH__ $"K'_P'3_"@"?\ M:Q_
MY_+?_OZO^-']K6/_ #^6_P#W]7_&H/\ A&M'_P"@58_^ Z?X4?\ "-:/_P!
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M?^?RW_[^K_C1_:UC_P _EO\ ]_5_QJ#_ (1K1_\ H%6/_@.G^%'_  C6C_\
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M'_"-:/\ ] JQ_P# =/\ "C_A&M'_ .@58_\ @.G^% $_]K6/_/Y;_P#?U?\
M&C^UK'_G\M_^_J_XU!_PC6C_ /0*L?\ P'3_  H_X1K1_P#H%6/_ (#I_A0!
M/_:UC_S^6_\ W]7_ !H_M:Q_Y_+?_OZO^-0?\(UH_P#T"K'_ ,!T_P */^$:
MT?\ Z!5C_P" Z?X4 3_VM8_\_EO_ -_5_P :/[6L?^?RW_[^K_C4'_"-:/\
M] JQ_P# =/\ "C_A&M'_ .@58_\ @.G^% $_]K6/_/Y;_P#?U?\ &C^UK'_G
M\M_^_J_XU!_PC6C_ /0*L?\ P'3_  H_X1K1_P#H%6/_ (#I_A0!/_:UC_S^
M6_\ W]7_ !H_M:Q_Y_+?_OZO^-0?\(UH_P#T"K'_ ,!T_P */^$:T?\ Z!5C
M_P" Z?X4 3_VM8_\_EO_ -_5_P :/[6L?^?RW_[^K_C4'_"-:/\ ] JQ_P#
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M+>:]MKC[39:C(IE%IAV \Y'<0 [A\^2#G<<MX"G%\KGJD[V\E?0#[;U?XY>
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M\N4X32K>1,EF;^%RC!MQX12#R2HKBP].$ZSC&/,O-VMW;M_F(WM4_;2\/O\
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MP[I7BCXSQ6.LZ99ZO9&PG<VU];I-'N&W!VL",CUKL/\ @H)_R5#P]_V!E_\
M1\M<?^QKXBTKPO\ &>*^UG4[/2+(6$Z&YOKA(8]QVX&YB!D^E?KM#F_L#W-^
M1[;]3SY?Q3ZDTOP+::[K-UI?B3]G[PYX:\-/'.LVNQ7EBS(@5L,%B19$+8'*
ML"N<YXKY%\%_!_PEXQEUB[N/B#;:#IBZF;#2+3[(U_J=\"^(V^RQE9.0R $+
MR<\#'/TMX5@TKP9XZ7Q3J7[2L&NZ1:O/<2:&^I"2.1&1P$"_:7W;=P( 0DE1
M@ XQSGAKX@^'?$WP\\70^!_&FC?#77]2\1W-U?7>JR+;S7%E(\A7RF/S!@C
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MR90, 6C)X+&KY_8LLKOQ!KWAO3/B387GBC2X%N3ILFG21J(V"E3))O8(23R
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MZ]>ZAIWA.&]_X2Z>P)T:66-A;^0UP&!-R2/-,6!\AW9[5\-ZQ\";;XF^#9_
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M .*K]JR7VW]GT>5*UO/N>;5MSLH_\(QK'_0)OO\ P&?_  H_X1C6/^@3??\
M@,_^%7O^%A^*O^AFUC_P/E_^*H_X6'XJ_P"AFUC_ ,#Y?_BJ]N]?LOQ_R,M"
MC_PC&L?] F^_\!G_ ,*/^$8UC_H$WW_@,_\ A5[_ (6'XJ_Z&;6/_ ^7_P"*
MH_X6'XJ_Z&;6/_ ^7_XJB]?LOQ_R#0H_\(QK'_0)OO\ P&?_  H_X1C6/^@3
M??\ @,_^%7O^%A^*O^AFUC_P/E_^*H_X6'XJ_P"AFUC_ ,#Y?_BJ+U^R_'_(
M-"C_ ,(QK'_0)OO_  &?_"C_ (1C6/\ H$WW_@,_^%7O^%A^*O\ H9M8_P#
M^7_XJC_A8?BK_H9M8_\  ^7_ .*HO7[+\?\ (-"C_P (QK'_ $";[_P&?_"C
M_A&-8_Z!-]_X#/\ X5>_X6'XJ_Z&;6/_  /E_P#BJ/\ A8?BK_H9M8_\#Y?_
M (JB]?LOQ_R#0H_\(QK'_0)OO_ 9_P#"C_A&-8_Z!-]_X#/_ (5>_P"%A^*O
M^AFUC_P/E_\ BJ/^%A^*O^AFUC_P/E_^*HO7[+\?\@T*/_",:Q_T";[_ ,!G
M_P */^$8UC_H$WW_ (#/_A5[_A8?BK_H9M8_\#Y?_BJ/^%A^*O\ H9M8_P#
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M_P #Y?\ XJC_ (6'XJ_Z&;6/_ ^7_P"*HO7[+\?\@T*/_",:Q_T";[_P&?\
MPH_X1C6/^@3??^ S_P"%7O\ A8?BK_H9M8_\#Y?_ (JC_A8?BK_H9M8_\#Y?
M_BJ+U^R_'_(-"C_PC&L?] F^_P# 9_\ "C_A&-8_Z!-]_P" S_X5>_X6'XJ_
MZ&;6/_ ^7_XJC_A8?BK_ *&;6/\ P/E_^*HO7[+\?\@T*/\ PC&L?] F^_\
M 9_\*/\ A&-8_P"@3??^ S_X5>_X6'XJ_P"AFUC_ ,#Y?_BJ/^%A^*O^AFUC
M_P #Y?\ XJB]?LOQ_P @T*/_  C&L?\ 0)OO_ 9_\*/^$8UC_H$WW_@,_P#A
M5[_A8?BK_H9M8_\  ^7_ .*H_P"%A^*O^AFUC_P/E_\ BJ+U^R_'_(-"C_PC
M&L?] F^_\!G_ ,*/^$8UC_H$WW_@,_\ A5[_ (6'XJ_Z&;6/_ ^7_P"*H_X6
M'XJ_Z&;6/_ ^7_XJB]?LOQ_R#0H_\(QK'_0)OO\ P&?_  H_X1C6/^@3??\
M@,_^%7O^%A^*O^AFUC_P/E_^*H_X6'XJ_P"AFUC_ ,#Y?_BJ+U^R_'_(-"C_
M ,(QK'_0)OO_  &?_"C_ (1C6/\ H$WW_@,_^%7O^%A^*O\ H9M8_P# ^7_X
MJC_A8?BK_H9M8_\  ^7_ .*HO7[+\?\ (-#[S_8H4Z-\$(XK\&QE;4K@A+G]
MVQ&$YP<5[U_:UC_S^6__ ']7_&O!OV-7;Q7\%(KG6V.L7":C<*LU^?/=1A.
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M ']7_&H/^$:T?_H%6/\ X#I_A1_PC6C_ /0*L?\ P'3_  H G_M:Q_Y_+?\
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M6L?^?RW_ ._J_P"-']K6/_/Y;_\ ?U?\:@_X1K1_^@58_P#@.G^%'_"-:/\
M] JQ_P# =/\ "@"?^UK'_G\M_P#OZO\ C1_:UC_S^6__ ']7_&H/^$:T?_H%
M6/\ X#I_A1_PC6C_ /0*L?\ P'3_  H G_M:Q_Y_+?\ [^K_ (T?VM8_\_EO
M_P!_5_QJ#_A&M'_Z!5C_ . Z?X4?\(UH_P#T"K'_ ,!T_P * )_[6L?^?RW_
M ._J_P"-']K6/_/Y;_\ ?U?\:@_X1K1_^@58_P#@.G^%'_"-:/\ ] JQ_P#
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M $"K'_P'3_"C_A&M'_Z!5C_X#I_A0!/_ &M8_P#/Y;_]_5_QH_M:Q_Y_+?\
M[^K_ (U!_P (UH__ $"K'_P'3_"C_A&M'_Z!5C_X#I_A0!/_ &M8_P#/Y;_]
M_5_QH_M:Q_Y_+?\ [^K_ (U!_P (UH__ $"K'_P'3_"C_A&M'_Z!5C_X#I_A
M0!/_ &M8_P#/Y;_]_5_QH_M:Q_Y_+?\ [^K_ (U!_P (UH__ $"K'_P'3_"C
M_A&M'_Z!5C_X#I_A0!/_ &M8_P#/Y;_]_5_QH_M:Q_Y_+?\ [^K_ (U!_P (
MUH__ $"K'_P'3_"C_A&M'_Z!5C_X#I_A0!/_ &M8_P#/Y;_]_5_QH_M:Q_Y_
M+?\ [^K_ (U!_P (UH__ $"K'_P'3_"C_A&M'_Z!5C_X#I_A0!/_ &M8_P#/
MY;_]_5_QH_M:Q_Y_+?\ [^K_ (U!_P (UH__ $"K'_P'3_"C_A&M'_Z!5C_X
M#I_A0!/_ &M8_P#/Y;_]_5_QH_M:Q_Y_+?\ [^K_ (U!_P (UH__ $"K'_P'
M3_"C_A&M'_Z!5C_X#I_A0!/_ &M8_P#/Y;_]_5_QH_M:Q_Y_+?\ [^K_ (U!
M_P (UH__ $"K'_P'3_"C_A&M'_Z!5C_X#I_A0!/_ &M8_P#/Y;_]_5_QH_M:
MQ_Y_+?\ [^K_ (U!_P (UH__ $"K'_P'3_"C_A&M'_Z!5C_X#I_A0!/_ &M8
M_P#/Y;_]_5_QH_M:Q_Y_+?\ [^K_ (U!_P (UH__ $"K'_P'3_"C_A&M'_Z!
M5C_X#I_A0!3L-5LO[<U7_3+?I#_RU7^Z?>M/^UK'_G\M_P#OZO\ C6+8>&](
M.N:H/[*LL 1?\NZ?W3[5I_\ "-:/_P! JQ_\!T_PIL""YE2>=GC=9$.,,IR#
MQZU%3YK:&SD,-O$D$2_=CC4*H[\ 4RF<,OB84444R0HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH N6=[;VT16
M:XBB8G(5W ./QJ?^UK'_ )_+?_OZO^-4X-(L-00R75E;W,@.T/-$KD#TR1[F
MI?\ A&M'_P"@58_^ Z?X5+.V'PHET^5)Y+QXW61#,,,IR#^[3O12:7;0V;7<
M-O$D$2S?+'&H51\B'@"BD6?#'_!03_DJ'A[_ + R_P#H^6N8_8J\-:1XJ^+]
MQ9:WI5EK%F-*FD%O?VZ3QA@\0#;7!&1D\^YKI_\ @H)_R5#P]_V!E_\ 1\M<
MQ^Q5XETCPK\7[B]UO5;+1[,Z5-&+B_N$@C+%XB%W.0,G!X]C7ZY1YO[ 7)OR
MO;?<X'_%/3=9^#7AV/\ :DL=432+%? [:(_B&:Q%N@M%2*,Q.@0 +CS/+<@C
M'SGUK+_:1^#WA?4?CUIFC0:AX>^'.A)X=2]N;EHHK>,L)YU^2)2GFR'"C .<
M+[ '2NOC7H=U^RIKHEU:QG\7%;O1XK5[I/M36\UUV7.YD$3#Y@,'9UZFNXU;
MXG>!;OXX75[!XIT&WU>;P=':Z/KTL\4UK977FW)<,^2JMAHSAB"1E?XL'R(U
M,;1J*HU+W(RA_P" VM+9]][/;J7:+5NYX-JG[*-A:1^"-3M?'/VGPSXGOET^
M+4KC1I;62.21':!A!(X+HY0@,2O#*1N!S6+X7_9DO=9^*?C#PEJ.LC2++PS!
M)<W6L&U\Q#&,&,E/,7;O0[\;N #UQ7I?QS\6Q7/[/>CV+_$32?%WC+2O$2W]
M[<V5^C,699F!@4X+HAFC *+M !  VD#KOCSX[TZV_9ZD\8V,!L_$/Q"L["RN
MFCP<*B,THY RNW?'G_:7IU'H0QV/M&/-=S;@G9:/F34ME?W;].BT)Y8?<> >
M#OV?+&_\"VOC#QCXR@\$:%J-R+73'GL'N9KHY;+,BL-B_*<-DC@DX&"W'_%_
MX3ZK\'?%[Z)J4L5W%)&MS9W]N?W=U Q.UQZ'((*GH0<$C#'VA;WPY\?/@3X+
M\-OXOT;PCXA\+2^1<1:_=?9X9H""H>-B,.V%7CJ#N!P"">1_:M^).B>-_%.A
MZ3X=N?[1TKPYIZZ>-1 PMS(,;F3U4;5&>Y#$97!/IX7$XN>+Y)WM>5U:RBE\
M+3MK?U=^EK&<HQ4;H]L^!'A&R;]G+P]K&G?"K0_B'KTU[<131WHM8)1$))?W
MAFF1MVTJB[>OS>@KC_C1X7N/%6N^!?"-]\*=)^$]QK>J>5%J>GS6ET\JC:C@
MK J'"F5#AF&>WJ-SX47ND>(_V9O#?AV+XM67PVUFVU&>ZEF344BN&CWS#RV3
MSHV"MO5N3CY1QW&)JOAW3O"/Q ^'6NZA\<[7XB);:] C17-^L@L8C\SS%FN9
M-B_NU!. .F3P*\*FW#&59M^\I3MI4OUM;7DMZHU>L4O3M_PYE3?L<:;-KWB#
MPUIOQ(LK_P 6Z5;&[_L@Z:\>Z/"E=\GF$*3N7(&[;N4GK7%>!_V?['5_AO'X
MX\7>,[3P7H=Y<?9=.9[-[N2Z<,RME58%0&4C(W=&)"@ GVCX>^//#-E^V+\0
M=:N/$6DP:/=:9)'!J,M]$MO*W^C?*DA;:Q^5N ?X3Z5R%A>^'OC;^SEX7\*2
M>+M#\*^(O#%V?-CUVX^S130L9-K1L<[SM*Y SRISM#*3VQQ>.BDJDW9^S;ER
MJ\>9-NRY;;I+5.UR>6/1=S?^/'[/O_"1^-OAOX2\):9I&G7UQI#R7MY9P+%
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ME?0U?//["W_)"U_["=Q_)*^AJ_"<W_Y&%;_$SU*?P(****\@T"BBB@ HHHH
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M@JW4L[8?"BK:?\?%[_UV'_HM**+3_CXO?^NP_P#1:44BSX4_X*"?\E0\/?\
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M=0!]L?$;XH^%OA)H=MK'BW5XM&T^YO8-.@DD1Y&EN9GV11JB*S,2?0< ,QP
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MR'-5^D/_ *":U*; R;[_ (^G_#^55ZL7W_'T_P"'\JKTSAE\3"BBBF2%%%%
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M'_[3WA?P0=,^QZ9K?C(7FC'Q&[^&;:.X6VTH8_TR0O(@,9S\JQ[Y&P=J'!H
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M_A_*J],X9?$PHHHIDA1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MLT/YU]Z#E?8XRBNS_P"%2:[_ ,_?AS_PJ-,_^2*/^%2:[_S]^'/_  J-,_\
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M=HK"_P"$RT__ )XZI_X*;O\ ^-4?\)EI_P#SQU3_ ,%-W_\ &J\DLW:*PO\
MA,M/_P">.J?^"F[_ /C5'_"9:?\ \\=4_P#!3=__ !J@#=HK"_X3+3_^>.J?
M^"F[_P#C5'_"9:?_ ,\=4_\ !3=__&J -VBL+_A,M/\ ^>.J?^"F[_\ C5'_
M  F6G_\ /'5/_!3=_P#QJ@#=HK"_X3+3_P#GCJG_ (*;O_XU1_PF6G_\\=4_
M\%-W_P#&J ,#XZ:UXZT#X4^(;SX:>'XO$_CD0"/2M/GN(H(C*S!?,=I71=J
ME]NX;MNT=:\ _9@T;Q_\+KQ(=9^!_B63Q'XCN8I?%/C[6?$NDW5Q<2XP9&6.
MX9Q#&,A(8UPJ\ 9R3]/?\)EI_P#SQU3_ ,%-W_\ &J/^$RT__GCJG_@IN_\
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M.@Z;J$D1A>[MHIVB88*%D#$$=L9K0K!3Q?IL:*B6^IJJC 4:1=  >G^JI?\
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M/A/1_"?A/P3I6L6_A6PURVUO5;S5#"U]>M','*;$.S@)'@Y&=B@XP2VIX?\
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M/Q=LO@Q\09-9U.QN+_3;JRDL+B.U(\U49D;<H) 8YC P2.O7BL#_ (5)KO\
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M9FVLP(^520,=3R39_P"%2:[_ ,_?AS_PJ-,_^2*/^%2:[_S]^'/_  J-,_\
MDBNNC#!X>;G3J6OTYM+O=VN2^9JS1ZKJ5R/%_P"Q-I4=H5,WA/7R+Q"<%8IF
ME*MCOEKA!^#>E/\ &O[1GAOQ'\9_A[XNMK'54TWP]:PPW44L40F=D9R?+ D(
M(^8=2*\UL/ ?C#2[&^LK+7-'M+.^54N[>#Q?IR1W"J25$BBYPX!)P#GK5'_A
M4FN_\_?AS_PJ-,_^2*Y(X;"<TG.HG=R:U6TTN;\;V*O+HOZ1ZWK^O_#[XI6O
MQ@\::AHM['=.86T:_OI3"(YGC$:0;(Y2'D8J[A=K )&Q) %?.-=G_P *DUW_
M )^_#G_A4:9_\D4?\*DUW_G[\.?^%1IG_P D5VX;ZOADXQJIK2R;V225EKY7
M)E>70]0T'XO>%?AX?A7HNF2_VMHNDW@US7KF.!U,E\X*?*KJI;R4/!'#<>E6
MOBGXI\/_ !/L/"/@3PUJ2:YJ-WXEOKK^T(K:9$A2[NG,:8E1&)Q(K-@8!7J>
MM>2_\*DUW_G[\.?^%1IG_P D5:TKX=^*]"U"&_TW6-$TZ^@.Z*YM/%NG12QG
M&,JRW((X)''K7&\+A%-5H5??5WJUJW?5_P#@3V]"KRVL=O\ MG>)[7Q#\<+V
MVLVWQ:/:0Z87R""Z[G8#Z&0J?=37A==Q=?"_Q)?74US<ZCX?N+F9S)+-+XJT
MUG=B<EF)N,DDG))J+_A4FN_\_?AS_P *C3/_ )(KNPDL/A:$*"J)\J2W1$DY
M-NQ]O_L+?\D+7_L)W'\DKZ&KY[_9&4^!O@Y#9:EB>9]0N) VDG^THL?)UDMO
M,0'V)S[5[/\ \)EI_P#SQU3_ ,%-W_\ &J_&\VDI8^LXNZYF>E#X4;M%87_"
M9:?_ ,\=4_\ !3=__&J/^$RT_P#YXZI_X*;O_P"-5Y)9NT5A?\)EI_\ SQU3
M_P %-W_\:H_X3+3_ /GCJG_@IN__ (U0!NT5A?\ "9:?_P \=4_\%-W_ /&J
M/^$RT_\ YXZI_P""F[_^-4 ;M%87_"9:?_SQU3_P4W?_ ,:H_P"$RT__ )XZ
MI_X*;O\ ^-4 ;M%87_"9:?\ \\=4_P#!3=__ !JC_A,M/_YXZI_X*;O_ .-4
M ;M%87_"9:?_ ,\=4_\ !3=__&J/^$RT_P#YXZI_X*;O_P"-4 ;M%87_  F6
MG_\ /'5/_!3=_P#QJC_A,M/_ .>.J?\ @IN__C5 $GC3PI8>//!VN^&=50R:
M9K-A/IUTBG!:&:-HW _X"QKYFTO]F_XN>(M&\"_#WQWXC\*7WPS\(WME=&]T
MV*X&K:Y%9,K6D-Q&X\J$92,R,CN7V<;<FOI7_A,M/_YXZI_X*;O_ .-4?\)E
MI_\ SQU3_P %-W_\:H W:*PO^$RT_P#YXZI_X*;O_P"-4?\ "9:?_P \=4_\
M%-W_ /&J -VBL+_A,M/_ .>.J?\ @IN__C5'_"9:?_SQU3_P4W?_ ,:H W:*
MPO\ A,M/_P">.J?^"F[_ /C5'_"9:?\ \\=4_P#!3=__ !J@#=HK"_X3+3_^
M>.J?^"F[_P#C5'_"9:?_ ,\=4_\ !3=__&J -VBL+_A,M/\ ^>.J?^"F[_\
MC5'_  F6G_\ /'5/_!3=_P#QJ@#=HK"_X3+3_P#GCJG_ (*;O_XU1_PF6G_\
M\=4_\%-W_P#&J -VBL+_ (3+3_\ GCJG_@IN_P#XU1_PF6G_ //'5/\ P4W?
M_P :H W:*PO^$RT__GCJG_@IN_\ XU1_PF6G_P#/'5/_  4W?_QJ@"S8?\A[
M5?\ =A_DU:E<?8^,=/&N:H?)U/!6'_F$W7HW_3.M/_A,M/\ ^>.J?^"F[_\
MC5-@;M%87_"9:?\ \\=4_P#!3=__ !JC_A,M/_YXZI_X*;O_ .-4@-VBL+_A
M,M/_ .>.J?\ @IN__C5'_"9:?_SQU3_P4W?_ ,:H W:*PO\ A,M/_P">.J?^
M"F[_ /C5'_"9:?\ \\=4_P#!3=__ !J@#=HK"_X3+3_^>.J?^"F[_P#C5'_"
M9:?_ ,\=4_\ !3=__&J -VBL+_A,M/\ ^>.J?^"F[_\ C5'_  F6G_\ /'5/
M_!3=_P#QJ@#=HK"_X3+3_P#GCJG_ (*;O_XU1_PF6G_\\=4_\%-W_P#&J -V
MBL+_ (3+3_\ GCJG_@IN_P#XU1_PF6G_ //'5/\ P4W?_P :H D\:>%+#QYX
M.UWPSJJ&33-9L)].ND4X+0S1M&X'_ 6-?,VE_LW_ !<\1:-X%^'OCOQ'X4OO
MAGX1O;*Z-[IL5P-6UR*R96M(;B-QY4(RD9D9'<OLXVY-?2O_  F6G_\ /'5/
M_!3=_P#QJC_A,M/_ .>.J?\ @IN__C5 &[16%_PF6G_\\=4_\%-W_P#&J/\
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M4SAE\3"BBBF2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M*S19P0 &.,%<MW]G\%?@[K_Q?\8_#:#PEJ%C=:;IPOQK":I*WDDI#E(HV)!
M\U6R^[+%QC 6L*F=4*=U*$KJ]U9:6:3OKYK:^A2I-]3XDK6U7PCKNA:K;Z7J
M6BZCI^I7 4PV=U:R132!CM4JC $Y((&!R17N_C?P!\/O%/[.MUX_\'^'KOPS
M<Z9J@L72>^>Y-U'N10S[CA6.]6PHX.X<C!KZ"T'0-!T#]K&'3SIUSJ-Z?#$=
MW9ZCJ6IW%Y)9D2RK(%\YG/SAE'4;<-@?.U95\ZC2@Y1INZYKIVO>/+YM?:OU
M^_0%3N]S\\IH9+>5XI4:*5&*NCC#*1P01V--KZI\#^!?"/Q'\0^.-:MOA;J&
MI0VU^MNEO-KAM=+M "/.FDNV=92WWW**CA5*C'S CH=4_9L\"6/[17@S28;'
M[1X8U_2Y[N33$O99(HY(XB0T<X8.R$[6Y/7/8A5UEG5"G)TZD6FDV_A>RYFM
M);V[V3Z,/9-ZH^-:E:TG2TCNFAD6VD=HDF*$([J%+*&Z$@.A([;E]17U/+\-
M_A;XV\'?%J#P]X5O=$U7P2DLD.J2:E+,;K893S&QVJ#Y++C!."#G.:G_ &G]
M4\*6_P "?A?!8>#H[ ZEI\EQI+17TF-*!-M)*NW&)S(&P6?!SENI-..;*I6A
M1A2E>3L[VT]WF3W[:^E^MDU[.R;N?)E%>R_LY?#+P_XR'B_Q+XKBGO?#_A73
MC?3Z?;2&-[IBKE4W @@8C?H1SMY S6A=>&/AK\8-6\":7X#L;OPIXBU:Z:WU
M/2WGDNK>UB4L3)YLN"SE1D!?E(X.TCYNR>84Z=65)Q=H[NVBTOKK?;RMMJ2H
M-JYX517US:?"GX1^,/B+K_PGTG0=0TO7-/M62V\5-J$D[37,:J7\R XC SG.
MT#.& V9!&,O@7X<_#7]GKPWXM\5>"G\2>(KK4+K39HHM6GMDD=+B==S%6( 5
M8<#:O)QGKFN3^V*3Y4J<N:35EI=\R;3^*UM'UNNJ17LWW/FJWTB^NX(YX+*X
MFAEG%LDD<3,KRD9$8('+$?P]:DUSP_JGAB_:QUC3;S2;U5#-;7T#PR 'H2K
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MXF\2Z/X=.H3?9[/^UK^*U^TR_P!R/S&&]N1P,FOF?X\_"WX2?!3X5>/HM4T
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MYK62>,^TG/2@#Z-HJMINH0ZMIUK?6[;K>YB2:-O56 (Z>QJS0 4444 %%%%
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M@XP?H[]N3P3J/B?XC:%<6<^E11QZ2L9%_K%I9OGSI#PLTJ,1SU Q[\5\X_\
M"I-=_P"?OPY_X5&F?_)%?LV53P]3+*=&K)6:LTVO,\ZHFIMH]^M/VCO@IX8U
M:Z\6^'OAMJ$?C.9&8>>RK:K(^/,V_O6"<;OF6($@D<!C7GGPZ^.6@1>#?%7@
MKQUHMS+X8UR\;4D;P\J1364Y*G;$C$((_D7 Z+@C#!N.$_X5)KO_ #]^'/\
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M_)%'_"I-=_Y^_#G_ (5&F?\ R16-/"8"DXR4]8M-7E?9-)>B38W*;Z'J5O\
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M%2:[_P _?AS_ ,*C3/\ Y(H_X5)KO_/WX<_\*C3/_DBCZS0_G7WH.5]C[?\
MV%O^2%K_ -A.X_DE?0U?/?[(RGP-\'(;+4L3S/J%Q(&TD_VE%CY.LEMYB ^Q
M.?:O9_\ A,M/_P">.J?^"F[_ /C5?B&;24L?6<7=<S/3A\*-VBL+_A,M/_YX
MZI_X*;O_ .-4?\)EI_\ SQU3_P %-W_\:KR2S=HK"_X3+3_^>.J?^"F[_P#C
M5'_"9:?_ ,\=4_\ !3=__&J -VBL+_A,M/\ ^>.J?^"F[_\ C5'_  F6G_\
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M_P#YXZI_X*;O_P"-4 ;M%87_  F6G_\ /'5/_!3=_P#QJC_A,M/_ .>.J?\
M@IN__C5 &[16%_PF6G_\\=4_\%-W_P#&J/\ A,M/_P">.J?^"F[_ /C5 &[1
M6%_PF6G_ //'5/\ P4W?_P :H_X3+3_^>.J?^"F[_P#C5 %FP_Y#VJ_[L/\
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M_C5 %FP_Y#FJ_2'_ -!-:E<A8^,=/&MZH?)U/!$7_,)NO[I_Z9UI?\)EI_\
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M!!XP:_0G2_ FGZQ^T)X5^*/AP!]-U1;RQU2-<DP7D<,B9([9\LJ>@RH/.^O
M_$GPY\.ZC\%/BOXRN-/\SQ)8>,)[2WO?/D&R(S0978&V'_6/R5)YZ\"KP^=P
MK3C&4;745YJ4I.+3\DT)T[(^;J*^M-#^!?@>\U;X 0S:)OB\4Z?>3ZNOVN<?
M:GCM(Y$/#_)AF)PFWKSQ5_2_AG\&?$=I\4H4\(ZKIZ> [EWFO8M4D>:\1'F9
MHU5CL5?W+QC(+;=I+!LD;2SNA':$G\EI[SAW[KI_G9>S?<^0K*RN-2O;>SL[
M>6ZN[B18H8($+R2.QPJJHY))(  ZYJ75M'O] U&:PU.RN=.OH2!+:W<312QD
M@$;E8 C@@\^M?4]Q\._!T3_ SXA>$M$E\-)K'B2SM[C3&O)+I01<<,'D).08
MV'& 01P".>K\9>'_ (7?$W]I#Q!X#U/PW?Q^([^(N/$B:A("MPMNL@1(!\FU
M8U)W-G)!&.0:S>=14]*;Y4I-[7CRNSOK:R\FQ^S\SXBHKZ_^'O[*]KHO@&+5
MM4\$S?$?7+O4I;9["+6!IT5C;1/)&9%;>OF,Q0'!/1E'RE26T]#_ &6O VD?
M&?Q=H6L6D^H:!'H<>L64;W+I+9AI&1EW(PWE2C8W9&,9R<DU+/L'%S2N^6^U
MM;-)V5[]>J5^EP]E+0^+:*ZCXAZ_X:\0ZU'/X6\*CPEIJ1!#:&_EO&D?<3YA
M>3ID%1M' QU.:]ID\%?#7X,?#GP'JOC3PS>>,]5\61"^?R=0DM4L;;"-\@0K
MO;;*GRL>2&^91C/I5<8J,8<T'S2VCI?:[ZVT7F0HWZGS[H?A_5/$]^MCH^FW
MFK7K*66VL8'FD('4A5!.!2:UH.I^&]0DL-7TZ[TJ^C +VM[ T,J@C()5@",@
M@U]Y?!;X;>'_ (+?&3Q9H.GV4M])-H8U6TU:>Z83+:.ZJ;8J %SYD9;>,'
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MSHP5E=MH(\I.<L#DC'0U\^45URRK#2G*HDTY<NJ?6.S]2?:2M8^I[O\ :?\
M T7C#X2WVEZ-K=GH_@V"]MYK:1(I)2DMND48C/F?/@KEBVWVS7(>&OCSX?T:
MW^.$<]GJ3'QP9CIOEQ1GRMQN2/.RXV_Z]/N[NA]L^#T4HY3AHQY5?IU[2<__
M $IA[21] 67[0/AVV^'7PFT!K/4S>>$M>@U2^<11^7)$DSN1$?,R6PPP&"C.
M>:Z^Y_:3^%%I\3-3^).G>&/$<GB][=H;:"Z:!;-G,803-ARR.4!0[=PQGC))
MKY0KL?A7\+-8^+_B670M#EM([Y+62Z'VR1D1E3 *@A3\QW#&<#U(K*OEF#A&
M56HVE[U]6E:3NT_*XU.3T1Z;H_QW\)^-OAS'X3^*=AK=X;'47U"QU+06B\X^
M8SO)'()6  R[8(SD$#"[ 6E^&_QX\"_#[QGXVO=-\,7^C:!JNFG3]/LK20W,
MH/\ STF:67@MU(4D+P!G!8^0^&_A]JOB67Q)#&([*?0-.FU*]AO=\;A(G1'0
M#:3ORXX;'0Y(KFJU_L_"U%4IQ;L]TF[*]GHMM;7_ "W%SR5F%?0&G_&CX>>.
M/ ?A+0?B9H>N2W7A8""RN= DC"W-OA08Y0[*5!"1@[3GY<AER0?%M1\+7NEV
M374TVFO$IC4K;:G;3R?.NX81)&8\=3CY3PV#Q61796P]+%J+;UB]&G9K2VZ\
MF2FXGT_X:_:[TZ3XN^(_%_B#2;RWL;S1AI%A9:<$F:%0X8;RS(#SO)(]<8[U
M\V:-_P ABQ_Z[Q_^A"J=*CM&ZNC%74Y#*<$'UJ:&"HX7F]BK727W:(')RW/N
MW]H3Q[\./ /QUT;7/$FBZY>^)](L$N++^SWB-K<9,OEB8.0RE'R0R^HSG %>
M$:S^T59^*/A-\1=#U6UO!XA\4:VFIPO"B&VAB5X"(V;<&RJPE1\IS@9/)KQG
M7O$NK^*KX7NMZK>ZQ>!!&+B_N'GD"@DA=SDG R>/<UG5YV$R>E0IP51N4HVU
MN_LN^G97+E4;;L>S6_QMTRQ_9UL? UK#?Q>([35QJ27?EQ_9U <L,'=NW#CC
M;BN^;]I;X<:WXLTKXB:YX6UMO'^G6GE"TLYHAILTRA@DC,Q\P'!_NG;P,/MR
M?ENBNF>5X:=V[IMMNS:^+=>CL)3:/<-2_:"MO$?P6\;^'=8@NY/%'B+7_P"V
M//@C7[(B'R/DR7WC'E, ,'C;SUKRCP5XE?P;XQT/7T@6Z?2[Z&]$#G D\MP^
MW.#C.,9QQUK&HKKI82C1A.$%I)W:^27Y(ER;U9]>Z;^U#\*M(\?>)?%5MHGB
MMM1\2VH@OI9A;LMMM15"PH)!D-C+%FX*+@8) \\\._&KP1XB^$6C^"/B-I>N
MW(T*Y\[3[S0Y(MTJ'?\ NY/,(VJ VWY<G 'W2.?!:*X(91AH+1N^EG=W7*FE
M;Y.Q?M),^B/BI^TMI/B?XG^ /%?AFQU#38_#L:)-;W*1@E0^7C0J[94H67)P
M>>@JO\:?VE[/QW\6/!WB70M/N5T?PU)%<PV%_''$\DPF$DA.TN &"(,]1C.,
MU\_T5I3RK"TW!J/PII>CW_-_>)U),^O=-_:A^%6D>/O$OBJVT3Q6VH^);407
MTLPMV6VVHJA84$@R&QEBS<%%P,$@>->*/BSI&M_L[>#? 4%M>IK&C7\UU<3R
M(@MV5WG8!&#EB<2KU4=#^/D]%*CE6'HR4HWNFGJ[_"FE^#!U&SZ?UW]K;21\
M==%\::1I5]-HT>A)H>HV=ZJ1S21F9Y',>UV'&8R,D9VD'&<URFN?%/X8^%-$
MLH_ASX5U-=>M]835X=8\0&,2VA1E*PH8G)DB(!4HY[D_,V"/"Z*<,JPU/EY;
MI))6N[.U[7[[O]0=23/H7Q_\6O@]XXU'5?%MUX-U^]\7ZC:(CZ;<WBQ:9'<X
M53*)(G$K;0O3 #=U4G<*GAWXU>"/$7PBT?P1\1M+UVY&A7/G:?>:')%NE0[_
M -W)YA&U0&V_+DX ^Z1SX+13664535.\O=::]YW5E96[::?GT#G=[GLW[3'Q
MGT+XRZMX=NM!T^]TV#3K#[+)!>(@VMNR A5FRH'&3@^U7/!?QD\(#X!:A\.?
M%EIK@8WC7EI=:.(6&[AE#^8PP XYP#D'L:\-HJUEU!4(8=7M!W6NJ:=]Q<[O
M<^A_'7[1'ASQ/\3OACXCM;+5(['PQ' EY'-%&))"CACY8$A!X'&2M:5U^TSX
M3\1>(/B-IGB#2-7N? OBR2*XC6V$27UK-'%&F\*6*$DQH?O$#8.#DBOF:BL?
M[)PO+&-GHK+7;WN:_K<?M)'NGAWXJ?#/P'\6O!NN^%O#6LV6B:*DWVVZNIA-
M?7[O"4#&,R>4FTD_=*@[CP, 4WX7_'S2/ ?QS\6^+;K3;R\T'Q ][&\401;J
M**:?S5(&[&X;0"-P').3@5X;16LLNH3C)3N[QY7=MNUV]^]W_2%SM;'T=J'Q
MG^'D?P=N/ASX4TSQ#;A]3M[JVO-5$#M.WG1NYF*, A !50JMD(N<$G'L'[0G
MCWX<> ?CKHVN>)-%UR]\3Z18)<67]GO$;6XR9?+$P<AE*/DAE]1G. *^$D=H
MW5T8JZG(93@@^M:&O>)=7\57PO=;U6]UB\"",7%_<//(%!)"[G).!D\>YKAG
MDU.56,E)\OO7U=VY63U^7^1:J.Q[3J'[2%OKWPN^(^E:A!?1>)?$^LQ:G;36
MRI]GMT22!E0ON# JL.T$*>BY/)-:WBCXX?"GXG3:?XG\;^$M=O\ QA;:?]EN
M+"PN4ATV\D7=L9I XE09.?E'RYP=^,GYOHKK_LO#+6%XN]]&UNDFM.EDON)Y
MWU/8_AG\0?AUHNEO_;&E^*/"WB".9GBUWP3J3)-+"Y<F!UFDVHB@H 1EFVC)
M&"6SOVB_C%;_ !J\>0ZO96,MCI]G9I8VPNB#/(BL[;Y",@,2YX!(&.O)KRVB
MNB.!I1K_ %C5RUM=MVOO;^M.@N9VY3Z(U*Y'B_\ 8FTJ.T*F;PGKY%XA."L4
MS2E6QWRUP@_!O2G^-?VC/#?B/XS_  ]\76UCJJ:;X>M88;J*6*(3.R,Y/E@2
M$$?,.I%>!6&O:GI=C?65EJ-W:6=\JI=V\$[)'<*I)42*#AP"3@'/6J-<L<LI
M\TG/6[DUZ32YOQO8?.^G]6/H[7]?^'WQ2M?C!XTU#1;V.Z<PMHU_?2F$1S/&
M(T@V1RD/(Q5W"[6 2-B2 *^<:**[<-AEADXQDVM+)]$DE9?=<F4N8^@]!^+W
MA7X>'X5Z+IDO]K:+I-X-<UZYC@=3)?."GRJZJ6\E#P1PW'I5KXI^*?#_ ,3[
M#PCX$\-:DFN:C=^);ZZ_M"*VF1(4N[IS&F)41B<2*S8& 5ZGK7SE5K2M7OM"
MU"&_TV]N-.OH#NBN;25HI8SC&592"."1QZUQO+*:FJT&^=7>O5N^KT_O/;TZ
M%<[V/:OVSO$]KXA^.%[;6;;XM'M(=,+Y!!==SL!]#(5/NIKPNI;JZGOKJ:YN
M9I+BYF<R2S2L6=V)R68GDDDY)-15W82@L+0A03ORI(F3YFV?HE^PM_R0M?\
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M0!DY. !76_&CX$^'/B)=2^(]3\2:YX1E@TF?3-3OM$O8[<7>F,=\L$YDC<!
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MZ[#_ -%I11:?\?%[_P!=A_Z+2BD6?"G_  4$_P"2H>'O^P,O_H^6OEROJ/\
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MQ@XSMWDXS@9QZ"L>O4PM!T(.+ZN^G3\OR1G)W84445V$A1110 4444 %%%%
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M[2O[^1205&;7P^_9(^$OPN\3VGB'PYX0BMM7LD:.RGNKVYO!8JPPRVR3R.L
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MA1113)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#3TW_ %#?[W]!5NJ]@A2W&>YS5BI9VP^%%6T_X^+W_KL/
M_1:446G_ !\7O_78?^BTHI%GPI_P4$_Y*AX>_P"P,O\ Z/EKY<KZC_X*"?\
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MAU[IYY+?3+>73;.Q7;S(5F@@660J%C5F9Y#QN; )%'XQ37?]D:;I6F#2]/\
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M7#V3[F+16U]GB_YYI_WR*/L\7_/-/^^11</9/N8M%;7V>+_GFG_?(H^SQ?\
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M ,*_8:BC_6^7_/C_ ,F_X ?5_,_'G_A&-8_Z!-]_X#/_ (4?\(QK'_0)OO\
MP&?_  K]AJ*/];Y?\^/_ ";_ ( ?5_,_'G_A&-8_Z!-]_P" S_X4?\(QK'_0
M)OO_  &?_"OV&HH_UOE_SX_\F_X ?5_,_'G_ (1C6/\ H$WW_@,_^%'_  C&
ML?\ 0)OO_ 9_\*_8:BC_ %OE_P ^/_)O^ 'U?S/QY_X1C6/^@3??^ S_ .%'
M_",:Q_T";[_P&?\ PK]AJ*/];Y?\^/\ R;_@!]7\S\>?^$8UC_H$WW_@,_\
MA1_PC&L?] F^_P# 9_\ "OV&HH_UOE_SX_\ )O\ @!]7\S\>?^$8UC_H$WW_
M (#/_A1_PC&L?] F^_\  9_\*_8:BC_6^7_/C_R;_@!]7\S\>?\ A&-8_P"@
M3??^ S_X4?\ ",:Q_P! F^_\!G_PK]AJ*/\ 6^7_ #X_\F_X ?5_,_'G_A&-
M8_Z!-]_X#/\ X4?\(QK'_0)OO_ 9_P#"OV&HH_UOE_SX_P#)O^ 'U?S/QY_X
M1C6/^@3??^ S_P"%'_",:Q_T";[_ ,!G_P *_8:BC_6^7_/C_P F_P" 'U?S
M/QY_X1C6/^@3??\ @,_^%'_",:Q_T";[_P !G_PK]AJ*/];Y?\^/_)O^ 'U?
MS/QY_P"$8UC_ *!-]_X#/_A1_P (QK'_ $";[_P&?_"OV&HH_P!;Y?\ /C_R
M;_@!]7\S\>?^$8UC_H$WW_@,_P#A1_PC&L?] F^_\!G_ ,*_8:BC_6^7_/C_
M ,F_X ?5_,_'G_A&-8_Z!-]_X#/_ (4?\(QK'_0)OO\ P&?_  K]AJ*/];Y?
M\^/_ ";_ ( ?5_,_'G_A&-8_Z!-]_P" S_X4?\(QK'_0)OO_  &?_"OV&HH_
MUOE_SX_\F_X ?5_,_'G_ (1C6/\ H$WW_@,_^%'_  C&L?\ 0)OO_ 9_\*_8
M:BC_ %OE_P ^/_)O^ 'U?S/GK]BA3HWP0CBOP;&5M2N"$N?W;$83G!Q7O7]K
M6/\ S^6__?U?\:=>:99ZCL^UVD%ULSM\Z,/MSUQD<=!5;_A&M'_Z!5C_ . Z
M?X5\-B\1]:KSKM6YG>QU17*DB?\ M:Q_Y_+?_OZO^-']K6/_ #^6_P#W]7_&
MH/\ A&M'_P"@58_^ Z?X4?\ "-:/_P! JQ_\!T_PKD*)_P"UK'_G\M_^_J_X
MT?VM8_\ /Y;_ /?U?\:@_P"$:T?_ *!5C_X#I_A1_P (UH__ $"K'_P'3_"@
M"?\ M:Q_Y_+?_OZO^-']K6/_ #^6_P#W]7_&H/\ A&M'_P"@58_^ Z?X4?\
M"-:/_P! JQ_\!T_PH G_ +6L?^?RW_[^K_C1_:UC_P _EO\ ]_5_QJ#_ (1K
M1_\ H%6/_@.G^%'_  C6C_\ 0*L?_ =/\* )_P"UK'_G\M_^_J_XT?VM8_\
M/Y;_ /?U?\:@_P"$:T?_ *!5C_X#I_A1_P (UH__ $"K'_P'3_"@"?\ M:Q_
MY_+?_OZO^-']K6/_ #^6_P#W]7_&H/\ A&M'_P"@58_^ Z?X4?\ "-:/_P!
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M ']7_&H/^$:T?_H%6/\ X#I_A1_PC6C_ /0*L?\ P'3_  H G_M:Q_Y_+?\
M[^K_ (T?VM8_\_EO_P!_5_QJ#_A&M'_Z!5C_ . Z?X4?\(UH_P#T"K'_ ,!T
M_P * )_[6L?^?RW_ ._J_P"-']K6/_/Y;_\ ?U?\:@_X1K1_^@58_P#@.G^%
M'_"-:/\ ] JQ_P# =/\ "@"G8ZK9?V[JG^F6_P!V'_EJOHWO6G_:UC_S^6__
M ']7_&H/^$:T?_H%6/\ X#I_A1_PC6C_ /0*L?\ P'3_  H G_M:Q_Y_+?\
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M6L?^?RW_ ._J_P"-']K6/_/Y;_\ ?U?\:@_X1K1_^@58_P#@.G^%'_"-:/\
M] JQ_P# =/\ "@"?^UK'_G\M_P#OZO\ C7C_ ,8_@POC[QKX<\=^$O'*^!/'
MVA6\UA#JHMHKZWN;.4AI+>XMV=?,7<H92'4JV3SQCUG_ (1K1_\ H%6/_@.G
M^%'_  C6C_\ 0*L?_ =/\* /,O@A\(;/X47?BC7M9\7GQGXX\4W,5QK/B"ZC
MBMA*L2;(((84)$4,:EMJ98Y=B6.>.7^+PM? G[1GPT^*@N;?^R)K6Y\%:Y-Y
MB_Z-%=R1RV<S'/""YA6-B>GVA3T!KW7_ (1K1_\ H%6/_@.G^%'_  C6C_\
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M^_J_XT?VM8_\_EO_ -_5_P :@_X1K1_^@58_^ Z?X4?\(UH__0*L?_ =/\*
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$% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>syre-20260630_g4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 syre-20260630_g4.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 'O!,,# 2(  A$! Q$!_\0
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M_P!#UX:_\&]O_P#%T?\ "Z?A]_T/7AK_ ,&]O_\ %U^4E%']E0_F8?ZE8?\
MY_2^Y'ZM_P#"Z?A]_P!#UX:_\&]O_P#%T?\ "Z?A]_T/7AK_ ,&]O_\ %U^4
ME%']E0_F8?ZE8?\ Y_2^Y'ZM_P#"Z?A]_P!#UX:_\&]O_P#%T?\ "Z?A]_T/
M7AK_ ,&]O_\ %U^4E%']E0_F8?ZE8?\ Y_2^Y'ZM_P#"Z?A]_P!#UX:_\&]O
M_P#%T?\ "Z?A]_T/7AK_ ,&]O_\ %U^4E%']E0_F8?ZE8?\ Y_2^Y'ZM_P#"
MZ?A]_P!#UX:_\&]O_P#%T?\ "Z?A]_T/7AK_ ,&]O_\ %U^4E%']E0_F8?ZE
M8?\ Y_2^Y'ZM_P#"Z?A]_P!#UX:_\&]O_P#%T?\ "Z?A]_T/7AK_ ,&]O_\
M%U^4E%']E0_F8?ZE8?\ Y_2^Y'ZM_P#"Z?A]_P!#UX:_\&]O_P#%T?\ "Z?A
M]_T/7AK_ ,&]O_\ %U^4E%']E0_F8?ZE8?\ Y_2^Y'ZM_P#"Z?A]_P!#UX:_
M\&]O_P#%T?\ "Z?A]_T/7AK_ ,&]O_\ %U^4E%']E0_F8?ZE8?\ Y_2^Y'ZM
M_P#"Z?A]_P!#UX:_\&]O_P#%T?\ "Z?A]_T/7AK_ ,&]O_\ %U^4E%']E0_F
M8?ZE8?\ Y_2^Y'ZM_P#"Z?A]_P!#UX:_\&]O_P#%T?\ "Z?A]_T/7AK_ ,&]
MO_\ %U^4E%']E0_F8?ZE8?\ Y_2^Y'ZM_P#"Z?A]_P!#UX:_\&]O_P#%T?\
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M_P".5^"E%']A4_YV'M&?O7_PTK\(O^BI>"__  H+3_XY1_PTK\(O^BI>"_\
MPH+3_P".5^"E%']A4_YV'M&?O7_PTK\(O^BI>"__  H+3_XY1_PTK\(O^BI>
M"_\ PH+3_P".5^"E%']A4_YV'M&?O7_PTK\(O^BI>"__  H+3_XY1_PTK\(O
M^BI>"_\ PH+3_P".5^"E%']A4_YV'M&?O7_PTK\(O^BI>"__  H+3_XY1_PT
MK\(O^BI>"_\ PH+3_P".5^"E%']A4_YV'M&?O7_PTK\(O^BI>"__  H+3_XY
M1_PTK\(O^BI>"_\ PH+3_P".5^"E%']A4_YV'M&?O7_PTK\(O^BI>"__  H+
M3_XY1_PTK\(O^BI>"_\ PH+3_P".5^"E%']A4_YV'M&?O7_PTK\(O^BI>"__
M  H+3_XY1_PTK\(O^BI>"_\ PH+3_P".5^"E%']A4_YV'M&?O7_PTK\(O^BI
M>"__  H+3_XY1_PTK\(O^BI>"_\ PH+3_P".5^"E%']A4_YV'M&?O7_PTK\(
MO^BI>"__  H+3_XY1_PTK\(O^BI>"_\ PH+3_P".5^"E%']A4_YV'M&?O7_P
MTK\(O^BI>"__  H+3_XY1_PTK\(O^BI>"_\ PH+3_P".5^"E%']A4_YV'M&?
MO7_PTK\(O^BI>"__  H+3_XY1_PTK\(O^BI>"_\ PH+3_P".5^"E%']A4_YV
M'M&?O7_PTK\(O^BI>"__  H+3_XY1_PTK\(O^BI>"_\ PH+3_P".5^"E%']A
M4_YV'M&?O7_PTK\(O^BI>"__  H+3_XY1_PTK\(O^BI>"_\ PH+3_P".5^"E
M%']A4_YV'M&?T#:5\7/ VO::-0TWQGX?U"P,K0"ZM=4@EB,BA69-RL1N ="1
MU =?45:_X61X2_Z&C1O_  /B_P#BJ_,?]E?_ )-UMO\ L:M3_P#233:]+KPJ
MV#C3J2@GL?"YGQ-6P&+GAXTTU&VMWU2?ZGW;_P +(\)?]#1HW_@?%_\ %4?\
M+(\)?]#1HW_@?%_\57PE16/U9=SR_P#7+$?\^5][/NW_ (61X2_Z&C1O_ ^+
M_P"*H_X61X2_Z&C1O_ ^+_XJOA*BCZLNX?ZY8C_GROO9]V_\+(\)?]#1HW_@
M?%_\51_PLCPE_P!#1HW_ ('Q?_%5\)44?5EW#_7+$?\ /E?>S[M_X61X2_Z&
MC1O_  /B_P#BJ/\ A9'A+_H:-&_\#XO_ (JOA*BCZLNX?ZY8C_GROO9]V_\
M"R/"7_0T:-_X'Q?_ !5'_"R/"7_0T:-_X'Q?_%5\)44?5EW#_7+$?\^5][/N
MW_A9'A+_ *&C1O\ P/B_^*H_X61X2_Z&C1O_  /B_P#BJ^$J*/JR[A_KEB/^
M?*^]GW;_ ,+(\)?]#1HW_@?%_P#%4?\ "R/"7_0T:-_X'Q?_ !5?"5%'U9=P
M_P!<L1_SY7WL^[?^%D>$O^AHT;_P/B_^*H_X61X2_P"AHT;_ ,#XO_BJ^$J*
M/JR[A_KEB/\ GROO9]V_\+(\)?\ 0T:-_P"!\7_Q5'_"R/"7_0T:-_X'Q?\
MQ5?"5%'U9=P_URQ'_/E?>S[M_P"%D>$O^AHT;_P/B_\ BJ/^%D>$O^AHT;_P
M/B_^*KX2HH^K+N'^N6(_Y\K[V?=O_"R/"7_0T:-_X'Q?_%4?\+(\)?\ 0T:-
M_P"!\7_Q5?"5%'U9=P_URQ'_ #Y7WL^[?^%D>$O^AHT;_P #XO\ XJC_ (61
MX2_Z&C1O_ ^+_P"*KX2HH^K+N'^N6(_Y\K[V?=O_  LCPE_T-&C?^!\7_P 5
M1_PLCPE_T-&C?^!\7_Q5?"5%'U9=P_URQ'_/E?>S[M_X61X2_P"AHT;_ ,#X
MO_BJ/^%D>$O^AHT;_P #XO\ XJOA*BCZLNX?ZY8C_GROO9]V_P#"R/"7_0T:
M-_X'Q?\ Q5'_  LCPE_T-&C?^!\7_P 57PE11]67</\ 7+$?\^5][/NW_A9'
MA+_H:-&_\#XO_BJ/^%D>$O\ H:-&_P# ^+_XJOA*BCZLNX?ZY8C_ )\K[V?H
M?UHI(_N+]!17 ?JPZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@"*Z_P"/6;_</\J_':OV)NO^/6;_ '#_
M "K\=J^ARG:?R_4_4N"-L1_V[_[<%.1&D=412SL<!5&23Z4VKFCVEW?ZM96U
MAG[=-.D=OB01GS"P"_,2 O)')(QZU[[T/T]NRNSZ2T_]BB.WM],M_$OQ$TCP
M[X@U!-T.D/$KNY_NJ6E0N1D [5//KU/GL/[.FJVOQSLOAMJ^H1V$]WN>+4H8
MC-&\7E.ZNJ$J3G85()&#GKCGW7QKXW\/:KJVBZ9\;?AEJ6G>+?+CC@U71Y?-
M$@&<,K0R _>+'RP7P3ZTQOAQ>> ?VN_A_--X@U3Q%9:E!/):S:U<--=PJL$N
M8F9N=H+9' ^\1C()/B0Q%5)\\M;-K16T[-?J?GM'-,=",W7J>\X3<?=CRWBK
MIPE&]TNJD<R/V+/#T^LRZ+:_%[2)]=0E3IGV6/SPPY(*"Y+#'TKB_!7[+ESX
MLU_QAX7N/$4.E^,M W-'I;VWF17J;04D67>"JDE<_(2H=2>3@>P>-?BY\%OA
MU\7]:U*?P5K-WXUL;MS)?*P:%I^[*&GP/KLX]*^<[CXYZVWQJE^)%M''::B]
MT)C:QL?+,04)Y+'N"@"DXZ\X%:498FI%N[VTNEO_ )'5@:F;XJG)J;2<$TY1
M@O>WLK;Q:ZO5&G\'_P!GR\^)9\2W6K:G_P (EHWA^-OMM_=6QD\N5<EHRI9,
M%55BW/'R\<U9\#? #3_$7@Z]\8Z]XPB\)^$UO396-]=6)EENSN(W>4K_ "_@
MS8P_9<GVK]M;QK)X>\(Z+X>T:UBTVT\3/)JFI-" &G8>60K<<Y)!)ZG8O;.>
M"\<(\G[#GP\:,;HX]<G\W;_"3)>8S^?ZBG&M5J1C.]E)V6VF]_OL52Q^-Q5&
MGB.;D56:BDDGRI)W=VMVU;6Z2."\9_L[^(O"OQ4TSP/!)#J5SJVQ]/O4RD4T
M3$Y<]=NW:Q8<X SSD9ZSQ/\ LJ06&D>)Y/#GC>T\4:UX93S-5TF.Q:%H1@LV
MUR[!R K< =5(Z\5] ZT\<'QV^ 5O.0M[%I-YYP<Y(S9D+G_@0:N-_9\1[/XV
M?'.:^#+:Q/>&X+G YN)#D_4!CFLOK55P4K[*_KK;^K'$\XQLJ"K*=G&"DU9>
M\_:.&O9672VK/GSX)? ?7?C7KPMK02:?H\6?M6KO 7BAP.% RH=B<?*#G!ST
MKE_B/X/_ .%?^.=:\.?:_M_]FW+6_P!I\KR_,QWVY./IDU[7^RG\6_$<GCKP
M/X$CNDM_#L5S=3/#"F'N&,4KCS&SR W( P.F<X%>;_M&_P#)<_&O_81D_I7=
M&I4^L.$MK77WGTE'$XMYI/#UFE#DNDO\5KM]WVV7J1?!3X077QD\47&FI?+I
M&GV=J]Y>ZB\)E6!%X'R@C))(X+#@,><8K@KE8DN95@D:6 .1'(Z;&9<\$KDX
M)';)^M?3G[.EI%8_LU_&/58?EOIK5[5GSR(U@;&/3_6O_D5-\$[P?#+]ESQA
MX_T**VF\5_;EM%NY(1(UI'NA0#!S_P ]"_/!++D$#F'B)1E+KJDEYLYYYI4I
M5JUES)2A"*V]YK5MV;Z^>VVI\L5ZW\ /V>-2^.M]J.R_.BZ38H/,U!K8S!I3
M]V-5W+DXR3SP,?WA7MGQBU'4O&O[.?@%;2UM;'5_&FKVW]H-!&(4NIRC(K/@
M<;BD3$_[(KVWX7>!=6^%VIZ+X2TS2@GA"QTN2:]UDR1AK[47=.=FXN %#]1C
MD#^$9YZV-DJ3<=):_AO_ , \O,.(:D,&W22A5;DE=IV4=&]4KMO1*VN_<^&/
MA=\"M3^*7C+6-&M+^"QL-(WM>ZG<J=D:*Q4$*#R3@G&0, \\5K?$']GRW\.?
M#N/QQX7\66WC'PXL_P!FN)TM&M7A;=M!V,S$C<0.QY4X(.:]Q^ /@K6O!^M?
M&[2M6L3:ZA-9)-' LB2%DD%R4(*$CD$<=:R-3NM*^+7[)FK_ /"'V<O@ZP\.
MS^;>:/Y@FBNB@5R3*1O;@[@3CYE&1T-#Q,_:Z/W;Q[6U7W^G0JIFV(>,7)/]
MTI4T[6<;35[M[W;=HVT[GG'@[X$_#SQUJ^GZ/I/Q;>ZUB\X2S3PO=9#;<L"Q
M<*  #DD@<4?\,RVE]\4/$'@72/&4>IZOIFFM>1-]@V)/<+]ZV)\T[&&Y?F^;
MJ00"M=-^S/'#\,_A)X_^*LZ*U];1_P!F:9YL9($AV\^X9Y(@<= C<]<<#^R[
MJ=U+^T5X6NY9WEN;BYG,TKL2TA>&3<2>Y.2:T<JMZCC-VBNMM]^QTRK8Q/%3
MI5VXTHZ74-9I<SVBM$K+YGDDT,EO*\4J-'*C%61QAE(X(([&F5Z/^T9I=KH_
MQP\96UF L'V]Y< Y 9P'8?\ ?3-QVKSBO1A+GBI=SZK#U57HPK)?$D_O5SW+
MXZ?LM:C\&O#6FZ]!JQU_3;AQ%<R+9F VK, 4R-[Y5N1GC!P/XA7/_$CX(?\
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M?GGU+$O#\L7:V\[/7RY7^9^<%>R? ?\ 9MU+XV6.KZD=2_L/2; ;%NFMO/\
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MX=_]#YX:_P#!O;__ !='U:O_ ,^W]S#F7<[6BN*_X7;\._\ H?/#7_@WM_\
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MKEJ;B&.08.Y0&4@Y"GKC(! !SG:_X8^^+?\ T*@_\&5I_P#':/\ AC[XM_\
M0J#_ ,&5I_\ ':RY\+R<G,K>J.1U\F=%8?VM/D6RYHZ:W[]SC_%?QB\4^+_'
M\'C*[U#R=<MF0VLELNU+8(<JJ*<_*"2<'.<G.<FNP\7_ +57B_Q?X?U32FLM
M$TG^UE$>HWNEV1BN;Q0-NV1RYR"..@XXZ4?\,??%O_H5!_X,K3_X[1_PQ]\6
M_P#H5!_X,K3_ ..T.6$=KN.FVJ%*MDDN2]2G[FWO1T_$\]^'GCJ_^&GC'3?$
MNF0VT]]8,[11W:LT1W(R'<%93T8]".:K^-?%MYX[\5ZIX@OXX(;W4)C/+';*
M5C5CV4$DX^I->E?\,??%O_H5!_X,K3_X[1_PQ]\6_P#H5!_X,K3_ ..U?ML/
MS<_.K^J.GZ_E?M?;>WAS6M?FCM>]M^YJ?LM>--(LE\:>"O$6IP:1I'BC2W@6
M^NIQ%'#,J.HY;Y5RLC')/5%'.17%_#;XT^(_@^NKZ;81Z;JFF7V8[O3-3C%U
M:2L/EW *P!XXR#AACK@8Z#_AC[XM_P#0J#_P96G_ ,=H_P"&/OBW_P!"H/\
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MT31-.O9?.O6T:R^SR7;Y!9I#N()8@$D $XYXXJW_ ,,??%O_ *%0?^#*T_\
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MI>)/A-\)_$&HB,1?:]5\-R7,VP9PN]YR<#)XSW-?+=?1W_#N_P#:!_Z$(?\
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M-*@EB:7SA%O,F^1P3^Y7&T+U/MCJ/^'=_P"T#_T(0_\ !SI__P ?H_X=W_M
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M>_'W_0!'_@9;_P#QRN;VD.YX']EX_P#Y\3_\!E_D>=T5Z)_PSWX^_P"@"/\
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M@I"?,P*IN/\ $-U<']O1LFJ;>D7Y>\[::7?W*^Q7LO,^':*]H^-7P<\->%?
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M.BLS^TI?[J?D?\:/[2E_NI^1_P :+![2)IT5F?VE+_=3\C_C1_:4O]U/R/\
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M-X/BUHGB:[G\'Z=XLG^UV5\MJUT(B%5-KI&"=Q"(W'!^<;@<;OGK_A6OB_\
MZ%76_P#P73?_ !-'_"M?%_\ T*NM_P#@NF_^)KJ65X35RK-O1)N2NK--6T[K
MK<GGEV/I.^^+WPVT;PW\']#T;Q)-?6_A?78[B^GN+":)O*4OOFV[3\K$[@@+
M, P!&0:TC\4?@WH'QGUKXK6?BR^U34&MG2#0%TR9#).46/S$F8!0A0'Y7 ()
M)SP%KY:_X5KXO_Z%76__  73?_$T?\*U\7_]"KK?_@NF_P#B:7]EX37]\]4T
M]8ZJ3NT].K[6'[278^E-2^(-]X>_9F^&/C-HTGOH?&4VI20CY%E/FWC.HX.
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M &[H\EQ<^'X7MY'$C21M\F]5(7YV?)8CB3VX^>O^%:^+_P#H5=;_ /!=-_\
M$T?\*U\7_P#0JZW_ ."Z;_XFB65X.I"4*M5RYN75N-_=T6R731BYY)Z(]@^
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M -2BLO\ X2G1?^@O8?\ @2G^-'_"4Z+_ -!>P_\  E/\: -2BLO_ (2G1?\
MH+V'_@2G^-'_  E.B_\ 07L/_ E/\: -2BLO_A*=%_Z"]A_X$I_C1_PE.B_]
M!>P_\"4_QH K>(/^0SX8_P"O]_\ TEGK=KD-?\3Z,=8\-$:M8D"_<G_24X_T
M6?WK;_X2G1?^@O8?^!*?XT :E%9?_"4Z+_T%[#_P)3_&C_A*=%_Z"]A_X$I_
MC0!J45E_\)3HO_07L/\ P)3_ !H_X2G1?^@O8?\ @2G^- &I167_ ,)3HO\
MT%[#_P "4_QH_P"$IT7_ *"]A_X$I_C0!J45E_\ "4Z+_P!!>P_\"4_QH_X2
MG1?^@O8?^!*?XT :E17<LD%K-)%"US*B,R0JP4R$#A020!GID\50_P"$IT7_
M *"]A_X$I_C1_P )3HO_ $%[#_P)3_&@#\R/AM\*/VE])_:'UGXT?$C]GB3X
MF^,97_XDJ3^.=+L[/1(\MM2&+,F2@;"'(VY9B"[;Q[EXT^&_QJ^%_P"TE>?'
M/X=?#>Q\:7/C;PQ;:=X@\)S:_!92Z7?QI%M?SY,1S(HB1/DY;#?=!#5]B_\
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M_P#(P?#[_KUU#_T.VKY$K]FX=C%Y93NN_P#Z4SSJWQLO_P#"0ZI_T$KS_O\
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M[]C_  K,\9^-=&^'WAZXUS7[W[#IL#1QM((GE=GD=8XXTC0,[NSLJJB@LQ8
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M LRKG<R@[E %;^S;3_GU@_[]C_"C^S;3_GU@_P"_8_PJS10!6_LVT_Y]8/\
MOV/\*/[-M/\ GU@_[]C_  JS10!6_LVT_P"?6#_OV/\ "C^S;3_GU@_[]C_"
MK-% %;^S;3_GU@_[]C_"C^S;3_GU@_[]C_"K-% %;^S;3_GU@_[]C_"C^S;3
M_GU@_P"_8_PJS10!6_LVT_Y]8/\ OV/\*/[-M/\ GU@_[]C_  JS10!S7B#3
MK0:QX9_T6'_C_?\ Y9C_ )]9ZW/[-M/^?6#_ +]C_"LOQ!_R&?#'_7^__I+/
M6[0!6_LVT_Y]8/\ OV/\*/[-M/\ GU@_[]C_  JS10!6_LVT_P"?6#_OV/\
M"C^S;3_GU@_[]C_"K-% %;^S;3_GU@_[]C_"C^S;3_GU@_[]C_"K-% %;^S;
M3_GU@_[]C_"C^S;3_GU@_P"_8_PJS10!6_LVT_Y]8/\ OV/\*/[-M/\ GU@_
M[]C_  JS10!6_LVT_P"?6#_OV/\ "C^S;3_GU@_[]C_"O+OB3^U9\*_A)XEE
M\/\ B?Q6MGK,$2W%S:6MC<WK6D3#*R7!@B<0*0<[I"HQSTYKTKP_X@TSQ7H=
MAK.C7]OJFDW\*7-K>VD@DBGC895U8<$$'K0!/_9MI_SZP?\ ?L?X4?V;:?\
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M&4E=R.N=RL!S7PQ^.OA/XP:[XIT[PK=RZG%X=E@AN-11!]DN3*A=3;R9_>H
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#8\&?\ (XZ#_P!A"W_]&K7[ 5^/_@S_ )''0?\
ML(6__HU:_8"OS#B[^/2]'^9W8?9A1117P)U!1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &%X@_
MY#/AC_K_ '_])9ZW:PO$'_(9\,?]?[_^DL];M !1110 4444 %%%% !1110
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M110!A>(/^0SX8_Z_W_\ 26>MVL+Q!_R&?#'_ %_O_P"DL];M !1110 4444
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MIHW 9'1U)#*0000<$$&K->*?L;.#^SOX:BCA(M8);V&VO0I2+4H5O)@E]"A
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M2TM+2'.V*)!A5R<D\#J223R22: -:BBB@ HHHH **** "BBB@ HHHH ****
M,*S_ .1XU;_L'67_ *-NJW:PK/\ Y'C5O^P=9?\ HVZK=H Q;C_7R?[Q_G4=
M27'^OD_WC_.HZHX'N%%%%,04444 %%%% !1110 4444 %%%% !1110 4444
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MZA_Z';5\B5^T<.?\BRG_ -O?^E,\VM\;"BBBOI3$**** "NP^$'@5_B3\2=
M\/ 'R+NY4W+ D;8%^>4Y X.Q6Q[XKCZ*SJ1E.$HP=FUH^WF-;GU&G[37@U?C
M6=>_X0:$%KK^SSK0U:YP;+_4[OL_^KQY7.S&,\]>:Z_PIX!\:?#+PM\6_#W@
M-;C^V[?6[1].>WVEGM7&]2#)\I_=G!/J#WKXMHKPZF40LHTI65HW4KR3Y6FM
MWMNK+34T51]3W?XP:5\=M1\&2W'Q AU"7P[83QW#O<FWV1R$^4C?)SUEV_\
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MYHH \'_:)T[2M,OM,7PMH6DVWQ?\:2C0--\21Z?$VH65KMS=71FV[]D%OO8
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M44 85G_R/&K?]@ZR_P#1MU6[6%9_\CQJW_8.LO\ T;=5NT 8MQ_KY/\ >/\
M.HZDN/\ 7R?[Q_G4=4<#W"BBBF(**** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** -:Q_X]4_'^=6*KV/_'JGX_SJ
MQ4'='X487@3_ )$G0/\ KP@_]%K11X$_Y$G0/^O"#_T6M%!1\?\ _!17_D8/
MA]_UZZA_Z';5\B5]=_\ !17_ )&#X??]>NH?^AVU?(E?M'#G_(LI_P#;W_I3
M/-K?&PHHHKZ4Q"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MA_Z';5\B5^T<.?\ (LI_]O?^E,\VM\;"BBBOI3$**** "BBB@ HHHH ****
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M^_Z]=0_]#MJ^1*^N_P#@HK_R,'P^_P"O74/_ $.VKY$K]HX<_P"193_[>_\
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M 4444 %%%% &%X@_Y#/AC_K_ '_])9ZW:PO$'_(9\,?]?[_^DL];M !1110
M4444 %%%% !1110 4444 %%%% !1110 5Y'KO[6?PD\->/7\&ZEXTM+;7HKJ
M.QF7R)VMK>X?&R&6Z5#!%(<@;'<'VKUROAGX,Z%IGBC_ ()8^)[K6X(?/UW0
M/$6L:Q/(@W&],UU(\SY_CC=%QNY7RE!^[0!]S45P7P!U>_U_X$?#C5-5+G5+
MWPWIMS=F1][><]K&SY;N=Q/-=[0 4444 %%%% !1110 4444 %%%% !1110
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MXQ_%WX$>,O#7B_Q?X=O_ !+KEY:S65E:0-;Z7ID44X=D241&:0LH'^L#8*@
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M444 %%%% !1110 4444 %%%% !1110!A>(/^0SX8_P"O]_\ TEGK=K"\0?\
M(9\,?]?[_P#I+/6[0 4444 %%%% !1110 4444 %%%% !1110 4444 %?+^M
M?L8:I=6'B'P=I/Q/U#1/A#XAOYK[4?!\6EQ/.%GD\VYMK>^+AH8)7+DKL8@.
MP##)KZ@HH @LK*#3;."TM8DM[:"-8HHHQA411A5 [   5/110 4444 %%%%
M!1110 4444 %%%% !1110 4444 85G_R/&K?]@ZR_P#1MU6[6%9_\CQJW_8.
MLO\ T;=5NT 8MQ_KY/\ >/\ .HZDN/\ 7R?[Q_G4=4<#W"BBBF(**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MY/\ >!V!,G /'&0.H\3^'M'\ ?M/:O\ $35_&NB#3M/GDNGTS[7NU-I#!M$
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M@_Y#/AC_ *_W_P#26>MVL+Q!_P AGPQ_U_O_ .DL];M !1110 4444 %%%%
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M4EQ_KY/]X_SJ.J.![A1113$%%%% !1110 4444 %%%% !1110 4444 %%%%
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M4>SBYJI;5*WR_I#OT"BBBK$%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ;'@S_ )''0?\ L(6_
M_HU:_8"OQ_\ !G_(XZ#_ -A"W_\ 1JU^P%?F'%W\>EZ/\SNP^S"BBBO@3J"B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** ,+Q!_R&?#'_7^__I+/6[6%X@_Y#/AC_K_?_P!)9ZW:
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M 4444 87B#_D,^&/^O\ ?_TEGK=K"\0?\AGPQ_U_O_Z2SUNT %%%% !1110
M4444 %%%% !1110 4444 %%%% !117R_K/[:&J6UCXB\8:3\,-1UKX0^';^:
MQU+QA%J<4<Y6"3R[FYM[(H6F@B<,"^]20C$*<' !]045!87UOJ=C;WEI,ES:
MW$:S0S1G*R(PRK ]P00:GH **** "BBB@ HHHH **** "BBB@ HHHH ****
M,*S_ .1XU;_L'67_ *-NJW:PK/\ Y'C5O^P=9?\ HVZK=H Q;C_7R?[Q_G4=
M27'^OD_WC_.HZHX'N%%%%,04444 %%%% !1110 4444 %%%% !1110 4444
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M* "BBB@ HHHH **** "BBB@#"\0?\AGPQ_U_O_Z2SUNUA>(/^0SX8_Z_W_\
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M?+_\31_PKGQ9_P!"OK/_ (+Y?_B:7_A8_BW_ *&C6O\ P83?_%4?\+'\6_\
M0T:U_P"#";_XJC_:?[OXA[HG_"N?%G_0KZS_ ."^7_XFC_A7/BS_ *%?6?\
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ML?Q;_P!#1K7_ (,)O_BJ/]I_N_B'NB?\*Y\6?]"OK/\ X+Y?_B:/^%<^+/\
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M0 ?VI9?\_<'_ ']7_&C^U++_ )^X/^_J_P"-']E67_/G;_\ ?I?\*/[*LO\
MGSM_^_2_X4 ']J67_/W!_P!_5_QH_M2R_P"?N#_OZO\ C1_95E_SYV__ 'Z7
M_"C^RK+_ )\[?_OTO^% !_:EE_S]P?\ ?U?\:/[4LO\ G[@_[^K_ (T?V59?
M\^=O_P!^E_PH_LJR_P"?.W_[]+_A0 ?VI9?\_<'_ ']7_&C^U++_ )^X/^_J
M_P"-']E67_/G;_\ ?I?\*/[*LO\ GSM_^_2_X4 ']J67_/W!_P!_5_QH_M2R
M_P"?N#_OZO\ C1_95E_SYV__ 'Z7_"C^RK+_ )\[?_OTO^% !_:EE_S]P?\
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M]P?]_5_QH_M2R_Y^X/\ OZO^-']E67_/G;_]^E_PH_LJR_Y\[?\ []+_ (4
M']J67_/W!_W]7_&C^U++_G[@_P"_J_XT?V59?\^=O_WZ7_"C^RK+_GSM_P#O
MTO\ A0 ?VI9?\_<'_?U?\:/[4LO^?N#_ +^K_C1_95E_SYV__?I?\*/[*LO^
M?.W_ ._2_P"% !_:EE_S]P?]_5_QH_M2R_Y^X/\ OZO^-']E67_/G;_]^E_P
MH_LJR_Y\[?\ []+_ (4 ']J67_/W!_W]7_&C^U++_G[@_P"_J_XT?V59?\^=
MO_WZ7_"C^RK+_GSM_P#OTO\ A0 ?VI9?\_<'_?U?\:/[4LO^?N#_ +^K_C1_
M95E_SYV__?I?\*/[*LO^?.W_ ._2_P"% !_:EE_S]P?]_5_QH_M2R_Y^X/\
MOZO^-']E67_/G;_]^E_PH_LJR_Y\[?\ []+_ (4 ']J67_/W!_W]7_&C^U++
M_G[@_P"_J_XT?V59?\^=O_WZ7_"C^RK+_GSM_P#OTO\ A0 ?VI9?\_<'_?U?
M\:/[4LO^?N#_ +^K_C1_95E_SYV__?I?\*/[*LO^?.W_ ._2_P"% !_:EE_S
M]P?]_5_QH_M2R_Y^X/\ OZO^-']E67_/G;_]^E_PH_LJR_Y\[?\ []+_ (4
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MO_WZ7_"@#.E=9)792&5B2"#D$4RGRHL<KJH"JI(  P *93.![A1113$%%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH V/!G_(XZ#_V$+?_ -&K7[ 5
M^/\ X,_Y''0?^PA;_P#HU:_8"OS#B[^/2]'^9W8?9A1117P)U!1110 4444
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MC6J3:A?K')!:Q&.!(Q\@GEF9ECC4&*$#>6?: >NT444 %%%% !1110 4444
M%%%% &%9_P#(\:M_V#K+_P!&W5;M85G_ ,CQJW_8.LO_ $;=5NT 8MQ_KY/]
MX_SJ.I+C_7R?[Q_G4=4<#W"BBBF(**** "BBB@ HHHH **** "BBB@ HHHH
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M* "BBB@ HHHH **** -CP9_R..@_]A"W_P#1JU^P%?C_ .#/^1QT'_L(6_\
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M6JWQ2^$&L^-_V<D\ 6-S8Q:R+338//N)'6WW6\T#N=P0M@B)L?+U(SCMY>/
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M\9VVFPV4^J:EX>M8)HK!+I=\1:%YDN)CY1$A%O#*0IQ@L"HY^R_9\UK3]/\
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M.X44458@HHHH **** -CP9_R..@_]A"W_P#1JU^P%?C_ .#/^1QT'_L(6_\
MZ-6OV K\PXN_CTO1_F=V'V84445\"=04444 %%%% !1110 4444 %%%% !11
M10!A>"O!&B_#OP^FB>'K+^S],2XN;M8/->7$MQ/)<3-N=BWS2RR-C.!NP,
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M^&']E^)--UG3=5T7P1:/?L()=->2.TU;4V<+?3R& .8YH$<,DA._!=@#] ?
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M8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH UK'_CU3\?YU8JO8_\>J?C_.K%0=T?A1A>!/\ D2= _P"O"#_T
M6M%'@3_D2= _Z\(/_1:T4%'Q_P#\%%?^1@^'W_7KJ'_H=M7R)7UW_P %%?\
MD8/A]_UZZA_Z';5\B5^T<.?\BRG_ -O?^E,\VM\;"BBBOI3$**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#8\&?\CCH/
M_80M_P#T:M?L!7X_^#/^1QT'_L(6_P#Z-6OV K\PXN_CTO1_F=V'V84445\"
M=04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!A>(/\ D,^&/^O]_P#TEGK=K"\0?\AGPQ_U_O\
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MSD ^MZCAN(KE"\,B2H&9"R," RDJPX[@@@CL0:^-?!WQ9\>7WQ=^'.@+XO\
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M-17VYSC(SBIJ ,*S_P"1XU;_ +!UE_Z-NJW:PK/_ )'C5O\ L'67_HVZK=H
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M^!B?_&Z_1LGS[!X+!0H5;\ROLN[;..I2E*3:/SRHK]#?^&#_ (:_\]=<_P#
MQ/\ XW1_PP?\-?\ GKKG_@8G_P ;KV?]:<O_ +WW?\$S]A,_/*BOT-_X8/\
MAK_SUUS_ ,#$_P#C='_#!_PU_P">NN?^!B?_ !NC_6G+_P"]]W_!#V$S\\J*
M_0W_ (8/^&O_ #UUS_P,3_XW1_PP?\-?^>NN?^!B?_&Z/]:<O_O?=_P0]A,_
M/*BOT-_X8/\ AK_SUUS_ ,#$_P#C='_#!_PU_P">NN?^!B?_ !NC_6G+_P"]
M]W_!#V$S\\J*_0W_ (8/^&O_ #UUS_P,3_XW1_PP?\-?^>NN?^!B?_&Z/]:<
MO_O?=_P0]A,_/*BOT-_X8/\ AK_SUUS_ ,#$_P#C='_#!_PU_P">NN?^!B?_
M !NC_6G+_P"]]W_!#V$S\\J*_0W_ (8/^&O_ #UUS_P,3_XW1_PP?\-?^>NN
M?^!B?_&Z/]:<O_O?=_P0]A,_/*BOT-_X8/\ AK_SUUS_ ,#$_P#C='_#!_PU
M_P">NN?^!B?_ !NC_6G+_P"]]W_!#V$S\\J*_0W_ (8/^&O_ #UUS_P,3_XW
M1_PP?\-?^>NN?^!B?_&Z/]:<O_O?=_P0]A,_/*BOT-_X8/\ AK_SUUS_ ,#$
M_P#C='_#!_PU_P">NN?^!B?_ !NC_6G+_P"]]W_!#V$S\\J*_0W_ (8/^&O_
M #UUS_P,3_XW1_PP?\-?^>NN?^!B?_&Z/]:<O_O?=_P0]A,_/*BOT-_X8/\
MAK_SUUS_ ,#$_P#C='_#!_PU_P">NN?^!B?_ !NC_6G+_P"]]W_!#V$S\\J*
M_0W_ (8/^&O_ #UUS_P,3_XW1_PP?\-?^>NN?^!B?_&Z/]:<O_O?=_P0]A,_
M/*BOT-_X8/\ AK_SUUS_ ,#$_P#C='_#!_PU_P">NN?^!B?_ !NC_6G+_P"]
M]W_!#V$S\\J*_0W_ (8/^&O_ #UUS_P,3_XW1_PP?\-?^>NN?^!B?_&Z/]:<
MO_O?=_P0]A,_/*BOT-_X8/\ AK_SUUS_ ,#$_P#C='_#!_PU_P">NN?^!B?_
M !NC_6G+_P"]]W_!#V$S\\J*_0W_ (8/^&O_ #UUS_P,3_XW1_PP?\-?^>NN
M?^!B?_&Z/]:<O_O?=_P0]A,_/*BOT-_X8/\ AK_SUUS_ ,#$_P#C='_#!_PU
M_P">NN?^!B?_ !NC_6G+_P"]]W_!#V$S\\J*_0W_ (8/^&O_ #UUS_P,3_XW
M1_PP?\-?^>NN?^!B?_&Z/]:<O_O?=_P0]A,_/*BOT-_X8/\ AK_SUUS_ ,#$
M_P#C='_#!_PU_P">NN?^!B?_ !NC_6G+_P"]]W_!#V$S\\J*_0W_ (8/^&O_
M #UUS_P,3_XW1_PP?\-?^>NN?^!B?_&Z/]:<O_O?=_P0]A,_/*BOT-_X8/\
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M9?\ 95]_T&KK_OU#_P#$4?V5??\ 0:NO^_4/_P 17RQN:E%9?]E7W_0:NO\
MOU#_ /$4?V5??]!JZ_[]0_\ Q% &I167_95]_P!!JZ_[]0__ !%']E7W_0:N
MO^_4/_Q% &I167_95]_T&KK_ +]0_P#Q%']E7W_0:NO^_4/_ ,10!J45E_V5
M??\ 0:NO^_4/_P 11_95]_T&KK_OU#_\10!J45E_V5??]!JZ_P"_4/\ \11_
M95]_T&KK_OU#_P#$4 :E%9?]E7W_ $&KK_OU#_\ $4?V5??]!JZ_[]0__$4
M:E%9?]E7W_0:NO\ OU#_ /$4?V5??]!JZ_[]0_\ Q% &I167_95]_P!!JZ_[
M]0__ !%']E7W_0:NO^_4/_Q% &I167_95]_T&KK_ +]0_P#Q%']E7W_0:NO^
M_4/_ ,10!J45E_V5??\ 0:NO^_4/_P 11_95]_T&KK_OU#_\10!J45E_V5??
M]!JZ_P"_4/\ \11_95]_T&KK_OU#_P#$4 :E%9?]E7W_ $&KK_OU#_\ $4?V
M5??]!JZ_[]0__$4 :E%9?]E7W_0:NO\ OU#_ /$4?V5??]!JZ_[]0_\ Q% &
MI167_95]_P!!JZ_[]0__ !%']E7W_0:NO^_4/_Q% &I167_95]_T&KK_ +]0
M_P#Q%']E7W_0:NO^_4/_ ,10!6\0?\AGPQ_U_O\ ^DL];M85WX:N+RXLYI-9
MN]]I*9H\1PCYBC)S\GH[59_LJ^_Z#5U_WZA_^(H U*Y3Q=\*_"GCSQ'X5U_7
MM%@U+6/"UT][HUW(S!K29TV,PP0&R,<,",JIQE01K_V5??\ 0:NO^_4/_P 1
M1_95]_T&KK_OU#_\10!S?C;X)^"_B-=ZK<^(=&_M"?5-)&AWC?:IHO-LA+YP
MBPCJ!^\^;<,-VSCBHO'?P-\'?$C78=9UNRO_ .TH[0Z>\^FZQ>Z>;FU+%_(G
M%M-&)XMQ8[)0RC>_'S-GJ?[*OO\ H-77_?J'_P"(H_LJ^_Z#5U_WZA_^(H Y
M7P%\!_ OPPNM+N/#&@KI,FEV%SI=D$N9G2"UGN?M4L2J[D!3, PX^4 *NU1M
MKH;7P/HEEXVU'Q=#9;/$.H6,&FW-YYKGS+>%Y7B386V#:T\IR "=W)( Q9_L
MJ^_Z#5U_WZA_^(H_LJ^_Z#5U_P!^H?\ XB@#S_0/V7_AIX:U.VN[+P]*\-H\
M\EEI5[J=W=Z78-+N\PVMA+*UM;<.ZCRHTVJ[*N%8@XVK_LJ>#]/\%Z]8>%["
MXBU>7P_?:'HS:UK5]?6NE)/ 8O+MHYY95M8\"-2($7Y$"X( %>L_V5??]!JZ
M_P"_4/\ \11_95]_T&KK_OU#_P#$4 >6?"[]E?P3X"\*6%G<Z5)>:F-#.C7+
M3ZM>W<%O'+&HNHK))I"MI%(PY6!8@0J# VJ!V.B?!?P7X>>^:RT*)1?:+:^'
M;F.>:2:.;3[99%@@9'9E(59I03C<V[YB<#'1?V5??]!JZ_[]0_\ Q%']E7W_
M $&KK_OU#_\ $4 >>>%_V7?ASX0\1Z!K]CI6I3ZUX?#)I5]JFOZCJ$MC&87A
M:*(W$\FV(I(P,0^0G:=N54A(_P!EOX<6WA[1-%M=*U/3[30IYI])FL/$&HVU
MWIPE0)+#;W,=PLT,#*%S;HXB^13LRJX]$_LJ^_Z#5U_WZA_^(H_LJ^_Z#5U_
MWZA_^(H YSPS\%/!/@V[\,7.B:##ILWAK3[C2]+,$L@$%O</&\X(W8D:1X8W
M:1PSE@Q+99B>:^&?PAO-&^,/Q!^)?B"PTFRU_P 1+::;;1:5<R7(2QME(1Y)
M'BB/FR,Y+*%*J(X@&;!->D?V5??]!JZ_[]0__$4?V5??]!JZ_P"_4/\ \10!
MF>*_AMX?\:ZWX<UC5;6X;5/#UT;O3;NTOKBTDA=@ ZL873S(W"@-$^Y' PRD
M5ST_[._@*7P1X5\)Q:3=V&C^%L'1&TW5KRSN[#$3Q?NKN*99QF.1T;]Y\P8A
MLUVG]E7W_0:NO^_4/_Q%']E7W_0:NO\ OU#_ /$4 >>:?^RU\,=)T+5M)L_#
MDEM;:IJ$&KW4T6IW8N3?Q(J)>)<>;YL=P0@+3(ZR.Q=G9F=B;%M^S7\/K2#2
MUBTF^6[T[5SKL&JG6KXZD]Z8FA,LMZ9OM$P,+F(I)(RE,(054 =W_95]_P!!
MJZ_[]0__ !%']E7W_0:NO^_4/_Q% %+Q%X T'Q7K>C:OJMA]JU'1Q<K8S>=(
MGDB>(Q3<*P#;D)'S XZC!YK+T[X,^#M)TSP+I]IH_E6?@?:?#\?VJ8_8MML]
ML.2^9/W,CK^\+=<]0#70_P!E7W_0:NO^_4/_ ,11_95]_P!!JZ_[]0__ !%
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M5_95]_T&KK_OU#_\11_95]_T&KK_ +]0_P#Q% &I167_ &5??]!JZ_[]0_\
MQ%']E7W_ $&KK_OU#_\ $4 5K/\ Y'C5O^P=9?\ HVZK=K!C\-7$>I3WRZS=
M^?-#'"_[N'&U&<KQL]9&_2K7]E7W_0:NO^_4/_Q% &I167_95]_T&KK_ +]0
M_P#Q%']E7W_0:NO^_4/_ ,10!J45E_V5??\ 0:NO^_4/_P 11_95]_T&KK_O
MU#_\10!J45E_V5??]!JZ_P"_4/\ \11_95]_T&KK_OU#_P#$4 :E%9?]E7W_
M $&KK_OU#_\ $4?V5??]!JZ_[]0__$4 :E%9?]E7W_0:NO\ OU#_ /$4?V5?
M?]!JZ_[]0_\ Q% &I167_95]_P!!JZ_[]0__ !%']E7W_0:NO^_4/_Q% &I1
M67_95]_T&KK_ +]0_P#Q%']E7W_0:NO^_4/_ ,10!J45E_V5??\ 0:NO^_4/
M_P 11_95]_T&KK_OU#_\10!J45E_V5??]!JZ_P"_4/\ \11_95]_T&KK_OU#
M_P#$4 :E%9?]E7W_ $&KK_OU#_\ $4?V5??]!JZ_[]0__$4 :E%9?]E7W_0:
MNO\ OU#_ /$4?V5??]!JZ_[]0_\ Q% &I167_95]_P!!JZ_[]0__ !%']E7W
M_0:NO^_4/_Q% &I167_95]_T&KK_ +]0_P#Q%']E7W_0:NO^_4/_ ,10!J45
ME_V5??\ 0:NO^_4/_P 11_95]_T&KK_OU#_\10!J45E_V5??]!JZ_P"_4/\
M\11_95]_T&KK_OU#_P#$4 :E%9?]E7W_ $&KK_OU#_\ $4?V5??]!JZ_[]0_
M_$4 5O G_(DZ!_UX0?\ HM:*TM)TV+1M*L["%G>&UA2!&D(+$*H )P ,\>E%
$(#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>syre-20260630_g5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 syre-20260630_g5.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 0^"L(# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M16+XP\::#\/] N=<\2:M::)I-N/WMW>RB- 3T&3U)[ <GL*A)MV0S:HKX_\
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MPH.Z-2BBBO*+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>O;_ %6W6Y@DTNWADB56D:,!B\R$'*GH#Q5KXX?MD?##X W_ /9GB/69+O7
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MC/[4?A7XM6X^'VCZ?K%MK/A7Q%<0WL]]#$EO(8A) WE,LK,06Y&Y5X]#Q6N
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?B)^R?\ !T?'OXTZ)X+N[FXM]"G9KW4_L[X)AA1FX[;B3L#$<>837[=^+O\
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M7PIOOB#X$TL^'[O29(C?6$$KO;SPO(L>\*Y.QE+J?E(! /&>:_1*O _V\?\
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M0RZOID-TT2F(DA3(I(!/85^C-C8VVF65O9V=O%:6EO&L,-O @2.)%&%55'
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M -B^?_2F&OU)N[2*_M)K:X0203(T<B'HRD8(_(U^6W_!)?\ Y+3XO_[%\_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MXQU:)#]E^T6RV]I!)@XE,(9B[*<$!GQQT/!%6R^,_;*;MORV_7L+WK6/#/\
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MM1G=O=6VT"%UHSJ:***\@T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM;CQ1)$+**52K?9(MVV3!Z!V=B/4(I'!%;7P@_X)C_#3X>:K!JGB.\O/'5[
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M<D]+'UG7PM_P5J_Y)!X+_P"PZ?\ TGDK[IKPK]K7]F'_ (:D\(:+H7_"2_\
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M%/A]JUII.NVFI^.+VW>#3K"QF65X'8%1/+M/R*G49(+$  =2//\ XE_\$U_
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MIW>4[-N\SSTQG=C&WC'>ML/BJ,,=.M*7NN^NHFGRI'UG7@?[>/\ R:5\1/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@4445F,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+C_Y H^KS[K_ ,"C_F%SLZ*XS^U?B'_T*_AG_P *2X_^0*/[5^(?_0K^&?\
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M_P#D"C^U?B'_ -"OX9_\*2X_^0*/J\^Z_P# H_YA<[.BN,_M7XA_]"OX9_\
M"DN/_D"C^U?B'_T*_AG_ ,*2X_\ D"CZO/NO_ H_YA<[.BN,_M7XA_\ 0K^&
M?_"DN/\ Y H_M7XA_P#0K^&?_"DN/_D"CZO/NO\ P*/^87.SHKC/[5^(?_0K
M^&?_  I+C_Y H_M7XA_]"OX9_P#"DN/_ ) H^KS[K_P*/^87.SHKC/[5^(?_
M $*_AG_PI+C_ .0*/[5^(?\ T*_AG_PI+C_Y H^KS[K_ ,"C_F%SLZ*XS^U?
MB'_T*_AG_P *2X_^0*/[5^(?_0K^&?\ PI+C_P"0*/J\^Z_\"C_F%SLZ*XS^
MU?B'_P!"OX9_\*2X_P#D"C^U?B'_ -"OX9_\*2X_^0*/J\^Z_P# H_YA<[.B
MN,_M7XA_]"OX9_\ "DN/_D"C^U?B'_T*_AG_ ,*2X_\ D"CZO/NO_ H_YA<[
M.BN,_M7XA_\ 0K^&?_"DN/\ Y H_M7XA_P#0K^&?_"DN/_D"CZO/NO\ P*/^
M87.SHKC/[5^(?_0K^&?_  I+C_Y H_M7XA_]"OX9_P#"DN/_ ) H^KS[K_P*
M/^87.SHKC/[5^(?_ $*_AG_PI+C_ .0*/[5^(?\ T*_AG_PI+C_Y H^KS[K_
M ,"C_F%SLZ*XS^U?B'_T*_AG_P *2X_^0*/[5^(?_0K^&?\ PI+C_P"0*/J\
M^Z_\"C_F%SLZ*XS^U?B'_P!"OX9_\*2X_P#D"C^U?B'_ -"OX9_\*2X_^0*/
MJ\^Z_P# H_YA<[.BN,_M7XA_]"OX9_\ "DN/_D"C^U?B'_T*_AG_ ,*2X_\
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M_P#A27'_ ,@4?VK\0_\ H5_#/_A27'_R!1]7GW7_ (%'_,+G9T5QG]J_$/\
MZ%?PS_X4EQ_\@4?VK\0_^A7\,_\ A27'_P @4?5Y]U_X%'_,+G9T5QG]J_$/
M_H5_#/\ X4EQ_P#(%']J_$/_ *%?PS_X4EQ_\@4?5Y]U_P"!1_S"YV=%<9_:
MOQ#_ .A7\,_^%)<?_(%']J_$/_H5_#/_ (4EQ_\ (%'U>?=?^!1_S"YV=%<9
M_:OQ#_Z%?PS_ .%)<?\ R!1_:OQ#_P"A7\,_^%)<?_(%'U>?=?\ @4?\PN=G
M17&?VK\0_P#H5_#/_A27'_R!1_:OQ#_Z%?PS_P"%)<?_ "!1]7GW7_@4?\PN
M=G17&?VK\0_^A7\,_P#A27'_ ,@4?VK\0_\ H5_#/_A27'_R!1]7GW7_ (%'
M_,+G9T5QG]J_$/\ Z%?PS_X4EQ_\@4?VK\0_^A7\,_\ A27'_P @4?5Y]U_X
M%'_,+G9T5QG]J_$/_H5_#/\ X4EQ_P#(%']J_$/_ *%?PS_X4EQ_\@4?5Y]U
M_P"!1_S"YV=%<9_:OQ#_ .A7\,_^%)<?_(%']J_$/_H5_#/_ (4EQ_\ (%'U
M>?=?^!1_S"YV=%<9_:OQ#_Z%?PS_ .%)<?\ R!1_:OQ#_P"A7\,_^%)<?_(%
M'U>?=?\ @4?\PN=G17&?VK\0_P#H5_#/_A27'_R!1_:OQ#_Z%?PS_P"%)<?_
M "!1]7GW7_@4?\PN=G17&?VK\0_^A7\,_P#A27'_ ,@4?VK\0_\ H5_#/_A2
M7'_R!1]7GW7_ (%'_,+G9T5QG]J_$/\ Z%?PS_X4EQ_\@4?VK\0_^A7\,_\
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M5Y]U_P"!1_S"YV=%<9_:OQ#_ .A7\,_^%)<?_(%']J_$/_H5_#/_ (4EQ_\
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MEQ_\@4?VK\0_^A7\,_\ A27'_P @4?5Y]U_X%'_,+G9T5QG]J_$/_H5_#/\
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MS"YV=%<9_:OQ#_Z%?PS_ .%)<?\ R!1_:OQ#_P"A7\,_^%)<?_(%'U>?=?\
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M_P"%)<?_ "!1]7GW7_@4?\PN=G17&?VK\0_^A7\,_P#A27'_ ,@4?VK\0_\
MH5_#/_A27'_R!1]7GW7_ (%'_,+G9T5QG]J_$/\ Z%?PS_X4EQ_\@4?VK\0_
M^A7\,_\ A27'_P @4?5Y]U_X%'_,+G9T5QG]J_$/_H5_#/\ X4EQ_P#(%']J
M_$/_ *%?PS_X4EQ_\@4?5Y]U_P"!1_S"YV=%<9_:OQ#_ .A7\,_^%)<?_(%'
M]J_$/_H5_#/_ (4EQ_\ (%'U>?=?^!1_S"YV=%<9_:OQ#_Z%?PS_ .%)<?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQ^S7Q8^)ND?!OX>:UXRUY;A]*TJ)9)DM%5I7W.J*J!F4$EG4#)'6OG_X9?\
M!2'X:?%7Q]H?A'2=#\5V^I:O<"V@EO;2V6%6(/+E;AB!QV!KA_\ @J]\0O[$
M^$OAKPC#*%GUW4C<S*#R8+=<X(]#))&<_P"P:^.?V=/"4W@/]MCP9X=N RW6
MF:ZEK.'&")%4AQCM\V>*6$P%*IA95JF^K7R_X(2DU*R/VKHKYI_:^_;4T?\
M9C@L])M-/'B#QC?PF>&P:3RX;:+)42S,.<$@A57D[6R5X)^<;/\ X*6?%SP5
MJ&G7OQ%^%5O9>'+\Y@DAL;O3Y94[M%).SI)@8X &?49X\ZEE^(K04XK1[:[^
MA3DEH?I)17F\G[0'@Y?@:WQ82_:3PB+ WXE"CS#SL\G;G_6>9^[VY^_QGO7Q
M"O\ P4A^-?Q!O;^Y^'/PFM=1T>T8^9C3KW4Y(5Z@R/ Z*IQR>*BC@JU>_*K)
M:.^FHW)(_2:BOCC]C_\ ;YF_: \:2>"O%/A^#0_$;0R3VL]@SFWG\L9="CDL
MC 9(Y(.#TP,\W^T?^W[XL^!'[2LG@O\ LC1+KP=9RV,EY.UK,]_Y$B1O/L83
MJF\*S;<KC.,YJU@,0ZKHV]Y*_P A<RM<^ZZ*_-;QA_P4N^+^FK;^(;+X5VFD
M>"+N4K9WFL65XPN%[!;D,D9;'HI_&OM/]F?]H#3/VDOA?;>+-/M&TVX69[._
MT]Y!(;:X4*64-@;E*LK X'#<@'-37P-?#P52:T];C4D]CU:HYYX[:&2::18H
M8U+O([!550,DDGH!4E?-O_!0'XP'X3?LYZU':3^3K'B(_P!C6A4X91(I,SC'
M(Q$'&>Q9:YJ-)UJD:<=VQMV5S(^'_P#P4?\ A9\1_B/I/@W3K'Q':WFJ7GV&
MVOKVU@2U:0DA/F6=G <X5?DSEAD#G'U37X0>)?@OXA^&_P )/AY\4?,D@A\0
MW=R;9D&&M6A=?)8\=7VR,OLF?K^T/P&^*-O\9_A!X6\8P% ^IV2/<QH1B.X7
MY)D^@D5P/;%>MF.#I4%&I0^'5/U1$)-Z,\K^.G[>GP__ &?O'\_A#Q%H_B6]
MU*&"*X:73+6WDA*N,@ O.ASZ\5Y]_P /8?A'_P!"[XU_\ ;3_P"2J^6_^"B\
M:3?MBF.15>-[33E96&001R"*_2VX_9Q^#\,$DDWPP\$Q1*I9W;0+-0J@<DGR
M^/K6E2CA,/1I3J1;<E?1^@DY-NQQ_P $OVVOA;\>==30]!U.ZT_79%+0Z;J]
MOY$LX );8061B "=H;..<8!QK?M&_M3>%/V8K/0KGQ3I^LW\>L231VXTB&*0
MJ8PA;?YDJ8^^,8SWZ5^8?Q2T;P]X1_;CM;'X3NK:?;^(-.-@FF2>;&ER3$9(
MXB,Y42%EQR!R.@KZ7_X*\?\ (O?#/_KZO_\ T""K> H_6*,5?EFKV>ZTN+F=
MF?<'PO\ B)IOQ9\ :)XOTB"ZMM-U>#[1!%>HJS*N2,,%9@#QV)KS;]HS]K[P
M;^S'J&B6?BG3=<OY=7BEF@.D00R*HC*AMWF2I@_,,8SWKC/V1?CM\-?#7[-G
M@#3-7^(?A32M2MM."3V=[K=M#-$V]N&1G!4^Q%?*G_!4?XA^%?B#XF\ 2^%O
M$VC^)8K:SNUG?2+^*Z6(EXRH8QL=I.#C/H:YL/@U4Q?LIQ?+=_A>Q3E:-S[_
M /B+^T1X<^&7P5M/B?JEEJEQH%U!:7"6UG%&UT%N-NP%6D5<C>,_-ZXS5CX!
M?'KP_P#M&>!I/%7ANSU*QTY+R2R,6JQ1QR[T5&)PCN,8<=\]>*^;_P!KG_E'
M+H/_ &#-"_E#6M_P2Q_Y-HN_^Q@NO_14%9RPU-825;JI6^0[OFL?8=%%?%'[
M3W_!0J[^%_Q)E^'WP\\,P^*?$=LZP7,]UYDD:W# $01Q1$-(PR <,,'*X)!K
MAH8>IB9<E-793:6Y]KU6U+4[/1K">^U"[@L;*W0R37-S((XXU'5F8D #W-?G
M#%_P4O\ BW\//$MI:?%#X76NE6DV':V6QN]-NS'GET%P[AL?0#W%=]_P4+^,
MOBW4/@IHT/@_P\=8^'GB[2$O]2UMM/GD-G&7@DMR9481Q;MPX<'/05VK+JRJ
M0A.R4NM]">=6N?5?PG^./A'XW1:Y<>#M0;5;'2+S[#->B,I%+)L#'RR>64 C
MYL 'MD<UWU?DI^P#\7_BKX*U;3_#/A#P3_;W@S6?$EHFM:Q_9-W<_84=HXY3
MYT3B./;%\^7!QU/%?K76>.POU6KR)Z=/^".,N9'SO!^W'X$D^/1^$DVD>(K/
MQ)_:3:6+JXMK<69E&=K!A.7VOQM.S)W#(%>P_$SXAZ5\)_ .N>+];\XZ7I%L
M;F=+90TK@8 5 Q +,2 ,D#)'(K\S/^"A.FS?"']L/P_X\L$*&\BL=95H_ES/
M;R"-A]<0QG_@5?0G_!3_ .*$&G_L[Z)HVGW(D7Q9?Q.K(V!+:1*)BV.XWF#\
MZ[)8*$Y4/9[3W^6Y/,];GH?P,_;W^'?Q_P#B!;^#]!TWQ#IVJW$$L\3ZM;6\
M<3^6-S*"D[G=MR<8Z*>:]0^.WQR\/?L]> 9/%OB6&^N=/6YCM5@TZ-'GDD<G
M 4.Z+P Q/S#@&OR$^&-AJW[-7Q[^$?B+5]UO!J$=AK2L5*'[#=$QOU_V#(*^
MMO\ @KAXU\CP]X \(QR'-S=7&J3Q@\ 1H(XR?KYLOY&MZN7TEBJ=.G\$OTW)
M4WRML^P_@/\ ''1?VA/ :^+O#^GZIIVEO<R6L::M%''*Y3&Y@(Y'&W)(ZYRI
MX]<#]HK]JOP7^S)9Z/+XI34;ZXU61UM[+2(XI9]J#YI&621 $!(&<YR>!P<>
M6VWBS6?V1?V&O!$^@^'H];\1?9;6--/<.0+FZ+3.65!N?:SM\H(SZC%?GE^T
MYX3^+:7FA>//BZL\&J^*C<BSM+P[)H(H/+RIA'$*?OQM3@\,2!G)RPN IXBN
MVW:%VDKZNPW)I'[4>"/%EGX]\%Z!XFT^.>&PUK3[?4K>.Y4+*D<T:R*'"D@,
M PR 2,]S7C_QQ_;;^%WP#UA]&US4KK5-=C&Z;2]%A$\T.1D>86944D$?*6S@
M@XP:[3]FW_DW7X6?]BKI7_I)%7RK\(_^"<^K67QSOO&GQ6U/0O&VE7!N;Q[1
M3,[3WDC@JTJ.@4H TA(+'Y@HP1DCBHT\/SS==V4=EU93;LK'K7PE_P""A7PB
M^+GB*UT*VO=2\.:I=N(K:'7K9(5F<G 021NZ!CV#,,]!SQ7TO7Y*?\%+_AYX
M%^&OQ3\,1>"],L/#]_<Z>T^H6&E(L,49$F(I!&N C,-_3&=H..Y_4?X:RZE<
M?#KPK+K/F?VN^E6K7OG'+^>85\S=[[LYJ\9AZ5.G3K4;I2OH_((MMM,W[FYA
ML[>6XN)4@@B0R22R,%5% R22>  .<U\C:]_P5'^#6C:W+86\'B76((W*?VA8
M6$7V=L'&X>9*CD=_NUU_[=GQ#\=^ /@Y*/!'AK_A(EU47%AJS?8)[K['9M;R
M;Y_W3#R]O]]\J.XK\N?V=M6\4Z1J>M2>%_A)I/Q8F>!$GM]6\.SZPMDNXX=4
MC(\LL1C<?[N!WKJP& IUJ4JU77LKV^\F4FG9'[?>$/$]GXV\*:-XAT]95T_5
MK.&_MA.FR3RI4#IN7)P=K#CM6O7PA^TM^W)XG_9I^.=EX!T?0?#[>#+&VL2X
MDM)FN8X& WK'MF1!A1A05P,#.:K?LX_\%!/'_P ??C]IWA&'PAH=MX=O7EE=
MHS-]JM+=$9B[R%RC'A1PBY+ <9KD>75W3]LE[MK[]"N=7L??%%?$/[1__!1U
M?A_X[NO _P -O#L7B[7K28VMQ>7!=X!< X,,<4>'E(/!(9>00,]:XCPY_P %
M,/'_ (&\7VNE_&3X:#0;2<J7:TLKFQNH8R?]8(;AF\P#T!7Z]J4<MQ,X*:CO
MK:^OW!SH_16BO"/VE_VA[GX8?LYR_$OP.VEZX)6M'LI;Q'DMIHII%&[".C?=
M;U&#U':OE+P[_P %,OBCXU\,0V/A?X96_B3QI'YLUZ^FV-U-:00 X0B"-VD/
M&2S%U X '>HHX&O7ASP6E[;V!R2T/TDHK\\/AI_P5<WZ'K:>/?"*+X@MHPVG
M0Z%O2*\EW!3"PD+F(C.[=EA@,,9P&Q9/^"G/Q2\$>,;2'Q[\,+/2-&N-LZV3
M6MU9WQMV/$B/,Q5^,X.P XQD=1M_9>*NUR[>:U] YXGZ4U6U&^CTS3[J\E#-
M%;Q-,X098A02<>_%5O#?B"Q\6>'=+US3)OM&FZG:Q7MK+C&^*1 Z-^*L#4?B
M[_D5-:_Z\IO_ $6U>6EK9EGB/[/?[;O@;]I3QI>^&?#.E>(;&_M-/?4GDU:V
M@CB,:R1QD QS.=V95XQC //K]"5^(/['OQ[?]GCXBZUKUKX?N/$^JZCHLNDZ
M?IUNQ&^XDN('4M@%BH$3<*"2<#C.1]/:7_P4U^)'@3QQ!IOQ7^&D&BZ?(59[
M:"SNK"^AB8\2!+AV$F!VPN<=17T&*RJ:JM8=:6[ZF49JVI^D%%>4_%S]H_PI
M\)O@JOQ*FF_M;2+J&%],BM7 :_>9=T2(3TRN6)/158X.,5\3)_P4<^/7B33K
MOQ#X;^%&GS^%;;)FO1I-_=Q0A?O;[A)%08'7(&*\RA@:U=.459+3734MR2/T
MOHKYB_8U_;0@_:?35M*U'1DT+Q/I<2W,D5M(9+>XA+;=Z9^92&(!4Y^\""><
M>??$+]O+QIXD^,E_\-_@?X'L_%VIV$DD,M[J3MY<CQMME*J)(PL:M@>8T@!]
M,8R+ UW4E2:LX[W>B^8<RM<^WJ*^#4_;@^.'PO\ '^F>'OBQ\'X46]^<+X:2
M1YC%G#/%B69)2O=0P[<C(KZN^-GQR\._ GX9W7C3Q 9S9KLCMK1(RD]S,X)2
M)5;!5B 2=V-H5B>F*BIA*M.48VOS;6=[@I)GHE%?FBW_  4K^-.L6UYXET3X
M5Z?)X)M'/G79L+VX2%0>CW2.L:G&.2@^E?7_ .RO^U3H/[4'A2[OK&T?1]<T
MUDCU'2991(8MP^5T8 ;HVPP!(!RI!'3.E; 5Z$.>:TZV=[>H*29E>$/VW? W
MC3X^S_"*QTKQ#%XDAU"^TUKJXMH!9F2U65I"&$Q?:1"VT[,G(R!S@_:%_;=\
M#?LU^-++PSXFTKQ#?7]WIZ:DDFDVT$D0C:22, F29#NS$W&,8(Y]/B/X!_\
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MO2K5&;>ZF5F9@@+$#*_*HR<]1R1,,NYJ=5;RBU;737_@!SZH_9RBOSF\$_\
M!3GQKH'Q(AT#XL^!;+0+)YTAN/LUM<6=W8*Q&'DCG=MP ()'RG'(]*_1FO+Q
M&%JX9I5%OL6I)[!14%]>V^F65Q>7<T=M:V\;2S32L%2-%&69B>@ !)-?GSXS
M_P""E_C/Q=XXN="^"OP]7Q/;P;O+FNK*YO+BZ13S*L$#*R)TZDGN<= 8?"U<
M2W[-;;OH#:6Y^AM?//QN_;@\"_ 3XCVW@KQ!I/B&\U6>"&X6;3;:!X LC,J@
MEYD;.5.?E_.O*/V9O^"B=S\2/B-;> ?B/X;@\+>(+R7[+:W5H)(XC<]!!)#*
M2T;,> =Q^8A2!G-?._\ P4E_Y.\TC_L&:?\ ^CI*]'#9>_K'L<0NER7+2Z/T
M-_:(_:2\,_LS^&],UKQ/8ZM?VNH7?V.)-(ABD=7V,^6$DB#&%/0GZ5U/PE^)
MVE_&7X=Z-XST6WO+72]5C>2"&_1$F4+(R'<$9E'*'HQXQ7S_ /\ !1#XK?\
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MO4:DF>PT5^=GB'_@IKXI\ _';QEX:U[PWH]_X8T35-2TZW338)H[ZX,,LD<
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MU]?N%SH^_P"BO#/VO_CMK7P#^"<GC/PQ;Z9J-[]LMX(UU%'E@:.3.6'ENA/
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M,>M^$K/PMJ&L7\6KV]Q-.=7FBD93&R!=OEQ)@?,<YSVK],OV1=#U+PU^S9X
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M:\2_8_[4^T_V/ITUWY&_[)LW^6IV[MK8SUVG'0UY&5M1Q<&WW_)FD_A/J_\
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MH*W756Z6(VCRV"TU:_U/_@E3J,5ZSM%9>(5MK4NV?W/VF-\#T =W&/:O?O\
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M<^E?0O\ P5GT;3YO@MX1U:2&,ZI;^(%M893C>(9+:=I%'?!:*(GZ"OD3X"_
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MVY1<2$1E0&;YE5GQT.<5Q4XT:T)5H<O,Y-OF>B5^Q3NG9F5_P2>_Y.*\1?\
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MLJ>'M0L88DO]5NKR?4)4QO>1+F2) Q'/$<:8!]<]Z['Q9^R?X?\ $/[,%O\
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MED+ NB%00""1GC-=N$C&AB8Q=3F?*[ZZ+;1,EZK8]0_X*U?\D@\%_P#8=/\
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MO(EKEYC@8RS] .!C=CLPT*-)TIP<;6U;>M^R[$N[N>S?\XE/^X7_ .Y.K_\
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M^)I*Z6ARGQ;\<_M-?$WX!^(;V^\%>&OA_P##?^QVFEA8+]IDLP@(149W93@
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M?\%</#^E'PMX!UPQQIK8O9[)9 N'DMRF\@GN%8# [;SCJ:\TM/@7^T+^P_\
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MM-0MG@N(!+=W.TM&X##*NK#(Y!![U\(?"'PA^TA^R3\0-?A\+_#2_P!5O;Z
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH _/?_@GM^RM\4?@=\9]:UWQMX7_L32KC
MP_-8Q7']H6MQNF:YMG"[8I78?+&YR1CCKR*_0BBBNK$XF>*J>TFE?R)2Y59!
M1117*4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %9WAS_ )%[2_\ KUB_] %:-9WAS_D7M+_Z]8O_
M $ 5:^%_+]1=31HHHJ!A1110 4444 %%%% !7PW_ ,%&/V;?B-\>/$'@FY\#
M>'?[<@TZUNH[IOMUM;^6SO&5&)9$)R%/3/2ON2BNG#UY8:HJL-UW$U=6.6^%
M>BWGAOX8>$-)U&'[/J%AH]G:W,.Y6\N5($5URI(."",@D>E=3116$GS-MC"B
MBBI **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#YY_;L^%/B
MGXR_ 2X\.>#]+_MC67U&VG6V^T1091"VX[I65>,CC.:/V$_A3XI^#7P$M_#G
MC#2_['UE-1N9VMOM$4^$<KM.Z)F7G!XSFOH:BNOZS/V'U>RM>_F3;6X4445R
M%!1110 4444 %%%% !1110 5\H?\%$/@?XV^.GPX\,:7X'T7^V[^SU8W,\7V
MN"WV1^2Z[LRN@/) P#FOJ^BMZ%:5"HJL=T)JZL>1?LE> ]=^&7[._@SPQXEL
M?[-US3[>5+FU\Z.7RRT\C@;HV93\K \$]:]=HHJ*DW4FYO=NX)6T"BBBLQA1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5G>'/^1>TO\ Z]8O_0!6C6=X<_Y%[2_^O6+_ - %6OA?R_474T:***@8
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 5G>'/^1>TO\ Z]8O_0!6C6=X<_Y%[2_^O6+_ - %6OA?R_47
M4T:***@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5G>'/^1>TO\ Z]8O_0!6C6=X<_Y%[2_^O6+_ - %
M6OA?R_474T:***@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 5G>'/^1>TO\ Z]8O_0!6C6=X<_Y%[2_^
MO6+_ - %6OA?R_474T:***@84444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *SO#G_(O:7_UZQ?^@"M&L[PY_P B]I?_
M %ZQ?^@"K7POY?J+J:-%%%0,**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZ+W*2/*S'\XD_,5]K>(?AQHNO_#>]\$&V6TT*XT\Z:D,(_U,6S:FW/=< CW
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L[PY_R+VE_
M]>L7_H K1K.\.?\ (O:7_P!>L7_H JU\+^7ZBZFC1114#"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MH\06UM>+:Z;I5XQ>VC+ OL*]"D49C55(()<DC(S7<_MX?LH^$/#GPMN/B5X
MT2U\'>)O#,T%TQT.(6L<T/F*I(CC 570LKAU .%;.>,=CPF'A46&G)\[ZZ63
M?3N3S.US[HHKRW]F+XK/\:_@3X1\77!0ZA>6IBO0G_/Q$S12G';+(6 ]&%>I
M5Y$X.G)PENM#3<****@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L[PY_R+VE_P#7
MK%_Z *T:SO#G_(O:7_UZQ?\ H JU\+^7ZBZFC1114#"BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9WA
MS_D7M+_Z]8O_ $ 5HUG>'/\ D7M+_P"O6+_T 5:^%_+]1=31HHHJ!A1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !6=X<_Y%[2_^O6+_P! %:-9WAS_ )%[2_\ KUB_] %6OA?R_474T:**
M*@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5G>'/^1>TO_KUB_\ 0!6C6=X<_P"1>TO_ *]8O_0!5KX7
M\OU%U-&BBBH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%?(WC?_ (*:_"[P%XTU_P ,:AH/BZ:_
MT74+C3;B2VL[5HGDAD:-BA:Y!*DJ<$@''85B_P##V'X1_P#0N^-?_ &T_P#D
MJN]8#%-75-D\R[GVG17Q9_P]A^$?_0N^-?\ P!M/_DJC_A[#\(_^A=\:_P#@
M#:?_ "55?V?BO^?;%S1[GVG17Q9_P]A^$?\ T+OC7_P!M/\ Y*H_X>P_"/\
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M/[/Q7_/MAS1[GVG17Q9_P]A^$?\ T+OC7_P!M/\ Y*H_X>P_"/\ Z%WQK_X
MVG_R51_9^*_Y]L.:/<^TZ*^+/^'L/PC_ .A=\:_^ -I_\E4?\/8?A'_T+OC7
M_P  ;3_Y*H_L_%?\^V'-'N?:=%>*_LX?M8>$?VH/^$B_X173M:L/[#^S_:?[
M8@ACW^=YNS9Y<LF<>2V<XZC&><>U5Q5*<Z4G":LT4G?8****S&%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !6=X<_P"1>TO_ *]8O_0!6C6=X<_Y
M%[2_^O6+_P! %6OA?R_474T:***@84444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^"?[2?_ "<5\4_^
MQJU7_P!*Y:\XKT?]I/\ Y.*^*?\ V-6J_P#I7+7G%?J5'^''T1Q/<****V *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /T9_X) _
M\U:_[A/_ +>U^C5?G+_P2!_YJU_W"?\ V]K]&J_/<U_WR?R_)'5#X4%%%%>2
M6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6=X<_Y%[2_P#KUB_]
M %:-9WAS_D7M+_Z]8O\ T 5:^%_+]1=31HHHJ!A1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]2H_PX^B.)[A1116P!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!^C/\ P2!_YJU_W"?_ &]K]&J_.7_@D#_S5K_N$_\ M[7Z-5^>
MYK_OD_E^2.J'PH****\DL**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *_-K]KSP:?VE/V]/"GPR^VS6%G:Z0D%Q<1*',/[N:Z=P#QDH8U_
M 5^DM?E9I6M?%3Q+^W=\3M;^&>@1:EXA>6ZT^&_UE"MM8VZ.D"W!)('W(=J
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP_R#_4S+_P">?WQ_^1/TK_X:^^$G_0VC_P %UW_\:H_X:^^$G_0VC_P77?\
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MIWL!!]CC_O2_]_G_ ,:/L<?]Z7_O\_\ C4]%%V!!]CC_ +TO_?Y_\:/L<?\
M>E_[_/\ XU/11=@0?8X_[TO_ '^?_&C[''_>E_[_ #_XU/11=@0?8X_[TO\
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M .-3T5Y-V60?8X_[TO\ W^?_ !H^QQ_WI?\ O\_^-3T478$'V./^]+_W^?\
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M(/L<?]Z7_O\ /_C1]CC_ +TO_?Y_\:GHHNP(/L<?]Z7_ +_/_C1]CC_O2_\
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M+L"#[''_ 'I?^_S_ .-'V./^]+_W^?\ QJ>BB[ @^QQ_WI?^_P _^-'V./\
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M?&__ & [W_T0]:4V^=>IU87_ 'BG_B7YGY14445]V?TR%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% '[#"U1@"6DR>>)6']:7[''_
M 'I?^_S_ .-2I]Q?I3J^ NS^7"#[''_>E_[_ #_XT?8X_P"]+_W^?_&IZ*+L
M"#[''_>E_P"_S_XT?8X_[TO_ '^?_&IZ*+L"#[''_>E_[_/_ (T?8X_[TO\
MW^?_ !J>BB[ @^QQ_P!Z7_O\_P#C1]CC_O2_]_G_ ,:GHHNP(/L<?]Z7_O\
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M4 %%%% !1110 4444 %%%% !1110!^C/_!('_FK7_<)_]O:_1JOSE_X) _\
M-6O^X3_[>U^C5?GN:_[Y/Y?DCJA\*"BBBO)+"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ K.\.?\B]I?_7K%_P"@"M&L[PY_R+VE_P#7K%_Z *M?
M"_E^HNIHT445 PHHHH **** "BBB@ HHHH **** "BBB@ KCOC)_R2'QO_V
M[W_T0]=C7'?&3_DD/C?_ + =[_Z(>M*?QKU.K"_[Q3_Q+\S\HJ***^\/Z9"B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#]C$^XOTI
MU-3[B_2G5^?G\N!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M44 %%%% !1110 4444 ?@G^TG_R<5\4_^QJU7_TKEKSBO1_VD_\ DXKXI_\
M8U:K_P"E<M><5^I4?X<?1'$]PHHHK8 HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH _1G_ () _P#-6O\ N$_^WM?HU7YR_P#!('_F
MK7_<)_\ ;VOT:K\]S7_?)_+\D=4/A04445Y)84444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %9WAS_ )%[2_\ KUB_] %:-9WAS_D7M+_Z]8O_ $ 5
M:^%_+]1=31HHHJ!A1110 4444 %%%% !1110 4444 %%%% !7'?&3_DD/C?_
M + =[_Z(>NQKCOC)_P DA\;_ /8#O?\ T0]:4_C7J=6%_P!XI_XE^9^45%%%
M?>'],A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^
MQB?<7Z4ZFI]Q?I3J_/S^7 HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^!_V^O\ DL.C_P#8
M!A_]*+BOOBO@?]OK_DL.C_\ 8!A_]*+BO4RW_>%Z,^SX2_Y&:_PL^::***^L
M/W **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O8_
MV0?^3B?"7_;W_P"DDU>.5['^R#_R<3X2_P"WO_TDFKGQ'\&?H_R/*S7_ )%^
M(_P2_P#26?I71117PY_.(4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% 'X)_M)_\ )Q7Q3_[&K5?_ $KEKSBO1_VD_P#DXKXI
M_P#8U:K_ .E<M><5^I4?X<?1'$]PHHHK8 HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH _1G_@D#_S5K_N$_\ M[7Z-5^<O_!('_FK
M7_<)_P#;VOT:K\]S7_?)_+\D=4/A04445Y)84444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7XC_  2_])9^E=%%%?#G\XA1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 ?@G^TG_ ,G%?%/_ +&K5?\ TKEKSBO1_P!I/_DX
MKXI_]C5JO_I7+7G%?J5'^''T1Q/<****V **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** /T9_X) _\U:_[A/\ [>U^C5?G+_P2!_YJ
MU_W"?_;VOT:K\]S7_?)_+\D=4/A04445Y)84444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %9WAS_D7M+_Z]8O_ $ 5HUG>'/\ D7M+_P"O6+_T 5:^
M%_+]1=31HHHJ!A1110 4444 %%%% !1110 4444 %%%% !7'?&3_ ))#XW_[
M =[_ .B'KL:X[XR?\DA\;_\ 8#O?_1#UI3^->IU87_>*?^)?F?E%1117WA_3
M(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?L8GW%
M^E.IJ?<7Z4ZOS\_EP**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M/P3_ &D_^3BOBG_V-6J_^E<M><5Z/^TG_P G%?%/_L:M5_\ 2N6O.*_4J/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZQ?]^S_\51LN?^>L7_?L_P#Q5%O,">BH-ES_ ,]8O^_9_P#BJ-ES_P ]8O\
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M-3OT7!NKIKBWWOZ[1@*H/15'?-?IO\6_$4OA#X4^,]>@D,4VEZ+>WR..JM'
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M_P#^@-X;_P# :X_^/T?V;B.R^\/]4LS[1^\^^**^!_\ AOKQ_P#] ;PW_P"
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M_/6+_OT?_BJ+>8$]%0;+G_GK%_WZ/_Q5&RY_YZQ?]^C_ /%46\P)Z*@V7/\
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M45]V?TR%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M49TJ+<G*UVU:R7WA9MW9IT445Y984444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O@?]OK_DL.C_\
M8!A_]*+BOOBO@?\ ;Z_Y+#H__8!A_P#2BXKU,M_WA>C/L^$O^1FO\+/FFBBB
MOK#]P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
MV/\ 9!_Y.)\)?]O?_I)-7CE>Q_L@_P#)Q/A+_M[_ /22:N?$?P9^C_(\K-?^
M1?B/\$O_ $EGZ5T445\.?SB%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!^"?[2?_)Q7Q3_[&K5?_2N6O.*]'_:3_P"3BOBG
M_P!C5JO_ *5RUYQ7ZE1_AQ]$<3W"BBBM@"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#]&?\ @D#_ ,U:_P"X3_[>U^C5?G+_ ,$@
M?^:M?]PG_P!O:_1JOSW-?]\G\OR1U0^%!1117DEA1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110!^4GQH_Y+#XY_P"P[??^CWKC
M*[/XT?\ )8?'/_8=OO\ T>]<97WE+X(^B/Z8PG^[T_\ "OR"BBBM#K"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH _8T=!2T@Z"EK\_/Y<"BBB@
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MA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7T;_P $\?\
MD\/P!_W$/_3?<U\Y5]&_\$\?^3P_ '_<0_\ 3?<UR8O_ ':I_A?Y#CNC]IJ*
M**_,CL"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBO1_VD_^3BOBG_V-6J_^E<M><5^I4?X<?1'$]PHHHK8 HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH _1G_@D#_P U:_[A/_M[7Z-5
M^<O_  2!_P":M?\ <)_]O:_1JOSW-?\ ?)_+\D=4/A04445Y)84444 %%%%
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ME_\ O5/U(G\+/R?HHHK](.4**** "BBB@ HHHH **** "BBB@ HHHH ****
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MV0?^3B?"7_;W_P"DDU<^(_@S]'^1Y6:_\B_$?X)?^DL_2NBBBOAS^<0HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /P3_:3_
M .3BOBG_ -C5JO\ Z5RUYQ7H_P"TG_R<5\4_^QJU7_TKEKSBOU*C_#CZ(XGN
M%%%%; %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '
MZ,_\$@?^:M?]PG_V]K]&J_.7_@D#_P U:_[A/_M[7Z-5^>YK_OD_E^2.J'PH
M****\DL**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** /RD^-'_)8?'/_8=OO_1[UQE=G\:/^2P^.?\ L.WW_H]ZXROO*7P1]$?T
MQA/]WI_X5^04445H=84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M'[&CH*6D'04M?GY_+@4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_:"_Z'__ ,HVG_\ R/7SE11]4PW_ #[C]R#F?<^C?^'AW[07_0__ /E&T_\
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M_HAZTI_&O4ZL+_O%/_$OS/RBHHHK[P_ID**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** /V,3[B_2G4U/N+]*=7Y^?RX%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %?%G_!6'_DW7P[_ -C5;?\ I)>5]IU\6?\ !6'_ )-U\._]C5;?
M^DEY7H9?_O5/U(G\+/R?HHHK](.4**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *^C?^">/_)X?@#_N(?\ ION:^<J^C?\ @GC_ ,GA^ /^
MXA_Z;[FN3%_[M4_PO\AQW1^TU%%%?F1V!1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !4=Q<16D$D\\B0PQ*7>21@JH
MH&223P !WJ2OSZ_:%U;Q+^V#^U/_ ,*,T+5Y]&\#>'D\_7;BVR?.9 ID9A_%
MM9TB13P')8YXQU8>A[>33=DE=OLB6['V=8_''X<:GJPTNS^('A:[U,ML%E!K
M5L\Q;TV!\Y]L5V]?(OC+_@F3\(-5\$7&F^'[&^T3Q"L+"VUE]0FF9I<?*98V
M)0KG&0BJ<="#77_L0>&?BUX&^%]QX;^*UD8)M.G"Z3++?174IMB/]6S1NW"%
M?ER<X<#HN!K4I4/9NI1GMT>C]5J";O9GT71117 4%%%% !1110 4444 %%%%
M !1110 4444 %? _[?7_ "6'1_\ L P_^E%Q7WQ7P/\ M]?\EAT?_L P_P#I
M1<5ZF6_[PO1GV?"7_(S7^%GS31117UA^X!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5['^R#_R<3X2_[>__ $DFKQRO8_V0?^3B
M?"7_ &]_^DDU<^(_@S]'^1Y6:_\ (OQ'^"7_ *2S]*Z***^'/YQ"BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _!/]I/_DXK
MXI_]C5JO_I7+7G%>C_M)_P#)Q7Q3_P"QJU7_ -*Y:\XK]2H_PX^B.)[A1116
MP!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^C/\
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M?S7_ .*J>BG<"#[0_P#S[2_FO_Q5'VA_^?:7\U_^*J>BBX$'VA_^?:7\U_\
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M?:'_ .?:7\U_^*J>BBX$'VA_^?:7\U_^*H^T/_S[2_FO_P 54]%%P(/M#_\
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MP(/M#_\ /M+^:_\ Q5'VA_\ GVE_-?\ XJIZ*+@0?:'_ .?:7\U_^*H^T/\
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M?:7\T_\ BJ/M$G_/M+^:?_%5/11?R @^T2?\^TOYI_\ %4?:)/\ GVE_-/\
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'X)_M)_\
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M2T@Z"EK\_/Y<"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH _!+]I+_DXKXI_]C5JO_I7+7G->C?M)?\
M)Q7Q3_[&K5?_ $KEKSFOU*C_  X^B.)[A1116P!1110 4444 %%%% !1110
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MO_!('_FK7_<)_P#;VOT:K\]S7_?)_+\D=4/A04445Y)84444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 ?E)\:/^2P^.?^P[??\
MH]ZXRNS^-'_)8?'/_8=OO_1[UQE?>4O@CZ(_IC"?[O3_ ,*_(****T.L****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#]C1T%+2#H*6OS\_EP****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\N$'YFX'SO\ *#@_+UKKG5=&"YM9>75GMXC&2R_#P=9.I4>B45N_T1XCXO\
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M\B_$?X)?^DL_2NBBBOAS^<0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** /P3_:3_ .3BOBG_ -C5JO\ Z5RUYQ7H_P"TG_R<
M5\4_^QJU7_TKEKSBOU*C_#CZ(XGN%%%%; %%%% !1110 5]I_P#!+_Q_X8\
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M2PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _
M*3XT?\EA\<_]AV^_]'O7&5V?QH_Y+#XY_P"P[??^CWKC*^\I?!'T1_3&$_W>
MG_A7Y!1116AUA1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?L:.@
MI:0=!2U^?G\N!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 ?@E^TE_R<5\4_^QJU7_TKEKSFO1OVDO\
MDXKXI_\ 8U:K_P"E<M><U^I4?X<?1'$]PHHHK8 HHHH **** "BBB@ HHHH
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M=7Y^?RX%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %?%G_  5A_P"3=?#O_8U6W_I)>5]IU\6?
M\%8?^3=?#O\ V-5M_P"DEY7H9?\ [U3]2)_"S\GZ***_2#E"BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "OHW_ ()X_P#)X?@#_N(?^F^Y
MKYRKZ-_X)X_\GA^ /^XA_P"F^YKDQ?\ NU3_  O\AQW1^TU%%%?F1V!1110
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M:X[XR?\ )(?&_P#V [W_ -$/6E/XUZG5A?\ >*?^)?F?E%1117WA_3(4444
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MEY7VG7Q9_P %8?\ DW7P[_V-5M_Z27E>AE_^]4_4B?PL_)^BBBOT@Y0HHHH
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M7/.[F^MG]R\CP<LQF%IU?;XARG7GHVX2LK](Z:(^9:***]D_0 HHHH ****
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M2EE+'+:S28Z[$F1&?_@(--4:CCSJ+MWMH%UL>KT445B,**** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MN,K[NE\$?1'],83_ '>G_A7Y!1116AUA4EO;RW=Q%!!$\T\K!(XHU+,[$X
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MH*Q*>25S@X<CX^_8_P#VC_\ AFKXJ?VY>6DVH^']0MC8:G:0$>9Y196$B D
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M5\.?SB)BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10
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M .@I:\>K4=6I*H^KN:)65@HHHK(84444 %%%% !1110 4444 %%%% !1110
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MA?R_474T:***@84444 %%%% !1110 4444 %%%% !1110 5QWQD_Y)#XW_[
M=[_Z(>NQKCOC)_R2'QO_ -@.]_\ 1#UI3^->IU87_>*?^)?F?E%1117WA_3(
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?L8GW%^
ME.IJ?<7Z4ZOS\_EP**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *^+/^"L/_)NOAW_L:K;_ -)+
MROM.OBS_ (*P_P#)NOAW_L:K;_TDO*]#+_\ >J?J1/X6?D_1117Z0<H4444
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M^3^7Y(ZH?"@HHHKR2PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH _*3XT?\EA\<_]AV^_]'O7&5V?QH_Y+#XY_P"P[??^CWKC
M*^\I?!'T1_3&$_W>G_A7Y!1116AUA1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 ?L:.@I:0=!2U^?G\N!1110 4444 %%%% !1110 4444 %%%%
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M)#XW_P"P'>_^B'K2G\:]3JPO^\4_\2_,_**BBBOO#^F0HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH _8Q/N+]*=34^XOTIU?GY_+@
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5\6?\%8?^3=?#O\ V-5M_P"DEY7VG7Q9_P %8?\
MDW7P[_V-5M_Z27E>AE_^]4_4B?PL_)^BBBOT@Y0HHHH **** "BBB@ HHHH
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M[7Z-5^>YK_OD_E^2.J'PH****\DL**** "BBB@ HHHH **** "BBB@ HHHH
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M[2_^O6+_ - %6OA?R_474T:***@84444 %%%% !1110 4444 %%%% !1110
M5QWQD_Y)#XW_ .P'>_\ HAZ[&N.^,G_)(?&__8#O?_1#UI3^->IU87_>*?\
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MW_>%Z,^SX2_Y&:_PL^::***^L/W **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "O8_P!D'_DXGPE_V]_^DDU>.5['^R#_ ,G$^$O^
MWO\ ]))JY\1_!GZ/\CRLU_Y%^(_P2_\ 26?I71117PY_.(4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'X)_M)_\G%?%/_L:
MM5_]*Y:\XKT?]I/_ ).*^*?_ &-6J_\ I7+7G%?J5'^''T1Q/<****V ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /T9_P""0/\
MS5K_ +A/_M[7Z-5^<O\ P2!_YJU_W"?_ &]K]&J_/<U_WR?R_)'5#X4%%%%>
M26%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '
MY2?&C_DL/CG_ +#M]_Z/>N,KL_C1_P EA\<_]AV^_P#1[UQE?>4O@CZ(_IC"
M?[O3_P *_(****T.L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#
M]C1T%+2#H*6OS\_EP**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'/\ D7M+_P"O6+_T 5:^%_+]1=31HHHJ!A1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *^!_V^O\ DL.C_P#8!A_]*+BOOBO@?]OK_DL.C_\ 8!A_]*+B
MO4RW_>%Z,^SX2_Y&:_PL^::***^L/W **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "O8_V0?^3B?"7_;W_P"DDU>.5['^R#_R<3X2
M_P"WO_TDFKGQ'\&?H_R/*S7_ )%^(_P2_P#26?I71117PY_.(4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'X)_M)_\ )Q7Q
M3_[&K5?_ $KEKSBO1_VD_P#DXKXI_P#8U:K_ .E<M><5^I4?X<?1'$]PHHHK
M8 HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _1G_@
MD#_S5K_N$_\ M[7Z-5^<O_!('_FK7_<)_P#;VOT:K\]S7_?)_+\D=4/A0444
M5Y)84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M ?E)\:/^2P^.?^P[??\ H]ZXRNS^-'_)8?'/_8=OO_1[UQE?>4O@CZ(_IC"?
M[O3_ ,*_(****T.L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#]
MC1T%+2#H*6OS\_EP**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@#\$OVDO^3BOBG_ -C5JO\ Z5RUYS7H
MW[27_)Q7Q3_[&K5?_2N6O.:_4J/\./HCB>X4445L 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% ']&=%%%?DYVA1110 4444 %%%% !1110 4444
M %%%% !6=X<_Y%[2_P#KUB_] %:-9WAS_D7M+_Z]8O\ T 5:^%_+]1=31HHH
MJ!A1110 4444 %%%% !1110 4444 %%%% !7'?&3_DD/C?\ [ =[_P"B'KL:
MX[XR?\DA\;_]@.]_]$/6E/XUZG5A?]XI_P")?F?E%1117WA_3(4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _!/]I/\ Y.*^*?\
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M&4^ZUUE>5*+BW%[HT"BBBI **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH _HSHHHK\G.T**** "BBB@ HHHH ****
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M/L:?WI?^_P W^-&@$]%0?8T_O2_]_F_QH^QI_>E_[_-_C1H!/14'V-/[TO\
MW^;_ !H^QI_>E_[_ #?XT: ?@U^TG_R<5\4_^QJU7_TKEKSBO1OVD5V_M$?%
M(#.!XIU0<G)_X^Y:\YK]1H_PX^B.)[A1116P!1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!^C/_!('_FK7_<)_P#;VOT:K\XO^"0L
M*S?\+8W%QC^R?NN5_P"?WT-?HM]C3^]+_P!_F_QK\^S6WUR?R_)'5#X43T5!
M]C3^]+_W^;_&C[&G]Z7_ +_-_C7DZ%D]%0?8T_O2_P#?YO\ &C[&G]Z7_O\
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M "BBB@ HHHH **** "BBB@ HHHH _8T=!2U!]E1N2TF3SQ*P_K1]CC_O2_\
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MJ#[''_>E_P"_S_XT?8X_[TO_ '^?_&C0">BH/L<?]Z7_ +_/_C1]CC_O2_\
M?Y_\:- )Z*@^QQ_WI?\ O\_^-'V./^]+_P!_G_QHT GHJ#[''_>E_P"_S_XT
M?8X_[TO_ '^?_&C0#\&?VDO^3BOBG_V-6J_^E<M><UZ-^TE_R<5\4_\ L:M5
M_P#2N6O.:_4:/\./HCB>X4445L 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% ']&=%0M:HS$EI,DYXE8?UI/L<?]Z7_O\_\ C7Y1H=I/14'V./\
MO2_]_G_QH^QQ_P!Z7_O\_P#C1H!/14'V./\ O2_]_G_QH^QQ_P!Z7_O\_P#C
M1H!/14'V./\ O2_]_G_QH^QQ_P!Z7_O\_P#C1H!/14'V./\ O2_]_G_QH^QQ
M_P!Z7_O\_P#C1H!/14'V./\ O2_]_G_QH^QQ_P!Z7_O\_P#C1H!/14'V./\
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M#[''_>E_[_/_ (T?8X_[TO\ W^?_ !HT GHJ#[''_>E_[_/_ (T?8X_[TO\
MW^?_ !HT GHJ#[''_>E_[_/_ (T?8X_[TO\ W^?_ !HT GHJ#[''_>E_[_/_
M (T?8X_[TO\ W^?_ !HT GHJ#[''_>E_[_/_ (T?8X_[TO\ W^?_ !HT GHJ
M#[''_>E_[_/_ (T?8X_[TO\ W^?_ !HT GHJ..!8B2I<Y_O.6_F:DI %%%%
M!1110 4444 %%%% !7XS?M _M)Z;\:/VE'U7QG;:AK'PYT.]DM['0;*?R3+"
MA(R3GY3*RAG8<X(4'@$?LS17H8/%1PLG)PNVK;VM^!,H\Q^?.B_\%5_ OAS2
M;/2]+^&>I:?IUG$L%O:V]U"D<2*,!5 &  *]_P#V6OVQ](_:CU/Q!9:9X<O=
M#;1X89G>[G202"1F  VCC&W]:^AZ**M;#SBU"E9]^9O] 2?<****\\H****
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M^I4?X<?1'$]PHHHK8 HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MWKC*[/XT?\EA\<_]AV^_]'O7&5]Y2^"/HC^F,)_N]/\ PK\@HHHK0ZPHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** /V-'04M(.@I:_/S^7 HHHH
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M_C7J=6%_WBG_ (E^9^45%%%?>'],A1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M17Z0<H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5]&_\
M!/'_ )/#\ ?]Q#_TWW-?.5?1O_!/'_D\/P!_W$/_ $WW-<F+_P!VJ?X7^0X[
MH_::BBBOS([ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ KX'_ &^O^2PZ/_V 8?\ THN*^^*^!_V^O^2PZ/\ ]@&'_P!*+BO4RW_>
M%Z,^SX2_Y&:_PL^::***^L/W **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "O8_V0?^3B?"7_ &]_^DDU>.5['^R#_P G$^$O^WO_
M -))JY\1_!GZ/\CRLU_Y%^(_P2_])9^E=%%%?#G\XA1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 ?@G^TG_R<5\4_P#L:M5_
M]*Y:\XKT?]I/_DXKXI_]C5JO_I7+7G%?J5'^''T1Q/<****V **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /T9_X) _\ -6O^X3_[
M>U^C5?G+_P $@?\ FK7_ '"?_;VOT:K\]S7_ 'R?R_)'5#X4%%%%>26%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'Y2?&C_D
ML/CG_L.WW_H]ZXRNS^-'_)8?'/\ V';[_P!'O7&5]Y2^"/HC^F,)_N]/_"OR
M"BBBM#K"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _8T=!2T@Z"
MEK\_/Y<"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH _!+]I+_DXKXI_]C5JO_I7+7G->C?M)?\G%?%/_
M +&K5?\ TKEKSFOU*C_#CZ(XGN%%%%; %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!_1G1117Y.=H4444 %%%% !1110 4444 %%%% !1110 5G
M>'/^1>TO_KUB_P#0!6C6=X<_Y%[2_P#KUB_] %6OA?R_474T:***@84444 %
M%%% !1110 4444 %%%% !1110 5QWQD_Y)#XW_[ =[_Z(>NQKCOC)_R2'QO_
M -@.]_\ 1#UI3^->IU87_>*?^)?F?E%1117WA_3(4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 ?L8GW%^E.IJ?<7Z4ZOS\_EP****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]K]&J_/<U_WR?R_)'5#X4%%%%>26%%%% !1110 4444 %%%% !1110 4444
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M%%%% !1110 4444 %%%% !1110 4444 %9WAS_D7M+_Z]8O_ $ 5HUG>'/\
MD7M+_P"O6+_T 5:^%_+]1=31HHHJ!A1110 4444 %%%% !1110 4444 %%%%
M !7'?&3_ ))#XW_[ =[_ .B'KL:X[XR?\DA\;_\ 8#O?_1#UI3^->IU87_>*
M?^)?F?E%1117WA_3(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 ?L8GW%^E.IJ?<7Z4ZOS\_EP**** "BBB@ HHHH **** "BBB@
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M+2#H*6OS\_EP**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH _!+]I+_ ).*^*?_ &-6J_\ I7+7G->C?M)?\G%?%/\
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M'_D\/P!_W$/_ $WW-<F+_P!VJ?X7^0X[H_::BBBOS([ HHHH **** "BBB@
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MRK_PSQ^T[_T=S_YC72__ (Y1_P ,\?M._P#1W/\ YC72_P#XY7U510!\J_\
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M:Z7_ /'*^JJ* /E7_AGC]IW_ *.Y_P#,:Z7_ /'*/^&>/VG?^CN?_,:Z7_\
M'*^JJ* /E7_AGC]IW_H[G_S&NE__ !RC_AGC]IW_ *.Y_P#,:Z7_ /'*^JJ*
M /E7_AGC]IW_ *.Y_P#,:Z7_ /'*/^&>/VG?^CN?_,:Z7_\ '*^JJ* /E7_A
MGC]IW_H[G_S&NE__ !RC_AGC]IW_ *.Y_P#,:Z7_ /'*^JJ* /E7_AGC]IW_
M *.Y_P#,:Z7_ /'*/^&>/VG?^CN?_,:Z7_\ '*^JJ* /E7_AGC]IW_H[G_S&
MNE__ !RC_AGC]IW_ *.Y_P#,:Z7_ /'*^JJ* /E7_AGC]IW_ *.Y_P#,:Z7_
M /'*/^&>/VG?^CN?_,:Z7_\ '*^JJ* /E7_AGC]IW_H[G_S&NE__ !RC_AGC
M]IW_ *.Y_P#,:Z7_ /'*^JJ* /E7_AGC]IW_ *.Y_P#,:Z7_ /'*/^&>/VG?
M^CN?_,:Z7_\ '*^JJ* /E7_AGC]IW_H[G_S&NE__ !RC_AGC]IW_ *.Y_P#,
M:Z7_ /'*^JJ* /S:\2_\$B_%?B_Q'JNO:O\ M _:]5U2[EO;NX_X0N)/-FD<
MN[;5NPHRS$X  &> *S?^'-.M_P#1>?\ RSD_^3*_3>BNI8O$)6527WLGE78_
M,C_AS3K?_1>?_+.3_P"3*/\ AS3K?_1>?_+.3_Y,K]-Z*?UO$_\ /R7WL.5=
MC\R/^'-.M_\ 1>?_ "SD_P#DRC_AS3K?_1>?_+.3_P"3*_3>BCZWB?\ GY+[
MV'*NQ^9'_#FG6_\ HO/_ )9R?_)E'_#FG6_^B\_^6<G_ ,F5^F]%'UO$_P#/
MR7WL.5=C\R/^'-.M_P#1>?\ RSD_^3*/^'-.M_\ 1>?_ "SD_P#DROTWHH^M
MXG_GY+[V'*NQ^9'_  YIUO\ Z+S_ .6<G_R91_PYIUO_ *+S_P"6<G_R97Z;
MT4?6\3_S\E][#E78_,C_ (<TZW_T7G_RSD_^3*/^'-.M_P#1>?\ RSD_^3*_
M3>BCZWB?^?DOO8<J['YD?\.:=;_Z+S_Y9R?_ "91_P .:=;_ .B\_P#EG)_\
MF5^F]%'UO$_\_)?>PY5V/S(_X<TZW_T7G_RSD_\ DRC_ (<TZW_T7G_RSD_^
M3*_3>BCZWB?^?DOO8<J['YD?\.:=;_Z+S_Y9R?\ R91_PYIUO_HO/_EG)_\
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M.Y_\QKI?_P <H_X9X_:=_P"CN?\ S&NE_P#QROJJB@#Y5_X9X_:=_P"CN?\
MS&NE_P#QRC_AGC]IW_H[G_S&NE__ !ROJJB@#Y5_X9X_:=_Z.Y_\QKI?_P <
MH_X9X_:=_P"CN?\ S&NE_P#QROJJB@#Y5_X9X_:=_P"CN?\ S&NE_P#QRC_A
MGC]IW_H[G_S&NE__ !ROJJB@#Y5_X9X_:=_Z.Y_\QKI?_P <H_X9X_:=_P"C
MN?\ S&NE_P#QROJJB@#Y5_X9X_:=_P"CN?\ S&NE_P#QRC_AGC]IW_H[G_S&
MNE__ !ROJJB@#Y5_X9X_:=_Z.Y_\QKI?_P <H_X9X_:=_P"CN?\ S&NE_P#Q
MROJJB@#Y5_X9X_:=_P"CN?\ S&NE_P#QRC_AGC]IW_H[G_S&NE__ !ROJJB@
M#Y5_X9X_:=_Z.Y_\QKI?_P <H_X9X_:=_P"CN?\ S&NE_P#QROJJB@#Y5_X9
MX_:=_P"CN?\ S&NE_P#QRC_AGC]IW_H[G_S&NE__ !ROJJB@#Y5_X9X_:=_Z
M.Y_\QKI?_P <H_X9X_:=_P"CN?\ S&NE_P#QROJJB@#Y5_X9X_:=_P"CN?\
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M3*_3>BCZWB?^?DOO8<J['YD?\.:=;_Z+S_Y9R?\ R91_PYIUO_HO/_EG)_\
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MW_H[G_S&NE__ !ROJJB@#Y5_X9X_:=_Z.Y_\QKI?_P <H_X9X_:=_P"CN?\
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M=+_^.4?\,\?M._\ 1W/_ )C72_\ XY7U510!\J_\,\?M._\ 1W/_ )C72_\
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MY8]O_P#)-'_#KGX@_P#1QG_ECV__ ,DU^AU%='UBM_._O9Z?]JYA_P!!$_\
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M (Y1_P ,\?M._P#1W/\ YC72_P#XY7U510!\J_\ #/'[3O\ T=S_ .8UTO\
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M )9R?_)E?IO173];Q/\ S\E][)Y5V/S(_P"'-.M_]%Y_\LY/_DRC_AS3K?\
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M (Y1_P ,\?M._P#1W/\ YC72_P#XY7U517*,^5?^&>/VG?\ H[G_ ,QKI?\
M\<H_X9X_:=_Z.Y_\QKI?_P <KZJHH ^5?^&>/VG?^CN?_,:Z7_\ '*/^&>/V
MG?\ H[G_ ,QKI?\ \<KZJHH ^5?^&>/VG?\ H[G_ ,QKI?\ \<H_X9X_:=_Z
M.Y_\QKI?_P <KZJHH ^5?^&>/VG?^CN?_,:Z7_\ '*/^&>/VG?\ H[G_ ,QK
MI?\ \<KZJHH ^5?^&>/VG?\ H[G_ ,QKI?\ \<H_X9X_:=_Z.Y_\QKI?_P <
MKZJHH ^5?^&>/VG?^CN?_,:Z7_\ '*/^&>/VG?\ H[G_ ,QKI?\ \<KZJHH
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MDD$('9F X[L?K7IU !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MT/X&>&-2T?4K=+JTO(=-NMDT3#*N,WW0@T ?IW17YB^(/^"@7[6GP=TYM?\
MB9^S_IL/AJ)E$US96MW;+$"<?/-YTZIDD %E SQSD5]?_"C]I;_AJ/\ 9YU/
MQK\(/L4'BJ..2"+2_$<;216U^@#>1.(Y$.U@1AU8<.&QP5H ][HKXA_84_;_
M -9_:#\<^)OAS\3]'TOPG\1--ED:TLK"*6".X2/*SPE)9'831LI8@-RN3@;"
M3]O4 %%?#?[6W[>WBWX?_'CPQ\&?@KH.C>,/'=](L>HKJD<LT-L\F#'$!%+&
M58+F21F.$3!/<K]._$KXP:9^S_\ !NX\:?$G4K5/[,M(_MTFF0,B75T0%\NV
MB=V;YW.%5F.!RS8!( /1Z*_.;0?VU_VN?C+I3>,?A?\ L_Z._@)F+6[ZQ.S7
M5S&#]Z(M<P&3.",QQ,,\<XKWG]C;]N/2?VI7UKP[JFA7'@KXBZ#DZEX>NV).
MP/L9XRP5OE;"NC*"A8#G.: /J"BO(/VHOVG/"O[*GPRG\6^)B]U-))]FTW2K
M=@)[^X()$:D_=4 $LYX4>I*J?D>V_;$_;.UCP^OCO3?V=M(/@-H_M26LC2G4
MY(,;LJGVA96R,$,+<Y'0'- 'Z+T5X-^R#^U[X8_:[\!7.LZ/;2Z/KFF2+!J^
MB7#AY+21@2K*PQOC;#;6P#\K @$5R_[8_P"W3HG[+-QH_AO3=#N/&WQ%UL*V
MG^';-BI",Y1))"JLWS."JHJEF*D<=: /J&BOSLU;]J_]MSP?HLWBW7_V>O#Y
M\)P1FYF@M)&-]'".6+(MW)(N #DF'CJ1Q7U!^R5^USX2_:Z\ S:[X?CDTO5K
M!UAU70KF0/-92-DJ=P #QL 2K@#."" 00 #W.BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK\^OB]_P
M5(U&]^)-]X ^ /PYNOBGK5DSI-J:)++;LR$!S%#"-\D8)P92R+D<94AB ?H+
M17YH:C^WE^UW\+;*77?B)^SM9R^'+=?,N)M*M+NW\E!]YI)?-N%C7I\S* />
MOL7]E?\ :Q\&?M:>!9=?\+--9WUDZP:GHU[@7%E(1D9QPR-@E7'!P1PP90 >
MU45\(?M[_MQ_$_\ 9J^,G@OP1\/?#WAS79/$.GQS)%J]K<2S/<O</"D:&.>,
M8.%X(/)ZUP__  U5^WO_ -&_>'?_  677_R?0!^D]%?F6G_!4+XQ?!+Q/I5A
M^T!\$_\ A'M,OF(^WZ5#/;':#RT2RO(DQ4%<J) ><Y&0*^K?VF_C=X[\,_LY
M1_%3X)6V@>+K>&WCU::#5+6>=;C363<TT/E31D,@(<JV?E#="N" ?0]%?./[
M#7[7EC^US\)AK%Q'::;XQTN3[-KFE6A(2)SDI-&K,6$4BC(R3@JZY.W)^C'=
M8T9W8*JC)8G  ]: '45\'>!OV\/B'^T+^U_>_#KX0Z+X<O/AKH\H_M3Q1J=K
M<3R&"-L331M'.B .WR1 AL_?/RY"^T_MB?MF>'OV2_#.G&;3Y?$WC'6G,6C^
M';5]CW!! ,CL Q1 6 X!+,<*/O%0#Z(HK\YM9_;,_;'^'>@/XZ\9?L]:-'X"
MBC^T3Q6<DB7]O#_>E N97C"C)8O  .IP!7V5^SE^T+X6_:<^%]AXV\*22K:S
M.UO=65S@3V5PH&^&0 D9 92"."K*>] 'I]%?*?[8'[=-K^SMK^C>!/"/AN;X
M@_%/6PK6F@6I;$",2$:38I9F8@[8UY(!)*C!;Q+Q!^W-^U/\!+:V\3?&GX#:
M5;^!998TEN_#\Y\ZU5S@&1A<W"J>0 )!&"V!D$T ?HS17*?"SXG>'OC+\/M$
M\:>%KS[=H6KVXGMY2-K+R0R./X75@RL.Q4BMS7M?TWPMHM[J^L7]OI>E6433
MW-Y=RB.*&-1DLS'@ #N: +]%?#OP)_X**R?M%?MD7GPX\):=I[_#>#3[B6#5
MYX91?7DT0&9%^<*D3$X"E"Q !)!;:OW%0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44UW6-
M&=V"JHR6)P /6OSU^)__  5*UKQ#\0]0\#_L]?#2Z^)^HV3,DFKF.:6W<J<,
MT<,(W-$#QYK.@/8$$$@'Z&45^9^I?M]_M9?"6S?7?B9^SO:MX9@^>XN-*M;N
MV$*#EF>7S;A4&/XF4"OM#]F+]J+P;^U9\/\ _A)O"4LT$EO(+?4=*O !<V,V
M,[7 )!4CE7'# 'H0P ![!17P+^W3^W7\5OV>?VB/"7PT^'/AKPWX@D\0:3:7
M%O#JUI<2W,MY/=W%NL2&.XC7!\J, $9RQYQC')?\-5?M[_\ 1OWAW_P677_R
M?0!^D]%?F?9?\%1_BK\&O&&DZ1^T+\&6\+6%^Q']HZ7#/;D(" TD<<K2+,%R
M,A9 1GZ _4/[6_QQ^(?P[^ %O\4?@S:^'/%NFV\2:C>QZG;3W FTZ1 RW,!B
MFCX4$,P.?D)/&TY /H^BOG_]BC]J[3?VM?@_;^(0MM8^*+!A::[I5N3MM[C!
M*N@8EO*D W+DGHRY)0FO?9IH[:&2::18HHU+O(Y 55 R22>@% #Z*^#_ (1?
MMV?$7]IC]K35/!'PNT/P[)\*-$EW:CXFU*TN)IVMT.UGC9)TC!F<%8E*D[<N
M00K >O\ [8_[:NA?LHZ5I-A#I4WB[Q[KS;-(\-6CE7E!;9YDA"L0NXA5 !9V
MX4<,5 /I&BOSEUW]M']L'X5Z'_PFWQ _9\T9/ 2+YTXTZ5UO+:$\[I<7,S1
M#J7A4#OBOM7X ?'?PQ^TA\+]+\<^$YI6TZ\W1RVUPH6>TG7B2&0 D!E..A((
M(()!!H ]%HKY*_:Y_;OC^!'C'2?AOX#\+3?$7XK:L%:+1+8OLM%890R[ 69F
M +"-<84%F91MW>-Z]^W;^T[^SY]BU[XZ? G3+3P1<2I'+?\ AJ;,EL&.,NPN
M9T#<\+)Y>X\9% 'Z,T5SGPZ^(.A?%7P-HGB[PS>KJ&A:Q;+=6EP 5)4]F!Y5
M@05*GD$$'I7QK\7_ /@HOXFU/XO:G\+/V>_AT?B9XHTQY(;[4KEF%E!(C;7
M"E<HK94R-(B[A@;@02 ?=M%?G)KO[?\ ^T9^SE?:;>?M _ [3].\+7MQY!U+
MPS<9\HD9 W"XN(R^ Q",R;L'!&#7WWX \>:%\4/!FC^*_#.H1ZIH.K6ZW-I=
M1Y =#Z@\JP((*GD$$'!% '04444 %%%% !1110 4444 %%%% !1110 4444
M%-1%B1410B*,!5& !Z"G44 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MXQ>"G^&7Q%:3R;5"[&UNI2,K%AN49ARAW,K\8;)4$ ^V:*** "BBB@ HHHH
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M8UYI^R;\.->_X*"?M/:M^T+\1K)H_ N@7:P:%I$XW0RR1'=#  >&CBW>9(>
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MK\H@?D?>4'J,U^GM?F%^WS_I_P#P4M_9ELX/WES%<:-</&.JQ_VNYW?E&_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!S_Q!TG4=>\ ^)=,TB?[+JU[IES;6<^<>7,\3+&V?9B#^
M%?E9_P $M/VAOAS^S4/'WP_^)]PO@/QC<ZLI:\U>W,2,(T\O[-++C]V8W$C?
MO,+^\.#G-?K+K6N:=X;TNXU+5M0M=+TZW ::[O9EAAC!( +.Q ') Y/>O"/B
ME^RI\!?VPM-@\3ZEI.E>(Y+D-'!XI\.7H667RV,9'GP-MEV,K)A]P4J1@$4
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M.,]UD1&ZCIUKYN_X(\>/[SQ=^RC/H][(\A\-:[<Z?;%F+8@=([A1GV>:08[
M"OKOXN7,5E\*/&EQ.XCAAT2]D=S_  J(')/Y5\.?\$3;>1?V=_&TY4B%_%3H
MK>K+:6Q(_#<OYT 7/B[^P/\ $S]J[]H;7-7^*'CVYTWX26&H9T30+*<27$D
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M_'#V<>G:I(\EEJ5G"Q,<5U$</LSSM8%7 .2 X!)QD_D'_P $^?V>/BC\>O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4"M+4-/M=6L+FQOK:&]LKF)H9[:XC$D<L; AD93PRD$@@\$&@#\]/^")G_)
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M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^/['Q_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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1** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>syre-20260630_g6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 syre-20260630_g6.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 2E"LD# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MLP\,7C*5"I\,G9GN/@7QMIOQ$\+66OZ3YOV"[W>7YZ;'^5BIR,GNIK?KQ_\
M9+(/P"\,D?\ 3Q_Z/DKV"IJQ4*DHKHV8XZC'#XJK1AM&32]$[!11161Q!111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MDVVJ7NN:;9Z9<[?(O;B[C2&7(R-KDX;(Y&#TK\O/^'6'Q8_Z#7AG_P "YO\
MXU7JO[>7@^]^'G[%_P +?#.HRQ2ZAI%U96,\ENQ,;/':2JQ4D D9'<5F\'AY
M5(4Z57FYG;T"[2NT?>VB>(-+\2V7VS2-2L]5M-Q3[193I-'N'4;E)&1Z5H5\
ME_\ !,CG]FB+_L*W7_LM?3OBOQ;HW@;0;K6M?U.VTC2K5=\UU=2!$4>GN3V
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MQ!P(Y>[1CIZK[C@5]0C6H^UPTN9K==1<UG9GZ?U2UC6].\/6+WNJW]KIMFA
M:XO)EBC4G@ LQ YKE?B3\9_"'PI\"2>+]?UB"+1O+#V\D#B1KLD9580#\Y8=
M,<8Y) YK\I?B_P#&WXB_MR_%"S\/:%87 TPS'^S=!MF)CB7H9IFZ$@'ESP,X
M&*QPF"GB6Y/W8K=C;L?K;IOQ*\(ZS?PV.G^*M$OKV8D16UMJ,,DCD#)VJK$G
M@$\5TE?.O[)_['7A_P#9RT9+^Z$6L^-KF+;=:HRY6$'K% #]U?4]6QSQ@#Z*
MKDK1IQFU2=UW&@HHHK 84444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\*];+\0TGJOQ1>DD?A-\-_"'C;]H#Q;X;^'5CJ,]YY!DCL[>]N6-O8QY+RL
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MD^K>&DN3O:PTJ2-;=6[E%=&*@^@.!V KZJ_MG3_^?ZV_[_+_ (T?VSI__/\
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M58]5LII%2.\MW=C@*LJDG\,U:K  HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /B/]J_]B+QQ\=OB]=>
M*M!\0Z;IVGRVL$"P74DJN&1<$X52*\9E_P""7'Q-G7;)XLT.1<YPTLQ'_H%?
MJ%17JT\RQ%*"A%JR\@/R\A_X);_$VW4K%XLT*,$Y(228?^R4DW_!+3XEW!!E
M\5Z#(1TWR3''_CE?J)15_P!K8KNON _+Y/\ @EU\3XD"IXNT1%'0++, /_'*
M\<_:5_9.\7?LX:+HVH>(M;L-5BU*>2")+1Y&*%5!).X#UK]I*^#/^"LXSX#\
M! ?]!&Y_]%I7;@LQKUL1&G-JS\O(F3:5SP7X:_\ !.?QU\3O 6A>*]/\0:);
M6>K6J7<44[2[T5AD X4C-=+_ ,.K/B-_T,WA_P#[ZE_^(K[I_9$_Y-F^''_8
M&@_]!KU^L*N:8F%244U9-]!K8_+?_AU9\1O^AF\/_P#?4O\ \17EW[0_[%?B
MW]G+P3:^)=<UC2]0M+B]2Q6*R,A<.R.P)W*!C"&OV9KXT_X*H@M^SWHV!G_B
MH8/_ $1/6N$S+$5J\*<FK-]A.Z1\I_!7]@[Q]\9?AKI'B_1_$FEV&G:CYABM
M[B64.NR1D.0JD=5)KM)O^"6_Q-N%"R^+-"D Y >28_\ LE?7?_!/[_DTWP1]
M+K_TJEKZ(K.OF>(IUIPBU9-]!J]C\O8O^"7'Q-@7;'XLT.->N%EF _\ 0*9-
M_P $L_B5<,#+XJT&0C@%Y)C_ .R5^HM%8?VMBNZ^X9^7R?\ !+OXGQJ%7Q=H
MBJ!@ 2S@#_QRG?\ #K[XH_\ 0X:+_P!_I_\ XFOT_HH_M;%=U]P'Y@?\.OOB
MC_T.&B_]_I__ (FC_AU]\4?^APT7_O\ 3_\ Q-?I_11_:N)[K[@/S _X=??%
M'_H<-%_[_3__ !-'_#K[XH_]#AHO_?Z?_P")K]/Z*/[5Q/=?<!^8'_#K[XH_
M]#AHO_?Z?_XFC_AU]\4?^APT7_O]/_\ $U^G]%']JXGNON _,#_AU]\4?^AP
MT7_O]/\ _$T?\.OOBC_T.&B_]_I__B:_3^BC^U<3W7W ?F!_PZ^^*/\ T.&B
M_P#?Z?\ ^)H_X=??%'_H<-%_[_3_ /Q-?I_11_:N)[K[@/S _P"'7WQ1_P"A
MPT7_ +_3_P#Q-'_#K[XH_P#0X:+_ -_I_P#XFOT_HH_M7$]U]P'Y@?\ #K[X
MH_\ 0X:+_P!_I_\ XFC_ (=??%'_ *'#1?\ O]/_ /$U^G]%']JXGNON _,#
M_AU]\4?^APT7_O\ 3_\ Q-'_  Z^^*/_ $.&B_\ ?Z?_ .)K]/Z*/[5Q/=?<
M!^8'_#K[XH_]#AHO_?Z?_P")H_X=??%'_H<-%_[_ $__ ,37Z?T4?VKB>Z^X
M#\P/^'7WQ1_Z'#1?^_T__P 31_PZ^^*/_0X:+_W^G_\ B:_3^BC^U<3W7W ?
MF!_PZ^^*/_0X:+_W^G_^)H_X=??%'_H<-%_[_3__ !-?I_11_:N)[K[@/S _
MX=??%'_H<-%_[_3_ /Q-'_#K[XH_]#AHO_?Z?_XFOT_HH_M7$]U]P'Y@?\.O
MOBC_ -#AHO\ W^G_ /B:/^'7WQ1_Z'#1?^_T_P#\37Z?T4?VKB>Z^X#\P/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *@NK"VOE47-O%<!3E1*
M@;'TS4]% #(88[>)8XD6.-1A408 'L*?110 5#=6=O>QA+B".= <A94##/K@
MU-10!'!;Q6L2Q01)#$O1(U"J/P%2444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"%6"WB7[\DCDYSV"J#GN1UH ]@HHHH ***\!_9@^+GQ2^)WBGXIV7Q%\%_\
M")Z;H&MFR\/7']E75E_:-IOF FW3NPE^5(SNCPOS=.10![]117RM^V_^U5XL
M_9IUOX2V?AC3]&OXO%NM-IU\=6@ED:.,-",Q>7*F&_>MRVX<#CU /JFBBB@
MHHHH ***XSXQ_%;1?@?\,?$/CKQ"MS)H^B6_VB>.SC$DSY8*JHI(!)9E') Y
MY(% '9T5YOX4^+P\=_L_V?Q+TRP-D-0T!M;M;*[;?LS"9$5RN,]LX/K@]Z\V
M_8&_:1\3?M3_  +E\:>*['2=/U1-7N+ 0Z-#+%!Y<:1,IQ))(V[+G/S8Z<4
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M .X_;_UI?AG^PY\2CH\2Z?;1:1#I$$%H@1(H9YX;38J@@*H24C Z#L>E7?\
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MG0:=;R7)4RO'%&$#R%552[8W,0 "23@5^?GP_P!;M?VEO^"L\GCCP0!>>$O
M&CRV.H:S",P7<IMY[<;7'!S)<$*>=RV[,,K@BQ\4?CW\1/\ @H+XVU3X3? :
M270/AA:R?9O$WC^565;B(Y#11=]C#.U!AY/XBB;L_:7[/'[._@_]F7X<V?A#
MP?9>5;I^]N[^8 W-_/C#33,!RQZ #A1@  "@#TZOD+]N[X\^.O@SX]^ 6G>#
MM<_L>S\4>*%T[5XOLD$_VFW,MLNS,J,4XD?E"IYZ\"OKVO@/_@I[_P E1_99
M_P"QU7_T?9T :7_!0O\ :U\>?LR?%SX-1^%[F:XT+5'NI-6T&WM8))-4$<D
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M#?Z-:RVNE6>E.T5@/+ -LI%ZH/E,&CX Y0\"@#UO]G+]J_XD:/\ 'F3X"?M
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M%9]*O]1^/W[.*/XAD\)Z;<7TMO!KZ1F3^RYS=6N^YQN7.P&)\;@?D/(KU/\
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M'S60R+_JTX5@./<UP'[-W_*53]H[_L#6W_H-E1^TC_RE4_9Q_P"P-<_^@WM
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MI8CG[K8"G0_: \)_'[PK^Q7\=H?C=XWT#QG$UC8G2)]&LE@=<W4?G"3;#$,
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M96'X5)^P[;QM_P %#_VIYR@,R7<J*_<*UX21^)5?RH P?B+^T[^TQ^PIX_\
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M^")+"'(!&?*>0P.5?G&#-U RPYK$_P""GC1Z;^TG^RAJVL#'AFU\2$W4LO\
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M\Y.[)]CERHY')''XT 9O[(WQ=F^.W[-O@'QM=.)-1U'3E2^<# :ZA9H9V [
MR1.0/0BO7J^.O^"3,%U%^Q3X7:X.8I=0U![?C_EG]I<'_P ?#U]BT %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !7R7^VO\ \$]?#'[74]GK\.JOX4\;V5O]ECU2.#SH;F$,
M66.>/*D[2S8=2"-W.X  ?6E% 'Y-6O\ P3)_:NTW2U\-V7QVLK?PDH\I;"+Q
M+JT<(CQC'V80^6!VQG%?47[$G_!.?P[^R7J5SXHU+6?^$M\<7$!MDOA!Y%O8
MQ-]]84+$EFP 78YP, *"V?L.B@#XM_;[_P"">0_:XU#2?%7AS7;7P]XSTZT^
MP-_:$;-:WL 9G179 61E9W^8*V0V,<"OGVR_X)-_&+QEX0N;#XD_&)-=.F6$
MT?A[1%U2]NK&"Y\LK 6>9/W42G&1'$21P,5^JE% 'R/_ ,$ZOV1O&'[(O@?Q
M;HWC#4M#U*ZU?48[N!]#GFE146+80QEBC(.?0'ZU\E^%?^",_CG4/%7BB_\
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MR1X-_9X^!L_PSMD_X2'3]2$S:W<W\0']IR2QB.4L@)"H44($R<*.I.2?<**
M/SZT?]@_X\_LVZWJL?[.?QATW3?"&I7#7#>'O%\!D2W8C'RL(9@S8 &]5C)"
MJ&W8KM/@7^PCXLC^-5I\8_CWX_C^)'CS3T"Z7:6<1CL+!AG:ZC:@.W<Q55C1
M0Q+$,V"/M&B@#A/CK\*[+XW_  >\7^!+\HD.N:=+:I*XR(9L9BEQ_L2!'_X#
M7SW_ ,$\OV*]=_9,T'Q9=>,]3TO6O%NN3P0K<Z5/-/%%8P1XBC#2QHP.YGR
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M[679?<O\BN=^7W(\]_L3XJ_]#GX._P#"1N__ )9T?V)\5?\ H<_!W_A(W?\
M\LZ]"HH]K+LON7^0<[\ON1Y[_8GQ5_Z'/P=_X2-W_P#+.C^Q/BK_ -#GX._\
M)&[_ /EG7H5%'M9=E]R_R#G?E]R//?[$^*O_ $.?@[_PD;O_ .6=']B?%7_H
M<_!W_A(W?_RSKT*BCVLNR^Y?Y!SOR^Y'GO\ 8GQ5_P"AS\'?^$C=_P#RSH_L
M3XJ_]#GX._\ "1N__EG7H5%'M9=E]R_R#G?E]R//?[$^*O\ T.?@[_PD;O\
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M(W?_ ,LZ]"HH]K+LON7^0<[\ON1Y[_8GQ5_Z'/P=_P"$C=__ "SH_L3XJ_\
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M^$C=_P#RSKT*BCVLNR^Y?Y!SOR^Y'GO]B?%7_H<_!W_A(W?_ ,LZ/[$^*O\
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M679?<O\ (.=^7W(\]_L3XJ_]#GX._P#"1N__ )9T?V)\5?\ H<_!W_A(W?\
M\LZ]"HH]K+LON7^0<[\ON1Y[_8GQ5_Z'/P=_X2-W_P#+.C^Q/BK_ -#GX._\
M)&[_ /EG7H5%'M9=E]R_R#G?E]R//?[$^*O_ $.?@[_PD;O_ .6=']B?%7_H
M<_!W_A(W?_RSKT*BCVLNR^Y?Y!SOR^Y'GO\ 8GQ5_P"AS\'?^$C=_P#RSH_L
M3XJ_]#GX._\ "1N__EG7H5%'M9=E]R_R#G?E]R//?[$^*O\ T.?@[_PD;O\
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M(W?_ ,LZ]"HH]K+LON7^0<[\ON1Y[_8GQ5_Z'/P=_P"$C=__ "SH_L3XJ_\
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M^$C=_P#RSKT*BCVLNR^Y?Y!SOR^Y'GO]B?%7_H<_!W_A(W?_ ,LZ/[$^*O\
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M679?<O\ (.=^7W(\]_L3XJ_]#GX._P#"1N__ )9T?V)\5?\ H<_!W_A(W?\
M\LZ]"HH]K+LON7^0<[\ON1Y[_8GQ5_Z'/P=_X2-W_P#+.C^Q/BK_ -#GX._\
M)&[_ /EG7H5%'M9=E]R_R#G?E]R//?[$^*O_ $.?@[_PD;O_ .6=']B?%7_H
M<_!W_A(W?_RSKT*BCVLNR^Y?Y!SOR^Y'GO\ 8GQ5_P"AS\'?^$C=_P#RSH_L
M3XJ_]#GX._\ "1N__EG7H5%'M9=E]R_R#G?E]R//?[$^*O\ T.?@[_PD;O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M2*6((T,*!26E0[LQDXQT(YK2G&\6TKLB;LTF['NO_";_ +6O_1/O!'_@0?\
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M?XS^#M,7R-#5WNHK8'Y(BDX"JH] LQ7Z**^RZSG%1E9%P=UJ%%%%9EA1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5'6];L/#>CWFJ
MZI=Q6.G6<337%S,VU(T49))J]7RA_P %&/%%YIOPAT;P_9.4;7=52*8!B-\<
M:E]A]M_E'G^[^5PCS22)D^5-C[+]J#XH?&*_NG^#WP[MKOP];R-$-=\22&.&
M<@\[5#I^09B,C('2B[_:G^(WP<U:RB^,_@"WT[0[QQ&FO>')&E@C8] REWST
M)QN#8!(#5](>"/"-CX"\(:/X=TV-8['3+6.VCVKC=M&"Q]V.2?<FJGQ-\#V7
MQ)\ :]X:OX4G@U&TDA4/_!)CY''H5;:P/J*OFC>UM">65KWU,GXG_$@^&?@O
MKOC?P[)9ZE]FTMM1L9)<O;S#;N0G:02I!'0BOG7X?_'3]IOXG>$;#Q-X>\#^
M"[O1[[S/(F=WC+;)&C;Y6NP1\R,.1VKD/@7XON/$/[ OQ)TNZD>5M%CO+:'<
M<XA>-)% /LSR<=ABNE_93_:L^%GPU^ ?A?PYXC\4?V=K-E]J\^V_L^ZEV;[J
M:1?F2)E.5=3P3U]:TY.5.RN[F?-S-7=M#4U/]JKXM?!G5]+?XP?#W3K#PY?3
MB ZIH4I81$\]/-E!8 $["5) ..E=M^UC^T5X@^"GASPCJ7A&UTG5#KERT0;4
MHY)$*;%9"FR1,9W=3FO%OVI_VB?#W[1GA[3/AO\ #2VOO%&JW^H13&X2UDBC
M0)G  <!NK9)( 4 DFK7[>>D'P7\*_@_I<S_:&TF5;9WC'W_*@C4D9]=M-03<
M;JPG)V=F>@?\)O\ M:_]$^\$?^!!_P#DRNN^%7BC]H/4_&UE;^/O"'AC2?##
M)(;B[TR8M.K!"4 'VE^K;0?E/![5R/\ P\1\!?\ 0I^-_P#P6V__ ,D5Z%\%
M?VH_#7QT\07VD:+HOB'3+BTM3=O)J]I%%&R[U7"E97);+#C'3-1)22UB6G&^
MDCR_XU_MFZM\&/VA[;PE?:=ITW@Y4MGN[D0RF]C21?F92)-IVDYQLY (ZG-?
M5ME>V^I65O=VDR7-K<1K+%-$P9)$895@1U!!!S7Q)\2_A[I7Q4_;HU?PMK,>
MZQU#PT8RZC+1.(,I(O\ M*P##Z5U7[(/Q%U;X?\ BK6/@3XWD*:OHKNVC7,A
MP+FW^]Y:D]1M(D3_ &2PXV@42@G%-;V",GS-/8[O0OC]XAU/]KOQ%\*Y;/3%
M\/:=8)=17*12"[9C;P289O,V$9E;H@X _'WVOC?PC_RDK\;?]@B/_P!([2OL
MBLYI*UNQ4&W>_<\/_:[^.&N_ 'X;:;XA\/6FG7E[<ZM%8/'J<<CQB-H9G) 1
MT.[,2]\8)XKW"ODS_@I9_P D*T+_ +&2#_TENJ^LZ&ER)^HT_>:"O$_VHOCG
MK'P:T+P[;^%]/M=7\6^(-22QL+&\C>1''\9VHRDG<T:@9ZO[5[97R+IN?CK^
MW1>7>/.\._#BT\A/[AO"2.<?Q"1G_P# <402;N]D$WI9=3VC]FOXR-\=/A1I
M_B6XB@M]5$LEIJ%O:JRQQ3H>BAB2 49&P2?O5D_M9?&C6_@1\+X/$F@6NGWE
M\^I169CU*-WBV,DC$X1T.<H._KQ7DWP4F7X$?M>>-_AS,1;Z%XK7^U](4\*)
M/F<(N3TP9D[Y,*UM_P#!1S_DW^T_[#EM_P"BIJTY5[1+HR.9\C[H@M?B'^UC
M>V4-U!\/_!,D4T8EC/GD%E(R.MY_.NI^!'[36K>-_'NI_#WQ_P"&?^$1\<V<
M9FCMXF+0W"  G;DG! (8$,P9<D'CGCM%_P""@O@;3=#L+5O"GC226"VCB)73
MX-K,J@<'S^G'I7-_L\>++/\ :-_:JU+XFFXM-#32M/\ LFGZ%)<J][<*4*&5
ME&/E&]R2.A91SC)IQ=GS1L2I:JSN=U^T-^T3\1O ?QR\.?#WP'HV@ZM<ZQID
M=W$NJI)O,IEG4J'$R*%VP@\CKGGI4'_";_M:_P#1/O!'_@0?_DRO._VKO'%G
M\-OVUOAWXFU"VN[RRT[0X998+"-7F<&:\7"JS*">>Y%>B?\ #Q'P%_T*?C?_
M ,%MO_\ )%'*^5<L;A=7=V>E_!'7OC'K%]JJ_%#PYH.A6J1H;%]'D+-(^3O#
M?OI. ,8X%97P"^.&N_%3XD_%OP]JUIIUO9>$=6%A8R64<BR21^=<IF4L[ MB
M!/NA1DGCICJO@I\<M%^.VBZAJ>BZ9J^F0V5P+:2/5X$B=F*ALJ$=\C!]17B7
M[&__ "77]I+_ +&0?^E5_6=M)71=]8V9]9T445B:G@/[6OQY\4? [3O"C^%;
M#2K^]UF^>S9-4CD=1PNW;LD3!RW4DUR__";_ +6O_1/O!'_@0?\ Y,K!_P""
MB]\FEZ=\,[V1'>.VUIYF6,98A0A( ]>*WO\ AXCX"_Z%/QO_ ."VW_\ DBNE
M1?(FHW,&US--V/1_@GX@^-&L:OJ,?Q/\-:!H>G) &M)='D+.\N[D-^_DXV^P
M^M<W\7OVJ9?#?C8> ?A[X;E\>>.,9G@A?;;61])&'4@=1E0N1E@>*[+P7\>M
M*^(WPGU[QQHVG:C86NF1W7^CZS"L4C/#$)"2$=OE.1SG/6O'/^"=GAV.7X<^
M)/&=YFYU[7M7E$]Y)@NR(%.,]>9'D8^N1Z5-EK*2V*OM%,O:C\5_VF/!]DVL
M:W\,O#>K:7"/,GM-%N7-VB=3_P MI,D?[*M]*]?^!OQV\.?'OPJ^L:"TL$]L
MXAOM/N<":UD(S@XZJ>=K#@X/0@@>CU\9^&[:+X6?\%#[W1M(46NE^+=->XGM
M8QB,2>2TS-CL=\#G_@;>N*2M-/2S0.\6M3U?X3_';7_'?[0'Q&\#7]IIL.D^
M'/\ CTFMHI%G?YPO[QBY4\'LHKW6OD/]G+_D\SXX?Y_Y:K7UY4U$D]"H.ZU/
M"OC3\==?^''QI^&'A#3;339]-\470AO);N*1IHU\U$_=E74 X8_>#=J]UKY$
M_:I_Y.I^ /\ U_C_ -*(J^NZ))*,0B[MD%]?6^F65Q>7<\=M:6\;3332L%2-
M%&69B>@ !)-?+I_:J\??%C7[VR^"O@*'6](LY#%)XAUYS%;.P[JN]..X&XL0
M02HK6_X*!^*[KPU^SQ=6]K*83K&HV^G2,#@F,AY6 ^ODX/L2*];^"/@VS\ ?
M"7PIH=C"L,=OIT)DP!EY60-(YQW9RQ_&FDHQYFKB;;ERH\*U3]IOXK_!F[M;
MCXN_#JS3PW.ZQ-K7AF4ND!)XW*SO^1*9[$]*]'^.GQLU+PG\!'^(W@#^S-;@
M46]PKWL;R1/;2.$) 1T8,"RY!/&&!'''J/BGPUI_C+PYJ6A:M;K<Z=J$#VT\
M3 '*L,'&>A'4'L0#7QQ^QMIUQX\^ OQ5^%]\XNHK*XN+2V9SPAFC<#'H!)&7
M'NQJERR7-;8EW3Y;[GUM\,_&"?$'X>>&_$J!%.JZ?#=ND8(5'9 749R>&R.I
MZ5\S^,_VTM=\.?M&R>$+?3=+;P-::Q:Z/?:I-#*9XI)!ASO$FP8828&P\1FM
MW]BKXB1V/[+U[+JK;3X.FOH+I&X=(XP;CGZ!R,_[/M7AVG?"Z[\9_L2^-_'%
MXCOK^JZ[)XH$I!+%8I&C8YZ\![EL^_XU48)2:EZ"E)M*Q^@VL:K;Z%I-[J5V
MVRTLX'N)F'9$4LQ_(&O'_P!D[XP^*?CE\/+WQ/XEL=,T]6U"2VLHM-CD0-$B
MKEF+NV3N8CC'W3Q7%?&CXT+JO[#C>*5G87OB'2H+ E3@F>4B.X7\ )ORKUO]
MG;P./AU\$?!VA,GESP:>DMPI7!$TO[V0'Z.[#\*SM:+OO<N]Y:'0?$[Q+=>"
M_AMXL\0V,<,M[I.DW=_!'< F-I(H7=0P!!*DJ,X(..XKC?V8/BQJ_P :OA%8
M>*=<MK*UU"XN)XFBT]'2(!'*C =V.<#GFMSX^?\ )"OB-_V+>I?^DLE>7?L
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJ?LI?!O1_A/\)=">VLXO[<U6SBO=2O\  ,LLDBA]F[^XN0H XXSU))UOC_\
ML_Z#\?\ PB=*U(I8:E$ZO9ZO' ))K;# L!R,JPR"I..0>H%/]W>WXB]^US<^
M+_Q8TCX*^![GQ3KEM>W6GV\L<31:>B/*2[!1@.ZC&3SS71^&]=M_%/AW2M:M
M$DCM=1M(KR))@ ZI(@=0P!(!P1G!/UKYJ_;)\/W'A3]CUM&N]4GUJ>P>PMFU
M"Y4+)/MD4!FQWP!D]3U.37O'P>_Y)'X(_P"P'8_^DZ5+BN6_F4F^:QU]>:?
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M? OP4C\2^&OB"!X6\>_VFYN+_5(&W2IM4",RX.W#!C\Q .\$$YKZ"^-'P?\
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M(,"Z@BU&"5R,Y'7K7GOP6_:3^(_A?X4>%=)TSX$Z[X@T^SL(X8-4M[N18[I
M.'4"V8 'ZGZUZO\ #S]HWXA^,/&FE:/J_P #M<\,Z;=R%)M6N;J1X[8;2=S
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M$J>!FOJ[X+_$/Q!\2O"UUJ?B3P5>^ [Z*\>V33K^5I'DC"(PE!,:<$NRXQ_
M>?3XI^"GP-M?CO\ #/XPZ2JI'KMIKYNM*N6.WRYP)/E)[*X^4_@>PJ8I/FYT
M.5].4_16OFG]ACXP>+OC'X&\1:AXPU?^U[RTU$00R?9H8-B>4K8Q$B@\D\D9
MK0_8Z^.5W\2_!UUX9\3%X?''AAOL=_%<<2S(IVK*P/.X$%'_ -H9/WA7GO\
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MXTF735006LD!MPD("[$*[<*,8&!TXI.45'EB-)MW9\R_\$X_^3?[O_L.7/\
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M ,&5O_\ (]#<9)7>P+FBW9'U-7R9^QO_ ,EU_:2_[&0?^E5_7I_P5_9<\-?
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** /@3XX?"^3XQ?MT'PM_:<NEV5WID#WTL+$/);)&&>->V6
MP!SP.N#C!V_C;\-;O]D'Q[H?Q5^'%BT7A,+%I^NZ1&Y*;.%R<Y^5P%^8YQ(
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M5I:?%SXE6=SX:@E6632?#T6P3X/0GRHQGK\S!\=A6B:B[J6A#3:UCJ:?Q?\
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M^+O^PNO_ *)2OKO6M&LO$6D7FEZE;1WFGWD+07%O*,K(C##*?J#7-?#+X/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** *MI?+=W%[$%*FUF$))_B)C1\_\ CX'X5:JK
M:0V\5Q>M"X:228-, V=K^6@ ]OE"G'OGO5J@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "JMI?+=W%[$%*FUF$))_B)C1\_P#CX'X5:JK:0V\5
MQ>M"X:228-, V=K^6@ ]OE"G'OGO0!:HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P"?<?N0<S[GT;_P\._:"_Z'_P#\HVG_ /R/1_P\._:"_P"A_P#_ "C:?_\
M(]?.5%'U3#?\^X_<@YGW/HW_ (>'?M!?]#__ .4;3_\ Y'H_X>'?M!?]#_\
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M>OG*BCZIAO\ GW'[D',^Y]&_\/#OV@O^A_\ _*-I_P#\CT?\/#OV@O\ H?\
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M<J*/JF&_Y]Q^Y!S/N?1O_#P[]H+_ *'_ /\ *-I__P CT?\ #P[]H+_H?_\
MRC:?_P#(]?.5%'U3#?\ /N/W(.9]SZ-_X>'?M!?]#_\ ^4;3_P#Y'H_X>'?M
M!?\ 0_\ _E&T_P#^1Z^<J*/JF&_Y]Q^Y!S/N?1O_  \._:"_Z'__ ,HVG_\
MR/1_P\._:"_Z'_\ \HVG_P#R/7SE11]4PW_/N/W(.9]SZ-_X>'?M!?\ 0_\
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M_:"_Z'__ ,HVG_\ R/7SE11]4PW_ #[C]R#F?<^C?^'AW[07_0__ /E&T_\
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M_P#Y1M/_ /D>C_AX=^T%_P!#_P#^4;3_ /Y'KYRHH^J8;_GW'[D',^Y]&_\
M#P[]H+_H?_\ RC:?_P#(]'_#P[]H+_H?_P#RC:?_ /(]?.5%'U3#?\^X_<@Y
MGW/HW_AX=^T%_P!#_P#^4;3_ /Y'H_X>'?M!?]#_ /\ E&T__P"1Z^<J*/JF
M&_Y]Q^Y!S/N?1O\ P\._:"_Z'_\ \HVG_P#R/1_P\._:"_Z'_P#\HVG_ /R/
M7SE11]4PW_/N/W(.9]SZ-_X>'?M!?]#_ /\ E&T__P"1Z/\ AX=^T%_T/_\
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MPW_/N/W(.9]SZ-_X>'?M!?\ 0_\ _E&T_P#^1Z/^'AW[07_0_P#_ )1M/_\
MD>OG*BCZIAO^?<?N0<S[GT;_ ,/#OV@O^A__ /*-I_\ \CT?\/#OV@O^A_\
M_*-I_P#\CU\Y44?5,-_S[C]R#F?<^C?^'AW[07_0_P#_ )1M/_\ D>C_ (>'
M?M!?]#__ .4;3_\ Y'KYRHH^J8;_ )]Q^Y!S/N?1O_#P[]H+_H?_ /RC:?\
M_(]'_#P[]H+_ *'_ /\ *-I__P CU\Y44?5,-_S[C]R#F?<^C?\ AX=^T%_T
M/_\ Y1M/_P#D>C_AX=^T%_T/_P#Y1M/_ /D>OG*BCZIAO^?<?N0<S[GT;_P\
M._:"_P"A_P#_ "C:?_\ (]'_  \._:"_Z'__ ,HVG_\ R/7SE11]4PW_ #[C
M]R#F?<^C?^'AW[07_0__ /E&T_\ ^1Z/^'AW[07_ $/_ /Y1M/\ _D>OG*BC
MZIAO^?<?N0<S[GT;_P /#OV@O^A__P#*-I__ ,CT?\/#OV@O^A__ /*-I_\
M\CU\Y44?5,-_S[C]R#F?<^C?^'AW[07_ $/_ /Y1M/\ _D>C_AX=^T%_T/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5B5MUB5I 3"BBBM"0H
MKPG]K#]J'_AF#0=!U+_A&?\ A)?[5N9+?ROM_P!D\K:@;.?*DSG.,8%?-/\
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M>(I?C;>?%"QG.G^(I=7DU>(JQ98F:0L(^VY IV8[KQ6T(5*KG&C*2C96;O\
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M6DJ',EN7SNY"R 9)*F-P6Z$Q?\%%[^XO/VO?&L4TADCM8K"&%3_ ALH'('_
MG8_C7H/B.UAOO^"67A:2X4/)9^*'>V))&QC-<*<>O#OP?7/85G!SA&C6<FW-
MJ^NGO*^BZ6\AOJC(7XM?L?NP5?@7XE9B< #6K@DG_P "ZZ7]M+X8? _X1?"3
M0(M"\"3^%/B1X@2*\AT^;5;FYFT^VSES.KS.@)^YC!^;?@G837G?_!/KX3:?
MX]^,TOB?7]B^%_!%J=;O'FQY?FKDPAN> "K2>G[G!ZUY#\?/B]J'QT^+/B#Q
MC?O+LO;@BSMY#_Q[6J\0Q 9(&% SC@L6/4FM(T;XE0A.5HZOWF]7LOU8KZ'T
MIK7PA^!_[*?@3PL/BSX?U7Q_\0O$%DFHRZ+::@]I#IT3$X!,3J>NY<DMN:-L
M!0*YKXX_ OX:^*?@!!\;/@]'?Z-HUK?#3=9\.ZG.9FLY"54%7+,V<O%P6;*R
M*1MP0?"M TCQ_P#M$^.=+T:WN-7\9>(946V@:]N9+EH(0Q/S.Y/EQ*7)))"C
M<?6OIC]I?7/#7[./[/%E^SOX>U&#7?$UW>IJGBR_A!,44WRN(UYX?,<(QU"1
M#(!?A.,Z=2$5-N;>JOI;KILEV\PW3/BROT O/AG^SS\'_P!F3X8>//''PTO_
M !)J'B.UA2>73]6NHG:=HC(7*_:%4 [3PH'TK\_Z^[OVLO\ DP3]G_\ [=__
M $DDK;&7<Z4$VDWK9VZ>0H]3.\#P_LA_';Q!;>#+#P?XC^&VM:FWD6&K3:C)
M-$9R0$C.^>50S$X *X/3<"17R_\ '/X.ZO\  ?XG:SX-UEEGGL7#0W:(52Z@
M89CE4<XW+U&3@@C)Q7#6]Q+:3QSP2/#-$P=)(V*LC Y!!'((/>OTV_:?^#&G
M?'7]LOX-:)JT3"#4/#YN-8$4NUFMX&EEV$@@C<Q:/<O/S<?=XB4OJ55)R;BT
MWJ[VMKU'\2/S%HK[@^)__!07Q5\-OB1J_A/X>^'?#>B^!O#][+IMOI3Z;D7*
M1,8V,F&& 2K$!=N 1G)R:Z+XI?"3X7:]\6?@!\4+C2K;PSX+^(++/K>ELRI:
M1W(C22,$8 "R.VQR,*0I;@L2=/KDXV=6%DTVM;[*]O6WJ+E71GY^T5^K?Q.\
M;_M'?"SXAW L_AOI'B#X-6MT$BTWP[81W+/IP?  B#"02B/!(V[ ?51FOFCX
M*_"GX>_M*?MM:G;Z/X?O?#_@.TCDU>X\-W]NL$B-%Y<<EN51V"(9WR5!&%R@
M X-33QZE!U)1]U*^CO\ )[68W'H?'=%?IIKGQD_:4T_QC-9^&_@=%%\-+:?R
M+;PY)I 436:G: S _(S*.R[5R!M;'/S5_P % O@9I'P;^+UA=^&]..D>'_$E
M@NHQ:?MVI:3[BLT2+_"H^1MO8N0,  5='&>TJ*G))-[6:?W]F)QLKGS!7VO^
MQ#^S;\//&7P]U;QM\5]+-_I-_K5IH&B1M=3VW[^1PC.#%(FX%Y8UYR!L>OBZ
MRLY]1O(+2UA>XN9Y%BBAC&6=V.%4#N22!7Z!?M:?#+Q]X%^$OP=^$_@#PEXC
MUB+P];KK.I:GH6DW,\?]H9.UEDC4@,)&N'*YR-\?3C*QLV^6C&7*Y/?:R6K_
M $0X]SXO^-_PRN/@W\6O%/@RY+L=)O7AADD(+20'#PN<8&6C9&_&N'K[J_X*
M)^!M1\6>"/AE\9KK1;K0]3U33XM+U[3KR%X9;6YV&2,,C*I'/GJ20,A8\#FO
MA6NC"5O;T8S>^S]5N3)684445UB"BBB@ HHHH **** "BBB@ HHHH **** /
MHC_@GS_R=_\ #[_?O?\ TAN*_:NOQ4_X)\_\G?\ P^_W[W_TAN*_:NOB,\_W
MB/\ A_5G13V"BBBOGC4IV5\;NYU"(H%^RSB$'.=V8T?/_C^/PJY56T-L;B]\
MC'FB8?:,9^_Y:8_\<V=*M4 %?.7_  4._P"3//'_ /W#_P#TX6U?1M?.7_!0
M[_DSSQ__ -P__P!.%M77A/\ >:?^)?F3+9GXLT445^FG(%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MEE7Y@ ?17[1W[2/AG]F'PEHOB+Q38ZM?V6K:Q!HD$>CPQ22+/+'*ZLPDD0!
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M.\/^&[67RWNI>-SLV"0BET!P"274< EE />**^&_%O[4/[3?[/>GV'B_XO\
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M]U45\[?'W]LG0_A#\$_"'C;1=*N/%>K^-UM4\*Z#"2DM_+<QK)'G )"@.F<
MG+*HY85XW\1/VHOVJ/@'\.M7\;_$;X6>#;C0?L4I@;PY=SR3:/<LA%L;U&E(
MEB\TQHYB9< D[AP" ?=M%?*\O[;MGX"_8N\)_&KQS8P3:SKEG#]GT31PT2WE
M[)NVPQ;V<JN$9B26(56/)P#Q>H?'[]K_ ,(>%9?B%XA^#_@N?P?;P_;KKPSI
M]]<+KUO:@!F+,7:,NJY)4)N[;<@B@#[<KS?]H/X[Z!^S9\+=2\>^)K/4K[1[
M"6&*6#28HY+@F618UVK(Z+C+#.6'&>M:?P9^+6@_'3X8^'_'7AF9I=(UFW$\
M:R8\R%P2LD3@$@.CJR'!(RIP2.:\]_;;^.^O_LV?L[:]X]\,V>FWVL6%Q:11
M0:M%));D2SI&VY8W1LX8XPPY]: /:- UF'Q%H6G:M;+(EO?VT=U$LH <*ZA@
M& )&<'G!-7Z^1_VF_P!LSQ#^S_I_P0U.WT"TUVW\:%UU&P@@D:ZD?[/$\45I
MB0!6>64+EP_!'''/%_%']JK]J+X ^'HOB+\0/A1X,_X5RD\2W^F:-J4TNK:;
M'(ZHIEF+&)CN8+E$(+,N2HYH ^[*\?\ VH/VH/"O[)G@#3_%_B_3]8U'3;W4
MX]*CBT2&*682O%+*&(DEC&W;"XSDG)''4CT_P[KUGXJ\/Z9K6G2&73]2M8KR
MVD(P6BD0.AQVR&%?"/\ P6K_ .36/"W_ &.=K_Z0WU '6-_P50\#0J7N/A/\
M7K6!>7FF\-0A(QW9C]IZ"O?_ ( _M.?#K]ICP]/JW@+7DU+[*0MY83(8;NT)
MSM\R)N0#@X894X."<&O5*_/KXR^'[7]F_P#X*4?![Q9X5M_[+L?B<ESH^NV-
MLGEP74P9%,I P-VZ6W<_[4>X\L<@'Z!2RI!$\LKK'&BEF=S@*!U)/85X!^S/
M^V_\._VK/$7B;1?!T6L6EYH:),W]KV\4*WD+.R>=!LD<L@91G<%(WIQUQA_\
M%&OC#/\ "/\ 9;\11Z6SGQ'XI9/#>E10Y\UY;C*R% .<B(2D8_BV^M?-GCGX
M:C]@#XC?LP_$"%Q!H4>G)X$\8S+\L1,NZ8S-CC'F23R]?^79.M 'Z57M[;Z;
M9SW=W/%:VEO&TLT\[A(XT499F8\   DD],5\?ZY_P51^$%KK%Y9^'=%\;^/;
M6S<QW&J>&-#$]I&1U):22,D=>0I! R,C&?9OVO\ P#XA^*/[,OQ%\+>%,MX@
MU/2GBM8E<(9R&5FA!) 'F*K)R<?-SQ7RQ^R/_P % /@O\+OA7X4^%WC2&_\
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M@/#/@#X?_#36]*\>?$^Y\1P/I<WARX2Z-HC(ZO\ Z1$2J[F:+*[OX-Q V T
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MK2 F%%%%:$GPE_P5@_Y$+P%_V$[C_P!%"O-/^">_[-_PZ^./A'Q=>^-O#O\
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M%%% !1110 4444 %%%% %W3?^6GX?UJ]5'3?^6GX?UJ]6,MRD%%%%2,****
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MFP*2(9F7EO\ 62M-M #8 7&<Y^,J*R^J.;<J\N9M-;623W[ZCYK;'W!\3_\
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M7,<L,JE71@<%6!Y!!!!!J*BG1PZH3FXO26MNSZ_>#=PHHHKK$%%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MMW;G,+7:6D4;*"."0]M<#/L?6N7\*_\ *#N?_KQO/_3]+7WE\-?V=? GP?\
MA;=^ /!^CC0]!NX98KAH7W7$S2)L>5Y&R7?'0MD   #  KD]/_8X\%Z;^RJW
MP!BU/7F\'-%+";Y[B'^T,/=M='Y_)\O.]B!^[^[QUYH ^,?VY=,U ?![]C+6
MD\0GPEHUC/IT-SK[6JW$>F3R6]FT-TR,P#",0S/M/# ')]?9O&O[.?QOTCP)
MK.K^)/VRY8/"L5A+-?W4_@BS\G[+L.\DB?D%2>G)SQUKZBUCX'>#_%'P?M?A
MGXBTM?$7A.#3H--^SZ@<NZ0HJ1N70+MD&T'>FT@\C%?.R?\ !+7X62""PO\
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M)_P3"^%%GJ>F2:]KOCCQQHVER"6P\.>)]=^TZ9;$= L*QH=H&!M+$$#!R,T
M?'GQ4T74- _X)5?LT6VIQO%<R>-K>Z19"<F&9M4FA//8Q21D>Q%?5/Q_MH[K
M_@IK^S(DJ[U&E:VX'^TMI<,I_ @&O>_VAOV9O"G[2G@O0?"_B.ZU/2M,T75K
M?6+4:))%"WFPQR1HAWQNOE[96X !X&".]SQ;^SYX=\9?'7P+\5[V]U2+Q%X/
MMKNUL+6"6,6DJW$3Q.95,9<D+(Q&UUY SGI0!\^?\%=?^3,]6_[#%A_Z,-9O
M[=5RTGBG]D"XN)-S-\0](DDDD/4[X2237TK^T9^SYX=_:<^&=QX&\4WNJ6&D
MSW,-TTVD2QQSAHVRH#21NN/7Y?RJA\?/V7/!G[1O@'2?"OBE]3MHM(N(KO3M
M3TJZ$%[:3(I0.CE67)!.05(Z' (! !Z]7PO^V%-'X7_;S_99\2ZU(MKX<,U_
MIXNYO]3'=.H5%8GA2S2Q8)]"?X:^NOA/\.HOA-\/])\)P:]K?B:+3A(%U7Q'
M=BZOYP\KR?O90JAMN_:.!A54<XS5+XT?!#P9^T#X'G\)^.=&CUC1Y)%F12Q2
M6"500LL3KAD< D9!Y!(.02" 0?'GXY^&/V<OAGJ/CGQ=)<#2+*2&(Q6:*]Q,
M\DBHJQHS*&/S%B,\*K'M7R'X-\3VEC_P57_MW6XYM-M/'7PYMV\.)J2!)-[?
M9W,7)(60"WN 5!/)QSNKT[PC_P $U?A;H'B32M5US6_&GQ!M](D673-(\7ZW
M]LL+)E^[LA6-,@<#:Q8?*,@\Y]:^/_[,7P__ &E]#LM/\;:4\\^GR&6PU2RF
M-O>V3G&3%*.0#@$J<J2 2,@8 /%/^"KWB32=(_8N\5Z5>W$2:GK=WI]IIENV
M#)/,EY#,X0=>(XI"2/IWKSCQ;%-X(_;6_8MM?$#_ &2[MO"=WIMPT[?\O1TZ
M2'9D]6,C*OKEAZU[3\-O^">/PS\!>.--\7ZMJOBSXD:_I1#:;<^.-6_M 61'
M*F- B+P>1N!P>1@@$>B?M$_LN> OVG] L--\:6-R;C393/IVJZ=/Y%Y9.V-Q
MCDP1@[5R&!!VJ<9 ( /G#_@L9XJT_1OV4(-(N+B-=0UC7;6.UMR_SN(P\DCA
M>X4*H)Z NO/(!T_VJK>.Z_;_ /V3TE7>H?67 /\ >6!64_@0#6UJ/_!,'X4Z
M]X0UC1]>USQIXEU34TAA/B?6]72\U2VACE$HB@>2$QQJ2H!Q'DC(SS7MWCW]
MGOP[\1/C#\/OB1J5[JD&N>"/M7]G6]K+&MM+]H0(_G*T;,V .-K+SUS0!XA_
MP5>_Y,D\8_\ 7YIW_I9%7"_MQW+2_#;]E">>3<[>.- >21SU/DY))KZP_:#^
M!&@?M)_"W4O 7B:\U*QT>_EAEEGTF6..X!BD61=K2(ZXRHSE3QGI6/\ &O\
M98\$_'SX3:5\/_%']HC3=):"73[^QN!#>VLL,9C257VE=VUF!!4J<YQP, 'L
M%?)'[;/BWXAP>)?"WA7PU\8/!?P2\+ZI:S2ZGXB\0ZC;V^H2%6"^7:)*X9L!
M@25V8)'[P=*^@_@_\,8?@[X T_PI;^(=?\4PV32LNI^)KT7=])OD9R'E"KN
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M4&OH+]O;_DSCXL_]@27_ -"6M+Q5^R=X5\8Z-\'].U+5]==/AA?6.H:1-'/
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MD%SC"CH.*^5]'_X)(?#7P]]H_LKXE_%73/M,GFS_ &/7K:+S7_O-MM1N/N:
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MM[_IU^/_  "/9>9_.917]&=%']O?].OQ_P" 'LO,_G,HK^C.BC^WO^G7X_\
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MV]_TZ_'_ ( >R\S^<RBOZ,Z*/[>_Z=?C_P  /9>9_.917]&=%']O?].OQ_X
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K$K;K$K2
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M[?\ ^-T?\-!^/_\ H/\ _DG;_P#QNO.Z*OZGAO\ GU'[D+FEW/1/^&@_'_\
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MT'X__P"@_P#^2=O_ /&Z\[HH^IX;_GU'[D'-+N>B?\-!^/\ _H/_ /DG;_\
MQNC_ (:#\?\ _0?_ /).W_\ C=>=T4?4\-_SZC]R#FEW/1/^&@_'_P#T'_\
MR3M__C='_#0?C_\ Z#__ ))V_P#\;KSNBCZGAO\ GU'[D'-+N>B?\-!^/_\
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M /).W_\ C=>=T4?4\-_SZC]R#FEW/1/^&@_'_P#T'_\ R3M__C='_#0?C_\
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M "3M_P#XW1_PT'X__P"@_P#^2=O_ /&Z\[HH^IX;_GU'[D'-+N>B?\-!^/\
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M_C='_#0?C_\ Z#__ ))V_P#\;KSNBCZGAO\ GU'[D'-+N>B?\-!^/_\ H/\
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M"1\12ZLTY:265KB"-8E3 "J%E8DDDDXZ8.?<* "BBB@ HHHH **** "BBB@
MHKP^;]HNY/[85O\ !.+18EM1X6;Q'-J[SDNQ\X1+$L>  !R2Q)SP,#J?<* "
MBOEGQ)_P4,^'_P -/C-K'P\^).EZWX!FMKHPV&O:C9N^FZC'A2LB2*NY0=PR
M=I0=WKZ0\+^+-$\;Z);:SX=U>QUW2;E=T-]IUPD\,@]G0D&@#6HHJOJ&H6ND
MV%S?7MQ%:65M$TT]Q,X1(HU!+,S'@  $DGTH L45\%?LW_ML>+_VB/VWM5T"
MR>;3OA&_AVYO=#LI[&.-]06*Y2$7WF,GFX=A* NX* H!7<":^]: "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *R?$W_(.A_P"OVT_]*(ZUJR?$
MW_(.A_Z_;3_THCH UJ*** "BN.^*WQ9\-?!CP?=^)/%%\+2QA&$C0;I;B0_=
MCC7^)C^0ZD@ FOA#QA_P53\12ZHX\+>"]+M=.4X4ZQ+)/,X]2(V0+]/F^M=^
M&P-?%*]*.G<Z:6&JUM8+0_2"BOB?X&_\%+=#\:ZS9Z)X[T9/"]U=.(H]4M93
M)9[SPH=2-T8)XSE@.Y R:^UHY$FC5T8.C ,K*<@@]"#66(PU7"RY:L;$5:,Z
M+M-6'445Y#^USX\UWX8?LU?$/Q5X9OO[-U_2M*>YL[OR8Y?*D!&&V2*RMUZ,
M"*Y3$]>HK\]O@EX9_;'^-GPG\,>.K/\ :,T?3+77;-;R.TG\*6+O$"2-I(M\
M$\5N>%?V@_CG^SA^T=X&^&'QXU30_&OASQU(;31/%FEVBVDPN@501O&BHOWY
M(E*[?^6J$,>5H ^[:*** "BBB@ HHHH **** "BLSQ-K2^&_#>K:NT1G6PM)
M;HQ!MI<(A;;GMG&,UX[^SY\9_$?[3G[*EIX^TNUL_"WB?7[75$TZ+S#-!9S1
MW-Q;V[.S(=^/*C9CL()S\N/EH ]UHKS_ . FC?$/P_\ "?0K#XK:[I_B;Q]#
MY_\ :6J:7&$MY\SR-%L BB VPF)3^[7E3UZGT"@ HHHH **** "BOA__ (*
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M!DX&3G@=* /4J*\)_;?\5^.O /[,7C3Q3\.=7;1?%&B0Q7\=P+6&X!@25/M
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MC:V^O:/,%6]MX]OG+\IVM^#GCU /&<5YK\/OAOJOQ$U,P6*B&TB(-S>RC]W
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M./:OU/L[2.PM(+:$%8846- 3G"@8'\J )J*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ K)\3?\@Z'_K]M/\ THCK6K)\3?\ (.A_Z_;3_P!*(Z -
M:BBB@#\J_P#@I9\0[WQ)\>5\+F8C3?#EE"B0 _+YTR+*[D>I5HQ]%%;'P]\%
M3M\$/!^H?"/X>>"_B5J<T4LGB=O$%M#>ZC;76[ B6&5U*1A1\NP988;N2R?\
M%,_A/J&A?%>T\=0P/+H^NVL<,TZKD17,*A-K>FY!&1GKAO2O*M#TCX-^*_#O
MAG4K?QU=?"7Q7I]JEMJ4,FGWFH1WEPG_ "^0RQ$F,N#RG !&  !EOO:*C+!T
M>3;R3:O;6Z6N_P")]-3L\/#E_*_WVU.1_:#.AM\0-^C>$-1\!W+V<+:MH%_;
MF!;6_()F$"%BPA/RLN[!Y.% Q7Z8?\$_OB'>_$']G#2AJ$QN;O1+J71S,YRS
M)&$>,'Z1R(OT45^=O[3GQ0TGXG^(?"MGH=_>^(X_#^BP:._B'483'=:K(K,Q
MD*DEMOS84-\W4G.:_2?]B#X5WWPE_9[T2PU6)K?5=3DDU:YMV&&B,H78I]&$
M:QY'8Y':N3-&OJ4%-6E?3O\ YF.-:^KQ4MSWNO OV]O^3./BS_V!)?\ T):]
M]KP+]O;_ ),X^+/_ &!)?_0EKXT^?/E3]E3]JCXW^#OV=? .B>'OV7]8\7Z+
M9:8D-IKL'B)($O4!.)!&;9BH/ID]*Z_P_P#"3XW?M:_M*?#SXD_%SP59?##P
M1X E:_TC0#?)=WES=%HY%9F7I\\4))8)@1 !226'OG[!/_)G'PF_[ D7_H35
M[[0!^:5W\"[?]HG_ (*6_'WPEXBU+4K?P$FG:/J&KZ9IURUO_:<J6%JEO#*Z
MX;RQYLKD C+(OIQT?QS\*WFB_$SX._L>?#+Q#K'@WPGJEG=:WKNIP7K27_\
M9_F3N((YG)8 F&90.?\ EF""JL#W'P(_Y2<_M-?]@?0O_2*VJ#]L_P )>*OA
M9^T7\+_VD?#'AR^\7Z;X:LYM$\2:5I<8DNUL'\W;-&G\6W[1,3C&"J9(4L0
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M^ R!&_"OA7_@D]_:OQ6\8>*_B3KMMY;>'/#FD> M,,F2ZI;PJ9P<]"3'$W_
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M/PXU6S2"Z\-65R\DVFS *#)!!DYR4W94'_6.IV_*:^H**U>+E*7--75K6?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJCIO_+3\/ZU>K&6Y2"BBBI&%%%% !1110 4444 %%%% !1110 4444 %%%%
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M3/\ P,C_ ,:/[>Q/\L?N?^8>RB?)G_#/GC__ * '_DY;_P#QRC_AGSQ__P!
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MNF?^!D?^-'_"9^'_ /H.Z9_X&1_XT?V]B?Y8_<_\P]E$^3/^&?/'_P#T /\
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M.Z9_X&1_XT?\)GX?_P"@[IG_ (&1_P"-']O8G^6/W/\ S#V43Y,_X9\\?_\
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M?_\ 0 _\G+?_ ..4?\,^>/\ _H ?^3EO_P#'*^L_^$S\/_\ 0=TS_P #(_\
M&C_A,_#_ /T'=,_\#(_\:/[>Q/\ +'[G_F'LHGR9_P ,^>/_ /H ?^3EO_\
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M -.O_)O^ 'LO,_.^BOT0HH_UA_Z=?^3?\ /9>9^=]%?HA11_K#_TZ_\ )O\
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M?^3?\ /9>9^=]%?HA11_K#_TZ_\ )O\ @![+S/SOHK]$**/]8?\ IU_Y-_P
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M_D'0_P#7[:?^E$=:U9/B;_D'0_\ 7[:?^E$= &M1110 4444 %%%% !1110
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M<"!],5S?_#0?C_\ Z#__ ))V_P#\;KSNBOTN& PL(J*IKYI/\SC<Y/J>B?\
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M .2=O_\ &Z/^&@_'_P#T'_\ R3M__C=>=T4?4\-_SZC]R#FEW/1/^&@_'_\
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MT'X__P"@_P#^2=O_ /&Z\[HH^IX;_GU'[D'-+N>B?\-!^/\ _H/_ /DG;_\
MQNC_ (:#\?\ _0?_ /).W_\ C=>=T4?4\-_SZC]R#FEW/1/^&@_'_P#T'_\
MR3M__C='_#0?C_\ Z#__ ))V_P#\;KSNBCZGAO\ GU'[D'-+N>B?\-!^/_\
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M /).W_\ C=>=T4?4\-_SZC]R#FEW/1/^&@_'_P#T'_\ R3M__C='_#0?C_\
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M "3M_P#XW1_PT'X__P"@_P#^2=O_ /&Z\[HH^IX;_GU'[D'-+N>B?\-!^/\
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M_P#7C!_Z50UH_L037$OP7D6?/E1ZI.L&?[FV,G_QXO6=_P %'?\ DR?XI_\
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M (?!O@V&YM]$AGEN42[G,SAY#EOF/.,US'BG]HW_ (1K]JCP7\&?^$>^T_\
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MXQG.&..2IY5E(;CSS]G#P'\:/&W[4_[5_P#PJ'XFV'PY^S>,YO[4^VZ1!?\
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MWN+6&1R<!5FEC6-B3P,-SGBOGG_@K!XKNY_$'P*\ 3Z3KNO^%]=UN:^UC0]
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MXX_LO7MQX3LX);6^\4^';.*^M;^-F;=+,=H3<5(.XRAN/NKC ZWQ6OPLM_\
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M\<>%/C+I%\NO^%9KG3K/Q+=1%$URU"R*LRD\R$%#^\P-ZO&>6+$_('_!-_\
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M=MF&_9H_:(TRZT7^QK:S\2ZN(]"GD$ZZ<PM$!A#8P2F NX 9VYH ]9_X)O\
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M.]*\AV7S)/+<*>&0@Y!]1W_ 'M0!RI!!P>#25TGQ'MXK7QSK,<("IYY; ]2
M3^I-<W0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M =A\(_\ DH>D?67_ -%/7TM7S3\(_P#DH>D?67_T4]?2U !1110!GZ9%-'>Z
MLTH8(]TK1;CP5\F(<>VX-^.:T*HZ?>R7=WJ<3A0MM<")"HY(,4;\^^7/Z5>H
M *\[_:#_ .20Z_\ ]N__ *41UZ)7G?[0?_)(=?\ ^W?_ -*(Z[,%_O-+_$OS
M1,OA9\9T445^J'"%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M$>FS:FWB?QUXG>6_U[6Y.#>73HV$4MSL4LV"W)9W8XW8'.?\$U/@AXU_9_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ KHOAQ_P E#\+_ /84M?\ T<M<[71?#=2W
MQ#\+@ D_VI:GC_KJM8UOX4O1C6Y]W4445^2G>%5;2>":XO4A0+)%,$F(7&Y_
M+1@??Y649]L=JM55M+-+6XO9$<LUS,)7!_A(C1,?D@/XT 6J*** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *R?$W_(.A_P"OVT_]*(ZUJR?$W_(.A_Z_
M;3_THCH UJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_9/_ (W1_P *#\0?\_FF?]_9/_C=>^44 >!_\*#\0?\ /YIG_?V3_P"-T?\
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M_.M"@ K(\7>'(/%WAK4='N25BNXC'O'53U5OP(!_"M>BJC)PDI1W0'PEXO\
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M'^L/_3K_ ,F_X >R\S\[Z*_1"BC_ %A_Z=?^3?\  #V7F?G?17Z(44?ZP_\
M3K_R;_@![+S/SOHK]$**/]8?^G7_ )-_P ]EYGYWT5^B%%'^L/\ TZ_\F_X
M>R\S\[Z*_1"BC_6'_IU_Y-_P ]EYGYWT5^B%%'^L/_3K_P F_P" 'LO,_.^B
MOT0HH_UA_P"G7_DW_ #V7F?G?17Z(44?ZP_].O\ R;_@![+S/SOHK]$**/\
M6'_IU_Y-_P  /9>9^=]%?HA11_K#_P!.O_)O^ 'LO,_.^BOT0HH_UA_Z=?\
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M/Z5T <[XO^(?AKP"^CIXBUNSTB76=0ATK3HKF4*]Y=2N$CAB7JS$L.@X&2<
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MX #J3X03_P"2*]5_9X_:\^'/[33:K:>$KV\M==TKF_T'6;4VM];+G;N9"2"
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MXJ\5ZKXUUVZUC6;Q[[4+AMSRO^@ Z #L!7TEXC_8)UV*^;^P/$FGW-F3\O\
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M2#P>" 1Z3X7T1_#7AS3-)DU.]UE[&VCMSJ&I,C7-SM4+YDI144N<9)"@$]J
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M+4"97<-Z_9P4('<#IR#T_P &?V$OAW\'/'J^.&O_ !+X[\9PQ^3:Z[XTU/\
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M7?#?P'>>)/%MUI'@'4SJFD3RW=L;EF,A<12M]GPT:DD !5(&!NP!0 WXP?\
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MZAI.A^)HC<Z>T3C>N"5*Q@@X(\@,".>1Q]XMX.T)_")\+'1['_A&C9?V=_9
MMU%K]EV;/)\O&W9L^7;C&.*^4Y/^"77PPMVN;31O&'Q'\->&;EF,WA?2?$A3
M37#$[E*/&SD'.#E\^] ':?L%?M&^(OVF?@E=Z_XLL;*T\0Z1K5SH=W+IH(MK
MIHDB<2QC<V 1, <$@E21@$ ?2%<I\+OA9X7^#'@?3?"/@[28M%T#3U(AMHBS
M'))+.S,2SLQ))9B2:ZN@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "LGQ-_P @Z'_K]M/_ $HCK6K)\3?\@Z'_ *_;3_THCH UJ*** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MFDW=1GDG!92I5ACJ>10!+X0\2ZWX;^!=]JU\SO<1;A8O,<MY;%$0GZ,S8SV
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MH **** "BBB@ HHHH **** "BBB@"IJ6DV.LVX@U"RM[Z -O$=S$LBAN1G#
MC/)_.IK:UALK>."WB2""-0J11*%50.@ ' %2T4 4=,T+3=$\W^SM/M;#S2#)
M]E@6/?C.,[0,]3^=-U+P]I>LR(^H:;9WSQC"-<P)(5^A8'%:%% #(88[>)(H
MD6.-!M5$& H] *SSX8T8WYOCI-B;TMO^TFV3S,]<[L9S6G10 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !3617&&4,,@X(SR#D?K3J* "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;;'"CO@97+8P"RC.2,@'IE%86L>.=!\-^$7\4:UJD&AZ!';K=2WVK$VB0QL
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M>!OCA_PD'_"$ZY_;7]@WS:;J/^B3P>1<#.4_>HN[H>5R/>@#OJ*** "BBB@
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M  3+\<Z_JL$WCN\M/"^D(X,UO;3K<W<J]PI3,:YZ;B3C^Z:_23P9X.TCX?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MY0 ]C^/O[*/C#]I7]M7PCJ'C?2?MWP)\.:>6BMUOH@EQ=[2["2(.),/(44D
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MU[PYHEQ?7.J7=I&FFS(+P#;%*)"S-_I"<%!]U^>!GU3]@_Q/\&_$G@OQM/\
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MQ>#?#>G:;!/-+K&C:-H4?VD;@NV>W@CPCD;2'&QF/R$9 ./C5_\ @KQXRNO
M#^!O&7P;L/$OB]K;[%/<:A,R17,NW;OET\VYR3R2BNH))P%'%?L!10!^8/\
MP2"_94\;?#G7O$?Q2\7:5=>';34M+.CZ9I]_&T5Q<(TT4KSM&P!5!Y*!2>6W
M,0,8)\#_ &O#XK_92_X**7?Q6O/#,^IZ.=7AUK3I90T-M?QM"JO$LP#!74[U
M/!((!VD$9_;JB@#\[/VD'\6_\%!?^">\'BK2/!MUI'B2QUPZO;^&HV>::2*
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M^&FO_#[PA\*_[$N_$%G)IUU<QZD^J3&WE'ER+'$MO'AF#%-QW?>X&<5^QU%
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MX6U(:E=ZUK:[);WE"5C.T N5!15C+@;]S-T%?J'10!^;7_!9/_FA7_8<NO\
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M6>WBBVLQ8$ FVRK!2&$BD&O5?V0O^4C/[4O_ &[_ /H0K[YHH _,E=0\5?\
M!-#]I?XD>(;_ ,'ZQXJ^!_CRY_M(ZCHD0FDTV;>\@4@D*NPS2)ARN]3&P8E"
MM6_BA^V'X[_;@U'PYX _9JTOQ?X8M3J4=QK/CF9#9QVL*C!3=&Y&SYBS*S!F
M,:JJG-?I710!5TJR;3=+L[-[B6[:WA2(W$[;I)2J@;F/=CC)/J:^#?\ @KC\
M+?&/C;P-\._$GA[0[KQ7H/A;59KK6]"M$:1IHW$6R1E4%BBB.5"0#M$Q)X!(
M^_** /@OPU_P5/\  NO^'K?0?AA\)O&NO>*XXA!;>%M/TJ*."VDP0$=XG;9&
M"#R$Z#D#G'GO_!,%_$GA[]J[]H;1?B';1Z3\0M3\G6-0T]'4@2//)+,5VL05
M!NH^A(PPYK]-J* /SL_X)<?\E_\ VN?^QGM__2O5*](_X*R>!]=\<?LCWB:#
MIEQJLVF:Q::C<PVL9DD6!1(C.% )(4R*3CH,D\ U]ET4 ? /C']K;P;^U1^P
M'\87\+0ZA:7OA_PY!;ZG:ZA$J&.21>-A5FW+F-P#Q]WI7M?_  3B_P"3)_A9
M_P!>,_\ Z535])T4 ? ?C'_E,?X&_P"Q*D_]%WE9FB_\IG]?_P"Q57_TCAK]
M#Z* / OV]O\ DSCXL_\ 8$E_]"6O+?AAX4U3QS_P2FM- T2T>_UC4? 5S;VE
MI']^>4QR;47_ &F/ ]R*^SZ* /@7_@E[^U1X7UWX=^&/@5<Z?JVD^/O#=A>/
M=0WEL$@=$N2V%8MN#[9ERK*,%6]!G _X)=6NOWW[._QTM_"E[!IOB>3Q/?KI
M=W=1B2&&Z-K'Y3.ISE0^W(],U^C-% 'YS?#K_@IIJ/P=T.Y\&_M/>"O%&F>-
M[.::.34K;28?LM_$78J FZ->%8*"@9750V[)YPOV8?!]U^T+^WK;?'GP;\-[
MWX9?##1]/EBW7]DEF=7N)+>:'<(T^0L3,&8J74>2,MN85^FU% !7Y^_\%8=$
MN/"LOP/^,5O%))'X(\4QF[\H9(1Y(IT8^@#6FT'UD'J*_0*N)^-7PFT;XY_"
MOQ+X$UY3_9NM6C6[2J,M _#1RJ/[R.JN.V5&>* .OL;ZWU.QM[RUE6>UN(UE
MBE0Y5T895A[$$&OS?_X(B?\ ))?B1_V&X/\ T0*^F/V%KSQUHGPCD^'?Q&T3
M4-.\1^ [DZ''J4]K(EIJMDG%K<6TS*%E7RQL.TDC8I8 MBOH^@ KC_B_;>,;
MOX8^)8OA]>6UAXU-D[:3/>1J\(N!RJL&!7#8VY(P-V>U=A10!^<_@+_@J/:?
M#WP?'X1_:-\"^+-+\?V8>WO631X?(U+#<.(V:,*2"H(52AX8-A@!B?LB>&)O
M%/[6/Q"_:5M? D_PD^$-MHLP@@U&W%H;K$,9EF$:X4+B)Y79<J&( +'<1^F=
M% 'YU?\ !+_3;_XT?%7XT_M&:[;LEQXBU)M*TKS1\T4&5EDC'JJH+2,$9_U;
M#/6OT5HHH _,7X3WG_#'?_!4;Q7X&F;[%X+^)ZBZL$)Q$L\S-+!CIC$PN;=0
M,_ZQ?P]K_P""M/C%-"_9%O\ P[&&FU+Q9J]CI5I;Q#<\C+,+DX Y_P"7<#ZL
M!WK[/KX\\1?#3Q'^TK^V_I>L^(M"U#2_A9\)D\S2_P"T[.2!-;UB3#&:$.!Y
MD411,.,C="-I(<X /HGX%> 7^%?P6\"^#YB#<:'HEG83L#D-+'"JR'CU8,?Q
MKNJ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** .:\5_$'2_!MQ!#?VNN7#S*
M74Z5H%]J*@ X^9K:&0*?9B#6%_PO/PY_T#?&/_A$ZU_\B5Z%16J=.VJ?W_\
M +3CU7X_\ \]_P"%Y^'/^@;XQ_\ ")UK_P"1*/\ A>?AS_H&^,?_  B=:_\
MD2O0J*=Z7\K^_P#X [P[/[_^ >>_\+S\.?\ 0-\8_P#A$ZU_\B4?\+S\.?\
M0-\8_P#A$ZU_\B5Z%11>E_*_O_X 7AV?W_\  //?^%Y^'/\ H&^,?_")UK_Y
M$H_X7GX<_P"@;XQ_\(G6O_D2O0J*+TOY7]__   O#L_O_P" >>_\+S\.?] W
MQC_X1.M?_(E'_"\_#G_0-\8_^$3K7_R)7H5%%Z7\K^__ ( 7AV?W_P# //?^
M%Y^'/^@;XQ_\(G6O_D2C_A>?AS_H&^,?_")UK_Y$KT*BB]+^5_?_ , +P[/[
M_P#@'GO_  O/PY_T#?&/_A$ZU_\ (E'_  O/PY_T#?&/_A$ZU_\ (E>A447I
M?RO[_P#@!>'9_?\ \ \]_P"%Y^'/^@;XQ_\ ")UK_P"1*/\ A>?AS_H&^,?_
M  B=:_\ D2O0J*+TOY7]_P#P O#L_O\ ^ >>_P#"\_#G_0-\8_\ A$ZU_P#(
ME'_"\_#G_0-\8_\ A$ZU_P#(E>A447I?RO[_ /@!>'9_?_P#SW_A>?AS_H&^
M,?\ PB=:_P#D2C_A>?AS_H&^,?\ PB=:_P#D2O0J*+TOY7]__ "\.S^__@'G
MO_"\_#G_ $#?&/\ X1.M?_(E'_"\_#G_ $#?&/\ X1.M?_(E>A447I?RO[_^
M %X=G]__  #SW_A>?AS_ *!OC'_PB=:_^1*/^%Y^'/\ H&^,?_")UK_Y$KT*
MBB]+^5_?_P  +P[/[_\ @'GO_"\_#G_0-\8_^$3K7_R)1_PO/PY_T#?&/_A$
MZU_\B5Z%11>E_*_O_P" %X=G]_\ P#SW_A>?AS_H&^,?_")UK_Y$H_X7GX<_
MZ!OC'_PB=:_^1*]"HHO2_E?W_P# "\.S^_\ X!Y[_P +S\.?] WQC_X1.M?_
M ")1_P +S\.?] WQC_X1.M?_ ")7H5%%Z7\K^_\ X 7AV?W_ / //?\ A>?A
MS_H&^,?_  B=:_\ D2C_ (7GX<_Z!OC'_P (G6O_ )$KT*BB]+^5_?\ \ +P
M[/[_ /@'GO\ PO/PY_T#?&/_ (1.M?\ R)1_PO/PY_T#?&/_ (1.M?\ R)7H
M5%%Z7\K^_P#X 7AV?W_\ \]_X7GX<_Z!OC'_ ,(G6O\ Y$H_X7GX<_Z!OC'_
M ,(G6O\ Y$KT*BB]+^5_?_P O#L_O_X!Y[_PO/PY_P! WQC_ .$3K7_R)1_P
MO/PY_P! WQC_ .$3K7_R)7H5%%Z7\K^__@!>'9_?_P  \]_X7GX<_P"@;XQ_
M\(G6O_D2C_A>?AS_ *!OC'_PB=:_^1*]"HHO2_E?W_\  "\.S^__ (!Y[_PO
M/PY_T#?&/_A$ZU_\B4?\+S\.?] WQC_X1.M?_(E>A447I?RO[_\ @!>'9_?_
M , \]_X7GX<_Z!OC'_PB=:_^1*/^%Y^'/^@;XQ_\(G6O_D2O0J*+TOY7]_\
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M *!OC'_PB=:_^1*/^%Y^'/\ H&^,?_")UK_Y$KT*BB]+^5_?_P  +P[/[_\
M@'GO_"\_#G_0-\8_^$3K7_R)1_PO/PY_T#?&/_A$ZU_\B5Z%11>E_*_O_P"
M%X=G]_\ P#SW_A>?AS_H&^,?_")UK_Y$H_X7GX<_Z!OC'_PB=:_^1*]"HHO2
M_E?W_P# "\.S^_\ X!Y[_P +S\.?] WQC_X1.M?_ ")1_P +S\.?] WQC_X1
M.M?_ ")7H5%%Z7\K^_\ X 7AV?W_ / //?\ A>?AS_H&^,?_  B=:_\ D2C_
M (7GX<_Z!OC'_P (G6O_ )$KT*BB]+^5_?\ \ +P[/[_ /@'GO\ PO/PY_T#
M?&/_ (1.M?\ R)1_PO/PY_T#?&/_ (1.M?\ R)7H5%%Z7\K^_P#X 7AV?W_\
M \]_X7GX<_Z!OC'_ ,(G6O\ Y$H_X7GX<_Z!OC'_ ,(G6O\ Y$KT*BB]+^5_
M?_P O#L_O_X!Y[_PO/PY_P! WQC_ .$3K7_R)1_PO/PY_P! WQC_ .$3K7_R
M)7H5%%Z7\K^__@!>'9_?_P  \]_X7GX<_P"@;XQ_\(G6O_D2C_A>?AS_ *!O
MC'_PB=:_^1*]"HHO2_E?W_\  "\.S^__ (!Y[_PO/PY_T#?&/_A$ZU_\B4?\
M+S\.?] WQC_X1.M?_(E>A447I?RO[_\ @!>'9_?_ , \]_X7GX<_Z!OC'_PB
M=:_^1*/^%Y^'/^@;XQ_\(G6O_D2O0J*+TOY7]_\ P O#L_O_ . >>_\ "\_#
MG_0-\8_^$3K7_P B4?\ "\_#G_0-\8_^$3K7_P B5Z%11>E_*_O_ . %X=G]
M_P#P#SW_ (7GX<_Z!OC'_P (G6O_ )$H_P"%Y^'/^@;XQ_\ ")UK_P"1*]"H
MHO2_E?W_ / "\.S^_P#X!Y[_ ,+S\.?] WQC_P"$3K7_ ,B4?\+S\.?] WQC
M_P"$3K7_ ,B5Z%11>E_*_O\ ^ %X=G]__ //?^%Y^'/^@;XQ_P#")UK_ .1*
M/^%Y^'/^@;XQ_P#")UK_ .1*]"HHO2_E?W_\ +P[/[_^ >>_\+S\.?\ 0-\8
M_P#A$ZU_\B4?\+S\.?\ 0-\8_P#A$ZU_\B5Z%11>E_*_O_X 7AV?W_\  //?
M^%Y^'/\ H&^,?_")UK_Y$H_X7GX<_P"@;XQ_\(G6O_D2O0J*+TOY7]__   O
M#L_O_P" >>_\+S\.?] WQC_X1.M?_(E'_"\_#G_0-\8_^$3K7_R)7H5%%Z7\
MK^__ ( 7AV?W_P# //?^%Y^'/^@;XQ_\(G6O_D2C_A>?AS_H&^,?_")UK_Y$
MKT*BB]+^5_?_ , +P[/[_P#@'GO_  O/PY_T#?&/_A$ZU_\ (E'_  O/PY_T
M#?&/_A$ZU_\ (E>A447I?RO[_P#@!>'9_?\ \ \]_P"%Y^'/^@;XQ_\ ")UK
M_P"1*/\ A>?AS_H&^,?_  B=:_\ D2O0J*+TOY7]_P#P O#L_O\ ^ >>_P#"
M\_#G_0-\8_\ A$ZU_P#(E'_"\_#G_0-\8_\ A$ZU_P#(E>A447I?RO[_ /@!
M>'9_?_P#SW_A>?AS_H&^,?\ PB=:_P#D2C_A>?AS_H&^,?\ PB=:_P#D2O0J
M*+TOY7]__ "\.S^__@'GO_"\_#G_ $#?&/\ X1.M?_(E'_"\_#G_ $#?&/\
MX1.M?_(E>A447I?RO[_^ %X=G]__  #SW_A>?AS_ *!OC'_PB=:_^1*/^%Y^
M'/\ H&^,?_")UK_Y$KT*BB]+^5_?_P  +P[/[_\ @'GO_"\_#G_0-\8_^$3K
M7_R)1_PO/PY_T#?&/_A$ZU_\B5Z%11>E_*_O_P" %X=G]_\ P#SW_A>?AS_H
M&^,?_")UK_Y$H_X7GX<_Z!OC'_PB=:_^1*]"HHO2_E?W_P# "\.S^_\ X!Y[
M_P +S\.?] WQC_X1.M?_ ")1_P +S\.?] WQC_X1.M?_ ")7H5%%Z7\K^_\
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M(G6O_D2O0J*+TOY7]_\ P O#L_O_ . >>_\ "\_#G_0-\8_^$3K7_P B4?\
M"\_#G_0-\8_^$3K7_P B5Z%11>E_*_O_ . %X=G]_P#P#SW_ (7GX<_Z!OC'
M_P (G6O_ )$H_P"%Y^'/^@;XQ_\ ")UK_P"1*]"HHO2_E?W_ / "\.S^_P#X
M!Y[_ ,+S\.?] WQC_P"$3K7_ ,B4?\+S\.?] WQC_P"$3K7_ ,B5Z%11>E_*
M_O\ ^ %X=G]__ //?^%Y^'/^@;XQ_P#")UK_ .1*/^%Y^'/^@;XQ_P#")UK_
M .1*]"HHO2_E?W_\ +P[/[_^ >>_\+S\.?\ 0-\8_P#A$ZU_\B4?\+S\.?\
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M , \]_X7GX<_Z!OC'_PB=:_^1*/^%Y^'/^@;XQ_\(G6O_D2O0J*+TOY7]_\
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M *!OC'_PB=:_^1*/^%Y^'/\ H&^,?_")UK_Y$KT*BB]+^5_?_P  +P[/[_\
M@'GO_"\_#G_0-\8_^$3K7_R)1_PO/PY_T#?&/_A$ZU_\B5Z%11>E_*_O_P"
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M*+TOY7]__ "\.S^__@'GO_"\_#G_ $#?&/\ X1.M?_(E'_"\_#G_ $#?&/\
MX1.M?_(E>A447I?RO[_^ %X=G]__  #SW_A>?AS_ *!OC'_PB=:_^1*/^%Y^
M'/\ H&^,?_")UK_Y$KT*BB]+^5_?_P  +P[/[_\ @'GO_"\_#G_0-\8_^$3K
M7_R)1_PO/PY_T#?&/_A$ZU_\B5Z%11>E_*_O_P" %X=G]_\ P#SW_A>?AS_H
M&^,?_")UK_Y$H_X7GX<_Z!OC'_PB=:_^1*]"HHO2_E?W_P# "\.S^_\ X!Y[
M_P +S\.?] WQC_X1.M?_ ")1_P +S\.?] WQC_X1.M?_ ")7H5%%Z7\K^_\
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M(G6O_D2O0J*+TOY7]_\ P O#L_O_ . >>_\ "\_#G_0-\8_^$3K7_P B4?\
M"\_#G_0-\8_^$3K7_P B5Z%11>E_*_O_ . %X=G]_P#P#SW_ (7GX<_Z!OC'
M_P (G6O_ )$H_P"%Y^'/^@;XQ_\ ")UK_P"1*]"HHO2_E?W_ / "\.S^_P#X
M!Y[_ ,+S\.?] WQC_P"$3K7_ ,B4?\+S\.?] WQC_P"$3K7_ ,B5Z%11>E_*
M_O\ ^ %X=G]__ //?^%Y^'/^@;XQ_P#")UK_ .1*/^%Y^'/^@;XQ_P#")UK_
M .1*]"HHO2_E?W_\ +P[/[_^ >>_\+S\.?\ 0-\8_P#A$ZU_\B4?\+S\.?\
M0-\8_P#A$ZU_\B5Z%11>E_*_O_X 7AV?W_\  //?^%Y^'/\ H&^,?_")UK_Y
M$H_X7GX<_P"@;XQ_\(G6O_D2O0J*+TOY7]__   O#L_O_P" >>_\+S\.?] W
MQC_X1.M?_(E'_"\_#G_0-\8_^$3K7_R)7H5%%Z7\K^__ ( 7AV?W_P# //?^
M%Y^'/^@;XQ_\(G6O_D2C_A>?AS_H&^,?_")UK_Y$KT*BB]+^5_?_ , +P[/[
M_P#@'GO_  O/PY_T#?&/_A$ZU_\ (E'_  O/PY_T#?&/_A$ZU_\ (E>A447I
M?RO[_P#@!>'9_?\ \ \]_P"%Y^'/^@;XQ_\ ")UK_P"1*/\ A>?AS_H&^,?_
M  B=:_\ D2O0J*+TOY7]_P#P O#L_O\ ^ >>_P#"\_#G_0-\8_\ A$ZU_P#(
ME'_"\_#G_0-\8_\ A$ZU_P#(E>A447I?RO[_ /@!>'9_?_P#SW_A>?AS_H&^
M,?\ PB=:_P#D2C_A>?AS_H&^,?\ PB=:_P#D2O0J*+TOY7]__ "\.S^__@'G
MO_"\_#G_ $#?&/\ X1.M?_(E'_"\_#G_ $#?&/\ X1.M?_(E>A447I?RO[_^
M %X=G]__  #SW_A>?AS_ *!OC'_PB=:_^1*/^%Y^'/\ H&^,?_")UK_Y$KT*
MBB]+^5_?_P  +P[/[_\ @'GO_"\_#G_0-\8_^$3K7_R)1_PO/PY_T#?&/_A$
MZU_\B5Z%11>E_*_O_P" %X=G]_\ P#SW_A>?AS_H&^,?_")UK_Y$H_X7GX<_
MZ!OC'_PB=:_^1*]"HHO2_E?W_P# "\.S^_\ X!Y[_P +S\.?] WQC_X1.M?_
M ")1_P +S\.?] WQC_X1.M?_ ")7H5%%Z7\K^_\ X 7AV?W_ / //?\ A>?A
MS_H&^,?_  B=:_\ D2C_ (7GX<_Z!OC'_P (G6O_ )$KT*BB]+^5_?\ \ +P
M[/[_ /@'GO\ PO/PY_T#?&/_ (1.M?\ R)1_PO/PY_T#?&/_ (1.M?\ R)7H
M5%%Z7\K^_P#X 7AV?W_\ \]_X7GX<_Z!OC'_ ,(G6O\ Y$H_X7GX<_Z!OC'_
M ,(G6O\ Y$KT*BB]+^5_?_P O#L_O_X!Y[_PO/PY_P! WQC_ .$3K7_R)1_P
MO/PY_P! WQC_ .$3K7_R)7H5%%Z7\K^__@!>'9_?_P  \]_X7GX<_P"@;XQ_
M\(G6O_D2C_A>?AS_ *!OC'_PB=:_^1*]"HHO2_E?W_\  "\.S^__ (!Y[_PO
M/PY_T#?&/_A$ZU_\B4?\+S\.?] WQC_X1.M?_(E>A447I?RO[_\ @!>'9_?_
M , \]_X7GX<_Z!OC'_PB=:_^1*/^%Y^'/^@;XQ_\(G6O_D2O0J*+TOY7]_\
MP O#L_O_ . >>_\ "\_#G_0-\8_^$3K7_P B4?\ "\_#G_0-\8_^$3K7_P B
M5Z%11>E_*_O_ . %X=G]_P#P#SW_ (7GX<_Z!OC'_P (G6O_ )$H_P"%Y^'/
M^@;XQ_\ ")UK_P"1*]"HHO2_E?W_ / "\.S^_P#X!Y[_ ,+S\.?] WQC_P"$
M3K7_ ,B5T7A/QQIWC1;HZ?;:Q;BV*A_[6T6\TXG=G&S[3%'O^Z<[<XXSC(ST
M%%2W"VB?W_\  $W&VB_K[@HHHK,@**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *:SJI4%@"QPH)ZG&>/P!IU4-1LY+F\TN1 "MO<M+)D_PF&1/
MYN* +]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:?\ R51_P]A^$?\ T+OC7_P!M/\ Y*K\GZ*/['PO9_>'M)'ZP?\ #V'X1_\
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MJ/\ A[#\(_\ H7?&O_@#:?\ R57Y/T4?V/A>S^\/:2/U@_X>P_"/_H7?&O\
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M2J/^'L/PC_Z%WQK_ . -I_\ )5?D_11_8^%[/[P]I(_6#_A[#\(_^A=\:_\
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M'L/PC_Z%WQK_ . -I_\ )5?D_17U']CX7L_O,?:2/U@_X>P_"/\ Z%WQK_X
MVG_R51_P]A^$?_0N^-?_  !M/_DJOR?HI_V/A>S^\/:2/U@_X>P_"/\ Z%WQ
MK_X VG_R51_P]A^$?_0N^-?_  !M/_DJOR?HH_L?"]G]X>TD?K!_P]A^$?\
MT+OC7_P!M/\ Y*H_X>P_"/\ Z%WQK_X VG_R57Y/T4?V/A>S^\/:2/U@_P"'
ML/PC_P"A=\:_^ -I_P#)5'_#V'X1_P#0N^-?_ &T_P#DJOR?HH_L?"]G]X>T
MD?K!_P /8?A'_P!"[XU_\ ;3_P"2J/\ A[#\(_\ H7?&O_@#:?\ R57Y/T4?
MV/A>S^\/:2/U@_X>P_"/_H7?&O\ X VG_P E4?\ #V'X1_\ 0N^-?_ &T_\
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ME5^3]%']CX7L_O#VDC]8/^'L/PC_ .A=\:_^ -I_\E4?\/8?A'_T+OC7_P
M;3_Y*K\GZ*/['PO9_>'M)'ZP?\/8?A'_ -"[XU_\ ;3_ .2J/^'L/PC_ .A=
M\:_^ -I_\E5^3]%']CX7L_O#VDC]8/\ A[#\(_\ H7?&O_@#:?\ R51_P]A^
M$?\ T+OC7_P!M/\ Y*K\GZ*/['PO9_>'M)'ZP?\ #V'X1_\ 0N^-?_ &T_\
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M_P#DJOR?HH_L?"]G]X>TD?K!_P /8?A'_P!"[XU_\ ;3_P"2J/\ A[#\(_\
MH7?&O_@#:?\ R57Y/T4?V/A>S^\/:2/U@_X>P_"/_H7?&O\ X VG_P E4?\
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M ;3_ .2J/^'L/PC_ .A=\:_^ -I_\E5^3]%']CX7L_O#VDC]8/\ A[#\(_\
MH7?&O_@#:?\ R51_P]A^$?\ T+OC7_P!M/\ Y*K\GZ*/['PO9_>'M)'ZP?\
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MBIG\-V?PJU0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445!9WD=
M]$TD1)59'B.1CYD<HWZJ: )Z*** "BBB@ HHHH **** "BBB@ HHHH ****
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M1G\N%=SO@9PH[D]A7SA^SM_P4!^%7[1.L3>'K2]N?"7C".=K<>'?$JK;74S
MD8B^8K(W!R@.\8.5P,UZ!_PUC\$/^BR?#_\ \*BQ_P#CM?.W[3?@7]D+]I^W
M>\UCXI^ = \7HO\ HWBC1O$]A%=JPY7S1YNV9<XX<;@,[67.: /MZBOR8\(_
MMQ>/?V*=?LO#/B_QWX3_ &A/AB9!;V>L^&]>M;K5K6)1QE5D+\+_  S @D!5
MF %?HU\#/VDOAU^T=X=&K^ _$EMJP5<W%BQ\J\M3T(EA;#+R<;L;3_"2.: /
M3:*** "BBB@#^<RBBBOU@X@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M^BOA'^P?\3_B[X1@\40)I'AC0+I0]K>^([MK87*'.'151VVG'!8 ,"",CFJG
MQH_8A^)GP2\,?\))J$&F^(/#J?Z_5/#]TUQ%;Y( ,@9$8*2?O!2H[D9&?J;]
MI#X+:[^VMX.\#^,?A%K^FZKX=TS2$M'\+RW0@>UN!DG ^XLFTJA5RN!&""0U
M>'?#KQ'\5/V(]-\6:1X]^&VIZKX+\26+V4^G7MQMT]9G^7S!,BRQ$E"ZL@P6
M!7)^45X5/%5JGO1DN:_P;/[V]_E8T:2/,OV=?V5/%7[3$7B67PUJFAZ7%H"V
M[7;ZW<2PJ1-YI4J8XGX'DOG.,9'7G'JZ_P#!,?XB2L$B\;_#V:5N%CCU>X+,
M>P ^S=:WOV =-O-9^ W[46GZ?:SWU_=^&HX+>UMHS)+-(UKJ*JB*H)9B2  !
MDDU\Y:;^R[\8=5OH;2'X7^+DEF;:K7.BW$$8/^U)(BJH]R0*VE5J2K5(*HHJ
M-MUY)]T*RLM#H;W]C_QWH7QHTKX9^(9=)\,ZUJZLVFW^I7#_ &"]QG CEC1S
MEB" &4'. 0"P!X#XN?"CQ!\$_'VI^$/$T$<6J6##,D!+0SHPRDD;$ LC \'
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M H2"#L*694KT(D8$88U;Q-64>>.TFE'_ #?Z!9'EWQ:_8C^(/PF\$R^+GN]
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M/K,\L2E7+ ;3'$_3:<YQ7KZ?\$QOB+,P2#QM\/KB4_=BBU>X+,?0#[-77_\
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M:Q;4+5(D8*5N()LMZ)*KD?DIJ[0 4444 %(2%!). .I-+7R9^VE\:K_198/
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MMNJR(RNL:[QRN]0".1N!!/IG@O\ ;&MOBE^R?\0?BCX>TG^Q_%/A'2M4>_\
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MW\7G>TTCXB1V][H/BB*%KPP0QY\RW=(@TJ#+(OW#G[.O4<UJ? ?Q-8?M4_\
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M3;'X,?"?Q9XXU+:UKH6G2WGEL<>:ZK^[C'N[E5'NPH \OT;]N3X;ZY^TW=_
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M@"K\!_VXOAK\?_%]SX0TT:UX8\9V\9F;PYXIT\V5XR*,L5 9E8@<E0V[&3C
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M81L1ZQBOM;3[U-1L+:[B#+'/$LJAQR P!&??F@"Q17SS^U%^TYK?P=\0>#/
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M(7;$& ^7(!]C4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &=J/\
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M7=?\$L_AG_;?Q)\1>-[F+-OH=F+.U9AQ]HGSN(/JL:,#_P!=17@'[17@J[^
M?[27B*QTS-E_9VJ+J6E2*/\ 5QN1/ 1Z[<A?JIK[*4H5I3P2Z17]?+0PV]X_
M;>BN7^%_CNT^)WP[\.^*[$C[/JUC%=;%S^[9E^=/JK;E_"NHKX:2<6XO='0%
M%%%2 4444 %%%% !3X/]?'_O#^=,I\'^OC_WA_.@9L54U;2K77-*O=-OHO/L
MKR%[>>+<5WQNI5AD$$9!/(.:MT5SE'RK_P .N/V8O^B9?^5_5/\ Y)H_X=<?
MLQ?]$R_\K^J?_)-?55% 'RK_ ,.N/V8O^B9?^5_5/_DFC_AUQ^S%_P!$R_\
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M[.Y2^/&J7FL_&SQ[=W]S+>73ZY>AI9G+,0LSJHR>P4  =@ !P*^EH+1_B?\
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M&+G7-=F("V\6"=B9XWL%8Y/"@%CT"MY3XQ\47?C?Q=KGB._2*.^U>^GU"X2
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5^T/_  3K_P"30/ W^_?_ /I=<5^+
MU?M#_P $Z_\ DT#P-_OW_P#Z77%?/9W_ +M'_$OR9K3W/I*BBBOB#H,_7#.+
M*/[/YGF?:K?/EYSL\Y-_3MMSGVS6A5/5;YM.M4E50Y:>&'!/9Y50G\-V:N4
M%%%% !7PQ^T)KTGPU_:FE\0WNE6^L6<UO;RI:7L8>.2(PB)MN1C.4?!YP:^Y
MZ\G_ &@O@19_&KP]$(Y5LM>L58V5VP^4YP3&^.=IP.>QYYY!Y<33E4A[FZU/
MDN)LOQ&88%+"?Q*<E./FU?373KI?J?/,OP4^&XF_X62=>1?AJ\?GKI8)^U&Z
MZFT S_7/;I\U>.?%WXNZE\5]:AEEB73M&LD\G3M*@XBMHQP, 8&[ &3CL!T
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M/$>I^+OBAJ^G.)+*3QUK']H);L,8Q&J(K $9PX89YQP, 'B?[>'CCQ/\3/\
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M5?M&V?[2_B[2?$47A/\ X1>^M+/[%/C4/M8N$#ED/^JCVE=SCOD$=,5^DO\
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M[^X/9R/R?HK]8/\ AT]\(_\ H8O&O_@=:?\ R+1_PZ>^$?\ T,7C7_P.M/\
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M_P #K3_Y%H_X=/?"/_H8O&O_ ('6G_R+1_;&%[O[@]G(_)^BOU@_X=/?"/\
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M[^X/9R/R?HK]8/\ AT]\(_\ H8O&O_@=:?\ R+1_PZ>^$?\ T,7C7_P.M/\
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M_P #K3_Y%H_X=/?"/_H8O&O_ ('6G_R+1_;&%[O[@]G(_)^BOU@_X=/?"/\
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M7HH SO#WAS2?"6CVVDZ'I=EHNE6R[8+'3[=(((AG.%1 %49]!6C110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %9/AG_D'3?\ 7[=_^E$E:U9/
MAG_D'3?]?MW_ .E$E &M1110 4444 %%%% !1110 4444 %%%% !6+HO@GP[
MX;UG6-8TG0-+TO5M9=)-3O[*SCAGOF0,$:>15#2%=S8+$XW''6MJB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** ,[4?]<O^[56K6H_ZY?]VJM;K8EA5;4].M]8TV[L+R/SK2ZB
M>":/<5W(P*L,C!&03R*LT4Q'B7@[]BSX-> ?$^F^(=!\'?8-8TZ43VMS_:E[
M)Y;CH=KS%3UZ$&O;:**TG4G4=YR;]=0M8****S \J^('[+'PG^*.HS:AXD\$
M:;>:A,=TUY!OM9I6SG<[PLC,?<DFLSPC^QI\%_ ^HQ7VE> =/^U1/YD;WTLU
M[L;L0)W< C'''%>T45NJ]91Y5-V]6*R,+QIX(T7XA>%-0\-:_:->:)?QB*YM
M4FD@WH"#MWQLK 9 Z$9'!X)KSSX<_LC?"7X3>*[;Q+X5\)+I>MVR.D-T=0NI
MR@=2K8665ER5)&<9Y->P45,:M2,7",FD^EQV04445D!X%>?L'? N_P!1GOI?
M P^U32M.[QZM?1C>3DD!9P%Y/0  =J][1!&BJ,D*,#<23^)/6G45K.K4J6YY
M-V[L+)!11160!1110 4444 %/@_U\?\ O#^=,I\'^OC_ -X?SH&;%%%%<Y04
M444 %%%% !7/^/?'N@_#'PGJ/B7Q+J,6EZ/81^9-<2G\E4=68G "CDD@"N@K
MP3]JK]F75?VE(/#%I;>-D\*Z?HMRUZUI)HZZA'=S_*(V=6E12$ <;2K ^8V?
M2M:2A*:51V1<%%R2D[(\TL/#7BS]NS4['6O%-K<^$/@;:SBXT_0&8K>^(2IR
MDTY'W(CU 'X9R''V!96<&G6<%I:PI;VT$:Q10QKM5$4850!T   Q7S_H_P $
M?CMI]]9-<_M&_:M/@D0RV<?@73X?,B!&8PP8[,@8R <>E>JR^&/%LGQ0AUQ?
M&OE>#H[+R&\*)I4/[R?G]^UV29.X^10!\H]\[UFI649*RV2O^JW?<TJ-/1-6
M^?\ D=@S!%+,0J@9)/05\J?L"AO%>E?%+XD2D&3Q?XNNYH".GV:(_N@#Z R2
M+]%'K7TMXLT>?Q%X5UG2K6]_LVZOK*:UBO?+\S[.[H563;D;MI(.,C..HKE/
M@%\(;?X$?"30/ ]M??VHNEI('OO(\DSN\KR,Q3<V.7(QN/ '-9QG&-*4>KM]
MW]6)4DH-=78]!HHHKG,@HHHH **** "BBB@ HHHH PO%GC+3O!UB+B^=BSY$
M<,8R[GV_Q->=R_M"H'(CT)F3L6N]I_+8:Y7XTW\EUX\NH'8F.VCCC12>!E Q
M_5JX2@#V/_AH;_J ?^3O_P!KH_X:&_Z@'_D[_P#:Z\<HH ]C_P"&AO\ J ?^
M3O\ ]KH_X:&_Z@'_ ).__:Z\<HH ]C_X:&_Z@'_D[_\ :Z/^&AO^H!_Y._\
MVNO'** /8_\ AH;_ *@'_D[_ /:Z/^&AO^H!_P"3O_VNO'** /8_^&AO^H!_
MY.__ &NC_AH;_J ?^3O_ -KKQRB@#V/_ (:&_P"H!_Y._P#VNC_AH;_J ?\
MD[_]KKQRB@#V/_AH;_J ?^3O_P!KH_X:&_Z@'_D[_P#:Z\<HH ]C_P"&AO\
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MH ]C_P"&AO\ J ?^3O\ ]KH_X:&_Z@'_ ).__:Z\<HH ]C_X:&_Z@'_D[_\
M:Z/^&AO^H!_Y._\ VNO'** /8_\ AH;_ *@'_D[_ /:ZZ/PG\9-*\27L=G/
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M -"[XU_\ ;3_ .2J/^'L/PC_ .A=\:_^ -I_\E5^3]%']CX7L_O#VDC]8/\
MA[#\(_\ H7?&O_@#:?\ R51_P]A^$?\ T+OC7_P!M/\ Y*K\GZ*/['PO9_>'
MM)'ZP?\ #V'X1_\ 0N^-?_ &T_\ DJC_ (>P_"/_ *%WQK_X VG_ ,E5^3]%
M']CX7L_O#VDC]8/^'L/PC_Z%WQK_ . -I_\ )5'_  ]A^$?_ $+OC7_P!M/_
M )*K\GZ*/['PO9_>'M)'ZP?\/8?A'_T+OC7_ , ;3_Y*H_X>P_"/_H7?&O\
MX VG_P E5^3]%']CX7L_O#VDC]8/^'L/PC_Z%WQK_P" -I_\E4?\/8?A'_T+
MOC7_ , ;3_Y*K\GZ*/['PO9_>'M)'ZP?\/8?A'_T+OC7_P  ;3_Y*H_X>P_"
M/_H7?&O_ ( VG_R57Y/T4?V/A>S^\/:2/U@_X>P_"/\ Z%WQK_X VG_R51_P
M]A^$?_0N^-?_  !M/_DJOR?HH_L?"]G]X>TD?K!_P]A^$?\ T+OC7_P!M/\
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M_)5?D_11_8^%[/[P]I(_6#_A[#\(_P#H7?&O_@#:?_)5'_#V'X1_]"[XU_\
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M?"]G]X>TD?K!_P /8?A'_P!"[XU_\ ;3_P"2J/\ A[#\(_\ H7?&O_@#:?\
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MBC^Q\+V?WA[21^L'_#V'X1_]"[XU_P# &T_^2J/^'L/PC_Z%WQK_ . -I_\
M)5?D_11_8^%[/[P]I(_6#_A[#\(_^A=\:_\ @#:?_)5'_#V'X1_]"[XU_P#
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M']DSPG#\4?%WCKP[\4O"UI<0#7O#%KHT=DUI%+(J9MYTC5W 9E7<_3()4C.
M#[[HK.\.:]:^*?#VEZU8[_L6HVL5Y!YJ[6\N1 ZY'8X(XK1H **** "BBB@
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MP"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ K]H?^"=?_ ":!X&_W[_\ ]+KBOQ>K]H?^"=?_
M ":!X&_W[_\ ]+KBOGL[_P!VC_B7Y,UI[GTE1117Q!T%74;F&TMT>=/,0S11
M@8!^9I%53SZ,0?PJU574;2*]MTCE<HBS12 @@?,DBLHY]2H'XU:H **** "O
MA[]K"3Q!\4OCG;^"]$MI=0DTRU416<1 &]XQ+(YR<#Y2@R?[H]:^X:^)/VQ_
M#&M>"?BIIOCW299K9+N./;>P9!@N8@%P3VRH3&>OS#M7#C+^R\KZ^A\#QM&3
MRI:-P4X\]M^76_XVW/F5]-NX]1.GM:S+?"7R#:F,^:),XV;>N[/&.N:]KU#X
M=^&O@GX'EE\;VRZOXWUFU*V>A)*0-.1AQ-*5/#^@^HP<$C?/[2'A/^SAXS_X
M1:$_%<Q_9//*?Z(#_P _>WIO[8QG(ZXKY\UK6M1\4:Q<:CJ5U+J&HW<A>2:0
M[F=B?\X X':O&?)3V=V_P_X)^(36!RR+E1FJU27PZ:13ZR3WGY:J.^KL?H+^
MR)XQN?&'P6L!>2F:XTN>333(QR2J!60'Z(ZC\*Y']L#]E#6OCMJ'A#QIX!\5
MCP3\4/!TDDFD:I,F^WD5\;HI1M; R.NUAAG!5@W'>_LN> ;KX??!_3+2_C,-
M_?.^H3PL.8S)C:I]PBID=CD5XC^UGJ_QD^!OQT\*?&'P=::]X^^&L%@VF^(_
M!&FW,K>226/VR.!<@G!3YMIVF(@E0^1]#1NJ<>;>Q_2621K1RS#QQ'Q\D;WW
MVZ^?<XR?]H[]LCX%6\DOQ$^">E?$;1+5=TNK^$+G;,R#[SE$,AX'/^I0?T;\
M4;CX9?M??\$[?']]\(] M/#L>G,^LR:-::?%9RVFHVVR>8/'%A6D>(, XSN#
MCG(P.A?_ (*V?".[L/)TCP[XVU;Q2RX3PS%H^+OS/[C8<J,=R"WT/2M__@GO
M\#/$W@GP/\0_%7CS1!X<U3XD:[/K3^%VSC3[:0L5B=>-K'S'!7 (4(#@Y5=C
MVSCOCU\9+SXX?L#?#2QTF\V>)?B[<:/X7$T?[PQW$LBB])Z95?(F5B2.&Y(K
MD/@U^T+<_#C_ ()8^,9M0N?(\4>"5U#P;W+Q7C2^7;@#_86YB_",^AKA/V+O
M!FO_ /#7.G?!S58'/AKX':CXAU2RF8DK<"[>.*UWCL?WCS+S_$>.#G$^(7PZ
MUB\_;\UCX ):9\$>,/'&G_$"Y"CY7@CMII[I",8VNS2+SP&B7@Y% 'H7B?2?
M%_PO^$?[,7[+G@W5[CP;K?CJW>[\2ZO9,$N;:(@3W,<;CG<6DF&002(57.&(
MKMOC#_P3I\*_!KX6Z[X[^$'B7Q3X0^(WAFQEUB/63J\DK:DT"&5X[E3\K;PK
M#@*N6^8%<K78_MX_#WQ?HGQ!^$OQX\$Z#<^*KSX?7DPU;1;)-]Q<6$P =XEZ
MDJOF X!/[P-C"FN/^,'_  45\*_&?X6Z[X#^#_AOQ1XO^(_B:QFTB/1FTAX3
MIK3H8WDN6;Y!L#,>"RY7YB%R: .*_:5^,UU^T%^Q+^S/X^OX8X=2U;XA:4+Q
M85*QFXA%]!,R@]%,D3$#G (Y->N_'?\ Y2<_LR_]@?7?_2*YKR+]I7X,W7[/
MO[$O[,_@&_FCFU+2?B%I1O&A8M&+B87T\RJ3U422L >,@#@5Z[\=_P#E)S^S
M+_V!]=_](KF@#QOXW?$[PO\ M'_MA^,OAY\5?B=%X!^#7@>%+8Z*NKBP_MZ^
M8#?YC9&Y5)<$<[0B@8+L:P=2\=_"S]CKXN_#?6O@#\5;?6O!.MZQ'H_B?P-'
MKPO[=(920+Q S$H4RQW'^(*,@,P/4?%?P)X<_9A_;!\>>/?BE\)[3X@_!WQX
MD-VFO/H,.J_V%>J/W@='1M@=BY)&"P9"-Q1A5S1/B5\*?CG\6_!WAS]GG]G3
MP-XCT;[6)O$7B[6_!$5M9Z=; C/DML0^<.2-W4@*H.2R@$OQ0^&VI_&7_@IS
MXC\%0>)-6\,^'[[P5;7.O2Z)-Y%U=6<3KBW$N"8U>5XMQ'501WJG\5_@7HW[
M!W[0WP*\2_"K5]7T'0?%OB:'P]XAT.YOY;BVNHY7C4RL&))(5W.&SAE0KC!S
MZKX1_P"4MOC?_LF,?_I99UE_\%-/^1F_9J_[*%9_^AQT ?<U?%_Q2_Y2H_!?
M_L3-1_\ ;JOM"OB_XI?\I4?@O_V)FH_^W5 'G_ASP1/_ ,%$?VB?BP?'>O:O
M#\)/ &JGP_I?A;2[PVL-_<(SK+-.5^9@?+W#HV)% ("D%OBOP1<_\$[?V@_A
M1-X U[5I_A1X]U=/#VJ^$M5O'NH;*9V14GM]W(QOW?WOD()(<!7>'/&\_P#P
M3N_:)^+ \=Z#J\WPD\?ZJ?$&E^*=+LS=0V%P[.TL,X7YE \S:.K8C4@$,2$\
M5^-KG_@HG^T#\*(O &@ZK!\*/ 6KIXAU7Q;JMHUK%>S(R,D%N&Y;.PKZ_.20
MH0%@#J?AO_RE_P#BK_V3Z'_T9IM>1?LD_LTVG[2GBOX\V'C?7-:;X>:7\0-4
M>'PUIEZ]I;WM[*^)I;ADPSA8XH J@C!+'OSZ[\-_^4O_ ,5?^R?0_P#HS3:U
MO^":?_-PW_93M5_]DH XS]GGP6?V9_V[?$_P+T37M2O?AEK_ (2.M6.BZC<O
M,+&;S A6)B>.!-R "05R25!KAOV6?V.?A9%^W3\8M*70[@67PXOM$U+PXG]H
M3YM9]HFW,=V9!O13A\CC'2O6-7_Y2^Z)_P!D];_T9-7.>#/B_H7[.G_!1WXS
M:?X]2_T5/B'+HL'AV\-G))!>2"-(@ Z@C&^7!;HI1@2"* /T)K\Z_"/@%_\
M@HA^T'\7+GXA:[K ^%O@76#X?TGPAIUZ]M;W4L;.KW$VT@DG9NS][]X!D!,'
M]%*_.[P?\0%_X)W_ +0/Q=L_B)HNL#X9>.M8;Q%HWBW3K%[FWMY)"[26\^W)
M!!<(, ME <%7R #U[X1?LM:Y^R9\6=7UKP?XOF;X%2:1)->^$]7O)KJXLKE
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M:*,E9$W$\EFBP3DC#C.UL#T7]EW_ )2!_M7_ /<$_P#2<UE_MB_\GY_LE_\
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MD2X+$G8N<'[;^,GA+6_'?PK\5:!X:UVX\,^(;_3Y8=.U>UE:)[6XVYC?>OS
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MPL1>)D1@.VTE2/3 K\]_^"4]IK/Q,^)NO>,O$=FUO+X \*6'@&Q67DKMD=Y
M!V9/+ /M)[G !^A_CWX5>$/BC_8X\7>'K'Q%%I%V+^RAU&+S8HIPI42;#\K$
M!CC<#C.>M?(/P.18_P#@K#^T.B*%5?#.E@*!@ ?9=.XK[IKX7^"/_*63]HG_
M +%K3/\ TETZ@#C_ -MSQAXG\,_\%!O@<WA'1;?Q)XG&@74.B:??R%+2.\N3
M<0?:)B!GRXU_>,!@XBX(/-=+\8/$G[6G[+/A>3XHZYXZ\,_%+POI[Q2:YX6@
MT6.P^RP,P5FMYE7S'"E@-SDD##%" 0.F_;K^&_BO0/B9\*/V@/!7AV?Q;?>
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M7^"WP!\'? 31[NQ\+64JS7KB6]U&]E\ZZNV&<&1\#.,G   &2<9)K/\ C/\
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MN98+W24C;:DUTT<@QG*^3*V/;E5/X4 :%%%% !7X+_M-?\G&_%+_ +&C4O\
MTJDK]Z*_!?\ ::_Y.-^*7_8T:E_Z525]-D7\6?H8U-D>:4445]D8!1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MY?\ =JK6ZV)84444Q!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P"@%IG_ (!Q_P"% 'RE17U;_P (9X?_ .@%IG_@''_A1_PAGA__ * 6F?\
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MF?\ @''_ (4 ?*5%?5O_  AGA_\ Z 6F?^ <?^%'_"&>'_\ H!:9_P" <?\
MA0!\I45]6_\ "&>'_P#H!:9_X!Q_X4?\(9X?_P"@%IG_ (!Q_P"% 'RE17U;
M_P (9X?_ .@%IG_@''_A1_PAGA__ * 6F?\ @''_ (4 ?*5%?5O_  AGA_\
MZ 6F?^ <?^%'_"&>'_\ H!:9_P" <?\ A0!\I45]6_\ "&>'_P#H!:9_X!Q_
MX4?\(9X?_P"@%IG_ (!Q_P"% 'RE17U;_P (9X?_ .@%IG_@''_A1_PAGA__
M * 6F?\ @''_ (4 ?*5%?5O_  AGA_\ Z 6F?^ <?^%'_"&>'_\ H!:9_P"
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M<_\ P2B^$,TSNFN^,H%8Y$<=]:E5]AFV)_,FF?\ #I[X1_\ 0Q>-?_ ZT_\
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M[^X/9R/R?HK]8/\ AT]\(_\ H8O&O_@=:?\ R+1_PZ>^$?\ T,7C7_P.M/\
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M_P #K3_Y%H_X=/?"/_H8O&O_ ('6G_R+1_;&%[O[@]G(_)^BOU@_X=/?"/\
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M *424 :U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 9VH_ZY?\ =JK5K4?]<O\ NU5K=;$L****8@HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ I\'^OC_P!X?SIE/@_U\?\ O#^= S8HHHKG
M*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"NE70\2>';/4]7DN[-)7O9;JW263S2P)8?O"H!X"@  "O+_VG_V:O"/[.'[
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MQ1_PCG@SX@6&JZX=WEV,T$]I)/M!)$0GC3S2 "?DSP">@KYM^(WPPT+XI?\
M!6?0K/Q'IUOJ^EZ;X$34VL+Q!)!,Z3RI'O0@APK2*X!XRBGM5G_@I+X3T#P3
MXD_9\\<Z1I%MIOB&Q\=V-F+RPC6"1[<GS#$Q4#(S&,9SC+8^\<@'WQ7)?$WX
MM>#O@SX;;7_&_B.P\-:2'\M;B^EV^8^"0B*,L[8!.U03P>*ZVO@CQ1X<T_\
M:!_X*HOX7\9VD>L>&O '@T:KIVD7D8EM9;F1X 9'C;AC_I0/(/,*>E 'T3\(
M_P!M;X)?'37UT/P5\0+#5-9DR(M/N()[*>8@;CY:7$<9DP 2=H/ /H:ZSXB?
MM ?#[X3>)M%T#Q?XEM] U/6;:\O+);J*41/#:Q&6X=I0ICC"("?G9<]!D\5\
MR_\ !4;X2>&+7]F34_B+IFEVVB>-/!MWI]WI.M:9$MO<PEKR&$IYB ':/-+
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MY^TM;;<" M_=Z\]<<9Q7GGAWP[J7BS6K32=)M)+[4+IQ'%#$N23ZGT ZDG@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQB6&XA8,DB$9!!'44L1A*V%=JL;7%5H5*+M-%NBBBN,P"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_2R6@#KO@9^W[\)_CQXN'A+3[K5?"WB]LB/0?%-E]BNI2!DJF&9&8#)V!MV
M3C -?2%?$W_!5CX666I?L^O\4=,C;3_'/@2^L[_3]7LEVW*QM<QQ,F\#.U3(
MLH_NF//&3GJ/BC^VAK/A;X:?!'_A$?"L'B?XD_%>PMKC2-+NKG[/:P;[>&66
M25O[JF9 %RN?F.[Y>0#ZQHKXHOOVI?V@/@'XN\'P_'3P#X2N?"/B;4DTE-<\
M"3W!.GSN"5\Z.9F+#:KN<8^5&()(P?M>@ HKYP_:C_:OU'X.^*_"OPZ\!>%#
MX\^*_BI6ETW1FG$$$$"E@9YW)&%^1\<@?(Y++MY\O\2_M9_'[]FJYTC6OC[\
M//"TWP\OKE+6[\0>!)YW?26?A3-%*[LXS_=P.P);"L ?;]%?)O[8'[8GB+]G
MSQG\&;'PAX>L?&ECX\:_A6T7=]INIE2V%DEO*'"());E0S,K_+R ,<^H_L_Z
MM\<M3;6Q\9=#\'Z0$\E],?PI<3R;PV[S$E$K-@IA.0<'<<#B@#V&BN"^.OQG
MT#]GWX5:_P"//$C2'3-)A#^1#@RW$K,$CB0'^)W95YX&23@ FOEB+]HC]K_5
M_!#?$FP^#O@NV\'&V_M&+PS>7UP==DM<;@P8,$#%/FVE W;9D@4 ?<E%?(?C
MC_@H#:6W[/\ \./&O@SPG<:WXN^(>HQZ+H7AJ^G%OLO6?RW$LA RBOM (QOW
MH<J"6'->+OVI?VC_ -G&31M?^-'P[\'ZGX#O[Z.QN;SP)/=/=Z<9,[6=)6?S
M.AX4 $C&X%ER ?:>NZU:>&]$U#5]0E$%A86\EU<2GHD:*69OP )KPK1OVU_!
MFL+\%C_87B6S?XLM=C0DN;:W#0+ 4R]SMG.P.)$9=F\D'D*>*R_^"A/C&YTC
M]E[6-#T:2.36_'-W:>$M+7=\LTE[($901US")NG\J^>OV[+ZT_9N^)_['/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;(XY!KZLH ^%/$EW!X*_X*WZ!>^(7%M9^)/!!L-#N)P/+:X$C9B5CP'/ER#
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M]_LP^%OV;QXNET&_U?6=2\5:HVK:KJFN2PRW,TQR=NZ**,; S2, 03F1N><
M ^._VL_V./VB_B)\%-;E\7?'.Q^(%KX>C?7;71(O"-K933301.<1S0@.KE"X
M '!) Q5[X^_'!?VAO^"0FM>,991)JTMII=GJ@'47L.J6D<Q([;BOF ?W76OT
M2=%D1D=0RL,%2,@CTKY=TC_@G=\.="^#'Q#^%EEKGBJ#P=XUU&#4[FT%W;;K
M"6*:.4"U/V?Y5/DQ(0X<[8UP0<D@&)\!?V+O@?\ $3]EOX:S:Y\,O#]Q?:QX
M0TN>]U&*T$-W)+)9Q,\OG)APY8DE@<Y->3_LF^);S]B;]I;4_P!FWQE':?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !63X9_Y!TW_7[=_P#I1)6M63X9_P"0=-_U^W?_ *424 :U%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !573K%=/MWB5BX::6;)]7D9R/PW8JU10 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110!E>*_%6D>!_#6I^(-?U"
M#2M%TVW>ZN[VX;:D,:C+,?\  <GH.:_.CQ__ ,%N/"&C:S-;>$/AOJGB>PC<
MHM]J.IIIWF@9^94$4QP>,;L'!Y Z5]!_\%.O"7B'QE^QGXVM/#D4UU-;-;7U
MW:V^2\MK#.DDO'<(%$A]HS7PM_P39_;C^#O[.'@:_P##/C?1+C1-;NKZ2Y;Q
M39V7VH7$3!0L<NW,J[,' 567OP2<@'UO^S+_ ,%5_AQ\?O%NG^$]9TB\\ ^(
M]098K-+VY2XL[B8](EG 0AR>%#(H8D ') /VW7YJ_%;]D;X+_M\_%*#Q[\(O
MC/H7AC51:1F^T_1],$US-.KLRW;Q&>&2)\;5)*<^6#G.:^A?^"A'Q?\ &_[/
M_P"RO<>)O!^OC3?%%M>V-JVI"SAE#AFVR'RYE=1NQZ$CUH ^I:*^8O\ @G/\
M9?&'QX_9FT[Q9XYUC^W-?EU*[MWN_LT-OE$<!!LB1%X'?&:^8O\ ALGXP_\
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M#[^HKPC7_P!J'3-?_9$\1?&KX>26^IQ6NA76IV<.HQL52>)&W0SHK @JZE6
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MBBL2 'S7W7X+\9:/\0_"6D>)O#]['J.BZM:QWEI=1'B2-QD'V/."#R""#R*
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M_")_\)'_ ,)_JDFF_:O[2^R_8-LMK'OV^4_FY^U9QE?N=>>/HJOSL_X*C_\
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M\[.NT;G4' 8X8<5[/7SY^V?^R%I'[77P[L]*FU%M!\3Z-,UWHNM)'O\ L\C
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MQK&NS16^B:?9S7=_-.NZ..WC0O(S#N H8GVKX$^&G[6?Q@^*VGZ@?V8_V<]
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MK?P\^#'@?PMXCO8-1UW1-&M-.O+NV=GBEDBB5"RLRJS#Y>K*">IYIOQT\?\
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M&_#OX66LJY6YU2[-W<1 DX8[))ER!C@Q]>H[#SO_ ((Z_P#)K'Q1_P"PW/\
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M^9@, D\^E 'VO8V4&F65O9VL8AMK>-8HHUZ(BC  ^@ KX'_X)Q?\G3_MH?\
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M#]@KP-\,O O@&>V^(4VEIH6KS_VQ81#2;:+]VTBR&XP[RH%V["VT,Y.U@HH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%<UXKO_&%G<0#P
MUH6AZM RDS/JNM36+(V> JQVDX88[DCZ5A?VW\5?^A,\'?\ A77?_P K*U5-
MR5U;[U_F6H-Z_JCT*BO/?[;^*O\ T)G@[_PKKO\ ^5E']M_%7_H3/!W_ (5U
MW_\ *RG[*7=?>O\ ,?(_+[T>A45Y[_;?Q5_Z$SP=_P"%==__ "LH_MOXJ_\
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M_%7_ *$SP=_X5UW_ /*RCV4NZ^]?YAR/R^]'H5%>>_VW\5?^A,\'?^%==_\
MRLH_MOXJ_P#0F>#O_"NN_P#Y64>REW7WK_,.1^7WH]"HKSW^V_BK_P!"9X._
M\*Z[_P#E91_;?Q5_Z$SP=_X5UW_\K*/92[K[U_F'(_+[T>A45Y[_ &W\5?\
MH3/!W_A77?\ \K*/[;^*O_0F>#O_  KKO_Y64>REW7WK_,.1^7WH]"HKSW^V
M_BK_ -"9X._\*Z[_ /E91_;?Q5_Z$SP=_P"%==__ "LH]E+NOO7^8<C\OO1Z
M%17GO]M_%7_H3/!W_A77?_RLH_MOXJ_]"9X._P#"NN__ )64>REW7WK_ ##D
M?E]Z/0J*\]_MOXJ_]"9X._\ "NN__E91_;?Q5_Z$SP=_X5UW_P#*RCV4NZ^]
M?YAR/R^]'H5%>>_VW\5?^A,\'?\ A77?_P K*/[;^*O_ $)G@[_PKKO_ .5E
M'LI=U]Z_S#D?E]Z/0J*\]_MOXJ_]"9X._P#"NN__ )64?VW\5?\ H3/!W_A7
M7?\ \K*/92[K[U_F'(_+[T>A45Y[_;?Q5_Z$SP=_X5UW_P#*RC^V_BK_ -"9
MX._\*Z[_ /E91[*7=?>O\PY'Y?>CT*BO/?[;^*O_ $)G@[_PKKO_ .5E']M_
M%7_H3/!W_A77?_RLH]E+NOO7^8<C\OO1Z%17GO\ ;?Q5_P"A,\'?^%==_P#R
MLH_MOXJ_]"9X._\ "NN__E91[*7=?>O\PY'Y?>CT*BO/?[;^*O\ T)G@[_PK
MKO\ ^5E']M_%7_H3/!W_ (5UW_\ *RCV4NZ^]?YAR/R^]'H5%>>_VW\5?^A,
M\'?^%==__*RC^V_BK_T)G@[_ ,*Z[_\ E91[*7=?>O\ ,.1^7WH]"HKSW^V_
MBK_T)G@[_P *Z[_^5E']M_%7_H3/!W_A77?_ ,K*/92[K[U_F'(_+[T>A45Y
M[_;?Q5_Z$SP=_P"%==__ "LH_MOXJ_\ 0F>#O_"NN_\ Y64>REW7WK_,.1^7
MWH]"HKSW^V_BK_T)G@[_ ,*Z[_\ E91_;?Q5_P"A,\'?^%==_P#RLH]E+NOO
M7^8<C\OO1Z%17GO]M_%7_H3/!W_A77?_ ,K*/[;^*O\ T)G@[_PKKO\ ^5E'
MLI=U]Z_S#D?E]Z/0J*\]_MOXJ_\ 0F>#O_"NN_\ Y64?VW\5?^A,\'?^%==_
M_*RCV4NZ^]?YAR/R^]'H5%>>_P!M_%7_ *$SP=_X5UW_ /*RC^V_BK_T)G@[
M_P *Z[_^5E'LI=U]Z_S#D?E]Z/0J*\]_MOXJ_P#0F>#O_"NN_P#Y64?VW\5?
M^A,\'?\ A77?_P K*/92[K[U_F'(_+[T>A45Y[_;?Q5_Z$SP=_X5UW_\K*/[
M;^*O_0F>#O\ PKKO_P"5E'LI=U]Z_P PY'Y?>CT*BO/?[;^*O_0F>#O_  KK
MO_Y64?VW\5?^A,\'?^%==_\ RLH]E+NOO7^8<C\OO1Z%17GO]M_%7_H3/!W_
M (5UW_\ *RC^V_BK_P!"9X._\*Z[_P#E91[*7=?>O\PY'Y?>CT*BO/?[;^*O
M_0F>#O\ PKKO_P"5E']M_%7_ *$SP=_X5UW_ /*RCV4NZ^]?YAR/R^]'H5%>
M>_VW\5?^A,\'?^%==_\ RLH_MOXJ_P#0F>#O_"NN_P#Y64>REW7WK_,.1^7W
MH]"HKSW^V_BK_P!"9X._\*Z[_P#E91_;?Q5_Z$SP=_X5UW_\K*/92[K[U_F'
M(_+[T>A45Y[_ &W\5?\ H3/!W_A77?\ \K*/[;^*O_0F>#O_  KKO_Y64>RE
MW7WK_,.1^7WH]"HKSW^V_BK_ -"9X._\*Z[_ /E91_;?Q5_Z$SP=_P"%==__
M "LH]E+NOO7^8<C\OO1Z%17GO]M_%7_H3/!W_A77?_RLH_MOXJ_]"9X._P#"
MNN__ )64>REW7WK_ ##D?E]Z/0J*\]_MOXJ_]"9X._\ "NN__E91_;?Q5_Z$
MSP=_X5UW_P#*RCV4NZ^]?YAR/R^]'H5%>>_VW\5?^A,\'?\ A77?_P K*/[;
M^*O_ $)G@[_PKKO_ .5E'LI=U]Z_S#D?E]Z/0J*\]_MOXJ_]"9X._P#"NN__
M )64?VW\5?\ H3/!W_A77?\ \K*/92[K[U_F'(_+[T>A5\\?M9?#GX_^/1X?
M7X(?$;2? T"I/#K4>J0@F=6*>6\3_9YF5EQ(.-GWASZ>B_VW\5?^A,\'?^%=
M=_\ RLH_MOXJ_P#0F>#O_"NN_P#Y64>REW7WK_,.1^7WHYG]DK]FC3/V6/A+
M#X4M;]];U:ZN9-1U?6)5*O>W<F SX))"A550,GA<GDDU[17GO]M_%7_H3/!W
M_A77?_RLH_MOXJ_]"9X._P#"NN__ )64>REW7WK_ ##D?E]Z/0J*\]_MOXJ_
M]"9X._\ "NN__E91_;?Q5_Z$SP=_X5UW_P#*RCV4NZ^]?YAR/R^]'H5%>>_V
MW\5?^A,\'?\ A77?_P K*/[;^*O_ $)G@[_PKKO_ .5E'LI=U]Z_S#D?E]Z/
M0J*\]_MOXJ_]"9X._P#"NN__ )64?VW\5?\ H3/!W_A77?\ \K*/92[K[U_F
M'(_+[T>A45Y[_;?Q5_Z$SP=_X5UW_P#*RC^V_BK_ -"9X._\*Z[_ /E91[*7
M=?>O\PY'Y?>CT*BO/?[;^*O_ $)G@[_PKKO_ .5E']M_%7_H3/!W_A77?_RL
MH]E+NOO7^8<C\OO1Z%17GO\ ;?Q5_P"A,\'?^%==_P#RLH_MOXJ_]"9X._\
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MH]E+NOO7^8<C\OO1Z%17GO\ ;?Q5_P"A,\'?^%==_P#RLH_MOXJ_]"9X._\
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M+NOO7^8<C\OO1Z%17GO]M_%7_H3/!W_A77?_ ,K*/[;^*O\ T)G@[_PKKO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%07%Y';2V
MT;D[KB0Q)@?Q!&?G\$- $]%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%5=1OET^W25E+AIHH<#U>14!_#=FK5 !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M *%WP5_X W?_ ,E4?V/BNR^\/:1/U@HK\G_^'L/Q<_Z%WP5_X W?_P E4?\
M#V'XN?\ 0N^"O_ &[_\ DJC^Q\5V7WA[2)^L%%?D_P#\/8?BY_T+O@K_ , ;
MO_Y*H_X>P_%S_H7?!7_@#=__ "51_8^*[+[P]I$_6"BOR?\ ^'L/Q<_Z%WP5
M_P" -W_\E4?\/8?BY_T+O@K_ , ;O_Y*H_L?%=E]X>TB?K!17Y/_ /#V'XN?
M]"[X*_\  &[_ /DJC_A[#\7/^A=\%?\ @#=__)5']CXKLOO#VD3]8**_)_\
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M1_P]A^+G_0N^"O\ P!N__DJC^Q\5V7WA[2)^L%%?D_\ \/8?BY_T+O@K_P
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M>P_%S_H7?!7_ ( W?_R51_8^*[+[P]I$_6"BOR?_ .'L/Q<_Z%WP5_X W?\
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M*H_X>P_%S_H7?!7_ ( W?_R51_8^*[+[P]I$_6"BOR?_ .'L/Q<_Z%WP5_X
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M^Q\5V7WA[2)^L%%?D_\ \/8?BY_T+O@K_P  ;O\ ^2J/^'L/Q<_Z%WP5_P"
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MA=\%?^ -W_\ )5'_  ]A^+G_ $+O@K_P!N__ )*H_L?%=E]X>TB?K!17Y/\
M_#V'XN?]"[X*_P# &[_^2J/^'L/Q<_Z%WP5_X W?_P E4?V/BNR^\/:1/U@H
MK\G_ /A[#\7/^A=\%?\ @#=__)5'_#V'XN?]"[X*_P# &[_^2J/['Q79?>'M
M(GZP45^3_P#P]A^+G_0N^"O_  !N_P#Y*H_X>P_%S_H7?!7_ ( W?_R51_8^
M*[+[P]I$_6"BOR?_ .'L/Q<_Z%WP5_X W?\ \E4?\/8?BY_T+O@K_P  ;O\
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M_P#DJC^Q\5V7WA[2)^L%%?D__P /8?BY_P!"[X*_\ ;O_P"2J/\ A[#\7/\
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M%% !1110 5^V'[ >LW&N?LD> )[EMTD4-S:@_P"Q%=S1I^2JH_"OQ/K]H?\
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M#PS6EP4&,NL4Z(S*,C)4$#/- 'L%%<%\7OCQ\/\ X"Z+#JOC[Q58>&K.=BL
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M$,B*JMM(8R2H0<^@-</X\_X*+?#GPEX#T/7;&SU'5M5UJ!KFVT(^7%/!&'9
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M?BNXA.'<L1B(G RI==@/!V6X!'S'/R?I7Q;\6Z)\-M:\ 66KM!X1UFX2ZO\
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M, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/^"E=]IW@:QBTGP]XN\ 7&NZEHEJ/*LS=0_:F5UB7Y5.;0= ,>=)C[QSU/\
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MM,UB'5=*N"WEIJ$$,ZR*GF;2%?"@,,':3G!!&?'O%^O_ /"5^+-;UOR/LO\
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M7?L__%[3FT&+2M6>X\*>((+FWNE9"[2)(J1RLP D,A*OL)2XVC!!( -74?\
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MB2SLQY9B222>2374^%_C'X^\$:6-,\.>./$F@::',@L]+U>XMH0QZML1P,G
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M/O\ A(?[6_X6%>65W_9_V+R?[/\ LZS+M\SS&\W=YW7:F-O?/'M-% !1110
M4444 %%%% !63X9_Y!TW_7[=_P#I1)6M63X9_P"0=-_U^W?_ *424 :U%%%
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M!VP 2Q/TK10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M 'U;17RE_P )GX@_Z#NI_P#@9)_C1_PF?B#_ *#NI_\ @9)_C0!]6T5\I?\
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ME4?\/8?BY_T+O@K_ , ;O_Y*I_V/BNR^\/:1/U@HK\G_ /A[#\7/^A=\%?\
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M?]"[X*_\ ;O_ .2J/^'L/Q<_Z%WP5_X W?\ \E4?V/BNR^\/:1/U@HK\G_\
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M  ]A^+G_ $+O@K_P!N__ )*H_L?%=E]X>TB?K!17Y/\ _#V'XN?]"[X*_P#
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M?#/P,\6_#CP[KUCJUW>^/-831-,DTZ&)XX9VDB0-,7D0JF9EY4,< \=,^KT
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M+T#2+#0]-C9F2STVV2WA4L<L0B  $GD\5IT5/-)KEOH 4445(!1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@[QU*CB>'P7HGB^SM-&M6YP&V2(7(!QE%0\<NXK[B^#7CSX+-:V_@WX5^)_
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MP$_9G\ 3:3X>\>W?@NPNM8\1^(H&F6V\FV9'CCB(PTF;:4DD,"2!Q\Q'C?\
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M?\'?CWX.TCPQXEUNW>XT#7?#DTCZ9J6P$M$!(S,K84]6SG *C<I+?B9^UO\
M$/Q5\;M:^$OP \%Z5XJU[PXB-XA\0^)+AXM+TYV^[%B-E9VZ@X;.58!3M8CD
M/VX)X_&/[8G[)_A+1'6Y\3:=XADUR[CAP9+:P22WDD+8Y572WF]CY9]!4?\
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MNJ^)7['G[3'Q8\"ZQX2\4?M*:7K>A:I#Y5S83>"+*)90&#*-Z ,F&52&4Y!
M(H ^N_%D<OC[X7:S'X:U%%FUK1IETS4(V(4-- ?)E!'.,LK9K\[_ -B7]KOX
M=?L?_#N'X,_%W1=5^&GC72;VY>_OKK3'D@OS).[1REH@S'"%4#;2A5%(8@\>
MA?L.?M+:QH'[%/BZUU+0KC7?&GP>%QIM[H*S>5/+!#N:(9VMMVHLD8^4Y^SG
MBOH3X._$+X:_MN?!;1_$EYH.@^(+>Z@ U#0M1CBU Z9<X_>0.'0$$$'#%5W+
MM8#!% '!M\,?AI^TS^T%\/OCC\,?B1HPU;PGYL>KIH21W,NJ0R*%2*X*R*T.
M%:5<NC$B0#C:*ZG]L+X]:M\-/#^C>!_ 2+?_ !<\=3G2_#EF"/\ 1LC][>R\
M';'"I+9((SC@JK8^4/VH?@MX)_9?_::^!FN_!&,>&/'NN>(HK&^\,:5<,8KN
MQ=T$CO#D^7&1E3@!2"6 RA-=]J/P-_:I\/\ [4/CWXK^'K3X8^()]49]-T6;
MQ/<7KR:;I22'R8HDB*+&SH$,ARV6W8(W-D YK]D;X(Z?^SW_ ,%%-?\ !UE=
M2ZE<0?#!;G4=3N'9I+Z]DO;1IYV+$GYG).,\# ]Z[6\BA^*G_!6N+3]547=E
M\/O!']H6%K.-T<=U))$#*JG(WXNU^;J#&IZJ*\1\/:A^U"/^"@_B>:TTSX8G
MXIGP,BW<$K7W]D#3OM-OAD(?S/.W^7U.W&[CI7M]W+!\*_\ @K5'J&K.+6S^
M(/@?^S]/N9CMBDNHY8B858X&_%HOR\DF1!U84 6/^"K^G1Z!\%?"7Q+T]$M_
M%7@GQ18WVG7R@"106.Z/=C.TL(V(]8Q7VMI]ZFHV%M=Q!ECGB650XY 8 C/O
MS7Q1_P %8M3CUSX)>%/AKI[+<^*_&GB>RLM.L$(,KA6):0+G)4,8U)]9!7VQ
M86<>G6-O:Q9,4$:Q)N.3A1@9_*@#YZ_:;_:>\1?"WQOX-^&_PZ\&KXV^(_BL
M226EO=SFWLK*! Q::=\<CY)#M!!Q&QSG ;QWQ[^UI^T;^S!<Z)KWQO\  /@B
M]^'E_?16-UJO@JXN!-I[.3RZS2,6^520 H4XQN!8"NK_ &B?VA?B;JW[3WAW
MX ?"2\T;PMK5YI+:SJ'B;7+8W'E1C>1%!$1M8[4R20<EL?+M8GY7_P""D/PN
M^('PY^!-K>?$_P#:&U+Q_JVI:I#%8>&H-+M]+M)"H9I)6BB8^8(Q_%@ ,Z>H
MH ]2_P""E5S\6%^-_P !UT6T\*OH:>,=.;PR]Z9_M$FK^8F%N]K8^S[MGW,-
MC//2OO#X7R^,I_ 6D/\ $&'1[?QB8V_M&+0#(;%7WMM\KS"7QLVYR>N:^5/^
M"A4T?_"R/V4Y=Z^5_P +-TUM^?EQYT1SGTK[4H ^'O\ @HS;?\*[^(7[/7QG
MB'EKX8\6Q:9J4J][.YP7W'L L4J@^LO?.*V/^"CLS^/+/X0_!:U?,WQ!\76T
M=]&I^;^SK8B2X; Y^4M$V?\ 8/X>E?MZ_#4?%7]D?XE:.D)FN[?3&U2U"C+>
M;:D7 "^[",K_ ,"([U\S_LL^.F_:P_:^\%^,Y9%N;'X=_#2P64ABRQZS>Q#S
MB/?9),I/_3(<9S@ [_\ 9#"?![]L;]HGX0^6+73M0NH?&NC0+PGE3A1<;!Z!
MI84'IY9]J@_9@MO^%M?M]_M#_$V0B:P\-BW\&:8^<JK)@7 7W#V^2?\ IL<<
M&JG[9.MV_P"SQ^V#\&/C9.RP:-=Z9J?AS6I#\JLB0R36X8^[R,<_],A7>?\
M!,KP7=>'/V5=*U_5!G6_&FHWGB:^<CEVGDVHV?>..-O^!4 >:_MG_L<ZS\3K
M3XO?$SX@^/\ 4-6\+^'O#VH:EX3\&6;M':V4T.GN5FE/ 9O,4M@#)X#.5RM>
MR_\ !.+_ ),G^%G_ %XS_P#I5-7??M8_\FL?&3_L3-9_](9JX'_@G%_R9/\
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M% !1110!\U_%_P#Y*)JW_;'_ -$I7&UV7Q?_ .2B:M_VQ_\ 1*5QM !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!UWPG_P"2@Z1_
MO2?^BVKK/%VG^ Y?$VHOJ6IZI#?&8F9(5!16]OD/'XUQOPRO(+#QSI=Q=3QV
MT",^Z69PJK^[8<D\"JWCVYAO/&6KSV\J3PO.Q22-@RL/4$=: .EUSQOH>E>&
M+G0/"]M<+'='_2+NXZN.,X^H&.@QSQ2?$3'_  A7@3()'V63(!QVBKSRO0_%
M6M6']@^ 2LT-X;*,M<V\<BLR@&([6 /&<$<T ;TEQXZ\1P6!T/37\/Z5'$JQ
MQB9%&!_$<@-C&.,>]+\3-.OKGP5X?&JRVUQK'VS[.]S#R,,&XR /1<^XI?&M
MIIOCN\COK?QG96E@\2@VEQ+M*$=]A(Y^HK.\97NB)\-],L=#U..X:PO0<,X6
M5^'W2!"=V-S<<=/I0!/\3/$U]X*O+'P_H<QTZRM[96)A #NQ)Y)_#/N2<UCQ
M>)&^)M_X=TC4K-&O(YPLM^KX:6+DLNT 8X YSU'O6IK\6B?%!+/55UVTT74E
MA$-S;7K!1D<Y4DC/4_7CH0:SM9UC0_!T.AVFB&WU34+&X%S<ZC&BCS,$GRPV
M#D'/8G  ZT =SXLTGQO-J@B\/O#I^D6ZJD$<4B)G Y)&/7C'3 K&^(^BW!TW
MPSJ^IPQPZR+I+6Y,)!63DD$X_P!W/MN(]*S?$6@^'O'>I-K5CXELM-:Y ,]M
M?L$9&  .,D>GTSGFL3Q'#X8TBZT>RT>07EU#*C7>I>8=C\] ,[>^<CI@<GF@
M#J/BYX\U?1O$HT_3+DV,4<:R2-&HW2.>Y/H  ,?6H=?MCX_\%^&M7N51-2>\
M6QGG0 %D9RN<?4 _B:M>/M%\/>-=>-U:^)]/L[B-%CE$TJF-QU#*V<$\X(]N
MW?G_ !CXGL-'TG1?#^@W(O(]-F%U)> ?*\P)(QZC))].G/% &A\2?&NH>&=;
M&@Z'*=+L;")%VPJ 68J&SGTP1^.:9KE[_P )Q\*SK=^BG5=-N1;FX50#*I*]
M<?[X/U'O4OB*Q\/_ !*GBUFWUVST6^>-4N;:^8)\P&,@DC/&!WR .E9OBS6M
M)T#P='X5T:[74FDE$]Y>(/D9N#A?R7UX7UH \\HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** /JWP9_R)^A?]>$'_ *+6MFL;
MP9_R)^A?]>$'_HM:V: "JMW-;QW%DLRAI))BL!*YVOY;DGV^4.,^_O5JJMW8
MK=W%E*SE3;3&50/XB8W3'Y.3^% %JBBB@ K\%_VFO^3C?BE_V-&I?^E4E?O1
M7X+_ +37_)QOQ2_[&C4O_2J2OILB_BS]#&ILCS2BBBOLC **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "OVA_X)U_\F@>!O\ ?O\ _P!+KBOQ>K]H?^"=?_)H'@;_ '[_ /\
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M6E_:6/QON[_5]0\5QZ7_ &39V=U+"UC8P[<%H4$0D5SF3),A'[Z3CD8]>HH
M*\9L_P!E7PGIG[3-W\<M/U#6=/\ %=]I_P#9M_8V\T(L+V/8J RH8BY;]W$<
MK(.8DXZY]FHH \@_9N_9A\+?LNZ#X@TCPK?ZQJ%MK>J/JUPVL312.DK(JE4,
M<<8"X0<$$]>:]3UC2;/7])O=+U&W2[T^]@>VN+>0966)U*NI]B"1^-7** /
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M-K<C1M'MQ;P->3F:9^<EG8]R23@ *,X4   <M^T+^S/X1_:9TSPSIOC&2_\
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M+J-YJ\EI;I U_J#(UQ<E5 \R0HJJ7;&20H&2>!6A10!\#_MA?#?P[\7OV_\
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M1RHKH-K21NN"LC@_+WKT'P?X6L/ WA'1/#>E1F+2]'L8-.M(V()6&*-8T!P
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^:_C "/B)JI/?RB/\
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M)_A1_P (9X@_Z 6I_P#@')_A0!C45L_\(9X@_P"@%J?_ (!R?X4?\(9X@_Z
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M@_Z 6I_^ <G^% &-16S_ ,(9X@_Z 6I_^ <G^%'_  AGB#_H!:G_ . <G^%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %9/AG_D'3?\ 7[=_^E$E:U9/AG_D
M'3?]?MW_ .E$E &M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% &=J/^N7_=JK5K4?\ 7+_NU5K=;$L****8@HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ I\'^OC_ -X?SIE/@_U\?^\/YT#-
MBBBBN<H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 9VH_P"N7_=JK5S45.]6[8Q5.MH[$L****H04444 %%%% !1110
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M,JL,C@J#U%8&H_!+X=ZOKEGK5_X!\,7NL62)':ZA<:-;27$"H,(J2%"RA1P
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
MD^&?^0=-_P!?MW_Z425K5D^&?^0=-_U^W?\ Z424 :U%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !7/:9X T#1]?N-:L]/6'4YR[23^:[9+G+$*6*C)]!70T4
M 8/B?P+H7C%[9M8L%O&M]WE'S'0KG&1\I&>@ZUN@   # '84M87B;QYX9\%(
MC^(?$6DZ"CC*MJ=]%;!OIO89II.3LD-)O1$ECX/TC3?$-WKEM:>7JEVA2:?S
M7.]25)&TG:/NKT':D\2^#-%\7Q1QZOI\=X(_N,25=?8,I!Q[9J3P]XMT/Q=:
MM<Z%K.GZU;*<&;3KI)T!]"4)%:U#33LP:MHS(\.>$](\)6KV^D6,=E$YW/M)
M9F/;+$DG\36O112$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <]X<\ :!X2O+
MB[TG3Q:7$Z[)'\UWR,YQAF('/I3M;\":%XCU:TU/4;!;F^M0HBE,CKM"MN (
M! /)/4&M^B@ K$3P7HT?B>3Q"MGC6)%VM<^:_(VA?NYV_= '2MNB@#G?$GP]
M\/>+ITGU;3([J=%VB4.T;8]"5()_&M31M$L/#UA'9:=:QVEJF2(XQQD]2>Y/
MN:O44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 5D^&?\ D'3?]?MW_P"E
M$E:U9/AG_D'3?]?MW_Z424 :U%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ K)\,_P#(.F_Z_;O_ -*)*UJR
M?#/_ "#IO^OV[_\ 2B2@#6HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M/$?VLOV;[;]H_P"'L>G13QV/B'3)&N=+O)?N!RN&B<@$A'PN2!D%5/;!_*_X
MA^%?B;\*/#3^ _%>DW^CZ"-2.J+;S6JF&2Y\ORO-2<*=PV<8#E>^,U^WU%>S
M@\SGA(\CCS1W]/0]##XR5!<K5T?AW\)_V>_'OQIU6"T\,^'[J>V=U234IXVC
MM( 3]YY2,<=<#)XX!K]??V?_ (*Z7\ OAGI_A/39/M3QLUQ>7K+M:YN'QN<C
MMP%4#^ZHKT>BIQV95,:E%JT5T%B<7/$:6L@HHHKR#@"BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *R?#/\ R#IO^OV[_P#2B2M:LGPS_P @Z;_K]N__ $HDH UJ*** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "LGPS_R#IO\ K]N__2B2M:HX+>.V0I$@12S.0/[S,68_B23^- $E
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
944 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jul. 28, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SPYRE THERAPEUTICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-4312787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">221 Crescent Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Building 23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">Suite 105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Waltham<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">651-5940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 Par Value Per Share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SYRE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,173,762<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001636282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 3 such as an Office Park</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 162,007<span></span>
</td>
<td class="nump">$ 85,721<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">983,339<span></span>
</td>
<td class="nump">670,812<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">27,657<span></span>
</td>
<td class="nump">21,248<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">1,173,003<span></span>
</td>
<td class="nump">777,781<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">1,173,003<span></span>
</td>
<td class="nump">777,781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">CVR liability</a></td>
<td class="nump">31,350<span></span>
</td>
<td class="nump">22,820<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued and other current liabilities</a></td>
<td class="nump">26,184<span></span>
</td>
<td class="nump">26,947<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">63,302<span></span>
</td>
<td class="nump">58,685<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Non-current CVR liability</a></td>
<td class="nump">7,270<span></span>
</td>
<td class="nump">3,860<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">1,290<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">71,862<span></span>
</td>
<td class="nump">62,545<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Notes 6 and 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS&#8217; EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 400,000,000 shares authorized as of June&#160;30, 2026 and December&#160;31, 2025; 88,064,133 shares and 78,189,811 shares issued and outstanding as of June&#160;30, 2026 and December&#160;31, 2025, respectively.</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">2,189,936<span></span>
</td>
<td class="nump">1,686,167<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive (loss) income</a></td>
<td class="num">(2,396)<span></span>
</td>
<td class="nump">869<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,232,840)<span></span>
</td>
<td class="num">(1,127,635)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="nump">1,101,141<span></span>
</td>
<td class="nump">715,236<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="nump">1,173,003<span></span>
</td>
<td class="nump">777,781<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=syre_SeriesANonVotingConvertiblePreferredStockMember', window );">Series A Non Voting Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS&#8217; EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="nump">146,425<span></span>
</td>
<td class="nump">146,425<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=syre_SeriesBNonVotingConvertiblePreferredStockMember', window );">Series B Non Voting Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS&#8217; EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,395<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=syre_PreferredStockExcludingSeriesAAndBNonVotingConvertiblePreferredStockMember', window );">Preferred Stock, Excluding Series A Non Voting Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS&#8217; EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember', window );">Nonrelated Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">5,722<span></span>
</td>
<td class="nump">8,904<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Related party accounts payable</a></td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 27: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 860<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481420/860-30-50-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=syre_SeriesANonVotingConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=syre_SeriesANonVotingConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=syre_SeriesBNonVotingConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=syre_SeriesBNonVotingConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=syre_PreferredStockExcludingSeriesAAndBNonVotingConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=syre_PreferredStockExcludingSeriesAAndBNonVotingConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">88,064,133<span></span>
</td>
<td class="nump">78,189,811<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="nump">88,064,133<span></span>
</td>
<td class="nump">78,189,811<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=syre_SeriesANonVotingConvertiblePreferredStockMember', window );">Series A Non Voting Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (in shares)</a></td>
<td class="nump">1,086,341<span></span>
</td>
<td class="nump">1,086,341<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued (in shares)</a></td>
<td class="nump">346,045<span></span>
</td>
<td class="nump">346,045<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (in shares)</a></td>
<td class="nump">346,045<span></span>
</td>
<td class="nump">346,045<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=syre_SeriesBNonVotingConvertiblePreferredStockMember', window );">Series B Non Voting Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (in shares)</a></td>
<td class="nump">271,625<span></span>
</td>
<td class="nump">271,625<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,667<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,667<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=syre_PreferredStockExcludingSeriesAAndBNonVotingConvertiblePreferredStockMember', window );">Preferred Stock, Excluding Series A Non Voting Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (in shares)</a></td>
<td class="nump">8,642,034<span></span>
</td>
<td class="nump">8,642,034<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=syre_SeriesANonVotingConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=syre_SeriesANonVotingConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=syre_SeriesBNonVotingConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=syre_SeriesBNonVotingConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=syre_PreferredStockExcludingSeriesAAndBNonVotingConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=syre_PreferredStockExcludingSeriesAAndBNonVotingConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 65,503<span></span>
</td>
<td class="nump">$ 40,145<span></span>
</td>
<td class="nump">$ 125,914<span></span>
</td>
<td class="nump">$ 81,768<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">16,136<span></span>
</td>
<td class="nump">11,790<span></span>
</td>
<td class="nump">31,366<span></span>
</td>
<td class="nump">23,734<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Gain on sale of in-process research and development asset</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(40,000)<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
<td class="num">(70,000)<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">41,639<span></span>
</td>
<td class="nump">41,935<span></span>
</td>
<td class="nump">87,280<span></span>
</td>
<td class="nump">95,502<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(41,639)<span></span>
</td>
<td class="num">(41,935)<span></span>
</td>
<td class="num">(87,280)<span></span>
</td>
<td class="num">(95,502)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Interest income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,053<span></span>
</td>
<td class="nump">5,874<span></span>
</td>
<td class="nump">17,048<span></span>
</td>
<td class="nump">12,367<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (expense) income, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,614)<span></span>
</td>
<td class="num">(656)<span></span>
</td>
<td class="num">(34,973)<span></span>
</td>
<td class="nump">1,630<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,439<span></span>
</td>
<td class="nump">5,218<span></span>
</td>
<td class="num">(17,925)<span></span>
</td>
<td class="nump">13,997<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(36,200)<span></span>
</td>
<td class="num">(36,717)<span></span>
</td>
<td class="num">(105,205)<span></span>
</td>
<td class="num">(81,505)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(36,200)<span></span>
</td>
<td class="num">(36,717)<span></span>
</td>
<td class="num">$ (105,205)<span></span>
</td>
<td class="num">(81,490)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1.09)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 3,100<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">200<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=syre_SeriesANonVotingConvertiblePreferredStockMember', window );">Series A Non Voting Convertible Preferred Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (5,052)<span></span>
</td>
<td class="num">$ (6,791)<span></span>
</td>
<td class="num">$ (15,147)<span></span>
</td>
<td class="num">$ (15,078)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (14.60)<span></span>
</td>
<td class="num">$ (19.62)<span></span>
</td>
<td class="num">$ (43.77)<span></span>
</td>
<td class="num">$ (43.57)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (14.60)<span></span>
</td>
<td class="num">$ (19.62)<span></span>
</td>
<td class="num">$ (43.77)<span></span>
</td>
<td class="num">$ (43.57)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common stock outstanding, basic (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">346,045<span></span>
</td>
<td class="nump">346,045<span></span>
</td>
<td class="nump">346,045<span></span>
</td>
<td class="nump">346,045<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common stock outstanding, diluted (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">346,045<span></span>
</td>
<td class="nump">346,045<span></span>
</td>
<td class="nump">346,045<span></span>
</td>
<td class="nump">346,045<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=syre_SeriesBNonVotingConvertiblePreferredStockMember', window );">Series B Non Voting Convertible Preferred Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (225)<span></span>
</td>
<td class="num">$ (327)<span></span>
</td>
<td class="num">$ (701)<span></span>
</td>
<td class="num">$ (726)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (14.60)<span></span>
</td>
<td class="num">$ (19.62)<span></span>
</td>
<td class="num">$ (43.77)<span></span>
</td>
<td class="num">$ (43.57)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (14.60)<span></span>
</td>
<td class="num">$ (19.62)<span></span>
</td>
<td class="num">$ (43.77)<span></span>
</td>
<td class="num">$ (43.57)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common stock outstanding, basic (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,385<span></span>
</td>
<td class="nump">16,667<span></span>
</td>
<td class="nump">16,022<span></span>
</td>
<td class="nump">16,667<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common stock outstanding, diluted (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,385<span></span>
</td>
<td class="nump">16,667<span></span>
</td>
<td class="nump">16,022<span></span>
</td>
<td class="nump">16,667<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (30,923)<span></span>
</td>
<td class="num">$ (29,599)<span></span>
</td>
<td class="num">$ (89,357)<span></span>
</td>
<td class="num">$ (65,686)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.36)<span></span>
</td>
<td class="num">$ (0.49)<span></span>
</td>
<td class="num">$ (1.09)<span></span>
</td>
<td class="num">$ (1.09)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.36)<span></span>
</td>
<td class="num">$ (0.49)<span></span>
</td>
<td class="num">$ (1.09)<span></span>
</td>
<td class="num">$ (1.09)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common stock outstanding, basic (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">84,729,435<span></span>
</td>
<td class="nump">60,333,838<span></span>
</td>
<td class="nump">81,656,119<span></span>
</td>
<td class="nump">60,300,073<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common stock outstanding, diluted (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">84,729,435<span></span>
</td>
<td class="nump">60,333,838<span></span>
</td>
<td class="nump">81,656,119<span></span>
</td>
<td class="nump">60,300,073<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt">Includes de minimis related party expenses for the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">three</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> months ended June&#160;30, 2026 and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Includes related party expenses of $3.1 million and $2.6 million for the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">six</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> months ended June&#160;30, 2026 and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2025, respectively</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt">Includes related party expenses of $0.2 million for the three months ended June&#160;30, 2026 and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2025, and</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> $0.5 million for the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">six months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">June&#160;30, 2026 and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3A<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3A<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=syre_SeriesANonVotingConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=syre_SeriesANonVotingConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=syre_SeriesBNonVotingConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=syre_SeriesBNonVotingConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 65,503<span></span>
</td>
<td class="nump">$ 40,145<span></span>
</td>
<td class="nump">$ 125,914<span></span>
</td>
<td class="nump">$ 81,768<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">16,136<span></span>
</td>
<td class="nump">11,790<span></span>
</td>
<td class="nump">31,366<span></span>
</td>
<td class="nump">23,734<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,100<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt">Includes de minimis related party expenses for the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">three</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> months ended June&#160;30, 2026 and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Includes related party expenses of $3.1 million and $2.6 million for the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">six</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> months ended June&#160;30, 2026 and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2025, respectively</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt">Includes related party expenses of $0.2 million for the three months ended June&#160;30, 2026 and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2025, and</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> $0.5 million for the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">six months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">June&#160;30, 2026 and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (36,200)<span></span>
</td>
<td class="num">$ (36,717)<span></span>
</td>
<td class="num">$ (105,205)<span></span>
</td>
<td class="num">$ (81,490)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(36)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (loss) gain on marketable securities</a></td>
<td class="num">(1,629)<span></span>
</td>
<td class="num">(192)<span></span>
</td>
<td class="num">(3,265)<span></span>
</td>
<td class="nump">296<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">$ (37,829)<span></span>
</td>
<td class="num">$ (36,945)<span></span>
</td>
<td class="num">$ (108,470)<span></span>
</td>
<td class="num">$ (81,216)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481839/830-10-45-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482014/830-20-35-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Series A Non-Voting Convertible Preferred Stock</div></th>
<th class="th">
<div>Series A Non-Voting Convertible Preferred Stock </div>
<div>Preferred Stock</div>
</th>
<th class="th"><div>Series B Non-Voting Convertible Preferred Stock</div></th>
<th class="th">
<div>Series B Non-Voting Convertible Preferred Stock </div>
<div>Preferred Stock</div>
</th>
<th class="th">
<div>Series B Non-Voting Convertible Preferred Stock </div>
<div>Common Stock</div>
</th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Beginning balance, preferred stock (in shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">346,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2024</a></td>
<td class="nump">$ 517,804<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 1,334,223<span></span>
</td>
<td class="nump">$ 180<span></span>
</td>
<td class="num">$ (972,432)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 146,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, common stock (in shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,257,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan', window );">Issuance of common stock in connection with exercise of stock options and employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan', window );">Issuance of common stock in connection with exercise of stock options and employee stock purchase plan</a></td>
<td class="nump">218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">8,859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (loss) gain on marketable securities</a></td>
<td class="nump">488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(44,773)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(44,773)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Ending balance, preferred stock (in shares) at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">346,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2025</a></td>
<td class="nump">482,610<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">1,343,300<span></span>
</td>
<td class="nump">682<span></span>
</td>
<td class="num">(1,017,205)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 146,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, common stock (in shares) at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,276,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Beginning balance, preferred stock (in shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">346,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2024</a></td>
<td class="nump">517,804<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">1,334,223<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="num">(972,432)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 146,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, common stock (in shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,257,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(22)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (loss) gain on marketable securities</a></td>
<td class="nump">296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(81,490)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (15,078)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (726)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Ending balance, preferred stock (in shares) at Jun. 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">346,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2025</a></td>
<td class="nump">455,773<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">1,353,408<span></span>
</td>
<td class="nump">454<span></span>
</td>
<td class="num">(1,053,922)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 146,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, common stock (in shares) at Jun. 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,373,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Beginning balance, preferred stock (in shares) at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">346,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2025</a></td>
<td class="nump">482,610<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">1,343,300<span></span>
</td>
<td class="nump">682<span></span>
</td>
<td class="num">(1,017,205)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 146,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, common stock (in shares) at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,276,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan', window );">Issuance of common stock in connection with exercise of stock options and employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan', window );">Issuance of common stock in connection with exercise of stock options and employee stock purchase plan</a></td>
<td class="nump">730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">9,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(36)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (loss) gain on marketable securities</a></td>
<td class="num">(192)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(192)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(36,717)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36,717)<span></span>
</td>
<td class="num">$ (6,791)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (327)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Ending balance, preferred stock (in shares) at Jun. 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">346,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2025</a></td>
<td class="nump">455,773<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">1,353,408<span></span>
</td>
<td class="nump">454<span></span>
</td>
<td class="num">(1,053,922)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 146,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, common stock (in shares) at Jun. 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,373,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Beginning balance, preferred stock (in shares) at Dec. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">346,045<span></span>
</td>
<td class="nump">346,000<span></span>
</td>
<td class="nump">16,667<span></span>
</td>
<td class="nump">17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2025</a></td>
<td class="nump">$ 715,236<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">1,686,167<span></span>
</td>
<td class="nump">869<span></span>
</td>
<td class="num">(1,127,635)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 146,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, common stock (in shares) at Dec. 31, 2025</a></td>
<td class="nump">78,189,811<span></span>
</td>
<td class="nump">78,190,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in connection with at-the-market and follow-on offering program, net of financing costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">296,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in connection with at-the-market and follow-on offering program, net of financing costs</a></td>
<td class="nump">$ 9,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan', window );">Issuance of common stock in connection with exercise of stock options and employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">354,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan', window );">Issuance of common stock in connection with exercise of stock options and employee stock purchase plan</a></td>
<td class="nump">3,663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">12,806<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,806<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (loss) gain on marketable securities</a></td>
<td class="num">(1,636)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,636)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(69,005)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(69,005)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Ending balance, preferred stock (in shares) at Mar. 31, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">346,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2026</a></td>
<td class="nump">670,811<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">1,712,383<span></span>
</td>
<td class="num">(767)<span></span>
</td>
<td class="num">(1,196,640)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 146,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, common stock (in shares) at Mar. 31, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,840,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Beginning balance, preferred stock (in shares) at Dec. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">346,045<span></span>
</td>
<td class="nump">346,000<span></span>
</td>
<td class="nump">16,667<span></span>
</td>
<td class="nump">17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2025</a></td>
<td class="nump">$ 715,236<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">1,686,167<span></span>
</td>
<td class="nump">869<span></span>
</td>
<td class="num">(1,127,635)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 146,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, common stock (in shares) at Dec. 31, 2025</a></td>
<td class="nump">78,189,811<span></span>
</td>
<td class="nump">78,190,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (loss) gain on marketable securities</a></td>
<td class="num">(3,265)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(105,205)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (15,147)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (701)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Ending balance, preferred stock (in shares) at Jun. 30, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">346,045<span></span>
</td>
<td class="nump">346,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2026</a></td>
<td class="nump">$ 1,101,141<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">2,189,936<span></span>
</td>
<td class="num">(2,396)<span></span>
</td>
<td class="num">(1,232,840)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 146,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, common stock (in shares) at Jun. 30, 2026</a></td>
<td class="nump">88,064,133<span></span>
</td>
<td class="nump">88,064,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Beginning balance, preferred stock (in shares) at Mar. 31, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">346,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2026</a></td>
<td class="nump">$ 670,811<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">1,712,383<span></span>
</td>
<td class="num">(767)<span></span>
</td>
<td class="num">(1,196,640)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 146,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, common stock (in shares) at Mar. 31, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,840,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of Series B Non-Voting Convertible Preferred Stock to common Stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,000)<span></span>
</td>
<td class="nump">667,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of Series B Non-Voting Convertible Preferred Stock to common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (9,395)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in connection with at-the-market and follow-on offering program, net of financing costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,475,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in connection with at-the-market and follow-on offering program, net of financing costs</a></td>
<td class="nump">434,898<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">434,897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan', window );">Issuance of common stock in connection with exercise of stock options and employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,083,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan', window );">Issuance of common stock in connection with exercise of stock options and employee stock purchase plan</a></td>
<td class="nump">19,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">13,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (loss) gain on marketable securities</a></td>
<td class="num">(1,629)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,629)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(36,200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36,200)<span></span>
</td>
<td class="num">$ (5,052)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (225)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Ending balance, preferred stock (in shares) at Jun. 30, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">346,045<span></span>
</td>
<td class="nump">346,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2026</a></td>
<td class="nump">$ 1,101,141<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 2,189,936<span></span>
</td>
<td class="num">$ (2,396)<span></span>
</td>
<td class="num">$ (1,232,840)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 146,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, common stock (in shares) at Jun. 30, 2026</a></td>
<td class="nump">88,064,133<span></span>
</td>
<td class="nump">88,064,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Options Exercised And Employee Stock Ownership Plan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Options Exercised And Employee Stock Ownership Plan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481839/830-10-45-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482014/830-20-35-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (105,205)<span></span>
</td>
<td class="num">$ (81,490)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">26,318<span></span>
</td>
<td class="nump">18,237<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Change in fair value of CVR liability</a></td>
<td class="nump">34,873<span></span>
</td>
<td class="num">(1,800)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Gain on sale of in-process research and development asset</a></td>
<td class="num">(70,000)<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Net accretion of discount on marketable securities</a></td>
<td class="num">(5,152)<span></span>
</td>
<td class="num">(4,655)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_InterestProceedsDebtSecurities', window );">Interest proceeds from maturities of zero coupon U.S. Treasury Bills</a></td>
<td class="nump">683<span></span>
</td>
<td class="nump">1,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Accounts payable</a></td>
<td class="num">(3,182)<span></span>
</td>
<td class="nump">3,046<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued and other liabilities</a></td>
<td class="nump">225<span></span>
</td>
<td class="num">(8,299)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable', window );">Related party accounts payable</a></td>
<td class="nump">32<span></span>
</td>
<td class="num">(572)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(5,841)<span></span>
</td>
<td class="num">(3,784)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(127,249)<span></span>
</td>
<td class="num">(87,557)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from maturities and sales of marketable securities</a></td>
<td class="nump">217,187<span></span>
</td>
<td class="nump">178,249<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(528,510)<span></span>
</td>
<td class="num">(106,312)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfIntangibleAssets', window );">Proceeds from sale of in-process research and development asset</a></td>
<td class="nump">70,000<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(241,323)<span></span>
</td>
<td class="nump">78,937<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of common stock in connection with follow-on offering, net of issuance costs</a></td>
<td class="nump">435,240<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_ProceedsFromIssuanceOfCommonStockAtTheMarketOfferingsNet', window );">Proceeds from issuance of common stock in connection with at-the-market offering program, net of issuance costs</a></td>
<td class="nump">9,750<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_PaymentForDeferredOfferingCosts', window );">Payment of deferred offering costs in connection with shelf registration</a></td>
<td class="num">(454)<span></span>
</td>
<td class="num">(93)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_PaymentsRelatedToContingentValueRightsLiability', window );">Payments related to contingent value rights liability</a></td>
<td class="num">(22,933)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from employee stock option exercises and employee stock plan purchases</a></td>
<td class="nump">23,255<span></span>
</td>
<td class="nump">949<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">444,858<span></span>
</td>
<td class="nump">856<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</a></td>
<td class="nump">76,286<span></span>
</td>
<td class="num">(7,764)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract', window );"><strong>CASH AND CASH EQUIVALENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Beginning of period</a></td>
<td class="nump">85,721<span></span>
</td>
<td class="nump">89,423<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">End of period</a></td>
<td class="nump">162,007<span></span>
</td>
<td class="nump">81,659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental Disclosure of Non-Cash Financing Information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_IssuanceOfConvertiblePreferredStockRelatedToPrivatePlacementUnpaidAmount', window );">Proceeds from stock option exercises received in subsequent period</a></td>
<td class="nump">157<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_DeferredOfferingCostsAllocatedAmountOfProceedsOfIssuanceOfCommonStock', window );">Allocation of deferred offering costs against proceeds of issuance of common stock</a></td>
<td class="nump">345<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_DeferredOfferingCostsUnpaidAmount', window );">Unpaid deferred offering costs in connection with shelf registration</a></td>
<td class="nump">301<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of Series B non-voting convertible preferred stock into common stock</a></td>
<td class="nump">$ 9,395<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_DeferredOfferingCostsAllocatedAmountOfProceedsOfIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Offering Costs, Allocated Amount of Proceeds of Issuance of Common Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_DeferredOfferingCostsAllocatedAmountOfProceedsOfIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_DeferredOfferingCostsUnpaidAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Offering Costs, Unpaid Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_DeferredOfferingCostsUnpaidAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_InterestProceedsDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest Proceeds, Debt Securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_InterestProceedsDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_IssuanceOfConvertiblePreferredStockRelatedToPrivatePlacementUnpaidAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of Convertible Preferred Stock Related to Private Placement, Unpaid Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_IssuanceOfConvertiblePreferredStockRelatedToPrivatePlacementUnpaidAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_PaymentForDeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment For Deferred Offering Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_PaymentForDeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_PaymentsRelatedToContingentValueRightsLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments Related To Contingent Value Rights Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_PaymentsRelatedToContingentValueRightsLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_ProceedsFromIssuanceOfCommonStockAtTheMarketOfferingsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Issuance of Common Stock, At-The-Market Offerings, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_ProceedsFromIssuanceOfCommonStockAtTheMarketOfferingsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">The Company and Basis of Presentation</a></td>
<td class="text">The Company and Basis of Presentation<div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Spyre Therapeutics, Inc., formerly Aeglea BioTherapeutics, Inc. (&#8220;Spyre&#8221; or the &#8220;Company&#8221;), is a clinical stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients. The Company was formed as a Limited Liability Company in Delaware on December 16, 2013 under the name Aeglea BioTherapeutics Holdings, LLC and was converted from a Delaware LLC to a Delaware corporation on March 10, 2015. On June 22, 2023, the Company acquired the assets of Spyre Therapeutics, Inc., a privately held biotechnology company (the &#8220;Asset Acquisition&#8221;), and on November 27, 2023, the Company completed its corporate rebranding, changing the name of the Company to Spyre Therapeutics, Inc. The Company operates in one segment and has its principal offices in Waltham, Massachusetts.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Asset Acquisition, a non-transferable contingent value right (&#8220;CVR&#8221;) was distributed to stockholders of record of the Company as of the close of business on July 3, 2023 (the &#8220;Legacy Stockholders&#8221;). Holders of the CVRs will be entitled to receive certain cash payments from proceeds received by the Company prior to the third anniversary of the contingent value rights agreement (the "CVR Agreement") we entered into with Equiniti Trust Company LLC (f/k/a American Stock Transfer &amp; Trust Company LLC) as rights agent in connection with the Asset Acquisition, if any, related to the disposition or monetization of its legacy assets during the one-year period following the closing of the Asset Acquisition.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 6, 2024, the Company entered into a sales agreement (the &#8220;2024 Sales Agreement&#8221;) with TD Securities (USA) LLC as its agent, pursuant to which the Company may issue and sell up to $200.0&#160;million of shares of common stock under an at-the-market (&#8220;ATM&#8221;) offering program. During the three and six months ended June&#160;30, 2026, the Company sold an aggregate of nil and 296,396, respectively, shares of common stock under the ATM offering program pursuant to the 2024 Sales Agreement resulting in net proceeds of $9.7&#160;million. The 2024 Sales Agreement was terminated on June 26, 2026 and the Company concurrently entered into a new sales agreement (the &#8220;2026 Sales Agreement&#8221;) with TD Securities (USA) LLC as its agent, pursuant to which the Company may issue and sell up to $500.0&#160;million of shares of common stock under an ATM offering program. During the three months ended June 30, 2026, the Company did not sell any shares under the ATM offering program pursuant to the 2026 Sales Agreement. As of June&#160;30, 2026, $500.0&#160;million remained available for sale under the 2026 Sales Agreement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 13, 2025, the Company entered into an underwriting agreement (the &#8220;October 2025 Underwriting Agreement&#8221;), pursuant to which the Company sold an aggregate of 17,094,594 shares of its common stock, inclusive of 2,229,729 shares pursuant to the full exercise of the underwriters' over-allotment option, at a public offering price per share of $18.50, resulting in net proceeds of approximately $296.4&#160;million after deducting approximately $19.9&#160;million of underwriting discounts and other offering costs (the &#8220;October 2025 Offering&#8221;). The over-allotment option was exercised in full on October 14, 2025 and the transaction closed on October 15, 2025.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 13, 2026, the Company entered into an underwriting agreement (the &#8220;April 2026 Underwriting Agreement&#8221;), pursuant to which the Company sold an aggregate of 7,475,000 shares of its common stock, inclusive of 975,000 shares pursuant to the full exercise of the underwriters' over-allotment option, at a public offering price per share of $62.00, resulting in net proceeds of approximately $435.2&#160;million after deducting approximately $28.2&#160;million of underwriting discounts and other offering costs (the &#8220;April 2026 Offering&#8221;). The over-allotment option was exercised in full on April 15, 2026 and the transaction closed on April 16, 2026.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a clinical stage biotechnology company with a limited operating history, and due to its significant research and development expenditures, the Company has generated operating losses since its inception and has not generated any revenue from the commercial sale of any products. There can be no assurance that profitable operations will ever be achieved, and, if achieved, whether profitability can be sustained on a continuing basis.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its inception and through June&#160;30, 2026, the Company has funded its operations by raising an aggregate of approximately $2.1&#160;billion of gross proceeds from the sale and issuance of convertible preferred stock and common stock, pre-funded warrants, the collection of grant proceeds, and the licensing of its product rights for commercialization of pegzilarginase in Europe and certain countries in the Middle East. As of June&#160;30, 2026, Spyre had an accumulated deficit of $1.2&#160;billion, and cash, cash equivalents, and marketable securities of $1.1&#160;billion.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on its current operating plans, the Company has sufficient resources to fund operations for at least one year from the issuance date of these financial statements with existing cash, cash equivalents, and marketable securities. The Company will need to secure additional financing in the future to fund additional research and development, and before a commercial drug can be produced, marketed and sold. If the Company is unable to obtain additional financing or generate license or product revenue, the lack of liquidity could have a material adverse effect on the Company.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (&#8220;U.S. GAAP&#8221;) as defined by the Financial Accounting Standards Board (&#8220;FASB&#8221;) and include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Financial Information</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interim condensed consolidated financial statements included in this Quarterly Report on Form 10-Q are unaudited. The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and reflect, in the opinion of management, all adjustments of a normal and recurring nature that are necessary for a fair statement of the Company&#8217;s financial position as of June&#160;30, 2026, and its results of operations for the three and six months ended June&#160;30, 2026 and 2025, changes in convertible preferred stock and stockholders&#8217; equity for the three and six months ended June&#160;30, 2026 and 2025, and cash flows for the six months ended June&#160;30, 2026 and 2025. The results of operations for the three and six months ended June&#160;30, 2026 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2026 or for any other future annual or interim period. The December&#160;31, 2025 balance sheet was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP for complete financial statements. These financial statements should be read in conjunction with the audited financial statements included in the Company&#8217;s Form 10-K for the year ended December&#160;31, 2025 (the &#8220;Annual Report&#8221;) as filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) on February 19, 2026.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.4-03(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480922/205-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481034/205-10-S45-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These interim condensed consolidated financial statements have been prepared in accordance with U.S. GAAP and SEC instructions for interim financial information, and should be read in conjunction with the Annual Report. Significant accounting policies and other disclosures normally provided have been omitted since such items are disclosed in the Annual Report. The Company uses the same accounting policies in preparing quarterly and annual financial statements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes from the significant accounting policies and estimates disclosed in the Notes titled &#8220;1. The Company and Basis of Presentation&#8221; and "2. Summary of Significant Accounting Policies&#8221; of the Annual Report, except as disclosed below:</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Value Rights</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2026, Contingent Value Rights are no longer a significant accounting policy. The Company determined that its future payment obligations under the CVR Agreement no longer qualify as derivatives under ASC 815, Derivatives and Hedging, as all contingencies have been resolved. Accordingly, the Company has measured the fair value of its CVR liability by discounting the estimated future payments to be made under the CVR Agreement using the Company&#8217;s weighted average cost of capital. This fair value measurement is based on inputs observable in the market and thus represents a Level 2 measurement as defined in ASC 820, Fair Value Measurement. The estimated value of the CVR consideration is based upon </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">available information and certain assumptions which the Company's management believes are reasonable under the circumstances. The ultimate payout under the CVRs may differ materially from the assumptions used in determining the fair value of the CVR consideration.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no recent accounting pronouncements or changes in accounting pronouncements adopted during the three months ended June&#160;30, 2026 that are of significance or potential significance to the Company.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Not Yet Adopted Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued Accounting Standards Update 2024-03 (&#8220;ASU 2024-03&#8221;) Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses to require more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation, amortization, and depletion) included in certain expense captions presented on the face of the income statement. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either (1) prospectively to financial statements issued for reporting periods after the effective date of this ASU 2024-03 or (2) retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact ASU 2024-03 will have on its disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures and reports certain financial instruments as assets and liabilities at fair value on a recurring basis. The following tables set forth the fair value of the Company&#8217;s financial assets and liabilities at fair value on a recurring basis based on the three-tier fair value hierarchy (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2026</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">139,330&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">139,330&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 15.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">256,457&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">256,457&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 15.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">176,095&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">176,095&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 15.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">425,578&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">425,578&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 15.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">146,141&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">146,141&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total financial assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">395,787&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">747,814&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,143,601&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 12.37pt;text-align:left;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CVR liability</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38,620&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38,620&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38,620&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38,620&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74,004&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74,004&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">266,064&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">266,064&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119,590&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119,590&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 15.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">194,355&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">194,355&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 15.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100,790&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100,790&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total financial assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">340,068&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">414,735&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">754,803&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CVR liability</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,680&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,680&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,680&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,680&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the fair value of money market funds and U.S. government treasury securities on quoted prices in active markets for identical assets or liabilities. The Level 2 assets include U.S. government agency securities, commercial paper and corporate bonds, and are valued based on quoted prices for similar assets in active markets and inputs other than quoted prices that are derived from observable market data. The Company evaluates transfers between levels at the end of each reporting period. There were no financial asset transfers between Level 1, Level 2, or Level 3 during the periods presented.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CVR Liability </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Asset Acquisition, a non-transferable CVR was distributed to the Legacy Stockholders. Holders of the CVR are entitled to receive certain cash payments from proceeds received by the Company for a three-year period ending July 3, 2026, related to the disposition or monetization of the Company&#8217;s legacy assets for a period of one year following the closing of the Asset Acquisition.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2025, the fair value of the CVR liability was determined using the probability weighted discounted cash flow method to estimate future cash flows associated with the sale of the legacy assets. Analogous to a dividend being declared/approved in one period and paid out in another, the liability was recorded at the date of approval, June 22, 2023, as a common stock dividend, returning capital to the Legacy Stockholders. Changes in fair value of the liability were recognized as a component of Other income (expense), net in the consolidated statement of operations and comprehensive loss in each reporting period. The liability value was based on significant inputs not observable in the market such as estimated cash flows, estimated probabilities of regulatory success, and discount rates, which represent a Level 3 measurement within the fair value hierarchy.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2026, all contingencies related to the disposition or monetization of the Company&#8217;s legacy assets are resolved and the fair value of the CVR liability was determined by discounting future estimated payments to holders of the CVR. Changes in fair value of the liability will be recognized as a component of Other income (expense), net in the consolidated statement of operations and comprehensive loss in each reporting period. The liability is based on inputs observable in the market such as estimated discount rates which represent a Level 2 measurement within the fair value hierarchy.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The significant inputs used to estimate the fair value of the CVR liability were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2026</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-adjusted discount rate</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.10%</span></div></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in fair value between December&#160;31, 2025 and June&#160;30, 2026 was a $34.9&#160;million increase, primarily driven by the achievement status of certain milestones and the receipt of certain cash consideration within the CVR term and time value of money adjustments, partially offset by a $22.9&#160;million payment to CVR holders. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents changes in the CVR liability for the periods presented (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">CVR Liability</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning balance as of December 31, 2025</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,680&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of the CVR liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34,873&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(22,933)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ending Balance as of June 30, 2026</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38,620&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Cash Equivalents and Marketable Securities</a></td>
<td class="text">Cash Equivalents and Marketable Securities<div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the estimated fair value of the Company&#8217;s cash equivalents and marketable securities and the gross unrealized gains and losses (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2026</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gains</span></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Losses</span></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">139,330&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">139,330&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 15.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,932&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,932&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash equivalents</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">160,262&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">160,262&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">405,173&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(527)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">404,646&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">146,423&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(283)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">146,141&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">257,111&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(741)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">256,457&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.68pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">177,028&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(935)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">176,095&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">985,735&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,486)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">983,339&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gains</span></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Losses </span></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74,004&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74,004&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,987&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,987&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash equivalents</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83,991&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83,991&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">184,423&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(80)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">184,368&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100,753&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(23)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100,790&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">265,316&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">748&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">266,064&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.68pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119,450&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">153&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119,590&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">669,942&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">986&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(116)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">670,812&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the available-for-sale securities in an unrealized loss position for which an allowance for credit losses has not been recorded as of June&#160;30, 2026 and December&#160;31, 2025, aggregated by major security type and length of time in a continuous unrealized loss position:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.506%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.964%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2026</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Less Than 12 Months</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">12 Months or Longer</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Losses </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Losses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Losses </span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">421,580&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(527)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">421,580&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(527)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">144,148&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(283)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">144,148&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(283)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">164,843&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(741)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">164,843&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(741)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">173,125&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(935)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">173,125&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(935)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total marketable securities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">903,696&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,486)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">903,696&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,486)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Less Than 12 Months</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">12 Months or Longer</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Losses </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Losses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Losses </span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99,837&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(80)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99,837&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(80)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58,296&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(23)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58,296&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(23)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,828&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,828&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">180,961&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(116)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">180,961&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(116)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated its securities for credit losses and considered the decline in market value to be primarily attributable to current economic and market conditions and not to a credit loss or other factors. Additionally, the Company does not intend to sell the securities in an unrealized loss position and does not expect it will be required to sell the securities before recovery of the unamortized cost basis. As of June&#160;30, 2026 and December&#160;31, 2025, an allowance for credit losses had not been recognized. Given the Company's intent and ability to hold such securities until recovery, and the lack of significant change in credit risk of these investments, the Company does not consider these marketable securities to be impaired as of June&#160;30, 2026 and December&#160;31, 2025. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial instruments that potentially subject the Company to a concentration of credit risk consist principally of cash deposits. Accounts at each of the Company's two U.S. banking institutions are insured by the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) up to $250,000 per depositor. As of June&#160;30, 2026 and December&#160;31, 2025, cash deposits at the Company's U.S. banking institutions exceeded the FDIC limits.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no realized gains or losses on marketable securities for both the three and six months ended June&#160;30, 2026 and 2025. Interest on marketable securities is included in interest income. Accrued interest receivable on available-for-sale debt securities as of June&#160;30, 2026 and December&#160;31, 2025, was $5.8 million and $4.5 million, respectively, and is reflected in Prepaid expenses and other current assets.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the contractual maturities of the Company&#8217;s marketable securities at estimated fair value (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due in one year or less</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">703,969&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">440,895&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due in 1 - 2 years</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">279,370&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">229,917&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">983,339&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">670,812&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may sell investments at any time for use in current operations even if they have not yet reached maturity. As a result, the Company classifies marketable securities, including securities with maturities beyond twelve months as current assets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalent, and debt and equity securities, including realized and unrealized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_AccruedAndOtherCurrentLiabilitiesTextBlock', window );">Accrued and Other Current Liabilities</a></td>
<td class="text">Accrued and Other Current Liabilities <div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued and other current liabilities consist of the following (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2025</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,722&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,940&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued contracted research and development costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,952&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,424&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued professional and consulting fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,375&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,404&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued other</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">135&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">179&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total accrued and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,184&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,947&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_AccruedAndOtherCurrentLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_AccruedAndOtherCurrentLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Licensing Agreements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_LicensingAgreementsAbstract', window );"><strong>Licensing Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Licensing Agreements</a></td>
<td class="text">Licensing Agreements<div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 12, 2023, December 14, 2023, and June 5, 2024, the Company exercised the Option (as defined below) available under the antibody discovery and option agreement, dated May 25, 2023, and subsequently amended and restated on September 29, 2023 and May 14, 2024, by and among the Company, Paragon Therapeutics, Inc. (&#8220;Paragon&#8221;) and Parapyre Holding LLC (&#8220;Parapyre&#8221;) (as amended, the &#8220;Paragon Agreement&#8221;) with respect to the SPY001, SPY002 and SPY072, and SPY003 research programs, respectively. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 14, 2024, the Company and Paragon entered into (i) a license agreement (the &#8220;SPY001 License Agreement&#8221;), pursuant to which Paragon granted the Company a royalty-bearing, world-wide, exclusive license to develop, manufacture, commercialize or otherwise exploit certain antibodies and products targeting &#945;4&#223;7 integrin and (ii) a license agreement (the &#8220;SPY002 and SPY072 License Agreement&#8221;), pursuant to which Paragon granted the Company a royalty-bearing, world-wide, exclusive license to develop, manufacture, commercialize or otherwise exploit certain antibodies and products targeting TL1A, respectively, which includes the Company's SPY002 and SPY072 product candidates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 11, 2024, the Company and Paragon entered into a license agreement (as amended, the &#8220;SPY003 License Agreement&#8221;, and together with the SPY001 License Agreement and the SPY002 and SPY072 License Agreement, the &#8220;License Agreements&#8221;), pursuant to which Paragon granted the Company a royalty-bearing, world-wide, exclusive license to develop, manufacture, commercialize or otherwise exploit certain antibodies and products targeting IL-23 in the field of IBD.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 24, 2025, the SPY003 License Agreement was amended and restated to, among other things, clarify each party's rights and obligations with respect to license exclusivity and patent prosecution. On May 29, 2026, the SPY003 License Agreement was further amended to expand the definition of &#8220;Field&#8221; to encompass all therapeutic, prophylactic, palliative and diagnostic uses of SPY003, subject to certain restrictions (as summarized below).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of each License Agreement, the Company is obligated to pay Paragon up to $22.0 million based on specific development, regulatory and clinical milestones for the first product under each agreement, respectively, that achieves such specified milestones, including a milestone payment of $3.0 million upon the first dosing of a human patient in a Phase 2 trial. In addition, the following summarizes other key terms of each License Agreement:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Paragon will provide the Company with an exclusive license to its patents covering the related antibody, the method of use and its method of manufacture.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Paragon will not conduct any new campaigns that generate anti-&#945;4&#223;7 or anti-TL1A monospecific antibodies in any field or anti-IL-23 monospecific antibodies in the field of IBD, in each case for at least 5 years.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The Company will pay Paragon a low single-digit percentage royalty for single antibody products and a mid single-digit percentage royalty for products containing more than one antibody from Paragon.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">There is a royalty step-down of 1/3rd if there is no Paragon patent in effect during the royalty term.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The royalty term ends on the later of (i) the last-to-expire licensed patent or Company patent directed to the manufacture, use or sale of a licensed antibody in the country at issue or (ii) 12 years from the date of first sale of a Company product. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Each License Agreement may be terminated on 60 days&#8217; notice by the Company; on material breach without cure; and to the extent permitted by law, on a party&#8217;s insolvency or bankruptcy.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">With respect to the SPY002 and SPY072 License Agreement only, on a product by product basis, the Company will pay sublicensing fees of up to approximately $20 million upon the achievement of mostly commercial milestones.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">With respect to the SPY003 License Agreement only, the Company will not dose a human patient in a clinical trial of SPY003 for an indication outside of inflammatory bowel disease as part of a combination until June 1, 2028 or as a monotherapy until June 1, 2030 (the &#8220;Monotherapy Dosing Restriction&#8221;). In the event the Company or a licensee of Paragon's retained rights under the SPY003 License Agreement consummates a material transaction, including a change of control of the Company or such licensee, then any remaining restrictions outside of the initial definition of &#8220;Field&#8221; set forth in the Monotherapy Dosing Restriction shall remain in effect only until June 1, 2028 and thereafter terminate and be of no further force or effect.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the expense associated with each milestone when the achievement of the milestone is deemed probable.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized no expenses related to milestone payments to Paragon for the three months ended June&#160;30, 2026 and 2025. The Company recognized expense related to Paragon license milestone payments, recorded within Research and development expenses, in the accompanying condensed statement of operations of $3.0 million and $2.5 million for the six months ended June&#160;30, 2026 and 2025, respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company paid milestone payments to Paragon totaling nil and $2.5&#160;million for the three months ended June&#160;30, 2026 and 2025, respectively. The Company paid milestone payments to Paragon totaling $3.0&#160;million and $2.5&#160;million for the six months ended June&#160;30, 2026 and 2025, respectively. As of June&#160;30, 2026 and December&#160;31, 2025, there were no milestone payments outstanding and payable to Paragon.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company did not recognize any sublicensing fees expense for the three or six months ended June&#160;30, 2026 or 2025.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no payments related to sublicensing fees for the three months ended June&#160;30, 2026 and 2025. The Company paid sublicensing fees to Paragon totaling no and $0.5&#160;million for the six months ended June&#160;30, 2026 and 2025, respectively. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2026 and December&#160;31, 2025, there were nil sublicensing fees outstanding and payable to Paragon.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_LicensingAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Licensing Agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_LicensingAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">Related Party Transactions<div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Paragon and Parapyre each beneficially own less than 5% of a class of the Company's voting securities through their respective holdings of the Company's common stock. Fairmount Funds Management LLC (&#8220;Fairmount&#8221;) beneficially owns more than 5% of a class of the Company's voting securities, has one seat on the Board (held by Tomas Kiselak) and beneficially owns more than 5% of Paragon. Fairmount appointed Paragon's </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">board of directors and has the contractual right to approve the appointment of any executive officers of Paragon.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is the summary of expenses related to the License Agreements and other Paragon reimbursable expenses, which are ultimately settled in cash (in millions) and recorded within Research and development in the consolidated statement of operations for the periods presented:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.023%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License Agreements milestone and sublicensing fees</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.0&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.5&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Paragon reimbursable expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total related party expense (excludes stock-based compensation)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized de minimis related party expenses in connection with other Paragon reimbursable expenses for the three months ended June&#160;30, 2026 and 2025, which were recorded as Research and development expenses in the consolidated statements of operations. For the six months ended June&#160;30, 2026 and 2025, the Company recognized $0.1 million of Paragon reimbursable expenses. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were de minimis Related party accounts payable as of June 30, 2026 and December 31, 2025.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended June&#160;30, 2026 and 2025, the Company made payments totaling $0.1 million and de minimis payments, respectively, in connection with Paragon reimbursable expenses. For the six months ended June&#160;30, 2026 and 2025, the Company made payments totaling $0.1 million and $0.2 million, respectively, in connection with Paragon reimbursable expenses.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Paragon License Agreements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 6 for disclosures related to the License Agreements entered into with Paragon.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mark McKenna Option Grant</span></div>On February 1, 2024, the Board appointed Mark McKenna as a Class I director. Mr. McKenna and the Company are parties to a consulting agreement, pursuant to which Mr. McKenna agreed to continue to provide consulting services as an independent contractor to the Company, with an effective date of August 1, 2023 (the &#8220;Vesting Commencement Date&#8221;). As compensation for Mr. McKenna&#8217;s consulting services, on November 22, 2023, he was granted non-qualified stock options to purchase 477,000 shares of the Company&#8217;s common stock under the 2016 Plan (as defined in Note 9) with an exercise price of $10.39 per share, which vest as to 25% on the one year anniversary of the Vesting Commencement Date and thereafter vest and become exercisable in 36 equal monthly installments, subject to Mr. McKenna&#8217;s continued service to the Company through each applicable vesting date. The Company recognized stock-based compensation expense related to Mr. McKenna's consulting agreement of $0.2 million for the three months ended June&#160;30, 2026 and 2025, respectively, and $0.5 million for the six months ended June&#160;30, 2026 and 2025, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7)(e)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock and Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockTextBlock', window );">Convertible Preferred Stock and Stockholders' Equity</a></td>
<td class="text">Convertible Preferred Stock and Stockholders&#8217; Equity<div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2026, a total of</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 1,532,591</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> warrants previously issued to Parapyre pursuant to the Paragon Agreement with a weighted-average exercise price of</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $22.49</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> remain outstanding.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Series A Non-Voting Convertible Preferred Stock</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Company's Certificate of Designation of Preferences, Rights and Limitations of the Series A Non-Voting Convertible Preferred Stock (the &#8220;Series A Certificate of Designation&#8221;), holders of Series A Preferred Stock are entitled to receive dividends on shares of Series A Preferred Stock equal to, on an as-if-converted-to-common stock basis, and in the same form as, dividends actually paid on shares of common stock. Except as provided in the Series A Certificate of Designation or as otherwise required by law, the Series A Preferred Stock does not have voting rights. However, as long as any shares of Series A Preferred Stock are outstanding, the Company will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series A Preferred Stock: (a) alter or change adversely the powers, preferences or rights given to the Series A Preferred Stock, or alter or amend the Series A Certificate of Designation, amend or repeal any provision of, or add any provision to, the Company&#8217;s Certificate of Incorporation or its Bylaws, or file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of preferred stock, if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series A Preferred Stock, regardless of whether any of the foregoing actions will be by means of amendment to the Certificate of Incorporation or by merger, consolidation, recapitalization, reclassification, conversion or otherwise, (b) issue further shares of Series A Preferred Stock or increase or decrease (other than by conversion) the number of authorized shares of Series A Preferred Stock, (c) prior to the stockholder approval of the conversion of the Series A Preferred Stock into shares of common stock in accordance with Nasdaq Stock Market Rules or at any time while at least 30% of the originally issued Series A Preferred Stock remains issued and outstanding, consummate (x) any Fundamental Transaction (as defined in the Series A Certificate of Designation) or (y) any merger or consolidation of the Company with or into another entity or any stock sale to, or other business combination in which the Company's stockholders immediately before such transaction do not hold at least a majority of the Company's capital stock immediately after such transaction or (d) enter into any agreement with respect to any of the foregoing. The Series A Preferred Stock does not have a preference upon any liquidation, dissolution or winding-up of the Company. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2026, 346,045 shares of Series A Preferred Stock remained outstanding and are convertible into 13,841,800 common shares.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Series B Non-Voting Convertible Preferred Stock</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Company's Certificate of Designation of Preferences, Rights and Limitations of Series B Non-Voting Convertible Preferred Stock (as amended, the &#8220;Series B Certificate of Designation&#8221;), holders of Series B Preferred Stock are entitled to receive dividends on shares of Series B Preferred Stock equal to, on an as-if-converted-to-common stock basis, and in the same form as, dividends actually paid on shares of common stock. Except as provided in the Series B Certificate of Designation or as otherwise required by law, the Series B Preferred Stock does not have voting rights. However, as long as any shares of Series B Preferred Stock are outstanding, the Company will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series B Preferred Stock, alter or change adversely the powers, preferences or rights given to the Series B Preferred Stock, or alter or amend the Series B Certificate of Designation, amend or repeal any provision of, or add any provision to, the Company&#8217;s Certificate of Incorporation or its Bylaws, or file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of preferred stock, if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series B Preferred Stock, regardless of whether any of the foregoing actions will be by means of amendment to the Certificate of Incorporation or by merger, consolidation, recapitalization, reclassification, conversion or otherwise. The Series B Preferred Stock does not have a preference upon any liquidation, dissolution or winding-up of the Company.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 23, 2026, 16,667 shares of Series B Preferred Stock were converted at the option of the holder into 666,680 shares of common stock. As of June 30, 2026, no shares of Series B Preferred Stock remained outstanding.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ATM Facility</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 6, 2024, the Company entered into the 2024 Sales Agreement, pursuant to which the Company may issue and sell up to $200.0&#160;million of shares of common stock under an ATM offering program. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2025, the Company sold an aggregate of 445,668 shares of common stock under its ATM offering program pursuant to the 2024 Sales Agreement resulting in net proceeds of $14.8&#160;million.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2026, the Company sold an aggregate of 296,396 shares of common stock under the ATM offering program pursuant to the 2024 Sales Agreement resulting in net proceeds of $9.7&#160;million. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Sales Agreement was terminated on June 26, 2026 and the Company concurrently entered into a new sales agreement (the &#8220;2026 Sales Agreement&#8221;) with TD Securities (USA) LLC as its agent, pursuant to which the Company may issue and sell up to $500.0&#160;million of shares of common stock under an ATM offering program. During the three months ended June 30, 2026, the Company did not sell any shares under the ATM offering program pursuant to the 2026 Sales Agreement. As of June&#160;30, 2026, $500.0&#160;million remained available for sale under the 2026 Sales Agreement. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">October 2025 Underwritten Offering</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 13, 2025, the Company entered into the October 2025 Underwriting Agreement, pursuant to which the Company sold an aggregate of 17,094,594 shares of common stock, inclusive of 2,229,729 shares pursuant to the full exercise of the underwriters&#8217; over-allotment option, at a public offering price per share of $18.50, resulting in net proceeds of approximately $296.4&#160;million after deducting approximately $19.9&#160;million of underwriting discounts and other offering costs. The over-allotment option was exercised in full on October 14, 2025 and the transaction closed on October 15, 2025.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">April 2026 Underwritten Offering</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 13, 2026, the Company entered into the April 2026 Underwriting Agreement, pursuant to which the Company sold an aggregate of 7,475,000 shares of its common stock, inclusive of 975,000 shares pursuant to the full exercise of the underwriters' over-allotment option, at a public offering price per share of $62.00, resulting in net proceeds of approximately $435.2&#160;million after deducting approximately $28.2&#160;million of underwriting discounts and other offering costs. The over-allotment option was exercised in full on April 15, 2026 and the transaction closed on April 16, 2026.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-13<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2016 Equity Incentive Plan</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's 2016 Equity Incentive Plan (the &#8220;2016 Plan&#8221;) became effective in April 2016 and serves as the successor to the Company&#8217;s 2015 Equity Incentive Plan. Under the 2016 Plan, the Company may grant stock options, stock appreciation rights, restricted stock awards, restricted stock units, performance awards, and stock bonuses. The 2016 Plan, as amended, provides for an automatic increase in the number of shares reserved for issuance thereunder on January 1 of each year for the remaining term of the plan equal to (a) 5.0% of the number of issued and outstanding shares of common stock </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(including such shares issuable pursuant to the exercise or conversion, as applicable, of any outstanding pre-funded warrants and nonvoting convertible preferred stock) on December 31 of the immediately preceding year, or (b) a lesser amount as approved by the board each year (the &#8220;Evergreen Provision&#8221;). As a result of the Evergreen Provision, on January 1, 2026 and </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025, an additional 4,711,544 and 3,814,905 shares, respectively, became available for issuance under the 2016 Plan.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2026, the 2016 Plan had 15,084,463 shares available for future issuance, of which 6,876,693 shares were subject to outstanding option awards and restricted unit awards.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 Equity Inducement Plan</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2018 Equity Inducement Plan (&#8220;2018 Plan&#8221;) became effective in February 2018.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2025, the Company amended the 2018 Plan to increase the number of shares of common stock reserved for issuance by 750,000. After this amendment and as of June&#160;30, 2026, the 2018 Plan had 6,481,956 shares available for future issuance, of which 5,981,072 shares were subject to outstanding option awards and restricted unit awards.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service-based awards granted under the 2018 Plan and 2016 Plan generally vest over four years and expire after ten years, although awards have been granted with vesting terms less than four years. Under the 2016 Plan and 2018 Plan, the Company may grant stock-based awards with service conditions, performance conditions, and market conditions. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s stock awards granted under all equity incentive and inducement plans for each of the periods indicated:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.676%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.026%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.026%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.218%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.218%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.218%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.616%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Grants</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Grant Date Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Grants</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Grant Date Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Grants</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Grant Date Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Grants</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">190,456</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62.94&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">427,800</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.29&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,769,061</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33.19&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,325,717</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20.32&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125,400</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30.61&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2016 Employee Stock Purchase Plan</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Company&#8217;s Amended and Restated 2016 Employee Stock Purchase Plan (&#8220;2016 ESPP&#8221;), the Company issued and sold 19,967 shares of the Company&#8217;s common stock during the three and six months ended June&#160;30, 2026, resulting in aggregate cash proceeds of $0.5&#160;million.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no shares issued and sold during the three months ended June&#160;30, 2025. The Company issued and sold 16,877 shares during the six months ended June&#160;30, 2025, resulting in aggregate cash proceeds of $0.3&#160;million. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based Compensation Expense</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation expense recognized from the Company&#8217;s equity incentive plans, 2018 Plan and 2016 ESPP during the periods presented was as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.869%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.839%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></div></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,218&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,100&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,009&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,612&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,294&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,278&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,309&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,625&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation expense</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,512&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,378&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,318&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,237&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the weighted-average Black-Scholes option pricing model assumptions used to estimate the fair value of stock options granted under the Company's equity incentive plans, and the shares purchased under the 2016 ESPP during the periods presented: </span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.545%"><tr><td style="width:1.0%"></td><td style="width:44.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.145%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock Options Granted</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.93</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.74</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.02</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.97</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.16%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.02%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.88%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.38%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 5.37pt;text-align:left;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2016 ESPP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.50</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.50</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.59%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.23%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sale of Pegzilarginase to Immedica<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Sale of Pegzilarginase to Immedica</a></td>
<td class="text">Sale of Pegzilarginase to Immedica<div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 27, 2023, the Company announced that it had entered into an agreement to sell the global rights to pegzilarginase to Immedica Pharma AB (&#8220;Immedica&#8221;) for $15.0&#160;million in upfront cash proceeds and up to $100.0&#160;million in contingent milestone payments.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The milestone payments are contingent on formal reimbursement decisions by national authorities in key European markets and pegzilarginase approval by the U.S. Food and Drug Administration (&#8220;FDA&#8221;), among other events. In the three months ended June 30, 2026, the Company recognized a gain of $40.0 million within Gain on Sale of in-process research and development, for achieving certain milestones during the period. As of June&#160;30, 2026 and December 31, 2025, $3.0 million remains outstanding and due to the Company from a previously achieved milestone, which is reflected in Prepaid expenses and other current assets. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestone payments received by the Company by July 3, 2026, net of allowable expenses and adjustments, will be distributed to CVR holders pursuant to the CVR agreement resulting from the Asset Acquisition and will reduce the CVR liability.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-3A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-4B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-4A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting</a></td>
<td class="text">Segment Reporting<div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates under a single operating and reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and rheumatic diseases. The Company's Chief Operating Decision Maker (&#8220;CODM&#8221;) is the Company's Chief Executive Officer. The CODM uses consolidated Net loss as the measure of segment profit or loss and uses consolidated Total Assets as reported on the balance sheet as the measure of segment assets. The CODM compares Net loss against budgeted and/or forecasted amounts to track the Company's financial performance against expectations and to inform, along with development timelines and scientific and commercial considerations, their decisions regarding resource allocations to fund the Company's development of its pipeline. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the significant expenses provided to the CODM on a regular basis (in thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.860%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Compensation</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12,862&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,120&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">24,305&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,111&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Stock-based compensation </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,512&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,378&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26,318&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18,237&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development, excluding compensation and stock-based compensation </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2) (3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">50,447&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">30,749&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">97,340&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">64,300&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other segment items</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> (4) (5)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(40,621)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(11,530)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(42,758)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(16,158)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Segment net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">36,200&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">36,717&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">105,205&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">81,490&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Includes related party expenses of $0.2 million for the three months ended June&#160;30, 2026 and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025, and</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $0.5 million for the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">six months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2026 and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Includes non-clinical study, clinical trial, and manufacturing expenses. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Includes de minimis related party expenses for the three months ended June 30, 2026 and 2025. Includes related party expenses of $3.1 million and $2.6 million for the six months ended June 30, 2026 and 2025, respectively. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Includes general and administrative expenses such as audit, legal, and other professional fees, interest income, and other expense, net. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Includes gains of $40.0 million and $10.0 million for the three months ended June 30, 2026 and 2025, respectively, related to the achievement of milestones under the 2023 sale of the global rights to the legacy assets, pegzilarginase, to Immedica. The 2026 gain was triggered by the sale of the related priority review voucher (&#8220;PRV&#8221;), while the 2025 gain was triggered by a favorable reimbursement decision for pegzilarginase in Europe.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Includes gains of $70.0 million and $10.0 million for the six months ended June 30, 2026 and 2025, respectively, related to milestone payments earned in connection with the 2023 sale of the global rights to the legacy assets, pegzilarginase, to Immedica. The 2026 gain was triggered by the FDA approval of pegzilarginase and the subsequent sale of the related PRV, while the 2025 gain was triggered by a favorable reimbursement decision for pegzilarginase in Europe.</span></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Includes a $4.6&#160;million increase and a $0.6&#160;million decrease in the fair value of the CVR liability for the three months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2026</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2025, respectively. Includes a $34.9&#160;million increase and a $1.8&#160;million decrease in the fair value of the CVR liability for the six months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2026</span> and 2025, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 22: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per Share<div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company computes net loss per share of common stock, Series A Preferred Stock, and Series B Preferred Stock using the two-class method required for multiple classes of common stock and other participating securities.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The two-class method is an earnings (loss) allocation method under which earnings (loss) per share is calculated for each class of common stock. The Company has determined that the Series A Preferred Stock and Series B Preferred Stock do not have preferential rights when compared to the Company's common stock and therefore it must allocate losses to these other classes of common stock, as illustrated in the table below.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per share is computed by dividing the net loss by the weighted-average number of shares outstanding during the period, without consideration of potential dilutive securities. For periods in which the Company generated a net loss, the Company does not include potential shares of common stock in diluted net loss per share when the impact of these items is anti-dilutive. The Company has generated a net loss for all periods presented, therefore diluted net loss per share is the same as basic net loss per share since the inclusion of potential shares of common stock would be anti-dilutive.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted net loss per share of common stock, Series A Preferred Stock, and Series B Preferred Stock (in thousands, except share and per share amounts):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.449%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="15" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="15" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Series A Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Series B Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Common<br/>Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Series A Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Series B Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Common<br/>Stock</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net loss per share, basic and diluted:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numerator</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Allocation of losses</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5,052)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(225)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(30,923)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6,791)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(327)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(29,599)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Denominator</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Weighted-average shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">346,045</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15,385</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">84,729,435</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">346,045&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">16,667&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">60,333,838</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net loss per share, basic and diluted</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(14.60)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(14.60)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(0.36)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(19.62)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(19.62)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(0.49)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="33" style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="15" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="15" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Series A Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Series B Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Common<br/>Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Series A Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Series B Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Common<br/>Stock</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net loss per share, basic and diluted:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numerator</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Allocation of losses</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(15,147)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(701)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(89,357)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(15,078)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(726)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(65,686)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Denominator</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Weighted-average shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">346,045</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">16,022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">81,656,119</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">346,045&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">16,667&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">60,300,073</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net loss per share, basic and diluted</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(43.77)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(43.77)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1.09)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(43.57)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(43.57)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1.09)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following weighted-average equity instruments were excluded from the calculation of diluted net loss per share because their effect would have been anti-dilutive for the periods presented:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.303%"><tr><td style="width:1.0%"></td><td style="width:41.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.731%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.435%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.731%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.435%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.731%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.435%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.736%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options to purchase common stock</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,042,158</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">805,306</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,630,827</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,324,645</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">137,358</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113,115</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,943</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding Parapyre warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,532,591</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,532,591</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481468/505-20-05-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2026 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=syre_HeidyKingJonesMember', window );">Heidy King-Jones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 16, 2026, Heidy King-Jones, our Chief Legal Officer and Corporate Secretary, adopted a trading plan intended to satisfy Rule 10b5-1(c) to sell up to 76,000 shares of our common stock over a period ending April 5, 2028, subject to certain conditions, all of which are to be acquired upon the exercise of employee stock options.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Heidy King-Jones<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief Legal Officer and Corporate Secretary<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">April 16, 2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">April 5, 2028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">720 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">76,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=syre_JeffreyAlbersMember', window );">Jeffrey Albers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 16, 2026, Jeffrey Albers, one of our directors, and Sessions LLC, an investment company of which Mr. Albers is a managing director and owns 10% or more of the equity interest in or otherwise exercises significant influence over, adopted a trading plan intended to satisfy Rule 10b5-1(c) to sell up to 23,000 shares of our common stock over a period ending July 31, 2027, subject to certain conditions, 5,000 of which  are to be acquired upon the exercise of director stock options.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Jeffrey Albers<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">directors<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">April 16, 2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">July 31, 2027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">461 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">23,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrAxis=syre_JeffreyAlbersRuleTradingArrangementDirectorStockOptionsMember', window );">Jeffrey Albers Rule Trading Arrangement, Director Stock Options [Member] | Jeffrey Albers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">5,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrSecuritiesAggAvailAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrSecuritiesAggAvailAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=syre_HeidyKingJonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=syre_HeidyKingJonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=syre_JeffreyAlbersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=syre_JeffreyAlbersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrAxis=syre_JeffreyAlbersRuleTradingArrangementDirectorStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrAxis=syre_JeffreyAlbersRuleTradingArrangementDirectorStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (&#8220;U.S. GAAP&#8221;) as defined by the Financial Accounting Standards Board (&#8220;FASB&#8221;) and include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Contingent Value Rights</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Value Rights</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2026, Contingent Value Rights are no longer a significant accounting policy. The Company determined that its future payment obligations under the CVR Agreement no longer qualify as derivatives under ASC 815, Derivatives and Hedging, as all contingencies have been resolved. Accordingly, the Company has measured the fair value of its CVR liability by discounting the estimated future payments to be made under the CVR Agreement using the Company&#8217;s weighted average cost of capital. This fair value measurement is based on inputs observable in the market and thus represents a Level 2 measurement as defined in ASC 820, Fair Value Measurement. The estimated value of the CVR consideration is based upon </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">available information and certain assumptions which the Company's management believes are reasonable under the circumstances. The ultimate payout under the CVRs may differ materially from the assumptions used in determining the fair value of the CVR consideration.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements and Not Yet Adopted Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no recent accounting pronouncements or changes in accounting pronouncements adopted during the three months ended June&#160;30, 2026 that are of significance or potential significance to the Company.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Not Yet Adopted Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued Accounting Standards Update 2024-03 (&#8220;ASU 2024-03&#8221;) Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses to require more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation, amortization, and depletion) included in certain expense captions presented on the face of the income statement. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either (1) prospectively to financial statements issued for reporting periods after the effective date of this ASU 2024-03 or (2) retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact ASU 2024-03 will have on its disclosures.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company computes net loss per share of common stock, Series A Preferred Stock, and Series B Preferred Stock using the two-class method required for multiple classes of common stock and other participating securities.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The two-class method is an earnings (loss) allocation method under which earnings (loss) per share is calculated for each class of common stock. The Company has determined that the Series A Preferred Stock and Series B Preferred Stock do not have preferential rights when compared to the Company's common stock and therefore it must allocate losses to these other classes of common stock, as illustrated in the table below.</span></div>Basic and diluted net loss per share is computed by dividing the net loss by the weighted-average number of shares outstanding during the period, without consideration of potential dilutive securities. For periods in which the Company generated a net loss, the Company does not include potential shares of common stock in diluted net loss per share when the impact of these items is anti-dilutive. The Company has generated a net loss for all periods presented, therefore diluted net loss per share is the same as basic net loss per share since the inclusion of potential shares of common stock would be anti-dilutive.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 450<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477850/954-450-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis</a></td>
<td class="text">The following tables set forth the fair value of the Company&#8217;s financial assets and liabilities at fair value on a recurring basis based on the three-tier fair value hierarchy (in thousands):<div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2026</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">139,330&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">139,330&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 15.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">256,457&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">256,457&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 15.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">176,095&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">176,095&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 15.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">425,578&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">425,578&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 15.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">146,141&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">146,141&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total financial assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">395,787&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">747,814&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,143,601&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 12.37pt;text-align:left;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CVR liability</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38,620&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38,620&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38,620&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38,620&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74,004&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74,004&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">266,064&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">266,064&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119,590&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119,590&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 15.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">194,355&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">194,355&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 15.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100,790&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100,790&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total financial assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">340,068&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">414,735&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">754,803&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CVR liability</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,680&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,680&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,680&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,680&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Significant Inputs Used to Estimate the Fair Value of CVR Liability</a></td>
<td class="text">The significant inputs used to estimate the fair value of the CVR liability were as follows:<div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2026</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-adjusted discount rate</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.10%</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Changes in CVR Liability</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents changes in the CVR liability for the periods presented (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">CVR Liability</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning balance as of December 31, 2025</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,680&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of the CVR liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34,873&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(22,933)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ending Balance as of June 30, 2026</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38,620&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Schedule of Estimated Fair Value of Cash Equivalents and Marketable Securities and Gross Unrealized Gains and Losses</a></td>
<td class="text"><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the estimated fair value of the Company&#8217;s cash equivalents and marketable securities and the gross unrealized gains and losses (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2026</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gains</span></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Losses</span></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">139,330&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">139,330&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 15.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,932&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,932&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash equivalents</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">160,262&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">160,262&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">405,173&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(527)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">404,646&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">146,423&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(283)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">146,141&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">257,111&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(741)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">256,457&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.68pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">177,028&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(935)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">176,095&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">985,735&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,486)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">983,339&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gains</span></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Losses </span></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74,004&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74,004&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,987&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,987&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash equivalents</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83,991&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83,991&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">184,423&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(80)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">184,368&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100,753&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(23)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100,790&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">265,316&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">748&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">266,064&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.68pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119,450&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">153&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119,590&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">669,942&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">986&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(116)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">670,812&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Schedule of Available-for-Sale Securities in an Unrealized Loss Position</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the available-for-sale securities in an unrealized loss position for which an allowance for credit losses has not been recorded as of June&#160;30, 2026 and December&#160;31, 2025, aggregated by major security type and length of time in a continuous unrealized loss position:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.506%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.964%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2026</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Less Than 12 Months</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">12 Months or Longer</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Losses </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Losses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Losses </span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">421,580&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(527)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">421,580&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(527)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">144,148&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(283)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">144,148&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(283)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">164,843&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(741)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">164,843&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(741)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">173,125&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(935)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">173,125&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(935)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total marketable securities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">903,696&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,486)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">903,696&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,486)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Less Than 12 Months</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">12 Months or Longer</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Losses </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Losses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Losses </span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99,837&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(80)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99,837&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(80)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58,296&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(23)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58,296&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(23)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,828&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,828&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">180,961&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(116)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">180,961&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(116)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Schedule of Contractual Maturities of Marketable Securities at Estimated Fair Value</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the contractual maturities of the Company&#8217;s marketable securities at estimated fair value (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due in one year or less</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">703,969&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">440,895&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due in 1 - 2 years</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">279,370&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">229,917&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">983,339&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">670,812&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash, cash equivalent, and investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued and Other Current Liabilities</a></td>
<td class="text"><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued and other current liabilities consist of the following (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2025</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,722&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,940&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued contracted research and development costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,952&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,424&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued professional and consulting fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,375&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,404&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued other</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">135&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">179&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total accrued and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,184&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,947&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of Expenses Related to Related Party Which are Settled in Cash</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is the summary of expenses related to the License Agreements and other Paragon reimbursable expenses, which are ultimately settled in cash (in millions) and recorded within Research and development in the consolidated statement of operations for the periods presented:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.023%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License Agreements milestone and sublicensing fees</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.0&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.5&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Paragon reimbursable expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total related party expense (excludes stock-based compensation)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock', window );">Schedule of Stock Awards Granted Under all Equity Incentive and Inducement Plans</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s stock awards granted under all equity incentive and inducement plans for each of the periods indicated:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.676%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.026%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.026%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.218%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.218%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.218%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.616%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Grants</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Grant Date Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Grants</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Grant Date Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Grants</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Grant Date Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Grants</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">190,456</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62.94&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">427,800</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.29&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,769,061</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33.19&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,325,717</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20.32&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125,400</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30.61&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation expense recognized from the Company&#8217;s equity incentive plans, 2018 Plan and 2016 ESPP during the periods presented was as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.869%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.839%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></div></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,218&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,100&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,009&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,612&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,294&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,278&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,309&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,625&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation expense</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,512&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,378&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,318&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,237&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Weighted-Average Assumptions Used in Calculating Fair Value of Awards</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the weighted-average Black-Scholes option pricing model assumptions used to estimate the fair value of stock options granted under the Company's equity incentive plans, and the shares purchased under the 2016 ESPP during the periods presented: </span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.545%"><tr><td style="width:1.0%"></td><td style="width:44.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.145%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock Options Granted</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.93</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.74</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.02</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.97</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.16%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.02%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.88%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.38%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 5.37pt;text-align:left;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2016 ESPP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.50</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.50</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.59%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.23%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the total intrinsic value of options exercised (or share units converted), share-based liabilities paid, and the total fair value of shares vested during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (d)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Schedule of Significant Expenses Provided to the CODM on a Regular Basis</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the significant expenses provided to the CODM on a regular basis (in thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.860%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Compensation</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12,862&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,120&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">24,305&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,111&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Stock-based compensation </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,512&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,378&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26,318&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18,237&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development, excluding compensation and stock-based compensation </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2) (3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">50,447&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">30,749&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">97,340&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">64,300&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other segment items</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> (4) (5)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(40,621)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(11,530)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(42,758)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(16,158)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Segment net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">36,200&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">36,717&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">105,205&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">81,490&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Includes related party expenses of $0.2 million for the three months ended June&#160;30, 2026 and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025, and</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $0.5 million for the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">six months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2026 and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Includes non-clinical study, clinical trial, and manufacturing expenses. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Includes de minimis related party expenses for the three months ended June 30, 2026 and 2025. Includes related party expenses of $3.1 million and $2.6 million for the six months ended June 30, 2026 and 2025, respectively. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Includes general and administrative expenses such as audit, legal, and other professional fees, interest income, and other expense, net. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Includes gains of $40.0 million and $10.0 million for the three months ended June 30, 2026 and 2025, respectively, related to the achievement of milestones under the 2023 sale of the global rights to the legacy assets, pegzilarginase, to Immedica. The 2026 gain was triggered by the sale of the related priority review voucher (&#8220;PRV&#8221;), while the 2025 gain was triggered by a favorable reimbursement decision for pegzilarginase in Europe.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Includes gains of $70.0 million and $10.0 million for the six months ended June 30, 2026 and 2025, respectively, related to milestone payments earned in connection with the 2023 sale of the global rights to the legacy assets, pegzilarginase, to Immedica. The 2026 gain was triggered by the FDA approval of pegzilarginase and the subsequent sale of the related PRV, while the 2025 gain was triggered by a favorable reimbursement decision for pegzilarginase in Europe.</span></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Includes a $4.6&#160;million increase and a $0.6&#160;million decrease in the fair value of the CVR liability for the three months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2026</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2025, respectively. Includes a $34.9&#160;million increase and a $1.8&#160;million decrease in the fair value of the CVR liability for the six months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2026</span> and 2025, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of reconciliation of profit (loss) by reportable segment to consolidated profit (loss). Includes, but is not limited to, reconciliation of income (loss) before income tax expense (benefit) and after income tax if income tax is allocated to reportable segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">Schedule of Computation of Basic and Diluted Net Loss Per Share</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted net loss per share of common stock, Series A Preferred Stock, and Series B Preferred Stock (in thousands, except share and per share amounts):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.449%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="15" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="15" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Series A Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Series B Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Common<br/>Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Series A Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Series B Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Common<br/>Stock</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net loss per share, basic and diluted:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numerator</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Allocation of losses</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5,052)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(225)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(30,923)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6,791)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(327)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(29,599)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Denominator</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Weighted-average shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">346,045</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15,385</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">84,729,435</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">346,045&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">16,667&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">60,333,838</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net loss per share, basic and diluted</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(14.60)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(14.60)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(0.36)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(19.62)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(19.62)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(0.49)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="33" style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="15" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="15" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Series A Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Series B Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Common<br/>Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Series A Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Series B Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Common<br/>Stock</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net loss per share, basic and diluted:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numerator</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Allocation of losses</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(15,147)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(701)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(89,357)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(15,078)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(726)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(65,686)</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Denominator</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Weighted-average shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">346,045</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">16,022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">81,656,119</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">346,045&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">16,667&#160;</span></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">60,300,073</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net loss per share, basic and diluted</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(43.77)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(43.77)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1.09)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(43.57)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(43.57)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1.09)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Weighted-Average Equity Instruments Excluded from Calculation of Diluted Net Loss Per Share</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following weighted-average equity instruments were excluded from the calculation of diluted net loss per share because their effect would have been anti-dilutive for the periods presented:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.303%"><tr><td style="width:1.0%"></td><td style="width:41.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.731%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.435%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.731%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.435%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.731%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.435%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.736%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options to purchase common stock</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,042,158</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">805,306</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,630,827</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,324,645</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">137,358</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113,115</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,943</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding Parapyre warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,532,591</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,532,591</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company and Basis of Presentation (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">136 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 16, 2026 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 15, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Jun. 22, 2023</div></th>
<th class="th">
<div>Jun. 30, 2026 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2026 </div>
<div>USD ($) </div>
<div>segment </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2026 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 06, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_CompanyAndBasisOfPresentationLineItems', window );"><strong>Company and Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_ProceedsFromRaisingCapital', window );">Proceeds from raising capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,232,840<span></span>
</td>
<td class="nump">$ 1,232,840<span></span>
</td>
<td class="nump">$ 1,127,635<span></span>
</td>
<td class="nump">1,232,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=syre_AtTheMarketOffering2024SalesAgreementMember', window );">At-The-Market Offering, 2024 Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_CompanyAndBasisOfPresentationLineItems', window );"><strong>Company and Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_SaleOfStockAuthorizedAmount', window );">Sale of stock, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=syre_AtTheMarketOffering2024SalesAgreementMember', window );">At-The-Market Offering, 2024 Sales Agreement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_CompanyAndBasisOfPresentationLineItems', window );"><strong>Company and Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares of common stock sold (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">296,396<span></span>
</td>
<td class="nump">445,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, proceeds received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,700<span></span>
</td>
<td class="nump">$ 14,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=syre_AtTheMarketOffering2026SalesAgreementMember', window );">At-The-Market Offering, 2026 Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_CompanyAndBasisOfPresentationLineItems', window );"><strong>Company and Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_SaleOfStockAuthorizedAmount', window );">Sale of stock, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in connection with at-the-market and follow-on offering program, net of financing costs (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_SaleOfStockRemainingAuthorizedAmount', window );">Sale of stock, remaining authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=syre_October2025UnderwrittenOfferingMember', window );">October 2025 Underwritten Offering | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_CompanyAndBasisOfPresentationLineItems', window );"><strong>Company and Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares of common stock sold (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,094,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, proceeds received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 296,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Placement agent and other offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_CompanyAndBasisOfPresentationLineItems', window );"><strong>Company and Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares of common stock sold (in shares) | shares</a></td>
<td class="nump">975,000<span></span>
</td>
<td class="nump">2,229,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=syre_April2026UnderwritingOfferingMember', window );">April 2026 Underwriting Agreement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_CompanyAndBasisOfPresentationLineItems', window );"><strong>Company and Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares of common stock sold (in shares) | shares</a></td>
<td class="nump">7,475,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, proceeds received</a></td>
<td class="nump">$ 435,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 62.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Placement agent and other offering costs</a></td>
<td class="nump">$ 28,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=syre_SpyreTherapeuticsIncMember', window );">Spyre Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_CompanyAndBasisOfPresentationLineItems', window );"><strong>Company and Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_AssetAcquisitionCashPaymentThresholdPeriod', window );">Asset acquisition, cash payment, threshold period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_AssetAcquisitionCashPaymentThresholdPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Cash Payment, Threshold Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_AssetAcquisitionCashPaymentThresholdPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_CompanyAndBasisOfPresentationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Company and basis of presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_CompanyAndBasisOfPresentationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_ProceedsFromRaisingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Raising Capital</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_ProceedsFromRaisingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_SaleOfStockAuthorizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Authorized Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_SaleOfStockAuthorizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_SaleOfStockRemainingAuthorizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Remaining Authorized Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_SaleOfStockRemainingAuthorizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=syre_AtTheMarketOffering2024SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=syre_AtTheMarketOffering2024SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=syre_AtTheMarketOffering2026SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=syre_AtTheMarketOffering2026SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=syre_October2025UnderwrittenOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=syre_October2025UnderwrittenOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=syre_April2026UnderwritingOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=syre_April2026UnderwritingOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=syre_SpyreTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=syre_SpyreTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Fair Value of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Money market funds</a></td>
<td class="nump">$ 160,262<span></span>
</td>
<td class="nump">$ 83,991<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">1,143,601<span></span>
</td>
<td class="nump">754,803<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">CVR liability</a></td>
<td class="nump">38,620<span></span>
</td>
<td class="nump">26,680<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">38,620<span></span>
</td>
<td class="nump">26,680<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. government treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Financial assets</a></td>
<td class="nump">256,457<span></span>
</td>
<td class="nump">266,064<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">U.S. government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Financial assets</a></td>
<td class="nump">176,095<span></span>
</td>
<td class="nump">119,590<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Financial assets</a></td>
<td class="nump">425,578<span></span>
</td>
<td class="nump">194,355<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Financial assets</a></td>
<td class="nump">146,141<span></span>
</td>
<td class="nump">100,790<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Money market funds</a></td>
<td class="nump">139,330<span></span>
</td>
<td class="nump">74,004<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">395,787<span></span>
</td>
<td class="nump">340,068<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">CVR liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | U.S. government treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Financial assets</a></td>
<td class="nump">256,457<span></span>
</td>
<td class="nump">266,064<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | U.S. government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Money market funds</a></td>
<td class="nump">139,330<span></span>
</td>
<td class="nump">74,004<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">747,814<span></span>
</td>
<td class="nump">414,735<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">CVR liability</a></td>
<td class="nump">38,620<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">38,620<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. government treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Financial assets</a></td>
<td class="nump">176,095<span></span>
</td>
<td class="nump">119,590<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Financial assets</a></td>
<td class="nump">425,578<span></span>
</td>
<td class="nump">194,355<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Financial assets</a></td>
<td class="nump">146,141<span></span>
</td>
<td class="nump">100,790<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Money market funds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">CVR liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">26,680<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">26,680<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | U.S. government treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | U.S. government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Money market funds</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (fff)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (ff)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 860<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481420/860-30-50-1A<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 24: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-7A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-21<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-20<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-15<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 22, 2023</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=syre_ContingentValueRightLiabilityMember', window );">CVR liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Increase in fair value of derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payment to CVR holders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=syre_SpyreTherapeuticsIncMember', window );">Spyre Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_AssetAcquisitionStockholderPaymentPeriod', window );">Asset acquisition, stockholder payment period (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_AssetAcquisitionCashPaymentThresholdPeriod', window );">Asset acquisition, cash payment, threshold period (in years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_AssetAcquisitionCashPaymentThresholdPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Cash Payment, Threshold Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_AssetAcquisitionCashPaymentThresholdPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_AssetAcquisitionStockholderPaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Stockholder Payment Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_AssetAcquisitionStockholderPaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 45<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480865/815-45-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=syre_ContingentValueRightLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=syre_ContingentValueRightLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=syre_SpyreTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=syre_SpyreTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Significant Inputs Used to Estimate the Fair Value of CVR Liability (Details)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=syre_ContingentValueRightLiabilityMember', window );">CVR liability | Level 3 | Risk-adjusted discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">0.1210<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=syre_ContingentValueRightLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=syre_ContingentValueRightLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Changes in CVR Liability (Details) - CVR Liability<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2026 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 26,680<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Changes in the fair value of the CVR liability</a></td>
<td class="nump">34,873<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments</a></td>
<td class="num">(22,933)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 38,620<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=syre_ContingentValueRightLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=syre_ContingentValueRightLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash Equivalents and Marketable Securities - Schedule of Estimated Fair Value of Cash Equivalents and Marketable Securities and Gross Unrealized Gains and Losses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents, amortized cost</a></td>
<td class="nump">$ 160,262<span></span>
</td>
<td class="nump">$ 83,991<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_CashEquivalentsUnrealizedGains', window );">Cash equivalents, gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_CashEquivalentsUnrealizedLosses', window );">Cash equivalents, gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, estimated fair value</a></td>
<td class="nump">160,262<span></span>
</td>
<td class="nump">83,991<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Marketable securities, amortized cost</a></td>
<td class="nump">985,735<span></span>
</td>
<td class="nump">669,942<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Marketable securities, gross unrealized gains</a></td>
<td class="nump">90<span></span>
</td>
<td class="nump">986<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Marketable securities, gross unrealized losses</a></td>
<td class="num">(2,486)<span></span>
</td>
<td class="num">(116)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities, estimated fair value</a></td>
<td class="nump">983,339<span></span>
</td>
<td class="nump">670,812<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Marketable securities, amortized cost</a></td>
<td class="nump">405,173<span></span>
</td>
<td class="nump">184,423<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Marketable securities, gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Marketable securities, gross unrealized losses</a></td>
<td class="num">(527)<span></span>
</td>
<td class="num">(80)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities, estimated fair value</a></td>
<td class="nump">404,646<span></span>
</td>
<td class="nump">184,368<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Marketable securities, amortized cost</a></td>
<td class="nump">146,423<span></span>
</td>
<td class="nump">100,753<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Marketable securities, gross unrealized gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Marketable securities, gross unrealized losses</a></td>
<td class="num">(283)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities, estimated fair value</a></td>
<td class="nump">146,141<span></span>
</td>
<td class="nump">100,790<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. government treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Marketable securities, amortized cost</a></td>
<td class="nump">257,111<span></span>
</td>
<td class="nump">265,316<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Marketable securities, gross unrealized gains</a></td>
<td class="nump">87<span></span>
</td>
<td class="nump">748<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Marketable securities, gross unrealized losses</a></td>
<td class="num">(741)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities, estimated fair value</a></td>
<td class="nump">256,457<span></span>
</td>
<td class="nump">266,064<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">U.S. government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Marketable securities, amortized cost</a></td>
<td class="nump">177,028<span></span>
</td>
<td class="nump">119,450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Marketable securities, gross unrealized gains</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">153<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Marketable securities, gross unrealized losses</a></td>
<td class="num">(935)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities, estimated fair value</a></td>
<td class="nump">176,095<span></span>
</td>
<td class="nump">119,590<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents, amortized cost</a></td>
<td class="nump">139,330<span></span>
</td>
<td class="nump">74,004<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_CashEquivalentsUnrealizedGains', window );">Cash equivalents, gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_CashEquivalentsUnrealizedLosses', window );">Cash equivalents, gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, estimated fair value</a></td>
<td class="nump">139,330<span></span>
</td>
<td class="nump">74,004<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents, amortized cost</a></td>
<td class="nump">20,932<span></span>
</td>
<td class="nump">9,987<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_CashEquivalentsUnrealizedGains', window );">Cash equivalents, gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_CashEquivalentsUnrealizedLosses', window );">Cash equivalents, gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, estimated fair value</a></td>
<td class="nump">$ 20,932<span></span>
</td>
<td class="nump">$ 9,987<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_CashEquivalentsUnrealizedGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents unrealized gains.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_CashEquivalentsUnrealizedGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_CashEquivalentsUnrealizedLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents unrealized losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_CashEquivalentsUnrealizedLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (fff)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (ff)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (fff)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (ff)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash Equivalents and Marketable Securities - Schedule of Available-for-Sale Securities in an Unrealized Loss Position (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less Than 12 Months</a></td>
<td class="nump">$ 903,696<span></span>
</td>
<td class="nump">$ 180,961<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Longer</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total, fair value</a></td>
<td class="nump">903,696<span></span>
</td>
<td class="nump">180,961<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract', window );"><strong>Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less Than 12 Months</a></td>
<td class="num">(2,486)<span></span>
</td>
<td class="num">(116)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Longer</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total, unrealized losses</a></td>
<td class="num">(2,486)<span></span>
</td>
<td class="num">(116)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less Than 12 Months</a></td>
<td class="nump">421,580<span></span>
</td>
<td class="nump">99,837<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Longer</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total, fair value</a></td>
<td class="nump">421,580<span></span>
</td>
<td class="nump">99,837<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract', window );"><strong>Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less Than 12 Months</a></td>
<td class="num">(527)<span></span>
</td>
<td class="num">(80)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Longer</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total, unrealized losses</a></td>
<td class="num">(527)<span></span>
</td>
<td class="num">(80)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less Than 12 Months</a></td>
<td class="nump">144,148<span></span>
</td>
<td class="nump">58,296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Longer</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total, fair value</a></td>
<td class="nump">144,148<span></span>
</td>
<td class="nump">58,296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract', window );"><strong>Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less Than 12 Months</a></td>
<td class="num">(283)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Longer</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total, unrealized losses</a></td>
<td class="num">(283)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. government treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less Than 12 Months</a></td>
<td class="nump">164,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Longer</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total, fair value</a></td>
<td class="nump">164,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract', window );"><strong>Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less Than 12 Months</a></td>
<td class="num">(741)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Longer</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total, unrealized losses</a></td>
<td class="num">(741)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">U.S. government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less Than 12 Months</a></td>
<td class="nump">173,125<span></span>
</td>
<td class="nump">22,828<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Longer</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total, fair value</a></td>
<td class="nump">173,125<span></span>
</td>
<td class="nump">22,828<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract', window );"><strong>Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less Than 12 Months</a></td>
<td class="num">(935)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Longer</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total, unrealized losses</a></td>
<td class="num">$ (935)<span></span>
</td>
<td class="num">$ (13)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Marketable Securities - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2026 </div>
<div>USD ($) </div>
<div>bank</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_CashEquivalentsAndMarketableSecuritiesLineItems', window );"><strong>Cash Equivalents And Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_NumberOfDomesticBankingInstitutions', window );">Number of domestic banking institutions (in banks) | bank</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">US Government Agencies Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_CashEquivalentsAndMarketableSecuritiesLineItems', window );"><strong>Cash Equivalents And Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest', window );">Allowance for credit loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_ImpairmentOfMarketableSecurities', window );">Impairment of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments', window );">Realized gains or losses on marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivable', window );">Accrued interest receivable on available-for-sale debt securities</a></td>
<td class="nump">5,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=syre_USBankingInstitutionMember', window );">U.S. Banking Institution | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_CashEquivalentsAndMarketableSecuritiesLineItems', window );"><strong>Cash Equivalents And Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Cash, FDIC insured amount (up to)</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_CashEquivalentsAndMarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_CashEquivalentsAndMarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_ImpairmentOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment of marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_ImpairmentOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_NumberOfDomesticBankingInstitutions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Domestic Banking Institutions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_NumberOfDomesticBankingInstitutions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=syre_USBankingInstitutionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=syre_USBankingInstitutionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash Equivalents and Marketable Securities - Schedule of Contractual Maturities of Marketable Securities at Estimated Fair Value (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due in one year or less</a></td>
<td class="nump">$ 703,969<span></span>
</td>
<td class="nump">$ 440,895<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne', window );">Due in 1 - 2 years</a></td>
<td class="nump">279,370<span></span>
</td>
<td class="nump">229,917<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Total marketable securities</a></td>
<td class="nump">$ 983,339<span></span>
</td>
<td class="nump">$ 670,812<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, After Year One</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued compensation</a></td>
<td class="nump">$ 5,722<span></span>
</td>
<td class="nump">$ 7,940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_AccruedContractedResearchAndDevelopmentCosts', window );">Accrued contracted research and development costs</a></td>
<td class="nump">17,952<span></span>
</td>
<td class="nump">17,424<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional and consulting fees</a></td>
<td class="nump">2,375<span></span>
</td>
<td class="nump">1,404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other</a></td>
<td class="nump">135<span></span>
</td>
<td class="nump">179<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Total accrued and other current liabilities</a></td>
<td class="nump">$ 26,184<span></span>
</td>
<td class="nump">$ 26,947<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_AccruedContractedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued contracted research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_AccruedContractedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Licensing Agreements (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 11, 2024</div></th>
<th class="th"><div>May 14, 2024</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,503,000<span></span>
</td>
<td class="nump">$ 40,145,000<span></span>
</td>
<td class="nump">$ 125,914,000<span></span>
</td>
<td class="nump">$ 81,768,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 3,100,000<span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=syre_ParagonAgreementMember', window );">Paragon Agreement | Related Party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_CampaignTimelineMinimumTerm', window );">Campaign timeline, minimum term (in years)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_RoyaltyStepDownPercent', window );">Royalty step-down (as percent)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_RoyaltyTermExpirationPeriod', window );">Royalty term expiration period (in years)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_TerminationNoticePeriod', window );">Termination notice period (in days)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_LicenseAgreementMilestonePayments', window );">Cash milestone payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_LicenseAgreementMilestonePaymentsOutstandingAndPayable', window );">Milestone payments, outstanding and payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_PaymentForSublicensingFee', window );">Payment for sublicensing fee</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=syre_Spy001LicenseAgreementMember', window );">SPY001 License Agreement | Related Party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_PaymentOfMilestone', window );">First milestone payment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=syre_SPY002AndSPY072LicenseAgreementMember', window );">SPY002 and SPY072 License Agreement | Related Party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_PaymentOfMilestone', window );">First milestone payment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=syre_SPY003LicenseAgreementMember', window );">SPY003 License Agreement | Related Party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_PaymentOfMilestone', window );">First milestone payment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=syre_ParagonAgreementLicenseMilestonePaymentsMember', window );">License Agreement | Related Party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">3,000,000.0<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_SublicensingFeeOutstandingAndPayable', window );">Sublicensing fee, outstanding and payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | SPY001 License Agreement | Related Party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_AmountToBePaidUnderAgreement', window );">Contingent obligation based on milestones</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | SPY002 and SPY072 License Agreement | Related Party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_AmountToBePaidUnderAgreement', window );">Contingent obligation based on milestones</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_SublicensingFee', window );">Sublicensing fee</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | SPY003 License Agreement | Related Party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_AmountToBePaidUnderAgreement', window );">Contingent obligation based on milestones</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 22,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="8"></td></tr>
<tr><td colspan="8"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt">Includes de minimis related party expenses for the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">three</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> months ended June&#160;30, 2026 and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Includes related party expenses of $3.1 million and $2.6 million for the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">six</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> months ended June&#160;30, 2026 and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2025, respectively</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_AmountToBePaidUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount to be paid under agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_AmountToBePaidUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_CampaignTimelineMinimumTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Campaign Timeline, Minimum Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_CampaignTimelineMinimumTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_LicenseAgreementMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_LicenseAgreementMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_LicenseAgreementMilestonePaymentsOutstandingAndPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Milestone Payments Outstanding and Payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_LicenseAgreementMilestonePaymentsOutstandingAndPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_PaymentForSublicensingFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment For Sublicensing Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_PaymentForSublicensingFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_PaymentOfMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_PaymentOfMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_RoyaltyStepDownPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Step-Down, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_RoyaltyStepDownPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_RoyaltyTermExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Term, Expiration Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_RoyaltyTermExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_SublicensingFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sublicensing Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_SublicensingFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_SublicensingFeeOutstandingAndPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sublicensing Fee, Outstanding And Payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_SublicensingFeeOutstandingAndPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_TerminationNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Termination Notice Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_TerminationNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7)(e)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 970<br> -SubTopic 810<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477383/970-810-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=syre_ParagonAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=syre_ParagonAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=syre_Spy001LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=syre_Spy001LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=syre_SPY002AndSPY072LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=syre_SPY002AndSPY072LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=syre_SPY003LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=syre_SPY003LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=syre_ParagonAgreementLicenseMilestonePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=syre_ParagonAgreementLicenseMilestonePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 22, 2023 </div>
<div>installment </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2026 </div>
<div>USD ($) </div>
<div>seat </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2026 </div>
<div>USD ($) </div>
<div>seat </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,503,000<span></span>
</td>
<td class="nump">$ 40,145,000<span></span>
</td>
<td class="nump">$ 125,914,000<span></span>
</td>
<td class="nump">$ 81,768,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted to purchase (in shares) | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">190,456<span></span>
</td>
<td class="nump">427,800<span></span>
</td>
<td class="nump">2,769,061<span></span>
</td>
<td class="nump">2,325,717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,512,000<span></span>
</td>
<td class="nump">$ 9,378,000<span></span>
</td>
<td class="nump">$ 26,318,000<span></span>
</td>
<td class="nump">$ 18,237,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,100,000<span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Total related party accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=syre_ParagonAgreementMember', window );">Paragon Agreement | Related Party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Amount of related party transaction</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=syre_AppointOfBoardMembersMember', window );">Appoint Of Board Members</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_RelatedPartyTransactionNumberOfBoardSeats', window );">Number of board seats held by related party | seat</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=syre_OtherParagonReimbursableExpensesMember', window );">Other Paragon Reimbursable Expenses | Related Party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=syre_ParagonAgreementSubsequentToAssetAcquisitionMember', window );">Subsequent to Asset Acquisition | Related Party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Amount of related party transaction</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=syre_ConsultingAgreementMember', window );">Consulting Agreement | Related Party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted to purchase (in shares) | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">477,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 10.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMonthlyInstallments', window );">Number of monthly installments | installment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=syre_ConsultingAgreementMember', window );">Consulting Agreement | Related Party | Share-Based Payment Arrangement, Tranche One</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vest period grant date (in years)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=syre_ParagonTherapeuticsIncMember', window );">Paragon Therapeutics Inc | Maximum | Paragon Agreement | Related Party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Percentage of ownership by noncontrolling owner</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=syre_FairmountFundsManagementLlcMember', window );">Fairmount Funds Management LLC | Minimum | Paragon Agreement | Related Party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Percentage of ownership by noncontrolling owner</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty', window );">Percentage of ownership held in third party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt">Includes de minimis related party expenses for the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">three</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> months ended June&#160;30, 2026 and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Includes related party expenses of $3.1 million and $2.6 million for the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">six</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> months ended June&#160;30, 2026 and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2025, respectively</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minority interest ownership percentage by noncontrolling owners held in third party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_RelatedPartyTransactionNumberOfBoardSeats">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Number Of Board Seats</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_RelatedPartyTransactionNumberOfBoardSeats</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMonthlyInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Monthly Installments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMonthlyInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a)(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7)(e)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 970<br> -SubTopic 810<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477383/970-810-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=syre_ParagonAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=syre_ParagonAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=syre_AppointOfBoardMembersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=syre_AppointOfBoardMembersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=syre_OtherParagonReimbursableExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=syre_OtherParagonReimbursableExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=syre_ParagonAgreementSubsequentToAssetAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=syre_ParagonAgreementSubsequentToAssetAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=syre_ConsultingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=syre_ConsultingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=syre_ParagonTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=syre_ParagonTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=syre_FairmountFundsManagementLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=syre_FairmountFundsManagementLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Schedule of Expenses Related to Related Party Which are Settled in Cash (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Total related party expense (excludes stock-based compensation)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 65,503,000<span></span>
</td>
<td class="nump">$ 40,145,000<span></span>
</td>
<td class="nump">$ 125,914,000<span></span>
</td>
<td class="nump">$ 81,768,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Total related party expense (excludes stock-based compensation)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,100,000<span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=syre_ParagonAndLicenseAgreementMember', window );">Paragon and License Agreement | Related Party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Total related party expense (excludes stock-based compensation)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,100,000<span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=syre_ParagonAgreementLicenseMilestonePaymentsMember', window );">License Agreement | Related Party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Total related party expense (excludes stock-based compensation)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,000,000.0<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=syre_OtherParagonReimbursableExpensesMember', window );">Other Paragon Reimbursable Expenses | Related Party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Total related party expense (excludes stock-based compensation)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt">Includes de minimis related party expenses for the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">three</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> months ended June&#160;30, 2026 and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Includes related party expenses of $3.1 million and $2.6 million for the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">six</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> months ended June&#160;30, 2026 and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2025, respectively</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7)(e)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 970<br> -SubTopic 810<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477383/970-810-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=syre_ParagonAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=syre_ParagonAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=syre_ParagonAgreementLicenseMilestonePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=syre_ParagonAgreementLicenseMilestonePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=syre_OtherParagonReimbursableExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=syre_OtherParagonReimbursableExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock and Stockholders' Equity (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 16, 2026</div></th>
<th class="th"><div>Oct. 15, 2025</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Jun. 23, 2026</div></th>
<th class="th"><div>Sep. 06, 2024</div></th>
<th class="th"><div>Jun. 22, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=syre_AtTheMarketOffering2024SalesAgreementMember', window );">At-The-Market Offering, 2024 Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_SaleOfStockAuthorizedAmount', window );">Sale of stock, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=syre_AtTheMarketOffering2026SalesAgreementMember', window );">At-The-Market Offering, 2026 Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_SaleOfStockAuthorizedAmount', window );">Sale of stock, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500.0<span></span>
</td>
<td class="nump">$ 500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in connection with at-the-market and follow-on offering program, net of financing costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_SaleOfStockRemainingAuthorizedAmount', window );">Sale of stock, remaining authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500.0<span></span>
</td>
<td class="nump">$ 500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=syre_SeriesANonVotingConvertiblePreferredStockMember', window );">Series A Non Voting Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_PreferredStockRemainsIssuedAndOutstandingPercentage', window );">Preferred stock issued and outstanding (as percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">346,045<span></span>
</td>
<td class="nump">346,045<span></span>
</td>
<td class="nump">346,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Number of common shares issuable upon conversion (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,841,800<span></span>
</td>
<td class="nump">13,841,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=syre_SeriesBNonVotingConvertiblePreferredStockMember', window );">Series B Non Voting Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,667<span></span>
</td>
<td class="nump">16,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Converted at the option of the holder (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">666,680<span></span>
</td>
<td class="nump">666,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | At-The-Market Offering, 2024 Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_SaleOfStockAggregateOfferingPrice', window );">Sale of stock, aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares of common stock sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">296,396<span></span>
</td>
<td class="nump">445,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, proceeds received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.7<span></span>
</td>
<td class="nump">$ 14.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | October 2025 Underwritten Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares of common stock sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,094,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, proceeds received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 296.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Placement agent and other offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares of common stock sold (in shares)</a></td>
<td class="nump">975,000<span></span>
</td>
<td class="nump">2,229,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | April 2026 Underwriting Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares of common stock sold (in shares)</a></td>
<td class="nump">7,475,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, proceeds received</a></td>
<td class="nump">$ 435.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share)</a></td>
<td class="nump">$ 62.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Placement agent and other offering costs</a></td>
<td class="nump">$ 28.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=syre_ParapyreWarrantsMember', window );">Outstanding Parapyre warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,532,591<span></span>
</td>
<td class="nump">1,532,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.49<span></span>
</td>
<td class="nump">$ 22.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_PreferredStockRemainsIssuedAndOutstandingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred stock remains issued and outstanding percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_PreferredStockRemainsIssuedAndOutstandingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_SaleOfStockAggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Aggregate Offering Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_SaleOfStockAggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_SaleOfStockAuthorizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Authorized Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_SaleOfStockAuthorizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_SaleOfStockRemainingAuthorizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Remaining Authorized Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_SaleOfStockRemainingAuthorizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-5<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-13<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleSharesIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleSharesIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=syre_AtTheMarketOffering2024SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=syre_AtTheMarketOffering2024SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=syre_AtTheMarketOffering2026SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=syre_AtTheMarketOffering2026SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=syre_SeriesANonVotingConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=syre_SeriesANonVotingConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=syre_SeriesBNonVotingConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=syre_SeriesBNonVotingConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=syre_October2025UnderwrittenOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=syre_October2025UnderwrittenOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=syre_April2026UnderwritingOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=syre_April2026UnderwritingOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=syre_ParapyreWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=syre_ParapyreWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Jan. 01, 2026</div></th>
<th class="th"><div>Jan. 01, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=syre_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember', window );">2015 and 2016 and 2018 Equity Inducement Plan | Service Based Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based award, vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=syre_TwoThousandAndSixteenEquityIncentivePlanMember', window );">2016 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares', window );">Annual percentage of additional shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant', window );">Additional number of shares available for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,711,544<span></span>
</td>
<td class="nump">3,814,905<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock available for future issuance (in shares)</a></td>
<td class="nump">15,084,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,084,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding option awards (in shares)</a></td>
<td class="nump">6,876,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,876,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=syre_TwoThousandAndEighteenEquityInducementPlanMember', window );">2018 Equity Inducement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock available for future issuance (in shares)</a></td>
<td class="nump">6,481,956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,481,956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding option awards (in shares)</a></td>
<td class="nump">5,981,072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,981,072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Common stock available for future issuance, additional amount authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=syre_TwoThousandAndSixteenEmployeeStockPurchasePlanMember', window );">2016 Employee Stock Purchase Plan | Employee Stock | 2016 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares sold (in shares)</a></td>
<td class="nump">19,967<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">19,967<span></span>
</td>
<td class="nump">16,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, proceeds received</a></td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual percentage of additional shares which equals to the issued and outstanding shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, additional number of shares available for grant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant to expiration date of share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=syre_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=syre_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=syre_ServiceBasedAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=syre_ServiceBasedAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=syre_TwoThousandAndSixteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=syre_TwoThousandAndSixteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=syre_TwoThousandAndEighteenEquityInducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=syre_TwoThousandAndEighteenEquityInducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=syre_TwoThousandAndSixteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=syre_TwoThousandAndSixteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=syre_A2016ESPPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=syre_A2016ESPPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Stock Awards Granted Under all Equity Incentive and Inducement Plans (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options, Grants (in shares)</a></td>
<td class="nump">190,456<span></span>
</td>
<td class="nump">427,800<span></span>
</td>
<td class="nump">2,769,061<span></span>
</td>
<td class="nump">2,325,717<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Stock options, Weighted Average Grant Date Fair Value (in dollars per share)</a></td>
<td class="nump">$ 62.94<span></span>
</td>
<td class="nump">$ 15.29<span></span>
</td>
<td class="nump">$ 33.19<span></span>
</td>
<td class="nump">$ 20.32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock units, Grants (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">125,400<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Restricted stock units, Weighted Average Grant Date Fair Value (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 30.61<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 13,512<span></span>
</td>
<td class="nump">$ 9,378<span></span>
</td>
<td class="nump">$ 26,318<span></span>
</td>
<td class="nump">$ 18,237<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeLocationBalanceAxis=us-gaap_GeneralAndAdministrativeExpense', window );">Location, Statement of Income, Balance [Axis]: us-gaap:GeneralAndAdministrativeExpense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">7,294<span></span>
</td>
<td class="nump">5,278<span></span>
</td>
<td class="nump">14,309<span></span>
</td>
<td class="nump">10,625<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeLocationBalanceAxis=us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 6,218<span></span>
</td>
<td class="nump">$ 4,100<span></span>
</td>
<td class="nump">$ 12,009<span></span>
</td>
<td class="nump">$ 7,612<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeLocationBalanceAxis=us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeLocationBalanceAxis=us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeLocationBalanceAxis=us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeLocationBalanceAxis=us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Weighted-Average Assumptions Used in Calculating Fair Value of Awards (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=syre_TwoThousandAndSixteenEquityIncentivePlanMember', window );">Stock Options Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 11 months 4 days<span></span>
</td>
<td class="text">5 years 8 months 26 days<span></span>
</td>
<td class="text">6 years 7 days<span></span>
</td>
<td class="text">5 years 11 months 19 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">67.00%<span></span>
</td>
<td class="nump">74.00%<span></span>
</td>
<td class="nump">73.00%<span></span>
</td>
<td class="nump">76.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest</a></td>
<td class="nump">4.16%<span></span>
</td>
<td class="nump">4.02%<span></span>
</td>
<td class="nump">3.88%<span></span>
</td>
<td class="nump">4.38%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=syre_TwoThousandAndSixteenEmployeeStockPurchasePlanMember', window );">2016 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">0 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">64.00%<span></span>
</td>
<td class="nump">69.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">3.59%<span></span>
</td>
<td class="nump">4.23%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=syre_TwoThousandAndSixteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=syre_TwoThousandAndSixteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=syre_TwoThousandAndSixteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=syre_TwoThousandAndSixteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sale of Pegzilarginase to Immedica (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 27, 2023</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Disposal Group, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfIntangibleAssets', window );">Proceeds from sale of in-process research and development asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Gain on sale of in-process research and development asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposal Group, Disposed of by Sale, Not Discontinued Operations | Global Rights to Pegzilarginase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Disposal Group, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfIntangibleAssets', window );">Proceeds from sale of in-process research and development asset</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_DisposalGroupIncludingDiscontinuedOperationContingentConsideration', window );">Contingent consideration</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Receivable outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_DisposalGroupIncludingDiscontinuedOperationContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Contingent Consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_DisposalGroupIncludingDiscontinuedOperationContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3A<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 102<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483474/205-20-55-102<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-4B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.Z.5.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480781/205-20-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480868/205-20-S45-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-4B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-4B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-4B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (d)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-4B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-4B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-4B<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480781/205-20-S99-3<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480837/205-20-S50-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-3<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=syre_GlobalRightsToPegzilarginaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=syre_GlobalRightsToPegzilarginaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2026 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Schedule of Significant Expenses Provided to the CODM on a Regular Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,318<span></span>
</td>
<td class="nump">$ 18,237<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 36,200<span></span>
</td>
<td class="nump">$ 69,005<span></span>
</td>
<td class="nump">$ 36,717<span></span>
</td>
<td class="nump">$ 44,773<span></span>
</td>
<td class="nump">105,205<span></span>
</td>
<td class="nump">81,490<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Gain on sale of in-process research and development asset</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_IncreaseDecreaseInFairValueOfContingentValueRightLiability', window );">Increase (decrease) in fair value of contingent value right liability</a></td>
<td class="nump">4,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,900<span></span>
</td>
<td class="num">(1,800)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development, excluding compensation and share-based compensation</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Reportable Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold', window );">Compensation</a></td>
<td class="nump">12,862<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,305<span></span>
</td>
<td class="nump">15,111<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">13,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,318<span></span>
</td>
<td class="nump">18,237<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development, excluding compensation and share-based compensation</a></td>
<td class="nump">50,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,340<span></span>
</td>
<td class="nump">64,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherItemAmount', window );">Other segment items</a></td>
<td class="num">(40,621)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,530)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(42,758)<span></span>
</td>
<td class="num">(16,158)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 36,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105,205<span></span>
</td>
<td class="nump">$ 81,490<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_IncreaseDecreaseInFairValueOfContingentValueRightLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Fair Value Of Contingent Value Right Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_IncreaseDecreaseInFairValueOfContingentValueRightLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit. Other employee benefit expense includes, but is not limited to, service component of net periodic benefit cost for defined benefit plan. Excludes compensation cost in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (j)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingOtherItemAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingOtherItemAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=syre_ReportableSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=syre_ReportableSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Allocation of losses</a></td>
<td class="num">$ (36,200)<span></span>
</td>
<td class="num">$ (69,005)<span></span>
</td>
<td class="num">$ (36,717)<span></span>
</td>
<td class="num">$ (44,773)<span></span>
</td>
<td class="num">$ (105,205)<span></span>
</td>
<td class="num">$ (81,490)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Denominator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1.09)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=syre_SeriesANonVotingConvertiblePreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Allocation of losses</a></td>
<td class="num">$ (5,052)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (6,791)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (15,147)<span></span>
</td>
<td class="num">$ (15,078)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Denominator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic', window );">Weighted-average shares outstanding (in shares)</a></td>
<td class="nump">346,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">346,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">346,045<span></span>
</td>
<td class="nump">346,045<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in dollars per share)</a></td>
<td class="num">$ (14.60)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (19.62)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (43.77)<span></span>
</td>
<td class="num">$ (43.57)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in dollars per share)</a></td>
<td class="num">$ (14.60)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (19.62)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (43.77)<span></span>
</td>
<td class="num">$ (43.57)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=syre_SeriesBNonVotingConvertiblePreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Allocation of losses</a></td>
<td class="num">$ (225)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (327)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (701)<span></span>
</td>
<td class="num">$ (726)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Denominator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic', window );">Weighted-average shares outstanding (in shares)</a></td>
<td class="nump">15,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,022<span></span>
</td>
<td class="nump">16,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in dollars per share)</a></td>
<td class="num">$ (14.60)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (19.62)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (43.77)<span></span>
</td>
<td class="num">$ (43.57)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in dollars per share)</a></td>
<td class="num">$ (14.60)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (19.62)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (43.77)<span></span>
</td>
<td class="num">$ (43.57)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Allocation of losses</a></td>
<td class="num">$ (30,923)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (29,599)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (89,357)<span></span>
</td>
<td class="num">$ (65,686)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Denominator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic', window );">Weighted-average shares outstanding (in shares)</a></td>
<td class="nump">84,729,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,333,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,656,119<span></span>
</td>
<td class="nump">60,300,073<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in dollars per share)</a></td>
<td class="num">$ (0.36)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.49)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1.09)<span></span>
</td>
<td class="num">$ (1.09)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in dollars per share)</a></td>
<td class="num">$ (0.36)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.49)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1.09)<span></span>
</td>
<td class="num">$ (1.09)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesIssuedBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=syre_SeriesANonVotingConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=syre_SeriesANonVotingConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=syre_SeriesBNonVotingConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=syre_SeriesBNonVotingConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Weighted-Average Equity Instruments Excluded from Calculation of Diluted Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">8,042,158<span></span>
</td>
<td class="nump">805,306<span></span>
</td>
<td class="nump">6,630,827<span></span>
</td>
<td class="nump">1,324,645<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">137,358<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">113,115<span></span>
</td>
<td class="nump">11,943<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=syre_ParapyreWarrantsMember', window );">Outstanding Parapyre warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">1,532,591<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,532,591<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=syre_ParapyreWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=syre_ParapyreWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>266</ContextCount>
  <ElementCount>245</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>67</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="syre-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://spyre.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="syre-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>9952151 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://spyre.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="syre-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952152 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://spyre.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="syre-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952153 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://spyre.com/role/CondensedConsolidatedStatementsofOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="syre-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952154 - Statement - Condensed Consolidated Statements of Operations (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://spyre.com/role/CondensedConsolidatedStatementsofOperationsParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Operations (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="syre-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952155 - Statement - Condensed Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://spyre.com/role/CondensedConsolidatedStatementsofComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="syre-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952156 - Statement - Condensed Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://spyre.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="syre-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952157 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://spyre.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="syre-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - The Company and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://spyre.com/role/TheCompanyandBasisofPresentation</Role>
      <ShortName>The Company and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="syre-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://spyre.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="syre-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://spyre.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="syre-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - Cash Equivalents and Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://spyre.com/role/CashEquivalentsandMarketableSecurities</Role>
      <ShortName>Cash Equivalents and Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="syre-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - Accrued and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://spyre.com/role/AccruedandOtherCurrentLiabilities</Role>
      <ShortName>Accrued and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="syre-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - Licensing Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://spyre.com/role/LicensingAgreements</Role>
      <ShortName>Licensing Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="syre-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://spyre.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="syre-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - Convertible Preferred Stock and Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://spyre.com/role/ConvertiblePreferredStockandStockholdersEquity</Role>
      <ShortName>Convertible Preferred Stock and Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="syre-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://spyre.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="syre-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9952167 - Disclosure - Sale of Pegzilarginase to Immedica</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://spyre.com/role/SaleofPegzilarginasetoImmedica</Role>
      <ShortName>Sale of Pegzilarginase to Immedica</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="syre-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9952168 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://spyre.com/role/SegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="syre-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9952169 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://spyre.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="syre-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="syre-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://spyre.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://spyre.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="syre-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9955512 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://spyre.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://spyre.com/role/FairValueMeasurements</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="syre-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9955513 - Disclosure - Cash Equivalents and Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://spyre.com/role/CashEquivalentsandMarketableSecuritiesTables</Role>
      <ShortName>Cash Equivalents and Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://spyre.com/role/CashEquivalentsandMarketableSecurities</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="syre-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9955514 - Disclosure - Accrued and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://spyre.com/role/AccruedandOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://spyre.com/role/AccruedandOtherCurrentLiabilities</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="syre-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9955515 - Disclosure - Related Party Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://spyre.com/role/RelatedPartyTransactionsTables</Role>
      <ShortName>Related Party Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://spyre.com/role/RelatedPartyTransactions</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="syre-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9955516 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://spyre.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://spyre.com/role/StockBasedCompensation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="syre-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9955517 - Disclosure - Segment Reporting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://spyre.com/role/SegmentReportingTables</Role>
      <ShortName>Segment Reporting (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://spyre.com/role/SegmentReporting</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="syre-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9955518 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://spyre.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://spyre.com/role/NetLossPerShare</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="syre-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9955519 - Disclosure - The Company and Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://spyre.com/role/TheCompanyandBasisofPresentationDetails</Role>
      <ShortName>The Company and Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://spyre.com/role/TheCompanyandBasisofPresentation</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="syre-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9955520 - Disclosure - Fair Value Measurements - Schedule of Fair Value of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://spyre.com/role/FairValueMeasurementsScheduleofFairValueofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Fair Value of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="syre-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9955521 - Disclosure - Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://spyre.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="syre-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9955522 - Disclosure - Fair Value Measurements - Schedule of Significant Inputs Used to Estimate the Fair Value of CVR Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://spyre.com/role/FairValueMeasurementsScheduleofSignificantInputsUsedtoEstimatetheFairValueofCVRLiabilityDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Significant Inputs Used to Estimate the Fair Value of CVR Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="syre-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9955523 - Disclosure - Fair Value Measurements - Schedule of Changes in CVR Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://spyre.com/role/FairValueMeasurementsScheduleofChangesinCVRLiabilityDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Changes in CVR Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="syre-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9955524 - Disclosure - Cash Equivalents and Marketable Securities - Schedule of Estimated Fair Value of Cash Equivalents and Marketable Securities and Gross Unrealized Gains and Losses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofEstimatedFairValueofCashEquivalentsandMarketableSecuritiesandGrossUnrealizedGainsandLossesDetails</Role>
      <ShortName>Cash Equivalents and Marketable Securities - Schedule of Estimated Fair Value of Cash Equivalents and Marketable Securities and Gross Unrealized Gains and Losses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="syre-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9955525 - Disclosure - Cash Equivalents and Marketable Securities - Schedule of Available-for-Sale Securities in an Unrealized Loss Position (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetails</Role>
      <ShortName>Cash Equivalents and Marketable Securities - Schedule of Available-for-Sale Securities in an Unrealized Loss Position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="syre-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9955526 - Disclosure - Cash Equivalents and Marketable Securities - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://spyre.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails</Role>
      <ShortName>Cash Equivalents and Marketable Securities - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="syre-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9955527 - Disclosure - Cash Equivalents and Marketable Securities - Schedule of Contractual Maturities of Marketable Securities at Estimated Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofContractualMaturitiesofMarketableSecuritiesatEstimatedFairValueDetails</Role>
      <ShortName>Cash Equivalents and Marketable Securities - Schedule of Contractual Maturities of Marketable Securities at Estimated Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="syre-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9955528 - Disclosure - Accrued and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://spyre.com/role/AccruedandOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://spyre.com/role/AccruedandOtherCurrentLiabilitiesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="syre-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9955529 - Disclosure - Licensing Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://spyre.com/role/LicensingAgreementsDetails</Role>
      <ShortName>Licensing Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://spyre.com/role/LicensingAgreements</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="syre-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9955530 - Disclosure - Related Party Transactions - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://spyre.com/role/RelatedPartyTransactionsNarrativeDetails</Role>
      <ShortName>Related Party Transactions - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="syre-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9955531 - Disclosure - Related Party Transactions - Schedule of Expenses Related to Related Party Which are Settled in Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://spyre.com/role/RelatedPartyTransactionsScheduleofExpensesRelatedtoRelatedPartyWhichareSettledinCashDetails</Role>
      <ShortName>Related Party Transactions - Schedule of Expenses Related to Related Party Which are Settled in Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="syre-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9955532 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://spyre.com/role/ConvertiblePreferredStockandStockholdersEquityDetails</Role>
      <ShortName>Convertible Preferred Stock and Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://spyre.com/role/ConvertiblePreferredStockandStockholdersEquity</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="syre-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9955533 - Disclosure - Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://spyre.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="syre-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9955534 - Disclosure - Stock-Based Compensation - Schedule of Stock Awards Granted Under all Equity Incentive and Inducement Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://spyre.com/role/StockBasedCompensationScheduleofStockAwardsGrantedUnderallEquityIncentiveandInducementPlansDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Stock Awards Granted Under all Equity Incentive and Inducement Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="syre-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9955535 - Disclosure - Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://spyre.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="syre-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9955536 - Disclosure - Stock-Based Compensation - Schedule of Weighted-Average Assumptions Used in Calculating Fair Value of Awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://spyre.com/role/StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedinCalculatingFairValueofAwardsDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Weighted-Average Assumptions Used in Calculating Fair Value of Awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="syre-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9955537 - Disclosure - Sale of Pegzilarginase to Immedica (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://spyre.com/role/SaleofPegzilarginasetoImmedicaDetails</Role>
      <ShortName>Sale of Pegzilarginase to Immedica (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://spyre.com/role/SaleofPegzilarginasetoImmedica</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="syre-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9955538 - Disclosure - Segment Reporting - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://spyre.com/role/SegmentReportingNarrativeDetails</Role>
      <ShortName>Segment Reporting - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="syre-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9955539 - Disclosure - Segment Reporting - Schedule of Significant Expenses Provided to the CODM on a Regular Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://spyre.com/role/SegmentReportingScheduleofSignificantExpensesProvidedtotheCODMonaRegularBasisDetails</Role>
      <ShortName>Segment Reporting - Schedule of Significant Expenses Provided to the CODM on a Regular Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="syre-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9955540 - Disclosure - Net Loss Per Share - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://spyre.com/role/NetLossPerShareScheduleofComputationofBasicandDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="syre-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9955541 - Disclosure - Net Loss Per Share - Schedule of Weighted-Average Equity Instruments Excluded from Calculation of Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://spyre.com/role/NetLossPerShareScheduleofWeightedAverageEquityInstrumentsExcludedfromCalculationofDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Weighted-Average Equity Instruments Excluded from Calculation of Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="syre-20260630.htm">syre-20260630.htm</File>
    <File>syre-20260630.xsd</File>
    <File>syre-20260630_cal.xml</File>
    <File>syre-20260630_def.xml</File>
    <File>syre-20260630_lab.xml</File>
    <File>syre-20260630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>syre-20260630_g1.jpg</File>
    <File>syre-20260630_g2.jpg</File>
    <File>syre-20260630_g3.jpg</File>
    <File>syre-20260630_g4.jpg</File>
    <File>syre-20260630_g5.jpg</File>
    <File>syre-20260630_g6.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="810">http://fasb.org/us-gaap/2026</BaseTaxonomy>
    <BaseTaxonomy items="31">http://xbrl.sec.gov/dei/2026</BaseTaxonomy>
    <BaseTaxonomy items="20">http://xbrl.sec.gov/ecd/2026</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>75
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "syre-20260630.htm": {
   "nsprefix": "syre",
   "nsuri": "http://spyre.com/20260630",
   "dts": {
    "inline": {
     "local": [
      "syre-20260630.htm"
     ]
    },
    "schema": {
     "local": [
      "syre-20260630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd",
      "https://xbrl.fasb.org/srt/2026/elts/srt-roles-2026.xsd",
      "https://xbrl.fasb.org/srt/2026/elts/srt-types-2026.xsd",
      "https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd",
      "https://xbrl.fasb.org/us-gaap/2026/elts/us-roles-2026.xsd",
      "https://xbrl.fasb.org/us-gaap/2026/elts/us-types-2026.xsd",
      "https://xbrl.sec.gov/country/2026/country-2026.xsd",
      "https://xbrl.sec.gov/dei/2026/dei-2026.xsd",
      "https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd",
      "https://xbrl.sec.gov/stpr/2026/stpr-2026.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "syre-20260630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "syre-20260630_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "syre-20260630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "syre-20260630_pre.xml"
     ]
    }
   },
   "keyStandard": 204,
   "keyCustom": 41,
   "axisStandard": 26,
   "axisCustom": 0,
   "memberStandard": 28,
   "memberCustom": 34,
   "hidden": {
    "total": 20,
    "http://xbrl.sec.gov/dei/2026": 5,
    "http://xbrl.sec.gov/ecd/2026": 2,
    "http://fasb.org/us-gaap/2026": 12,
    "http://spyre.com/20260630": 1
   },
   "contextCount": 266,
   "entityCount": 1,
   "segmentCount": 67,
   "elementCount": 517,
   "unitCount": 8,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2026": 810,
    "http://xbrl.sec.gov/dei/2026": 31,
    "http://xbrl.sec.gov/ecd/2026": 20
   },
   "report": {
    "R1": {
     "role": "http://spyre.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://spyre.com/role/CondensedConsolidatedBalanceSheets",
     "longName": "9952151 - Statement - Condensed Consolidated Balance Sheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://spyre.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "longName": "9952152 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://spyre.com/role/CondensedConsolidatedStatementsofOperations",
     "longName": "9952153 - Statement - Condensed Consolidated Statements of Operations",
     "shortName": "Condensed Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:OperatingExpenses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://spyre.com/role/CondensedConsolidatedStatementsofOperationsParenthetical",
     "longName": "9952154 - Statement - Condensed Consolidated Statements of Operations (Parenthetical)",
     "shortName": "Condensed Consolidated Statements of Operations (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R6": {
     "role": "http://spyre.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
     "longName": "9952155 - Statement - Condensed Consolidated Statements of Comprehensive Loss",
     "shortName": "Condensed Consolidated Statements of Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:ComprehensiveIncomeNetOfTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://spyre.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquity",
     "longName": "9952156 - Statement - Condensed Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders' Equity",
     "shortName": "Condensed Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-64",
      "name": "us-gaap:PreferredStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-71",
      "name": "syre:StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://spyre.com/role/CondensedConsolidatedStatementsofCashFlows",
     "longName": "9952157 - Statement - Condensed Consolidated Statements of Cash Flows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GainLossOnDerivativeInstrumentsNetPretax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "unique": true
     }
    },
    "R9": {
     "role": "http://spyre.com/role/TheCompanyandBasisofPresentation",
     "longName": "9952158 - Disclosure - The Company and Basis of Presentation",
     "shortName": "The Company and Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://spyre.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "9952159 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://spyre.com/role/FairValueMeasurements",
     "longName": "9952160 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://spyre.com/role/CashEquivalentsandMarketableSecurities",
     "longName": "9952161 - Disclosure - Cash Equivalents and Marketable Securities",
     "shortName": "Cash Equivalents and Marketable Securities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://spyre.com/role/AccruedandOtherCurrentLiabilities",
     "longName": "9952162 - Disclosure - Accrued and Other Current Liabilities",
     "shortName": "Accrued and Other Current Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "syre:AccruedAndOtherCurrentLiabilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "syre:AccruedAndOtherCurrentLiabilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://spyre.com/role/LicensingAgreements",
     "longName": "9952163 - Disclosure - Licensing Agreements",
     "shortName": "Licensing Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://spyre.com/role/RelatedPartyTransactions",
     "longName": "9952164 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://spyre.com/role/ConvertiblePreferredStockandStockholdersEquity",
     "longName": "9952165 - Disclosure - Convertible Preferred Stock and Stockholders' Equity",
     "shortName": "Convertible Preferred Stock and Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PreferredStockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PreferredStockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://spyre.com/role/StockBasedCompensation",
     "longName": "9952166 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://spyre.com/role/SaleofPegzilarginasetoImmedica",
     "longName": "9952167 - Disclosure - Sale of Pegzilarginase to Immedica",
     "shortName": "Sale of Pegzilarginase to Immedica",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://spyre.com/role/SegmentReporting",
     "longName": "9952168 - Disclosure - Segment Reporting",
     "shortName": "Segment Reporting",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://spyre.com/role/NetLossPerShare",
     "longName": "9952169 - Disclosure - Net Loss Per Share",
     "shortName": "Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "ecd:NonRule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-15",
      "name": "ecd:NonRule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://spyre.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://spyre.com/role/FairValueMeasurementsTables",
     "longName": "9955512 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesTables",
     "longName": "9955513 - Disclosure - Cash Equivalents and Marketable Securities (Tables)",
     "shortName": "Cash Equivalents and Marketable Securities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://spyre.com/role/AccruedandOtherCurrentLiabilitiesTables",
     "longName": "9955514 - Disclosure - Accrued and Other Current Liabilities (Tables)",
     "shortName": "Accrued and Other Current Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://spyre.com/role/RelatedPartyTransactionsTables",
     "longName": "9955515 - Disclosure - Related Party Transactions (Tables)",
     "shortName": "Related Party Transactions (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://spyre.com/role/StockBasedCompensationTables",
     "longName": "9955516 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://spyre.com/role/SegmentReportingTables",
     "longName": "9955517 - Disclosure - Segment Reporting (Tables)",
     "shortName": "Segment Reporting (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://spyre.com/role/NetLossPerShareTables",
     "longName": "9955518 - Disclosure - Net Loss Per Share (Tables)",
     "shortName": "Net Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://spyre.com/role/TheCompanyandBasisofPresentationDetails",
     "longName": "9955519 - Disclosure - The Company and Basis of Presentation (Details)",
     "shortName": "The Company and Basis of Presentation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-106",
      "name": "syre:ProceedsFromRaisingCapital",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "unique": true
     }
    },
    "R31": {
     "role": "http://spyre.com/role/FairValueMeasurementsScheduleofFairValueofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
     "longName": "9955520 - Disclosure - Fair Value Measurements - Schedule of Fair Value of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "shortName": "Fair Value Measurements - Schedule of Fair Value of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "unique": true
     }
    },
    "R32": {
     "role": "http://spyre.com/role/FairValueMeasurementsNarrativeDetails",
     "longName": "9955521 - Disclosure - Fair Value Measurements - Narrative (Details)",
     "shortName": "Fair Value Measurements - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-154",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-154",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://spyre.com/role/FairValueMeasurementsScheduleofSignificantInputsUsedtoEstimatetheFairValueofCVRLiabilityDetails",
     "longName": "9955522 - Disclosure - Fair Value Measurements - Schedule of Significant Inputs Used to Estimate the Fair Value of CVR Liability (Details)",
     "shortName": "Fair Value Measurements - Schedule of Significant Inputs Used to Estimate the Fair Value of CVR Liability (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-153",
      "name": "us-gaap:DerivativeLiabilityMeasurementInput",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-153",
      "name": "us-gaap:DerivativeLiabilityMeasurementInput",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://spyre.com/role/FairValueMeasurementsScheduleofChangesinCVRLiabilityDetails",
     "longName": "9955523 - Disclosure - Fair Value Measurements - Schedule of Changes in CVR Liability (Details)",
     "shortName": "Fair Value Measurements - Schedule of Changes in CVR Liability (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-155",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-155",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofEstimatedFairValueofCashEquivalentsandMarketableSecuritiesandGrossUnrealizedGainsandLossesDetails",
     "longName": "9955524 - Disclosure - Cash Equivalents and Marketable Securities - Schedule of Estimated Fair Value of Cash Equivalents and Marketable Securities and Gross Unrealized Gains and Losses (Details)",
     "shortName": "Cash Equivalents and Marketable Securities - Schedule of Estimated Fair Value of Cash Equivalents and Marketable Securities and Gross Unrealized Gains and Losses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "syre:CashEquivalentsUnrealizedGains",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetails",
     "longName": "9955525 - Disclosure - Cash Equivalents and Marketable Securities - Schedule of Available-for-Sale Securities in an Unrealized Loss Position (Details)",
     "shortName": "Cash Equivalents and Marketable Securities - Schedule of Available-for-Sale Securities in an Unrealized Loss Position (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails",
     "longName": "9955526 - Disclosure - Cash Equivalents and Marketable Securities - Narrative (Details)",
     "shortName": "Cash Equivalents and Marketable Securities - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "syre:NumberOfDomesticBankingInstitutions",
      "unitRef": "bank",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "syre:NumberOfDomesticBankingInstitutions",
      "unitRef": "bank",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofContractualMaturitiesofMarketableSecuritiesatEstimatedFairValueDetails",
     "longName": "9955527 - Disclosure - Cash Equivalents and Marketable Securities - Schedule of Contractual Maturities of Marketable Securities at Estimated Fair Value (Details)",
     "shortName": "Cash Equivalents and Marketable Securities - Schedule of Contractual Maturities of Marketable Securities at Estimated Fair Value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://spyre.com/role/AccruedandOtherCurrentLiabilitiesDetails",
     "longName": "9955528 - Disclosure - Accrued and Other Current Liabilities (Details)",
     "shortName": "Accrued and Other Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AccruedSalariesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AccruedSalariesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://spyre.com/role/LicensingAgreementsDetails",
     "longName": "9955529 - Disclosure - Licensing Agreements (Details)",
     "shortName": "Licensing Agreements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-174",
      "name": "syre:CampaignTimelineMinimumTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://spyre.com/role/RelatedPartyTransactionsNarrativeDetails",
     "longName": "9955530 - Disclosure - Related Party Transactions - Narrative (Details)",
     "shortName": "Related Party Transactions - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-180",
      "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://spyre.com/role/RelatedPartyTransactionsScheduleofExpensesRelatedtoRelatedPartyWhichareSettledinCashDetails",
     "longName": "9955531 - Disclosure - Related Party Transactions - Schedule of Expenses Related to Related Party Which are Settled in Cash (Details)",
     "shortName": "Related Party Transactions - Schedule of Expenses Related to Related Party Which are Settled in Cash (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-193",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://spyre.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
     "longName": "9955532 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Details)",
     "shortName": "Convertible Preferred Stock and Stockholders' Equity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-95",
      "name": "syre:SaleOfStockAuthorizedAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-207",
      "name": "syre:PreferredStockRemainsIssuedAndOutstandingPercentage",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://spyre.com/role/StockBasedCompensationNarrativeDetails",
     "longName": "9955533 - Disclosure - Stock-Based Compensation - Narrative (Details)",
     "shortName": "Stock-Based Compensation - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-217",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-217",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://spyre.com/role/StockBasedCompensationScheduleofStockAwardsGrantedUnderallEquityIncentiveandInducementPlansDetails",
     "longName": "9955534 - Disclosure - Stock-Based Compensation - Schedule of Stock Awards Granted Under all Equity Incentive and Inducement Plans (Details)",
     "shortName": "Stock-Based Compensation - Schedule of Stock Awards Granted Under all Equity Incentive and Inducement Plans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://spyre.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails",
     "longName": "9955535 - Disclosure - Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Details)",
     "shortName": "Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-230",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://spyre.com/role/StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedinCalculatingFairValueofAwardsDetails",
     "longName": "9955536 - Disclosure - Stock-Based Compensation - Schedule of Weighted-Average Assumptions Used in Calculating Fair Value of Awards (Details)",
     "shortName": "Stock-Based Compensation - Schedule of Weighted-Average Assumptions Used in Calculating Fair Value of Awards (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-234",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-234",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://spyre.com/role/SaleofPegzilarginasetoImmedicaDetails",
     "longName": "9955537 - Disclosure - Sale of Pegzilarginase to Immedica (Details)",
     "shortName": "Sale of Pegzilarginase to Immedica (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProceedsFromSaleOfIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-242",
      "name": "us-gaap:ProceedsFromSaleOfIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://spyre.com/role/SegmentReportingNarrativeDetails",
     "longName": "9955538 - Disclosure - Segment Reporting - Narrative (Details)",
     "shortName": "Segment Reporting - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R50": {
     "role": "http://spyre.com/role/SegmentReportingScheduleofSignificantExpensesProvidedtotheCODMonaRegularBasisDetails",
     "longName": "9955539 - Disclosure - Segment Reporting - Schedule of Significant Expenses Provided to the CODM on a Regular Basis (Details)",
     "shortName": "Segment Reporting - Schedule of Significant Expenses Provided to the CODM on a Regular Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-15",
      "name": "syre:IncreaseDecreaseInFairValueOfContingentValueRightLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://spyre.com/role/NetLossPerShareScheduleofComputationofBasicandDilutedNetLossPerShareDetails",
     "longName": "9955540 - Disclosure - Net Loss Per Share - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details)",
     "shortName": "Net Loss Per Share - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:WeightedAverageNumberOfSharesIssuedBasic",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://spyre.com/role/NetLossPerShareScheduleofWeightedAverageEquityInstrumentsExcludedfromCalculationofDilutedNetLossPerShareDetails",
     "longName": "9955541 - Disclosure - Net Loss Per Share - Schedule of Weighted-Average Equity Instruments Excluded from Calculation of Diluted Net Loss Per Share (Details)",
     "shortName": "Net Loss Per Share - Schedule of Weighted-Average Equity Instruments Excluded from Calculation of Diluted Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-250",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-250",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20260630.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "syre_A2016ESPPMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "A2016ESPPMember",
     "presentation": [
      "http://spyre.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2016 ESPP",
        "label": "2016 ESPP [Member]",
        "documentation": "2016 ESPP"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://spyre.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related party accounts payable",
        "label": "Accounts Payable and Other Accrued Liabilities, Current",
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://spyre.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r835",
      "r956",
      "r959"
     ]
    },
    "us-gaap_AccountsPayableOtherCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccountsPayableOtherCurrent",
     "crdr": "credit",
     "presentation": [
      "http://spyre.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total related party accounts payable",
        "label": "Accounts Payable, Other, Current",
        "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r956",
      "r958"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://spyre.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net accretion of discount on marketable securities",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "syre_AccruedAndOtherCurrentLiabilitiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "AccruedAndOtherCurrentLiabilitiesTextBlock",
     "presentation": [
      "http://spyre.com/role/AccruedandOtherCurrentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued and Other Current Liabilities",
        "label": "Accrued And Other Current Liabilities [Text Block]",
        "documentation": "The entire disclosure for accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "syre_AccruedContractedResearchAndDevelopmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "AccruedContractedResearchAndDevelopmentCosts",
     "crdr": "credit",
     "calculation": {
      "http://spyre.com/role/AccruedandOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://spyre.com/role/AccruedandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued contracted research and development costs",
        "label": "Accrued Contracted Research And Development Costs",
        "documentation": "Accrued contracted research and development costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://spyre.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://spyre.com/role/AccruedandOtherCurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://spyre.com/role/AccruedandOtherCurrentLiabilitiesDetails",
      "http://spyre.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued and other current liabilities",
        "totalLabel": "Total accrued and other current liabilities",
        "label": "Accrued Liabilities and Other Liabilities",
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://spyre.com/role/AccruedandOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://spyre.com/role/AccruedandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued professional and consulting fees",
        "label": "Accrued Professional Fees, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r960"
     ]
    },
    "us-gaap_AccruedSalariesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccruedSalariesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://spyre.com/role/AccruedandOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://spyre.com/role/AccruedandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation",
        "label": "Accrued Salaries, Current",
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r774",
      "r960"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://spyre.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive (loss) income",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r8",
      "r16",
      "r102",
      "r347",
      "r571",
      "r572",
      "r582",
      "r620",
      "r651",
      "r652",
      "r1090"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r5",
      "r8",
      "r463",
      "r466",
      "r469",
      "r521",
      "r647",
      "r648",
      "r977",
      "r978",
      "r979",
      "r991",
      "r992",
      "r993",
      "r994",
      "r1046",
      "r1048"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://spyre.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r965",
      "r1045"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-In Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r612",
      "r666",
      "r991",
      "r992",
      "r993",
      "r994",
      "r1091",
      "r1168"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r863",
      "r873",
      "r883",
      "r915"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r866",
      "r876",
      "r886",
      "r918"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r867",
      "r877",
      "r887",
      "r911",
      "r919",
      "r923",
      "r931"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://spyre.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://spyre.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "verboseLabel": "Total stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r405",
      "r410",
      "r411"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://spyre.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "syre_AmountToBePaidUnderAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "AmountToBePaidUnderAgreement",
     "crdr": "credit",
     "presentation": [
      "http://spyre.com/role/LicensingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent obligation based on milestones",
        "label": "Amount To Be Paid Under Agreement",
        "documentation": "Amount to be paid under agreement."
       }
      }
     },
     "auth_ref": []
    },
    "syre_AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares": {
     "xbrltype": "percentItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares",
     "presentation": [
      "http://spyre.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual percentage of additional shares",
        "label": "Annual Percentage Of Additional Shares Which Equals To Issued And Outstanding Shares",
        "documentation": "Annual percentage of additional shares which equals to the issued and outstanding shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://spyre.com/role/NetLossPerShareScheduleofWeightedAverageEquityInstrumentsExcludedfromCalculationofDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://spyre.com/role/NetLossPerShareScheduleofWeightedAverageEquityInstrumentsExcludedfromCalculationofDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://spyre.com/role/NetLossPerShareScheduleofWeightedAverageEquityInstrumentsExcludedfromCalculationofDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://spyre.com/role/NetLossPerShareScheduleofWeightedAverageEquityInstrumentsExcludedfromCalculationofDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "syre_AppointOfBoardMembersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "AppointOfBoardMembersMember",
     "presentation": [
      "http://spyre.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Appoint Of Board Members",
        "label": "Appoint Of Board Members [Member]",
        "documentation": "Appoint Of Board Members"
       }
      }
     },
     "auth_ref": []
    },
    "syre_April2026UnderwritingOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "April2026UnderwritingOfferingMember",
     "presentation": [
      "http://spyre.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://spyre.com/role/TheCompanyandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "April 2026 Underwriting Agreement",
        "label": "April 2026 Underwriting Offering [Member]",
        "documentation": "April 2026 Underwriting Offering"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AssetAcquisitionAxis",
     "presentation": [
      "http://spyre.com/role/FairValueMeasurementsNarrativeDetails",
      "http://spyre.com/role/TheCompanyandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Acquisition [Axis]",
        "label": "Asset Acquisition [Axis]",
        "documentation": "Information by asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r654",
      "r1084"
     ]
    },
    "syre_AssetAcquisitionCashPaymentThresholdPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "AssetAcquisitionCashPaymentThresholdPeriod",
     "presentation": [
      "http://spyre.com/role/FairValueMeasurementsNarrativeDetails",
      "http://spyre.com/role/TheCompanyandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset acquisition, cash payment, threshold period (in years)",
        "label": "Asset Acquisition, Cash Payment, Threshold Period",
        "documentation": "Asset Acquisition, Cash Payment, Threshold Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetAcquisitionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AssetAcquisitionDomain",
     "presentation": [
      "http://spyre.com/role/FairValueMeasurementsNarrativeDetails",
      "http://spyre.com/role/TheCompanyandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Acquisition [Domain]",
        "label": "Asset Acquisition [Domain]",
        "documentation": "Asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r654",
      "r1084"
     ]
    },
    "syre_AssetAcquisitionStockholderPaymentPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "AssetAcquisitionStockholderPaymentPeriod",
     "presentation": [
      "http://spyre.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Asset acquisition, stockholder payment period (in years)",
        "label": "Asset Acquisition, Stockholder Payment Period",
        "documentation": "Asset Acquisition, Stockholder Payment Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://spyre.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL ASSETS",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r75",
      "r86",
      "r128",
      "r130",
      "r131",
      "r168",
      "r177",
      "r195",
      "r199",
      "r239",
      "r300",
      "r301",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r309",
      "r310",
      "r350",
      "r430",
      "r432",
      "r507",
      "r571",
      "r572",
      "r573",
      "r590",
      "r591",
      "r615",
      "r708",
      "r793",
      "r794",
      "r803",
      "r835",
      "r842",
      "r843",
      "r854",
      "r1037",
      "r1038",
      "r1114"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://spyre.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r75",
      "r105",
      "r128",
      "r130",
      "r131",
      "r239",
      "r300",
      "r301",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r309",
      "r310",
      "r350",
      "r430",
      "r432",
      "r507",
      "r835",
      "r953",
      "r1037",
      "r1038",
      "r1114"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CURRENT ASSETS",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://spyre.com/role/FairValueMeasurementsScheduleofFairValueofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://spyre.com/role/FairValueMeasurementsScheduleofFairValueofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total financial assets",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r480",
      "r481",
      "r823"
     ]
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://spyre.com/role/FairValueMeasurementsScheduleofFairValueofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Assets:",
        "label": "Assets, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "syre_AtTheMarketOffering2024SalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "AtTheMarketOffering2024SalesAgreementMember",
     "presentation": [
      "http://spyre.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://spyre.com/role/TheCompanyandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "At-The-Market Offering, 2024 Sales Agreement",
        "label": "At-The-Market Offering, 2024 Sales Agreement [Member]",
        "documentation": "At-The-Market Offering, 2024 Sales Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "syre_AtTheMarketOffering2026SalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "AtTheMarketOffering2026SalesAgreementMember",
     "presentation": [
      "http://spyre.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://spyre.com/role/TheCompanyandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "At-The-Market Offering, 2026 Sales Agreement",
        "label": "At-The-Market Offering, 2026 Sales Agreement [Member]",
        "documentation": "At-The-Market Offering, 2026 Sales Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofEstimatedFairValueofCashEquivalentsandMarketableSecuritiesandGrossUnrealizedGainsandLossesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofEstimatedFairValueofCashEquivalentsandMarketableSecuritiesandGrossUnrealizedGainsandLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities, gross unrealized gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r212"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofEstimatedFairValueofCashEquivalentsandMarketableSecuritiesandGrossUnrealizedGainsandLossesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofEstimatedFairValueofCashEquivalentsandMarketableSecuritiesandGrossUnrealizedGainsandLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Marketable securities, gross unrealized losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r213"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofEstimatedFairValueofCashEquivalentsandMarketableSecuritiesandGrossUnrealizedGainsandLossesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofEstimatedFairValueofCashEquivalentsandMarketableSecuritiesandGrossUnrealizedGainsandLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Marketable securities, amortized cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r255",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r614",
      "r1124"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract",
     "presentation": [
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "crdr": "debit",
     "calculation": {
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofContractualMaturitiesofMarketableSecuritiesatEstimatedFairValueDetails": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofContractualMaturitiesofMarketableSecuritiesatEstimatedFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due in one year or less",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r608"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://spyre.com/role/FairValueMeasurementsScheduleofFairValueofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://spyre.com/role/FairValueMeasurementsScheduleofFairValueofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial assets",
        "label": "Debt Securities, Available-for-Sale",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r255",
      "r480",
      "r502",
      "r503",
      "r504",
      "r505",
      "r571",
      "r572",
      "r585",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r823",
      "r826",
      "r833",
      "r834",
      "r1007",
      "r1095",
      "r1096",
      "r1097",
      "r1116",
      "r1129"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://spyre.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofEstimatedFairValueofCashEquivalentsandMarketableSecuritiesandGrossUnrealizedGainsandLossesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 3.0
      },
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofContractualMaturitiesofMarketableSecuritiesatEstimatedFairValueDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofContractualMaturitiesofMarketableSecuritiesatEstimatedFairValueDetails",
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofEstimatedFairValueofCashEquivalentsandMarketableSecuritiesandGrossUnrealizedGainsandLossesDetails",
      "http://spyre.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities",
        "verboseLabel": "Marketable securities, estimated fair value",
        "totalLabel": "Total marketable securities",
        "label": "Debt Securities, Available-for-Sale, Current",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r255"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r927"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://spyre.com/role/StockBasedCompensationNarrativeDetails",
      "http://spyre.com/role/StockBasedCompensationScheduleofStockAwardsGrantedUnderallEquityIncentiveandInducementPlansDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r923"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r923"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://spyre.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r984"
     ]
    },
    "syre_CampaignTimelineMinimumTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "CampaignTimelineMinimumTerm",
     "presentation": [
      "http://spyre.com/role/LicensingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Campaign timeline, minimum term (in years)",
        "label": "Campaign Timeline, Minimum Term",
        "documentation": "Campaign Timeline, Minimum Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CashAndCashEquivalentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://spyre.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalent",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r124",
      "r125",
      "r772",
      "r1116"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofEstimatedFairValueofCashEquivalentsandMarketableSecuritiesandGrossUnrealizedGainsandLossesDetails",
      "http://spyre.com/role/FairValueMeasurementsScheduleofFairValueofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Axis]",
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofEstimatedFairValueofCashEquivalentsandMarketableSecuritiesandGrossUnrealizedGainsandLossesDetails": {
       "parentTag": "us-gaap_CashEquivalentsAtCarryingValue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofEstimatedFairValueofCashEquivalentsandMarketableSecuritiesandGrossUnrealizedGainsandLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents, estimated fair value",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r503",
      "r504",
      "r505",
      "r1093",
      "r1094"
     ]
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "presentation": [
      "http://spyre.com/role/CashEquivalentsandMarketableSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Equivalents and Marketable Securities",
        "label": "Cash, Cash Equivalent, and Marketable Security [Text Block]",
        "documentation": "The entire disclosure of cash, cash equivalent, and debt and equity securities, including realized and unrealized gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r1006"
     ]
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://spyre.com/role/TheCompanyandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, cash equivalents, and marketable securities",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r966"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning of period",
        "periodEndLabel": "End of period",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r124",
      "r125"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract",
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH AND CASH EQUIVALENTS",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://spyre.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r26"
     ]
    },
    "syre_CashEquivalentsAndMarketableSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "CashEquivalentsAndMarketableSecuritiesLineItems",
     "presentation": [
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Equivalents And Marketable Securities [Line Items]",
        "label": "Cash Equivalents And Marketable Securities [Line Items]",
        "documentation": "Cash equivalents and marketable securities."
       }
      }
     },
     "auth_ref": []
    },
    "syre_CashEquivalentsAndMarketableSecuritiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "CashEquivalentsAndMarketableSecuritiesTable",
     "presentation": [
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Equivalents And Marketable Securities [Table]",
        "label": "Cash Equivalents And Marketable Securities [Table]",
        "documentation": "Cash equivalents and marketable securities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://spyre.com/role/FairValueMeasurementsScheduleofFairValueofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      },
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofEstimatedFairValueofCashEquivalentsandMarketableSecuritiesandGrossUnrealizedGainsandLossesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofEstimatedFairValueofCashEquivalentsandMarketableSecuritiesandGrossUnrealizedGainsandLossesDetails",
      "http://spyre.com/role/FairValueMeasurementsScheduleofFairValueofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market funds",
        "totalLabel": "Cash equivalents, amortized cost",
        "label": "Cash Equivalents, at Carrying Value",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r125",
      "r957",
      "r1134"
     ]
    },
    "syre_CashEquivalentsUnrealizedGains": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "CashEquivalentsUnrealizedGains",
     "crdr": "credit",
     "calculation": {
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofEstimatedFairValueofCashEquivalentsandMarketableSecuritiesandGrossUnrealizedGainsandLossesDetails": {
       "parentTag": "us-gaap_CashEquivalentsAtCarryingValue",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofEstimatedFairValueofCashEquivalentsandMarketableSecuritiesandGrossUnrealizedGainsandLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents, gross unrealized gains",
        "label": "Cash Equivalents Unrealized Gains",
        "documentation": "Cash equivalents unrealized gains."
       }
      }
     },
     "auth_ref": []
    },
    "syre_CashEquivalentsUnrealizedLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "CashEquivalentsUnrealizedLosses",
     "crdr": "debit",
     "calculation": {
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofEstimatedFairValueofCashEquivalentsandMarketableSecuritiesandGrossUnrealizedGainsandLossesDetails": {
       "parentTag": "us-gaap_CashEquivalentsAtCarryingValue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofEstimatedFairValueofCashEquivalentsandMarketableSecuritiesandGrossUnrealizedGainsandLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cash equivalents, gross unrealized losses",
        "label": "Cash Equivalents Unrealized Losses",
        "documentation": "Cash equivalents unrealized losses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashFDICInsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CashFDICInsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, FDIC insured amount (up to)",
        "label": "Cash, FDIC Insured Amount",
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "CityAreaCode",
     "presentation": [
      "http://spyre.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedBalanceSheets",
      "http://spyre.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://spyre.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquity",
      "http://spyre.com/role/CondensedConsolidatedStatementsofOperations",
      "http://spyre.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://spyre.com/role/NetLossPerShareScheduleofComputationofBasicandDilutedNetLossPerShareDetails",
      "http://spyre.com/role/StockBasedCompensationNarrativeDetails",
      "http://spyre.com/role/TheCompanyandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r81",
      "r82",
      "r94",
      "r95",
      "r96",
      "r98",
      "r99",
      "r100",
      "r128",
      "r131",
      "r156",
      "r157",
      "r159",
      "r161",
      "r170",
      "r171",
      "r239",
      "r300",
      "r303",
      "r304",
      "r305",
      "r309",
      "r310",
      "r316",
      "r317",
      "r319",
      "r320",
      "r322",
      "r325",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r345",
      "r346",
      "r349",
      "r350",
      "r351",
      "r507",
      "r571",
      "r572",
      "r579",
      "r580",
      "r581",
      "r612",
      "r658",
      "r659",
      "r660",
      "r661",
      "r666",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r696",
      "r716",
      "r738",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r941",
      "r986",
      "r987",
      "r996",
      "r1047",
      "r1049"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://spyre.com/role/ConvertiblePreferredStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r82",
      "r94",
      "r99",
      "r100",
      "r170",
      "r319",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r339",
      "r340",
      "r342",
      "r343",
      "r345",
      "r346",
      "r349",
      "r351",
      "r461",
      "r571",
      "r572",
      "r580",
      "r581",
      "r658",
      "r659",
      "r660",
      "r661",
      "r941",
      "r985",
      "r986",
      "r1047"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://spyre.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://spyre.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Axis]",
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r1042"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://spyre.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://spyre.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Domain]",
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": [
      "r1042"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://spyre.com/role/ConvertiblePreferredStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price per warrant (in dollars per share)",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r132",
      "r340"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://spyre.com/role/ConvertiblePreferredStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants to purchase shares (in shares)",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r1042"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://spyre.com/role/LicensingAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Licensing Agreements",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r428",
      "r429"
     ]
    },
    "us-gaap_CommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommercialPaperMember",
     "presentation": [
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetails",
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofEstimatedFairValueofCashEquivalentsandMarketableSecuritiesandGrossUnrealizedGainsandLossesDetails",
      "http://spyre.com/role/FairValueMeasurementsScheduleofFairValueofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial paper",
        "verboseLabel": "Commercial paper",
        "netLabel": "Commercial paper",
        "label": "Commercial Paper [Member]",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r83",
      "r88",
      "r299",
      "r571",
      "r572",
      "r574",
      "r848",
      "r849",
      "r850",
      "r851"
     ]
    },
    "us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember",
     "presentation": [
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofEstimatedFairValueofCashEquivalentsandMarketableSecuritiesandGrossUnrealizedGainsandLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial paper",
        "label": "Commercial Paper, Not Included with Cash and Cash Equivalents [Member]",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents."
       }
      }
     },
     "auth_ref": [
      "r1050",
      "r1051"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://spyre.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies (Notes 6 and 7)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r571",
      "r572",
      "r578",
      "r617",
      "r695"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "presentation": [
      "http://spyre.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent Value Rights",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies."
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://spyre.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock available for future issuance (in shares)",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r1042"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommonStockMember",
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquity",
      "http://spyre.com/role/CondensedConsolidatedStatementsofOperations",
      "http://spyre.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://spyre.com/role/NetLossPerShareScheduleofComputationofBasicandDilutedNetLossPerShareDetails",
      "http://spyre.com/role/TheCompanyandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "verboseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r346",
      "r571",
      "r572",
      "r581",
      "r844",
      "r845",
      "r846",
      "r848",
      "r849",
      "r850",
      "r851",
      "r991",
      "r992",
      "r994",
      "r1091",
      "r1165",
      "r1168"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r963",
      "r1044",
      "r1119",
      "r1120",
      "r1122"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r346",
      "r571",
      "r572",
      "r581",
      "r696"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r346",
      "r571",
      "r572",
      "r581"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://spyre.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, outstanding (in shares)",
        "periodStartLabel": "Beginning balance, common stock (in shares)",
        "periodEndLabel": "Ending balance, common stock (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r346",
      "r571",
      "r572",
      "r581",
      "r696",
      "r714",
      "r1041",
      "r1168",
      "r1169"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://spyre.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.0001 par value; 400,000,000 shares authorized as of June\u00a030, 2026 and December\u00a031, 2025; 88,064,133 shares and 78,189,811 shares issued and outstanding as of June\u00a030, 2026 and December\u00a031, 2025, respectively.",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r317",
      "r324",
      "r346",
      "r571",
      "r572",
      "r581",
      "r619",
      "r835"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r908"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r907"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r909"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "syre_CompanyAndBasisOfPresentationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "CompanyAndBasisOfPresentationLineItems",
     "presentation": [
      "http://spyre.com/role/TheCompanyandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company and Basis of Presentation [Line Items]",
        "label": "Company and Basis of Presentation [Line Items]",
        "documentation": "Company and basis of presentation."
       }
      }
     },
     "auth_ref": []
    },
    "syre_CompanyAndBasisOfPresentationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "CompanyAndBasisOfPresentationTable",
     "presentation": [
      "http://spyre.com/role/TheCompanyandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company and Basis of Presentation [Table]",
        "label": "Company and Basis of Presentation [Table]",
        "documentation": "Company and basis of presentation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CompensationExpenseExcludingCostOfGoodAndServiceSold",
     "crdr": "debit",
     "calculation": {
      "http://spyre.com/role/SegmentReportingScheduleofSignificantExpensesProvidedtotheCODMonaRegularBasisDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://spyre.com/role/SegmentReportingScheduleofSignificantExpensesProvidedtotheCODMonaRegularBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation",
        "label": "Compensation Expense, Excluding Cost of Good and Service Sold",
        "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit. Other employee benefit expense includes, but is not limited to, service component of net periodic benefit cost for defined benefit plan. Excludes compensation cost in cost of good and service sold."
       }
      }
     },
     "auth_ref": [
      "r793",
      "r980"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://spyre.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r111",
      "r113",
      "r117",
      "r588",
      "r628",
      "r629"
     ]
    },
    "srt_ConsolidationItemsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "ConsolidationItemsAxis",
     "presentation": [
      "http://spyre.com/role/SegmentReportingScheduleofSignificantExpensesProvidedtotheCODMonaRegularBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation Items [Axis]",
        "label": "Consolidation Items [Axis]"
       }
      }
     },
     "auth_ref": [
      "r128",
      "r129",
      "r134",
      "r135",
      "r168",
      "r179",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r199",
      "r200",
      "r201",
      "r300",
      "r301",
      "r302",
      "r303",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r350",
      "r593",
      "r793",
      "r794",
      "r1037",
      "r1038"
     ]
    },
    "srt_ConsolidationItemsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "ConsolidationItemsDomain",
     "presentation": [
      "http://spyre.com/role/SegmentReportingScheduleofSignificantExpensesProvidedtotheCODMonaRegularBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation Items [Domain]",
        "label": "Consolidation Items [Domain]"
       }
      }
     },
     "auth_ref": [
      "r128",
      "r129",
      "r134",
      "r135",
      "r168",
      "r179",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r199",
      "r200",
      "r201",
      "r300",
      "r301",
      "r302",
      "r303",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r350",
      "r593",
      "r793",
      "r794",
      "r1037",
      "r1038"
     ]
    },
    "syre_ConsultingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "ConsultingAgreementMember",
     "presentation": [
      "http://spyre.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consulting Agreement",
        "label": "Consulting Agreement [Member]",
        "documentation": "Consulting Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "syre_ContingentValueRightLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "ContingentValueRightLiabilityMember",
     "presentation": [
      "http://spyre.com/role/FairValueMeasurementsNarrativeDetails",
      "http://spyre.com/role/FairValueMeasurementsScheduleofChangesinCVRLiabilityDetails",
      "http://spyre.com/role/FairValueMeasurementsScheduleofSignificantInputsUsedtoEstimatetheFairValueofCVRLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CVR liability",
        "verboseLabel": "CVR Liability",
        "label": "Contingent Value Right Liability [Member]",
        "documentation": "Contingent Value Right Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockAmountConverted1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ConversionOfStockAmountConverted1",
     "crdr": "debit",
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of Series B non-voting convertible preferred stock into common stock",
        "label": "Conversion of Stock, Amount Converted",
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r983"
     ]
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "presentation": [
      "http://spyre.com/role/ConvertiblePreferredStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Converted at the option of the holder (in shares)",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r337",
      "r340"
     ]
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CorporateBondSecuritiesMember",
     "presentation": [
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetails",
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofEstimatedFairValueofCashEquivalentsandMarketableSecuritiesandGrossUnrealizedGainsandLossesDetails",
      "http://spyre.com/role/FairValueMeasurementsScheduleofFairValueofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate bonds",
        "verboseLabel": "Corporate bonds",
        "netLabel": "Corporate bonds",
        "label": "Corporate Bond Securities [Member]",
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount)."
       }
      }
     },
     "auth_ref": [
      "r1171"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://spyre.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest",
     "crdr": "credit",
     "presentation": [
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowance for credit loss",
        "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Excluding Accrued Interest",
        "documentation": "Amount excluding accrued interest, of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r255"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "crdr": "debit",
     "calculation": {
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "12 Months or Longer",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r259",
      "r799"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "crdr": "debit",
     "calculation": {
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "12 Months or Longer",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r259"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "crdr": "debit",
     "calculation": {
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less Than 12 Months",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r259",
      "r799"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "crdr": "debit",
     "calculation": {
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less Than 12 Months",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r259"
     ]
    },
    "syre_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne",
     "crdr": "debit",
     "calculation": {
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofContractualMaturitiesofMarketableSecuritiesatEstimatedFairValueDetails": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofContractualMaturitiesofMarketableSecuritiesatEstimatedFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due in 1 - 2 years",
        "label": "Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, After Year One",
        "documentation": "Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, After Year One"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetails",
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofEstimatedFairValueofCashEquivalentsandMarketableSecuritiesandGrossUnrealizedGainsandLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-Sale [Table]",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "crdr": "debit",
     "calculation": {
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total, fair value",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r257",
      "r799"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "crdr": "debit",
     "calculation": {
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total, unrealized losses",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r258"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "presentation": [
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Available-for-Sale Securities in an Unrealized Loss Position",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r799",
      "r1026"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract",
     "presentation": [
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "syre_DeferredOfferingCostsAllocatedAmountOfProceedsOfIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "DeferredOfferingCostsAllocatedAmountOfProceedsOfIssuanceOfCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allocation of deferred offering costs against proceeds of issuance of common stock",
        "label": "Deferred Offering Costs, Allocated Amount of Proceeds of Issuance of Common Stock",
        "documentation": "Deferred Offering Costs, Allocated Amount of Proceeds of Issuance of Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "syre_DeferredOfferingCostsUnpaidAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "DeferredOfferingCostsUnpaidAmount",
     "crdr": "credit",
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unpaid deferred offering costs in connection with shelf registration",
        "label": "Deferred Offering Costs, Unpaid Amount",
        "documentation": "Deferred Offering Costs, Unpaid Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DerivativeContractTypeDomain",
     "presentation": [
      "http://spyre.com/role/FairValueMeasurementsNarrativeDetails",
      "http://spyre.com/role/FairValueMeasurementsScheduleofSignificantInputsUsedtoEstimatetheFairValueofCVRLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Contract [Domain]",
        "label": "Derivative Contract [Domain]",
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r548",
      "r685",
      "r687",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r709",
      "r710",
      "r711",
      "r712",
      "r726",
      "r727",
      "r728",
      "r729",
      "r732",
      "r733",
      "r734",
      "r735",
      "r748",
      "r749",
      "r752",
      "r754",
      "r775",
      "r776",
      "r779",
      "r820",
      "r821",
      "r837",
      "r844",
      "r846",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1105",
      "r1106"
     ]
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://spyre.com/role/FairValueMeasurementsNarrativeDetails",
      "http://spyre.com/role/FairValueMeasurementsScheduleofSignificantInputsUsedtoEstimatetheFairValueofCVRLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instrument [Axis]",
        "label": "Derivative Instrument [Axis]",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r548",
      "r685",
      "r687",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r709",
      "r710",
      "r711",
      "r712",
      "r726",
      "r727",
      "r728",
      "r729",
      "r732",
      "r733",
      "r734",
      "r735",
      "r748",
      "r749",
      "r752",
      "r754",
      "r775",
      "r776",
      "r779",
      "r820",
      "r821",
      "r837",
      "r844",
      "r846",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1105",
      "r1106"
     ]
    },
    "us-gaap_DerivativeLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DerivativeLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://spyre.com/role/FairValueMeasurementsScheduleofFairValueofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://spyre.com/role/FairValueMeasurementsScheduleofFairValueofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CVR liability",
        "label": "Derivative Liability",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r107",
      "r460",
      "r480",
      "r481",
      "r494",
      "r503",
      "r504",
      "r505",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r709",
      "r711",
      "r712",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r775",
      "r777",
      "r778",
      "r779",
      "r1095",
      "r1096",
      "r1097",
      "r1166"
     ]
    },
    "us-gaap_DerivativeLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DerivativeLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://spyre.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CVR liability",
        "label": "Derivative Liability, Current",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DerivativeLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://spyre.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current CVR liability",
        "label": "Derivative Liability, Noncurrent",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "us-gaap_DerivativeLiabilityMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DerivativeLiabilityMeasurementInput",
     "presentation": [
      "http://spyre.com/role/FairValueMeasurementsScheduleofSignificantInputsUsedtoEstimatetheFairValueofCVRLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative liability, measurement input",
        "label": "Derivative Liability, Measurement Input",
        "documentation": "Value of input used to measure derivative liability."
       }
      }
     },
     "auth_ref": [
      "r482",
      "r483",
      "r484"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://spyre.com/role/StockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r374",
      "r377",
      "r406",
      "r407",
      "r408",
      "r812"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DisposalGroupClassificationAxis",
     "presentation": [
      "http://spyre.com/role/SaleofPegzilarginasetoImmedicaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Classification [Axis]",
        "label": "Disposal Group Classification [Axis]",
        "documentation": "Information by disposal group classification."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r56",
      "r70",
      "r71",
      "r72",
      "r73",
      "r74",
      "r77",
      "r79",
      "r282",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r771",
      "r1027",
      "r1032",
      "r1033",
      "r1034",
      "r1035"
     ]
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DisposalGroupClassificationDomain",
     "presentation": [
      "http://spyre.com/role/SaleofPegzilarginasetoImmedicaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Classification [Domain]",
        "label": "Disposal Group Classification [Domain]",
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r56",
      "r70",
      "r71",
      "r72",
      "r73",
      "r74",
      "r77",
      "r79",
      "r282",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r771",
      "r1027",
      "r1032",
      "r1033",
      "r1034",
      "r1035"
     ]
    },
    "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember",
     "presentation": [
      "http://spyre.com/role/SaleofPegzilarginasetoImmedicaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group, Disposed of by Sale, Not Discontinued Operations",
        "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]",
        "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration",
     "crdr": "debit",
     "presentation": [
      "http://spyre.com/role/SaleofPegzilarginasetoImmedicaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Receivable outstanding",
        "label": "Disposal Group, Including Discontinued Operation, Consideration",
        "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r1028"
     ]
    },
    "syre_DisposalGroupIncludingDiscontinuedOperationContingentConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "DisposalGroupIncludingDiscontinuedOperationContingentConsideration",
     "crdr": "debit",
     "presentation": [
      "http://spyre.com/role/SaleofPegzilarginasetoImmedicaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration",
        "label": "Disposal Group, Including Discontinued Operation, Contingent Consideration",
        "documentation": "Disposal Group, Including Discontinued Operation, Contingent Consideration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposal",
     "crdr": "credit",
     "calculation": {
      "http://spyre.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": -1.0,
       "order": 3.0
      },
      "http://spyre.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://spyre.com/role/CondensedConsolidatedStatementsofOperations",
      "http://spyre.com/role/SaleofPegzilarginasetoImmedicaDetails",
      "http://spyre.com/role/SegmentReportingScheduleofSignificantExpensesProvidedtotheCODMonaRegularBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Gain on sale of in-process research and development asset",
        "negatedLabel": "Gain on sale of in-process research and development asset",
        "terseLabel": "Gain on sale of in-process research and development asset",
        "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal",
        "documentation": "Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r286",
      "r982",
      "r1027"
     ]
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "presentation": [
      "http://spyre.com/role/SaleofPegzilarginasetoImmedica"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Pegzilarginase to Immedica",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r59",
      "r60",
      "r61",
      "r281"
     ]
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "presentation": [
      "http://spyre.com/role/SaleofPegzilarginasetoImmedicaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Name [Domain]",
        "label": "Disposal Group Name [Domain]",
        "documentation": "Name of disposal group."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r63",
      "r64",
      "r65",
      "r66",
      "r67",
      "r68",
      "r287",
      "r289",
      "r809",
      "r810",
      "r949",
      "r950",
      "r1032",
      "r1033",
      "r1034",
      "r1035"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://spyre.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://spyre.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://spyre.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://spyre.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Quarterly Report",
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://spyre.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r890"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentType",
     "presentation": [
      "http://spyre.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share [Abstract]",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedStatementsofOperations",
      "http://spyre.com/role/NetLossPerShareScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share, basic (in dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r118",
      "r139",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r154",
      "r156",
      "r159",
      "r160",
      "r161",
      "r167",
      "r279",
      "r315",
      "r358",
      "r409",
      "r422",
      "r427",
      "r476",
      "r477",
      "r589",
      "r630",
      "r786"
     ]
    },
    "us-gaap_EarningsPerShareBasicLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EarningsPerShareBasicLineItems",
     "presentation": [
      "http://spyre.com/role/NetLossPerShareScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]",
        "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r157",
      "r159",
      "r161"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedStatementsofOperations",
      "http://spyre.com/role/NetLossPerShareScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share, diluted (in dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r118",
      "r139",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r156",
      "r159",
      "r160",
      "r161",
      "r167",
      "r279",
      "r315",
      "r358",
      "r409",
      "r422",
      "r427",
      "r476",
      "r477",
      "r589",
      "r630",
      "r786"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://spyre.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "us-gaap_EarningsPerShareReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EarningsPerShareReconciliationAbstract",
     "presentation": [
      "http://spyre.com/role/NetLossPerShareScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share, basic and diluted:",
        "label": "Earnings Per Share Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://spyre.com/role/NetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r162",
      "r164",
      "r165",
      "r166",
      "r354"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://spyre.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails",
      "http://spyre.com/role/StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedinCalculatingFairValueofAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r1079"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://spyre.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock",
        "label": "Employee Stock [Member]",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://spyre.com/role/NetLossPerShareScheduleofWeightedAverageEquityInstrumentsExcludedfromCalculationofDilutedNetLossPerShareDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Options to purchase common stock",
        "terseLabel": "Stock Options",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://spyre.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://spyre.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://spyre.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Three",
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://spyre.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://spyre.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://spyre.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://spyre.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://spyre.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://spyre.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://spyre.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://spyre.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://spyre.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://spyre.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://spyre.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r940"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://spyre.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://spyre.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://spyre.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://spyre.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r936"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r936"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r936"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity [Abstract]",
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r50",
      "r81",
      "r99",
      "r100",
      "r114",
      "r115",
      "r116",
      "r136",
      "r137",
      "r138",
      "r140",
      "r147",
      "r149",
      "r151",
      "r169",
      "r240",
      "r241",
      "r278",
      "r279",
      "r280",
      "r314",
      "r339",
      "r344",
      "r345",
      "r346",
      "r349",
      "r351",
      "r353",
      "r356",
      "r357",
      "r359",
      "r360",
      "r409",
      "r416",
      "r417",
      "r419",
      "r420",
      "r421",
      "r423",
      "r426",
      "r427",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r567",
      "r571",
      "r572",
      "r580",
      "r581",
      "r612",
      "r626",
      "r647",
      "r648",
      "r649",
      "r666",
      "r738",
      "r1049"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r905"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r863",
      "r873",
      "r883",
      "r915"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r860",
      "r870",
      "r880",
      "r912"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://spyre.com/role/FairValueMeasurementsNarrativeDetails",
      "http://spyre.com/role/FairValueMeasurementsScheduleofFairValueofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r478",
      "r480",
      "r481",
      "r494",
      "r823"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://spyre.com/role/FairValueMeasurementsNarrativeDetails",
      "http://spyre.com/role/FairValueMeasurementsScheduleofFairValueofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r478",
      "r480",
      "r481",
      "r494",
      "r823"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://spyre.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Significant Inputs Used to Estimate the Fair Value of CVR Liability",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r482",
      "r483",
      "r826"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://spyre.com/role/FairValueMeasurementsScheduleofFairValueofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://spyre.com/role/FairValueMeasurementsScheduleofSignificantInputsUsedtoEstimatetheFairValueofCVRLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r311",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r369",
      "r370",
      "r478",
      "r479",
      "r481",
      "r482",
      "r483",
      "r484",
      "r493",
      "r494",
      "r496",
      "r503",
      "r533",
      "r534",
      "r535",
      "r540",
      "r801",
      "r802",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r823",
      "r826",
      "r833",
      "r834"
     ]
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueByLiabilityClassAxis",
     "presentation": [
      "http://spyre.com/role/FairValueMeasurementsScheduleofChangesinCVRLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability Class [Axis]",
        "label": "Liability Class [Axis]",
        "documentation": "Information by class of liability."
       }
      }
     },
     "auth_ref": [
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r495"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Disclosures [Abstract]",
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://spyre.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r482",
      "r489",
      "r491",
      "r492",
      "r493",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r570",
      "r823",
      "r827"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://spyre.com/role/FairValueMeasurementsScheduleofFairValueofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r311",
      "r362",
      "r367",
      "r369",
      "r481",
      "r494",
      "r503",
      "r533",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r823",
      "r833",
      "r834"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://spyre.com/role/FairValueMeasurementsScheduleofFairValueofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r311",
      "r362",
      "r367",
      "r369",
      "r371",
      "r481",
      "r482",
      "r494",
      "r503",
      "r534",
      "r801",
      "r802",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r823",
      "r833",
      "r834"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://spyre.com/role/FairValueMeasurementsScheduleofFairValueofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://spyre.com/role/FairValueMeasurementsScheduleofSignificantInputsUsedtoEstimatetheFairValueofCVRLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r311",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r369",
      "r370",
      "r481",
      "r482",
      "r483",
      "r484",
      "r494",
      "r503",
      "r535",
      "r801",
      "r802",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r823",
      "r826",
      "r833",
      "r834"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "presentation": [
      "http://spyre.com/role/FairValueMeasurementsScheduleofChangesinCVRLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value by Liability Class [Domain]",
        "label": "Fair Value by Liability Class [Domain]",
        "documentation": "Represents classes of liabilities measured and disclosed at fair value."
       }
      }
     },
     "auth_ref": [
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r495"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "presentation": [
      "http://spyre.com/role/FairValueMeasurementsScheduleofChangesinCVRLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "presentation": [
      "http://spyre.com/role/FairValueMeasurementsScheduleofChangesinCVRLiabilityDetails",
      "http://spyre.com/role/FairValueMeasurementsScheduleofSignificantInputsUsedtoEstimatetheFairValueofCVRLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "presentation": [
      "http://spyre.com/role/FairValueMeasurementsScheduleofChangesinCVRLiabilityDetails",
      "http://spyre.com/role/FairValueMeasurementsScheduleofSignificantInputsUsedtoEstimatetheFairValueofCVRLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "documentation": "Disclosure of information about financial instrument liability measured at fair value on recurring basis using unobservable input."
       }
      }
     },
     "auth_ref": [
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r495"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://spyre.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Changes in CVR Liability",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r485",
      "r490",
      "r495"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "crdr": "credit",
     "presentation": [
      "http://spyre.com/role/FairValueMeasurementsNarrativeDetails",
      "http://spyre.com/role/FairValueMeasurementsScheduleofChangesinCVRLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Increase in fair value of derivative",
        "negatedTerseLabel": "Changes in the fair value of the CVR liability",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r486",
      "r495"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "crdr": "debit",
     "presentation": [
      "http://spyre.com/role/FairValueMeasurementsNarrativeDetails",
      "http://spyre.com/role/FairValueMeasurementsScheduleofChangesinCVRLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Payment to CVR holders",
        "negatedTerseLabel": "Payments",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r488",
      "r495"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://spyre.com/role/FairValueMeasurementsScheduleofChangesinCVRLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r485",
      "r495"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://spyre.com/role/FairValueMeasurementsScheduleofFairValueofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://spyre.com/role/FairValueMeasurementsScheduleofSignificantInputsUsedtoEstimatetheFairValueofCVRLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r311",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r369",
      "r370",
      "r478",
      "r479",
      "r481",
      "r482",
      "r483",
      "r484",
      "r493",
      "r494",
      "r496",
      "r503",
      "r533",
      "r534",
      "r535",
      "r540",
      "r801",
      "r802",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r823",
      "r826",
      "r833",
      "r834"
     ]
    },
    "syre_FairmountFundsManagementLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "FairmountFundsManagementLlcMember",
     "presentation": [
      "http://spyre.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fairmount Funds Management LLC",
        "label": "Fairmount Funds Management LLC [Member]",
        "documentation": "Fairmount Funds Management LLC."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails",
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetails",
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofEstimatedFairValueofCashEquivalentsandMarketableSecuritiesandGrossUnrealizedGainsandLossesDetails",
      "http://spyre.com/role/FairValueMeasurementsScheduleofFairValueofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r256",
      "r260",
      "r261",
      "r313",
      "r338",
      "r461",
      "r501",
      "r506",
      "r509",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r537",
      "r538",
      "r539",
      "r540",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r549",
      "r550",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r613",
      "r627",
      "r799",
      "r823",
      "r824",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1092",
      "r1095",
      "r1096",
      "r1097",
      "r1104",
      "r1107",
      "r1108",
      "r1109"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r867",
      "r877",
      "r887",
      "r919"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r867",
      "r877",
      "r887",
      "r919"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r867",
      "r877",
      "r887",
      "r919"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r867",
      "r877",
      "r887",
      "r919"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r867",
      "r877",
      "r887",
      "r919"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "GainLossOnDerivativeInstrumentsNetPretax",
     "crdr": "credit",
     "calculation": {
      "http://spyre.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in fair value of CVR liability",
        "label": "Gain (Loss) on Derivative Instruments, Net, Pretax",
        "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects."
       }
      }
     },
     "auth_ref": [
      "r1085"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://spyre.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedStatementsofOperations",
      "http://spyre.com/role/CondensedConsolidatedStatementsofOperationsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r718"
     ]
    },
    "syre_GlobalRightsToPegzilarginaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "GlobalRightsToPegzilarginaseMember",
     "presentation": [
      "http://spyre.com/role/SaleofPegzilarginasetoImmedicaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Global Rights to Pegzilarginase",
        "label": "Global Rights To Pegzilarginase [Member]",
        "documentation": "Global Rights To Pegzilarginase"
       }
      }
     },
     "auth_ref": []
    },
    "syre_HeidyKingJonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "HeidyKingJonesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Heidy King-Jones [Member]",
        "documentation": "Heidy King-Jones"
       }
      }
     },
     "auth_ref": []
    },
    "syre_ImpairmentOfMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "ImpairmentOfMarketableSecurities",
     "crdr": "credit",
     "presentation": [
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of marketable securities",
        "label": "Impairment Of Marketable Securities",
        "documentation": "Impairment of marketable securities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://spyre.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before income tax expense",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r34",
      "r590",
      "r592",
      "r624",
      "r770",
      "r780",
      "r782",
      "r783",
      "r788",
      "r793",
      "r999",
      "r1001",
      "r1002",
      "r1004",
      "r1005"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "presentation": [
      "http://spyre.com/role/SaleofPegzilarginasetoImmedicaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Name [Axis]",
        "label": "Disposal Group Name [Axis]",
        "documentation": "Information by name of disposal group."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r63",
      "r64",
      "r65",
      "r66",
      "r67",
      "r68",
      "r287",
      "r289",
      "r809",
      "r810",
      "r949",
      "r950",
      "r1032",
      "r1033",
      "r1034",
      "r1035"
     ]
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "presentation": [
      "http://spyre.com/role/SaleofPegzilarginasetoImmedicaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group, Including Discontinued Operations [Line Items]",
        "label": "Disposal Group, Including Discontinued Operations [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r56",
      "r57",
      "r58",
      "r62",
      "r63",
      "r64",
      "r65",
      "r66",
      "r67",
      "r68",
      "r70",
      "r71",
      "r72",
      "r73",
      "r74",
      "r76",
      "r77",
      "r78",
      "r79",
      "r282",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r771",
      "r949",
      "r950",
      "r1027",
      "r1032",
      "r1033",
      "r1034",
      "r1035"
     ]
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "presentation": [
      "http://spyre.com/role/SaleofPegzilarginasetoImmedicaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r57",
      "r58",
      "r62",
      "r63",
      "r64",
      "r65",
      "r66",
      "r67",
      "r68",
      "r70",
      "r71",
      "r72",
      "r73",
      "r74",
      "r76",
      "r77",
      "r78",
      "r79",
      "r282",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r771",
      "r949",
      "r950",
      "r1027",
      "r1032",
      "r1033",
      "r1034",
      "r1035"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://spyre.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income tax benefit",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r46",
      "r128",
      "r150",
      "r151",
      "r168",
      "r185",
      "r199",
      "r414",
      "r415",
      "r418",
      "r631",
      "r770",
      "r780",
      "r782",
      "r783",
      "r814"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "crdr": "debit",
     "calculation": {
      "http://spyre.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable, Trade",
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://spyre.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued and other liabilities",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r981"
     ]
    },
    "syre_IncreaseDecreaseInFairValueOfContingentValueRightLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "IncreaseDecreaseInFairValueOfContingentValueRightLiability",
     "crdr": "credit",
     "presentation": [
      "http://spyre.com/role/SegmentReportingScheduleofSignificantExpensesProvidedtotheCODMonaRegularBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (decrease) in fair value of contingent value right liability",
        "label": "Increase (Decrease) In Fair Value Of Contingent Value Right Liability",
        "documentation": "Increase (Decrease) In Fair Value Of Contingent Value Right Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncreaseDecreaseInOtherAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://spyre.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related party accounts payable",
        "label": "Increase (Decrease) in Other Accounts Payable",
        "documentation": "Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://spyre.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r867",
      "r877",
      "r887",
      "r911",
      "r919",
      "r923",
      "r931"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r859",
      "r935"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r859",
      "r935"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r859",
      "r935"
     ]
    },
    "syre_InterestProceedsDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "InterestProceedsDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://spyre.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest proceeds from maturities of zero coupon U.S. Treasury Bills",
        "label": "Interest Proceeds, Debt Securities",
        "documentation": "Interest Proceeds, Debt Securities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "InterestReceivable",
     "crdr": "debit",
     "presentation": [
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest receivable on available-for-sale debt securities",
        "label": "Interest Receivable",
        "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable."
       }
      }
     },
     "auth_ref": [
      "r955",
      "r964",
      "r1170"
     ]
    },
    "us-gaap_InvestmentIncomeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "InvestmentIncomeNet",
     "crdr": "credit",
     "calculation": {
      "http://spyre.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Investment Income, Net",
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r23"
     ]
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "presentation": [
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Contractual Maturities of Marketable Securities at Estimated Fair Value",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments."
       }
      }
     },
     "auth_ref": [
      "r1009",
      "r1010"
     ]
    },
    "syre_IssuanceOfConvertiblePreferredStockRelatedToPrivatePlacementUnpaidAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "IssuanceOfConvertiblePreferredStockRelatedToPrivatePlacementUnpaidAmount",
     "crdr": "credit",
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from stock option exercises received in subsequent period",
        "label": "Issuance of Convertible Preferred Stock Related to Private Placement, Unpaid Amount",
        "documentation": "Issuance of Convertible Preferred Stock Related to Private Placement, Unpaid Amount"
       }
      }
     },
     "auth_ref": []
    },
    "syre_JeffreyAlbersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "JeffreyAlbersMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Jeffrey Albers [Member]",
        "documentation": "Jeffrey Albers"
       }
      }
     },
     "auth_ref": []
    },
    "syre_JeffreyAlbersRuleTradingArrangementDirectorStockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "JeffreyAlbersRuleTradingArrangementDirectorStockOptionsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Jeffrey Albers Rule Trading Arrangement, Director Stock Options [Member]",
        "documentation": "Jeffrey Albers Rule Trading Arrangement, Director Stock Options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://spyre.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r75",
      "r128",
      "r130",
      "r131",
      "r239",
      "r300",
      "r301",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r309",
      "r310",
      "r350",
      "r431",
      "r432",
      "r433",
      "r507",
      "r694",
      "r787",
      "r803",
      "r854",
      "r967",
      "r1037",
      "r1114",
      "r1115"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://spyre.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS\u2019 EQUITY",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r571",
      "r572",
      "r584",
      "r622",
      "r835",
      "r842",
      "r843",
      "r985",
      "r988",
      "r1015",
      "r1110"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://spyre.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r75",
      "r80",
      "r89",
      "r128",
      "r130",
      "r131",
      "r239",
      "r300",
      "r301",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r309",
      "r310",
      "r350",
      "r431",
      "r432",
      "r433",
      "r507",
      "r835",
      "r1037",
      "r1114",
      "r1115"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CURRENT LIABILITIES",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "calculation": {
      "http://spyre.com/role/FairValueMeasurementsScheduleofFairValueofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://spyre.com/role/FairValueMeasurementsScheduleofFairValueofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities, Fair Value Disclosure",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r481",
      "r1093"
     ]
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "presentation": [
      "http://spyre.com/role/FairValueMeasurementsScheduleofFairValueofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities:",
        "label": "Liabilities, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "syre_LicenseAgreementMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "LicenseAgreementMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://spyre.com/role/LicensingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash milestone payments",
        "label": "License Agreement, Milestone Payments",
        "documentation": "License Agreement, Milestone Payments"
       }
      }
     },
     "auth_ref": []
    },
    "syre_LicenseAgreementMilestonePaymentsOutstandingAndPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "LicenseAgreementMilestonePaymentsOutstandingAndPayable",
     "crdr": "credit",
     "presentation": [
      "http://spyre.com/role/LicensingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payments, outstanding and payable",
        "label": "License Agreement, Milestone Payments Outstanding and Payable",
        "documentation": "License Agreement, Milestone Payments Outstanding and Payable"
       }
      }
     },
     "auth_ref": []
    },
    "syre_LicensingAgreementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "LicensingAgreementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Licensing Agreements [Abstract]",
        "documentation": "Licensing Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://spyre.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments",
     "crdr": "credit",
     "presentation": [
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Realized gains or losses on marketable securities",
        "label": "Marketable Security, Realized Gain (Loss)",
        "documentation": "Amount of realized gain (loss) on investment in marketable security."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "MaximumMember",
     "presentation": [
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails",
      "http://spyre.com/role/LicensingAgreementsDetails",
      "http://spyre.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Maximum",
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r76",
      "r78",
      "r172",
      "r295",
      "r296",
      "r297",
      "r298",
      "r373",
      "r401",
      "r402",
      "r403",
      "r412",
      "r484",
      "r536",
      "r537",
      "r538",
      "r539",
      "r541",
      "r542",
      "r543",
      "r544",
      "r568",
      "r643",
      "r645",
      "r653",
      "r686",
      "r687",
      "r744",
      "r745",
      "r746",
      "r747",
      "r756",
      "r762",
      "r763",
      "r764",
      "r765",
      "r767",
      "r768",
      "r798",
      "r811",
      "r815",
      "r817",
      "r818",
      "r826",
      "r827",
      "r831",
      "r832",
      "r840",
      "r1039",
      "r1040"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "MeasurementInputDiscountRateMember",
     "presentation": [
      "http://spyre.com/role/FairValueMeasurementsScheduleofSignificantInputsUsedtoEstimatetheFairValueofCVRLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-adjusted discount rate",
        "label": "Measurement Input, Discount Rate [Member]",
        "documentation": "Measurement input using interest rate to determine present value of future cash flows."
       }
      }
     },
     "auth_ref": [
      "r815",
      "r817",
      "r818",
      "r839",
      "r1095",
      "r1096",
      "r1097"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://spyre.com/role/FairValueMeasurementsScheduleofSignificantInputsUsedtoEstimatetheFairValueofCVRLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Axis]",
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r482",
      "r483",
      "r484",
      "r815",
      "r817",
      "r818",
      "r826",
      "r1117"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://spyre.com/role/FairValueMeasurementsScheduleofSignificantInputsUsedtoEstimatetheFairValueofCVRLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Domain]",
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r482",
      "r483",
      "r484",
      "r815",
      "r817",
      "r818",
      "r826",
      "r1117"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "MinimumMember",
     "presentation": [
      "http://spyre.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r76",
      "r78",
      "r172",
      "r295",
      "r296",
      "r297",
      "r298",
      "r373",
      "r401",
      "r402",
      "r403",
      "r412",
      "r484",
      "r536",
      "r537",
      "r538",
      "r539",
      "r541",
      "r542",
      "r543",
      "r544",
      "r568",
      "r643",
      "r645",
      "r653",
      "r686",
      "r687",
      "r744",
      "r745",
      "r746",
      "r747",
      "r756",
      "r762",
      "r763",
      "r764",
      "r765",
      "r767",
      "r768",
      "r798",
      "r811",
      "r815",
      "r817",
      "r818",
      "r826",
      "r827",
      "r831",
      "r840",
      "r1039",
      "r1040"
     ]
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "presentation": [
      "http://spyre.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of ownership by noncontrolling owner",
        "label": "Subsidiary, Ownership Percentage, Noncontrolling Owner",
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity."
       }
      }
     },
     "auth_ref": []
    },
    "syre_MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty": {
     "xbrltype": "percentItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty",
     "presentation": [
      "http://spyre.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of ownership held in third party",
        "label": "Minority Interest Ownership Percentage By Noncontrolling Owners Held In Third Party",
        "documentation": "Minority interest ownership percentage by noncontrolling owners held in third party."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofEstimatedFairValueofCashEquivalentsandMarketableSecuritiesandGrossUnrealizedGainsandLossesDetails",
      "http://spyre.com/role/FairValueMeasurementsScheduleofFairValueofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market funds",
        "verboseLabel": "Money market funds",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r1050",
      "r1051"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://spyre.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://spyre.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash (used in) provided by investing activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://spyre.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r28"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://spyre.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://spyre.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://spyre.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://spyre.com/role/SegmentReportingScheduleofSignificantExpensesProvidedtotheCODMonaRegularBasisDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://spyre.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquity",
      "http://spyre.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
      "http://spyre.com/role/CondensedConsolidatedStatementsofOperations",
      "http://spyre.com/role/NetLossPerShareScheduleofComputationofBasicandDilutedNetLossPerShareDetails",
      "http://spyre.com/role/SegmentReportingScheduleofSignificantExpensesProvidedtotheCODMonaRegularBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "terseLabel": "Net loss",
        "negatedTotalLabel": "Net loss",
        "verboseLabel": "Allocation of losses",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r28",
      "r35",
      "r50",
      "r69",
      "r75",
      "r110",
      "r112",
      "r116",
      "r128",
      "r130",
      "r131",
      "r134",
      "r139",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r150",
      "r151",
      "r158",
      "r239",
      "r279",
      "r300",
      "r301",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r309",
      "r310",
      "r315",
      "r318",
      "r321",
      "r326",
      "r350",
      "r358",
      "r409",
      "r422",
      "r427",
      "r477",
      "r507",
      "r625",
      "r715",
      "r736",
      "r737",
      "r780",
      "r782",
      "r783",
      "r852",
      "r1037"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "presentation": [
      "http://spyre.com/role/NetLossPerShareScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Numerator",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://spyre.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Adopted Accounting Pronouncements and Not Yet Adopted Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r867",
      "r877",
      "r887",
      "r911",
      "r919"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental Disclosure of Non-Cash Financing Information:",
        "label": "Noncash Investing and Financing Items [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://spyre.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income (expense)",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r951",
      "r952",
      "r1015"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense):",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonrelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NonrelatedPartyMember",
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nonrelated Party",
        "label": "Nonrelated Party [Member]",
        "documentation": "Party not related to reporting entity."
       }
      }
     },
     "auth_ref": [
      "r985",
      "r989",
      "r990"
     ]
    },
    "syre_NumberOfDomesticBankingInstitutions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "NumberOfDomesticBankingInstitutions",
     "presentation": [
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of domestic banking institutions (in banks)",
        "label": "Number Of Domestic Banking Institutions",
        "documentation": "Number Of Domestic Banking Institutions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://spyre.com/role/SegmentReportingNarrativeDetails",
      "http://spyre.com/role/TheCompanyandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r794",
      "r1000"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://spyre.com/role/SegmentReportingNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r789",
      "r797",
      "r1000"
     ]
    },
    "syre_October2025UnderwrittenOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "October2025UnderwrittenOfferingMember",
     "presentation": [
      "http://spyre.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://spyre.com/role/TheCompanyandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "October 2025 Underwritten Offering",
        "label": "October 2025 Underwritten Offering [Member]",
        "documentation": "October 2025 Underwritten Offering"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://spyre.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r783",
      "r951",
      "r952",
      "r1015"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://spyre.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r780",
      "r783",
      "r788",
      "r951",
      "r952",
      "r999",
      "r1001",
      "r1002",
      "r1004",
      "r1005",
      "r1015"
     ]
    },
    "us-gaap_OperatingSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OperatingSegmentsMember",
     "presentation": [
      "http://spyre.com/role/SegmentReportingScheduleofSignificantExpensesProvidedtotheCODMonaRegularBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Segments",
        "label": "Operating Segments [Member]",
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r200",
      "r793",
      "r794"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://spyre.com/role/TheCompanyandBasisofPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "The Company and Basis of Presentation",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r51",
      "r52",
      "r53",
      "r655",
      "r656"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://spyre.com/role/AccruedandOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://spyre.com/role/AccruedandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued other",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r960"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://spyre.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquity",
      "http://spyre.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation adjustment",
        "verboseLabel": "Foreign currency translation adjustment",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax",
        "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r14",
      "r15",
      "r16",
      "r511",
      "r512",
      "r513"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income (loss):",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://spyre.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquity",
      "http://spyre.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized (loss) gain on marketable securities",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r109",
      "r238"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://spyre.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r961"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://spyre.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other (expense) income, net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r819"
     ]
    },
    "syre_OtherParagonReimbursableExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "OtherParagonReimbursableExpensesMember",
     "presentation": [
      "http://spyre.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://spyre.com/role/RelatedPartyTransactionsScheduleofExpensesRelatedtoRelatedPartyWhichareSettledinCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Paragon Reimbursable Expenses",
        "label": "Other Paragon Reimbursable Expenses [Member]",
        "documentation": "Other Paragon Reimbursable Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r865",
      "r875",
      "r885",
      "r917"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r868",
      "r878",
      "r888",
      "r920"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r868",
      "r878",
      "r888",
      "r920"
     ]
    },
    "us-gaap_OverAllotmentOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OverAllotmentOptionMember",
     "presentation": [
      "http://spyre.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://spyre.com/role/TheCompanyandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Over-Allotment Option",
        "label": "Over-Allotment Option [Member]",
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://spyre.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership [Axis]",
        "label": "Ownership [Axis]"
       }
      }
     },
     "auth_ref": [
      "r349",
      "r351"
     ]
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://spyre.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership [Domain]",
        "label": "Ownership [Domain]"
       }
      }
     },
     "auth_ref": [
      "r349",
      "r351"
     ]
    },
    "syre_ParagonAgreementLicenseMilestonePaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "ParagonAgreementLicenseMilestonePaymentsMember",
     "presentation": [
      "http://spyre.com/role/LicensingAgreementsDetails",
      "http://spyre.com/role/RelatedPartyTransactionsScheduleofExpensesRelatedtoRelatedPartyWhichareSettledinCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License Agreement",
        "label": "Paragon Agreement, License Milestone Payments [Member]",
        "documentation": "Paragon Agreement, License Milestone Payments"
       }
      }
     },
     "auth_ref": []
    },
    "syre_ParagonAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "ParagonAgreementMember",
     "presentation": [
      "http://spyre.com/role/LicensingAgreementsDetails",
      "http://spyre.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Paragon Agreement",
        "label": "Paragon Agreement [Member]",
        "documentation": "Paragon agreement."
       }
      }
     },
     "auth_ref": []
    },
    "syre_ParagonAgreementSubsequentToAssetAcquisitionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "ParagonAgreementSubsequentToAssetAcquisitionMember",
     "presentation": [
      "http://spyre.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent to Asset Acquisition",
        "label": "Paragon Agreement, Subsequent to Asset Acquisition [Member]",
        "documentation": "Paragon Agreement, Subsequent to Asset Acquisition"
       }
      }
     },
     "auth_ref": []
    },
    "syre_ParagonAndLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "ParagonAndLicenseAgreementMember",
     "presentation": [
      "http://spyre.com/role/RelatedPartyTransactionsScheduleofExpensesRelatedtoRelatedPartyWhichareSettledinCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Paragon and License Agreement",
        "label": "Paragon and License Agreement [Member]",
        "documentation": "Paragon and License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "syre_ParagonTherapeuticsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "ParagonTherapeuticsIncMember",
     "presentation": [
      "http://spyre.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Paragon Therapeutics Inc",
        "label": "Paragon Therapeutics Inc [Member]",
        "documentation": "Paragon therapeutics, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "syre_ParapyreWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "ParapyreWarrantsMember",
     "presentation": [
      "http://spyre.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://spyre.com/role/NetLossPerShareScheduleofWeightedAverageEquityInstrumentsExcludedfromCalculationofDilutedNetLossPerShareDetails",
      "http://spyre.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Parapyre warrants",
        "label": "Parapyre Warrants [Member]",
        "documentation": "Parapyre Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "syre_PaymentForDeferredOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "PaymentForDeferredOfferingCosts",
     "crdr": "credit",
     "calculation": {
      "http://spyre.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payment of deferred offering costs in connection with shelf registration",
        "label": "Payment For Deferred Offering Costs",
        "documentation": "Payment For Deferred Offering Costs"
       }
      }
     },
     "auth_ref": []
    },
    "syre_PaymentForSublicensingFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "PaymentForSublicensingFee",
     "crdr": "credit",
     "presentation": [
      "http://spyre.com/role/LicensingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment for sublicensing fee",
        "label": "Payment For Sublicensing Fee",
        "documentation": "Payment For Sublicensing Fee"
       }
      }
     },
     "auth_ref": []
    },
    "syre_PaymentOfMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "PaymentOfMilestone",
     "crdr": "credit",
     "presentation": [
      "http://spyre.com/role/LicensingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "First milestone payment",
        "label": "Payment Of Milestone",
        "documentation": "Payment of milestone."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://spyre.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://spyre.com/role/TheCompanyandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Placement agent and other offering costs",
        "label": "Payments of Stock Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "syre_PaymentsRelatedToContingentValueRightsLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "PaymentsRelatedToContingentValueRightsLiability",
     "crdr": "credit",
     "calculation": {
      "http://spyre.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payments related to contingent value rights liability",
        "label": "Payments Related To Contingent Value Rights Liability",
        "documentation": "Payments Related To Contingent Value Rights Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "crdr": "credit",
     "calculation": {
      "http://spyre.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of marketable securities",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r121",
      "r206"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://spyre.com/role/StockBasedCompensationNarrativeDetails",
      "http://spyre.com/role/StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedinCalculatingFairValueofAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://spyre.com/role/StockBasedCompensationNarrativeDetails",
      "http://spyre.com/role/StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedinCalculatingFairValueofAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r939"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "us-gaap_PreferredStockConvertibleSharesIssuable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PreferredStockConvertibleSharesIssuable",
     "presentation": [
      "http://spyre.com/role/ConvertiblePreferredStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of common shares issuable upon conversion (in shares)",
        "label": "Preferred Stock, Convertible, Shares Issuable",
        "documentation": "Number of common shares issuable upon conversion of preferred stock."
       }
      }
     },
     "auth_ref": [
      "r331"
     ]
    },
    "syre_PreferredStockExcludingSeriesAAndBNonVotingConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "PreferredStockExcludingSeriesAAndBNonVotingConvertiblePreferredStockMember",
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedBalanceSheets",
      "http://spyre.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock, Excluding Series A Non Voting Convertible Preferred Stock",
        "label": "Preferred Stock, Excluding Series A and B Non Voting Convertible Preferred Stock [Member]",
        "documentation": "Preferred Stock, Excluding Series A and B Non Voting Convertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock",
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r99",
      "r344",
      "r345",
      "r353",
      "r571",
      "r572",
      "r580",
      "r844",
      "r845",
      "r848",
      "r849",
      "r850",
      "r851",
      "r1165",
      "r1168"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r954",
      "r962",
      "r1043",
      "r1119",
      "r1120",
      "r1121"
     ]
    },
    "syre_PreferredStockRemainsIssuedAndOutstandingPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "PreferredStockRemainsIssuedAndOutstandingPercentage",
     "presentation": [
      "http://spyre.com/role/ConvertiblePreferredStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock issued and outstanding (as percent)",
        "label": "Preferred Stock Remains Issued and Outstanding Percentage.",
        "documentation": "Preferred stock remains issued and outstanding percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r99",
      "r345",
      "r571",
      "r572",
      "r580",
      "r696"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, issued (in shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r99",
      "r329",
      "r345",
      "r571",
      "r572",
      "r580"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://spyre.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquity",
      "http://spyre.com/role/ConvertiblePreferredStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, outstanding (in shares)",
        "periodStartLabel": "Beginning balance, preferred stock (in shares)",
        "periodEndLabel": "Ending balance, preferred stock (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r99",
      "r345",
      "r571",
      "r572",
      "r580",
      "r696",
      "r714",
      "r1041",
      "r1168",
      "r1169"
     ]
    },
    "us-gaap_PreferredStockTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PreferredStockTextBlock",
     "presentation": [
      "http://spyre.com/role/ConvertiblePreferredStockandStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Preferred Stock and Stockholders' Equity",
        "label": "Preferred Stock [Text Block]",
        "documentation": "The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r94",
      "r97",
      "r319",
      "r571",
      "r572",
      "r583"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://spyre.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r99",
      "r317",
      "r323",
      "r345",
      "r571",
      "r572",
      "r580",
      "r618",
      "r835"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://spyre.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r966"
     ]
    },
    "syre_ProceedsFromIssuanceOfCommonStockAtTheMarketOfferingsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "ProceedsFromIssuanceOfCommonStockAtTheMarketOfferingsNet",
     "crdr": "debit",
     "calculation": {
      "http://spyre.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock in connection with at-the-market offering program, net of issuance costs",
        "label": "Proceeds From Issuance of Common Stock, At-The-Market Offerings, Net",
        "documentation": "Proceeds From Issuance of Common Stock, At-The-Market Offerings, Net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "calculation": {
      "http://spyre.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock in connection with follow-on offering, net of issuance costs",
        "label": "Proceeds from Issuance of Private Placement",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "crdr": "debit",
     "calculation": {
      "http://spyre.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from employee stock option exercises and employee stock plan purchases",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised",
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r6"
     ]
    },
    "syre_ProceedsFromRaisingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "ProceedsFromRaisingCapital",
     "crdr": "debit",
     "presentation": [
      "http://spyre.com/role/TheCompanyandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from raising capital",
        "label": "Proceeds From Raising Capital",
        "documentation": "Proceeds From Raising Capital"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "crdr": "debit",
     "calculation": {
      "http://spyre.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from maturities and sales of marketable securities",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r122",
      "r1008"
     ]
    },
    "us-gaap_ProceedsFromSaleOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ProceedsFromSaleOfIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://spyre.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://spyre.com/role/SaleofPegzilarginasetoImmedicaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of in-process research and development asset",
        "verboseLabel": "Proceeds from sale of in-process research and development asset",
        "label": "Proceeds from Sale of Intangible Assets",
        "documentation": "The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "RangeAxis",
     "presentation": [
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails",
      "http://spyre.com/role/LicensingAgreementsDetails",
      "http://spyre.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r76",
      "r78",
      "r172",
      "r295",
      "r296",
      "r297",
      "r298",
      "r361",
      "r373",
      "r401",
      "r402",
      "r403",
      "r408",
      "r412",
      "r484",
      "r536",
      "r537",
      "r538",
      "r539",
      "r541",
      "r542",
      "r543",
      "r544",
      "r551",
      "r568",
      "r643",
      "r645",
      "r653",
      "r686",
      "r687",
      "r744",
      "r745",
      "r746",
      "r747",
      "r756",
      "r762",
      "r763",
      "r764",
      "r765",
      "r767",
      "r768",
      "r798",
      "r811",
      "r815",
      "r817",
      "r818",
      "r826",
      "r827",
      "r831",
      "r832",
      "r840",
      "r846",
      "r1036",
      "r1039",
      "r1040",
      "r1096"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "RangeMember",
     "presentation": [
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails",
      "http://spyre.com/role/LicensingAgreementsDetails",
      "http://spyre.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r76",
      "r78",
      "r172",
      "r295",
      "r296",
      "r297",
      "r298",
      "r361",
      "r373",
      "r401",
      "r402",
      "r403",
      "r408",
      "r412",
      "r484",
      "r536",
      "r537",
      "r538",
      "r539",
      "r541",
      "r542",
      "r543",
      "r544",
      "r551",
      "r568",
      "r643",
      "r645",
      "r653",
      "r686",
      "r687",
      "r744",
      "r745",
      "r746",
      "r747",
      "r756",
      "r762",
      "r763",
      "r764",
      "r765",
      "r767",
      "r768",
      "r798",
      "r811",
      "r815",
      "r817",
      "r818",
      "r826",
      "r827",
      "r831",
      "r832",
      "r840",
      "r846",
      "r1036",
      "r1039",
      "r1040",
      "r1096"
     ]
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "presentation": [
      "http://spyre.com/role/SegmentReportingTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Significant Expenses Provided to the CODM on a Regular Basis",
        "label": "Segment Reporting, Reconciliation of Profit (Loss) by Segment to Consolidated [Table Text Block]",
        "documentation": "Tabular disclosure of reconciliation of profit (loss) by reportable segment to consolidated profit (loss). Includes, but is not limited to, reconciliation of income (loss) before income tax expense (benefit) and after income tax if income tax is allocated to reportable segment."
       }
      }
     },
     "auth_ref": [
      "r1002",
      "r1003",
      "r1005"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r860",
      "r870",
      "r880",
      "r912"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedBalanceSheets",
      "http://spyre.com/role/CondensedConsolidatedStatementsofOperations",
      "http://spyre.com/role/CondensedConsolidatedStatementsofOperationsParenthetical",
      "http://spyre.com/role/LicensingAgreementsDetails",
      "http://spyre.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://spyre.com/role/RelatedPartyTransactionsScheduleofExpensesRelatedtoRelatedPartyWhichareSettledinCashDetails",
      "http://spyre.com/role/SegmentReportingScheduleofSignificantExpensesProvidedtotheCODMonaRegularBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related and Nonrelated Parties [Domain]",
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r84",
      "r87",
      "r90",
      "r91",
      "r128",
      "r133",
      "r134",
      "r205",
      "r368",
      "r372",
      "r525",
      "r526",
      "r571",
      "r572",
      "r575",
      "r576",
      "r577",
      "r586",
      "r616",
      "r623",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r713",
      "r743",
      "r773",
      "r1167",
      "r1172"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedBalanceSheets",
      "http://spyre.com/role/CondensedConsolidatedStatementsofOperations",
      "http://spyre.com/role/CondensedConsolidatedStatementsofOperationsParenthetical",
      "http://spyre.com/role/LicensingAgreementsDetails",
      "http://spyre.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://spyre.com/role/RelatedPartyTransactionsScheduleofExpensesRelatedtoRelatedPartyWhichareSettledinCashDetails",
      "http://spyre.com/role/SegmentReportingScheduleofSignificantExpensesProvidedtotheCODMonaRegularBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r84",
      "r87",
      "r90",
      "r91",
      "r128",
      "r133",
      "r134",
      "r525",
      "r526",
      "r527",
      "r528",
      "r571",
      "r572",
      "r577",
      "r616",
      "r623",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r713",
      "r743"
     ]
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "crdr": "debit",
     "presentation": [
      "http://spyre.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount of related party transaction",
        "label": "Related Party Transaction, Amounts of Transaction",
        "documentation": "Amount of transactions with related party during the financial reporting period."
       }
      }
     },
     "auth_ref": [
      "r525"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://spyre.com/role/LicensingAgreementsDetails",
      "http://spyre.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://spyre.com/role/RelatedPartyTransactionsScheduleofExpensesRelatedtoRelatedPartyWhichareSettledinCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Axis]",
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r133",
      "r134",
      "r525",
      "r526",
      "r1113"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://spyre.com/role/LicensingAgreementsDetails",
      "http://spyre.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://spyre.com/role/RelatedPartyTransactionsScheduleofExpensesRelatedtoRelatedPartyWhichareSettledinCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Domain]",
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r133",
      "r134",
      "r1113"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://spyre.com/role/LicensingAgreementsDetails",
      "http://spyre.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://spyre.com/role/RelatedPartyTransactionsScheduleofExpensesRelatedtoRelatedPartyWhichareSettledinCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Line Items]",
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r133",
      "r134",
      "r205",
      "r525",
      "r526",
      "r528",
      "r571",
      "r572",
      "r575",
      "r576",
      "r577",
      "r586",
      "r719",
      "r720",
      "r723",
      "r1172"
     ]
    },
    "syre_RelatedPartyTransactionNumberOfBoardSeats": {
     "xbrltype": "integerItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "RelatedPartyTransactionNumberOfBoardSeats",
     "presentation": [
      "http://spyre.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of board seats held by related party",
        "label": "Related Party Transaction, Number Of Board Seats",
        "documentation": "Related Party Transaction, Number Of Board Seats"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transactions [Abstract]",
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedBalanceSheets",
      "http://spyre.com/role/CondensedConsolidatedStatementsofOperations",
      "http://spyre.com/role/CondensedConsolidatedStatementsofOperationsParenthetical",
      "http://spyre.com/role/LicensingAgreementsDetails",
      "http://spyre.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://spyre.com/role/RelatedPartyTransactionsScheduleofExpensesRelatedtoRelatedPartyWhichareSettledinCashDetails",
      "http://spyre.com/role/SegmentReportingScheduleofSignificantExpensesProvidedtotheCODMonaRegularBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related and Nonrelated Parties [Axis]",
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r84",
      "r87",
      "r90",
      "r91",
      "r128",
      "r133",
      "r134",
      "r205",
      "r368",
      "r372",
      "r525",
      "r526",
      "r571",
      "r572",
      "r575",
      "r576",
      "r577",
      "r586",
      "r616",
      "r623",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r713",
      "r743",
      "r773",
      "r1113",
      "r1167",
      "r1172"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://spyre.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transactions",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r522",
      "r523",
      "r524",
      "r526",
      "r529",
      "r571",
      "r572",
      "r587",
      "r663",
      "r664",
      "r665",
      "r721",
      "r722",
      "r723",
      "r741",
      "r742"
     ]
    },
    "syre_ReportableSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "ReportableSegmentMember",
     "presentation": [
      "http://spyre.com/role/SegmentReportingScheduleofSignificantExpensesProvidedtotheCODMonaRegularBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reportable Segment",
        "label": "Reportable Segment [Member]",
        "documentation": "Reportable Segment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://spyre.com/role/SegmentReportingScheduleofSignificantExpensesProvidedtotheCODMonaRegularBasisDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://spyre.com/role/SegmentReportingScheduleofSignificantExpensesProvidedtotheCODMonaRegularBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development, excluding compensation and share-based compensation",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r413",
      "r769",
      "r780",
      "r781",
      "r793",
      "r1118"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "crdr": "debit",
     "calculation": {
      "http://spyre.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedStatementsofOperations",
      "http://spyre.com/role/CondensedConsolidatedStatementsofOperationsParenthetical",
      "http://spyre.com/role/LicensingAgreementsDetails",
      "http://spyre.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://spyre.com/role/RelatedPartyTransactionsScheduleofExpensesRelatedtoRelatedPartyWhichareSettledinCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "verboseLabel": "Total related party expense (excludes stock-based compensation)",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "documentation": "Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r1081"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r861",
      "r871",
      "r881",
      "r913"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r862",
      "r872",
      "r882",
      "r914"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r869",
      "r879",
      "r889",
      "r921"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofEstimatedFairValueofCashEquivalentsandMarketableSecuritiesandGrossUnrealizedGainsandLossesDetails",
      "http://spyre.com/role/FairValueMeasurementsScheduleofFairValueofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Domain]",
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://spyre.com/role/NetLossPerShareScheduleofWeightedAverageEquityInstrumentsExcludedfromCalculationofDilutedNetLossPerShareDetails",
      "http://spyre.com/role/StockBasedCompensationScheduleofStockAwardsGrantedUnderallEquityIncentiveandInducementPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock Units (RSUs)",
        "verboseLabel": "Unvested restricted stock units",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://spyre.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedBalanceSheets",
      "http://spyre.com/role/TheCompanyandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "negatedTerseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r103",
      "r347",
      "r571",
      "r572",
      "r582",
      "r621",
      "r650",
      "r652",
      "r662",
      "r697",
      "r835"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r50",
      "r136",
      "r137",
      "r138",
      "r140",
      "r147",
      "r149",
      "r151",
      "r240",
      "r241",
      "r278",
      "r279",
      "r280",
      "r314",
      "r344",
      "r353",
      "r356",
      "r357",
      "r359",
      "r360",
      "r409",
      "r416",
      "r417",
      "r419",
      "r420",
      "r421",
      "r423",
      "r426",
      "r427",
      "r462",
      "r463",
      "r464",
      "r465",
      "r467",
      "r468",
      "r470",
      "r475",
      "r520",
      "r567",
      "r612",
      "r647",
      "r649",
      "r666",
      "r1046",
      "r1048",
      "r1168"
     ]
    },
    "syre_RoyaltyStepDownPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "RoyaltyStepDownPercent",
     "presentation": [
      "http://spyre.com/role/LicensingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty step-down (as percent)",
        "label": "Royalty Step-Down, Percent",
        "documentation": "Royalty Step-Down, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "syre_RoyaltyTermExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "RoyaltyTermExpirationPeriod",
     "presentation": [
      "http://spyre.com/role/LicensingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty term expiration period (in years)",
        "label": "Royalty Term, Expiration Period",
        "documentation": "Royalty Term, Expiration Period"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "syre_SPY002AndSPY072LicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "SPY002AndSPY072LicenseAgreementMember",
     "presentation": [
      "http://spyre.com/role/LicensingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SPY002 and SPY072 License Agreement",
        "label": "SPY002 And SPY 072 License Agreement [Member]",
        "documentation": "SPY002 And SPY 072 License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "syre_SPY003LicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "SPY003LicenseAgreementMember",
     "presentation": [
      "http://spyre.com/role/LicensingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SPY003 License Agreement",
        "label": "SPY003 License Agreement [Member]",
        "documentation": "SPY003 License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "syre_SaleOfStockAggregateOfferingPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "SaleOfStockAggregateOfferingPrice",
     "crdr": "credit",
     "presentation": [
      "http://spyre.com/role/ConvertiblePreferredStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, aggregate offering price",
        "label": "Sale of Stock, Aggregate Offering Price",
        "documentation": "Sale of Stock, Aggregate Offering Price"
       }
      }
     },
     "auth_ref": []
    },
    "syre_SaleOfStockAuthorizedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "SaleOfStockAuthorizedAmount",
     "crdr": "credit",
     "presentation": [
      "http://spyre.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://spyre.com/role/TheCompanyandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, authorized amount",
        "label": "Sale of Stock, Authorized Amount",
        "documentation": "Sale of Stock, Authorized Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://spyre.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://spyre.com/role/StockBasedCompensationNarrativeDetails",
      "http://spyre.com/role/TheCompanyandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, proceeds received",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://spyre.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://spyre.com/role/StockBasedCompensationNarrativeDetails",
      "http://spyre.com/role/TheCompanyandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://spyre.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://spyre.com/role/StockBasedCompensationNarrativeDetails",
      "http://spyre.com/role/TheCompanyandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares of common stock sold (in shares)",
        "verboseLabel": "Number of shares sold (in shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://spyre.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://spyre.com/role/TheCompanyandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, price per share (in dollars per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "syre_SaleOfStockRemainingAuthorizedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "SaleOfStockRemainingAuthorizedAmount",
     "crdr": "credit",
     "presentation": [
      "http://spyre.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://spyre.com/role/TheCompanyandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, remaining authorized amount",
        "label": "Sale of Stock, Remaining Authorized Amount",
        "documentation": "Sale of Stock, Remaining Authorized Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://spyre.com/role/AccruedandOtherCurrentLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued and Other Current Liabilities",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://spyre.com/role/NetLossPerShareScheduleofWeightedAverageEquityInstrumentsExcludedfromCalculationofDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://spyre.com/role/NetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Weighted-Average Equity Instruments Excluded from Calculation of Diluted Net Loss Per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r998"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetails",
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofEstimatedFairValueofCashEquivalentsandMarketableSecuritiesandGrossUnrealizedGainsandLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-Sale [Line Items]",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611"
     ]
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "presentation": [
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Estimated Fair Value of Cash Equivalents and Marketable Securities and Gross Unrealized Gains and Losses",
        "label": "Cash, Cash Equivalent, and Investment [Table Text Block]",
        "documentation": "Tabular disclosure of cash, cash equivalent, and investment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "presentation": [
      "http://spyre.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock-Based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable",
     "presentation": [
      "http://spyre.com/role/NetLossPerShareScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table]",
        "label": "Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table]",
        "documentation": "Disclosure of information about basic earnings per share by class of stock. Includes, but is not limited to, two-class method."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r157",
      "r159",
      "r161"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://spyre.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails",
      "http://spyre.com/role/StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedinCalculatingFairValueofAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://spyre.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1093",
      "r1094"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://spyre.com/role/LicensingAgreementsDetails",
      "http://spyre.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://spyre.com/role/RelatedPartyTransactionsScheduleofExpensesRelatedtoRelatedPartyWhichareSettledinCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Table]",
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r133",
      "r134",
      "r525",
      "r526",
      "r528",
      "r571",
      "r572",
      "r575",
      "r576",
      "r577",
      "r586",
      "r719",
      "r720",
      "r723",
      "r1172"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "presentation": [
      "http://spyre.com/role/RelatedPartyTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Expenses Related to Related Party Which are Settled in Cash",
        "label": "Schedule of Related Party Transactions [Table Text Block]",
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r1111",
      "r1112"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://spyre.com/role/SegmentReportingScheduleofSignificantExpensesProvidedtotheCODMonaRegularBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting [Table]",
        "label": "Segment Reporting [Table]",
        "documentation": "Disclosure of information about segment reporting. Includes, but is not limited to, reconciliation of reportable segment amount to corresponding consolidated total."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r199",
      "r200",
      "r201"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock",
     "presentation": [
      "http://spyre.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock Awards Granted Under all Equity Incentive and Inducement Plans",
        "label": "Schedule of Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value [Table Text Block]",
        "documentation": "Tabular disclosure of the total intrinsic value of options exercised (or share units converted), share-based liabilities paid, and the total fair value of shares vested during the year."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://spyre.com/role/StockBasedCompensationNarrativeDetails",
      "http://spyre.com/role/StockBasedCompensationScheduleofStockAwardsGrantedUnderallEquityIncentiveandInducementPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r375",
      "r376",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r408"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://spyre.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Weighted-Average Assumptions Used in Calculating Fair Value of Awards",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://spyre.com/role/ConvertiblePreferredStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock, Class of Stock [Table]",
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r41",
      "r43",
      "r44",
      "r81",
      "r99",
      "r100",
      "r170",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r339",
      "r340",
      "r342",
      "r343",
      "r345",
      "r346",
      "r349",
      "r351",
      "r461",
      "r571",
      "r572",
      "r580",
      "r581",
      "r658",
      "r659",
      "r660",
      "r661",
      "r941",
      "r985",
      "r986",
      "r1047"
     ]
    },
    "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
     "presentation": [
      "http://spyre.com/role/NetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Computation of Basic and Diluted Net Loss Per Share",
        "label": "Schedule of Weighted Average Number of Shares [Table Text Block]",
        "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit)."
       }
      }
     },
     "auth_ref": [
      "r997"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "Security12bTitle",
     "presentation": [
      "http://spyre.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r855"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://spyre.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SegmentDomain",
     "presentation": [
      "http://spyre.com/role/SegmentReportingScheduleofSignificantExpensesProvidedtotheCODMonaRegularBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Domain]",
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r168",
      "r174",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r199",
      "r200",
      "r201",
      "r204",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r277",
      "r283",
      "r289",
      "r292",
      "r294",
      "r424",
      "r425",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r790",
      "r793",
      "r794",
      "r800",
      "r841",
      "r1135",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1160",
      "r1161",
      "r1162",
      "r1163",
      "r1164"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://spyre.com/role/SegmentReporting"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting",
        "label": "Segment Reporting [Text Block]",
        "documentation": "The entire disclosure for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r189",
      "r191",
      "r192",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r789",
      "r791",
      "r792",
      "r793",
      "r795",
      "r796",
      "r797"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://spyre.com/role/SegmentReportingScheduleofSignificantExpensesProvidedtotheCODMonaRegularBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting [Line Items]",
        "label": "Segment Reporting [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r199",
      "r200",
      "r201"
     ]
    },
    "us-gaap_SegmentReportingOtherItemAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SegmentReportingOtherItemAmount",
     "crdr": "debit",
     "calculation": {
      "http://spyre.com/role/SegmentReportingScheduleofSignificantExpensesProvidedtotheCODMonaRegularBasisDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://spyre.com/role/SegmentReportingScheduleofSignificantExpensesProvidedtotheCODMonaRegularBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other segment items",
        "label": "Segment Reporting, Other Segment Item, Amount",
        "documentation": "Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss)."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r191",
      "r192",
      "r199",
      "r793"
     ]
    },
    "syre_SeriesANonVotingConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "SeriesANonVotingConvertiblePreferredStockMember",
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedBalanceSheets",
      "http://spyre.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://spyre.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquity",
      "http://spyre.com/role/CondensedConsolidatedStatementsofOperations",
      "http://spyre.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://spyre.com/role/NetLossPerShareScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A Non Voting Convertible Preferred Stock",
        "netLabel": "Series A Non-Voting Convertible Preferred Stock",
        "verboseLabel": "Series A Preferred Stock",
        "label": "Series A Non Voting Convertible Preferred Stock [Member]",
        "documentation": "Series A non voting convertible preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "syre_SeriesBNonVotingConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "SeriesBNonVotingConvertiblePreferredStockMember",
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedBalanceSheets",
      "http://spyre.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://spyre.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquity",
      "http://spyre.com/role/CondensedConsolidatedStatementsofOperations",
      "http://spyre.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://spyre.com/role/NetLossPerShareScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B Non Voting Convertible Preferred Stock",
        "netLabel": "Series B Non-Voting Convertible Preferred Stock",
        "verboseLabel": "Series B Preferred Stock",
        "label": "Series B Non Voting Convertible Preferred Stock [Member]",
        "documentation": "Series B Non Voting Convertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "syre_ServiceBasedAwardsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "ServiceBasedAwardsMember",
     "presentation": [
      "http://spyre.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Service Based Awards",
        "label": "Service Based Awards [Member]",
        "documentation": "Service-based awards."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://spyre.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://spyre.com/role/SegmentReportingScheduleofSignificantExpensesProvidedtotheCODMonaRegularBasisDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://spyre.com/role/SegmentReportingScheduleofSignificantExpensesProvidedtotheCODMonaRegularBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://spyre.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional number of shares available for issuance (in shares)",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Additional Number Of Shares Available For Grant",
        "documentation": "Share-based compensation arrangement by share-based payment award, additional number of shares available for grant."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://spyre.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://spyre.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vest period grant date (in years)",
        "verboseLabel": "Share-based award, vesting period (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://spyre.com/role/StockBasedCompensationScheduleofStockAwardsGrantedUnderallEquityIncentiveandInducementPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock units, Grants (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://spyre.com/role/StockBasedCompensationScheduleofStockAwardsGrantedUnderallEquityIncentiveandInducementPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock units, Weighted Average Grant Date Fair Value (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "presentation": [
      "http://spyre.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price",
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award."
       }
      }
     },
     "auth_ref": [
      "r1073"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://spyre.com/role/StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedinCalculatingFairValueofAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r402"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://spyre.com/role/StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedinCalculatingFairValueofAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r401"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://spyre.com/role/StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedinCalculatingFairValueofAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r403"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://spyre.com/role/StockBasedCompensationNarrativeDetails",
      "http://spyre.com/role/StockBasedCompensationScheduleofStockAwardsGrantedUnderallEquityIncentiveandInducementPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r375",
      "r376",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r408"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://spyre.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock available for future issuance, additional amount authorized (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1080"
     ]
    },
    "syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMonthlyInstallments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMonthlyInstallments",
     "presentation": [
      "http://spyre.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of monthly installments",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Monthly Installments",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Monthly Installments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://spyre.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://spyre.com/role/StockBasedCompensationScheduleofStockAwardsGrantedUnderallEquityIncentiveandInducementPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options granted to purchase (in shares)",
        "verboseLabel": "Stock options, Grants (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r954",
      "r962",
      "r963",
      "r1043",
      "r1044"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://spyre.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding option awards (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r381",
      "r382"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://spyre.com/role/StockBasedCompensationNarrativeDetails",
      "http://spyre.com/role/StockBasedCompensationScheduleofStockAwardsGrantedUnderallEquityIncentiveandInducementPlansDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://spyre.com/role/StockBasedCompensationScheduleofStockAwardsGrantedUnderallEquityIncentiveandInducementPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options, Weighted Average Grant Date Fair Value (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://spyre.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement, Tranche One",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": [
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://spyre.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting percentage",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1052"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://spyre.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration term (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant to expiration date of share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://spyre.com/role/StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedinCalculatingFairValueofAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r400"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://spyre.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r127"
     ]
    },
    "syre_Spy001LicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "Spy001LicenseAgreementMember",
     "presentation": [
      "http://spyre.com/role/LicensingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SPY001 License Agreement",
        "label": "SPY001 License Agreement [Member]",
        "documentation": "SPY001 License Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "syre_SpyreTherapeuticsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "SpyreTherapeuticsIncMember",
     "presentation": [
      "http://spyre.com/role/FairValueMeasurementsNarrativeDetails",
      "http://spyre.com/role/TheCompanyandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Spyre Therapeutics, Inc.",
        "label": "Spyre Therapeutics, Inc. [Member]",
        "documentation": "Spyre Therapeutics, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://spyre.com/role/SegmentReportingScheduleofSignificantExpensesProvidedtotheCODMonaRegularBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Axis]",
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r168",
      "r174",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r199",
      "r200",
      "r201",
      "r204",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r277",
      "r283",
      "r289",
      "r292",
      "r294",
      "r424",
      "r425",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r790",
      "r793",
      "r794",
      "r800",
      "r841",
      "r1135",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1160",
      "r1161",
      "r1162",
      "r1163",
      "r1164"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedBalanceSheets",
      "http://spyre.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://spyre.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquity",
      "http://spyre.com/role/CondensedConsolidatedStatementsofOperations",
      "http://spyre.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://spyre.com/role/NetLossPerShareScheduleofComputationofBasicandDilutedNetLossPerShareDetails",
      "http://spyre.com/role/StockBasedCompensationNarrativeDetails",
      "http://spyre.com/role/TheCompanyandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r81",
      "r82",
      "r94",
      "r95",
      "r96",
      "r98",
      "r99",
      "r100",
      "r128",
      "r131",
      "r156",
      "r157",
      "r159",
      "r161",
      "r170",
      "r171",
      "r239",
      "r300",
      "r303",
      "r304",
      "r305",
      "r309",
      "r310",
      "r316",
      "r317",
      "r319",
      "r320",
      "r322",
      "r325",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r345",
      "r346",
      "r349",
      "r350",
      "r351",
      "r507",
      "r571",
      "r572",
      "r579",
      "r580",
      "r581",
      "r612",
      "r658",
      "r659",
      "r660",
      "r661",
      "r666",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r696",
      "r716",
      "r738",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r941",
      "r986",
      "r987",
      "r996",
      "r1047",
      "r1049"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r50",
      "r81",
      "r99",
      "r100",
      "r114",
      "r115",
      "r116",
      "r136",
      "r137",
      "r138",
      "r140",
      "r147",
      "r149",
      "r151",
      "r169",
      "r240",
      "r241",
      "r278",
      "r279",
      "r280",
      "r314",
      "r339",
      "r344",
      "r345",
      "r346",
      "r349",
      "r351",
      "r353",
      "r356",
      "r357",
      "r359",
      "r360",
      "r409",
      "r416",
      "r417",
      "r419",
      "r420",
      "r421",
      "r423",
      "r426",
      "r427",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r567",
      "r571",
      "r572",
      "r580",
      "r581",
      "r612",
      "r626",
      "r647",
      "r648",
      "r649",
      "r666",
      "r738",
      "r1049"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementLineItems",
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedBalanceSheets",
      "http://spyre.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://spyre.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquity",
      "http://spyre.com/role/CondensedConsolidatedStatementsofOperations",
      "http://spyre.com/role/CondensedConsolidatedStatementsofOperationsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r82",
      "r83",
      "r84",
      "r87",
      "r90",
      "r91",
      "r94",
      "r98",
      "r99",
      "r100",
      "r103",
      "r136",
      "r137",
      "r138",
      "r169",
      "r316",
      "r317",
      "r319",
      "r322",
      "r327",
      "r339",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r351",
      "r352",
      "r353",
      "r355",
      "r520",
      "r569",
      "r571",
      "r572",
      "r579",
      "r580",
      "r581",
      "r657",
      "r667",
      "r678",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r696",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r717",
      "r718",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r738",
      "r773",
      "r782",
      "r783",
      "r847",
      "r1167"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Comprehensive Income [Abstract]",
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeLocationBalanceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementOfIncomeLocationBalanceAxis",
     "presentation": [
      "http://spyre.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Location, Statement of Income, Balance [Axis]",
        "label": "Location, Statement of Income, Balance [Axis]",
        "documentation": "Information by location in statement of income line item where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r290",
      "r291",
      "r293",
      "r435",
      "r441",
      "r458",
      "r459",
      "r486",
      "r490",
      "r495",
      "r508",
      "r509",
      "r510",
      "r644",
      "r646",
      "r723",
      "r769",
      "r815",
      "r816",
      "r821",
      "r822",
      "r825",
      "r833",
      "r834",
      "r1082",
      "r1083",
      "r1136"
     ]
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementTable",
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedBalanceSheets",
      "http://spyre.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://spyre.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquity",
      "http://spyre.com/role/CondensedConsolidatedStatementsofOperations",
      "http://spyre.com/role/CondensedConsolidatedStatementsofOperationsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r81",
      "r82",
      "r83",
      "r84",
      "r87",
      "r90",
      "r91",
      "r94",
      "r98",
      "r99",
      "r100",
      "r103",
      "r136",
      "r137",
      "r138",
      "r169",
      "r205",
      "r316",
      "r317",
      "r319",
      "r322",
      "r327",
      "r339",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r351",
      "r352",
      "r353",
      "r355",
      "r520",
      "r569",
      "r571",
      "r572",
      "r579",
      "r580",
      "r581",
      "r612",
      "r657",
      "r667",
      "r678",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r696",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r717",
      "r718",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r738",
      "r773",
      "r782",
      "r783",
      "r847",
      "r1167"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r864",
      "r874",
      "r884",
      "r916"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": [
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of Series B Non-Voting Convertible Preferred Stock to common Stock (in shares)",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r340",
      "r954",
      "r962",
      "r963",
      "r1041",
      "r1043",
      "r1044",
      "r1046",
      "r1048",
      "r1119",
      "r1120",
      "r1121",
      "r1122"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquity",
      "http://spyre.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://spyre.com/role/TheCompanyandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in connection with at-the-market and follow-on offering program, net of financing costs (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r658",
      "r738",
      "r758",
      "r954",
      "r962",
      "r963",
      "r1041",
      "r1043",
      "r1044",
      "r1046",
      "r1048",
      "r1119",
      "r1120",
      "r1121",
      "r1122"
     ]
    },
    "syre_StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan",
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in connection with exercise of stock options and employee stock purchase plan (in shares)",
        "label": "Stock Issued During Period, Shares, Options Exercised And Employee Stock Ownership Plan",
        "documentation": "Stock Issued During Period, Shares, Options Exercised And Employee Stock Ownership Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of Series B Non-Voting Convertible Preferred Stock to common stock",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r954",
      "r962",
      "r963",
      "r1041",
      "r1043",
      "r1044",
      "r1046",
      "r1048",
      "r1119",
      "r1120",
      "r1121",
      "r1122"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in connection with at-the-market and follow-on offering program, net of financing costs",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r666",
      "r738",
      "r758",
      "r853",
      "r954",
      "r962",
      "r963",
      "r1041",
      "r1043",
      "r1044",
      "r1046",
      "r1048",
      "r1119",
      "r1120",
      "r1121",
      "r1122"
     ]
    },
    "syre_StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan",
     "crdr": "credit",
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in connection with exercise of stock options and employee stock purchase plan",
        "label": "Stock Issued During Period, Value, Options Exercised And Employee Stock Ownership Plan",
        "documentation": "Stock Issued During Period, Value, Options Exercised And Employee Stock Ownership Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r954",
      "r962",
      "r963",
      "r1041",
      "r1043",
      "r1044",
      "r1046",
      "r1048",
      "r1119",
      "r1120",
      "r1121",
      "r1122"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://spyre.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedBalanceSheets",
      "http://spyre.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL STOCKHOLDERS\u2019 EQUITY",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r698",
      "r714",
      "r739",
      "r740",
      "r835",
      "r854",
      "r967",
      "r985",
      "r987",
      "r988",
      "r1015",
      "r1110",
      "r1168"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "STOCKHOLDERS\u2019 EQUITY",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "syre_SublicensingFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "SublicensingFee",
     "crdr": "debit",
     "presentation": [
      "http://spyre.com/role/LicensingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sublicensing fee",
        "label": "Sublicensing Fee",
        "documentation": "Sublicensing Fee"
       }
      }
     },
     "auth_ref": []
    },
    "syre_SublicensingFeeOutstandingAndPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "SublicensingFeeOutstandingAndPayable",
     "crdr": "credit",
     "presentation": [
      "http://spyre.com/role/LicensingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sublicensing fee, outstanding and payable",
        "label": "Sublicensing Fee, Outstanding And Payable",
        "documentation": "Sublicensing Fee, Outstanding And Payable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://spyre.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://spyre.com/role/StockBasedCompensationNarrativeDetails",
      "http://spyre.com/role/TheCompanyandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "syre_TerminationNoticePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "TerminationNoticePeriod",
     "presentation": [
      "http://spyre.com/role/LicensingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination notice period (in days)",
        "label": "Termination Notice Period",
        "documentation": "Termination Notice Period"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r909"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "TradingSymbol",
     "presentation": [
      "http://spyre.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails",
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetails",
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofEstimatedFairValueofCashEquivalentsandMarketableSecuritiesandGrossUnrealizedGainsandLossesDetails",
      "http://spyre.com/role/FairValueMeasurementsScheduleofFairValueofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r313",
      "r338",
      "r461",
      "r501",
      "r506",
      "r509",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r537",
      "r538",
      "r539",
      "r540",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r549",
      "r550",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r613",
      "r627",
      "r823",
      "r824",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r838",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1092",
      "r1095",
      "r1096",
      "r1097",
      "r1104",
      "r1107",
      "r1108",
      "r1109"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r932"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r932"
     ]
    },
    "syre_TwoThousandAndEighteenEquityInducementPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "TwoThousandAndEighteenEquityInducementPlanMember",
     "presentation": [
      "http://spyre.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2018 Equity Inducement Plan",
        "label": "Two Thousand And Eighteen Equity Inducement Plan [Member]",
        "documentation": "2018 equity inducement plan."
       }
      }
     },
     "auth_ref": []
    },
    "syre_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember",
     "presentation": [
      "http://spyre.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2015 and 2016 and 2018 Equity Inducement Plan",
        "label": "Two Thousand And Fifteen And Two Thousand And Sixteen Equity Incentive Plan And Two Thousand And Eighteen Equity Inducement Plan [Member]",
        "documentation": "Two thousand and fifteen and two thousand and sixteen equity incentive plan and two thousand and eighteen equity inducement plan."
       }
      }
     },
     "auth_ref": []
    },
    "syre_TwoThousandAndSixteenEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "TwoThousandAndSixteenEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://spyre.com/role/StockBasedCompensationNarrativeDetails",
      "http://spyre.com/role/StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedinCalculatingFairValueofAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2016 Employee Stock Purchase Plan",
        "verboseLabel": "2016 ESPP",
        "label": "Two Thousand And Sixteen Employee Stock Purchase Plan [Member]",
        "documentation": "Two thousand and sixteen employee stock purchase plan."
       }
      }
     },
     "auth_ref": []
    },
    "syre_TwoThousandAndSixteenEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "TwoThousandAndSixteenEquityIncentivePlanMember",
     "presentation": [
      "http://spyre.com/role/StockBasedCompensationNarrativeDetails",
      "http://spyre.com/role/StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedinCalculatingFairValueofAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2016 Equity Incentive Plan",
        "verboseLabel": "Stock Options Granted",
        "label": "Two Thousand And Sixteen Equity Incentive Plan [Member]",
        "documentation": "Two thousand and sixteen equity incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "syre_USBankingInstitutionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://spyre.com/20260630",
     "localname": "USBankingInstitutionMember",
     "presentation": [
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Banking Institution",
        "label": "U.S. Banking Institution [Member]",
        "documentation": "U.S. Banking Institution [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "presentation": [
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "US Government Agencies Debt Securities",
        "label": "US Government Agencies Debt Securities [Member]",
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)."
       }
      }
     },
     "auth_ref": [
      "r784",
      "r785",
      "r804",
      "r806",
      "r836",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133"
     ]
    },
    "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember",
     "presentation": [
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetails",
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofEstimatedFairValueofCashEquivalentsandMarketableSecuritiesandGrossUnrealizedGainsandLossesDetails",
      "http://spyre.com/role/FairValueMeasurementsScheduleofFairValueofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. government agency securities",
        "verboseLabel": "U.S. government agency securities",
        "netLabel": "U.S. government agency securities",
        "label": "US Government Corporations and Agencies Securities [Member]",
        "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac)."
       }
      }
     },
     "auth_ref": [
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133"
     ]
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetails",
      "http://spyre.com/role/CashEquivalentsandMarketableSecuritiesScheduleofEstimatedFairValueofCashEquivalentsandMarketableSecuritiesandGrossUnrealizedGainsandLossesDetails",
      "http://spyre.com/role/FairValueMeasurementsScheduleofFairValueofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. government treasury securities",
        "verboseLabel": "U.S. government treasury securities",
        "netLabel": "U.S. government treasury securities",
        "label": "US Treasury Securities [Member]",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r784",
      "r785",
      "r804",
      "r806",
      "r808",
      "r823",
      "r836",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "VestingAxis",
     "presentation": [
      "http://spyre.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting [Axis]",
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "VestingDomain",
     "presentation": [
      "http://spyre.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting [Domain]",
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r898"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average common stock outstanding, diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r161"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesIssuedBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "WeightedAverageNumberOfSharesIssuedBasic",
     "presentation": [
      "http://spyre.com/role/NetLossPerShareScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted-average shares outstanding (in shares)",
        "label": "Weighted Average Number of Shares Issued, Basic",
        "documentation": "This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic)."
       }
      }
     },
     "auth_ref": [
      "r995"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://spyre.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average common stock outstanding, basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r161"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract",
     "presentation": [
      "http://spyre.com/role/NetLossPerShareScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Denominator",
        "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-12A"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-7"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r45": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r46": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r47": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/808/tableOfContent"
  },
  "r48": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r49": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r50": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r51": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r52": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481034/205-10-S45-5"
  },
  "r53": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.4-03(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-3"
  },
  "r54": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205-20/tableOfContent"
  },
  "r55": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-10"
  },
  "r56": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-11"
  },
  "r57": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3A"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4A"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5A"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480868/205-20-S45-2"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480837/205-20-S50-1"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.Z.5.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480781/205-20-S99-2"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480781/205-20-S99-3"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-11"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-13"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-8"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-9"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-12"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-2"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-20"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-3C"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-3D"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-5"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-4"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482705/350-40-65-4"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482705/350-40-65-4"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-14"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-11"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480125/505-10-S35-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-3"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-4"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-8"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480070/505-10-S50-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480070/505-10-S50-6"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 4.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-5"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SAB Topic 5.Q.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-7"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481468/505-20-05-5"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-3"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-3"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CC"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CCC",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CCC",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CCC",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480339/815-10-65-8"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480339/815-10-65-8"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480339/815-10-65-8"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "45",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480865/815-45-50-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-9"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-3"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-12"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(cc)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4D"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-5"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477657/942-210-S45-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478478/942-210-S50-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13)(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(7)(e)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(7)(e)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.9-06)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(ff)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(fff)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "405",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "805",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478072/944-805-50-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5A",
   "Subparagraph": "(SX 210.12-13A(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "450",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477850/954-450-50-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3A"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483474/205-20-55-102"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-15"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-20"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "181",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-181"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "184",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480088/860-10-S50-1"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "108",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481296/860-20-55-108"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-2"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5A"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-11"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-2"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-8"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-12"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-20"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-3C"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-3D"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-5"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-2"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-3"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-4"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480070/505-10-S50-1"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480070/505-10-S50-2"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-4"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-2"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477657/942-210-S45-1"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478478/942-210-S50-1"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "810",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477383/970-810-45-1"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>76
<FILENAME>0001636282-26-000096-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001636282-26-000096-xbrl.zip
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M>HBP#/P%C(0CW@Y,O9C#5#TU>BHID=5\TIU4VX[R9-5H,Y=HG94F\AR_ U5
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M+M?&\;1Y*C=> %HMW) 3DE47GF'MMGZSRU?>&>H^X^M+1^&UJ?\#4$L#!!0
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MC>.Y\XRVO@1:K^60'?KK+C+%<F[\=I?/?#S4_L;OF$["]U/_ U!+ P04
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M@-N86=$QH!4& PJW(;@#8( CLG,;U/IJVL3636+=POS< .^>I_F/IV>7$B\
M9Y'J ?J"E"O9*XX-5KB-7A4>!,4QP@JWH:S"@Z! 5IC;8-4A0, 1W;D-!"6@
M^Z_.*W5M%BQRW)'C$@S8>> R=5\HW$H]/J6R0/:9VW2QTT5'@0PWMU&TTT5'
M@2PZM_&UHZ*#(X9P&^S:RA#<\:$N7O% 8,X\"61QC+G*;:"KR/POCKE6BQMQ
MXYC_Q3'(:G&#;>GXSQ')BQO:BOT>^L6Q#3Y]X0*9WN)&MPJ @P*9X.)&VPJ
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MR!MQZ0&=M<(2^9F\WT8[E6&MCWE[V"IU:HU*35/49JNYD7Z%06LKF2YF@)/
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M5&,QV%60GV3SH*,XY\RSAY9G'A$&%:G[:NKA^B_,VXB<>B0T,["1G^#2*"J
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M;.<1FK^(X1U\>&=?C^&1>I2X^H %Y@SZ2BUGA$%'*1:Q#$92K[;J"0:S8@\
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M.JJLLZR,S<G8W/EB<Y\^?[W[^E[&YJ['?K=\/S2="=GP$W>QP*:5V-,><Y.
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MX__\_OD?=[]]_/I0G+*TAP;W$@E^.[TCL>/_/OX96D] SF3'^X%G3<"4QR]
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M(Y'\(8 8YH]8XDHYXAR7I?3/#DH!AW'Q\&P%<[HIRBU5[B9_AA:?M@U4 +@
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M/P=L(:&"7'XR 44'W@KO9";0H9 *">$6HN+8=/[8.F9L$Q-!3X$;O)]]<!=
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MV?7LZ<VS-64JML"T0Q^N(]X6K"J"NJJR,)T0FXH#+U0Q3VN!%$@]"N.FX\]
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MV-@;:[FH92;?JIIT,'=CW$08@S[.881\(.[#&:F4S47!WV,-&/C?@B!!F%+
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M'CY'U[^?I3[+HX5!/BVL=19.(4:Z-W-ZCFT.Q]Y!,<=SPTK 6]32K2+P#O<
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M;KM93Z3"D']RT\3&$:G)(BI6<?]+C'<KX-N\?UK$MC<D2]RRDIIW@DP%[83
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M#\0PSL3F(*4M\=C-9'VY:;+S=9"IBIWB)+P#.S>>(TB*GOP^APG\:QD#T>=
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M3#CO^,TUW.XG@4M5YJ"_*K_C,9^!C03,42)SH;',&\RYZ'1:-T]#SUAS^<!
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M@OK+K)CI^:^KZ,Q]>09:SM^9[Z71NT9NN]3Q[G:IXTT'3MSG-.6TB6[@ 2Y
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MP.[9. G=V&71^^]C+W&8\R$,YF^#^2*)J0? I\DJ7K["2W[V@O&W%!\8.&6
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ME5;=SQ,RFI[VIZ>+[H):T23_M$ C.C+BP%@DX7AF@ZT\I@:R\/Y=&_8><"[
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M![,?!-EAOEJPM+UXV1C!NP#;)C9^\9P&Z"B&ITQC+Z%L,/%0=?*BB<.$$TP
M24)F*EX])I9AEHH<C&M0^J\+0IW/3%;'"?%>\#0I*S^SLS?L%*3>B1:5$B0O
M\Y.B^6^_B/VG<,^%\<B.NED_799 +GAD[KJ-3Z=Q"6M6J,!+$>/E<6%OB8T3
M(8-;HC>"+,M!WRD%#H=-', #41>G\\#+,":3#PJR -:NS<G"M5^S&56RNL5E
MGB.")#Q3MVSMU&( )R:S/Q+>\]N>\V,R,?(^EGDR:;2<QJ+SI"H>XY5WN"FK
M]LDFP=-;OD,:3NI*RU]LXP,N4L*.A@3241K.B,. 3S;AE%JU+V9+#TT?_ M^
M=[GI0_.Q>$\G]%<29-ZLPZ6I=D:6I(!["MVQ../^FHKY-<&%W:=R%AT_@@_9
M'!LP@ S,A.0&>;C/^-SS*H_?TDV!QN0..6G) N)\Y$/6@A%FQPD5OP!2D-#
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MP^+(-!9L^J?K$5$!?1(+?IS/F0-JVC0>9RX@YY&%##7V= H?B'OQ.>J+Y$*
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MK=6\W>'^7M/ (<1RF:53S&>P;Q8:<]M/)O8X3D*U(9)IC $Z*!.-&,&J_("
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M8:?XIU;3*OR^[%$6,.]M\2UECRK_OMOJ'VY1G8V/>J+T?&-=R'#MLJ=&%?!
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MB@L9+QV>+%@R@\>OD-IZ+V1Q0)1&"//S,9PG&VVN&&R[AQ5O+R6LV&WR@]'
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MA'I#AD4X6!',LZ&S8S>E$,ZS'S7BCBF#TP[;,BM-X'(U;1N+7GD>5.)/[(>
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M!T1AL# T1*:3+&.@B>D!<*!+Q_$4#>2=)-0 LL;;:9)>N*2;+'DBOJCTP.Q
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M(:%AU/K8?!P,\7N<>*#EQ_%R"D2( [0Q']$CTL80]C1M@@]G=^%SB$:UAYJ
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M?*_^X<.'.MDOZW''0^=\%C*)BN3TA4N5Y=/.Y"G-;MFU8"?M*$_]?:2U-\S
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MVK&-3HY>%!NOG5E+&^7"4_,/@A&?PNMUS%)V$#5'.2?PV&'CKU_!-NIIP>O
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M?+8[*ML5^2>K6BB(52W&%8UEC[KV'VX]?Z!E?%?+4A5E2P8\A,#K&S6=B&B
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MA3@-M$KS @YW[8\$T[8FRX<RQJ]@E?_\_&FTNX6T6>NZS8 %B!!WD(+NB5A
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M9V=E!)N%IMOL2E2U$VIU'TJ=6SONHF?;=B[78?RAL>0!<UP3V66!RI*3N\P
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M&N&43ZLLC>V@7$-UQ/"/S8U0H8J"'.C-7PD/W #LP3&E0< X<*=KPVV=]L
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M&P+(9@;+1*=RPHR@QR;KRXB2=J2_E&<OJE0S0?B@H+ZC)&@4?JFTOD7<B%0
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MOJ2C3<-NI!W8SW5B=U2^T,$HR[''5BSU4JW_M.60@P-!H3J!8:Y9^)./5I
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M?Z&^.-I7[97X0='+T"49<[S"?B$$%]?$P)J_"3>_3:O?"<!]_9>O7TR"(_V
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M^HT_U9(["XTM:79?,_8)I(O7HZNM9NR+XBN@$$\.@G)CAL"C75<XB/OAB$;
MV"0]0[K-ET;6DC@;51I-LK'Y&U8:F JLC?SKG_^XI4>@";I<_X'Q3C@+RH2*
M[01-7%2YJ0<4A"FL )WZ4W4\Q]7:I_K2T*1-'#((,0EI[79D[=I3)6*"[M+
MRL6E%ZD[+0?B@8$4Z"R\C7,P$L]!N3?M#>8E,\77H?L]J5"SH>'_HFPV(X@/
M-YNQOF.7W3^J)4ZTWP1*6GL1PLE9 ZK9<R[PW94,0=(2<>0'0PMN^,;-T&WX
M>G.21_WU?(@648CB8#$U@!##=<V!^=G6X5R4!L&Q):14%SU^>L9_A(TFSI>.
MTM2T/S%ZAAA2>_/7Y""Z@D;'[="%FPE&G2JZ/-U,!Y<C"KF6M],T,#NUV=!:
MJTX.0"!.XN8N>_D<IMJPS##'T -+:%CS'+\PX>Y8E83X8\C98$_SIKTJ41EZ
MXI(SWL<,8,[>Q9S;4Z1PO6\-0 \?;:J)"^0!K*>_DMW$M)-MG"\X[/[!PM&9
MG  7-;0M$1)P=QYX1CV,?ITX-LN1Z%UV2E@:+CKI"/UZ%&*7>R1]F;6T8D]K
MSS!XX3$G(JD1 Q GM>-[996*H.<Y300LL#TK91)53%=&SYOVJ;X^%:-P NLS
M30$4:E/2,\1C@2JE0E>+I+_P@)N)C,Y<RPCH2Y.5%KI,5M_@1&%X[.) K8R5
MA=&%S //>)F.O-T(6\TH5#GA&\*0%H^VU+K/?%F*L+9.]8BA":] Z'%+7_,V
MG&0*X&\&)X_^^Z%&F-4(/WFH$;[]Z$4D4[VI]X<H:@BK[QKLTS0C8GZ2F11O
M@AR$_#NQG9];VTJM!77;YVB_&&*<Y7Y*.]3.,Y1)WVF'KGK4'&<<2SYCB*)$
M))E+A2]5VFN((K![D=*"\U)  "C?P#;:DELPY37K(_\G&_."81&<<)07=@>M
MT=KB*]>H$XY'DI SQJ"(38A2S,W$D+%YDPK3"FA*1^)S$5NC'N$C]7XPK?7=
M#:E@@_T/U.>:=_"*;_("(@4$@777T^@9DY%1B]3'QDW 53N,4B0^2G^5E-KF
M#*I%]M2(L$[2DU)M\@-/%$.RH&4<B:TX355Q/-5)?6W0&3=7FS8+<#BTF%(?
M/+CO[78[K7[GKB=_HCPC_0:I^W0F-#7Q026P<?K=[YRXQ_2!H?5BMY*+$&G\
MG]V$4,2E':A8!2;F5#%F<LO,R"FTM*=3E![O9_K:/:\^<@X+Q/HN"RU.1#SW
M+;Z>I^7X<Z+:#:O#A+ER*2(CO9CUM66T"LKB4B4<K/+C\=CW^K;NJ66U0M^L
MN,9?KSL7&7QUJ9@*&D/V.B$:9B/D?$"-872H,^AI"79:9(K/QZ$]B!$7HGH%
M8X[W>A\CS!*_#]A0&A-.;OKQ>;QZ:F_3"4W@%U]]\^V7S[Y_^25@;^K($H%\
M".:--N=_5A]]^-&GJ[\K__+S9HNJVU/.?OP4@7,W0J\1<=' 0@8[(;H8Q7:)
M_9'0;E/*U6^;B]S%*K5$46F8,V65;4G:>;2O(H[MT*QO>JH32Z*W%^@P80C#
M5"N^S:!^S[YY9DE1I>@,9YOUA"8)$FYZY4=(GM#J8L>>DR1X";5QSI*SI\WG
M!X:(D+U1$X'@Q=XB_G#\?]N(9M05$HX*IF)5VQ/FNJ-'O[XAVV.\G@ KPXR?
MF@.# OIZQS->K^C5&:T;02,,;R8,!R.AV_3+2 4+>,/S9$UA2 @X3R0;M\TL
M[%DP8JI2'V[JX.=R@#N]ASM-;JR/J52!NXU%-?%4G"68SN'#9R443!3S*FK6
M3=E^#0"2A6+UGE=+VUBVL1TWJD?JV6$Q:7Z>17EW%N[P8& *B8:I-\7Y2,,_
M4%4/(/N&K:0@SL,6:XUVDK-'UGP[!^%KI@(>ES^;]20'N*TZZ\Q$X7?AYSL2
MPF,[K(\8MGE:HR%DL"34[,<I)8X7>]C5_QC&U.W+_;QX:MPV/FM"RP; (N'_
M"],9W&D].>L3=TO6:V%C]<]*&679U>E+N%H-J&4TU#:?Q_R);;/!)U?'#8MD
MDE?(O@DQS4J97"#3J1C&%VK2@:8+AJO,WZZ?.A#U2XRQVCOQ$D%<(S/ZM$?9
MXB4J45K%A41[0T5>*JPBQ6AQR7P"4S$((6)-6MBN&HRRA"AY?C$,^6'N]5?Y
MAES*65ZRFF2B<I)1.VE\0?\MH4H]CA1(LOLL.BM.%Z[*1*.W"J*#C]:3&:W1
MG.$[E,*ZQT^U4I[I4FM'1_38IE*QUA$>)@O$(D?2%,M0!#^B<,*I9$O@7VZ>
M\7V?2WD0TD#21KYD"I!/ZTY^*K=C?13MNJNCI.]GZN2+:G&3?";:FQ, (+!R
M<9B\<YZ,"%]0+G?3[B>C)O#$D:;-5*ZU$*,!$'!3.+?6-Y6D*4A_J.ND>5UP
M"<LX#=_)E)Z+A_B. @BH(%JN.1FE&9,0UNKF.;X3H\CM6K*53DRGUR)5>4=G
M>FSC+*1:V&S/'OX_[F49/Z7D)CE4_?6CKMGRSGG=[GKTY(^_\O;"&?;IY^^R
M\E&Z<3HT3_[P^!-Z;SW+MV$_-M9NS_^*&0[AMD&Y<A=\7-06(S@1"R=,&JIU
M6!9>3I1<P6M<@GXS3JJ$3;7R\ DGN"=F=N&SLF9F8VZ]EP^Y>.T>4UA53NJ6
MN_02.3C8DO$6N_I5^?+4"!&O;*_,Q_LAN^6^;C?WTLIY6(IOOA1A660Y$ACB
MT:MV_>JJ7K^B]:4GKJZRJ;S&>'UI,$99'K%2*,@*;L#SNG.Z@I/#NV/?*')I
M$V+!]8'[5 D%R?^JF.(!7;U2U;'>DU':N'K'T4UKM-*<N.0)! T O")[X;3\
M 'MR:938F*E+7!+;:-SA'@<=K/1\9=)9S81]#1RC-"'R/QZ6\*^RA#EV">>L
MBLN^"'&)IW=ZND8^5?\DG9M/_O2G3RV=\]>O7CS-.S<1Q6K:@-N?VUL"#>^M
M3S57-4X7"*?GG O42$MZ%7>72U;6JXG(G80N7AVID[^HL,#KZN.:RBL&!Z4'
M29(-]_6*&I"8AX7Y#A?FGY\_>ZIFM&0[.;O9&6R>F)Q8XT7<-+\^TI0+S&UT
MYRSY&9;FX$#97&Y#;GF[?<3,F^J-QYNBV=!CH(%'I3K,F?7QKUK@_O12"]P/
MN_CMG77XVYZU+\]AIKN3DOUUM\;VJ@2JS0X]X=RW)RL_*"N@QE^454SZ#-#A
M*D&@\[?-CVKL4H#''J7:/S97RL3AB\ .PHPKA&/LT+C3: AKM>?4N0E6,CRQ
MW5T=QXD==?:%W'4+[I":/3R_BJ!(Q0'52AF>X@V4EB6^43]C!GHXN7X-E^J;
M$'*N7K _/*U^-T076/REZ4@IEK[1-''8*$9X8027V5Y!01F.<:?DC['2YGJU
M8IN#+?*8\0'GA6;*&8 OWRGZ7K*%GN' P(%H?OJ_AY/N<_/45]]J3=&75*@&
M]YPP80<-?L79I&?\ZS'L_OB[+?;?HZB#K3=GE&K:HW'7BP@'<]%2%@]W4*WI
M*;Q.QXI%V@WENR#:'0TD;6)>%&%<J7OU87.\ZP.!)5S1C)!PU1S[;=VF7=P^
M?:V)4O6]TAYCU[9%>=/X3^X(<"WD$'K09WB8[7<UVW5?=\,UR8TAH"KFJWW2
MF+^5IE*0MW>Y/ED/;[B \!G^@\]==OH1AE)*>AU)*LCK#.&CJY@FO6/D=*CS
MT8[KXX[Q*$S6=XJ)94;L<)P!E<M!(;4>LT].+7LK[#E(]GI/U&-[J;HBI*:,
M]W$2..%:@<36OB2%7$@T/2SF=[.8W1(^Y\DF1[%O>U<>1C]OQK@=6W26SNBK
MYG!'Y?G%VZ&(7SB[S8%.\%):?W=KNSKK'LA>R*^-S(F&T=R5TAX4R/E['.6Q
M$]WW6M)6R=Z%^E69_1,)=$8.7&Y5\KM"6N"J'18 D"#E<%7=!;VL,]8S$D1P
M\_"CV#T,$C/?/LR 4+5[68.M< 4C4Z? %3 P"/Z,^OU$O7CA92YWTGY1- CS
MS#A,R-_T*'H6;<!+-_B_)%I$CZEHL= 2$KF9O;H::K@7K)?V)26MLT,Q;"B"
M9SYB5R'2'U 3()I7 (8':BM"]@HXN79RO#NLOI$?O"F+:3"##'3?K!I(J<N&
M)@ 4-1>DE7Z:G\>KO[2W0AE$#LCF8"RX99])Z]M$]8 ' :S.SWCVD_@T-! N
M^9 JE$[G;QM_1W%H)@FV'Z:IO8+4G,D1U8<,.&Q=\>SK](]T, ^/5\2 (IQ3
M]75-%/N ,84WNVV'F.R(M7^A@.=VC$3MCAC:T4C EVD/50+=9]@% QH3?I+F
M.K+<*,<^D2LH:D^(08Q:C:H /9,D:3=P(@60(O2%@M<C5- E=>R5MCW,7O*N
MXE/:C.1-I\HA#4.ST#;')$N -BA9[5GJGJ1E]FS#[Z;>U5"^W-(+5DJ,I:-A
M(L'J.;\NYW6V!LCJ"^TT] (6E-:.,(=D #6O!S_J:/C]?,2K5>*F\Z(X2UWO
MW2++ZBT( U9*R_L+* .^/S167DTHA066"8PKI9.C8.QV8*H/=3@SF\22NA%'
M!8H"=5#2M&9LP;HK"E2A>LYKJ-3*>8A!X6TCF>),#)*UL4M"D)=[,OZP3)/\
M.JE,VK)7@[ VS*E<*)9M5)!:\/-)>XIVB&:ZDO!N^L8D(8N_O9?\6VK N%TL
M/_>0@B2H7?9HWZ0>4*Z5^MI%GC39"1(^8</+0GWN\.B+3'_I.@?X5G:!=-!.
M37%)*U /3 ]-?5!$HS":LWA!)QW ,^,[DW7RY/[S;V<U<Q3?N0!B:9()Y9MH
MQ_G W$C0R#U#L3:30"0?>U<Z9R.SLF\&MU0:?V&P:[RD:'/B@=@+)33\'Q*2
MZ-HI'_&.IN\M'X&[]((;P D;[5,9.FF)N(I]..R?\LQ6^C56XCBTQHF/3!6Y
M=]8"LZ,JSKS,LU42$,;YN]>'U)IT/MB#TCJ%E+2X6"#W"N<?UADY1722,2."
M5<-)2[B]=:(RW+<!(25P[$1A5_3/17[>2"K(+?DLU)#O:MF'#T7RK$C^V:46
MR=^'+O W)5Y)3#]B9*9PG;F%G(\M%XI5H'%,&[.TRNSY_H12SVQ\KADIC')[
M$OQHE:O'RAQY6V':/W8^?-7V[R3J@ %383-14A[H71/(BP2&0_$D<A$%Y#/<
MH9RR/UJ#B7>[G'CJ64><2P%S7WS6PC/]O*S-,^^"OO0F5],S],';7=O]2:;V
MRR,-?-@;P<$:^E\R 91A'O)DP.PL<\'Y:])%]^H-NMS01QH/W2I& 5L!*"BD
MB\\JS=K*2#4>]%@G+Z@V,JQF=Q5>>N!^PD/[:#V,H@8G>0S.%X5/"*Q^@A"2
MH&W+/1Y,%R.Z)AJ91Q6ZZ+%(3(-Z&=.R-5E*)1$,^N<*?+)9M,YZ]L_<I+VN
M,&D@AB_Y$D]3S_FE_Q6^]PS-/E-Z/5)VI+D@/95AUZYY&XZ$C[:UDFY3N4TS
M1NX+7/Z[$8U_)P>JL)34-\0ABE/ES[)(GTX3=3T^LY5IU]%O/./UN'IA%L#
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M4P_($1+Y*VD#!.?KF@DNPRDOOZE_7)&-#LMODH8T!I8(%0836<"A17]"5(5
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M4SBG:S<M<GY@.;E.7SQEI.1>_^QE96#I95R/_IPX8%BKZ1:)DZ9M\U&O@;7
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MGI%!U64@B-PDBU4D[Q3%;Z:T=<F=Y"YY[H1%0A(..&4E]4,5)C[9EI'/A 5
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MK@=T/T.7IZ787'H0Q@1A;&3'3Q2\O:YJQ<:-'@MIAY(2YL.XVZLYTZN#P^I
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M. >DB/D(ZNWJ56Z;-.4X$TL=[0-<B/#PZZHV901]!.[V56$IYZ.HG7-[8SJ
MTD"_ME0;'4\=69=N_7:!<2MI_OS%YN@W!,8Z";WZOA[>#JOO8PZ8$A;A1]9Y
M#>/!";+OV* \E,:RTMB7O[/2V*_?VMO300-C;KQ'NKL6^MQ%?SG).D9O$<8^
M?IP_'99S>4TJC'-!A2>H1'8T>1##+.?/X=@0W^-;)B@1@^<BL4$NA,O5^/X]
MS.>OWG$<BSXZYQG?U;\U[S+%!6L.).<*&O-B5TK$2*[+/?L%=:4=)<9]><%N
M\8O[KD6-9F9Z>Z^J9(5JQE!1;Y#&9.@;N1BW-4_H@46E8LM#I*)2//=$L\7@
M;]B=#MV]_$DXVGU-N;B!0VGN+*MZQ%LXR5@^B#A).;''?X,VPBS)2-WG;%Z4
MT% JER%";>>E4B5ML\VH9CB3*@2JP_)]0/.B:%93MYK 6I47UVS$#"P\$RCW
MY.%E])>F8S"S&;MYHN*XZ519G=^>>U^48TRR*V=FTGH%#IX).S+F9LP]100=
M<4^E5YWZ$$*(4WA+)'<( LANJ. /,NG)E'8=A3\"&TMJO0J^<D;PYTEW7YT!
MA!ITP''KLE9])(;II87R! QSPCNC =<..1-+3^:OI":7/D?BO<A$:OJ8RMO%
M6<:%8M54Y::.?-]1>\U2V6<[!I%D _XP9NI='$@&O[^J#WT90\TIQIXVSR,(
M2.TTZ6CL$:Y5SM)M[UG%R\+==%8UO\<6LY(4H*R\&'+-'G&Q=YJK<=S+O*E%
MTA=!F/WD&P*B#8GDR%O)!?B'BW6[<D;DQRLP(T'0U&^1&^C2,R*^$7<Q2J4C
M5111<\O51X4<<MXA3$VW$^7:\L!R:,JWP0*H%WL@/Q\PG;K(422IKID28]^4
MZ+6OH&U'&DFF @CD9W\8VUJ;&:OVAD\WLANY\R*HL9Q'<E_O^=#@A"VHN1/1
MQGXU35XG%[>%U\B9QOT"28]HB':,)^JJ:JMM?9@[\R7_V'"\><(W\<&]M4:K
M8 5W3OCJ E/YMV V)C]3=[C@GF\(K\(G5V^DWZV6^)JNO7Y$:Y(-0AA^$BXH
M1/K;93XP$.&$&P]\!8.D(A]!]>"*SS?1W<"'LB2?Y>\N=C7+K..8RSI$36*)
MBC2RAUF 6;/DJ>TI(L;19 "DC9)9!3QV;A^,P,BCC?TC>\)J:F$RU[PFSB,0
MO(R)5UB/AD>9)-)GD7R2MY"Q&Q9 B; >-]:I5%.5XZ?*YY5B2K<$0SMG3==A
MF($"/<\ Z[?FY-#19\6+64INU#Q<?/(H/#.VY,S+"4VPJNO6.WZ1?@A=X2+#
M<4=;LD0O:_ ^D+:]]72X'(0E^SZ)&=AY*'<=1>Q:>$2:$D<O46$/'H_J5TUD
M)DR&$C'!H1ZXVNE<TDB59NC6L RZ 0O-/Z!V[,S\V=U5#+7IL444W%:[9+,
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M)/?OP^CTH8KM(ZU*;%%-6+I[F:^),]44@T@SB^+IZT%'X>@11(8+ Q6^=)I
M'[1]V]+!@EXG!HILQ#L@7;..Q,6XA<*"'E85S<C0DEE77!F/5!F)G(A;>R2Q
M0\+P@348ERE/<YF#R3MR3_Z[A<W?@"669 .-&<B5N3@>R\H"<LR /AW# GP'
M#796PO=0V/J,2@]=G^YAWT\BF>[85R(R5"=US8H\9### F4WZ4TU2O4KR-^A
M'91X395VG<S%QGKQ^+''5ER(GX0S->YM.+Z'KA!N$-&"#<[N:)$X*R=6(2(
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MDE,1+Y[=_IBTG2N:T.!!^$UH03:%: C)D!P9P"9HK*CYPN(<XZ6W18&F?./
MD\$IX[252CXYEGCOF1;<&%'$GCZK%CH4T:PT3E2*BL?8@E2WU/AGI-HNU][^
MZ$&"GOZ5W PKC7"1@J:#"R592D]WQ+=_M_W 44JY[CO12/:CQ0D!'\ZX>J\/
M?GPT4]-6AORR=5'Q#/=1Y@.FU10RVPV"F2)-$BJ.%%E+.39"U$=X#T58-'58
M'L<UB'XB=7:R81>[>L3T%(A-6&J05T]V2OGX6_MN.=[[FKH&8/;HZ<E%"N-N
MX1C%3'(820(*F=BN3_,8FS![Z,O$2QGI<EG/BXT72JH7SLKK8)@1S*64>#*L
M109*\#W:B::2*C]Z;:7"(#;T=J0^IDYV(3"@U)&\X(T%+#AAOE4Q0C:/P-]]
MPH!CE3+$UE?PY"(C9TIVU V57^P1X58XQ[[P!2R52%23&(Q9N OC&6)'FZW)
MQ#-QZ;0,)KZ0$7"/1@LV$K// -^3@F/*RZ"Z&ZCPT52Z5@)S-+)2H:NI4I1/
MKC^+WR4-RIZ<@M.I#=%D'Q,%R1#&H?)KV0)^"\L9&!]:>,D+7I[?I"'ME%F4
M>]%(-1@U[O'0H'NL9$@O4P 1VD2S/.9;:95(FRTU%P;Q&K;)6 3K(35 M K*
M1K)1P:R*?\^JT*B?T2XBQR!:ZR(QU2@FL>FB^*%*HX+,Y$NK&7Q2=BW@'%"E
M[0_?_GVEF3TJR8NMI(7W3$ZMY!$-E<CX'0_3<OIX3==>,X'D;5W=:7]:7&%N
M#>>5>6WOAV;PVXHPE,$Z;D139I3M8*P(57O#I32/*AL'7K.%[W]Q.WF:QK =
M;">70SA$!RW9UFF%WM7WYA,O,#CATV_#(1M.BN#T'F[6)0CBRW$CR.V1Z.#S
M4,<P*_/D:Y0'KUL]N=-2XT,5,*L"?O%0!?SPT4.Z7&0_V>HQY:O ;N,9I>=J
MV'/4C)'S&/[POU=_^>J[[['FO_Z!__U)]?CZ<3') $[KXRNICW/LVVWKA@D[
MT=^.C4"1?^X%,^Y%2!R82NK3QZNO*%EWK5CI6#-(LI3LUR?<F\F13B])I4G1
M@+5 /+C%(X/"";;D[#BX'("PEF #-WHV@PU*3<Q"-C81)=?DK[-VX3RC]H<A
M]9RT74*HY$H14<D]4T[R7'BLG3#[\UG1@C5066\P&,$8]\=PR-Q9(D2U@\6/
M+=^!]!_0<M,Q^!F8^G]=[^@'I(M>*]+K\R^?XMT___)S)3W0 N+J>R$2>R'L
M0D_^Z\L_ >@:W"$Z;I#.H8(7U[5H5R 9==VAEX\(,,+BO*GW@EPLA*+!/BY%
MV2&?L1J,"]4C 3R>G3Q+6[WZNT+ /O751W>M;%8-(VP:(_0!.'\'SGEWV^U0
M'?B1@L>CU^$>(V0%RW?3Y8&H0BB/&&*$[/=D2 101)DN8"T53@]"O>MK8L0F
M=K=#MW[KODL9FK9B;9A>_FSX15 OCGM&,OJ_D(0?^ $(8!3<N</JB__@'J:Y
M*>%[JN<W8 #B$Q#ZJ<-SAI?ZXC.N9+70,MMW->B]"3U 7VJZNV#&W'?=9_&A
M<O7YHV/%VC)U%\;N!ZJGZ6:$>TC\?>KV42.N]&\)P])7P;JB 4L5=V+_C$JI
MH7G//N=7;+C%T\^>?%$(O57DM')248BHPIJYOJYZL!$K8C&?3L4?QBR^ 8=S
MJ9S\JT;1J&VZJ9!W.,O8R3RLPI>V!ZLOY6OC$Q3UJ1T2\#@ A,?#4&^,^4(.
MK$]10-9[%,*33'DO;+BPK 7FS,UTW;QA=5N+=M^]-EW<55!CV%8;!+3I'2=;
MRU$RN2))RG#D233FY!(4K!V>)ZX1%8#QZ)92]*#1RTH=XXU65>1I>*T.*E'/
M#W&([4H8#+"3#GOVS37FN*,6?L-&^:>G0[F1DA=VPZYL&3]@ 1@_$(\+T4A>
M\$DMD@N>G-?\N=(36U.ZHECYID=V_J2&$>-=2J%0J.1C3,^V&_.7G Q2HFN7
M(8IIH3>@/>7K]:Y2?PK1[6^<^G+GRO!^&6@I<%W?UKBYY%J;&,%^*MX@CT1I
M[B#>$*4N*X9+U5T=1:MMRZC1#2<M*CZK#?^8"P/(<%PREY>LNS-]X!''(?T5
MO6QZF"6W7DWN8D/^]D$TN90-?;)LBW3=NG3;Z84Y!XA,.'3\VO=5H@3CK[16
MO-+HUDVY7[D6>6,%<&]H>Q#0ACUUM$N=XSF8(,F"L9>CBY9&]:\OOWO^_ ]_
M??GFZQ=_S9)G1NXE&9$<6ZZGOL+*G[$GQ/[FZL6+[YZ[$P9XO>J&D"*W:AHU
M%+4<)P,I$W2;FY-G\C5Y&D[:A*\^LU-)YNS  !N:<4^1SY]U]!;<7*+X$OHB
M'7G/;,5]]>IOJS^/S5MN8/A^;, 6SN?S3*+R;F(DZ4,40;,S_548D."^?%FL
MOOKA^7/^7:5]&%]!9J@FC)?3MXC\41RMB_Q08KS4*Q;?U1VXLD:#/0J_^DE^
M9<DKTFVA8CY998;[V^)$U,Z CS\PQ0;UJ0X[:<_* _@H!2GA>S$WP%:X/)-$
M>#271'B\^H>@!RU)CE63% VKW?ZF!&T9KXUN'5NKY^Z-[,&C*]&RI[?:6F>E
M!>F2H^>T,/:"L4JXTR$$$;$Y=WH !1=\'!+(JQFR[&Q*FLYGNHZ\IY2F'&;.
MJN(^2"M_/+FTJ[6!87B&:?HG L!FV1N\[I45@A*&C$AH&<W$'$!N@8$CPR?-
MUM)GZN>GRN>OT]ZJI=8JQ%TA<IAOL-*__GMM5EK%2O5@LC,G:7([UT<EPN\(
M!3<DBMA@TU%U>*_L ^ FHGUE9(]N6*="@!?LT2X+]%3M;=UW4JS3:H X;U"Z
MLN,J\1>L#V'J>_#^@F&0[<5U\O4H]6B_PKDB&,$%NB,JF0B1#1 !!@D3?P^>
M7GYXFL?V@1.2EZRC"V<$PL><4YN&-KA1&\Y;H^)#2$N4A2+!OY#UA&.(Q8EN
MRI_",4J/FHKZW1&_A>3D';24>^H Z/91:+P*/-.FW.U$Y$FNZ5]I?5/MR&\<
MDE*FN$!$E=&5:^%(DV]G0;-D2W@14L*"."!J-<DP)GPLIIL#+<9< I3X_(-F
M1]V:Z>7LTP_EL:P\]J>'\MB'CY[/2&#=,P9I6>4]01>I$RD$.='96^:)SQ8\
MIQ1395"_Z_*R=ZQZ6\;@@@_;R,>0: +SP=:$T&;@W>L(L\@X([TO"5=W0LZ#
MTF=<O<L]#2FAU8\-N!<8C(+UY5.PA42Z  I2I*.Y6$K-LJ/;LQ]-:ZPY"O:8
M81\4D'!3QJ!'T49SVGX^/$,YZT),*TZOI3]2ST\\Y)L>3: AKB7!T@.'2"]T
M+CO.ZM(^T6R:_,DR^'UUZ/4,<P1>2@$SBZ'-:RLCP]<Y>&6":B.#4XYS>I">
MA&!W$EGJF;KK-A:ZXI&K=T390>Y$^ J< 6$,(8AU6H(V+6R\BCOZA7FDWQ%N
M->6"BOY=@I=!HH=:19W&F5YX1\18P9<990=8PMREYA7 [\4K5<P)'!Y:&H]O
M;X0J#$'C1(5@X+>1^"-^ =I4Q-2%5^!*8WLL\H_=1?\V?TL60SL:,UR\>X;Y
MFZ1=#"C':W,K0=CWI)"(?SWG^7[ZV=.G)D2F":8A%1.511A^N7KR'^&>:\K^
MTVR[$A>7<*[&XQ43LR9.U578.FTKP%.^(SW6FW")%Z,D9?_670UX*,/HF[K*
M+:U(6M*Q*<&T&39XH5CZ%/8G.Z^H6D5FSUQ9R1U@A>_+(VT),KH[:@?Z27C,
M74&3BGM;VFQ4W1.5:KN786L5WA6M13H9".3I4D^^N/>%NJ6,6G"<V]7?QO!T
M?RQH-+\HHGUY$68-/#1^^E^%3?7G^GKUYXID:K9C$WX*2_DYK4F9><Y\4BG-
M^G&0V.AZ!<#4.R;$JV3(:]?XI:GC>\V"4-^:Q8$H3EO=4:(J@CMU*] R4]>4
M=V 4J+CI[E3A0!ZY'A+*)4["2=:WNI^I%GCOK&;:-%:0YFO7G51B/8DI*;C1
MB:[+#UL/[FFG9[\RXR!9K/Y6'UZX;(2^)^Y%EPUEJM=9VQ^5A6#1H14WE^7A
MSEM>]]'^_"PNPV_#R1)&,GLWR3Q86Q_S7^Y4G9$*(0UGYP9#X/))DM)1>85@
M[?(V$F?/VG:Y7E<V@JY+=FDPET<2I4 TDOR3,!:483\(71D"A20%+/ %H2+5
M1C7=X,PG<\W_1'N2."*QSY*S63-3+Y _(DH Z8TH3'9]QO_N= JI*\Z()29S
M#A< ]S$66W<[QB5 X\;8*215Q22DQI''!Q >+WDGYRPIJ2!Y'.NPD</P&4*C
M:B%@3#VL5MBKJ>MD;-0MBT#FO(6$E[5)9X?+4R/L#.NJFVO75")(ENFT8Z+B
M3N!Y!9R0K\3H:6UWY,&58Z?N(\%WW%V*H<ZE57&T$*_&,.T8I479--V=OEJ^
M/UGLFE:8URP>CBVU1U2.OM^G@&1[LB<8>1L7):M.I2\G[FT88C2G7WR$R]HV
MC-LIAQL"IG@I)F[JE"XC\ "&#U^5Z')2KMMWZXK*1ASB-<=':*8%2FI7*\FN
MT<!N%RY_*D;RO-WE,6V)HRB$'!@Q<\#X"S[HXHFJ7^FDW%0-4RYV[2/X3,&E
M>W05W#FU#--?LB;[(+/#D>0W4G(.\2UY;=2S*YOPA0.L*=CQFZ]>OK">Q-@@
MK;/Z4H[1J[)]R]&#FTR-B6C:79F!^$80>J*JLQ=&=/B9^,N.GUE?EYY]B =V
M]@R:E?UK=U>AKYF;;EZ^L%,!BZ&$U<!HK!Q2,1)L2G^(Z5?0"YF64.95FJIM
M=D&<'@WK_1)M-06Y?!/16(6Q8)3@S&V*_(+*)F3*?6)O;5H18@_@<M'1RCX1
M'5A-V*%%59BXG[?':.^ >/5X1 <C3$&#* 'I=I3:G%Z%=!($MH87E6*/&18Z
M&>D?%.,QF_^0E(_:!;O[[^W^# %WJHWYMV3*3QKN[]&[^WWL&21#\:+;A:@C
MA*$AUO\-O<A[GDEO3%)<I, -4XJWXTP&==41%VT'W2_0'X5M>=M1'J5QZ*NS
M%Z*UOJFHJ3=;Z)=[9MQ[ &G,8K244DP4"6K2M9AN&V)'4\O[K;L/9TT$*2"\
MF-HM39(M!-SF-NEJ!#=H017 2%3L 174F+@:T,C^H-<V+:K]YT-1[<-'CX,S
M:V.>FI&H54-"B6)3'J]>"^J=29=9?,@ )\Q]="^30TZ1;"(#-?ZO^UB;SVF5
MDR?27C]JJBV;EG/FY]&3+W]A^P./\4_/](U^J1NG0_/DCX^_H/?.$4!7B'5\
M_I!DN&XIT:_*"-.(6FD\0$(>%2T&=T6.5_5:S^[5VOXPG^\_GRZ*=$K><U-&
M/CKF [6@J*[LV#<DQ_,P6Q][MD"XY/(,L2CI>%R">\@"; 3"80[5\KJO*NEE
M?9BCCS-'KC=L3OW+B8.)U,YTLSU[F)N/,S=DXF*T'4\;(S&2?;*LP"4B$<E%
M-L&C[\ *%\S?_H"Y90_^82(_UD1.F^BU<'FT%H*'X?]8PZ_L9YIL=(63P136
MN?R5$+*(9#,$T0[$%O8P1;^$JU!5S,0C906K%N2XA3"%_U26 <E;JJJGM#&)
M<)BF@[CY1+B%H"-_.#[,Z$>:48P_]10E?1II"HB:L,+(!7,HX ^>L,+@?!1F
M.<ZTH7B8RU_'$6D[8JOCOA\JQ[B4H(=1%*[ '!Y3>A;X+RFD@,$&Y9X2PYC!
M^L!73[K.'DSOQY]<:@H9#QZ][8QLWM].DN5,3JY-DXXPO3QPP<7U[^V(,%SW
M[7PVAK_F&\0T%>,/XX?I_VB^Z28*5VX ?$9R*^SRMY4"KMNJ>9B CS0!WI92
M"#[6<]L*E*(1*N[VV,/$?*RP89N4L_KHK;  #0FJ,[T\W);A)D)L399[<%#W
MV.%+UQ+P.%AF?>T;A/(#T7HPLJQN&>Y[7?:;'%(EW %A53PL@H^?'W/E'5$Z
M$@T%E<ZPTM+#;'RDV5 ,M$P#$!_KOJO67=OMF"IQHYYHM*"B851KHT6)'EH6
M6J?P@F&F"J$"#CO\6N]E%Q^:[F[3W;%T)+K5(8]:)/Q:97C7[1](^+V2CAP1
M<U'9]0) *76#2,!L'@YG:E "-&0BM>%F// S;&-?@3*)1 Z@AP7XT19@1Q.I
MT6N<2"#T([6"<5FD1*5=>]T!TDQ?HE5AW#AA(?SPEF2ZJL)^:5;GVWJS::K5
MU^5P*)0F06CKPB?^.RS4G\;@IM.:=8]W(-X:6DI7U>&.*ML+K2]"=3.VA[Y.
MN55?W(2UB0^][,O6!=^*\BXUMC?Y1)3$E74C(X+@72&A?L9#P[>R$"0.Y4/M
MY^-YGF53#;,@A20(3SH4$Y34P]1\M.Q9S_[?;=>,NUD@R8.)_T6275='#QE0
ML4_IM-?<E!85_">MOF"2(>%7W/XG53G68*:>B&Y;)"DU$_$J_"4Y$Q,,^DV]
M7\R?/2R+CYC/S@M),4'%[D#;W9:62Z$%0;,;YBA2 ="2J6('4>RDUO7R8%)_
MH4@N"OT2C0T3P$ ^08#CJF@*9JN'.?DX<\+= F'X'DG?@,<7*SE8#)"D-_9R
MP=E1@P]$Y6*^M<$QO*\&G1.M5L^[(J!4TP>&R QZLP!@'5NG)H2HPXA6PS_
MABFR2HX#T7(7RG)TU7>E=ARFTV)DTY-F"NFTVPCEZ#P"-B-'J(9@.Z7"@/A
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MCK\H%1"'8B#2NG#!.PGNF"V+"?_W9:^Z(>*A3,?!#=+)][Y<RHA7[^%(6H/
MC0APO0C+$R/W KJ_O8T;"M,\P^(4U4RB$]R89H0@3)BS<<<BRT*T>3CN>8G9
MW#%5%.5WPAIT'>-79.MJ. R;N:,W(F;ER3>RT'CN%?*QIL>WR<V*^\O/:X\G
MV!<.AGA]6$H"%)101#%5'V'QH?-D\L1&63/M5UMMR]LP&71H_W/<L",3'\8
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M<Z0_5"[F]K70F[(9_?C3_P%02P,$%     @ 1* $714RQ.XJ%   ^MH  !4
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MP&$;K8<6WQ[EZ\O9M*F/[?<V4[-F;%D>B-&"$>D9!,W3QP8]#ER)9#0TWI$
M*SSWKG(?=IUQ#2)*$R*?B81-!!<R&J7'S@;<AV<T,T1D/J#I ',64,T@W"T2
M65X!ZT64WA!+(R56425T+IT)V!4(&P$;S9P1WVX@:P63,+=-VG7VMH=XG1RD
M(]IS(%2&W E)+9/HD=Z6&$<S<1S6_>#J:HE1OQPN"^]C>HU3 ?ZE23^[FL,R
M'IU#U5T>KQ1\S>7Q:\(W&0=2<?A-6N!]8MF\3G.6YH$WMWT-L:P6Z8.O]A+J
M=Y=-91/;BZFMOG](0+O*A_27:4#I-B<?I@U44/=8H@00ER5'I:E0TF12B1Q[
M<7[ X>Q<IS.'T%[P"F-/0C(0ZX0B##*>ZV!,SK%MW@H8HXFJQT+&7J7/CJI#
M<ZII;.5=+(O%T5Y-==#$ ,](C$)%!H(SB1UYK04SFJA\K'S"4>/^6:6I)E9K
M2M+\DW)II :IGH95C_%T%TEOK5>=7_8/Z$^EN"'.T4B4DWFN;70FQY[.KH Q
M&ON+0X1EMN\J>-Q*V8W'""P2RYPD1J9YDA146HT=KMR/:#1V=!A>(*H#CR)7
M6!8H^IN5N":.I<ESR#+J0\QRY;$W"?5 [#JJWV&:KCA)\[I7X:R8%G53=<FE
M-:(./B,ZZ$@$M3%-[KQ5Z+4>#T :C4G<C1#+E,=4!.**; WI,FUQ[UNX@$EY
MWMKJ!:1WEWXR:SL"O/+_GA45A _3XZKT4-=ORGX4%-IU'"$BD5;Q/!.Y-@)[
M76L'N*,QJ+BLVI<"\988BOJ\K.WD]ZJ<G?]1-NFUGP?G$*YC\]]M,6U#]Z/I
MU==[WD9YHE7FB DAISGS.JH,>_7A<5"W3#B3YT*U?6@.WYFOG[9;(XC-&".2
M!ZV<4RGPQ#98#V9<!@A3A%+I-YTFCDYG!@"8$]@SF0?"E >=]CY(_TC-KTT
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M4]=!02:!E(H#RK17(6!OE<I,A%8@.;G09N#W$V$?#56YQ;NI<YCSS6]'%-$
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M@Q]M)G2@>'%E&/!@4!"6VWA=R;\]; =V-A3)KX82=\3'6]K]/78#>P>W Y?
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M)412',"*UH<^!U8<+NW<>\6EG5<10\3&_IC%S_NSGLSG?G:'N9VW4G!@6 B
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MHXB(\B 1I6<4\'@3,U82BV3NU-E3Z^TR&GWR:R1C3Z#U8_:C3T)+HWE;SMM
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M'%Z0?7E3(.EJE%,RKA!HR1'0)'#"F!4T^P32@C95GC#QVI U/7._Z_J??IZ
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MR$:01&.@54#40R\1')0>OP.G>N"<&6=R"7Z\,-ZJ%W)S&1[\;.,28B0PQ#%
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M*.+KJ6Z:R[!\:"?[!.1 *XD %<HKZ1FG(G?_G58@^>*%R\]]=;-\2GLW#<>
M5((!*!REGANOL<J\QAXX8\7^#M=W=\#O,!F?2ECO5D)_3Y-39_/+>IE'V=K
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M9<V7$6EWG_\L=L/2!H[47/)RTQ:60 H-@3202L6TLS3[@)P.+$^9"5GEW$*
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ML%Q%.,SBW+U@-T \60KD$6N!@-"Z#9S&A<SL9#I9];8US;S6=B,D =-75CM
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MC*HRPN_;8S PB@Q@A$ "^%;;T^2+YHZNJF3+3MG8?;EL.E=9O"JBAE'"K?7
MH]HO$[ GE% D>!*FDX?1FG*8J'*LG1@7G<Z-1U_DOZHJ>P[6X\5.>SF>XE)[
MV P1@MZ)@'"V,Q(,3? PDG#U)%;CEF?%TFCQO);8X2PZ_C']XS$Z8O5%G@3W
M+=BL4GZ7E[1*Q<^*7U7SQQ-NSYL2X'GM9CBN"GP+)J<[E9">"]T>[?)TT?3]
M%HD";MV5>^+$.FNGGXX\#/\Y/QC[JHG:\>.W2;C3#C_L'LZ_@PG2J3)M(]"*
M7UR92LU+XRKSI783,!:-S6WW6!SD;W[5+6:B()QHM*^WM#!L('2LKE*9;>B:
M\/YX(_IHK>-,T;!EPSEEED@A6;PM=%-WB@B2JW4H,2CJ=/!VE7DDX\%ZX57Y
M:V4O':^;H[0@+7.E>^Z9]P[;\Q^@3.9)M[^3 3/GR("QU$I393+@;1U\OQ.Q
M)_;IS? [(^V[%Q87>Y\Z*WW%UM 9%21^?L#!F!PR>LN&GN4,+Y71K(HV"DU)
M;%?%K*F,I1.L3G,XL<%R9$#B(TLRH.HR8@]LWD<&U*A@.?V7=V81G8$R0/IV
M$6@4UJW(9-(G[M)EF4KZ;#,:L6M4L5ELYJ$LA?YC^7SO5I0S:_5U4@^W<VS!
MM9H('"A!XP9>NMMOC@P(WP]R\]!M&HC?GCJ\++Q<(F@:LD%''6AV"A,+DN])
MF.T_>$X(QY3IJ\*XT1!VZ'<EUQOT29?'^Y8",(9BG8RO:GXJC]'Q]+$8FN,/
MS_P#)CX.NX8*P>A[<!'6^OF^!OI&Y ?E]WJXYG^,RT9KQ\OPW@[9I5V;S!)H
M0MW8\;HWXPPK7QJ:@Q!?%RX<6T8?-6_V0EC;J8F/<,PI:"1?+YZJ:^E*JYOP
MJ'?AK:>^3P,^UVDSJIMBO.@N1NC:NLIWM(L2!O%KW7.C/2 &Z+?AKF/5]I:P
M[B6>--T(J$=>8V(>DZ\Z"7\_/I8EU43NVHCCOJ.[N\,P$AQL_NOX#(!3HPF!
MPYB97@\V&/#T@[L/@O.6,QHBX.)O&5Q<8K7>L"LBM\YIOQM*0P-@I,0NF)P;
MD-#\@'?M:=<DF.<3]'4FVR77KVOF^"M-N) !%WR'P3P2<3J,7 <' 29)6EE<
M=!TT"[JJI:EL1DDQ22V(X#3KUC98V/OC!]%'_,M +$LY(1\MGP"[U*X9B39+
M+"; 3UP-\,+CQETF;Q5THU(XC6_2&_/(J?9KS'!+]+'$S;%L%180_1%X[(=Y
M<$7!!!1RPK4 7NJ8N>Q^/YF&328>_%739LIJF?F:Z;Y4UD)%P9ZUKX=[SH?P
MKPDM3E7OZPTY88\(6GA_E&]5M(:G*[I"HL^_9KUQ[DZ@HG+U#X.?.V:-*2#H
M$#_587@4U0W"L5^3B['/UH[/R<M>B1=YT=*L[[9 ,Q#X#/PTT67ET>>S9/+R
M3,B  ^VR%.,%RFC)$D"5#"'YQ!"F3-!& [= G)LS?.[%/V7[4X22 [S:P?94
M[3S6\-?XK)F2:<,8Q$^3:<3FD,<IUU2AY@./E]8!ZL&Q]W<3Z$BS9  MT;_2
M.4,G')T9<W)ZS[>A[E8>,D]/1$!R:8Q&X%"48M-F'B(>/*HICJ<-(P.6LTF"
MTQK2;D]]JRS7:^L_3;GG-]3%9C9IZ<LD7?UTQ_B;5[>ZY](7PG\O6^])A*UE
MY>MN-=3/>&@7?TV15=+$Y+5;XM+>M$O#'IU^;)<B!/>C*:&N74NLD^732SQU
M0:[I16Q=/%T6,Z^/!%)/CCPC +:%.,<W[7*P8$,.***K7;46]RS,KG31>8XK
M4CR.:1PBV_+\JO40&7 ]2O"Q[:4672]7VG#/)3TW9&79QZ.$3Y)5D7:GE:W6
M^:2O< :E&XZ0"9]17L*P*:*Z&2]4\CSGV<23T%W[)(C4%<Y95CMMGDZ-K*PU
M#U0Q5D4*YH";"7U*:+'#V]W'W^?F6H<SIS%]6$WT%W#XGFZKK2?R@@X0&WKN
MP;4/0N=*C5]6(8M.90]CTH&/G81DOQ,?*5=Q)7[2^J29#)MS.WSK)=QDHNL4
MM?Y%)BK+1X+V[<V9JA0RP':4@9!P#R_?QU^AW^=O.?5.2'&RW+$ZM6N.LZF%
MWJ5OKUG8P18AD5J@0RO\K/U3I>7>U.4O$E[)S><E\S[S1!::CH-^LCN0 5;L
M9, M3J>]TF9=8NASQ&8H_->ELH]<FU^#)8/'$<S!C)L'@1(Q^T>*(\;;\]BW
M\]I%BXO<,9[6LQ$25*O&5QZX3I3]!,5IJL,C(8W U_M.Q&M5A&H$BBX;N$4&
M,,W)CLR,^"$U^WSX==34MJ7SF?1,,V-;5(I>-]K-D@1)DPB&,U.&^P"9")72
M%<YC@X+A4X6]6>.?J)-B-)P@ /;=M=P]I7FH87\&=SS$RH#M!%N1Y^+UZ_C5
MKGW"8$N<43;H@\X6/?NJ5<DH]?+,2+#(%[PA]C(^$N6&3>B&L!)$M'$1Y;Y!
M6(]>O^^6#X;88Z!V%KSOU3HD5)<="^V)?+C(GBI.0@[F/2XM 8533J%-\!7A
M3BFX%:0T,ALON.2<>='6E/7)I0BQS%4>P-XPDV%*O;3SU-+<?-XIC=_+9&U8
M4S$L&#]S1I7M1^FA2W.8FV-*I_<.M_C:&TOU.90M[8T6]:D/GXHFWHD[*2^_
MF:2/8U:P0G;MS$D;@^K,PS0X'?!>\VA2.%K5EVZ[D$]1V:UHU(,V*S:I*SJ)
M]GPW4/EZ=IF%C*!. 1F0>GKL,8X,TEK5_;%GWDU[$(6/;T(;LOUP@? JYH2W
M*]=,5LIN:7"B99E5?=:B1*7I4W?OR'5I\R[%J_WZTA<T.B=RD#2IP8NGZEP"
MD &O9W0(7L<1":>-980B_:?0ZB(,GY9+$F6Y];A64V=7I><FQ+CD:_[4\=F-
M$=*15S7+\MJ?GF; G08UW/!V/4#F%7Q;0L^PJ]MEWS90SX&9JQ,)DO%YV$W#
MB=+#S.?)T#DM[U\W#OM)_),:$!23OL[X_@F"86GI4E]S?6B9H7M+I[<0E-'D
M:@1)<!9K-24Y].Y(HGC_,$X](@Q#!K 0<GJ"A<=\*AY(8\'=.XR6'UKO(7^-
M2J5JR\85O&6^*1H?>>ZL8( ?&.'.)>-:,)']58Q.KJH3Y>X^-^)\KQDHQA\(
MV2>I-\I\W=XR+!-*V:?A1/%YKX0UU\ #[W/EFNSE$' )&\ACUK(4PS-B?89[
M%61 +M_PQ^&451 'R!D2"3KG>W*#O?>8F/&LQ-_M8, M;\)].Z;W2^56-WO(
M[\L\$DKK4[O OAQ!1'?5?$)78%TP[PSQ,1+WVI#E !Z!Y5K=7&WQR+&[SI0O
MD'7(^3VBH'2DSSISXC:X^BPLF,D %T@XDA-VNYDE@FC..5WWRSZ^:V,<_<W9
MA%)/.UM1_A7]D??8,1]60QYS2ML7&(]XFH\\K=FYU7;=+Q^8?"F /9RI5N:C
MRE#'BI?:)D29$(_I!=45]P'#&QM 3##=Y3CN+K[JJ9UZ!.>\MK.ZY -95)S]
MLR=K@"Q,2'9*"JZV"W*!:(&'8+X&L^-_VM!,/,4_RE$6%.??C(E)]@"RK#F8
MB5% C9IB@._MLM.?ELS680OW_1L:IH?W.&</M#EWBQ+Q9$#_TL73-$4X>^%2
M2![AW29+OJN-\.3/:'XF39Y*^VAPIT!\GLY<S)N0P6>JU(QFP/^FT[]\4%BP
M=^CQ;]#X S9P(A1->$+ZKJDPHZ&'!C/I8\23<8U]TY8IO6V1H:W:N?W,67C1
M\*=7E^Z&_[B;K_Z]_P8WSVC R9W@<<O(,$UAJ'H'$)?Q"\D,>7A&$1OVX1R#
MS^6Y%!?L[KH9WS2-:;[KKZIJ^NV&ZX:IVKM !&1W9N7%JNZ4;Q1&GN\7A$5#
MS;\*FFS:\+TNZ";CC+]A/;<$(##)$,"8!*5LA_UWHV+SC$<R$]7QEV;T&_#B
M&<V%#>F?.DOG>G:;I1:Z].)^2 .6V8)UAK*7I]D+MUPDI^:'&T?W^?PM!?J[
M=^:T4*.]+!>4PU%(UHIO-1=5&.S\'3T=%:OCJ_A&^7BY%Z_9I$%D79L7@'4>
M6-GEQ.4?J9O=2*:=2KG]!,[^,(8%#3!7WV+_<1?TJMTKA5\49SQL#V/0GZ9?
MD;VYNT^]S6FH>T:;38M/O2 KYE+9"62 <)GA\4_$T.=?5U<"/'IVYKQ1C9VC
M[/.$H-YVX32#:<=:, %K.R&W'17R84SS:53'4?[34._^!SHO[[7?(7S ,Y'X
M2$L-QUG!G'A@S%<$$]?\EB9/+;CLW;=/V-6KM1_IE)]D[3M@LJ^_F,PW,]#/
M\]#U^"W6(C2%FS_((CC@O6U>LG>1I*(/'S_^FM>U.AVDMD@KEB@1Q_!*3=T[
M%GAOJU4",\+0+U\I'O7R8/J[DIK/RYL!5W5_+O9]&@5^R_>CCOHM9[(6^L)U
M%:O=:G2B _,G0"KGB"IXEI Z>5KK!8B-J]#EQNCIU9??P\'0?/-G4OTEWT R
M AYA-A<(*6@$.]%;B U/U#PW_A&_76"[6_=&_EE3BT)WR\@U>YE[>3+4#WMJ
M8=T H:BS(*F7=LJN/)A>Y!Y]:IUC_QTB-1L\IGD=#]JJ74[@[0[Z"(6837ED
M]%OAN4IDC.:<7W1KC V_2-2[%&5O1S?/(R$V*D#Q&$D+=XI[L',0/:;!XHHW
M0Z)W(NM;&)I$VTA]$8-;<L(&RS)O\T1+.X2N>&;7ITUN6!H:^OUG7O Q[VHV
MQW)C0&P;@75\"7UN_*C&'@:WVTZ7<-Q1=:K8NI_:[\N=#N,C=)$\M($@XROM
M;6M8^I-[U@0PNB\,AX?Y%\*N-EY7G=J'LXTZ-58T917X30]>2A'%/I,9"K;R
MYU'$F9J\NTX\AM4?65D-'#=_)CIC7M*B9B)V-&ZAK8V1.M^Q@&O6"PV<7B]H
M2T3? @!)@>=Q\K-A!V\RT;0]$$[H^;4^+B"K[<1S])0B&<#QPU*V))OK29*6
MQCU*>M:AY4^ B%\*-CL84&2[$"&2*YG[35W/U*7Q>CI?L.J*OVG\JLR1UX6"
M<WV&3&^]!Y1&K]OT%8M9MR*6284VFUI4J/Y^) 7,8M*]C@Q@((3(UTL_[AG_
ML0 V<'XA(D%YBV,@_E'B;X"N2+;KF.M/><)=F*[GB2.!^Q$A!=6Y_ 9IT#[1
MJG# $-X6\S"ESSY^U5>Z.O1)>= 5O9-^@=,@TS<%):J[6U.'"'0=?)S-_WQ)
M 7Q :I3TI7B7T[W4&;A[OI8,J+Q,#/?>DPS._01V5N96F4D6:RNL,U"<N/NB
M.B_4(FH/P&XUVD4&Q AQ$$91GFCY<QN;%4ZKCHTGM[M%1>]^62@4-7VB<^NG
MC_#,V^!%&U!,-YS.K54RHZT]ZB7FY6U! &3Q_N=>5U<1EOK[VSV2VC%27KK'
MG58J'1[\4 E4/]:H$LK2F2W^O;Z*%MI]+^S1A,BX+T\EIA[1D#"4P68GP8C7
M7A78GP,Q_WC:].MZ!M*LQ<+C-. J>+K_QU0B>I3K%XD&=[K45+5Q83W0X"/D
M^H9WN/575MT2L703BD%1BL&J#W4&8/1,;TX,@DOC1@%1.Z%SCC;"]Z[;5F&8
M=D-+D[B^/5SF**9Q^%%3S2TO"/\KRM9:#&T<S!$?=@"<KK?VMDIX,%4'NB">
M6*;[U)$UTL2I_NXEW:,0!3?;&MAKAS3:%=72"*:FOJM)4V4[A0>_Y.RPLEK]
MQ\PI&&N1+G-SDOD;7]> RJUR8CI+)L?CW_Q0ZYBX[@CA+'S&+]>U-KO^;"F"
M,SX'A0Q7RN$RJ')F(P0]GO2-*2F7S4W"+\_AFU@__C!]''OQH>> T@!!VHJP
MC_= 61)-<(<Q=2?\F2BQ@X3EBX7@MO*#7UML])594=1)4J>XC8^)$UF.^ZZ]
M^NEBB\B6W5TR(%0]1Z\J05$<OTF0@3CVE!3)?9[6O)]EJ5AT4?RT1?,XL=%O
M^UJL-WA_>8+X &]+&KN>$+$M3OHV84OP$&J?,QLH.-'\Z+X2ESG"D-KUR<I=
MTF]-8+6UL4M(@G!:3AHY0'#;XTG9A]/'>E-IW?)YX,R@36BR-^\S"FN'1-.<
M0P<3>TG!]7)I9_7"AIVR/<C,BU7-X4^5E;G5#1FKJTY8+$I+-&FHTXB#,=46
M"F#64_H-ZF6);U[*+2)J3#TG.N8317#F;^K$IK<UM$HR73/[4N_$86H;&]\1
M>V3",PQE(P " N=01!I\6D\.MX8:OKM3F0Q@C8QRV[,69\#*]Z7.*2J/CS F
MUAHPW!Q<^7R1[PHJ\-J5-7>!%]Z>:QX/6M8K6L K09%7?YPP=&N*36C8?7R\
M&:B$AJR;?Z>OJ,RGEOD4>&6 ]ES=)HJ%F?@$3[MU<G*1*#V//GDVJ6$UG9KA
MEUMAH=/0#JQ3>&9VZ0IC)P 3_#CUY]LK@9!(2#V[<PXO3!#E2V@I)C[YWGI_
MU^+>=V=/"^OUM(LJ.I@A4_.H :E;*X$_#YN>..ZHNJ2<[!V!=QK?-B4>F'KG
M,),N08/0B+ S@."$FC\D38YY$$=KK8^N:JT^3\R')VF;\?@\'1"\JMH+!89J
MZ.-=,3M$,4UY'")NBWCQX_IQ_5)F[B\OIVJK_N &;.W7EK-"#)JGRZC :IT_
M&6O62&1'T\O"[4&46E);J<J31I,'(D9-U&:/NDM]5BZ# A0KYM9WBM-N%?L%
M>KQIOP[E[X*S^T BFQN:&VSDIY^"8YC4L$67[)\EFASE,KKH1=^DNJ(FJ,:+
MQ(_&*X(BEM@G6PW0^OOC>S>N*\A.S>>KQNG3 *4H>Y(Z !2B&83\@Q9<W$X4
MW.6EX:-Q"J&+N*IN29AAX=5];JZ,T?20C?O!MLOPP#:J@R2\;TZ_!SV4JONZ
M5I3/!_C]S+[FZ+ 6M_#"+ZF2"S[="WKG<P[Y&H\+@+7.+3>(S>N[\U^MYK/Q
M=OCA3K[XN&6L&1+\6T8#\D+61Z]]4/7$JN :3>?]8KJ%+T:]K@0MM$HD+. E
MFN$&P\,3WV\AP<<V!=EW$H^XI2CLAS\QQ<:;BRRUFQ&T,*=!G3F49(!#)I,0
M&;#EEW%0E/$7N>4_PO&LN:4[B 4[T$J']5MV?V^_IH\#=L'K^J.?HT)?/H3=
MROC6*S=X@7[E1^DXZ[=>FO?'V'[>$96PEG=/V[80.&G7C]Y 7R,( SAX.IG
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MZO"-TM3TOB&-4T9J33F/BTJ@@-<"Y76@0KYLXG[E&UNAB?@/21/',_"OJ2U
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MNJ2'.]J/:J7Z^!BJV],<W)H!C$Q=?]I\!?2USS%!\K:[Z2U>ZJ:%A?/''G\
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MYC4U.&7<29FX>O=Q\9"9$L4Y>M&,8_X_^7=Q5/F.;]LQ7)D,>-]D]%LBA@2
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MS;#O$SGS]\0+?S%?I2^$./%B3T=5/#!FQ_?$L$:]83@@/]S4?J$L\ISX *]
MO*''G\FOTP//F&APR&X:\:I\K SI DQVW*V*J!2$AE-MFA\7'P27UAH40&)B
MT@M,O2ZH.EAP,WU&-?HNSY@6PM@)F64P?P(<S][+%_D:58<[K=^/S>"*J"WP
M^V[ / DM\/E::47L?/W4U)Q7;73LGX'#5\/ ,:AB9Z+]#!++$U);(2?786"\
M2J@O'.#"UQC:"D%M%GV)'NT5NAR]N@:N:4R9C1PR35R)5: CV6(8.CHXIS8A
MM?W1&MQH."VT!15?6P2\X)0M&-DU,YTMSG:::5H30R/X\PVWGA;C=K?C*RB/
MYOX?0G;\>,2QL&YO"64?@.@"4<%N3L ,T$ .XFW\C;:#W%+1AY8$^)U4NT+G
M:N&??6*= 0*[WTR$%,:6G6$N.)7H5E<45JV5$UVB(8V6E2/)WE[2E7.3IW3T
M;1N_2(-^$2#XYES+/]=?U6LYH!L()DW4>C6J&=+%<I;,@R]#'_4B.:I:E3P<
M4-=DCFTB4=X:U</^EYY?&Y$9BMM-:(Y6R&(+#-N9,OR#XQ<:/RIQK6B@R?7Z
M^Q&:Q-_=R*?B <V$+ 6[_9W\-P('0E,YT@T= ;K1[916,-W3O#HR@(?0+ @T
MP]E$Y@TZ%#C]+ODP\O,;X\0(?_]GIE>2W>R[)1C.-'SW@4T]GBDG0BDAPM(P
M4D," V':5#XN_##6 %9UU%9-I;?A26^HR=G.?O_+(*CJ#RYMS5IE*2?K,S%\
M;%NC@4&I=&$A'<@+)$E"F''VD#Z$TR7U<-K3<F ;?PE<_EQT(9IB@?F*H= '
MZ1%WA .2W29X)/L&(=#70%S0PPK/>#R5\FW=9I8#V>_+I[=[COK-0<.89S9]
M5<&?-D X74JMAE^"=JU#!_!-FFR$[EXR@%.# @/BDH]$7S>+*5EO[HU/]]1(
M'#BDN1T@AC$>K@YVZ[TK\2IPAC^7R$R8Q9$!J/W1;GEZ:&/W0\+-@.DY_S?;
MO4.;UWW+8_7NW!$"#X2\E\F<$1!@/'\,_H/!2DTWQ%R=YY:J]I_:0WMG.D?
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M=E3=PN)QD+*Z>97YD,GK$H,N5Y/G'_;/2^;5\AAI<P#^DO^[U]2%'"N")\D
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M38L!1K7Z9;SUF?9ID57RF6J8$^9:U?JBU[*ZN&K'KZ,PN=IR7(+.,C9!:A/
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MSE!Y*B J#11]"=>''M^$44!Q-[+]AO<3Z&;*)"Z=4>C]&,9U0\/P%A40G$)
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M%3!X!%+XFV&C_V@DM-$RH(%68H <%9"U W;^#RSG4+@X,8?D,VIZ5,!K4RJ
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M6>:-+P9X*RQD535&^Q62..0LM89%PG*89S!G=.)=LB$WGSZT.3399V1T->W
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MDB1'0^=""G1/7E";-E/-?N<O*P!$%P=6XCP/6G"H-@V6K.**(+[QZ7,<#E2
M=C)JTO,P*/8H;:GML8318<XWM>>#X3+*DJ,YVZV]WFLH$P+HII%.$?]M<:;<
MIZP_A]'OX6__K53W3\>)/X>F_.-GJZF DE72VM+#2=J[_WE)(KL^ZI<4B/S2
MC<S@O/30[8A1FPIXQ$L%W++\^MKCCV\X^V<5?AE_SI#Y]VU1CV]6KV.QAF=@
MB Z?;C<L,Z,^VO7GTI/1HL4?)N#FYI,U((+]_!O$GIX:.\W?VL^G GB1VI^_
M*8BR.U:%V@U ,.E!K%3 T%6<&>7B>!;I1?Q_].^%T\84A\/0A.67E $$P^:2
MQ66"[4+7KX?)7CCR)Z$5>.U61?^U7LVRJ$'#BN"6@4L1FYN?S1<U5MAOGBPV
M,A+O@5[\\4<=Q>L_YRB=_8?2"=/X?\B+J3TQ:$,2P2GF^:G/SH>HJ7O[N@OI
MR>\ZW5?MVO#HZWLHG*@KO-]_FZ8>[3"'Y+.-/%1 LR:*"F"U3F:W&0Z<'"TU
M&8_*(4YVT*CM_1_;5;>DPU X(S<JH,WH/_H06X N%2 '+,9"EG\U'KBC<%_
M(,3/: R2Q/9'<@4;XJ]6S)YI"@PC^EK78?%'1](-']U(XO'A\WN7_RB[/<U!
M!9 T07^QP3YII%V1M7O]>$Z($J2W[<#[]^O0_IL1'V.C35%2'[@Z@@K(2OS_
M[^<_N1_VGRLVO,-PZ6<'ZKQZ9<-22IP[5UV'N0X%\IU?R5G*/_!\5_$\$EUH
MY#'@BE1LB1+[>OU?AJ+_QZN._RL'E"UH%$$3.3%7X0$(W&%+ O^-G 2IJ=_3
MTMXOMSZ%&FZ1%Y27YVK%[J=<AI>JXLPEWJ\U#F2DFL[?\4=NNN 1+5/ 5M>
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M] K>IZS6*ZUR1F9.I,S*,EO(S]ZTNPMRC=XH)O&T\LB[I9Z4O*$64Z3)T)O
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MX[."(5U"#5)^B(UV=Y'Y)FFZWJNQDE7IW%>7A?'K-ME0:>4=_<Y2?*50MY)
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MLF:MWSA+=H?$'I;\_VU:7AS!U?=T>!OTW,Q,/W]#A4IQ46*_Y.D[1K*)?88
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MA.(Y6]4?8@Z#P2RH: H/U ;F]HA0_I40K4.PO2R<ZI-VKU2R_:FM!UO7R?+
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MC,Z"T_8TX?%SL10_O&$L\BQ!+E1![OA\LDMX]L]%AFF3'A>YV:1<AT.PN'5
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M?JFJYP@F5*$ &YK&'$XI=;?M.LF9KL:]E6QH_,/7AF=;,[%I--(P)(YL6OL
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M.*UX9)%3%=%N!6$NF88E';;,+P<GJW>\ :\DWP(_XJN!P:C2,Z&$W/8A=?G
MEC0IHER8[',5/P;\1HL7<5Q7]7R51_R85G%OG/?#GV(?TX')FZC1E&E&.-TP
M"&X9'H%? _F/S'Y.?F3VU&H,Q#DRJM9LR9;'\@T8SH&6T9I^67OLBRJD%;1Q
M!37<9T$#+&^19.F@_? JV2:=W-9L$FI"?$[EZRLW7"D AFY?Z4"Q6U@SW.P4
M?O\MH/!; Y_8[*F 7&=G&+69RM2/*E?MLFP![V=,SU-%.TMF@8E&M_ 2^]V[
M,<B%3AJ@\BI(#HZFLM:A,A N_9LSH4T7R))Z1"'[B_.)+'2(TG3=G57W5]VF
M\5%J6_CG1,X:YB9Y@HYCZ9X)\@>(5UT>(;N?)4.YB%MCR6V",=\;)T.-_:[A
M<0H=JP^D2@V/C#7/9)54# %* @Z-P7=M@3^SFD:@K4+=_//6BN1@G)/*BE%Y
MRB2+O8A$0N>-FIHGWB6ZA^]#UE@#&BXS\^.0%G-4*52CBKHPPI@H&;D%CN4D
MCU[MJ[U+ S@,UJJD+UT;O5E7PR^ZJ.<NQ/SFLOFAAU"?P+*-E\>P(Z%4H]0B
M&N!G$IWXS)^'=D%*Z?NY#/(B0GB0RHI@)R<1FI8,M*N)2"P>7EQT:>5.2T--
M9E3GI0*YI#.L^4R+0@YLU9 ?:!$$VP_D:<KQ:K)IGM7B>;C/W*W0F[XIYC:6
MG[@?,'RTO992K_&Z5!C.,SHO>$E=^$?9RIGA;%]?-ON5APXZLJ;<4N>N,EX^
M.<4*H&SMIT >QS(@?T(.,;=APWW2BCY0](@RWS/@:6=BS3\'UUYY6)5PF6N
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MON,?S.C&@[\2/#FZMNI2^]:Y=L'"\,RX8KN(KHJ)I]&[0PNPZQC*"2SIA2V
M?%A*,F_P.05(B;6>)H"I+#",M2-I)+%5YN:006^62HIF[ZS\6#>U\^OY3[$>
MLH9B,64YD4VWZPSMT=]I +D61(G/W2T860+2G+)V''&:SNHQ#^Q/M'C-5[QH
M4_TBTRSW5BVR0YH&:#CNAS4I<Q9L;Z[6?Y_TWD+S0>Z(UL=&9P8FG1_' (""
M<L+;Y&Y."U.8<0X8_'<!.<#L@1#P7P,Y9B(ED9T@;M7K1,G6Y&(T+K;L+LQQ
MR,MLG0:PMR@F3]@]?G(I/2J _>B1*@SY$3 2O7D6-7.SCP:(&1KN:S&ZK=OE
M/ [Z\?E)WR%![CX,V[#?!]*6JDL$R?"/B7OH(_&"Z$X-EJ/D6:"((]A"(ZK'
M=E;N'I2.S]/#4%/TV7NQ;1[SB 8(N?J;,UHBU:0(0EX!$;Z ^"#S]-GZ-9Z.
M>X2SEKA1J7[SD/)G-,#NT5 J$VCC7RA._9/VSM!$X'^7]O]8:;Z0Y:4]8>N%
M*U^&ZD\-:Y\8J7>^A%8X<ZPY.XY;0D<X$6+Q_;UL].4J=\GY[_?,?!-Q'[YB
M*J**>F44J;-VU$Y0R:=^_=PHQ&.'2*/P)Y>J$O?MW,3]29NPEJ&1YQ$9)@
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M<JK7]V[=FR_Y,OF00$UU=CYLOG-=CS]U5"3WVVV_-S[0//_F<V:GKUE*>-Y
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M]MKU6#-CML"2V*?J76RGMBVGX3*[]'$BV0B^^)_D;[@,C$;P9./LH\J1S#]
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MR4MR [7+$EEBC.<UO1@6D6055[8]\9.P&08:P%:3K.+XZW^ _6)[6Q(Q6S1
MA2RLERBSR0GOA1"])L!;=T1H@$8VZA<XT6L(^.M_!VB -M,?QJ=@C@]I  0.
M,L\%5H/-#CZA ?JOOJ0! '39G!!1OS)"D/YQZL 2KM!)6M4E5]V6DOF@:;=Q
MMW*Q,M")0$!+!IU_/!:&P-U]7)S8O%044>\,70B/L6'^ZO[<-.=9AVG1^?S$
M^LQIW<_)D1^ 1)'A!C]BL"AXI1&&-X*U?'Q/ V0&BU$!;%0)]/5<I!Q)GYM,
M X30 &=7@_QI@-_=T.!(*8;91M$ =M*:+2,E*VO%,$=UD?"W;))=8]\Z#-,K
M2&#(.S3..$V"9(@'!H,Z[=V]3HX$MO.\:29C\P[6LZ %HXJBGDO<6K&>C$Z.
MRIX!$T590'(XZT@D4%#;U9O_<O%S\,.O/<NL<K7O[%!T6]P![N;^FUW7@,$E
M=1 &5:[XY_$UNE42,R%LR2JA5CWN^G)MY\MSB&<^_*KPS+\KO&]L!JKC8001
M ";F4Y@RLTB&?VG>F6]D>A 0J=M$ Z@?U"<#@&3C ,1J#HDO9[5K3MK32/]D
M934EVS&9:F'Q-$"Q<G513&&KGC/I=I!HN8"89,Y\2)/Z*=/TB_\*6T]$!BH3
MC*2X''0FL64N)[)POHXDF%LZ\CY<1Z4=2<IKCM?B'[7H.Z(F!X'=^PVE6(YZ
MPJU/+(47K_$>-K4#LDM)VYJ(5'07PI2'AR'DNWA0#M+/WKQZB-RCW^(SDOS6
MB!Z?1@6F2QH<KUECCAP/[@K1]W#:[IHS)7.TS*!;XVY9W2"=7&GA+I-U>(3;
M;D1I@AH,)=O1.$Y.NHE;<O;WL_K:L! R:SD-,&^^U_;N@>C+1-^MBP0/L!+4
M"M_22E5&#=F,G,%-;"Y?L*VI"VVNL:J?B+<( (^=K32[P37_Z;Z>GG9G?@U#
M.YC;[R&FF3#FDR=PQ\_FSDOC >'$+XSJ18.KDS)?(]V['VNLADL< V"6[,DJ
M ;- "HNUPG[.M/ZO.=,X.#5"AH\&F/'.H7_E_92\8)WD,7\&$7@WD)5\'<\=
MKNKI@I66-'Z+:1W9L=M3NQGN^S/ZW)O0@_S*RBS'E$^''+<#CY,-BZ]H'K)V
M-/U9%N5R&M I7*FEU0>XI,_T_D ?$\403F6\AHL6O+="E7MQZ$O%]D>V!<?C
M ?9-B%&.6=_&U*0&7&\D^W;2$0UD[F=7UP@-UA%7X<\B@L$>*M\_?G2/"/G^
M,34HF>_CWCL:8/4*"309U(LX<G]P.VH$?')YYWCNLA8K-/FTE+M]P]!=!.%-
MP0]S<61\@8GQQV5]']>DI/WLT(A_.X#T]PL"Y_]@6/!MA^U*@>@XY1-]1%!?
MJ;E7[''/P;ZE-$Y)XB\4%4TN-YR)WS"H3=Y\%#$'B-E4]F%B$0E.OMP)-N_Y
M)7$W<#]Q=Y]BQ)@>[O @<R)LKLMJHW: Y7USA95I/-=U)T4J-T%',QMV_\;M
M^XF^LSN4HZHZ-$"P"0U ?H@DZ;!-4N@^9L75; KBCE/@W.DE7Y1IV=ACV2?!
M.4A'2[\F2;.A?\C.0<A,J%\2FAT>D-!5X)&)LKH&[(RCY :">!\2.;W%@Y>A
M'K&@ 7[-D@;"^FQ:T41.M_U\9NI RP[L":RHVOYI8$?CD.DT^$]"6PZ20?NI
MOM$PG,3T?C8S)3MRG4J?82P\OFZ2X,&YR ;8'\7^K4;^TJ0F:N5"VL(.\-!=
M"/271.G?B]Y/9\:1J*%"Y_;3F6%464U",K"6%$IQZ;K2M?[/VP^^)@7VW6'8
M&T_V39F 'E</_/EGR7^VY]B]H(UUMFV4U(9,%9$OAK3X9[E_,FCY)\KT!/#?
MNLG93Z?9'!D/O>:0^:,2_C37LG(H3A/P2Z#JM [\X\-;^XQ;!U0E<=;,&1GJ
M[NZ^'K" P* 5D86 TQ+Y!TD'M@N7[;Q>040+Y]O<@YA./<(M?0GD,('(79D!
M-JI)SB CFW-U>H(6KM6A)3O!$_KJ0*2A-5*=\Z?ANWSM+WIKB(0Y64YW;UOS
M<J0H?11<Z_YO+1#\-^?^HZ4H!^C@80W+Q:?7:G_F_?@UXL]('V!.5/UADR*H
M]/XR>=E1_ #G=7'C T9/ #_./_X_6*#PO_%8(TK]J48%R9 L@R.4P+(=A<1(
M:I3GF^83ZA2$U[B(AD174E1HR+'/(L8R^W6*PF"_UBG:H 'B3+K8S);?4[_[
M.TEV=(KFZDW/INP*=:K[3>_7*6H&_U*GR/>OE9$T?ZV,M$^%-@PT+2+#UVVH
M7[K!/X1@1!;T9\(M2?H<-(ND[CLN.JY^-8ZF*FC^4=!>O=L\S)-MM;"%&KQ(
M SSK(L,?9=:Y4??YYX"4X^A=W5KZ1&*T7V%)^"\5EE PLB.\8(2JN7/Q_[_N
M7_]UQJM)[Y:^(CJXZO7,B;<UN*:FWF4$%K]%3]&'@9W'?^DXXG_Y5 )QD;!%
M*:C3Q'D$<C19,QR4X7"2W44&?-+"9;A$)>11%94743S(D@(L<'R%8(K7;$N=
M9.ZP/FSH.:<F!):P./4D\5;^^(!6)]8_?53 9J">A:%TKS6P<BH DMV9M)8Q
M]P)ZF5)1/!,/(VHI?*L;9BO9-C*H7CQL#\\&4SDCU^B>XX8HO1="O6@ /BV0
M2M!HY9WLZCZW#YNO1'?E+YNE"CQ*JT/XP\@R&^-*U' 2FGRBA09HQ?29HQPU
M_)_&T6.W!R0G6%\G7=#,)+B]7A(+C*;*D 4ID<Y(J.:<H(X^,5BH,D$_]]RW
MI]U2FYP&V,J^RP2D5 .E#.: #OLYNB*DC,.YL'P1]MLH3T+%WZ!,RP(DM+Z"
MB_P7UZKQ2K>);236I: + S?.?<S.,^N<K^ZZ20-<?@2:"9'D;4>6?\B_KEJL
M<X]Z+3L-[D^)AYH6^HT3?''I94A');[B/$^.-\7K"&CBB7F6=++)3@?;&'\3
M J"J.I82HW!.)]*08*5XD._[0CUG !L!?I >X4/6%IQP]@1G7$ZH*K^=MQM?
ME."Y=+_>A$?=BSS6I6 UE4"G151=51UQ,F<97'X8)!*@TZX3.SG3\:1?2<+H
M(BF]*U[%TTQ3REM2SUL^;C)Q<H_M;=>-'T4RV)PU9M(CLH8L6;6F%F<:431M
MH^MP)I[9"]PF7T7!8HF:,X#O#;M$&QSZ+LXT9&' NY=G)5UJV/5%;)K)WE)=
MVT-9T@OP</"XP(Z"[PP>=P,*&DB=723 R&?;90ENJWV'@W8W:C&^H(HQTY28
MUGQ$;=BIAS7>NZ4#RT%NU#X^U-H1DK ?H;?UDU^O*3[GV7,:H,;EU@WYJ\#=
M!T_0S>Z-[IA*-DZ"TNH*29MH08C#)2[[BS2/&P5?10_8/EBT %.[P[8>[/%M
M%<&N#M899EDMJ=2_4HE/]>6-"; (8TD\OWQ,8?<&R9K:6Q.Y&HS5T84UII^I
M'2P'GXA>FXGA';T@W<[PAO'!SHL('K7 0*=2>&GWV3QMCR$+^?*@#[4=AC_0
MXQP$O-#):D0CA'F1#QYCZU8VL5S9TFUA(B9D>=H>6HT5#EYWZD,_@H2#N:2\
MJN@!#J1#96U[NUMS=4KH[>HKE DPR,UT"S*[AY$AL06U^XNU%#'H$(/GP)(6
M>.N,@Y/FZ_R9)9J\1SQ'KK-)CU<$OKPWYV20#2R8'29U%6QM\NDN]_8B1S6Q
M,+@4S EY"JJ"1\5X"SH.\=<Z^;E]OR"<K#21>NW'K>\-7XBS>(.6&50S): -
MLZ!5\NSU&1NXBDWK8U 1O$5AET+2U9@^C)YY;\V/?W1^?LQ123$EN^80>L>0
M[A[A?-_HT6LD61]-1.%-6\!'ZZ2^KW2F*]9HQ=],,;A_]IV/NC+H#2AIW)!9
M0-?1\%;_*U>J16+:2U74[,[:(#Z@!79B"\%%S#&M'U(5SIM\E?[U<8ECOVMK
M"'L\DSU*]?XV<J1>S*@"(U^KJ_'%MJJL)MHNPDB9Y?DEMGFG^=XQ#L+5P778
M(QTVQA\F7:)EL_QN*'.M?"7]TY83; 6;0?F2P918L .>>[4+J\MA6G.^T$],
M[ZV3R0MRCZM15 ?YR&=(!F>ZZ"G\*TJED**[CU-7%E^=U1O#&4Q[KR#Y(:6F
M(DYBL.WM:YQ&FK?WY4'AUY0W&5'.QI*#R:<QDT*J^,H4W&+3&#K:.Z^M(?6C
M147K5_T[#$QJG8U"WQO8Z'8Q\KNE0Z(!@'YC"[Z=4@G?LA+ZHR\I RV+/*=Q
MAI Q)9*O9>BL:Z1G38>>.Z@8CSJI3Y8%[C"(39 ,BR+N/7_8TF2F+DE]GY;E
MXWZ2#*5\" )-$FO;@UB&%2R K(^KWUKH7KIVR@3/\N(9C/\(KYK>):=5V#<+
M0E8J(01W[FO:''_4=+N*+*.7T6&EBXCJBX?0-O%8M97O\&<05$X+.AC([+5Q
M[!N1PZA&/'RCV'Q.9BLO=:/DB+\/8$O ]!GQ!I:0ABL@T+%1&!VFCP5.)<TN
MN7;U?+#4XDE]RK;Q\/-,?';@1<F^@C"_*#U$Z0*J>0N#&7JU-D0Z1*C%H3O<
M0OQ3B8N-Z6KXHR4SQ(6?Z_*C.7(*D<HMYTDX F&C0V$-6&J_%O<^J/^MA,-.
MA#2P?:3_^XJN=/@[UM(;Z5G#_O <A?5T7CQ7$G:#R6'O:ZJ4[YY&GG/932)+
MJ08V QA_#/D5/@XGF(3.J'6#N4&"CFRSW]27I484O]HX.4Q?>10<J2XB@'2=
M<+?6Y=;AYHPLK+;O'\?97BFZNV6Z!B.Y.  !SJ)]JJ"^9:I*VL5/]EXF@'@A
M"*&>XR<6R4$2]&/#^K:>+ZKSQ(MUI)\MZQ.L(ZFQ3+P>^ZD:D0"+D%%?#@Q_
M0H]1X:MQ.="K%2AB/78\88YWO5C(B9^Q,\%<_2'+X,N=>$WFP>HU2*9CQBF)
M9_E' 8>>2;AS9(?'MO2;IIB!.X];+;=EQDBV2_W'9WI:6B&HR&>J2G-.*XQ>
M^EQ3C[GX2G^@K"^6#=Q\*Z5D=N>'_13/JG3(P9-/;D4<T5X"B5)'J Q$96S<
MC1:0;*Q17W;H+1=SS)VJ$#F'O+/8B^.?7I3IOBMN-U[0ORRA3T<EIV"VX'@T
M>R'T9@W=<S["V\>L*;R1H8=#G-/$)O/SSF/W01VVC[J%@_4VE"XY'[C["N C
M'0!><\$QS$'6-+&75UW*8R&L?J;->\ZHM\8+I+'>"P5Y6OG0M/SNAU$N1BY$
M Z-W%\?A[K.XF#MZM\:FC1?LZ@-!YKS6FC8D=>H Z&P?V+9'9DXFM+S^1LLE
M)R63OOJOJ/NE^A_,;W=GKFO=_:#G+M37"I\6U= ;RR!=AEKAZPDY<^-I3AU\
MIFW3D28J*LLC#=(#,V6E=3$N,3WVTJ\\&*)CHGF>YK/>68CP0>IB;^ 'VX$
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M!1T X3]W (27X=JA&SGFI>C/I(1XTV[\9>,,5VE^'>"ML[+]^A[? .#7M+,
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M7S=AXV!=P[F/9]\^'B%^/GZA__;&; (.[^?TYO7G8#L%L!]FXSC,QFP#( #
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M,WZH,89GJO(;\.$-5R(437Q@UHW#*FLW-;HYK<^?THOD4!>Z?O6D[X^#9RY
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MT)<UYZU/'(B.J&#;4]3&T-3\B".DSXU2@Z?(N@XG!G(:MBYM-:F_0KZ=I#Q
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M?O'._E6(&2*5I()5!]*/$[>UG>UZ/EX#FT-ELTP.HAY'TH6N<R]HKX7,6IY
M*O_U.0F:$9D)//:9JQU&RAQ\7>1\^4V1';].Q^G1B\,=+;>+DR_<^>7314>
MRN20B^ ZJ;65<9XTW.&D"*L^HG3_8BH/M^ E$*]SSLU@-ED-SH\0,:\8Q>'+
MH,<"J50/K)(O34Y,Y.CF1X_YI,\:(W=O(TY&7I38?D6RM*YE=1Z &LO [==<
M*403+) 7L]>RC@VKG#CMYO_]L,VOK9/$8]"UZ#@/V4>Z4&[T-]>_OD'BSDWT
MGLJ/1AKV$4V<"9S&D/OH3ZV8P&*=3@/U&JH'4H9N0R=-2Y-%VG#Q6LYBY,KU
M<5R%1G>]@^N=_M6J^'/E!W+#[DDGU:S4247*<_Q95MSD8XC&_06I.9/YK%(:
MSGJ+B5#\K;U*I\HBX*VX<LU*7%M^'2[-E+0VN:SF/%'4J]\V],M,[ZY4WC59
M[F=LUWGPD6S;1L*[4T7(&_0JM%LAK UZ:"N";Q86=:R^ATQX::-R7VI6%_GQ
MU -NJ+K1J4<';1]X?P4U64*!OX%>:*"",&N%'D")@Y&3K=ZZ/<0DM%UUHK&;
M8,OJ*<,39>R#H:X!9^Z<9;\[?T%?G5)%+]-@ N,? B,XS$FCA2S%@SJ5]"/N
MG6>_+D_\&]_@ZQ9L#*%]R;H"+Y'-+#B:'&T\Z<T$*IE 9T)?O))QLGU+OY<6
M-3UU>/U;TVL3-BO3C\ ;U\+S<EN/MWSTMSVVKY16^5B<2ZIU?GGS>VE:ZF/R
ML[S-Q%E-4L9J#"O=Q^B%Z+49)G!)B&T57HU]:J#BR01X WLY\-/IGRR)\,/+
M5DMC.C\R^'0]M0K6>VLNJJ6:8E]ATD.>703&GH(]#)X@@BH'\NRHGLU[Y 5R
M4ER[N;IEAI6!FDZNXB]'XV/!T[G[7.]\)53+-RO]/$_GP,:B?57'JREIX)!
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MMCB8NF4C;&4E^\,'\E C3\R'IZWG)QV29E5#L&+M/\5I><EGV@X=?E@AZR@
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MSB@(IIT>>Y8?\$G><,GO8FL"+J<])YJLB$.&U:+9" (8ZZ/:,XG.E8^O9Z=
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MS1U\.@40OT,-MUE"%?F<9P!*QX$=8MMYBD8P+7)AD^Y>8E[*20UYHXV^FP+
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M!_' *$W6T6:7@.4MN;,;SQ%2+3I"DTW0@H[,L>)9QF:L?\4OCC"3>>&PQL>
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M=_]B#AC[49,+.6*,\R<#=_Y<UL3%:9^YCT:3 ?9".8L4 .#GXK^:HT]4T.]
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M[$)K6.GWU$ >[MEQJKX)HPJD]Z?^&X-99S(.:"WU/H1:$-$.JPN=:!'H>R@
MMMIAVHWKQW/$>Q^I*$(K3H0Z$29IDABY/>$KB;%\EJM.;[\[^UBC.<C2!+.E
MX:@Q"#ZIA)2<U](Q&Y]</:#I_+#+\HG!8*_%.N]RZWE2$GI5A (0H !V52F
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ML##!=6A?90^]0'RHE><J(F0] QU8=GXR-9AX]-/7U2I^D570 <3>()CCD_0
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M+BG3^D]2[?\KUO0*3IBM_$'Y;M FN7#./WG6,4N7.JV<J$5 \W8LGS_9H;V
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MO.=#D5Q-/G)_0N3 GUMTB?:$L9-YX_5'/:1>&2C3$Y5R9;K9V0]'WR$?F<2
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MPQHF/&-Z(CL%4+TV!@T9[VF ^96M0K'7M3;K%^N][5;@FSLX%S"Q"(N(,'*
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M+1SI6HL!>QTGOGGE%^=47[S LFI,Y<9M)V1.J\:9K8W'FK;O7;2,NW,FYS.
MXZ/L1_6$'*.YN5XSX:7!_UWI-L7^JUY4P[<M0H/QI%:O="$\RWR6G:VS;]+:
MM6\B#E=B;6(!HD.=L[IS%5^4$'\61I^E:TM6&%U;NM*U)6_)TXAP_<F? SKU
MP/MKZKQ#^TRQ^XW7NO0_ "Z,)_:PO5!FJ#P_T4L#,*"6R.JWZ:'_(QV'DJ)1
M=6YHKR]3JPM/&T80U*%^8ZST51B&>[KIN\"OBVV,"29?E[Q^UUDSDYE_J5[!
M.[6C+FYN'TAXED"!U];/+D?.7%UF[?[.P$!"KG<59">#)S*FWTT+,9$T?+R-
M*"GJMR;)[W#(XG@?V),O9L2\QZ'!+S9/Q M6"P@08C5 ,"YOZMEEOPLYZ)C/
M25Y;3>=BV'IN. ?*%'\,"MIT6C=@\_$SP+\)@F4YCA?XY2ZT$@XO/E3T>!FH
MUM2H;8:&GH:<Q!UN4KZOFX%#7>0D^YQ(L9["CFY=PD7.YX+%/]\.F 66@)7?
M5\Q:1.ENV'32 "]=CEC^G&=9EFY 838[9(V&<5:B/EFS>#9Z/VF(GD=+9>OQ
MZ@7'^05F:WU6CJ^)Q&;T;%D9^I%.^5S?,!V3$X>88O75+;76]6JQY:,9X6K;
M'=& H(R>3AW%'3"=US%#Y(:0^7)J1OKN'7O-WMK SRZ?\$$SUS\'A%:\%EH<
M$F.Z^::]-@X9K4+W1[F=0-@K()<:6<I%'?FR8#U3H?LE_\P'^X=;"6$F?K?R
M4:]A4Q-H%)V2V2&8G9+ITN^MIYK9QA;4?W;FL&FF-M8]A"'X.3#8_SF&]<(T
M,:9-.3%8G7C#97.Y#%:!-A7V$/=Z??$,4_090K%+,(CE#BJ(>F*8+)QEX.V>
MNS;ODB"U5]0__QHA^>YZ(6O_TOD3G>J5:5HCVY.C-X98 ]7/$_G1#5N@$(AD
MKOWA#?F4ORX+N0JEO^RS2?^&@,/>FO,C0E%<ZKR0%]'3Y@.2]VNYE?/#W%X%
MIR:XM.N(;_T<2M=21Q8F5\7;(AR2S+RRG%@.@D??2&R57E1UN\)[O1FG^>#-
M:&FO:UWY%3H/^^PQR+5*J*N*\3^=DSMW.8X_Q>Y"=-ZOF.51<"^LFC6< R/7
M%0QE(;YY-@K1+UR/-?#F9()-8IZ_4.T')NVX**WFZS1?GK#S))TC7E"9"?-0
M<^EHXD#6O!HVL4]&)3'850D*8/$[5@&X%((W3J$%IDP/E]JDQY PI-[4^4,C
MN_QYZ*I:ZT=6WTHL3_\W*5W=?CSK3-ZC4,T_:VS49[RGME0UG%V$L/%(FVE9
M(K,=F9.#ZF! ":7SSCF_B4[60#-@9[WE!1:WG2=(?:$CSS,7X"+V9IJ\)PZS
M;*%_J1_P=$H'*#-U+A"U:8#JFP>2!IMZ@U4S=&#[+KE %?U7IX#B:S$EB@,W
MS?=K=*5F5V".\ !AK%T;YLZL!F:.+VH[QB//Z4,08T?]#_^L]'Y. N(O=3;R
MJP9B!\D4 JP;EUI"XJ_%YBPXF!4^#/8V$&R<MQ:,.'E6,.7]6CCE#$+48"JI
MA4 #"*"))6\G"-"K^IN$7WJ\E=_F>8*S7XN;NX+%0A@N"WCV?AJ.>"1Z>MK^
MH/!(EJ!  \1MD'1@D]V@_4)J4P5"E>B  ]TC@C&#_,10G?K1=](02U_IG:S&
M./EH)=4>.-LIS2ON*A1,%\!]XC;W5[/MIV"':.(.W@B[B&ISOM]1=7P^_:JY
M6*2>@P#U\>B;:8NJSF;&2/S\MTPZ>4%1,E7Y\ISB'<RDPS;?;8UBMN=5DJI%
M7G?JG<^2$+$)9/%.(G!/YWPE>%?AK<P>ARB5K-S%=W]Z422Q&*@<9*V\#O\!
M:O.+,O*;$R*UIW/*QEFQ<!BQ=4TH4C!*757O);H2IU=;]JSU#:3HRK1MD 5R
MCE)(Y>K"=7J/R$F]HKP8OR/I,/U,S]CC_"9?V//7#OP.V,.7'WD1M9(]36S0
M?B$&HE2^7L%JH@)/\FRA(=+9R$5]26*=<_'Z2NV3LZM.X_:IM<5L4:6<AIIO
M3 PU.0'_A)WX[#NDL:'I<?'/;A+H2Y^G&*\TD@1U?H']P."2N=7]'"?9A;SI
M*Y_*PE6*_MK.^DO:^)$XTSL#,0"6JYKT 3H!9(7*DN^,J (7_4AIT*T#181M
M'7=<"Z?NYW4>]L**VS>5S[__L"JY[1)& YQL8, GBW-T0GG+)X1.27"UIV2E
MRZD]M[U7>OKQ^PNR VY4)DHT]0)$>7QQ;%_ZY-3]_.86=/KVAYWSCY1EPK+?
M%ZM<E%$!UPN\X>N5R^,9Y*PW-VB/!I<M6E?:-:MYFU."5%ER9Z;T0)]5Q6QM
M\V=-"^%W+E=+NO):+:OVIQ,_8TNO Z<BJ,P,N)6[1-D,HE_GX80R-S+#)#?]
M^]N<=)4:S)-8SMN2+\-/,:K/:ZRD3LP>8*BW*%'JYWUV3).>CY&97AT.U\;I
MW%A)[W_8OE1Q0^9JG(%([(![&Y=NCH+>Q32$Q_CQ<7#RF- 5DAIUW I$R80Y
M-!H-MOT2 3)O&2XGJO3)R6I<C"RVZS>Z+1*'KHJ;Y"]+0Q(:W:$,1%=T3/#Q
MI54JYZ_-2BE%^3V6U)?>U8=I=?5>?>SO3WDD='TN>)R]HZM:\.>E[M'7>'.X
M!+5WZ#LE'^90P%P0ZZFO=-_FRYFZ[L$FIB4)NFX"+5\%<=( F^ *JO'8#I63
M:(Z.8?2!MU.O#'D,ECD)B28J'3C!*_7$IJW42!<F7A7$W";>E4WW9;ZS$SS/
M.]QTU;%)&3FBBN!R3"RP_0 CA!FD,#M/-YDZ!_'S?,G 3Y2XW'A@D4OJD*Y;
M6)($JM( /W5AVP_I"@W9"^'!1<%C4 [2T_ VWX^G^XRC;N2(>CN;,D;4L!JF
MQKR77*>'K.=6W'3:D4 GV30 P9K\?.$E=8 Z1'J PN^D;NX>?O#WVQILU$;#
M/D$Y<-:1$&U,";\.2:@1PPT>W::.2%(R"D0$(Y?!!:2,Y_Z.UZ4D%Q*DD[W/
M <]#KN&Y<_!>(VBQ9DM3"RN?^];U2>V_ZF*I$7FWY/'5_I&OV;R63R#>$3_0
M !)LQ#P:X%4C?+<*X8G;:8&?]C' G*['^HO=CQ[LN(3YX!N24?&PT[8W3IY;
MO%8\>\LP3L;=N/*?[*#GCYY=6^XM3H;Y.: V?ND(2> F"%_*\/!HLA]N!#-7
M';HOY:([FBQY3J5RRB5_*G97<>];PFQ,2J!,^4V>$ 0_I4I=B"R"TPZM;/1N
M/I?G \-\']VBLX:M!NFKQ=477O-7,-K9 P1"IM6=B^+KN0X6VA<^HEBI,F=B
M(B%2-B7Z[+S8VO=#CR,H0S=L+2ZX1V+EHG KA&=$0QP<'/,<UQ6X6>RIV'/;
MRD"DVJC]8:=AKK>X:VQ"EYD'GM.AYUG4R&85+'KPE[/"]S5EMB9G#@/EY$Q'
MK7E9CWP-PYM##>==HZ80XL0$DJ8FKAKK'=C 5^I@.$ET;Z_:Y24;N'N6BV\G
MO>=>9EYT7X9TH);S%VWD-I$_?0[1$R%0<1^H/D>'KU1N;4X]T^[->!5>#]N7
M(5I+4;T:+<*-[Y]^Y4086L*L8PVZCY*HS&(E#O,21'?T8&BRQ8]UJ,S$0?W3
M/(=?MSX\ [0-7'Y=2$9[>\_Z,5@AL0O!"]R>6ZXW5:7P!0VB.24-AC"[ZN 2
MZ9Y8,.N51"V6/2'7Z<HF7FB_]3DJRSJB@'B_53[9*KOWB97.C6K9J[&!;+^]
M)6+I(M1IU"GS.9:WDQ.I2\H9GY.S/%OMO@*,ED8C3I'9Z%0AA*HR;P6YAQSS
ME!O95M5TRNUX_>/GKLI]E<*'C"?OJ'A?$?GT-J@F" NK=&F1#H4S4<]9/9J7
MQH.B/2,V7#9I &;[X]^UA%5L(FPN%!G I3$=V2Y_0;%+!#R3?AV7&X/U/[GW
M8&)_QM]<IUX_?MKRLH=K:K2:!B!0B?&DY$\HD-H#/ZO.XQ,LM\!"O/ZSSS@R
M,7S=(;?67F<'F+Q]D53*XJ3-=<E!?F['3]*4!DCJ><MBL48]2Y2'A:+.J/*A
MZRM2!J1UJJIJEBZ*FDST,PA6O^NJDD1FAN_EB$DHJ>><XC0T.IV31/83PY+7
M?0/[J&KQ>*JGVHO#&^*9X7>Y=D/IHY &N&P= B/(TN5"1O)Q4RWH,Y"9+(W7
M%921YEB#3;NN5=_;_>6?:=)0^['99:Y\9=5-K7#QZ'7*-;UO)D<H*C/=Z^_D
M4>F_)K]KK"=\)DK8X&?02$* ?+><(FK8HZ]3H.5]QE8/=<.M9--]E'F!&(1+
M:H73 UHY"BT^C$*"RDO5Q^RHL3?4GZ5"%NH]!S5:NDN;X.JQ5:L6=?4'(&7H
M&;(&GC62!G""!2=;1Y2\J<8K!&^Z[.M-I.SHVE377Q^@CH\#THESZ4Z3,'N5
M#6<%P@!1VM/;E:NDTGBD8D#ETP-@PU)\,P*:M(@(S"6FN.#/K+HB(B_?"RL0
MV2UHB<I4R3K/%MTI&9>-%<#=UL-X;QXMLD;Z1J4=1MYAW?(K4HR\J$/H^RQ_
M14F8[6'&WH:9<JS;X[DS3QS,^R?&U*6(PIIER;N''<>"C96ZIFD'9^I.I)_>
MC-]4DMM3H(^0.R@AE.,@-]D,61T'8G8PI@&F?"UVOS]5V7S6/0CR[K=9^RTN
MMYX(+Q-KT9/\E QB?/ S[[)^_EPW*KRR'=@.+EOUO9""3KN^\&CXAE3E@/J<
MEZ:3P\7H.T(!=YOS?T<^75Y_GCU=NPML%_0:64S:FK'%+' HE>$6/N\'.'%G
M8P\-%34C0]1^#.7Z,WY,EUQC92-[$&%HRY/^KTB=EQ0F,9'=JA&K.1]\NMD*
MRVYV_>!JQ$J?),(P0I''!F%W(O2=#-ZP+EEV\DI>B,PK3&\(9+W6T&9 B:">
M6TL.G+^_Z&3WS?R]>43?MZR?[OTN$O?4RL*5LD1J X?!92LTP ]@Z$ZI*C_6
MFF==_LTT*Y<3JZN+0$]_V<W-ZD=<4L+YA\:E+@1;_)LTTFWR/3RBU8!OOBO3
MS" _3?O!J/29Z'-?WW-\8P64BYCT=#[O=(^D)#DYL214&A/PHHT-XL+1XE^O
M7PWXF'$!P!#)_)OLCZMOA7%Z$#<;GF>8.KU_H/-YMFNOW< R^E9?ZOG%R)$5
M_?K-CNYAXSE>$*<ZB"B)!G_:1C8:F)?7O(Y,\>,W__IA&PZ\?C700(Q8=R'W
M!\H6Q$$\[%Q@SL"SQBQ'(9!\TTZ<YK8!B1. *R]J@+=GM8'>#BMW=BY NX%,
M#1*%VOD.5*8*!<,?'@KQ@Q[AVO?83?G<B>"R9]6<Q>&ZX'KU1S1 8"*LA_D7
M:O-U$ V@\ZYH0WFI290L@:ON9&%FX>^8MB8TI9SJG>MBFA8-?5M8'%"MU6O0
MNWT[U7TDP-)93 3S1=1!'E*!A1T]#&W;(7$N4[W'XO'%EM!!:Z10/#[0W'1;
ME;]T^F9\J87Y]VMC5862MP2UA(-#?(_>*F\ALA%-/$0[(V)8'G$=^VA/]7G>
M-#^_$PV@;KC<ZKT,^3'#>CRQ5 !2L#JM+*CWJ&+\K5TYJC+PN-=S2@K9_^KA
MDK66T1GAR;&]$K4;-_4ICV&/B06+ ^8/+%^-=/C>F3:_1@,@(U8#Q3NAK\R7
MA56# E4F^GQ_U[)NV9&,B.H@%H9\'YYF(_Z-1K#=MEC-/ +I=GK13/RK[\=-
M=2N#'[/4#CH9VD8R^%)/5YE&O)L17.[5A!__+O]$CV=C#;?1:OPM9JK*CP-R
MINV/WX+<IG]R19W8?BBHTR6RZS=L%.D9O3B:DZ7^BAA%YP*7B/18^6IVX5C:
MJ!1!:")*Y/O,W!LANZ-/$N;5<=])SU-_"*CB"N:'6(V9;F2A^E%=5M4%$ E<
M%0(/U,4OSR?])B+TJIST].]OL2,2V-A/-IF\" W+_E^=,ZVT.6+)$*\%?XI>
MF(SO&L3?)P038S'?G)MZU'-RS?ON"&=VGW<D$F;SA"81-46A..N6/^MA\5H5
M&. %>\,ULZH?.HW)$CD2UZP_M-N&BPW\Y-+TYLP3%?-0%.-Z\^\A_/]7#-RU
M4+&531=G53Q=?DZ?QYT^Q&;%R?.=S]5D!.;+$5C<A 2(>FB#LSZ#%O@W\3G^
M\=;C-,#2E0^$,.N?*R#7U,)=T"?FFMZ>TB4=RZS%24\IZS:J )YG<^!<KYS*
M(&^;G;.\LD,<7&Y!+(-?V+WKJC'B/26WLLCR'!:\V94[V7ZYO&+,MCI0=#4V
M:^HZ8A' M3,,$<1YH#B$B8'3UX$\73Q?ZI+@-^]MWJ8,S,C^2/@YBVTTQ=NU
MT@#GB2OM0OSC!XVR6W5YH79.:3=AZB;406%.T:JL4^]L'O.R==66^&?6P<:Z
ME[S*=KNVA%^ZDK2I(U!>XM/<=:.U8Z\ AVM9!58S@ $72?$7VFIW=Y]YM'R=
M,"V"=OA2ZW-G'8Z3NJ0%'+D5SM@DCV]OZ[R*-7BC]35$J+-QI UXID%L<8=W
MH^GZ\)TL9PS+^\11::O?#F9OJS8!V\]/^XDS?%0^81FEES^L*_SD\;9V+_"'
M703"HT2R \[L.3%33-2B:C#?5FW^>3^88,H@<*R+M"/0J7=<+>D!;')*C/K5
M$EQK"A' 05/PU_:ZQNM 4V33#SSQKC#!_F;=E.?OAUQV!\\T;/V\J_:AR.H"
MT1H-!ZQ3KX[=$93=Y)F_4J\PG=H$*??/?/6SX\?FO3WA5'&&]%1FT3L[[S(R
MQQIB4E O68\$FNBH3_K#]FT'W&&5>9\.0%,(C% 67K*5,"#V217L<O,;AD49
M6"\PG,6J('C:9(>)A$ZZK,AU$/J1RDY\BD[;KO5&ETB2Y+'F-:3G)$JF*61-
MILM+Q.M<7_6Y@,'AJH;G:&?)SGE!U"]DG_B!X#6J,$M'Y:>/Z_XMC!??:S!>
MO'LY4)R03CEF$JM_EQ=$;0;M.OLJ4*!S-,#JB,7@/VP[M'X( 1$_H.E*8_Y2
M:!N5=X0&J+CSV7))#Z:L\[[?K<LC<J!''0G&6+?"ST%>_,H8:K#,H5.&M1\6
M);/OZ?3%J[>PF]_C;3:Y%,O7I:;(*8%P^*G T]/KB<1/1,JIJ &IS%+HC2)2
MS0WGIW=?C,QVEV7^/MO<Q\YD1N)N0&&D-P=P$YBNSZAJR',T:LL2W&.B/D38
M^ NJ^7.H2HG+IV>%K^#35_.:I93)#13:AFA #8GBH0%._YF1?AZ&E[8:D:,!
M@N:5DQZ-.LOQQFLV@?UTQI_D;6Z_UXT/LA CWYIH 1ZSPW9+_/_LBZW#@9MC
M&" JN-(*-(K5'C9U?/.'H$M)TX1JTWN/W9G?WC=JK=2-0,IJ'86L'[8_6&_R
M.9S^3KKE4%5]6X0P,CO?<</H?%%!0H"12N %R=_ :0X-NM.^L93LLF;!1OL-
MAL[+[KI4ZO"55\5KNI^/_J;6>JU5.799H00:0OXG.MD<H]V*8"9;_L(.JUIF
M=16;:-Y*5YS6N?KZ_9E9!+_DA;,"0NX#9OE?9U:[W[^3\%3EP.:UC^"P!"D<
MV:M\<PPYQ]ZF4_D,!-J1FAAXH8SG=8W]57X\#FX;G$QJ;P+BWB4X,W6R\A#?
M: >(U0SO%R6%G!'S9+E:6/SQ?7LD-O5-(PW0#CI)9L-4X@H=IR4:(UI)H/*K
M?CVMYIM3U=<%SMY>SCAJLQ,X4-IQ\-.3? !)\K9KO00+/F"=)!$*<(T_LS"2
M.VSVZG+!FPA/YT?4@]\. -')^#C$DCS&'3D)_H#GIQK)X2JH';6H?:L<:PV(
M'O$^&AAYR3DM-*+2<ZRD>(7T@&$P\704(:';?LK\^UJJ!S9 [P,NOC4YM%T0
MV,6C;*./*;GZ:\IT7=KS]NW6!Q\+]$F\& ?U-XSD.1]>Z)":%>%'[:4A9_<>
M^@#="4P.C:J4 G6I7Y1VQNXP Y&F?2?:!IG3MBX>O'#K52'WD3V74&5B,7!,
MZ-8YO'"'S(Q_G+_>H^I$>VW-+[QC^*W:QVIEUJY@UD54()29Z(V)LFM7%_B5
M-8QT?A'O=^>IKM&CIKW/?9P&*:G7PW6AV C^T(;LF&2R7.DTM'<!&1I5 M&_
MO@9EQ:,O!:<77,6<6;FP@YPA AS>6&M\%0,L^<MB8)'I9W&AH=<F/$&<#JYK
M0YVV[-H><7>R?D0]BULBG$L=1T6JLF5 [@[!=?%"L0XE#MO>'WABF9@7YI^.
MF:=G,8+_<J"KW="6*-DGYI,0%L<]B5ENS/9O>Q3O_+W0M?#'AHGELPZZRL(*
M!"-B"C8FTI@JB;=JXEYH!2L'B84Z9U<_2'AY?JKOIL)'YIN/W5IJ,0WU!#:\
M>DP&J$-D3,Y)4&YI(DRSOO9AQ F4R#MA.8)^2;&\\9#Y3'LB 9<1K9CY)#_\
M],F/BH +MR3;=V"O7 */H[8ZYKJ"5/O"EAQ>P[;TAFK_6DH]^T-)K:"@8T[M
MYDU3AW>A>31 :Q<.3F&Y)$T]?X4&P!1Y3?_F[_,IE5K664Q@C.WC/PTVDN%E
M:V%T3\8-$E\B D'[(C3 LAF)!HB9J%R]Q!43O"^EH#5RF22?DF>N[>!TF@"[
M*3YZ]>9O$7HX%HGS2Q[8W9>R+H#^9XL,_&W_>6M7LR^2,>D5V.)/*AM0V'P*
M<S_@:AP2^7.$UJL4$CP_ZW]>XOR78SMSJ2OKXB3.A5F*)L_=/\=O2:!JC\/5
M.Q0.08::ORX:/J6$NVQ#,V/*]"F#HX8>C/\M_R7#]%^NG)J1)A(,NHY&#P38
MC@ROVXD\2XB8S<@,E_@OHZ#__S1M%^4Y\PX9N]?A@NZK6IH G?_R57C:-S;.
MM4:E]L[P"-7KP43E1/_-NE3_;0T<#_V%$MI29R)ZS3^KUK]OWO2J*O$="<S
MGX;_.10[4J#8C8A"T !OX>&'22PB5E=".E@?.N]ON&5125J@$N]?+<\10O:K
M#8-Y?37>_-^&":,EO/MNSM;#/?#L9^#?"#*=L74,'O/#=E/HZ:LSGP8(01%K
M:8#[+M2GSB#BF <-8#N^C0+NJKD<R-ZB^OCOTH61P7"AY!Z8>HF>+U8H+*@C
M_3\5QI[!VJS)%C3 ]VJZ.JV"DQUC-NOF)K!4#6KN&^ @:Y,U.>SXN2;4D0;X
MQW9$ND"/@._+T_.*/)V,11E2DLSKR+!NT&A_VQ'ZL(\&B 7IYB,&K/]50QJ
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MPYZ3\?W^ZMXLC7Z5S@$U%[" &%UB$)JU968G;&)OUN!]'2CD#OZWH]E 5Y^
M!&5,+,1]TFO=_UB:DVPUY(&Z1+2$G,KNR+5OXJL]/8[KHB;X)PK9/)SL81WL
M]1.:8X+KL1D+D>=#?Q^!V7_7: J\4:^6DU 1KT1(>;HBBS/KMOP59O9?-6E2
MD"@7NCZS@?/X/-5*:49@NCWK36\NU<8\)PF;%S[D_!C",_]>A]0W(G1P, ;U
MH\X*G1YIND:=LP8TB!9E^"N8#\FEJ6,COY2;]^>$UOS4KN':AJ/@4/MC9&YC
M]I2C%X?40-3F67<7&8\XA2>];9.!+) RO"R!5([CV?)##P9XJ5^DSL8;UI15
M-$V G^UJ?CI4LHUL6ZK:%1:G ?S=:Z)OQP/)''N8KXGP\NWOWWTZE\PV@,P(
MZ0:E$M4\H4?&K\L50*T_T"=H@%RMION_*B4I>ITT0 6H0\U-01^&@76<VV'O
MCDL;/)6EUN#U9854Q/[.V@$$.'&\H@EQQO=UP2ZJ*T''GI!/X'@BWE&!]F;J
MD74[X0W:.?F7@HK*/V^5S,;,Q0G)UGXXBGE]?;:ZO9T80#I)1#4WB0=A8.%-
MUR#7)Y#Y=P2]]? #JZB&,H=RH]_\485WG\3L+EX *,TR?_1?UH2PX(4-B7EX
M)BJS:"E9&I?7[FS7,L];BXM"4K-$LZ-N5P8(>B.+'S\RU!=N>/AF)L%8Y#7.
MN<4%BY@Z1Z@GZBQB\08=L(M4(;*6.4G'6=79C_+=V\&=T;$7/UC)MJ=SL?G$
M>VLE]%>&[75)C NW3SR&:<N.])2(1;N$J'H7D>6(+CC"N=?C!T 6Q:!GHXAW
M%\NU!98XV$NG3FN3]]Z&S-8[J1?1A=0D@A!"=$!'/<5P-^(5T.!V%6QF._5F
MJJ6CKW&&[N?/M0 ^KJE?+S[>1GV\*\*P.L=!^#1$UB!I^X0N4G+3O"DE&:ME
M&SQUGW*,6>?OO%+,XA.-GI+1:>8%V(GQP4[#['>(YBB^IML^3%2VG4TX$5R=
M: R?!CKOH2K5?U7([TCW64NZQ(^XKWB_=<<?ML&F-K:L<4]!89>LR3=0G[_\
M(4#RRCLS5R>J9N>WX^8-RF912:0^PWK[" ;F0MF.^[@B=%(D50I*9PC(TT'?
MB203HC_Z?L&D?JD5T>6M65H?XS=G= @ZH2%@[W%_,[M7_D$&ZPBS)"8F4+DK
MBGJ2.GT(9Y!# 3=0;!#^8B*8RJYV=:-#-J)$ZZ=F6I;X!._INP_<5BZSUGZL
M46G 8+%(U)8F/@LCE1=& ]@G$'EP"ZUU*:O)Q@F9Q.@1K3%/TU>O1.H=EISG
M#84_GC#BO<!<]H)U:%T2;3"5A=V:" (Y@HA&,%RU%%311]9\&/CLSU9F&J#2
M>6=GTR["-6[XMX])V-D'WK.SE%G 6880RC<R*]UQON-!G47^+EB7F(;;:#B+
MSX)A]3"X[;A"V\WNIG:22#D3Z$V8<,3;<\']T3Z#EX'97\%]<$YU;H@-$8GW
M)RM3Y2?4+Y&YABH_XTN([H:!@C9F#5>\$U/.XPI9IE2>L9\]JC[9I(-;Z1 2
M)IXEN?OPH]63\"FFQ(I%!/=:]:[EM _\6<S3IN'2RX$.7[\E_68\NGSJBA9?
MC2(CP)^B"?59,P9R0Y6A,S @5&B-!N DZRS2 *');^ML!S;KGF^D]+UP+A-$
M1BC9(MDK>H3KQ$5:T]R<*G%6C5C4%(A0CH.UHMB))'-B#&X%PY(S]&N';"@S
MZVCFN<G,EQ6'!?06RT<'?0,SW](#^",U(4&DZSXC[="SE#RJ(H0;#_OLZ?PA
MH\Z D_@*:]:8N/XT]R>GZNV&3VFQW,$ )OZ&MH !2PJ\P0XC'06O8NJ$<5UK
M+("UUN-\(EJFC>.YE@);,4=G_.J#+CI'7;UU'<@W=?V8&7#<V<1!-*<!3C$2
M^_"(5D,?> NH?&R\\;N>9'/2%^+XO-S-T/.W"+T^ZF.'ME +6,O_8.^]PYK^
MEG[1+X+2A- [1 4$*2)*D2+!1A&1HE($B8I($Q"E!(%$0'J)@("B$&DBTJ0K
M8$)'0$%Z$P()T@,)-9!VXK[W/L_[[OT^9^^[SSWG/O?<WQ_KCP2>F;5FULQ\
M)FO6+!TF0%4+AS(]T@,OO1:X#JE\1P8C4A#X: <U;CLJ9OS(<CU.U,GXX?PS
M@RRR+^7QU'3(K9]TB1 [\NT2ZA&2$SJR^DEPL#0M<3."7NK-?\-''SAE9&)]
M7KEA\$\OFPF?9FR5=W3A;5C,M,>MWE+(N!^2=Y%(R[,:>G^6Y6B\K*S\>>=G
MW(IS+T"=4"&XZB(S,&,)DD1C8_)%ER)/&6FB<8QHFP0V(;O%P4[56CNVS:HQ
MKD3\>2@'6P42>-86:,!29Q&+(-[$QF9,#,0_)X*B5%:W[$[J-@UVLB&53C"
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M,*R8;)'P;NGUX2U/'GB+@_2U;JQEU<N[,U\23!*WV>Y]6;'>*;(?+T6^Z=U
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M3SZ/4XMRDAJL?CZB62Y%CI*68%'IT*B)/EIVD@/(&(N.9+N?W%=^%V=!ME/
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MA/RYF&S& )1L4-2 !GJ%\=[H-+* /MSSYS8#F"R$^$ZJ5QZ'S+XP.(GX6<
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MBZU:IX$8P)[1$&1/!B-BVI6+;K[OI[INBOU--Y+I1U5CB<3U\5TZ,WQ0\SS
M5*0Q55]O)Y2)<_[<^U*<8'XO.XK[P=R&GXC8'VI?$2^"C>"#B-96C"MV'\P
M-A(_(#;.@?^."#1>PXH6'45W#UVA1DR<V7E#EY&F&#" GW^(OO2ZR "2%QE
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MIQ.E!'/K3#7[.OWML]'"0F<;DGQ\H0,2[23S>41@TI1T^6OEZ^/1AO4I]OV
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M)>D&-1Y^>:;R.MA^!]^-_*F^,+0!_+N!/NVMIK(90F2L:23PM4C]>]2)S)$
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M*FG2S.H V$6>90O+QJ&?,]V 78@I*;!-C6R/):;!"F^1U,880"7]!ZWBPX_
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MZI9<:0B#H- 5X&7B95%N$QQOJ\PQ\@7\LQ(<AOOW)_L&Z*#(=AG:KG>(#P"
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M5OH(':FJMY#F<^:UK33_F&C@ZF'-M,C4EX;=( 1]F>=>K_-=@\[#F!Q&<[A
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M/DBK?S>3%E&6*VRM8<A_,*5ES,XX[WF4<NK/.*T7($Z TH4(+Y"IQ/Z%QM4
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M;Z.XHP<D3CX,K\.R2)V09:T4QL+%F0&BF!G%KC( .@]BGXN^O<D,_4RXJ2.
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M%)/\5D#X;4Z4H 5?#7#$.HB8>IK+&/#3:H7.R0W )0D9> [BX%)MRA^:;9^
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M%T_;=L%34YW!.CJI\3-*L:5C70<+3DTIBW+Q>*87*C_"A04L#,A5/TXD>2<
MY+<)!,XX3'UO&V>T-N5()HXJY?9U+6O+*6>^@S5QES6E:'E>Z\37OP9BD>T5
MUT$3XFP;1&3/K18&@"7F1/7/;+RH*BVN-G,#R5N,!<^]&XV>>U\56>)9H0%\
MK5"D+LB:?[T(00.ZFP)B<M$!Z2)C63G(D&U%;G8)O(3.?;S$N)4. 4["@#KD
MJ^Y5;J&,Q(F8^B_B:NCI;>[);/F2@S>//YS[Q;%DT T$\_ <9I)-J+/4<V-0
M."HFC3-.LVZ!DR(@M5F8(+]8UVP;'')3U9>5.<[XS8^O24QWUK2+USSV9,S
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M+30NH#-$UCW@Z/YYW;MKFDGI(3N?1=E_* 9%)US]#)<.TU\EF'>C3B)-S].
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MM>+Z*6'OS/_=>QZMBOA0Z28"/*QVSNO'%>=OE;5NBR;MREF0>2 R]2,/'LJ
M<A=:B&N5#V'NRFH*2>[N\*K,ZK/GF?.QYM>I,Q%.<MI*'S0,0O6F'DJT*M*
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MLL4:F22MYX>G;,8O3GYXV#X.W@OJ/UK=V0J)-41NDX41A=9$_=A%:_4/#C3
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M]!8N/?<A70#]\^$'!H<3&(FT8!%(USSW<28->)::%+2PJ835F4,B4N]YH-G
MG&T3^VN35Y!]#P-M>_1=WW(?JCCMW'S$-@FC<%_'#QQLGB/(F.H#H$L9B,)Q
M1)9T!WHOFEFVRXM_:W*=Y^>=E__3PVO5G[*1&]WVG7D$]7\>8:9^N$N''8-)
M3UW#3]1![=JH$KUD&I"XZ56V9'$:,>?D_,BX2&SJKSJ U*3OYP-&ER#@I.#A
M9IF\^9:H5M4IQ]&M9:-+9D5& ;=2?BZ*&07:=Z:9!1]$8IRVHT3901AG&([
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MIH5JOPV!';\+54+ \+V1P[T:C1_71#DF!&"/SIO 9:;S9=Y7;:DPK+N&[0\
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MTB6SR&K09*TW#I6 .=LZ4O1[S9^/G7O&;BMV _\S+D* /]LS-E)"5D9 WYG
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M]7W#^7KP-:=C63+<-6M=)YU=GD7(A72-<%8#[5+%@,A]$(8^@!DKC?$::B<
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M\73]*7GV3TZR(?QJ3>,2]7Q)1<OG]_.6 QR4M:3KU].G5PF E7)%&@)@&%L
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MD\^1_-!2H-M_F.(H- M\SOEFV-\5I?A)4JC8V4-!\.YZ(U;FO-GC 5_[O&"
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MR;JR+L2+ !"4U)GN?GD[+:O$(5[S8J836RYMGD8Y^=!UJA_W&.S_"?\R/X<
MZ&7IP+<04Y1AU<>?S<5P0:7 W47@&:GQ[#\=@U_M?RS2,>;Y"Q%/FZ>*Y,^I
MN_ZOE]3KJ*QM=K#SXK]W8U>EWY8>..?;V]763XE8)PC0O>_MM^FON!Y,<SVR
MJ-L 8]RZOU4Z1.V3JX:*3>8H_N2(9OF>SB6>_SW]5>J5+X9AYX;?:\AS. EI
M8 J7X5><$NP;05%'[-J/HM^?>F854M51J%MVESZRWE87KAE[(AO)7\K)X$,
M='"<#UYTO>83IX%<EZ8R8)9TVBHS,2'A%H@/TV /Y<[(?,\Z;LJY,A2=!4"%
ME3&D?L)L=KQ>+.1_'CN@.X'8YWV9*ZS,E?#R'%\LH 0OA(E:T3O/1!;AKY?K
MXS,/+F8ISZ:'?L0??.@ AIIR0P><[VW9%PF[(FKD[KKL[=]LJOFHTB5/S<YM
M.%Q"?>F87N%O)S3T']U78U@&K*J&]R7]F"2;>F<MG*4LDBP^CK@W)(A[WV*2
MN?[D6?7V3%DK4</W_M^OMV9I8I$2KK3:1:IY.VB6O#3/#K/%_.3^!\Z%H!:Z
M(,WIM<;:2T>%=O4L'OJJU_]Z48KH7_9&^7>;I&Q<)]),-6+VC_A) /"$JQ,
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M*?[^+ 8Z:GS;'1/)?'T6T\=:PCVC7UVP]K5U0:9$C.6>6@*Q96=Z$===TFG
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MX(*59>VMW'B.R'HZ.;JAPE[CG6#$L=K'>$/@>?GA#9NL,^J?:GH6@,^]%JB
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M(,0,AH_"I!:>ITO@A0@"3[7B:RS8U[C__KZ::A*L%$*T@@+.T/J<GIWD3+:
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M8@?[MC&: 2;OR*($5&<JH_,ZUQX,W850J7'@C%G@Y=(5_'3.KXZ]KUAN*4L
M9")K0'H,6'8AZ $"21,.P:^^"#JKXH!;!^2#_;J:6[3WP/PF6S]30)>%P)\>
ME>=4M1GRXM3)E"@7K!]P ]GIPVT2M=G\)!^/V@S^[.>VBTM9WV(+N2F*O<TK
MFOEK*H\L 9QW(>E29C%UVXFX 9/[F5_5?#]Z:.[$>LL6U\9:?,E6L4WNO-,O
M4B@:^)"&*IN^@14MR-VE)7=&OI+AJD L_<M6O3+ ?@/[O*(Q-R5'2M(UX%KW
MS\A)[&=KR6@[[F=ZC=1>EL2[>$A<JPK)#C'QO*?RC$@X9U:L-]_)=3W9>IO6
M ?\H.!T<J7^OAN[7EQMF*DP'[UBI !>2BKWPG!C.;Y/$G:"AYX57,1W=@NN>
M@AA>\56L7TM?CM;[\EKE]95YC8J^*A6?U&#<%Z%H/$V',K@63.;@[P*?AS,'
M(-WP&S9X^XWEVRVM&2O\)M7^_]!"V\=^@T9BH3]N.89@F,F7<)+"@ 2X&W/I
MUU^^?$P,&G[MH8]71;_;U9E?QI@G\P*!G-,_E1NLV/592U0H%U/9D)W#8.P-
MRM<),);[K$\*(0IO8:I_$&7KPLM#,E>W9C "6X,!@^(TR2<9K?Q%Y#M &\D-
M<.E21L[R":%QJ&KGV2,T=QYC8I;K0K3=4];[ETG_;(['U,1N[N$G]B$Q9Q[%
M:5 %]R!$A?)IQA*)Q6MEWYX*'?O[&C)$**OX&U>K6CUT+L?[0OC)3 25K<3E
MQV=$6]-S&\DFO?VBM+=TD-].O=1*#OXF6\[)1/'AYR\:!.>')$FX]40[YT:!
M&)!(D%R"]$*XR \)=W\&"3H/?=V>; C^2MF>G()_ZN>A"MQ-;2Y/$A>E^7O"
M2+Q/4/D*F?ZVAT5^0W+9_47(98MH+B8<V#V.42K0*5UY?*/BT1'WHXOR$>=^
M/# Z<EE>_8:<H<>N?H.P>:K)=O.@$3<]9AW';(%4,X)/]W9)Z$<#7G%!EZP1
M^ \.B2,;=Y?O/5ZS2"]-@UYH@\UF3GGG$CBV71U?OXU".VB]QZ*XUA9G5&8'
M7KG;WXF&]_S**U >?'I7"B0&(AQOK9+%A.GAYDO(*%0UL64)?'%]]I\;%)8#
MF9T-LW>XTOL917]F9KA^"8_.\I<WLISCH/I!F5*[7]:#!*XM=NXD:-V,/T )
MKO$%I=5.BA;H!:EP7]3S_YG0(5ALFWEM?"E2_[S2!&4&? XNB%<@/@&NO(.)
M&%"Z1F6TQ/[.OLP^!7GF+C_;M?_E%S[:\GEPY.LMGJ7[E2%+AZD(D5-0AZ@B
MFLX><+C?2&C+*FE&L2Y,__""+;J-R]OTO9+TO2E#Z!WH44BW/@5Y5'IU"]>E
M;O[!QZS> 1R6M[@M1]I%UAB115[VM"/.>AS*F:$Y.DI,II_E/YV1?VUZVD<1
M:CNSCW8<3]Z!O1;I*4/^0*PE?NI%X;!P%^6:FFE'8]/X\AZ?8OT>=]J;\^F_
MU(4^E39!9MV6N)))(,# ^"Q)*X=#OE7_;<ZO4SN,F;,L6.FTK<OJ\A8URJ?
MLT!1/;C;=-I"Y:2[<'G"8032@Y6>,HQB@:N()>=V&B-9S]2K7$O;W%0M,U@S
M%X/-M]NK>VHLQB-E0$/ V #)).1:+G>G)BL6DD3A!=B=S!@7+P%1O=:ZICG?
MX[9WI9>D!JX\N1PCW%6>=@X'D@>[^]$YD5W.LLEK,AA_D(WY! O3F]3B+_*<
M4KMSEI);<KN<G8T?V-&+BSZ+MT6KFS#MF1!TEV)CP8]D9\%+UUOPN3Z6G6H&
M27!3X9B#+5:2<5BYP\3;0JFD6G7VSC"!#'^=+%!*N$.7$-74&<D.6,*PV\/"
M++78:P'_V< -MIGOW@]?.SFQT4"27Q!K\HM7F5A4/X)]S]J^Q.Y%-O"3Q'S&
MVQ-*Y>%B.!E4^(>!,KL?:G8.%2-<N8\2[@1$G)>:IJ'/!1TO_/N VX7_[G:P
MUFY=LNS@*#@-S@>AR&Y4XI&CTI<\DF2N$('<R1W[#_<O*B)<C_;!I;*LYRJM
MF)86>4D7SSW?3+^@#*;V+'*]-O!YHJH*<9TL,+8$?"3=AEF/=6L?P(*V@J]\
M#,V05^K-DWG<?X6)\?$N@\94%5P5G_."<ITRG(ON5*7P>SRW3I$)XH=LM5TG
M69"<(G5$9_Q[O#Y>O<QQ+^3ZJ$,C=1.4"?#TFZDEEN)/4,EOZN;\6#?2( &P
MA\$V#794EPH_2/7UJ3!1AP5QIA),EJ>2-9QP4$X'O>4==D\A;DS[EUWOT@E?
MT[KL 4D.RTO*U%MSN^F]=VW6.$741D_&#AV?A00?C 5N%)=8."^/SN6=@JIS
M4OQ:J4C&@%*%K\*Y,GBNYFBI#H1C\U*:OC]/4=)R%B=)"9J!Q$-V(F=CNY#)
MQVYQ"^<O=5)XTJ".3IQ'SDNLO[I8#QL?#I'$P_40#38_W3*BNJX)CHX3:L6X
M[U]KJ[\ V!"IDCQ/0?6L6Z&5BY13D%UJ#[V973%IS4O@T(N=56\V3I,H6Q(^
M >6&&P,.!!&BUTF)TDXR]$*KS.)%C9O+XE=CN]M9Z]\\;$UQ_WH^Q*= X 1G
MD_E&=)F)5\M_%U*S([4T+BU6WQRIGN<Q4IC-FZ9FF"37UP>['*E]KMWDS).S
M8$@3/(9\Z12$4\XK\FAXKI\/&J.U#KXH>K$'7"]]R^H>B$SW&*YS4JXE37;$
M5[W'RKY<!%&NP$*Z^=Y>'ZC?$?3H+Y[Q>-%AG2^8WSIIGO'.Y:V LG*#P185
M2<$+Q819>JVV^JV26MJA%R$6PZQ9XL#PI+6IY>UZ\.C '_UWF.P(N7OTYWG$
MWBM2Z1)?GX+2242^4]#G>0PEOJX"F@QF]FV707;<JVR54CJQO#V\@Q#6#ZHM
M^I7GE=@BVARB_,U\[VIK.0NN-8M)7B%W&^D.C:6(3[;ZD?@A93 _&TR4]N3E
M'.OLR6]VW&;:G!^D_>\;QE%7R .DLM%F5D!'0^\4Q'K[%/2RG$1C=?8$I7 N
M3B,;*+UBT^TCQ,H%"*KQ"3FP4;7WUCM6*4).1SX]\?I)I1:-(UPBSQ*_&*,1
M],GQ;_-.+$N1YD1)QQQ/BE.MNN!,IFCVK>D6@WMAJ3&9O3YG':@Q,*-8)9(
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M,I7*>B_6]>DLZ%C=$TSK5:<FQX3K6RW$;E*)182O@4,D6'HV59R>88RK=HC
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M*P6=RE^ZH0%VN],\M[ 4--EZN>Y]EI7KC"AH(\?L.Q,16#$F/S&!8*:"&(G
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M;IV:0]W6PCOV&*'Y6N6M$X=PFF+LCBK;5%)?2WE#)%N,,=TS#OM.P)_SU<"
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MG1I83#0?:18D/B)XEH2<Q]66<P\6: 8@^/+MB^E_+<?NG.?I 7[-.M1ZFXE
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M6LU4 N=?NMC/U AA16PF_%[8+_1Z->.SL:$6VX3;1]>&XQ#X3VY#D5 !6;
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M7[WYB^9H"OJ9Q\)1W3'(9.5-M7)"T%N;[T$B'*VHU\WL!!9,^&<"Q,":)5!
MH[,CH7EQI>OE,.21N 3-;_\S#1N7*RSU!_?UYS[4+N^T-9O_<\B<;@<;D$26
M@64N2D#/-8L3#.QP+#H3_9A05^'+CR5<8W-9O#OL:=IO+&><E,0F@Z@)5WOM
M ?3D^H(( HLT)NLBH;C"K4X,2FP#RES#9FTQ\:61X.$C.I\N5Q_=M!R;7+%9
M^>?=!;!IBH6]1!U2#*4-!**V&;'BMTD%9+X-NS,XQ=4O#OD+_:R50P7](@%
MY\6>!JN[?EUF3E=A0_?"EV2W,&C/)#OZ[]BZ^)OKGC*^J_KNLKD?V@,=KP)T
MW^_]N#HI@M=H;:':]BNPWC][>BXAJF,[-V<H ">L>Q$4=[BMM#>_,62#$VN6
M?;$]S#\O\[O1FN_2$V4@\X> _:_0I*6)K3]HZ+2RP8@'T=K!.R,R57GZ9I.;
M0;V;-0EL!W9^;J=[^Z6F34G6LS,:IK' \0PF:DL1;1R5K?X=5U%: 4,M0N-N
MKD@7NLYKC%L_3&MQ(#].*"G1?6J6/,IIG2.*> :E)0;CQ-XMAM[9M,4B$VX6
MQ?/97<%FYXT+Q9L\RY$=H'EM4\69*O'"G?/'V@P5-E@(,J>B!"DT*OY%R-.,
M])@0CR67[<'/..7XP^>CGBEGO!UT+IAK'K)D3[7>RL=!\1)82,<NR'CI$\0:
MY]F>)#AW]WS3A#ISF=)'KZ!P@+GYT2,5P,E9@B;EY8T#7FIHH "T$"<..O*0
MG<BH+Y+%TL;P>NFMGV-^AH]\_(*+[_GL#TE[4X# 'RVT/N?DN\&Z)53/5H&+
M@ M+]#%('@(%P)"C2@9&-L0$L>G1V4/W&IZ?8M"7)TU5I@L %0"X<>C(0[,/
MZ=Y]T\Q-$#]E(C[ IH<=P'P-SPZU"[W6NRCY<;9MIB!Y,BU 8RI&0PV0[J(
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M*HQ6Q$#KM!^ \.N:0/?JL#8J0LVM<//^Q9_M-AQ=_;_1JF0]B!C](:.*R?[
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ML2?_E@3_/"]I >(SP-)$&>5-Z3@L<3 9[E3]@)8G=@<HVS)_W]!BSR=?=3%
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MCO%_;J:LTD[&6?INN VE"H#8(_UOZ&^Q@8[_.0")P T Y+XXXO.T%<GZ>%@
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MBI%6ZN>SQHX EG:74MA"!,_-89OW?J56/&@1%G:LG=3T.8?VW^Z=;KGG?H/
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M3H9N#/!7TY6IT\ED*!CP=;A2N&X2[%'9L<O_*</Q:NS?"01PHHKGT=5,E8V
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MX@6"S##&:K>74&HS7FA[Q*)O_#EV3/RZ(_OZW7'?U+T U]1;7UW8?F0CNY+
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MC.V<DP8?K2NQD?<<_+:_?"KC6/!9A0LV="H9MVPVUHV1M?[8*,1I<9G?!#+
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M98WSH6E=/5G7&?N>OF:F&97=\%&"!I)BVCV<42016>.;VPWZP1<_UZD&_,E
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M]AB8=0C#7V;JAB\FSK&T 9G\88"Y.5HRP+"J0>].#NF@A+Z=?W=3QS&D7>0
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M].O,:LUY,9.Q&EO/Q.=Z-U?5N)>I6P-?=0C5*'0P>G*:%-]*!M!_I@$ _,_
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MFB8W3I/;3SPB?I Z(T2;L'I;S8L&LSTAWNSS8:8[L_$/O"7B0T!;^9.-5H-
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M.ZS0>'K_OO9&M<_;L]G[N5.#_29JPP4.?A7E_>=\FA_=S2\R-2TN#]X@Z;V
MMIO5-(C@FY<T=:AX>-0DTR7SZ#2BC2?70*\0&1$LP3I:(A K##1F-;FP;ES1
MT]9Z7)^VU]W\SC-57L,>V%W< OX2N$M('6W<LR$R(L]]9#0D8W9OW_'I\/6E
MN14I/3N>\\9E 2O ZJ*XUU_APA' S;0WK#KE,W36)S)>4@7UBV7&2PY(-J-<
M&FF$/$%A3N>NBO-\SS@88P%B@W;I+;(PW93[)BM3(9\U#:0^2JDLX!*.Y '
M+7M"\4=++(1T^#GHE'<?&:!7&/Z(XJ7,AK3ZL>KMH?.VQ&MZ83(<>Z15EP@:
M-3+@8^B)_^X>]"OP6%J+G@SX,I=)@MU-:I5XGMP,&GLOBRPKGX8_@;8_( -6
M,Z _*<3OR>]!U&(&&;#W5%B$#*AT7"8#[FY+#T$7RZ#[!J =:3*@+F!M 6,
M/59A885.55)6;6%@^IHI&9"J?@ ],5-]1%K:@[Y; =?U$'+D.UE."# RX):>
MPP5P'J@&1.#81P.[$$FD2]A 6!G><=9P7([]@2.RJ4'_S?EAYL4O5VBE0CG
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MH/O/T[]!?_3\K;YN$%ZDF0Q8#O@_VGO/L":[;5WX09"B-.E-@E(% :5+"Q9
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MB4$:EV:O=<I(K.SAQ<XC"!*#,>#*FD[GEAAI1FB%7/"]!TI6$I\I*P-.FZ\
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M#:0?EN^HX7.:3_ZF 29M';['.0+"B!AB<]<&OL#*[B.6>_'C1WS!@^ 3ORB
MT_<9.*9?X\.Q"N,&]QVG0.,BX-U%XCKA#XYQ.J[<XEM/E3C:(>V3M%'>IBWP
M?UCW'XP.-C]DW.]))QS! LF P':]Z*SA/ZS[F\UJ'_%1_W;Z_V"GA^(8_50/
MV^+.!;W)^Y)%( [I+;Z>"P"^J>RQF%Y/%W7"3\DZO'Q/NVKY1OBP)(O(8G3/
M.X+%Z.:I_XF#[P(9:+V%6'# P(B!AI3]NA2:#K: _7;*X1D9\(O:'R'B(\G
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M.5981?9%#%,;A(.<)R:7E^[027?:87G[7;6DC6LR%7J0RGBDR[9=,>F;Q>9
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M#J>]FO-Q5SWZZKL3E,%8"7(<.!)4HB$VPE9OIQCAU6#?+O\ ;<Z3 3W!G,8
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MQ2'OTCM,KK GCR^T-X%MG:V[173P'PO* T5[LC\[;KWQ=J!G/6-@7JBUOI!
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M.Q=4'>.MQCHBDXY98)KB>8RZGZ:KXW"N)['NZHD][EI'X0)6A>_]:;30Y)A
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MWT.]Z>^M.'*J!D/^TJ([.9S&=?=YU<2$TU9V'&1)Z%IP[JI[#)C9=!8>WLP
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MO.1Y!E&J>OZ8Y3B/U[8>ARTLGG595S8YW.6*0%7R3*(FX]O1CB<'+L$9X8W
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MME^T&8SE?;(C!+Z*_3?G,7X.T?@-@\ADF<MF[&:OX]+G9\A-JI[5LOCE(:>
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M(<L+YBT/6]0"J=3$GZ+#=%J3"6W;6"-R -H Y@-Z1 ?'M7$_0<AQ8V])._U
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M&V2&/[YP&%Z$_!W<#XLW]#CT'.!S3%9K*/[77$9>^@><GM&_S4\P9&*Q/N<
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MK2&RQ]LS-'\\=Z*)KW#JJT37WC 3= J8Z-#^_(G!%5.R^13?-@YB6"]6H4=
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M91\1$4A:AD_-P^N(5N&YL<28 GZD;_8+(^)("F?*N$4?O*Q;9.K>ID**[$_
MI=E?W/I9B*I$'%T\<^ +\HA0 $RC0WFJFI,=UM=Q*(8_4%)HFQ-M'$42M-&+
M]@E:OE)O(VQV1.YG]3R^,G?AM:^+IMZ;3-[)EG\\ %P__T]&CM_ _S/ M+!"
MNY.Z@E/ )[.]/YS,H5X3^!3P)P%%9D":53+S<;(#PR1 %-%B]#AWNO)L3_2+
MU*^7S#\G# RR%KUT"S-X#=O/R]\U4W7@#IOC#>8[+NO*?.2S0&GWKQ0WNMBG
M,./O&-GO=O6^[IV&(#?\V"]+S^D]BUK8AS#M0D'_=^>F.1P3>SC>\7P;:_F+
M,_SC4>[=>GB^8G+LF:KV3'9R9(?@N4@=D6E6Z8:_*9NZ_$J*,FM)M?6JOA#>
MADAYYCWY5%'S!Z16)YS";J> ,F2X)_(JW"&R^_&HT+X_C[5"*F3=,T4)Y4([
M<<'6[X_G$+\F)-2> KY.=I@:AQ(E.@.*UKS]U%Z7IM'T[[>K<BS6D'A<$@\0
MW)]FF__*L4*(=3Y*A[=$^M6\('(3A/!-BU/-[$[*Y'MIYZ"V*=/L>O<O"WTT
MZ;7[&7]]ZARY+[5O^^M'[V'S+Y4=C(>:.?#;G<!BPAS3Y-(PJ-U9Y?BV<<3=
MYB>(Y&M/O#>5Y'>[R_ &Z.WVP1<@4#*&/Q/GH369]/EQB?6HY."-'/&>>WD=
M[CT#I+NM#P<HN%4&1%\T0CX2GN*5<1JHR73>8?B-DO5F'F?[6:F^3"AYS!P#
M5>,KMV7Z!;JAN %(4B+X008(F#KE_WY2WV_7?V)ETGESR<#8*.GHO7#&!NJ@
M83#TS(]J5Q#I"L$E,@$ARM8[:"TQ8LWAN_EH0FT7.)WO))T@^@$_-],>@=/0
MEB^W>%O%WU(A[7UPZ:*0K81BJNWKF ]W<[?%+@;I0Z:W%8W1-, NJXK^-&1T
MI<6]P=O5S35-+9$[4J]X#ASC3._7;*'H96>C,8W;:,[H1H'<P$E+D0FOS7NM
MX$/&Z;A1+^UPXQHMTT4Q3=[C#[[60<\6XP:E*L7>3G49^N;842A<+[92C)^3
MF1(&!6R]?UIYBZ!]++;*8OR\6-'A$VQC+9"!.!0V<D ,H/0WH!:]QET;P1R1
M]JCVN)'M$@77\S4.43SC0@L%P1$/^8#W.]8E#B?U/PW@?#P\=R#X]L!"P7)@
M9MC6WHYJ>?D>6K,]SS06HQS)L'C@BJN.0<+UAN#.F.-4O*CTU_G.LJ=7[EQP
M%?W,2L4J9S+VI(*:KN\9+*.CF7$2I$P0P8<[+^K15$>Q1_O!L=(?([Q<5@3S
M9?I8;?KTTHR%5*AO\\29Z]%%Y[,..,],"S/$SNK*'!H>>GL;5X>:"MI]Q0E:
M!;G#NKM:KD@)ZYF,-@J@E6G6:MPLU^),2D--[BWP-=67+8:>DXG/?$/3#>@L
M)'Y9F3?!WJU7CG2NVB;'E^PH"%KXS8UEJ?&PT<.8R\E1;@W*/"25T<:9X&9Q
M+#)F+S:&DW:+H)W[PV,]G:]AW+/8=,>U6@+S9(T:=?/J3\%!UT47/=)O'+>P
MN:A-@85#5$^C0<YZLJG>2_3XOHYIE^LSX38P[; 8MR:'V_>38$US3$.Z!"NC
M[>PI(#E9UU)[UW)F%]Q4;Y)N\GYIOJPK5;H) Z0!MUP10A+,<LQ86S9"/C7Z
M9[4GS@N\O9-0YTZZV? FO6HW,"WWV]I1:'',>V$W'Z^;*.H;AVE?@PJ4>KF,
MOR* <%]TJN@,(X:VR@TCS$_#L7X_7E:*&?K1S-?LA'59B\K99J<&< J@V$,F
M$*@P%[#),02E$FU6;8YW>3-SE>"8+SR)YL_3Q;TGLY(G.GMU#%WTDF@L^ IU
MU^_6(Q_='?,LVP(>\SR.>8+7 EU;U<&QF5(A\1HZV<%"BVYZE=]9J^''WB[=
MLC.[QA_AU[$"SQ7/'2L[$7DFU$,11:IPZZ8&'# \_><S$=(.Z4"3)_UAO- [
MI%8"W&ZZ8#@%9_<H+IN@,10;#H^MHA&V$S"08 (-+I]D;-O@*Z(/9F+3:S=M
M,*!PC-64#P9 '"FO&M]'T&OG=6;W>@:O]\7#,JXI;G%1[Y""#%8MV=:>XMQR
M=0T2HEQ7#O4KG'<UG)-BD:GV^>HR@;GOB9^G01D8:"R1N6Q\0UA*@37$VZZR
MX3EO* XB09W)"N.ZW'T!>.\;_B&Z7^#A24E7C$_.E 68<T8^VFIJURQK9L,P
MP^FGK7-K:VLW$T=B)W%P3FZ4R$JPQDZ^]#+R'"VVCQ.(EQ1YR!N!$7W>2]7"
M2_V>)$B/?F\E=*'EQ=QY?%T 3IO(T)7HZQ3_S>FR(W:0.D$H09"4DR?95;&[
MG1P5\"TA)$-/HO@F?<&GG.W1RF>IATAAR:FUZ(62Y 0Y( 4<A-5[L042@M_'
MJ<=P(+/QB X9/_O4#QHLQ2UO^<^IW'<6//XZ=EXZ[YMW&=4KFV[EJR @00_O
M5MB OR9Z'M_<\SRG^V-'CHB/#=_4%4DN>A09\P.5.UI/I$',<'VL0X>% $8Y
MB& 62&0>)1@6Z12#C[*7[ZA*]!1=43TTYC!WB+\:M.B>5M>+:VF?#YFG!K&N
M4PF\XL9-1FTCEJX>218P?"WYMOW(]^IY,R%;N2>W@BZ9UN7GL*F5F1,G<,O+
M377/6C9GH/T!/C<VMZ:[W\*IL-16=,U", ]4C=PQ?7];_#HS<YB4N&;=A<MU
M#_*4HBCW8E^V4$ENOX3BS#J)K"F#]ZPHU_B_PERZVKA5G5)M=E&"U\TW$GN^
M>I3N)D1^/HF1@GDBITE4'M<RNIF;"3H$=?'S*.O7$B!%>*K"DMCC^S!4V_0;
M^P#!CH0U>;6E"ZZ:8')>1*L%8L&^P6V\<+1C+$V&('O#K'X%/N]GM'5?'RPP
M_MXP=V.TP,GR$I;FI"27&4<6[9(NJ,0"N_M4P8NVWW5DFS?O0?3M^^AN@R H
MK.( 7%J./8R$-@HL1EDQ.G$P0/%IX+XG!\4N(:[>&O;7=')891<I?0?.[2'9
M"'8C(';BN"5CE3,.9M!V /F8&"-#[M-NN&1H&6@Q'$RJ>TWV J8(;HL/QU!!
M:?&?M9KE?K!\"@_DK1Z55&(9F-A96V$V; M[6D!][E'HKOCLD?0YC,F7=H/L
M;3O)[)*&/O2(\"JKUZM#YX]UUO:^WU&#4QYJN T6P_>(*\_T(J#%-(M@4Z/W
M1]'>46,46SP!<1Q!X=U?7&7<4@(I3MX^F80+8DX\.D!B-=@.#J9Q_E'1V*^F
M*\JSSK1K;>.OM)]<-T^(-3U2T,!'H%OPFG"2?,<6ND9E]':X-\/->-@3<UY&
M&D^CNQQ.T;?TYL[/# S9T(2DH7KAQIAB&A YP764T7+D4\L8_,EADO>052?/
M[.U)ABW>:,$KZY5T<>^=Y=K(F$:[;=;Z.[4*:T\287-&$)/BQ):4V:[%"Z_T
M]$Y2&L4$0NDZ4Y([>O8&*>?62%':8S.J[XAC*G:BU\A(S]7QDKAU,?*>Q=%8
M#/"%-58Y2K0RRAFBBZ//OD_-DIXLKTV-2W]$R-YTZ=1:".EE$OB!F!KM.AH,
M4[Q(B?? Y(8^6];*V.1@Q)6SFOD_72+N,*.VX9MD3F@5;UX7Q;;%%A(8</%[
M=Y,]JMV/F(:>T=:Y]7ET>EI0+6].?<-NYY$\]">M=HE'V5M;>/=05@Q2E4Y?
M]IV,KLS$S.-"B^NY",EI_\)K; :1R]]^SK19LIV=HE!=IK0A!['E"">KF:\G
M6?:G ,'^. /O;]&+WFYQ[[WH]\1.HH1*""I(&/0^/L':%Q,C<K%._EF*9UQ>
M3'"BN%93\!4]+C(N>H%MXS#XM:::T4 AV,V='8R@F7: R^?'N6GM&BQ"/QZ_
MBP4 *'CW.@/,%DX!+T$,52?YQ!MKH[!DS:A[C2/Z"I#O+1%/T@@-;E5LU1-R
M1@L<W2.5_6Y,]08(XP0ME::$AI5[T[G#3<&4PDZP\%<(!_)**\!76$6[I6!(
MUS3\*&B4WPPB76/[MGI\JB[V+16A#N#@'O=:BW6'V%.:=@=!-8,_UJG%QUY\
MW92 >CJ@PL1V)<-I8':&Z1:KN[LLI0]-QCFX^K#BC>,;TUU':2_JQV,CG/?/
M9;-F,XKS^H@I7_[N36XP(#@&!^.<CDW&M^ :'^"P(46YA;IG\1@EV2DSB[4'
MGP&D8L]Z>.6XJK5MKZA_HYY,-69^VZZ;DA2I;]X/A3P&F6@W3 GN^3%DT0R^
M#V0D7!A6]/ADTHQ<G+$@>SPFRC(P>:>J-.#.L6"MA#:U"POW3ED?-4!<L]_3
ME&S#-V^MY7*C%9IU\(H9>-?1N]?GXO>IJ$XOMG?7S;Z3BI#U'Y9ZQ+2>#^!L
M5;Y<&84,)K+(R\3N(2Y8JN0W'48]K?<*.SH&KMP;OIGORQST(%,^GR+C38X7
M2WB',@4P*N.J:'?DGDSY&%R8VBCA4PZ%5C;5M;=C6VWPV(;)N.YK'ZNMW]Y,
M?,1J-F5ZX*2%N#DK,V$*^7#]SN?O R!Q/(TUNB7,:/X2X<:BH!43^-*<<%.K
MLU1Q8W(/R0U!:5QMD.$;VUNR7.,9TUEM]>J)13#CSG3VT<V]8JI.O_O&PX]G
MU'DT<R@;6F\#'E8M*OH(=Y>4A&)B6#B_(CM,V5*:(B'ZZUI"?A#S#W6>\^>^
M\0Q@0 8#"ISWD@]R$!O;8:> "WLW>F+URX?NC\XD[';Q:I[?8J^+Z![7R_&3
M=)H\FI4=2_!^OUB2''L3W,!;Z3W1(5EGT1B;=OUCY%'6OYO&O:=]P'!V)&%H
M.:"K)6I9J1H/*O^:I]="T7\*6+(V(]S?OT$@/Q.X0_-OY^(()N&S%MX%\A+D
M<8RAUA-01<6CSC=)&@:CN.\SA3%%/7KJ;3Q*%;<Y12T(=CB?#N3T/)HV*W.M
MAL6G74XJQN%.9?"<T2/<52S81T]I)LB[J=%#O:R#G*O275.^.$ ;)]/9BST[
M6;9$-C[D$DH12?3*2R3A_?F@\BU)G8*?<0^'\$ERX'6\&4:TU9E'%5^%$2QF
MU6AHJ:YNJ<1^2BK%^]&/?+_[E*=Z!\?50=+?\R4$VA]BI0/+PC!&5 G&<N(A
M;>E,+2&=*0SOV >2"_"1;0EWQDKL8E)DL][9&B6 'Y3;N+2C$FYSLA$' KF'
MGCW!JWGA2#I. 1R5_5 S!B!I$T;'FZA,NU:?>C%A(_-^]Y(W=4%\5]3-5S(D
M@S]"X78X8.><Y$D!7&8A(SP#6ZCX&"UL"_%SR<+$F%F.QE1GY/!E]TEV32^D
MU=S?Y.@A?)P")@E:V?]]EOT_F Y1X->54C^0X)_;>"B=[T/2.CKU9:B?R4ZP
M7L;R89@[DSOY!<//UTG0HI$9%TI$0+(P ;3,\^:;<)/J"=%K\F<>;5\.[I'W
MI=X[EG6C/3^9X]D.<9-B8(CYI2S]OM4F!>ZF7D@&2:/7(@0V FD":M8U5D?>
MOJ>X%O[9J!N;?!-8#1D\!=AO4SD=<C($*L(..TS5MM[E.1$%6*13H)OI//S)
MUA?<5'FY6[_H:^[*VOTT(;2^#S$]!;!L9.,/%[:C,LB%]]@]M!L"R'JK)_=9
M>1@2?11Q$G>YWHOM4KL4KE#3U'7+?0 R37IRLA('+)GQ8)S\+L8ALM$X;XUE
M(-%ZD4;&;.QNO5V'S$!IS\$!?NK9TZ1'MCMEKVN=I_H#<JP8U^L/8Q".\S0$
M2;R-+W:P,Y"^970_[>8IH(LEJ2;WI><,3,C"/DYX2UQ_J9]7,W_9!2!MQM09
MD/EW"U?\CX)0?[XV(4VJ\_^7?3+Y[U<F/KGV8:S5KAKP_GNUH_]7G]'_GIB6
M_^D4D <];/E0Z"6T&=X>6?VGNQ'7_USS6;,"?0J86=1L&0OD_P&$V+FY1V45
M)(7QNP+31)G/-]O\2IH9CV74A$=ZI5%AC$)H4POG5['-KTN&I[\UWNO_?D_\
M3MP  )F"^ L?5GA0E#R#<!A>OC>QN^5;Y3SP^5\BL0ZV_\9B]?U?0Z?]IAG_
M#]O%/NX3/O;.^+,J01H0<?IHP+.VYIVSR=LE=>HB<;$VP&3A*B<[ ?H1?VB)
MBP:1#6=/>MG'$(=!L1)5"4+JTA!OT3J9?(7R#KJOM(*?SRSY=\Q88OK5X251
MZ-I>C46E-X%2=T9<R4 ;QU"5/[O&6!^8Z>;O(_%-3\(,9!OWMD*L=4M+RO@_
M.$XEB9OQY=IG/>-V?/BK31[^.@$*Y[&E!,-3@*KTV7?/=TX!N$>(=A3.^(1Z
MNIM(UG<*Z#3X_TST/PDR^O3B+,(DP*<M/F79'E8C[13CIJL/0B.3'LRXUTV?
M$PQ6X9%]2JW\]\0_ZC6*KWQC^O,4\'KO7QW- N3?9H7I5<2?Y])5Q)^%WCPD
M""G3(X;ZBQ +\!:"(>?_I*!EBQW^3)M_V7 /_4Z2%XDJF4;SJ)1*B6Z>'\D>
M'V_97$W:N>@*G%5P=?5S53FD'X/KXD2C04+X$@N$Z0A_Y/)'39[@@8&[84Q#
M3VZ2Q).Z^PHD286< JB G59[$A!./*?H*8!>X]<^V*Z.>1BRV7AYUJRW+"D4
M1_Y+*VOB;TL\-%/CERFG\<N"1_ZUJW]54&W]P"KV)VDHYR^>@?-7O9K^3K<8
MD5.!RDLL_W>-YO]C9@GX?GSUQG SN08]7EJ\.L?UCCEQ\V6[1TCD(?)/C([4
MPGQ984TDD5+-H[AL0H3N8:UA"N'G5A9%JVA"Y*'H+Q1>('>JU?I^7<V*0ZX>
M^NX_2VT:QSOJ_<(5Q_Y9';)_AT'\#?L-^Z\-,R@;?]92XZ6WUX=H !*JK-0/
MBY7_C(VP03=QK==_('XN;S5!+,\JL4Y7_86E_4KW"P>;=6S:340(GP*VUTX!
M,2J_YFED_3F#1/.?3O?X\!OY&_D;^8\A*;U9BI,/5@J)[Z CG#^=6F9!^[F_
MX,N>*<IDLWL\XIPR,CDO^M-';RO#:?17F09/5#QNZBDHNI1S=S'KJBQ.?,SM
M=Z9Y'\8*BR=/WNIF"7TX'W3CS;]24X%1:-MY\Z.@5,=#,3G*K7/=BP:_>)4"
M5S #2S"S2%'QEBV9H^]'8RX_VU@/_;.-U)\W!C<?SP!#KZSN9.]8_J'J6^LW
M2YRSN7XW)!L<GTUO_:%L$C1)=NQF;!P0\,>3AMA?7^393>QJ9A]I?(A+%V1W
MN%\QOA'S8LL963SB>$A3JV!R.6[=(OS7ZW.+IP ;J\M@2T;\(/U!1?[4*L.=
M=D\9F4D*:O]7WVB^W.[=0TXZ>B">^*?N*-6L^>X0;^R)ON :;N:&??[>7E^S
ML0@,V_--@F580"Z&&CZZQ&RU@4L4[J($+6CR9/+TP]FQ=^8[6\X1^<"63,-"
M^]N7IO"?M(5E'KQ[8I8 96T;\9D),G#CND2[^+P?#%<XR>'%Q^3C,UKGE'':
MX"3&09D#XPBA+8:VXGO?G23CWNB_H [^1O>ZLX;:(Y -IVA%=0JP1[PTI<U8
M9*5"T*$P?-+Q/Z;+*4JNG0+42$VHH75Q;V1X2I^XJI#TA[(94LB['=KUZW[>
M>6/90C_3DF#ZS *SOR^Y&7C!DB!_DD3D,H?UM4](I_-HOUTN;TATWA+A>5E)
MM7,O-#)ZFZEG+0"2>E*A*/@1;V6,U7><5@M[G<QR.\FNM%KS0FS#MO20>$"_
M(\P DPJ9+X_MT ;2P1K7Y F3<5':%F8&NR[9T4RT/(^9RLS#%-W:#HM. 3,2
MG::BD5*(BZ"8PJ].J]!L\D\0JC?OU8^;UYT%R+Y.NM"M*UO%5A/!<Y,U;:S0
MT7U^\\847^8,&@)[S@]$A4,LP;< G%2?>#):$I,3U6.D<NYIL%96CZS;"MNM
M-E(0>;]G'+&;19$QD*YB+)!/U3H 8^8F')H_/#L[_\1;EV\:0 VRYQ$(NEF2
MX9TROR%<H$)^38?32D^1 SU+SC-S^"% !7D;YQ/;*.:!,UZ0^@;B&>&K''WV
M>5XW>?AJ%4B?^EY;:3A7;"K[#<..I^/WTC_K@)R2R_70P6ZFN1"BS(4L.P3/
M%R_@%,]&BFB4_DS7D7<69I#:+ #Y8%AXD_<R+\S!W%P,4!:C-<T8UAX/VK>#
M:1RXCB+APN@FFRX.V6KLLW3^MVI94U(AL[VN%  %>KO+P8]]%0&?M9@[_3E?
MP /04=#(%HZ2%1Q''/VG''N&+I_FEWS#.^^?\@N'RW'!Z]8-8!J8V?DHT!4\
MY6"[U55/8'A]6"PEN+[_4].!Z\BUFS?[&%-RW<YI 2[1$ACTJ]Z7307'BLKL
M-$-,)T,WL^URI3.H EC70"8<%-;8\^P"G7,"PW"O16&!-K<?U\.TEDX!FO$;
MM=_"YMBR>G)\>:FCG]?(=6MA1*=$ L@P L\;08J:]J-PH_C4@#O.XMJ^"XY#
M"A3":2&TS+)"0 $NFPQ=/ )W#_4($7%M'F,9G7&)?^?:J*)-R6/57)3;LV#%
MCYD7'[G0B@7K&F*]%YS6FR6Q,[#N!:D^V*'F9+**?Y^.P:/4ASI$ZU#&_@1_
M%\I^.O1,2.+2%K/'%[&UXI+)^KWE$>+ :F'7^MR43,FW@M9,*H3%X/6FDSBA
M>>*5$P4-_'-P$:P0Y5K5V15=[QE'JON8[/U@C=M]6T";R:80:!_6@HJE A.E
M<)]2/Z[5[]>$"8E$!UL8[4(32;].A6T.A,1G^EKW 7,"E+!1W9:LHX$*!/LQ
M4475'-.O5CD]E?7I![R1W\7C%:N%PWN^1T]^4:95%,[%3W:EN$05K$_,,976
MBU-XF?4W/V*UL6>MD:>]%[H<+@1*7'^RCF&#J#?.Q47I+QL;Q\S&FTYM%,UK
M>,CQY?Q1!W4[F./J) @(5QXN(5[_,6WQ*I:^>TI*ZX6E44X#&&3I0!)-&ST+
M69I_/L<T#'? .:#D15_:[51&]96QH?IW"*C*-[$^#YN"<YF492ZPL1RI=BE3
M*=[ #)Z#05 R"+9&EFH0ZZN'CA.XN_S)@11S.JMD'[H R+?$JY8P_;[N>@/8
M7&<5D*JATN=E[+5*ZS>AKWV?%>]4C]P>N"U[ 5,GWJN]EKC($I]PF!Y78>SN
M8_RPP7_Z2$GR)N+*T#%9UP3H0DT33C2, ,:ZP@3:L;?/O!<N/3GW)RJ<ZFJZ
M72/99X$PE(2W,:<863!>3OE%(]FQN!-1;$*1[B-L9&W4#&((Z7,\U(Q9OMX1
M?_?+51?>\PH'2#WLJS)T1I@?,0>IC2,*>[0+Q5S#.ZWM**P:WH+7CJ<\YOWI
MXWG7Z)G(!J:6$Z"U (W(. <W1D?%,CG.D83KXX0.)TJM^L_W7F!=A$WVBN<R
ML<)DF60'!-MS!?7=DF4$)$5.CKU6AH][#RL@$)/Q[>](&]8N/Y_GS8H$BLE&
M,#J#; 8FVF')DA@X#'YZF3OIVK>ECQ];/FO;YCTQ8'O5J+<IMK IPJ[0FBX_
M5-G@S*F'4T]@2V:0%KL0S)IM.%]YG;*.EA3 ?+U_+&43;E4 8UP0;1V\!!-$
M68I6X6I>-MY;<Z@OGQY2HW75Z]DHN)//-&>23,;J=A95*R\NC+0XZ 5/L[V5
MH9MJ_A!@2)E_/]9-E"@/F6R_YUJL-^7A+M>K?M@BRC=W-*4%#KB_#%'8MEDY
MNOZQ>6CEG[D5^;_IQ:D_#P_:)T"B4S R_1!TQ,B>(/F>__&F5:?/2%)=J>;3
MN3+3VZ"]$>LR'O;\Z/VV$IG%R8YB"(JS5"!\W\S"X7$-3J0AQY'%TZ\ZC1>9
M1U&2,L67R"S!HUV6\\18J/_YV&0+W'5TJPH:/*=<5E:=<G#P'77TXI:969=M
M_&.6Z=MY!7+VO$& I01+#X\"@B;>[?@67+8):Q6:8#'I&:.LP3(8#KUFVY32
MRQWC@JFA_G%E5>,F)\^RW;3)\]ML,AN;!; [W8O<0SGC((D?@<+'U),,\IP=
MFRY;_L[WOE[B@'CZYD3>>:>O<DUMX%XTFY=5=7)G7T9X("O6Y3D8TX&]C'.I
M.J":ORH]=&3WXH&6FQ>O6MM#0:$[DKQ7J.M(N(P8TKR*B<,ME9,H9693&$]'
M,Q";C)JQT/?U C* 8W+-K6;GS*+<G*FO!&(_EGP'BU4F/@#>G\2O0PH(4&QX
M^RD@TE0&-7A%RVO!BN$4X#2X<.+=)NRE7>CXY74/[L[&HUH%_FBZW8M,;=>"
M>$\2"2HV")QQA[<E.;ZJ ';<6@:.J]H*7S1+G9*:E7BX2]K[D?%!=MB$2<2
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MQ@KJ[JVLRB1F^GC?8H(+/M<:.]H)8L4'Y$>QI@FT'M2;6.@3UZY/N91@1E%
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M>3>%JYX#\@1XN$1,8,DA</$Y(5Q)./K[VZ_-N7DJ3^P=#]_>C[_I,A/WWF5
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MAYEU)IT"&.$ZA8'#/D3^X$%]O(42[E@^K/[RMRGIQ&"N,(6  9%;H)5-PD)
M=OVKLEP3X N6@(R76;@+'&2[FP3/"67<#;-$3KM'Q^K;^*.Y"W.6\W6[#E5P
M+^7G+OM64UEJ>-4<P@4<* [W:<BT2U'_Z$X;&)+??4TRI>6@5<&,5S)#4#*F
MP?Z;?9"RFE<35!<[$>=;L'9X4&^4[$"GY^'O+XZZ<#FO3Z'A4L$'=RU9^MWY
M%\K.L>$IVUT9;'C[78QRD#5VX)U#=N]'IQLE9H56@VX'&95=O!)7WW39!#G?
MIOR9(>TC[)\<B7PRU$B7-^LT(6-YK::JPJ&^HKQ4QF#NHM4[_5D5D?Z!2R3O
M%XR[01=QB!=[&;&!RCB=P38$:QJP0]I/ZM.[L\A..4&0*JJ>=Z)K"*NA8+)1
MO"M>-H!J8&(&'!MW&/N%AH?O*Z3QMWGIZ+,^MJTL [^XMO+D1;;=($5=$&LL
MB1SR78M]OP^F?W)3 ">@B\\OFNJ#P96RG:2;.8=M7Z].W^E3PO@^W%)N?/WR
M36/V^8X%>$'5O@XL]@5!J< L\*O59:_\RIF>2G\DA6/2Q%%(*V8.;%/;(JX>
M?[GJG6KF3=K;=H,/;W/D+EJHFHW >8HL85"M*(O)A:JX#<FI$K5Z\P'&)?77
MV*#WM@?(#(3MI@W&:["S)?K(H5/TDNG:T6SJCU&^5XDK(JF?(HJS7[<]*_%X
MOA/\?<6]3@[3--H.4CSS8@T6./5W9P>\K9:/9TO#,DJTVND I-:<]89F91JT
MN-(A45E-QA5MG Z_B27FYP:.M+![:3=)[TS>'T.4-G?Z2U*_GO7U=BGWU57G
MA%QB!<LJL@ ./O\O[C*(;R@O*16< AJ .TYC10W GT"GEBT4(:7J1NG9SZ__
M<RR_.H(U<AYOA3ZH*<Y)L71*\4Y66JAX45%4H4&GG-1$<3&,3+4?+I&W3A3$
M^Q]?6^6L1.,;,!;0SM&9KY":>K6!3[DJ==H1F,>>8Q6"RYU5%EG4&8VT+[9X
MEI%(@@"&=9 :PB+3OINU/ED?EH:6A2+0(NFM:2R/;:RA2U*M3W1Z>?K%GL##
MO?V-47[=K:G0B&::C%:CC(J5PH66R*/9P:_[_9"-24&T$OO]D$WC U*M]&_)
M+V_%6'/8V[8ILK=R9AD3^4<J,VC[D$[R,=7OLE2A!W7([1P3[C#VAJB&LG./
M:+5XSUF2H($S-NB5!EQN-XBY$1^[P 27^/1X5=PQ)1*2M#:Y^RT@=U,L@KJ3
M3^SM NN#\\T._6E]ELN8AC1E5"#EF'W]B(M7@/CG_JC5)&EG?TG<V9@7:@*$
M!2_=NGI>!^ZQ8,6(U]/"'RZ>G7>^$1AQ=4,$58<L4W#2/+88BC+M<S[(5*B%
MN,:%272H"K)M*)0]?PVL@JOYY)G $ 9U(\\8'XUS5R5I:S.\O2-B3WY/W1R;
M^O9<+58BY6?JP;/)0*'9P!'$%<_MR)3^]S7AJ&GU+ CZA$&+-BU;J&).()%C
M\;B7/$+[\VTA7;+/A5:/)E_B_QM[[QW69+?MBP9!Z;UW%) N@O06%6DB("(@
M-2(@-?02(! !Z1T$%)3>$2)=:J2+@ A(KTFDMX0:(,#EV_?L?;^RUUGKK+.?
M^^Q[[OIC_I.\XYUCSG>.,<>8\S?&T.N<+FS8"L,RFV;JM,1H-&'2HL"N)4I4
M8LMIBC%[? [7V4W>*-#E_+IF?L! (+OEB^4UQ]EAC'97.B;T)W'%SWZ*2E$*
M[S[KB@$KSPVX^<WH$>4U?R8.>4IHZ>.E##NTP<UARKYS<T/@/99,V.ZQ\;!+
MY[_AJ6R/R+#S!-.1S&:GA,OMKW%TR-MH,A+6V;.\S8.A!! %WBX7!^K(6,J.
M5F*$.YRDI7DWZSLX?1QRDC(&KB8SW="<,T13N1$F9;W[J+<U&'"8B5O 5.Z*
M R#P]C8FC/+@>'.Y.:[AD<Q-L^5ZIX  )^\7CYH?C2AJ-C[B(8CB!7 ;#O^-
MFH!_J,%9?2FT\F5GUR\ /W0<#9[;+/R/.IQC,9<; ZSSV-#?CJ+MMYK"DO>C
M!7.H GJSJ5ODL<!.8Q5NK&Z2:X4#,W?0_"(7%0G%1Q(;JY3P)R1#USXGA&=7
M9W=DO^:ZP784IL3M6NQ$%L?AFV(^Y,UW+YARZ5U!X.N0IZGM/$GOZ43&!2L,
M39-B7MN,!(KG<*FA85,B2($N5Q;9:*CJ8K/VF?L4FUG8YRS&=V\P-O&R3STG
MTPP2 ?*,RS!.X,N9A:B%VN).Q36HD%,95&;4*R9.\:F!J$3WE>I'57G=K>;/
M:P,>62_)\80T<C\=-AWM-BS:&0RXF;I3N/^#&H@+P! CCSH0E([3Q.%*X@[%
M:PJ?;'_R^ 2$>A4^?).T]/*EQ<<O0G+LF0 7^<YAH WB]3P7QK(.*2).W*&D
M_%$SQ7)JR-==SH^&)KZ"+W;X$Q$RL?0(;IY7<WC@LJ X,1B\9$E[EM;&A*/N
M5.'Y(25.,C.YUH2G=BJEKAWBFZ"IWK+'KWC>J%04 5#S9CG.YY[*XA7&H)S(
M;+(YB._@#ZBLVZW:<KT&\X2:AZ37&Z)D@:(0#PWIM:>/-\9<MEW./U+)N(;.
MTWS&)0@DV(S(0JHVX]]/1TR_9&W@O:K4>@KD;#R"*T0<,N&8"3[-8,Y_GD7A
MOS;,S\F@/\ONW!':4]?0DJ5PC^4P;A[6E5[O1&:"9(BS\'IGV6U<>-M/H\YX
M$#+&PHA3]ESIFU+:T!4T.R/*YOG;WKX/+82QP=&^H!I@IR(B7!^J[$IFUHLD
M63'+WEP5R+BQ&Y^L5(+2</5YH7O-GVQ_7=C0L52P5%&LCB"Q(PW3RV#M;)_[
MU$Z.,-A2!$T]V;RXD-"B5X*+ &'\?DK'J1LHC_4[-I0NR^_4O213H )<::V/
M?ES^)*6%;W37A[ _[^QM&TLWION<ZP+0(4241>.4 I$ZKK1++.C:N_'PNXWZ
MNN1'.3XO/OI'OSVXBJ \ !$\@QB)Z)$[5E:#3-6\%?H\OJUOM,'N#,H)WY9%
M<WCQ&9<,&VZM7P 4YT];3T^"D6S<FW<PJIW^\]GE:VVDIS+Y5NZ<<[4+TQ.#
M2]]B6=DIY8F)"$-(#BIC>H'5O1W949:2,=V6?!C;M,+*W-BZON1G:2\BA%_&
M<3YQ^7(</?688>DNXWJMH9+.R^/W<V?/*$)(*I['LUAK6L7=YW,O,30D!  4
M (H&JWF-7_Z5(?!?D,G_<Z&D"PBL;*PT,-S?-7B[UN'EB-?,2EOMVZF^E2YS
MF=70P+FP=YE7/5,F.(SY_U?##(S<PA[Z/HXUG#O9/EI5+/K?C5HP2O^W!&%B
M_[VF[[_/LJ+D)K# Q2!W8O:':$T@?CNN4L<4/SH#[40Z0 Z Q$+=>XKA)+_(
M<E'L(#I(ON5/[SA5G;:TDW.4]KM9,Q7R9B8Y='#*2.;? ?+;;JY[GNH^VS.=
MF+":,_U74,#_/Y;6?Z]Y.1TZ%#3(A]+$BV"<;<$/%U\WGLW0OEXA9MP!_;YJ
M6#O"VMB5$<\0O6)F_='\9KY;N?3QWIPZ_2N0 .,VZ$_ -+RJ#&)BP]-U8$@W
MNR/JGT7"POE^_--@=<"_*/]%^2_*?XRRV+IL"N:RGKV6]EO4^[%C6]R.*>SW
MPD_7V^E_;\+[WEFJ[:M/%X#^)G_9.L<_(<<__5/E(Q/_V12"=_]%^"_"?Q'^
M+4*&36DS\:U!XS/)A0+@[ABL*7!#[P_4+R8AKIH*RR7 ZH^?B$"[V]ES*F/%
M?WQCT9>0Y:=9/I Y&]58R?>AO15J>AG3[/(4,E@^6O&YWRH0(@ &0N\E<6_U
MU1CZ_IFT0+=,YF=F'A@Y1>:]\&"<)4SH*?Z]#GFZ."(J321I86(V^Y7JQ]Z#
MRKO[?5S+A7^T&9[6U'.3\8\N:?UJ^8W1VYU"7X'-NOM/''Q^3-7-_L:JZ(*H
M>XDA]PTN0%Z272<WYK'>L3 7UP7@D^0%8/78Z>U9=(MT :0<==:=UE!HXL1D
M_3#CGBO,):6'1>FNS 21C<W>ME/Q7\!UO9N&* O>#@3SMKAWJU&_1HW"T^&8
MF-/7(9+=J.N^\H0"Q G6H$K]Y?,OYIF[K0VSB[!N95D3G#1R\@+@J,VI+Q7#
MB%&T3T"Q?E1K(E?3S)=0( +<4AH2^\K++7_P$3&ML7@4=L"=8/HR[EHN<B="
M@0[B+>[B8BI8@185^!"D^:8X\WI'+.%[\4_$#S?0EA'>I\).>1:F/3!FQN9A
M5%U P:F!V:#WE&=CXH/.94)B.\NBYC@SE&^PR[F<A64[ZL.U!>/,]N'IU9/]
MFF[IBM2)3 _S.[_*ZMGNA/,DI9Z+<M^0EJAU%([3GHW-O31+IT>FCN:'7 JG
MQ<P:%Z>+-_.M'+A#I!5!'&?%G2H";18J8@_1ZFGCFK^2.'.LB.+)\]_P2(AT
M"K$'#[[ @0YM6L>#A'"=':;QU5(QXA3M_(/CG\#0+HE8ECX]"9\=503[9\!!
MMS^H%\C4[7FJO'HHCJ77POK&UL)IQ<ZV!E-/[C#9O@L.UB7/8\T'Y&T!: #3
M=S?:E' [NO5G6078N-AK0UU FH^;HI492AS"O%+YB9+-OKW9A^G%^JNJG FU
MUH.^,HL?TA+>28NEGLWLK]8*I'&[+W)1G66+NN+)G=#4++AOU$3VIG%?ZT:Y
M H@;,U:7J@>B.U_@BRF3Y?@6GS=P8V%(E7*,;_=.GN.3;E^&I(K!#V>-9W,_
M*70GN")X0HISB8EB)0[#6C$KO4/!*N28&1Q"'9,0"1433W)G0G@?0EZ^"LE%
MO[B]%6:I$/J9XPKI+YCC0I2"0!S>('=-A;/Q?'BD1;ZX,DN:YG:#)(6+S8%^
MG7I 8I>MFUYQ6!=J)>;7ART_"]-O0E Q12>8<5!:U?M\1O;\&14BB'H?PDZ<
MVHG-MZ."&L75*KW59:#A+_;\S0.^]*-PAZ0&L'!, WQP520!-XP,2&!T:KN*
MB3OJ^"" 5.YI*//3=_2'CJ?K"<>5+'XDBR"S50VWRIK/]T2J;2>A@%.9G4&<
M,:BQ]$[PRQG]K'63%'W-2C;E/6JQE.]Q(?4'+KHJ^KWN464X7UU,0A=UA.EV
M+O;[!.J&F=,/7C7/H&IREH2!/2:G=S+BVS_I7RG88$0ZBF8E4E\NM!0J.CPY
M X/]Q-;C+*NT1QOP\JFRF^Y%@W!(:*>I:U>,R 6 :<VH9^>49PW.M8HI].U;
MIBG8-@]N=ED2J'"W)#[+WO2&A6-QZ.[Y.[48RP@_]T,+^:S![5]-;@,5J497
M[]KR\OJJ\PD"LNUQ >@ABJF@202-=WD"K<-M^R-3FZ3VDOY NIEO"ZL+PIIF
M3MRIGXEQ>H4>3,QM7+B94WD(J",9TJR*@4>V2/A )P]F$FK4I$1MIH>KON_5
M5MX=$O:LE4R9X;!4$!).\0D:;/0H[WTGL]D(;M)^NN7A9SWL*WNN%#2$P"3A
M9I"(URW\10YLW@<]B;N6\R9?JN[.6PZ.:GYMM,IZ'9O<.=XRU,U=$_X^BPY[
MK7DQF],$-Z6DR'NKPC%-QX&/3*')Y26=.(4OA1"93UJ/R*JR)]HW6(D9:_W%
M6 (7/_'T!PS)D:F9==ZC+]'0_^#K2)EM8K;@%8FDK/=L>YPWJ,G.AT"4*C?-
M&N*E@$R.7 )U@>*/:GY4JO631'\-,8G&1-#]BL^^1?#"31[S]B-8X2G:-U"T
M,4AD<,^BSMMV^:.\NEC-M;U#P^$6^6LIMBAXE#\L7$FG=))]4E3<ZX@I-+Q#
M&NG.H@2 ?!5X-64Q&]$)#R9%51!W9?%AF:,JE,20RE2PJL%ROILX'?=&]:_)
M,NP3%,5NP)[/%*0B^PV=P"B@[7#MC(4=JB&DQ6J1]..W^7:49EM_>4]T?!&!
MBTE+>ZKY.UFFOA[UD7GO7$A-.X+^G!5Z%^=K6[&61459V5]N[[%!)0;FJ[MS
MI2H=Z!7+G<Y*D$Y07\4^VFM=(3?88,?>IV$S7Z\K5)2N7@C>%F#9EU,V.S0=
M9T85I2YN$9N-UJUZ*TJ4S*S;SS I!C:*2SVOT9AQ?3R33BQ/=@%@"/K.Y@'1
M[F+;"8%ZVZ%M,)NQ375E)M(%B8+K:XUO-5LD9F\7"$V;L51.(-MJ,.A#;]Q,
M<6%Q3&876^!\[+A"?;YSB%F 4_KN@I>'P,)]@[S0&E[17C<#S= .1,U$IUY4
MVA8ZCKH[(R)J"Z0]*KHODN31<:.:)^U%R_6N1M[B_E?/WE,NQ7:7JJGKK+$'
MI*TTU\*+TDQ7)P+#^KDW<M7W#M4QAU'<88@&%4$S!WI<O%Q;I^O-Q.\[(F&*
M<ND$ZDOLD\')"L:R*/B4G3ZF.!1O5Z;SL;"G AE0@FX<O5&G:-N0R,O?H0E2
M?-CX5:@]K@<"]\?U88[4L3'0ZVT_H=9Y./.U\<=:2O[=7QONS 33TY/+?OM.
MPNO0.T_,RX'&6:.O16'-#M]C=8,)G++)(.4:8.8!LF]V$EV#RQ2OGCX?(![3
MX_QLORPW97 XG)D<[9'>E&Q>/:4HA@YJ&,W5I6W]"%U!)X0B,"%0<8QOM*NW
MVW1"%.$@4Z(8=NGNM0=9+_?>AT>B[4_/("N7_H.-WA4(S!0#CX6J L/%H-XH
ML%2!C__5F1[:I(CYKG>/JN;V;LM-]0IDW3ELQGIQ\> :59**$YLTPBO0PUMY
MZL<,/4"_, XAJH?<)\LJH1J'+C%?%"HC*M::$%$"&.IX\O11)7U.?'V'7'3E
MZB[?LR'A*<J0CD>$2;WED:G^4W:U)=,>-</.F4TZ(HK\^?7-B1^+;1R"?B P
MH1M!@)$#6XSY!8 <[W]STHMY]&5#_/+DG2O?YA^Y2["G-CR7O:KK5MLO/G6-
M9MS_9@5Z#JB!W1I_>Y(!\7>2M4??^QR6_$MFC$=H+DRNDX:%(NL(#>P2H^[(
M)D1CYG:Z%('1;8(*8:W?W_DQN&L=2H<-QVA^W?2LL_"]D^XJ=4BAIA=ERMV9
MD&!Y>_2<!X17&]D'4O47P(K6/,SS'#\-LD!O=-P3"U%W(P4C;BZV1V2JTEM^
M8.FY]3ALI>)]?8/PPX=XN,5!4UV_NTX6<-'U%:T3%P4"&Q'38NBPN$!A-L?.
M E?Y/C'D*?>\0#VIGO-.\XJ1:Q/D"Y^7$:Q:>:NW6XR]DQ)EYB!EX=)CH?H(
M>[40\8&S2S/G E ^?]OM&^3%[4ZB\;;00*1K-*)F$-[Y%@\JPOF:8LXKQ+8*
MSJ^G;/H<)4HE6\5 V\WHLQ.9>.!%S_SMPB\M!1%-'!PSU&ET+CBZ[;5 8N_K
M8VRZ.<K'E#R [?JL\7(:]G,E1&, ('"MOLO:?3A55WV[<7]IF*]U2DS69::A
MM2+GC77A$&/#V3NI5J<>#TC ?>Q!?=&)N><@2F1-JN]YPTCR34-G19F;+[07
MK^1$]O'Y+)_?P%/788:"-UL<D*X,G6@@V9";<V%+_#=M+?#*<9MQ5-]U-^(!
MS:4(CI! [DM1KRK :: 072+L6RZ<=-2TM6MV\!J17E>Y-%7ZY"^Y3_C$&MO,
M2XA#GYXKX]!=.YC=A8<3;;?MVV1:$)\-9.)R3&;ZB=QS1:NE?SH6<(0=RX1X
MSE),/!!!Y\?$L>IBCWQ!=(X[R B-O'$A,[/Y7]-*#;>!MM17'+AN8"T;44#:
MF7L!R,L5YY"\SBPS(5BM)@(&YPX'4^0^B#M0.X+[GWU0X<8!+[WR*WPM$TIW
M<NMS/UK.F\:T%W=5WQ^Y0T1;/_>5(9'9X1C2^W"7>DIZP@ 3T0.DON_KZ)\>
MP1=@CT!4\:N>? O%5B8@5RZ_<3NL>CDRU+1&YV5_5Z*ER@?.D<#R;]IU20FI
M'[H?EFZ%4+J_3();5F@:N.!_CC2H?9L[/\(QD_/!EWV U<SMX&O49.N>$$2G
MJ4MYV;RCY\Q]:?9GVT3N,U;<]FX^Y]CW'-Y?ANX9G[- Q/4B%KLKBPOP C^@
M@1_;:@)<^9BU'9S72#Z_)=ZS54ULUK]_(LM!MI".I@[^V :$^/?K89EB7'/,
M[*?#!AJJ%KK$5$:]W9(ET^<:!F[*O" ]!_JCH==+[;-$<,RVN:9XBT\XW[+.
MRGE+Y0&%9 W%+KMLDJ<Z[&#P^O%WJN'VQ02VCUCI]^6&30;N/M!Q[060G45R
M:QQC6LS)Y%*;F/UA1G'T.1?$M^L"0%J;'99F6O0I1'M+97O<N#'JX<<D^BM"
M]TY_'K]=M)-;1 _CK8H@[)TJ-WXJB:#T0K0+(<(B-XQ[_ .#&Z?8BJEY.VF3
M[Z0^?]8(:WIF%<6EB"7L.&?&?*] ZIAU(YB9T52Q&0E3E;6%;0[\]2$/P'M"
MVNEN! _X;LG2Y&2-;9R3(3#9G6<02(0V[HP<POB<7@.I.)/:E,QNQ?6$I"M9
MJK3A%:TUG=5]CBRGLK8W#I_EI5+J4A\TPH>;^QXN#+S7,D/@B%]#Y3# "#P,
MDXWJB2J>OA=0"@ERW8KC-F7"-65=G653"3ZL5NO@DM7^D!.]FQ"61>H:>0&@
ME:*F+'^;\KCIV5*2)D42=88Z*W%B<"2Z4F1U*+B-?^07EKAW@<U!)F_T7H+>
MYXSY*S*_-$=JK;D[S*R._2DG.45Z@;9SI@MJN-/%_ICB7913?0,%#"'JRD;=
M_4$MD%-A+)?#+&Z'(:-M[;,%O&UH[&UMMOC!S_TYZ\7O*=BAPW!L<802T+T8
M M3&',!326I&T_M](C]Z$)/U[?G%'GNFA'&ZFVO$7@#L6N]HXHP]T7 *"&JT
M>]H[;GIJ@<]('+PD+USL\)(?\_U#N*J-<1E>=,QK 7 ^PLUJT*50&!_;0+MP
M+ [S2!0MT@Z^(9S.RU=.&&Q.'0K5R9\^[VE3&KXYYFPU[N+]V394-WF)"?64
MTB'M6=]LYY++W7/Z5:?H5&=#^?M2R\?,U4;5OD]PF3Z(K"5IYK:3+ *0!9X:
M WQ=!PKG8LS:>S"RLQ_0;.'0HE]N8::^.SG(JE<3*M]OEL0MS)@N/Q?[?B($
MZHPS<\*D=S.96B1$WL!*%\YG,^4RY1+=D)NS>$_YV9?B=DXX\?M1%1*H2@)*
MHTN14@'[VE2LK.Z\7)&.242NS8&4)^1.AXW7+6K' VS+VX$;%63Q$I8'FX<U
M9O8[%1,9#]2QJ1D*W"SV37:=B.!Y]E$7T0H!K%VTN=.3V3XRI7'_((DKO$F-
MT [9)<VO1&SC.&NDC@!*8','2_9SK;X4!:3XFM'=5G3=\%W%MX9WM-[L[^YW
M7^^DD^Q?ZX5#Y1$C;;(6($C!JD)0C9\W:O7C3H4WN5REF>Z/M"E\(NT1B;';
M\H.9-,KO5ST05Z]E(V'40<.F\6G8"T '$&PGG94M[S'\E656E$<ER#GD0Y]B
M1 F<"])XRMI>5*:NGS)1GFRT7Q_3]+..T]AZR5\PKVU@Y;\XT?#_2NO_= %(
M/"P_WP3VE?\;QN@_@(%%OP$=[OYG^47_T?:'#'^_X0RI'!&:L'UZTS>3K++_
MGN/OX,7IN4HVYMS0\O=Q_O^S0JO_:69!/9T+P..%'=@]H_6BS/-<Q/QY2,7/
MWTY6A*=AO=T[9S[<)V*">;]/_'=C* RXF).]^U1)^0+PW/;RM]V)_M0#[C^6
M23CV0+A_O0#\LM 8/5#ZAF"__$2MG3>68TIAUDY,"A%38'A;GY+G6=HA4)*T
M_A,X60![O8=DFY1Q$FJ(ZZ^$FJ=K6NC.Z(XZ2\5X@JV+UF26V>T9T(I/:V@3
M2R3> T(!QL1JUL)22T^D;5J7:K;<YZ;;C?8_<%T 0#^M/HV*5GJSKT71FDX_
M&.F_#DBI>TH'(<*N&8JX=O@O-Q?,S4WA I=/+>N<IQ\ESG3PIZ'D3>Y%J9/V
MT^0O_5KA_"HKR\^$=CK>)"F'0YR,,168ZO']\CDN3$ZBV<),"QTCWZL9<\+0
MT*&JC^L'L%@#,YQO^SPIAB&=U \.\;+4*E-Z0LI;FX92@U6+$(;;'W[ ?:4:
M(/CJN!O=2VDX7E0T <MHKCFN"'H^]N%R&58F_1XRRKERN<W$9DQTQX"H[Y5/
M3YK=C'(ZU+:V92_UZHAM6W'.3O3J#1(>ZDB(5T"T3^YD/AC>%XDY?;_Y\X"<
M5VRLWMB!5L[JE?]B""FGR/>22HW7.:MG%NT>/FNSE78!*2#+H5++68NYAT?,
MQG12U?W7^Q6K^B64^_@RPJ-%*D3LHWXO3@H)X0C:.EB8I7@MEBGZA6S:^JK5
M9XH? [&%#S7+OCWS?&]70ESGV9!.[NNGM$'DTR\:BV*Y1\HBH&C,]YXJE"_;
M/SQZT" DLR0-KM?L.AA_=B5:L(+HM\7M/>W;M66LA;,KAW"-LVONMS[95>QO
M3A!K&[XYV,P[U^SRY2L[N^?[O=#H)7#ER^K&:-2\<0A*@$Y#])'A</#7YQH\
MH=_5--3LV-PB9(7GYHZKYC[H=0U%-D5TZS'IH<2,1KY-Z'^.EUN1D:CF*V00
M]&#-7!8&R'U9=#>O8S HUI7*R;UJ4WMW[N!E<114OPS2:91B,"[.=H@=,P@0
M-#34#U,S)#"\RT*60S!I9,%@J"Y,JB[<1R(";\#EEIM ;S=A^&METD[4EG87
MYG0C%^P_O &4##RK;*_3O1*:RG$P=%WMP5I'8>/8YLZ>&:7BY2<U)?F]UCBC
M.PM#_ J#G[W>!B8;_QC;&_H3RK_#$W;,8G0!H%=^"+MR^1U:0N_^66*!_VUP
MW=3(MU #;,T7;L8@L74@,U0?R4T#@1F.@[U:>35_JM6GY_&':E9I>-M_*=AL
M)_SZ\KMJ7+.<] 'W)A8KZ1J;30BE1#N5/)G?,Q\![]QZ$:-(]R)T@#QKIM-Z
MNNTA[L/BAE^++Y;""5:358X2CTH_VJ6F7F_CJF_BXAR_[B*Z[7UM;["ZGPD6
ML%+IT?C80^)@XHMX>!S&=;$X1(F6;\W;/==!YM!@B.8ZW[O'?K&-*U>/:#?M
M"2-QXE@RUT@N/EP^EMY@K*@:XY)2,H3<NCEOEISF/O/,QF)!8<7!06 O?%>2
M-QC08Z9BAS%&I<>KW R:]#F9+PX(*,0#)_#D,!ARB.+K=LSALSIR020B2VEK
MK]B$S_OKMP>KC7V.^9B(Q4[H\[.W+:Z8\!W+)DS=<@(ZSG3((.O;O#R7X?F/
M@*]CZ$1&R%(T1(N(YNM=GI![=050,EQY?M!D%MW/G4M?*,9L1+1%P'-E@QI9
MH<+N&^5-+@,6RQ#QCE-:>C+%\H8DON.:_17@C"):-N;6R-Y]7$"9^>JTZVMI
M"SI7AHUZ RF7W=EUIA^=10_6[U$\<54PYZ)1CXC2++\ U/7&W?P1Q%N7':GD
M ,>Q=[KC[B\?==:L^HZ:7 #LG5!&5^BL";?H1%_0I0V8@ :@N3,9B^>20;TP
M&CP!AMAX&"J!!75S"=4W3FQ*"^T_P\M;*1VETZV/CPQZ\Y429*G'U4CP1W;)
MN2;2@BS73XH:, U(SK&M4<=LVA:UPLDJ4/5DWMQZ R?M@\<E#T2[[UV_7]+/
M = !^,&"E<S0W#%<\IA;"27FLZM;BV=,0\;8:I.O/Z(.RC/5=FN79V(+K):S
M'JRE@)-"HV?/RO FY5 A3% 25E&GM5D;2.KX>+#"(4ES7N<P72GJZ@_[WF]#
M=$W?8_T,2 '(2=E8R-YB*$Y##V<:Q .Q?HI+04[QC1WHL4^O-D&;HIHF*O-?
MMWL<5EWSNY$ [I)(E&"YO4)PCUE%P 22WW$!P.A$X>51N.(F;&5IGBH2YUSY
M:V_;='W;NZ$N>$8 6L8?><=F-];#_2ZWM<8-';8^=F)U@M0WOVC\:1S&5.^.
MFJG_J)U37G*8'IF6H_CH85X6-JO7=L=X]6^F^YV&GU[NMS<K'O[!TLB\_%_H
M+X!G/9-Q9R7% LOUIL)?;#[O;,EGYRSF-'FC29*T%9NY&.\2)?L36)IA]@[K
M<#I8@VZF-D[,0DQ^\[BXM9]SQ;:SBW/W+L_LH/->5XP<F2P]K8O\VJ O@B:(
M>Q7(@&<OPUU2"!C\D-9LR>R_)Y5X7/I99@Y;_>D7U6M_+_A[J%6Y2=#(!8!+
MZ2H2?L5,S1T)"VOCT7&RP-I6#H,I?S[6XO W+*?B\UP.O0U*962@;U[*H<Y3
MLL7>N9Q4ZIT695L4Y<N%1RW8:SD9EJG@FZ9FS>FKD66D^_W6CK]L8B?T0#Q!
M(S "O!!R)P9&%<0?"9?F9MG@II52- @LF9-"?9\D)9[:2L1_ZGEX[;JZEH!
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M?17F93-6 ,F$L'+P ]M5SD(RU<*WKT*VO?J/V6QMC8CH*=L_1WU&D\!B[:I
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M3JPC-37$Z.C!&)0NN8^J]&:A:,^&U9L]=LXRZN3^6/H0*L^,[,/L,24A5XP
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M*98ZBPGA;1QZKX(8L3FC52@CK%IK:=O>KV4@D-W'9>H'E<]R5?[[T5+U.V]
M=Y8LC=_XI5N$K]5N0L_^9ZR);.E%JQ",XOU.GVY4K:LPC^%!G$5Q%%4._LY5
M,]U\8;?;H#LW_!S6:M,$.&C(+A<1E 5#_%I<A062#"0S"?LI?3 BS4DV89I\
M/M#\CE;[$5IT6('R*^")8>(OCQ>L2[=,'=VA(]'^9CZ9]95GLG4M[2/^DSC4
M^DB $)-BI$U#4A(_J3 C/Z<J[_-#6]OG 2$D&_K&TR#:-DZ(*]INRZX4XH_6
M2=&TN#'@R#9?3(E6RGCS@MR*KNSV#-7@>K&++T46E<CWWI V=NA+G#OZ@UU[
M$%LKQK(<*1>WJN4ZORZR\8(UV.W7F\ JX+=B0-(>$%SZ<G^%Y*&;X[K8YD^_
M6N,)N+9 T1KIJ*^/W7<IXY^P6KO7;<Q0GI':5D4]C*+%1L9X\DOMGK%M0V<0
MB\D#V\P!_AC.@K!C8HX,%,P&'J'"B<O$$IJ,0K4O35P'$[/5&HMNYFP^,UL3
MJ\=3<6^R.,-)>Y5%\E@_R%OQQ[HEA^PWKQ4A/H1]/6[4H\MK+6^_ %#AE<O.
M^RV5L('CV<NXF$<_*[:VQ)76B-/B^#];?9+I3.+=O:=T2G8$H@WZ'G3UA]3;
M)[W(RAK4V16=ZP(@9@C,A'Y>:3#Q8UJXFC':*20XG4+%8-#63"[WOBZ=+OZ[
M,E.IP!A\V6C]X(=CIET7@_$8\!K,SD+V">Z1$D@VU*7MQGI&V&:BJ0/Q4[8G
M9NWLU:R<1PF9'C+&8F/J"G5^0UMJ&)?>Q9WX+?!^MH*RP-,ZYD^FLW)^8EHO
MV#@[%4,2;WOH4I'RV6QH2'6.=[6(@EHJFUP:-F"M? =U78L__1)$1O' ,L=#
MXXDT!?#25F$(Z:UML44_W@:#]U*Q!"14U *<E(_A^=(D+S"^FVI%K7FP DBS
M.= Y\4"(O*].XY/,JOOY*-M^' QIW+Y#BM?&"(0)8-1Z<MU13@\<^-A:!]RG
MLWR^,ON8-]O0MEPE(6$54!H91.OT9U!N\%6 <]+O^#I5;*W-!GT_@Q5!C8V\
MYB3W3! AO7JU62>'/E.,=;4OM?A<U0R)4C9%2G#=B^6P"! ]7@/9KV63,=*Q
M6D!]2_;8YMK=+F^>VT38]W:$A5[<-:X)^ZZ7YC3]UH$%Y&WML9A=G:PV:^*,
M5%3PS3&BI,E%^G EM@.!2%>*C>$$F73MMO0'_#LF[YGRD3JN&N/6(^+[ :><
MIO>CTYAEX!R;9MO!K 3Q'A*]4@)AWJ72%X!-OA'Q&3.J%^>#9G:RBE_Z0.+L
M-<'O7[25CM0M4*T;G7-@G0FD3\7#@SC#!V^-D!J):1A#^6MIHWBIOL7MV=D+
M/[Q\UJ<QLQM!K<+C,,^'O99:ZC#]H\WB*>7#J:TL9%?SU*=O<F*);A*#[DAL
MG<B>1JH0?\W&K?']FL#*:'=-]#:XJ+HQ;1XE$((2D.AC*#,<#FY_0LT3VD.I
M8;EQ:H>SG.A$L&]O._=,UF7*>4N^ C#.>,@N6XL&3DZ$&?O0TU0]O6XAXLG7
ME[P$YLX#?6K )]9= #Y]Z-U]>,+6YO='Q#8NR_4"P$NV@+(KU%N\I\9@G&C_
MM^Y5&0<<@ Q05CBD:*]3P2ZF5DRC*\U/5D&YJ)"B(=&Z$F<84ZG<[<E=>Q2S
M@R<\E<<_PC*E7H\P&(4JPMR=).LI#$BXK1..S(@Q\'?GM_#\&$2[Z^0% %D<
M"Q7+FW8X%\2 =R+JV"V,1J:,#I=-MBMRFZC0RRE#9E&RY73L2OLL@-.,_^1B
M^<^7S/^>PUKD#Z!3Y\N_"_ZF^V?>DX+5:,\XBG95NE,$:;[_$ZIEE^*9/^WX
MN-_OFL).V+,F]*RQQ*D>Y+=$9\":[*XA6H<G+-[*LIT-1TPU(L^[;P<?RET
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M8'P-._T&6?+L0^GQV(2W?N/!P@Z]0!Q.WC\WFG>4_;]1R0]0?,L):7TR,91
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M+-:Y< DV[8X*;"B=5?<N-OLMT8U&6Z5]FO"BMYJMG4W>L">:4*@3V]W.R[L
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M=!L/OF8/ZES?<F9^S.'"DIP<;,ZL[,37&+;$)=/4DS)7N^UUM.M]=M>]IN+
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MN1+<$%8.]B[PD?F,42V^VE_-H^.8F-YLJ"V (OS_:.\[HYK:UK6#B(BB](Z
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ML7:\7(D!@Z0U8DAX+JL] ':4/&Q[KIZ8'N:#C!8\6486'(>/?;%C<A,SCZ6
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M'XT[Y6!86?,1RH8QJ]"4LS!JU%2[+W%.BX][P=ISNN"XHZU<6U#[V"57 3X
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M/!K)(DDR+2F+.9:C^*Y&KZC%M7"2I[ E7O^LZTE]<$/:PAS=K8L6!R+?3(!
M7';!_!FOO*&]+?ZU]":9CQ6IH1^+)J>Y[]F_C-3W">$6T +3OG3ZF/[KVG1^
M_1:"Q<BC5&HY/<B#G\UXG?UJ%(EL10%A1R@@WK _4/\UE,2X6XW=5$;Y3\=F
M7>3B.PK(YV TY]^1Z!^H/U#_VU"B0XMZ"XWPF0=:%]LDNB -AKMWXMQ=/'!W
MH?.ZPM8;B0HG\EX2Z-AI*!/_!U!+ P04    " !$H 1=BJ0E!&4+ 0 I80$
M%    '-Y<F4M,C R-C V,S!?9S0N:G!G[+QW5%-MMR^Z$!"DBM);5$ 0!)3>
M8WEIHB HO:E(C8!TI"1*ERH@H%01$.G2.Z$C73H$!!) .B24$"#EY#WC?-\^
MVW>/_;WWWG'NN&/<;Y'G#U;6\\SYF_4WQUA FB8M N?O:6AK !04%, [\@]
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MR]O."4@;H-F>N8_0L0O*((4P?T+[G\C^'K"@_UO(_@GL/W A  9*"K+S*%D
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M=VK\=J+=8N3^OH>*S$O?OO>7*_S\5(T7VR-%2IAOB'R.!/Y<!*:X'<D?^G_
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MPXB*UD)OBW0-<\>3"<.]'EMG)6IL##S7^K1G#=FGVIOBE#\W7R1R[?8L'%"
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M(*0[JXH$1#3=9IP*;])W5NW*.ZU-HZMR,Q?<H=)O+\ZNOYP;0T'I%*?=@&8
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ML_FP$41[5\!*%%EH/#8@QSH8(FINL11HRZ5>"%-N=GKIM3IVL/)KLE\Y2=N
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M^U/+ICR4V;.*4&:()-'CRQ<EK9SE;6JS4E,BKL;QZJW,U*Y@WM)\^"_<)R5
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M?*N_J%C(HJ<K6$;3N?"[L^K4=P;GE66'!!^0V)"%@6"[_I7:JO%=TV5(;W&
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M0@588+LE*+I:B'5_AN->G:ZNKI9/K< +>S-^'K1\JK9BJO9;:M<_:06)EQ,
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M\G_!L><E]Q&2->P68+."@"';ZM'WCS5P.^_4(.]IC++:'&=]HKIA8VT]R.A
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M,G:N4"E'WU'A]BYCKRSK2:Q0W>R%[T#NAM^E[HB?GD;+I:L(_UASB*"I-25
M.H/G<S6FF (S5 J1F78@S86(-)QE<QZ-+F>DU!WQ0TCRK>/[WPG95%?W=AP/
MMAS]@D6U<6#"T$1(S2](,A+%-3!64C;2:+YE1W8^%DS<7,DB;E>?0_I[")^
M\>O)2Y9F17!Q+VMX +D< PCQJ8*ZC3:WL[[I/.T[PN[^+%+#1/M*KZJ/M]1U
ML]Q5QF0C:8!\D-A@N%=Q\0UT[M_4DR=@[3RM!&0N.>[@D;GG+ZR?<\Y1V]SD
MEM CMK91Q<8$^;WO4_Y0SRMF9B*R*2M4-YBLXLU4LJGA.^7)BS99U%&TW!WC
MZ^1""Z_YEX%S-!3V#8W[POXD3JX5??K-\<+J(KU?DBO>C>"5F?P7&8XB" W*
M-K:H"OVE/A2N;D$M%BVCP9G&@8VP_UD01:YG<#R?'OZI5^BSYT(<9=3Y-TPN
M29;7$++T/3M49_2\[LB%ENX68&HE9+OB!4I'.?<X/P+?^WMS]'JV")YQ"[B1
MPTZK3JYN27HD&+W_DZ,RQI6C 9FN'G[S;34CVN/")U-S[&K"GF=PA/&D;/%O
MYLO&B3-8S)UX[1=0:B]?-K*OLI?JF*@4P8ARQ,YJ<;^LSBN/";7Y]/9Z(HLD
MKV6OBT5FMNTYEA63+Q\E^JF)2"P$M)D22Q-,Y?/\\>O '_?7!Y@!^_@^-G-]
MK$SFF-ZN'N&]XZ&*WV]0B-%QQ6H\#VL;E3J?#S1>3 (![WBRIB!F94 6YED/
M'O5V'K59XOM_5X:43J)YC06^!@\%=V,+;&4V[Y221,$&J%)=%K&1F:2N6)BA
M-N (8N<2O?9EU0-9D$.T\Z"37A;$I]=2\Q!BIX/3B;4J*T:3D4_;>:ID0TG'
M-8UW?ULR&5Q3PSX^_BE%#.U:A;PF*UJ@&JU9XXBSU$Y1?DCN='0<-.9[LN>,
MD$8JYH0VO35_WFBB%[C GJ.GM/:T5ZQ\0V:B[ZTX<YGX+WD&+ BUIYKY%G73
M<"X%J;X\<#I'O\U[B],*Z78L#AI<+]20J6OE(NQ1E%@HN\C0D!1W9&G-+5F<
M:I++1'.%'[00H4W-=E,9LHO&\-^;,$,[^PZT\E1464#Y]ZB9: :V?NZ"!FX!
M=@UG%N08K4[S9VG=&18Q(NX</7<15C^%Z#VW[7?F1XKM4N/6!O6-Y*APA=1A
M3M87M"B58<I(Z;@#ZVH-B449[?9TIUQ/=IU"Z[.A8-4_24;F4ICOR+@('81\
M^)GA-'Y>]4)WE3*Q-F[,@HZH/MZJ]3H7[F094>KL=^-L9<=',&@,$+P4L*H:
MX/4W4E=#Q/<B\%2>%&-U[O>/\<R9W8E@@ZT^6K\/#5%:B>CEP9E>PX_5!TL\
M3%GQ+YG]O.OO!/56=WOD"F&+)<TTE&O"\^U.1N%TW<HG6L/9^"JE5"'5^R^C
MCK."J9@?P%):%-<U0#VI&;*59;Y.CK51BE55X4H)Y8*Q(0_O:Y4Q5:VS(XNG
MY!YCHI10+3DL5=,Y"ZJ@/].?M7N#)C< 1-RJ,=L=SS;>>Y25IAEFIJA,U_[9
M@ ZHFF@(>"3[(O:^/:\H]R=:M8AFD<"$%&'-IR":P2 _+>)=8O+Y F7->/*V
MU_'? GT8Z1(AW_P8&M>6A,:0LBMW[#K*..%*,2ZLMC0N/':M^4 *?)_RMZ0
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MG*K,NJ-HK3A%V#IO&;>@;L>?C_E3-\*8.76T_U$D'U;!K6EC=[^QT266TQ1
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M#O+X7SWV;L1EQ^WU8TB=ZT;(7H3U-CO^^+UH]PG7352B4KLB^B6E]<FKA5J
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M[N8YFC3=F:;:7EDO<8F?4N ,"GEL9,WV@2JA@9A% L:8ESCT<\!(L:(N.76
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M'7LZ6XY],8Y]@80],#/J@R' XDB2;$QS]<P93R/?P2%?I*-@!*YCS,SQ0O@
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MFNRV-8.H(+T(2$>I4@6ITL1"%5&17B+2B1!02H! !*1W$! 04#I2(KT%0D=
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ME8U6P::D4T"/FBLRA*@CW7A3=8)-?K=*/"GY>#5X55'WRXSBS:5XN<A]*9[
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MF*+GBK-;;$[H:__R4[%'W[U5%-\;=!![<6-8BP!R19]HZK<:Y_%4^[B/H(/
M\U^Z'SYE62O<.F!95Z\Z(@K"<' U,5@'XQJLX_'*.LQV5QY\1H/#]Z21*Z<
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M]5RQS6H([\CD$:-5.Q=.._FN:+@._[/^#4V-\U[G?> 9.Y@:@N.Q(&1'NYH
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M)I3A[9,%:PP#MD_Y]A7R$17G9=B5(BSSLC(GC,6% _9&Y>H25KVK]\ZXJ_C
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MXO=[;W,4VD?(O#SLT%?]R_3L(%7 (QE5Z*>C6 VD\J;-KU'#O4%$]5&Z=[_
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MM0"<H :JO:NU9R4Y/12KYXYU%$"O5 KS.<)]<0_Q6H./?MJ,UK[C]5=CSB6
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MJ \V/"1W)R>-EQL5+9)U\G%!I)A,)#G8E KXC$+(PA92YO?\G"Y2 956JU3
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MW#D%E^'[][0W%W,)E^5)V2M)5,"#09J -C "EYG?>M>3U!-[_O&IKY>^W]4
M2"]1 2AC/"LMYT426MUI7[D#^Z8S[.7KC6??2JS9V<O."LI8_:+4S#_3HSG^
M /=\,3;5,V?#@PJP.VL>6F<P&;  JT\D95IWF9T<1M!\.0\>6L&X.-R!(#@B
MF+3T%A*WS;; VY#\V.UY]WU2>55!QMZ1W-96[YRPUT!GGVZ-A&P*.,/79<GL
MWP\P-< (5Q+;PPQ,<5%O<<8FX?IC%9\2[XQ+OCX_\UO?*$I?[-.C"S<.X\XR
M"9R,X0W(J0ATFA8(PZ9$X4PD&%$!M17YC?NP:DK?LK=NL]]*7[/ZT#-I%,D
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M6'ZRJ=OF+OA^=@*Y)*W"HA1.&\J7,@D5^$4ZBV#5<BZ=60NZIM0GEQ@4)IK
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M[0B<[\EDNG2JS[,S.V>THNC/!=-;=^M<H_$A8XB!%>+/',_?PQZ<G>9%3GI
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M-9O]*!EW#>\",%IHT;(GF,0%_I[+Y[VE=3//,UWGS*2\]^?,+5H.ZRZHXK8
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M-[9ET0LYD'&R3'1X<,(Q6?M><7T8%:*?OC=S.*5-+H.8;9DMY)Z#CB!JRZ@
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MZ LL%; ML."A=1_=K'V[]XYQGTR<79EYK]S!O8=/$Q;Y_>:U(? L*L K]]A
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M.$.$F1;!982YC7G+:#ML8/S7C7V9I^N\=C)\'+[96?0_[&Q9+O%W%-,GJ_/
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MORS^I )L9J!N,T-FYY'A-'>Y18(M)O*'.H>I=D.%*%TC!YJE Z;,NUM*,U3
M8_O@6.+LGH(M=(,T\E)]_0=<7^"Y)S)2\UF14*L/Y9;_M /9R?>-G2=)44>#
MPZ$N01FV#;]T\7B%76IHICY0=7M1J#*'O#D(<P>AB.V(FI6\\FF"O2E21F+T
M8HS'$)Q>H92)Y?3,<O\QZ/*0'ZJ%$0\C=./ -!7V3TM8'F2Q'8A-@+@88L^7
MYF_ IE4#$=[W:UTM5_J7Q?L!\Z("0R^L^V&5OML\?MA3BSV@*8I "PX64SM5
M[JW<>F5"H+XIPS8C_%07*[P_7TK;0-Q$<<<SP&HOU@II"EM@U"DF?_R,4&_A
MHKFC.J[B%>ZB,!UF^-63&A:I[ L-1)7:[NS9\$K^8+'LF:> <(-^OQ\'\)',
M/1R_78-;JEY;=XG4-_.[8*>9]31KOG1_ V\O7R%CY=%O]^*Y'V6\70/0IX!S
M=91H12.=,-P]I];XJXV9I WFFFEO'LC<Z%_9PZQS[U]IIY.^^'S#:,?O%W^H
MK(,Q=-"[>8VML/%$"*Q%\B$W:+%@N3#:]>$M-PH(4?OW<\[X\'I?0S&^E(GK
M_Y2>(:1NF9N^#[]$SD L? X"<>J(V4,8,:"H!6S]&WD)HFSYQ*=DM?CA&_3O
M^HWU?T(8_8[?6##X@S7_O#L3MK2KG$AD\* "3C1N'SR=#CGIK>R22Y<8,,X_
M4,6_(1>T*!&5"+XFDRUF+J5@U 8?S.6M,HW83."5EE\GB_9P'TBM.YIU@-^B
MP#W@Z!>J<0?V(0..\O?CE\*%#FYEZ/[X$43O9MXO$@?I#J4":#-\CE!.!3!G
MH7NC5-@)-TE2B_(U&SWL581Z$^)S#NCR3*A78R""?SA/92Q4DE +050R$=X6
MK6F<?0MS0<\:WZL?52Y5\OW2+2X2<J7LRO$9DP??6)D&GBDY))[-$>3A#O!!
M(M8T-UW6,J7WK;__V><5(43?;AO+^LZK(X8K'\?U%MBL74.RB/Q42"HP4S02
M?[+-7%)/>*L%"/C35M*TQ=D%IX'L!/*&\CA_FAE\GI;.:3OSV_;W^E878*];
MJ?&!(A/P,IVX.[_&@'2W_HGWROFUD_W_Z#2MP:K-N@9!%N0TDNJBMUWG32PT
M+8U/-=T*I5T__9RHMICIV"TVX,UOT>6ZE+)I\[_0\I[A;/YQO'!42XW:FZ)H
MU59[)M76KJIJJRC1JKVJ=HT4M5=1M*C4KIG:6VRUMQ KJ*H2$B-"AI/_.=?S
MXKQXKN><%\^+^V6N^[Z_XS-^WSO?X8@7+^;,YMILR1V7R"<I[@5P#2U=ROUD
M\7&;4&[PSAIM&-^MME)DVO#I<U6+TR</U(ZLI/S!MP75;M;L[NQ :E.('!PA
M+M@>//< DE&0%_N@?W[:S<*A*>_!Y7KI-(?"=/J%$0%4,A-5R]9"]EN?S_YK
M-A:_.&;\@:,%G1JD2KA7'08T2(<RI0T,$V+'ESU7]#UE^L,?\,GA!FOIF-A'
M#K7+=O(":=Z;JD*8)Y D,%-# A56:/U99M8KOZ,B-A=$ZYLC/>91>Y>5[EW2
M].W2S W)[D=2H0T6=G]23[?[890 =\-BWD\DGE0$CU3)&26)Y?%?UO\::?!#
M)<;!?"2Y4FWLW5H=''US'8JT[WV?U["><-VJ!V':1A HJ^CE\)R@,)MHZH!\
M;YF0T1$4V31HY=1WL*#?+R@UE:TWHQPJ.;U/)8GVN^;#]"S&T?R3=^JGMR9!
MI40V"[(A;1)H3P-TG*?Q8[WP1'T^[?1SU=D5TJZ0[Y1N""=!A])M]T*L,:JX
MK_,A;.>WXH)1)$GK^TI0IR]K0QR9/T?7P>.LT:.)')^[-H6/\AX"^4IN/>*8
M+WM9,KU,F(_'6^,>DMJU((0'1!?(-7"@M4XM9L-J(E1[+/^;8UT4#4=;76VG
M32&X%1J8W?_?YL\KTEC9ADT"E)'(CM$*D[5V\K4>R;%.:&I'OK6]+>SP2JB0
MS? R&W>Q[P7 Z;5V8:G'DS;$ U.-AHE)#:D-K\4Z,OT-4)]0K/\:,_EFH".(
M+C![WZO6>MDZ3N3C\C&+(6-1^\/!J+,<Z;M=XZZ0I1C<-!:^-X5ET)ELOU/\
MEQN7=?ZB(^,D..CW)U".R*N'/L(#+'Z7M[5F2??@C4_YYG9__W>$,%T 5]/R
MICRK'/[[I/$&Y"I1-AZQ_F\YB-6-;R5C=DAB7-XI:5K,A[3<J)B8ZS/SDA+#
M1\I"/('&#VKQ?IA_A#XAUNI-_X[I>3I/#[1*KJ=N;% Z#0KE@606RY[:^O(Y
M?8OX/*\C\IM0".(#>?("T)@5 7),8=]IY8X[[@@C[Y,GT#7 5*_+J1]7AZ(5
M'L:HWY]D3?2QE2-(_L>'RE[Q:^Q51&HL=6^FQBU8R*&.2U!)98W(^ ?HK1?%
M3@[B+H!]0M<E]5]#%'2/"0F^ $298D&][P.(4E! X A:0ZV9 $[P!36]U"6<
M<;\&?6DSWQJ_,YN^6IU,X]U7KEP87'%P'D=!V@-MC7-M4].&]EB%?F^VT? !
M'AI (N'HN5L/Q!F$A!B0<CJ9=P3%.F>BR&5E^@(:GJGNJT\,;R0J.OSTUXM<
MR'L:\.L,QXRLP\%F0S@Z-6OQFNNG&/?,C7,)?P/$-4_SP$_BR(^)Q6%V/=*L
MOZJM C4:[,<K,_:JI^'YCPR%0LQL.0GBY.DL2'W 1R^Y!A =&&_Q[.<;R^<O
MBE2R)+O0@3<=> FE4D.VZNIC@<\;",$A]_%0K/Y33$"75PQ.4(+/'XV,KA#U
M^,H:4=_,UE>3__I29DANY,#;JZA=HW=152,=R-JS& 7@/Y@XJ0#D(L=('B7S
MSRC#V!?^(7"M46L+&R8B/$5^H8EGK\1B[T1ITYU;C)'Y2<U >;S<1D9,9)@T
M492@U*3) (_^GFTI$O?EQU<.K1&%2U<UK6L&13G_6[O] "@%Z2G!>Z\GW2>S
M7 #H\)3HUT3N=<K, %<N@UO\U_CV;6 #BG]-W!@%"FTY_DF5^0<3^[:*IXYI
M_X] V>]DXP)01]NGJ1V,>XT93%2^IOD DQ&SX"F[+Z/DYE7K@O,>5&J+UT^O
M>1N5(IYF$E*U<8"7:$ILM]_D3^)&3?3F;_ 4R&P9![OX!'F_^X#Z)8.2-'OO
M)W8\3M<5B_HW7Z$V;:7;L;HF_\?0-2QV"LQ O$2IJ323#;!@-PH:O\H;TXWL
M[]MUN7[,(";?KX[2UU)(P[Y!>4K?_?6+6L:VBN!-GK:]1?I*I%LGN?5R:9B0
MYO/+*+K (MJ2U7PX8#CV]_W<'_],IS__?+;Y7.E-0[ _87"TRF='4NHH$=)M
MU"F.;^O!):' T:R[V<5)!6/5KA*E*\N6W>(W(W39]Q]0"RD.#4WP")QO[SD0
M @T)>H'1VSVVXE-52F#V04^$_XP+14PZMND.G%S=^LI#W78@+ZI]9SQ#84_W
MMD::E<P)6_9[(3LSW4!3M!/AV0ZH]N"C-,RQAHQ$G.@'UJ/EC;>BD0J';7:?
MXHTBP]->4"4;K!<_\BLIZ[:IS6FL/'65.E+8)=,K8\F#NBG]JB#ZXQ$(K='3
MDF+9E!\R;15OFUL4SIS$\P>!&<?@2) [14-S[PUNI%P/9.B!^6R.L18V0IB4
MV%8K1FV!9J^1AS?T''FZKSQZ1V/J]["U0RPWK0'=.3&:H31AGX4+QZ@29;Z!
MUAL:&P0+-PCYBMH960=7?B2K^!_EOHVAUUO.'!*@&GLO$\9+%,9_Q3+W@.J?
M#2:$R*R;HF&"VG/'L'R(T\N7'FEFXGF=#]QO\JN">(?1VVK*!!F,1;^@*+:T
M!WYM-T]V&O*SW3C8]6;G3-C83?CB[V6]-=E[-H'4T6)'5O88T-,MEQ5E_ 7@
M4Z&L?3*I$.(*8R"/FCF;!Y8:(/RN*D=_%<[1C^!]QJ?]L>(LK82.Z>J 3^2.
M;1+F=%##JV^"VME6:HHX5>+&Y;W:5??#DM5&9P'%1BTQ_(F.E_;R"2P'A"I9
MO2PH1?JZ[^>\L>:SOJ*W2I0G]*AZW1B<.2T?)(WB*N$+[)O7JE+VP*%EKN:5
MJ?B;!]-^3O2K3^203YUFV-"TI%S_?OVY?"T!-YW@Y7E(Z5]-PKPR6832B4:=
MW"%*V/FV=6.2:+\JXEQ[.=."?<'*6NN:I(#:$P3](./5+7UAQ)Q&6+Y7A0L.
M,9]6B<NZ(STY_.TZSZ5*[5AA!,H%XPC?7*/%SVP\+!KS*G7UW_UA\)1X:%,_
MUB[D>/?J!: D$@J>@7V\  CX4^ZH+H:U?O0HOR#0?]MPV3JC.5:YG1=X]O&<
MN-JPDCQ2-O51._.T[L3YRUC'^#8J"]V/,DV!LVYCG**.H:RAK3RW6MR6VIRY
M$,-)$5G+=8IVF8^!X W>_F"GI';[XA!M3#)LP\839;5C95.W\M)XX-Z/<<#^
MX ?:=W=A'T"HU%7:"T!:^":O_04 &BJ"?!CJ\ 7R-_X(FM*IB=\A6.%]^K+;
MLSGRN/&6Z\TE'8&=@5756I6?'B92OS2<H=+KWXW2^E+VH53:O)C660_A<8K^
M(S".<%J#UF6A3=9-D?X3-BV81FCE@G[A$&, M47T[1%>ZHQ%BDTBQ*@/>C8@
MB);X$8K7C!#D\0@>L!JU,HFS%Y#4"?(4&_#7YXL87=,)G_VD#HN_ * ^70 .
MY4(>7@!@%<RD2^^/F9?,<4H47ZRZ.<;_;(IH4KAS?BOGM4S!SUD^!X=/O\;$
M(E_+CUR*;#JO>?&L]W&T\E1NBQW\ETNG=?H+2+<Y^9JM:\2\&XACH>L1<,6[
MM.^5(-[P*Y9BU]#@9_C[ WQR*>WJ]C!\\)-(BZF#PB.9?73.[<W\T\LL.K24
M"Q!_QH[K)65W,H>HD#*4%_?:Y8J=6Y/3+TN4_/-^4!:LW.W[S.+SM>E,_EI^
M+4\M>U%-,IVR=_D(QJ>_9KE^K$BWBLJI?8MS]+8#P\Z\0NA$2WE53.\$(Y9#
MMA(->VRR.DI(B[\-XYB\71 /^/^ZI#1[H8=R+I"376[R!RF]NG;U"X (CJ*@
M;&L@?R]5A<AMG2>4%>IR/&7$#Y^2Z6&8[)[#8!<M[4U%,04E]^?#,Y<C(U..
M8:[^4(J0L<!K![VK,2G"MW8S6U9+RPPSZ=MD,8:>^\-2+@"O0'3.82JD*K$9
M+=U"EW-<]J0KT_S[;Y4!\IF\W;=1B<F#G#@(NHR@$B(R W&"<;G]##36P914
M%"//<-S(9T7/I9T85?0>O+I_(.XY3WOPQNZ#_LQ\+^K'?!*=[LJ2]>F=1R8O
MS]VZA%C:-;'&/8VVHIC&"IJ:0IN(URT?\@K+:W,Y[0(ENUB7+73!.6L8(S"[
M*P[(BV_R_)IE_#-^_IPS%1YPO=NP^\QG?"O))^7LC[:NCY4XD3-KT&Q'HWM>
M2V9]),F@0#:[\?&R+EOGP;>2%<W,QX54%BYB)UW;T4$.%E:^?_\5>O55^[U9
M/$_2#2DCW"$O:,#[3,-79?%96$73::)ZOK/YF6%0B5AY$\_C%U=7<O>7L07K
MR7_<O>,Q%13"].H'QVIL'4/H.SEURW8:H8K2.(OW&3V#B[^Y]B*T4+GO:!_F
M.OY,!MOZ?&;#!P1,AOPB"1=T:I$RX*CO\T+\6A9"$>VO"O773;E&QS.K.!(]
MJK^]>_@"DJVNIO;$0&W@W;VO$$\HDC  KA-L6I<",;BT7B=:=73TS7RSI2MR
MN%/[WPG$%Z$[XS[(PG_*I-KO<T7_L>3N/ZFCA+X+ .8)--YJU *)^ #DN>^'
M0FM];)F7.R:T?3D$+(]B-8K4?T>][F-\@YA:J[D H-.+PV;Y/$A) WFMS GU
MO^;=JK3%CD2R1?S/IMC'J5GH\Y[6'OIDES<SZO*%31OK=K:]CS-4M?][+O4;
M@AS!$:?) 'P"F97YV@[=1@IW>86-6.WGQEII*MU0N&++Y>N%/(SJ0_V!Q4U$
MCL*-TP]^)D"O. B]W4R]];*2K4W4GQRE&NA&4JF3Q68>@';6K[PTZ_7_,DIS
MD=E60D6^%MF]6)@A-J KU'Q#/]+SU6SEYM1^ X/9VU(&:3/-H"<_A",JVUY0
M+Z".E3&"_]D)!RPRT,N"/(5IBKF%R#;@-E&97-;WX'MMJEYR35,Q]^S&O8Q_
MO_,B"J)I.D5S4MWW!GZGGGM5[R*]HI42JBQ>P!MGE$:>'HFWM7W6YS#^-QK(
M.4*\B1]<3TE"7L%1<M$B=YQC?:9T 6AHUU/^.F7V]9/JS;"W5,).M(EVT%$H
MDA8'P_=B9W"AD02OKO>A*1%^ZL]*$;Y+#'4LF1*8[T;32MY;",_YY4=,5W]5
MYY#IMK )&_"8[4DM[GR\*,%X?3Z_JLT5>(,\U):U-_HK?!#)VF?XH>ST\V:
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M!K_43RSF6. K4*7U<Z]-I%U5A#STG*'2-(N<EM;":5<9KPHGSV$1$7!4Z06
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MV(-UN3O4$+&1M]R#S8G4A\703SS-Z@L#3_^M$7G %NUX$PO?-2G;6@12O&?
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MFK%E63FQ-26)8K>X D/L#(7: "0("K2<GBN7BX>@Q1%KE<BP#CNP>J2-\^/
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MHF+FJSY3Z :EP;OP-JMF<10W"_7T1Z?10Q;Y6UI'T:F\ >%*D,?IT6W2Y7J
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M<X]\R>YOLY1?B9*]P]\;U;O";QYP9]F\>U-O%&7&*]YUOP.?0K!?@LKZ1C=
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MKVK+==/<4DS#;U"(V:4^RBS2D:?#X^U\+]KCJ9'A:1;?Y-_ZUW^-*98E,O$
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MR]OG $[R+W#3<<\;&[NEKE<RRW/3B.G&'@',J.*%>_ZH&T*%$WOG@(:1';H
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MV.S7HB5BFM*4>-JT:3Q$!,,"$+]@<XQ;<X:D]U#?3MD'>>J[JWH @*W'[UO
M1S(-QO>O-U>O3Y;]";^<3A D_PX" J%LP>V#^H7BOPNN?0E^*VTO\OK/#\[P
MT<#6JWY9W[^J"WD3G"-FK,X!K"HA4+9EFZ<.(9<$=1]+BQ*N.:5S>KW0^G')
MZ&K,=X"[)C0-!\ R8.X"N8@6H)L1:44U/P:#+0.4;LJ'W^\#!&B@6]-F%+Z9
M0WU)Y=7'+"]A'K(<IH@M\=NMQEMS.8&AKV_TO_%/3S>9Z;W_*.SJ1F:B2:#U
M5*<IP9@H/=HX(@ )G4IL)"GA] [$D,C#%=D(5QNYF7<&;UBIBS>:PC<)\M
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MQPYRJZ2]GW[N?:DJ(T3(CO/6'I-X_DY,"/0.!C+-/,F7$70785NJ\,@GMS)
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M(U;0-#JLUS\!)XW,9TS[>P_[_]>V;P\PZN9X<2SW-#YJT+Q.G9_C5WOH*50
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MJ/-A2HAO-_S(ROQ+MW\]*Q,C2@N&M'C\8&"(TP4&HM;G"7\+"YON0XJ#=A?
M#F2%O?%FG_CY=+&.X%'/[_4)Z=Y3@@/'X_ZV#4)&H\/^Z"2#?TLKY&07DGN?
M(>$/?8$7H@E;94<)\[7]E!QB#XU]F;.Z&!@. ]QJ%HA"?.'Y\-WC% 30]R/N
MTYL:QBZ8_:)U8T_($/B<A_58QX,\/ H#6IO2<)I4,V0>XE4U8"_V+@PL(D^$
MXD,0W$_M&[_[.V1I 4/JEW(2$=QD@9Y6(A% NJ(E>08CYU2&C]5D7)_0Y/V
M>.66[\[MJ"/./9.4GQ/R?6AFCX'RE:(G&"=TU?E[0__PBSU_</LWW/OBGYN1
MEE8^;^,3[><<<08[10"[L0^GU1&SVH%Z_[U^@7/HXFQ246+BK(Z3:FL_O?K.
MZ/ /;..@'S93R@TT8PN('BPWJ&I5+%=/O2]MFILK+M2ZMH]#?,NU:'&I0,S2
M(S'WSZ>U7'%6YQ\31)2\*Z%SB5W!V2TC%VF;O+B5=%Y8"N,NKWZK@$N\A -?
M67U9(6CPC+8^V"S)PN'>H+!=K[9J06.>E__I"_>J-!>M-F@L:7QJ8R'@$>XB
M:!Y%Z/MU@_P*\7[-K%!1%/0*B2@&U,M<:5@.J!,[=N8FR 1*$ @MR#]H2A[E
MKB.:%6/'=F I9C4[$;AU@7GK>]5]+D;(OS'/T-3>A9:S4;U.9TDL'QJJ*PP*
MJJU_*1U5N ZZ_GLP$'K1?/OAC/X%'-&0  ,KU>YVNR".Q?"[;=;,#L3@N<%
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M K-DYM)W V+?OV$>Q=G[SHW3TZR<?RFEE6;&XO>"CC67D.F*AN" Y"?7>*P
M6'0&[/V(VXN =[T74) QYBG"CX)3DQM!;K14?Q2!+?;INXS:S&Z(JP?1.*\N
M'N9=<*#P<^&-^5NKP8+0\"F6_-@Z!\UA123Z>"CZ'_$]\_#-5!F.A^D*5EY
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M3K.QHO%Z#I[",QP<'"&:N+&.;I;WY>_#[P:R-MX:#66ZN*K*8] #XK:W)=%
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M/NCQJ;#2Y?E$U672T UVLL[#)Z*BL76[4HMG@GSCZITUYRYHA=N5$5[ ]%;
MQ5,B284L]=6MK/ [(_%'$R]-@SK>YIU(%5L4>Q)H9916\HXO7IWRBP9+_ !&
MH%;AS'M!IX-M-YCFM;;Q :].:<I9/'_''2S<FST]CC\IS$R,SJGA>Y9M2I4X
M+C[0KS<]]3IK()ZWX$&7-46)Y6G[,.J>=K7+T<L(/O)0T:%!SI@V,U-AU)8,
M !^%C]\-^ZM(3OZR.=&?:AS8BOI?5A#K& VW.3LP'KFRH26\-U2PMU#NV%,
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M) -*S^2(SKZ:!1?7V,^D* -DHCYR>TA ]%R>=!L!@0O1/7DMD\6!,BP\DYX
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MO<[MA:%O>*:)E3-FKJV\(.%-E/C9AXN*G&[L*4HG$2G4!5A@8Y*_Z9D>D.8
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M*YU^$> ]*WZ:W9$= QA#L)",9D8=D_/<X#$!V] A,/Z4$AG@9Y=S1MX=H]7
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MX4\ 4H;^OWD.^3!V]S 1,T#!@]!?X\ETIB? J>QC1"X8NX5X 3[P1QP[SYP
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M6I+-X^#1[69V=VFK5HS&8\&0_&>1_@F_1>Y,/='*_/,,\AI6=:\^GOJGY2>
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M>Z_M$L1ZX+L:]D3)P8+Y[WL@5N]Z]<A*-]D7PF(-=Q'N.3JIK<Q_=I=6?UI
MF#4\_:^_6(R_]2UM]@1@?B&4<6S9@<#>F@GEPP?C:E8-8DGW?Y5O]GD^,B"I
MRJ]K\VG)45I/ &ZPURY:T&Z<(AF"7S<A&#H5N]\:DBGBLC,$[%PYV*6X#/WF
M%4*OO+SO[P"ACKH?6_=FP6]F%!^'G4_R]5&.%-H,"\S\&@238JS53;TZVYD1
M^W=3D]#DYGNH$ZQ-ZP18I4)S+0,9Y@W^$T)E8_3_J VBI&GJ=$T3Y#O#)CM
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MCI8KOY5\M.WSH:HF-DC7SX\_55DDL2"*:I:Q)P")%TPQX9VA=-O*DWDTPT^
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M,9%(*MS+?KBI,5^&<.MJK__MFRLO\DY82@L*=/# OA B2HN*)PKPAZBU+[]
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M: B%=US-9SUZ#5G]QZJ2^^3NE3W/+/(KJ':V:%2@W?R M3!'YE!KB_-O8RY
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MZ!VD=Z)2%1!%$) 241$1:=($A*B(@)$N'1) Z1U$!$445*1+EQKI( +2!<1
MZ"60((0%:3?OMT_9^]MGG]O._9USS^^=Y/DG:\ZYYAASK&<\(VM"_4F=!X[=
MN&9T#:"CHP/2:'\ =1:X C#0T__UH35&VH>)E8F)D9&)G86%F963G9.3@YV#
M@XN;[Q@7-R\W!\<QH6.\_ *"@H*</,(B0@(B? *" G]-0L= &\/(Q,;$Q";
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M+#C,NF_#/Y&CU15YB8K@1<7$5SY935P2&2I7_%08Q<!9PFLP\!.E#RU9BX*
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M4I%\5.!Q/@_I]M1C/0&2/ X9W\+ DTY^5?(HV^=#UV'4A>R@B\^N>KS\5G@
M[TAIO<[R4\!V);;;:Y:!, ="Y@<JA8(6%^0[RQDNU3]),6[TG+SL."1H+3TA
M.I=:4*S)N,?<ED=^C7)7$:#5B=6O42((=?<FUZ>8VT7CZ4]^RJ9<&(LJ3K"0
MR+A.?*]=GT1JSV18$06.;B20#FG,DD.\1?E!. \6SA>U<S%#Z>-=4D:)W8%?
M<HG.@M^0[R^=3]/_^H23?4=&;!\Z?9ZPV 1.+&+]%@*[8*Q&N!U,15*R3)-E
MHYOGB$]KP=RWSYSBGK<%3F2]= 4@=B,&03Q8*-X/D]T)$2 I58/^\RC06&T.
MZ2#D=.(+Y5M3*V6H%LUZWC-RW&"W)?9)#BR[B#E"]^B_^3),,0%$+SKLQ*"8
M2.$8LJIB\+XR0^=13"E<<*;F\FZ[A\RG"L'G64H1QU@UAU@W+TF6"RY JN1[
MPY&$3')>+40*S!TVJ9I4V3Z#><$E=TJZ@?[4;_69:NUZ[T(MYZ$0V^8?= 8"
MYO\"P<4#9.UP; 'YXV,]-GWG<!^,T9.BB6TO5JOZAF=GK/6'5@/VO@*!\@D
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MZLS;KAQL35623$>H@/OF /0I[BM%9_)!V^C6ZI=D1P^+G[4U)+3"S[C!%YP
MR[(\?1N)ML23R'Y9,)T*W/L"W;M4^1(Z_Y*B.!IVCAAB)%2J9*Y7+O2AR*Y?
MT0/BYLI=PE/*.GUI^S;W>WJZ4=+C1G(U;5BXK0&^(4%/;@[,-A[W?,;44ZY7
M]/%PUIC\YK:\->\+ZS !BX[Z24;;C>RM,7Q/)R$9E%U Q@D="T\EVOPB?QR3
M(;]9N7!N4,I,AN5:^_87W<T5%*ATH:%H'5U]KJKIC5KKN/JLYM;"?8UFN0-?
MECM,EIG;+"%_>*:AIN"8\U__W#GJ LKS&RXVMX9@0E4[OGO5$8UERO2FB&5A
M25JK*33:_(92@+JKS#1@O'K0LS=@D0A^, 7%HG/*/5PN[>C; "$PPPWCFF$D
MQW1'R.5<3\(&VZG,%WUK+1!:$2A+!9XU7*7,48$TR.Q;(I*4B,3OK*B\.M#S
M:F[>_K,^&&*(C:0MX@"T)5XG661:C[8=MP.E,0$E%P:*<NXU.AI@+AN37S;U
M25R+]3O1PR_KRW9<(J".*$_Y20586HS?P4@7P,-/)).:-S=I-^DP"5KG!.XF
MX^^8:#ZYE_YR:.$GYY(_#&=9&8,2;@DF:J_IR5;AE?.CRUJT"^=^!<U>&=L/
M_8+=%TKW\!%X5(7]<O7!*ZF 7RPB&_!%6 **!>EN!LIU?\S$Z&ICSJ9V:FA@
M>GZN'25ES+1\$#.P*RLRCU44_U,7T2XJ*DILP CW)*)FQ"EL,(Q9G%CTZP"Q
ME,J%TDA_QN-Q7;A?:GRJ]$;LP_QG&5\S2^0"H"&%K14GOVC6-6@29HC[@X&0
M3KXY-J)SY<'1=CJY(=25L&]C)!%L7FAXQIG)YX3H$(_@!OJ8GD:8 2UFHJIF
MP,OHWM\*3SL\,*VJO];.P344[]]WNZL"28,\'+V=\:6]?[_RQK\+SC<(99@^
M[7ER5O94>2#T(U74;</)%)CCJJX(IU/26A\*,6=9TR )#/=<I (1*%IP"&[J
MB4ZIJW!O'IO[J60?DQDH6]YUKZ+0AD/FP5E&/FZ>X^EWS$C\\AA*90FE5VPG
M6>]X4*'U5$I6R<;YN4>Y$WL-?H8>G+S7.\.23"?$4\ZGF/QU0+@1C!F^3D[V
M3Q2/+S1.MK6NJJM/?LT<:'=UL#:PHZNG!4J0&_7R1X.RD!Y%+BU[X^G%J1>:
M8]KOH?>3MD0V;M,#.Z_-69+<J( D]!$45(CM<829@7!,,Q5@<+MP]9=L6U[Q
MP$=[]_KNA&Y"_+S4@VH-A+C,.6OK.SQGR*V>>MI!GK1<C>)ITW)R@$^U21D/
ME$MW7<"N<!!#,UGOK6!O$<70D(NER;T!UV:.4BFL@1C=T\)@S=N6S]WEP^2\
M4(F;ES*"^(>O23>RCIX)UQG9M(/@[JCPNFL@SH!F!?HZ7N4_IS<T;'U.B6>(
MOIF[I[SO)M_[XP=S S99OLN,D=*!JO'JXJ$#9[NEA.L_XX8R/SZ:/.(N]W$7
MB%=_ILPYJF1:N!PTK6JH]RBEHVV:G(BX*-^C,@UM;U.?5#E VZ\/PLOF?C4J
MK\ZL:+FDO=D^=L.,Z!^Y,/PL "U)8_77OWEPLAT],#LP\(/!XUWRSXH7/<(-
M:52@^70/.AIA36(BEU2TL5'Z45((0:<^0N[0YY'.#S,#:?TRJULS$7K/+B<8
M?E&CVTO=8L-;8KRPEL3'00W=@0A-_'V2[JC3'ULQNLDSS&]*U9(E\THO01X*
MWOXBTGY6@DCY;-L%Q5W?B4+CRJ$/!?#JRZBL4G 47R?W4.2>NY1S ^Q=5P:/
M>REV P#1%/8J?"%%T&RKJ-1=J"9N'RDRU"1S/'R!@?Y >6]WO >Y^:DR->P4
M42J/]I!H5P3EE!GA3;H/\;5,F:L.QF&=#=)Y'V>'7W('^^1[>E'8V_$J5N L
MT7H]GUOG/#RP MFA_+@I3 R1Q__+6)>TX/+R6GS&8$/_3;K7/1._:6%3SX.-
M+P@2&FZ?1-?(.'?6Y_JZ6TQ#Z#=#];Y7Q3U[P-8KSJS ,(V<3T*)HA:404@E
M2;?YE?_JL\H6HI4,%>C-&W$%0C N+U\_^=W60IS"ME(!+EI&9<V.H0(+>:@E
M+<(JA2;MTP))H8=(%1*"A HEME $#\UH/(<#GY8B!O/K7T07@H6F+;CUR7[<
M2G'1AK=N[>3*HK-^FP90_.<JRPK$/WX'UOH$L)0UNZ!A\KTY4M0R2B\F_S;D
M6)B%1I0.$P;&Z[!>O7E^7<QEZ)W4*P:/#&Q!_'O>4^V=6HYOYW?=&'9["1[@
M7.!?+U7Q&DEZPJ0[.*?J(^:BTO &4[Q--A"T;7X\Z6+,"4?VDG/LW6G93$;S
MX7E%E"EH33[6<;[5^>LZGL'T=HN!RYD<O;P25[.FDU:GXJ([HMV9?3\$WHN0
MUJS()-B3"\+.$^%A(ME=MT#$T.2Y4/5H*A"[\]!X@>/$-Z]?"=S@-^C<UU_7
M3,_?@?9Z@7(-7[T2I,3&E^IQ=;$1_M&1OR5=]2'."3\C\X;ITSF.]VJ9^[Q6
MW7_+8PN:X2"T0MWK:VD^/>BT:=DR4O:VZ<4I=?=)]X;KHOE9!N8<?-X"G)DP
M=MJC?+Q-C:0+NN.N]-A(J>!78\).A4/CDG"S\)#NUM?5A@0WVY"RBO<5^J(2
M#\3VJ  H&]@-X0N[1D[5,7;!B/?["^"6]R>SBN9,NU\[A+_0LCG96]$I3;?V
MP?"2XBJ-A8:W@G&QA$00BFGUPD">(1=.3"CYC[EX00E9R_5]B&%^["QG7]%*
M@-;Q-R$_6.;R1:B )RI2B@Y$EFWPD:[B>A-<B#*EW*D%&Q:/^)VT;@DII]7<
M/3=?<^^2E@P['@I*NW;.>77 :@(:RC<^&[N[8G3=*_;6/HC\.7X]X_Q9J:2-
M^9"X]C5]O8&%?%">90N]H&RJ3>2);@H;ZVG/\E><;5ZKOOA0:^4)-*ZR$.MQ
MKZHN9F9&!(M=T)<P[WIG(<#)9*X)T$4P 8C[E!]MHN/(^;S\NIXL?&_'"S\C
M7%%/MMQP5Y/CYZZ T;[ &R6%*=ZNB>3WZ7K6Q\51O/MLT/F/^771L9%/.!;]
M<.(+>_&A91L7JGF%BGU]SXES-W\>.2$I^- ;X<*RB9JMI"73G6D6FB).?JU1
MI?_VSEQ7C<+=S*MO'OCR7+.U/DZTS4*VR]3J0F^2DVHY9HTU/;;W):]10OL+
MS:4"'6*3[5)]>7D-JQ. ;:@7V1TA2NG,YTM)Y5LGC+@?6S^F[Q;)I^#Z1MPD
MX6U$"=^MLQ>Y>S_0M&]4&&@ZU4X%JAHZ9AUN9T#KW(T_?>N?6/H2D!.O*0IM
MZ?T,/!&DJ5C#CD I-1J;GG:?_+1K+)0G]=9&K]G#\V2CWP]\/9]90Y%]/H7M
M$-,,%4'T4 &.,V7+1DP5&4U/WO&<DFU64WH?H'63S*K+^I8G#_DH'WP+G?\$
MK6F(WT//.6[6%QJU6!V&C;O+/JL)(34 R%GU/<$C""R/"M09%Z72NL)J*F.4
M>%[Y%S@@'\V]/-Q]KC/FX67VXA>D,-4"YD(90?(;ME=&ZFGC2[*$Q2ZD^_@]
MAA3>>:Q(GU\6S;)X"<)%NJY*B_-+2"]-/<EXDUZ:N=&>GOYQ/R@;E'T'>&&
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MM/OWEQZ:WYIK:67?.;$=I2?$'E[J>BWJ&_4W5)JJPQA^/M:UQ(V/'.C>01P
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MIG_Y$::I]H'8!LF>8!DX_\_#09YG2*?>/3?/$5SMZPC7SO7.6[N)_\X6+5#
M\9+=\_Q[FL+?PT)&RI>,"P>T #V^$ZT)^G4IX0-YC4!*OH+I0 0K#_J!\[@>
M/'AK866'!:?1&;&7 4ZMCD M]#KIGW;GW?F<F7HT:^*8ZDF-L*?=)Y4S;W^8
M8OO..#V)#@4G,430),(8 BJ!*]_;C$)U$#-E[H(UKN@;E&1 YH?+SQ^RLS6T
MEF\]L%WQ(]B4TJ[1GQZE].#4I8W4 P*\PB(J%ZY(942U+*T]W=4>[HI6"9<2
M:MI]34?"@['SH^PJ<3 -%ZC#5XW'3_>*[NVT/A._%Q_"+B&UPO%1(3$]-!,>
M&.M'[F/=X&V:&TDFX(P_3&7BLY/,RR,^61VI>9@O&CE^&A*OHF5=<GF,<A)-
M93QY*"U4=P;F\#)D8-6S;'4LD=65VWQ^_//LYI&<)4_PFS/VO48.[ D\RAQV
MX6RQ;V>]B,[D,DH#<0#/>$:\1,ZHFW@WW32W3XGN.Y"YVSPEY_?MWB'$TX17
MCRY6QSD+R72 R5;T/!,UFAV]J$,"!^)F3*,4B:BD2/]N3;Z!J]$9MI$Y!99L
MDFE%-;)%)<9A7R(?8+<D*Q=H7I2@2N@5>O4U=.V/YV]E"C)*@\@G):;[1U)=
M<[&QI-!G$\>'*V_EK[P\Q/83R0?WUTKUE&'==AQE9Z6V5Q.RJ0"<VGKA1'QH
MY1?,;@8\P!YW4QU_>^BL=D'X@![JVZP?*^N%Z"5-H?,-Y)C6Z0ZM&#)(>E/R
M:X";SAN.EP/J\KN@@HWAN?3S@$&E"*V)C@P&7^SJPECRP7XW"*-T*1YK1S1I
M$JPI^Q;?%G12>;&BEPD06E6&DW>#9''9[X.H8%;C88:2A%A<"RN'**TN%P+3
M=Y:L3BI/5#GT/3YWM*!.ROBY;9BIP@"IG?QZ%NUM.U_2Y>QY>@F/R#A8/#SG
M/I?J]<ACXVI\J:_E182:WJV/IORBB0E]*2_<(=8,/K:*GR=Q[UAUO+&RW[91
M*T&F7_1,YA^MDRUW@,T<O?>T\2]CUFD2R"OH*1@(-JK*.);7_2"X;Z^9&/13
M.H]Z*B(R"+4N6VC(ED;Z"'R\J\ZRK:L)#!/X^'=(.RLNHDS ;B3@ 7K+F>IF
M3;T*">J5"4W= U/,390AYEL!#,7Q)R(R5JW3W@CEQV\'%/.5\[V5E"54\&/S
M/>0G]"HF(# #(4DQ["I6&V^D+HDYY.+V^PU&D7<Y2QN@!>2P2_*M3K[^:W<^
M9]XSV5T).> G:] +-$QX:,&41)P3A>!#\NH]*&IW#7(Z<T$NVFF?WZ @%Q\\
M5=VA77]XF$<CAN )9_F2^\FZQ+'^@(NJ^1UV$B^%G\9EFJI\]6;XS<09\^.8
M ((U299L3Y%?R>+NYWT'O41_U>$8<0+Y;C[ ;JOAN>TY-<OAU[QVM8<[;YS:
MB6\\9*$%>H1>>243]9BAS@0\VNG$).%4,+8)1_KE3O=#XU5;[,$M!S1X<] (
M2X_>FLC.0/]J(M^'Q'XQ"-^L_>2;^DFH&8>Y1=TG_8B$C?:\7,]Y&*4_8@%Y
MBPE(YJ?\80(L\G$[-'%K)F!HBFT#6[]/< BBWJ )D83>AY6VI-#<WV@<A'PJ
M.7W7?3%U[/.+UKFY<X+#^3[G%_)VX32Q.R!I-$VL!;>(%-:U&*<%A>+4J=5J
M:X:0,DV=*#UMGN8KV2F?^;R^0[ Y"6<])ZFRC,\84*<K3#NP#=Y?9(B;*</Q
M1%3R2WEE6P<]Q7QKL*E?N]MNE(MX>I(3C)4;HXDX,&R\^D#D\TOPGX)9@(?1
M-+%?Y/0I4$#H?+L%20']4&(_0R/DQ*3N,Z\L1:R!WK?PU$,U/XI/&)I*JP"\
M)/HHA?@=1 ?++G(*?V4<I@ ]9$(3:&??LC(!\DFI(<'W8SA[E;F5DN\%ZH+C
M'S[D,N@\N\(E(K#W"*C.F=!%&EDEUQW]0 2EZKSO""H]<E1-^>3QWO3$3$X$
MX0I\<QK6] -(M$;R!BH<)Z)[M;)1BFG):)*ZY\?61ZV:]:,G;ZK5OOKEYMC/
M/2(:U0\PP=?F@X*U,'G]:!Y=)H"=9D1Q7RV'7B!)]D<\K3XQ)9)5E.OG[]ME
MYU*T7L#FI.?+<0M8L8E'8D;(G:2!1)0^A"7,7=7<5V=@RI $+,'><U,#-N(E
M(JJ_)-!Z6\[>LO<E)W]2^!Q  8X/%61@@4)&9^!X)=+9+L^3")OXG9 ._:!W
MW:U9DA$:=X.]_(ZR#SQ]2U;&?=HA^]!K[^]D8NL;:)XDW0X%H,<)V88:L[NN
MN"1"?(#,:=A=[>!;;W/U@T=$\E:!AQD<C)GE8Y18G+$U3H4@]@;B=[EQ\E1(
MS1;T3*FJ@TSOYQ^^\^QQ-PY;>2$>D(3G=Y>WUQD\FZ08C0+SIX'Z(=U*B=\K
M71N1R9WSY"^LQ=PSEHENFB742>QDH"0W3.0IQL2?I[Q3KGV<UA3=P%&.J<7D
M2E]:(7ZN2.=1TY?0782-L>H>LG\3G.7&!'1J9;;!D, L[)6"7Q=((8B[L"'#
MF+N#$X!V/?G<PPMB3Y_QY0;-@%:*G0LDT74IW<V3Q9)).OWIMD<!'",Z"79A
M-/<>/ZS*IP>>K:3U3D]92FT)5&<*:B;8DAV9$1;M5?)'NS'/C#KV5/O]!<:[
M:_SL26-7[;B_IW3]W1G0V/R:>@_J.4XS)+E?G&"H8 *(J$^XDWN#GI@#1<WF
MJC!97T>E^S=39[<58M8)P"RT C1R57B!M5#+>H)5;E)5$FAF[VS#*@*0WO&,
M<<6,*J#NXT'TQF32K7/[NIVP+]C=?%N,(:-S!GL@F ]L1-!*'<BL5/Z@.\9(
M?&@J'_H(Y ]*]>1E%9=T2,K*3G;3#@',14'8!-MVJQ\OZM ,B?J#<H'@G>YQ
M1)^A?4_;?;RNO/X5M/(*V&BSOS5)U=OT5/ZZ(SK2YSS94_ICHC'@Q$@:KV]L
M=E5UO7+^A\Z$&^PS'=$,/N0J/Q/ %P 2A!E#'HA&CJ4\V!(.M\-_;LR]<?3\
M]IL;EP>N7OL]0@LE21027E CH,)$H<PU5I%1D)Y8):$J(G8'&Y0C>NM5MQRV
M,F89GB\V3(TC<$B"#2YT7I]\@ZA0@B]BZ%.&<+*0ZN ]/,<]V:R+9K_D#$PK
MC#Y&O_6[DS!P:Z7U=O?_O=7EIPREY?]MH0 'V'&O:PW ,6@\*I$*"0)SF\C=
MG ^LVVCS^=2<\2Y0[ZMF4]+GQQ8Z+;E7E'YY>&7Y!9>FKF\W'RH2QK!WPX$=
MZE0)6E0*/CIK3UBZ=T9/Q1)I7N\B'Q$)?*F\(' )L,6G]W+7BN"XE^I5R."_
M5-WPIMUB-=);0_L&/5TDY\<]RP,Q3R: =<_R3$">"J6,"? \#?]Y0X?EPK=>
M5\*FP3(@OU"N.9K*5(<N$=UE()@Z&?R[VE>BO7UZ+2LU?UQ&VM%+N-7DQW=;
MC7#).2; 6QA3@JM>'V "Q*&'*-\#RK[@/10^8]V"'GA;RT6G'CJS**[VP3O?
MP_7Z.0&I0^JSZ%OGE%KH62BQ*LNZ]^,Y@]>S71?S*+FV>$\^ )#H@H_/I*BH
M8+^]$LK CQ%NDT#]:&"("2=L%./[#)1^OQS*!!RF(-T]9I[['[LV+9=9LR=P
MI75QX:*/E9QMMHDR; Y<-_.".QNF%.0I31D@'O"^L?'5U![7#-GR\N7_Q'=!
MB.M*7.^YD?!7T)Y.% ?M"&F]#[T (F>-ZVAER2"[;<46@@H+(^"^&)V=]YVA
MOK(?BQ5%]'LM/(_+"3A_!8G ;\'3ST*47#,&@,V^C<6BN>P*;R,_G2Y%/ND]
M=#Q JSM).7YH6Y5]$AX,Q\!=B2U;'JR$6-5#8;PQ56U0LD'B?,_9&+&7^?YK
M%G9S*PG:/+I[\"[Z VH?B!<J5AV81Z]TF+IO*#ORGLS2OJ%#ALW3 ($Z%0#
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M(UZVN]OW!F"V3M]FRUCA9!D$;OA* 5J>(4"S;&C]RM#\Z:0@9'-M9I>\W'W
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M936&"E#JL38R/DOH5)'/ G$&VQYU5Z2TSW%*GU.5TGL0^YIUJ6D2E6R20?Y
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M^;NF>]$+ZJO OFHMN_%7Q/5'P;WZ,RT1PRVY0&U?^D35U4=WS*BCGP1C'<P
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M ]ATK"3J>*";0B4.?F38P=;F2,P[=T._)X.D!BN!V$/N;U;NI_YB@679!-(
MP9HJ3\'B) FZQ#&\;8^@[86)IAVANPB'#+?68K88\?"0RP[BVNO0<%M94>YA
M9VE"*1/ J4_)"ENUG7^^W_W H&DVO2,V-G2U^M3P*9^7PRO#@+&CKTX6/\N/
M#=IT(]D>9GRQ@RR0GWY%:4!>>#!F&XBCQ3,H.2)VCGSI=OBZ]E)'\J6UP9XX
M/56/\A@U0<!];$-+-P3%11,F.L<K>N?LV>BI/TQ3HM;?%$%%*WQ1-Q2N?J#Y
M?\&/>O]_'3<%1[-(%VJ.GX;T=)_I='DZ8<OG8:BV'N<2:"J639'>D\!>=Y8^
M1_BC\N?)VYF!8B;@#M21"7@]UH6E6"XQ ;NCB"W;=/3>>8HA$\ KBV:XSKZ^
M[DSPF8\=H:6OP\#A1OM4,5PM70@FQ 1TF^\P 07WX?_Y$9_XTHVKVK5:X8\C
MT%JM"@_I:21G1@J(&[ZJ%,T$C!B ZDS4F("OZRL[-.40)N"/GV>2F<*,1^$B
M>O \MG 18<SHI50R 9>0B6AB3CL3\+T(.(>4@/^(($8S1/7AM(;:BV\00:=&
MML'?Y'9&MBW^G]V%15.AS[[6KE#T]WVE,?A_3L&"K-('/I"CL<S1HRPL$Z"Q
M^;6\!#-23RW\PVVX2\U91_^O4RCYSS!$_KAQ_7_$*;'H3^S@+^Q_S&#\/Z.P
MIZ9*KM]"?6=<&*6AOL7L_.<$?OQO47@@(?[0-0H<S@0<_8?B'XI_*/ZA^(?B
M'XI_*/ZA^(?B'XI_*/ZA^(?B'XI_*/ZA^(?B'XI_*/ZA^(?B'XI_*/ZA^(?B
M'XI_*/ZA^(?B'XK_<A3.'ZS+MX)SR?XU6D=TQ;Z$BJ3KY[%'J!VY4W'-TOZS
M*5ZEVN5->N_G__,_6_[7CC68"J1@LPLNV.&*DY5:+=BWF@C96<E>$9.U$C^U
M(76(U_Z&'X=<M,3N0 \2P00THOO@_!=P6H(0E:[HMANCI+>C$Y>ME8)O-]5T
M;:C_!"*0NQ=12O"YEO?PGQKYW[$?A&DO/+.8 ' +_$!G9KP^,4H[?[$Z(K>-
M7H52H2G,:"A11HAK"]9?=Y1WS6M?6WJ>&ZLQ&F(/HQGF9_-*]ZMO"H)N-$XW
MC@2;C^(,7\@^=<+)IBZ<5+[[.K]K[VCB\Q4FP+^6?PZ"7@G-VJ-?/%YP?"+D
ME)>R]]LZ<^^L@8\^#F!URB6<;\E;)J#K7.3#^/"AF)")'P43VX:9X8L5CWE^
MIGZ_9_S$X;N#56GP7?6/AF<G(\<P8[T,8U+D?C*#EW+&Z,Z,@/VF!SIOY(,3
M$^"];6?!S?%1$_%$)"%@$]FH-2"<2*RI)2FMUN3'KB:!?NHO2Q5EN)\\&G)K
MPFIQ'R,4]M&Y%#8(XV\BVF[]6OD1O.I2.G5WTO%CV(RKRB'3 0;@.BQ=?5;K
M;O5O=?4,ZX_V:S,XO707'[LAQ=,])[G+C^:D7[M^;>9K@%7E8A^1&]%HFX82
M^T "IM1R;A<^>)%#2K87DI:&)SWY)D+PM* "H3"2,(%]53#:D211_,PGS NF
MZ>6A?5+IXCO=NQ]BY-95ZB36F( /M F($@[1#TP>'][]Z>;T;G(N^<Y%SGR<
M%\+INA!\<><J$Y#@PP0,G25%TY-FF8#+I0X)Z86#5VR:?IG4DWPK]1)7/?P<
M6F[$;%6]:\WRYGCO?;%3[G!8SH;Z(,@7F=W&!/2#$S M&;\K;?1F[1O;6I//
M52GF'%.7L]Q\O#UPWJLX:(JAQ/I\(Y(%/6$;O6?M_!G[(9KVO"4-M,GX>U*@
M%:X\_6;6DX4URW[*;:HY; (D!3UWL)/4(;DR0M ])3,U<BQ7;$W5WGRVG;M$
M*"@$CJG$%78#10,.0WV)1XK>0N#V+P8]P)>?U%]>+MNO9\\NM7*(LQP]XVE-
M58+->$I25(CU<.%-&<DT7?66J7?M8@%Z8=8\3I:=T@$WMO\(2VVKK0^$8@S-
MZ95:1KI$_-66O*Z#FYB7SM$/!M*6#</C'9^HE?M*FWAY:0[QG>-X_N/>?A7^
M=7IA^\.-6&NJ/<U[FL%+.Q$J3H$)FAS\(CPVK80AE(\#SY^S<"CF.E][E5A<
MJ?=IU4/6X>,-JYV[KUMSO#A4_4Q[!7+#\C:"UFT7#H:-]<E^[I894J^F-' 7
M!U3XI 08CBQ=$@)]*X: &5U1Z(/C0<]*!Y^UA3XK<7;_%*MOAFY/5;<*#56N
MD/,6K; <:Y$@E76/86S)V90OJ]2LT.YB :(/HXASTG5(N=A;^4IYMKG"ED*N
MEO'YV@\T5R9 L;F!"?!T@/_@0IO O="8RAX0.TQZXX%0TVM*AD/;Q^GO*-?[
M&9:EJ4J7^#B/EUYJ/Y.7>5_I^<3+T",3[8HA7TYL/:REG6 "FFKI8CL<\)4+
M3,"WX0.+[KR-?<\CXVNSA)7&V;<-2;_Y'WH]??-15: B17,W99%;)>Z\<=#:
M#@6"B$/_<""A&?S!+/U61+TK?QX4>:?$K^&C<]\R+[T4Y ]*;T.DYG45'R;"
M2GU*L,8O$6%KEWL*%HIFK7---SAC2\!%P 8+@M8J-NX T:NN&6H^VW1>5S!@
M+:OQH<O:#;Z;A_N^755XZ%OQO"U8O<YFOOKN@YE6J@WM+D57-[F4Y+#:GR^9
MY/?R@BXY\8QO!HB,N5Z\HO=UB8WKTP)NMD\:JD34=R&MIYB,P+[^',?.R[[U
M37:,+;7F]#FG-K^2_D>%G$ROO6^+4!!#K,XDE7I0HHP#UQ8] ADGSV#Z[J:I
MH>Y5T7PD-7/ZS86"?@@C9#C122 O3;_+C6V2,VVA*<%5N#9[GF=*(HIHN7!Q
M!>/ ES#92NT;+0VM/\#L1M%PDOZJ5C+T>L6E8*[7[S%_)BU\J^K40V[O)OL>
M#5M\OKTY"/>&_]';88//IC"F'OS>Z+XRX3]C\!8BV85$+!^CI)'6<18)D>K&
MVH+J/>&#!7EN?8IC1UT[ZM:.Y#PA_2AYOI)'QJ"^@@*^.'0JJ#1.5-%.2E!_
M?MVP&U"T%7L9$ZJNDW3EV\KC$NDQTT#$5BL3H))$FF2@5)B B9*;@BU=&<!L
M=*,P@6UU(?<#5NO@&C*JQ\1L>% /N7_M"M+7F.1A5->.FCFSEI_?CGPUO0)F
M8X @*;B4?E"ZB=CTW;V16,/NV5W,O+6?>(9.>HMHKT#2VUO7IKB_\X_"\A%4
M:5H@FN2;""=2^Q8('6&KVL&^V=\89!R'(3O0Z>*A,SN[<D7]'\?FF #&M8?D
M!); ?1I@%"PZW2RPMWT-G0VK4\8VUO;O'*'=(:$3C3A7X7P;=92H7?^&!_4#
M*KGUXDZ^^FIO]T8!!XZ$"'P*09VXVVT3U ?DO\]/%UH,;67T%V66)^9"BNVY
M#+>.>CW_0B\$?2.B#."SO4S P8V@K2B[#<<X'R4.A>2*8#-,=WJX<VLW39(R
M\(H61C1#I^FHW+_8+_OB?-T:YC- 4]9K+D'XW@6R_!(T@'J\!\B:;B \DR$T
M*3GX=7IY0_T6S#+]VJ$*A&F#Q(%J;?WF^3YS)[.NI4#QZV:^+M?-Q '_7P]'
M^5#W#\1E1$S%1F&8R\^9,)U9R;-Z4UGBWKF!OZ&OF0!.*9+9V@MBBCF1GO<D
M.-K1\AU;*E8N$'R;C/VN &__<U/IBW):WG<;1#V]W$05>@?=!D_$"A%J:,:A
M2I=UL:*67LGAPH8W#& 7GF9FQD]DH#%(G'[7%[=AK4P&H&6RT7! Y-VGU2$9
M%R6OK]J%T#T5V<1;HNS.$PH\Q"Q$7,>Q$DJT3997W:2F5S,B$!\UGC"PE&VU
M?Z(":D,T+NQ% H*69=!)*HG7&W,EA&FB7M_"?C@V?S!Y4_M<OZE1I<#ITV]M
MF K-TD2:HE5#P?;4NVZ ?2<6KM?EWOS4T1/R326 XSW'?454) 5.FB2_H!2M
MR@J+01YV,OC;QW<ZQA3]HC.;AV3T_KAMB?Q2$K((_&;"24'A>T$?M'J+3FU8
MY#>Z[&B^7HQ(]=3),37YO!LV=Z<-/&]+KJ*X$F=7@$FT\SB0.-PO2 \<^(N
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MBF_2/N]@O=#)TPFT."W%#V#/$:% V^FQBF.]X^)=P:ZY>H8D!E&BW7.>ZF6
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MXJ/NQD2=Q9ES@6X1IM]Y'"+55UI'R72K%,"M'=KS4!DXWF(H9=%ESVEX7S1
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M4KZ9R=>$\RX&YS&+Z]1Y)"RX!JWST8C$UYO!%]7O;$VWW2?S(M"5YWSA$10
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M..I9VLP]4EALL&%8XA_:0=^T]UI+@ZY7=)6A;N^E<7*,H#BNDFS,ADTG=[+
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M+.?!1XPB^I7D1E/4$,#Q/#GAH6K%$8VG55OC[B7L[D(7,K,6/>P_<NNRE(+
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M<Z$71\A\,&:EC1;>OX<HHG!T,)I4_HG_F,R-921I!Z_ R?SP;G;B+I$*9-7
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MEC,8XZC #N?*6WG#^H9)DNLROZ7/.Z^Y-W+V9V]P'FAEKG67#(BG%3TY0GX
M>X0'=$&J4[=QKD0MPG/+*"><RL*F9\'5MI><7'>A%6+.(="^LWT6Z2P1D)<K
MFH$7N55_+7[^XU"1)S'W7>T6H:I-3UZ7GX(",U*!Q^8Q(MJXOBY3*L#A*2)6
M&RV58SY9\3[H[7M%7AE\M 7;>.>+0R3J#[$)7T4%,D^1:0)]!TVC:/'RRIR
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M#R-_A G#QL-8ITJ6=/PA)H\&ZV<#OQLR-ZEZ[QR(^?K[^P]EJ8MRZ#.L[LV
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M"C8[?EF&[U?"D$UE).7L+A<3CX:+C44[!P/0I2[N]JT\[ 3> ZIIC2?*POK
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M#=;_3*XRCI)4^C8A%GW46<T>1IA-6'Y[KF!TY-5.^+@-)+?2I,P.X0Z;U)7
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MR.?O6XVQJ+=4X'Y;\A_>7N1,7H?BQO0/DR_NN:ZMZ64_S]![.<2)7>#8R(_
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M4.VWY&RP4])92C\-Z#TT13 "-U+D=KW\&$)5U"/;>%T*/+>"F6.O H!EH>4
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MR<M/;)9EGFM);]+E37Z\Z^K8.[-Q0ZZ27-D+T>C[J:&RJ.%MU/TBS;9,L6C
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M5DJ?HW)E*Z/6SJLNR]Q2\T\K?$^3X$]I5T8?*[FA*-(D?YQ*A";\F_-QT)2
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M>:SF]K$L#M-#>@-FI *3YA-4P$#6P89@ON]@D^-OIL=U)#G'E5,PV_<BN-A
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M)43$]-A@<43%#Q""#'A3$P!8KEX$-,+69(DY;8+D;/BRY)^/$>2@5<21K"Q
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M.6H6ATRKD1[:I#F.$TH3VUM6\P2-I:((FYEKOD[JY8>L/YVB6:MV\^M>(&R
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MTR'8Q><PPZ#S^;*XIPDLOT8F5.9.*TEWVS^POB)Q;,'F=;3LG'X7_-"("O1
MB%*TF/+W-]6V"1PH=J^=T5WM:*'^@^VJC>YS>;^ D,#3R=).9IFN3I^//0-?
M!3\$335W+E8I=.1!T-L=?U!Y.L0N80=MYP8?!UB?2[FCER<.7='_XG@KNU<U
M/?5N-&:+"D125'+1IIV0XX0F])S-?<\CT>0RR::]N.)P25FM*!S!LMMF>3L6
MOO1!2S52?^1M.W9R8^C-0OED4_EP#;^83$-2[ YJZ.QI?\KV@@_B8?%O,43Q
MK(<JWX2JK[ZGFS=7%^NI"V-)/$!IX4< . %8_3^MP2UW,T\>"(Z,GRX]X$L
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MP!,ZF]H@AK">]NJ?>%#==G)-=+.=$8H*=++IWT[O&@9L-&PKC%S/'/_)+6*
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M^B*V1;?<;%8RFE@:9[!9+K$HF\_&8$ZK?KCZ,-7YPINY6R*/$DKGFR_WZ+Y
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M\K7UM-?=E6/_Z32*5DA2#%ZJK::)KJ8Q:4'QVN@%<;<*MS+K@#-SP$*RR/,
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M4P QTU2N[R47S?J.^S&/"M/2D]X?4D^1WB)T<;AD8A!XLYL*W-"@ G+")51
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M0FRR'JMK:F,BQFI^7@8Z@1Z4TN#J?4^C*1U1)U:9/(28R;R>0V$5*^L7833
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M!-0U,TMR2'?V61@#X5\6PV:JRBF\L$MCH9PP=1PJO$YMYN.J_T7KZ[-75#Q
M:HG)6/^YE?E$7^'6*L=\UP";S)) AKP2I,&XG;V]D52<M$7:CUX T,X&#H,)
MS<>IK6P;D-J8Q"=P.FA )\]JD.(O2E[9F@WLTAVD"=NMM3V#\M<R5^2@$D?H
M:'B[,LSY,W&6< D7U?/=1W&)<-?>=7**)^+;5L'K"GUP%R\L[$A"[&H50.S$
M!_2 <'>J1,QQ\6@44BTO@J!Q[B2T#1-+8C.4.AJ6K]_]'^R]:3R4W_\_/K)O
MC36[J1"15$C6H;(E279BBF0+;1A,QKXO(12B0G:37;:Q3Y+L9) MV3-C&5=F
M^XW/]W?G^WG_;WS__QO_[V]QX]R8\SC7N:[S>K[.Z_5\7G/.=4+-Y-*2(I_2
M>4;GYPYZ1] 298U"&!4$KH$PP=TG-@+.)+C7U>'W')G/;0167WSH-/,Z9Y=N
M=.(;LE(A)N@X$$<Y@23)0MG<*0)$E>C\. ?*>%KNIM_LY56GF2>7^7;:)BF;
M+U1A],AV&2KH-QKY8TN%,J MMH0B\4O/O<IA&VV^YG_Y\T?-C^5G$HXG/''A
M71,8.9VG>(WO3L-%TII*DTPOYHYB.0Y"8=/%(1>W$A9P03D'RQ'-QH]_J]NK
M=XT;>NV?9[HAH2\9+0+I^)9/8&H]U#%0TOE!93 /XBY^:3-<(',OYY/2E$C,
M(L=X- +SLL=DQF4Z./D[KQCK@,XA*1@L4T+'0:J38C8VG6HG!F(T(D=/WZYJ
ME!Q'"3X4\ZV4>C;R!&,+(HNCH, ^'G6-_+:5=QW-U6SH4>2PT@A-)D0K-0P;
M1>ZX)#+^J%@IY)1-31>E'\6].-9J<7C2.!74&T,RIH(:7"AOY67H!7JH()R%
M0F@.^\BN6YX)-Y"X307=J!M;'JF18RG,,HZ$6SK;I;NE2_E8B:39UV6'V7NB
M2'QV<_83[>- HH8E?E7.AT!?:.B^:$JT'/QI$%8JEB_V]8834#R+N[45F0GI
MG)T4F-]Q\^6ZYE/AEKR&3?CZ;N?\QRR%-R)"GB7M3 &,QUK-R1$4;O@M!4 F
M:9-19J@\%NYPL+(R_EOYHG5-O8L\CQ.;A95[\K[Y2QGZ55@(&G<'&0X5"SK9
M.9>EA&>.T#!\^M/^;6[,QIW93>^$=NZ\%&W!1.VGGU<N&3!/!UTD>>&LVA28
M^A:2Q#P^N=I>O1(CKCT@N<UE0 L@)WQ/\@9? :4&LZ*B:$RG)-,X)QGO37B$
M-WY;8WEP ,_H)2)<&>)C-,N22\7GK2N%5C]7CHXAL>K:=>1WR#F:@N8($@,^
M*J-Q?E&[3D54D+-Q>J0_XG.%8-7N*>P5_I#Y= WQ&KJ53"L2_\Z<,Z6402!=
MZ])0S>?\BY@*V,HJ0:6]7:(O[9<$A2[7G2C=\5-VB.0]O\X9V'GPMJ(Z#]9U
MIK:UZI4AWY? TN/@)QLZ_&\732);!8&(N;A9%GC8]>I1A*H_75VJ2<I)"=9X
MSN 7'2WF%6PO6=KY_\*(BJ0[>.9VU"28\!GG&5GH=PK'OXAULPIRN?S[CTVY
MS0=HQ[6K#^9 0C&BM AJC[A#<XY\!"_@O"@WP-%^!KUHK->CEX@GR=_+N#!5
MA?N;8BAAR3[]<4[-Y>1$/XRK51.0)L0=;JH*^D:1PYVO:/SXVK,Y)GD0HUG6
M81?JF*[X]1,#Y"K+R9<ZJ$+TW&LT"PF*6R08XR)1A=8=C1,Q-#5>O";"G*6N
ME+3TWJO)]'*1PYOI@,J!8,I@+@L"BENGL*7AY.QQY'CA>WAU<LD!%GLA>N+B
M&XN/;7,"=]Y@[N3G6 \R_X2(!&D"(@0_W!.\2I+REQI/I=Y?'4W"AA7.)Y-%
M38O.;0:;T(.>&HA.](N+T9ZV$<$Y[I-E9WQUI/NGX*?/GI_6U7I>AO;_[=&)
MM8&($Z]LQ?ZM)K0":3X5R':CS4>H5E$/J, NBL[MY8NL=JPYYY440_GAN>]#
M94^];D]PIW_=67JGP6%52C(A?R+9X0/;A.O#FHV( B3#425[O9EWKLXC7M;7
M'U_]DKN2*_>^W5+P9$@LB!B'0?+O0N@0,N-!IXTE,]%12OWR>\_.I-QYV%!O
M/OO:T-ERNCGI-7U.[?:?<EI > 1 "E:%.=?LX(6FJ69U GXG?(41E_H+KM]]
MIP+/=>1-F#+-WG26Y&RS2J ,7(9Q::C39$\=,#:?&RTN.J&AJA7G7-+Y40=E
MW>]VMB;0(I4MI4CJ.NH\RV*V+XHF.4-OP=GU!Y%.8+#[..'VB_JN":L)V_B/
MIQJ=Q$;'OY0A8ZY>O:#&V8^1/BG>@L\E? 7L<,P=:N)-BYKNGJI[3>;-([OA
MM7ZC9Q)>7;XI\:IG@V=)6U5H@']!39K$OS[W@E+K>;]TM541ERW \&C4IUR,
ML77X2=.^H@'Q18=%+C;0C)REQ10T=*#2/1NK=0K=!(0QY9P:0:@Q3^4EGA2Z
MXUS/G7LN]('LM[6F-]%]'$G'R2@JR&N+G3*46[T<AX#.H\.T+D\\7Z[A58CQ
M\3SE6#TB>.'T+X./Q@WTQ6>SDP>WZ?;T-S%$ U<H!]KYK8=E#65T_#X^)\GO
MHVMC8>38&8/\AJJT]XUN&MU37//-7=/Z#/0.M)3$D$/^B-"L0)S&);5'/X=R
M=2^("?>9MF999 XKCTCIH5.T*[]*GK<38+MP^VGY +VF2GO?9Q1R[F7&MHG$
MC74:KXI7%'U9S(DM.F"\#66;I%D9 ;P&%"BLY?-(KO"=XZD?/3*(T)8EF$,K
M%(\]/%/6%0K("'0H3/9US>+BUS,.$EL6WO'UO@=\!^WO7FMPOI;^0->1Y931
MGW9FP9.I! 2MQV"2)#E/@Q;*67IB HOAR.X'BOKOX2F#MM/?^)SK^%WT[C'Y
M1LW$9]\3#0H(:H="F@UQI?IX_01YM$NN,()&@:)K#0L:\15I+DJ=;E@'QN?U
MC\&O[6<Y+MD\U3*U0]<I="7%P&I*X28.N*V-6KQT.X0+H5JLZ^^VX#Q4L?2Z
M*SB9>^I1_H*.2+'D)O8'Y.([\ ^V)2U9A.XG0!^WY8!/+'9&%JT>*%?;&WL4
M=%5-?WT7$CWV1L<KX 3_S@!F )"9"*:"'LK[=0:)XY<C2>8'E/+W=AY))Y)<
MZ+N/?1T^%=.\NGAO#=>J]_/ULBK]!W(ZU&L+1)D(^-.4#Z@;X,]D/<F;TO=Y
MC%VJ;3;XNF'.<-'DE+1$ Q\='D+BW2)\Q6U%!JF1C#^-[D)/K%GE\I!<O)2F
MHCTETAZ%3_!@!)L?OA8D_.U]VX3CKLSFH(0'#4%JZSNADWXFU;F8@-7:EA9+
M#TW9KQ)/_!_GE;)@9N[&>S\MS5',_)M%8:71$BE]PD<JJ'(,O?MBZ>GA"R\:
M0<724]@TB=KPD9[+E>L"XBSH%W+ZM<WBCRQ[U&/D%]/XJ^C,ZQPUA2V]6_I!
M@>#. 4!VH&U+%)XRHCN:U:5%W] L*[^,?YB33MAJBCACL)1L:CCPC6@5EB*W
M8?W+,,]&XMY*VZ6J[%#P54ZXP.80SJ43+01]Z"UNMV[[HK:;DIPWL]9HOQ'+
MD)YQ^^JPA-S>[6[?.K52KD/=4$_8'PRB#^I LC=?PXM/=*FM]_K[S:](#;^/
M=+LQU218[U^MOUUFQ\5E^%?-[QUX*.!O(8$&3F@8S<7>DFQ_\HV?KX5QPRLN
ME%^.F6^ZZ*,ADO$TZMQ*;/?C*3^O=H9X[ARK.=ITIY]WV>3%.UT% N=;Z'M.
MV(Y7+I-S7MSY/J[NL_TNQ?=G[].-2Y47!,UZQ9@EEN7-S/]U>#P51"ZE*""N
MCK;RVI/T<"8)>ZP*"WCQ[++A55SSMM%2S%7H*^8WE7F/0TBOO]P#?6&>R*V>
M)?$QST,V(0M.\PEL1-/!9O-K2@&0Z'+&\F]3.N>Y2M4491C2P$V@['L\FG:+
M*A@P8]  A2.K6TMMXM20TJLG?(_6AHTT\GDD8I49WR:RMHF"#-L8DJ*;3^&)
M!&MR-=H5$N5PL;%U L&.U[_6F/"\SZXKL=]']7KTD.ZY+Y(VVK*F7%\BPBL:
M5$'^A9L#>+9EFO ,C05,]%IQ3"B: 7 /T\2Z@MB&W[ME_G&3<,N\$YMHH^/*
M?BR?FX4YU)5^)8&7PH;'J9B-;6ZBRIKOOW/+ %=I/C,;FM@P_GZ)XTYS.+)-
MW6IP5@CM!F8G"0#RTMWJ62^N=6OQZ-9G;(H+6WO9O'^3YO3&[TNLV?FP4^CH
M)^.MAOC9S;<+LS%!;*,:T@O0'Z@%O<)W,&W/I>J,6Y]E!009D8,42X>2SK23
MW/'FN;A;N1%!%_ F&R%XWGE(-X3#@R(Z7-C86#7R <^4JYQ?ZOF,17[I7$FS
M9%,^8X!B)HB8,3^;N)L;*TY/4^-QNV<=["%VE5&W:]U 5MQ?0H(?LW9RS,7C
M=,1*OV\AW5%L=I012R2]_.Z,]QW\HW$(5D4@_?'5\1,7_1\!;[^]'ZLK>7X5
M&@C1P.^@2#RS"P\H(H#BXE:D^,6&Q$X+P*)TQF[FC74(9YY&HG5J+_LY/XW$
MN+HJY%R6I2+B)A[9,X!U@=4E2^,O%RHGOI*\_2"RYYS!6F%#6WW\L_'I0>9!
M9(W+YA@NC^ T=F\(85;\TUU+*O.BK*N:6#W6JR.WT?J$N?'T/?5CSUY>[+^/
M8*5!%X^@2?!%0824TY-2P*Q;A;-NRA"OFX+M>_SCB_D#/^.N>Q'G!)>#/786
M"6?('YIUYP<$2%>!HB Z>/TB)(YTK:0)&KWK8>/%>XM#I:7Q4ON9'BW'7\>T
M= 3;Z'-&"-^!PD5:=*AOQSZXC*R*ZD*Q P,&+8GKQOA+JRK>FHUA.YBT.DLL
M_/[.XZ^%M:"@:,H0LE8A'/E0!,DV#6^<,,\!<[M?NUF?<2OQA+7D2;$=(2GM
M(KI>">FP;O^)3C1PEKG#.S97Z%&0*/!PMBLSX<_[9_+EB569KI3O3?#1ZM>S
MWV9K9*N]+H:$9$_TS>+,C=ZZ8*#5TANK3Q;4;7:17.N\V-YBV^F.7OGRT3H#
M9_V$3^UIDR%FH2SMW4%)NODK:#8M4:FZU(^='GEP#V,G-S<V1FY]#GVZQU?4
M=83VM6KH%F=KH)N;N R"^\0B;C^Z5H3LU'VN9/DJCES4V*@]^RS(QI3]280+
MAPXM=XU!@F&XV[/AL!KIV)&.1HN?I?,H_KX&G0] YC?; 2TF@ZL5^'2,NM\?
MB9=7KI!VR>&TU&C" QQ?[IGEMB(@\5$]"D+P.*M,HR2!E?%G-]/GTQP,^,=9
MCUUT8[_ <4GX@AZHHI#P#7B#YR7D#R&@?OE!7V=YFL466YAO)_[I[,*O"GAK
M/*DPC)-[5)XP)78KR/)F8N%)\2$:S]*G@E*H(*($\L? $RJH(,#^A>G"%G:@
M0YR)G(=0Q#G9CO@T0;F Q!]W5[%Y=EW/)Y]*=OCG>.&6/CS 9.S'[H1E LL4
M-MZ2-=O]+MB/)+/Q<[]&:@-GS._^M.D3T@_URS)TDW ^R2_;%<K"X-A"BP#=
MN"U3DT@',("9?[\$SYWOJ69<FY9-L9SY9?)ZL6(RA7Z#??<=N&%/\\:$[HC7
M'OOJ./;KL$".?^X?C'#Q0Z<-T)EF-,&-G$_2))K!V99[Q$\,*_<KZ,4>&+',
MWJV/%6AX8'$.'[V4>G9GLU?B9:>HU4!N/7)3CI$*VE#\N!;$J_"D&&$6.7)C
MN'R>L>#LTY!E^Q;#[<ZN%\*ZJ'Q:9J:"P@AHNB FN&);^M>LW01-B<84:)/\
M"&*?!_PP+3O)489^N/07+1J@<6:PT%S69CN_^8C&\68WE,V7P1D;X$Z7O?^E
MLZ<&FYI=NQ\_Y4^\H/.+&V;N?F)AN^,W4Z:1<_J9:TH*E8L,W)_M*L5T-F%O
M9]FI(+>!276"N-IR6!#$ 1Z'">@>VTUUF'&S-$+Z*(4@Q^3;N26CFVY=3@=5
MB_Y*U1:GX:6%;+^N!:8,_3QKPK[BA\T)6XCQ^RL,I26#YI%7#)_T].%](-8I
MM"_=8EB2(]")KVZ'T6E %&)(/BB[%35:<DF2<4EQ8Y'4%W5G5^=B[0AKD\2Q
MHKY200E0\8Q%Y"::J )\[)Q'1@>)J.*E(MZ,[A$5JJ8]N&OW&G/B(LVMG+__
MIH+L$M6))IMN^5,(7UHXR29Q Q8+T=U;H1LU;Y3U1QY(?6AXK>^GON5PJ4+^
MU%5-NKUN4,#Q-)K/(0 A9$D[XU)2?(WG>3>.)S3BI_8B ??88'O)GX4*"G;!
M5M*$*4U9UJ"CGF]-/H1QK&P6KZ4@M"LCEV],/+^7XK;P4[W)37+G(\^Q$P9]
M,FQE(D^809E$D065#F]VA!G@70(7@ W?:\#]?._N*3Q^9>RZ7+Q$=P_WX'Q:
M\%\#AN>H9*0G)#138&./EHJ_X"="$,K/BNU=,Y]9UWX>\V+81KTIG3+H:Y -
M5E'D HFYT@<2),B%) @^D. =U0'%)<+3L5!ZN&S'@'6J:6VBH$+RHV]W7J2-
M.WX'IP#2]SO/+FK8 B+$JR1!0)\H,(,P!)X<+@I$<M0TK2)FA(Y-KW$WW:SL
M/2_5^-CLV3%D8%MO6W> 0@?X[P4TC1A,*E5102.V5E'(]HL(D8^DPX]#(._"
M[:SCO@_7EKZU,VF\]5O54 _3*G*2<.4=N%+K!,)PJ/4"0@VWE8#0V&Y-J+#1
M#_22IG/6[GSUF)5N=,GZF+;S%>GRQT$GR27-9]]1A@/ [8PC/BUFW0>U2820
MAD_U,1ME'Z;DD/GJ-\JB'EW')>R/-#FV>M/N:P,,[[1K'0>R<%;=SPI:2W$C
MMMG>J;]TW"2^V$2:S/!@Y)8_2L%LW]/,N/PI8Q&%@2:@:Q(+N%WWWAK6R#,6
MW!&2OWWJD9?8![OK7_Y4@=U!!]*$1')]*W]0WT0ZUCNNUJX4S37=<R;JZE Y
M900^E!K<Q5,4_/))2\:5*]\YG^8R'!XF@F;6N@Q\G>JX;5(.AW9E>$G4C#1;
M/*@K?[K\IT1-(UJ08'G/^B5(<@$-I8(>F& 5[U8#+7CUA0,2,]Z[QYMGO3%/
MN;4VW]9(;96[\N&V>1D/@V.",$Z')38O]-G/H,G<$R0_HC5)/<P(-BFWH!>R
MT*_V6RY!KLLS?Z97_J.H$*^<>YE%AH97SUSYZ&WF=?NG5!"?UBFW6=96,7A2
M3T"SBI6:0]C]R^^?<:;(W<+W%+P^^=!"/J3'&ASP%6 N Z*ZH P(YB*@[NOZ
M+;SN]YB'!P6U&R9\JSZ_4%DMHDR6"@UI&O$+GZ%39A1CB85]<IP %70@543?
MJ[P%R&:T>X([<H3&\J*Z&NL**Z9$OI!4"W[H:N5YG"#<'BEZ?3U\XYS -_F:
MR!X6E#DY"_T(%0FIU2T?Q-U"75H;?Q+C56-\"W*:P"<M0OA56O&87>("0["!
MI%42LEV&P@$/;(-5?0]96+=C <<T6RW/P-;4%>7TJGM%;T=JA%O$B^4E?.MI
MKB=\&E2B@D*@.%/TY'K/3^[:I!NC&AY%Y]/*=1YI%%4T]T67YUC1AW:?UX/_
MZHJJ, :]L"#J!TU!V-'.4TWR*MT':3,3T0J.O%,KMLKU6&_)^,K;2X86V@8G
MO9VG=7H>/^E&B- \[35"", L&IFPGL,NAR&N!9[N='%>*.6O(UY/V#>UETRF
M5Q&Y=NF/)%V*-HJ!G+\+CD%70S8'2BB#C?J=9UOEX%#+X0\U%[&EAN=?W6%Q
M]+U3LDD/EGB<>O].M<%GAA1%A!/1.N@KNE[W<,4=.D:_"\G1;)@'BSFWQQX1
M.QUU,HRU63?U@5WLYY^G.T]GA[S4ANIJ29)NXC =8*8U<3E\9+7W>]?+[(V!
M32F/6>=DBQC?QLS)AAK.T<-.)P'GF-M&BE^CJQ&N2LD*J>0F<F*NHS2%"O+/
M ;9W-N\JD/C4OB"<R)_0+M!PX9IA"/.L";GPA8=HA.7Z\P)K4?'6N\=+9O2S
M?ZS#D$9S)L>-YPBXK!6U9_#[Y:T]SY%5A9,:\4Y]VY7U7NJ.P2<!/SRD$W("
M(7%_(8G%P[*1$H9H>M=2@RC&6-Q[;!$R5PIJPVDK;]O7D_C[YA*60T_A&2Z+
MGTO_X_&W[#1N-P#!XWY+(O&L^(NXQZ:.7>^87!A>I;+YIMYE)O&FC[5R!8W-
MUEBUEU_VG^W(=%XF)&8]VA8PNE?]B%YRV3_1VB()*>E2<(\*:N<FL>=CYL#1
M09<N5QI6&)?HYI?WO5/@X^ZH2K-<HU?Z?._BVYCLN7OT/UIE$"\ >KP9C/RZ
MV6X!Q01DV8Z23,H_X^1_8VHI_4T"OJ[.G^/O]K#YHUTDEEYQBW"Q0%5HQ(3F
M$ZX0.LKW'%X8%[#O$*=;F4S*@A.4JJ=[XS=H N;U8G$/\U-&1!@MGPA&JB.Q
M283SB9+6@_#^3T47F ]\T[ M"H3)(:3+)GN/. A(P#=U6?E.:(DE3^D.6K0.
M,>XP'2>6,WA]5_$/S))%RS)=F0M^>H$VL/M:K"(K/.O7\.-O"V]-.8U5U,!U
M2\%;G-49$BMO"*AWI"=$"[A(!X3.;(&2LT]1Q#UO-7E)$0YQ:<CZ]DIW&R.A
M'UIFX.PHY/M)0H)_N[ ;"<C,A@0I(A3QD C2*9P+!L9=IK"[.N?[@E\WWN-3
MR"GG2UQ<I*DZSB8=YI%2VD10M^]_1CSY>BGYK3Q)-U#T!B;\SJ<ZYKK?3D F
M"(<")/TVC?+@?OI9\Y:E!?",.WC]6(297S&F7-<KY4?%^A7%Y6_#4<>-FU*W
M568=_*\<;,V9Q 0=7T/61O6\4&EOY1O;S8VQ#+(B21YT_RH;KY^4\$[Y.-_6
MCC%8)'E@H'.QN=L>XF=I&O_[.A5D\,C=>Y*=<D>1>(<*FD)3PF7H5\!8%<(4
M8$94,.9,BE=^4SBQ'&]\(BQ?AY U'O^+2>YE$:N@R.2SJ2M7%B@<R':C5D[$
M0WQ!87A>QEV<7S3J@?6CC68+Q[J/O_5.2KJO2D8+55V.O-_PDLGP6+,$A75^
M_BUT47_3F*A#LL7;E]G6Q]3,(#=LS>P57BL!6$/,G]X5RRL?$NR$V IS7T],
MH&N\-S+F(-C061UQA5 "E@JZWD@T3B_.^U:W'WU!)ZY?%G/?$142]IDO5/4+
M<_4$='$6 OC-(\/WP+P RJINL$9,DWYZUKYN5-L %)!B"))A2-$&I=I]POSJ
M2/[C@GWOI]HGZB<]WDQ/F 60N&H,S=<<H/$.LFA<1NCN^H^M!XV?FKAJJAE]
MKD\M?7&&JG/%YJ?0T<>"\)MF%'9&G-[7WV9N>?!%Z^$/+_4.^M.3N&KN&(B^
MD=87TVF_NWUE@']WN0V%Y6W+K8D*&XC18"X_7^XDFJ/;92*BJUG6\+W7Z1Y;
MMCCXVBB/W%(@&#B+:>\SYH&P(2X"GHLFPFZ$E^3$*6,<);C4M9(1=&9X*O3E
M#TQZX'+10!:R77)/I0E8)AI$U[ VB[EIY7$L=O(47RO(K75P_%%L@1TZYB3A
M2FQAO@':?^%!8<O >71BNE_"[(!T3:O.@[X5)T,CF0=-HRYZ/KYUNJ_#A%__
M=6-[L2MFQ[^=2^*[1MC!>=-L,3EP S<1OHL4=-MVG_ ]R+)?LV3U=G=,-(K.
M8?9)J[^2HC%_3:%OO^J".@HX8Q6R6VY'J"<7:ECX>/!A*^+*>UV<ST4+O;?+
MZAN1.PM]GNQ5FOR=5:A==3<7.'?7$+P1Y57YX4,NKTTEVX5+3@V29$-)BA(=
MI,L$Z](Y6X/:H,/'[G0>0**?&^P:\S]R,>&RU?<:;NU2SV.5^ -[EE3P!$9+
M$&1<*<&7_$KK! "SRK#"*\2FWDHWW#7AL"F?Z6ZL'>T28E<[G<TU9>35SBPH
M 34,FD1O.T*YT!O6D ,V*PB-U:  ^W=P:8(N+J?%Z;Y7YE:,UE!@L?NQB[_[
MXV)XE.0GW#^<9,]V>4*1T!;/(BI1)JD@#J3[5& WSK+ YP3*F2MG_?J8)RGN
MBY,DYZ]C7_I2Z&2^T4E<^3*@B3>AL#'C4'.8;F]>.'MW?^EJ0&)(P<=B37Q]
M3+D7??37:\>E=L0M=ZS8/QT73*&)'AXDIQN%C18@>EV7=>N2;ADC.ZIFW;FG
MBJYGFC&L?=->E&P7@5@RY!@J#WB(,PPW^]&<]=WS<?D/+77#-=$^!IO+\6H:
M0S].1K\,S&ML@/[4T1:?1M?5MZ.Q5G.0[K@6NXX<A=P.+=&1H>9K^;#).+N8
M=QE2)RXGSG%\NJ.]PS?G$C]Q"D\%$:* %[@!"NMJ/BJ$I+[@*=?I<!%'_IXQ
MWQ3XG*?O8V0,H?9;@OHEF=X^YI<3GRD_/_6@*[>Z>_GY# Y$0[*/6S,)]A)Z
M2>L]A^_K94(S*+V;$Y2XE&!:R&D_AW1#@^$3\R81K5Q8UZ!3=1/-JA_NPNZN
M9?@F?\RZQ-YVN5OF9;7*P=7'MU],+(?DFI/#2"8X[ZX<=GP-%<1$.EL*Z!N$
M=2GJEG26??L^\C-ZL+G(=N'1J3MY);M0F5(D[I;"WTO(B-R]12@ES1BF@6Q7
MT%"'QD-=H$EJG+43/[Q\3+C7+E^T?T;,2._G@HKBK,4U9>A'FP-IEK0%).8&
M>'ZN8-WA61@>FXM&66CVU6+-F@>/3=Z<J_P#HH)XEDP</6@AR"4)BYI';U[[
M,#,+@&T]>C=\XV8N_Y%@G*G8V%006CM^7,CHO([0%^6_JT2-H!%Q!1JBWG"]
MY?F!;F3(07E=VO'WYZ@@7-I*T7NOON3X)K#L4S4Y5O,(MH*G<BOH'UOVY,S6
M<T&#XN> ][A"V]&:+8B')8>R"=M/V4F,Z$W''2F#8YY/'20?/DAN<Y%<?/P.
M7._Q>PN0 6^R^A'5@OH/OJ/R;CKB+2ME71O/7MLIZ&JO/AWR_8YR,H:HHQ]P
MH(?6@,X5[(,K*,/H*N_P/R(4*96?9_4;XI_]/M%<&<V[:XE MKK2KT,FU><B
MZC?^XG@[<K@,TGRNE*=O6>:J>L3]U0Z,<O2'JLJR4OA-L:U,M-%IDD1PS%VS
MD5K01GQ42+/*0E.IIZ/@N]R[P_);XI(7'I34%'7K^;>AQ@)(!K3F/G 1PFN\
M2PC)3J4-19.?N(=))_*$W2\?+#4:[)@L.=L8V0P$"R26[FYI0PK1W,C[-&XJ
MKHKS*LZ;)BGB/@9G<*DEF.D-RY>=][QU)4TJ@2^T,.?6<56&!U;?:';50XFN
M64$9- +?N],FB"MN*W+O[;A M=:/O$2#OJ\E=G_>G?U];_=2Y9;1 IBFR7\
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M0J/=%2;5#I>+!9MTF##E9]:AYOO5NLLDVJQ:4R9??@'->?OPO(0V:Z-01>_
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M(M55H3H='^V"?9<E5F&3Q\#Q^G-+:?L]Y#MR6T*S7[P8RWQ?3M6F?;9@Y?O
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M>D"VLNB*9$@[+03R0G\%TURFQY<*&C:0V[T5"P+H*6SJ5)"T"5& "OKQ>_;
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MX)3>,@AL,/F:-ER"$DA >"F=QL)*,!H.16EQ'RIT<Z2>HZQZ+^>*M;P^LQ2
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MS\%+92TY42C'3%7EX^FHGZ*3?5"B58$_8(<XC_9 II(X%>#*^"G4X"V;;8_
M:$K&0_[+]\#WPY?Y:D]27.P--<R#F+#84/77/U%7L3']2!VB20ZNY7Z@P0*Y
M[%D V0"W,\[_VTUU1JD3V\")"295Q+X;\U7;;C1S4ZBIX@V8P\C#^II+FU/C
M;07=,!Q%LFW?*;< CQLG5'&=:+]Z]/T@1;U(>3\@P(O=W,/+K\U?M<5$R/3*
M%P:KMIV@>6=&RC^QP'6*6^1OR!EXK4^%M\ =8-+H!<Q2]NE[PL.]<_*7KNO4
M;]Z)'.#'$AO1_N@9,/Y)K+D+KM9_<5!Y-\?V-EM4&VYSQ_)80VOQ%\LDA%M7
M\@0\P-'!_OP \FZ"R2_4C]N3 JK@G_>"/=SB;$2S]$3SAX#+I$!C8)O8HD?Z
M^\(WPJ-TW4IG@NAM]?Z!Q(G%_6XUK]\GG@KKAD=0/&B]VL-=ZY8I6!Y="8 .
MNC/>JH3;YO06SHNE"CW>%*M^]6MUR];+DJ%@P'J*429JR$[.N?\_]Q0:8V@@
M$<@C0!B1K6LBDG_L[GV27>H6@<<0EW%V*J*-:A3&_O.;S;.K#*^YF?4N(".'
M(0V341 OTWU?"":CTDM<:@3D:X IED!1+I8^*2,$&G][\>#E65LM:?T>HTB)
MXRRTUS (KDM2ZLY(HLDU3, =278]"Y?;HGMO$/\6!XO9J+5$Q)UZ*V$H_J!B
MH$]0[^O0D&XLP';RD-%@%'93$](-.?< R, @^%#7Q5#?S3J;NRZ[R<UFV0T6
MG_O\R'TAY=NC?T*Z!#GS),!N_S?KLQB*/M)!-= #[VJ',<2D$J7!MLF1N_,;
M.@FQ8_%OZZN'!>AC[O$1.TV2$LVT-QF]P1-*![UW0"5TQ48*PC6('.](QKW/
ME6+W*JNK]\4<%AWU%0@JG9\#^_EL)0*FA(^>[]+.^I+\9J;_9-@3TV8_X@7]
M:QB;1H.;,P:224K3=@ZCU&N4FP";];A_-6I0>_:NJ4QKZQO7>.F.PS=34:5S
M^<>AZ.,/;5RKC8,Z:![XQ97O-X4'6X<!V:LR.\@O \KVR7R2PK)K\S5NO/EC
MU-!Z-(D.VF@A.8T+KV/$%7Y_8%,[W6$G>*ZA_=JCM+&8L7@FKJG)39E.<&((
MEE]7".;33:X]5%Z;,'WZ:UGW7I'4[8,97!X1^:-D%D+@3R*A"37E>$X.Y@AQ
M$<\G#[\%7?*[^?"O>=DI!GF]82VKT?*(CVTZ)):-DX)C6B;^+?<2JB=)Y2IC
M/$=JS%N<+';D8\%X^[F7G"0W25$[71?3R8I;Y@[/O"((*?4>XVV7@!P<)Y-)
M+9#2[7#QA>2YCF!S(Q%7XQJQ.%4,A%='A&#:)2Y.\HM#WGX&_ZYJ'8_[NMZI
MK'XH25&+'#C*V/3%@\\/AQ'"(RZL_<YR?(.T02KYY9LO?;VQ9G^NM=8/WXQ,
MA7X1Z$+'.$QD!"\>^NOXB^YD\VTE>4AI:F35L-9_?+S3L8$[BAE-);6B.84H
MEVU1QVJT-K>_X5/'/I^.TM_YEJT>:$YF*WPO1YFKC4+F;]XQ4R:#>)S=*2H^
MXI!QVOE58_SC;(T<?/]C'Z]\7';$F$]:]I4;(5D<9[2NO2H$&88=4'G!^$P@
M@*+M/6$[>JA=DB3E= %4MMS_]/;RZA\Y)2J[738K1W .[W8U2O'H ;6+]*&J
M)O(W6E1]T]*R,6O79A+II^B[:;S =:'^ N>!:RHG<.XY'43E*<"_(;)LLOB4
M/C"K-R?=//?AAR#U?<!N.]:I[PYB\J[3))5[&%="QG:5<,$6_LK/KH2X#HV_
M#B G[7Z-6:LM9:2#G QA+)M\BU7H* 0J+_%ST, TPL,[I=++^A(=9">2J</T
M?/,']%,^Y?(MOG(=[E6^8SCJRNP"Q'>E!HI#I&_JRL"O$;>3-TPHNM5N?!/=
MPUO3><N6GQK_4.4^(N.S OR4@H).\UI9__?O?I8QQW#$-N?R[8H.6AOD(&'W
M[>/N>^.H*J? 6]]'_=_O;B#_"0_#S]G!_<KM'YWX59V8_";#P%?P*CJ(X^OQ
M:_3*&\0?Q(D"6,J'X";!]0+'/$I4Y%H)-1MJ8Z4'EJ6#,#60QTI'%Z&'T''(
MX<4,(+AWXX0Q;YZ F]Q1!1TD-3E^[PY+'YJXGC&=0DO*H]GM6]),2VEB 11E
MQ&\5.JB/5DD'_53?M^%EV$%2M0EDUY,Z=Z>#<H[OTD%9GG10PH/( >C>;?0.
M^A-BQ_S?=MS_'S\<4@T@4"[0NL#U%0D<M00TZZS7F;5!WT<Z^I],0T.,B9@S
MW^:6M8165'\RYE/:MJX^;LC7NDC1&4JMU/@U*Y@NPA(3,R1'4(I%$&_309Q>
M;5=+>DN$6FW"2?4]%H?IYKYGZE(9=_[R>V!?M-OZIA3S1.FQ8+19-J(AODJ\
MLP^H@H!N"4NDP(TE,-_Z3-KFW$%5EDJ2_ 9R-#;Q_)EKY4NLQU>.<^@@%T0\
MMBXGR\G3UO\SK-F$73-2>LS(3XKE=*XZ6/Z2"5AV-TIE<*(MKJDI>6CADD22
M1+3T65&KCS:&C""0%HAC7!KT'^L^3P;BZBLKP\@O :?__4#^/QI0XG%<3172
MJ]&NJ?_#_0=SO>P'0P43"QH/A6]\$V(]J_5C2#:.]S58#QX)\! 04[.]N003
M$O_G&=\_*'\/?-%EZ2^F_:<<%'Y*NKRJO!::9331/AAQF<)$#06R2<-=^0?1
MK0A)V&P[9YD9>;;:8=K)=[B/3]SWJ^]BH\U/&9$7(A:188 5!4ZU :QP]CKJ
MHD=VR6K7'G$Y.L#2?]<P<:4G?DY/O1?$D 0",;/PHGGI(/^29 AOZS_!N.@@
M?]:5/&_KM5E,B*^?A\%!YIOYJ<M;O*GI'/H76AU0RGSO-CX9*=!!FNL^_KMJ
MY@I6&]@O"Q]U^(A8<NT8_/)'DZJRU0L$T[$K;!FR8J9O\YC<(+)-DGR[>W10
MDT"O66*^!I!6&><2;7W)"GWJ/!=@ITXL(,>1!#J&3U/UB4,I[N7S]K!92V&_
M4FFJM4ZM\9]A<1>Y"W%/'D#D!1\IB07^Y1MGEW=RR*[DW?:!.F7=W/7,4E/?
M/N]=?'G<8VR_^M:NW5B%1'\8XMJP6BS[N:&N[-Y*9#5Z,5<X9[QI$QSNQ=>5
M.3.W8L?L:9/^D_4GE[7Q#7T9ED;+2F2ZSV_:*7CHY(DD\Q?33*9J>GQ86+LX
M8@:1LTDV_6?JCZF6L4')J]!]?&.W=;#GK4+^:D^IC2UK@/3)V0<BHA,>B@A4
M^#.ZGO>N_$V_,IOJI]3B#CU0"(BA'5G^%H5(HH.(M^^A1D;,4H9/ 45()5_<
MC>$_RJ_RVG].\1-K_4!<M3J7D2_AYL@Y6%57?DU32*9Q<*53?YC*C3.&8:(M
MIYFRF.T)4L<^38 (11_H)X>1Q'JJ<7)3F7Z$\PNK![6'C4V)JBB3-RQ_I%[V
M&;!G%JHR\GWLN[?XKM7!Y\\OK_7*/4XJC\CM/%.@ H\5PW+6 6Z8-O%O/O,W
M[C9>FGXC>/G$Z!E+AI]&G@;X%LG /.4FS,[P>_I5R8F&G/RC*V=L8Y7SGT(6
M68&:?GSOYG<2&QX=74Y,<?#4Y2;N8_Q::HG=*0X*DU>[XHJ&SBY%Z5W?=78C
M^N/;JHD0O$4&P9=UIF?79H1*8-=.]2-JOF'KFLT1LL<]DG))D(B0TQKY?%QM
M6WU93CKB<U'#ODOP^^OA-%8NDBA5[[A"Q]"7_>?% MQXQLT&^XR^XCL#&#&5
MBU[Z=% 0Q_A@9#^Z7N,=Q0#(W]_RS],CVB8)?IM4GTYD\^<_._6&$'[:+;LS
MRGZ/=>$N <SK!&"[9Y83MT<N;3>$K^ZSQ49Q"?^43Y,\S92=6MMCJK7E,QO)
M1)MU5CDNT6$)Q"EQPL([9^(+ D,.LG]6W1^6KVN1K62W#K(&&8)\-VUD@[U<
M<K3!W*:( K8/6T/9Y)3CCWM@P,"X4RF:[(NC@^)S4VW7#LT4>E!S[H5?V,]G
M#FTY,FHQ^L*14.<3J!W4E4#\2B#^^^7H 'P"P7(GD5<],5Q'/=\"F?@GM8N6
M)NLPWG'_I)4]^V-E*G5)7H^I6/EG16SL:G?/G::BK=G=7]*5Y!,&Q=)\!(Y?
M/*2#9O:):>$L&YN4.[ *\N/ODWZMJA6>,RD^YWM/=_I<,9.-N]'ER]57%"JZ
MK+Z^>F)2K@)IC"Q-1"AF_7["?+[8A45M\)W(W_8[=N7.Y2;ZZG+!C?V_GJME
M3B)<H9%#"*+Y\?/>KLS&-WC+1.&ZAN*"8*[[I;&OGPD]SYC7V\Y.#?MXAJ4&
MNDEX0I,\25(=H,*XT0WWB C4V29&;DVXL0LF1>$<N9I/=)_.ZQ#D:YHR_!FI
MI#>#6[&!H."R+Y?XJM?WU,=TMD<RTFZI3[_7/2]DST[>H)V-G"HYKWL:\%O'
M/'<9V:>#V(=.&*D6;N#M5UWZ^$\CJ*]/<,?NFNG/'E,9];@JYBK/Y9"9U4\-
MV3OZP;6;)5_$/A>+ ^H4?5BI32.,>F(:SAPV>"U!YX=E,5<]Q\2%OJPITT'F
MO*&?(AF ;<)P%()11ZZ4>@^X7P$[P-G6Z1R?W3?]Y]G' ,5?[;>8-;<,,VT2
M!A@Z<7 $P6,S@4 'I4>*-! 7/@2A.0%79L[C%-SL71]?2<:<!3;5*W=_/-@<
MXE!AX&_CB)R!GM=E!]1;I7V8D_#^["Q*'#EX,\E@=J8LQ\>3-QBD"KF-GND)
M7;7&W"M1-^W6O%A4LV?J:#P7:F8PH7N%J@RHDWS(CTDR/1GQD6+C\'/A[]:N
M3"]XA2H5^,1GF5A%*RZ#.*^;7+H'_\RZI[X%;D1VEYR"&=%!'<+8Q#;6&;CI
MKV G_HNC.OJ*=6221#]D>MQ61FCF!ZY.DV5U9[(;*H+PP8I3@XB;%0G!^N6>
MND*- ;(K;>(HC<8APK7[+QZ[I1:>FPT<4F&H!L=B&[%=T-@%3NC9LN=**3KJ
M_+K#'V#%/^:[_50LSE>5NLEL9>GU@@(+%SCJK5XUU#\/O#8]NQEF?S5S2Q,K
M/-1$D:;JZ9X[+GI'S,-\M]0X:!X!WK K/_BK;LI_^8+=JX2=WI\=$NQ+KFWG
MD3XGPL(91@<1)E(\WJVK>,UH)BC8:WOFGZMM;%!4;7C-__B)1Y0C8XWJ(&P\
MIW/&6?]:!]^(X846?8W-+%!@0^/+I\]%SX<M)N]=03D)]JT-MFQA%[#6C[8B
M$U:/L"\0[DI3F(X%(2 &%X[F,2=QE=B.J15<^RE?_NAX+M%IK.K2/8I*#M.C
M7-'4$=I/-*JD/4T5'XR.I4H2>T[>K#D>K]9?T#+HY_A52DHS1Z2L[DJ_\M29
M916W[_# DRPG)Y @FV+X"(@#25Z#7Z%B6B&M(?=5EK&O,/-C>:ZE9X);'5>7
M9-/'EQTLJD+?>3<ZY,1N^D1XJ#QP'"IY?I4K1H[SJ9[ZCR_B(Z^^5\%'6D+\
M)E<_S'CJ^ESG()"C 3O-#FAJFRPQZ%VJ=C A(G,JZU'C4W%F&4:IGI\E\).K
MYJQ!4 *;9VMH(^)RM21PDEJ1B,6X[Y/NS#SC9,^NWU6JBB2I&A6V)DE14=%%
MM_ZJT=+A#<*FKIRW 5;O?;+<P__9SSB0<,AC[*$F-*Z$++L*/3+E>WX]K'=C
ME@ZZN$ZLIW4[R=%!IA>0QLA^.02W\^<-Q],>:X\#PLL.G3UR_0J&I@N?[+CW
M;/O./C_H]K2YMOX7U3R*9Q5TLG"1*FEFLCBD@WJ5@0D#Q7]=K]TB>E.=#I(1
M(9G1>M+,Z*!;9<B%9*K \0?T$B'R,F+J=R5B]5[.WK0 R6/%[>ZCL')>*^BC
MA_]-IOWO//@H!B>T<$(-V7I$3<H!'73D% !-&?\?';U>1 >U&%/-=AZC#G2S
M3B*'YXB!/%!-N40;_AM6XMTTG%>XL9N-L)@-+'DR$7=WW+_ HL'4QB"W6/"I
MI4?.G1),B/>?_WI/8N_F6:0I<9+\(:]+L]FFK=9#_7MKI5>X(&PIL?."[S?!
M(2MB6 ?RV_I/.LA3Z04_0KCU^OETF[K)SS9I.;.<KY:9>H!EK_;EVN5B_3]=
MHSDFX075EEGX)VBNUP^M.Q'<A:\(?\?W)BV:H96[ ^C3NB)):-RCHC !7%7O
M<DWN68I5\YHO:'A_V*]$';;<C4UISNN.\!9R3PK:%/ZI4W3M5DQB=:DH.\.+
M%M CPA<Q4-6"U'%)FS3@'3):06RK#C_U+5@[2"F8393A:U@8B"#V%%:#P4$W
M8@B<@FLAHT#TD.6YE1<=;VKB9Q.L?M[+^"CSP5%P?4C96=5&9NL&__9Q"(2K
MVEBYMW]-2T>D?&!;+=LNKR#<,"B]?^!(@"PUJBBORWHX&L^UX'UW3O\K G06
M+#Y;ZGVP-DRDQ;GCTKA[349=^,G\=SZ?[[DFF\I9N7]]T-,.;2$^Q'H]8P6.
M9-ZAGA.5"WV:;'ZX3[6,@ORG)88.=% T>C5TE"H.!%:6[ZXV&Q411#S0;68N
M3^4QAK+E';>I'1R1SJGV[*F3(^C3D!/+QTH]<X(S7=L"*\+QM6&5</VQGJI/
MAI7F/!CV]XY)(>W<4K(M-66"KLL,88O9*VWJ1-LXDDAG<UY\JWGY[+H#?[E
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M6YL<QU%1 VNRRNAK)6DF;IMOE:H$Y.R>8="7/3M3JB4TQ RZWO/_> ULU4L
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MT=M%-CT"518>_QGY(/FK2A8W.-15W+-SZ^);=,^7_UV[@?[?O"3WXJBG)X]
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MFTA;8@Z^EX0=R"*RFK\ @F\UA^D'JO=6/+2"Y=Q6>.?;*3Q&Y[=,'&Y$/2F
M3&A>1K0:NQ(CWF!;#-MF[I03#@T"U*\Y:I1^EN+^=<'F79)$GZR4_R>S@9$2
MM/%;1.LUQ'(Q=1QY[ .R%"%ID"^2EGQL94S'-Z9G,(Y&<TW67HT0#$&U&57<
M6U5+&1T4RFKKO4B9OL9ZJ%%R;9S0F1AMQ_K%>*H)>Q-*N&N<Y,!I?V;9#4T7
MIS,>P(NHD9CS]AFR'?C6WR3/*I?0SJX>@+(%TH] EQ" Q;$O''I3^#Y8:6)X
M B#3&.H9%^*]K>[AA=5#J[0 //^D]IC.NPSM0'EMS]/V7UDT?18+HAT'Y.5I
M#MF@BM0)2$W<QN]%^PO>+'#S3'UB#$FH$K@CH/I;?<4_F8;G@KB&8WZF!.]5
M5%'I3M+U6B)X@T1,ZN;'1",>X(T[0VL.?Y.'@1%21WKS?N(D.YOB^7+]>CT&
M'_/65E"VB")-'DDA8@#)$0A.:=1+B^ 'O*TIK]#LTAO!P?/\$X$)%3\FS[-+
MJI(8E[57SEW*@9R[?_?5&8HL*D.#@V1##B9*).\R2UA3LI10++]4#F-:RE<J
M91-$LJ0<'W,YYS^S96[ES)9,SV_H096OTC)V^P.)LZVARVBVNLIFXJWI6P$-
M2BHNM;#RN*\[B<_F'3:\6NF2%Z/[(_RT2X&=+XAZGO9!#NIXG8%H_9.:!;HU
M89YG0@S&33G++NF\C_,2 @]>+7-;7C6GO]:$0^)5B+1[]RCOE$K3$NKN95<3
M.*RK4VH\O?5'1DS>?@=I='R6J]C)GM=\$&$?HZU._('DHEXP.,:>#R@E5+=#
M&7>9':E"(4[V2= )LN=[FVNUG^1V8X46N1\TQ:IE.V['F([1X)$U)-;CR%:K
MMW% J-3*_=I^%]D=VNS2H+\Q5%YLU5CS;<V_6X@$WRD'"G%ZY&L"2S)/"%U]
MAGE=:MD)Q5.MY>M-N:,W1CN+7DVROQCS>O:2R=&J>)^O!_4&X<K\Y]"]1ZQI
M&(Z&/..AY3K"R<PK/]WJ3)2VHU==W0884$IM\+"1WYAIV[W1Z+VX&@*Z$.=-
M$Y)S@Y\A$:I;O[-9LV+&W1?-NUPLC3_X]=1'7TP;A%I*2T;4L&Z8X;;.K(-Y
M-!P+X>: !6K-]Y?53#DZD_ME<.'7Q:S[E:"B$Z7*UG77KXB=-@W!I#A<)J[D
M'<^,04$W=C.KQ&->;DR#@R6KR YVNZWOEN4S(^FQ-R=7+'1>T MFIX=21H[S
MX9+,<=BE%\UIQ9Q"G_VEUE6.K2[7_AB2V5EOR6YK\VMON/2#UF"4\_FIQ2<9
MG#)^MPY5\$Y8!#O\#.5C,QO)8%68#TWTCBVOZ1[2L"IQOW)0[Z-EN-%X4[".
M+OI:7 ;-9; /J!LH):KO95$29PV("QU@/K<%'BI??[A0<:VW>^&-XKE?22*.
M#F IYL4 ^C[GQ;,J7N#'U@NV:T'*^]E597OU;&65M^(NK[9?;I^*8H[PI8XB
M:PI>DL)#5(R!2P0]O8EF;?\*#TM4.:P^U+EN[YY2C>EIOB+7+E[Y#]W7:4#9
M+ER'EUZ[$4/"KH\&O.?+911PPSL]7+/@O"A!X*2)^'^FO\S872 &I0? '0[G
M75@:[^3[1E@TLG'>!B#[_5X3QDD:UUB3X))EJ\%2I@MF5;E?=6E%I>+O(GL_
M%GJY]'\:KZB(.!^B8C(*#R;FZ*.!)^_U UJL;%(]/7Y/10WW7I2O?!3U>GDY
MK5%>[];A4B>5?PP.*5^[T8&@T9 M)0OYJ]TH!U@-8Y?NVAJ5W2]0CU]9:(#'
MY-ZFW0FZ@+X;W9Z-9(B0+TXCBK1GK!T&9<*'/'+OW28H==RX[*!B:1JF]NR+
M,DB";K(>+CN.YH0S$3<<Y E'H*ZY!UN&M5D5&"Q/]5#%F\86+0&7LBK-<UZG
M+)VZ395?L1T*7_*_=[?)<J2W=AOFNK)+-BXM0[D*S[CA@4>#=( >\<PZ5J_3
MF!4H,6Q(1U1[9^B*/I+_8LLN KI#>_Z^KK%#R_J^ X8C@H6LT4)Y$Z%IXSX3
M]$I:ZK>0"0HE\O2AI"3T2N^Y = 7NX^[O3/JD_BL$)OUI'S(2AVF9.WQR[P[
M)EOW44\@;N<.)\E<>7LA(X%<"X6V(:%KA]/0&)[KUW2J6&]'TW\FTX?O0T6I
M<PLTS4ZX/A0-W!ZP?92SP*XI-)_W7K'K"/0B/^^L2R0+?IOP.LIB&;0I"94)
MZ9X8SR[@&G8BTN5NK^XQ5AB<??);SB/J1R%?&Y]OP_O>+P-7E;;%D<=N8@T8
MN;X3C9 9;K9?W.*]X(ELRVF40@6)"_(N/:+WTJ7Q?+I_)H03XI+&"-<#B"3#
M]>/4:)4:$&[VI4" /WA/(J99.ERDTU<45"=1H*EZL'*?UV^4'7.Y] I#8D0_
MLOHFI";MCZ9P:%_G#+6>M;U%O?LPR0#;(D/$.XYM+C<VT%<(7?E6^;:"YQI4
MP[]I",T8HA71@R#<S3..+F"?..;!@B'U;6GE-]ZL\1CY<L6T]4+DLB&RY#"#
M0=$$T*-%MIECHOW?)U-GLOXQC<>0+Q^!JL)5J,EC[T^ DQ#5)3%D1R*L2UB,
M\D%3^I<<8(K30G,1$D->ULP:VNI(K&2KR.7D/?UQNL]K(.(NVH4D'1+]9>&8
MQ(2K8(] 7P;C52(D %O4JA6'!__-'#_[>],.757Z=#)?:-O.?V<$SZM*A=#&
M ?XXV:='H%-H%;BU]\QH:TXNID/@"'36P+=H+7<^1;G(];'[*]WLU> /#GD1
MILJ<=N0&(40D/-@;=3P*/2KS>J-KNSN5AWP-,QPH!&X/FLR%WX,Y/(W"Z7TF
MJ44ZL6Q?OGA-Z[HFD9.F'(N*JB:''Q/3R(@13>XQLDZ9&Y76<@05F,?,_JO<
M>>R'H8MAB$N6[DTM0Y]OKU,Z9(MU6^+:\F2G$'OK@ YV,"YTX(/CL9?@N%KP
M=878TME>&>D1MT(Q9Z..;9NWK5=%6!1J/UWCV;,_GLLGU/$CT#[=$6C$WP91
M)TM&(C=RCD#0W+3MQ,BK+^#LQW7(7<1,"0Z=N63D;QZ-E6U7'QLJ;Y8MGJNM
M\N!Y\\[&Y=6'/A"A=Y#AY)5WCO4^"+YCTLD'>;@UL[3G.@*_BEKG66 .9.4H
MF_&*^SBG-+*ZKT\H^\!8_TTDP*W'[!6G4V;NYFMB]1_6Y#&8>(A*";"W]'ZZ
MP.%M9E]+U$1Z[,O]VB]:?OS@Q<6>OGX)P5=2+MI]3C' *.G8$-KUJ5.0*LK/
MV #F!Y/8WR7Q"R2%>V/E_%,>.W%UL(3S*6@G3C='FAX^F2/0W&MFU(PLKO@)
M<7^OE\C0ADP <X@ @018:Y"OTH^,M:0',Y3U=UY.P:(N5M_.I?I<6#Q!RDDC
MIJ5JLE$[J>H$<#+&=3!Q8@89ZZT47S/("7!+PZ&SAN[G'DS>*NLH%)\X&/#Y
MED_CXK6^5-].X=GSHU3!S8@0G$1;*30!S #W=:=I&+.]$6?N>?(W%UM^88"Z
M11V[L<#3:/J79U[DX!!MX%0HFX8$UGAZ<L^/()LLO2EK#L1UY&X]<8R^,_KH
M\"K# _ 5U^#^UAFN&SQ?(R.>3QZ7_^R0'[)'H#.8#:31$:A0Z3+I+9KG/W+!
MNPRY9%6 ]]BUC?$E)$/ U9[(4ET"U_PT7BZK9"2BVPB#X@WC4C+H"BP.FHO,
M7VS0.3_S[PS09 9@GB2N8]O5TA0$.+Z$SI=X$F9Q+%FADPZ"Z*8,G$#8"\>L
M\:7OQF*%R2>O.J*U7YUE0)#X$+TK$5/(/=YAQ*[]#Q?J*'0[(VTZFMK\&T+A
MD@:%]T-I '6J&7@)26(O/ (-!P7N_XBP)QM27L//DY2.[V9!AN$6!.SL;=VV
M0^[-=SH,?!^@PMH]OBJG3NFN1$),)!>1@,09F9>DFQ&3,]*9R U;63Y)V^OO
M32X$?1[CUC'9$-'9/\4:.DP$D[F\OQ2<'_$*."XX"SB(KAW>_ .QZLS*H_J!
M*2X:DK>TI6N$?3X:=*FN70!$L-+0O=.49+0(7)^X6VE Y+GG3M;^H+M9P;UG
M)U9>+4_H_N9CRT=3!&<'*=)T_UK@@S,0P=0SCC@$)]#7114B_(Q%<__R?+-:
M6N'QZ9YTU^L?&3C]CK(WB=P-EB*JLSRULAN_B59M8";(8F&$)B'M*=GB;4C:
MER,09_FD;57>C;$+35$+YG>W1%T*@RP>7EA>BM[1Z;ZU 7$TGD)]X8_;&,<B
MV<BW",I). QOR.M>E#T49FG@KVH8.W=FT^<.DX-M.N6GQPIB\0VT:BL&S4*6
M&*)*DT4)J9E8,$<(JVWM^+M,O2IK^*I&)_25N I]YE<O_YB%J5Q0_W&4B0TI
MO$> XFM):NL10H1O\W(3&Z\_9T]>KV\X>VW]X+^P]]Y137;?NFCHTGLO00%!
M:2)%I"2@TD1$17J)@H" @(#TF%"D-P$!!2F""$@3:5)#+R+203H)O2<(X96$
M</+M?>X9]^ZSSSZ_?<8]X_SN'=\?\Q_&XGU7UISK6<^SUESS??M+_/)L@/BZ
MRZ9=FC\!AABS*FQ.;X3N)!1;;#TH8;-QA5R,6=+MI>E-%=&K.SJ9>D=T!F(^
M$6U.J\] #L;\&[M-=Z>4CEMC?%)%B.FZ9R 7Z\MZ]I]0^AM4*T._ZO&&4Q!>
M@!.C<P;JOBZKS"H(O]N:>=QEAK_#I- KF47([@R;_I8=8T=+I/1*76D% _0$
M<U)/W=@&DM87QD*\![A1'Q@7 4@8(\WJY^;XO="X6U<-.9/E&#G\Y)XC9H%^
MM*QG+Y*!:)H7X&;[#3L4[7GXY_%8;;"EE63MM]FWBT'$-@\JU77JJ:XS$#UY
M^*XM5J->U9R!0*11!!L.&46TS-?#RP,&5M.5[K5/[G(X*+@/G>>C>=/'%S8;
MJJY%9X!=Q@^-P1UPE1UV]*=Y"(8S4,<W(+;Z*N!L/N'^8&]NZ+R63LT0WU/+
MZ?L^@E=3/C-2A9JAEDIAW'I1"(:G,.9R96M;,?),+[WY27-^!<-77I9RRV4U
MN9_BGN*-,@,JM[J[BG;^RXLB\_^RBLC#I<=:18!K-F,0, "U28*--_N46YZ^
M$W]X&9[ED)I"\(K?DW2Y3,GAJY3$M+%85TGD,NF]AC@_)JMA@%U'.[U1DBJK
M%..T-B[6_P'V!K]Y3?;'>NX1.^$15?KIMV9+;$$'BA;" 22AH5U)-%L+TH!.
ML47VY4ZCJ7+)AH9J2M4%!2%O'GC-\^I'X#<&6T:(&*(Z[N<[W+4VA C.(^%\
MJN'DSOEQV9@MCEM,%,?\[<+1RJM!4SN*6$&+D?T=,NHR3&<5BX?OJC3:W!_@
M695NX0.91GJ?6V&3[D MI2-4QS6@Z$HP>6[)=)'[T%JMP2:=\,GPN@3B(6<*
M=?[-G"RGQ!!(,]#T*0!E#;A@9*%M5FGI21A"J5GXW7%?X06CFGBMJ\*?>R\7
MQA(_>C#F*,)RK5 [381+ 3[MV/H>:(*"&Y)+I[&U!,.-B\DYD6ZM&.Y@5)F
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M(DHXW?*/<*VO.3N R>WJF,S9>]Z<@YQ70MNH&./[P2:3K49 %4&'* JT.'\
MU/&Q@.8R.%0@.WO'Y]=VNI\VS\(MU0OJH>=2!T3#_'0[04)A7%.?29/U5Q9(
M<[E?N;M;.A:L!S2)R7.7J&\7/CX?*B24&+"<"3KIQ!SW)D6=@2A>6/C"P &?
M.SO-?*HL: 84#:]3R8C%4*DOQ^^:Q"?=MSENSYU91+/NTB"5HT+@/H\KMNZ?
M3RL3N.[N<9LJ#,.?+/SFR9,0K;ZCRK<DK@!S0S):DGG&!6"Z/&"FA]E//@I?
MI^84_FFQH]IZ9M_FG:F@&&(E.50L_)(8GXTVN:4AUB\!6]1.H@5FT49JBS?(
M B"2:.@B9)6>RQ>Z]^A)<KPB=\_1#U?(,[1AI9X2Q5%]',H%&IE#@4LO0<,X
M NJ&;DX>#O*Y'7O!/B;K<,>\>\SQIQO^]4[B9S8%;_V.J6MD])\")'"H;C V
M,4 10Q-96B&\8!L_;.PB3M 6OR69H#$*DEP9 N6$M;H#"=C.&T AN5O.PV5$
MO2+KK1.[K*5;XS,=..K7=S8U2D0.1:,81J5# KY?VC5#+GULY1S6X,083__N
M5=--=O\$1/;V^JG8'W0HA^G52_Y04+AW59&OQR>^#H+KHUOD[H<; ;5+^^$0
M07=D#TGL"W8R!3Q@';?I]R<I[,:%^.HZ"O6'G.V8QAE K%M$B"S$GX*!RW$
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M#^%W!D[J/O&@P(PVY"]CO$U4CYIQ H)_VP!CJ]=Y7+5PTZL0>*=\+O\=BWE
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M.\VJOUXM<- IY!X=Z"05U65W=6B\)4O'4<:!PL1,\FLB>A 5/8\>J.>WG0E
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M]=AN9Y@%_RW8,2%2!\!L]1!1>"^UWUU_2OE-15?C#,*TYM%\?=T;6_7%TV<
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M^C7"A8'"UN2 9J6GG=E:;!FZI<_.S-[+-G>$LV<Y8_'K$IL*9 _* BD.'S$
M32E4Z(>QH'H5UKJ.43\0R>7T]$?>]$H06B-H7R'<"GDIN5&$=7/LHB+KS\MX
M['G:'6)5-PJP!=$@E51HCO*,^'7&<'Z4?==KGJ1WUW,<]""81;89$XM:?8L\
M1A).@1RGN+I/-OTY2!?NTQ_'S=SW^-A_0OOZ!0!HN+,F:(TO=TH.8)?*X"C
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MHM;W5[4D.\GKY<Z:;4+.!"&+Q \9;D6Q7G^^V)YCE0#\@7HC%Z -,VBJ(T(
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MSI*#* \#2)PWQR7Z:BF)#D4#K^8_B=1*_UGG8G$03XM^YW"R[H2-&C=C"28
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M]].B23Y]6JE(+9)6\LZ1B<;-@RE)[VI[>M3\E-0Y7(;9#:=GYG*,A$O4XK]
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M(TR@H?P^RAMZT.D7PZ2]O6E\\RVR/ZCI8?#ML8^U:)\/Q[&JS0N*AC6/&YC
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MXI=8A-^?^#IPX?Q)H%UGOT]0T5GVC8W@^J/LA%8&;]0XX] 9JEH?5N*W"NA
MYK;YLA*C]"KSCG_M@.*I(HV-Z^^'CGSG2))YGKMK!=4R6"NBWD(.A5@Q 7[$
M.52UK]B3LFLF!F_2G]PNS4>_FV=[:-HS,/_4<PJ/;H:MU2S"9B.)],R:>%I
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MGM;@3AP45-<HI"FEO7H/MIM#?T)6*='Z)9=-F^B?5K+X[DV]9+Q'DV#H=#P
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M_H_/.OK=DPE1(AE=2/L@870MSC!"-OI <S#6$YO%(G.6_3CAJ%[*K1CA/HP
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MQ5F<IK@W.97Z5H\K$#.S?_B'U)<QO9B1]M<?S\EWG_QS]T8&_;XY! T7@7K
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M8&:"(3-SGXIKOW7$61*G-BI^[=2\:Y16GFB@5EJZIX8(G_W4:7[#PG+%'"*
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MP+O&I(<8Q?K&-*^F)W[T1:]7B2_GVA-]4UVG?]SYB1='^4"S49Q,P!<O@/
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M':_;<XX.24I#2.=14O-PQK"X&S Y6HVP9DD0YXY1K;5O-SQ3)$L<AHT/1'M
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M(P3I,WG,= W8%QBT_1APIH9FX>2A(/!FQ,)K+W7"<,4H_-X$[M2B9Q$@)$F
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M02*/<P6(L@E/_E[QO3T:C0X2.#+EOVOW/H-'Y8/MH$S?^D=F(9E$)7_DJ6.
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MS#G6TL3ZYS6=BE<"9M^M6=]] )PTU=Q8='R6YJ.1F^$S,["E\'[0?PLX930
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M,G[)QA+9_"'-4:'A"Z"SN?8[+1.\6!2$#0HK>S0&OX+? 3A!FS+B'NN7J@<
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M0C,$"/1N>EJ,HU#8QK8W?:Q.*6G?2:WJZ6.ROKBR+.XFWW/?=02A#0<2;>/
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M1PN]><T]QCOZ]1T2!,_FAL1P.*;7*PD# )< )U##M *$@!FQ<Q&9I'^*]1A
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M!G)KY;@D1ZNFIC=/<L4^UR(ON]>_T[!2^Z KK]#@YB;N\>H*97%G<Y2PT+;
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M$PB=R1=0)4?;[\3MC\5K8_/7J[*O/OWF8G.UD^-'X\GM!J?3;BNV=T=>#,>
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M%X'"$GA$'70!-YUUIF*4J^Q<;9,8J?]!^;4'.TUY;?2[%B1=^$U\#E _"(Z
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MZ*-?A?,#X,)1K'W@\86RE?N=8YW%F;*?;7^N?_XJ2M[BOUR08/:=[OI&5PQ
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M_(B)=_[ET+1_ JJ#[JKXD\S)PIFPF<-7API</]2?M5UM*NMK'S5^U5OGS'Q
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M=T 11#][.N)7WJK*WO),O)=P,?G;:UXJG0FM2U2'M-R$^ZC3) <M]$^AX;)
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MM]R591LJ6&:$<@RUQR@N5F1=PU'3U$$1;?N+93:$H>3CJUL.9V>@KFGT\+.
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M@% $FG'9"=W!Y9$5=K-P%R(CRUCF6)7VXXUNKRS^*)5$YTD/0U19=7[U _O
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M'NDVJG./&%CW];&[&E?RJ3,:: YUC2ZYTW8 E;6X]PBUI5<]<L>9N+/U6F?
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M@/)":X<\Q[8BSW8K^=_; W^59YR6EY/3#GTR8D!"$2ZM"/@*0U@IUH3V(8%
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MFZP!]VRCOH*R1.J,AG]CP=:EO7A;\H,;>\_@T2&[;=\^ TKONM/8GY&=?.@
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MZYP9^\OV.3K[AD6-7C+IR_.1'0YHOI"9H;2R.RBSK^\N3-Q>9Z,GOV#8!Q)
MB]HLUAW4/6LD*U.E$7LD]?@N9_F3OSV), 5%B-[\G:G%J',72VJT9'(;VQG.
M"),!SOZ9RL:6@HF-:%'B7J;)-4SX'X?@=+4O572Q..9\4_(&56I5[CI<^Z77
M5$PWSM\S"H7XD/=X-VQ'G1S['8&>O054HINZ'1L& U_C#[#M;PRG<39IM4UB
MV877+25@#D!FZE%U.2%A!06@7O=S$?<H;W\"[2-].4QZ8%*3?:EYWQT"S3'O
MJH%Q=#BIZ6*!\_FK@^JEGTM*CCCEQ-\^5@B(YP/X$.YIGCM;[07O9B(#N;B'
MR>]H:RJ_.N;[P<BW6)]KW*ENJJK1"8FI.IPB^"/LBH[R@22D 7MOTYAXJ!S_
M"U2X CN$;N54UN;-54EV3XA"VLZ$C"@-M]N;X)+D%,C/-X;>>R8*[A?8-&9A
MPWGZ$XMJ7-UFCE#*N+$A;KEL;OWL""K-PU#!5BLBQ!Z[BZ?-C&GR<?:M@S'<
M)!L'^]/[43FS'X9R,VUA]D)A!E;_A]LA/]MI)%!^HCS; 2Q49)(V],/)8Y3<
M=^IX6 ^_)XG;_B,5^3J/_SWT2H77BZE+9>F;Z<H;22O:!(SEYB2OVZO/0FLO
M>&RHGQ",U+)8]\\<M>D:3)"ZI?XO-[#I=))1.>TM/!GP:S>V+"K,^W)!ZJSY
MR<:?W?+Y;Q!3F=A'2:R')/2D!_MY!'C;7E2L*#D@+;)3I @DI\"7;IZG[BN=
M8$L4H,WO')E+\53E?WC\2/VR1W6YV$VSFX3A#?(%6L4J;?5E)_@TK":*[A'/
M[##E!WRGAI<LU9F/0\79+O[=[S)RX<TO,S[;TC<%?;> .V= A7A%5D$VAI$I
M;5KRM=NO<*9X1:/N:3I3BE?MD2:$VAYCCXPYI$73AL8X4@X/H,^P=G73F%65
M5<&IJ$96_#10=HV.D^[&>Z[PY"?<;BUTR(RAR]P^SXBMC896QV\!8P&+6X#H
M:N*"V@XOW!VP;[*%7"N8CX,2(< *.<I=F27SAN7H?-<M(^CY-1<4Z4=,>]AR
M'*!T8S<(/-_>>\Z:!6I)+7C'$F2C3W^2;:JYDW=Q:9G7_<P0)5D+*_@F]WZZ
MJ,AH^W16!HWW<E8)FV*0;[QS6;-[6<-3T/WMD[.R0<^,'ERRZ/( 7LWH[M!Z
M]+$P2QS%_A-_2F0X@5)4V%(ZT]&VD)KJIO#MLT0K2C)BM][U9QMD*_(>-FK]
M#G*<0KW(F!V>:**87DM6K=YUP[17[U+]H0F=I8&?W37]I^%(Y 4GV98S;><@
MGFLC\9551R^'.*<:Y7K>P#W*?%9RV_P">]D"L@7<#2"*YJ>>QWP&N=&OHWE!
MPL *-O:0/B63\2E*Z&FPD4'RJTN;:W7%B0^S#"8/;JZ?_=%'[X6.BM^%K'5_
M^_K1NP9+!!%5(SO 6P"MS*-79%O_AGW:RTQ:/*3&RHR^-K6KQ%_O\K.0BT,-
M6P E'<0X@[>VSMP;1&KFB):/?W3(./ PKMXH!1#?>);8&&9,8.#>'$]@DKF!
MZ $$PCX^!0[O*H%%@KP+54,6Z;>KWOFA1>L"2]CD\:GY+[6%Q=/W+??7=XS:
M*G61VC\6B/GUNKQAG;,:](5O%]3<4S)<^SY5W_''4X:[,R4->+7.-"<QH=N8
M*>7^Z@182VHD&BQ6!(U&9-?XGR24"S$4?I_,P2QA!/[ UN@A$X" U/2-6!,E
MO/F@_QT5=Z+9Q]6L=F+@!><GB_K#IOK7UHP$QJ@HIG4+)[D:^W(6TMTV'"!Z
M["(T;7HZ0#'&Y.VQX WI[B#E\^5,;$LO!%7L9D$JZ2H_=3 %=.GA9820S8M*
M"[)W+1.&(X^CP?,O=E?5U&P.M8E6C_1."O/]!18&?ODQ_SUP77].%]UI\6E)
MYZ6Q\<6!:42_S53MY>K.??GWXS--W42E!.Z.$W;,N&N$7!E4E6&5; 1;=/FK
MI%W&YV&RYL]G <!. "?U)FH<>R@(TW R<1PJ<=5 6*^CDG1'^A6V8!U<D)14
MCK)\)Z&8>'<U0;=9]_:W-Z24%V[9EJ05UV5;NT<5Z;E+9-/AI&:*2!\>+>4W
MQ\$'1B#?-C\-6!?).QAR)8^Y$>>/E'5YTQ-5/,NAE:>!*^;ST@56%?=(EZ!.
M&:IO5^^PI@S)?B-%[W6.>3SNK/Y7KN45CR^JELHL';*Y5.3/<A?_?W!K]"!3
M*)RATAGW3ME&)D6RM!W:'?B^QR_Z$LCDR2*V/E7VWIK/*9NSK\X3Y\_D_/[7
M@UJS2OINP9WMQJ8EG*- \9],]P1H["1+>&C"Z1'N36\J+R$[= FW^0%D]24G
M3']L/]YX.]PDRS5?3<.B/EPLJL(WT<PN@@ 9Z*NP%A=WLO DN;1=]7Y^1*\-
M;&RY9%/]<N#GK-K_Z<WYGY&^_AW 3W!]0_M7^+VA0$7,GQJ9,CX)"L=5Z>J5
M"7;8M*+WBM:'SYS88UQ_A*K/4V/>:D9">%H$%LB-'<Y8//1Y#O/78VX+YPFK
M4Z<M6;'^HF3$\:J##V(>J(P0Z"_4W<@M:-!?7$HC1T7!/>-">B<_ 3KK"FI*
M81H1RD8:6 LFAS.MMH!(Y@]84Y+IP7'LPEKKA&;YPI?:K!Z_930VO. 56\^.
MQ+*<VPC)M(B^GV^F&;TP&4"(&37<3*5_X!\.\FF%G,XO<'4C>NF,[9F#^UU'
M[+NN;@6650@[/6B[6XAJ0_5,3#S#_T 5AAN9L=I\BL]W#-Y.+\9\>Q  ++ES
MG9V=[IQ<1"=O 9)\1-!I+B.9R)QG; $Q:W#E)@=.]F I.:"S)6/]^W+'=[N'
M]R6DSSR*FF^HU^\=I#*M#$-:F&/-SF/("R&U"G$?N^R>M'.T"?DG,.8#C08T
M^WQ94HC[<%(\J1<U?,J;"ELV.)I#4?U!_Q<H[/XV_"\_FO_%/QTCB_7R3>(B
MU6M[LY3-]MG()][S;X=,6]>E+(%4HF/?"T;B$2?!N^S6&WAD=@P#'4L5-M+F
M[V2Y)Q%R9V"V!CE?NKT+P @\5:7;LC&]"2,GYDC10E<-.+Z^VS4=F0A+U Y<
M7346,=&TDU5QM&",-1*&EMNHD  GN)$6@UNTF$Y3&" EY%:$26YDV&JTN8ID
MZ E1T03,%A!1@ZY7B[Y-B%P=,AE@O79U=R]?]"'&M$[#J@3LQ)<*R18Y)/GG
M=JWY,B72'YS27%D0E_='<^Y_%_OIJ_GOQ*^=^8N_&?^E8_M"#SY1:?;HL+EJ
MSQ_\%8TKR%@%OK: XG_ZZ7[QBU_\XA=_.Z!;0_\!4$L#!!0    ( $2@!%U,
M0%C,.]H  !44"0 5    <WER92TR,#(V,#8S,%]L86(N>&ULW+U[<^0XDB?X
M_WX*7,_97I694,5'\-7S6(M4*FNTDY72I)35VU9V5@:2H,3N$*DF&<K4?/H#
M0$8$XT$2C@"HG#.;J59*)-S]!\+A[G"X_\O_^O:T0B^TJO.R^-<_V3]9?T*T
M2,HT+Q[^]4]?[C_@\$__Z]_^Q__XE_\+X__S[O-']+Y,UD^T:-!E14E#4_0U
M;QY1\TC17\KJ[_D+0;<KTF1E]83QOXG7+LOGURI_>&R08SG^YK'-7ZL_6W9$
M'2=9X)#:+@ZB),2$V &.W=@+8^*ZON==//S9)D%@^8&-T]"Q\<+R,AQ:"XH3
M*_03*W.B.([%H*N\^/N?^7]B4E/$Q"MJ\<]__=-CTSS_^>>?OW[]^M.WN%K]
M5%8//SN6Y?Z\>?I/W>/?CI[_ZHJG[2B*?A9_W3Y:YZ<>9,/:/_^?7S_>)8_T
MB>"\J!M2))Q G?^Y%K_\6":D$:A/\H4&G^#_PIO',/\5MAWLVC]]J],__=O_
M0*B%HRI7]#/-$/_?+Y^O!TE&/_,G?B[H Y_;6UKE97K7D*KY2&*Z8MR+T9K7
M9_JO?ZKSI^<5W?SNL:+9Z6%75;4W*N<RXES:/N?RGX:(_7P&^YKX;8YYU<"<
M$/>3+A[',/VDC=U[IB&H>89[9,YFN?V@KHITKF]W2^ILULUSK.NS*!NRFN&S
MV)'IL;SBO_C(?NK(\(%&E*F@TZGN'JOT6T.+E+;:<F]HE*?_^B?VTQ\T2?^X
MKPC?$Y=5]>[UNDCO2;RB?S3;S_4/6N O=YN1Q>OC[_X)P'0SL/@J6I?K*FFW
M+4:4;]DM'__6D42,)OLUY3MV?8'B5\3HYR]YNB:K?_EYQZN"["OC8J]T2XQ^
M%SS\OX.2E\D>M17?H<OJ4+PRF11O]\773#XA6TV3GQ[*EY_9JS]S0XC_@/D/
MXD,?'/#GHZE95ALN295,X-@]\7-2,N/CN<%[D&95^20G3E/*S6H+&R/Z)U16
M*:V807E"@(%O:_DMK^$KBK\U_UKZL\KB$0)"E@U4MK,7#/J=D]2^/OIRG+DR
MQ%!OL";Z(IQ>#7M/P-9!735__$J^Y4_KIU_I4TRK/[8^460O+!Q0S\:Q'<4X
M\.PT($$:IG[V!_/:XG)JM1R-#?F@^A2DOZN.FMP*F10]3B@.(]?"29;%EAN0
MB :NC)HX2W %+7&FV.-ZX2QA8&JA(X-^;PEI4 :#S)_0!1FI8\$^>ZE3!JNF
MYO_::83C\691"(-B;/3!\ - =?!:T3]N244>RF+Y4%&AFH]7AYOA@"^1,$HI
M)@OJD(#2U,[D5L<P#</KI".*ME0E5\P(*!-K1X^HL%5T).7T>I(6-^U"<")Z
M9%KL/6)@\<F&\$\:U,BT0*U"X0\*;6'YKM5JC)%7Y]$=T[QOM8C$HW#SXC,W
M\8YTB!4$S+C((AQZ,<&)YQ.?6@NF2!S9';8WKF&]<<<_P;K)$^;'_4I)O:ZZ
M=?6^?")Y(;NN#K"8WG85)82I"V7A0)OP"5'.V(+[H\VV 9\0H;_]GOHS;+&D
M-/_CCB;K*F]>;2>^SYL5W5LQ/@ZLQ,%A'$;8)6E('=>-G<"663&G!C?MO'(:
MJ,R0[?P0_X@VU.56RTDPQI?,N2("?5B@=-++94R,$1>6O=8N&?;#;K6<'&R6
M)3,FQF;=C#X#6SSK&C\0\OS'>QHWW9 YK9<O)%_Q,-&'LKHC*]K&#P_6E.,X
MF'A>BA<9V[83+XRB2&I- 6@:7FJ< [1CX0)MF<!966'.QF0$4AG.\55I""38
M8M6!C_0"5I!X;"_LANOMA]UO=JL<0G&6Q:\ P48GJ+P*WV<WN00?\IH9/G^E
MI/K ?E,?JH:,)C@* A='81"&D1=8ON?+;K<#-$RK@DV61$L6<;I($);?>(?0
MF=Y_-<@,7-EP<4$[\81 2AORT)BS[<L30O6WYZE'%>)+UT52,4>#OJ?M_UX7
M'TA>_496:WJ3799%DS-+NFC$+S[S[)V/.8GS%;,1#F-0%C.$"75L'$2Q&X1I
MG"RR2#H&I<Z'X26\80S]D':L_8CR F6,._3"N>%F9[)EL/M=F^BTVO ("/:<
M,2$2\:]Y8(9IC1W"[[<(7Q>(,X8$(^@F0SO>NM\)[M#'>1$&A-SF05HM+&<6
M<5@D[WR<1J-]9PP_7T3P? SVHH8:AH,?X"_3O]V7E^73\_*ID3V^[[]C6(TS
M4NNZ$<9)4R).DQ:U6#7,_W@JU[+G#T>BCBO=<Z2$:=%A :?D YWFGQ)&Z2Q_
M;Z#93O)/L=\_QS_Y=[7@QX>\($62D]5U43>5T-(B\^/ ;'(]!T=N1ID!E5I9
M$/#_DPJ[3] QO)ZV5-&.[%3:" @FN4"&!N%ARTQ%;G"P8D(J30&*(2JS!B4F
M1#T,1$P]KK94[^@#'^DS?2XKOCDN8S8X2::4^]3K!L^)6HIH2Y)]@AU1C9_A
ME%R:OL-!,K-^B%/"'GZ)D\^K?8IL[WDJB[NF3/XN[+/#/*AH$6"2D #[CNLG
MS.=.(QL4'S\D8'B?:,FAFM.[0/^W]9-E639Z)IWS_,]H85D75OO_J'XD;"A$
MULUC6>7_15-$:NY>_^]U0?_G/]F^]<^N==%>'R)%BIA]*X[XNC_9XD_>/Z,P
MO+#\Q87MNML1V=-!>&&'T45HVYO?YG6]YC38'\MUPV_FB$1(!9H7B(WW3),F
M?Z&KU^$D![DIE],ZYTPD3-MT<WC7SJ$@=H&N!7CZE,V0.)J4S-'PLRJ7(>$.
ME<K@<W!_[#-E'W0CT@?>4[9PG]C.R;V!]^R7LO[9V!B&]4:/--JCC3AQ>5]M
M%(9IWTT7 K %IR@\R)&3D4S)L1L=>#9'3T:\ON,G];SBEKXB=7V3_87P!/OF
MIA(AES:AY] 9#*P0Q_'"Q:'ED2QR$M^WI8ZX)&B9WN@Y9;YQ=K091%W$$):9
M)8.:Y :I!PO@7JD. WS+G!90U^XY0FG>C71:Y*,]5>(5U?26*G\AW.;;>:.?
M\_KOAV$><77#RG!LN2G.[,7"=JF7!E$"RVL9)F8\H65#^MQ@SRAB<JM:%PZP
M9:T$@4*2RK1LVK)31DC-G)8R+?1Q/HK$.QIWZT]K[O/=9+L<F$NR6M'TW6OW
M7-T]>+3N/=?&D1>ZV(Z"T(N3.+!I?/:.+L^/8=6P(<?/')[9,X_\5+%SKW_(
MB^[''S5L_8 I.,,\, .L)A/B K7L\;_M&$0MA_R*\W8V-F]HR+O1#)=)@P3
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M_69W*GZXS9',P7$0.=AW8M\GSH*XCE2VOQPYP\NX90#M'VRW3* >%_*;H@2
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M\KS52Z8$/"IG,OF"ZGGQ,DW9]U#SHM7TIKJMRI><B7#4FR -<&S[(4/4\Z/
MM2.'2MU G2(TSQEQ1_L"">H\LWI#'WHZ/ #7^(+6"0)L/:O+KW 6/"[<&:?
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MEX-D1Z%@'#?$D6LG.%H$A,9!'+@NR%F2)VW<0&KO\K763U'U6FWFM%;*A@3
M*J=6S( %4RSGX016)W"1-2D4 .%950H<D$.EHC#"N0V2>0- IJMZA8X'6R.+
MY"[7<W 8VP1[7I8FKAV$/@4E=\F3-JQ6^NU[.U;:0AHB;Z0K]XQZW*FV/YZ$
M6$[%F $.IF).8=9C8Z9>Q[+R:^]R/$GXC?H;RP(RW-E8>H0SLT=[!'ZEA-_/
M2V^*S[Q3+X\OB^LB7XHRKFGUPNF+-#CV9P8(>TN<& Q&AQ/7PG%HL?]824!\
MIIX(D:J:9)+)&778Y2,_'19':[R) K!4A-&9DE-P;XT_3!7VTV?[*G##,>]&
MO>59N'+BL&K'=IMTB_89-ZI!30*L.WE7)XMOD_5K .3!=&$3M-0T?7=9Z"^$
M)ZLT-Y6HX7'UC59)7M/;*D_H]H]U]]?:/C0R+9?@,(LBG,7L%UX46DX**KNA
MQ(5A7;TACYXY?5Y*#'UM61#!L;1<K4@E*N"U@3)@G$P->#G-;!Q.F.K=7@SL
M:/+.&X+H!=J"++CJ/5-O']+8]/$L7#1I3#4>9E6)9\%TJ//.&TPA<>N2U(^\
M4/,+6?%#A"]%1<DJ_R]F+)=U3>LCW>413#*RP-0.D]2S_7A!TTV1MW'M)4-.
M:E7MUW.#J2E.']$= Q?HH>))"^LM(V@E. $D(TU!.*Z%M,&BIFPX'CW*:$<:
M?=0-!" G2R,@:AE9AQ_*\1>BJT:FI*BCR5A38\R7BB4IS5XBENP[\*9D[[NY
M;RO,7Q7I>Z8R#L\2K(3B.$HR[-'(]5T_<,)$*A5UD()A6VM#L^O[@!A5Q,G*
M-R,[C<NXHM(B+4P[@04%-2$;%4:I!=GI$6=K0#8J4+_]V/B#:J[1=9&P95O3
M][3]W^OB9G/;ZY(\YPU9G;B+*6R*++%P2(,%#CPO2 )GL8@<4(L?>=*&%V8O
M2+6[E,@,.MIE-_4:70-O:@+0E7-ZS& &6][+]&_KNA$+O"FWH2**>"II=Y63
M_5[LQ+=5^9*G;.^-7]$/7W@;A+SX$6U91LNDR5]$8]&-8.B'C6@_\OG8/=J)
M9^1N*!Q537X2@/"LSA$<D$./2&$$U<S-AG]JFR_MW2O_S*Z+Z^*%UIQ:]XGE
M>TZ1B,U'7(%E48@7BY NK,2-,LOZH^%7W^04F#QID +;,@!((VQ0PM?;#^O-
M&GONK;Q\PQ B6XZ@B9C2(,OI,3/0*3A1IS74EH]]#;5:B[0Q7EA0% 7F)XW=
M9SUR,4@A)1,*CK9D3&G",Z=A0@$Y3L $CW!VFY6K;]T'<\?L-5HOET7Z[E-9
M_%8*)5@RTE63QRNZ_]91^1KA['BQCV,[#K%C6ZE-LM1=Q+%B]Y5S^#)LB1VT
M%.&AT\VB:YE%2YY%A%I>48]9=/"J<HN1LV9-(F;T-G,!TXPRT\ -XW>2DZ'2
M#E?CK"CW@YEK=LYM$Z-GEHPTC]$!(:"GS%GDWJK5C Z,1CK0:!D>7N'AZA_-
MZ_)KE=;,7ZPY#P^_D=7GYZIA^^[=^NFI>N6=T.JFN(]7W4*5+/T ']GT*6K;
M^544GV:K;NL?U_TUV?7Y$&V>A9FYWSI0I%C(EXU00'=\<S(/+&P/4L2T>:0G
M<-58.^X\G)1*52B0FZV&A3H4_>(69XRBF!'2^T2Z>E;;KXI?*+_)?BE+WJZ+
MZ<R7/*%WY>JHQ[EMNY@$:8BMQ+6I%2\6F2-EDY_#A.E0:(\E8*J'"J)RP0+3
M. '#!GWMTK'3UTF<(Y[CP7D2]E?'%>)L:4SS. ,475D>*BS,F^1Q!DA'.1[G
MC*403.BRGWG+0)[\W^7^]Y.AARZC!S;!D4-]G,1.8$5V8+EA*!TLD*=K6!=I
MO/\ !53"CS<#$_ DID-H.8:07#F]L^ ".-AF8%-SH.^9K<A>RBN*TEUKGJRL
M$.F [0JT,IM3-%T5$/=. YFU21K$FZPG/ $LSW+^N=8HZ6:!_;$1-'BI*?%C
M)4S5O.W:FI>IKFP4.*RC3C5@N/F<9KB,>TZQPNMJMN6^']U>ONUU?3TT(UT:
M8Y+8 4[CR$JMS')LZD#,R EZLX5LZS8*I>6"/1!#/_5X7>@0VYY'DHPX*;')
M'^T2NVM(U<R.Y"%M:3S?T8>\X)5N4$S8'Q)F6SX?](.>"U4W3'#,@,2.;Q-_
MP9P<DC@=JE?%1-ZH,4PWE.4C">VW.#^<<MZ-1H#.C/)WE1YZQ/6Y*Y)2:O),
MIJC-ZH1(BG[H;\B^!D^OO.-W</+FE;DO(O/I$WFB1V7M,AN'BXCM2IX3^O;"
M<VPY'V*(@.%M:$,2;6@B3E0^M?(D)N,+6(>DL!4+%!*45CDFB5)6Y<D!9TNJ
M'!.GGU,Y^IQB'0.^5-^1FJ;]D$&O4'+][G7W3-=O6L2Y;YY%985?Q#V1ZZ+-
M\SPHZK)WJ^30\R<+@L,DH]BSF$7IV-:"9*"0Y(R\FU8(8F\O6ZXNT%&!(\&H
M2$M&NUNS6BZ]S3G_<B;&=SJK0.7'&<2"P_T3GKX</(VK_V G2WN,=(%N-I]#
M*Q _,&I%.O&![-_:TU@R8O[)T%5S8D;.YRU:,?^4'%6]> ,6%(+2DVP.<;E,
M4]$&G:SVJY(M7TB^XD>T'\I*B'!DB ;,M8_#"/M!G&5.FGBI7'_4F?@U'03?
M\H&*;4F^KI0AV? B8I9Y7:^Y@POW9^>:68FH^O<U7PH;%!K?H-"[;G]")_8G
MU)OLKO[BS;;^XE80Q"1I]Z_O:W8!AP#?URRK'1ZT5D8L9C'ISS;IS3:S1NK>
M<\_=;)/6&B'2:_N!RZ3KK& ^]$?/&&9@8[ZSB?DPW3O3F)&L@K%PDS0E&YM-
MO?>E8.]\98YV0XM-XX;C3'<1RH]XIKN3X2SR+7>Q\&UO(54Q2YZDX2V[XP%Q
M)E"?BVV;$(#BEL-08F?5C@QL<YP&125)7 X=P,ZD'26US>6,3PBV%X#D'57G
M<B/-IY%!DNTI5=B;.LZ(!\L'!BYS?CR+8MN+W32R(XM:H/*! W2,9Q$.7P41
M&7'\I[:S8/W_H#;3]YRC-VA1/PVHG'74IKG#I:181L[6WJB@W82HXV=IYR9Z
MM*87X25*Q7C+=?-85KSRR:YI7G\56V2!24 SO%BX3NA3XJ0A((0Q3,AT")VT
M13R[Q ZRI8X(M//;&%HR80$]& #]^4[\[G1\1QC>^&Y,?(C?K <&18=7%0Z@
M=SHMX[A;.?+^C/[@M!3[CIS$\^HYQ&P_%J46:/J9UI0-\;@LTO?TA:[*9_XA
MB!9Z1UG$5HQCWU[@D'H+S_6(;5E2]5W E&?*(TZVO*"J8T98(^F.G;81*#Q)
M5@Y@"45G"C:8YML@MF,#;?@0N<8]3MJ.EZ80@R<6:T=.35F"OSG-B< @&&12
M@>4&G#T9&"3GJ71@V !JSEXOQWA;'/G]-N'\4._&3H9CRTIQEH4133/'L?FU
M,OFR-./D0,H67HI&=([OY\C#_+H)J.3<.WT P-1FC^Y%/ZED1UN?KR<GHR:7
M;X+8K)Z?G."'#J#D6VKKFZF2]=-:],)IKQ:43\\5?:1%G;_0MB(:+XGYB38W
MV3WY=N@>$CO!)(P)=ITD]L+4"C,JY1XJTC=O;FVXZ6[,)'U^T ^\#BLO[L;Y
M@FD'*-!RZL(@?&"S:XM<=YUK#[FNN-X/G)L?+T2]/>:/,9;TJ15%+#3I&2CU
M616/(C2'FDAU&'B:]U71Y,WKW2-=K3@14KP>FAIN2G$4T 6.B4=#GX96G$F%
MET\/;UBQM 21H(@ZDO()WB?0&%</Y\L(6_T@\4"IW<-2*"5VGQANMK3N85'Z
M2=TC3P&#*%7S!_,0ZG*5I\(!O&[H4_V^?")Y<=2$SH]QY#@.]H)%DGJQDP0)
ME8J7C! Q?U"S(XL$7?1[2UGV&'8,H8F AR:Y8<M,261Y'UQ"IK'-DKW?VRC9
MOW9+;W3H>1QO">&V/K;,LV?V;>NZ"G$W_2]Y\WC43*C>[R:TWWIHVXKL%\81
MWW';^IZ\*N05J?@%S*.(:!2E.,P<?L4BR#S/R19N9L':8\_&.V0!*?77WA9L
MS@N4<5_W1?BZS"!E,YF_,*Y?@-;]F\VK%S$SR%UDF&9A:(41)=1W-MU1[A5Z
M]7T7D[O?;^5>87/8E47GI0OV)UG4V?KM\S;2H]K1S_A<R_F W]?4G=W[KR<%
M^LK$.-'CKSYH\G=QW!AP*\X%X@)UCB?:",4_C(U8!OH!SC43NIL$&N?[;3H'
MSC4=@^T$9V- S2IY3^.FNTR:[^?1\K/=R[9>>+D^:)-S6]8B#]=V?F5//-8W
MU<>2*=VC^L\+$N$X"T*\2&F49)%/[2B Q CULF?8+;$=U-+C_?%:BK#M1?-D
MR.TA;P<Q;*/@?*(=HQ>[JR4X*RO,F;U .W8/>XNA#<<7"#)/X(W #)R:M+UF
MYF95Z6: /=3;AJ@H7LEOF W,=XZ;K VQ+HOT1.#U1*NC5OLN4DS<18A]WZ'4
M=<B">C;H6CV,ONF\O@TWHD/WJ2,&B28[6G"64ZP&T8-I3BW P2^,JXFOZ](W
MD/J\%[?5H#FZ?*TXC$K:\#/[[_TCK<@S73=YP@W1HXM05A#@(.*!IL *<6"'
MGLV+>CJ))Y\U/$C'M'+AA%&?LFB=,YS?!,)H(J*L3W*@8A@06N5.TXCTD%1A
M+2@H9@I#/P%@AO"D:.,)PL.OSY@?/"G#?GKP].-JAM'&^;VEE;@ .G@3:9$X
M.'8M@F,G<GSF?KIIMH"80(.4#.LCGB71NBVT:N_2PTR:883DC!<M<L.TT8;D
M3F1#%XXF9=-D@PS3F=7:F!3WT*Z8?@'>5J57 I 'O%YH]7I=I*)<G63[E.$1
M3"]%Z8I\$X*.KSQ],L*678\FVA#E&U^:O^3IFM?TT%*L3TX\I48C(\/.UE!D
M6K1^XQ")I_5LC$.A@9"R+3'T%YB&Q+*LB%A> NJ"/$3(=#+5B3U"T>D?A$IM
M@S3OQJO)?O;N:,A!'R3SIGOCE,L]^3Q\9Q2%3>Z?'OZ]_/IK\9Q?%G7*_KTU
MUR1WQ_%1#*_*M@S4??[$H+E C 7TZZ?;:QZ,KW,& AWN'P-%8WH+U0<$;'5.
M8J#9F)6756E/G1AZMGU53L3^WBKYAF)$/GFDZ9I?>CTH5;A?CTAT;QMQ2BF.
M@Y1@.\XB2FFP6'B@\AA*7)@.H'4\;6+,ZS;ZPO_)C[(3<7_P?;Y:\VL"YWJW
M:M,@&;8W#2XP1M?#]:C8ZZ=M_;6NW-[O;=] (V[S6<#H"NLK\3!O</\<F(Y"
M_&<-!K]\\;Z+G'[(ZX2LVJ*L']COZL.T\3BC.+2)CRW'L8GG1O$B(K)W, :I
M&-91&[JH)=P544:"M/R5C&&,QA6,-LEA"D1):-!%C4FAE.YK#(\ZV[6-2<'Z
MMS>F'X;[!K>45K]4Y?KYNJ[7['O_4( =@Y$A#*\V3AD)TJBC?<&^NK(IR@80
M3QN#8-H;T"0];,6-"6[ "Y"04<D%&!MW-OM?0KB^\2_S^-G5$([R;"P;QTEB
M8SMU'2<* ^I%CF+I ]":5*AS<'.__(@^7B_?77^\OK^^NE.N<P O:F!NP<DT
MUCRG5(%F([8_\EL5(1@R.$\] C<C[RO"8]MWKT]QN3IR?QT;DRR-<13ZR2(*
M L]*I<YDCT8VO(%UM%!+3-Y W)=^VBA4E@FV2B3% 9E^)UE7,O?V1YK-Q#LI
M0-^L._V VA[2NPL@<O]Y*0]>*^TS:>CILM*+V,=APM:*;<5LS629E7D6)%0T
M3=+P(OJ<UW_')/W;NN:!B[0CCRHB:P0"P)/;DO1" EN#_1M.@O@%VI!'G/YT
MYA5X'Y,75]/V)D%PUEU/'H##S1#PIII"Z%4</M4W41BQZ9?GLF@?K'G^'-,0
MO%-L@-W 37&0Q@[3$'Z$$\=W%@O;"V,W@V@(!1X,JXR.(UZPM>U$W;9#V]S?
M;"LPJ_<_50%=3K,8AA*F:D:J66][IK8<H35C">UXTJ=[S@!$DS)2X6!6[70&
M1(?JZIRAX+&I#_Q^X[*^R6ZKZJ_559'>9%?_:%Z77ZNT_J4JFO2Z$'^I/ZS2
MW^JF>&!4T_I]Q7YXJ=*_5MV>+1G&TD/-=,2KRLL*_962"C$.^[7TF.IJZ\6W
M+9/JMA-2>QEY6;RBWIO-(]-Z[-45:DKT*Z4-6CX_K_)$'.S\1NN&V_!<.G'C
MJ$;OUU7[FQ=QRLS'D(^N:9K$Z4#<_/,'C-E])U.GT0#4#[M2&%$3"[-%'/5"
MU@].:AY9I;!V<_](?R75WWF9MK8O")NK!;_:6"\?*BI,W6-/E <Y$[K ),H"
M'%"/!+8=6IXG96=""9O.56HP8P6WO&S[TESPGC4+)/A!6X8@]:$!R(YK2Y-X
MP70B!"J5*T,0S" EM<U@IUA16\?G!JRE#9=_O)0V8+P9*VG#I=POI*WPOL(!
M;E$7R_1O-=/K=R_)9=W K-Z!UXT?W!:U:  JHG9M@^K6RKFCU4N>4%$]'W"$
M.P#"M-6H07Z@&2@ENF8C;4)*M</;@3'G.[@=%VKOT';B4;78VFC"5.\"ALA.
M/'%/0MQFCMT8AYD;X3ARJ141/XX6*22ZIL2%Z30H6I1/><&_2%CD3 U2N=B9
M<:!@BF ZU;+'TT67XFKB.L99N&@*HJGQ,&L8[2R8#@-IYPVFX)?=?RWO'\MU
MS89=%NE=_JVAM&BC#M=,_()7I;QEW^?I0\*$VCA<.!%VW30A7D)IMI!OU :C
M;5@U.9;M;\(M6^J(DP?X%>>A&40.)DYDX30);<NVG,AS4[ERJ8;Q5"IXVG9N
MO'EN(TY=[,H<F!*^K3F 8"J>\8$VC(C^4!TKI[\_%0<7B!W QS6'H9J;R[%L
M-ECR_Z\[+&F+9;[%\IF]IZNDAAH*H\XN<,CY_%TU6?=<7L4AX%[O97E'5Y1W
MI^I.T"'W_$^^;/S$693;1QO*FTJTXW??)>6>=G//%AEZ,JPB+<BE'95(R:$]
M/>)L[NRH0'UG=OQ!Q5N'NS:;?+2;[)YMXS6S.9F*/NKJT';!=%P<,I\5NU%&
M(B<+%XD%\ENG21I>DGM]6X'='0"XR3FG>M& K58@$/!K?=*RZ;K#-TUPW@M[
MT@ <W<Z3?U-MX=^25Q&#O"^7"=NG*WI8D'17JI07+CV\I+>P'1SY&<64)"2V
MDH D7K;I$""G!X <2"V#_1+_P-@T^_TCJ6G-E\23"-^+T_5ZRP9,14 1EM,7
M)E!3BV=WC/"$A(X5)%%(69]V441"DZJ!4I]5[RA"<ZB$5(=1TTB?F&RD?KPN
M7MIT%N9(?,@+4B3L9]$KYV0DG>DB+XEQ&,4)MFD0AW869\DBA%@DTI1-&R;K
MY^>5.!TDJUZ/5*Z/&(OXDO&(MHRAZX*MJ2?A3/\9IIGDD9;324;P@VFCC@6T
MY4&$"GI@M6VM#$31P<)K4D#R=&=5/6 X#I4.?  U=?/E[A>>'%>T/:VKY[(2
M2ZEF])8/E)&C]4Z]G2A(S"L5D Q':6)CGQ"RR*(PL6VI@L1G\&!8!7WYZ>XG
M]+!E"A'.QJNR#:0!9#]AEF:8.CBD]F)!B9=Y"P_68\PPS$K!\^\/:#L)<>A1
M#X=.R/YOX;J.'S"3OGE;D+<F??/?#F"YW=/PUPG;1[_<H1TWJ,^.V% W#/6,
M? /WRLY 1-/FJL+!K-OL&1 =;KCG#*6GE*@X[/Z8%U3L[T>[;.SBR/-=G$7$
MCQ96$D<4=%%UG)SA#?6XM&:7TG&!XE=>SNR)7Y!:D;HM";]:BXO4_-!+_!+]
M2IO',D6_<WY;*_;,8J0'8,OI*'T0PM31G.B=7<[T-"B&BIH>$'O3TJ:G!9\J
M<#KPED*.RWAGI5V_/-+P1UZ7*S&WM#VJ+!Y6V[^\9[]=9FR5\_LR-P4]OC,?
MX3CP++SPDY!2)_!B1ZHTF5DV32?UK45/6QMAY*!71E+2=#(\-^.:Z_M!'*;Q
M1D*H'[:]Z/8ZFW8LLB<W['<I)UR [9\1%X$]PX5HKX,Q,;Z+>03DIGP7\ZF6
MQO)]S"LL"<8XW*/Y,N:HSY=:8QS!O2P<\]3.+6W,0]C\_WEJT OCJ6BXFW'W
M6%;-/:V>VJ!?>^8P5.=8^ 21X^,H<"),W" .LM"-HU J+U4?2Z;/ GK%>:_J
M)G\2"F#_\K X$.CQ+5ST7W<GESTGG?_EEXK71>XU+^6M?]L_\8K)T(B(AEF5
M<S[FG2O8=LVYN3B<B N!Z8Z;F6HGGXN.]D+*R@R]457E<P$<+K%\]LAJBO<S
M77&U<4NJYK670'+J)%7X-U'L89)2!],T"Y/(3^C"E<JNE"5H6&EVY)&@C_H,
M*/=RF8103H?I! :FH<[#!*R.9 75I&PFR<VJ2F2%/U04TN\I9E;0ABN?VZI\
MR5.:OGO]4M/TNKAYICS46SPL&;67UF8<2+&P0AM'GI-AVW$M&CB.DSF@IDYP
M%@RKBLOEW;^C#Q]O_G*'/GR^^17=W%Y]7MY??_H%+2_OKW]3J&"K@+*<[C"+
M'=S>01M.> SV!\X,RHL?T98?U#'TVH_)B@)WHL4Y>[Q[M"S,9&0HXZ4K-0/.
MP+PY&LH '25KJ(^DI=$COV^P?&K.:/38C6!:VS JE*EU\<TOGWBEQ[/Z/F[D
M'E<@^D2&*8E3?1\1!()S6S\>2*BK]>-FV+=L_7@@VD3KQ\.GX8MNUZUS^2VO
M91?:_EN&%]>.F&0>Y FYIA>2NDBPQ=-KC_H[IZ2I$LAI]I56QL%0LZV&TR+T
M5\# $UJK?'2-QHYN[!_YTI:%8TIBG 610V(G<ZTHT5#?8XB^X46VX0:3KFI%
MTAZ^U^+N4-FO6)%VK=B4R^A"D9<SHPWB"5OAP (@'8/&ZWY, 6&VXL<@]>^A
MUL<4-))5/B:'@;?#N&(N5?-Z]42K!S;0+U7YM7GL+N$>*B3?#7$4.QZ.B!U0
MRTI3GTI=W)R@8SJ!2E!&&]*HI8TZXO*M,\:0&E<@&N6'*0I%T4%M-B0$4VJZ
M,3;N;"TX)(3K-^20>1QN0;=E$/BAG?!]EG6]?A(U4][GO#H@95(H-%^#C6IZ
MC;:E.+;<H!T[:,>/2H\V('C39KPYW(!K&PB9@>YN:E HN0Q 4K.Y%&H0]%T.
MQ1&TGN=]'$J=I@L'QY&?X=2W:9(DH>M8(!]DBN!;G>>=D0\]B>%9!WI*R&@Z
MT#.4YBPKJ=D3O8]OD^HL*[SDB=[Q>VJ*X'U>/Y<U68F&E/7VE*5_R+(]8ZEY
M 8G3M5P<S\<D9?_TB+L(V7^(1:7RF<_DP[#:V'#5=4KE=!7+O*CB+*=#9D /
MIEJ4@ ,KE#/%UJ1G5+F85?V<"=6A5CIW.+CS\Z5(J]7K0Y>)^/KKWYO;*D_H
MY6/Q<)M(G]N-CV)8FS#BE%$7_2T[!KHD2R2X0)>/['& 3S.!R;0/HP\.F'J0
M1.*"W]9*M'0=D)=6R2V9&'HV-T1.Q+[;(?F&:N_ IR<V@SE9W1*F#DX7L\U2
M#T>9[V"+$,NU_=B+TQC6'? $%?/G\!U-],R)0MO[2>!B>1$F<6CC)*/)PK.M
MU(YB6+V"LY%1JD@P S8+XN+0BBV<V2ZUO2!)L\R7+S&@CHMJ$0$3F,C9AF=_
M S#5WA-4T#-PJW]4(FT]&4_1F+GKXHB8QWT5QQY6+6QS7XGZH*^C%3\"'+@>
M/Z).$^Q&_L):+(+834$WZX=)F;;)#HI[-!T;9Y3WD ;-CYD.<RE.HB"V?=>E
M?NQ#Z]'H@$U+V9D9@0L6 0-NX>$DM8/%P@T7M@NJ+W,6:+K*R)@$3&YGT//U
M "W_.[0A:KKTRY1PVBJ\#!*:N9#+E,#']5HFWU"\ILGS$F)2T[2?J[FL*N[4
M\8__W>OND:XVI&A<*O[3-2']S#,?ZLX!) ]')11"C^#(S2SL^0YQF=,09A'(
M;3#"I>'M:M.@]7E+$'C5TLC,R*F;-\<;IJD$+_@=9^8@Y7C',;^WT'^NX[KM
MPGO1_L^VJ6[+^C:F,39W\+N;)K'5=9W3"(_SWO T"?/1I4^CQ,Z]@+^IO#/(
M7=VQ]^Z0/7$Q]2C8L; QL6P/VU&6A0%E_@.-U.[AG\F980V^O8Y_TR5IHG$5
M4Z-WKWL/[NF8[D(XM.> MEF4U/QO,3= ;=^KDB"C^>M1U3\Y+6=<SM<$H?8[
M^N?R]497]37!.7QC7Q<!^)%9.\C3PVU%TZ9Z*M(/*_(@>U)V\F7#NK%=._?Y
M$S>7.&'*!F'_D&T&-RST]%'8V?+"],VPJ.AW3EE39MZH5$HG7:='G.V :U2@
M_KG6^(/G6C_#_0L^GDBA$Q:.[5C,PG%33-+(24@4>X2 F@N J)M.C)GNSW%&
M9AT,9Z@-HAD]V+K7!MP9%@0  .U6@@SM-[($ + ,[_:0010*E/YOFF45?5VN
M8K9F/S.*]Q7AB3<]<^)]7M&$?0JBY5/74U6^\>E9!,PMFXXMU/*%.&.HXZQO
ME?,[;BUS:+^GK$)CU/.@!M2BG URM7J39T*OJ8*D%I!&JT2>1V&^2I!:D-BK
M]JAG1 7_)/W;?7E+2^X7*5Q<&GC=M(^2_FW=%>.[+]'MU<U>B$#E9M(0#!(^
MR_D( +T62>$-W#&:D%7-EQD8<SYO9ERH/7]FXE$UCV9;RO6Z>%XW]4?Z0E?V
MZ5-W)W%QM/ ]G&097?@962P6H!R/$5J&UZP@A6R8$S(&C9S+H4E@V!+M5WYN
MZ5Z@3GX#I^P2(FIR(<8HS>HP2(A\Z![(O*+@#"R?JWS%@1+IU%^YFU$\W/#+
M@NQ_3[=F6E@.CBW/QU[L.PLW\",KMJ7[#D@0-+W[<@X09P'U>4#+AXH*0P5@
MX,O )^$Q:08%N"$/X+&AK^+XR. "<&\TXZ/FQ$SAI,E+ <@ZZHO(C#.?QP&0
M:L^O@+RG9K[<5 ^DR/]+? N7S"4I5WG:'J\4Z2W['#;?R4W6=7XDJSOVF_;8
MY53M8GZ7T?8#'$9AB*T@6:11L(@]>P$Q=+1P95B1]GF\0'M<BIKC?3[YF>B6
M4[1C5;D4LIYIDS/"9I\,F *?:Q[ EIU6W#39@'IXFM5:U KCH5VI=W %"_22
M/#V3_*&XSY\H>X;^FA?YT_J)5Z(_U*J\V54<1I1KU8Q:)/4ID=*J4X0,*\H-
M9=1TI"_04TL<\1-;49M.M+*2+$TWB9N$R:D)#9BFV@)QOP6BHXLX84W2 PQ+
M32BH&92J:,#L20D11^W(L??GLQ\EI-BS&V6>5X@VKU97WVBR;O(7>LF4X$-9
M[2Y,R(:<1\8P[?FN5FA+&^V( ^+,8P!(!)LUR0YT< ?$UAC+DA5.+<0\-O!\
M<68)\?:"S3+/PY?@;5$7R_1O]=U+<EDWL*5WZEW#2^Z6%K5(^]R>>O!VU=6+
M*%!0UH#"ZR<%GUYRY\H,6VI3XFI><F/"*2VUDP/.ML3&Q.DOK='G%*,@S2.M
M^+E011_Y'+[0ZR(IGRCOQ?:)-C?9/?EV6U;",6B:*H_7HJO;?7E+*IYK.M"J
M1?SD+%SLQ8GE6S1V$@\6!]'#E^E(".>2%Z'>L8ERP2?Z8<4X_5&R%KSNV9 ,
M;\R/,3# (>#=XQ!==_!R)G^\0(Q/'MI@G%Z@CE?49Q8U)6K9-1/IT NAKEB'
M)J[FC7;HA?(HWJ%Y>#5UN^N+N4ON^]QUPN2-,#DW5]^ZBEB"Y?M'4MS3I^>R
M(M7K-7=N*K&]'L9(O,CF1^PN#D,_"3,K<FP;=*55'VN&E>Z&*?0@.H>6%5J)
MQJ&(+?VG7=]1U:OQ&J=(3@V_#? P37S<S_7U GWNMW#M-+(^U:H?%DW:52-C
MLRI8_8 >ZE@#%-34["V;:5I5-!4YATR#WU0B>)V*3(I;6HE+4X<JU'4R'"5I
MC%/'HF'L4N*F#D2%RI$U[7ENF&B[HER@9U*A%]&MF<>;TW*U(E7-JP"T?5&
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MBF"0D.$]HJ.\"ZITQ$$5]H=1DM#7FF2'J>0AL=4Z# S+#^HLH 4'U8X"P,\
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MJ37C1)P8MEW^1,&[&EC5ZMQID%,W,X +TT#[N(HC+X[HABD.JD05=7V:ZDR
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MZ2[F]L+"060%.";1 B=^MG"L@!*Z -UI&29E.@:X)8PVE&7B9U"\)'6)%A2
M,4,U . *8E(V7:I@F-"\BWY2X*/E/?T&/-CRF=:;GBWO2UI_*IO/O"I8M?6Q
MP/5>Y$<TO'9[C*"4<8**LD%5R\LV/" ?/0$@-1TS,0,2;&GW\>%,B./"SP?X
MH-^U5WR!RZX4$0&0F2T. A>]'_U0>%LQU_1TJ>U=H/S=Z^Z1SN<1-6IX+QO1
MRF99U^NGML3HY[S^^X>*TNN"K6$FP6=^M>/ 0+!HC.,L"'&<AHLP7;BIY8)*
MR1GGV+2N8B1QQFBBO",*3&(T/F-R)LIW-0\P==AO9+!_L[YWX8>G5IQJ>,!%
MN.BW<NJ)<8&X((A+@C:BH,]:+@S-#KNN+%#C_,Z;5#H7_$<YJK,15NPCWY*L
MNRN2FRX HC'#X1ZP("Z.'9+BS(Y3)^;WHS,7U"Q^A)CI0/J*)*V"( _BOT7:
MI<&6649%:78>D8*V?Q]#3TX?Z\)$*<!>;^\\HVW_A\M1&. MVB7DT]6'?8S4
MO,W6)80^ZJ@N\P[<?;QN+SAUN10;OY2W;_\H661<<A1S'VM''&WR0;9A#KZ(
M12/ZM"V ^5%GFR*@V$H>D,SXL[D^ &'[/@_DM9F=G:Z%0J\'YZ?U0;:W.'RA
M28(CWR>8D)1?S?.H[4JE=AGCT/!NV.]*VMV/)VV967!_'G.39-B?T0'][/[+
MS<9AZ;%]@5K&OP-G90K3MW9.!OG[[^&,3,&KS?F8)'2&'9+VMPA15(*F'U;D
M039Z/3F08=TI:XUT',F'KZ<1 MAI.L Q8Z5US*#?.3NZ[;0IL<^ST@9'G]]&
MFQ+TI(4V^9)B#*&BSR1/NUM\RR*]X8YUFW%_N:ZJ_5+E;2@AMG!D>1YV4XM2
MFWI!()>-!Z!I.J+0<H"ZZ[-U+Z20M P@(M@!AA0DP)2,+.B%"!A@Z-#IJ MP
M!'W4,G"!.A8T1AKDY=45<)"@.&_<01Z"H_ #X%4U-;&-:'[,29RO1,I+5P,R
MO>'UV!@5MG&(Q)<O11G7M!+UCT1Q2'Z 5B3LK;9L"UDEZU5;QZU<K3Z4%;=:
M#I4,O\Q&DMC%+G$2$CII2'V0DC'.L6$5M3OMN$ ]$=!&!M06-VRE0$*,"]07
MI*N1NB\*6[H[8=#O7!S4R0/,MS'_1<AIRN]JGF%Z]CN:8K#"G@UV3>K>/+^S
M;A:SP7^XU<Q'&.ZFBF+BO>+BO]6?:--6J0#G6<F,97@'V \S[=6F?ZE_0HR?
MKA"*O)LJA="TIZH;')C:E,;%0'851'(E?U6*P&PN*T3<OM<*>D\Q/[IH\C1?
MK9O\I=>N\^H;KQC(/&,F!F=BW72WUJY(Q8N[U;>T$F&S]CKBX6$"<2P<AWZ&
MG85+L\1WG2"-0*G4.K@RG77=X[%WP8,YPRV7B'\#*-GQR0^::<<I[^_5'C*H
M'S?HF3HY\W#V"8'ILKVYZ/58OMJ;B\O]N=@PR9MOM0<.^J[7&L%-5W*Y%I[F
MS4/7">-1RKK6P17+[HFSA9OL9E,5[(X^B%2(PZI<GI7@T(TB3#T:.]0*:&"#
MSFD'*1E6ERU=ONYV!>CJCC2P[-X@5G*Z3 L",/VT$WY+%-U-"0^ONC<EF*ZJ
M>X-TYJVZ-R7N4=6]R1?4%B]/>:_RI*&I2%OZ4N1-_?GNRU%9O=8VLD(<$<?'
MD4M(XL7$6UB@+/)1:J8SP+>TNY0Y01W]P.A#K1<0:%;DX-!*4QQ[B4=HE%JA
MD\&JW&N#3:F4_9?BA=%GL%4[!$5'&K3FC.B$3DX):H,#I@A'/R #Y?ZDQ-2D
M%L=IS:H:I<0^5(]R+RGFKR6/-%WS-C1G6EN[^,J!BLBX863'$28+-UM8L>V$
M#JQIE786#2OC#</<K/@+S1\>V<SA)5-/Y(&BKO7I=<'F=-WF.1\X0[WH-AO@
M/9>7_8V'?3Z6=<\I N; Z9]H.87VMM,'TX+]F=/DNJ+?1:MUI#549QY;7=EP
M^AF<-QW.&,!'^7#F*,%VAI3F?UPQ%IK72Z:=*K*Z+E+Z[3_HZZ''ZR]L'":>
MBU.'>+:7T2#VI.I0#U(PK)=;FJ@CB@15Q,C**=)A7,;UH!9I86H,+*BTXID4
M9N10@+W;J@SVPTY3#(\XRT*?%&BS3J<?5(SSIVG.%S)9\8.$Z^*2/.<-6;$E
M_E06PMX[3!VQ+8*9"45PE$4DI99K>VX,"N)/DC0=H=\R@'A>#\X+E+0\  /M
MT]A)1M&U(@(,D>_ $&=\#(R./.\ QAEH/3*-L6]I:74%MJ<)SANUE@;@*"0M
M_R;\?'^Y6BW3O]V7?'OO8@:2I_G';YI>P:L58A37==.Z,$VY=VM$_L3^A,SC
M2_9\<8'+<UQ2C:&1<<F43MM/##?;V?JP*/V3])&GU/;3UK\^V4. V:R)%^#8
M=7P<NH'O)PL[BBAH[]P?WK3!VL8*5$N&'4 AMQ6J"PBT4:5E ^]OIT70M)<=
M##[KOG5:L,,]:N IU?L3;5MV[G9NKGW?9+=5_D(:NBU<<&BBN@'!)$XS3*W,
M=6E@+Q9N"KM"(4/6\/+;,-%&>O)-$8(RX\DCW"YK#PJX]5H6!15=NM'7O'E$
M6;E:E5^QB FU%1PN4$$;_NIV&)62#G*3(;?0]4,,4P#[Z%[WT.UX0%LF=-[#
M@ BM[2J&%-&9;V- @#B^D %Z&VX*OW])T_JFNFD>JZN*![?2F^+J'TRK?:W2
M^E/#?_^U_IRMDH89X?<--\"?/Y35Y4N5_K6"V<X:2!G60^]Y4Q%:L*525MU%
MI5V<F;N,3,]TV^FRO2G/:Q6*![_F-:_&EZVH.-ICJJKMLKAGPO("[I>\!!Q[
MXJ^4#%_6-C)-T^;^S#,$4V-S3XYFAT,CMDH>B@[ZL[DT&L'J^T ZAU7,<J/-
M):D?F5KG'W/Z[O5+31FM;3[.DMDV+^(8XBAKQK-QO'!L;*>V[]/ #8,,U#9<
MGC1(R\*KPO,#UH1Q@M9UNQAWZ7!DRP,P(4X>5CF;S0Q8,(7'&4 ;#GA)D!^^
MM(#]V,NAZQAYY3VQNA[W [TD-6;9@<'1E78G3WC>/#PP($>)>? 1U!10>W?B
M;E.@]E0I>*YM0NIC$D4$^Y1DF9TQ/Y."<O0&Z!@VX+KK.ENRRA&=(9CDM(<&
MX6&J0D5N\+*?D$K3&A^B,NN"GA#U</5./:Z8,7;4V7ZH<4/J)#AT'!>')%Q$
M(2560$"-JH=)F<[@NK^Y_(]_O_GX_NKSW?_\I]"Q@W]&5__YY?K^K\"DJV&L
MY):L'@14(K,7:-DT51ZOVT8Y3<F\F<K4&IX64U<^TC"A>?.*)@4^R@^:?@.>
MY_.^:_UU7Y&B%@>;G^ES61T=FUAIC*/,<7! %UD0AHE-'*GJNF-$3$=-.K)H
M1Q>UA.7S?0;Q&5^]NJ0&1B+@ H/R?J8D4DK]&1QTMNR?*;'Z"4"3SP*[1+(O
MZ>9KP;[MQ_QY^2T_JFJ=^;SSFI/A)"34"F+/31*I<Y2CD0TOMBTMMCTP:I)F
M[;'\X^OJ+*E@BTE:(/F6AD/,CVUM[*7>ML;^M5L]Q^/-T]=P2(QM*\/!!Q1:
MJ-Y_+>\?RW5-BG19I!_RK*&T8#_M__XN_\9_WVZ+S.IE*S1_X><0QX]>B73\
MW;/INCVKX \?77&R@H#M?4F((S>,\8+P!I.^F\:9W!I\(P$,+W7'LCU1,HW]
MX&]^"'?W&C8,\>,[R42@-YOJ"77SWV "85J-<8(VK"#&"^KD$3\?_;$3:C>U
MG5AB9D^_LA%NX'.8/KSX/KX+0 O>[_S[4&ONR^>UV<PK__^L^T[XS\WA'^ON
M.Z'MG.?;[^293_G)5^CF.]F^L_U.^$L_:>H@_(:3,]J;^"WXFJ_K\1NBOM=/
M^2WY.+,,Y;O7[8__GM.*#?3X^I&^L#G[=MR?.:8!)@$)<!I;BR3) G>Q )6>
MD"-KV*[HM;_:TA:ZXM/R-Y!7 013+A"G'R+8SGT..NK%#Z6$U5W!<)SHVY0A
ME )BL):@W-MJ*F-[%M=5QQULHVP%*8Z",,-^9,6QOTA(FCD0+3%(R71L87NJ
MO"EG_6>8(AB&2&[M:Q$<&'[8RKRA:23N/BF9IK4]3&?6Y3PI[N$*GG[AC#.T
MY?-S19.V5NAG;EG4=\O/=_+)B]*#F3XL$UG0?090RP'Z@?$ [M4S"0W@Y$P7
M*K#%.P6(@7(JTM+J/$<;I3?_<9J,^"=/U:1>5 A>+HMB35:WM.(^!7G@5_NW
MUP?%5?WZ+X]Y\LB\";*J[TN>2$VYF]%K;=,^=G0LD#HX7L0!7F19XE@Q=:PL
MDPY):F/+L%YI^>0%.3M&^=T LKLMV];F!$22],V'1-SP35"&Z:D.X!V/Z"9#
MO>O(+7TD^$0MH^B^1"VK(MS7[]5V]W;3 0C7O<FTJ 7AY+Y_]%5,#VVGI^%Q
M-BHN&=$VTE;VIJA]0U=P33N4HR$S?=3F"X1I1V@OO*5_]'-+B)UNV";VV*YK
M&_>!VT9ON\[1HC[2R?)A?*\+?0^'Z<+'BRATW,1V%JX+:I2BESW3MO18Z; >
M4ZC+N=Y5"V/+NQ<CXO6KQ&T3U2)A6J92TE)_LPD"FO6]N1EI@]E:_]MFF%N.
M]Z9OGJ)@.O'47A!,"W-O5 Q,)[##A<"T4H$G!U[R',.*DLLRI8=:.4XM3 (O
MP)'C^I9#G21<2'D@AP,;UJ>7XMX=HX4X,?G$OSW9Q]78.1+!%)"D,*"DOE.<
M*R7R[0TT6_+>*?;["7LG_ZY8J"MA1CS?:FG;?H[?PJOH(RWJ_(6VJ?;'-9+Y
M6G$2!X>VM\#$MI(LC ++3F'UNF0IFW;(=WQT-UWW. %UZX&C*F=,&,$*Z%;?
M7%X/)L]KC_R!!=95TTN:[KREO:!P'%7X @^@DM9(JZ>\$#OWI[+)$\J\N+Q,
M#P_V:>A@LO )3N(LRJS M]W$ET\]/$W$L)+H4>4WW1E9'L%@=$4_G92\RAX(
MC (E$8#3(#YLW?<E;RFBEJ0&>2$):>?+K9@T!I8?F,PU+MAXPM7 NS,F18US
MOY^X-/&L4FG!Z_^/NW==CAQ'TD1?!69KMEMM)HSQ?IG]I51F5NML5DJ;J:JQ
M/O6C#"1!B3,A4DTR5*5Y^@. 9 0C@D'"$0"5?79MNJ04"7?_0'< #K^4&2]5
MP9U!X.*")^^:WFEL1-7:@2:HG."IG//&0H>(P W"H73Z2PB>E46UB.#I@&N6
M$3PKSE$AP?//*2S1WYG*T>;Z:U7^5G'OVDU5OM*Z+=A^[IZA2.NZ;\<PD37
M"PU2@N/,\7#FVGE,7(O&F93;4H6X::>DX 9=,ZM>HHXA-.(([5A:*%2K'>3
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M&PFYT>]:V]1(B*G6Q.O,F.OU\9H7ZJ"5U\*CBO5!?RVS>O/V.*J +5_2Y>P
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MN]:<[1OEN+S?1.JP6<S]T(NCP)/+3C?%H&';]_#4=4TCY9M0P:YI.-/2,:]
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M5%3.LH+O-,C&LYS7J2L\V<+*2P.9]DSLZ"/&P$^O?QM=VP%J*B_",:^JVI$
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M2BXE/]WY45?SSRT*-O;++3^LM@S_1INV*!^G[KU(YF%"+0?GJ>=&N>]X?A9
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MX*>[^#_.@O9L&\=Q&&$2^;EMTXS][,"*<BR1-'U4[AE ?#91TY?D*TK\PO_
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M:0/OOH3WI8&7Z^"_*?(,3X%DT%$L-?!\?N,I<I^XD2<-)%N6IJH"SKMF'VJ
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M-X^&]_-)!HF[ ,0\:@/:2+]2)&XD*.-?(:>*6.]Y[A>671JF?O4=!2N#!%T
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MX2'U;&;EG ?1!1" &$NYB3969:]2&-8:;J+.M]T:/K8U7*>X"\#-\WU?E M
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M&S:U&E>.6& E4Q1A*C ?#2P/9!1RG9G9^3]2S 4@Y6.UJ)YR<3=HO*V=7;!
MX]2ND'L161+:L=R7#,\25<B=0QX4Y55! <[4^\4WO]P,/-BR\]'OCR&W&$BL
M \ X8(F=<M;F;K/<0,:TH5]F15=YI5X <#;=>5NEM'__F\H.( 78>\Z$H1;B
MW",FNBF:]C ;%TX9=5$ LGHS HT$AF@,$$4\&,JHS3Z<>1B>1CO6QL53'@T4
MX#$]^'KOH@BWXWS6D:F'O/=7/E3U;6/QK_J[7[[]'N47U3=;Z/IFXS"D$63Q
M7T;2YAMY1*3[_:LXP1G0UG#@B:6&*HU#]O9O([)3>M'N05Y:*6HO9@=$%F]W
M\"N_\&&_L;GS$F@O7!KA8%6(4;>4XZ!WCY32"WN/0-XP<0^]Q<IS"/M5>Z!,
M# '2.P>P$8@JCJTUN>_IGQ!0>LGN83'DT:(MP)[<S4JX*U-_I9<SN\N$E0Q(
MX3U@1#ON34 HY+Y:;R2D] +=@W R7-0%./.[3+R9S=>KAB8^S@"MN %.>BB"
M(2)H,3)B;DDIO2AW$&:.$7<!J/F;GUU<1KK/OD6'[<)_7*<DL/.P5V?<N"4X
M@_$KQ %RRBD;8QU&<E=='D1@+X2I%X*P\513+NYN=]&S9>XA3?D03D:+'$]O
M3PA4V?,7#B2QWRTJ?-G@RZ*?E]R&8)R)*7W6.EF#@O%GJ/2L7O=8 *DI =Q;
M" VAW.O<]0&3="MPB@ =A 0>\1 W2(!&YLY<?X'="CKU?5BW@DX)%W#\'5\&
M8J-#*6$ZW0EA-AB%C<H=\66NPYJHGT$W!K+5874JI#"H-9>,2!+25(8 7/!6
M8<LY%O]3AW6<O@^NP^H4?F'P:2X1LFBSSQ20F$!DN2)>YD]L?VEU6-UZ/;@.
MJU/(!<#D^?##IO9V!!F !23"2">LSYW<\K*&"1QT0 T4< $0R5B-P8D#TO'H
M+C(5 C,N4)N[D\&+K:49BI3QBF@ZU58 0@\LWPC& HT< EQ*R6U@ NY.?/JQ
MBV@R(RVG^%_>'=/KZBHN<AE_)[*\>8H=XW9I?Y61[Y6>82O_5-[M94,$T9.5
M;[_;<O,@' ::>@Z0]$Q:$@V5S#^K_2 21TTK8"PUSS<:.&DAAD9CF7T@\>%I
M!:>8U)L='0?E''3*O8 #<)/>VB"9Q$MD[#Q\U=\_5?5&;ZM5/3/K57)LOU;;
M.^/6B[T8MVC.!!!:2(>(BC+(7EB?A_1"#M03 '4*71<,\7=5[6<7B]?K2-/"
M/KX3BCK8_&W^I'#RK)XMH]_[9EW'/S_Y>E:Y.ZGMY>Y: 33F&D0WA2%%-24\
M]W7_"=B:N$/ %'#MN66FPD[!V^FW1>WU/ W'^*]JG@+$AX+C+]Y&QE>IL6=_
M.2@5@,)$ Z@#HX):Q[(/%!B+EXD['12\<4Z*D@)V2X,(VECQ5 +-, (X*&DE
MY$'@$89!M9%32"WI"?R@7#K)EC)\NAN'2[VX\'%OM3;"U8OM?R_C[HR;X.T_
MU[/5S3CW$D?2,O;M10X1Y;_CV%^QM<-#_$HCPH W,"B&N TJ=[E)+\+&S:@)
M3 $C%0-.8X(,@3"@W \")674Y,?"8?DUG?(NX*#M/;_ ZP",UQKH0&%@+G"#
M1ML?+VD:2+>&CYT&TBGN G#S?+]PE[)H/>-IJ+;@ @M,LS>)?+'30+K5>_ T
MD$Y9ES&_X>C9%#QPH"QG0!KH/:>!2Z6?<Z-^Q&D@W4K.. VD4^(#2D%7D\\"
M080"8Q&,82]&F'%F]>Z$HC_&+)!#L32.Q"?#TIZ]WOJ#*<*M%BF@:;+9)&X+
MX[D$U@2H; R51?:WP$Z""GERR>@%#19[ 9[0#@_-^\UP!Q02$D#.,$1>.IJ]
M+TPC(87X0\,5O5M5.ECJ!4"GUV%,XV'L' (R/6D@31DGN>_SR_.&,JBWRBSK
M O#R[%0E;BA0E&C 121><B4M''$0>0F^3GZD#)-R 3 Y<VZ6Q*_GG_3,O5^\
MUM>SE9XW,Z.\C$Y@L(!8P[B0FEB?.TSO)&C:!Y3\\,DG_1*@9.WZ:KVIN6A[
MFFSQ^ST&,7I,MQP.1H$1Q$-N2]2;N&D[B8T L5&T4@#</OM5E(UW=SU#6NPO
M]*G\5<2=HSPB.C@'\T_8:Z)DVL9@^8&40=X%H.;Y['JNHD\G#0)!("=3%VV/
M<_?R>5FCK8Z+UX\3< $0B4:Q]GKIW_CM?]\O]E\#/U?S^;NJ_EW7>\V)J%%Q
M!]@ H*'4&.F=SMZU_$ 2"PGLCT3$?H_"T=13 /J>QI[/]H1Q<5LJGL)0!TG<
MJ51+E]M:/4/2Y&TPQH-#Y[W ,-T<#;7K3;)>W%1UKGOM77'MN0FI0EI+#A@U
MCCA#.,G>':,M"VFJJX)3PFJ@!HI!TJ/+D&?WA@P,2"(@$%@Z'/U.2N0(F9BM
M]$SK;YT27=FT4@S.-KR\7R[7WCW.7]YRMWUS7$9%GH='[X\/F<^)Y\ \UX#Z
MQ"FQ%BCK:=QE"%JM#;4A?Y;;$(JGO9(XN24\C68+</5:N/VKGJ]];V8-("P5
M#%#G8RQ/'3#>8V:1AW"$G-0!!$]['U( BD?0:[D@WF[9C_[WS8_V:W:EB:XQ
MA( '3*-CS+C/?BW7C[)I>[,7 ,LAFBH7?YO-ULH4=@$8221 S'!"/:0T^QU-
M+\*F[?A> /H&Z&GR7-6N_71^O>E\]_:[K^ULZ=W9PKV]NIY7-]YO_MWY[XM(
MQ>7L^M-<[]W+A^BS&&,PX @JRH0-$NYTSFA+/<Q&T[1]Y4^!S"F56"AV-[MQ
M$->;'6N] DP9QX)VB&H\!+J'DS1MO_JID3NR"@L_\>\FC?A-9:M?+#=ZW\ND
M<!!HIR6P1 DBF678Y6\5?2B5$_>Z+\49R*#" D Z05<+K3B0V'*@-'86^X!X
M_C';I71$^2'>DTH#R='[YINO3?7"FI_H8( TB $D"=:(VWCNY;XPF[3Y"?HA
M'L>*@$,!!TIG"SQ,4"3>&2"$9)A9:6.\G!G+1[0>_"'>SXX7? &H.3!C 1(*
MM-$44"P5"4*XD+T..TLVR0_QVI53.0,?9]\N\LQ=?3Z5(;KK44).@D!$E W6
M4/-1KEX/3R9!/\[KT_$J* 1(AV0M8*2!X5C'OPIE#(M_E[E?\ ?GDJ ?X@TI
MFUJRPNQTS;WT\O+=O/I]I#;B]Y\^=@.N9C;RM]2Z7ZBM>Q)4:8@XBJ8H!J:(
M,JT<S^VX=M&3P2M/G_FIKK[-HN1>W?RV3.,:;N?^I0D.J]FW;2C2(@&9VNII
M*4!0$D4/TC$A<B?"'4YE(1GC0Q'4X,N/J:X"'/[.:"4:=Z"EBO;>$J8$8A+B
MW!WY"^I0/[:V#PD4.T5? &[.W/^W7JXVY\/7ZK.WU<+.YOX)2U^K@=),O8(,
MY1;H8(3W2&M*<\\T&X./:3/13XSBR8%0P&;H]P3E( >*< .DT%9SZR5"V6>O
M#7@I' N0TR-D-^(=KJX"0/=P?_TFACC?-D.:WB^B>-8;44?Y?JK]:O_BFD@,
MC.$0L,"U]4P%ZW-?J/2E;5I+61PP1U'I@$9H%RD0S +6-[/E=;74\U_J:GW]
ML5K%OT=Q1Q&NO;L?>OZ(_=M?WYMDYJ(TD40 4FYD@)1QG_OFYDA2IRT0*@[*
MIU!X$<@^LS;NR:3FJS2_X5\;QL[#AM]UZD:V<''37LW65\OWBV_^5DE[.YCP
M]"X$ 0I2!"F#Q29W6>YQE$Y;3%0<KD^@[DEAO4D5?+^(;DJD?3-%U+OE&V]6
M3RM.GEP(6Q?E)S@@SDL8"%=^=P)G2PIG]SK3%@ 5@[S<&BG ==U_@;@7VFU'
MJS:)41:BL"P&F,3_"(LYI;ECJ/[437OFGSC0'TEI1<(Q6OF--?^D;S9CF&KM
M&B;?QO@P^B0 "4$<%M82FCLIN!]EI374R(.+9^$W6$FE0J^./O*'F3:S^7;W
M+K:=V.[%^NAG>]5WZ2OJ!."8.8.%L@CEOC(=2G-IC3I.!]>Q%%LDD#>L[>S1
M_72X368)!=AJ(03R1.#Q;6@39:7U]S@1* <KJ4CHQ0CL6L_<FUMZ;D?7WVVW
ML^72[X=DC#F@%%+ "2\IU4SA0$>'8A]*2VOG<2)H9E=B$==%_9WV7=Z$D, 0
M%>-HQ;%S 3*6/=>V/W73@O+T+_5C*"W;L,KL<-Q>7?42)/8L;CFE@2?!&L0-
MQCJWW3R<RD+&F9PH'RF7N@HXS.\NN-Y%H7[1\V3O?]6K=,]U<Q[.ONG9/+DH
M[ZHZ_;#C!HP)H*2U !)-M0@(4Y<[2^Y(4HO,<<J&H+V2A?'560)J]<WM3?&9
M_>=Z5OMVUM+-[5ZR%W5 &V8!\X%K;X2W+O>SYH$D%IG#-!I*1U1?$5[G[C9,
M$[U7>G&16HDU>]+8:""1C\<2<Y1)!['(/F/A>:J*O& _E:T<J*0"S&)_ >XE
M7TD+E. ,4"ZQ@-!(C7.W$.Y/79'!SE@P'$EIY08[[V8+O;"]!*E]_$I[!215
MVD+A!%(GBL$[J"QD%L2)@IU<ZBK /CZV^*F[3>0K6OU/F]0__VFN[4:N=QT^
M"?"<8R $A<"(Z!%3EIH.:(:@SS^UKP]E188RV?#1<3QG4M;47=V:67I4LWFV
M^GKI?]7U/U(3C$A?FN,3Q;XW^BG:?$6U 9(I3%*BM//]FK@=2T&1X4ENY)U.
M1Y,#<1N Q6CK[KK_CI77U7+?[Q4X!ES:QC^D93A*#T)N^N&M>Z$BXXUQ8)51
MXD-#W*]90;3\[#?3Z[Y6KS<)QQ?Q>YM&<9]G%Y>KY=T;^\V=I:: $VG2+ ,+
MI',88,,Q#"J@ -4AH.J[<)'1Q)@@&T4CTX.NVS'8MCOX;1&U^3Y^8Y%J.<X6
MKKGV*+757,9?FZ]38X1MR\UM2\Z]%\XH'<V% HH1;"!S3)@Q+[:S,S1M5F\1
M/N,4T"@@VNDO^[T+UM09A/C4&MDH;#W'BN9NO=>?NFDG )P8P2,IK8#;H,16
M^G]J>/--S[?G5)38S,;3(?T@;LFGWWCTF]O>@/M)*[?;].UW>ZGC.?<YGC1O
MHU_5D!P#.9!2:, #DX*;0)',?9-T6@ZG=6M&NX4J&"8O?1/=R^%)L6#\%XW%
M@JWJI!0!8X0!VAIM@U("NMP9*%/P.:VG5.:&.@5D"G"5!LEH3SM> TDL!-PZ
MC[W$$F6OF1I$\+37R.7C,><&.@@<Q4QPS,HR,P28Q#?$3BBBI XP=]_[\??#
M:)?;?^S]T F.0GJ=?JP6-G+Q\"*_</?QV&9>>GM&/@9QAPN #)<"6J*YS/UR
MV)NX:</H\5ZM1U'.U \TCU^>[H=0/NU'?7_)N_LD^MLBU7&<7:4:H[LK7@8@
M(0((A"G0T'I  ^>8:^B1V?'=VWH'9*)HXC?L<=!23:VZJ?':^*AU-M_\*W_+
M4'J\WU[/GH?&E]7]-DOI+9^C*'VB(8+"2:)[@34+.1._>8^/U-,KK4B8-FTZ
M#H0P+C6.84 9BH%2CBCM X.FWZ3'9Y>:^.U[(G@=+>P2;@D>S8;>IH)LV+@U
M\]ZA.X8$"%2+U&\F ,.8!MABXBUT!)G<[RC/$C7Q\_>H.!M',]F@EJOO_==+
MGYXH]>)&+]PKO9PMJVB6'S[T*>']NMT_^YG#>MP?1G*FSO;G]85>W/8(>^BM
MOQW+]GCQ\W"+03U_:+O?!D1!(A -D\D#LY 8)M#N$3!\#ED.P@</=AM"1+IO
MF%?+=>V_1F6^FC=X!D8;8!P4@"&'<8A>K-*Y:PQR\S!MM')Z/.]-=YL2$\79
MX2_KJRM=WU3AR^QB,0LSJQ>KVV8>:7Y=%(Y-^0I'6..>GSS,)A]#?B;+O+],
M&SR133WZ1*K@9Q(YZ=-X[LQ6HIV:P9W)NR3;N@M@D, H9P$,$%DLI#,V-\_]
M*)NX<WD>E.SU'\^OE.),TSL]JS<YGK]ZG2SNMI?L$9:H^8.&&9X>Q&6R,_<K
M/9P][0<A-D!1X@ ) 5,1-8Q0[ME&7?0,M35-G]V*9NDE4 1A8"2%DD/+[6[3
MV%&8+<2R9,/%KFW)IX3B3,K.RYU.K212U4NJTW_47N,(&]/SDP=.63N"_$Q6
MZ/81=(>"?;PI*-+=%TD]BZP!3#)EN.8&FMP])+LI&B%=X*Q9W U;8RL$1V",
M2JP&5F-)J-(06C:"$ XD<_I4F4PXZO&(GU5EQ5FSVW:@^K:?W>MUG33PN$WJ
M$8;L^0\=9L,.)#J3^;KM2YD L2% SULQ1QP&,O4AL$XK(F6(/\J="]I!SJ#'
MH%OAGK4*MQ7YA(=XCBL#?"#(<(^@P/8YK!RXYK26)Q<$GCP(C23PXDS-AYGU
MBV5Z[+BH_?&16-/'##,GSQ(VT(!LM-RP2!MT$$XCOY0&A#@FN0P0>M1K'W4L
M,OR5;QZ_6]6;:5!G=9T*!M("G;>96WXXBOQPA2-G3E"AJ34L>Y%)?_*F,2%9
M0;#_T#>.<HJS(;<I0I]TO;KY&ME<1LEMRCF/,"2MGS7,FO0C,9-/TK98&ZI2
M]R7M* '8>R:TU!J*W$_OS]$TU!*U?7X/L*>T,86-3VGF"M(03^;L-\H'D#>M
M,Y,5.[L6:2PE%6>16K,98W2R^>]E-8]Z7*:(<G5SU+7082L,O!X:P$XFF[;]
MZ#84!NZ!@=(!IS#FSFF#5>[D\:<4#&_,\%B.K;"'Z<"W.D2WWFB")?'0Y<X#
M:"%E6CLT0-_[C0Z&B[HX"[/A97^8\C'/Z<V?-/#YO =YF2S#P^&QR;6]7^SV
ML-ED4F[:5YA$SEW;ES9DP0"!05@!3(UQ!EF)?.X--XSB#.-N^ZW^ZO'J[=M&
M.Z"HU0#Q&"@(SC@BN:>##B1Y6DMV0GPV#+H]F:K+LY!Z[JOPR5_\:S;7]<5L
M$7E<5>^OKKR;67V4I>S^Q($6\P!R,UK.AKK'34'D0X%D*Q1E>IPE2 #&#74>
M(BU9[OOL TG,.@K\2<%H Q4]HA9#4LI>ND?QQJ?Q5#RH46>"'T'S]-9Q+ QV
MSOT>6[OEV4-_D<S[9W^=AD,O+HZR@+N?,=#F=9*4R<KM+M(&)<<MD)HC +54
MRF*%-<V]5]MH&9Q*N?.Y/<"[J1E!D ")%5<*(T5Y[DR*'F1-:WVR8&,OA3*S
M,HJS)!_]*HT8_^3KC?-XC"'9_8AA=J23H%P74+I>I/;%=XNT0D5K(!5-P]LL
MDQI:Y[._\K?1,M2,['YNQVVL S*8%(HXQCC!6)O<Z:"MQ$Q\,94#![LF(X_@
MBS,4_8HHQJ\%.6E-2"&U(1A#H 4-(,@ O7$PA.S3ML>K#=E409Z'G05NMG^V
M5TAA"71P&CA-(47"&4US/P/TH^REU(9THF372HV@E"(JU:^N9JNKVZS.^R[@
M]UOY*6=!FT  ]=ZE :H:&.\9\$APJ RB3.1^..Y/W;0M.$:"W$C**0!V'_WO
MCV165XOXY;:QS;+7MF(* @F9 X0+[H*D%-K\LVT/HW':-ATC07!4114 Q%W?
M\SESS@@PTA"@I% <2QL=4SVRZW\,S$;KTC$2S'*JH;A H+&H\>LF:_H8K[_K
MXT:HOFPB=((:3$4",,9#8*&)7A16%OO<[L:8-9A?[*5WZS0[]'Z5[>C0>+(_
M2FR_E;P[7WQ.=36I&]+&\=QHH;U<$!,@N0X :RB-%18&E+MF,RL#+Z?&LQ-W
M>Y>?DRFY@*/T4);C+WRL%O43":1_OX'!5V\O%[-_KOTS0F$L-0%#&D"EE&3Q
M9U3D[KES$L:F#6!&VQ'E@:*DG=+#)ORVJ,S2U]\2P^\7U^M5_'$50\#Y[%8D
M+3)0. T4)! 0R4/ 6F$!<]\&C<''M%'4^/M@*I47YQ7WJ[H_WDT^Z/-/T4!@
M1$?ZL/)O:PG03$M@&"6(:<RLRMYL<M0V @]^5G-U^I?+JEY]]?75MIOD0QS3
M7J(N%- HI!0_Z@B4S'.?VX\83O5+:C+0B;)VQ_DD"BW !WCCS>K!-IQ]T[-Y
MXN==5:=<R-^B"Z3GLW]%LM+3?K6<)27?'R+=K%-AH_N# V 0,X^TEQ;F?OS*
M2/[T0S5& O54*BX W8^VZ>NY7BYG899&%*8GC"36M9[_JE=),#=O].H97C&3
M4>9& (>L9H)X)5%N3W8(O=-ZK"/B]V1*+,XW?;:;RO%N:=^/'KD=S(C.Z $=
M083!0'H91>0QTIJRP'7NDVJ$IC#[7LNMO'<%W.Z=1-,MG90 <22@<YY!F[O0
MJC]U+Z:#3"=>VGW*K-HISEBUU94?;Z.>^<1QFD&,:)$.+>OWS '))0-.1NUI
M"K4+N9]3QFX)\8#^3H&W[@&%!-#:,6 1,XHHC$+(/8OO4!I?5G.(3A2U&ZL1
MU%6<R6HND#[>8'5^WABUW",:J[P5LR:>F,I1 ZA2PHL0#+2YM_&T%=T/.^>A
MF/<Q%8]Z/[VZV:OW/?M=U^[\>K/#?HF_F 9E;F>#;_Z6 IOW,=R9+98SVR,N
MQ]H#Q3T&!CK*K93Q?[GSTB9E>/IZR1/MC78#73K,"KC^>72=^TA$23WI\FM/
M. ^BNQLJMQD4TBSHC9)?W7R:ZT6WD*36P&"O@<=4&J2<5WZ\O7A"1J>],"UB
M#Y8*JZ+V7K,5VC@TMZ;H/K/B;+E<7UWW\#.-8D %)P'3# 9,@L79VQ[DY6#:
MZ]DB=LO)@5!>P+%3E3P@U&C^I+RM $8,+_H6?0O"@&$\  *#DEP$PJ7,O=%'
M:@CP-%_F/-SVM=@4,(39IEKZ7=RIM\LOOU8/ \N\:V\ Q""0GA*@.3<2,D*"
MRWU9G8?RE]%6H!-A^\TS3Z[2XHS83J'_\3:L^8.R=B$8T8+UK4&7T $C' %!
M2*R%\91E?UP:JQ?!P]G]-S^[N$Q#MK]%P%_XC^LKX^O;(_V9(]H[#Z2"Z;%7
M6TB=I<KE+E8ZBM"7T<.@$S_MSM98"BLJM#A;K&9N-E^GYNH/*2YOOZ>F4MXE
M2YR<W?7=R,_>'1Z,,$!IBH"5S%J"@\<Z^WS#[%Q,&Y"/C.=)5%W<V?O<E.HW
M?J5G\Z-.X[X?/>Z8[48&2IZV':*Q5(1C$(-0H57@ ;O<(S0FG;:]&8]QJ[.S
M6YV=/]'9YC39&TJHX@[S' %A/4&:.AX@?PZ#/=?Z 8=<=\+HR5"BS*HHX#S?
MU&2=V7^N9]ODT[/OL^5>J;6S0"'$ *$2.VJ)%"KW-FNB8\*1-+D57666>H'(
M>5-=Z=EBEPM++3!<8H DQ,82%'W;W %(,R43=R :K.%G('.$N"<$S693?4GN
M2'1":GWMHR]I4P?:7WV*C?8:1V@'M&<20*.U)MH*A62O ZQ]C;+P<(SZJORR
M+,".?%F;98PN='V32B)BE)S>))JVBPX62",M(-Z'X"D-$N6N66LE9IKX[A1G
M41[YEP"D!_(_ZJOXY:/4N>;MIDSDR*7X,_(&D97<B-QSA)^G:N*K^CSJWP55
M7EU,?7*=K:*IW1;TGD?>4YEV5#1-7"[OAQ8VFU\A'#!$&^ 5U0@ZC.ENNZBV
M\:_]%YT80IF579U \F4BBK?Q%21U#K#@"1 H<FA2WW]JM8*(2HBD&("HQD6G
MO<\\/:*&2WYJ1)W;515ICKRPWQ91/;_7L]7*+^YX;-XC4G!@6 B 4BI]0 (C
M1'IAJ==RTR;>C(FB_-(NP(,Z_^;KE":W*?C<I@6U,,(4T)8&@(7C1 GJ5<@]
M\ZJ5F&F['XX$JKPJF-H6G5W7LWG2Z/W>B'NB>V^$8("$$*7YIDQC STT_4+^
M'HOU@@Q[89 91=(%6*'["_M-Q7E'1((M BI%))8S*J7$U(?L$US:B)GF:#O)
MA4 6^1< I,?T-^\S8].!C"F(\0$W1A/"8>X,QWTJ)H[6\JAWMT_Y,%F7@);J
MZJI:;!AHMIN6&: HY  IS1@W3I+L)<%[1$S<[FF@5AN:V1\OXJF=FDZS^V&V
M\._COMK;10X)H)3 4=?(!:\MXKS?_4^_]:;QAL<\A\82=@$VYBX3\#YU^2Y9
M>4]0G@.EE0:.1G\-"<*XSGTSW4I,J>_N1ZI]=YQ!%AU,;8QVWQ-3\Z?;RIZO
M$1_+RVKNMM6ENVQQI($TU@,++8H"BU:;L5X&J?^:I;Z6#4/0F(*?&D^/'W_6
MJ\NJ3EWISJ[2H(?]AR"3*M T@"@0;:!F7N!> .I8I-1P*@-B<HFV@//K\4W&
MDZ3V]\OEVKOWBT<W&WOFE&E@+'+ .N.-]T'C74<HZV/K<_25ZCCE.>5&TU19
M*$PYH#-W.[+ZL[=^]BTUT^Y@3B$(#'4*0&$,L2I %4:$X?,$3G,W.0$.,^NJ
M!" FMK8;ZLTZ7;AN#_[M1OOH?]_\:+D=S(:= T81$>5'(E>>4<"Q1<9*8I',
MG4[;C[)>T.,O%GKYM5.0E_;9I^N85%O;X%,$PBR*# 62(FT/# X,,":=MH(A
M1OJE"_19K1>$Q$N#T#C"+L%B/?#TJ9Y9?U>BM2LEI%+NS.;N5QK'I'4$CWA*
M/J&E%Z3D2X-45@T4@*2[/B6WO"1CJA?6;[J9[+TD1-E(EB9 8N2("X1P:C.C
MJ8N>7HA2+Q51V30Q]>GVJ:ZB_72;+@Z?]6P9[>UK?3U;Z?G>JP.50'&A(R_>
M6!N_Q[3K=::UK]'OUA.^-)3DE&P!9N=SJE%=>'=78WQF[?IJO6FD],:'F9WM
MW:F8=.WF83R7N3)2:!(\S]UG^WFJ^J'KQ5ZJ9U;+X4!36Z M_,6VVTNV5^'>
MLVCVTFQX9)!0 C!55@N(/::Y9U;TIZX?_E[<E?S(:BJN!T'C>-Z[1@W5P\C1
MZJ'^>3MU43=.7=2KAW^Q,X%N0#>#TQ,YPLSCTPEU@DG*"$?0*\%!/..1QHK&
M<"-WWM.8DY1SC!1M3%# /D9=3E/ %7.4.Z,HS=TK.QOQ+V>"<B?>QI@7>[AR
M"_!M[QE_=7/_Y7_-?!V)NKSYX+_Y>5.:GE<PGI.> "N\(%(JJT3N7/Q^E!6"
MQ]/"I@V\^718$C(?GY#[_+45M:,43?+TJ"V-<4J9\6QJ'P(+P6E&A+2!,+NZ
M2L+B9B[R<B,QU)Q.2C %REH&8K )+0M0NC#:9/A]<@K!67X0M,%MH$8*!1=N
M9B7Z,)$5H0'CS%+!J;0A]S-N!SG3%NA."ZYC-%(HN$@S*UH;H&'\*B JD86:
M0,=/ "Y20MWNM. Z1B,%@*ME"&R#*T%QE) 5.+)#$?-:(:YS7XBW4U.(W9HT
M2,BDJP)0]]G'@']FTQB+1IZ:O]M2EVI0ZL1. 4(>$^>-5#SW@3J$WHE+L3)A
M9N_AYD0*+ "LOU8+?[/M_/%NO7 M7% ;(RU)'0@V?D-2@T5V&#93,O5LRU,A
MH<JNE@+ =?\T\'X1Y;C>C-AIVIP<I@0Q!(PF+&BBD FYAR>UD%*(4S?M]5P&
M+14 MDW.=%QY\\CIZV\SN^GZT,#=\FO\R&7SCUIZ3S@.C!!1GH$'A*R15N4.
M/7+2/_$M2PY 585HMP!D__;E:[TQ!C</@P::#P2FHH>#@P0(<XMDC/1\]G+\
M=FJF1=UT"*E&45<1P/NE^N;KQ:8S1E5?5]LZE23ALPL?1>>7S[&(490<5"[]
M%7I%&2<F]^22(\B<-N(N"*KC*K@ #*?^&KY.HONDKWW=S 0DT3=WD@$N"<0>
MQ;T8<K<6:"1D6O^S&!P.5U(12-MN(/^J2N+LWC;:"Z "(P C2^/^$03JW!D*
MG01-VS&P(.3E4EH!",P13WYHRSV5-@"MI$@EJ-Q2+'6 )::!?9BV"U!AL?UD
MB"A@.VQY;LC):TO)P]P!A0D!@A,L>>1/99^F\"Q1A61(G!XP3<-=LFFO #CN
M/E.L7NNZOHE"V_"W%QL:!;3F\:_$<>B%ABS['(9NB@H8#I-/_0VOC9ET40"R
MSK[IV3R=%>^J.M72/O@Q;[Q9/?QMKYPD[D?C/02!0.F$U)K*W,UB^](V;40^
M+MI&T4\)N&N3VMY5K_9 1FL/"&,,61&BYY+;F+42,VV,/3*RLFC@>"A5*SW/
M J5'7L8!LK*! &4Q \QR0QCEDLC<#EL_REY^"D\>KVT$/19@Z-[X.KH*:=3S
M(_[V4RU)M-;( B2EH$P22%SNS.I&0J9UU,;0>)5;_ 5@J%M.>]5AQ@--HM%&
M,A!#C>+<YKYMZ:9H6HMV E1E5$BV W34FNB/,<;9[*+<=<Q['SQ"[7$W\1/4
M"T=G'&B+$-"&"<Z9# CF?FM_D?7"!F*@D?! !:(%9'$;NM$*J?\X]<*=>#M9
MO7"G<@LX9?O,F(8H2E*Q "SQCD5K[D7V&3GES&Z?&!)'3'GOU$^!&&MYAI08
M&.MBV$TX%<$ASD5N,_A2I[QW:_BH*>^=XIZZBUO_R>0R!& 0BIM):>LY]<CO
MY@7\D%/>N]5WW)3W3ED68$<>PMJ'G(;/LV7CX"GCTB4,]X +H1AW%$<QC7:Y
ML$_/R[_?&GYV9=-74=A[72TV_F;*LVG>F\(ZH(PE@#B",?%2:YX[A[.+GFGM
M5SZMM\)IH JF/MT2^7&71;EL]NCGV<7EZFY_WK0,-?,4*(@D<,18XQR&UH=>
MQUR/Q4K!RU"U5B/*N  3-.JCA;<!*.P8<$I[QP76-N2V6:?/5GMYE6@'';#3
M(6)J$[KK)&^Z5J>Q6;Z^;67=/#^+LN@V0ZV 0#P8&P7ME>IE1_NN^/(O+8Y$
M1-> LRSJ.1ISWWQMJFD'YE%E@#98 $T(EE@J2&V_"9ZE#\PK''F95%32\?_H
ME>=OL]7E;XO*+'W]+9TFVQ8T4<;5PD;1WTU)>B+B6Q_HE^A>?:B6Z39@OG9I
MFM==W^V]RR?M0'2S A!,<R\0$B2,UAQR;.9>OMLP;).4C:9)3?Q(HOGB5ZNY
MO^\;GN9$*0"#\4!HE33&!8#"6:]#E(L>K4-7=FY>?KU(D5OI6+QDW#LGZC3_
M97:QF(69U8O55CZ_+;U;56^7J]F57OG5I7_4-OWU7S_?BVB\OO*#21JUBWQ>
M@4V0 \(\ E(*"9@*"HFXSPC*_9)\DAR0;ENSV=![V__I[F^,_I-H)#$*$ :%
ML4X+Q$9K-IN)AT("WJ'H:[7J4ZBZ@'#CD&M\A^)7,OZ5$FM\%*TU,'>[L\&/
M;>-#<!*D#'ASZU1;41!\_F6 ,@HTAA)@Q!P41!-L<H\'_#'>W+JU/N#-K5,%
M4U\8'_$>Y)0"TB1I(>0AEU3NY67^$=[<NM4Z\,VM4\8%F*#C!BU0Y)/($#!2
MN)1VZI@=[3%M^#B5\>^$2S@91U!E20 ]IL^Y=B1=>;OH&DMEM-78D]$RSW_4
MJ2K=",DY5:53725A\?E.^%XRH' T_E!:YK (0IC1WA2.G$U0YE25;A </YN@
M4R,%@.N1K#;,)(>E:3LJJZ-' 16(GJV,$;\UQ.<N<6ZCI9#'I1).VRSJ*A1V
MS1N349UJ*0W@(AX!A*K@\_=\;Z5F6HN61]L]('2$Z L$4;JKK-8Q1-<KWVR-
M38A[32,'$#%$<&A2ZN/(8-JGJCQ0':/_9V U4!D%P"NCX6]]$24(11D('D6,
M))+1T<4^]_W:&'P4\DA=PI$\.4P*V"K[G3%N=NW!GHP)!DH$ ABGA@O'F#.Y
MIVWT(*N0D&4R[#S;XF28(K-A\T2Y$Z\O]>+"+V>+T^1%="XW:LY#?T8GR&?P
M2*963PQH3P)37"%M1KM >U'Y# K&C2P$1\ HA8 R*%"-"8%JM&N>/UP^0R?Z
M3I?/T$/5!9S\CRYW[\W(Z[E>[HR_VS*#@P%28@),$%P*&VP\C<9[P-DGJ! 0
M3H*5]G>;@8HK"87#);LKCMW0>"L0YV&R%@@PBZ)<8"#.9I\5-S93A>R&X0 <
MSR9G0,.+2M'8\N.-C?P@#(SDT",N&=V=W_524S0*P\;1>1X]%%56U<<H$>[M
MN4=Y//<H X18+AV$CHF"W>'#+M%>8!;)$&]D*IC\6$[,:SVWZ_FV'*::S]]5
M]>^Z=KL"8:F7*(]_]<8I;$T@7A?LQ#0S]<,<)T?B=KR-E %$)>VJ \O(EBUU
M9#N3.;9"X$P"0R0$2A#LN,%,<S/63LK)R ^S>W* -5,!8C[D'+U]KC>E^%]6
MNEZ56+O;IZSYUL'%"A@*HPO-$&?<>"_$:.^C113)OP1_KZ#--B["#M^ :KL!
M%_Y"K[S[.ODQUK,:6J9Q?DX[%M7&%9"2V+A1@J;<>2QLX5ONT.KYEY K6/X>
M.Q9#+W]3'73"1\$ +6,PK$G@A#$K:/:ASM/YAB\AQZ>@K90/.0-]P[<+-T)V
MQ<X\0[UPO^KZ'WZ5Q/$P7^XA"^&NQ8)[W&"AUV?$;_]2QP/^MT7M]7SV+^_2
MD9^^G8[]--'NZ)R-\I@8E@E2'C]CY)<D"L\6;G>BYMX;_W9K:2J A(C'K25@
MTKZ'+G<B<#=%PU/N'H]LW!WMV'@CBUS*U!(2!$RH%T08*G*/BNE!UK1W#AEQ
MLI\\EU<E!=R>M4BKX856* *DLO$/(:.L4&KYFSMGJYV:J>N^,RN^84QP!BT4
M@*?//NZSF8V'2S-/S=]M?OR$W (3(PM L:?2242TR-WF;0B]1=JY@S%33:3
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M/G!TV:2&P NB@@X6.WU:HSV0H2*S(D; Y:B._!"0%)'%F]=[>T8<WF.@#7*
M>,6U@<2)[-<_HS)4Y-UFZ7LF)TA>P)[IY9/NO>PR#XSE!&B,#72!4\]U 2'
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M_*96_#:UKZ4P(7@0(W +,%*$!!D983R'XA\O.IU;D$7Q1\NOB-R&WLU*'"/
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MIOT-8$X$3XU#KM]5\P_=:*A;KX<W&NH2<@$P^:M?;D[OA@T#;1HOS3#PB,+
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MF+5KK:: N[;1V7VQS/>NQC'AB 1!@K 32L_G?A#@N9=M.R(97K'-[K   ;&
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M\?]02P$"% ,4    " !$H 1=N1LT#ZT'   ])0  &               @ $
M    <W!Y<F4M,C R-C V,S!X97@S,3$N:'1M4$L! A0#%     @ 1* $7:D\
M9A6Q!P  1B4  !@              ( !XP<  '-P>7)E+3(P,C8P-C,P>&5X
M,S$R+FAT;5!+ 0(4 Q0    ( $2@!%UCHM\@_P4  '4<   8
M  "  <H/  !S<'ER92TR,#(V,#8S,'AE>#,R,2YH=&U02P$"% ,4    " !$
MH 1='6WG ZI9 @# %1D $0              @ '_%0  <WER92TR,#(V,#8S
M,"YH=&U02P$"% ,4    " !$H 1= 0?GVJ01   &N@  $0
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M              "  10^"@!S>7)E+3(P,C8P-C,P7V<U+FIP9U!+ 0(4 Q0
M   ( $2@!%W?G<]=T20$ )>I!0 4              "  24;# !S>7)E+3(P
M,C8P-C,P7V<V+FIP9U!+ 0(4 Q0    ( $2@!%U,0%C,.]H  !44"0 5
M          "  2A $ !S>7)E+3(P,C8P-C,P7VQA8BYX;6Q02P$"% ,4
M" !$H 1=T+;3 I-Y  #$Q@8 %0              @ &6&A$ <WER92TR,#(V
B,#8S,%]P<F4N>&UL4$L%!@     /  \ Z ,  %R4$0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>syre-20260630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2026"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2026"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2026"
  xmlns:syre="http://spyre.com/20260630"
  xmlns:us-gaap="http://fasb.org/us-gaap/2026"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="syre-20260630.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <instant>2026-07-28</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesBNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesBNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:PreferredStockExcludingSeriesAAndBNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:PreferredStockExcludingSeriesAAndBNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesBNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesBNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesBNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesBNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesBNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesBNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesBNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesBNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesBNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesBNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesBNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesBNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">syre:SpyreTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-22</startDate>
            <endDate>2023-06-22</endDate>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">syre:AtTheMarketOffering2024SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-06</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">syre:AtTheMarketOffering2024SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">syre:AtTheMarketOffering2024SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">syre:AtTheMarketOffering2026SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">syre:AtTheMarketOffering2026SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">syre:October2025UnderwrittenOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-15</startDate>
            <endDate>2025-10-15</endDate>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-15</startDate>
            <endDate>2025-10-15</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">syre:October2025UnderwrittenOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-15</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">syre:April2026UnderwritingOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-16</startDate>
            <endDate>2026-04-16</endDate>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-16</startDate>
            <endDate>2026-04-16</endDate>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">syre:April2026UnderwritingOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-04-16</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <startDate>2015-03-10</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">syre:ContingentValueRightLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">syre:ContingentValueRightLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">syre:ContingentValueRightLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">syre:ContingentValueRightLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">syre:ContingentValueRightLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">syre:USBankingInstitutionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:SPY003LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-11</instant>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:SPY002AndSPY072LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-14</instant>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:Spy001LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-14</instant>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:SPY003LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-11</startDate>
            <endDate>2024-10-11</endDate>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:SPY002AndSPY072LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-14</startDate>
            <endDate>2024-05-14</endDate>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:Spy001LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-14</startDate>
            <endDate>2024-05-14</endDate>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ParagonAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:SPY002AndSPY072LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ParagonAgreementLicenseMilestonePaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ParagonAgreementLicenseMilestonePaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ParagonAgreementLicenseMilestonePaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ParagonAgreementLicenseMilestonePaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ParagonAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ParagonAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ParagonAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ParagonAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ParagonAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ParagonAgreementLicenseMilestonePaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">syre:ParagonTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ParagonAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">syre:FairmountFundsManagementLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ParagonAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:AppointOfBoardMembersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:OtherParagonReimbursableExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:OtherParagonReimbursableExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:OtherParagonReimbursableExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:OtherParagonReimbursableExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ParagonAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ParagonAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ParagonAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ParagonAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-22</startDate>
            <endDate>2023-11-22</endDate>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-22</instant>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-22</startDate>
            <endDate>2023-11-22</endDate>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ParagonAgreementSubsequentToAssetAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ParagonAgreementSubsequentToAssetAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">syre:ParapyreWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-22</instant>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesBNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-23</instant>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">syre:AtTheMarketOffering2024SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-06</instant>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">syre:AtTheMarketOffering2024SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-01</instant>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-01</instant>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndEighteenEquityInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndEighteenEquityInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">syre:ServiceBasedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">syre:A2016ESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">syre:A2016ESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">syre:A2016ESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">syre:A2016ESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis">
                    <us-gaap:QName.domain>us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</us-gaap:QName.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis">
                    <us-gaap:QName.domain>us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</us-gaap:QName.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis">
                    <us-gaap:QName.domain>us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</us-gaap:QName.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis">
                    <us-gaap:QName.domain>us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</us-gaap:QName.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis">
                    <us-gaap:QName.domain>us-gaap:GeneralAndAdministrativeExpense</us-gaap:QName.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis">
                    <us-gaap:QName.domain>us-gaap:GeneralAndAdministrativeExpense</us-gaap:QName.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis">
                    <us-gaap:QName.domain>us-gaap:GeneralAndAdministrativeExpense</us-gaap:QName.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis">
                    <us-gaap:QName.domain>us-gaap:GeneralAndAdministrativeExpense</us-gaap:QName.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">syre:GlobalRightsToPegzilarginaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-27</startDate>
            <endDate>2023-07-27</endDate>
        </period>
    </context>
    <context id="c-243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">syre:GlobalRightsToPegzilarginaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-27</instant>
        </period>
    </context>
    <context id="c-244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">syre:GlobalRightsToPegzilarginaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">syre:GlobalRightsToPegzilarginaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">syre:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">syre:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">syre:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">syre:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">syre:ParapyreWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">syre:ParapyreWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">syre:ParapyreWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">syre:ParapyreWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">syre:HeidyKingJonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">syre:HeidyKingJonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">syre:JeffreyAlbersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">syre:JeffreyAlbersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">syre:JeffreyAlbersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">syre:JeffreyAlbersRuleTradingArrangementDirectorStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>syre:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="bank">
        <measure>syre:bank</measure>
    </unit>
    <unit id="seat">
        <measure>syre:seat</measure>
    </unit>
    <unit id="installment">
        <measure>syre:installment</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-27">0001636282</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-28">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:AmendmentFlag contextRef="c-1" id="f-29">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-30">2026</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-31">Q2</dei:DocumentFiscalPeriodFocus>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-32" decimals="-5" id="f-208" unitRef="usd">0</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-33" decimals="-5" id="f-209" unitRef="usd">0</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <syre:RoyaltyStepDownPercent contextRef="c-184" decimals="2" id="f-675" unitRef="number">0.33</syre:RoyaltyStepDownPercent>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c-204" decimals="-5" id="f-709" unitRef="usd">0</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c-205" decimals="-5" id="f-710" unitRef="usd">0</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:AccountsPayableOtherCurrent contextRef="c-7" decimals="INF" id="f-711" unitRef="usd">0</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent contextRef="c-8" decimals="INF" id="f-712" unitRef="usd">0</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c-181" decimals="-5" id="f-713" unitRef="usd">0</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-240" id="f-822">P0Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-865"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-866"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-33" decimals="-5" id="f-867" unitRef="usd">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-32" decimals="-5" id="f-868" unitRef="usd">0</us-gaap:ResearchAndDevelopmentExpense>
    <ecd:TrdArrDuration contextRef="c-262" id="f-951">P720D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration contextRef="c-264" id="f-952">P461D</ecd:TrdArrDuration>
    <dei:DocumentType contextRef="c-1" id="f-1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c-1" id="f-2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2026-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-37722</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-6">SPYRE THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-8">46-4312787</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-9">221 Crescent Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-10">Building 23</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3 contextRef="c-1" id="f-11">Suite 105</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-12">Waltham</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-13">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-14">02453</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-15">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-16">651-5940</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock, $0.0001 Par Value Per Share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">SYRE</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-20">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-21">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityFilerCategory contextRef="c-1" id="f-22">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-23">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-24">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="c-1" id="f-25">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="INF" id="f-26" unitRef="shares">88173762</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-32" unitRef="usd">162007000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-33" unitRef="usd">85721000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-3" decimals="-3" id="f-34" unitRef="usd">983339000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-4" decimals="-3" id="f-35" unitRef="usd">670812000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-3" decimals="-3" id="f-36" unitRef="usd">27657000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-37" unitRef="usd">21248000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-3" decimals="-3" id="f-38" unitRef="usd">1173003000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-3" id="f-39" unitRef="usd">777781000</us-gaap:AssetsCurrent>
    <us-gaap:Assets contextRef="c-3" decimals="-3" id="f-40" unitRef="usd">1173003000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-4" decimals="-3" id="f-41" unitRef="usd">777781000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-5" decimals="-3" id="f-42" unitRef="usd">5722000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-6" decimals="-3" id="f-43" unitRef="usd">8904000</us-gaap:AccountsPayableCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-44" unitRef="usd">31350000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-45" unitRef="usd">22820000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="c-3" decimals="-3" id="f-46" unitRef="usd">26184000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="c-4" decimals="-3" id="f-47" unitRef="usd">26947000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c-7" decimals="-3" id="f-48" unitRef="usd">46000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c-8" decimals="-3" id="f-49" unitRef="usd">14000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-50" unitRef="usd">63302000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-51" unitRef="usd">58685000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="c-3" decimals="-3" id="f-52" unitRef="usd">7270000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="c-4" decimals="-3" id="f-53" unitRef="usd">3860000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-3" decimals="-3" id="f-54" unitRef="usd">1290000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-4" decimals="-3" id="f-55" unitRef="usd">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-3" decimals="-3" id="f-56" unitRef="usd">71862000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-4" decimals="-3" id="f-57" unitRef="usd">62545000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-3" id="f-58" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-4" id="f-59" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-9"
      decimals="INF"
      id="f-60"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-10"
      decimals="INF"
      id="f-61"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-10" decimals="INF" id="f-62" unitRef="shares">1086341</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-9" decimals="INF" id="f-63" unitRef="shares">1086341</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-10" decimals="INF" id="f-64" unitRef="shares">346045</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="c-10" decimals="INF" id="f-65" unitRef="shares">346045</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-9" decimals="INF" id="f-66" unitRef="shares">346045</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="c-9" decimals="INF" id="f-67" unitRef="shares">346045</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue contextRef="c-9" decimals="-3" id="f-68" unitRef="usd">146425000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-10" decimals="-3" id="f-69" unitRef="usd">146425000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-11"
      decimals="INF"
      id="f-70"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-12"
      decimals="INF"
      id="f-71"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-12" decimals="INF" id="f-72" unitRef="shares">271625</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-11" decimals="INF" id="f-73" unitRef="shares">271625</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-11" decimals="INF" id="f-74" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="c-11" decimals="INF" id="f-75" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="c-12" decimals="INF" id="f-76" unitRef="shares">16667</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-12" decimals="INF" id="f-77" unitRef="shares">16667</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue contextRef="c-11" decimals="-3" id="f-78" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-12" decimals="-3" id="f-79" unitRef="usd">9395000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-13"
      decimals="INF"
      id="f-80"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-14"
      decimals="INF"
      id="f-81"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-13" decimals="INF" id="f-82" unitRef="shares">8642034</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-14" decimals="INF" id="f-83" unitRef="shares">8642034</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="c-13" decimals="INF" id="f-84" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="c-14" decimals="INF" id="f-85" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-13" decimals="INF" id="f-86" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-14" decimals="INF" id="f-87" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue contextRef="c-14" decimals="-3" id="f-88" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-13" decimals="-3" id="f-89" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-90"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-91"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-92" unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-93" unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-3" decimals="INF" id="f-94" unitRef="shares">88064133</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-95" unitRef="shares">88064133</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-96" unitRef="shares">78189811</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="INF" id="f-97" unitRef="shares">78189811</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue contextRef="c-3" decimals="-3" id="f-98" unitRef="usd">16000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-4" decimals="-3" id="f-99" unitRef="usd">15000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-3" decimals="-3" id="f-100" unitRef="usd">2189936000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-4" decimals="-3" id="f-101" unitRef="usd">1686167000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-3" decimals="-3" id="f-102" unitRef="usd">-2396000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-4" decimals="-3" id="f-103" unitRef="usd">869000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-3" id="f-104" unitRef="usd">-1232840000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-3" id="f-105" unitRef="usd">-1127635000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-106" unitRef="usd">1101141000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-107" unitRef="usd">715236000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-3" decimals="-3" id="f-108" unitRef="usd">1173003000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-3" id="f-109" unitRef="usd">777781000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-15" decimals="-3" id="f-110" unitRef="usd">65503000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-16" decimals="-3" id="f-111" unitRef="usd">40145000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-1" decimals="-3" id="f-112" unitRef="usd">125914000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-17" decimals="-3" id="f-113" unitRef="usd">81768000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-15" decimals="-3" id="f-114" unitRef="usd">16136000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-16" decimals="-3" id="f-115" unitRef="usd">11790000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-116" unitRef="usd">31366000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-17" decimals="-3" id="f-117" unitRef="usd">23734000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal contextRef="c-15" decimals="-3" id="f-118" unitRef="usd">40000000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal contextRef="c-16" decimals="-3" id="f-119" unitRef="usd">10000000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal contextRef="c-1" decimals="-3" id="f-120" unitRef="usd">70000000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal contextRef="c-17" decimals="-3" id="f-121" unitRef="usd">10000000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:OperatingExpenses contextRef="c-15" decimals="-3" id="f-122" unitRef="usd">41639000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-16" decimals="-3" id="f-123" unitRef="usd">41935000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-124" unitRef="usd">87280000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-17" decimals="-3" id="f-125" unitRef="usd">95502000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-15" decimals="-3" id="f-126" unitRef="usd">-41639000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-16" decimals="-3" id="f-127" unitRef="usd">-41935000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-128" unitRef="usd">-87280000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-17" decimals="-3" id="f-129" unitRef="usd">-95502000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeNet contextRef="c-15" decimals="-3" id="f-130" unitRef="usd">10053000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet contextRef="c-16" decimals="-3" id="f-131" unitRef="usd">5874000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet contextRef="c-1" decimals="-3" id="f-132" unitRef="usd">17048000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet contextRef="c-17" decimals="-3" id="f-133" unitRef="usd">12367000</us-gaap:InvestmentIncomeNet>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-15" decimals="-3" id="f-134" unitRef="usd">-4614000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-16" decimals="-3" id="f-135" unitRef="usd">-656000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-136" unitRef="usd">-34973000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-17" decimals="-3" id="f-137" unitRef="usd">1630000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-15" decimals="-3" id="f-138" unitRef="usd">5439000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-16" decimals="-3" id="f-139" unitRef="usd">5218000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-140" unitRef="usd">-17925000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-17" decimals="-3" id="f-141" unitRef="usd">13997000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-15" decimals="-3" id="f-142" unitRef="usd">-36200000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-16" decimals="-3" id="f-143" unitRef="usd">-36717000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-144" unitRef="usd">-105205000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-17" decimals="-3" id="f-145" unitRef="usd">-81505000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-15" decimals="-3" id="f-146" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-16" decimals="-3" id="f-147" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-148" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-17" decimals="-3" id="f-149" unitRef="usd">-15000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-15" decimals="-3" id="f-150" unitRef="usd">-36200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-16" decimals="-3" id="f-151" unitRef="usd">-36717000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-152" unitRef="usd">-105205000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-17" decimals="-3" id="f-153" unitRef="usd">-81490000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-18"
      decimals="2"
      id="f-154"
      unitRef="usdPerShare">-14.60</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-18"
      decimals="2"
      id="f-155"
      unitRef="usdPerShare">-14.60</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-19"
      decimals="2"
      id="f-156"
      unitRef="usdPerShare">-19.62</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-19"
      decimals="2"
      id="f-157"
      unitRef="usdPerShare">-19.62</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-20"
      decimals="2"
      id="f-158"
      unitRef="usdPerShare">-43.77</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-20"
      decimals="2"
      id="f-159"
      unitRef="usdPerShare">-43.77</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-21"
      decimals="2"
      id="f-160"
      unitRef="usdPerShare">-43.57</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-21"
      decimals="2"
      id="f-161"
      unitRef="usdPerShare">-43.57</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-18" decimals="0" id="f-162" unitRef="shares">346045</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-18" decimals="0" id="f-163" unitRef="shares">346045</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-19" decimals="0" id="f-164" unitRef="shares">346045</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-19" decimals="0" id="f-165" unitRef="shares">346045</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-20" decimals="0" id="f-166" unitRef="shares">346045</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-20" decimals="0" id="f-167" unitRef="shares">346045</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-21" decimals="0" id="f-168" unitRef="shares">346045</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-21" decimals="0" id="f-169" unitRef="shares">346045</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-22"
      decimals="2"
      id="f-170"
      unitRef="usdPerShare">-14.60</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-22"
      decimals="2"
      id="f-171"
      unitRef="usdPerShare">-14.60</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-23"
      decimals="2"
      id="f-172"
      unitRef="usdPerShare">-19.62</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-23"
      decimals="2"
      id="f-173"
      unitRef="usdPerShare">-19.62</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-24"
      decimals="2"
      id="f-174"
      unitRef="usdPerShare">-43.77</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-24"
      decimals="2"
      id="f-175"
      unitRef="usdPerShare">-43.77</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-25"
      decimals="2"
      id="f-176"
      unitRef="usdPerShare">-43.57</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-25"
      decimals="2"
      id="f-177"
      unitRef="usdPerShare">-43.57</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-22" decimals="0" id="f-178" unitRef="shares">15385</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-22" decimals="0" id="f-179" unitRef="shares">15385</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-23" decimals="0" id="f-180" unitRef="shares">16667</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-23" decimals="0" id="f-181" unitRef="shares">16667</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-24" decimals="0" id="f-182" unitRef="shares">16022</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-24" decimals="0" id="f-183" unitRef="shares">16022</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-25" decimals="0" id="f-184" unitRef="shares">16667</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-25" decimals="0" id="f-185" unitRef="shares">16667</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-26"
      decimals="2"
      id="f-186"
      unitRef="usdPerShare">-0.36</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-26"
      decimals="2"
      id="f-187"
      unitRef="usdPerShare">-0.36</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-27"
      decimals="2"
      id="f-188"
      unitRef="usdPerShare">-0.49</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-27"
      decimals="2"
      id="f-189"
      unitRef="usdPerShare">-0.49</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-28"
      decimals="2"
      id="f-190"
      unitRef="usdPerShare">-1.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-28"
      decimals="2"
      id="f-191"
      unitRef="usdPerShare">-1.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-29"
      decimals="2"
      id="f-192"
      unitRef="usdPerShare">-1.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-29"
      decimals="2"
      id="f-193"
      unitRef="usdPerShare">-1.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-26" decimals="0" id="f-194" unitRef="shares">84729435</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-26" decimals="0" id="f-195" unitRef="shares">84729435</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-27" decimals="0" id="f-196" unitRef="shares">60333838</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-27" decimals="0" id="f-197" unitRef="shares">60333838</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-28" decimals="0" id="f-198" unitRef="shares">81656119</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-28" decimals="0" id="f-199" unitRef="shares">81656119</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-29" decimals="0" id="f-200" unitRef="shares">60300073</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-29" decimals="0" id="f-201" unitRef="shares">60300073</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-30" decimals="-5" id="f-202" unitRef="usd">3100000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-31" decimals="-5" id="f-203" unitRef="usd">2600000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-32" decimals="-5" id="f-204" unitRef="usd">200000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-33" decimals="-5" id="f-205" unitRef="usd">200000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-31" decimals="-5" id="f-206" unitRef="usd">500000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-30" decimals="-5" id="f-207" unitRef="usd">500000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:NetIncomeLoss contextRef="c-15" decimals="-3" id="f-210" unitRef="usd">-36200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-16" decimals="-3" id="f-211" unitRef="usd">-36717000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-212" unitRef="usd">-105205000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-17" decimals="-3" id="f-213" unitRef="usd">-81490000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c-15" decimals="-3" id="f-214" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c-16" decimals="-3" id="f-215" unitRef="usd">-36000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c-1" decimals="-3" id="f-216" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c-17" decimals="-3" id="f-217" unitRef="usd">-22000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-15" decimals="-3" id="f-218" unitRef="usd">-1629000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-16" decimals="-3" id="f-219" unitRef="usd">-192000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-1" decimals="-3" id="f-220" unitRef="usd">-3265000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-17" decimals="-3" id="f-221" unitRef="usd">296000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-15" decimals="-3" id="f-222" unitRef="usd">-37829000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-16" decimals="-3" id="f-223" unitRef="usd">-36945000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-224" unitRef="usd">-108470000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-17" decimals="-3" id="f-225" unitRef="usd">-81216000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-34" decimals="-3" id="f-226" unitRef="shares">346000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-34" decimals="-3" id="f-227" unitRef="usd">146425000</us-gaap:StockholdersEquity>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-35" decimals="-3" id="f-228" unitRef="shares">17000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-35" decimals="-3" id="f-229" unitRef="usd">9395000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-36" decimals="-3" id="f-230" unitRef="shares">78190000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-36" decimals="-3" id="f-231" unitRef="usd">15000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-37" decimals="-3" id="f-232" unitRef="usd">1686167000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-38" decimals="-3" id="f-233" unitRef="usd">869000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-39" decimals="-3" id="f-234" unitRef="usd">-1127635000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-235" unitRef="usd">715236000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c-40" decimals="-3" id="f-236" unitRef="shares">296000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-41" decimals="-3" id="f-237" unitRef="usd">9747000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-42" decimals="-3" id="f-238" unitRef="usd">9747000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <syre:StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan contextRef="c-40" decimals="-3" id="f-239" unitRef="shares">354000</syre:StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan>
    <syre:StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan contextRef="c-41" decimals="-3" id="f-240" unitRef="usd">3663000</syre:StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan>
    <syre:StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan contextRef="c-42" decimals="-3" id="f-241" unitRef="usd">3663000</syre:StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-41" decimals="-3" id="f-242" unitRef="usd">12806000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-42" decimals="-3" id="f-243" unitRef="usd">12806000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-43" decimals="-3" id="f-244" unitRef="usd">-1636000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-42" decimals="-3" id="f-245" unitRef="usd">-1636000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-44" decimals="-3" id="f-246" unitRef="usd">-69005000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-42" decimals="-3" id="f-247" unitRef="usd">-69005000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-45" decimals="-3" id="f-248" unitRef="shares">346000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-45" decimals="-3" id="f-249" unitRef="usd">146425000</us-gaap:StockholdersEquity>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-46" decimals="-3" id="f-250" unitRef="shares">17000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-46" decimals="-3" id="f-251" unitRef="usd">9395000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-47" decimals="-3" id="f-252" unitRef="shares">78840000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-47" decimals="-3" id="f-253" unitRef="usd">15000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-48" decimals="-3" id="f-254" unitRef="usd">1712383000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-49" decimals="-3" id="f-255" unitRef="usd">-767000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-50" decimals="-3" id="f-256" unitRef="usd">-1196640000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-51" decimals="-3" id="f-257" unitRef="usd">670811000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-52"
      decimals="INF"
      id="f-258"
      unitRef="shares">-17000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-52" decimals="-3" id="f-259" unitRef="usd">-9395000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-53"
      decimals="INF"
      id="f-260"
      unitRef="shares">667000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-54" decimals="-3" id="f-261" unitRef="usd">9395000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-15" decimals="-3" id="f-262" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c-55" decimals="-3" id="f-263" unitRef="shares">7475000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-55" decimals="-3" id="f-264" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-54" decimals="-3" id="f-265" unitRef="usd">434897000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-15" decimals="-3" id="f-266" unitRef="usd">434898000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <syre:StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan contextRef="c-55" decimals="-3" id="f-267" unitRef="shares">1083000</syre:StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan>
    <syre:StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan contextRef="c-54" decimals="-3" id="f-268" unitRef="usd">19749000</syre:StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan>
    <syre:StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan contextRef="c-15" decimals="-3" id="f-269" unitRef="usd">19749000</syre:StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-54" decimals="-3" id="f-270" unitRef="usd">13512000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-15" decimals="-3" id="f-271" unitRef="usd">13512000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-56" decimals="-3" id="f-272" unitRef="usd">-1629000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-15" decimals="-3" id="f-273" unitRef="usd">-1629000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-57" decimals="-3" id="f-274" unitRef="usd">-36200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-15" decimals="-3" id="f-275" unitRef="usd">-36200000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-58" decimals="-3" id="f-276" unitRef="shares">346000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-58" decimals="-3" id="f-277" unitRef="usd">146425000</us-gaap:StockholdersEquity>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-59" decimals="-3" id="f-278" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-59" decimals="-3" id="f-279" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-60" decimals="-3" id="f-280" unitRef="shares">88064000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-60" decimals="-3" id="f-281" unitRef="usd">16000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-61" decimals="-3" id="f-282" unitRef="usd">2189936000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-62" decimals="-3" id="f-283" unitRef="usd">-2396000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-63" decimals="-3" id="f-284" unitRef="usd">-1232840000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-285" unitRef="usd">1101141000</us-gaap:StockholdersEquity>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-64" decimals="-3" id="f-286" unitRef="shares">346000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-64" decimals="-3" id="f-287" unitRef="usd">146425000</us-gaap:StockholdersEquity>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-65" decimals="-3" id="f-288" unitRef="shares">17000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-65" decimals="-3" id="f-289" unitRef="usd">9395000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-66" decimals="-3" id="f-290" unitRef="shares">60257000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-66" decimals="-3" id="f-291" unitRef="usd">13000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-67" decimals="-3" id="f-292" unitRef="usd">1334223000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-68" decimals="-3" id="f-293" unitRef="usd">180000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-69" decimals="-3" id="f-294" unitRef="usd">-972432000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-70" decimals="-3" id="f-295" unitRef="usd">517804000</us-gaap:StockholdersEquity>
    <syre:StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan contextRef="c-71" decimals="-3" id="f-296" unitRef="shares">19000</syre:StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan>
    <syre:StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan contextRef="c-72" decimals="-3" id="f-297" unitRef="usd">218000</syre:StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan>
    <syre:StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan contextRef="c-73" decimals="-3" id="f-298" unitRef="usd">218000</syre:StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-72" decimals="-3" id="f-299" unitRef="usd">8859000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-73" decimals="-3" id="f-300" unitRef="usd">8859000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c-74" decimals="-3" id="f-301" unitRef="usd">14000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c-73" decimals="-3" id="f-302" unitRef="usd">14000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-74" decimals="-3" id="f-303" unitRef="usd">488000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-73" decimals="-3" id="f-304" unitRef="usd">488000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-75" decimals="-3" id="f-305" unitRef="usd">-44773000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-73" decimals="-3" id="f-306" unitRef="usd">-44773000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-76" decimals="-3" id="f-307" unitRef="shares">346000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-76" decimals="-3" id="f-308" unitRef="usd">146425000</us-gaap:StockholdersEquity>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-77" decimals="-3" id="f-309" unitRef="shares">17000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-77" decimals="-3" id="f-310" unitRef="usd">9395000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-78" decimals="-3" id="f-311" unitRef="shares">60276000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-78" decimals="-3" id="f-312" unitRef="usd">13000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-79" decimals="-3" id="f-313" unitRef="usd">1343300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-80" decimals="-3" id="f-314" unitRef="usd">682000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-81" decimals="-3" id="f-315" unitRef="usd">-1017205000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-82" decimals="-3" id="f-316" unitRef="usd">482610000</us-gaap:StockholdersEquity>
    <syre:StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan contextRef="c-83" decimals="-3" id="f-317" unitRef="shares">97000</syre:StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan>
    <syre:StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan contextRef="c-84" decimals="-3" id="f-318" unitRef="usd">730000</syre:StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan>
    <syre:StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan contextRef="c-16" decimals="-3" id="f-319" unitRef="usd">730000</syre:StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-84" decimals="-3" id="f-320" unitRef="usd">9378000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-16" decimals="-3" id="f-321" unitRef="usd">9378000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c-85" decimals="-3" id="f-322" unitRef="usd">-36000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c-16" decimals="-3" id="f-323" unitRef="usd">-36000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-85" decimals="-3" id="f-324" unitRef="usd">-192000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-16" decimals="-3" id="f-325" unitRef="usd">-192000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-86" decimals="-3" id="f-326" unitRef="usd">-36717000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-16" decimals="-3" id="f-327" unitRef="usd">-36717000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-87" decimals="-3" id="f-328" unitRef="shares">346000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-87" decimals="-3" id="f-329" unitRef="usd">146425000</us-gaap:StockholdersEquity>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-88" decimals="-3" id="f-330" unitRef="shares">17000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-88" decimals="-3" id="f-331" unitRef="usd">9395000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-89" decimals="-3" id="f-332" unitRef="shares">60373000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-89" decimals="-3" id="f-333" unitRef="usd">13000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-90" decimals="-3" id="f-334" unitRef="usd">1353408000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-91" decimals="-3" id="f-335" unitRef="usd">454000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-92" decimals="-3" id="f-336" unitRef="usd">-1053922000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-93" decimals="-3" id="f-337" unitRef="usd">455773000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-338" unitRef="usd">-105205000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-17" decimals="-3" id="f-339" unitRef="usd">-81490000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-340" unitRef="usd">26318000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-17" decimals="-3" id="f-341" unitRef="usd">18237000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="c-1" decimals="-3" id="f-342" unitRef="usd">-34873000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="c-17" decimals="-3" id="f-343" unitRef="usd">1800000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal contextRef="c-1" decimals="-3" id="f-344" unitRef="usd">70000000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal contextRef="c-17" decimals="-3" id="f-345" unitRef="usd">10000000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-1" decimals="-3" id="f-346" unitRef="usd">5152000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-17" decimals="-3" id="f-347" unitRef="usd">4655000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <syre:InterestProceedsDebtSecurities contextRef="c-1" decimals="-3" id="f-348" unitRef="usd">683000</syre:InterestProceedsDebtSecurities>
    <syre:InterestProceedsDebtSecurities contextRef="c-17" decimals="-3" id="f-349" unitRef="usd">1760000</syre:InterestProceedsDebtSecurities>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="c-1" decimals="-3" id="f-350" unitRef="usd">-3182000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="c-17" decimals="-3" id="f-351" unitRef="usd">3046000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c-1" decimals="-3" id="f-352" unitRef="usd">225000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c-17" decimals="-3" id="f-353" unitRef="usd">-8299000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable contextRef="c-1" decimals="-3" id="f-354" unitRef="usd">32000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable contextRef="c-17" decimals="-3" id="f-355" unitRef="usd">-572000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-356" unitRef="usd">5841000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-17" decimals="-3" id="f-357" unitRef="usd">3784000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-358" unitRef="usd">-127249000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-17" decimals="-3" id="f-359" unitRef="usd">-87557000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="c-1" decimals="-3" id="f-360" unitRef="usd">217187000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="c-17" decimals="-3" id="f-361" unitRef="usd">178249000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-1" decimals="-3" id="f-362" unitRef="usd">528510000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-17" decimals="-3" id="f-363" unitRef="usd">106312000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfIntangibleAssets contextRef="c-1" decimals="-3" id="f-364" unitRef="usd">70000000</us-gaap:ProceedsFromSaleOfIntangibleAssets>
    <us-gaap:ProceedsFromSaleOfIntangibleAssets contextRef="c-17" decimals="-3" id="f-365" unitRef="usd">7000000</us-gaap:ProceedsFromSaleOfIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-366" unitRef="usd">-241323000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-17" decimals="-3" id="f-367" unitRef="usd">78937000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="c-1" decimals="-3" id="f-368" unitRef="usd">435240000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="c-17" decimals="-3" id="f-369" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <syre:ProceedsFromIssuanceOfCommonStockAtTheMarketOfferingsNet contextRef="c-1" decimals="-3" id="f-370" unitRef="usd">9750000</syre:ProceedsFromIssuanceOfCommonStockAtTheMarketOfferingsNet>
    <syre:ProceedsFromIssuanceOfCommonStockAtTheMarketOfferingsNet contextRef="c-17" decimals="-3" id="f-371" unitRef="usd">0</syre:ProceedsFromIssuanceOfCommonStockAtTheMarketOfferingsNet>
    <syre:PaymentForDeferredOfferingCosts contextRef="c-1" decimals="-3" id="f-372" unitRef="usd">454000</syre:PaymentForDeferredOfferingCosts>
    <syre:PaymentForDeferredOfferingCosts contextRef="c-17" decimals="-3" id="f-373" unitRef="usd">93000</syre:PaymentForDeferredOfferingCosts>
    <syre:PaymentsRelatedToContingentValueRightsLiability contextRef="c-1" decimals="-3" id="f-374" unitRef="usd">22933000</syre:PaymentsRelatedToContingentValueRightsLiability>
    <syre:PaymentsRelatedToContingentValueRightsLiability contextRef="c-17" decimals="-3" id="f-375" unitRef="usd">0</syre:PaymentsRelatedToContingentValueRightsLiability>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c-1" decimals="-3" id="f-376" unitRef="usd">23255000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c-17" decimals="-3" id="f-377" unitRef="usd">949000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-378" unitRef="usd">444858000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-17" decimals="-3" id="f-379" unitRef="usd">856000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-380" unitRef="usd">76286000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-17" decimals="-3" id="f-381" unitRef="usd">-7764000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-382" unitRef="usd">85721000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-70" decimals="-3" id="f-383" unitRef="usd">89423000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="-3" id="f-384" unitRef="usd">162007000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-93" decimals="-3" id="f-385" unitRef="usd">81659000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <syre:IssuanceOfConvertiblePreferredStockRelatedToPrivatePlacementUnpaidAmount contextRef="c-1" decimals="-3" id="f-386" unitRef="usd">157000</syre:IssuanceOfConvertiblePreferredStockRelatedToPrivatePlacementUnpaidAmount>
    <syre:IssuanceOfConvertiblePreferredStockRelatedToPrivatePlacementUnpaidAmount contextRef="c-17" decimals="-3" id="f-387" unitRef="usd">0</syre:IssuanceOfConvertiblePreferredStockRelatedToPrivatePlacementUnpaidAmount>
    <syre:DeferredOfferingCostsAllocatedAmountOfProceedsOfIssuanceOfCommonStock contextRef="c-1" decimals="-3" id="f-388" unitRef="usd">345000</syre:DeferredOfferingCostsAllocatedAmountOfProceedsOfIssuanceOfCommonStock>
    <syre:DeferredOfferingCostsAllocatedAmountOfProceedsOfIssuanceOfCommonStock contextRef="c-17" decimals="-3" id="f-389" unitRef="usd">0</syre:DeferredOfferingCostsAllocatedAmountOfProceedsOfIssuanceOfCommonStock>
    <syre:DeferredOfferingCostsUnpaidAmount contextRef="c-1" decimals="-3" id="f-390" unitRef="usd">301000</syre:DeferredOfferingCostsUnpaidAmount>
    <syre:DeferredOfferingCostsUnpaidAmount contextRef="c-17" decimals="-3" id="f-391" unitRef="usd">0</syre:DeferredOfferingCostsUnpaidAmount>
    <us-gaap:ConversionOfStockAmountConverted1 contextRef="c-1" decimals="-3" id="f-392" unitRef="usd">9395000</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockAmountConverted1 contextRef="c-17" decimals="-3" id="f-393" unitRef="usd">0</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c-1" id="f-394">The Company and Basis of Presentation&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Spyre Therapeutics, Inc., formerly Aeglea BioTherapeutics, Inc. (&#x201c;Spyre&#x201d; or the &#x201c;Company&#x201d;), is a clinical stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients. The Company was formed as a Limited Liability Company in Delaware on December 16, 2013 under the name Aeglea BioTherapeutics Holdings, LLC and was converted from a Delaware LLC to a Delaware corporation on March 10, 2015. On June 22, 2023, the Company acquired the assets of Spyre Therapeutics, Inc., a privately held biotechnology company (the &#x201c;Asset Acquisition&#x201d;), and on November 27, 2023, the Company completed its corporate rebranding, changing the name of the Company to Spyre Therapeutics, Inc. The Company operates in one segment and has its principal offices in Waltham, Massachusetts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Asset Acquisition, a non-transferable contingent value right (&#x201c;CVR&#x201d;) was distributed to stockholders of record of the Company as of the close of business on July 3, 2023 (the &#x201c;Legacy Stockholders&#x201d;). Holders of the CVRs will be entitled to receive certain cash payments from proceeds received by the Company prior to the third anniversary of the contingent value rights agreement (the "CVR Agreement") we entered into with Equiniti Trust Company LLC (f/k/a American Stock Transfer &amp;amp; Trust Company LLC) as rights agent in connection with the Asset Acquisition, if any, related to the disposition or monetization of its legacy assets during the one-year period following the closing of the Asset Acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 6, 2024, the Company entered into a sales agreement (the &#x201c;2024 Sales Agreement&#x201d;) with TD Securities (USA) LLC as its agent, pursuant to which the Company may issue and sell up to $200.0&#160;million of shares of common stock under an at-the-market (&#x201c;ATM&#x201d;) offering program. During the three and six months ended June&#160;30, 2026, the Company sold an aggregate of nil and 296,396, respectively, shares of common stock under the ATM offering program pursuant to the 2024 Sales Agreement resulting in net proceeds of $9.7&#160;million. The 2024 Sales Agreement was terminated on June 26, 2026 and the Company concurrently entered into a new sales agreement (the &#x201c;2026 Sales Agreement&#x201d;) with TD Securities (USA) LLC as its agent, pursuant to which the Company may issue and sell up to $500.0&#160;million of shares of common stock under an ATM offering program. During the three months ended June 30, 2026, the Company did not sell any shares under the ATM offering program pursuant to the 2026 Sales Agreement. As of June&#160;30, 2026, $500.0&#160;million remained available for sale under the 2026 Sales Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 13, 2025, the Company entered into an underwriting agreement (the &#x201c;October 2025 Underwriting Agreement&#x201d;), pursuant to which the Company sold an aggregate of 17,094,594 shares of its common stock, inclusive of 2,229,729 shares pursuant to the full exercise of the underwriters' over-allotment option, at a public offering price per share of $18.50, resulting in net proceeds of approximately $296.4&#160;million after deducting approximately $19.9&#160;million of underwriting discounts and other offering costs (the &#x201c;October 2025 Offering&#x201d;). The over-allotment option was exercised in full on October 14, 2025 and the transaction closed on October 15, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 13, 2026, the Company entered into an underwriting agreement (the &#x201c;April 2026 Underwriting Agreement&#x201d;), pursuant to which the Company sold an aggregate of 7,475,000 shares of its common stock, inclusive of 975,000 shares pursuant to the full exercise of the underwriters' over-allotment option, at a public offering price per share of $62.00, resulting in net proceeds of approximately $435.2&#160;million after deducting approximately $28.2&#160;million of underwriting discounts and other offering costs (the &#x201c;April 2026 Offering&#x201d;). The over-allotment option was exercised in full on April 15, 2026 and the transaction closed on April 16, 2026.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is a clinical stage biotechnology company with a limited operating history, and due to its significant research and development expenditures, the Company has generated operating losses since its inception and has not generated any revenue from the commercial sale of any products. There can be no assurance that profitable operations will ever be achieved, and, if achieved, whether profitability can be sustained on a continuing basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since its inception and through June&#160;30, 2026, the Company has funded its operations by raising an aggregate of approximately $2.1&#160;billion of gross proceeds from the sale and issuance of convertible preferred stock and common stock, pre-funded warrants, the collection of grant proceeds, and the licensing of its product rights for commercialization of pegzilarginase in Europe and certain countries in the Middle East. As of June&#160;30, 2026, Spyre had an accumulated deficit of $1.2&#160;billion, and cash, cash equivalents, and marketable securities of $1.1&#160;billion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on its current operating plans, the Company has sufficient resources to fund operations for at least one year from the issuance date of these financial statements with existing cash, cash equivalents, and marketable securities. The Company will need to secure additional financing in the future to fund additional research and development, and before a commercial drug can be produced, marketed and sold. If the Company is unable to obtain additional financing or generate license or product revenue, the lack of liquidity could have a material adverse effect on the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (&#x201c;U.S. GAAP&#x201d;) as defined by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) and include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unaudited Interim Financial Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The interim condensed consolidated financial statements included in this Quarterly Report on Form 10-Q are unaudited. The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and reflect, in the opinion of management, all adjustments of a normal and recurring nature that are necessary for a fair statement of the Company&#x2019;s financial position as of June&#160;30, 2026, and its results of operations for the three and six months ended June&#160;30, 2026 and 2025, changes in convertible preferred stock and stockholders&#x2019; equity for the three and six months ended June&#160;30, 2026 and 2025, and cash flows for the six months ended June&#160;30, 2026 and 2025. The results of operations for the three and six months ended June&#160;30, 2026 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2026 or for any other future annual or interim period. The December&#160;31, 2025 balance sheet was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP for complete financial statements. These financial statements should be read in conjunction with the audited financial statements included in the Company&#x2019;s Form 10-K for the year ended December&#160;31, 2025 (the &#x201c;Annual Report&#x201d;) as filed with the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) on February 19, 2026.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-395"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <syre:AssetAcquisitionCashPaymentThresholdPeriod contextRef="c-94" id="f-396">P1Y</syre:AssetAcquisitionCashPaymentThresholdPeriod>
    <syre:SaleOfStockAuthorizedAmount contextRef="c-95" decimals="-5" id="f-397" unitRef="usd">200000000.0</syre:SaleOfStockAuthorizedAmount>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-96"
      decimals="INF"
      id="f-398"
      unitRef="shares">0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-97"
      decimals="INF"
      id="f-399"
      unitRef="shares">296396</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-97" decimals="-5" id="f-400" unitRef="usd">9700000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <syre:SaleOfStockAuthorizedAmount contextRef="c-98" decimals="-5" id="f-401" unitRef="usd">500000000.0</syre:SaleOfStockAuthorizedAmount>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-99"
      decimals="INF"
      id="f-402"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <syre:SaleOfStockRemainingAuthorizedAmount contextRef="c-98" decimals="-5" id="f-403" unitRef="usd">500000000.0</syre:SaleOfStockRemainingAuthorizedAmount>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-100"
      decimals="INF"
      id="f-404"
      unitRef="shares">17094594</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-101"
      decimals="INF"
      id="f-405"
      unitRef="shares">2229729</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-102"
      decimals="2"
      id="f-406"
      unitRef="usdPerShare">18.50</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-100" decimals="-5" id="f-407" unitRef="usd">296400000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-100" decimals="-5" id="f-408" unitRef="usd">19900000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-103"
      decimals="INF"
      id="f-409"
      unitRef="shares">7475000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-104"
      decimals="INF"
      id="f-410"
      unitRef="shares">975000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-105"
      decimals="2"
      id="f-411"
      unitRef="usdPerShare">62.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-103" decimals="-5" id="f-412" unitRef="usd">435200000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-103" decimals="-5" id="f-413" unitRef="usd">28200000</us-gaap:PaymentsOfStockIssuanceCosts>
    <syre:ProceedsFromRaisingCapital contextRef="c-106" decimals="-8" id="f-414" unitRef="usd">2100000000</syre:ProceedsFromRaisingCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-8" id="f-415" unitRef="usd">-1200000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="c-3" decimals="-8" id="f-416" unitRef="usd">1100000000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-417">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (&#x201c;U.S. GAAP&#x201d;) as defined by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) and include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-418">Summary of Significant Accounting Policies&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These interim condensed consolidated financial statements have been prepared in accordance with U.S. GAAP and SEC instructions for interim financial information, and should be read in conjunction with the Annual Report. Significant accounting policies and other disclosures normally provided have been omitted since such items are disclosed in the Annual Report. The Company uses the same accounting policies in preparing quarterly and annual financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no significant changes from the significant accounting policies and estimates disclosed in the Notes titled &#x201c;1. The Company and Basis of Presentation&#x201d; and "2. Summary of Significant Accounting Policies&#x201d; of the Annual Report, except as disclosed below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Value Rights&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June 30, 2026, Contingent Value Rights are no longer a significant accounting policy. The Company determined that its future payment obligations under the CVR Agreement no longer qualify as derivatives under ASC 815, Derivatives and Hedging, as all contingencies have been resolved. Accordingly, the Company has measured the fair value of its CVR liability by discounting the estimated future payments to be made under the CVR Agreement using the Company&#x2019;s weighted average cost of capital. This fair value measurement is based on inputs observable in the market and thus represents a Level 2 measurement as defined in ASC 820, Fair Value Measurement. The estimated value of the CVR consideration is based upon &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;available information and certain assumptions which the Company's management believes are reasonable under the circumstances. The ultimate payout under the CVRs may differ materially from the assumptions used in determining the fair value of the CVR consideration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no recent accounting pronouncements or changes in accounting pronouncements adopted during the three months ended June&#160;30, 2026 that are of significance or potential significance to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Not Yet Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued Accounting Standards Update 2024-03 (&#x201c;ASU 2024-03&#x201d;) Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses to require more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation, amortization, and depletion) included in certain expense captions presented on the face of the income statement. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either (1) prospectively to financial statements issued for reporting periods after the effective date of this ASU 2024-03 or (2) retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact ASU 2024-03 will have on its disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock contextRef="c-1" id="f-419">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Value Rights&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June 30, 2026, Contingent Value Rights are no longer a significant accounting policy. The Company determined that its future payment obligations under the CVR Agreement no longer qualify as derivatives under ASC 815, Derivatives and Hedging, as all contingencies have been resolved. Accordingly, the Company has measured the fair value of its CVR liability by discounting the estimated future payments to be made under the CVR Agreement using the Company&#x2019;s weighted average cost of capital. This fair value measurement is based on inputs observable in the market and thus represents a Level 2 measurement as defined in ASC 820, Fair Value Measurement. The estimated value of the CVR consideration is based upon &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;available information and certain assumptions which the Company's management believes are reasonable under the circumstances. The ultimate payout under the CVRs may differ materially from the assumptions used in determining the fair value of the CVR consideration.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-420">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no recent accounting pronouncements or changes in accounting pronouncements adopted during the three months ended June&#160;30, 2026 that are of significance or potential significance to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Not Yet Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued Accounting Standards Update 2024-03 (&#x201c;ASU 2024-03&#x201d;) Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses to require more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation, amortization, and depletion) included in certain expense captions presented on the face of the income statement. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either (1) prospectively to financial statements issued for reporting periods after the effective date of this ASU 2024-03 or (2) retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact ASU 2024-03 will have on its disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-421">Fair Value Measurements&lt;div style="margin-top:18pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures and reports certain financial instruments as assets and liabilities at fair value on a recurring basis. The following tables set forth the fair value of the Company&#x2019;s financial assets and liabilities at fair value on a recurring basis based on the three-tier fair value hierarchy (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;139,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;139,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 15.4pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. government treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;256,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;256,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 15.4pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;176,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;176,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 15.4pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;425,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;425,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 15.4pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;146,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;146,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;395,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;747,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,143,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 12.37pt;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;CVR liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;74,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;74,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. government treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;266,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;266,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;119,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;119,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 15.4pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;194,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;194,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 15.4pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;100,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;100,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;340,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;414,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;754,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;CVR liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures the fair value of money market funds and U.S. government treasury securities on quoted prices in active markets for identical assets or liabilities. The Level 2 assets include U.S. government agency securities, commercial paper and corporate bonds, and are valued based on quoted prices for similar assets in active markets and inputs other than quoted prices that are derived from observable market data. The Company evaluates transfers between levels at the end of each reporting period. There were no financial asset transfers between Level 1, Level 2, or Level 3 during the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;CVR Liability &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Asset Acquisition, a non-transferable CVR was distributed to the Legacy Stockholders. Holders of the CVR are entitled to receive certain cash payments from proceeds received by the Company for a three-year period ending July 3, 2026, related to the disposition or monetization of the Company&#x2019;s legacy assets for a period of one year following the closing of the Asset Acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2025, the fair value of the CVR liability was determined using the probability weighted discounted cash flow method to estimate future cash flows associated with the sale of the legacy assets. Analogous to a dividend being declared/approved in one period and paid out in another, the liability was recorded at the date of approval, June 22, 2023, as a common stock dividend, returning capital to the Legacy Stockholders. Changes in fair value of the liability were recognized as a component of Other income (expense), net in the consolidated statement of operations and comprehensive loss in each reporting period. The liability value was based on significant inputs not observable in the market such as estimated cash flows, estimated probabilities of regulatory success, and discount rates, which represent a Level 3 measurement within the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June 30, 2026, all contingencies related to the disposition or monetization of the Company&#x2019;s legacy assets are resolved and the fair value of the CVR liability was determined by discounting future estimated payments to holders of the CVR. Changes in fair value of the liability will be recognized as a component of Other income (expense), net in the consolidated statement of operations and comprehensive loss in each reporting period. The liability is based on inputs observable in the market such as estimated discount rates which represent a Level 2 measurement within the fair value hierarchy.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The significant inputs used to estimate the fair value of the CVR liability were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.748%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.052%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-adjusted discount rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12.10%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The change in fair value between December&#160;31, 2025 and June&#160;30, 2026 was a $34.9&#160;million increase, primarily driven by the achievement status of certain milestones and the receipt of certain cash consideration within the CVR term and time value of money adjustments, partially offset by a $22.9&#160;million payment to CVR holders. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents changes in the CVR liability for the periods presented (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;CVR Liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning balance as of December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the fair value of the CVR liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;34,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(22,933)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ending Balance as of June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c-1" id="f-422">The following tables set forth the fair value of the Company&#x2019;s financial assets and liabilities at fair value on a recurring basis based on the three-tier fair value hierarchy (in thousands):&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;139,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;139,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 15.4pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. government treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;256,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;256,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 15.4pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;176,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;176,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 15.4pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;425,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;425,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 15.4pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;146,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;146,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;395,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;747,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,143,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 12.37pt;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;CVR liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;74,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;74,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. government treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;266,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;266,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;119,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;119,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 15.4pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;194,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;194,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 15.4pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;100,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;100,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;340,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;414,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;754,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;CVR liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-107" decimals="-3" id="f-423" unitRef="usd">139330000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-108" decimals="-3" id="f-424" unitRef="usd">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-109" decimals="-3" id="f-425" unitRef="usd">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-110" decimals="-3" id="f-426" unitRef="usd">139330000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-111" decimals="-3" id="f-427" unitRef="usd">256457000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-112" decimals="-3" id="f-428" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-113" decimals="-3" id="f-429" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-114" decimals="-3" id="f-430" unitRef="usd">256457000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-115" decimals="-3" id="f-431" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-116" decimals="-3" id="f-432" unitRef="usd">176095000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-117" decimals="-3" id="f-433" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-118" decimals="-3" id="f-434" unitRef="usd">176095000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-119" decimals="-3" id="f-435" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-120" decimals="-3" id="f-436" unitRef="usd">425578000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-121" decimals="-3" id="f-437" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-122" decimals="-3" id="f-438" unitRef="usd">425578000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-123" decimals="-3" id="f-439" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-124" decimals="-3" id="f-440" unitRef="usd">146141000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-125" decimals="-3" id="f-441" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-126" decimals="-3" id="f-442" unitRef="usd">146141000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-127" decimals="-3" id="f-443" unitRef="usd">395787000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-128" decimals="-3" id="f-444" unitRef="usd">747814000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-129" decimals="-3" id="f-445" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-3" decimals="-3" id="f-446" unitRef="usd">1143601000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeLiabilities contextRef="c-127" decimals="-3" id="f-447" unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="c-128" decimals="-3" id="f-448" unitRef="usd">38620000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="c-129" decimals="-3" id="f-449" unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="c-3" decimals="-3" id="f-450" unitRef="usd">38620000</us-gaap:DerivativeLiabilities>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-127" decimals="-3" id="f-451" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-128" decimals="-3" id="f-452" unitRef="usd">38620000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-129" decimals="-3" id="f-453" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-3" decimals="-3" id="f-454" unitRef="usd">38620000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-130" decimals="-3" id="f-455" unitRef="usd">74004000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-131" decimals="-3" id="f-456" unitRef="usd">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-132" decimals="-3" id="f-457" unitRef="usd">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-133" decimals="-3" id="f-458" unitRef="usd">74004000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-134" decimals="-3" id="f-459" unitRef="usd">266064000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-135" decimals="-3" id="f-460" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-136" decimals="-3" id="f-461" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-137" decimals="-3" id="f-462" unitRef="usd">266064000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-138" decimals="-3" id="f-463" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-139" decimals="-3" id="f-464" unitRef="usd">119590000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-140" decimals="-3" id="f-465" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-141" decimals="-3" id="f-466" unitRef="usd">119590000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-142" decimals="-3" id="f-467" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-143" decimals="-3" id="f-468" unitRef="usd">194355000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-144" decimals="-3" id="f-469" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-145" decimals="-3" id="f-470" unitRef="usd">194355000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-146" decimals="-3" id="f-471" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-147" decimals="-3" id="f-472" unitRef="usd">100790000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-148" decimals="-3" id="f-473" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-149" decimals="-3" id="f-474" unitRef="usd">100790000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-150" decimals="-3" id="f-475" unitRef="usd">340068000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-151" decimals="-3" id="f-476" unitRef="usd">414735000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-152" decimals="-3" id="f-477" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-4" decimals="-3" id="f-478" unitRef="usd">754803000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeLiabilities contextRef="c-150" decimals="-3" id="f-479" unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="c-151" decimals="-3" id="f-480" unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="c-152" decimals="-3" id="f-481" unitRef="usd">26680000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="c-4" decimals="-3" id="f-482" unitRef="usd">26680000</us-gaap:DerivativeLiabilities>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-150" decimals="-3" id="f-483" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-151" decimals="-3" id="f-484" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-152" decimals="-3" id="f-485" unitRef="usd">26680000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-4" decimals="-3" id="f-486" unitRef="usd">26680000</us-gaap:LiabilitiesFairValueDisclosure>
    <syre:AssetAcquisitionStockholderPaymentPeriod contextRef="c-94" id="f-487">P3Y</syre:AssetAcquisitionStockholderPaymentPeriod>
    <syre:AssetAcquisitionCashPaymentThresholdPeriod contextRef="c-94" id="f-488">P1Y</syre:AssetAcquisitionCashPaymentThresholdPeriod>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="c-1" id="f-489">The significant inputs used to estimate the fair value of the CVR liability were as follows:&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.748%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.052%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-adjusted discount rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12.10%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:DerivativeLiabilityMeasurementInput contextRef="c-153" decimals="4" id="f-490" unitRef="number">0.1210</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-154" decimals="-5" id="f-491" unitRef="usd">34900000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="c-154" decimals="-5" id="f-492" unitRef="usd">22900000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="c-1" id="f-493">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents changes in the CVR liability for the periods presented (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;CVR Liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning balance as of December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the fair value of the CVR liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;34,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(22,933)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ending Balance as of June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-155" decimals="-3" id="f-494" unitRef="usd">26680000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-156" decimals="-3" id="f-495" unitRef="usd">-34873000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="c-156" decimals="-3" id="f-496" unitRef="usd">22933000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-157" decimals="-3" id="f-497" unitRef="usd">38620000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock contextRef="c-1" id="f-498">Cash Equivalents and Marketable Securities&lt;div style="margin-top:18pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the estimated fair value of the Company&#x2019;s cash equivalents and marketable securities and the gross unrealized gains and losses (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;139,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;139,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 15.4pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;160,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;160,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;405,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(527)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;404,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;146,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(283)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;146,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. government treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;257,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(741)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;256,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.68pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;177,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(935)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;176,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;985,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,486)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;983,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Losses &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;74,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;74,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;83,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;83,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;184,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(80)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;184,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;100,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;100,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. government treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;265,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;266,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.68pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;119,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;119,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;669,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(116)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;670,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the available-for-sale securities in an unrealized loss position for which an allowance for credit losses has not been recorded as of June&#160;30, 2026 and December&#160;31, 2025, aggregated by major security type and length of time in a continuous unrealized loss position:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.506%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.964%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Less Than 12 Months&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;12 Months or Longer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Losses &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Losses &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;421,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(527)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;421,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(527)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;144,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(283)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;144,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(283)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. government treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;164,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(741)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;164,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(741)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;173,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(935)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;173,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(935)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;903,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,486)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;903,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,486)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Less Than 12 Months&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;12 Months or Longer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Losses &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Losses &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;99,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(80)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;99,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(80)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;58,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;58,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;180,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(116)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;180,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(116)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated its securities for credit losses and considered the decline in market value to be primarily attributable to current economic and market conditions and not to a credit loss or other factors. Additionally, the Company does not intend to sell the securities in an unrealized loss position and does not expect it will be required to sell the securities before recovery of the unamortized cost basis. As of June&#160;30, 2026 and December&#160;31, 2025, an allowance for credit losses had not been recognized. Given the Company's intent and ability to hold such securities until recovery, and the lack of significant change in credit risk of these investments, the Company does not consider these marketable securities to be impaired as of June&#160;30, 2026 and December&#160;31, 2025. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The financial instruments that potentially subject the Company to a concentration of credit risk consist principally of cash deposits. Accounts at each of the Company's two U.S. banking institutions are insured by the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;) up to $250,000 per depositor. As of June&#160;30, 2026 and December&#160;31, 2025, cash deposits at the Company's U.S. banking institutions exceeded the FDIC limits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no realized gains or losses on marketable securities for both the three and six months ended June&#160;30, 2026 and 2025. Interest on marketable securities is included in interest income. Accrued interest receivable on available-for-sale debt securities as of June&#160;30, 2026 and December&#160;31, 2025, was $5.8 million and $4.5 million, respectively, and is reflected in Prepaid expenses and other current assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the contractual maturities of the Company&#x2019;s marketable securities at estimated fair value (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30,&lt;br/&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;703,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;440,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due in 1 - 2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;279,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;229,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;983,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;670,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may sell investments at any time for use in current operations even if they have not yet reached maturity. As a result, the Company classifies marketable securities, including securities with maturities beyond twelve months as current assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock contextRef="c-1" id="f-499">&lt;div style="margin-top:18pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the estimated fair value of the Company&#x2019;s cash equivalents and marketable securities and the gross unrealized gains and losses (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;139,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;139,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 15.4pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;160,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;160,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;405,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(527)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;404,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;146,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(283)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;146,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. government treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;257,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(741)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;256,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.68pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;177,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(935)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;176,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;985,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,486)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;983,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Losses &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;74,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;74,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;83,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;83,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;184,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(80)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;184,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;100,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;100,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. government treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;265,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;266,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.68pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;119,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;119,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;669,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(116)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;670,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-110" decimals="-3" id="f-500" unitRef="usd">139330000</us-gaap:CashEquivalentsAtCarryingValue>
    <syre:CashEquivalentsUnrealizedGains contextRef="c-110" decimals="-3" id="f-501" unitRef="usd">0</syre:CashEquivalentsUnrealizedGains>
    <syre:CashEquivalentsUnrealizedLosses contextRef="c-110" decimals="-3" id="f-502" unitRef="usd">0</syre:CashEquivalentsUnrealizedLosses>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-110" decimals="-3" id="f-503" unitRef="usd">139330000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-158" decimals="-3" id="f-504" unitRef="usd">20932000</us-gaap:CashEquivalentsAtCarryingValue>
    <syre:CashEquivalentsUnrealizedGains contextRef="c-158" decimals="-3" id="f-505" unitRef="usd">0</syre:CashEquivalentsUnrealizedGains>
    <syre:CashEquivalentsUnrealizedLosses contextRef="c-158" decimals="-3" id="f-506" unitRef="usd">0</syre:CashEquivalentsUnrealizedLosses>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-158" decimals="-3" id="f-507" unitRef="usd">20932000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-508" unitRef="usd">160262000</us-gaap:CashEquivalentsAtCarryingValue>
    <syre:CashEquivalentsUnrealizedGains contextRef="c-3" decimals="-3" id="f-509" unitRef="usd">0</syre:CashEquivalentsUnrealizedGains>
    <syre:CashEquivalentsUnrealizedLosses contextRef="c-3" decimals="-3" id="f-510" unitRef="usd">0</syre:CashEquivalentsUnrealizedLosses>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-3" decimals="-3" id="f-511" unitRef="usd">160262000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-159" decimals="-3" id="f-512" unitRef="usd">405173000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-159" decimals="-3" id="f-513" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-159" decimals="-3" id="f-514" unitRef="usd">527000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-159" decimals="-3" id="f-515" unitRef="usd">404646000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-126" decimals="-3" id="f-516" unitRef="usd">146423000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-126" decimals="-3" id="f-517" unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-126" decimals="-3" id="f-518" unitRef="usd">283000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-126" decimals="-3" id="f-519" unitRef="usd">146141000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-114" decimals="-3" id="f-520" unitRef="usd">257111000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-114" decimals="-3" id="f-521" unitRef="usd">87000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-114" decimals="-3" id="f-522" unitRef="usd">741000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-114" decimals="-3" id="f-523" unitRef="usd">256457000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-118" decimals="-3" id="f-524" unitRef="usd">177028000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-118" decimals="-3" id="f-525" unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-118" decimals="-3" id="f-526" unitRef="usd">935000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-118" decimals="-3" id="f-527" unitRef="usd">176095000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-3" decimals="-3" id="f-528" unitRef="usd">985735000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-3" decimals="-3" id="f-529" unitRef="usd">90000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-3" decimals="-3" id="f-530" unitRef="usd">2486000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-3" decimals="-3" id="f-531" unitRef="usd">983339000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-133" decimals="-3" id="f-532" unitRef="usd">74004000</us-gaap:CashEquivalentsAtCarryingValue>
    <syre:CashEquivalentsUnrealizedGains contextRef="c-133" decimals="-3" id="f-533" unitRef="usd">0</syre:CashEquivalentsUnrealizedGains>
    <syre:CashEquivalentsUnrealizedLosses contextRef="c-133" decimals="-3" id="f-534" unitRef="usd">0</syre:CashEquivalentsUnrealizedLosses>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-133" decimals="-3" id="f-535" unitRef="usd">74004000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-160" decimals="-3" id="f-536" unitRef="usd">9987000</us-gaap:CashEquivalentsAtCarryingValue>
    <syre:CashEquivalentsUnrealizedGains contextRef="c-160" decimals="-3" id="f-537" unitRef="usd">0</syre:CashEquivalentsUnrealizedGains>
    <syre:CashEquivalentsUnrealizedLosses contextRef="c-160" decimals="-3" id="f-538" unitRef="usd">0</syre:CashEquivalentsUnrealizedLosses>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-160" decimals="-3" id="f-539" unitRef="usd">9987000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-540" unitRef="usd">83991000</us-gaap:CashEquivalentsAtCarryingValue>
    <syre:CashEquivalentsUnrealizedGains contextRef="c-4" decimals="-3" id="f-541" unitRef="usd">0</syre:CashEquivalentsUnrealizedGains>
    <syre:CashEquivalentsUnrealizedLosses contextRef="c-4" decimals="-3" id="f-542" unitRef="usd">0</syre:CashEquivalentsUnrealizedLosses>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-4" decimals="-3" id="f-543" unitRef="usd">83991000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-161" decimals="-3" id="f-544" unitRef="usd">184423000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-161" decimals="-3" id="f-545" unitRef="usd">25000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-161" decimals="-3" id="f-546" unitRef="usd">80000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-161" decimals="-3" id="f-547" unitRef="usd">184368000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-149" decimals="-3" id="f-548" unitRef="usd">100753000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-149" decimals="-3" id="f-549" unitRef="usd">60000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-149" decimals="-3" id="f-550" unitRef="usd">23000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-149" decimals="-3" id="f-551" unitRef="usd">100790000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-137" decimals="-3" id="f-552" unitRef="usd">265316000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-137" decimals="-3" id="f-553" unitRef="usd">748000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-137" decimals="-3" id="f-554" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-137" decimals="-3" id="f-555" unitRef="usd">266064000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-141" decimals="-3" id="f-556" unitRef="usd">119450000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-141" decimals="-3" id="f-557" unitRef="usd">153000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-141" decimals="-3" id="f-558" unitRef="usd">13000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-141" decimals="-3" id="f-559" unitRef="usd">119590000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-4" decimals="-3" id="f-560" unitRef="usd">669942000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-4" decimals="-3" id="f-561" unitRef="usd">986000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-4" decimals="-3" id="f-562" unitRef="usd">116000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-4" decimals="-3" id="f-563" unitRef="usd">670812000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock contextRef="c-1" id="f-564">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the available-for-sale securities in an unrealized loss position for which an allowance for credit losses has not been recorded as of June&#160;30, 2026 and December&#160;31, 2025, aggregated by major security type and length of time in a continuous unrealized loss position:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.506%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.964%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Less Than 12 Months&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;12 Months or Longer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Losses &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Losses &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;421,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(527)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;421,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(527)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;144,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(283)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;144,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(283)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. government treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;164,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(741)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;164,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(741)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;173,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(935)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;173,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(935)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;903,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,486)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;903,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,486)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Less Than 12 Months&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;12 Months or Longer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Losses &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Losses &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;99,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(80)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;99,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(80)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;58,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;58,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;180,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(116)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;180,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(116)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-122" decimals="-3" id="f-565" unitRef="usd">421580000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-122" decimals="-3" id="f-566" unitRef="usd">527000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-122" decimals="-3" id="f-567" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-122" decimals="-3" id="f-568" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-122" decimals="-3" id="f-569" unitRef="usd">421580000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-122" decimals="-3" id="f-570" unitRef="usd">527000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-126" decimals="-3" id="f-571" unitRef="usd">144148000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-126" decimals="-3" id="f-572" unitRef="usd">283000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-126" decimals="-3" id="f-573" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-126" decimals="-3" id="f-574" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-126" decimals="-3" id="f-575" unitRef="usd">144148000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-126" decimals="-3" id="f-576" unitRef="usd">283000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-114" decimals="-3" id="f-577" unitRef="usd">164843000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-114" decimals="-3" id="f-578" unitRef="usd">741000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-114" decimals="-3" id="f-579" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-114" decimals="-3" id="f-580" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-114" decimals="-3" id="f-581" unitRef="usd">164843000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-114" decimals="-3" id="f-582" unitRef="usd">741000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-118" decimals="-3" id="f-583" unitRef="usd">173125000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-118" decimals="-3" id="f-584" unitRef="usd">935000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-118" decimals="-3" id="f-585" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-118" decimals="-3" id="f-586" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-118" decimals="-3" id="f-587" unitRef="usd">173125000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-118" decimals="-3" id="f-588" unitRef="usd">935000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-3" decimals="-3" id="f-589" unitRef="usd">903696000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-3" decimals="-3" id="f-590" unitRef="usd">2486000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-3" decimals="-3" id="f-591" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-3" decimals="-3" id="f-592" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-3" decimals="-3" id="f-593" unitRef="usd">903696000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-3" decimals="-3" id="f-594" unitRef="usd">2486000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-145" decimals="-3" id="f-595" unitRef="usd">99837000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-145" decimals="-3" id="f-596" unitRef="usd">80000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-145" decimals="-3" id="f-597" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-145" decimals="-3" id="f-598" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-145" decimals="-3" id="f-599" unitRef="usd">99837000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-145" decimals="-3" id="f-600" unitRef="usd">80000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-149" decimals="-3" id="f-601" unitRef="usd">58296000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-149" decimals="-3" id="f-602" unitRef="usd">23000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-149" decimals="-3" id="f-603" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-149" decimals="-3" id="f-604" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-149" decimals="-3" id="f-605" unitRef="usd">58296000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-149" decimals="-3" id="f-606" unitRef="usd">23000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-141" decimals="-3" id="f-607" unitRef="usd">22828000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-141" decimals="-3" id="f-608" unitRef="usd">13000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-141" decimals="-3" id="f-609" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-141" decimals="-3" id="f-610" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-141" decimals="-3" id="f-611" unitRef="usd">22828000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-141" decimals="-3" id="f-612" unitRef="usd">13000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-4" decimals="-3" id="f-613" unitRef="usd">180961000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-4" decimals="-3" id="f-614" unitRef="usd">116000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-4" decimals="-3" id="f-615" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-4" decimals="-3" id="f-616" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-4" decimals="-3" id="f-617" unitRef="usd">180961000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-4" decimals="-3" id="f-618" unitRef="usd">116000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest contextRef="c-162" decimals="INF" id="f-619" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest contextRef="c-163" decimals="INF" id="f-620" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest>
    <syre:ImpairmentOfMarketableSecurities contextRef="c-164" decimals="INF" id="f-621" unitRef="usd">0</syre:ImpairmentOfMarketableSecurities>
    <syre:ImpairmentOfMarketableSecurities contextRef="c-165" decimals="INF" id="f-622" unitRef="usd">0</syre:ImpairmentOfMarketableSecurities>
    <syre:NumberOfDomesticBankingInstitutions contextRef="c-3" decimals="INF" id="f-623" unitRef="bank">2</syre:NumberOfDomesticBankingInstitutions>
    <us-gaap:CashFDICInsuredAmount contextRef="c-166" decimals="INF" id="f-624" unitRef="usd">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments contextRef="c-165" decimals="INF" id="f-625" unitRef="usd">0</us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments>
    <us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments contextRef="c-167" decimals="INF" id="f-626" unitRef="usd">0</us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments>
    <us-gaap:InterestReceivable contextRef="c-162" decimals="-5" id="f-627" unitRef="usd">5800000</us-gaap:InterestReceivable>
    <us-gaap:InterestReceivable contextRef="c-163" decimals="-5" id="f-628" unitRef="usd">4500000</us-gaap:InterestReceivable>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock contextRef="c-1" id="f-629">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the contractual maturities of the Company&#x2019;s marketable securities at estimated fair value (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30,&lt;br/&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;703,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;440,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due in 1 - 2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;279,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;229,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;983,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;670,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="c-3" decimals="-3" id="f-630" unitRef="usd">703969000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="c-4" decimals="-3" id="f-631" unitRef="usd">440895000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <syre:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne contextRef="c-3" decimals="-3" id="f-632" unitRef="usd">279370000</syre:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne>
    <syre:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne contextRef="c-4" decimals="-3" id="f-633" unitRef="usd">229917000</syre:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-3" decimals="-3" id="f-634" unitRef="usd">983339000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-4" decimals="-3" id="f-635" unitRef="usd">670812000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <syre:AccruedAndOtherCurrentLiabilitiesTextBlock contextRef="c-1" id="f-636">Accrued and Other Current Liabilities &lt;div style="margin-top:18pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued and other current liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30,&lt;br/&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued contracted research and development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued professional and consulting fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</syre:AccruedAndOtherCurrentLiabilitiesTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-637">&lt;div style="margin-top:18pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued and other current liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30,&lt;br/&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued contracted research and development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued professional and consulting fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedSalariesCurrent contextRef="c-3" decimals="-3" id="f-638" unitRef="usd">5722000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent contextRef="c-4" decimals="-3" id="f-639" unitRef="usd">7940000</us-gaap:AccruedSalariesCurrent>
    <syre:AccruedContractedResearchAndDevelopmentCosts contextRef="c-3" decimals="-3" id="f-640" unitRef="usd">17952000</syre:AccruedContractedResearchAndDevelopmentCosts>
    <syre:AccruedContractedResearchAndDevelopmentCosts contextRef="c-4" decimals="-3" id="f-641" unitRef="usd">17424000</syre:AccruedContractedResearchAndDevelopmentCosts>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c-3" decimals="-3" id="f-642" unitRef="usd">2375000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c-4" decimals="-3" id="f-643" unitRef="usd">1404000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-644" unitRef="usd">135000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-645" unitRef="usd">179000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="c-3" decimals="-3" id="f-646" unitRef="usd">26184000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="c-4" decimals="-3" id="f-647" unitRef="usd">26947000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="c-1" id="f-648">Licensing Agreements&lt;div style="margin-top:18pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 12, 2023, December 14, 2023, and June 5, 2024, the Company exercised the Option (as defined below) available under the antibody discovery and option agreement, dated May 25, 2023, and subsequently amended and restated on September 29, 2023 and May 14, 2024, by and among the Company, Paragon Therapeutics, Inc. (&#x201c;Paragon&#x201d;) and Parapyre Holding LLC (&#x201c;Parapyre&#x201d;) (as amended, the &#x201c;Paragon Agreement&#x201d;) with respect to the SPY001, SPY002 and SPY072, and SPY003 research programs, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 14, 2024, the Company and Paragon entered into (i) a license agreement (the &#x201c;SPY001 License Agreement&#x201d;), pursuant to which Paragon granted the Company a royalty-bearing, world-wide, exclusive license to develop, manufacture, commercialize or otherwise exploit certain antibodies and products targeting &#x3b1;4&#xdf;7 integrin and (ii) a license agreement (the &#x201c;SPY002 and SPY072 License Agreement&#x201d;), pursuant to which Paragon granted the Company a royalty-bearing, world-wide, exclusive license to develop, manufacture, commercialize or otherwise exploit certain antibodies and products targeting TL1A, respectively, which includes the Company's SPY002 and SPY072 product candidates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 11, 2024, the Company and Paragon entered into a license agreement (as amended, the &#x201c;SPY003 License Agreement&#x201d;, and together with the SPY001 License Agreement and the SPY002 and SPY072 License Agreement, the &#x201c;License Agreements&#x201d;), pursuant to which Paragon granted the Company a royalty-bearing, world-wide, exclusive license to develop, manufacture, commercialize or otherwise exploit certain antibodies and products targeting IL-23 in the field of IBD.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 24, 2025, the SPY003 License Agreement was amended and restated to, among other things, clarify each party's rights and obligations with respect to license exclusivity and patent prosecution. On May 29, 2026, the SPY003 License Agreement was further amended to expand the definition of &#x201c;Field&#x201d; to encompass all therapeutic, prophylactic, palliative and diagnostic uses of SPY003, subject to certain restrictions (as summarized below).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of each License Agreement, the Company is obligated to pay Paragon up to $22.0 million based on specific development, regulatory and clinical milestones for the first product under each agreement, respectively, that achieves such specified milestones, including a milestone payment of $3.0 million upon the first dosing of a human patient in a Phase 2 trial. In addition, the following summarizes other key terms of each License Agreement:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Paragon will provide the Company with an exclusive license to its patents covering the related antibody, the method of use and its method of manufacture.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Paragon will not conduct any new campaigns that generate anti-&#x3b1;4&#xdf;7 or anti-TL1A monospecific antibodies in any field or anti-IL-23 monospecific antibodies in the field of IBD, in each case for at least 5 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;The Company will pay Paragon a low single-digit percentage royalty for single antibody products and a mid single-digit percentage royalty for products containing more than one antibody from Paragon.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;There is a royalty step-down of 1/3rd if there is no Paragon patent in effect during the royalty term.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;The royalty term ends on the later of (i) the last-to-expire licensed patent or Company patent directed to the manufacture, use or sale of a licensed antibody in the country at issue or (ii) 12 years from the date of first sale of a Company product. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Each License Agreement may be terminated on 60 days&#x2019; notice by the Company; on material breach without cure; and to the extent permitted by law, on a party&#x2019;s insolvency or bankruptcy.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;With respect to the SPY002 and SPY072 License Agreement only, on a product by product basis, the Company will pay sublicensing fees of up to approximately $20 million upon the achievement of mostly commercial milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;With respect to the SPY003 License Agreement only, the Company will not dose a human patient in a clinical trial of SPY003 for an indication outside of inflammatory bowel disease as part of a combination until June 1, 2028 or as a monotherapy until June 1, 2030 (the &#x201c;Monotherapy Dosing Restriction&#x201d;). In the event the Company or a licensee of Paragon's retained rights under the SPY003 License Agreement consummates a material transaction, including a change of control of the Company or such licensee, then any remaining restrictions outside of the initial definition of &#x201c;Field&#x201d; set forth in the Monotherapy Dosing Restriction shall remain in effect only until June 1, 2028 and thereafter terminate and be of no further force or effect.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes the expense associated with each milestone when the achievement of the milestone is deemed probable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized no expenses related to milestone payments to Paragon for the three months ended June&#160;30, 2026 and 2025. The Company recognized expense related to Paragon license milestone payments, recorded within Research and development expenses, in the accompanying condensed statement of operations of $3.0 million and $2.5 million for the six months ended June&#160;30, 2026 and 2025, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company paid milestone payments to Paragon totaling nil and $2.5&#160;million for the three months ended June&#160;30, 2026 and 2025, respectively. The Company paid milestone payments to Paragon totaling $3.0&#160;million and $2.5&#160;million for the six months ended June&#160;30, 2026 and 2025, respectively. As of June&#160;30, 2026 and December&#160;31, 2025, there were no milestone payments outstanding and payable to Paragon.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, the Company did not recognize any sublicensing fees expense for the three or six months ended June&#160;30, 2026 or 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no payments related to sublicensing fees for the three months ended June&#160;30, 2026 and 2025. The Company paid sublicensing fees to Paragon totaling no and $0.5&#160;million for the six months ended June&#160;30, 2026 and 2025, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2026 and December&#160;31, 2025, there were nil sublicensing fees outstanding and payable to Paragon.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <syre:AmountToBePaidUnderAgreement contextRef="c-168" decimals="-5" id="f-649" unitRef="usd">22000000.0</syre:AmountToBePaidUnderAgreement>
    <syre:AmountToBePaidUnderAgreement contextRef="c-169" decimals="-5" id="f-650" unitRef="usd">22000000.0</syre:AmountToBePaidUnderAgreement>
    <syre:AmountToBePaidUnderAgreement contextRef="c-170" decimals="-5" id="f-651" unitRef="usd">22000000.0</syre:AmountToBePaidUnderAgreement>
    <syre:PaymentOfMilestone contextRef="c-171" decimals="-5" id="f-652" unitRef="usd">3000000.0</syre:PaymentOfMilestone>
    <syre:PaymentOfMilestone contextRef="c-172" decimals="-5" id="f-653" unitRef="usd">3000000.0</syre:PaymentOfMilestone>
    <syre:PaymentOfMilestone contextRef="c-173" decimals="-5" id="f-654" unitRef="usd">3000000.0</syre:PaymentOfMilestone>
    <syre:CampaignTimelineMinimumTerm contextRef="c-174" id="f-655">P5Y</syre:CampaignTimelineMinimumTerm>
    <syre:RoyaltyTermExpirationPeriod contextRef="c-174" id="f-656">P12Y</syre:RoyaltyTermExpirationPeriod>
    <syre:TerminationNoticePeriod contextRef="c-174" id="f-657">P60D</syre:TerminationNoticePeriod>
    <syre:SublicensingFee contextRef="c-175" decimals="-6" id="f-658" unitRef="usd">20000000</syre:SublicensingFee>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-176" decimals="INF" id="f-659" unitRef="usd">0</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-177" decimals="INF" id="f-660" unitRef="usd">0</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-178" decimals="-5" id="f-661" unitRef="usd">3000000.0</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-179" decimals="-5" id="f-662" unitRef="usd">2500000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <syre:LicenseAgreementMilestonePayments contextRef="c-180" decimals="-5" id="f-663" unitRef="usd">0</syre:LicenseAgreementMilestonePayments>
    <syre:LicenseAgreementMilestonePayments contextRef="c-181" decimals="-5" id="f-664" unitRef="usd">2500000</syre:LicenseAgreementMilestonePayments>
    <syre:LicenseAgreementMilestonePayments contextRef="c-174" decimals="-5" id="f-665" unitRef="usd">3000000.0</syre:LicenseAgreementMilestonePayments>
    <syre:LicenseAgreementMilestonePayments contextRef="c-182" decimals="-5" id="f-666" unitRef="usd">2500000</syre:LicenseAgreementMilestonePayments>
    <syre:LicenseAgreementMilestonePaymentsOutstandingAndPayable contextRef="c-183" decimals="INF" id="f-667" unitRef="usd">0</syre:LicenseAgreementMilestonePaymentsOutstandingAndPayable>
    <syre:LicenseAgreementMilestonePaymentsOutstandingAndPayable contextRef="c-184" decimals="INF" id="f-668" unitRef="usd">0</syre:LicenseAgreementMilestonePaymentsOutstandingAndPayable>
    <syre:PaymentForSublicensingFee contextRef="c-180" decimals="-5" id="f-669" unitRef="usd">0</syre:PaymentForSublicensingFee>
    <syre:PaymentForSublicensingFee contextRef="c-181" decimals="-5" id="f-670" unitRef="usd">0</syre:PaymentForSublicensingFee>
    <syre:PaymentForSublicensingFee contextRef="c-174" decimals="-5" id="f-671" unitRef="usd">0</syre:PaymentForSublicensingFee>
    <syre:PaymentForSublicensingFee contextRef="c-182" decimals="-5" id="f-672" unitRef="usd">500000</syre:PaymentForSublicensingFee>
    <syre:SublicensingFeeOutstandingAndPayable contextRef="c-178" decimals="-5" id="f-673" unitRef="usd">0</syre:SublicensingFeeOutstandingAndPayable>
    <syre:SublicensingFeeOutstandingAndPayable contextRef="c-185" decimals="-5" id="f-674" unitRef="usd">0</syre:SublicensingFeeOutstandingAndPayable>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c-1" id="f-676">Related Party Transactions&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Paragon and Parapyre each beneficially own less than 5% of a class of the Company's voting securities through their respective holdings of the Company's common stock. Fairmount Funds Management LLC (&#x201c;Fairmount&#x201d;) beneficially owns more than 5% of a class of the Company's voting securities, has one seat on the Board (held by Tomas Kiselak) and beneficially owns more than 5% of Paragon. Fairmount appointed Paragon's &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;board of directors and has the contractual right to approve the appointment of any executive officers of Paragon.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is the summary of expenses related to the License Agreements and other Paragon reimbursable expenses, which are ultimately settled in cash (in millions) and recorded within Research and development in the consolidated statement of operations for the periods presented:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.627%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.023%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;License Agreements milestone and sublicensing fees&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other Paragon reimbursable expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total related party expense (excludes stock-based compensation)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized de minimis related party expenses in connection with other Paragon reimbursable expenses for the three months ended June&#160;30, 2026 and 2025, which were recorded as Research and development expenses in the consolidated statements of operations. For the six months ended June&#160;30, 2026 and 2025, the Company recognized $0.1 million of Paragon reimbursable expenses. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were de minimis Related party accounts payable as of June 30, 2026 and December 31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended June&#160;30, 2026 and 2025, the Company made payments totaling $0.1 million and de minimis payments, respectively, in connection with Paragon reimbursable expenses. For the six months ended June&#160;30, 2026 and 2025, the Company made payments totaling $0.1 million and $0.2 million, respectively, in connection with Paragon reimbursable expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Paragon License Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 6 for disclosures related to the License Agreements entered into with Paragon.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Mark McKenna Option Grant&lt;/span&gt;&lt;/div&gt;On February 1, 2024, the Board appointed Mark McKenna as a Class I director. Mr. McKenna and the Company are parties to a consulting agreement, pursuant to which Mr. McKenna agreed to continue to provide consulting services as an independent contractor to the Company, with an effective date of August 1, 2023 (the &#x201c;Vesting Commencement Date&#x201d;). As compensation for Mr. McKenna&#x2019;s consulting services, on November 22, 2023, he was granted non-qualified stock options to purchase 477,000 shares of the Company&#x2019;s common stock under the 2016 Plan (as defined in Note 9) with an exercise price of $10.39 per share, which vest as to 25% on the one year anniversary of the Vesting Commencement Date and thereafter vest and become exercisable in 36 equal monthly installments, subject to Mr. McKenna&#x2019;s continued service to the Company through each applicable vesting date. The Company recognized stock-based compensation expense related to Mr. McKenna's consulting agreement of $0.2 million for the three months ended June&#160;30, 2026 and 2025, respectively, and $0.5 million for the six months ended June&#160;30, 2026 and 2025, respectively.</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners contextRef="c-186" decimals="2" id="f-677" unitRef="number">0.05</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners contextRef="c-187" decimals="2" id="f-678" unitRef="number">0.05</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <syre:RelatedPartyTransactionNumberOfBoardSeats contextRef="c-188" decimals="INF" id="f-679" unitRef="seat">1</syre:RelatedPartyTransactionNumberOfBoardSeats>
    <syre:MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty contextRef="c-187" decimals="2" id="f-680" unitRef="number">0.05</syre:MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="c-1" id="f-681">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is the summary of expenses related to the License Agreements and other Paragon reimbursable expenses, which are ultimately settled in cash (in millions) and recorded within Research and development in the consolidated statement of operations for the periods presented:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.627%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.023%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;License Agreements milestone and sublicensing fees&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other Paragon reimbursable expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total related party expense (excludes stock-based compensation)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-176" decimals="INF" id="f-682" unitRef="usd">0</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-177" decimals="INF" id="f-683" unitRef="usd">0</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-177" decimals="-5" id="f-684" unitRef="usd">0</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-178" decimals="-5" id="f-685" unitRef="usd">3000000.0</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-179" decimals="-5" id="f-686" unitRef="usd">2500000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-189" decimals="-5" id="f-687" unitRef="usd">0</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-190" decimals="-5" id="f-688" unitRef="usd">0</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-191" decimals="-5" id="f-689" unitRef="usd">100000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-192" decimals="-5" id="f-690" unitRef="usd">100000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-193" decimals="-5" id="f-691" unitRef="usd">0</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-194" decimals="-5" id="f-692" unitRef="usd">0</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-195" decimals="-5" id="f-693" unitRef="usd">3100000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-196" decimals="-5" id="f-694" unitRef="usd">2600000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-191" decimals="-5" id="f-695" unitRef="usd">100000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-192" decimals="-5" id="f-696" unitRef="usd">100000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c-180" decimals="-5" id="f-697" unitRef="usd">100000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c-174" decimals="-5" id="f-698" unitRef="usd">100000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c-182" decimals="-5" id="f-699" unitRef="usd">200000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-197"
      decimals="INF"
      id="f-700"
      unitRef="shares">477000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="c-198"
      decimals="2"
      id="f-701"
      unitRef="usdPerShare">10.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-199" decimals="2" id="f-702" unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-199" id="f-703">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <syre:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMonthlyInstallments
      contextRef="c-198"
      decimals="0"
      id="f-704"
      unitRef="installment">36</syre:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMonthlyInstallments>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-200" decimals="-5" id="f-705" unitRef="usd">200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-201" decimals="-5" id="f-706" unitRef="usd">200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-202" decimals="-5" id="f-707" unitRef="usd">500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-203" decimals="-5" id="f-708" unitRef="usd">500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:PreferredStockTextBlock contextRef="c-1" id="f-714">Convertible Preferred Stock and Stockholders&#x2019; Equity&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2026, a total of&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 1,532,591&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; warrants previously issued to Parapyre pursuant to the Paragon Agreement with a weighted-average exercise price of&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; $22.49&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; remain outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Series A Non-Voting Convertible Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Company's Certificate of Designation of Preferences, Rights and Limitations of the Series A Non-Voting Convertible Preferred Stock (the &#x201c;Series A Certificate of Designation&#x201d;), holders of Series A Preferred Stock are entitled to receive dividends on shares of Series A Preferred Stock equal to, on an as-if-converted-to-common stock basis, and in the same form as, dividends actually paid on shares of common stock. Except as provided in the Series A Certificate of Designation or as otherwise required by law, the Series A Preferred Stock does not have voting rights. However, as long as any shares of Series A Preferred Stock are outstanding, the Company will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series A Preferred Stock: (a) alter or change adversely the powers, preferences or rights given to the Series A Preferred Stock, or alter or amend the Series A Certificate of Designation, amend or repeal any provision of, or add any provision to, the Company&#x2019;s Certificate of Incorporation or its Bylaws, or file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of preferred stock, if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series A Preferred Stock, regardless of whether any of the foregoing actions will be by means of amendment to the Certificate of Incorporation or by merger, consolidation, recapitalization, reclassification, conversion or otherwise, (b) issue further shares of Series A Preferred Stock or increase or decrease (other than by conversion) the number of authorized shares of Series A Preferred Stock, (c) prior to the stockholder approval of the conversion of the Series A Preferred Stock into shares of common stock in accordance with Nasdaq Stock Market Rules or at any time while at least 30% of the originally issued Series A Preferred Stock remains issued and outstanding, consummate (x) any Fundamental Transaction (as defined in the Series A Certificate of Designation) or (y) any merger or consolidation of the Company with or into another entity or any stock sale to, or other business combination in which the Company's stockholders immediately before such transaction do not hold at least a majority of the Company's capital stock immediately after such transaction or (d) enter into any agreement with respect to any of the foregoing. The Series A Preferred Stock does not have a preference upon any liquidation, dissolution or winding-up of the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June 30, 2026, 346,045 shares of Series A Preferred Stock remained outstanding and are convertible into 13,841,800 common shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Series B Non-Voting Convertible Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Company's Certificate of Designation of Preferences, Rights and Limitations of Series B Non-Voting Convertible Preferred Stock (as amended, the &#x201c;Series B Certificate of Designation&#x201d;), holders of Series B Preferred Stock are entitled to receive dividends on shares of Series B Preferred Stock equal to, on an as-if-converted-to-common stock basis, and in the same form as, dividends actually paid on shares of common stock. Except as provided in the Series B Certificate of Designation or as otherwise required by law, the Series B Preferred Stock does not have voting rights. However, as long as any shares of Series B Preferred Stock are outstanding, the Company will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series B Preferred Stock, alter or change adversely the powers, preferences or rights given to the Series B Preferred Stock, or alter or amend the Series B Certificate of Designation, amend or repeal any provision of, or add any provision to, the Company&#x2019;s Certificate of Incorporation or its Bylaws, or file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of preferred stock, if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series B Preferred Stock, regardless of whether any of the foregoing actions will be by means of amendment to the Certificate of Incorporation or by merger, consolidation, recapitalization, reclassification, conversion or otherwise. The Series B Preferred Stock does not have a preference upon any liquidation, dissolution or winding-up of the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 23, 2026, 16,667 shares of Series B Preferred Stock were converted at the option of the holder into 666,680 shares of common stock. As of June 30, 2026, no shares of Series B Preferred Stock remained outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ATM Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 6, 2024, the Company entered into the 2024 Sales Agreement, pursuant to which the Company may issue and sell up to $200.0&#160;million of shares of common stock under an ATM offering program. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2025, the Company sold an aggregate of 445,668 shares of common stock under its ATM offering program pursuant to the 2024 Sales Agreement resulting in net proceeds of $14.8&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the six months ended June&#160;30, 2026, the Company sold an aggregate of 296,396 shares of common stock under the ATM offering program pursuant to the 2024 Sales Agreement resulting in net proceeds of $9.7&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2024 Sales Agreement was terminated on June 26, 2026 and the Company concurrently entered into a new sales agreement (the &#x201c;2026 Sales Agreement&#x201d;) with TD Securities (USA) LLC as its agent, pursuant to which the Company may issue and sell up to $500.0&#160;million of shares of common stock under an ATM offering program. During the three months ended June 30, 2026, the Company did not sell any shares under the ATM offering program pursuant to the 2026 Sales Agreement. As of June&#160;30, 2026, $500.0&#160;million remained available for sale under the 2026 Sales Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;October 2025 Underwritten Offering&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 13, 2025, the Company entered into the October 2025 Underwriting Agreement, pursuant to which the Company sold an aggregate of 17,094,594 shares of common stock, inclusive of 2,229,729 shares pursuant to the full exercise of the underwriters&#x2019; over-allotment option, at a public offering price per share of $18.50, resulting in net proceeds of approximately $296.4&#160;million after deducting approximately $19.9&#160;million of underwriting discounts and other offering costs. The over-allotment option was exercised in full on October 14, 2025 and the transaction closed on October 15, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;April 2026 Underwritten Offering&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 13, 2026, the Company entered into the April 2026 Underwriting Agreement, pursuant to which the Company sold an aggregate of 7,475,000 shares of its common stock, inclusive of 975,000 shares pursuant to the full exercise of the underwriters' over-allotment option, at a public offering price per share of $62.00, resulting in net proceeds of approximately $435.2&#160;million after deducting approximately $28.2&#160;million of underwriting discounts and other offering costs. The over-allotment option was exercised in full on April 15, 2026 and the transaction closed on April 16, 2026.&lt;/span&gt;&lt;/div&gt;</us-gaap:PreferredStockTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-206"
      decimals="INF"
      id="f-715"
      unitRef="shares">1532591</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-206"
      decimals="2"
      id="f-716"
      unitRef="usdPerShare">22.49</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <syre:PreferredStockRemainsIssuedAndOutstandingPercentage contextRef="c-207" decimals="2" id="f-717" unitRef="number">0.30</syre:PreferredStockRemainsIssuedAndOutstandingPercentage>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-9" decimals="INF" id="f-718" unitRef="shares">346045</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockConvertibleSharesIssuable contextRef="c-9" decimals="INF" id="f-719" unitRef="shares">13841800</us-gaap:PreferredStockConvertibleSharesIssuable>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-208"
      decimals="INF"
      id="f-720"
      unitRef="shares">16667</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="c-11"
      decimals="INF"
      id="f-721"
      unitRef="shares">666680</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-11"
      decimals="INF"
      id="f-722"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <syre:SaleOfStockAggregateOfferingPrice contextRef="c-209" decimals="-5" id="f-723" unitRef="usd">200000000.0</syre:SaleOfStockAggregateOfferingPrice>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-210"
      decimals="INF"
      id="f-724"
      unitRef="shares">445668</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-210" decimals="-5" id="f-725" unitRef="usd">14800000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-97"
      decimals="INF"
      id="f-726"
      unitRef="shares">296396</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-97" decimals="-5" id="f-727" unitRef="usd">9700000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <syre:SaleOfStockAuthorizedAmount contextRef="c-98" decimals="-5" id="f-728" unitRef="usd">500000000.0</syre:SaleOfStockAuthorizedAmount>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-99"
      decimals="INF"
      id="f-729"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <syre:SaleOfStockRemainingAuthorizedAmount contextRef="c-98" decimals="-5" id="f-730" unitRef="usd">500000000.0</syre:SaleOfStockRemainingAuthorizedAmount>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-100"
      decimals="INF"
      id="f-731"
      unitRef="shares">17094594</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-101"
      decimals="INF"
      id="f-732"
      unitRef="shares">2229729</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-102"
      decimals="2"
      id="f-733"
      unitRef="usdPerShare">18.50</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-100" decimals="-5" id="f-734" unitRef="usd">296400000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-100" decimals="-5" id="f-735" unitRef="usd">19900000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-103"
      decimals="INF"
      id="f-736"
      unitRef="shares">7475000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-104"
      decimals="INF"
      id="f-737"
      unitRef="shares">975000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-105"
      decimals="2"
      id="f-738"
      unitRef="usdPerShare">62.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-103" decimals="-5" id="f-739" unitRef="usd">435200000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-103" decimals="-5" id="f-740" unitRef="usd">28200000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-741">Stock-Based Compensation&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2016 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's 2016 Equity Incentive Plan (the &#x201c;2016 Plan&#x201d;) became effective in April 2016 and serves as the successor to the Company&#x2019;s 2015 Equity Incentive Plan. Under the 2016 Plan, the Company may grant stock options, stock appreciation rights, restricted stock awards, restricted stock units, performance awards, and stock bonuses. The 2016 Plan, as amended, provides for an automatic increase in the number of shares reserved for issuance thereunder on January 1 of each year for the remaining term of the plan equal to (a) 5.0% of the number of issued and outstanding shares of common stock &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(including such shares issuable pursuant to the exercise or conversion, as applicable, of any outstanding pre-funded warrants and nonvoting convertible preferred stock) on December 31 of the immediately preceding year, or (b) a lesser amount as approved by the board each year (the &#x201c;Evergreen Provision&#x201d;). As a result of the Evergreen Provision, on January 1, 2026 and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2025, an additional 4,711,544 and 3,814,905 shares, respectively, became available for issuance under the 2016 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2026, the 2016 Plan had 15,084,463 shares available for future issuance, of which 6,876,693 shares were subject to outstanding option awards and restricted unit awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2018 Equity Inducement Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2018 Equity Inducement Plan (&#x201c;2018 Plan&#x201d;) became effective in February 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the second quarter of 2025, the Company amended the 2018 Plan to increase the number of shares of common stock reserved for issuance by 750,000. After this amendment and as of June&#160;30, 2026, the 2018 Plan had 6,481,956 shares available for future issuance, of which 5,981,072 shares were subject to outstanding option awards and restricted unit awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Service-based awards granted under the 2018 Plan and 2016 Plan generally vest over four years and expire after ten years, although awards have been granted with vesting terms less than four years. Under the 2016 Plan and 2018 Plan, the Company may grant stock-based awards with service conditions, performance conditions, and market conditions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s stock awards granted under all equity incentive and inducement plans for each of the periods indicated:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.676%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.356%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.026%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.356%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.356%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.026%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.356%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.218%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.356%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.218%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.356%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.218%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.356%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.616%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Grants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Grants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Grants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Grants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;190,456&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;62.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;427,800&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,769,061&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;33.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,325,717&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;125,400&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;30.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2016 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Company&#x2019;s Amended and Restated 2016 Employee Stock Purchase Plan (&#x201c;2016 ESPP&#x201d;), the Company issued and sold 19,967 shares of the Company&#x2019;s common stock during the three and six months ended June&#160;30, 2026, resulting in aggregate cash proceeds of $0.5&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no shares issued and sold during the three months ended June&#160;30, 2025. The Company issued and sold 16,877 shares during the six months ended June&#160;30, 2025, resulting in aggregate cash proceeds of $0.3&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total stock-based compensation expense recognized from the Company&#x2019;s equity incentive plans, 2018 Plan and 2016 ESPP during the periods presented was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.869%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.839%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.023%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the weighted-average Black-Scholes option pricing model assumptions used to estimate the fair value of stock options granted under the Company's equity incentive plans, and the shares purchased under the 2016 ESPP during the periods presented: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.545%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.145%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock Options Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.93&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.74&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.02&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.97&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;67%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;74%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;73%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;76%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.16%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.02%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.88%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.38%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 5.37pt;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2016 ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.50&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;64%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;69%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.59%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.23%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <syre:AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares contextRef="c-211" decimals="3" id="f-742" unitRef="number">0.050</syre:AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares>
    <syre:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant
      contextRef="c-212"
      decimals="INF"
      id="f-743"
      unitRef="shares">4711544</syre:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant>
    <syre:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant
      contextRef="c-213"
      decimals="INF"
      id="f-744"
      unitRef="shares">3814905</syre:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-214"
      decimals="INF"
      id="f-745"
      unitRef="shares">15084463</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-214"
      decimals="INF"
      id="f-746"
      unitRef="shares">6876693</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-215"
      decimals="INF"
      id="f-747"
      unitRef="shares">750000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-216"
      decimals="INF"
      id="f-748"
      unitRef="shares">6481956</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-216"
      decimals="INF"
      id="f-749"
      unitRef="shares">5981072</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-217" id="f-750">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-217" id="f-751">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-217" id="f-752">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock contextRef="c-1" id="f-753">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s stock awards granted under all equity incentive and inducement plans for each of the periods indicated:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.676%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.356%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.026%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.356%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.356%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.026%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.356%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.218%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.356%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.218%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.356%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.218%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.356%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.616%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Grants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Grants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Grants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Grants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;190,456&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;62.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;427,800&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,769,061&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;33.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,325,717&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;125,400&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;30.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-15"
      decimals="INF"
      id="f-754"
      unitRef="shares">190456</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-15"
      decimals="2"
      id="f-755"
      unitRef="usdPerShare">62.94</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-16"
      decimals="INF"
      id="f-756"
      unitRef="shares">427800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-16"
      decimals="2"
      id="f-757"
      unitRef="usdPerShare">15.29</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="INF" id="f-758" unitRef="shares">2769061</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-759"
      unitRef="usdPerShare">33.19</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-17"
      decimals="INF"
      id="f-760"
      unitRef="shares">2325717</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-17"
      decimals="2"
      id="f-761"
      unitRef="usdPerShare">20.32</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-218"
      decimals="INF"
      id="f-762"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-218"
      decimals="2"
      id="f-763"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-219"
      decimals="INF"
      id="f-764"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-219"
      decimals="2"
      id="f-765"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-220"
      decimals="INF"
      id="f-766"
      unitRef="shares">125400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-220"
      decimals="2"
      id="f-767"
      unitRef="usdPerShare">30.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-221"
      decimals="INF"
      id="f-768"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-221"
      decimals="2"
      id="f-769"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-222"
      decimals="INF"
      id="f-770"
      unitRef="shares">19967</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-223"
      decimals="INF"
      id="f-771"
      unitRef="shares">19967</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-222" decimals="-5" id="f-772" unitRef="usd">500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-223" decimals="-5" id="f-773" unitRef="usd">500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-224"
      decimals="INF"
      id="f-774"
      unitRef="shares">0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-225"
      decimals="INF"
      id="f-775"
      unitRef="shares">16877</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-225" decimals="-5" id="f-776" unitRef="usd">300000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="c-1" id="f-777">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total stock-based compensation expense recognized from the Company&#x2019;s equity incentive plans, 2018 Plan and 2016 ESPP during the periods presented was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.869%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.839%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.023%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-226" decimals="-3" id="f-778" unitRef="usd">6218000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-227" decimals="-3" id="f-779" unitRef="usd">4100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-228" decimals="-3" id="f-780" unitRef="usd">12009000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-229" decimals="-3" id="f-781" unitRef="usd">7612000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-230" decimals="-3" id="f-782" unitRef="usd">7294000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-231" decimals="-3" id="f-783" unitRef="usd">5278000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-232" decimals="-3" id="f-784" unitRef="usd">14309000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-233" decimals="-3" id="f-785" unitRef="usd">10625000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-15" decimals="-3" id="f-786" unitRef="usd">13512000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-16" decimals="-3" id="f-787" unitRef="usd">9378000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-788" unitRef="usd">26318000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-789" unitRef="usd">26318000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-17" decimals="-3" id="f-790" unitRef="usd">18237000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-791">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the weighted-average Black-Scholes option pricing model assumptions used to estimate the fair value of stock options granted under the Company's equity incentive plans, and the shares purchased under the 2016 ESPP during the periods presented: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.545%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.145%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock Options Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.93&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.74&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.02&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.97&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;67%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;74%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;73%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;76%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.16%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.02%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.88%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.38%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 5.37pt;text-align:left;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2016 ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.50&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;64%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;69%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.59%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.23%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-234" id="f-792">P5Y11M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-235" id="f-793">P5Y8M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-236" id="f-794">P6Y7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-237" id="f-795">P5Y11M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-234" decimals="2" id="f-796" unitRef="number">0.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-235" decimals="2" id="f-797" unitRef="number">0.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-236" decimals="2" id="f-798" unitRef="number">0.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-237" decimals="2" id="f-799" unitRef="number">0.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-234" decimals="4" id="f-800" unitRef="number">0.0416</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-235" decimals="4" id="f-801" unitRef="number">0.0402</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-236" decimals="4" id="f-802" unitRef="number">0.0388</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-237" decimals="4" id="f-803" unitRef="number">0.0438</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-234"
      decimals="INF"
      id="f-804"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-235"
      decimals="INF"
      id="f-805"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-236"
      decimals="INF"
      id="f-806"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-237"
      decimals="INF"
      id="f-807"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-238" id="f-808">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-239" id="f-809">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-240" decimals="2" id="f-810" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-241" decimals="2" id="f-811" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-238" decimals="2" id="f-812" unitRef="number">0.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-239" decimals="2" id="f-813" unitRef="number">0.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-240" decimals="4" id="f-814" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-241" decimals="4" id="f-815" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-238" decimals="4" id="f-816" unitRef="number">0.0359</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-239" decimals="4" id="f-817" unitRef="number">0.0423</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-240"
      decimals="INF"
      id="f-818"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-241"
      decimals="INF"
      id="f-819"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-238"
      decimals="INF"
      id="f-820"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-239"
      decimals="INF"
      id="f-821"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock contextRef="c-1" id="f-823">Sale of Pegzilarginase to Immedica&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 27, 2023, the Company announced that it had entered into an agreement to sell the global rights to pegzilarginase to Immedica Pharma AB (&#x201c;Immedica&#x201d;) for $15.0&#160;million in upfront cash proceeds and up to $100.0&#160;million in contingent milestone payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The milestone payments are contingent on formal reimbursement decisions by national authorities in key European markets and pegzilarginase approval by the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;), among other events. In the three months ended June 30, 2026, the Company recognized a gain of $40.0 million within Gain on Sale of in-process research and development, for achieving certain milestones during the period. As of June&#160;30, 2026 and December 31, 2025, $3.0 million remains outstanding and due to the Company from a previously achieved milestone, which is reflected in Prepaid expenses and other current assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Milestone payments received by the Company by July 3, 2026, net of allowable expenses and adjustments, will be distributed to CVR holders pursuant to the CVR agreement resulting from the Asset Acquisition and will reduce the CVR liability.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:ProceedsFromSaleOfIntangibleAssets contextRef="c-242" decimals="-5" id="f-824" unitRef="usd">15000000.0</us-gaap:ProceedsFromSaleOfIntangibleAssets>
    <syre:DisposalGroupIncludingDiscontinuedOperationContingentConsideration contextRef="c-243" decimals="-5" id="f-825" unitRef="usd">100000000.0</syre:DisposalGroupIncludingDiscontinuedOperationContingentConsideration>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal contextRef="c-15" decimals="-5" id="f-826" unitRef="usd">40000000.0</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration contextRef="c-244" decimals="-5" id="f-827" unitRef="usd">3000000.0</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration contextRef="c-245" decimals="-5" id="f-828" unitRef="usd">3000000.0</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c-1" id="f-829">Segment Reporting&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates under a single operating and reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and rheumatic diseases. The Company's Chief Operating Decision Maker (&#x201c;CODM&#x201d;) is the Company's Chief Executive Officer. The CODM uses consolidated Net loss as the measure of segment profit or loss and uses consolidated Total Assets as reported on the balance sheet as the measure of segment assets. The CODM compares Net loss against budgeted and/or forecasted amounts to track the Company's financial performance against expectations and to inform, along with development timelines and scientific and commercial considerations, their decisions regarding resource allocations to fund the Company's development of its pipeline. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the significant expenses provided to the CODM on a regular basis (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.860%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;12,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;24,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;15,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Stock-based compensation &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;26,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;18,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Research and development, excluding compensation and stock-based compensation &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2) (3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;50,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;30,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;97,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;64,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other segment items&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (4) (5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(40,621)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(11,530)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(42,758)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(16,158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Segment net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;36,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;36,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;105,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;81,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Includes related party expenses of $0.2 million for the three months ended June&#160;30, 2026 and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2025, and&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; $0.5 million for the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;six months ended &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June&#160;30, 2026 and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Includes non-clinical study, clinical trial, and manufacturing expenses. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Includes de minimis related party expenses for the three months ended June 30, 2026 and 2025. Includes related party expenses of $3.1 million and $2.6 million for the six months ended June 30, 2026 and 2025, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Includes general and administrative expenses such as audit, legal, and other professional fees, interest income, and other expense, net. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Includes gains of $40.0 million and $10.0 million for the three months ended June 30, 2026 and 2025, respectively, related to the achievement of milestones under the 2023 sale of the global rights to the legacy assets, pegzilarginase, to Immedica. The 2026 gain was triggered by the sale of the related priority review voucher (&#x201c;PRV&#x201d;), while the 2025 gain was triggered by a favorable reimbursement decision for pegzilarginase in Europe.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Includes gains of $70.0 million and $10.0 million for the six months ended June 30, 2026 and 2025, respectively, related to milestone payments earned in connection with the 2023 sale of the global rights to the legacy assets, pegzilarginase, to Immedica. The 2026 gain was triggered by the FDA approval of pegzilarginase and the subsequent sale of the related PRV, while the 2025 gain was triggered by a favorable reimbursement decision for pegzilarginase in Europe.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Includes a $4.6&#160;million increase and a $0.6&#160;million decrease in the fair value of the CVR liability for the three months ended &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June&#160;30, 2026&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and 2025, respectively. Includes a $34.9&#160;million increase and a $1.8&#160;million decrease in the fair value of the CVR liability for the six months ended &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June&#160;30, 2026&lt;/span&gt; and 2025, respectively.</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock contextRef="c-1" id="f-830">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the significant expenses provided to the CODM on a regular basis (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.860%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;12,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;24,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;15,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Stock-based compensation &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;26,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;18,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Research and development, excluding compensation and stock-based compensation &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2) (3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;50,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;30,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;97,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;64,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other segment items&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (4) (5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(40,621)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(11,530)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(42,758)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(16,158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Segment net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;36,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;36,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;105,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;81,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Includes related party expenses of $0.2 million for the three months ended June&#160;30, 2026 and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2025, and&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; $0.5 million for the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;six months ended &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June&#160;30, 2026 and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Includes non-clinical study, clinical trial, and manufacturing expenses. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Includes de minimis related party expenses for the three months ended June 30, 2026 and 2025. Includes related party expenses of $3.1 million and $2.6 million for the six months ended June 30, 2026 and 2025, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Includes general and administrative expenses such as audit, legal, and other professional fees, interest income, and other expense, net. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Includes gains of $40.0 million and $10.0 million for the three months ended June 30, 2026 and 2025, respectively, related to the achievement of milestones under the 2023 sale of the global rights to the legacy assets, pegzilarginase, to Immedica. The 2026 gain was triggered by the sale of the related priority review voucher (&#x201c;PRV&#x201d;), while the 2025 gain was triggered by a favorable reimbursement decision for pegzilarginase in Europe.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Includes gains of $70.0 million and $10.0 million for the six months ended June 30, 2026 and 2025, respectively, related to milestone payments earned in connection with the 2023 sale of the global rights to the legacy assets, pegzilarginase, to Immedica. The 2026 gain was triggered by the FDA approval of pegzilarginase and the subsequent sale of the related PRV, while the 2025 gain was triggered by a favorable reimbursement decision for pegzilarginase in Europe.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Includes a $4.6&#160;million increase and a $0.6&#160;million decrease in the fair value of the CVR liability for the three months ended &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June&#160;30, 2026&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and 2025, respectively. Includes a $34.9&#160;million increase and a $1.8&#160;million decrease in the fair value of the CVR liability for the six months ended &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June&#160;30, 2026&lt;/span&gt; and 2025, respectively.</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold contextRef="c-246" decimals="-3" id="f-831" unitRef="usd">12862000</us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold>
    <us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold contextRef="c-247" decimals="-3" id="f-832" unitRef="usd">8120000</us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold>
    <us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold contextRef="c-248" decimals="-3" id="f-833" unitRef="usd">24305000</us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold>
    <us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold contextRef="c-249" decimals="-3" id="f-834" unitRef="usd">15111000</us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold>
    <us-gaap:ShareBasedCompensation contextRef="c-246" decimals="-3" id="f-835" unitRef="usd">13512000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-247" decimals="-3" id="f-836" unitRef="usd">9378000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-248" decimals="-3" id="f-837" unitRef="usd">26318000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-249" decimals="-3" id="f-838" unitRef="usd">18237000</us-gaap:ShareBasedCompensation>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-246" decimals="-3" id="f-839" unitRef="usd">50447000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-247" decimals="-3" id="f-840" unitRef="usd">30749000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-248" decimals="-3" id="f-841" unitRef="usd">97340000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-249" decimals="-3" id="f-842" unitRef="usd">64300000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-246" decimals="-3" id="f-843" unitRef="usd">-40621000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-247" decimals="-3" id="f-844" unitRef="usd">-11530000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-248" decimals="-3" id="f-845" unitRef="usd">-42758000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-249" decimals="-3" id="f-846" unitRef="usd">-16158000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:NetIncomeLoss contextRef="c-246" decimals="-3" id="f-847" unitRef="usd">-36200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-247" decimals="-3" id="f-848" unitRef="usd">-36717000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-248" decimals="-3" id="f-849" unitRef="usd">-105205000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-249" decimals="-3" id="f-850" unitRef="usd">-81490000</us-gaap:NetIncomeLoss>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-32" decimals="-5" id="f-851" unitRef="usd">200000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-33" decimals="-5" id="f-852" unitRef="usd">200000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-202" decimals="-5" id="f-853" unitRef="usd">500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-203" decimals="-5" id="f-854" unitRef="usd">500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-30" decimals="-5" id="f-855" unitRef="usd">3100000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-31" decimals="-5" id="f-856" unitRef="usd">2600000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal contextRef="c-15" decimals="-5" id="f-857" unitRef="usd">40000000.0</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal contextRef="c-16" decimals="-5" id="f-858" unitRef="usd">10000000.0</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal contextRef="c-1" decimals="-5" id="f-859" unitRef="usd">70000000.0</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal contextRef="c-17" decimals="-5" id="f-860" unitRef="usd">10000000.0</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <syre:IncreaseDecreaseInFairValueOfContingentValueRightLiability contextRef="c-15" decimals="-5" id="f-861" unitRef="usd">4600000</syre:IncreaseDecreaseInFairValueOfContingentValueRightLiability>
    <syre:IncreaseDecreaseInFairValueOfContingentValueRightLiability contextRef="c-16" decimals="-5" id="f-862" unitRef="usd">-600000</syre:IncreaseDecreaseInFairValueOfContingentValueRightLiability>
    <syre:IncreaseDecreaseInFairValueOfContingentValueRightLiability contextRef="c-1" decimals="-5" id="f-863" unitRef="usd">34900000</syre:IncreaseDecreaseInFairValueOfContingentValueRightLiability>
    <syre:IncreaseDecreaseInFairValueOfContingentValueRightLiability contextRef="c-17" decimals="-5" id="f-864" unitRef="usd">-1800000</syre:IncreaseDecreaseInFairValueOfContingentValueRightLiability>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-869">Net Loss Per Share&lt;div style="margin-top:18pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company computes net loss per share of common stock, Series A Preferred Stock, and Series B Preferred Stock using the two-class method required for multiple classes of common stock and other participating securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The two-class method is an earnings (loss) allocation method under which earnings (loss) per share is calculated for each class of common stock. The Company has determined that the Series A Preferred Stock and Series B Preferred Stock do not have preferential rights when compared to the Company's common stock and therefore it must allocate losses to these other classes of common stock, as illustrated in the table below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted net loss per share is computed by dividing the net loss by the weighted-average number of shares outstanding during the period, without consideration of potential dilutive securities. For periods in which the Company generated a net loss, the Company does not include potential shares of common stock in diluted net loss per share when the impact of these items is anti-dilutive. The Company has generated a net loss for all periods presented, therefore diluted net loss per share is the same as basic net loss per share since the inclusion of potential shares of common stock would be anti-dilutive.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of basic and diluted net loss per share of common stock, Series A Preferred Stock, and Series B Preferred Stock (in thousands, except share and per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.596%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.449%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Series A Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Series B Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Common&lt;br/&gt;Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Series A Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Series B Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Common&lt;br/&gt;Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Net loss per share, basic and diluted:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Numerator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Allocation of losses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(5,052)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(225)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(30,923)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(6,791)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(327)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(29,599)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Denominator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Weighted-average shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;346,045&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;15,385&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;84,729,435&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;346,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;16,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;60,333,838&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(14.60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(14.60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(0.36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(19.62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(19.62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(0.49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Series A Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Series B Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Common&lt;br/&gt;Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Series A Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Series B Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Common&lt;br/&gt;Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Net loss per share, basic and diluted:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Numerator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Allocation of losses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(15,147)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(701)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(89,357)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(15,078)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(726)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(65,686)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Denominator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Weighted-average shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;346,045&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;16,022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;81,656,119&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;346,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;16,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;60,300,073&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(43.77)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(43.77)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(43.57)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(43.57)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following weighted-average equity instruments were excluded from the calculation of diluted net loss per share because their effect would have been anti-dilutive for the periods presented:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.303%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.666%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.731%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.435%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.731%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.435%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.731%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.435%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.736%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,042,158&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;805,306&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,630,827&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,324,645&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;137,358&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;113,115&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,943&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding Parapyre warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,532,591&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,532,591&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-870">&lt;div style="margin-top:18pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company computes net loss per share of common stock, Series A Preferred Stock, and Series B Preferred Stock using the two-class method required for multiple classes of common stock and other participating securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The two-class method is an earnings (loss) allocation method under which earnings (loss) per share is calculated for each class of common stock. The Company has determined that the Series A Preferred Stock and Series B Preferred Stock do not have preferential rights when compared to the Company's common stock and therefore it must allocate losses to these other classes of common stock, as illustrated in the table below.&lt;/span&gt;&lt;/div&gt;Basic and diluted net loss per share is computed by dividing the net loss by the weighted-average number of shares outstanding during the period, without consideration of potential dilutive securities. For periods in which the Company generated a net loss, the Company does not include potential shares of common stock in diluted net loss per share when the impact of these items is anti-dilutive. The Company has generated a net loss for all periods presented, therefore diluted net loss per share is the same as basic net loss per share since the inclusion of potential shares of common stock would be anti-dilutive.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock contextRef="c-1" id="f-871">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of basic and diluted net loss per share of common stock, Series A Preferred Stock, and Series B Preferred Stock (in thousands, except share and per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.596%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.449%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Series A Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Series B Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Common&lt;br/&gt;Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Series A Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Series B Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Common&lt;br/&gt;Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Net loss per share, basic and diluted:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Numerator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Allocation of losses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(5,052)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(225)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(30,923)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(6,791)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(327)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(29,599)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Denominator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Weighted-average shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;346,045&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;15,385&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;84,729,435&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;346,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;16,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;60,333,838&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(14.60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(14.60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(0.36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(19.62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(19.62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(0.49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Series A Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Series B Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Common&lt;br/&gt;Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Series A Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Series B Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Common&lt;br/&gt;Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Net loss per share, basic and diluted:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Numerator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Allocation of losses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(15,147)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(701)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(89,357)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(15,078)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(726)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(65,686)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Denominator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Weighted-average shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;346,045&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;16,022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;81,656,119&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;346,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;16,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;60,300,073&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(43.77)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(43.77)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(43.57)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(43.57)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c-18" decimals="-3" id="f-872" unitRef="usd">-5052000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-22" decimals="-3" id="f-873" unitRef="usd">-225000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-26" decimals="-3" id="f-874" unitRef="usd">-30923000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-19" decimals="-3" id="f-875" unitRef="usd">-6791000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-23" decimals="-3" id="f-876" unitRef="usd">-327000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-27" decimals="-3" id="f-877" unitRef="usd">-29599000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic contextRef="c-18" decimals="0" id="f-878" unitRef="shares">346045</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic contextRef="c-22" decimals="0" id="f-879" unitRef="shares">15385</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic contextRef="c-26" decimals="0" id="f-880" unitRef="shares">84729435</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic contextRef="c-19" decimals="0" id="f-881" unitRef="shares">346045</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic contextRef="c-23" decimals="0" id="f-882" unitRef="shares">16667</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic contextRef="c-27" decimals="0" id="f-883" unitRef="shares">60333838</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-18"
      decimals="2"
      id="f-884"
      unitRef="usdPerShare">-14.60</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-18"
      decimals="2"
      id="f-885"
      unitRef="usdPerShare">-14.60</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-22"
      decimals="2"
      id="f-886"
      unitRef="usdPerShare">-14.60</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-22"
      decimals="2"
      id="f-887"
      unitRef="usdPerShare">-14.60</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-26"
      decimals="2"
      id="f-888"
      unitRef="usdPerShare">-0.36</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-26"
      decimals="2"
      id="f-889"
      unitRef="usdPerShare">-0.36</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-19"
      decimals="2"
      id="f-890"
      unitRef="usdPerShare">-19.62</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-19"
      decimals="2"
      id="f-891"
      unitRef="usdPerShare">-19.62</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-23"
      decimals="2"
      id="f-892"
      unitRef="usdPerShare">-19.62</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-23"
      decimals="2"
      id="f-893"
      unitRef="usdPerShare">-19.62</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-27"
      decimals="2"
      id="f-894"
      unitRef="usdPerShare">-0.49</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-27"
      decimals="2"
      id="f-895"
      unitRef="usdPerShare">-0.49</us-gaap:EarningsPerShareDiluted>
    <us-gaap:NetIncomeLoss contextRef="c-20" decimals="-3" id="f-896" unitRef="usd">-15147000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-24" decimals="-3" id="f-897" unitRef="usd">-701000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-28" decimals="-3" id="f-898" unitRef="usd">-89357000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-21" decimals="-3" id="f-899" unitRef="usd">-15078000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-25" decimals="-3" id="f-900" unitRef="usd">-726000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-29" decimals="-3" id="f-901" unitRef="usd">-65686000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic contextRef="c-20" decimals="0" id="f-902" unitRef="shares">346045</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic contextRef="c-24" decimals="0" id="f-903" unitRef="shares">16022</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic contextRef="c-28" decimals="0" id="f-904" unitRef="shares">81656119</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic contextRef="c-21" decimals="0" id="f-905" unitRef="shares">346045</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic contextRef="c-25" decimals="0" id="f-906" unitRef="shares">16667</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic contextRef="c-29" decimals="0" id="f-907" unitRef="shares">60300073</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-20"
      decimals="2"
      id="f-908"
      unitRef="usdPerShare">-43.77</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-20"
      decimals="2"
      id="f-909"
      unitRef="usdPerShare">-43.77</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-24"
      decimals="2"
      id="f-910"
      unitRef="usdPerShare">-43.77</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-24"
      decimals="2"
      id="f-911"
      unitRef="usdPerShare">-43.77</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-912"
      unitRef="usdPerShare">-1.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-28"
      decimals="2"
      id="f-913"
      unitRef="usdPerShare">-1.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-21"
      decimals="2"
      id="f-914"
      unitRef="usdPerShare">-43.57</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-21"
      decimals="2"
      id="f-915"
      unitRef="usdPerShare">-43.57</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-25"
      decimals="2"
      id="f-916"
      unitRef="usdPerShare">-43.57</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-25"
      decimals="2"
      id="f-917"
      unitRef="usdPerShare">-43.57</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-29"
      decimals="2"
      id="f-918"
      unitRef="usdPerShare">-1.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-29"
      decimals="2"
      id="f-919"
      unitRef="usdPerShare">-1.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-920">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following weighted-average equity instruments were excluded from the calculation of diluted net loss per share because their effect would have been anti-dilutive for the periods presented:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.303%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.666%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.731%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.435%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.731%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.435%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.731%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.435%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.736%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,042,158&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;805,306&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,630,827&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,324,645&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;137,358&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;113,115&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,943&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding Parapyre warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,532,591&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,532,591&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-250" decimals="0" id="f-921" unitRef="shares">8042158</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-251" decimals="0" id="f-922" unitRef="shares">805306</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-252" decimals="0" id="f-923" unitRef="shares">6630827</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-253" decimals="0" id="f-924" unitRef="shares">1324645</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-254" decimals="0" id="f-925" unitRef="shares">137358</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-255" decimals="0" id="f-926" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-256" decimals="0" id="f-927" unitRef="shares">113115</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-257" decimals="0" id="f-928" unitRef="shares">11943</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-258" decimals="0" id="f-929" unitRef="shares">1532591</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-259" decimals="0" id="f-930" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-260" decimals="0" id="f-931" unitRef="shares">1532591</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-261" decimals="0" id="f-932" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-15" id="f-933">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-15" id="f-934">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-15" id="f-935">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="c-262" id="f-936">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 16, 2026, Heidy King-Jones, our Chief Legal Officer and Corporate Secretary, adopted a trading plan intended to satisfy Rule 10b5-1(c) to sell up to 76,000 shares of our common stock over a period ending April 5, 2028, subject to certain conditions, all of which are to be acquired upon the exercise of employee stock options.&lt;/span&gt;&lt;/div&gt;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:TrdArrAdoptionDate contextRef="c-262" id="f-937">April 16, 2026</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrIndName contextRef="c-262" id="f-938">Heidy King-Jones</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-262" id="f-939">Chief Legal Officer and Corporate Secretary</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-262" id="f-940">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-263"
      decimals="INF"
      id="f-941"
      unitRef="shares">76000</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrExpirationDate contextRef="c-262" id="f-942">April 5, 2028</ecd:TrdArrExpirationDate>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="c-264" id="f-943">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 16, 2026, Jeffrey Albers, one of our directors, and Sessions LLC, an investment company of which Mr. Albers is a managing director and owns 10% or more of the equity interest in or otherwise exercises significant influence over, adopted a trading plan intended to satisfy Rule 10b5-1(c) to sell up to 23,000 shares of our common stock over a period ending July 31, 2027, subject to certain conditions, 5,000 of which  are to be acquired upon the exercise of director stock options.&lt;/span&gt;&lt;/div&gt;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:TrdArrAdoptionDate contextRef="c-264" id="f-944">April 16, 2026</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrIndName contextRef="c-264" id="f-945">Jeffrey Albers</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-264" id="f-946">directors</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-264" id="f-947">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-265"
      decimals="INF"
      id="f-948"
      unitRef="shares">23000</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrExpirationDate contextRef="c-264" id="f-949">July 31, 2027</ecd:TrdArrExpirationDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-266"
      decimals="INF"
      id="f-950"
      unitRef="shares">5000</ecd:TrdArrSecuritiesAggAvailAmt>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#f-113"
          xlink:label="f-113"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-111"
          xlink:label="f-111"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-110"
          xlink:label="f-110"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-112"
          xlink:label="f-112"
          xlink:type="locator"/>
        <link:footnote id="fn-1" xlink:label="fn-1" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt">Includes de minimis related party expenses for the </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">three</xhtml:span><xhtml:span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> months ended June&#160;30, 2026 and </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2025</xhtml:span><xhtml:span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Includes related party expenses of $3.1 million and $2.6 million for the </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">six</xhtml:span><xhtml:span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> months ended June&#160;30, 2026 and </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2025, respectively</xhtml:span><xhtml:span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-113"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-111"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-110"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-112"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-114"
          xlink:label="f-114"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-116"
          xlink:label="f-116"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-115"
          xlink:label="f-115"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-117"
          xlink:label="f-117"
          xlink:type="locator"/>
        <link:footnote id="fn-2" xlink:label="fn-2" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt">Includes related party expenses of $0.2 million for the three months ended June&#160;30, 2026 and </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2025, and</xhtml:span><xhtml:span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> $0.5 million for the </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">six months ended </xhtml:span><xhtml:span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">June&#160;30, 2026 and </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2025</xhtml:span><xhtml:span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-114"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-116"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-115"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-117"
          xlink:to="fn-2"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
